
Research publications
Our researchers, scientists and clinical partners are active members of the scientific community and have published their work in well-respected, peer-reviewed journals.
Researchers
R&D expert voices
Research publications
NOTE: The links provided below redirect to third-party websites that may require a subscription to access publications.
2024 publications
A Pilot Study to Assess the Suitability of Riboflavin as A Surrogate Marker of Breast Cancer Resistance Protein (BCRP) in Healthy Participants.
Shen H, Huo R, Zhang Y, Wang L, Tong N, Chen W, Paris AJ, Mensah K, Chen M, Xue Y, Li W, Sinz M.
J Pharmacol Exp Ther. 2024 Jan 31:JPET-AR-2023-002015. doi: 10.1124/jpet.123.002015. Online ahead of print.
PMID: 38296646
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
Zhao Y, Hu Z, Bathena SP, Keidel S, Miller-Moslin K, Statkevich P, Bello A, Roy A, Suryawanshi S.
Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2396. Online ahead of print.
PMID: 38295151
Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning.
Román Ivorra JA, Trallero-Araguas E, Lopez Lasanta M, Cebrián L, Lojo L, López-Muñíz B, Fernández-Melon J, Núñez B, Silva-Fernández L, Veiga Cabello R, Ahijado P, De la Morena Barrio I, Costas Torrijo N, Safont B, Ornilla E, Restrepo J, Campo A, Andreu JL, Díez E, López Robles A, Bollo E, Benavent D, Vilanova D, Luján Valdés S, Castellanos-Moreira R.
RMD Open. 2024 Jan 30;10(1):e003353. doi: 10.1136/rmdopen-2023-003353.
PMID: 38296310
Is the price right? Paying for value today to get more value tomorrow.
Ramagopalan SV, Diaz J, Mitchell G, Garrison LP Jr, Kolchinsky P.
BMC Med. 2024 Jan 30;22(1):45. doi: 10.1186/s12916-024-03262-w.
PMID: 38287326
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
Cella D, Choueiri TK, Hamilton M, Blum SI, Ivanescu C, Karu K, Ejzykowicz F, Motzer RJ.
Oncologist. 2024 Jan 27:oyae003. doi: 10.1093/oncolo/oyae003. Online ahead of print.
PMID: 38280218
Payer approval and rejection of oral anticoagulant prescriptions and prescription abandonment patterns among patients with venous thromboembolism.
Hines DM, Doshi R, Anupindi VR, Dai F, Russ C, Stellhorn R, Cheng D, Deeba S, Wang Y, DeKoven M.
J Manag Care Spec Pharm. 2024 Jan 26:1-15. doi: 10.18553/jmcp.2024.23194. Online ahead of print.
PMID: 38277234
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y.
Jpn J Clin Oncol. 2024 Jan 25:hyad195. doi: 10.1093/jjco/hyad195. Online ahead of print.
PMID: 38271158
A High-Fidelity Combined ATC-Rxnorm Drug Hierarchy for Large-Scale Observational Research.
Ostropolets A, Talapova P, De Wilde M, Abedtash H, Rijnbeek P, Reich CG.
Stud Health Technol Inform. 2024 Jan 25;310:53-57. doi: 10.3233/SHTI230926.
PMID: 38269764
Trends in Neosubstrate Degradation by Cereblon-Based Molecular Glues and the Development of Novel Multiparameter Optimization Scores.
Szewczyk SM, Verma I, Edwards JT, Weiss DR, Chekler ELP.
J Med Chem. 2024 Jan 25;67(2):1327-1335. doi: 10.1021/acs.jmedchem.3c01872. Epub 2024 Jan 3.
PMID: 38170610
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li HT, Liang G, Leong R, Brown PA, Kaplan J, Schafer ES, Slone T, Pauly M, Chang BH, Stieglitz E, Wayne AS, Hijiya N, Bhojwani D.
Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496.
PMID: 38339248
Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer.
Kole E, Jadhav K, Singh R, Mandpe S, Abhang A, Verma RK, Naik J.
Curr Drug Deliv. 2024 Jan 24. doi: 10.2174/0115672018278617231207051907. Online ahead of print.
PMID: 38275043
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, Shao Y, Banerjee S, Morita A.
J Dermatol. 2024 Jan 24. doi: 10.1111/1346-8138.17074. Online ahead of print.
PMID: 38268101
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis.
Dubinsky MC, Charles L, Selmaj KW, Comi G, Krakovich A, Rosen M, van der Woude CJ, Mahadevan U.
Inflamm Bowel Dis. 2024 Jan 24:izae011. doi: 10.1093/ibd/izae011. Online ahead of print.
PMID: 38267826
Determining the Impact of Roller Compaction Processing Conditions on Granulate and API Properties: Impact of Formulation API Load.
Clarke J, Gamble JF, Jones JW, Tobyn M, Ingram A, Greenwood R.
AAPS PharmSciTech. 2024 Jan 24;25(1):24. doi: 10.1208/s12249-024-02744-7.
PMID: 38267745
Membrane transporters in drug development and as determinants of precision medicine.
Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sjöstedt N, Aleksunes L, Chu X, Evers R, Hafey MJ, Lai Y, Matsson P, Riselli A, Shen H, Sparreboom A, Varma MVS, Yang J, Yang X, Yee SW, Zamek-Gliszczynski MJ, Zhang L, Giacomini KM.
Nat Rev Drug Discov. 2024 Jan 24. doi: 10.1038/s41573-023-00877-1. Online ahead of print.
PMID: 38267543
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach.
Serrano D, Cella D, Husereau D, King-Kallimanis B, Mendoza T, Salmonson T, Stone A, Zaleta A, Dhanda D, Moshyk A, Liu F, Shields AL, Taylor F, Spite S, Shaw JW, Braverman J.
Qual Life Res. 2024 Jan 24. doi: 10.1007/s11136-023-03587-8. Online ahead of print.
PMID: 38265747
ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi.
Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P, Winchester CC, Tovey D, Goldman K, Hungin AP, Harrison N.
PLoS Med. 2024 Jan 23;21(1):e1004326. doi: 10.1371/journal.pmed.1004326. eCollection 2024 Jan.
PMID: 38261576
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC.
J Clin Oncol. 2024 Jan 22:JCO2301017. doi: 10.1200/JCO.23.01017. Online ahead of print.
PMID: 38252907
Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.
Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L.
Dermatol Ther (Heidelb). 2024 Jan 22. doi: 10.1007/s13555-023-01089-6. Online ahead of print.
PMID: 38252376
Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
Harrold LR, Wittstock K, Kelly S, Han X, Zhuo J, Schrader A, Middaugh N, Moore PC, Khaychuk V.
Adv Rheumatol. 2024 Jan 19;64(1):10. doi: 10.1186/s42358-024-00352-4.
PMID: 38243281
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
Betts KA, Gao S, Ray S, Schoenfeld AJ.
Future Oncol. 2024 Jan 19. doi: 10.2217/fon-2023-0612. Online ahead of print.
PMID: 38240151
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.
Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, Griffin TA, Alexeeva E, Bohnsack JF, Zeft A, Horneff G, Vehe RK, Staņēviča V, Tarvin S, Trachana M, Del Río AQ, Huber AM, Kietz D, Orbán I, Dare J, Foeldvari I, Quartier P, Dominique A, Simon TA, Martini A, Brunner HI, Ruperto N.
Rheumatology (Oxford). 2024 Jan 18:keae025. doi: 10.1093/rheumatology/keae025. Online ahead of print.
PMID: 38243722
Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation.
Acheampong T, Gu T, Le TK, Keating SJ.
Future Oncol. 2024 Jan 17. doi: 10.2217/fon-2023-0385. Online ahead of print.
PMID: 38230990
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.
Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A.
Br J Dermatol. 2024 Jan 16:ljae014. doi: 10.1093/bjd/ljae014. Online ahead of print.c
PMID: 38226713
Circulating Biomarker Analyses in a Longitudinal Cohort of Patients with IPF.
Ebert C, Walsh AM, Sereda L, Wilson C, Schafer PH, Fischer A, Zhao L, Ramirez-Valle F, Gordon D, Schnapp LM.
Am J Physiol Lung Cell Mol Physiol. 2024 Jan 16. doi: 10.1152/ajplung.00222.2023. Online ahead of print.
PMID: 38226605
A Future European Scientific Dialogue Regulatory Framework: Connecting the Dots.
Hey C, Hunter A, Muller M, Roux NL, Bennett S, Nowok K, Oliveira L.
Clin Ther. 2024 Jan 15:S0149-2918(23)00494-0. doi: 10.1016/j.clinthera.2023.12.006. Online ahead of print.
PMID: 38228459
Randomised, siteless study to compare systematic atrial fibrillation screening using enrichment by a risk prediction model with standard care in a Swedish population aged ≥ 65 years: CONSIDERING-AF study design.
Etminani F, Sandgren E, Holm J, Magnusson P, Modica A, Moberg K, Davidsson T, Stalpe L, Kiflemariam S, Younan N, Parikh P, Wadhwa M, Sundin A, Engdahl J.
BMJ Open. 2024 Jan 12;14(1):e080639. doi: 10.1136/bmjopen-2023-080639.
PMID: 38216189
Drug Utilization Studies in Pregnant Women for Newly Licensed Medicinal Products: A Contribution from IMI ConcePTION.
Lopez-Leon S, Geldhof A, Scotto J, Wurst K, Sabidó M, Mo J, Molgaard-Nielsen D, Bergman JEH, Phi XA, Jordan S.
J Pregnancy. 2024 Jan 11;2024:8862801. doi: 10.1155/2024/8862801. eCollection 2024.
PMID: 38250012
Miniaturized CAR knocked onto CD3ε extends TCR function with CAR specificity under control of endogenous TCR signaling cascade.
Manske K, Dreßler L, Fräßle SP, Effenberger M, Tschulik C, Cletiu V, Benke E, Wagner M, Schober K, Müller TR, Stemberger C, Germeroth L, Busch DH, Poltorak MP.
J Immunol Methods. 2024 Jan 11;526:113617. doi: 10.1016/j.jim.2024.113617. Online ahead of print.
PMID: 38215900
Repotrectinib in  ROS1  Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators.
N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299.
PMID: 38197815
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
Simon TA, Dong L, Suissa S, Michaud K, Pedro S, Hochberg M, Boers M, Askling J, Frisell T, Strangfeld A, Meissner Y, Khaychuk V, Dominique A, Maldonado MA.
Ann Rheum Dis. 2024 Jan 11;83(2):177-183. doi: 10.1136/ard-2023-224356.
PMID: 37932010
A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma.
Liu FF, Bartlett M, Craigie S.
Pharmacoecon Open. 2024 Jan 10. doi: 10.1007/s41669-023-00464-5. Online ahead of print.
PMID: 38198111
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and common cancers or cancers with high venous thromboembolism risk.
Cohen AT, Noxon V, Dhamane AD, Shah S, Hines DM, Alfred T, Luo X.
Future Oncol. 2024 Jan 10. doi: 10.2217/fon-2022-1254. Online ahead of print.
PMID: 38197229
Interval estimation of relative risks for combined unilateral and bilateral correlated data.
Wang K, Ma CX.
J Biopharm Stat. 2024 Jan 9:1-24. doi: 10.1080/10543406.2023.2297789. Online ahead of print.
PMID: 38196244
Novel Independent Trans- and Cis-Genetic Variants Associated with CYP2D6 Expression and Activity in Human Livers.
Smith D, He B, Shi J, Zhu HJ, Wang X.
Drug Metab Dispos. 2024 Jan 9;52(2):143-152. doi: 10.1124/dmd.123.001548.
PMID: 38050015
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.
He L, Zhang MY, Cox M, Zhang Q, Donnell AF, Zhang Y, Tarby C, Gill P, Subbaiah MAM, Ramar T, Reddy M, Puttapaka V, Li YX, Sivaprakasam P, Critton D, Mulligan D, Xie C, Ramakrishnan R, Nagar J, Dudhgaonkar S, Murtaza A, Oderinde MS, Schieven GL, Mathur A, Gavai AV, Vite G, Gangwar S, Poudel YB.
ACS Med Chem Lett. 2024 Jan 9;15(2):189-196. doi: 10.1021/acsmedchemlett.3c00456. eCollection 2024 Feb 8.
PMID: 38352849
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Neri P, Barwick BG, Jung D, Patton JC, Maity R, Tagoug I, Stein CK, Tilmont R, Leblay N, Ahn S, Lee H, Welsh SJ, Riggs DL, Stong N, Flynt E, Thakurta A, Keats JJ, Lonial S, Bergsagel PL, Boise LH, Bahlis NJ.
Blood Cancer Discov. 2024 Jan 8;5(1):56-73. doi: 10.1158/2643-3230.BCD-23-0061.
PMID: 37934799
Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology.
Poudel YB, He L, Cox M, Zhang Q, Johnson WL, Cong Q, Cheng H, Chowdari NS, Tarby C, Donnell AF, Broekema M, O'Malley DP, Zhang Y, A M Subbaiah M, Kumar BV, Subramani L, Wang B, Li YX, Sivaprakasam P, Critton D, Mulligan D, Sandhu B, Xie C, Ramakrishnan R, Nagar J, Dudhgaonkar S, Oderinde MS, Murtaza A, Schieven GL, Mathur A, Gavai AV, Vite G, Gangwar S.
ACS Med Chem Lett. 2024 Jan 8;15(2):181-188. doi: 10.1021/acsmedchemlett.3c00455. eCollection 2024 Feb 8.
PMID: 38352830
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV.
Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775-w. Online ahead of print.
PMID: 38177857
Adaptive modeling optimized by the data fusion strategy: Real-time dying cell percentage prediction using capacitance spectroscopy.
Wu S, Ketcham SA, Corredor C, Both D, Zhao Y, Drennen JK, Anderson CA.
Biotechnol Prog. 2024 Jan 4:e3424. doi: 10.1002/btpr.3424. Online ahead of print.
PMID: 38178645
Corrigendum to "Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score" [Eur. Urol. 83(5) (2024) 432-440].
Galsky MD, Bajorin DF, Witjes JA, Gschwend JE, Tomita Y, Nasroulah F, Li J, Collette S, Valderrama BP, Grimm MO, Appleman L, Gravis G, Necchi A, Ye D, Stenner F, Wind-Rotolo M, Zhang J, Ünsal-Kaçmaz K.
Eur Urol. 2024 Jan 3:S0302-2838(23)03306-7. doi: 10.1016/j.eururo.2023.12.013. Online ahead of print.
PMID: 38176992
Enhanced mapping of small-molecule binding sites in cells.
Wozniak JM, Li W, Governa P, Chen LY, Jadhav A, Dongre A, Forli S, Parker CG.
Nat Chem Biol. 2024 Jan 2. doi: 10.1038/s41589-023-01514-z. Online ahead of print.
PMID: 38167919
Undertaking multi-centre randomised controlled trials in primary care: learnings and recommendations from the PULsE-AI trial researchers.
Pollock KG, Dickerson C, Kainth M, Lawton S, Hurst M, Sugrue DM, Arden C, Davies DW, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Hill NR, Camm AJ, Cohen AT.
BMC Prim Care. 2024 Jan 2;25(1):7. doi: 10.1186/s12875-023-02246-8.
PMID: 38166641
MRCK as a Potential Target for Claudin-Low Subtype of Breast Cancer.
Yamaguchi H, Chang LC, Chang OS, Chen YF, Hsiao YC, Wu CS, Hung MC.
Int J Biol Sci. 2024 Jan 1;20(1):1-14. doi: 10.7150/ijbs.88285. eCollection 2024.
PMID: 38164185
Acute myeloid leukemia: Current understanding and management.
Becker M, Farina KA, Mascarenhas J.J
AAPA. 2024 Jan 1;37(1):34-39. doi: 10.1097/01.JAA.0000995680.52352.b5.
PMID: 38128137
Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
Klink AJ, Gajra A, Knoth RL, Marshall L, Hou Y, McBride A, Copher R.
Leuk Res. 2024 Jan;136:107430. doi: 10.1016/j.leukres.2023.107430. Epub 2024 Jan 9.
PMID: 38199929
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
Rader F, Oręziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT, Abraham TP, Garcia-Pavia P, Zwas DR, Masri A, Owens A, Hegde SM, Seidler T, Fox S, Balaratnam G, Sehnert AJ, Olivotto I.
JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028.
PMID: 38176782
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Yoon BW, Tanne D, Toni D, Yperzeele L, von Weitzel-Mudersbach P, Sampaio Silva G, Avezum A, Dawson J, Strbian D, Tatlisumak T, Eckstein J, Ameriso SF, Weber JR, Sandset EC, Goar Pogosova N, Lavados PM, Arauz A, Gailani D, Diener HC, Bernstein RA, Cordonnier C, Kahl A, Abelian G, Donovan M, Pachai C, Li D, Hankey GJ.
Lancet Neurol. 2024 Jan;23(1):46-59. doi: 10.1016/S1474-4422(23)00403-9.
PMID: 38101902
Clinical characteristics, treatment patterns, and outcomes among African American and White patients with multiple myeloma in the United States.
Saunders A, Slaff S, Subbiah K, Gu T, Ang KK, Quan MA, Rosenberg AS.
Leuk Lymphoma. 2024 Jan;65(1):109-117. doi: 10.1080/10428194.2023.2273746. Epub 2024 Jan 10.
PMID: 37917858
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.
Zhu D, Hadjivassiliou H, Jennings C, Mikolon D, Ammirante M, Acharya S, Lloyd J, Abbasian M, Narla RK, Piccotti JR, Stamp K, Cho H, Hariharan K.
MAbs. 2024 Jan-Dec;16(1):2310248. doi: 10.1080/19420862.2024.2310248. Epub 2024 Feb 13.
PMID: 38349008
2023 publications
Towards in vitro models for reducing or replacing the use of animals in drug testing.
Stresser DM, Kopec AK, Hewitt P, Hardwick RN, Van Vleet TR, Mahalingaiah PKS, O'Connell D, Jenkins GJ, David R, Graham J, Lee D, Ekert J, Fullerton A, Villenave R, Bajaj P, Gosset JR, Ralston SL, Guha M, Amador-Arjona A, Khan K, Agarwal S, Hasselgren C, Wang X, Adams K, Kaushik G, Raczynski A, Homan KA.
Nat Biomed Eng. 2023 Dec 27. doi: 10.1038/s41551-023-01154-7. Online ahead of print.
PMID: 38151640
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.
El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B.
Ann Oncol. 2023 Dec 25:S0923-7534(23)05115-3. doi: 10.1016/j.annonc.2023.12.008. Online ahead of print.
PMID: 38151184
Conformational states of the microtubule nucleator, the γ-tubulin ring complex.
Romer B, Travis SM, Mahon BP, McManus CT, Jeffrey PD, Coudray N, Raghu R, Rale MJ, Zhong ED, Bhabha G, Petry S.
bioRxiv. 2023 Dec 21:2023.12.19.572162. doi: 10.1101/2023.12.19.572162. Preprint.
PMID: 38187763
Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data.
Park JE, Campbell H, Towle K, Yuan Y, Jansen JP, Phillippo D, Cope S.
Value Health. 2023 Dec 20:S1098-3015(23)06235-6. doi: 10.1016/j.jval.2023.11.011. Online ahead of print.
PMID: 38135212
Development, Characterization, and Radiation Dosimetry Studies of  18 F-BMS-986229, a  18 F-Labeled PD-L1 Macrocyclic Peptide PET Tracer.
Kim J, Donnelly DJ, Tran T, Pena A, Shorts AO, Petrone TV, Zhang Y, Boy KM, Scola PM, Tenney DJ, Poss MA, Soars MG, Bonacorsi SJ Jr, Cole EL, Grootendorst DJ, Chow PL, Meanwell NA, Du S.
Mol Imaging Biol. 2023 Dec 20. doi: 10.1007/s11307-023-01889-4. Online ahead of print.
PMID: 38123744
Adult stem cell activity in naked mole rats for long-term tissue maintenance.
Montazid S, Bandyopadhyay S, Hart DW, Gao N, Johnson B, Thrumurthy SG, Penn DJ, Wernisch B, Bansal M, Altrock PM, Rost F, Gazinska P, Ziolkowski P, Hayee B, Liu Y, Han J, Tessitore A, Koth J, Bodmer WF, East JE, Bennett NC, Tomlinson I, Irshad S.
Nat Commun. 2023 Dec 20;14(1):8484. doi: 10.1038/s41467-023-44138-6.
PMID: 38123565
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
Papp KA, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont JL, Pham TP, Kisa R, Napoli AA, Banerjee S, Armstrong AW.
JAMA Dermatol. 2023 Dec 20:e235058. doi: 10.1001/jamadermatol.2023.5058. Online ahead of print.
PMID: 38117487
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect.
Hu Z, Liu S, Zhao Y, Du S, Hamuro L, Shen J, Roy A, Zhu L.
CPT Pharmacometrics Syst Pharmacol. 2023 Dec 19. doi: 10.1002/psp4.13098. Online ahead of print.
PMID: 38115545
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D.
J Am Acad Dermatol. 2023 Dec 18:S0190-9622(23)03374-1. doi: 10.1016/j.jaad.2023.11.060. Online ahead of print.
PMID: 38122848
Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation.
Elkrief A, Waters NR, Smith N, Dai A, Slingerland J, Aleynick N, Febles B, Gogia P, Socci ND, Lumish M, Giardina PA, Chaft JE, Eng J, Motzer RJ, Mendelsohn RB, Markey KA, Zhuang M, Li Y, Yang Z, Hollmann TJ, Rudin CM, van den Brink MRM, Shia J, DeWolf S, Schoenfeld AJ, Hellmann MD, Babady NE, Faleck DM, Peled JU.
Cancer Immunol Res. 2023 Dec 18. doi: 10.1158/2326-6066.CIR-23-0498. Online ahead of print.
PMID: 38108398
Phenoxythiazoline (FTz)-Cobalt(II) Precatalysts Enable C(sp 2  )-C(sp 3  ) Bond-Formation for Key Intermediates in the Synthesis of Toll-like Receptor 7/8 Antagonists.
Mills LR, Di Mare F, Gygi D, Lee H, Simmons EM, Kim J, Wisniewski SR, Chirik PJ.
Angew Chem Int Ed Engl. 2023 Dec 18;62(51):e202313848. doi: 10.1002/anie.202313848. Epub 2023 Nov 20.
PMID: 37917119
The Natural Products Discovery Center: Release of the First 8490 Sequenced Strains for Exploring Actinobacteria Biosynthetic Diversity.
Kalkreuter E, Kautsar SA, Yang D, Teijaro CN, Bader CD, Fluegel LL, Davis CM, Simpson JR, Steele AD, Gui C, Meng S, Li G, Viehrig K, Ye F, Su P, Kiefer AF, Lauterbach L, Nichols A, Cepeda AJ, Yan W, Fan B, Jiang Y, Adhikari A, Zheng CJ, Shen B.
bioRxiv. 2023 Dec 15:2023.12.14.571759. doi: 10.1101/2023.12.14.571759. Preprint.
PMID: 38168313
Free Energy Perturbation Approach for Accurate Crystalline Aqueous Solubility Predictions.
Hong RS, Rojas AV, Bhardwaj RM, Wang L, Mattei A, Abraham NS, Cusack KP, Pierce MO, Mondal S, Mehio N, Bordawekar S, Kym PR, Abel R, Sheikh AY.
J Med Chem. 2023 Dec 14;66(23):15883-15893. doi: 10.1021/acs.jmedchem.3c01339. Epub 2023 Nov 28.
PMID: 38016916
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2).
Chen Y, Whitefield B, Nevius E, Hill M, DelRosario J, Sinitsyna N, Shanmugasundaram V, Mukherjee D, Shi L, Mayne CG, Rousseau AM, Bernard SM, Buenviaje J, Khambatta G, El Samin M, Wallace M, Nie Z, Sivakumar P, Hamann LG, McDonnell DP, D'Agostino LA.
J Med Chem. 2023 Dec 14;66(23):15750-15760. doi: 10.1021/acs.jmedchem.3c01137. Epub 2023 Nov 27.
PMID: 38009718
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation.
Norris S, Ba X, Rhodes J, Huang D, Khambatta G, Buenviaje J, Nayak S, Meiring J, Reiss S, Xu S, Shi L, Whitefield B, Alexander M, Horn EJ, Correa M, Tehrani L, Hansen JD, Papa P, Mortensen DS.
J Med Chem. 2023 Dec 14;66(23):16388-16409. doi: 10.1021/acs.jmedchem.3c01848. Epub 2023 Nov 22.
PMID: 37991844
A Review of the Use of EQ-5D for Clinical Outcome Assessment in Health Technology Assessment, Regulatory Claims, and Published Literature.
Shaw C, Longworth L, Bennett B, McEntee-Richardson L, Shaw JW.
Patient. 2023 Dec 12. doi: 10.1007/s40271-023-00662-7. Online ahead of print.
PMID: 38085457
Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease.
Payne RM, Burns KM, Glatz AC, Male C, Donti A, Brandão LR, Balling G, VanderPluym CJ, Bu'Lock F, Kochilas LK, Stiller B, Cnota JF 2nd, Rahkonen O, Khan A, Adorisio R, Stoica S, May L, Burns JC, Saraiva JFK, McHugh KE, Kim JS, Rubio A, Chía-Vazquez NG, Meador MR, Dyme JL, Reedy AM, Ajavon-Hartmann T, Jarugula P, Carlson-Taneja LE, Mills D, Wheaton O, Monagle P.
J Am Coll Cardiol. 2023 Dec 12;82(24):2296-2309. doi: 10.1016/j.jacc.2023.10.010.
PMID: 38057072
Titanium Dioxide (E171 Grade) and the Search For Replacement Opacifiers and Colorants: Supplier Readiness Survey, Case Studies and Regulatory Perspective.
Hancock B, Harris D, Kaye J, Meehan L, Melnick J, Tobyn M, Gibbard B, Grou J, Guarino CT, Halota M, Howard M, Marshall CL, Varghese S, Khaled H, Butterworth P.
J Pharm Sci. 2023 Dec 11:S0022-3549(23)00515-4. doi: 10.1016/j.xphs.2023.12.006. Online ahead of print.
PMID: 38092288
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML.
J Clin Oncol. 2023 Dec 10:JCO2302214. doi: 10.1200/JCO.23.02214. Online ahead of print.
PMID: 38072625
Meeting Report on the 3rd Chinese American Society for Mass Spectrometry Conference-Advancing Biological and Pharmaceutical Mass Spectrometry.
Chen H, Fu Y, Han M, Han X, Hao L, Huan T, Huang L, Huang M, Ji Q, Jiang T, Jiang Y, Li L, Li L, Liang X, Lih M, Lin Y, Liu X, Liu T, Liu Y, Ma S, Peng J, Qi YA, Qu J, Shou W, Sun L, Wang M, Wang S, Wu R, Wu S, Yan X, Yang J, Yang W, Yang Z, Yu Y, Zhang H, Zhang H, Zhao S, Zhu J, Zhu Y, Wang Y, Weng N.
Biomed Chromatogr. 2023 Dec 10:e5795. doi: 10.1002/bmc.5795. Online ahead of print.
PMID: 38071756
Inhibiting stromal Class I HDACs curbs pancreatic cancer progression.
Liang G, Oh TG, Hah N, Tiriac H, Shi Y, Truitt ML, Antal CE, Atkins AR, Li Y, Fraser C, Ng S, Pinto AFM, Nelson DC, Estepa G, Bashi S, Banayo E, Dai Y, Liddle C, Yu RT, Hunter T, Engle DD, Han H, Von Hoff DD, Downes M, Evans RM.
Nat Commun. 2023 Dec 6;14(1):7791. doi: 10.1038/s41467-023-42178-6.
PMID: 38057326
The discovery and evaluation of [ 18 F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement.
Donnelly DJ, Kim J, Tran T, Scola PM, Tenney D, Pena A, Petrone T, Zhang Y, Boy KM, Poss MA, Cole EL, Soars MG, Johnson BM, Cohen D, Batalla D, Chow PL, Shorts AO, Du S, Meanwell NA, Bonacorsi SJ Jr.
Eur J Nucl Med Mol Imaging. 2023 Dec 5. doi: 10.1007/s00259-023-06527-3. Online ahead of print.
PMID: 38049658
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Prabhala R, Pierceall WE, Samur M, Potluri LB, Hong K, Peluso T, Talluri S, Wang A, Katiki A, Vangala SD, Buonopane M, Bade V, Seah H, Krogman A, Derebail S, Fulciniti M, Lazo SB, Richardson P, Anderson K, Corre J, Avet-Loiseau H, Thakurta A, Munshi N.
Front Oncol. 2023 Dec 4;13:1271807. doi: 10.3389/fonc.2023.1271807. eCollection 2023.
PMID: 38111533
Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database.
Juge PA, Wemeau L, Ottaviani S, Desjeux G, Zhuo J, Vannier-Moreau V, Flipo RM, Crestani B, Dieudé P.
RMD Open. 2023 Dec 1;9(4):e003491. doi: 10.1136/rmdopen-2023-003491.
PMID: 38053461
Cloud security in a bioanalytical world: considerations for use of third-party cloud services for bioanalysis.
Davis S, Mitra-Kaushik S, Woolf E, Evens J, Dawes M, Kentner J, Subbarao N, Sundman P, Rusnak D.
Bioanalysis. 2023 Dec;15(24):1461-1468. doi: 10.4155/bio-2023-0164. Epub 2023 Dec 4.
PMID: 38044848
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
Borghaei H, O'Byrne KJ, Paz-Ares L, Ciuleanu TE, Yu X, Pluzanski A, Nagrial A, Havel L, Kowalyszyn RD, Valette CA, Brahmer JR, Reck M, Ramalingam SS, Zhang L, Ntambwe I, Rabindran SK, Nathan FE, Balli D, Wu YL.
ESMO Open. 2023 Dec;8(6):102065. doi: 10.1016/j.esmoop.2023.102065. Epub 2023 Nov 20.
PMID: 37988950
Risk profiles and incidence of cardiovascular events across different cancer types.
Mitchell JD, Laurie M, Xia Q, Dreyfus B, Jain N, Jain A, Lane D, Lenihan DJ.
ESMO Open. 2023 Dec;8(6):101830. doi: 10.1016/j.esmoop.2023.101830. Epub 2023 Nov 17.
PMID: 37979325
Understanding the lived experience of chronic pain: A systematic review and synthesis of qualitative evidence syntheses.
van Rysewyk S, Blomkvist R, Chuter A, Crighton R, Hodson F, Roomes D, Smith BH, Toye F.
Br J Pain. 2023 Dec;17(6):592-605. doi: 10.1177/20494637231196426. Epub 2023 Aug 25.
PMID: 37969135
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.
Wang C, Chen KN, Chen Q, Wu L, Wang Q, Li X, Ying K, Wang W, Zhao J, Liu L, Fu J, Zhang C, Liu J, Hu Y, Ntambwe I, Cai J, Bushong J, Tran P, Lu S.
ESMO Open. 2023 Dec;8(6):102040. doi: 10.1016/j.esmoop.2023.102040. Epub 2023 Nov 1.
PMID: 37922691
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
Merali S, Wang Z, Frost C, Meadows-Shropshire S, Hawthorne D, Yang J, Seiffert D.
Platelets. 2023 Dec;34(1):2222846. doi: 10.1080/09537104.2023.2222846.
PMID: 37394920
Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies.
Thai S, Zhuo J, Zhong Y, Xia Q, Chen X, Bao Y, Dhanda D, Priya L, Wu JJ.
J Dermatolog Treat. 2023 Dec;34(1):2176708. doi: 10.1080/09546634.2023.2176708.
PMID: 36794863
Current approaches to evaluate the function of cytotoxic T-cells in non-human primates.
Kamperschroer C, Frank B, Genell C, Lebrec H, Mitchell-Ryan S, Molinier B, Newsome C, Piche MS, Weinstock D, Collinge M, Freebern W, Rubio D.
J Immunotoxicol. 2023 Dec;20(1):2176952. doi: 10.1080/1547691X.2023.2176952.
PMID: 36788724
Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis.
Wu JJ, Wang CA, Jobson G, Davidson D, Kalirai S, Zhu J, Suryavanshi M, Mittal M, Patel V, Seigel L.
J Dermatolog Treat. 2023 Dec;34(1):2177095. doi: 10.1080/09546634.2023.2177095.
PMID: 36736349
Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.
Jing S, Lin Y, Dockens R, Marchisin D, He B, Girgis IG, Chimalakonda A, Murthy B, Aras U.
Dermatol Ther (Heidelb). 2023 Dec;13(12):3153-3164. doi: 10.1007/s13555-023-01050-7. Epub 2023 Nov 19.
PMID: 37981596
Evaluating stored platelet shape change using imaging flow cytometry.
Özpolat T, Yakovenko O, Stratiievska A, Bailey SL, Miles J, Usaneerungrueng C, Byrne D, Wu X, Stolla M.
Platelets. 2023 Dec;34(1):2136646. doi: 10.1080/09537104.2022.2136646. Epub 2022 Nov 2.
PMID: 36325604
Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolf DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen A, Charles L, Long M.
Clin Gastroenterol Hepatol. 2023 Nov 30:S1542-3565(23)00956-4. doi: 10.1016/j.cgh.2023.11.018. Online ahead of print.
PMID: 38040274
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, Tukachinsky H, Pratt J, Fusaro G, Oxnard GR, Green G, Fabrizio D, Baden J.
J Immunother Cancer. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339.
PMID: 38035725
Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice.
Ramos F, Hermosín ML, Fuertes-Núñez M, Martínez P, Rodriguez-Medina C, Barrios M, Ibáñez F, Bernal T, Olave MT, Álvarez MÁ, Vahí M, Caballero-Velázquez T, González B, Altés A, García L, Fernández P, Durán MA, López R, Rafel M, Serrano J.
J Pers Med. 2023 Nov 28;13(12):1667. doi: 10.3390/jpm13121667.
PMID: 38138894
Trends in cardiac rehabilitation rates among patients admitted for acute heart failure in Japan, 2009-2020.
Kim J, Jiang J, Shen S, Setoguchi S.
PLoS One. 2023 Nov 28;18(11):e0294844. doi: 10.1371/journal.pone.0294844. eCollection 2023.
PMID: 38015991
Propensity score-incorporated adaptive design approaches when incorporating real-world data.
Lu N, Chen WC, Li H, Song C, Tiwari R, Wang C, Xu Y, Yue LQ.
Pharm Stat. 2023 Nov 28. doi: 10.1002/pst.2347. Online ahead of print.
PMID: 38014753
Controlled synthesis of polycarbonate diols and their polylactide block copolymers using amino-bis(phenolate) chromium hydroxide complexes.
Ni K, Dawe LN, Sarjeant AA, Kozak CM.
Dalton Trans. 2023 Nov 28;52(46):17249-17257. doi: 10.1039/d3dt03168c.
PMID: 37966801
Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study.
Albigès L, Bellera C, Branchoux S, Arnaud M, Gouverneur A, Néré S, Gaudin AF, Durand-Zaleski I, Négrier S.
Clin Genitourin Cancer. 2023 Nov 24:S1558-7673(23)00263-X. doi: 10.1016/j.clgc.2023.11.012. Online ahead of print.
PMID: 38105152
Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.
Ammar D, Schapitz I, Luu M, Hudecek M, Meyer M, Taps T, Schröder B, Ivics Z, Sanges C, Franz P, Koehl U, Negre H, Johanna I, Awigena-Cook J.
Front Immunol. 2023 Nov 24;14:1280826. doi: 10.3389/fimmu.2023.1280826. eCollection 2023.
PMID: 38077331
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.
Alsuhebany N, Pan C, Holovac E, Do B, McBride A.
Blood Lymphat Cancer. 2023 Nov 24;13:67-76. doi: 10.2147/BLCTT.S426588. eCollection 2023.
PMID: 38034984
DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity.
Kureshi R, Bello E, Kureshi CTS, Walsh MJ, Lippert V, Hoffman MT, Dougan M, Longmire T, Wichroski M, Dougan SK.
Sci Adv. 2023 Nov 24;9(47):eadk1853. doi: 10.1126/sciadv.adk1853. Epub 2023 Nov 24.
PMID: 38000024
Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Passamonti F, Lou Y, Chevli M, Abraham P.
Future Oncol. 2023 Nov 22. doi: 10.2217/fon-2022-1256. Online ahead of print.
PMID: 37991002
Ligand-Enabled Carboamidation of Unactivated Alkenes through Enhanced Organonickel Electrophilicity.
Hwang Y, Wisniewski SR, Engle KM.
J Am Chem Soc. 2023 Nov 22;145(46):25293-25303. doi: 10.1021/jacs.3c08855. Epub 2023 Nov 8.
PMID: 37938051
The Association between Direct Oral Anticoagulants Prescribing Behavior and Non-Valvular Atrial Fibrillation Outcomes: An Instrumental Variable Analysis of Real-World Data.
Atreja N, Severtson SG, Jiang J, Gao C, Hines DM, Cheng D, Hagan M, Breeze JL, Paulus JK, Secemsky EA.
J Clin Med. 2023 Nov 20;12(22):7190. doi: 10.3390/jcm12227190.
PMID: 38002802
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Ballas L, Ailawadhi S, Narang M, Gasparetto CJ, Lee HC, Hardin JW, Durie BGM, Toomey K, Omel J, Wagner LI, Abonour R, Terebelo HR, Joshi P, Yu E, Liu L, Rifkin RM, Jagannath S.
Pract Radiat Oncol. 2023 Nov 19:S1879-8500(23)00300-4. doi: 10.1016/j.prro.2023.11.004. Online ahead of print.
PMID: 37984714
Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.
Xia H, Booth BP, Wang Y, Fan C, Bhatnagar V, Kluetz P, Fourie Zirkelbach J.
J Patient Rep Outcomes. 2023 Nov 17;7(1):116. doi: 10.1186/s41687-023-00651-2.
PMID: 37975967
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.
Chen Y, Wyatt D, Attanasio M, Thomas M, Thomas M, He B, Nishii R, Liu L, Shan V, Xue Y, Carayannopoulos LN, Ogasawara K, Krishna G.
Cancer Chemother Pharmacol. 2023 Nov 13. doi: 10.1007/s00280-023-04612-w. Online ahead of print.
PMID: 37955741
The Interplay of Permeability, Metabolism, Transporters, and Dosing in Determining the Dynamics of the Tissue/Plasma Partition Coefficient and Volume of Distribution-A Theoretical Investigation Using Permeability-Limited, Physiologically Based Pharmacokinetic Modeling.
Gaohua L, Zhang M, Sychterz C, Chang M, Schmidt BJ.
Int J Mol Sci. 2023 Nov 12;24(22):16224. doi: 10.3390/ijms242216224.
PMID: 38003416
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Ravandi F, Döhner H, Wei AH, Montesinos P, Pfeilstöcker M, Papayannidis C, Lai Y, Wang K, See WL, de Menezes DL, Petrlik E, Prebet T, Roboz GJ.
Br J Haematol. 2023 Nov 12. doi: 10.1111/bjh.19202. Online ahead of print.
PMID: 37952982
Selection of a statistical analysis method for the Glasgow Outcome Scale-Extended endpoint for estimating the probability of favorable outcome in future severe TBI clinical trials.
Wang Y, Yeatts SD, Martin RH, Silbergleit R, Rockswold GL, Barsan WG, Korley FK, Rockswold S, Gajewski BJ.
Stat Med. 2023 Nov 10;42(25):4582-4601. doi: 10.1002/sim.9877. Epub 2023 Aug 20.
PMID: 37599009
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy.
Friedberg JW, Bordoni RE, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia R, Cline VJM, Mamidipalli A, Liu J, Akyol A, Yasenchak C.
Blood. 2023 Nov 9:blood.2022019536. doi: 10.1182/blood.2022019536. Online ahead of print.
PMID: 37946283
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.
Jeyaraju DV, Alapa M, Polonskaia A, Risueño A, Subramanyam P, Anand A, Ghosh K, Kyriakopoulos C, Hemerich D, Hurren R, Wang X, Gronda M, Ahsan A, Chiu H, Thomas G, Lind EF, Menezes DL, Schimmer AD, Hagner PR, Gandhi A, Thakurta AG.
Haematologica. 2023 Nov 9. doi: 10.3324/haematol.2023.283437. Online ahead of print.
PMID: 37941406
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
Oriol A, Dimopoulos M, Schjesvold F, Beksac M, Facon T, Dhanasiri S, Guo S, Mu Y, Hong K, Gentili C, Galli M, Yagci M, Larocca A, Richardson P, Weisel K.
Clin Lymphoma Myeloma Leuk. 2023 Nov 8:S2152-2650(23)02157-2. doi: 10.1016/j.clml.2023.10.009. Online ahead of print.
PMID: 38072743
A mean-field description for the expansion kinetics of activated T cell populations.
Straube R, Schmidt BJ.
Proc Natl Acad Sci U S A. 2023 Nov 7;120(45):e2305774120. doi: 10.1073/pnas.2305774120. Epub 2023 Nov 1.
PMID: 37910551
Essential team science skills for biostatisticians on collaborative research teams.
Slade E, Brearley AM, Coles A, Hayat MJ, Kulkarni PM, Nowacki AS, Oster RA, Posner MA, Samsa G, Spratt H, Troy J, Pomann GM.
J Clin Transl Sci. 2023 Nov 6;7(1):e243. doi: 10.1017/cts.2023.676. eCollection 2023.
PMID: 38033706
Gene-educational attainment interactions in a multi-population genome-wide meta-analysis identify novel lipid loci.
de Las Fuentes L, Schwander KL, Brown MR, Bentley AR, Winkler TW, Sung YJ, Munroe PB, Miller CL, Aschard H, Aslibekyan S, Bartz TM, Bielak LF, Chai JF, Cheng CY, Dorajoo R, Feitosa MF, Guo X, Hartwig FP, Horimoto A, Kolčić I, Lim E, Liu Y, Manning AK, Marten J, Musani SK, Noordam R, Padmanabhan S, Rankinen T, Richard MA, Ridker PM, Smith AV, Vojinovic D, Zonderman AB, Alver M, Boissel M, Christensen K, Freedman BI, Gao C, Giulianini F, Harris SE, He M, Hsu FC, Kühnel B, Laguzzi F, Li X, Lyytikäinen LP, Nolte IM, Poveda A, Rauramaa R, Riaz M, Robino A, Sofer T, Takeuchi F, Tayo BO, van der Most PJ, Verweij N, Ware EB, Weiss S, Wen W, Yanek LR, Zhan Y, Amin N, Arking DE, Ballantyne C, Boerwinkle E, Brody JA, Broeckel U, Campbell A, Canouil M, Chai X, Chen YI, Chen X, Chitrala KN, Concas MP, de Faire U, de Mutsert R, de Silva HJ, de Vries PS, Do A, Faul JD, Fisher V, Floyd JS, Forrester T, Friedlander Y, Girotto G, Gu CC, Hallmans G, Heikkinen S, Heng CK, Homuth G, Hunt S, Ikram MA, Jacobs DR Jr, Kavousi M, Khor CC, Kilpeläinen TO, Koh WP, Komulainen P, Langefeld CD, Liang J, Liu K, Liu J, Lohman K, Mägi R, Manichaikul AW, McKenzie CA, Meitinger T, Milaneschi Y, Nauck M, Nelson CP, O… See abstract for full author list ➔
Front Genet. 2023 Nov 2;14:1235337. doi: 10.3389/fgene.2023.1235337. eCollection 2023.
PMID: 38028628
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Rosiñol L, Hebraud B, Oriol A, Colin AL, Ríos Tamayo R, Hulin C, Blanchard MJ, Caillot D, Sureda A, Hernández MT, Arnulf B, Mateos MV, Macro M, San-Miguel J, Belhadj K, Lahuerta JJ, Garelik MB, Bladé J, Moreau P.
Front Oncol. 2023 Nov 2;13:1197340. doi: 10.3389/fonc.2023.1197340. eCollection 2023.
PMID: 38023148
Covalent Degrader of the Oncogenic Transcription Factor β-Catenin.
Gowans FA, Forte N, Hatcher J, Huang OW, Wang Y, Poblano BEA, Wertz IE, Nomura DK.
bioRxiv. 2023 Nov 2:2023.10.31.565018. doi: 10.1101/2023.10.31.565018. Preprint.
PMID: 37961622
Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation.
Hong SH, Osa A, Huang OW, Wertz IE, Nomura DK.
bioRxiv. 2023 Nov 2:2023.10.20.563371. doi: 10.1101/2023.10.20.563371. Preprint.
PMID: 37904950
Proteomic Correlates of the Urinary Protein/Creatinine Ratio in Heart Failure With Preserved Ejection Fraction.
Gan S, Zhao L, Salman O, Wang Z, Ebert C, Azzo JD, Dib MJ, Zamani P, Cohen JB, Kammerhoff K, Schafer P, Seiffert DA, Ramirez-Valle F, Gordon DA, Cvijic ME, Gunawardhana K, Liu L, Chang CP, Cappola TP, Chirinos JA.
Am J Cardiol. 2023 Nov 1;206:312-319. doi: 10.1016/j.amjcard.2023.08.146. Epub 2023 Sep 19.
PMID: 37734292
The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development.
Moore KT, Zannikos PN, Masters JC, Willmann S, Shen J, Frost C.
J Clin Pharmacol. 2023 Nov;63 Suppl 2:S78-S84. doi: 10.1002/jcph.2361.
PMID: 37942912
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
Armstrong AW, Park SH, Patel V, Hogan M, Wang WJ, Davidson D, Chirikov V.
Dermatol Ther (Heidelb). 2023 Nov;13(11):2605-2607. doi: 10.1007/s13555-023-01043-6.
PMID: 37853229
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW, Warren RB, Zhong Y, Zhuo J, Cichewicz A, Kadambi A, Junqueira D, Westley T, Kisa R, Daamen C, Augustin M.
Dermatol Ther (Heidelb). 2023 Nov;13(11):2839-2857. doi: 10.1007/s13555-023-01034-7. Epub 2023 Oct 6.
PMID: 37801281
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal JA, Lai Y, Vodala S, Rosettani B, Giuseppi AC, Yucel A, Fenaux P.
Leukemia. 2023 Nov;37(11):2314-2318. doi: 10.1038/s41375-023-02031-7. Epub 2023 Sep 26.
PMID: 37752285
Dynamic Regulatory Assessment: Unpacking the Process Reveals Readiness to Pilot for Europe-An EFPIA View.
Todd I, Faust R, Herrero-Martinez E, Hussain N, Kawinski A, Lennard A, Roux NL, Macdonald J, Mayer M, Palacios R, Dangy-Caye A.
Clin Ther. 2023 Nov;45(11):1142-1147. doi: 10.1016/j.clinthera.2023.08.006. Epub 2023 Sep 11.
PMID: 37704457
Azacitidine (Vidaza ® ) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).
Rubio-San-Simón A, van Eijkelenburg NKA, Hoogendijk R, Hasle H, Niemeyer CM, Dworzak MN, Zecca M, Lopez-Yurda M, Janssen JM, Huitema ADR, van den Heuvel-Eibrink MM, Laille EJ, van Tinteren H, Zwaan CM.
Paediatr Drugs. 2023 Nov;25(6):719-728. doi: 10.1007/s40272-023-00588-5. Epub 2023 Sep 11.
PMID: 37695474
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure.
Davies FE, Leleu X, Vogel P, Dhanasiri S, Le Nouveau P, Weisel K.
Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):829-837.e1. doi: 10.1016/j.clml.2023.07.010. Epub 2023 Aug 6.
PMID: 37684184
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS, Smithy JW, Li Y, Zhuang M, Maher CA, Aleynick N, Peng X, Al-Ahmadie H, Funt SA, Rosenberg JE, Iyer G, Bajorin D, Mathews JC, Nadeem S, Panageas KS, Shen R, Callahan MK, Hollmann TJ.
J Pathol. 2023 Nov;261(3):349-360. doi: 10.1002/path.6197. Epub 2023 Sep 5.
PMID: 37667855
Metabolism and Excretion of Therapeutic Peptides: Current Industry Practices, Perspectives, and Recommendations.
He MM, Zhu SX, Cannon JR, Christensen JK, Duggal R, Gunduz M, Hilgendorf C, Hughes A, Kekessie I, Kullmann M, Leung D, Terjung C, Wang K, Wesche F.
Drug Metab Dispos. 2023 Nov;51(11):1436-1450. doi: 10.1124/dmd.123.001437. Epub 2023 Aug 17.
PMID: 37591731
Complex peptide macrocycle optimization: combining NMR restraints with conformational analysis to guide structure-based and ligand-based design.
Jain AN, Brueckner AC, Jorge C, Cleves AE, Khandelwal P, Cortes JC, Mueller L.
J Comput Aided Mol Des. 2023 Nov;37(11):519-535. doi: 10.1007/s10822-023-00524-2. Epub 2023 Aug 3.
PMID: 37535171
Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD, Di Fusco M, Keshishian A, Delinger R, Ferri M, Jiang J, Seigel L, Yuce H, Guo JD.
J Thromb Thrombolysis. 2023 Nov;56(4):626-634. doi: 10.1007/s11239-023-02855-1. Epub 2023 Aug 2.
PMID: 37530954
Cortical laminar necrosis mimicking leptomeningeal recurrence in a child with medulloblastoma and epilepsy.
Mironova D, Benjamin P, Zacharoulis S, Stapleton S, Bridges LR, Jacques TS, Mandeville H, Carceller F.
Pediatr Blood Cancer. 2023 Nov;70(11):e30641. doi: 10.1002/pbc.30641. Epub 2023 Aug 29.
PMID: 37644658
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.
Provencio M, Carcereny E, López Castro R, Calvo V, Rodríguez Abreu D, Cobo M, Ortega AL, Bernabé R, Guirado M, Massutí B, Del Barco-Morillo E, Bosch-Barrera J, Camps C, Carroll R, Rault C, Chaib C, Penrod J, Vo L, Ralphs E, Daumont MJ.
Transl Lung Cancer Res. 2023 Oct 31;12(10):2113-2128. doi: 10.21037/tlcr-23-176. Epub 2023 Oct 27.
PMID: 38025806
Real-world evidence for regulatory decision-making: updated guidance from around the world.
Burns L, Le Roux N, Kalesnik-Orszulak R, Christian J, Dudinak J, Rockhold F, Khozin S, O'Donnell J.
Front Med (Lausanne). 2023 Oct 30;10:1236462. doi: 10.3389/fmed.2023.1236462. eCollection 2023.
PMID: 38020096
Reproductive justice advocacy efforts among genetic counselors and family planning providers.
Johnstonbaugh HZ, Lee JK, Semesky P, Sagaser KG.
J Genet Couns. 2023 Oct 25. doi: 10.1002/jgc4.1806. Online ahead of print.
PMID: 37877499
Snap-on Adaptor for Microtiter Plates to Enable Continuous-Flow Microfluidic Screening and Harvesting of Crystalline Materials.
Coliaie P, Bhawnani RR, Ali R, Kelkar MS, Korde A, Langston M, Liu C, Nazemifard N, Patience DB, Rosenbaum T, Skliar D, Nere NK, Singh MR.
ACS Omega. 2023 Oct 23;8(44):41502-41511. doi: 10.1021/acsomega.3c05478. eCollection 2023 Nov 7.
PMID: 37969966
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia.
Klink AJ, Keating SJ, Brokars J, Feinberg B, Jabbour E.
Clin Lymphoma Myeloma Leuk. 2023 Oct 20:S2152-2650(23)02149-3. doi: 10.1016/j.clml.2023.10.005. Online ahead of print.
PMID: 38135632
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, Sznol M, Franke F, Ciuleanu TE, Pereira C, Muñoz Couselo E, Bronzon Damian F, Schenker M, Perfetti A, Lebbe C, Quéreux G, Meier F, Curti BD, Rojas C, Arriaga Y, Yang H, Zhou M, Ravimohan S, Statkevich P, Tagliaferri MA, Khushalani NI.
J Clin Oncol. 2023 Oct 20;41(30):4756-4767. doi: 10.1200/JCO.23.00172. Epub 2023 Aug 31.
PMID: 37651676
Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.
Siontis KC, Abreau S, Attia ZI, Barrios JP, Dewland TA, Agarwal P, Balasubramanyam A, Li Y, Lester SJ, Masri A, Wang A, Sehnert AJ, Edelberg JM, Abraham TP, Friedman PA, Olgin JE, Noseworthy PA, Tison GH.
JACC Adv. 2023 Oct;2(8):100582. doi: 10.1016/j.jacadv.2023.100582. Epub 2023 Sep 13.
PMID: 38076758
Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma.
Toner K, Allen CE, Jain S, Kahl B, Leonard J, Wasserstrom H, Friedberg JW, Seibel NL, Kelly K.
EJHaem. 2023 Sep 7;4(4):921-926. doi: 10.1002/jha2.787. eCollection 2023 Nov.
PMID: 38024612
Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39.
Campagne S, Jutzi D, Malard F, Matoga M, Romane K, Feldmuller M, Colombo M, Ruepp MD, Allain FH.
Nat Commun. 2023 Sep 4;14(1):5366. doi: 10.1038/s41467-023-40254-5.
PMID: 37666821
Development and validation of a psoriasis treatment acceptability measure through group concept mapping.
Hudgens S, Howerter A, Keith S, Evans C, Pelletier C.
Health Qual Life Outcomes. 2023 Aug 8;21(1):83. doi: 10.1186/s12955-023-02162-6.
PMID: 37553594
Refinement of Multiconformer Ensemble Models from Multi-temperature X-ray Diffraction Data.
Du S, Wankowicz SA, Yabukarski F, Doukov T, Herschlag D, Fraser JS.
bioRxiv. 2023 May 5:2023.05.05.539620. doi: 10.1101/2023.05.05.539620. Preprint.
PMID: 37205593
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.
Conaghan PG, Nowak M, Du S, Luo Y, Landis J, Pachai C, Fura A, Catlett IM, Grasela DM, Østergaard M.
Lancet Rheumatol. 2023 May;5(5):e263-e273. doi: 10.1016/S2665-9913(23)00089-9.
PMID: 38251590
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob JJ, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA.
NEJM Evid. 2023 Apr;2(4):EVIDoa2200239. doi: 10.1056/EVIDoa2200239. Epub 2023 Mar 22.
PMID: 38320023
Mass Spectrometry-Based Approaches for the Analysis of Protein Higher Order Structure.
Liu XR, Huang Y.
J Vis Exp. 2023 Mar 3;(193). doi: 10.3791/64979.
PMID: 37602868
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach.
Chien HT, Prior H, Andrews L, van Aerts L, Cauvin A, Clarke DO, Datta K, Dempster M, Dybdal N, Freebern W, de Haan L, Herzyk D, Hey A, Kissner T, Kronenberg S, Leach MW, Lee D, Schutte K, Sewell F, Trouba K, Ulrich P, Weir L, van Meer P.
Regul Toxicol Pharmacol. 2023 Feb;138:105329. doi: 10.1016/j.yrtph.2022.105329. Epub 2022 Dec 30.
PMID: 36592682
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Lee HC, Ramasamy K, Weisel K, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Terebelo HR, Durie BGM, Tang D, Joshi P, Liu L, Jou YM, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner LI, Jagannath S.
Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):112-122. doi: 10.1016/j.clml.2022.11.008. Epub 2022 Nov 23.
PMID: 36567211
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Deitelzweig S, Keshishian A, Kang A, Jenkins A, Atreja N, Schuler P, Jiang J, Yuce H, Sun X, Lip GYH.
Eur J Intern Med. 2023 Feb;108:37-42. doi: 10.1016/j.ejim.2022.10.021. Epub 2022 Nov 28.
PMID: 36456387
Physicians' experience in blood supply shortages and the top factors that impact the clinical, economic, and humanistic outcomes of patients with myelodysplastic syndromes in 5 European countries.
Gupta S, Kulasekararaj AG, Costantino H, Grisolano J, Tang J, Jones S, Tang D.
Curr Med Res Opin. 2023 Feb;39(2):239-247. doi: 10.1080/03007995.2022.2151735. Epub 2022 Dec 7.
PMID: 36453466
An Intercompany Perspective on Practical Experiences of Predicting, Optimizing and Analyzing High Concentration Biologic Therapeutic Formulations.
Desai PG, Garidel P, Gbormittah FO, Kamen DE, Mills BJ, Narasimhan CN, Singh S, Stokes ESE, Walsh ER.
J Pharm Sci. 2023 Feb;112(2):359-369. doi: 10.1016/j.xphs.2022.11.020. Epub 2022 Nov 25.
PMID: 36442683
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares LG, Gainor JF, Ahmed S, Reck M, Maio M, O'Byrne KJ, Memaj A, Nathan F, Tran P, Hellmann MD, Brahmer JR.
Ann Oncol. 2023 Feb;34(2):173-185. doi: 10.1016/j.annonc.2022.11.006. Epub 2022 Nov 19.
PMID: 36414192
SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma.
Leeksma AC, Derks IAM, Garrick B, Jongejan A, Colombo M, Bloedjes T, Trowe T, Leisten JC, Howarth M, Malek M, Mortensen DS, Blease K, Groza MC, Narla RK, Loos R, Kersten MJ, Moerland PD, Guikema JEJ, Kater AP, Eldering E, Filvaroff EH.
Mol Oncol. 2023 Feb;17(2):284-297. doi: 10.1002/1878-0261.13343. Epub 2022 Dec 16.
PMID: 36400430
Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics.
Grimaldi C, Ibraghimov A, Kiessling A, Rattel B, Ji C, Fuller CL, Brennan FR, Regenass-Lechner F, Shenton J, Price KD, Piché MS, Steeves MA, Prell R, Dudal S, Kronenberg S, Freebern W, Blanset D.
Drug Discov Today. 2023 Feb;28(2):103440. doi: 10.1016/j.drudis.2022.103440. Epub 2022 Nov 12.
PMID: 36375739
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S.
Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11.
PMID: 36369798
Development of UV-Vis Imaging Compatible Chromatographic Matrix with Application for Injectable Formulation Characterization.
Bock F, Hu A, Cicale V, Larsen SW, Lu X, Østergaard J.
Anal Chem. 2023 Oct 31;95(43):15861-15866. doi: 10.1021/acs.analchem.3c03648. Epub 2023 Oct 19.
PMID: 37857348
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Deutsch JS, Cimino-Mathews A, Thompson E, Provencio M, Forde PM, Spicer J, Girard N, Wang D, Anders RA, Gabrielson E, Illei P, Jedrych J, Danilova L, Sunshine J, Kerr KM, Tran M, Bushong J, Cai J, Devas V, Neely J, Balli D, Cottrell TR, Baras AS, Taube JM.
Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660-6. Online ahead of print.
PMID: 37903504
Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: A retrospective cohort study.
Wang Y, Gao W, Han X, Jiang J, Sandler B, Li X, Zema C.
J Med Econ. 2023 Oct 30:1-16. doi: 10.1080/13696998.2023.2277076. Online ahead of print.
PMID: 37902966
An integrated approach for early in vitro seizure prediction utilizing hiPSC neurons and human ion channel assays.
Rockley K, Roberts R, Jennings H, Jones K, Davis M, Levesque P, Morton M.
Toxicol Sci. 2023 Oct 30;196(1):126-140. doi: 10.1093/toxsci/kfad087.
PMID: 37632788
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, Purev E, Maloney DG, Andreadis CB, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T.
Blood. 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854. Online ahead of print.
PMID: 37890149
Molecular complexes of drug combinations: a review of cocrystals, salts, coamorphous systems and amorphous solid dispersions.
Li J, Wang X, Yu D, Zhoujin Y, Wang K.
Int J Pharm. 2023 Oct 25:123555. doi: 10.1016/j.ijpharm.2023.123555. Online ahead of print.
PMID: 37890646
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity.
Wichroski M, Benci J, Liu SQ, Chupak L, Fang J, Cao C, Wang C, Onorato J, Qiu H, Shan Y, Banas D, Powles R, Locke G, Witt A, Stromko C, Qi H, Zheng X, Martin S, Ding M, Gentles R, Meanwell N, Velaparthi U, Olson R, Wee S, Tenney D, Parker CG, Cravatt BF, Lawrence M, Borzilleri R, Lees E.
Sci Transl Med. 2023 Oct 25;15(719):eadh1892. doi: 10.1126/scitranslmed.adh1892. Epub 2023 Oct 25.
PMID: 37878674
Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use.
Marquez L, Raheja R, Chan-Liston M, Marcinak J, Estilo A, Pineda Salgado L, Jiang J, Chang C, Beninger P.
Drug Saf. 2023 Oct 24. doi: 10.1007/s40264-023-01360-x. Online ahead of print.
PMID: 37874451
Cereblon influences the timing of muscle differentiation in  Ciona  tadpoles.
Long J, Mariossi A, Cao C, Mo Z, Thompson JW, Levine MS, Lemaire LA.
Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2309989120. doi: 10.1073/pnas.2309989120. Epub 2023 Oct 19.
PMID: 37856545
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM, Bröckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trněný M, Provencio M, Jäger U, Willenbacher W, Wen R, Akyol A, Mikita-Geoffroy J, Shipp MA, Engert A, Armand P.
Blood Adv. 2023 Oct 24;7(20):6266-6274. doi: 10.1182/bloodadvances.2023010334.
PMID: 37530622
Assessing the Content Validity of Preference-Based Measures in Cancer.
Gibson A, Longworth L, Bennett B, Pickard AS, Shaw JW.
Value Health. 2023 Oct 23:S1098-3015(23)06152-1. doi: 10.1016/j.jval.2023.10.006. Online ahead of print.
PMID: 37879402
Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.
Du S, Zhao Y, Hu Z, Liu S, Roy A, Shen J, Zhu L, Hamuro L.
CPT Pharmacometrics Syst Pharmacol. 2023 Oct 23. doi: 10.1002/psp4.13070. Online ahead of print.
PMID: 37873561
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF, Huang Y, Lance JR, Mao HCC, Dunbar A, McNulty S, Druley TE, Li Y, Baer MR, Stock W, Kovacsovics T, Blum W, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Boyiadzis M, Collins RH Jr, Chervin J, Shoben AB, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM.
Blood Adv. 2023 Oct 23:bloodadvances.2023010563. doi: 10.1182/bloodadvances.2023010563. Online ahead of print.
PMID: 37871309
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators.
N Engl J Med. 2023 Oct 22. doi: 10.1056/NEJMoa2309863. Online ahead of print.
PMID: 37870949
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J.
BMJ. 2023 Oct 20;383:e076386. doi: 10.1136/bmj-2023-076386.
PMID: 37863491
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ.
BMJ. 2023 Oct 20;383:e076387. doi: 10.1136/bmj-2023-076387.
PMID: 37863501
Stereocontrolled access to thioisosteres of nucleoside di- and triphosphates.
Zhang HJ, Ociepa M, Nassir M, Zheng B, Lewicki SA, Salmaso V, Baburi H, Nagel J, Mirza S, Bueschbell B, Al-Hroub H, Perzanowska O, Lin Z, Schmidt MA, Eastgate MD, Jacobson KA, Müller CE, Kowalska J, Jemielity J, Baran PS.
Nat Chem. 2023 Oct 19. doi: 10.1038/s41557-023-01347-2. Online ahead of print.
PMID: 37857844
Deoxyfluorination of 1°, 2°, and 3° Alcohols by Nonbasic O-H Activation and Lewis Acid-Catalyzed Fluoride Shuttling.
Moon HW, Lavagnino MN, Lim S, Palkowitz MD, Mandler MD, Beutner GL, Drance MJ, Lipshultz JM, Scola PM, Radosevich AT.
J Am Chem Soc. 2023 Oct 18;145(41):22735-22744. doi: 10.1021/jacs.3c08373. Epub 2023 Oct 9.
PMID: 37812176
The best of both worlds: Blending cutting-edge research with clinical processes for a productive exome clinic.
Sullivan JA, Spillmann RC, Schoch K, Walley N, Alkelai A, Stong N, Shea PR, Petrovski S, Jobanputra V, McConkie-Rosell A, Shashi V.
Clin Genet. 2023 Oct 18. doi: 10.1111/cge.14437. Online ahead of print.
PMID: 37853563
A Paradigm Shift in Catalysis: Electro- and Photomediated Nickel-Catalyzed Cross-Coupling Reactions.
Palkowitz MD, Emmanuel MA, Oderinde MS.
Acc Chem Res. 2023 Oct 17;56(20):2851-2865. doi: 10.1021/acs.accounts.3c00479. Epub 2023 Sep 29.
PMID: 37772915
Best Practices for Microbial Challenge In-use Studies to Evaluate the Microbial Growth Potential of Parenteral Biological Products; Industry and Regulatory Considerations.
Zamiri C, Leiske DL, Hughes PF, Kirwan JP, Der E, Cox E, Warburton R, Goss M, Weiser S, Perez-Brown J, Gopalrathnam G, Liu J, Mehta SB, Shereefa S, Specht S, Aedo SJ, Goldbach P, Jia F, Kuehnle B, Page S, Voeten L, Yi L, Zhu C.
PDA J Pharm Sci Technol. 2023 Oct 17:pdajpst.2022.012806. doi: 10.5731/pdajpst.2022.012806. Online ahead of print.
PMID: 37848203
Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study.
Morimoto T, Hoshino H, Matsuo Y, Ibuki T, Miyata K, Koretsune Y.
Am J Cardiovasc Drugs. 2023 Oct 17. doi: 10.1007/s40256-023-00611-7. Online ahead of print.
PMID: 37847442
Acquired CD38 Gene Deletion as a Mechanism of Tumor Antigen Escape in Multiple Myeloma.
Portuguese AJ, Fang M, Tuazon SA, Pont M, Qu X, Shasha C, Comstock ML, Lyons J, Cole G, Newell EW, Glynn E, Soma LA, Green DJ.
Blood Adv. 2023 Oct 16:bloodadvances.2023011295. doi: 10.1182/bloodadvances.2023011295. Online ahead of print.
PMID: 37844282
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV.
Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583-2. Online ahead of print.
PMID: 37845511
Reproducibility and Robustness of a Liver Microphysiological System PhysioMimix LC12 under Varying Culture Conditions and Cell Type Combinations.
Lim AY, Kato Y, Sakolish C, Valdiviezo A, Han G, Bajaj P, Stanko J, Ferguson SS, Villenave R, Hewitt P, Hardwick RN, Rusyn I.
Bioengineering (Basel). 2023 Oct 14;10(10):1195. doi: 10.3390/bioengineering10101195.
PMID: 37892925
Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation.
Fujimoto H, Fukuzato S, Kanno K, Akutsu T, Ohdaira H, Suzuki Y, Urashima M.
Nutrients. 2023 Oct 13;15(20):4361. doi: 10.3390/nu15204361.
PMID: 37892436
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
Wang A, Spertus JA, Wojdyla DM, Abraham TP, Nilles EK, Owens AT, Saberi S, Cresci S, Sehnert A, Lakdawala NK.
JACC Heart Fail. 2023 Oct 12:S2213-1779(23)00522-X. doi: 10.1016/j.jchf.2023.07.030. Online ahead of print.
PMID: 37855754
Changes in the cis-trans isomer selectivity of a reversed-phase liquid chromatography column during use with acidic mobile phase conditions.
Dahlseid T, Florea A, Schulte G, Cash K, Xu X, Tattersall P, Wang Q, Stoll D.
J Chromatogr A. 2023 Oct 11;1708:464371. doi: 10.1016/j.chroma.2023.464371. Epub 2023 Sep 7.
PMID: 37725873
Non-contact Laser Interferometer Method to Characterize Tablet Punches: New Methodology to Assess Surface Roughness.
Hughes H, Leane M, Wray PS, Tobyn M.
AAPS PharmSciTech. 2023 Oct 10;24(7):209. doi: 10.1208/s12249-023-02664-y.
PMID: 37817056
Delayed Solid Tumor Presentations in Adolescent and Young Adults Patients in the Bronx.
Offenbacher R, Norris S, Loeb DM, Levy A.
J Adolesc Young Adult Oncol. 2023 Oct 9. doi: 10.1089/jayao.2023.0078. Online ahead of print.
PMID: 37870570
Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development.
Tomlinson L, Ramsden D, Leite SB, Beken S, Bonzo JA, Brown P, Candarlioglu PL, Chan TS, Chen E, Choi CK, David R, Delrue N, Devine PJ, Ford K, Garcia MI, Gosset JR, Hewitt P, Homan K, Irrechukwu O, Kopec AK, Liras JL, Mandlekar S, Raczynski A, Sadrieh N, Sakatis MZ, Siegel J, Sung K, Sunyovszki I, Van Vleet TR, Ekert JE, Hardwick RN.
Adv Biol (Weinh). 2023 Oct 9:e2300131. doi: 10.1002/adbi.202300131. Online ahead of print.
PMID: 37814378
Characteristics, management, and healthcare resources of patients with advanced non-small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis.
Assié JB, Grumberg V, Reynaud D, Gaudin AF, Batisse A, Jolivel R, Jouaneton B, Cotté FE, Chouaïd C.
Respir Med Res. 2023 Oct 6;84:101051. doi: 10.1016/j.resmer.2023.101051. Online ahead of print.
PMID: 37897879
Can we collect health-related quality of life information from anticoagulated atrial fibrillation participants who have recently experienced a bleed? An observational feasibility study in primary and secondary care in Wales and through a UK online forum.
Hutchings HA, Lanyon KJ, Holland G, Alikhan R, Jenkins R, Laing H, Hughes A, Lobban T, Pollock K, Tod D, Lister S.
BMJ Open. 2023 Oct 6;13(10):e075335. doi: 10.1136/bmjopen-2023-075335.
PMID: 37802619
Promoting Catalytic  C -Selective Sulfonylation of Cyclopropanols against Conventional  O -Sulfonylation Using Readily Available Sulfonyl Chlorides.
Ramar T, Ilangovan A, A M Subbaiah M.
J Org Chem. 2023 Oct 6;88(19):13553-13567. doi: 10.1021/acs.joc.3c01230. Epub 2023 Sep 14.
PMID: 37708032
Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility.
Mazaheri M, Saggu M, Wuchner K, Koulov AV, Nikels F, Chalus P, Das TK, Cash PW, Finkler C, Levitskaya-Seaman SV, Case J, Parsons J, Gonzalez K.
J Pharm Sci. 2023 Oct 5:S0022-3549(23)00411-2. doi: 10.1016/j.xphs.2023.10.002. Online ahead of print.
PMID: 37802369
Antiplatelet Treatment Patterns and Outcomes for Secondary Stroke Prevention in the United Kingdom.
Liu X, Jiang J, Li D, Horrow J, Tamada H, Kahl A, Hariharan V, Avinav A, Li X.
Cardiol Ther. 2023 Oct 4. doi: 10.1007/s40119-023-00332-7. Online ahead of print.
PMID: 37789237
Complex molecule synthesis by electrocatalytic decarboxylative cross-coupling.
Zhang B, He J, Gao Y, Levy L, Oderinde MS, Palkowitz MD, Dhar TGM, Mandler MD, Collins MR, Schmitt DC, Bolduc PN, Chen T, Clementson S, Petersen NN, Laudadio G, Bi C, Kawamata Y, Baran PS.
Nature. 2023 Oct 3. doi: 10.1038/s41586-023-06677-2. Online ahead of print.
PMID: 37788684
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Mudarris L, Gong Z, Lampl K, Sehnert AJ, Nissen SE.
JAMA Cardiol. 2023 Oct 1;8(10):968-977. doi: 10.1001/jamacardio.2023.3342.
PMID: 37639243
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
Baumgartner CK, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel KM, Olander KE, Davis TGR, McGuire KA, Halvorsen GT, Avila OI, Patel CH, Kim SY, Kammula AV, Muscato AJ, Halliwill K, Geda P, Klinge KL, Xiong Z, Duggan R, Mu L, Yeary MD, Patti JC, Balon TM, Mathew R, Backus C, Kennedy DE, Chen A, Longenecker K, Klahn JT, Hrusch CL, Krishnan N, Hutchins CW, Dunning JP, Bulic M, Tiwari P, Colvin KJ, Chuong CL, Kohnle IC, Rees MG, Boghossian A, Ronan M, Roth JA, Wu MJ, Suermondt JSMT, Knudsen NH, Cheruiyot CK, Sen DR, Griffin GK, Golub TR, El-Bardeesy N, Decker JH, Yang Y, Guffroy M, Fossey S, Trusk P, Sun IM, Liu Y, Qiu W, Sun Q, Paddock MN, Farney EP, Matulenko MA, Beauregard C, Frost JM, Yates KB, Kym PR, Manguso RT.
Nature. 2023 Oct;622(7984):850-862. doi: 10.1038/s41586-023-06575-7. Epub 2023 Oct 4.
PMID: 37794185
Plasma proteomic associations with genetics and health in the UK Biobank.
Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, Surendran P, Mahajan A, Robins C, Vasquez-Grinnell SG, Hou L, Kvikstad EM, Burren OS, Davitte J, Ferber KL, Gillies CE, Hedman ÅK, Hu S, Lin T, Mikkilineni R, Pendergrass RK, Pickering C, Prins B, Baird D, Chen CY, Ward LD, Deaton AM, Welsh S, Willis CM, Lehner N, Arnold M, Wörheide MA, Suhre K, Kastenmüller G, Sethi A, Cule M, Raj A; Alnylam Human Genetics; AstraZeneca Genomics Initiative; Biogen Biobank Team; Bristol Myers Squibb; Genentech Human Genetics; GlaxoSmithKline Genomic Sciences; Pfizer Integrative Biology; Population Analytics of Janssen Data Sciences; Regeneron Genetics Center; Burkitt-Gray L, Melamud E, Black MH, Fauman EB, Howson JMM, Kang HM, McCarthy MI, Nioi P, Petrovski S, Scott RA, Smith EN, Szalma S, Waterworth DM, Mitnaul LJ, Szustakowski JD, Gibson BW, Miller MR, Whelan CD.
Nature. 2023 Oct;622(7982):329-338. doi: 10.1038/s41586-023-06592-6. Epub 2023 Oct 4.
PMID: 37794186
DMD-Associated Dilated Cardiomyopathy: Genotypes, Phenotypes, and Phenocopies.
Johnson R, Otway R, Chin E, Horvat C, Ohanian M, Wilcox JAL, Su Z, Prestes P, Smolnikov A, Soka M, Guo G, Rath E, Chakravorty S, Chrzanowski L, Hayward CS, Keogh AM, Macdonald PS, Giannoulatou E, Chang ACY, Oates EC, Charchar F, Seidman JG, Seidman CE, Hegde M, Fatkin D.
Circ Genom Precis Med. 2023 Oct;16(5):421-430. doi: 10.1161/CIRCGEN.123.004221. Epub 2023 Sep 6.
PMID: 37671549
Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review.
Sparks JA, Harrold LR, Simon TA, Wittstock K, Kelly S, Lozenski K, Khaychuk V, Michaud K.
Semin Arthritis Rheum. 2023 Oct;62:152249. doi: 10.1016/j.semarthrit.2023.152249. Epub 2023 Aug 6.
PMID: 37573754
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.
Cree BAC, Maddux R, Bar-Or A, Hartung HP, Kaur A, Brown E, Li Y, Hu Y, Sheffield JK, Silva D, Harris S.
Ann Clin Transl Neurol. 2023 Oct;10(10):1725-1737. doi: 10.1002/acn3.51862. Epub 2023 Aug 7.
PMID: 37550942
Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.
Wu F, Liu L, Gaudy A, Wang X, Carayannopoulos L, Pourdehnad M, Lamba M.
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1473-1484. doi: 10.1002/psp4.13024. Epub 2023 Sep 13.
PMID: 37705327
Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment.
Qosa H, de Oliveira CHMC, Cizza G, Lawitz EJ, Colletti N, Wetherington J, Charles ED, Tirucherai GS.
Clin Transl Sci. 2023 Oct;16(10):1791-1802. doi: 10.1111/cts.13581. Epub 2023 Aug 31.
PMID: 37654022
Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory.
Gervais A, Dirksen EHC, Pohl T, Bechtold-Peters K, Burkitt W, D'Alessio V, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer JW, Spencer D, Xu W, Yi L.
Eur J Pharm Biopharm. 2023 Oct;191:57-67. doi: 10.1016/j.ejpb.2023.08.008. Epub 2023 Aug 13.
PMID: 37582411
Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans.
Chimalakonda A, Li W, Marchisin D, He B, Singhal S, Deshpande P, Brown J, Aras U, Murthy B.
Clin Pharmacol Drug Dev. 2023 Oct;12(10):956-965. doi: 10.1002/cpdd.1308. Epub 2023 Aug 16.
PMID: 37587797
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
McGarvey N, Ung B, Carattini T, Imanak K, Lee A, Campbell TB, Patwardhan P.
Adv Ther. 2023 Oct;40(10):4626-4638. doi: 10.1007/s12325-023-02623-w. Epub 2023 Aug 19.
PMID: 37597153
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M, Ohe Y, Ikeda S, Yokoyama T, Hayashi H, Fukuhara T, Sato Y, Tanaka H, Hotta K, Sugawara S, Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H.
Int J Clin Oncol. 2023 Oct;28(10):1369-1370. doi: 10.1007/s10147-023-02408-9.
PMID: 37684530
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M, Ohe Y, Ikeda S, Yokoyama T, Hayashi H, Fukuhara T, Sato Y, Tanaka H, Hotta K, Sugawara S, Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H.
Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7.
PMID: 37548831
Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL.
Rogiers A, Willemot L, McDonald L, Van Campenhout H, Berchem G, Jacobs C, Blockx N, Rorive A, Neyns B.
Cancers (Basel). 2023 Sep 30;15(19):4823. doi: 10.3390/cancers15194823.
PMID: 37835517
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose.
Jessen BA, Cornwell P, Redmond S, Visalli T, Lemper M, Bunch T, Hart T.
Cancer Chemother Pharmacol. 2023 Sep 29. doi: 10.1007/s00280-023-04595-8. Online ahead of print.
PMID: 37773538
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept.
Bessette L, Haraoui B, Rampakakis E, Dembowy J, Trépanier MO, Pope J.
Arthritis Res Ther. 2023 Sep 28;25(1):183. doi: 10.1186/s13075-023-03151-2.
PMID: 37759330
Transgenic Mice Expressing Functional TCRs Specific to Cardiac Myhc-α 334-352 on Both CD4 and CD8 T Cells Are Resistant to the Development of Myocarditis on C57BL/6 Genetic Background.
Sur M, Rasquinha MT, Arumugam R, Massilamany C, Gangaplara A, Mone K, Lasrado N, Yalaka B, Doiphode A, Gurumurthy C, Steffen D, Reddy J.
Cells. 2023 Sep 25;12(19):2346. doi: 10.3390/cells12192346.
PMID: 37830560
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Mascarenhas J, Harrison C, Schuler TA, Liassou D, Garretson M, Miller TA, Mahadevan S, McBride A, Tang D, DeGutis IS, Abraham P, Kish J, Feinberg BA, Gerds AT.
Clin Lymphoma Myeloma Leuk. 2023 Sep 29:S2152-2650(23)02130-4. doi: 10.1016/j.clml.2023.09.008. Online ahead of print.
PMID: 37839939
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
Ruiu R, Cossu C, Iacoviello A, Conti L, Bolli E, Ponzone L, Magri J, Rumandla A, Calautti E, Cavallo F.
J Exp Clin Cancer Res. 2023 Sep 29;42(1):254. doi: 10.1186/s13046-023-02830-x.
PMID: 37770957
The Importance of Tracking "Missing" Metabolites: How and Why?
Wang S, Ballard TE, Christopher LJ, Foti RS, Gu C, Khojasteh SC, Liu J, Ma S, Ma B, Obach RS, Schadt S, Zhang Z, Zhang D.
J Med Chem. 2023 Sep 28. doi: 10.1021/acs.jmedchem.3c01293. Online ahead of print.
PMID: 37769129 Review.
Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug-Drug Interaction Studies in Healthy Participants.
Perera V, Gretler DD, Seroogy JD, Chiang M, Palmisano M, Florea V.
Clin Pharmacol Drug Dev. 2023 Sep 28. doi: 10.1002/cpdd.1332. Online ahead of print.
PMID: 37771180
Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company's data collection, reporting, and interpretation of race and ethnicity.
Candelario NM, Major J, Dreyfus B, Sattler D, Paulucci D, Misra S, Micsinai M, Kuri L.
Ann Oncol. 2023 Sep 27:S0923-7534(23)03945-5. doi: 10.1016/j.annonc.2023.09.3107. Online ahead of print.
PMID: 37774795
Industry Perspective on Temperature Cycling Studies to Meet Regulatory Temperature Excursion Support Requirements: Survey Outcome and Recommendations.
Arana C, Ji J, Krug E, Liu J, McCaig L, Rozaieski B, Santos C, Sloan J, St Charles AM, Wiegeshoff F.
J Pharm Sci. 2023 Sep 27:S0022-3549(23)00378-7. doi: 10.1016/j.xphs.2023.09.014. Online ahead of print.
PMID: 37774951
Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.
Kikuchi R, Chothe PP, Chu X, Huth F, Ishida K, Ishiguro N, Jiang R, Shen H, Stahl SH, Varma MVS, Willemin ME, Morse BL.
Clin Pharmacol Ther. 2023 Sep 26. doi: 10.1002/cpt.3062. Online ahead of print.
PMID: 37750401
ACOEM Guidance Statement Update Role and Value of the Corporate Medical Director.
Stave GM, Burton WN, Heron RJL, Hudson TW, Pawlecki JB, Roomes D, Sepulveda MJ, Rendel M, Hymel PA; ACOEM Corporate Medicine Section Task Force.
J Occup Environ Med. 2023 Sep 25. doi: 10.1097/JOM.0000000000002979. Online ahead of print.
PMID: 37757772
Lack of improvement in anorectal manometry parameters after implementation of a pelvic floor/anal sphincter biofeedback in persons with motor-incomplete spinal cord injury.
Aloysius MM, Korsten MA, Radulovic M, Singh K, Lyons BL, Cummings T, Hobson J, Kahal S, Spungen AM, Bauman WA.
Neurogastroenterol Motil. 2023 Sep 25:e14667. doi: 10.1111/nmo.14667. Online ahead of print.
PMID: 37743783
Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm.
Sugarman R, Betts KA, Nie X, Hartman J, Nguyen H.
Clin Ther. 2023 Sep 23:S0149-2918(23)00318-1. doi: 10.1016/j.clinthera.2023.08.014. Online ahead of print.
PMID: 37748935
Harmonisation of read-across methodology for drug substance extractables and leachables (E&Ls).
Masuda-Herrera M, Rosen HT, Burild A, Broschard T, Bell T, Graham J, Griffin T, Hillegass J, Leavitt P, Huta B, Parris P, Bruen U, Cruz M, Bercu J.
Regul Toxicol Pharmacol. 2023 Sep 23;145:105494. doi: 10.1016/j.yrtph.2023.105494. Online ahead of print.
PMID: 37748702
Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B, Jiang C, Daouti S, Kumar S, Mehta P, Jacques MK, Menard L, Manjarrez-Orduno N, Dolfi S, Mukherjee P, Rai SC, Lako A, Koenitzer JD, David JM.
Front Immunol. 2023 Sep 19;14:1151748. doi: 10.3389/fimmu.2023.1151748. eCollection 2023.
PMID: 37795090
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Jerusalem G, Prat A, Salgado R, Reinisch M, Saura C, Borrego MR, Nikolinakos P, Ades F, Filian J, Huang N, Mazzei-Abba A, Tolaney SM.
Breast. 2023 Sep 15;72:103580. doi: 10.1016/j.breast.2023.103580. Online ahead of print.
PMID: 37741273
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L.
J Clin Oncol. 2023 Sep 15:JCO2300170. doi: 10.1200/JCO.23.00170. Online ahead of print.
PMID: 37713657
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodríguez Otero P, Casas-Avilés I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ; CC-92480-MM-001 Study Investigators.
N Engl J Med. 2023 Sep 14;389(11):1009-1022. doi: 10.1056/NEJMoa2303194. Epub 2023 Aug 30.
PMID: 37646702.
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer.
Hatswell AJ, Chaudhary MA, Monnickendam G, Moreno-Koehler A, Frampton K, Shaw JW, Penrod JR, Lawrance R.
Pharmacoeconomics. 2023 Sep 14. doi: 10.1007/s40273-023-01314-2. Online ahead of print.
PMID: 37707719
Orange Light-Driven C(sp 2 )-C(sp 3 ) Cross-Coupling via Spin-Forbidden Ir(III) Metallaphotoredox Catalysis.
Xie KA, Bednarova E, Joe CL, Lin C, Sherwood TC, Simmons EM, Lainhart BC, Rovis T.
J Am Chem Soc. 2023 Sep 13;145(36):19925-19931. doi: 10.1021/jacs.3c06285. Epub 2023 Aug 29.
PMID: 37642382
Splenic iron decreases without change in volume or liver parameters during luspatercept therapy.
Denton CC, Vodala S, Veluswamy S, Hofstra TC, Coates TD, Wood JC.
Blood. 2023 Sep 13:blood.2023021839. doi: 10.1182/blood.2023021839. Online ahead of print.
PMID: 37704579
A quantum chemical interaction energy dataset for accurately modeling protein-ligand interactions.
Spronk SA, Glick ZL, Metcalf DP, Sherrill CD, Cheney DL.
Sci Data. 2023 Sep 12;10(1):619. doi: 10.1038/s41597-023-02443-1.
PMID: 37699937
A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer.
Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C.
Thromb Haemost. 2023 Sep 11. doi: 10.1055/a-2145-7238. Online ahead of print.
PMID: 37527782
Recent advances in upstream process development for production of recombinant adeno-associated virus.
Ou J, Tang Y, Xu J, Tucci J, Borys MC, Khetan A.
Biotechnol Bioeng. 2023 Sep 10. doi: 10.1002/bit.28545. Online ahead of print.
PMID: 37691172
Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective.
Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Franca JR, Li Y, Marden S, Mohan S, Ultramari M, Huang Z, Adams N, Campbell JM, Jansen PJ, Kotoni D, Laue C.
J Pharm Sci. 2023 Sep 9:S0022-3549(23)00362-3. doi: 10.1016/j.xphs.2023.09.003. Online ahead of print.
PMID: 37690775
Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.
FitzGerald O, Behrens F, Barton A, Bertheussen H, Boutouyrie-Dumont B, Coates L, Davies O, de Wit M, Fagni F, Goodyear CS, Gurke R, Hahnefeld L, Huppertz C, Ioannidis V, Ibberson M, Katz A, Klippstein M, Koehm M, Korish S, Mackay S, Martin DA, O'Sullivan D, Patel K, Rueping S, Schett G, Scholich K, Schwenk JM, Siebert S, Simon D, Vivekanantham A, Pennington SR.
Ther Adv Musculoskelet Dis. 2023 Sep 8;15:1759720X231192315. doi: 10.1177/1759720X231192315. eCollection 2023.
PMID: 37694182
Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment.
King-Concialdi K, Beusterien K, Senglaub SS, Will O, Jaffe DH, Patel MY, Harrison MR.
Patient Prefer Adherence. 2023 Sep 8;17:2237-2248. doi: 10.2147/PPA.S411751. eCollection 2023.
PMID: 37706208
Development of a Crystallization-Induced Diastereomer Transformation of Oxime Isomers for the Asymmetric Synthesis of (1 S ,6 R )-3,9-Diazabicyclo[4.2.1]nonane.
Lisnyak VG, Tan Y, Ramirez A, Wisniewski SR, Sarjeant AA.
J Org Chem. 2023 Sep 1;88(17):12493-12501. doi: 10.1021/acs.joc.3c01228. Epub 2023 Aug 23.
PMID: 37610241
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model.
Geerts H, Bergeler S, Walker M, van der Graaf PH, Courade JP.
Sci Rep. 2023 Sep 1;13(1):14342. doi: 10.1038/s41598-023-41382-0.
PMID: 37658103
Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
Stenehjem D, Lubinga SJ, Wu A, Betts KA.
J Manag Care Spec Pharm. 2023 Sep;29(9):1054-1064. doi: 10.18553/jmcp.2023.29.9.1054.
PMID: 37610116
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A.
Target Oncol. 2023 Sep;18(5):639-641. doi: 10.1007/s11523-023-00987-1. Epub 2023 Sep 2.
PMID: 37659025
Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R, Tony HP, Bannert B, Nüßlein H, Rauch C, Connolly SE, Chartier M, Lozenski K, Hackl R, Forster A, Peichl P.
Clin Rheumatol. 2023 Sep;42(9):2321-2334. doi: 10.1007/s10067-023-06649-x. Epub 2023 Jun 14.
PMID: 37314665
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN.
Nat Med. 2023 Sep;29(9):2286-2294. doi: 10.1038/s41591-023-02496-0. Epub 2023 Aug 17.
PMID: 37592106
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
Gordon LI, Liu FF, Braverman J, Hoda D, Ghosh N, Hamadani M, Hildebrandt GC, Peng L, Guo S, Shi L, Sehgal A.
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283162. Online ahead of print.
PMID: 37646670
Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension.
Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, Afzali A, Wolf DC, Chiorean MV, Vermeire S, Jain A, Charles L, Lawlor G, Osterman MT, Wu H, Canavan JB, Petersen AK, Colombel JF, Regueiro M.
J Crohns Colitis. 2023 Aug 31:jjad146. doi: 10.1093/ecco-jcc/jjad146. Online ahead of print.
PMID: 37651686
Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma.
Peterse EFP, Verburg-Baltussen EJM, Stewart A, Liu FF, Parker C, Treur M, Malcolm B, Klijn SL.
Pharmacoecon Open. 2023 Aug 31. doi: 10.1007/s41669-023-00435-w. Online ahead of print.
PMID: 37651087
Staff experiences of the use of virtual consultations in non-surgical oncology systemic anticancer therapy services.
Warnock C, Pelton J, Hilton A.X
Support Care Cancer. 2023 Aug 30;31(9):541. doi: 10.1007/s00520-023-08005-w.
PMID: 37646821
3D Printing of Personalised Carvedilol Tablets Using Selective Laser Sintering.
Tabriz AG, Gonot-Munck Q, Baudoux A, Garg V, Farnish R, Katsamenis OL, Hui HW, Boersen N, Roberts S, Jones J, Douroumis D.
Pharmaceutics. 2023 Aug 29;15(9):2230. doi: 10.3390/pharmaceutics15092230.
PMID: 37765199
Engaging an HIV vaccine target through the acquisition of low B cell affinity.
Ronsard L, Yousif AS, Nait Mohamed FA, Feldman J, Okonkwo V, McCarthy C, Schnabel J, Caradonna T, Barnes RM, Rohrer D, Lonberg N, Schmidt A, Lingwood D.
Nat Commun. 2023 Aug 28;14(1):5249. doi: 10.1038/s41467-023-40918-2.
PMID: 37640732
The role of intermolecular interactions on monoclonal antibody filtration through virus removal membranes.
Billups M, Minervini M, Holstein M, Feroz H, Ranjan S, Hung J, Zydney AL.
Biotechnol J. 2023 Aug 28:e2300265. doi: 10.1002/biot.202300265. Online ahead of print.
PMID: 37641433
Myosin in autoinhibited  off  state(s), stabilized by mavacamten, can be recruited via inotropic effectors.
Ma W, Del Rio CL, Qi L, Prodanovic M, Mijailovich S, Zambataro C, Gong H, Shimkunas R, Gollapudi S, Nag S, Irving TC.
bioRxiv. 2023 Aug 28:2023.04.10.536292. doi: 10.1101/2023.04.10.536292. Preprint.
PMID: 37090664
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
Toyoda K, Arakawa S, Ezura M, Kobayashi R, Tanaka Y, Hasegawa S, Yamashiro S, Komatsu Y, Terasawa Y, Masuno T, Kobayashi H, Oikawa S, Yasaka M.
J Atheroscler Thromb. 2023 Aug 26. doi: 10.5551/jat.64223. Online ahead of print.
PMID: 37635060
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
Jiang Y, Arora T, Klakamp S, Davis J, Chandrasekher YA, Young G, Du Y, Yu B, Miller KJ.
Drugs R D. 2023 Aug 26. doi: 10.1007/s40268-023-00437-3. Online ahead of print.
PMID: 37632627
Analysis of cellularity in H&E-stained rat bone marrow tissue via deep learning.
Shiffman S, Rios Piedra EA, Adedeji AO, Ruff CF, Andrews RN, Katavolos P, Liu E, Forster A, Brumm J, Fuji RN, Sullivan R.
J Pathol Inform. 2023 Aug 25;14:100333. doi: 10.1016/j.jpi.2023.100333. eCollection 2023.
PMID: 37743975
Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational "ORIGAMI" study.
Harigai M, Tanaka E, Inoue E, Tamura N, Misaki K, Azuma T, Hirata S, Hirano F, Taniguchi Y, Mitsuhashi M, Kondo M, Oribe M, Aoki K, Kadode M, Tsuritani K, Yamanaka H.
Mod Rheumatol. 2023 Aug 25:road082. doi: 10.1093/mr/road082. Online ahead of print.
PMID: 37624029
Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease.
Tan SPF, Willemin ME, Snoeys J, Shen H, Rostami-Hodjegan A, Scotcher D, Galetin A.
Clin Pharmacol Ther. 2023 Aug 24. doi: 10.1002/cpt.3029. Online ahead of print.
PMID: 37620246
Imidazophenothiazine-Based Thermally Activated Delayed Fluorescence Materials with Ultra-Long-Lived Excited States for Energy Transfer Photocatalysis.
Hojo R, Bergmann K, Elgadi SA, Mayder DM, Emmanuel MA, Oderinde MS, Hudson ZM.Y
J Am Chem Soc. 2023 Aug 23;145(33):18366-18381. doi: 10.1021/jacs.3c04132. Epub 2023 Aug 9.
PMID: 37556344
In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival.
Haselager MV, van Driel BF, Perelaer E, de Rooij D, Lashgari D, Loos R, Kater AP, Moerland PD, Eldering E.
Hemasphere. 2023 Aug 23;7(9):e938. doi: 10.1097/HS9.0000000000000938. eCollection 2023 Sep.
PMID: 37637994
Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants.
Hollingsworth SA, Noland CL, Vroom K, Saha A, Sam M, Gao Q, Zhou H, Grandy DU, Singh S, Wen Z, Warren C, Ma XS, Malashock D, Galli J, Go G, Eddins M, Mayhood T, Sathiyamoorthy K, Fridman A, Raoufi F, Gomez-Llorente Y, Patridge A, Tang Y, Chen SJ, Bailly M, Ji C, Kingsley LJ, Cheng AC, Geierstanger BH, Gorman DM, Zhang L, Pande K.
Sci Rep. 2023 Aug 22;13(1):13668. doi: 10.1038/s41598-023-40919-7.
PMID: 37608223
Effects of Additives on the Physical Stability and Dissolution of Polymeric Amorphous Solid Dispersions: a Review.
Li J, Wang Y, Yu D.
AAPS PharmSciTech. 2023 Aug 21;24(7):175. doi: 10.1208/s12249-023-02622-8.
PMID: 37603110
Comparative Evaluation of the Powder and Tableting Properties of Regular and Direct Compression Hypromellose from Different Vendors.
Mawla N, Alshafiee M, Gamble J, Tobyn M, Liu L, Walton K, Conway BR, Timmins P, Asare-Addo K.
Pharmaceutics. 2023 Aug 17;15(8):2154. doi: 10.3390/pharmaceutics15082154.
PMID: 37631368
Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression in Exploratory Analysis.
de Leon VC, Kumar A, Nagele P, Palanca BJ, Gott B, Janski A, Zorumski CF, Conway CR.
J Clin Psychiatry. 2023 Aug 16;84(5):22br14725. doi: 10.4088/JCP.22br14725.
PMID: 37585253
Stopper Movement and Headspace (Air Bubble Size) Limitations for 2.25mL Prefilled Syringe.
Evans CM, Oni Y, Paniagua D, Franck J, Dahlheim C, Kulshrestha A.
PDA J Pharm Sci Technol. 2023 Aug 14:pdajpst.2022.012749. doi: 10.5731/pdajpst.2022.012749. Online ahead of print.
PMID: 37580129
Adaptive designs for best treatment identification with top-two Thompson sampling and acceleration.
Wang J, Tiwari R.
Pharm Stat. 2023 Aug 12. doi: 10.1002/pst.2331. Online ahead of print.
PMID: 37571869
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M.
J Clin Oncol. 2023 Aug 10;41(23):3917-3929. doi: 10.1200/JCO.22.02199. Epub 2023 Jun 12.
PMID: 37307514
Mechanistic Investigations of Phenoxyimine-Cobalt(II)-Catalyzed C(sp 2 )-C(sp 3 ) Suzuki-Miyaura Cross-Coupling.
Mills LR, Gygi D, Simmons EM, Wisniewski SR, Kim J, Chirik PJ.
J Am Chem Soc. 2023 Aug 9;145(31):17029-17041. doi: 10.1021/jacs.3c02103. Epub 2023 Jul 25.
PMID: 37490763
Erratum to "Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project": [Annals of Oncology 32 (2021) 1626-1636].
Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, Fabrizio D, Funari V, Newberg J, Bruce LK, Chen SJ, Baden J, Carl Barrett J, Beer P, Butler M, Cheng JH, Conroy J, Cyanam D, Eyring K, Garcia E, Green G, Gregersen VR, Hellmann MD, Keefer LA, Lasiter L, Lazar AJ, Li MC, MacConaill LE, Meier K, Mellert H, Pabla S, Pallavajjalla A, Pestano G, Salgado R, Samara R, Sokol ES, Stafford P, Budczies J, Stenzinger A, Tom W, Valkenburg KC, Wang XZ, Weigman V, Xie M, Xie Q, Zehir A, Zhao C, Zhao Y, Stewart MD, Allen J; TMB Consortium.
Ann Oncol. 2023 Aug 7:S0923-7534(23)00770-6. doi: 10.1016/j.annonc.2023.07.005. Online ahead of print.
PMID: 37558578
Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
Saeedian M, Badaracco J, Botros A, Gitlin M, Keating SJ.
Transplant Cell Ther. 2023 Aug 5:S2666-6367(23)01437-9. doi: 10.1016/j.jtct.2023.08.001. Online ahead of print.
PMID: 37544410
Proteomic profiling across breast cancer cell lines and models.
Kalocsay M, Berberich MJ, Everley RA, Nariya MK, Chung M, Gaudio B, Victor C, Bradshaw GA, Eisert RJ, Hafner M, Sorger PK, Mills CE, Subramanian K.
Sci Data. 2023 Aug 4;10(1):514. doi: 10.1038/s41597-023-02355-0.
PMID: 37542042
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research.
Flick ED, Terebelo HR, Fish S, Kitali A, Mahajan V, Nifenecker M, Sullivan K, Thaler P, Ussery S, Grinblatt DL.
Oncologist. 2023 Aug 3;28(8):657-663. doi: 10.1093/oncolo/oyad110.
PMID: 37285045
Behavior of host-cell-protein-rich aggregates in antibody capture and polishing chromatography.
Herman CE, Min L, Choe LH, Maurer RW, Xu X, Ghose S, Lee KH, Lenhoff AM.
J Chromatogr A. 2023 Aug 2;1702:464081. doi: 10.1016/j.chroma.2023.464081. Epub 2023 May 18.
PMID: 37244165
Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD, Guo JD, Keshishian A, Delinger R, Russ C, Rosenblatt L, Jiang J, Yuce H, Ferri M.
J Thromb Thrombolysis. 2023 Aug 2. doi: 10.1007/s11239-023-02838-2. Online ahead of print.
PMID: 37530955
Assessment of Oxygen Pulse in Hypertrophic Cardiomyopathy-Reply.
Wheeler MT, Chen YM, Myers J.
JAMA Cardiol. 2023 Aug 1;8(8):796-797. doi: 10.1001/jamacardio.2023.1889.
PMID: 37405726
Organizational Impact of Immunotherapies in Advanced Cancers in France.
Grumberg V, Chouaïd C, Gaudin AF, Le Tourneau C, Marabelle A, Bongiovanni-Delarozière I, Cotté FE, Borget I.
JCO Glob Oncol. 2023 Aug;9:e2300026. doi: 10.1200/GO.23.00026.
PMID: 37595168
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L, Bushong J, Gupta RG, Grootendorst DJ, Eccles LJ, Brahmer JR.
J Thorac Oncol. 2023 Aug;18(8):1055-1069. doi: 10.1016/j.jtho.2023.04.021. Epub 2023 May 3.
PMID: 37146754
Journal of Pharmaceutical Sciences Topic Cluster on Co-Processed Active Pharmaceutical Ingredients (APIs).
Erdemir D, Ferguson S, Marziano I, Hancock B.
J Pharm Sci. 2023 Aug;112(8):2009. doi: 10.1016/j.xphs.2023.05.020. Epub 2023 Jun 4.
PMID: 37279837
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A.
Immunotherapy. 2023 Aug;15(12):963-973. doi: 10.2217/imt-2023-0061. Epub 2023 May 7.
PMID: 37150952
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA.
Immunotherapy. 2023 Aug;15(11):787-797. doi: 10.2217/imt-2023-0062. Epub 2023 May 7.
PMID: 37150956
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Ely S, Fernandez-Martín C, Fineberg S, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hardas A, Hart SN, Hartman J, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm… See abstract for full author list ➔
J Pathol. 2023 Aug;260(5):514-532. doi: 10.1002/path.6165. Epub 2023 Aug 23.
PMID: 37608771
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
Petersohn S, McGregor B, Klijn SL, May JR, Ejzykowicz F, Kurt M, Dyer M, Malcolm B, Branchoux S, Nickel K, George S, Kroep S.
J Comp Eff Res. 2023 Aug;12(8):e230004. doi: 10.57264/cer-2023-0004. Epub 2023 Jul 11.
PMID: 37431849
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol.
Colet JC, Mainar AS, Salazar-Mendiguchía J, Del Campo Alonso MI, Echeto A, Larena DV, Sánchez OD.
J Comp Eff Res. 2023 Aug;12(8):e230007. doi: 10.57264/cer-2023-0007. Epub 2023 Jul 25.
PMID: 37489950
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, Azmoudeh-Ardalan F, Badve S, Baharun NB, Balslev E, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Chon U Cheang M, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dahl AB, Dantas Portela FL, Deman F, Demaria S, Doré Hansen J, Dudgeon SN, Ebstrup T, Elghazawy M, Fernandez-Martín C, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hauberg S, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, … See abstract for full author list ➔
J Pathol. 2023 Aug;260(5):498-513. doi: 10.1002/path.6155. Epub 2023 Aug 23.
PMID: 37608772
Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases.
Weeks EM, Ulirsch JC, Cheng NY, Trippe BL, Fine RS, Miao J, Patwardhan TA, Kanai M, Nasser J, Fulco CP, Tashman KC, Aguet F, Li T, Ordovas-Montanes J, Smillie CS, Biton M, Shalek AK, Ananthakrishnan AN, Xavier RJ, Regev A, Gupta RM, Lage K, Ardlie KG, Hirschhorn JN, Lander ES, Engreitz JM, Finucane HK.
Nat Genet. 2023 Aug;55(8):1267-1276. doi: 10.1038/s41588-023-01443-6. Epub 2023 Jul 13.
PMID: 37443254
Impact of diabetes on remodelling, microvascular function and exercise capacity in aortic stenosis.
Dattani A, Brady EM, Alfuhied A, Gulsin GS, Steadman CD, Yeo JL, Aslam S, Banovic M, Jerosch-Herold M, Xue H, Kellman P, Costet P, Cvijic ME, Zhao L, Ebert C, Liu L, Gunawardhana K, Gordon D, Chang CP, Arnold JR, Yates T, Kelly D, Hogrefe K, Dawson D, Greenwood J, Ng LL, Singh A, McCann GP.
Open Heart. 2023 Aug;10(2):e002441. doi: 10.1136/openhrt-2023-002441.
PMID: 37586847
Oral prednisone regulates human skin T cells in delayed-type hypersensitivity reaction elicited by diphencyprone.
Mehta H, Jack C, Maari C, Proulx ÉS, Bissonnette R, Ramirez-Valle F, Sarfati M.
Allergy. 2023 Aug;78(8):2255-2265. doi: 10.1111/all.15764. Epub 2023 May 19.
PMID: 37163280
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary Fibrosis.
Horan G, Ye Y, Adams M, Parton A, Cedzik D, Tang S, Brown EA, Liu L, Nissel J, Carayannopoulos LN, Gaudy A, Schafer P, Palmisano M, Ramirez-Valle F.
Clin Pharmacol Drug Dev. 2023 Aug;12(8):779-789. doi: 10.1002/cpdd.1294. Epub 2023 Jun 28.
PMID: 37378860
2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine).
Szapacs M, Jian W, Spellman D, Cunliffe J, Verburg E, Kaur S, Kellie J, Li W, Mehl J, Qian M, Qiu X, Sirtori FR, Rosenbaum AI, Sikorski T, Surapaneni S, Wang J, Wilson A, Zhang J, Xue Y, Post N, Huang Y, Goykhman D, Yuan L, Fang K, Casavant E, Chen L, Fu Y, Huang M, Ji A, Johnson J, Lassman M, Li J, Saad O, Sarvaiya H, Tao L, Wang Y, Zheng N, Dasgupta A, Abhari MR, Ishii-Watabe A, Saito Y, Mendes Fernandes DN, Bower J, Burns C, Carleton K, Cho SJ, Du X, Fjording M, Garofolo F, Kar S, Kavetska O, Kossary E, Lu Y, Mayer A, Palackal N, Salha D, Thomas E, Verhaeghe T, Vinter S, Wan K, Wang YM, Williams K, Woolf E, Yang L, Yang E, Bandukwala A, Hopper S, Maher K, Xu J, Brodsky E, Cludts I, Irwin C, Joseph J, Kirshner S, Manangeeswaran M, Maxfield K, Pedras-Vasconcelos J, Solstad T, Thacker S, Tounekti O, Verthelyi D, Wadhwa M, Wagner L, Yamamoto T, Zhang L, Zhou L.
Bioanalysis. 2023 Aug;15(16):955-1016. doi: 10.4155/bio-2023-0167. Epub 2023 Aug 31.
PMID: 37650500
2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 - Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization.
Sumner G, Keller S, Huleatt J, Staack RF, Wagner L, Azadeh M, Bandukwala A, Cao L, Du X, Salinas GF, Garofolo F, Harris S, Hopper S, Irwin C, Ji Q, Joseph J, King L, Kinhikar A, Lu Y, Luo R, Mabrouk O, Malvaux L, Marshall JC, McGuire K, Mikol V, Neely R, Qiu X, Saito Y, Salaun B, Scully I, Smeraglia J, Solstad T, Stoop J, Tang H, Teixeira P, Wang Y, Wright M, Mendez L, Beaver C, Eacret J, Au-Yeung A, Decman V, Dessy F, Eck S, Goihberg P, Alcaide EG, Gonneau C, Grugan K, Hedrick MN, Kar S, Sehra S, Stevens E, Stevens C, Sun Y, McCush F, Williams L, Fischer S, Wu B, Jordan G, Burns C, Cludts I, Coble K, Grimaldi C, Henderson N, Joyce A, Lotz G, Lu Y, Luo L, Neff F, Sperinde G, Stubenrauch KG, Wang Y, Ware M, Xu W.
Bioanalysis. 2023 Aug;15(15):861-903. doi: 10.4155/bio-2023-0151. Epub 2023 Aug 16.
PMID: 37584363
Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials.
Michaud K, Conaghan PG, Park SH, Lozenski K, Fillbrunn M, Khaychuk V, Swallow E, Vaile J, Lane H, Nguyen H, Pope J.
Rheumatol Ther. 2023 Aug;10(4):951-967. doi: 10.1007/s40744-023-00552-2. Epub 2023 May 25.
PMID: 37231194
Real-world relationship of early end points to survival end points in patients with resectable non-small-cell lung cancer.
Nadler E, Vasudevan A, Wentworth C, Robert N, Penrod JR, Fiore J, Vo L.
Future Oncol. 2023 Aug;19(26):1785-1800. doi: 10.2217/fon-2023-0170. Epub 2023 Sep 4.
PMID: 37665271
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and Reporting.
Patel JL, Erba HP, Savona MR, Grinblatt DL, Clark M, Clive TC, Smart TB, Makinde AY, DeGutis IS, Yu E, Eggington JM, George TI.
J Mol Diagn. 2023 Aug;25(8):611-618. doi: 10.1016/j.jmoldx.2023.05.002.
PMID: 37517825
Comparison of Preferences and Data Quality between Discrete Choice Experiments Conducted in Online and Face-to-Face Respondents.
Jiang R, Pullenayegum E, Shaw JW, Mühlbacher A, Lee TA, Walton S, Kohlmann T, Norman R, Pickard AS.
Med Decis Making. 2023 Aug;43(6):667-679. doi: 10.1177/0272989X231171912. Epub 2023 May 18.
PMID: 37199407
Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C.
Ann Hematol. 2023 Aug;102(8):2299. doi: 10.1007/s00277-023-05327-x.
PMID: 37341779
International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials.
Brady KJS, Peipert JD, Atkinson TM, Pompili C, Pinto M, Shaw JW, Roydhouse J; International Society for Quality of Life Research Clinical Practice Special Interest Group, the International Society for Quality of Life Research Clinical Practice Special Interest Group, the International Society for Quality of Life Research Regulatory Health, Technology Assessment Engagement Special Interest Group, and the International Society for Quality of Life Research Psychometrics Special Interest Group.
Qual Life Res. 2023 Aug;32(8):2155-2163. doi: 10.1007/s11136-023-03396-z. Epub 2023 May 23.
PMID: 37217665
Molecular magnetic resonance imaging of liver inflammation using an oxidatively activated probe.
Jordan VC, Sojoodi M, Shroff S, Pagan PG, Barrett SC, Wellen J, Tanabe KK, Chung RT, Caravan P, Gale EM.
JHEP Rep. 2023 Jul 18;5(10):100850. doi: 10.1016/j.jhepr.2023.100850. eCollection 2023 Oct.
PMID: 37818152
2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach).
Pan L, Mora J, Walravens K, Wagner L, Hopper S, Loo L, Bettoun D, Bond S, Dessy F, Downing S, Garofolo F, Gupta S, Henderson N, Irwin C, Ishii-Watabe A, Kar S, Jawa V, Joseph J, Malvaux L, Marshall JC, McDevitt J, Mohapatra S, Seitzer J, Smith J, Solstad T, Sugimoto H, Tounekti O, Wu B, Wu Y, Xu Y, Xu J, Yamamoto T, Yang L, Torri A, Kirshner S, Maxfield K, Vasconcelos JP, Abhari MR, Verthelyi D, Brodsky E, Carrasco-Triguero M, Kamerud J, Andisik M, Baltrukonis D, Bivi N, Cludts I, Coble K, Gorovits B, Gunn GR, Gupta S, Millner AH, Joyce A, Kubiak RJ, Kumar S, Liao K, Manangeeswaran M, Partridge M, Pine S, Poetzl J, Rajadhyaksha M, Rasamoelisolo M, Richards S, Song Y, Swanson S, Thacker S, Wadhwa M, Wolf A, Zhang L, Zhou L.
Bioanalysis. 2023 Jul;15(14):773-814. doi: 10.4155/bio-2023-0135. Epub 2023 Aug 1.
PMID: 37526071
Association Between Psoriasis and Obesity Among US Adults in the 2009-2014 National Health and Nutrition Examination Survey.
Smith B, Devjani S, Collier MR, Maul JT, Wu JJ.
Cutis. 2023 Jul;112(1):49-51. doi: 10.12788/cutis.0807.
PMID: 37611301
Real-world complication burden and disease management paradigms in transfusion-related β-thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross-sectional study.
Kattamis A, Voskaridou E, Delicou S, Klironomos E, Lafiatis I, Petropoulou F, Diamantidis MD, Lafioniatis S, Evliati L, Kapsali E, Karvounis-Marolachakis K, Timotheatou D, Deligianni C, Viktoratos P, Kourakli A.
EJHaem. 2023 May 23;4(3):569-581. doi: 10.1002/jha2.695. eCollection 2023 Aug.
PMID: 37601860
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N, Decimoni TC, Dyer MTD, May JR, van de Wetering G, Petersohn S, Nickel K, Silva A, Muniz DQB, Casagrande D Oliveira AP.
J Med Econ. 2023 Jan-Dec;26(1):1108-1121. doi: 10.1080/13696998.2023.2252716.
PMID: 37632452
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity.
Lietz CB, Deyanova E, Cho Y, Cordia J, Franc S, Kabro S, Wang S, Mikolon D, Banks DD.
MAbs. 2023 Jan-Dec;15(1):2259289. doi: 10.1080/19420862.2023.2259289. Epub 2023 Sep 24.
PMID: 37742207
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT.
Diong SJ, Jashnani A, Drake AW, Bee C, Findeisen F, Dollinger G, Wang F, Rajpal A, Strop P, Lee PS.
MAbs. 2023 Jan-Dec;15(1):2253788. doi: 10.1080/19420862.2023.2253788.
PMID: 37675979
An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
McBride A, Brokars J, Reddy SR, Chang E, Tarbox MH, LeBlanc TW.
Acta Haematol. 2023;146(4):259-266. doi: 10.1159/000530512. Epub 2023 Apr 10.
PMID: 37037194
Refinement of multiconformer ensemble models from multi-temperature X-ray diffraction data.
Du S, Wankowicz SA, Yabukarski F, Doukov T, Herschlag D, Fraser JS.
Methods Enzymol. 2023;688:223-254. doi: 10.1016/bs.mie.2023.06.009. Epub 2023 Jul 27.
PMID: 37748828
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
Armstrong AW, Park SH, Patel V, Hogan M, Wang WJ, Davidson D, Chirikov V.
Dermatol Ther (Heidelb). 2023 Jul 31. doi: 10.1007/s13555-023-00977-1. Online ahead of print.
PMID: 37525000
Analysis of the bile acid composition in a fibroblast growth factor 19-expressing liver-humanized mouse model and its use for CYP3A4-mediated drug-drug interaction studies.
Mezler M, Jones RS, Sangaraju D, Goldman DC, Hoffmann M, Heikkinen AT, Mannila J, Chang JH, Foquet L, Pusalkar S, Chothe PP, Scheer N.
Drug Metab Dispos. 2023 Jul 31:DMD-AR-2023-001398. doi: 10.1124/dmd.123.001398. Online ahead of print.
PMID: 37524541
PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper.
Kavita U, Sun K, Braun M, Lembke W, Mody H, Kamerud J, Yang TY, Braun IV, Fang X, Gao W, Gupta S, Hofer M, Liao MZ, Loo L, McBlane F, Menochet K, Stubenrauch KG, Upreti VV, Vigil A, Wiethoff CM, Xia CQ, Zhu X, Jawa V, Chemuturi N.
AAPS J. 2023 Jul 31;25(5):78. doi: 10.1208/s12248-023-00842-1.
PMID: 37523051
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
Chu J, Panfen E, Wang L, Marino A, Chen XQ, Fancher RM, Landage R, Patil O, Desai SD, Shah D, Xue Y, Sinz M, Shen H.
Pharm Res. 2023 Jul 31. doi: 10.1007/s11095-023-03563-4. Online ahead of print.
PMID: 37523014
Payer formulary tier increases of apixaban: how patients respond and potential implications.
Deitelzweig S, Terasawa E, Atreja N, Kang A, Hines DM, Dhamane AD, Hagan M, Noman A, Luo X.
Curr Med Res Opin. 2023 Jul 31:1-9. doi: 10.1080/03007995.2023.2232636. Online ahead of print.
PMID: 37519272
The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.
Uemura H, Shinohara N, Tomita Y, Nonomura N, Yamada T, Yoshida A, Komoto A.J
pn J Clin Oncol. 2023 Jul 31;53(8):730-737. doi: 10.1093/jjco/hyad034.
PMID: 37151051
Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors.
Schmidt L, Wang CA, Patel V, Davidson D, Kalirai S, Panda A, Seigel L.
Dermatol Ther (Heidelb). 2023 Jul 30. doi: 10.1007/s13555-023-00975-3. Online ahead of print.
PMID: 37517029
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G.
Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10.
PMID: 37311468
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, Zhao Y, Gueorguieva I, Man M, Estrem ST, Liu J, Avsar E, Lin WH, Benhadji KA, Gandhi L, Guba SC, Diaz IA.
BMC Cancer. 2023 Jul 28;23(1):708. doi: 10.1186/s12885-023-11153-1.
PMID: 37507657
Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients.
Nag S, Gollapudi SK, Del Rio CL, Spudich JA, McDowell R.
Sci Adv. 2023 Jul 28;9(30):eabo7622. doi: 10.1126/sciadv.abo7622. Epub 2023 Jul 28.
PMID: 37506209
An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.
Jessen BA, Cornwell P, Redmond S, Visalli T, Lemper M, Bunch T, Hart T.
Cancer Chemother Pharmacol. 2023 Jul 28. doi: 10.1007/s00280-023-04570-3. Online ahead of print.
PMID: 37505272
Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688.
Battista C, Shoda LKM, Watkins PB, Groettrup-Wolfers E, Rottmann A, Raschke M, Generaux GT.
Clin Pharmacol Ther. 2023 Jul 28. doi: 10.1002/cpt.3010. Online ahead of print.
PMID: 37501650
Mechanistic investigation of liver injury induced by BMS-932481, an experimental ɣ-secretase modulator.
Zhuo X, Howell BA, Shen H, Woodhead JL, Mosure K, Zhang Y, Scialis RJ, Iyer R, Sun Y, Boy KM, Lentz KA, Denton RR, Soars MG, Johnson BM, Humphreys WG.
Toxicol Sci. 2023 Jul 28;194(2):235-245. doi: 10.1093/toxsci/kfad057.
PMID: 37261863
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
Rodríguez Otero P, Towle K, Cope S, Caisip C, Davies FE, Delforge M, Weisel K, Marshall TS, Karampampa K, Ayers D, Mojebi A, Braverman J, Farrell J, Dhanda D.
Leuk Lymphoma. 2023 Jul 27:1-6. doi: 10.1080/10428194.2023.2235042. Online ahead of print.
PMID: 37497883
Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse.
DeWolf S, Elhanati Y, Nichols K, Waters NR, Nguyen CL, Slingerland JB, Rodriguez N, Lyudovyk O, Giardina PA, Kousa AI, Andrlová H, Ceglia N, Fei T, Kappagantula R, Li Y, Aleynick N, Baez P, Murali R, Hayashi A, Lee N, Gipson B, Rangesa M, Katsamakis Z, Dai A, Blouin AG, Arcila M, Masilionis I, Chaligne R, Ponce DM, Landau HJ, Politikos I, Tamari R, Hanash AM, Jenq RR, Giralt SA, Markey KA, Zhang Y, Perales MA, Socci ND, Greenbaum BD, Iacobuzio-Donahue CA, Hollmann TJ, van den Brink MRM, Peled JU.
Sci Transl Med. 2023 Jul 26;15(706):eabq0476. doi: 10.1126/scitranslmed.abq0476. Epub 2023 Jul 26.
PMID: 37494469
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Uno S, Motegi Y, Minehata K, Aoki Y.
Int J Hematol. 2023 Jul 26. doi: 10.1007/s12185-023-03634-7. Online ahead of print.
PMID: 37493867
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized
O'Halloran JA, Ko ER, Anstrom KJ, Kedar E, McCarthy MW, Panettieri RA Jr, Maillo M, Nunez PS, Lachiewicz AM, Gonzalez C, Smith PB, de Tai SM, Khan A, Lora AJM, Salathe M, Capo G, Gonzalez DR, Patterson TF, Palma C, Ariza H, Lima MP, Blamoun J, Nannini EC, Sprinz E, Mykietiuk A, Alicic R, Rauseo AM, Wolfe CR, Witting B, Wang JP, Parra-Rodriguez L, Der T, Willsey K, Wen J, Silverstein A, O'Brien SM, Al-Khalidi HR, Maldonado MA, Melsheimer R, Ferguson WG, McNulty SE, Zakroysky P, Halabi S, Benjamin DK Jr, Butler S, Atkinson JC, Adam SJ, Chang S, LaVange L, Proschan M, Bozzette SA, Powderly WG; ACTIV-1 IM Study Group Members.
JAMA. 2023 Jul 25;330(4):328-339. doi: 10.1001/jama.2023.11043.
PMID: 37428480
The ubiquity of the tabletability flip phenomenon.
Wang Z, Wang C, Bahl D, Sun CC.
Int J Pharm. 2023 Jul 24;643:123262. doi: 10.1016/j.ijpharm.2023.123262. Online ahead of print.
PMID: 37495026
Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel.
Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martin N, Anderson LD, Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser S.
Blood Cancer Discov. 2023 Jul 24:BCD-23-0044. doi: 10.1158/2643-3230.BCD-23-0044. Online ahead of print.
PMID: 37486974
Remote C-H Olefination of Heterocyclic Biaryls Enabled by Reversibly Bound Templates.
Liu LY, Fan Z, Hoque ME, Qian S, Meng G, Chekshin N, Tanaka K, Qiao JX, Yeung KS, Yu JQ.
Angew Chem Int Ed Engl. 2023 Jul 20:e202307581. doi: 10.1002/anie.202307581. Online ahead of print.
PMID: 37470111
Epidemiology and clinical characteristics of interstitial lung disease in patients with rheumatoid arthritis from the JointMan database.
Zhuo J, Lama S, Knapp K, Gutierrez C, Lovett K, Thai S, Craig GL.
Sci Rep. 2023 Jul 19;13(1):11678. doi: 10.1038/s41598-023-37452-y.
PMID: 37468565
MYD88L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8.
Mandato E, Yan Q, Ouyang J, Paczkowska J, Qin Y, Hao Y, Bojarczuk K, Hansen J, Chapuy B, Rodig SJ, Khan SJ, Redd RA, Shipp MA.
Blood. 2023 Jul 19:blood.2023019865. doi: 10.1182/blood.2023019865. Online ahead of print.
PMID: 37467575
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M, Sychterz C, Perera V, Merali S, Palmisano M, Templeton IE, Gaohua L.
Clin Pharmacol Ther. 2023 Jul 19. doi: 10.1002/cpt.3005. Online ahead of print.
PMID: 37467157
Stereocontrolled Radical Thiophosphorylation.
Nassir M, Ociepa M, Zhang HJ, Grant LN, Simmons BJ, Oderinde MS, Kawamata Y, Cauley AN, Schmidt MA, Eastgate MD, Baran PS.
J Am Chem Soc. 2023 Jul 19;145(28):15088-15093. doi: 10.1021/jacs.3c05655. Epub 2023 Jul 3.
PMID: 37399078
A rank-based approach to improve the efficiency of inferential seamless phase 2/3 clinical trials with dose optimization.
Wang X, Chen M, Chu S, Fan R, Chan ISF.
Contemp Clin Trials. 2023 Jul 17;132:107300. doi: 10.1016/j.cct.2023.107300. Online ahead of print.
PMID: 37467949
Unmet Needs in Real-World Advanced Therapy-Naïve and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the United States.
Afzali A, Lukanova R, Hennessy F, Kakehi S, Knight H, Milligan G, Gupte-Singh K.
Adv Ther. 2023 Jul 17. doi: 10.1007/s12325-023-02605-y. Online ahead of print.
PMID: 37458875
Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: Successes, learnings, and recommendations for future pandemics.
Buenconsejo J, Liao R, Lin J, Singh P, Cooner F, Ghosh S, Gamalo M, Russek-Cohen E, Zariffa N.
Contemp Clin Trials. 2023 Jul 16;132:107292. doi: 10.1016/j.cct.2023.107292. Online ahead of print.
PMID: 37454729
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.
Ruperto N, Lovell DJ, Berman A, Anton J, Viola DO, Lauwerys B, Rama ME, Bohnsack J, Breedt J, Fischbach M, Lutz T, Minden K, Ally M, Rubio-Pérez N, Gervais E, Van Zyl R, Wong R, Askelson M, Martini A, Brunner HI; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology INternational Trials Organisation (PRINTO).
J Rheumatol. 2023 Jul 15:jrheum.2022-1320. doi: 10.3899/jrheum.2022-1320. Online ahead of print.
PMID: 37453737
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variations.
Xiao Z, Yang MG, Liu C, Sherwood T, Gilmore JL, Lin J, Li P, Wu DR, Tokarski J, Li S, Cheng L, Xie C, Fan J, Dierks E, Strnad J, Cvijic ME, Khan J, Ruzanov M, Galella M, Khandelwal P, Dyckman AJ, Mathur A, Lombardo LJ, Macor JE, Carter PH, Aranibar N, Burke JR, Weinstein DS.
Bioorg Med Chem Lett. 2023 Jul 15;91:129373. doi: 10.1016/j.bmcl.2023.129373. Epub 2023 Jun 12.
PMID: 37315697
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders.
Moore F, Wang W, Zhao G, Mignone J, Meng W, Chu CH, Ma Z, Azzara A, Cullen MJ, Pelleymounter MA, Appiah K, Cvijic ME, Dierks E, Chang S, Foster K, Kopcho L, O'Malley K, Li YX, Khandelwal P, Whaley JM, Mathur A, Hou X, Wu DR, Robl JA, Cheng D, Devasthale P.
Bioorg Med Chem Lett. 2023 Jul 15;91:129362. doi: 10.1016/j.bmcl.2023.129362. Epub 2023 Jun 8.
PMID: 37295614
Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats.
Maher J, Stagg N, Cain G, Andaya R, Katavolos P, Gallardo-Chang F, Pham A, Ye X, Januario T, Alcantar T, Caothien R, Roose-Girma M, Zhang D, Li R, Chen S, Yauch RL.
Toxicol Appl Pharmacol. 2023 Jul 14;475:116627. doi: 10.1016/j.taap.2023.116627. Online ahead of print.
PMID: 37453479
Understanding the Non-Equivalency of Bio-Fluorescent Particle Counts versus the Colony Forming Unit.
Salvas J, Merker P, Dingle M, Joossen C, Knutsen C, Govezensky D, Cannon J, Villari P, Cundell AM, Navarro V, Franz-Riethdorf M, Scott A.
PDA J Pharm Sci Technol. 2023 Jul 14:pdajpst.2022.012790. doi: 10.5731/pdajpst.2022.012790. Online ahead of print.
PMID: 37451837
A comprehensive strategy for the identification of biologics by liquid-chromatography-mass spectrometry for release testing in a regulated environment.
Morales A, Candreva J, Jayarathne T, Esterman AL, Voruganti S, Flagg SC, Slaney T, Liu P, Adamo M, Patel S, Das TK, Zeng M, Li X.
J Pharm Biomed Anal. 2023 Jul 13;234:115580. doi: 10.1016/j.jpba.2023.115580. Online ahead of print.
PMID: 37478550
Endotrophin, a fibroblast matrikine, may be a driver of fibroblast activation in fibro-inflammatory diseases.
Reese-Petersen AL, Genovese F, Zhao L, Banks G, Gordon DA, Karsdal MA.
Front Mol Biosci. 2023 Jul 12;10:1228232. doi: 10.3389/fmolb.2023.1228232. eCollection 2023.
PMID: 37503538
Smoking, blood DNA methylation sites and lung cancer risk.
Domingo-Relloso A, Joehanes R, Rodriguez-Hernandez Z, Lahousse L, Haack K, Fallin MD, Herreros-Martinez M, Umans JG, Best LG, Huan T, Liu C, Ma J, Yao C, Jerolon A, Bermudez JD, Cole SA, Rhoades DA, Levy D, Navas-Acien A, Tellez-Plaza M.
Environ Pollut. 2023 Jul 11;334:122153. doi: 10.1016/j.envpol.2023.122153. Online ahead of print.
PMID: 37442331
Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
Brunner AM, Huggar D, Copher R, Zhou ZY, Zichlin ML, Anderson A, Downes N, McBride A.
Leuk Res. 2023 Jul 10;132:107353. doi: 10.1016/j.leukres.2023.107353. Online ahead of print.
PMID: 37562330
Genome-Wide Association Study for the Genetic Determinants of Thiopurine Methyltransferase Protein Expression in Human Livers and Racial Differences.
Smith LS, Wang X, Shi J, He B, Zhu HJ.
Pharm Res. 2023 Jul 10. doi: 10.1007/s11095-023-03558-1. Online ahead of print.
PMID: 37430149
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Gogate A, Bennett B, Poonja Z, Stewart G, Medina Colmenero A, Szturz P, Carrington C, Castro C, Gemmen E, Lau A, Carral Maseda A, Winquist E, Arrazubi V, Hao D, Cook A, Martinez Galan J, Ugidos L, Fernández Garay D, Gutierrez Abad D, Metcalf R.
Cancers (Basel). 2023 Jul 9;15(14):3552. doi: 10.3390/cancers15143552.
PMID: 37509217
Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
Gaudy A, Laille E, Bailey R, Zhou S, Skikne B, Beach CL.
Clin Pharmacol Ther. 2023 Jul 8. doi: 10.1002/cpt.2982. Online ahead of print.
PMID: 37422689
Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices.
Masilamani M, Jawa V, Dai Y, Das R, Park A, Lamba M, Wu F, Zheng X, Lu E, Gleason C, Mack T, Mora J, Surapaneni S.
Clin Pharmacol Ther. 2023 Jul 8. doi: 10.1002/cpt.2991. Online ahead of print.
PMID: 37422675
Neutralizing Antibody Validation Testing and Reporting Harmonization.
Myler H, Pedras-Vasconcelos J, Lester T, Civoli F, Xu W, Wu B, Vainshtein I, Luo L, Hassanein M, Liu S, Ramaswamy SS, Mora J, Pennucci J, McCush F, Lavelle A, Jani D, Ambakhutwala A, Baltrukonis D, Barker B, Carmean R, Chung S, Dai S, DeWall S, Dholakiya SL, Dodge R, Finco D, Yan H, Hays A, Hu Z, Inzano C, Kamen L, Lai CH, Meyer E, Nelson R, Paudel A, Phillips K, Poupart ME, Qu Q, Abhari MR, Ryding J, Sheldon C, Spriggs F, Warrino D, Wu Y, Yang L, Pasas-Farmer S.
AAPS J. 2023 Jul 8;25(4):69. doi: 10.1208/s12248-023-00830-5.
PMID: 37421491
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials.
King-Kallimanis BL, Calvert M, Cella D, Cocks K, Coens C, Fairclough D, Howie L, Jonsson P, Mahendraratnam N, Maues J, Sarac S, Shaw J, Stigger N, Trask P, Wieseler B.
Value Health. 2023 Jul 6:S1098-3015(23)03036-X. doi: 10.1016/j.jval.2023.06.019. Online ahead of print.
PMID: 37422075
Trapping mode two-dimensional liquid chromatography for quantitative low-level impurity enrichment in pharmaceutical development.
Lin Z, Wang Q, Zhou Y, Shackman JG.
J Chromatogr A. 2023 Jul 5;1700:464043. doi: 10.1016/j.chroma.2023.464043. Epub 2023 May 3.
PMID: 37172541
Factors associated with oral anticoagulant prescription status among patients with a new diagnosis of atrial fibrillation.
Manning E, Burns K, Laurie M, Patten L, Ho M, Sandhu A.
Clin Cardiol. 2023 Jul 4. doi: 10.1002/clc.24077. Online ahead of print.
PMID: 37401357
Interlaboratory Variability in the Madin-Darby Canine Kidney Cell Proteome.
Harwood MD, Zettl K, Weinheimer M, Pilla-Reddy V, Shen H, Jacobs F, Chu X, Huth F, Nakakariya M, Chothe PP, Neuhoff S, Wiśniewski JR.
Mol Pharm. 2023 Jul 3;20(7):3505-3518. doi: 10.1021/acs.molpharmaceut.3c00108. Epub 2023 Jun 7.
PMID: 37283406
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
Apollonio B, Spada F, Petrov N, Cozzetto D, Papazoglou D, Jarvis P, Kannambath S, Terranova-Barberio M, Amini RM, Enblad G, Graham C, Benjamin R, Phillips E, Ellis R, Nuamah R, Saqi M, Calado DP, Rosenquist R, Sutton LA, Salisbury J, Zacharioudakis G, Vardi A, Hagner PR, Gandhi AK, Bacac M, Claus C, Umana P, Jarrett RF, Klein C, Deutsch A, Ramsay AG.
J Clin Invest. 2023 Jul 3;133(13):e166070. doi: 10.1172/JCI166070.
PMID: 37219943
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
Mody H, Ogasawara K, Zhu X, Miles D, Shastri PN, Gokemeijer J, Liao MZ, Kasichayanula S, Yang TY, Chemuturi N, Gupta S, Jawa V, Upreti VV.
Clin Pharmacol Ther. 2023 Jul 2. doi: 10.1002/cpt.2986. Online ahead of print.
PMID: 37393588
Harmonization of criteria and terminology in fetal rat skeletal evaluations.
Posobiec LM, Kopp C, Murzyn SM, Olitan T, Rendemonti J, French J, Tamborini E, Campey J, Longo M, Danberry T, Vaillancourt M, Nowland W, Daoud M, Qualls C, Harris SB.
Birth Defects Res. 2023 Jul 1;115(12):1109-1119. doi: 10.1002/bdr2.2189. Epub 2023 May 26.
PMID: 37243321
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ.
Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2.
PMID: 37414012
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
Hunger SP, Tran TH, Saha V, Devidas M, Valsecchi MG, Gastier-Foster JM, Cazzaniga G, Reshmi SC, Borowitz MJ, Moorman AV, Heerema NA, Carroll AJ, Martin-Regueira P, Loh ML, Raetz EA, Schultz KR, Slayton WB, Cario G, Schrappe M, Silverman LB, Biondi A.
Lancet Haematol. 2023 Jul;10(7):e510-e520. doi: 10.1016/S2352-3026(23)00088-1.
PMID: 37407142
Erratum to High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma [Modern Pathology 36(5) (2023) 100154].
Robert ME, Rüschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, Kodach LL, Srivastava A, Wang HL, Tang LH, Troncone G, Rojo F, Van Treeck BJ, Pratt J, Shnitsar I, Kumar G, Karasarides M, Anders RA.
Mod Pathol. 2023 Jul;36(7):100238. doi: 10.1016/j.modpat.2023.100238. Epub 2023 Jun 14.
PMID: 37327723
HTS driven by fluorescence lifetime detection of FRET identifies activators and inhibitors of cardiac myosin.
Muretta JM, Rajasekaran D, Blat Y, Little S, Myers M, Nair C, Burdekin B, Yuen SL, Jimenez N, Guhathakurta P, Wilson A, Thompson AR, Surti N, Connors D, Chase P, Harden D, Barbieri CM, Adam L, Thomas DD.
SLAS Discov. 2023 Jul;28(5):223-232. doi: 10.1016/j.slasd.2023.06.001. Epub 2023 Jun 10.
PMID: 37307989
Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo.
Chaudhuri D, Lu T, Jacob B, Abraham S, Shankar P, Poss MA, Neamati N, Camarero JA.
J Control Release. 2023 Jul;359:26-32. doi: 10.1016/j.jconrel.2023.05.026. Epub 2023 May 30.
PMID: 37236320
Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ro SK, Zhang W, Jiang Q, Li XN, Liu R, Lu CC, Marchenko O, Sun L, Zhao J.
Ther Innov Regul Sci. 2023 Jul;57(4):899-910. doi: 10.1007/s43441-023-00528-y. Epub 2023 May 13.
PMID: 37179264
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D, Tawbi H, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob JJ, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV.
Eur J Cancer. 2023 Jul;187:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22.
PMID: 37167764
Technical considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory.
Pohl T, Gervais A, Dirksen EHC, D'Alessio V, Bechtold-Peters K, Burkitt W, Cao L, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer JW, Spencer D, Xu W, Yi L.
Eur J Pharm Biopharm. 2023 Jul;188:231-242. doi: 10.1016/j.ejpb.2023.04.024. Epub 2023 May 3.
PMID: 37146738
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Çakar E, Oniangue-Ndza C, Schneider RP, Klijn SL, Vogl UM, Rothermundt C, May JR.
Pharmacoecon Open. 2023 Jul;7(4):567-577. doi: 10.1007/s41669-023-00395-1. Epub 2023 Feb 9.
PMID: 36757568
Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA, Suissa S, Boers M, Hochberg MC, Skovron ML, Askling J, Michaud K, Strangfeld A, Pedro S, Frisell T, Meissner Y, Dominique A, Gomez A.
Semin Arthritis Rheum. 2023 Jun 30:152240. doi: 10.1016/j.semarthrit.2023.152240. Online ahead of print.
PMID: 37500379
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition.
Hassel JC, Zimmer L, Sickmann T, Eigentler TK, Meier F, Mohr P, Pukrop T, Roesch A, Vordermark D, Wendl C, Gutzmer R.
Cancers (Basel). 2023 Jun 30;15(13):3448. doi: 10.3390/cancers15133448.
PMID: 37444558
SpatialSort: a Bayesian model for clustering and cell population annotation of spatial proteomics data.
Lee E, Chern K, Nissen M, Wang X; IMAXT Consortium; Huang C, Gandhi AK, Bouchard-Côté A, Weng AP, Roth A.
Bioinformatics. 2023 Jun 30;39(39 Suppl 1):i131-i139. doi: 10.1093/bioinformatics/btad242.
PMID: 37387130
Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.
Bailey H, Lee A, Eccles L, Yuan Y, Burlison H, Forshaw C, Varol N.
BMC Cancer. 2023 Jun 30;23(1):603. doi: 10.1186/s12885-023-11074-z.
PMID: 37386452
External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real World Data Sources.
Swaminathan AC, Snyder LD, Hong H, Stevens SR, Long AS, Yanchenko E, Qiu Y, Liu R, Zhang H, Fischer A, Burns L, Wruck LM, Palmer SM.
Am J Respir Crit Care Med. 2023 Jun 29. doi: 10.1164/rccm.202210-1947OC. Online ahead of print.
PMID: 37384378
A quantitative assessment of deformation energy in intermolecular interactions: How important is it?
Sargent CT, Kasera R, Glick ZL, Sherrill CD, Cheney DL.
J Chem Phys. 2023 Jun 28;158(24):244106. doi: 10.1063/5.0155895.
PMID: 37352421
Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model.
Chiang M, Sychterz C, Gaohua L, Perera V, Gretler DD, Florea V, Merali S.
J Clin Pharmacol. 2023 Jun 27. doi: 10.1002/jcph.2298. Online ahead of print.
PMID: 37376778
Beyond Amide Bond Formation: TCFH as a Reagent for Esterification.
Luis NR, Chung KK, Hickey MR, Lin Z, Beutner GL, Vosburg DA.
Org Lett. 2023 Jun 26. doi: 10.1021/acs.orglett.3c01611. Online ahead of print.
PMID: 37364890
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Lisano JM, Wen R, Akyol A, Moskowitz AJ.
Blood Adv. 2023 Jun 23:bloodadvances.2023010254. doi: 10.1182/bloodadvances.2023010254. Online ahead of print.
PMID: 37352266
Perception of Nursing Activities That Contribute to the Quality of Care: Validity and Reliability Testing of the French Version.
Estefania C, Silvia FC, Rosa L, Teresa M, Narcisa GM, Manuela MM.
J Nurs Meas. 2023 Jun 22:JNM-2022-0090.R1. doi: 10.1891/JNM-2022-0090. Online ahead of print.
PMID: 37348891
Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma.
Yamazaki N, Kiyohara Y, Uhara H, Tsuchida T, Yoshida A, Yamada T, Komoto A.
J Dermatol. 2023 Jun 22. doi: 10.1111/1346-8138.16820. Online ahead of print.
PMID: 37350027
Metallaphotoredox-Mediated Decarboxylative Cross-Coupling of α-Oxy Morpholine Carboxylic Acids and (Hetero)Aryl Halides.
Sloane JL, Santos AB, Simmons EM, Sherwood TC.
Org Lett. 2023 Jun 16;25(23):4219-4224. doi: 10.1021/acs.orglett.3c01478. Epub 2023 Jun 6.
PMID: 37279441
Streamlining Food Effect Assessment - Are Repeated Food Effect Studies Needed? An IQ Analysis.
Kesisoglou F, Basu S, Belubbi T, Bransford P, Chung J, Dodd S, Dolton M, Heimbach T, Kulkarni P, Lin W, Moir A, Parrott N, Pepin X, Ren X, Sharma P, Stamatopoulos K, Tistaert C, Vaidhyanathan S, Wagner C, Riedmaier AE.
AAPS J. 2023 Jun 15;25(4):60. doi: 10.1208/s12248-023-00822-5.
PMID: 37322223
The implementation of value-based frameworks, clinical care pathways, and alternative payment models for cancer care in the United States.
Panchal R, Brendle M, Ilham S, Kharat A, Schmutz HW, Huggar D, McBride A, Copher R, Au T, Willis C, Brixner D.
J Manag Care Spec Pharm. 2023 Jun 15:1-10. doi: 10.18553/jmcp.2023.22352. Online ahead of print.
PMID: 37321967
Data-driven strategies for increasing patient diversity in Bristol Myers Squibb-sponsored US oncology clinical trials.
Kuri L, Setru S, Liu G, Reed DM, Weigand D, Surampudi A, Berger S, Paulucci D, Rai A, Sethuraman V, Vito B, Kellar-Wood H, Balan MM.
Clin Trials. 2023 Jun 13:17407745231180506. doi: 10.1177/17407745231180506. Online ahead of print.
PMID: 37309819
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries.
Dominique A, Hetland ML, Finckh A, Gottenberg JE, Iannone F, Caporali R, Kou TD, Nordstrom D, Hernandez MV, Sánchez-Piedra C, Sánchez-Alonso F, Pavelka K, Bond TC, Simon TA.
Arthritis Res Ther. 2023 Jun 12;25(1):101. doi: 10.1186/s13075-023-03067-x.
PMID: 37308978
Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.
Chupak L, Wichroski M, Zheng X, Ding M, Martin S, Allard C, Shi J, Gentles R, Meanwell NA, Fang J, Tenney D, Tokarski J, Cao C, Wee S.
ACS Med Chem Lett. 2023 Jun 12;14(7):929-935. doi: 10.1021/acsmedchemlett.3c00063. eCollection 2023 Jul 13.
PMID: 37465293
A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States.
Hernandez I, Divino V, Xie L, Hood DW, DeKoven M, Kariuki W, Bell G, Russ C, Cheng D, Cato M, Atreja N, Hines DM.
Am J Cardiovasc Drugs. 2023 Jun 10. doi: 10.1007/s40256-023-00588-3. Online ahead of print.
PMID: 37301789
Identification and validation of G protein-coupled receptors modulating flow-dependent signaling pathways in vascular endothelial cells.
Qiu D, Xu K, Chung N, Robbins J, Luo R, Lawrence M, He A, Yu F, Alt A, Miller MM, Hangeland J, Feder JN, Seiffert D, Arey BJ.
Front Mol Biosci. 2023 Jun 8;10:1198079. doi: 10.3389/fmolb.2023.1198079. eCollection 2023.
PMID: 37363403
Correction: Harmonizing Biopredictive Methodologies Through the Product Quality Research Institute (PQRI) Part I: Biopredictive Dissolution of Ibuprofen and Dipyridamole Tablets.
Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, Fushimi M, Gonzalez-Alvarez I, Guo Y, Jankovsky C, Lu X, Matsui K, Patel S, Sanderson N, Sun CC, Thakral NK, Yamane M, Zöller L.
AAPS J. 2023 Jun 8;25(4):58. doi: 10.1208/s12248-023-00827-0.
PMID: 37291273
Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions.
Allen J, Berry D, Cook F, Hume A, Rouce R, Srirangam A, Wellman J, McCombs C.
Mol Ther Methods Clin Dev. 2023 May 16;29:513-521. doi: 10.1016/j.omtm.2023.05.015. eCollection 2023 Jun 8.
PMID: 37287748
Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors.
Hartz RA, Ahuja VT, Luo G, Chen L, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Xu S, Tokarski JS, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM.
J Med Chem. 2023 Jun 8;66(11):7534-7552. doi: 10.1021/acs.jmedchem.3c00364. Epub 2023 May 26.
PMID: 37235865
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.
Manier S, Dimopoulos M, Hulin C, Leleu X, Delforge M, Weisel K, Mouro J, Costa B, Sturniolo M, Facon T.
Clin Lymphoma Myeloma Leuk. 2023 Jun 7:S2152-2650(23)00183-0. doi: 10.1016/j.clml.2023.06.002. Online ahead of print.
PMID: 37393121
Synthesis of Bicyclo[1.1.0]butanes from Iodo-Bicyclo[1.1.1]pentanes.
Mandler MD, Mignone J, Jurica EA, Palkowitz MD, Aulakh D, Cauley AN, Farley CA, Zhang S, Traeger SC, Sarjeant A, Paiva A, Perez HL, Ellsworth BA, Regueiro-Ren A.
Org Lett. 2023 Jun 7. doi: 10.1021/acs.orglett.3c01417. Online ahead of print.
PMID: 37284784
Screening Clones for Monoclonal Antibody Production Using Droplet Microfluidics Interfaced to Electrospray Ionization Mass Spectrometry.
D'Amico CI, Robbins G, Po I, Fang Z, Slaney TR, Tremml G, Tao L, Ruotolo BT, Kennedy RT.
J Am Soc Mass Spectrom. 2023 Jun 7;34(6):1117-1124. doi: 10.1021/jasms.3c00055. Epub 2023 May 16.
PMID: 37192521
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG.
Lancet. 2023 Jun 5:S0140-6736(23)01052-8. doi: 10.1016/S0140-6736(23)01052-8. Online ahead of print.
PMID: 37295445
Activation-inducible CAR expression enables precise control over engineered CAR T cell function.
Fraessle SP, Tschulik C, Effenberger M, Cletiu V, Gerget M, Schober K, Busch DH, Germeroth L, Stemberger C, Poltorak MP.
Commun Biol. 2023 Jun 5;6(1):604. doi: 10.1038/s42003-023-04978-w.
PMID: 37277433
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
Liang G, Wang L, You Q, Cahill K, Chen C, Zhang W, Fulton N, Stock W, Odenike O, He C, Han D.
Adv Sci (Weinh). 2023 Jun 4:e2300445. doi: 10.1002/advs.202300445. Online ahead of print.
PMID: 37271891
Discovery of pyrrolo[2,1- f ][1,2,4]triazine-based inhibitors of adaptor protein 2-associated kinase 1 for the treatment of pain.
Dzierba CD, Dasgupta B, Karageorge G, Kostich W, Hamman B, Allen J, Esposito KM, Padmanabha R, Grace J, Lentz K, Morrison J, Morgan D, Easton A, Bourin C, Browning MR, Rajamani R, Good A, Parker DD, Muckelbauer JK, Khan J, Camac D, Ghosh K, Halan V, Lippy JS, Santone KS, Denton RR, Westphal R, Bristow LJ, Conway CM, Bronson JJ, Macor JE.
Med Chem Res. 2023 Jun 3:1-7. doi: 10.1007/s00044-023-03079-x. Online ahead of print.
PMID: 37362320
Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development.
Gokemeijer J, Wen Y, Jawa V, Mitra-Kaushik S, Chung S, Goggins A, Kumar S, Lamberth K, Liao K, Lill J, Phung Q, Walsh R, Roberts BJ, Swanson M, Singh I, Tourdot S, Kroenke MA, Rup B, Goletz TJ, Gupta S, Malherbe L, Pattijn S.
AAPS J. 2023 Jun 2;25(4):55. doi: 10.1208/s12248-023-00820-7.
PMID: 37266912
Examining the Scope of Deriving β-Aryl Enones from Enol Silanes as Ketone Equivalents  via  Pd(II)-Mediated Sequential Dehydrosilylation and Arylation.
Polimera SR, Ilangovan A, Subbaiah MAM.
J Org Chem. 2023 Jun 2;88(11):7256-7271. doi: 10.1021/acs.joc.3c00502. Epub 2023 May 16.
PMID: 37192466
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.
Barrera C, Corredor G, Viswanathan VS, Ding R, Toro P, Fu P, Buzzy C, Lu C, Velu P, Zens P, Berezowska S, Belete M, Balli D, Chang H, Baxi V, Syrigos K, Rimm DL, Velcheti V, Schalper K, Romero E, Madabhushi A.
NPJ Precis Oncol. 2023 Jun 1;7(1):52. doi: 10.1038/s41698-023-00403-x.
PMID: 37264091
Enabling Efficient Design of Biological Formulations through Advanced Characterizations.
Chen K, Cheung JK, Kim HA, Leone A, Mallela K, Su Y.
Pharm Res. 2023 Jun;40(6):1313-1316. doi: 10.1007/s11095-023-03557-2.
PMID: 37407877
Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in  BRD4-NUTM1  NUT Carcinoma Harboring a  BRD4  Splice Site Mutation.
Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA.
JCO Precis Oncol. 2023 Jun;7:e2200633. doi: 10.1200/PO.22.00633.
PMID: 37384867
Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities.
Davies L, Milner DA Jr, Shulman LN, Kyokunda L, Bedada A, Vuylsteke P, Masalu N, Jackson P, Jennings N, Odunlami A, Mtshali P, Dugan U.
JCO Glob Oncol. 2023 Jun;9:e2200203. doi: 10.1200/GO.22.00203.
PMID: 37290022
Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey.
Thai S, Barlow S, Lucas J, Piercy J, Zhong Y, Zhuo J, Wu JJ.
Dermatol Ther (Heidelb). 2023 Jun;13(6):1289-1303. doi: 10.1007/s13555-023-00927-x. Epub 2023 May 31.
PMID: 37253874
General population reference values for the Functional Assessment of Cancer Therapy-Lung and PROMIS-29.
Mohindra NA, Peipert JD, Blum SI, Shaw JW, Penrod JR, Cella D.
Cancer Med. 2023 Jun;12(11):12765-12776. doi: 10.1002/cam4.5920. Epub 2023 May 6.
PMID: 37148552
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study.
Matsuoka K, Hisamatsu T, Mikami Y, Yamamoto T, Motoya S, Shinzaki S, Iwakiri R, Sugiura K, Nishimura K, Kajita M, Fernandez JL.
Adv Ther. 2023 Jun;40(6):2902-2914. doi: 10.1007/s12325-023-02500-6. Epub 2023 May 4.
PMID: 37140705
Quantifying The Burden of Persistent Musculoskeletal Pain in Employees at Rolls-Royce in The United Kingdom: A Real-World Cross-Sectional Survey.
Abraham L, Russell R, Sanchez-Riera L, Emir B, Roomes D, Green K, Taylor-Stokes G, Mirams L, Wallis H, Burton K.
J Occup Environ Med. 2023 Jun 1;65(6):e424-e434. doi: 10.1097/JOM.0000000000002845. Epub 2023 Mar 25.
PMID: 36977358
Predictors of 30-day readmission, mortality, and length of stay for hospitalized U.S. patients with Alzheimer's and related dementias from 2010 to 2015.
Sanogo V, Chen Z, Almutairi RD, Hong X, Diaby V.
Expert Rev Pharmacoecon Outcomes Res. 2023 Jun;23(5):555-559. doi: 10.1080/14737167.2023.2195628. Epub 2023 Mar 29.
PMID: 36974630
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.
Emery P, Tanaka Y, Bykerk VP, Huizinga TWJ, ra G, Bingham CO 3rd, Banerjee S, Soule BP, Nys M, Connolly SE, Lozenski KL, Zhuo J, Wong R, Huang KG, Fleischmann R.
Rheumatol Ther. 2023 Jun;10(3):707-727. doi: 10.1007/s40744-022-00519-9. Epub 2023 Mar 3.
PMID: 36869251
Peripheral Blood Monocytosis Is Associated With Long-Term Disease Severity in Pediatric-Onset Inflammatory Bowel Disease.
Zhang X, Ramos-Rivers C, Prathapan K, Wang X, Tang G, Kim S, Binion DG.
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):756-762. doi: 10.1097/MPG.0000000000003755. Epub 2023 Feb 23.
PMID: 36827967
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP.
Harrold LR, Wittstock K, Kelly S, Han X, Shan Y, Guo L, Moore PC, Khaychuk V.
Rheumatol Ther. 2023 Jun;10(3):575-587. doi: 10.1007/s40744-022-00523-z. Epub 2023 Feb 7.
PMID: 36749478
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Faulk KE, Kairalla JA, Dreyer ZE, Carroll AJ, Heerema NA, Devidas M, Carroll WL, Raetz EA, Loh ML, Hunger SP, Borowitz M, Wang C, Guest E, Brown PA.
Pediatr Blood Cancer. 2023 May 31:e30467. doi: 10.1002/pbc.30467. Online ahead of print.
PMID: 37259259
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.
Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, Borowitz MJ, Raetz EA, Carroll A, Heerema NA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Hunger SP, Loh ML.
J Clin Oncol. 2023 May 31:JCO2202200. doi: 10.1200/JCO.22.02200. Online ahead of print.
PMID: 37257143
Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan.
Uno S, Midorikawa S, Inoue K, Ichikawa D, Ito T, Kuroda J, Suzuki K.
PLoS One. 2023 May 31;18(5):e0285947. doi: 10.1371/journal.pone.0285947. eCollection 2023.
PMID: 37256880
Measurement of Moisture Content in Pharmaceutical Tablets by Handheld Near-Infrared Spectrometer: Adopting Quality by Design Approach to Analytical Method Lifecycle Management.
Patel A, Jin C, Handzo B, Kalyanaraman R.
J Pharm Biomed Anal. 2023 May 30;229:115381. doi: 10.1016/j.jpba.2023.115381. Epub 2023 Apr 5.
PMID: 37058983
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart
Yonese J, Hinata N, Masui S, Nakai Y, Shirotake S, Takeuchi A, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Morishima N, Ito H, Uemura H.
Int J Urol. 2023 May 29. doi: 10.1111/iju.15206. Online ahead of print.
PMID: 37248753
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH.
Br J Haematol. 2023 May 29. doi: 10.1111/bjh.18883. Online ahead of print.
PMID: 37246588
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis.
Gombolay G, Brenton JN, Yang JH, Stredny CM, Kammeyer R, Otten CE, Vu N, Santoro JD, Robles-Lopez K, Christiana A, Steriade C, Morris M, Gorman M, Moodley M, Hardy D, Kornbluh AB, Kahn I, Sepeta LN, Yeshokumar A; Conquering Neuroinflammation and Epilepsies Consortium (CONNECT).
Neurol Neuroimmunol Neuroinflamm. 2023 May 26;10(4):e200130. doi: 10.1212/NXI.0000000000200130. Print 2023 Jul.
PMID: 37236807
Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
Misaki K, Tamura N, Azuma T, Shinoda K, Tanaka M, Fujiwara H, Tsuboi H, Kasama T, Yoshimi R, Hanyu T, Kusaka Y, Hirao M, Onishi M, Uchino A, Izumiyama T, Yang KS, Ogawa N, Matsui K, Kurasawa K, Kawai S, Yasuoka H, Okumura N, Ueda Y, Tanaka E, Inoue E, Tsuritani K, Matsumoto S, Yamanaka H, Harigai M.
Mod Rheumatol. 2023 May 26:road045. doi: 10.1093/mr/road045. Online ahead of print.
PMID: 37233722
A review of HTA guidelines on societal and novel value elements.
Breslau RM, Cohen JT, Diaz J, Malcolm B, Neumann PJ.
Int J Technol Assess Health Care. 2023 May 25;39(1):e31. doi: 10.1017/S026646232300017X.
PMID: 37226807
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept.
Brunner HI, Tzaribachev N, Louw I, Calvo Penades I, Avila-Zapata F, Horneff G, Foeldvari I, Kingsbury DJ, Paz Gastanaga ME, Wouters C, Breedt J, Wong R, Askelson M, Zhuo J, Martini A, Lovell DJ, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) investigators.
Arthritis Care Res (Hoboken). 2023 May 23. doi: 10.1002/acr.25156. Online ahead of print.
PMID: 37221146
Adaptively leveraging external data with robust meta-analytical-predictive prior using empirical Bayes.
Zhang H, Shen Y, Li J, Ye H, Chiang AY.
Pharm Stat. 2023 May 23. doi: 10.1002/pst.2315. Online ahead of print.
PMID: 37220997
Preventive effect and mechanism of Tibetan tea extract on thrombosis in arachidonic acid-induced zebrafish determined via RNA-seq transcriptome profiles.
Wang N, Lan C, Lu H, Li L, Liao D, Xu K, Sun H, Tang Y, Wang Y, Mei J, Wei M, Wu T, Zhu H.
PLoS One. 2023 May 19;18(5):e0285216. doi: 10.1371/journal.pone.0285216. eCollection 2023.
PMID: 37205684
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
Rudin CM, Balli D, Lai WV, Richards AL, Nguyen E, Egger JV, Choudhury NJ, Sen T, Chow A, Poirier JT, Geese WJ, Hellmann MD, Forslund A.
J Thorac Oncol. 2023 May 18:S1556-0864(23)00554-3. doi: 10.1016/j.jtho.2023.05.008. Online ahead of print.
PMID: 37210008
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development.
Sauna ZE, Jawa V, Balu-Iyer S, Chirmule N.
Front Immunol. 2023 May 12;14:1151888. doi: 10.3389/fimmu.2023.1151888. eCollection 2023.
PMID: 37251396
Shallow shotgun sequencing reduces technical variation in microbiome analysis.
La Reau AJ, Strom NB, Filvaroff E, Mavrommatis K, Ward TL, Knights D.
Sci Rep. 2023 May 11;13(1):7668. doi: 10.1038/s41598-023-33489-1.
PMID: 37169816
Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).
Sangro B, Yau T, El-Khoueiry AB, Kudo M, Shen Y, Tschaika M, Roy A, Feng Y, Gao L, Aras U.
Clin Transl Sci. 2023 May 11. doi: 10.1111/cts.13544. Online ahead of print.
PMID: 37165980
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators.
N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851.
PMID: 37163623
Engineering protein A ligands to mitigate antibody loss during high-pH washes in protein A chromatography.
Bhoyar S, Foster M, Oh YH, Xu X, Traylor SJ, Guo J, Ghose S, Lenhoff AM.
J Chromatogr A. 2023 May 10;1696:463962. doi: 10.1016/j.chroma.2023.463962. Epub 2023 Apr 3.
PMID: 37043977
HIV and AIDS prevention: knowledge, attitudes, practices and health literacy of older persons in the Western Cape and KwaZulu-Natal Provinces, South Africa and in Lesotho.
Kalula SZ, Blouws T, Ramathebane M, Sayed AR.
BMC Geriatr. 2023 May 8;23(1):279. doi: 10.1186/s12877-023-04009-7.
PMID: 37158837
Investigation of Unusual  N -(Triphenyl-λ 5 -phosphanylidene) Amide Fragmentation Observed upon MS/MS Collision-Induced Dissociation.
Kurmi M, Kadambar VK, Srinivas P, Reddi Y, Panda M, Peddicord M, Miller SA, Young J, Bhutani H, Bajpai L.
J Am Soc Mass Spectrom. 2023 May 3;34(5):969-976. doi: 10.1021/jasms.3c00051. Epub 2023 Apr 5.
PMID: 37018737
Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.
Gogate A, Ranjan S, Kumar A, Bhandari H, Papademetriou E, Kim I, Potluri R.
Front Oncol. 2023 May 2;13:1119102. doi: 10.3389/fonc.2023.1119102. eCollection 2023.
PMID: 37205193
Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics.
Villafuerte-Vega RC, Li HW, Slaney TR, Chennamsetty N, Chen G, Tao L, Ruotolo BT.
Anal Chem. 2023 May 2;95(17):6962-6970. doi: 10.1021/acs.analchem.3c00344. Epub 2023 Apr 17.
PMID: 37067470
Small-Area Analysis of Treatment and Clinical Outcomes in Patients with Venous Thromboembolism in Denmark: A Nationwide Cohort Study.
Johnsen SP, Jensen M, Münster AM, Frost L, Harboe L, Poulsen PB, Albertsen IE, Vinter N, Grove EL, Larsen TB.
Thromb Haemost. 2023 May 1. doi: 10.1055/a-2073-4336. Online ahead of print.
PMID: 37054981
A Gene Panel Associated With Abemaciclib Utility in  ESR1 -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, Che D, Nayar U, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Han HS, Iafrate AJ, Ryan LY, Juric D, Moy B, Ellisen LW, Maheswaran S, Wagle N, Haber DA, Bardia A, Wander SA.
JCO Precis Oncol. 2023 May;7:e2200532. doi: 10.1200/PO.22.00532.
PMID: 37141550
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.
Zhang T, Forde PM, Sullivan RJ, Sharon E, Barksdale E, Selig W, Ebbinghaus S, Fusaro G, Gunenc D, Battle D, Burns R, Hurlbert MS, Stewart M, Atkins MB.
J Immunother Cancer. 2023 May;11(5):e006555. doi: 10.1136/jitc-2022-006555.
PMID: 37137552
Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M.
J Dermatol. 2023 May;50(5):588-595. doi: 10.1111/1346-8138.16740. Epub 2023 Mar 7.
PMID: 36882942
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
Galsky MD, Bajorin DF, Witjes JA, Gschwend JE, Tomita Y, Nasroulah F, Li J, Collette S, Valderrama BP, Grimm MO, Appleman L, Gravis G, Necchi A, Ye D, Stenner F, Wind-Rotolo M, Zhang J, Ünsal-Kaçmaz K.
Eur Urol. 2023 May;83(5):432-440. doi: 10.1016/j.eururo.2023.01.016. Epub 2023 Mar 2.
PMID: 36868932
SAIL study of stroke, systemic embolism and bleeding outcomes with warfarin anticoagulation in non-valvular atrial fibrillation (S 4 -BOW-AF).
Harris DE, Torabi F, Mallory D, Akbari A, Thayer D, Wang T, Grundy S, Gravenor M, Alikhan R, Lister S, Halcox J.
Eur Heart J Open. 2023 Apr 13;3(3):oead037. doi: 10.1093/ehjopen/oead037. eCollection 2023 May.
PMID: 37143610
Integrated model of the vertebrate augmin complex.
Travis SM, Mahon BP, Huang W, Ma M, Rale MJ, Kraus J, Taylor DJ, Zhang R, Petry S.
Nat Commun. 2023 Apr 13;14(1):2072. doi: 10.1038/s41467-023-37519-4.
PMID: 37055408
An Update on Anti-thrombotic Therapy Following Transcatheter Aortic Valve Implantation: Expert Cardiologist Opinion from a UK and Ireland Delphi Group.
Zaman A, Prendergast B, Hildick-Smith D, Blackman D, Anderson R, Spence MS, Mylotte D, Smith D, Wilding B, Chapman C, Atkins K, Pollock KG, Qureshi AC, Banning A.
Interv Cardiol. 2023 Apr 10;18:e13. doi: 10.15420/icr.2022.11. eCollection 2023.
PMID: 37398870
Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy.
W DeClue R, Fisher MD, Gooden K, Walker MS, Le TK.
Future Oncol. 2023 Apr;19(13):909-923. doi: 10.2217/fon-2022-0894. Epub 2023 May 16.
PMID: 37191097
Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study.
Mascarenhas J, Nguyen H, Saunders A, Oliver L, Tomkinson H, Perry R, McBride A.
Future Oncol. 2023 Apr;19(11):763-773. doi: 10.2217/fon-2022-1298. Epub 2023 May 10.
PMID: 37161798
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
Van Le H, Van Naarden Braun K, Nowakowski GS, Sermer D, Radford J, Townsend W, Ghesquieres H, Menne T, Porpaczy E, Fox CP, Schusterbauer C, Liu FF, Yue L, De Benedetti M, Hasskarl J.
Leuk Lymphoma. 2023 Mar;64(3):573-585. doi: 10.1080/10428194.2022.2160200. Epub 2023 Feb 8.
PMID: 36755418
Reproductive and developmental toxicity following exposure to organophosphate ester flame retardants and plasticizers, triphenyl phosphate and isopropylated phenyl phosphate, in Sprague Dawley rats.
Witchey SK, Sutherland V, Collins B, Roberts G, Shockley KR, Vallant M, Krause J, Cunny H, Waidyanatha S, Mylchreest E, Sparrow B, Moyer R, Behl M.
Toxicol Sci. 2023 Feb 17;191(2):374-386. doi: 10.1093/toxsci/kfac135.
PMID: 36562586
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.
Ghosh I, Gutka H, Krause ME, Clemens R, Kashi RS.
MAbs. 2023 Jan-Dec;15(1):2205540. doi: 10.1080/19420862.2023.2205540.
PMID: 37243580
Ranking mAb-excipient interactions in biologics formulations by NMR spectroscopy and computational approaches.
Zhang C, Gossert ST, Williams J, Little M, Barros M, Dear B, Falk B, Kanthe AD, Garmise R, Mueller L, Ilott A, Abraham A.
MAbs. 2023 Jan-Dec;15(1):2212416. doi: 10.1080/19420862.2023.2212416.
PMID: 37218059
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States.
Naidu SS, Sutton MB, Gao W, Fine JT, Xie J, Desai NR, Owens AT.
J Med Econ. 2023 Jan-Dec;26(1):682-690. doi: 10.1080/13696998.2023.2208966.
PMID: 37170479
Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors.
Hu Z, Sitkoff D, Glunz PW, Zou Y, Wang C, Muckelbauer JK, Adam LP, Wexler RR, Quan ML.
Bioorg Med Chem Lett. 2023 Apr 28;88:129304. doi: 10.1016/j.bmcl.2023.129304. Online ahead of print.
PMID: 37119973
Applications of single-cell RNA sequencing in drug discovery and development.
Van de Sande B, Lee JS, Mutasa-Gottgens E, Naughton B, Bacon W, Manning J, Wang Y, Pollard J, Mendez M, Hill J, Kumar N, Cao X, Chen X, Khaladkar M, Wen J, Leach A, Ferran E.
Nat Rev Drug Discov. 2023 Apr 28:1-25. doi: 10.1038/s41573-023-00688-4. Online ahead of print.
PMID: 37117846
An adaptive modeling approach using spiking-augmentation method to improve chemometric model performance in bioprocess monitoring.
Zhao Y, Tang Y, Wasalathanthri D, Xu J, Ding J.
Biotechnol Prog. 2023 Apr 27:e3349. doi: 10.1002/btpr.3349. Online ahead of print.
PMID: 37102507
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
Gorovits B, Azadeh M, Buchlis G, Fiscella M, Harrison T, Havert M, Janetzki S, Jawa V, Long B, Mahnke YD, McDermott A, Milton M, Nelson R, Vettermann C, Wu B.
AAPS J. 2023 Apr 26;25(3):47. doi: 10.1208/s12248-023-00814-5.
PMID: 37101079
Development of tandem-column liquid chromatographic methods for pharmaceutical compounds using simulations based on hydrophobic subtraction model parameters.
Liu Z, Zhou Y, Wang Q, Foley JP, Stoll DR, Shackman JG.
J Chromatogr A. 2023 Apr 26;1695:463925. doi: 10.1016/j.chroma.2023.463925. Epub 2023 Mar 12.
PMID: 36965284
Evaluation of oncology infusion pharmacy practices: A nationwide survey.
Boyd AM, Sue C, Khandoobhai A, Vinson B, Shaikh H, Sorenson S, Patel V, Snyder B, Bondarenk C, Koukounas Y, Earl M, Jenkins M.
J Oncol Pharm Pract. 2023 Apr 25:10781552231170358. doi: 10.1177/10781552231170358. Online ahead of print.
PMID: 37122190
Meeting Report on the 2 nd
Chinese American Society for Mass Spectrometry (CASMS) Conference Advancing Biological and Pharmaceutical Mass Spectrometry.
Chen Y, Ge Y, Han X, Hao L, Huan T, Li L, Li L, Li W, Liang X, Lin Y, Liu X, Liu Y, Ma S, Peng J, Shou W, Sun L, Tao WA, Tian Y, Wang YK, Wang Y, Wu R, Wu S, Xia J, Yang Z, Zhang H, Zhang H, Zhao S, Weng N, Huang L.
Mol Cell Proteomics. 2023 Apr 25:100559. doi: 10.1016/j.mcpro.2023.100559. Online ahead of print.
PMID: 37105363
Caregivers of patients with malignant pleural mesothelioma: who provides care, what care do they provide and what burden do they experience?
Moore A, Bennett B, Taylor-Stokes G, Daumont MJ.
Qual Life Res. 2023 Apr 25. doi: 10.1007/s11136-023-03410-4. Online ahead of print.
PMID: 37097405
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Cappellini MD, Taher AT, Piga A, Shah F, Voskaridou E, Viprakasit V, Porter JB, Hermine O, Neufeld EJ, Thompson AA, Tang D, Yucel A, Lord-Bessen J, Yu P, Guo S, Shetty JK, Miteva D, Zinger T, Backstrom JT, Oliva EN.
Eur J Haematol. 2023 Apr 24. doi: 10.1111/ejh.13975. Online ahead of print.
PMID: 37095595
On Ternary Complex Stability in Protein Degradation: In Silico Molecular Glue Binding Affinity Calculations.
Weiss DR, Bortolato A, Sun Y, Cai X, Lai C, Guo S, Shi L, Shanmugasundaram V.
J Chem Inf Model. 2023 Apr 24;63(8):2382-2392. doi: 10.1021/acs.jcim.2c01386. Epub 2023 Apr 10.
PMID: 37037192
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.
Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Citera G, Huang KG, Wu C, Connolly SE, Elbez Y, Wong R, Lozenski K, Fleischmann R.
Arthritis Res Ther. 2023 Apr 22;25(1):67. doi: 10.1186/s13075-023-03038-2.
PMID: 37087459
Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.
Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, Harrison SA, Jacobson IM, Imajo K, Gunn N, Halegoua-DeMarzio D, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Loomba R.
Clin Gastroenterol Hepatol. 2023 Apr 21:S1542-3565(23)00311-7. doi: 10.1016/j.cgh.2023.04.012. Online ahead of print.
PMID: 37088458
Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study.
Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, Lawitz EJ, Gunn N, Imajo K, Ravendhran N, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Abdelmalek MF.
Clin Gastroenterol Hepatol. 2023 Apr 21:S1542-3565(23)00310-5. doi: 10.1016/j.cgh.2023.04.011. Online ahead of print.
PMID: 37088457
Harmonizing Biopredictive Methodologies Through the Product Quality Research Institute (PQRI) Part I: Biopredictive Dissolution of Ibuprofen and Dipyridamole Tablets.
Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, Fushimi M, Gonzalez-Alvarez I, Guo Y, Jankovsky C, Lu X, Matsui K, Patel S, Sanderson N, Sun CC, Thakral NK, Yamane M, Zöller L.
AAPS J. 2023 Apr 21;25(3):45. doi: 10.1208/s12248-023-00793-7.
PMID: 37085637
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.
Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, Abedi M, Garcia-Manero G, Kurtin SE, Maciejewski JP, Patel JL, Revicki DA, George TI, Flick ED, Kiselev P, Louis CU, DeGutis IS, Nifenecker M, Erba HP, Steensma DP, Scott BL.
Transplant Cell Ther. 2023 Apr 20:S2666-6367(23)01243-5. doi: 10.1016/j.jtct.2023.04.011. Online ahead of print.
PMID: 37086851
The AAPS Journal Theme Issue: Compendium of Immunogenicity Risk Assessments: an Industry Guidance Built on Experience and Published Work.
Mora JR, Richards SM.
AAPS J. 2023 Apr 20;25(3):43. doi: 10.1208/s12248-023-00796-4.
PMID: 37081214
Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.
Vaclaw C, Merritt K, Griffin VP, Whitaker N, Gokhale M, Volkin DB, Ogunyankin MO, Dhar P.
AAPS PharmSciTech. 2023 Apr 20;24(5):104. doi: 10.1208/s12249-023-02561-4.
PMID: 37081185
Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Iberdomide.
Cheng Y, Gaudy A, Liu L, Ye Y, Thomas M, Xue Y, Zhou S, Li Y.
Clin Pharmacol Drug Dev. 2023 Apr 20. doi: 10.1002/cpdd.1254. Online ahead of print.
PMID: 37079714
An interlaboratory capillary zone electrophoresis-UV study of various monoclonal antibodies, instruments, and ε-aminocaproic acid lots.
Wiesner R, Zagst H, Lan W, Bigelow S, Holper P, Hübner G, Josefsson L, Lancaster C, Lo L, Lößner C, Lu H, Neusüß C, Rüttiger C, Schlecht J, Schürrle P, Selsam A, van der Burg D, Wang SC, Zhu Y, Wätzig H, Sänger-van de Griend C.
Electrophoresis. 2023 Apr 20. doi: 10.1002/elps.202200284. Online ahead of print.
PMID: 37079448
Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Egeler MD, van de Poll-Franse LV, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Neyns B, Janssen KJ, Blank CU, Retèl VP, Boekhout AH.
Qual Life Res. 2023 Apr 20. doi: 10.1007/s11136-023-03427-9. Online ahead of print.
PMID: 37079262
Transfer learning in a biomaterial fibrosis model identifies in vivo senescence heterogeneity and contributions to vascularization and matrix production across species and diverse pathologies.
Cherry C, Andorko JI, Krishnan K, Mejías JC, Nguyen HH, Stivers KB, Gray-Gaillard EF, Ruta A, Han J, Hamada N, Hamada M, Sturmlechner I, Trewartha S, Michel JH, Davenport Huyer L, Wolf MT, Tam AJ, Peña AN, Keerthivasan S, Le Saux CJ, Fertig EJ, Baker DJ, Housseau F, van Deursen JM, Pardoll DM, Elisseeff JH.
Geroscience. 2023 Apr 20. doi: 10.1007/s11357-023-00785-7. Online ahead of print.
PMID: 37079217
Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States.
Greene SJ, Spertus JA, Tang W, Kang A, Zhong Y, Myers MC, Shen S, Jiang J, Liu X, Steffen DR, Viola MG, Felker GM.
Circ Heart Fail. 2023 Apr 20:e010430. doi: 10.1161/CIRCHEARTFAILURE.123.010430. Online ahead of print.
PMID: 37078276
Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions.
Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, Byrne MF.
Intest Res. 2023 Apr 20. doi: 10.5217/ir.2023.00020. Online ahead of print.
PMID: 37075809
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.
Larkin J, Del Vecchio M, Mandala M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA, Weber J.
Clin Cancer Res. 2023 Apr 14:CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145. Online ahead of print.
PMID: 37058595
Integrated model of the vertebrate augmin complex.
Travis SM, Mahon BP, Huang W, Ma M, Rale MJ, Kraus J, Taylor DJ, Zhang R, Petry S.
Nat Commun. 2023 Apr 13;14(1):2072. doi: 10.1038/s41467-023-37519-4.
PMID: 37055408
Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer.
Cohen A, Noxon V, Dhamane A, Bruette R, Shah S, Hines DM, Alfred T, Luo X.
Thromb Res. 2023 Apr 13;226:117-126. doi: 10.1016/j.thromres.2023.04.009. Online ahead of print.
PMID: 37146438
Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin as a Breast Cancer Resistance Protein -Specific Endogenous Biomarker that Demonstrates Prediction of Transporter Activity In Vivo.
Zhang Y, Shipkova PA, Warrack BM, Nelson DM, Wang L, Huo R, Chen J, Panfen E, Chen XQ, Fancher M, Ruan Q, Christopher LJ, Xue Y, Sinz M, Shen H.
Drug Metab Dispos. 2023 Apr 13:DMD-AR-2023-001284. doi: 10.1124/dmd.123.001284. Online ahead of print.
PMID: 37055191
Enantioselective Total Synthesis of (+)-KB343.
Bi C, Wang Y, He C, Baran PS.
J Am Chem Soc. 2023 Apr 12;145(14):7753-7757. doi: 10.1021/jacs.3c01991. Epub 2023 Mar 30.
PMID: 36995337
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1.
Markwalder JA, Balog AJ, Williams DK, Nara SJ, Reddy R, Roy S, Kanyaboina Y, Li X, Johnston K, Fan Y, Lewis H, Marsilio F, Yan C, Critton D, Newitt JA, Traeger SC, Wu DR, Jure-Kunkel MN, Jayaraman L, Lin TA, Sinz MW, Hunt JT, Seitz SP.
Bioorg Med Chem Lett. 2023 Apr 11;88:129280. doi: 10.1016/j.bmcl.2023.129280. Online ahead of print.
PMID: 37054759
Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective.
Ghadessi M, Di J, Wang C, Toyoizumi K, Shao N, Mei C, Demanuele C, Tang RS, McMillan G, Beckman RA.
Orphanet J Rare Dis. 2023 Apr 11;18(1):79. doi: 10.1186/s13023-023-02693-7.
PMID: 37041605
Guest editors' note on special issue on application of estimand.
Seifu Y, Wang W.
J Biopharm Stat. 2023 Apr 11:1-2. doi: 10.1080/10543406.2023.2199835. Online ahead of print.
PMID: 37039452
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Campbell KM, Amouzgar M, Pfeiffer SM, Howes TR, Medina E, Travers M, Steiner G, Weber JS, Wolchok JD, Larkin J, Hodi FS, Boffo S, Salvador L, Tenney D, Tang T, Thompson MA, Spencer CN, Wells DK, Ribas A.
Cancer Cell. 2023 Apr 10;41(4):791-806.e4. doi: 10.1016/j.ccell.2023.03.010.
PMID: 37037616
Therapy effect on AI-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study.
Jakimovski D, Silva D, Niels Bergsland, Dwyer MG, Weinstock-Guttman B, Benedict RH, Riolo J, Zivadinov R; DeepGRAI Registry Study group.
Mult Scler Relat Disord. 2023 Apr 9;74:104708. doi: 10.1016/j.msard.2023.104708. Online ahead of print.
PMID: 37084495
The association between brain volume loss and disability in multiple sclerosis: A systematic review.
Matthews PM, Gupta D, Mittal D, Bai W, Scalfari A, Pollock KG, Sharma V, Hill N.
Mult Scler Relat Disord. 2023 Apr 9;74:104714. doi: 10.1016/j.msard.2023.104714. Online ahead of print.
PMID: 37068369
Strategies for controlling afucosylation in monoclonal antibodies during upstream manufacturing.
Rish AJ, Siddiquee K, Huang Z, Xu J, Anderson CA, Borys MC, Khetan A.
Biotechnol J. 2023 Apr 7:e2200604. doi: 10.1002/biot.202200604. Online ahead of print.
PMID: 37029472
Cross-platform dataset of multiplex fluorescent cellular object image annotations.
Aleynick N, Li Y, Xie Y, Zhang M, Posner A, Roshal L, Pe'er D, Vanguri RS, Hollmann TJ.
Sci Data. 2023 Apr 7;10(1):193. doi: 10.1038/s41597-023-02108-z.
PMID: 37029126
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
Fakih M, Raghav KPS, Chang DZ, Larson T, Cohn AL, Huyck TK, Cosgrove D, Fiorillo JA, Tam R, D'Adamo D, Sharma N, Brennan BJ, Wang YA, Coppieters S, Zebger-Gong H, Weispfenning A, Seidel H, Ploeger BA, Mueller U, Oliveira CSV, Paulson AS.
EClinicalMedicine. 2023 Apr 6;58:101917. doi: 10.1016/j.eclinm.2023.101917. eCollection 2023 Apr.
PMID: 37090438
Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats.
Sivaraman L, Sanderson T.
Toxicol Appl Pharmacol. 2023 Apr 6;469:116512. doi: 10.1016/j.taap.2023.116512. Online ahead of print.
PMID: 37030625
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R.
JAMA Oncol. 2023 Apr 6:e230147. doi: 10.1001/jamaoncol.2023.0147. Online ahead of print.
PMID: 37022706
3D Printed Flavor-Rich Chewable Pediatric Tablets Fabricated Using Microextrusion for Point of Care Applications.
Tabriz AG, Hui HW, Boersen N, Roberts S, Jones J, Douroumis D.
Mol Pharm. 2023 Apr 6. doi: 10.1021/acs.molpharmaceut.2c01061. Online ahead of print.
PMID: 37022302
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC.
Blood. 2023 Apr 6;141(14):1724-1736. doi: 10.1182/blood.2022017094.
PMID: 36603186
Analytical characterization of host-cell-protein-rich aggregates in monoclonal antibody solutions.
Herman CE, Min L, Choe LH, Maurer RW, Xu X, Ghose S, Lee KH, Lenhoff AM.
Biotechnol Prog. 2023 Apr 5:e3343. doi: 10.1002/btpr.3343. Online ahead of print.
PMID: 37020359
Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
Liu Y, Klein J, Bajpai R, Dong L, Tran Q, Kolekar P, Smith JL, Ries RE, Huang BJ, Wang YC, Alonzo TA, Tian L, Mulder HL, Shaw TI, Ma J, Walsh MP, Song G, Westover T, Autry RJ, Gout AM, Wheeler DA, Wan S, Wu G, Yang JJ, Evans WE, Loh M, Easton J, Zhang J, Klco JM, Meshinchi S, Brown PA, Pruett-Miller SM, Ma X.
Nat Commun. 2023 Apr 5;14(1):1739. doi: 10.1038/s41467-023-37438-4.
PMID: 37019972
Greetings from the ASMS Publications Committee.
Valentine S, Phelan V, Zhou M, Thomas S, Cannon J.
J Am Soc Mass Spectrom. 2023 Apr 5;34(4):519-520. doi: 10.1021/jasms.3c00094.
PMID: 37016835
Determining sequential micellization steps of bile salts with multi-CMC modeling.
Rovnyak D, He J, Kong S, Eckenroad KW, Manley GA, Geffert RM, Krout MR, Strein TG.
J Colloid Interface Sci. 2023 Apr 5;644:496-508. doi: 10.1016/j.jcis.2023.03.146. Online ahead of print.
PMID: 37146486
Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.
Jurica EA, Wu X, Williams KN, Haque LE, Rampulla RA, Mathur A, Zhou M, Cao G, Cai H, Wang T, Liu H, Xu C, Kunselman LK, Antrilli TM, Hicks MB, Sun Q, Dierks EA, Apedo A, Moore DB, Foster KA, Cvijic ME, Panemangalore R, Khandelwal P, Wilkes JJ, Zinker BA, Robertson DG, Janovitz EB, Galella M, Li YX, Li J, Ramar T, Jalagam PR, Jayaram R, Whaley JM, Barrish JC, Robl JA, Ewing WR, Ellsworth BA.
Bioorg Med Chem. 2023 Apr 4;85:117273. doi: 10.1016/j.bmc.2023.117273. Online ahead of print.
PMID: 37030194
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC.
Leuk Res. 2023 Apr 3;129:107074. doi: 10.1016/j.leukres.2023.107074. Online ahead of print.
PMID: 37087950
Surface ID: a geometry-aware system for protein molecular surface comparison.
Riahi S, Lee JH, Sorenson T, Wei S, Jager S, Olfati-Saber R, Park A, Wendt M, Minoux H, Qiu Y.
Bioinformatics. 2023 Apr 3;39(4):btad196. doi: 10.1093/bioinformatics/btad196.
PMID: 37067488
Corrigendum to real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States [Urologic oncology: Seminars and original investigations 40 (2022) 195.e1-195.e11].
Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S.
Urol Oncol. 2023 Apr 3:S1078-1439(23)00086-8. doi: 10.1016/j.urolonc.2023.03.001. Online ahead of print.
PMID: 37019763
Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human Serum.
Dai Y, Dong H, Gleason C, Mora J, Kolaitis G, Balasubramanian N, Surapaneni S, Kozhich A, Jawa V.
AAPS J. 2023 Apr 3;25(3):35. doi: 10.1208/s12248-023-00805-6.
PMID: 37012501
Effect of light source and UVA quotient on monoclonal antibody stability during ambient light exposure studies.
More HT, Bindra DS, Zumba A, Zhou K, Carvalho T, Mantri R.
Eur J Pharm Biopharm. 2023 Apr;185:177-182. doi: 10.1016/j.ejpb.2023.03.001. Epub 2023 Mar 7.
PMID: 36894037
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Cheng Y, Sakai H, Paz-Ares L, Lu S, John T, Sun X, Moisei A, Taylor F, Lawrance R, Zhang X, Sylvester J, Yuan Y, Blum SI, Penrod JR, Carbone DP.
Eur J Cancer. 2023 Apr;183:174-187. doi: 10.1016/j.ejca.2023.01.015. Epub 2023 Jan 28.
PMID: 36871487
Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors.
Wang R, Baxi V, Li Z, Locke D, Hedvat C, Sun Y, Walsh AM, Shao X, Basavanhally T, Greenawalt DM, Patah P, Novosiadly R.
ESMO Open. 2023 Apr;8(2):100784. doi: 10.1016/j.esmoop.2023.100784. Epub 2023 Feb 28.
PMID: 36863094
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder.
Merali SJ, Byon W, Patel YT, Elsrougy A, Marchisin D, Perera V, Chen W, He B, Murthy B.
CPT Pharmacometrics Syst Pharmacol. 2023 Apr;12(4):500-512. doi: 10.1002/psp4.12935. Epub 2023 Mar 5.
PMID: 36861188
Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer.
Dhamane AD, Shah S, Noxon V, Bruette R, Ferri M, Liu X, Jiang J, Luo X.
Thromb Res. 2023 Apr;224:52-59. doi: 10.1016/j.thromres.2023.02.001. Epub 2023 Feb 15.
PMID: 36848784
Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.
Miret M, Anderson A, Hindocha P, Cirneanu L, Lymperopoulou C, Markov E, Kizito W, Vegni FE.
Leuk Res. 2023 Apr;127:107042. doi: 10.1016/j.leukres.2023.107042. Epub 2023 Feb 14.
PMID: 36812661
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.
Cohen AT, Sah J, Dhamane AD, Hines DM, Lee T, Rosenblatt L, Emir B, Keshishian A, Yuce H, Luo X.
Adv Ther. 2023 Apr;40(4):1705-1735. doi: 10.1007/s12325-023-02440-1. Epub 2023 Feb 22.
PMID: 36811795
Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study.
Ogdie A, Shaw Y, Almonte M, Maksabedian Hernandez EJ, Stolshek B, Michaud K.
ACR Open Rheumatol. 2023 Apr;5(4):167-172. doi: 10.1002/acr2.11530. Epub 2023 Feb 10.
PMID: 36762609
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C.
Ann Hematol. 2023 Apr;102(4):749-754. doi: 10.1007/s00277-023-05109-5. Epub 2023 Feb 3.
PMID: 36732419
Chronic Expression of a Clinical
SFTPC
Mutation Causes Murine Lung Fibrosis with Idiopathic Pulmonary Fibrosis Features.
Rodriguez L, Tomer Y, Carson P, Dimopoulos T, Zhao M, Chavez K, Iyer S, Huang L, Ebert C, Sereda L, Murthy A, Trujillo G, Beers MF, Katzen J.
Am J Respir Cell Mol Biol. 2023 Apr;68(4):358-365. doi: 10.1165/rcmb.2022-0203MA.
PMID: 36473455
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States.
Kantor D, Pham T, Patterson-Lomba O, Swallow E, Dua A, Gupte-Singh K.
Neurol Ther. 2023 Mar 31. doi: 10.1007/s40120-023-00463-y. Online ahead of print.
PMID: 37000386
A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
Cichewicz A, Tencer T, Gupte-Singh K, Egodage S, Burnett H, Kumar J.
Adv Ther. 2023 Mar 31;40(5):2116-46. doi: 10.1007/s12325-023-02488-z. Online ahead of print.
PMID: 37000363
Evolving regulatory perspectives on digital health technologies for medicinal product development.
Colloud S, Metcalfe T, Askin S, Belachew S, Ammann J, Bos E, Kilchenmann T, Strijbos P, Eggenspieler D, Servais L, Garay C, Konstantakopoulos A, Ritzhaupt A, Vetter T, Vincenzi C, Cerreta F.
NPJ Digit Med. 2023 Mar 29;6(1):56. doi: 10.1038/s41746-023-00790-2.
PMID: 36991116
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Menezes DL, See WL, Risueño A, Tsai KT, Lee JK, Ma J, Khan R, Prebet T, Skikne B, Beach CL, Thakurta A, Gandhi A.
Br J Haematol. 2023 Mar 29. doi: 10.1111/bjh.18783. Online ahead of print.
PMID: 36990798
SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol.
Espinasse A, Solovyeva O, Dimairo M, Weir C, Jaki T, Mander A, Kightley A, Evans J, Lee S, Bedding A, Hopewell S, Rantell K, Liu R, Chan AW, De Bono J, Yap C.
BMJ Open. 2023 Mar 29;13(3):e068173. doi: 10.1136/bmjopen-2022-068173.
PMID: 36990492
Morphological distribution mapping: Utilisation of modelling to integrate particle size and shape distributions.
Gamble JF, Akseli I, Ferreira AP, Leane M, Thomas S, Tobyn M, Wadams RC.
Int J Pharm. 2023 Mar 25;635:122743. doi: 10.1016/j.ijpharm.2023.122743. Epub 2023 Feb 17.
PMID: 36804520
TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.
Chandhasin C, Dang V, Perabo F, Del Rosario J, Chen YK, Filvaroff E, Stafford JA, Clarke M.
Anticancer Drugs. 2023 Mar 24. doi: 10.1097/CAD.0000000000001514. Online ahead of print.
PMID: 37067993
Variables associated with joint involvement and development of a prediction rule for arthritis in patients with psoriasis. An analysis of the Italian PsoReal database.
Heidemeyer K, Cazzaniga S, Dondi L, Ronconi G, Pedrini A, Bellatreccia A, Zhong Y, Martini N, Naldi L.
J Am Acad Dermatol. 2023 Mar 23:S0190-9622(23)00500-5. doi: 10.1016/j.jaad.2023.02.059. Online ahead of print.
PMID: 36965671
Development and validation of a measure of adolescent and young adult goal-based quality of life (MAYA-GQOL).
Darabos K, Tucker CA, Brumley L, King-Dowling S, Butler E, Stevens E, O'Hagan B, Henry-Moss D, Deatrick JA, Szalda D, Barakat LP, Schwartz LA.
Qual Life Res. 2023 Mar 23. doi: 10.1007/s11136-023-03392-3. Online ahead of print.
PMID: 36952075
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.
Wei AH, Roboz GJ, Dombret H, Dohner H, Schuh AC, Montesinos P, Selleslag D, Bondarenko SN, Prebet T, Lai Y, Skikne B, Beach CL, Ravandi F.
Haematologica. 2023 Mar 23. doi: 10.3324/haematol.2022.282296. Online ahead of print.
PMID: 36951156
Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2- b ]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.
Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM.
J Med Chem. 2023 Mar 23;66(6):4231-4252. doi: 10.1021/acs.jmedchem.3c00133. Epub 2023 Mar 9.
PMID: 36950863
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.
Taher AT, Musallam KM, Viprakasit V, Kattamis A, Lord-Bessen J, Yucel A, Guo S, Pelligra C, Shields AL, Shetty JK, Miteva D, Bueno LM, Cappellini MD.
BMJ Open. 2023 Mar 22;13(3):e066683. doi: 10.1136/bmjopen-2022-066683.
PMID: 36948565
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C, Liu FF, Deger KA, Franco-Villalobos C, Proskorovsky I, Keating SJ, Sorensen S.
Adv Ther. 2023 Mar 22;40(5):2355-74. doi: 10.1007/s12325-023-02444-x. Online ahead of print.
PMID: 36947328
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.
Pape M, Vissers PAJ, Dijksterhuis WPM, Bertwistle D, McDonald L, Mostert B, Derks S, Oving IM, Verhoeven RHA, van Laarhoven HWM.
Ther Adv Med Oncol. 2023 Mar 21;15:17588359231162576. doi: 10.1177/17588359231162576. eCollection 2023.
PMID: 36970109
Characterization of serum and tissue oxytocinase and tissue oxytocin in the pregnant and non-pregnant mare.
Diel de Amorim M, Dong L, Byron M, Foster RA, Klein C, Saleh M, Saleh T, Card C.
Sci Rep. 2023 Mar 21;13(1):4616. doi: 10.1038/s41598-023-31540-9.
PMID: 36944665
Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Lin D, Nguyen H, Shah R, Qiao Y, Hartman J, Sugarman R.
Gastric Cancer. 2023 Mar 21;26(3):415-24. doi: 10.1007/s10120-023-01372-7. Online ahead of print.
PMID: 36943511
Comparison of host cell protein removal by depth filters with diatomaceous earth and synthetic silica filter aids using model proteins.
Chu LK, Borujeni EE, Xu X, Ghose S, Zydney AL.
Biotechnol Bioeng. 2023 Mar 16. doi: 10.1002/bit.28386. Online ahead of print.
PMID: 36929487
Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
Roupret M, Brouquet A, Colrat F, Diez-Andreu P, Prudent A, Chartier M, Gaudin AF, Bugnard F, Chillotti L, Bénard S, Branchoux S, Bellera C, Negrier S.
World J Urol. 2023 Mar 16:1-7. doi: 10.1007/s00345-023-04335-w. Online ahead of print.
PMID: 36929410
Modeling unmeasured baseline information in observational time-to-event data subject to delayed study entry.
Stegherr R, Beyersmann J, Bramlage P, Bluhmki T.
Stat Methods Med Res. 2023 Mar 16:9622802231163334. doi: 10.1177/09622802231163334. Online ahead of print.
PMID: 36924264
A strategy for evaluation of isotopic enrichment and structural integrity of deuterium labelled compounds by using HR-MS and NMR.
Kumar S, Gajjela R, Kumar H, Arulraj RA, Subramaniam S, Kothandaramachandran T, Sudhir V S, Chauthe SK, Gupta A, Mathur A, Roy A, Bagadi M, Caceres-Cortes J.
Anal Methods. 2023 Mar 16;15(11):1470-1477. doi: 10.1039/d2ay01980a.
PMID: 36876453
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S.
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.c
PMID: 36762851
Machine Learning and Assay Development for Image-based Phenotypic Profiling of Drug Treatments.
Sexton JZ, Fursmidt R, O’Meara MJ, Omta W, Rao A, Egan DA, Haney SA.
2023 Mar 15.
In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Gorshkov K, Haas JV, Hall MD, Hoare S, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ Jr, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–.
PMID: 36921077
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA.
Future Oncol. 2023 Mar 15. doi: 10.2217/fon-2022-1149. Online ahead of print.
PMID: 36919706
Role of the gradient slope during the product internal recycling for the multicolumn countercurrent solvent gradient purification of PEGylated proteins.
Kim TK, Bham AA, Fioretti I, Angelo J, Xu X, Ghose S, Morbidelli M, Sponchioni M.
J Chromatogr A. 2023 Mar 15;1692:463868. doi: 10.1016/j.chroma.2023.463868. Epub 2023 Feb 10.
PMID: 36803771
High Interobserver Variability among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction and Esophageal Adenocarcinoma.
Robert ME, Rüschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, Kodach LL, Srivastava A, Wang HL, Tang LH, Troncone G, Rojo F, Van Treeck BJ, Pratt J, Shnitsar I, Kumar G, Karasarides M, Anders RA.
Mod Pathol. 2023 Mar 14:100154. doi: 10.1016/j.modpat.2023.100154. Online ahead of print.
PMID: 36925069
Capillary blood collection: exploring a new method to promote noninvasive prenatal screening access.
Ehrich M, Sagaser KG, Porreco RP, Bellesheim D, Patil AS, Shulman LP, Van Den Boom D.
Am J Obstet Gynecol. 2023 Mar 13:S0002-9378(23)00153-9. doi: 10.1016/j.ajog.2023.03.008. Online ahead of print.
PMID: 36921913
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.
Moreno V, Vieito M, Sepulveda JM, Galvao V, Hernández-Guerrero T, Doger B, Saavedra O, Carlo-Stella C, Michot JM, Italiano A, Magagnoli M, Carpio C, Pinto A, Sarmiento R, Amoroso B, Aronchik I, Filvaroff E, Hanna B, Wei X, Nikolova Z, Braña I.
Nat Commun. 2023 Mar 13;14(1):1359. doi: 10.1038/s41467-023-36976-1.
PMID: 36914652
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A.
Lancet. 2023 Mar 11;401(10379):821-832. doi: 10.1016/S0140-6736(22)02574-0. Epub 2023 Feb 9.
PMID: 36774933
Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
Santoro A, Moskowitz AJ, Ferrari S, Carlo-Stella C, Lisano JM, Francis S, Wen R, Akyol A, Savage KJ.
Blood. 2023 Mar 10:blood.2022017951. doi: 10.1182/blood.2022017951. Online ahead of print.
PMID: 36898084
Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study.
Lee KK, Doudesis D, Bing R, Astengo F, Perez JR, Anand A, McIntyre S, Bloor N, Sandler B, Lister S, Pollock KG, Qureshi AC, McAllister DA, Shah ASV, Mills NL.
J Am Heart Assoc. 2023 Mar 7;12(5):e027211. doi: 10.1161/JAHA.122.027211. Epub 2023 Mar 2.
PMID: 36864741
Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.
Sagawa ZK, Goman C, Frevol A, Blazevic A, Tennant J, Fisher B, Day T, Jackson S, Lemiale F, Toussaint L, Kalisz I, Jiang J, Ondrejcek L, Mohamath R, Vergara J, Lew A, Beckmann AM, Casper C, Hoft DF, Fox CB.
Nat Commun. 2023 Mar 6;14(1):1138. doi: 10.1038/s41467-023-36789-2.
PMID: 36878897
Silver Nanoparticles in Dental Applications: A Descriptive Review.
Mallineni SK, Sakhamuri S, Kotha SL, AlAsmari ARGM, AlJefri GH, Almotawah FN, Mallineni S, Sajja R.
Bioengineering (Basel). 2023 Mar 5;10(3):327. doi: 10.3390/bioengineering10030327.
PMID: 36978718
Bayesian optimal phase II designs with dual-criterion decision making.
Zhao Y, Li D, Liu R, Yuan Y.
Pharm Stat. 2023 Mar 5. doi: 10.1002/pst.2296. Online ahead of print.
PMID: 36871961
Principled leveraging of external data in the evaluation of diagnostic devices via the propensity score-integrated composite likelihood approach.
Song C, Li H, Chen WC, Lu N, Tiwari R, Wang C, Xu Y, Yue LQ.
Pharm Stat. 2023 Mar 5. doi: 10.1002/pst.2295. Online ahead of print.
PMID: 36871949
HLH-like toxicities predict poor survival following use of tisagenlecleucel in children and young adults with B-ALL.
McNerney KO, Si Lim S, Ishikawa K, Dreyzin A, Vatsayan A, Chen JJ, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Verneris MR, Myers D, Karras NA, Brown PA, Bonifant CL, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Baumeister SHC, Fabrizio VA, Chinnabhandar V, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM.
Blood Adv. 2023 Mar 1:bloodadvances.2022008893. doi: 10.1182/bloodadvances.2022008893. Online ahead of print.
PMID: 36857419
Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States.
Turakhia MP, Guo JD, Keshishian A, Delinger R, Sun X, Ferri M, Russ C, Cato M, Yuce H, Hlavacek P.
Clin Cardiol. 2023 Mar 1. doi: 10.1002/clc.23983. Online ahead of print.
PMID: 36855960
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
Kluger H, Barrett JC, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H, Sharon E.
J Immunother Cancer. 2023 Mar;11(3):e005921. doi: 10.1136/jitc-2022-005921.
PMID: 36918224
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.
Hu S, Tang Z, Harrison JP, Hertel N, Penrod JR, May JR, Juarez-Garcia A, Holdgate O.
Pharmacoecon Open. 2023 Mar;7(2):273-284. doi: 10.1007/s41669-022-00383-x. Epub 2023 Mar 10.
PMID: 36897427
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.
Shankar LK, Schöder H, Sharon E, Wolchok J, Knopp MV, Wahl RL, Ellingson BM, Hall NC, Yaffe MJ, Towbin AJ, Farwell MD, Pryma D, Poussaint TY, Wright CL, Schwartz L, Harisinghani M, Mahmood U, Wu AM, Leung D, de Vries EGE, Tang Y, Beach G, Reeves SA.
Lancet Oncol. 2023 Mar;24(3):e133-e143. doi: 10.1016/S1470-2045(22)00742-2.
PMID: 36858729
Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.
Burke JM, Yu KS, Mordi U, Bloudek B, Liu N, Phillips T.
J Manag Care Spec Pharm. 2023 Mar;29(3):314-323. doi: 10.18553/jmcp.2023.29.3.314.
PMID: 36840956
Author Correction: FinnGen provides genetic insights from a well-phenotyped isolated population.
Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta Parolo P, Lehisto AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K, Rüeger S, Lemmelä S, Zhou W, Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S, Paajanen T, Llorens V, Gracia-Tabuenca J, Siirtola H, Reis K, Elnahas AG, Sun B, Foley CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas S, Bizaki-Vallaskangas A, Carpen O, Chen CY, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M, Finucane H, Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman ÅK, Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J, Jacob H, Jensen JN, Joensuu H, John S, Julkunen V, Jung M, Junttila J, Kaarniranta K, Kähönen M, Kajanne R, Kallio L, Kälviäinen R, Kaprio J; FinnGen; Kerimov N, Kettunen J, Kilpeläinen E, Kilpi T, Klinger K, Kosma VM, Kuopio T, Kurra V, Laisk T, Laukkanen J, Lawless N, Liu A, Longerich S, Mägi R, Mäkelä J, Mäkitie A, Malarstig A, Mannermaa A, Maranville J, Matakidou A, Meretoja T, Mozaffari SV, Niemi MEK, Niemi M, Niiranen T, O Donnell CJ, Obeidat… See abstract for full author list ➔
Nature. 2023 Mar;615(7952):E19. doi: 10.1038/s41586-023-05837-8.
PMID: 36829046
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community Study.
Hernandez KM, Bramlett KS, Agius P, Baden J, Cao R, Clement O, Corner AS, Craft J, Dean DA 2nd, Dry JR, Grigaityte K, Grossman RL, Hicks J, Higa N, Holzer TR, Jensen J, Johann DJ, Katz S, Kolatkar A, Keynton JL, Lee JSH, Maar D, Martini JF, Meyer CG, Roberts PC, Ryder M, Salvatore L, Schageman JJ, Somiari S, Stetson D, Stern M, Xu L, Leiman LC.
J Mol Diagn. 2023 Mar;25(3):143-155. doi: 10.1016/j.jmoldx.2022.12.003.
PMID: 36828596
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N.
Future Oncol. 2023 Mar;19(8):549-557. doi: 10.2217/fon-2023-0007. Epub 2023 Feb 23.
PMID: 36815433
Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.
Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K.
Mult Scler Relat Disord. 2023 Mar;71:104551. doi: 10.1016/j.msard.2023.104551. Epub 2023 Feb 6.
PMID: 36791623
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
Van Le H, Van Naarden Braun K, Nowakowski GS, Sermer D, Radford J, Townsend W, Ghesquieres H, Menne T, Porpaczy E, Fox CP, Schusterbauer C, Liu FF, Yue L, De Benedetti M, Hasskarl J.Leuk Lymphoma. 2023 Mar;64(3):573-585. doi: 10.1080/10428194.2022.2160200. Epub 2023 Feb 8.
PMID: 36755418
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S.
Lung Cancer. 2023 Mar;177:11-20. doi: 10.1016/j.lungcan.2023.01.006. Epub 2023 Jan 11.
PMID: 36669321
Baseline risk factors associated with immune related adverse events and atezolizumab.
Madjar K, Mohindra R, Durán-Pacheco G, Rasul R, Essioux L, Maiya V, Chandler GS.
Front Oncol. 2023 Feb 28;13:1138305. doi: 10.3389/fonc.2023.1138305. eCollection 2023.
PMID: 36925916
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.
Cheng Y, Ye Y, Gaudy A, Ghosh A, Xue Y, Wang A, Zhou S, Li Y.
Clin Pharmacol. 2023 Feb 28;15:9-19. doi: 10.2147/CPAA.S397826. eCollection 2023.
PMID: 36880014
Residue-Level Characterization of Antibody Binding Epitopes Using Carbene Chemical Footprinting.
Hogan JM, Lee PS, Wong SC, West SM, Morishige WH, Bee C, Tapia GC, Rajpal A, Strop P, Dollinger G.
Anal Chem. 2023 Feb 28;95(8):3922-3931. doi: 10.1021/acs.analchem.2c03091. Epub 2023 Feb 15.
PMID: 36791402
Peripheral blood monocytosis is associated with long-term disease severity in pediatric-onset inflammatory bowel disease.
Zhang X, Ramos-Rivers C, Prathapan K, Wang X, Tang G, Kim S, Binion DG.
J Pediatr Gastroenterol Nutr. 2023 Feb 27:e003755. doi: 10.1097/MPG.0000000000003755. Online ahead of print
.PMID: 36827967
Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.
Zhang R, Singh S, Pan C, Xu B, Kindblom J, Eng KH, Krolewski JJ, Nastiuk KL.
Am J Clin Exp Urol. 2023 Feb 25;11(1):12-26. eCollection 2023.
PMID: 36923722
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C.
Eur Urol Oncol. 2023 Feb 24:S2588-9311(23)00031-7. doi: 10.1016/j.euo.2023.01.012. Online ahead of print.
PMID: 36842942
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial.
Weisel K, Dimopoulos MA, San-Miguel J, Paner A, Engelhardt M, Taylor F, Lord-Bessen J, Yip C, Greenwood M, Tang J, Cavo M.
Hemasphere. 2023 Feb 24;7(3):e843. doi: 10.1097/HS9.0000000000000843. eCollection 2023 Mar.
PMID: 36860268
Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
Xiao H, Bertwistle D, Khela K, Middleton-Dalby C, Hall J.
BMC Cancer. 2023 Feb 23;23(1):186. doi: 10.1186/s12885-023-10553-7.
PMID: 36823552
Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis.
Singh H, Wilson L, Tencer T, Kumar J.
Clinicoecon Outcomes Res. 2023 Feb 22;15:125-138. doi: 10.2147/CEOR.S391413. eCollection 2023.
PMID: 36855750
Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials.
Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, Byrne MF.
J Crohns Colitis. 2023 Feb 22:jjad029. doi: 10.1093/ecco-jcc/jjad029. Online ahead of print.
PMID: 36812142
Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group.
Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, Heimbach T, Huang Y, Morrison C, Mundhra D, Palaparthy R, Saha P, Siemons M, Shaik NA, Shi Y, Shum S, Thakral NK, Urva S, Vargo R, Koganti VR, Barrett SE.
Pharm Res. 2023 Feb 22. doi: 10.1007/s11095-022-03391-y. Online ahead of print.
PMID: 36811809 Review.
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.
Deutsch JS, Lipson EJ, Danilova L, Topalian SL, Jedrych J, Baraban E, Ged Y, Singla N, Choueiri TK, Gupta S, Motzer RJ, McDermott D, Signoretti S, Atkins M, Taube JM.
Cell Rep Med. 2023 Feb 21;4(2):100947. doi: 10.1016/j.xcrm.2023.100947.
PMID: 36812889
Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment.
Szabo PM, Vajdi A, Kumar N, Tolstorukov MY, Chen BJ, Edwards R, Ligon KL, Chasalow SD, Chow KH, Shetty A, Bolisetty M, Holloway JL, Golhar R, Kidd BA, Hull PA, Houser J, Vlach L, Siemers NO, Saha S.
Sci Rep. 2023 Feb 21;13(1):3051. doi: 10.1038/s41598-023-28480-9.
PMID: 36810872
Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD, Allo MA, Gu L, Vashistha V, Press A, Kelley M.
PLoS One. 2023 Feb 21;18(2):e0282020. doi: 10.1371/journal.pone.0282020. eCollection 2023.
PMID: 36809528
Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS/MS and NMR: Formation of possible geometrical isomers.
Panda S, Das M, Kandula RR, Gajjela R, Ravuri NDH, Kumar H, Kalamse S, Mathur A, Roy A, Bagadi M.
J Pharm Biomed Anal. 2023 Feb 20;225:115214. doi: 10.1016/j.jpba.2022.115214. Epub 2022 Dec 29.
PMID: 36621281
A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan.
Komine M, Kim H, Yi J, Zhong Y, Sakai Y, Crawford B, Habiro K, Hikichi Y, Feldman SR.
J Dermatol. 2023 Feb 20. doi: 10.1111/1346-8138.16746. Online ahead of print.
PMID: 36808765
Nivolumab With or Without Ipilimumab in Pediatric Patients With High-Grade CNS Malignancies: Safety, Efficacy, Biomarker, and Pharmacokinetics: CheckMate 908.
Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, André N, Hansford JR, Hassall T, Eyrich M, Gururangan S, Bartels U, Gajjar A, Howell L, Warad D, Pacius M, Tam R, Wang Y, Zhu L, Cohen K.
Neuro Oncol. 2023 Feb 20:noad031. doi: 10.1093/neuonc/noad031. Online ahead of print.
PMID: 36808285
Structurally Diverse Bench-Stable Nickel(0) Pre-Catalysts: A Practical Toolkit for In Situ Ligation Protocols.
Tran VT, Kim N, Rubel CZ, Wu X, Kang T, Jankins TC, Li ZQ, Joannou MV, Ayers S, Gembicky M, Bailey J, Sturgell EJ, Sanchez BB, Chen JS, Lin S, Eastgate MD, Wisniewski SR, Engle KM.
Angew Chem Int Ed Engl. 2023 Feb 20;62(9):e202211794. doi: 10.1002/anie.202211794. Epub 2023 Jan 18.
PMID: 36524997
In Support of Early-Career Researchers.
Bandichhor R, Borovik AS, Bettencourt-Dias A, Eastgate MD, Radu NS, Shi F, McElwee-White L.
J Org Chem. 2023 Feb 17;88(4):1923-1927. doi: 10.1021/acs.joc.3c00130. Epub 2023 Feb 2.
PMID: 36727963
Reproductive and developmental toxicity following exposure to organophosphate ester flame retardants and plasticizers, triphenyl phosphate and isopropylated phenyl phosphate, in Sprague Dawley rats.
Witchey SK, Sutherland V, Collins B, Roberts G, Shockley KR, Vallant M, Krause J, Cunny H, Waidyanatha S, Mylchreest E, Sparrow B, Moyer R, Behl M.Toxicol Sci. 2023 Feb 17;191(2):374-386. doi: 10.1093/toxsci/kfac135.PMID: 36562586
Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions.
Fisher KJ, Kinsey R, Mohamath R, Phan T, Liang H, Orr MT, Lykins WR, Guderian JA, Bakken J, Argilla D, Ramer-Denisoff G, Larson E, Qi Y, Sivananthan S, Smolyar K, Carter D, Paddon CJ, Fox CB.
NPJ Vaccines. 2023 Feb 16;8(1):14. doi: 10.1038/s41541-023-00608-y.
PMID: 36797262
In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
Selkirk JV, Yan YG, Ching N, Paget K, Hargreaves R.
Eur J Pharmacol. 2023 Feb 15;941:175442. doi: 10.1016/j.ejphar.2022.175442. Epub 2022 Dec 5.
PMID: 36470447
Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Connarn JN, Witjes H, van Zutphen-van Geffen M, de Greef R, Campbell TB, Hege K, Zhou S, Lamba M.
CPT Pharmacometrics Syst Pharmacol. 2023 Feb 15. doi: 10.1002/psp4.12922. Online ahead of print.
PMID: 36794354
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ.
J Clin Oncol. 2023 Feb 13:JCO2202072. doi: 10.1200/JCO.22.02072. Online ahead of print.
PMID: 36780608
In Support of Early-Career Researchers.
Bandichhor R, Borovik AS, Bettencourt-Dias A, Eastgate MD, Radu NS, Shi F, McElwee-White L.
Inorg Chem. 2023 Feb 13;62(6):2489-2493. doi: 10.1021/acs.inorgchem.3c00207. Epub 2023 Feb 2.
PMID: 36727951
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS.
J Clin Oncol. 2023 Feb 10;41(5):943-954. doi: 10.1200/JCO.22.02272.
PMID: 36750016
In Support of Early-Career Researchers.
Bandichhor R, Borovik AS, Bettencourt-Dias A, Eastgate MD, Radu NS, Shi F, McElwee-White L.
Org Lett. 2023 Feb 10;25(5):715-719. doi: 10.1021/acs.orglett.3c00187. Epub 2023 Feb 2.
PMID: 36727953
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Çakar E, Oniangue-Ndza C, Schneider RP, Klijn SL, Vogl UM, Rothermundt C, May JR.
Pharmacoecon Open. 2023 Feb 9. doi: 10.1007/s41669-023-00395-1. Online ahead of print
.PMID: 36757568
Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold.
Gillis EP, Parcella K, Bowsher M, Cook JH, Iwuagwu C, Naidu BN, Patel M, Peese K, Huang H, Valera L, Wang C, Kieltyka K, Parker DD, Simmermacher J, Arnoult E, Nolte RT, Wang L, Bender JA, Frennesson DB, Saulnier M, Wang AX, Meanwell NA, Belema M, Hanumegowda U, Jenkins S, Krystal M, Kadow JF, Cockett M, Fridell R.
J Med Chem. 2023 Feb 9;66(3):1941-1954. doi: 10.1021/acs.jmedchem.2c01732. Epub 2023 Jan 31.
PMID: 36719971
A Distributional Model of Bound Ligand Conformational Strain: From Small Molecules up to Large Peptidic Macrocycles.
Jain AN, Brueckner AC, Cleves AE, Reibarkh M, Sherer EC.
J Med Chem. 2023 Feb 9;66(3):1955-1971. doi: 10.1021/acs.jmedchem.2c01744. Epub 2023 Jan 26.
PMID: 36701387
Experimental and computational characterization of mass transfer in high turndown bioreactors.
Schlaich EM, Thomas JA, Kandari L, Tremml G, Khetan A.
Biotechnol Prog. 2023 Feb 8:e3330. doi: 10.1002/btpr.3330. Online ahead of print.
PMID: 36751946
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U.
Blood Cancer J. 2023 Feb 7;13(1):24. doi: 10.1038/s41408-023-00793-y.
PMID: 36746923
Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.
Blackhall F, Girard N, Livartowski A, McDonald L, Roset M, Lara N, Juarez García A.
BMJ Open. 2023 Feb 6;13(2):e052556. doi: 10.1136/bmjopen-2021-052556.
PMID: 36746549
Measurement of LAG-3 Expression Across Multiple Staining Platforms With the 17B4 Antibody Clone.
Wojcik JB, Desai K, Avraam K, Vandebroek A, Dillon LM, Giacomazzi G, Rypens C, Benci JL.
Arch Pathol Lab Med. 2023 Feb 6. doi: 10.5858/arpa.2022-0082-OA. Online ahead of print.
PMID: 36745202
Follow Your Nose: Repeat Nasal Bone Evaluation in First-Trimester Screening for Down Syndrome.
Miller KA, Sagaser KG, Hertenstein CB, Blakemore KJ, Forster KR, Lawson CS, Jelin AC.
J Ultrasound Med. 2023 Feb 6. doi: 10.1002/jum.16190. Online ahead of print.
PMID: 36744578
Amorphous Drug-Polymer Salts: Maximizing Proton Transfer to Enhance Stability and Release.
Neusaenger AL, Yao X, Yu J, Kim S, Hui HW, Huang L, Que C, Yu L.
Mol Pharm. 2023 Feb 6;20(2):1347-1356. doi: 10.1021/acs.molpharmaceut.2c00942. Epub 2023 Jan 20.
PMID: 36668815
Declining enrolment and other challenges in IBD clinical trials: Causes and potential solutions.
Uzzan M, Bouhnik Y, Abreu M, Ahmad HA, Adsul S, Carlier H, Dubinsky M, Germinaro M, Jairath V, Modesto I, Mortensen E, Narula N, Neimark E, Oortwijn A, Protic M, Rubin DT, Oh YS, Wichary J, Peyrin-Biroulet L, Reinisch W.
J Crohns Colitis. 2023 Feb 4:jjad020. doi: 10.1093/ecco-jcc/jjad020. Online ahead of print.
PMID: 36738443
Structure-activity relationship (SAR) studies on substituted N-(pyridin-3-yl)-2-amino-isonicotinamides as highly potent and selective glycogen synthase kinase-3 (GSK-3) inhibitors.
Luo G, Chen L, Jacutin-Porte S, Han Y, Burton CR, Xiao H, Krause CM, Cao Y, Liu N, Kish K, Lewis HA, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett. 2023 Feb 1;81:129143. doi: 10.1016/j.bmcl.2023.129143. Epub 2023 Jan 18.
PMID: 36669575
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Antonio JN Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD.
Future Oncol. 2023 Feb;19(6):413-426. doi: 10.2217/fon-2022-1294. Epub 2023 Mar 15.
PMID: 36919916
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L.
J Immunother Cancer. 2023 Feb;11(2):e006127. doi: 10.1136/jitc-2022-006127.
PMID: 36725084
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain.
Prior H, Andrews L, Cauvin A, Chien H, Clarke DO, Datta K, Dempster M, Dybdal N, Freebern W, de Haan L, Herzyk D, Hey A, Kissner T, Kronenberg S, Leach MW, Lee D, Reid K, Schutte K, Sewell F, Trouba K, Ulrich P, van Aerts L, van Meer P, Weir L.
Regul Toxicol Pharmacol. 2023 Feb;138:105339. doi: 10.1016/j.yrtph.2023.105339. Epub 2023 Jan 14.
PMID: 36649820
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Germing U, Fenaux P, Platzbecker U, Buckstein R, Santini V, Díez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji RS, Zeidan AM, Garcia-Manero G.
Ann Hematol. 2023 Feb;102(2):311-321. doi: 10.1007/s00277-022-05071-8. Epub 2023 Jan 13.
PMID: 36635381
Development and Clinical Evaluation of a Rapid Point of Care Test for Ebola Virus Infection in Humans.
Wang Z, Bennett RS, Roehler M, Guillon G, Fischl MJ, Donadi MC, Makovetz J, Holmes N, Zaveri T, Toolan E, Gontz HL, Yearwood GD, Logue J, Bohannon JK, Mistretta L, Byrum R, Ragland D, St Claire M, Kurtz LA, Miller T, Reed MR, Young J, Lee J, Hensley LE, Kardos K, Berry JD.
Viruses. 2023 Jan 25;15(2):336. doi: 10.3390/v15020336.
PMID: 36851550
Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal Injury.
Guo Z, Valenzuela Ripoll C, Picataggi A, Rawnsley DR, Ozcan M, Chirinos JA, Chendamarai E, Girardi A, Riehl T, Evie H, Diab A, Kovacs A, Hyrc K, Ma X, Asnani A, Shewale SV, Scherrer-Crosbie M, Cowart LA, Parks JS, Zhao L, Gordon D, Ramirez-Valle F, Margulies KB, Cappola TP, Desai AA, Pedersen LN, Bergom C, Stitziel NO, Rettig MP, DiPersio JF, Hajny S, Christoffersen C, Diwan A, Javaheri A.
JACC Basic Transl Sci. 2023 Jan 4;8(3):340-355. doi: 10.1016/j.jacbts.2022.09.010. eCollection 2023 Mar.
PMID: 37034289
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA, Minnich A, Sanyal AJ, Loomba R, Du S, Schwarz J, Ehman RL, Karsdal M, Leeming DJ, Cizza G, Charles ED.
JHEP Rep. 2023 Jan 7;5(4):100661. doi: 10.1016/j.jhepr.2022.100661. eCollection 2023 Apr.
PMID: 36866389
Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation study.
Ishida T, Nakakoji M, Murata T, Matsuyama F, Iida S.
J Med Econ. 2023 Jan-Dec;26(1):565-573. doi: 10.1080/13696998.2023.2197811.
PMID: 37010489
Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway.
Winge-Main A, Robsahm TE, Nyakas M, Festervoll G, Torkilseng E, Thybo S, Pati S, Carroll R.
Future Oncol. 2023 Jan;19(3):205-215. doi: 10.2217/fon-2022-0969. Epub 2023 Mar 28.
PMID: 36974621
Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
Crosbie A, Le TK, Zhang Y, Das R, Ades F, Davis C, Gogate A.
Future Oncol. 2023 Jan;19(3):229-244. doi: 10.2217/fon-2022-0801. Epub 2023 Mar 28.
PMID: 36974619
Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study.
Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Neil EC, Chakravarti A, Willmarth N, Balajonda BC, Menon J, Ma J, Bauer H, Nelson RS, Tan MS, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D.
Future Oncol. 2023 Jan;19(2):173-188. doi: 10.2217/fon-2022-0904. Epub 2023 Mar 28.
PMID: 36974606
In Vitro Generation of Human Cross-Presenting Type 1 Conventional Dendritic Cells (cDC1s) and Plasmacytoid Dendritic Cells (pDCs).
Luo X, Balan S, Arnold-Schrauf C, Dalod M.
Methods Mol Biol. 2023;2618:133-145. doi: 10.1007/978-1-0716-2938-3_10.
PMID: 36905514
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.
Assié JB, Chouaïd C, Nunes H, Reynaud D, Gaudin AF, Grumberg V, Jolivel R, Jouaneton B, Cotté FE, Duchemann B.
Ther Adv Med Oncol. 2023 Jan 31;15:17588359231152847. doi: 10.1177/17588359231152847. eCollection 2023.
PMID: 36743523
Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients.
Huuhtanen J, Kasanen HH, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S.
J Clin Invest. 2023 Jan 31:e164809. doi: 10.1172/JCI164809. Online ahead of print.
PMID: 36719749
Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting.
Parekh K, LeBlang S, Nazarian J, Mueller S, Zacharoulis S, Hynynen K, Powlovich L.
Neoplasia. 2023 Jan 27;37:100876. doi: 10.1016/j.neo.2023.100876. Online ahead of print.
PMID: 36709715
Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States.
Desai NR, Sutton MB, Xie J, Fine JT, Gao W, Owens AT, Naidu SS.
Am J Cardiol. 2023 Jan 27;192:16-23. doi: 10.1016/j.amjcard.2022.12.030. Online ahead of print.
PMID: 36709525
Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies.
Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL.
Transplant Cell Ther. 2023 Jan 26:S2666-6367(23)00045-3. doi: 10.1016/j.jtct.2023.01.021. Online ahead of print.
PMID: 36709800
Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an  In Vivo  Model of  Trypanosoma cruzi  Infection.
Tawaraishi T, Ochida A, Akao Y, Itono S, Kamaura M, Akther T, Shimada M, Canan S, Chowdhury S, Cao Y, Condroski K, Engkvist O, Francisco A, Ghosh S, Kaki R, Kelly JM, Kimura C, Kogej T, Nagaoka K, Naito A, Pairaudeau G, Radu C, Roberts I, Shum D, Watanabe NA, Xie H, Yonezawa S, Yoshida O, Yoshida R, Mowbray C, Perry B.
J Med Chem. 2023 Jan 26;66(2):1221-1238. doi: 10.1021/acs.jmedchem.2c00775. Epub 2023 Jan 6.
PMID: 36607408
Rapid Sterility Test Systems in the Pharmaceutical Industry: Applying a Structured Approach to their Evaluation, Validation and Global Implementation.
Deutschmann S, Paul M, Claassen-Willemse M, van den Berg J, IJzerman-Boon P, Grunert da Fonseca V, Brunbech E, Johnson L, Knutsen C, Plourde L, Salvas J, Villari P, Wysocki L, Franz-Riethdorf M.
PDA J Pharm Sci Technol. 2023 Jan 25:pdajpst.2021.012672. doi: 10.5731/pdajpst.2021.012672. Online ahead of print.
PMID: 36697213
Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
Chatterjee S, Deshpande AA, Shen H.
Biopharm Drug Dispos. 2023 Jan 24. doi: 10.1002/bdd.2345. Online ahead of print.
PMID: 36692150
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, Stock W, Jabbour EJ.
Am J Hematol. 2023 Jan 24. doi: 10.1002/ajh.26853. Online ahead of print.
PMID: 36691748
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S, Ananthakrishnan R, Kuwayama S, Nishio M, Kanda Y, Suzuki K.
Int J Hematol. 2023 Jan 24. doi: 10.1007/s12185-023-03538-6. Online ahead of print.
PMID: 36690910
Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J, Kara V, Haack R, Vogel U, Garg A, Krupp M, Gofman K, Dreyfus B, Hauben M, Bate A.
Drug Saf. 2023 Jan 23. doi: 10.1007/s40264-023-01272-w. Online ahead of print.
PMID: 36689132
A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK.
Cohen AT, Benson G, Bradbury CA, Choudhuri S, Hutchinson Jones N, Maraveyas A, Venugopal B, Young AM, Chapman C, McIntyre S, Burney D, Pollock KG, Morgan AR, Gabb PD, Alikhan R.
Curr Med Res Opin. 2023 Jan 23:1-13. doi: 10.1080/03007995.2023.2167441. Online ahead of print.
PMID: 36629478 Review.
Assessing the Impact of Open-Label Designs in Patient-Reported Outcomes: Investigation in Oncology Clinical Trials.
Lord-Bessen J, Signorovitch J, Yang M, Georgieva M, Roydhouse J.
JNCI Cancer Spectr. 2023 Jan 20:pkad002. doi: 10.1093/jncics/pkad002. Online ahead of print.
PMID: 36661326
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Wei AH, Döhner H, Sayar H, Ravandi F, Montesinos P, Dombret H, Selleslag D, Porkka K, Jang JH, Skikne B, Beach CL, Prebet T, Zhang G, Risueño A, Ugidos M, See WL, Menezes D, Roboz GJ.
Am J Hematol. 2023 Jan 19. doi: 10.1002/ajh.26847. Online ahead of print.
PMID: 36655608
A fast and powerful linear mixed model approach for genotype-environment interaction tests in large-scale GWAS.
Zhong W, Chhibber A, Luo L, Mehrotra DV, Shen J.
Brief Bioinform. 2023 Jan 19;24(1):bbac547. doi: 10.1093/bib/bbac547.
PMID: 36545787
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
Wheeler MT, Olivotto I, Elliott PM, Saberi S, Owens AT, Maurer MS, Masri A, Sehnert AJ, Edelberg JM, Chen YM, Florea V, Malhotra R, Wang A, Oreziak A, Myers J.
JAMA Cardiol. 2023 Jan 18:e225099. doi: 10.1001/jamacardio.2022.5099. Online ahead of print.
PMID: 36652223
Phosphine-Dependent Photoinitiation of Alkyl Thiols under Near-UV Light Facilitates User-Friendly Peptide Desulfurization.
Venneti NM, Samala G, Morsy RMI, Mendoza LG, Isidro-Llobet A, Tom JK, Mukherjee S, Kopach ME, Stockdill JL.
J Am Chem Soc. 2023 Jan 18;145(2):1053-1061. doi: 10.1021/jacs.2c10625. Epub 2023 Jan 5.
PMID: 36602440
Authentication of Human and Mouse Cell Lines by Short Tandem Repeat (STR) DNA Genotype Analysis.
Almeida JL, Korch CT.
2023 Jan 17. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Gorshkov K, Haas JV, Hall MD, Hoare S, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ Jr, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–.
PMID: 23805434
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network.
Inman RD, Choquette D, Khraishi M, Gladman D, Hussein S, Neish D, Leclerc P.
J Rheumatol. 2023 Jan 15:jrheum.220824. doi: 10.3899/jrheum.220824. Online ahead of print.
PMID: 36642434
Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer.
Dercle L, Fronheiser M, Rizvi NA, Hellmann MD, Maier S, Hayes W, Yang H, Guo P, Fojo T, Schwartz LH, Zhao B, Leung DK.
J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01995-5. doi: 10.1016/j.jtho.2022.12.019. Online ahead of print.
PMID: 36646209
Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
Wolf A, Stratmann JA, Shaid S, Niklas N, Calleja A, Ubhi H, Munro R, Waldenberger D, Carroll R, Daumont MJ, Penrod JR, Lacoin L, Rohde G.
BMC Pulm Med. 2023 Jan 13;23(1):16. doi: 10.1186/s12890-022-02288-1.
PMID: 36639770
A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma.
Zhang M, Gray F, Cushman I, Wurmser A, Chan H, Couto S, Wang M, Nakayama Y, Hagner P, Al-Masri H, Williams S, Hersey S.
Mod Pathol. 2023 Jan 12;36(4):100050. doi: 10.1016/j.modpat.2022.100050. Online ahead of print.
PMID: 36788077
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U.
Blood Cancer J. 2023 Jan 12;13(1):12. doi: 10.1038/s41408-023-00787-w.
PMID: 36631435
Correction: End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.
Morales AM, Sreedhara A, Buecheler J, Brosig S, Chou D, Christian T, Das T, de Jong I, Fast J, Jagannathan B, Moussa EM, Nejadnik MR, Prajapati I, Radwick A, Rahman Y, Singh S.
AAPS J. 2023 Jan 11;25(1):15. doi: 10.1208/s12248-023-00780-y.
PMID: 36631711
Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019).
Joy M, Williams J, Emanuel S, Kar D, Fan X, Delanerolle G, Field BC, Heiss C, Pollock KG, Sandler B, Arora J, Sheppard JP, Feher M, Hobbs FR, de Lusignan S.
Heart. 2023 Jan 11;109(3):195-201. doi: 10.1136/heartjnl-2022-321377.
PMID: 36371664
FDA/M-CERSI Co-Processed API Workshop Proceedings.
Schenck L, Patel P, Sood R, Bonaga L, Capella P, Dirat O, Erdemir D, Ferguson S, Gazziola C, Gorka LS, Graham L, Ho R, Hoag S, Hunde E, Kline B, Lee SL, Madurawe R, Marziano I, Merritt JM, Page S, Polli J, Ramanadham M, Sapru M, Stevens B, Watson T, Zhang H.
J Pharm Sci. 2023 Jan 10:S0022-3549(23)00007-2. doi: 10.1016/j.xphs.2023.01.006. Online ahead of print.
PMID: 36638959
Understanding the Impact of Microstructures on Reconstitution and Drying Kinetics of Lyophilized Cake Using X-ray Microscopy and Image-Based Simulation.
Pu YE, Ma L, Dear B, Zhu A, Li J, Zhang S, Shi W.
J Pharm Sci. 2023 Jan 7:S0022-3549(23)00004-7. doi: 10.1016/j.xphs.2023.01.002. Online ahead of print.
PMID: 36627053
Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.
Sengupta S, Ntambwe I, Tan K, Liang Q, Paulucci D, Castellanos E, Fiore J, Lane S, Micsinai Balan M, Viraswami-Apanna K, Sethuraman V, Samant M, Tiwari R.
Clin Pharmacol Ther. 2023 Jan 6. doi: 10.1002/cpt.2841. Online ahead of print.
PMID: 36606735
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Buckstein R, Chodirker L, Yee KWL, Geddes M, Leitch HA, Christou G, Banerji V, Leber B, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Parmentier A, Thambipillai A, Tang D, Westcott C, Cameron C, Spin P.
Leuk Lymphoma. 2023 Jan 6:1-11. doi: 10.1080/10428194.2022.2156793. Online ahead of print.
PMID: 36606533
Coupling-Condensation Strategy for the Convergent Synthesis of an Imidazole-Fused 2-Aminoquinoline NLRP3 Agonist.
Bi C, Chadwick J, Davies ML, DelMonte AJ, Geng P, Glace AW, Green RA, Gurak JA Jr, Haley MW, He BL, Inankur B, Jamison CR, Joe CL, Kolotuchin S, Lin D, Lou S, Nye J, Ortiz A, Purdum GE, Rosso VW, Shah M, Simmons EM, Stevens JM, Strotman NA, Tan Y, Zhang L.
J Org Chem. 2023 Jan 6;88(1):384-394. doi: 10.1021/acs.joc.2c02395. Epub 2022 Dec 14.
PMID: 36516991
Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor-free, Belatacept Plus Everolimus-based Immunosuppression.
Peddi VR, Marder B, Gaite L, Oberholzer J, Goldberg R, Pearson T, Yang H, Allamassey L, Polinsky M, Formica RN.
Transplant Direct. 2023 Jan 6;9(2):e1419. doi: 10.1097/TXD.0000000000001419. eCollection 2023 Feb.
PMID: 36700062
A Cartographic Tool to Predict Disease Risk-associated Pseudo-Dynamic Networks from Tissue-specific Gene Expression.
Chen C, Shen B, Zhang L, Yu T, Wang M, Wu R.
Bio Protoc. 2023 Jan 5;13(1):e4583. doi: 10.21769/BioProtoc.4583. eCollection 2023 Jan 5.
PMID: 36789091
Understanding the Association between Red Blood Cell Transfusion Utilization and Humanistic and Economic Burden in Patients with β-Thalassemia from the Patients' Perspective.
Knoth RL, Gupta S, Perkowski K, Costantino H, Inyart B, Ashka L, Clapp K.
J Clin Med. 2023 Jan 4;12(2):414. doi: 10.3390/jcm12020414.
PMID: 36675342
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report.
Al Shoyaib A, Riedmaier AE, Kumar A, Roy P, Parrott NJ, Fang L, Tampal N, Yang Y, Jereb R, Zhao L, Wu F.
CPT Pharmacometrics Syst Pharmacol. 2023 Jan 3. doi: 10.1002/psp4.12913. Online ahead of print.
PMID: 36597353
The lncRNA LUCAT1 is elevated in inflammatory disease and restrains inflammation by regulating the splicing and stability of NR4A2.
Vierbuchen T, Agarwal S, Johnson JL, Galia L, Lei X, Stein K, Olagnier D, Gaede KI, Herzmann C, Holm CK, Heine H, Pai A, O'Hara Hall A, Hoebe K, Fitzgerald KA.
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2213715120. doi: 10.1073/pnas.2213715120. Epub 2022 Dec 28.
PMID: 36577072
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.
Olson NE, Ragan SP, Reiss DJ, Thorpe J, Kim Y, Abramson JS, McCoy C, Newhall KJ, Fox BA.
Mol Cancer Ther. 2023 Jan 3:MCT-21-0506. doi: 10.1158/1535-7163.MCT-21-0506. Online ahead of print.
PMID: 36595660
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G Jr, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ.
JAMA Oncol. 2023 Jan 1;9(1):102-111. doi: 10.1001/jamaoncol.2022.5409.
PMID: 36480191
Trends in Disease Severity Among Critically Ill Children With Severe Acute Respiratory Syndrome Coronavirus 2: A Retrospective Multicenter Cohort Study in the United States.
Ross CE, Burns JP, Grossestreuer AV, Bhattarai P, McKiernan CA, Franks JD, Lehmann S, Sorcher JL, Sharron MP, Wai K, Al-Wahab H, Boukas K, Hall MW, Ru G, Sen AI, Rajasekhar HR, Kleinman LC, McGuire JK, Arrington AS, Munoz-Rivas F, Osborne CM, Shekerdemian LS.
Pediatr Crit Care Med. 2023 Jan 1;24(1):25-33. doi: 10.1097/PCC.0000000000003105. Epub 2022 Nov 17.
PMID: 36516349
Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA, Palaia J, Rosenblatt L, Pisupati R, Huang N, Nguyen C, Barron J, Gallagher K, Bond TC.
J Immunother Cancer. 2023 Jan;11(1):e006072. doi: 10.1136/jitc-2022-006072.
PMID: 36657815
Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J, Kara V, Haack R, Vogel U, Garg A, Krupp M, Gofman K, Dreyfus B, Hauben M, Bate A.
Drug Saf. 2023 Jan;46(1):39-52. doi: 10.1007/s40264-022-01251-7. Epub 2022 Dec 24.
PMID: 36565374
The influence of input material properties on hot melt granules prepared using a counter-rotating batch mixer.
Pafiakis A, Armenante P, Gogos CG.
Pharm Dev Technol. 2023 Jan;28(1):1-17. doi: 10.1080/10837450.2022.2156539. Epub 2022 Dec 30.
PMID: 36533900
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
Bodd MH, Locke SC, Wolf SP, Antonia S, Crawford J, Hartman J, Herring KW, Ready NE, Stinchcombe TE, Troy JD, Williams C, Clarke JM, LeBlanc TW.
Lung Cancer. 2023 Jan;175:17-26. doi: 10.1016/j.lungcan.2022.11.010. Epub 2022 Nov 21.
PMID: 36442383
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox B.
Leukemia. 2023 Jan;37(1):240-243. doi: 10.1038/s41375-022-01766-z. Epub 2022 Nov 27.
PMID: 36437356
Economic Burden of Comorbidities in Patients with Psoriasis in the USA.
Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L.
Dermatol Ther (Heidelb). 2023 Jan;13(1):207-219. doi: 10.1007/s13555-022-00832-9. Epub 2022 Nov 19.
PMID: 36402940
Improvements to in silico skin sensitisation predictions through privacy-preserving data sharing.
Macmillan DS, Chilton ML, Hillegass J.
Regul Toxicol Pharmacol. 2023 Jan;137:105292. doi: 10.1016/j.yrtph.2022.105292. Epub 2022 Nov 15.
PMID: 36400282
Mass spectrometry in gene therapy: Challenges and opportunities for AAV analysis.
Serrano MAC, Furman R, Chen G, Tao L.
Drug Discov Today. 2023 Jan;28(1):103442. doi: 10.1016/j.drudis.2022.103442. Epub 2022 Nov 14.
PMID: 36396118
First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.
Catlett IM, Aras U, Hansen L, Liu Y, Bei D, Girgis IG, Murthy B.
Clin Transl Sci. 2023 Jan;16(1):151-164. doi: 10.1111/cts.13435. Epub 2022 Nov 22.
PMID: 36325947
FinnGen provides genetic insights from a well-phenotyped isolated population.
Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta Parolo P, Lehisto AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K, Rüeger S, Lemmelä S, Zhou W, Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S, Paajanen T, Llorens V, Gracia-Tabuenca J, Siirtola H, Reis K, Elnahas AG, Sun B, Foley CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas S, Bizaki-Vallaskangas A, Carpen O, Chen CY, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M, Finucane H, Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman ÅK, Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J, Jacob H, Jensen JN, Joensuu H, John S, Julkunen V, Jung M, Junttila J, Kaarniranta K, Kähönen M, Kajanne R, Kallio L, Kälviäinen R, Kaprio J; FinnGen; Kerimov N, Kettunen J, Kilpeläinen E, Kilpi T, Klinger K, Kosma VM, Kuopio T, Kurra V, Laisk T, Laukkanen J, Lawless N, Liu A, Longerich S, Mägi R, Mäkelä J, Mäkitie A, Malarstig A, Mannermaa A, Maranville J, Matakidou A, Meretoja T, Mozaffari SV, Niemi MEK, Niemi M, Niiranen T, O Donnell CJ, Obeidat ME, Okafo G, Ollila HM, Palomäki A, Palotie T, Partanen J, Paul DS, Pelkonen M, Pendergrass RK, Petrovski S, Pitkäranta A, Platt A, Pulford D, Punkka E, Pussinen P, Raghavan N, Rahimov F, Rajpal D, Renaud NA, Riley-Gillis B, Rodosthenous R, Saarentaus E, Salminen A, Salminen E, Salomaa V, Schleutker J, Serpi R, Shen HY, Siegel R, Silander K, Siltanen S, Soini S, Soininen H, Sul JH, Tachmazidou I, Tasanen K, Tienari P, Toppila-Salmi S, Tukiainen T, Tuomi T, Turunen JA, Ulirsch JC, Vaura F, Virolainen P, Waring J, Waterworth D, Yang R, Nelis M, Reigo A, Metspalu A, Milani L, Esko T, Fox C, Havulinna AS, Perola M, Ripatti S, Jalanko A, Laitinen T, Mäkelä TP, Plenge R, McCarthy M, Runz H, Daly MJ, Palotie A.
Nature. 2023 Jan;613(7944):508-518. doi: 10.1038/s41586-022-05473-8. Epub 2023 Jan 18.
PMID: 36653562
Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction.
Qiu J, Xu B, Ye D, Ren D, Wang S, Benci JL, Xu Y, Ishwaran H, Beltra JC, Wherry EJ, Shi J, Minn AJ.
Nat Cancer. 2023 Jan;4(1):43-61. doi: 10.1038/s43018-022-00490-y. Epub 2023 Jan 16.
PMID: 36646856
Probing the effect of glycosaminoglycan depletion on integrin interactions with collagen I fibrils in the native extracellular matrix environment.
Roth J, Hoop CL, Williams JK, Hayes R, Baum J.
Protein Sci. 2023 Jan;32(1):e4508. doi: 10.1002/pro.4508.
PMID: 36369695
Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
Karampampa K, Zhang W, Venkatachalam M, Cotte FE, Dhanda D.
J Med Econ. 2023 Jan-Dec;26(1):243-253. doi: 10.1080/13696998.2023.2173466.
PMID: 36705644
Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration.
Din N, Fan J, Schmitt S, Guo JD, Hlavacek P, Pundi K, Russ C, Emir B, Turakhia MP, Perino AC.
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231152474. doi: 10.1177/10760296231152474.
PMID: 36694957
2022 Publications
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, Accordino M, Crew KD, Hershman DL, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J.
Nat Cancer. 2022 Dec 30. doi: 10.1038/s43018-022-00489-5. Online ahead of print.
PMID: 36585452
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.
Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, Ramos F, Romero R, Salido-Fiérrez E, Pedro C, Bargay J, Muñoz-Novas C, López R, Rafel M, Valcárcel D; ERASME study group.
Leuk Lymphoma. 2022 Dec 28:1-12. doi: 10.1080/10428194.2022.2154604. Online ahead of print.
PMID: 36577016
Imaging Non-alcoholic Fatty Liver Disease Model Using H-1 and F-19 MRI.
Lister D, Blizard G, Hosseini M, Messer K, Wellen J, Sirlin CB, Ahrens ET.
Mol Imaging Biol. 2022 Dec 27. doi: 10.1007/s11307-022-01798-y. Online ahead of print.
PMID: 36575339
Analyzing dental fluorosis data using a novel Bayesian model for clustered longitudinal ordinal outcomes with an inflated category.
Kang T, Gaskins J, Levy S, Datta S.
Stat Med. 2022 Dec 27. doi: 10.1002/sim.9641. Online ahead of print.
PMID: 36574753
The autism risk factor CHD8 is a chromatin activator in human neurons and functionally dependent on the ERK-MAPK pathway effector ELK1.
Haddad Derafshi B, Danko T, Chanda S, Batista PJ, Litzenburger U, Lee QY, Ng YH, Sebin A, Chang HY, Südhof TC, Wernig M.
Sci Rep. 2022 Dec 27;12(1):22425. doi: 10.1038/s41598-022-23614-x.
PMID: 36575212
Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Chin K, Yamamoto S, Takahashi M, Kadowaki S, Kubota Y, Amanuma Y, Okada M, Kanda M, Kimura Y, Nogi Y, Arimitsu Y, Kitagawa Y.
Esophagus. 2022 Dec 23. doi: 10.1007/s10388-022-00972-z. Online ahead of print.
PMID: 36564602
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.
Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B.
Sci Rep. 2022 Dec 23;12(1):22239. doi: 10.1038/s41598-022-25936-2.
PMID: 36564395
Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults.
Harker-Murray P, Mauz-Körholz C, Leblanc TM, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano JM, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S.
Blood. 2022 Dec 23:blood.2022017118. doi: 10.1182/blood.2022017118. Online ahead of print.
PMID: 36564047
A single-arm phase 2 trial of Sitravatinib in advanced well-differentiated/dedifferentiated liposarcoma.
Ingham M, Lee S, Van Tine BA, Choy E, Oza J, Doshi S, Ge L, Oppelt P, Cote G, Corgiat B, Sender N, Sta Ana S, Panchalingam L, Petricoin E, Schwartz GK.
Clin Cancer Res. 2022 Dec 22:CCR-22-3351. doi: 10.1158/1078-0432.CCR-22-3351. Online ahead of print.
PMID: 36548343
Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics.
Seifu Y, Mt-Isa S, Duke K, Gamalo-Siebers M, Wang W, Dong G, Kolassa J.
J Biopharm Stat. 2022 Dec 22:1-12. doi: 10.1080/10543406.2022.2153202. Online ahead of print.
PMID: 36545791
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study.
Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, Izutsu K, Morschhauser F, Lunning MA, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M.
Blood. 2022 Dec 21:blood.2022018730. doi: 10.1182/blood.2022018730. Online ahead of print.
PMID: 36542826
Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis.
Hirano I, Rothenberg ME, Zhang S, de Oliveira C, Charriez CM, Coyne KS, Bacci ED, Dellon ES.
Am J Gastroenterol. 2022 Dec 20. doi: 10.14309/ajg.0000000000002094. Online ahead of print.
PMID: 36647838
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN.
Cancer Immunol Immunother. 2022 Dec 20. doi: 10.1007/s00262-022-03351-w. Online ahead of print.
PMID: 36538061
Using Digestion by IdeS Protease to Improve Quantification of Degradants in Monoclonal Antibodies by Non-Reducing Capillary Gel Electrophoresis.
McClain A, Zhang Y, Yin Y, Wang Q, Hwang LY, Gu Y, Beckman J, Ludwig R.
Anal Chem. 2022 Dec 20;94(50):17388-17395. doi: 10.1021/acs.analchem.2c02630. Epub 2022 Dec 6.
PMID: 36472948
Effect of solution condition on the binding behaviors of monoclonal antibody and fusion protein therapeutics in Protein A chromatography.
Guo J, Noyes S, Jin W, Curtis H, Xu X, Ghose S.
J Chromatogr A. 2022 Dec 20;1686:463652. doi: 10.1016/j.chroma.2022.463652. Epub 2022 Nov 16.
PMID: 36434831
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Dhamane AD, Ferri M, Keshishian A, Russ C, Atreja N, Gutierrez C, Emir B, Yuce H, Di Fusco M.
Adv Ther. 2022 Dec 17. doi: 10.1007/s12325-022-02387-9. Online ahead of print.
PMID: 36527598
Adjuvant  nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators.
J Clin Oncol. 2022 Dec 15:JCO2201134. doi: 10.1200/JCO.22.01134. Online ahead of print.
PMID: 36521097
Regioselective synthesis of N1-substituted-4-nitropyrazole-5-carboxylates  via  the cyclocondensation of ethyl 4-(dimethylamino)-3-nitro-2-oxobut-3-enoate with substituted hydrazines.
Zhao R, Hong Z, Wang B, Kempson J, Cornelius L, Li J, Li YX, Mathur A.
Org Biomol Chem. 2022 Dec 14;20(48):9746-9752. doi: 10.1039/d2ob02006h.
PMID: 36444969
Overcoming Photochemical Limitations in Metallaphotoredox Catalysis: Red-Light-Driven C-N Cross-Coupling.
Goldschmid SL, Soon Tay NE, Joe CL, Lainhart BC, Sherwood TC, Simmons EM, Sezen-Edmonds M, Rovis T.
J Am Chem Soc. 2022 Dec 14;144(49):22409-22415. doi: 10.1021/jacs.2c09745. Epub 2022 Nov 23.
PMID: 36417474
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.
Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotté FE, Audigier-Valette C, Griesinger F.
Cancers (Basel). 2022 Dec 13;14(24):6148. doi: 10.3390/cancers14246148.
PMID: 36551632
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F.
J Clin Oncol. 2022 Dec 13:JCO2200972. doi: 10.1200/JCO.22.00972. Online ahead of print.
PMID: 36512738
Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia.
Tabah A, Huggar D, Wang ST, Johnson SJ, Copher RM, O'Connell T, McBride A, LeBlanc TW.
Future Oncol. 2022 Dec 12. doi: 10.2217/fon-2022-0820. Online ahead of print.
PMID: 36507931
Collaborative Assessment of Molecular Geometries and Energies from the Open Force Field.
D'Amore L, Hahn DF, Dotson DL, Horton JT, Anwar J, Craig I, Fox T, Gobbi A, Lakkaraju SK, Lucas X, Meier K, Mobley DL, Narayanan A, Schindler CEM, Swope WC, In 't Veld PJ, Wagner J, Xue B, Tresadern G.
J Chem Inf Model. 2022 Dec 12;62(23):6094-6104. doi: 10.1021/acs.jcim.2c01185. Epub 2022 Nov 26.
PMID: 36433835
Strategies for Managing Solid Form Transformation Risk in Drug Product.
Kestur U, Patel A, Badawy S, Mathias N, Zhang L.
J Pharm Sci. 2022 Dec 10:S0022-3549(22)00565-2. doi: 10.1016/j.xphs.2022.12.002. Online ahead of print.
PMID: 36513146
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.
Cope S, Chan K, Campbell H, Chen J, Borrill J, May JR, Malcolm W, Branchoux S, Kupas K, Jansen JP.
Value Health. 2022 Dec 9:S1098-3015(22)04749-0. doi: 10.1016/j.jval.2022.11.017. Online ahead of print.
PMID: 36503035
Role of the Clinical Data Managers during the COVID-19 Pandemic: An Overview.
Sajja R.
Rev Recent Clin Trials. 2022 Dec 8. doi: 10.2174/1574887118666221208123724. Online ahead of print.
PMID: 36503462
Pulmonary Thromboembolism Developed During Hospitalization: A Nationwide Retrospective Observational Study Using Claims Data.
Imura M, Yamamoto T, Hiasa KI.
Cardiol Ther. 2022 Dec 8:1-15. doi: 10.1007/s40119-022-00290-6. Online ahead of print.
PMID: 36482141
Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development.
Coutant DE, Boulton DW, Dahal UP, Deslandes A, Grimaldi C, Pereira JNS, Säll C, Sarvaiya H, Schiller H, Tai G, Umehara K, Yuan Y, Dallas S.
Clin Pharmacol Ther. 2022 Dec 8. doi: 10.1002/cpt.2814. Online ahead of print.
PMID: 36477720
Synthesis, Structure-Activity Relationships, and  In Vivo  Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity.
Hartz RA, Xu L, Sit SY, Chen J, Venables BL, Lin Z, Zhang S, Li Z, Parker D, Simmons TS, Jenkins S, Hanumegowda UM, Dicker I, Krystal M, Meanwell NA, Regueiro-Ren A.
J Med Chem. 2022 Dec 8;65(23):15935-15966. doi: 10.1021/acs.jmedchem.2c01618. Epub 2022 Nov 28.
PMID: 36441509
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM.
Cancer Med. 2022 Dec 7. doi: 10.1002/cam4.5434. Online ahead of print.
PMID: 36479637
Capacitance spectroscopy enables real-time monitoring of early cell death in mammalian cell culture.
Wu S, Ketcham SA, Corredor CC, Both D, Drennen JK, Anderson CA.
Biotechnol J. 2022 Dec 7:e2200231. doi: 10.1002/biot.202200231. Online ahead of print.
PMID: 36479620
Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML.
de Botton S, Cluzeau T, Vigil CE, Cook R, Rousselot P, Rizzieri DA, Liesveld JL, Fenaux P, Braun T, Banos A, Jurcic JG, Sekeres MA, Savona MR, Roboz GJ, Bixby D, Madigan K, Volkert A, Stephens K, Kang-Fortner Q, Baker K, Paul S, McKeown MR, Carulli JP, Eaton ML, Hodgson G, Fiore C, Kelly M, Roth DA, Stein EM.
Blood Adv. 2022 Dec 7:bloodadvances.2022008806. doi: 10.1182/bloodadvances.2022008806. Online ahead of print.
PMID: 36477975
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A.
J Clin Oncol. 2022 Dec 6:JCO2200332. doi: 10.1200/JCO.22.00332. Online ahead of print.
PMID: 36473143
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Willis C, Bauer H, Au TH, Menon J, Unni S, Tran D, Rivers Z, Akerley W, Schabath MB, Badin F, Sekhon A, Patel M, Xia B, Gustafson B, Villano JL, Thomas JM, Lubinga SJ, Cantrell MA, Brixner D, Stenehjem D.
Oncotarget. 2022 Dec 6;13:1306. doi: 10.18632/oncotarget.28318.
PMID: 36473137
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB; RENAL-AF Investigators.
Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6.
PMID: 36335914
Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes.
Maus RLG, Leontovich AA, Moore RM, Fogarty Z, Guo R, Davidson TM, Tekin B, Atherton C, Schimke JM, Dicke BA, Chen BJ, Markovic SN.
Front Immunol. 2022 Dec 5;13:1024039. doi: 10.3389/fimmu.2022.1024039. eCollection 2022.PMID: 36544759
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A, Longo F, Gamberini MR, Voskaridou E, Ricchi P, Caruso V, Pietrangelo A, Zhang X, Shetty JK, Attie KM, Tartaglione I.
Ther Adv Hematol. 2022 Dec 5;13:20406207221134404. doi: 10.1177/20406207221134404. eCollection 2022.
PMID: 36505885
End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.
Morales AM, Sreedhara A, Buecheler J, Brosig S, Chou D, Christian T, Das T, de Jong I, Fast J, Jagannathan B, Moussa EM, Nejadnik MR, Prajapati I, Radwick A, Rahman Y, Singh S.
AAPS J. 2022 Dec 5;25(1):6. doi: 10.1208/s12248-022-00773-3.
PMID: 36471030
Wuliangye Baijiu but not ethanol reduces cardiovascular disease risks in a zebrafish thrombosis model.
Zhu H, Lan C, Zhao D, Wang N, Du D, Luo H, Lu H, Peng Z, Wang Y, Qiao Z, Huang Y, Sun B.
NPJ Sci Food. 2022 Dec 5;6(1):55. doi: 10.1038/s41538-022-00170-2.
PMID: 36470888
Immunopurification Reagents and Their Application in Biologics and Biomarker Quantitation Using LC-MS/MS in Drug Discovery.
Gautam SS, Singh SP.
J Chromatogr Sci. 2022 Dec 5:bmac096. doi: 10.1093/chromsci/bmac096. Online ahead of print.
PMID: 36469494
Cardiac myosin filaments are directly regulated by calcium.
Ma W, Nag S, Gong H, Qi L, Irving TC.
J Gen Physiol. 2022 Dec 5;154(12):e202213213. doi: 10.1085/jgp.202213213. Epub 2022 Nov 1.
PMID: 36327149
Continuous feeding and blending demonstration with co-processed drug substance.
Erdemir D, Gawel J, Yohannes B, Yates P, Tang D, Ha K, Breza B, DiMaso E, Abebe A, Zombek J.
J Pharm Sci. 2022 Dec 1:S0022-3549(22)00535-4. doi: 10.1016/j.xphs.2022.11.023. Online ahead of print.
PMID: 36462708
iCoreDrop: A robust immune monitoring spectral cytometry assay with six open channels for biomarker flexibility.
Jensen HA, Kim J.
Cytometry A. 2022 Dec 1. doi: 10.1002/cyto.a.24708. Online ahead of print.
PMID: 36458334
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations.
Jadon DR, Corp N, van der Windt DA, Coates LC, Soriano ER, Kavanaugh A, Raine T, Rieder F, Siebert S, Zummer M, Schwartzman S, Rosenbaum JT, Michelsen B, Laxminarayan R, Wu D, Gupta L, Ng B, Jethwa H, De Windt N, Gudu T, Hutton J, O'Sullivan D, Luchetti MM, Stoll M, Singh JA, Peluso R, Rademacher J, Husni ME.
J Rheumatol. 2022 Dec 1:jrheum.220317. doi: 10.3899/jrheum.220317. Online ahead of print.
PMID: 36455946
One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Lindström U, Pavelka K, Yilmaz N, Favalli EG, Nissen MJ, Michelsen B, Vieira-Sousa E, Jones GT, Ionescu R, Relas H, Sanchez-Piedra C, Tomšič M, Geirsson AJ, van der Horst-Bruinsma I, Askling J, Loft AG, Nekvindova L, Direskeneli H, Iannone F, Ciurea A, Fagerli KM, Santos MJ, Macfarlane GJ, Codreanu C, Eklund K, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Rusman T, Østergaard M, Hetland ML.
J Rheumatol. 2022 Dec 1:jrheum.220459. doi: 10.3899/jrheum.220459. Online ahead of print.
PMID: 36455943
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study.
Moreno V, Sepulveda JM, Reardon DA, Pérez-Núñez Á, González León P, Hanna B, Filvaroff E, Aronchik I, Chang H, Amoroso B, Zuraek M, Sanchez-Perez T, Mendez C, Stephens D, Nikolova Z, Vogelbaum MA.
Neuro Oncol. 2022 Dec 1:noac263. doi: 10.1093/neuonc/noac263. Online ahead of print.
PMID: 36455228
A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors.
Kumar N, Papillon-Cavanagh S, Tang H, Wang S, Stromko C, Ho CP, Soni-Sheth S, Vasquez-Grinnell S, Broz ML, Tenney DJ, Wichroski MJ, Walsh AM, Hu Y, Benci JL.
Int J Cancer. 2022 Dec 1;151(11):2043-2054. doi: 10.1002/ijc.34218. Epub 2022 Aug 6.
PMID: 35932450
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis.
Wu C, Hu Y, Schafer P, Connolly SE, Wong R, Nielsen SH, Bay-Jensen AC, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TW, Fleischmann R, Liu J.
RMD Open. 2022 Dec;8(2):e002683. doi: 10.1136/rmdopen-2022-002683.
PMID: 36585217
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM.
J Immunother Cancer. 2022 Dec;10(12):e005445. doi: 10.1136/jitc-2022-005445.
PMID: 36549781
Ovarian cancer mutational processes drive site-specific immune evasion.
Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP.
Nature. 2022 Dec;612(7941):778-786. doi: 10.1038/s41586-022-05496-1. Epub 2022 Dec 14.
PMID: 36517593
Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases.
Qosa H, Hassan HE, Younis IR.
J Clin Pharmacol. 2022 Dec;62 Suppl 2:S72-S78. doi: 10.1002/jcph.2167.
PMID: 36461747
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Cremer PC, Geske JB, Owens A, Jaber WA, Harb SC, Saberi S, Wang A, Sherrid M, Naidu SS, Schaff H, Smedira NG, Wang Q, Wolski K, Lampl KL, Sehnert AJ, Nissen SE, Desai MY.
Circ Cardiovasc Imaging. 2022 Dec;15(12):e014986. doi: 10.1161/CIRCIMAGING.122.014986. Epub 2022 Nov 6.
PMID: 36335645
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
Apolo AB, Powles T, Escudier B, Burotto M, Zhang J, Simsek B, Scheffold C, Motzer RJ, Choueiri TK.
Eur J Cancer. 2022 Dec;177:63-71. doi: 10.1016/j.ejca.2022.09.020. Epub 2022 Oct 4.
PMID: 36327527
The Dog as a Second Species for Toxicology Testing Provides Value to Drug Development.
Bower N, Achanzar WE, Boulifard V, Brinck PR, Kittel B, Vahle JL.
Int J Toxicol. 2022 Dec;41(6):431-441. doi: 10.1177/10915818221125670. Epub 2022 Sep 15.
PMID: 36112859
Rejoinder: Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.
Zhang H, Chiang AY, Wang J.
Stat Med. 2022 Nov 30;41(27):5497-5500. doi: 10.1002/sim.9561.
PMID: 36394103
SERPINB9  is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.
Ibáñez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, Sanders J, Hofland I, Landeloos E, Van Herck Y, Bechter O, Kuilman T, Zhong W, Marine JC, Wessels L, Peeper DS.
Oncoimmunology. 2022 Nov 29;11(1):2139074. doi: 10.1080/2162402X.2022.2139074. eCollection 2022.
PMID: 36465485
Evaluation of Novel Urinary Biomarkers in Beagle Dogs With Amphotericin B-Induced Kidney Injury.
Adedeji AO, Sonee M, Chen Y, Lynch K, Peron K, King N, McDuffie JE, Vinken P.
Int J Toxicol. 2022 Nov 25:10915818221142542. doi: 10.1177/10915818221142542. Online ahead of print.
PMID: 36427267
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT, Jacoby D, Elliott PM, Saberi S, Hegde SM, Lakdawala NK, Myers J, Sehnert AJ, Edelberg JM, Li W, Olivotto I.
Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2737. Online ahead of print.
PMID: 36404399
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).
Lu S, Cheng Y, Zhou J, Wang M, Zhao J, Wang B, Chen G, Feng J, Ma Z, Wu L, Wang C, Ma K, Zhang S, Liang J, Song Y, Wang J, Wu YL, Li A, Huang Y, Chang J.
Ther Adv Med Oncol. 2022 Nov 19;14:17588359221138380. doi: 10.1177/17588359221138380. eCollection 2022.
PMID: 36425873
Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal.
Waller JA, Zheng J, Dyer R, Slaney T, Wu W, Tao L, Ghose S.
Antib Ther. 2022 Nov 19;6(1):30-37. doi: 10.1093/abt/tbac030. eCollection 2023 Jan.
PMID: 36683764
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y.
Esophagus. 2022 Nov 19. doi: 10.1007/s10388-022-00970-1. Online ahead of print.
PMID: 36401133
The challenges inherent with anchor-based approaches to the interpretation of important change in clinical outcome assessments.
Wyrwich KW, Norman GR.
Qual Life Res. 2022 Nov 18. doi: 10.1007/s11136-022-03297-7. Online ahead of print.
PMID: 36396874
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.
Royle KL, Coulson AB, Ramasamy K, Cairns DA, Hockaday A, Quezada S, Drayson M, Kaiser M, Owen R, Auner HW, Cook G, Meads D, Olivier C, Barnard L, Lambkin R, Paterson A, Dawkins B, Chapman M, Pratt G, Popat R, Jackson G, Bygrave C, Sive J, de Tute R, Chantry A, Parrish C, Cook M, Asher S, Yong K.
BMJ Open. 2022 Nov 17;12(11):e063037. doi: 10.1136/bmjopen-2022-063037.
PMID: 36396306
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, Lluch R, Marrero C, Zudaire M, Gironella M, Hernández-Rivas JÁ, Arnan M, Olivier C, Encinas C, Soler JA, Payer ÁR, Casado A, Fernández P, Vilanova D, Bonanad S.
J Geriatr Oncol. 2022 Nov 17:S1879-4068(22)00520-3. doi: 10.1016/j.jgo.2022.10.016. Online ahead of print.
PMID: 36404260
Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.
Tanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D, Yoshizawa Y, Abe M, Saka K, Sugano E, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M.
PLoS One. 2022 Nov 16;17(11):e0277566. doi: 10.1371/journal.pone.0277566. eCollection 2022.
PMID: 36383610
Assessment of spatial transcriptomics for oncology discovery.
Lyubetskaya A, Rabe B, Fisher A, Lewin A, Neuhaus I, Brett C, Brett T, Pereira E, Golhar R, Kebede S, Font-Tello A, Mosure K, Van Wittenberghe N, Mavrakis KJ, MacIsaac K, Chen BJ, Drokhlyansky E.
Cell Rep Methods. 2022 Nov 15;2(11):100340. doi: 10.1016/j.crmeth.2022.100340. eCollection 2022 Nov 21.
PMID: 36452860
Noninvasive Moisture Detection in Lyophilized Drug Product Using NIR Spectrometer and Headspace Moisture Analyzer.
Pu YE, Li Y, Xiang D.
J Pharm Sci. 2022 Nov 15:S0022-3549(22)00524-X. doi: 10.1016/j.xphs.2022.11.009. Online ahead of print.
PMID: 36395899
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial.
Van den Bosch F, Wei JC, Nash P, Blanco FJ, Graham D, Zang C, Arthur E, Borlenghi C, Tsekouras V, Vlahos B, Deodhar A.
J Rheumatol. 2022 Nov 15:jrheum.220353. doi: 10.3899/jrheum.220353. Online ahead of print.
PMID: 36379575
Frailty in Inflammatory Arthritis: A Fragile Construct.
van Onna M, Boonen A.
J Rheumatol. 2022 Nov 15:jrheum.220954. doi: 10.3899/jrheum.220954. Online ahead of print.
PMID: 36379574
Assessing fatigue and sleep in chronic diseases using physiological signals from wearables: A pilot study.
Antikainen E, Njoum H, Kudelka J, Branco D, Rehman RZU, Macrae V, Davies K, Hildesheim H, Emmert K, Reilmann R, Janneke van der Woude C, Maetzler W, Ng WF, O'Donnell P, Van Gassen G, Baribaud F, Pandis I, Manyakov NV, van Gils M, Ahmaniemi T, Chatterjee M.
Front Physiol. 2022 Nov 14; 13:968185. doi: 10.3389/fphys.2022.968185. eCollection 2022.
PMID: 36452041
Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop.
Mills CE, Subramanian K, Hafner M, Niepel M, Gerosa L, Chung M, Victor C, Gaudio B, Yapp C, Nirmal AJ, Clark N, Sorger PK.
Nat Commun. 2022 Nov 14;13(1):6918. doi: 10.1038/s41467-022-34536-7.
PMID: 36376301
Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution.
Sodir NM, Pellegrinet L, Kortlever RM, Campos T, Kwon YW, Kim S, Garcia D, Perfetto A, Anastasiou P, Swigart LB, Arends MJ, Littlewood TD, Evan GI.
Nat Commun. 2022 Nov 9;13(1):6782. doi: 10.1038/s41467-022-34079-x.
PMID: 36351945
Facile Amide Bond Formation with TCFH-NMI in an Organic Laboratory Course.
M Baldwin OW, Conrad-Marut LH, Beutner GL, Vosburg DA.
J Chem Educ. 2022 Nov 8;99(11):3747-3751. doi: 10.1021/acs.jchemed.2c00760. Epub 2022 Oct 3.
PMID: 36398314
An epitope-enriched immunogen expands responses to a conserved viral site.
Caradonna TM, Ronsard L, Yousif AS, Windsor IW, Hecht R, Bracamonte-Moreno T, Roffler AA, Maron MJ, Maurer DP, Feldman J, Marchiori E, Barnes RM, Rohrer D, Lonberg N, Oguin TH 3rd, Sempowski GD, Kepler TB, Kuraoka M, Lingwood D, Schmidt AG.
Cell Rep. 2022 Nov 8;41(6):111628. doi: 10.1016/j.celrep.2022.111628.
PMID: 36351401
Dose-Blinded Myosin Inhibition in Patients with Obstructive HCM Referred for Septal Reduction Therapy: Outcomes Through 32-Weeks.
Desai MY, Owens AT, Geske JB, Wolski K, Saberi S, Wang A, Sherrid MV, Cremer PC, Naidu SS, Smedira N, Schaff HV, McErlean E, Sewell C, Balasubramanyam A, Lampl K, Sehnert AJ, Nissen SE.
Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062534. Online ahead of print.
PMID: 36335531
Molecular glue CELMoD compounds are regulators of cereblon conformation.
Watson ER, Novick S, Matyskiela ME, Chamberlain PP, H de la Peña A, Zhu J, Tran E, Griffin PR, Wertz IE, Lander GC.
Science. 2022 Nov 4;378(6619):549-553. doi: 10.1126/science.add7574. Epub 2022 Nov 3.
PMID: 36378961
Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
Iida S, Nakakoji M, Spanopoulos D, Okazuka K, Parulekar V, Ishida T.
Future Oncol. 2022 Nov 4. doi: 10.2217/fon-2022-0846. Online ahead of print.
PMID: 36331578
Quantum Cascade Laser Based Infrared Spectroscopy: A New Paradigm for Protein Secondary Structure Measurement.
Jin C, Patel A, Peters J, Hodawadekar S, Kalyanaraman R.
Pharm Res. 2022 Nov 3. doi: 10.1007/s11095-022-03422-8. Online ahead of print.
PMID: 36329374
On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.
De Backer M, Legrand C, Péron J, Lambert A, Buyse M.
Pharm Stat. 2022 Nov 2. doi: 10.1002/pst.2271. Online ahead of print.
PMID: 36321470
A Multi-Objective Active Learning Platform and Web App for Reaction Optimization.
Torres JAG, Lau SH, Anchuri P, Stevens JM, Tabora JE, Li J, Borovika A, Adams RP, Doyle AG.
J Am Chem Soc. 2022 Nov 2;144(43):19999-20007. doi: 10.1021/jacs.2c08592. Epub 2022 Oct 19.
PMID: 36260788
Quantification of Utilization Management Barriers for Patients Initiating Therapy to Lower Lipid Levels.
O'Neil A, Calderbank S, Brown J, Vandigo J, Yin P, Bratti K, Howell S.
JAMA Netw Open. 2022 Nov 1;5(11): e2240513. doi: 10.1001/jamanetworkopen.2022.40513.
PMID: 36346635
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.
Cheng D, Zinker BA, Luo Y, Shipkova P, De Oliveira CH, Krishna G, Brown EA, Boehm SL, Tirucherai GS, Gu H, Ma Z, Chu CH, Onorato JM, Kopcho LM, Ammar R, Smith J, Devasthale P, Lawrence RM, Stryker SA, Dierks EA, Azzara AV, Carayannopoulos L, Charles ED, Lentz KA, Gordon DA.
Cell Metab. 2022 Nov 1;34(11):1732-1748.e5. doi: 10.1016/j.cmet.2022.10.007.
PMID: 36323235
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Laheru D, Antony A, Carneiro S, Di Lernia V, Garg A, Love TJ, Del Rocio Macias Garcia K, Mendonça JA, Mukherjee S, Olteanu R, Perez-Chada L, Rosen CF, Tannenbaum R, Yazbek MA.
J Rheumatol. 2022 Nov 1: jrheum.220313. doi: 10.3899/jrheum.220313. Online ahead of print.
PMID: 36319021
Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Campanholo CB, Maharaj AB, Corp N, Bell S, Costa L, de Vlam K, Gullick NJ, Khraishi M, Kishimoto M, Palmou-Fontana N, Reddy S, Scarpa R, Vega L, Duarte GV, Zisman D, van der Windt DA, Duruoz MT, Ogdie A.
J Rheumatol. 2022 Nov 1: jrheum.220310. doi: 10.3899/jrheum.220310. Online ahead of print.
PMID: 36319003
Pseudoprolines as stereoelectronically tunable proline isosteres.
Kashif Khan R, Meanwell NA, Hager HH.
Bioorg Med Chem Lett. 2022 Nov 1; 75:128983. doi: 10.1016/j.bmcl.2022.128983. Epub 2022 Sep 9.
PMID: 36096342
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A.
Bioorg Med Chem Lett. 2022 Nov 1; 75:128951. doi: 10.1016/j.bmcl.2022.128951. Epub 2022 Aug 27.
PMID: 36031020
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J.
JCO Precis Oncol. 2022 Nov;6: e2200454. doi: 10.1200/PO.22.00454.
PMID: 36446042
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B.
J Immunother Cancer. 2022 Nov;10(11): e005780. doi: 10.1136/jitc-2022-005780.
PMID: 36328377
MAPK activated kinase 2 inhibition shifts the chemokine signature in arthritis synovial fluid mononuclear cells from CXCR3 to CXCR2.
Kragstrup TW, Sørensen AS, Brüner M, Lomholt S, Nielsen MA, Schafer P, Deleuran B.
Int Immunopharmacol. 2022 Nov; 112:109267. doi: 10.1016/j.intimp.2022.109267. Epub 2022 Sep 28.
PMID: 36179420
Correction: Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID‑19 in the United States: a retrospective cohort study.
Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G.
J Thromb Thrombolysis. 2022 Nov;54(4):696. doi: 10.1007/s11239-022-02708-3. Epub 2022 Sep 19.
PMID: 36121539
Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
Klink AJ, Gajra A, Knoth RL, Marshall L, Hou Y, McBride A, Copher R.
Leuk Res. 2022 Nov; 122:106946. doi: 10.1016/j.leukres.2022.106946. Epub 2022 Sep 5.
PMID: 36108427
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
Dixon JG, Çağlayan Ç, Chihara D, Nielsen T, Dimier N, Zheng J, Wall AK, Salles G, Morschhauser F, Marcus R, Herold M, Kimby E, Blum KA, Ghielmini M, Shi Q, Flowers CR.
Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11): e1009-e1018. doi: 10.1016/j.clml.2022.07.015. Epub 2022 Aug 3.
PMID: 36045021
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer.
Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L.
Breast Cancer Res Treat. 2022 Nov;196(1):221-227. doi: 10.1007/s10549-022-06712-2. Epub 2022 Aug 26.
PMID: 36028784
Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines.
Trejo-Martin A, Bercu JP, Thresher A, Tennant RE, Thomas RF, Cross K, Czich A, Waese K, Nicolette JJ, Murray J, Sonders P, Kondratiuk A, Cheung JR, Thomas D, Lynch A, Harvey J, Glowienke S, Custer L, Escobar PA.
Regul Toxicol Pharmacol. 2022 Nov; 135:105247. doi: 10.1016/j.yrtph.2022.105247. Epub 2022 Aug 23.
PMID: 35998738
The Role of Titanium Dioxide (E171) and the Requirements for Replacement Materials in Oral Solid Dosage Forms: An IQ Consortium Working Group Review.
Blundell R, Butterworth P, Charlier A, Daurio D, Degenhardt M, Harris D, Hancock B, Johnston M, Kasina R, Kaye J, Kelly R, Lienbacher P, Meehan L, Melnick J, Ojakovo P, Schoell J, Schimmelle B, Tobyn M, Wagner-Hattler L, Wakeman J, Wiedey R.
J Pharm Sci. 2022 Nov;111(11):2943-2954. doi: 10.1016/j.xphs.2022.08.011. Epub 2022 Aug 13.
PMID: 35973604
Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
Tada Y, Kim H, Spanopoulos D, Habiro K, Tsuritani K, Yamada Y, Mandal A, Zhong Y, Hikichi Y.
J Dermatol. 2022 Nov;49(11):1106-1117. doi: 10.1111/1346-8138.16543. Epub 2022 Aug 10.
PMID: 35946343
Developability Assessments of Monoclonal Antibody Candidates to Minimize Aggregation During Large-Scale Ultrafiltration and Diafiltration (UF-DF) Processing.
Whitaker N, Pace SE, Merritt K, Tadros M, Khossravi M, Deshmukh S, Cheng Y, Joshi SB, Volkin DB, Dhar P.
J Pharm Sci. 2022 Nov;111(11):2998-3008. doi: 10.1016/j.xphs.2022.08.001. Epub 2022 Aug 5.
PMID: 35940242
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma.
Vieito M, Simonelli M, de Vos F, Moreno V, Geurts M, Lorenzi E, Macchini M, van den Bent MJ, Del Conte G, de Jonge M, Martín-Soberón MC, Amoroso B, Sanchez-Perez T, Zuraek M, Hanna B, Aronchik I, Filvaroff E, Chang H, Mendez C, Arias Parro M, Wei X, Nikolova Z, Sepulveda JM.
Neurooncol Adv. 2022 Oct 28;4(1):vdac146. doi: 10.1093/noajnl/vdac146. eCollection 2022 Jan-Dec.
PMID: 36382109
Tracking the Progeny of Virus-specific T-cell Products in Patients Post-Transplant using TCR-Sequencing.
Huisman W, Roex MCJ, Hageman L, Koster EAS, Veld SAJ, Hoogstraten C, van Balen P, van Egmond HME, Van Bergen CAM, Einsele H, Germeroth L, Amsen D, Falkenburg JHF, Jedema I.
Blood Adv. 2022 Sep 19:bloodadvances.2022007270. doi: 10.1182/bloodadvances.2022007270. Online ahead of print.
PMID: 36121440
Preclinical target validation for non-addictive therapeutics development for pain.
Hargreaves R, Akinsanya K, Ajit SK, Dhruv NT, Driscoll J, Farina P, Gavva N, Gill M, Houghton A, Iyengar S, Jones C, Kavelaars A, Kaykas A, Koroshetz WJ, Laeng P, Laird JM, Lo DC, Luthman J, Munro G, Oshinsky ML, Sittampalam GS, Woller SA, Tamiz AP.
Expert Opin Ther Targets. 2022 Sep;26(9):811-822. doi: 10.1080/14728222.2022.2147063.
PMID: 36424892
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.
Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N.
JTO Clin Res Rep. 2022 Aug 27;3(11):100400. doi: 10.1016/j.jtocrr.2022.100400. eCollection 2022 Nov.
PMID: 36275912
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study.
Ruperto N, Lovell DJ, Berman A, Ávila-Zapata F, Horneff G, Alessio M, Becker ML, Belot A, Burgos-Vargas R, Gamir ML, Goldenstein-Schainberg C, Scheibel IM, Terreri MT, Zemel L, Zhuo J, Askelson M, Wong R, Martini A, Brunner HI; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation.
Arthritis Care Res (Hoboken). 2022 Aug 3. doi: 10.1002/acr.24989. Online ahead of print.
PMID: 36710243
Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England.
Hill NR, Groves L, Dickerson C, Ochs A, Pang D, Lawton S, Hurst M, Pollock KG, Sugrue DM, Tsang C, Arden C, Wyn Davies D, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT.
Eur Heart J Digit Health. 2022 Mar 23;3(2):195-204. doi: 10.1093/ehjdh/ztac009. eCollection 2022 Jun.
PMID: 36713002
Ru-Catalyzed Enantioselective Hydrogenation of 2-Pyridyl-Substituted Alkenes and Substrate-Mediated H/D Exchange.
Hao W, Joe CL, Ayers S, Darù A, Daley RA, Chen JS, Domanski M, Schmidt MA, Blackmond DG.
ACS Catal. 2022 Jan 21;12(2):1150-1160. doi: 10.1021/acscatal.1c05061. Epub 2022 Jan 4.
PMID: 36386561
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.
Ménochet K, Yu H, Wang B, Tibbitts J, Hsu CP, Kamath AV, Richter WF, Baumann A.
MAbs. 2022 Jan-Dec;14(1):2145997. doi: 10.1080/19420862.2022.2145997.
PMID: 36418217
Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review.
Syeed MS, Poudel N, Ngorsuraches S, Diaz J, Chaiyakunapruk N.
J Med Econ. 2022 Jan-Dec;25(1):1176-1184. doi: 10.1080/13696998.2022.2143170.
PMID: 36346390
Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study.
Beecroft S, O'Connell M, Nassar A, Noon K, Pollock KG, Palmer D, Cross TJS.
Frontline Gastroenterol. 2022 May 9;14(1):19-24. doi: 10.1136/flgastro-2022-102142. eCollection 2023.
PMID: 36561791
Anti-drug Antibody Sample Testing and Reporting Harmonization.
Jani D, Marsden R, Gunsior M, Hay LS, Ward B, Cowan KJ, Azadeh M, Barker B, Cao L, Closson KR, Coble K, Dholakiya SL, Dusseault J, Hays A, Herl C, Hodsdon ME, Irvin SC, Kirshner S, Kolaitis G, Kulagina N, Kumar S, Lai CH, Lipari F, Liu S, Merdek KD, Moldovan IR, Mozaffari R, Pan L, Place C, Snoeck V, Manning MS, Stocker D, Tary-Lehmann M, Turner A, Vainshtein I, Verthelyi D, Williams WT, Yan H, Yan W, Yang L, Yang L, Zemo J, Zhong ZD.
AAPS J. 2022 Oct 28;24(6):113. doi: 10.1208/s12248-022-00762-6.
PMID: 36307592
Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.
Huggar D, Knoth RL, Copher R, Cao Z, Lipkin C, McBride A, LeBlanc TW.
Future Oncol. 2022 Oct 28. doi: 10.2217/fon-2022-0706. Online ahead of print.
PMID: 36305495
Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.
Shankar LK, Huang E, Litière S, Hoekstra OS, Schwartz L, Collette S, Boellaard R, Bogaerts J, Seymour L, de Vries EGE.
Clin Cancer Res. 2022 Oct 27:CCR-21-3143. doi: 10.1158/1078-0432.CCR-21-3143. Online ahead of print.
PMID: 36302172
Increased CaMKK2 expression is an adaptive response that maintains the fitness of tumor-infiltrating natural killer cells.
Juras PK, Racioppi L, Mukherjee D, Artham S, Gao X, D'Agostino LA, Chang CY, McDonnell DP.
Cancer Immunol Res. 2022 Oct 27:CIR-22-0391. doi: 10.1158/2326-6066.CIR-22-0391. Online ahead of print.
PMID: 36301267
Embryo-fetal Exposure and Developmental Outcome of Lenalidomide Following Oral Administration to Pregnant Cynomolgus Monkeys.
Hui JY, Fuchs A, Kumar G.
Reprod Toxicol. 2022 Oct 26:S0890-6238(22)00155-1. doi: 10.1016/j.reprotox.2022.10.005. Online ahead of print.
PMID: 36309155
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
Tomita Y, Kobayashi K, Kimura G, Oya M, Uemura H, Nishiyama H, Galsky MD, Nasroulah F, Collette S, Broughton E, Ünsal-Kaçmaz K, Kamisuki Y, Bajorin DF.
Jpn J Clin Oncol. 2022 Oct 26:hyac155. doi: 10.1093/jjco/hyac155. Online ahead of print.
PMID: 36300304
Synthetic Access to α-Oxoketene Aminals by the Nucleophilic Addition of Enol Silane-Derived Palladium(II) Enolates to Carbodiimides.
Polimera SR, Ilangovan A, Meanwell NA, Subbaiah MAM.J Org Chem. 2022 Oct 26. doi: 10.1021/acs.joc.2c02107. Online ahead of print.
PMID: 36285601
Three-Component Asymmetric Ni-Catalyzed 1,2-Dicarbofunctionalization of Unactivated Alkenes via Stereoselective Migratory Insertion.
Apolinar O, Kang T, Alturaifi TM, Bedekar PG, Rubel CZ, Derosa J, Sanchez BB, Wong QN, Sturgell EJ, Chen JS, Wisniewski SR, Liu P, Engle KM.
J Am Chem Soc. 2022 Oct 26;144(42):19337-19343. doi: 10.1021/jacs.2c06636. Epub 2022 Oct 12.
PMID: 36222701
Autoimmune gene expression profiling of fingerstick whole blood in Chronic Fatigue Syndrome.
Wang Z, Waldman MF, Basavanhally TJ, Jacobs AR, Lopez G, Perichon RY, Ma JJ, Mackenzie EM, Healy JB, Wang Y, Hersey SA.
J Transl Med. 2022 Oct 25;20(1):486. doi: 10.1186/s12967-022-03682-3.
PMID: 36284352
From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology (QSP) Modeling in Cancer Immunotherapy.
Lemaire V, Bassen D, Reed M, Song R, Khalili S, Lien YTK, Huang L, Singh AP, Stamatelos S, Bottino D, Hua F.
Clin Pharmacol Ther. 2022 Oct 25. doi: 10.1002/cpt.2770. Online ahead of print.
PMID: 36282521
Amination of Nitro-Substituted Heteroarenes by Nucleophilic Substitution of Hydrogen.
Mandler MD, Suss N, Ramirez A, Farley CA, Aulakh D, Zhu Y, Traeger SC, Sarjeant A, Davies ML, Ellsworth BA, Regueiro-Ren A.
Org Lett. 2022 Oct 21;24(41):7643-7648. doi: 10.1021/acs.orglett.2c03133. Epub 2022 Oct 10.
PMID: 36214755
Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21.
Sychterz C, Gardner I, Chiang M, Rachumallu R, Neuhoff S, Perera V, Merali S, Schmidt BJ, Gaohua L.
Metabolites. 2022 Oct 20;12(10):1001. doi: 10.3390/metabo12101001.
PMID: 36295903
Use of Monte Carlo simulations for improved facility fit planning in downstream biomanufacturing and technology transfer.
Furcht C, VanSeveren M, Holstein M, Feroz H, Ghose S.
Biotechnol Prog. 2022 Oct 20:e3306. doi: 10.1002/btpr.3306. Online ahead of print.
PMID: 36264017
A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
Badaracco J, Gitlin M, Keating SJ.
Transplant Cell Ther. 2022 Oct 19:S2666-6367(22)01704-3. doi: 10.1016/j.jtct.2022.10.009. Online ahead of print.
PMID: 36272529
Particle Property Characterization and Data Curation for Effective Powder Property Modeling in the Pharmaceutical Industry.
Wadams RC, Akseli I, Albrecht J, Ferreira AP, Gamble JF, Leane M, Thomas S, Schuman Y, Taylor L, Tobyn M.
AAPS PharmSciTech. 2022 Oct 19;23(8):286. doi: 10.1208/s12249-022-02434-2.
PMID: 36261755
The Effectiveness of Patient Training in Inflammatory Bowel Disease Knowledge via Instagram: Randomized Controlled Trial.
Blunck D, Kastner L, Nissen M, Winkler J.
J Med Internet Res. 2022 Oct 19;24(10):e36767. doi: 10.2196/36767.
PMID: 36260385
Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
Chaudhary MA, Edmondson-Jones M, Baio G, Mackay E, Penrod JR, Sharpe DJ, Yates G, Rafiq S, Johannesen K, Siddiqui MK, Vanderpuye-Orgle J, Briggs A.
Med Decis Making. 2022 Oct 19:272989X221132257. doi: 10.1177/0272989X221132257. Online ahead of print.
PMID: 36259353
Unexpected Stability of a Prodrug to Enzymatic Hydrolysis within a Hydrated HPMC Matrix Tablet.
Hanley S, Brown J, Timmins P, Davies C, Dennis A.
Pharmaceutics. 2022 Oct 18;14(10):2222. doi: 10.3390/pharmaceutics14102222.
PMID: 36297657
In-process Vapor Composition Monitoring in Application to Lyophilization of Ammonium Salt Formulations.
Strongrich AD, Tobyn M, Iyer L, Park Y, Hong J, Alexeenko AA.
J Pharm Sci. 2022 Oct 18:S0022-3549(22)00456-7. doi: 10.1016/j.xphs.2022.10.004. Online ahead of print.
PMID: 36270539
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.
Ye Y, Gaudy A, Thomas M, Reyes J, Burkhardt B, Horan G, Liu L, Chen J, Ghosh A, Carayannopoulos LN, Tatosian DA, Palmisano M.
Clin Pharmacol Drug Dev. 2022 Oct 18. doi: 10.1002/cpdd.1178. Online ahead of print.
PMID: 36256505
Identification of Rodent Husbandry Refinement Opportunities through Benchmarking and Collaboration.
Bratcher NA, Allen CM, McLahan CL, O'Connell DM, Burr HN, Keen JN, Stanislawczyk LM, Burns MA.
J Am Assoc Lab Anim Sci. 2022 Oct 17. doi: 10.30802/AALAS-JAALAS-21-000099. Online ahead of print.
PMID: 36253074
Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
Ayers D, Cope S, Towle K, Mojebi A, Marshall T, Dhanda D.
BMC Med Res Methodol. 2022 Oct 15;22(1):272. doi: 10.1186/s12874-022-01745-z.
PMID: 36243687
Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by Domain.
Soriano ER, Kavanaugh A, Coates LC.
J Rheumatol. 2022 Oct 15:jrheum.220486. doi: 10.3899/jrheum.220486. Online ahead of print.
PMID: 36243414
Drs. Bessette and Kinch reply.
Bessette L, Kinch CD.
J Rheumatol. 2022 Oct 15:jrheum.220909. doi: 10.3899/jrheum.220909. Online ahead of print.
PMID: 36243412
Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Leung YY, Korotaeva TV, Candia L, Pedersen SJ, Molano WB, Ruderman EM, Bisoendial R, Perez-Alamino R, Olsder W, Möller B, Grazio S, Gudu T, Mody GM, Pineda C, Raffayova H, Rohekar S, Goldenstein-Schainberg C, Gutierrez Urena SR, Casasola Vargas JC, Meghnathi B, Prasad R, Richette P, Miranda JRS, Malliotis N, Lindqvist U, Simon D, Ezeonyeji A, Soriano ER, FitzGerald O.
J Rheumatol. 2022 Oct 15:jrheum.220315. doi: 10.3899/jrheum.220315. Online ahead of print.
PMID: 36243409
Personalised paediatric chewable Ibuprofen tablets fabricated using 3D micro-extrusion printing technology.
Tabriz AG, Nandi U, Scoutaris N, Sanfo K, Alexander B, Gong Y, Hui HW, Kumar S, Douroumis D.
Int J Pharm. 2022 Oct 15;626:122135. doi: 10.1016/j.ijpharm.2022.122135. Epub 2022 Aug 24.
PMID: 36028083
NMR spectroscopy as a characterization tool enabling biologics formulation development.
Ma J, Pathirana C, Liu DQ, Miller SA.
J Pharm Biomed Anal. 2022 Oct 14;223:115110. doi: 10.1016/j.jpba.2022.115110. Online ahead of print.
PMID: 36308923
Determination of ICH-Q3D Elemental Impurity Leachables in Glass Vials by Inductively Coupled Plasma-Mass Spectrometry.
Breckenridge L, Oni Y, Evans C, Franck J, Wood S, Xu M, Sahin E, Zacour B.
PDA J Pharm Sci Technol. 2022 Oct 14:pdajpst.2021.012655. doi: 10.5731/pdajpst.2021.012655. Online ahead of print.
PMID: 36241213
Payer formulary exclusions of apixaban: how patients respond and potential implications.
Deitelzweig S, Terasawa E, Kang A, Atreja N, Hines DM, Noman A, Luo X.
Curr Med Res Opin. 2022 Oct 14:1-6. doi: 10.1080/03007995.2022.2128189. Online ahead of print.
PMID: 36164763
Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents.
Torrens L, Puigvehí M, Torres-Martín M, Wang H, Maeda M, Haber PK, Leonel T, García-López M, Esteban-Fabró R, Leow WQ, Montironi C, Torrecilla S, Varadarajan AR, Taik P, Campreciós G, Enkhbold C, Taivanbaatar E, Yerbolat A, Villanueva A, Pérez-Del-Pulgar S, Thung S, Chinburen J, Letouzé E, Zucman-Rossi J, Uzilov A, Neely J, Forns X, Roayaie S, Sia D, Llovet JM.
Clin Cancer Res. 2022 Oct 14;28(20):4509-4520. doi: 10.1158/1078-0432.CCR-22-0632.
PMID: 35998012
Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies.
Lee A, Yuan Y, Eccles L, Chitkara A, Dalén J, Varol N.
Cancer Treat Res Commun. 2022 Oct 13;33:100648. doi: 10.1016/j.ctarc.2022.100648. Online ahead of print.
PMID: 36270164
Toxicologic Pathology Forum: Opinion on Not Euthanizing Control Animals in the Recovery Phase of Non-Rodent Toxicology Studies.
Janardhan KS, Sura R, Salian-Mehta S, Flandre T, Palazzi X, Zane D, Singh B, Jacob B, Hukkanen RR, Al-Haddawi M, Bennet B, Laast V, Lee D, Peterson R 2nd, Romeike A, Schorsch F, Guffroy M.
Toxicol Pathol. 2022 Oct 13:1926233221129214. doi: 10.1177/01926233221129214. Online ahead of print.
PMID: 36226581
Comprehensive characterization and optimization of Caco-2 cells enabled the development of a miniaturized 96-well permeability assay.
Cai X, Patel S, Huang C, Paiva A, Sun Y, Barker G, Weller H, Shou W.
Xenobiotica. 2022 Oct 13:1-9. doi: 10.1080/00498254.2022.2133648. Online ahead of print.
PMID: 36217915
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D.
Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293.
PMID: 35960871
Design of a Re-dispersible High Drug Load Amorphous Formulation.
Oberoi HS, Arce F, Purohit HS, Yu M, Fowler CA, Zhou D, Law D.
J Pharm Sci. 2022 Oct 12:S0022-3549(22)00455-5. doi: 10.1016/j.xphs.2022.10.002. Online ahead of print.
PMID: 36243131
Computational prediction of blend time in a large-scale viral inactivation process for monoclonal antibodies biomanufacturing.
Sirasitthichoke C, Hoang D, Phalak P, Armenante PM, Barnoon BI, Shandil I.
Biotechnol Bioeng. 2022 Oct 12. doi: 10.1002/bit.28264. Online ahead of print.
PMID: 36224707
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Ansari-Pour N, Samur MK, Flynt E, Gooding S, Towfic F, Stong N, Ortiz Estevez M, Mavrommatis K, Walker BA, Morgan GJ, Munshi NC, Avet Loiseau H, Thakurta A.
Blood. 2022 Oct 12:blood.2022017010. doi: 10.1182/blood.2022017010. Online ahead of print.
PMID: 36223594
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227.
Brahmer JR, Lee JS, Ciuleanu TE, Caro RB, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS.
J Clin Oncol. 2022 Oct 12:101200JCO2201503. doi: 10.1200/JCO.22.01503. Online ahead of print.
PMID: 36223558
A Sterically Tuned Directing Auxiliary Promotes Catalytic 1,2-Carbofluorination of Alkenyl Carbonyl Compounds.
Liu Z, Oxtoby LJ, Sun J, Li ZQ, Kim N, Davies GHM, Engle KM.
Angew Chem Int Ed Engl. 2022 Oct 11. doi: 10.1002/anie.202214153. Online ahead of print.
PMID: 36221812
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia.
Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, Litalien V, Thompson ER, Morley TD, MacRaild S, Tiong IS, Morris R, Dun K, Zordan AC, Shah JS, Banquet S, Halilovic E, Morris EJ, Herold MJ, Lessene GL, Adams JM, Huang DCS, Roberts AW, Blombery P, Wei AH.
Blood. 2022 Oct 11:blood.2022016090. doi: 10.1182/blood.2022016090. Online ahead of print.
PMID: 36219880
Design and economic investigation of a Multicolumn Countercurrent Solvent Gradient Purification unit for the separation of an industrially relevant PEGylated protein.
Kim TK, Sechi B, Romero Conde JJ, Angelo J, Xu X, Ghose S, Morbidelli M, Sponchioni M.
J Chromatogr A. 2022 Oct 11;1681:463487. doi: 10.1016/j.chroma.2022.463487. Epub 2022 Sep 7.
PMID: 36115185
Surface-induced protein aggregation and particle formation in biologics: current understanding of mechanisms, detection and mitigation strategies.
Kopp MRG, Grigolato F, Zürcher D, Das TK, Chou D, Wuchner K, Arosio P.
J Pharm Sci. 2022 Oct 9:S0022-3549(22)00459-2. doi: 10.1016/j.xphs.2022.10.009. Online ahead of print.
PMID: 36223809
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, Facon T, Weisel K, Larsen JT, Minnema MC, Abdallah AO, Badros AZ, Knop S, Stadtmauer EA, Cheng Y, Amatangelo M, Chen M, Nguyen TV, Amin A, Peluso T, van de Donk NWCJ.
Lancet Haematol. 2022 Oct 6:S2352-3026(22)00290-3. doi: 10.1016/S2352-3026(22)00290-3. Online ahead of print.
PMID: 36209764
Detection of bisphenols in Indian surface water, tap water, and packaged drinking water using dispersive liquid-liquid microextraction: exposure assessment for health risk.
Karsauliya K, Bhateria M, Sonker AK, Yahavi C, Gautam SS, Karsauliya S, Singh SP.
Environ Sci Pollut Res Int. 2022 Oct 6. doi: 10.1007/s11356-022-23293-1. Online ahead of print.
PMID: 36201081
Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: A nationwide medical claims database study.
Terasaka N, Spanopoulos D, Miyagoshi H, Kubo T, Kitaoka H.
J Cardiol. 2022 Oct 5:S0914-5087(22)00247-7. doi: 10.1016/j.jjcc.2022.09.015. Online ahead of print.
PMID: 36208832
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, Pearlman J, Son V, Marta C, Wolf DC, D'Haens GG.
Contemp Clin Trials. 2022 Oct 5;122:106958. doi: 10.1016/j.cct.2022.106958. Online ahead of print.
PMID: 36208720
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN.
Cancer Immunol Immunother. 2022 Oct 5. doi: 10.1007/s00262-022-03302-5. Online ahead of print.
PMID: 36197494
Ligand-Enabled C-H Hydroxylation with Aqueous H2O2 at Room Temperature.
Li Z, Park HS, Qiao JX, Yeung KS, Yu JQ.
J Am Chem Soc. 2022 Oct 5;144(39):18109-18116. doi: 10.1021/jacs.2c08332. Epub 2022 Sep 22.
PMID: 36137252
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
Thudium K, Selby M, Zorn JA, Rak G, Wang XT, Bunch RT, Hogan JM, Strop P, Korman AJ.
Cancer Immunol Res. 2022 Oct 4;10(10):1175-1189. doi: 10.1158/2326-6066.CIR-22-0057.
PMID: 35981087
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M.
Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326.
PMID: 35969233
Synthesizing secondary data into survival analysis to improve estimation efficiency.
Chen C, Yu T, Shen B, Wang M.
Biom J. 2022 Oct 3. doi: 10.1002/bimj.202100326. Online ahead of print.
PMID: 36192158
Electrophilic Hydrazination of Cyclopropanols Using Azodicarboxylates via Copper(II) Catalysis: An Umpolung Strategy to Access β-Hydrazino Ketone Motifs.
Ramar T, Ilangovan A, Meanwell NA, Subbaiah MAM.
J Org Chem. 2022 Oct 3. doi: 10.1021/acs.joc.2c01980. Online ahead of print.
PMID: 36190309
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience.
Foti R, Visalli E, Amato G, Dal Bosco Y, Foti R, Baccano G.
J Rheumatol. 2022 Oct 1:jrheum.220333. doi: 10.3899/jrheum.220333. Online ahead of print.
PMID: 36182113
A perspective on the current use of the phase distribution model for predicting milk-to-plasma drug concentration ratio.
Zhang M, Sychterz C, Chang M, Huang L, Schmidt BJ, Gaohua L.
CPT Pharmacometrics Syst Pharmacol. 2022 Oct 1. doi: 10.1002/psp4.12865. Online ahead of print.
PMID: 36181346
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
Morschhauser F, Nastoupil L, Feugier P, Schiano de Colella JM, Tilly H, Palomba ML, Bachy E, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Le Gouill S, Daguindau N, Guidez S, Pica GM, García-Sancho AM, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Kalung W, Sehn LH, Izutsu K, Cartron G, Gkasiamis A, Crowe R, Xerri L, Fowler NH, Salles G.
J Clin Oncol. 2022 Oct 1;40(28):3239-3245. doi: 10.1200/JCO.22.00843. Epub 2022 Aug 10.
PMID: 35947804
MPN-036 Treatment Failure and Transition to Next-Line Therapy in Myelofibrosis: A Modified Delphi Panel Approach.
Mascarenhas J, Nguyen H, Saunders A, Oliver L, Tomkinson H, Perry R, McBride A.
Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S323. doi: 10.1016/S2152-2650(22)01431-8.
PMID: 36163980
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Diener HC, Gailani D, Kahl A, Donovan M, Perera V, Li D, Hankey GJ.
J Stroke Cerebrovasc Dis. 2022 Oct;31(10):106742. doi: 10.1016/j.jstrokecerebrovasdis.2022.106742. Epub 2022 Aug 27.
PMID: 36037679
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators.
Lancet Haematol. 2022 Oct;9(10):e733-e744. doi: 10.1016/S2352-3026(22)00208-3. Epub 2022 Aug 22.
PMID: 36007538
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Jänicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C.
Lung Cancer. 2022 Oct;172:65-74. doi: 10.1016/j.lungcan.2022.08.001. Epub 2022 Aug 6.
PMID: 36007281
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, Liu L, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2022 Oct;90(4):325-334. doi: 10.1007/s00280-022-04464-w. Epub 2022 Aug 24.
PMID: 36001108
Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies.
Burns L, Kalesnik-Orszulak R, Spring R, Zeegers F, Rutstein M, Hukkelhoven M, Wruck L, O'Donnell J.
Adv Ther. 2022 Oct;39(10):4772-4778. doi: 10.1007/s12325-022-02257-4. Epub 2022 Aug 16.
PMID: 35972721
Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable.
Brown LV, Coles MC, McConnell M, Ratushny AV, Gaffney EA.
J Pharmacokinet Pharmacodyn. 2022 Oct;49(5):539-556. doi: 10.1007/s10928-022-09819-7. Epub 2022 Aug 6.
PMID: 35933452
Association between Human Leukocyte Antigen Polymorphism and Human Papillomavirus Infection in Brazilian Women.
de Araujo-Souza PS, El-Zein M, Bolpetti ADN, Maciag PC, Rabachini T, Franco EL, Villa LL.
Sex Transm Dis. 2022 Sep 30. doi: 10.1097/OLQ.0000000000001718. Online ahead of print.
PMID: 36194829
Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases.
Pavel AB, Del Duca E, Cheng J, Wu J, Ungar B, Estrada YD, Jack C, Maari C, Proulx ÉS, Ramirez-Valle F, Krueger JG, Bissonnette R, Guttman-Yassky E.
Allergy. 2022 Sep 30. doi: 10.1111/all.15538. Online ahead of print.
PMID: 36178084
Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study.
Danchin N, Steg G, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Cotte FE, Gollety S, Van Ganse E, Belhassen M.
Arch Cardiovasc Dis. 2022 Sep 29:S1875-2136(22)00174-7. doi: 10.1016/j.acvd.2022.06.006. Online ahead of print.
PMID: 36257903
Design and conduct considerations for studies in patients with hepatic impairment.
Ravenstijn P, Chetty M, Manchandani P, Elmeliegy M, Qosa H, Younis I.
Clin Transl Sci. 2022 Sep 29. doi: 10.1111/cts.13428. Online ahead of print.
PMID: 36176049
Overcoming Limitations in Decarboxylative Arylation via Ag-Ni Electrocatalysis.
Palkowitz MD, Laudadio G, Kolb S, Choi J, Oderinde MS, Ewing TE, Bolduc PN, Chen T, Zhang H, Cheng PTW, Zhang B, Mandler MD, Blasczak VD, Richter JM, Collins MR, Schioldager RL, Bravo M, Dhar TGM, Vokits B, Zhu Y, Echeverria PG, Poss MA, Shaw SA, Clementson S, Petersen NN, Mykhailiuk PK, Baran PS.
J Am Chem Soc. 2022 Sep 28;144(38):17709-17720. doi: 10.1021/jacs.2c08006. Epub 2022 Sep 15.
PMID: 36106767
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV.
J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Online ahead of print.
PMID: 36162037
Role of harvest depth filtration in controlling product-related impurities for a bispecific antibody.
Espah Borujeni E, Jin W, Shao C, Chennamsetty N, Xu X, Ghose S.
Antib Ther. 2022 Sep 26;5(4):268-279. doi: 10.1093/abt/tbac023. eCollection 2022 Oct.
PMID: 36299416
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason JE, Glass B, Mutsaers PGNJ, Lunning M, Braverman J, Liu FF, Crotta A, Montheard S, Previtali A, Guo S, Shi L, Solomon SR.
Blood Adv. 2022 Sep 23:bloodadvances.2022008106. doi: 10.1182/bloodadvances.2022008106. Online ahead of print.
PMID: 36149968
Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.
Cohen AT, Sah J, Dhamane AD, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X.
PLoS One. 2022 Sep 23;17(9):e0274969. doi: 10.1371/journal.pone.0274969. eCollection 2022.
PMID: 36149864
The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.
Regueiro-Ren A, Sit SY, Chen Y, Chen J, Swidorski JJ, Liu Z, Venables BL, Sin N, Hartz RA, Protack T, Lin Z, Zhang S, Li Z, Wu DR, Li P, Kempson J, Hou X, Gupta A, Rampulla R, Mathur A, Park H, Sarjeant A, Benitex Y, Rahematpura S, Parker D, Phillips T, Haskell R, Jenkins S, Santone KS, Cockett M, Hanumegowda U, Dicker I, Meanwell NA, Krystal M.
J Med Chem. 2022 Sep 22;65(18):11927-11948. doi: 10.1021/acs.jmedchem.2c00879. Epub 2022 Aug 31.
PMID: 36044257
Preclinical Characterization and Phase 1 Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.
Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S.
Cancer Immunol Res. 2022 Sep 21:CIR-21-0722. doi: 10.1158/2326-6066.CIR-21-0722. Online ahead of print.
PMID: 36129967
Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality.
Maass KF, Barfield MD, Ito M, James CA, Kavetska O, Kozinn M, Kumar P, Lepak M, Leuthold LA, Li W, Mikhailov D, Patel S, Perez NL, Jackson Rudd D, Vakkalagadda B, Williams TM, Zha J, Zhang X, Anderson MD.
Clin Transl Sci. 2022 Sep 21. doi: 10.1111/cts.13411. Online ahead of print.
PMID: 36129129
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
Morga A, Latimer NR, Scott M, Hawkins N, Schlichting M, Wang J.
Value Health. 2022 Sep 20:S1098-3015(22)02148-9. doi: 10.1016/j.jval.2022.08.008. Online ahead of print.
PMID: 36150999
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
McGregor B, Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Del Tejo V, Du EX, Yang X, Sendhil SR, Betts KA, Huo S.
Oncologist. 2022 Sep 19:oyac186. doi: 10.1093/oncolo/oyac186. Online ahead of print.
PMID: 36124890
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Yang N, Lu J, Shitara K, Lei M, Li M, Bao N, Chen T, Shen L.
Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34296. Online ahead of print.
PMID: 36121651
Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy.
Sidhom JW, Oliveira G, Ross-MacDonald P, Wind-Rotolo M, Wu CJ, Pardoll DM, Baras AS.
Sci Adv. 2022 Sep 16;8(37):eabq5089. doi: 10.1126/sciadv.abq5089. Epub 2022 Sep 16.
PMID: 36112691
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.
Johannet P, Liu W, Fenyo D, Wind-Rotolo M, Krogsgaard M, Mehnert JM, Weber JS, Zhong J, Osman I.
Clin Cancer Res. 2022 Sep 15;28(18):4121-4130. doi: 10.1158/1078-0432.CCR-22-0404.
PMID: 36106402
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA.
J Am Acad Dermatol. 2022 Sep 14:S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061. Online ahead of print.
PMID: 36115523
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
George DJ, Spigel DR, Gordan LN, Kochuparambil ST, Molina AM, Yorio J, Rezazadeh Kalebasty A, McKean H, Tchekmedyian N, Tykodi SS, Zhang J, Askelson M, Johansen JL, Hutson TE.
BMJ Open. 2022 Sep 14;12(9):e058396. doi: 10.1136/bmjopen-2021-058396.
PMID: 36104138
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial Infarction.
Lupisella J, St-Onge S, Carrier M, Cook EM, Wang T, Sum C, Fernando G, Apgar K, Zhang R, Carson N, Snyder BJ, Ryan CS, Ma X, Dierks EA, Little S, Kick EK, Wurtz NR, Bouvier M, Héroux M, Garcia RA.
ACS Pharmacol Transl Sci. 2022 Sep 14;5(10):892-906. doi: 10.1021/acsptsci.2c00042. eCollection 2022 Oct 14.
PMID: 36268126
Photochemical Identification of Auxiliary Severe Acute Respiratory Syndrome Coronavirus 2 Host Entry Factors Using μMap.
Suzuki S, Geri JB, Knutson SD, Bell-Temin H, Tamura T, Fernández DF, Lovett GH, Till NA, Heller BL, Guo J, MacMillan DWC, Ploss A.
J Am Chem Soc. 2022 Sep 14;144(36):16604-16611. doi: 10.1021/jacs.2c06806. Epub 2022 Sep 1.
PMID: 36049228
Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.
Sangesland M, Torrents de la Peña A, Boyoglu-Barnum S, Ronsard L, Mohamed FAN, Moreno TB, Barnes RM, Rohrer D, Lonberg N, Ghebremichael M, Kanekiyo M, Ward A, Lingwood D.Immunity. 2022 Sep 13;55(9):1693-1709.e8. doi: 10.1016/j.immuni.2022.07.006. Epub 2022 Aug 10.PMID: 35952670
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D.
Leuk Lymphoma. 2022 Sep 12:1-10. doi: 10.1080/10428194.2022.2109154. Online ahead of print.
PMID: 36095125
Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study.
Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Niu B, Wang J, Xu W, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H.
J Am Soc Mass Spectrom. 2022 Sep 7;33(9):1659-1677. doi: 10.1021/jasms.2c00129. Epub 2022 Aug 26.
PMID: 36018776
Kinetics of Surface Enrichment of a Polymer in a Glass-Forming Molecular Liquid.
Yu J, Yao X, Que C, Huang L, Hui HW, Gong Y, Qian F, Yu L.
Mol Pharm. 2022 Sep 5;19(9):3350-3357. doi: 10.1021/acs.molpharmaceut.2c00484. Epub 2022 Aug 19.
PMID: 35985030
How Dangerous Is Too Dangerous? A Perspective on Azide Chemistry.
Treitler DS, Leung S.
J Org Chem. 2022 Sep 2;87(17):11293-11295. doi: 10.1021/acs.joc.2c01402.
PMID: 36052475
Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis.
Broughton EI, Chun DS, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G.
Curr Urol. 2022 Sep;16(3):147-153. doi: 10.1097/CU9.0000000000000072. Epub 2022 Aug 2.
PMID: 36204362
Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Javaheri A, Diab A, Zhao L, Qian C, Cohen JB, Zamani P, Kumar A, Wang Z, Ebert C, Maranville J, Kvikstad E, Basso M, van Empel V, Richards AM, Doughty RN, Rietzschel E, Kammerhoff K, Gogain J, Schafer P, Seiffert DA, Gordon DA, Ramirez-Valle F, Mann DL, Cappola TP, Chirinos JA.
Circ Heart Fail. 2022 Sep;15(9):e009693. doi: 10.1161/CIRCHEARTFAILURE.121.009693. Epub 2022 Aug 9.
PMID: 36126144
Epilogue to the Gerald Maggiora Festschrift: a tribute to an exemplary mentor, colleague, collaborator, and innovator.
Shanmugasundaram V, Bajorath J, Christoffersen RE, Petke JD, Howe WJ, Johnson MA, Agrafiotis DK, Lee P, Kuhn LA, Goodwin JT, Holloway MK, Doman TN, Walters WP, Schreyer S, Medina-Franco JL, Martinez-Mayorga K, Restifo LL.
J Comput Aided Mol Des. 2022 Sep;36(9):623-638. doi: 10.1007/s10822-022-00473-2. Epub 2022 Sep 17.
PMID: 36114380
Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report.
Schlichting M, Hennig M, Rudell K, McLeod L, Bennett B, Shaw J, Doward L, Molsen-David E, Chassany O.
Value Health. 2022 Sep;25(9):1463-1468. doi: 10.1016/j.jval.2022.07.010.
PMID: 36049796
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067.
Baker T, Johnson H, Kotapati S, Moshyk A, Hamilton M, Kurt M, Paly VF.
Pharmacoecon Open. 2022 Sep;6(5):697-710. doi: 10.1007/s41669-022-00348-0. Epub 2022 Aug 25.
PMID: 36006606
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, De la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelson M, Ascierto PA, Mandalá M.
Eur J Cancer. 2022 Sep;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Epub 2022 Aug 11.
PMID: 35964471
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
Armstrong A, Xia Q, John AR, Patel V, Seigel L.
Dermatol Ther (Heidelb). 2022 Sep;12(9):2087-2103. doi: 10.1007/s13555-022-00775-1. Epub 2022 Aug 10.
PMID: 35947341
Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model.
Aulin J, Hijazi Z, Lindbäck J, Alexander JH, Gersh BJ, Granger CB, Hanna M, Horowitz J, Lopes RD, McMurray JJV, Oldgren J, Siegbahn A, Wallentin L; ARISTOTLE Investigators.
Am Heart J. 2022 Sep;251:13-24. doi: 10.1016/j.ahj.2022.03.009. Epub 2022 May 13.
PMID: 35569564
Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19.
Deitelzweig S, Zhu J, Jiang J, Luo X, Keshishian A, Ferri M, Rosenblatt L, Schuler P, Gutierrez C, Dhamane AD.
Curr Med Res Opin. 2022 Aug 30:1-6. doi: 10.1080/03007995.2022.2112871. Online ahead of print.
PMID: 36000258
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Amin A, Keshishian A, Hines DM, Dina O, Le H, Rosenblatt L, Liu X, Zhang Q, Vo L.
Curr Med Res Opin. 2022 Aug 30:1-10. doi: 10.1080/03007995.2022.2115772. Online ahead of print.
PMID: 35993487
Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Paz-Ares LG, Ciuleanu T, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Popat S, Peters S, Memaj A, Nathan F, Aanur N, Borghaei H.
J Thorac Oncol. 2022 Aug 29:S1556-0864(22)01556-8. doi: 10.1016/j.jtho.2022.08.014. Online ahead of print.
PMID: 36049658
Application of Immunocompetent Microphysiological Systems in Drug Development: Current Perspective and Recommendations.
Wang X, Kopec AK, Collinge M, David R, Grant C, Hardwick RN, Navratil A, Patel N, Rowan W, Marshall N.
ALTEX. 2022 Aug 29. doi: 10.14573/altex.2205311. Online ahead of print.
PMID: 36044561
New Development in Understanding Drug-Polymer Interactions in Pharmaceutical Amorphous Solid Dispersions from Solid-State Nuclear Magnetic Resonance.
Pugliese A, Tobyn M, Hawarden LE, Abraham A, Blanc F.
Mol Pharm. 2022 Aug 29. doi: 10.1021/acs.molpharmaceut.2c00479. Online ahead of print.
PMID: 36037249
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.
Belhassen M, Hanon O, Steg PG, Mahé I, Née M, Jacoud F, Dalon F, Cotté FE, Guitard-Dehoux D, Marant-Micallef C, Van Ganse E, Danchin N.
Eur J Health Econ. 2022 Aug 28. doi: 10.1007/s10198-022-01513-2. Online ahead of print.
PMID: 36030485
A Combined Rheological and Thermomechanical Analysis Approach for the Assessment of Pharmaceutical Polymer Blends.
Isreb M, Chalkia M, Gough T, Forbes RT, Timmins P.
Polymers (Basel). 2022 Aug 27;14(17):3527. doi: 10.3390/polym14173527.
PMID: 36080602
Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study.
Halvorsen S, Smith JA, Söderdahl F, Thuresson M, Solli O, Ulvestad M, Jonasson C.
BMC Prim Care. 2022 Aug 25;23(1):214. doi: 10.1186/s12875-022-01824-6.
PMID: 36008778
Discovery of Substituted Di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as Novel Macrofilaricidal Compounds for the Treatment of Human Filarial Infections.
Hawryluk N, Robinson D, Shen Y, Kyne G, Bedore M, Menon S, Canan S, von Geldern T, Townson S, Gokool S, Ehrens A, Koschel M, Lhermitte-Vallarino N, Martin C, Hoerauf A, Hernandez G, Dalvie D, Specht S, Hübner MP, Scandale I.
J Med Chem. 2022 Aug 25;65(16):11388-11403. doi: 10.1021/acs.jmedchem.2c00960. Epub 2022 Aug 16.
PMID: 35972896
Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3.
Liu C, Jalagam PR, Feng J, Wang W, Raja T, Sura MR, Manepalli RKVLP, Aliphedi BR, Medavarapu S, Nair SK, Muthalagu V, Natesan R, Gupta A, Beno B, Panda M, Ghosh K, Shukla JK, Sale H, Haldar P, Kalidindi N, Shah D, Patel D, Mathur A, Ellsworth BA, Cheng D, Regueiro-Ren A.
J Med Chem. 2022 Aug 25;65(16):11084-11099. doi: 10.1021/acs.jmedchem.2c00517. Epub 2022 Aug 15.
PMID: 35969688
Improving Drug Delivery While Tailoring Prodrug Activation to Modulate  C max and  C min by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir.
A M Subbaiah M, Subramani L, Ramar T, Desai S, Sinha S, Mandlekar S, Kadow JF, Jenkins S, Krystal M, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Meanwell NA.
J Med Chem. 2022 Aug 25;65(16):11150-11176. doi: 10.1021/acs.jmedchem.2c00632. Epub 2022 Aug 11.
PMID: 35952307
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.
Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR.
Cancers (Basel). 2022 Aug 23;14(17):4079. doi: 10.3390/cancers14174079.
PMID: 36077617
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A.
J Clin Oncol. 2022 Aug 23:JCO2102476. doi: 10.1200/JCO.21.02476. Online ahead of print.
PMID: 35998303
Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer.
Pape M, Vissers PAJ, Bertwistle D, McDonald L, Beerepoot LV, van Berge Henegouwen MI, Lagarde SM, Mook S, Mohammad NH, Jeene PM, van Laarhoven HWM, Verhoeven RHA.
Br J Surg. 2022 Aug 23:znac290. doi: 10.1093/bjs/znac290. Online ahead of print.
PMID: 35998093
Identification of cognitive impairment, depression, and fatigue among multiple sclerosis patients in a large comprehensive care center: A mixed-methods, qualitative study.
Tornatore C, Ahmad A, Pham T, Gupte-Singh K, Wahid N, Lynch J, Pratt KJ.
Mult Scler Relat Disord. 2022 Aug 20;68:104117. doi: 10.1016/j.msard.2022.104117. Online ahead of print.
PMID: 36037754
Container Closure Integrity of Vial Primary Packaging Systems under Frozen Storage Conditions: A Case Study.
Oni Y, Franck J, Evans C, Paniagua D, Kulshrestha A, Mantri RV.
PDA J Pharm Sci Technol. 2022 Aug 19:pdajpst.2021.012719. doi: 10.5731/pdajpst.2021.012719. Online ahead of print.
PMID: 35987519
Location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of high-risk NDMM patients.
Stong N, Ortiz Estevez M, Towfic F, Samur MK, Agarwal A, Corre J, Flynt E, Munshi NC, Avet-Loiseau H, Thakurta A.
Blood. 2022 Aug 19:blood.2022016212. doi: 10.1182/blood.2022016212. Online ahead of print.
PMID: 35984902
CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production.
Gaur R, Mensah KA, Stricker J, Adams M, Parton A, Cedzik D, Connarn J, Thomas M, Horan G, Schafer P, Mair S, Palmisano M, Ramírez-Valle F.
Arthritis Res Ther. 2022 Aug 18;24(1):199. doi: 10.1186/s13075-022-02850-6.
PMID: 35982464
Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
Cheng Y, Xue Y, Chen L, Masin M, Maciag P, Peluso T, Zhou S, Li Y.
Br J Clin Pharmacol. 2022 Aug 18. doi: 10.1111/bcp.15498. Online ahead of print.
PMID: 35981078
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry.
Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE, Zhuo J, Patel V, Mease PJ.
J Am Acad Dermatol. 2022 Aug 17:S0190-9622(22)02543-9. doi: 10.1016/j.jaad.2022.07.060. Online ahead of print.
PMID: 35987397
Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease.
Venkataraman AV, Mansur A, Rizzo G, Bishop C, Lewis Y, Kocagoncu E, Lingford-Hughes A, Huiban M, Passchier J, Rowe JB, Tsukada H, Brooks DJ, Martarello L, Comley RA, Chen L, Schwarz AJ, Hargreaves R, Gunn RN, Rabiner EA, Matthews PM.
Sci Transl Med. 2022 Aug 17;14(658):eabk1051. doi: 10.1126/scitranslmed.abk1051. Epub 2022 Aug 17.
PMID: 35976998
Intensive behavioural interventions based on applied behaviour analysis (ABA) for young children with autism: A cost-effectiveness analysis.
Hodgson R, Biswas M, Palmer S, Marshall D, Rodgers M, Stewart L, Simmonds M, Rai D, Le Couteur A.
PLoS One. 2022 Aug 16;17(8):e0270833. doi: 10.1371/journal.pone.0270833. eCollection 2022.
PMID: 35972929
Prevalence of psoriatic arthritis among patients with psoriasis in Italy.
Cazzaniga S, Heidemeyer K, Dondi L, Ronconi G, Pedrini A, Bellatreccia A, Zhong Y, Naldi L, Martini N.
J Eur Acad Dermatol Venereol. 2022 Aug 16. doi: 10.1111/jdv.18528. Online ahead of print.
PMID: 35972199
Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe.
Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A.
J Rheumatol. 2022 Aug 15:jrheum.220154. doi: 10.3899/jrheum.220154. Online ahead of print.
PMID: 35970531
Impact of Physician-Defined Flares on Quality of Life and Work Impairment: An International Survey of 2,238 Psoriatic Arthritis Patients.
Orbai AM, Tillett W, Grieb S, Peterson S, Holdsworth E, Booth N, Chakravarty S, Gossec L.
J Rheumatol. 2022 Aug 15:jrheum.211302. doi: 10.3899/jrheum.211302. Online ahead of print.
PMID: 35970528
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies.
Palmer S, Borget I, Friede T, Husereau D, Karnon J, Kearns B, Medin E, Peterse EFP, Klijn SL, Verburg-Baltussen EJM, Fenwick E, Borrill J.
Value Health. 2022 Aug 13:S1098-3015(22)02105-2. doi: 10.1016/j.jval.2022.07.009. Online ahead of print.
PMID: 35970706
Investigating the feasibility of recruitment to an observational, quality-of-life study of patients diagnosed with atrial fibrillation (AF) who have experienced a bleed while anticoagulated: EQUAL-AF feasibility study protocol.
Hutchings HA, Lanyon K, Lister S, Alikhan R, Halcox J, Holland G, Hughes A, Jenkins R, Laing H, Lobban T, Owen D, Pollock KG, Todd C, Wareham K.
Pilot Feasibility Stud. 2022 Aug 12;8(1):180. doi: 10.1186/s40814-022-01135-8.
PMID: 35962446
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J.
J Clin Oncol. 2022 Aug 12:JCO2102815. doi: 10.1200/JCO.21.02815. Online ahead of print.
PMID: 35960908
Ni/Photoredox-Catalyzed C(sp2)-C(sp3) Cross-Coupling of Alkyl Pinacolboronates and (Hetero)Aryl Bromides.
Cauley AN, Ramirez A, Barhate CL, Donnell AF, Khandelwal P, Sezen-Edmonds M, Sherwood TC, Sloane JL, Cavallaro CL, Simmons EM.
Org Lett. 2022 Aug 12;24(31):5663-5668. doi: 10.1021/acs.orglett.2c01942. Epub 2022 Aug 3.
PMID: 35920644
Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response.
Stefanovic F, Gomez-Caminero A, Jacobs DM, Subramanian P, Puzanov I, Chilbert MR, Feuerstein SG, Yatsynovich Y, Switzer B, Schentag JJ.
Clin Pharmacol. 2022 Aug 10;14:69-90. doi: 10.2147/CPAA.S369008. eCollection 2022.
PMID: 35975122
The win odds: statistical inference and regression.
Song J, Verbeeck J, Huang B, Hoaglin DC, Gamalo-Siebers M, Seifu Y, Wang D, Cooner F, Dong G.
J Biopharm Stat. 2022 Aug 10:1-11. doi: 10.1080/10543406.2022.2089156. Online ahead of print.
PMID: 35946932
Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective.
Gupta S, Kulasekararaj AG, Costantino H, Grisolano J, Tang J, Jones S, Tang D.
Cancer Rep (Hoboken). 2022 Aug 9:e1680. doi: 10.1002/cnr2.1680. Online ahead of print.
PMID: 35942648
Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.
Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM.
Blood Adv. 2022 Aug 8:bloodadvances.2022007246. doi: 10.1182/bloodadvances.2022007246. Online ahead of print.
PMID: 35938863
ELIMINATOR: essentiality analysis using multisystem networks and integer programming.
Antoranz A, Ortiz M, Pey J.
BMC Bioinformatics. 2022 Aug 6;23(1):324. doi: 10.1186/s12859-022-04855-z.
PMID: 35933325
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies.
Easton A, Jensen ML, Wang C, Hagedorn PH, Li Y, Weed M, Meredith JE, Guss V, Jones K, Gill M, Krause C, Brown JM, Hunihan L, Natale J, Fernandes A, Lu Y, Polino J, Bookbinder M, Cadelina G, Benitex Y, Sane R, Morrison J, Drexler D, Mercer SE, Bon C, Pandya NJ, Jagasia R, Ou Yang TH, Distler T, Grüninger F, Meldgaard M, Terrigno M, Macor JE, Albright CF, Loy J, Hoeg AM, Olson RE, Cacace AM.
Mol Ther Nucleic Acids. 2022 Aug 4;29:625-642. doi: 10.1016/j.omtn.2022.07.027. eCollection 2022 Sep 13.
PMID: 36090761
Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
Kojima T, Kato R, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Nakaigawa N, Sugino Y, Hamamoto S, Ito H, Murakami H, Obara W.
Jpn J Clin Oncol. 2022 Aug 3:hyac124. doi: 10.1093/jjco/hyac124. Online ahead of print.
PMID: 35920793
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.
Yang TY, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, Tarcsa E, Fang X, Hofer L, Kavita U, Upreti VV, Gupta S, Loo L, Johnson AJ, Chandode RK, Stubenrauch KG, Vinzing M, Xia CQ, Jawa V.
Mol Ther Methods Clin Dev. 2022 Aug 2;26:471-494. doi: 10.1016/j.omtm.2022.07.018. eCollection 2022 Sep 8.
PMID: 36092368
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.
Nauwelaers I, Laudus N, Peeters D, Acs B, Denkert C, Michiels S, Horlings H, Siziopikou KP, Ely S, Zardavas D, Mustimbo R, Bartlett J, Floris G, Hartman J, van Deurzen CHM, Ceusters D, Dequeker E, Salgado R.
Cancers (Basel). 2022 Aug 2;14(15):3762. doi: 10.3390/cancers14153762.
PMID: 35954426
Joint semiparametric models for case-cohort designs.
Zhong W, Diao G.
Biometrics. 2022 Aug 2. doi: 10.1111/biom.13728. Online ahead of print.
PMID: 35917392
Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.
Hagner PR, Chiu H, Chopra VS, Colombo M, Patel N, Estevez MO, Waldman MF, Loos R, Towfic F, Gandhi AK.
Clin Cancer Res. 2022 Aug 2;28(15):3367-3377. doi: 10.1158/1078-0432.CCR-21-3347.
PMID: 35583604
Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
Dowlati A, Abbas A, Chan T, Henick B, Wang X, Doshi P, Fu P, Patel J, Kuo F, Chang H, Balli D.
JCO Precis Oncol. 2022 Aug;6:e2200257. doi: 10.1200/PO.22.00257.
PMID: 36044718
Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Lip GYH, Murphy RR, Sahiar F, Ingall TJ, Dhamane AD, Ferri M, Hlavacek P, Preib MT, Keshishian A, Russ C, Rosenblatt L, Yuce H, Deitelzweig S.
JAMA Netw Open. 2022 Aug 1;5(8):e2229333. doi: 10.1001/jamanetworkopen.2022.29333.
PMID: 36044214
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK.
J Immunother Cancer. 2022 Aug;10(8):e004761. doi: 10.1136/jitc-2022-004761.
PMID: 35977756
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, Rosenthal A, Anagnostou V, Baden J, Beaver JA, Chaudhuri AA, Chudova D, Fine AD, Fiore J, Hodge R, Hodgson D, Hunkapiller N, Klass DM, Kobie J, Peña C, Pennello G, Peterman N, Philip R, Quinn KJ, Raben D, Rosner GL, Sausen M, Tezcan A, Xia Q, Yi J, Young AG, Stewart MD, Carpenter EL, Aggarwal C, Allen J.
JCO Precis Oncol. 2022 Aug;6:e2100372. doi: 10.1200/PO.21.00372.
PMID: 35952319
(-)-Epicatechin Ameliorates Cardiac Fibrosis in a Female Rat Model of Pre-Heart Failure with Preserved Ejection Fraction.
Bustamante-Pozo M, Ramirez-Sanchez I, Garate-Carrillo A, Ito B, Navarrete V, Haro M, Garcia R, Carson N, Ceballos G, Villarreal F.
J Med Food. 2022 Aug;25(8):836-844. doi: 10.1089/jmf.2021.0158. Epub 2022 Aug 2.
PMID: 35917528
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Nassif M, Fine JT, Dolan C, Reaney M, Addepalli P, Allen VD, Sehnert AJ, Gosch K, Spertus JA.
JACC Heart Fail. 2022 Aug;10(8):531-539. doi: 10.1016/j.jchf.2022.03.002. Epub 2022 May 4.
PMID: 35902155
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.
Li C, Horton JK, Sale M, Curd L, Goti V, Tao W, Beelen A.
Clin Drug Investig. 2022 Aug;42(8):679-692. doi: 10.1007/s40261-022-01179-x. Epub 2022 Jul 16.
PMID: 35842567
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.
Lancet Oncol. 2022 Aug;23(8):1066-1077. doi: 10.1016/S1470-2045(22)00339-4. Epub 2022 Jul 12.
PMID: 35839786
An Industry Survey on Managing the Pharmacovigilance System Master File in a Global Environment: The Need for a Pragmatic Approach.
Lavery C, Emmott J, Jeck-Thole S, Rouben P, Usher D, van der Spuij W, Woodward L.
Pharmaceut Med. 2022 Aug;36(4):233-245. doi: 10.1007/s40290-022-00422-2. Epub 2022 Jun 20.
PMID: 35723862
Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.
Mattis C, Bratcher N, Burns M, Carosino C, de Zafra C, Fancher RM, Georgi K, Graff C, Hukkanen RR, Johnson C, Lao Y, Lange A, Lee D, Lepherd M, Maguire S, Malisauskas M, Manuel M, Miranda S, Reed L, Santos R, Sayers B, Shaw D, Shuster D.
Int J Toxicol. 2022 Aug;41(4):291-296. doi: 10.1177/10915818221101791. Epub 2022 Jun 2.
PMID: 35656559
Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.
Zhang Y, Chen SJ, Chen C, Chen XQ, Chatterjee S, Shuster DJ, Dexter H, Armstrong L, Joshi EM, Yang Z, Shen H.Drug Metab Dispos. 2022 Aug;50(8):1077-1086. doi: 10.1124/dmd.122.000875. Epub 2022 May 30.
PMID: 35636769
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL.
Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.
PMID: 35605882
Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors.
Parcella K, Patel M, Tu Y, Eastman K, Peese K, Gillis E, Belema M, Dicker IB, McAuliffe B, Ding B, Falk P, Simmermacher J, Parker DD, Sivaprakasam P, Khan JA, Kish K, Lewis H, Hanumegowda U, Jenkins S, Kadow JF, Krystal M, Meanwell NA, Naidu BN.
Bioorg Med Chem. 2022 Aug 1;67:116833. doi: 10.1016/j.bmc.2022.116833. Epub 2022 May 19.
PMID: 35605346
Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs.
Patel V, Pulungan Z, Shah A, Jones B, Petrilla A, Ferri L, Han X, Michaud K.
Rheumatol Ther. 2022 Aug;9(4):1091-1107. doi: 10.1007/s40744-022-00453-w. Epub 2022 May 23.
PMID: 35604547
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
Alten R, Mariette X, Flipo RM, Caporali R, Buch MH, Patel Y, Marsal S, Sanmartí R, Nurmohamed MT, Griffiths H, Peichl P, Bannert B, Chartier M, Connolly SE, Lozenski K, Rauch C.
Clin Rheumatol. 2022 Aug;41(8):2361-2373. doi: 10.1007/s10067-022-06176-1. Epub 2022 May 10.
PMID: 35536413
Enhanced aqueous dissolution of hydrophobic apixaban via direct incorporation of hydrophilic nanographene oxide.
Islam MS, Renner F, Foster K, Oderinde MS, Stefanski K, Mitra S.
Colloids Surf B Biointerfaces. 2022 Aug;216:112512. doi: 10.1016/j.colsurfb.2022.112512. Epub 2022 Apr 26.
PMID: 35533561
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
Tehlirian C, Singh RSP, Pradhan V, Roberts ES, Tarabar S, Peeva E, Vincent MS, Gale JD.
J Am Acad Dermatol. 2022 Aug;87(2):333-342. doi: 10.1016/j.jaad.2022.03.059. Epub 2022 Apr 6.
PMID: 35398218
Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.
Swanson MD, Rios S, Mittal S, Soder G, Jawa V.
Front Immunol. 2022 Jul 27;13:915412. doi: 10.3389/fimmu.2022.915412. eCollection 2022.
PMID: 35967308
Association of Use of Statins with Progression of Diabetic Retinopathy at a Tertiary Care Hospital in Southern India.
Priyadarshini P, Chogtu B, Bhandary SV, Kabirdev, Magazine R.
J Curr Ophthalmol. 2022 Jul 26;34(2):234-240. doi: 10.4103/joco.joco_70_21. eCollection 2022 Apr-Jun.
PMID: 36147261
Creating standards for liquid biopsies: the BLOODPAC experience.
Leiman LC, Baden J, D'Auria K, Lin CJ, Meier K.
Expert Rev Mol Diagn. 2022 Jul;22(7):677-679. doi: 10.1080/14737159.2022.2113059. Epub 2022 Aug 24.
PMID: 35979936
Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK.
Carpenter L, Rockenschaub P, Hatton GB, D'Abrantes S, Sims E, Scott-Ram N, Ducès A, Emanuel G, Mead AJ, Drummond MW, Lipunova N.
EJHaem. 2022 Jun 29;3(3):785-793. doi: 10.1002/jha2.519. eCollection 2022 Aug.
PMID: 36051073
Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients.
Cheng Y, Hong K, Chen N, Yu X, Peluso T, Zhou S, Li Y.
EJHaem. 2022 Jun 2;3(3):815-827. doi: 10.1002/jha2.494. eCollection 2022 Aug.
PMID: 36051011
Reply to T. Olivier et al.
Wolchok JD, Kluger H, Campigotto F, Larkin J, Hodi FS.
J Clin Oncol. 2022 May 10;40(14):1597-1598. doi: 10.1200/JCO.22.00209. Epub 2022 Mar 8.
PMID: 35258992
Cobalt-Catalyzed C(sp2)-C(sp3) Suzuki-Miyaura Cross-Coupling Enabled by Well-Defined Precatalysts with L,X-Type Ligands.
Mills LR, Gygi D, Ludwig JR, Simmons EM, Wisniewski SR, Kim J, Chirik PJ.
ACS Catal. 2022 Feb 4;12(3):1905-1918. doi: 10.1021/acscatal.1c05586. Epub 2022 Jan 20.
PMID: 36034100
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.
Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Bello A, Murthy B.
Clin Pharmacokinet. 2022 Jul 30. doi: 10.1007/s40262-022-01150-1. Online ahead of print.
PMID: 35906349
Relationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review.                                       Shah F, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Yucel A, Moro Bueno L, Oliva EN.                                                             J Clin Med. 2022 Jul 30;11(15):4448. doi: 10.3390/jcm11154448.                                                                                       PMID: 35956067
Imaging the Alternatively Spliced D Domain of Tenascin C in a Preclinical Model of Inflammatory Bowel Disease.
Zhang L, Wang Y, Homan KT, Gaudette SM, McCluskey AJ, Chan Y, Murphy J, Abdalla M, Nelson CM, Sun VZ, Erickson JE, Knight HL, Clabbers A, Sterman AJS, Mitra S.
Mol Imaging Biol. 2022 Jul 29. doi: 10.1007/s11307-022-01758-6. Online ahead of print.
PMID: 35906512
Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.
Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Benedict RHB, Riolo J, Silva D, Dwyer MG; DeepGRAI Registry Study group.
J Neurol Neurosurg Psychiatry. 2022 Jul 28:jnnp-2022-329333. doi: 10.1136/jnnp-2022-329333. Online ahead of print.
PMID: 35902228
Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium.
Rusyn I, Sakolish C, Kato Y, Stephan C, Vergara L, Hewitt P, Bhaskaran V, Davis M, Hardwick RN, Ferguson SS, Stanko JP, Bajaj P, Adkins K, Sipes NS, Hunter ES, Baltazar MT, Carmichael PL, Sadh K, Becker RA.
Toxicol Sci. 2022 Jul 28;188(2):143-152. doi: 10.1093/toxsci/kfac061.
PMID: 35689632
Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference.
Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, Camm AJ, Casadei B, Chua W, Dagres N, de Melis M, Desteghe L, Diederichsen SZ, Duncker D, Eckardt L, Eisert C, Engler D, Fabritz L, Freedman B, Gillet L, Goette A, Guasch E, Svendsen JH, Hatem SN, Haeusler KG, Healey JS, Heidbuchel H, Hindricks G, Hobbs FDR, Hübner T, Kotecha D, Krekler M, Leclercq C, Lewalter T, Lin H, Linz D, Lip GYH, Løchen ML, Lucassen W, Malaczynska-Rajpold K, Massberg S, Merino JL, Meyer R, Mont L, Myers MC, Neubeck L, Niiranen T, Oeff M, Oldgren J, Potpara TS, Psaroudakis G, Pürerfellner H, Ravens U, Rienstra M, Rivard L, Scherr D, Schotten U, Shah D, Sinner MF, Smolnik R, Steinbeck G, Steven D, Svennberg E, Thomas D, True Hills M, van Gelder IC, Vardar B, Palà E, Wakili R, Wegscheider K, Wieloch M, Willems S, Witt H, Ziegler A, Daniel Zink M, Kirchhof P.
Europace. 2022 Jul 27:euac062. doi: 10.1093/europace/euac062. Online ahead of print.
PMID: 35894842
Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.
Kanthe AD, Carnovale MR, Katz JS, Jordan S, Krause ME, Zheng S, Ilott A, Ying W, Bu W, Bera MK, Lin B, Maldarelli C, Tu RS.
Mol Pharm. 2022 Jul 26. doi: 10.1021/acs.molpharmaceut.2c00152. Online ahead of print.
PMID: 35882380
Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
Samlowski W, Robert NJ, Chen L, Schenkel B, Davis C, Moshyk A, Kotapati S, Poretta T, Weber JS.
Cancer Med. 2022 Jul 25. doi: 10.1002/cam4.5061. Online ahead of print.
PMID: 35880244
Bioactivation and Reactivity Research Advances - 2021 year in review.
Jackson KD, Argikar UA, Cho S, Crouch RD, Driscoll JP, Heck C, King L, Maw HH, Miller GP, Seneviratne HK, Wang S, Wei C, Zhang D, Khojasteh SC.
Drug Metab Rev. 2022 Jul 25:1-83. doi: 10.1080/03602532.2022.2097254. Online ahead of print.
PMID: 35876116
Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.                                                                                                                                                                         Shah N, Delforge M, San-Miguel J, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Miera M, Williams A, Murphy R, Devlen J, Hege K, Campbell TB, Munshi NC.                                                                                                                                                                   Leuk Res. 2022 Jul 21;120:106921. doi: 10.1016/j.leukres.2022.106921. Online ahead of print.                                           PMID: 35930999
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
Ding X, Zhu Z, Lapek J, McMillan EA, Zhang A, Chung CY, Dubbury S, Lapira J, Firdaus S, Kang X, Gao J, Oyer J, Chionis J, Rollins RA, Li L, Niessen S, Bagrodia S, Zhang L, VanArsdale T.
Sci Rep. 2022 Jul 21;12(1):12501. doi: 10.1038/s41598-022-16623-3.
PMID: 35864202
Optimization of antidote stocking, availability, and administration practices for a large multihospital organization.
Antoniello AA, Pauls P, Awad NI, Sobolewski K, Fernández D, Bridgeman P.
Am J Health Syst Pharm. 2022 Jul 21:zxac191. doi: 10.1093/ajhp/zxac191. Online ahead of print.
PMID: 35861156
One-Step Synthesis of β-Alkylidene-γ-lactones via Ligand-Enabled β,γ-Dehydrogenation of Aliphatic Acids.
Sheng T, Zhuang Z, Wang Z, Hu L, Herron AN, Qiao JX, Yu JQ.
J Am Chem Soc. 2022 Jul 20;144(28):12924-12933. doi: 10.1021/jacs.2c04779. Epub 2022 Jul 8.
PMID: 35802794
Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey.
Petersson C, Zhou X, Berghausen J, Cebrian D, Davies M, DeMent K, Eddershaw P, Riedmaier AE, Leblanc AF, Manveski N, Marathe P, Mavroudis PD, McDougall R, Parrott N, Reichel A, Rotter C, Tess D, Volak LP, Xiao G, Yang Z, Baker J.
AAPS J. 2022 Jul 19;24(5):85. doi: 10.1208/s12248-022-00735-9.
PMID: 35854202
Comparing patient global impression of severity and patient global impression of change to evaluate test-retest reliability of depression, non-small cell lung cancer, and asthma measures.
Eremenco S, Chen WH, Blum SI, Bush EN, Bushnell DM, DeBusk K, Gater A, Nelsen L, Coons SJ; PRO Consortium’s Communication Subcommittee.
Qual Life Res. 2022 Jul 19. doi: 10.1007/s11136-022-03180-5. Online ahead of print.
PMID: 35854060
Loss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma.
Gooding S, Ansari-Pour N, Kazeroun MH, Karagoz K, Polonskaia A, Angulo Salazar M, Fitzsimons E, Sirinukunwattana K, Chavda SJ, Ortiz Estevez M, Towfic F, Flynt E, Pierceall W, Royston D, Yong KL, Ramasamy K, Vyas P, Thakurta A.
Blood. 2022 Jul 19:blood.2022015909. doi: 10.1182/blood.2022015909. Online ahead of print.
PMID: 35853156
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.
Casulo C, Santoro A, Cartron G, Ando K, Munoz J, Le Gouill S, Izutsu K, Rule S, Lugtenburg P, Ruan J, Arcaini L, Casadebaig ML, Fox B, Kilavuz N, Rettby N, Dell'Aringa J, Taningco L, Delarue R, Czuczman M, Witzig T.
Cancer Rep (Hoboken). 2022 Jul 19:e1662. doi: 10.1002/cnr2.1662. Online ahead of print.
PMID: 35852004
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
Baxi V, Lee G, Duan C, Pandya D, Cohen DN, Edwards R, Chang H, Li J, Elliott H, Pokkalla H, Glass B, Agrawal N, Lahiri A, Wang D, Khosla A, Wapinski I, Beck A, Montalto M.
Mod Pathol. 2022 Jul 15. doi: 10.1038/s41379-022-01119-2. Online ahead of print.
PMID: 35840720
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG 3rd, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD Jr, Mullins RD, Eyquem J, Wells JA, Wiita AP.
Nat Commun. 2022 Jul 15;13(1):4121. doi: 10.1038/s41467-022-31810-6.
PMID: 35840578
Challenges Encountered in the Implementation of Bio-Fluorescent Particle Counting Systems as a Routine Microbial Monitoring Tool.
Scott A, Vanbroekhoven A, Joossen C, Knutsen C, Govezensky D, Anders HJ, Cannon J, Salvas J, Dingle M, Hutchins P, Merker P, Villari P, Ramsey S, Cundell AM, Navarro V, Franz-Riethdorf M.
PDA J Pharm Sci Technol. 2022 Jul 15:pdajpst.2021.012726. doi: 10.5731/pdajpst.2021.012726. Online ahead of print.
PMID: 35840344
Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey.
Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie A.
J Rheumatol. 2022 Jul 15:jrheum.211288. doi: 10.3899/jrheum.211288. Online ahead of print.
PMID: 35840154
Development and validation of a self-administered questionnaire measuring essential knowledge in patients with axial spondyloarthritis.
Beauvais C, Pereira B, Pham T, Sordet C, Claudepierre P, Fayet F, Wendling D, Costantino F, Carton L, Grange L, Soubrier M, Legoupil N, Perdriger A, Tavares I, Dernis E, Gossec L, Rodère M.
J Rheumatol. 2022 Jul 15:jrheum.211314. doi: 10.3899/jrheum.211314. Online ahead of print.
PMID: 35840152
Low rate of subsequent malignant neoplasms following CAR T-cell therapy.
Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard JD, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble A.
Blood Adv. 2022 Jul 14:bloodadvances.2022008093. doi:10.1182/bloodadvances.2022008093.Online ahead of print.
PMID: 35834728
Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
Priestley ES, Banville J, Deon D, Dubé L, Gagnon M, Guy J, Lapointe P, Lavallée JF, Martel A, Plamondon S, Rémillard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A.
J Med Chem. 2022 Jul 14;65(13):8843-8854. doi: 10.1021/acs.jmedchem.2c00359. Epub 2022 Jun 21.
PMID: 35729784
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Nara SJ, Jogi S, Cheruku S, Kandhasamy S, Jaipuri F, Kathi PK, Reddy S, Sarodaya S, Cook EM, Wang T, Sitkoff D, Rossi KA, Ruzanov M, Kiefer SE, Khan JA, Gao M, Reddy S, Sivaprasad Lvj S, Sane R, Mosure K, Zhuo X, Cao GG, Ziegler M, Azzara A, Krupinski J, Soars MG, Ellsworth BA, Wacker DA.
J Med Chem. 2022 Jul 14;65(13):8948-8960. doi: 10.1021/acs.jmedchem.2c00165. Epub 2022 Jun 15.
PMID: 35704802
Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience.
Xu J, Zhang L, Shao X.
Drug Dev Ind Pharm. 2022 Jul 13:1-19. doi: 10.1080/03639045.2022.2098315. Online ahead of print.
PMID: 35786119
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.
Gao K, Wang R, Chen J, Cheng L, Frishcosy J, Huzumi Y, Qiu Y, Schluckbier T, Wei X, Wei GW.
Chem Rev. 2022 Jul 13;122(13):11287-11368. doi: 10.1021/acs.chemrev.1c00965. Epub 2022 May 20.
PMID: 35594413
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium.
Starcevic Manning M, Hassanein M, Partridge MA, Jawa V, Mora J, Ryman J, Barker B, Braithwaite C, Carleton K, Hay L, Hottenstein C, Kubiak RJ, Devanarayan V.
AAPS J. 2022 Jul 12;24(4):81. doi: 10.1208/s12248-022-00728-8.
PMID: 35821280
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C, Li W, Sterling L, Lampl K, Edelberg JM, Sehnert AJ, Nissen SE.
J Am Coll Cardiol. 2022 Jul 12;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048.
PMID: 35798455
Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model.
Axelsson Raja A, Wakimoto H, DeLaughter DM, Reichart D, Gorham J, Conner DA, Lun M, Probst CK, Sakai N, Knipe RS, Montesi SB, Shea B, Adam LP, Leinwand LA, Wan W, Choi ES, Lindberg EL, Patone G, Noseda M, Hübner N, Seidman CE, Tager AM, Seidman JG, Ho CY.
Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2204174119. doi: 10.1073/pnas.2204174119. Epub 2022 Jul 5.
PMID: 35787042
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A.
J Am Acad Dermatol. 2022 Jul 9:S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print.
PMID: 35820547
Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database.
Munir MB, Hlavacek P, Keshishian A, Guo JD, Mallampati R, Ferri M, Russ C, Emir B, Cato M, Yuce H, Hsu JC.
J Interv Card Electrophysiol. 2022 Jul 9. doi: 10.1007/s10840-022-01274-1. Online ahead of print.
PMID: 35804258
Design and preparation of N-linked hydroxypyridine-based APJ agonists.
Richter JM, Alex Bates J, Gargalovic P, Onorato JM, Generaux C, Wang T, Gordon DA, Wexler RR, Finlay HJ.
Bioorg Med Chem Lett. 2022 Jul 8;73:128882. doi: 10.1016/j.bmcl.2022.128882. Online ahead of print.
PMID: 35817293
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T, Hou Y, Pignon JC, Walton E, West DJ, Freeman GJ, Braun DA, Wu CJ, Gupta S, Motzer RJ, Atkins MB, McDermott D, Choueiri TK, Shukla SA, Signoretti S.
Clin Cancer Res. 2022 Jul 8:ccr.22.0923. doi: 10.1158/1078-0432.CCR-22-0923. Online ahead of print.
PMID: 35802667
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma A, Mufti Obe GJ, Buckstein RJ, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS.
Blood. 2022 Jul 7:blood.2022016171. doi: 10.1182/blood.2022016171. Online ahead of print.
PMID: 35797468
Ligand-Enabled β-C(sp3 )-H Lactamization of Tosyl-Protected Aliphatic Amides Using a Practical Oxidant.
Zhuang Z, Liu S, Cheng JT, Yeung KS, Qiao JX, Meanwell NA, Yu JQ.
Angew Chem Int Ed Engl. 2022 Jul 5:e202207354. doi: 10.1002/anie.202207354. Online ahead of print.
PMID: 35790471
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties.
Hill MD, Fang H, Norris D, Delucca GV, Huang H, DeBenedetto M, Quesnelle C, Schmitz WD, Tokarski JS, Sheriff S, Yan C, Fanslau C, Haarhoff Z, Huang C, Kramer M, Madari S, Menard K, Monereau L, Morrison J, Raghavan N, Shields EE, Simmermacher-Mayer J, Sinz M, Tye CK, Westhouse R, Xie C, Zhang H, Zhang L, Zvyaga T, Lee F, Gavai AV, Degnan AP.
ACS Med Chem Lett. 2022 Jul 5;13(7):1165-1171. doi: 10.1021/acsmedchemlett.2c00219. eCollection 2022 Jul 14.
PMID: 35859878
Trends in FDA Transporter-Based Post Marketing Requirements and Commitments Over the Last Decade.
Younis IR, Manchandani P, Hassan HE, Qosa H.
Clin Pharmacol Ther. 2022 Jul 3. doi: 10.1002/cpt.2701. Online ahead of print.
PMID: 35780478
hERG block potencies for 5 positive control drugs obtained per ICH E14/S7B Q&As best practices: Impact of recording temperature and drug loss.
Alvarez Baron C, Thiebaud N, Ren M, Viatchenko-Karpinski S, Indapurkar A, King T, Matta MK, Ismaiel OA, Patel V, Mashaee M, Vicente J, Wu WW.
J Pharmacol Toxicol Methods. 2022 Jul 2:107193. doi: 10.1016/j.vascn.2022.107193. Online ahead of print.
PMID: 35792285
Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior.
Beisel C, Poretta T, Sheppard VB, Hurtado-de Mendoza A, Sipsma H, Fuqua E, Stwalley B, Salvatore A, Yang M.
Adv Ther. 2022 Jul 1. doi: 10.1007/s12325-022-02221-2. Online ahead of print.
PMID: 35776398
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA.
Clin Cancer Res. 2022 Jul 1;28(13):2854-2864. doi: 10.1158/1078-0432.CCR-21-3695.
PMID: 35522533
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG, Aronson R, Jordan JD, Kolls BJ, Dombrowski KE, Vinereanu D, Halvorsen S, Berwanger O, Windecker S, Mehran R, Granger CB, Alexander JH, Lopes RD.
JAMA Cardiol. 2022 Jul 1;7(7):682-689. doi: 10.1001/jamacardio.2022.1166. PMID: 35612866
A comparison of the lowest effective concentration in culture media for detection of chromosomal damage in vitro and in blood or plasma for detection of micronuclei in vivo.
Kirkland D, Whitwell J, Smith R, Hashimoto K, Ji Z, Kenny J, Koyama N, Lovell DP, Martus HJ, Meurer K, Roberts D, Takeiri A, Uno Y, van der Leede BJ, White P, Zeller A.
Mutat Res Genet Toxicol Environ Mutagen. 2022 Jul-Aug;879-880:503503. doi: 10.1016/j.mrgentox.2022.503503. Epub 2022 May 28.
PMID: 35914859
Why 90% of clinical drug development fails and how to improve it?
Sun D, Gao W, Hu H, Zhou S.
Acta Pharm Sin B. 2022 Jul;12(7):3049-3062. doi: 10.1016/j.apsb.2022.02.002. Epub 2022 Feb 11.
PMID: 35865092
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y.
RMD Open. 2022 Jul;8(2):e002235. doi: 10.1136/rmdopen-2022-002235.
PMID: 35798511
Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer.
Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, Xie X, Gao T, Cheng X, Sun SC.
Nat Cell Biol. 2022 Jul;24(7):1165-1176. doi: 10.1038/s41556-022-00942-8. Epub 2022 Jun 30.
PMID: 35773432
Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial.
Reaney M, Addepalli P, Allen V, Spertus JA, Dolan C, Sehnert AJ, Fine JT.
Pharmacoecon Open. 2022 Jul;6(4):575-586. doi: 10.1007/s41669-022-00340-8. Epub 2022 Jun 20.
PMID: 35718845
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, Del Tejo V, Du EX, Yang X, Betts KA, Choueiri TK, McGregor B.
Clin Drug Investig. 2022 Jul;42(7):611-622. doi: 10.1007/s40261-022-01170-6. Epub 2022 Jun 13.
PMID: 35696045
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK.
Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7.
PMID: 35688173
An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
Cheng Y, Liu L, Xue Y, Zhou S, Li Y.
Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):579-592. doi: 10.1007/s13318-022-00776-7. Epub 2022 Jun 3.
PMID: 35657581
Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument.
Reaney M, Allen V, Sehnert AJ, Fang L, Hagège AA, Naidu SS, Olivotto I.
Pharmacoecon Open. 2022 Jul;6(4):563-574. doi: 10.1007/s41669-022-00335-5. Epub 2022 Jun 2.
PMID: 35653062
Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA, Leung L, Singh P, Kurt M, Kim I, Pourrahmat MM, Kanters S.
Eur J Cancer. 2022 Jul;170:119-130. doi: 10.1016/j.ejca.2022.04.027. Epub 2022 May 20.
PMID: 35605522
Compatibility rules of human enhancer and promoter sequences.
Bergman DT, Jones TR, Liu V, Ray J, Jagoda E, Siraj L, Kang HY, Nasser J, Kane M, Rios A, Nguyen TH, Grossman SR, Fulco CP, Lander ES, Engreitz JM.
Nature. 2022 Jul;607(7917):176-184. doi: 10.1038/s41586-022-04877-w. Epub 2022 May 20.
PMID: 35594906
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Lip GYH, Keshishian A, Kang A, Luo X, Atreja N, Zhang Y, Schuler P, Jiang J, Yuce H, Deitelzweig S.
J Thromb Thrombolysis. 2022 Jul;54(1):33-46. doi: 10.1007/s11239-022-02660-2. Epub 2022 May 17.
PMID: 35579733
Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses.
Yang Z, Rajendran S, Spires V, Poirson B, Gururajan M, Lin Z, Arbanas J, Krystek S, Loy J, Cheng Y, Carl S, Pace S, Wang Y, Mehl J, Xu S, Vasudevan K, Broz M, Lehman-McKeeman L, Morin P, Graziano RF.
Drug Metab Dispos. 2022 Jul;50(7):898-908. doi: 10.1124/dmd.121.000799. Epub 2022 May 11.
PMID: 35545256
Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials.
Zhang W, Ro S, Jiang Q, Li X, Liu R, Lu C', Marchenko O, Zhao J, Xu Z.
Ther Innov Regul Sci. 2022 Jul;56(4):552-560. doi: 10.1007/s43441-022-00407-y. Epub 2022 May 3.
PMID: 35503503
End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
Dixon JG, Dimier N, Nielsen T, Zheng J, Marcus R, Morschhauser F, Evens AM, Federico M, Blum KA, Shi Q.
Br J Haematol. 2022 Jul;198(2):333-337. doi: 10.1111/bjh.18217. Epub 2022 May 2.
PMID: 35491747
Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells.
Richardson K, Keam SP, Zhu JJ, Meyran D, D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, Quach H, Ritchie DS, Harrison SJ, Prince HM, Trapani JA, Jenkins MR, Beavis PA, Darcy PK, Neeson PJ.
Haematologica. 2022 Jun 30. doi: 10.3324/haematol.2021.279930. Online ahead of print.
PMID: 35770527
Quantification of Linrodostat and its metabolites: Overcoming bioanalytical challenges in support of a discovery Indoleamine 2,3 dioxygenase program.
Discenza LN, Balog A, Huang C, Moore R, Ranasinghe A, Lin TA, D'Arienzo C, Olah TV.
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jun 28;1207:123305. doi: 10.1016/j.jchromb.2022.123305. Online ahead of print.
PMID: 35839627
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.
Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584. Online ahead of print.
PMID: 35765217
OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.
Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler AM, Lampl M, Linker RA.
Front Neurol. 2022 Jun 27;13:913616. doi: 10.3389/fneur.2022.913616. eCollection 2022.
PMID: 35832177
Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.
Dong G, Huang B, Verbeeck J, Cui Y, Song J, Gamalo-Siebers M, Wang D, Hoaglin DC, Seifu Y, Mütze T, Kolassa J.
Pharm Stat. 2022 Jun 27. doi: 10.1002/pst.2251. Online ahead of print.
PMID: 35757986
New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans.
Merali S, Wang Z, Frost C, Callejo M, Hedrick M, Hui L, Meadows Shropshire S, Xu K, Bouvier M, DeSouza MM, Yang J.
Platelets. 2022 Jun 26:1-10. doi: 10.1080/09537104.2022.2088719. Online ahead of print.
PMID: 35758258
Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ.
Ann Oncol. 2022 Jun 25:S0923-7534(22)01737-9. doi: 10.1016/j.annonc.2022.06.008. Online ahead of print.
PMID: 35764271
Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization.
Hawryluk N, Zhiru L, Carlow C, Gokool S, Townson S, Kreiss T, Chojnowski A, Prorok M, Siekierka J, Ehrens A, Koschel M, Lhermitte-Vallarino N, Martin C, Hoerauf A, Hernandez G, Canan S, Khetani V, Zeldis J, Specht S, Hübner MP, Scandale I.
Int J Parasitol Drugs Drug Resist. 2022 Jun 23;19:89-97. doi: 10.1016/j.ijpddr.2022.06.002. Online ahead of print.
PMID: 35834918
Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
Moore A, Bennett B, Taylor-Stokes G, McDonald L, Daumont MJ.
BMC Cancer. 2022 Jun 23;22(1):693. doi: 10.1186/s12885-022-09750-7.
PMID: 35739480
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS.
Cancer. 2022 Jun 23. doi: 10.1002/cncr.34366. Online ahead of print.
PMID: 35737639
Propensity score matching and stratification using multiparty data without pooling.
Wang J, Marion-Gallois R.
Pharm Stat. 2022 Jun 22. doi: 10.1002/pst.2250. Online ahead of print.
PMID: 35733398
Considerations for Human ADME strategy and design paradigm shift(s) - an Industry white paper.
Young GC, Spracklin DK, James AD, Hvenegaard MG, Scarfe G, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, van Groen B, Romeo AA, Cassidy KC, Da-Violante G, Bister B, Blech S, Lyer R, Schulz SI, Cuyckens F, Moliner P.
Clin Pharmacol Ther. 2022 Jun 22. doi: 10.1002/cpt.2691. Online ahead of print.
PMID: 35733280
Systematic identification of genomic elements that regulate FCGR2A expression and harbor variants linked with autoimmune disease.
Dahlqvist J, Fulco CP, Ray JP, Liechti T, de Boer CG, Lieb DJ, Eisenhaure TM, Engreitz JM, Roederer M, Hacohen N.
Hum Mol Genet. 2022 Jun 22;31(12):1946-1961. doi: 10.1093/hmg/ddab372.
PMID: 34970970
Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein.
Yang Z, Loy J, Poirson B, Dai Y, Rajendran S, Xu S, Spires V, Gururajan M, Lin Z, Arbanas J, Carl S, Pace S, Wang Y, Mehl J, Vasudevan K, Spires T, Novosiadly R, Coker S, Perez R, Covello K, Morin P, Graziano R, Broz M, Lehman-McKeeman L.
Front Pharmacol. 2022 Jun 20;13:829063. doi: 10.3389/fphar.2022.829063. eCollection 2022.
PMID: 35795558
An Evaluation of the Occupational Health Hazards of Peptide Couplers.
Graham JC, Trejo-Martin A, Chilton ML, Kostal J, Bercu J, Beutner GL, Bruen US, Dolan DG, Gomez S, Hillegass J, Nicolette J, Schmitz M.
Chem Res Toxicol. 2022 Jun 20;35(6):1011-1022. doi: 10.1021/acs.chemrestox.2c00031. Epub 2022 May 9.
PMID: 35532537
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators.
Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6.
PMID: 35717989
Oral Cryotherapy for Oral Mucositis in Patients Receiving Busulfan: A Retrospective/Prospective Descriptive Study.
Grossman A, Froggatt N, Hendricks L, Kannenberg M, Klink K, Koch N, Reid K, Pitcher D, Bullock P, Neubauer J.
Oncol Nurs Forum. 2022 Jun 17;49(4):327-335. doi: 10.1188/22.ONF.327-335.
PMID: 35788737
Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.
Selkirk JV, Bortolato A, Yan YG, Ching N, Hargreaves R.
Front Pharmacol. 2022 Jun 17;13:892097. doi: 10.3389/fphar.2022.892097. eCollection 2022.
PMID: 35784713
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.
de Botton S, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei AH, Ommen HB, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol FR, Chromik J, Byrne JL, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin VA, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martín-Regueira P, DiNardo CD.
Blood. 2022 Jun 17:blood.2021014901. doi: 10.1182/blood.2021014901. Online ahead of print.
PMID: 35714312
Confirmatory efficacy testing for individual dose-placebo comparisons using serial gatekeeping procedure in dose-finding trials with multiple comparison procedures-modeling.
Yamaguchi Y, Sugitani T, Yoshida S, Maruo K.
Pharm Stat. 2022 Jun 16. doi: 10.1002/pst.2246. Online ahead of print.
PMID: 35708144
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Goring S, Varol N, Waser N, Popoff E, Lozano-Ortega G, Lee A, Yuan Y, Eccles L, Tran P, Penrod JR.
Lung Cancer. 2022 Jun 15;170:122-132. doi: 10.1016/j.lungcan.2022.06.009. Online ahead of print.
PMID: 35767923
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T, Lefere S, Hundertmark J, Kohlhepp M, Penners C, Van de Velde F, Lapauw B, Hoorens A, Devisscher L, Geerts A, Boehm S, Zhao Q, Krupinski J, Charles ED, Zinker B, Tacke F.
Int J Mol Sci. 2022 Jun 15;23(12):6696. doi: 10.3390/ijms23126696.
PMID: 35743140
Evaluation of patients with rheumatoid arthritis in teleconsultation during the first wave of the COVID-19 pandemic.
Avouac J, Molto A, Frantz C, Wanono S, Descamps E, Fogel O, Combier A, Poiroux L, Miceli-Richard C, Allanore Y.
J Rheumatol. 2022 Jun 15:jrheum.220073. doi: 10.3899/jrheum.220073. Online ahead of print.
PMID: 35705239
Long-term behavioral changes during the COVID-19 pandemic and impact of vaccination in patients with inflammatory rheumatic diseases.
Glintborg B, Jensen DV, Terslev L, Hendricks O, Østergaard M, Rasmussen SH, Pfeiffer Jensen M, Adelsten T, Colic A, Danebod K, Kildemand M, Loft AG, Munk HL, Pedersen JK, Østgård RD, Sørensen CM, Krogh NS, Agerbo JN, Ziegler C, Hetland ML.
J Rheumatol. 2022 Jun 15:jrheum.211280. doi: 10.3899/jrheum.211280. Online ahead of print.
PMID: 35705237
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL.
Clin Cancer Res. 2022 Jun 14:clincanres.4020.2021. doi: 10.1158/1078-0432.CCR-21-4020. Online ahead of print.
PMID: 35699599
An overview of the BOIN design and its current extensions for novel early-phase oncology trials.
Ananthakrishnan R, Lin R, He C, Chen Y, Li D, LaValley M.
Contemp Clin Trials Commun. 2022 Jun 13;28:100943. doi: 10.1016/j.conctc.2022.100943. eCollection 2022 Aug.
PMID: 35812822
Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians.
Mocek A, Weber V, Schmölders J, Witt H, Gothe H.
Prev Med Rep. 2022 Jun 13;28:101861. doi: 10.1016/j.pmedr.2022.101861. eCollection 2022 Aug.
PMID: 35757576
Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.
Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J.
Curr Med Res Opin. 2022 Jun 11:1-11. doi: 10.1080/03007995.2022.2081453. Online ahead of print.
PMID: 35608153
Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics.
Humphreys SC, Davis JA, Iqbal S, Kamel A, Kulmatycki K, Lao Y, Liu X, Rodgers J, Snoeys J, Vigil A, Weng Y, Wiethoff CM, Wittwer MB.
Nucleic Acids Res. 2022 Jun 10;50(11):6020-37. doi: 10.1093/nar/gkac456. Online ahead of print.
PMID: 35687098
Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders.
Malona J, Chuaqui C, Seletsky BM, Beebe L, Cantin S, VAN Kalken D, Fahnoe K, Wang Z, Browning B, Szabo H, Koopman LA, Oravecz T, McDonald JJ, Ramirez-Valle F, Gaur R, Mensah KA, Thomas M, Connarn JN, Hu H, Alexander MD, Corin AF.
Transl Res. 2022 Jun 9:S1931-5244(22)00138-4. doi: 10.1016/j.trsl.2022.06.005. Online ahead of print.
PMID: 35691544
A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative change.
Zhang H, Chhibber A, Shaw PM, Mehrotra DV, Shen J.
NPJ Genom Med. 2022 Jun 9;7(1):33. doi: 10.1038/s41525-022-00303-2.
PMID: 35680959
The Relevance of Experimental Charge Density Analysis in Unraveling Noncovalent Interactions in Molecular Crystals.
Thomas SP, Dikundwar AG, Sarkar S, Pavan MS, Pal R, Hathwar VR, Row TNG.
Molecules. 2022 Jun 8;27(12):3690. doi: 10.3390/molecules27123690.
PMID: 35744821
Propensity score-integrated approach to survival analysis: leveraging external evidence in single-arm studies.
Chen WC, Lu N, Wang C, Li H, Song C, Tiwari R, Xu Y, Yue LQ.
J Biopharm Stat. 2022 Jun 8:1-14. doi: 10.1080/10543406.2022.2080701. Online ahead of print.
PMID: 35675348
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2.
Meanwell NA, Loiseleur O.
J Agric Food Chem. 2022 Jun 8. doi: 10.1021/acs.jafc.2c00729. Online ahead of print.
PMID: 35675052
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 1.
Meanwell NA, Loiseleur O.
J Agric Food Chem. 2022 Jun 8. doi: 10.1021/acs.jafc.2c00726. Online ahead of print.
PMID: 35675050
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Awad MM, Le Bruchec Y, Lu B, Ye J, Miller JA, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A.
Front Oncol. 2022 Jun 7;12:889996. doi: 10.3389/fonc.2022.889996. eCollection 2022.
PMID: 35747830
Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
Fox RJ, Mehta R, Pham T, Park J, Wilson K, Bonafede M.
BMC Neurol. 2022 Jun 7;22(1):211. doi: 10.1186/s12883-022-02738-7.
PMID: 35672686
Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.
Waddell T, Fife K, Griffiths R, Sharma A, Dhokia P, Groves L, Hurst M, Tsang C, Sugrue D, McKenna S, Houghton J, Carroll R.
BMC Cancer. 2022 Jun 6;22(1):617. doi: 10.1186/s12885-022-09694-y.
PMID: 35668384
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.
Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, Velu P, Leo P, Beig N, Li H, Toro P, Berezowska S, Baxi V, Balli D, Belete M, Rimm DL, Velcheti V, Schalper K, Madabhushi A.
NPJ Precis Oncol. 2022 Jun 3;6(1):33. doi: 10.1038/s41698-022-00277-5.
PMID: 35661148
Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.
Lai Y, Chu X, Di L, Gao W, Guo Y, Liu X, Lu C, Mao J, Shen H, Tang H, Xia CQ, Zhang L, Ding X.
Acta Pharm Sin B. 2022 Jun;12(6):2751-2777. doi: 10.1016/j.apsb.2022.03.009. Epub 2022 Mar 17.
PMID: 35755285
Calibration and validation of the rabbit model of electrolytic-mediated arterial thrombosis against the standard-of-care anticoagulant apixaban.
Wong PC, Crain E.
Pharmacol Res Perspect. 2022 Jun;10(3):e00963. doi: 10.1002/prp2.963.
PMID: 35680619
Combining SNP-to-gene linking strategies to identify disease genes and assess disease omnigenicity.
Gazal S, Weissbrod O, Hormozdiari F, Dey KK, Nasser J, Jagadeesh KA, Weiner DJ, Shi H, Fulco CP, O'Connor LJ, Pasaniuc B, Engreitz JM, Price AL.
Nat Genet. 2022 Jun;54(6):827-836. doi: 10.1038/s41588-022-01087-y. Epub 2022 Jun 6.
PMID: 35668300
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH.
Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3.
PMID: 35662283
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators.
Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.
PMID: 35550060
Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice.
Dickson NR, Beauchamp KD, Perry TS, Roush A, Goldschmidt D, Edwards ML, Blakely LJ.
J Comp Eff Res. 2022 Jun;11(8):609-619. doi: 10.2217/cer-2021-0290. Epub 2022 May 12.
PMID: 35546311
Corrigendum to a cross-industry collaboration to assess if acute toxicity (Q)SAR models are fit-for-purpose for GHS classification and labelling. Regulatory toxicology and pharmacology (2021) 104843.
Bercu J, Masuda Herrera MJ, Trejo-Martin A, Hasselgren C, Lord J, Graham J, Schmitz M, Milchak L, Owens C, Lal SH, Robinson RM, Whalley S, Bellion P, Vuorinen A, Gromek K, Hawkins WA, Van de Gevel I, Vriens K, Kemper R, Naven R, Ferrer P, Myatt GJ.
Regul Toxicol Pharmacol. 2022 Jun;131:105165. doi: 10.1016/j.yrtph.2022.105165. Epub 2022 Apr 23.
PMID: 35474000
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Zardavas D.
Expert Opin Investig Drugs. 2022 Jun;31(6):633-644. doi: 10.1080/13543784.2022.2070064. Epub 2022 May 2.
PMID: 35451891
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.
Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B.
Cardiol Ther. 2022 May 31. doi: 10.1007/s40119-022-00266-6. Online ahead of print.
PMID: 35641780
Dual-detection approach for a charge variant analysis of monoclonal antibody combination products using imaged capillary isoelectric focusing.
Candreva J, Esterman AL, Ge D, Patel P, Flagg SC, Das TK, Li X.
Electrophoresis. 2022 May 30. doi: 10.1002/elps.202200026. Online ahead of print.
PMID: 35634791
Fibronectin extra domain A as a drug delivery targeting epitope for rheumatoid arthritis.
Sun VZ, Melim TL, Mitra S, Erickson JE, Bryant SH, Farnham A, Westmoreland S, Knight H, Zhang L, Ritacco W, Homan K, Benatuil L, Sterman AJS, Goodearl AD.
Adv Rheumatol. 2022 May 27;62(1):17. doi: 10.1186/s42358-022-00247-2.
PMID: 35624488
Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis.
Tsutsué S, Makita S, Yi J, Crawford B.
PLoS One. 2022 May 27;17(5):e0269169. doi: 10.1371/journal.pone.0269169. eCollection 2022.
PMID: 35622820
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, Ogasawara K, Stepan L, Schusterbauer C, Rettby N, Hasskarl J, Izutsu K.
Cancer Med. 2022 May 26. doi: 10.1002/cam4.4820. Online ahead of print.
PMID: 35619325
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists.
Wurtz NR, Johnson JA, Viet A, Shirude PS, Baligar V, Madduri S, Cheney DL, Park H, Lupisella JA, Hsu MY, Abousleiman M, Galella MA, Aulakh D, Dierks EA, Garcia RA, Ostrowski J, Kick EK, Wexler RR.
ACS Med Chem Lett. 2022 May 25;13(6):943-948. doi: 10.1021/acsmedchemlett.2c00079. eCollection 2022 Jun 9.
PMID: 35707160
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?
Zheng S, Prell R, Sheng J, Wang YM, Hamuro L.
Clin Transl Sci. 2022 May 25. doi: 10.1111/cts.13345. Online ahead of print.
PMID: 35611545
The impact of phosphorylated PTEN at threonine 366 on cortical connectivity and behaviour.
Ledderose JMT, Benitez JA, Roberts AJ, Reed R, Bintig W, Larkum ME, Sachdev RNS, Furnari F, Eickholt BJ.
Brain. 2022 May 23:awac188. doi: 10.1093/brain/awac188. Online ahead of print.
PMID: 35603900
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Santini V, Giagounidis A, Pelligra CG, Franco-Villalobos C, Tang D, Morison J, Beach CL, Hu A, Platzbecker U, Fenaux P.
Clin Lymphoma Myeloma Leuk. 2022 May 21:S2152-2650(22)00152-5. doi: 10.1016/j.clml.2022.05.001. Online ahead of print.
PMID: 35710702
Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications.
Teoh J, Brown LF.
Cytotherapy. 2022 May 21:S1465-3249(22)00611-9. doi: 10.1016/j.jcyt.2022.03.013. Online ahead of print.
PMID: 35610089
The influence of a solvent environment on direct non-covalent interactions between two molecules: A symmetry-adapted perturbation theory study of polarization tuning of π-π interactions by water.
Sirianni DA, Zhu X, Sitkoff DF, Cheney DL, Sherrill CD.
J Chem Phys. 2022 May 21;156(19):194306. doi: 10.1063/5.0087302.
PMID: 35597646
Optimal adaptive promising zone designs.
Mehta C, Bhingare A, Liu L, Senchaudhuri P.
Stat Med. 2022 May 20;41(11):1950-1970. doi: 10.1002/sim.9339. Epub 2022 Feb 14.
PMID: 35165917
PP2 protects from keratin mutation-associated liver injury and filament disruption via SRC kinase inhibition in male but not female mice.
Li P, Maitra D, Kuo N, Kwan R, Song Y, Tang W, Chen L, Xie Q, Liu L, Omary MB.
Hepatology. 2022 May 19. doi: 10.1002/hep.32574. Online ahead of print.
PMID: 35586977
Nivolumab in Esophageal Squamous-Cell Carcinoma. Reply.
Kato K, Lei M.
N Engl J Med. 2022 May 19;386(20):1961. doi: 10.1056/NEJMc2202880.
PMID: 35584169
ACPA-negative and ACPA-positive RA-patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation.
Verstappen M, Matthijssen XME, Connolly SE, Maldonado MA, Huizinga TWJ, van der Helm-van Mil AHM.
Rheumatology (Oxford). 2022 May 18:keac294. doi: 10.1093/rheumatology/keac294. Online ahead of print.
PMID: 35583256
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.
Cerisoli F, Ali F, Bereczky T, Bolaños N, Bullinger L, Dhanasiri S, Gallagher J, Pérez SG, Geissler J, Guillevic Y, Harrison K, Naoum A, Portulano C, Rodríguez Vicente AE, Schulze-Rath R, Gómez GY, Sanz G, Hernández Rivas JM.
Value Health. 2022 May 17:S1098-3015(22)01931-3. doi: 10.1016/j.jval.2022.04.1729. Online ahead of print.
PMID: 35595634
2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization).
Loo L, Harris S, Milton M, Meena, Lembke W, Berisha F, Bertholet S, Dessy F, Dodge R, Fang X, Fiscella M, Garofolo F, Gorovits B, Gupta S, Jawa V, Ishii-Watabe A, Long B, Lu Y, Mack T, McGuire K, Nolan K, Pan L, Potthoff B, Purushothama S, Smith D, Solstad T, Sonderegger I, Taddeo F, Tangri S, Wagner L, Wu B, Xu Y, Kirshner S, Verthelyi D, Yan H, Maxfield K, Pedras-Vasconcelos J, Abhari MR, Gupta S, Wu Y, Rajadhyaksha M, Andisik M, Baltrukonis D, Cherry E, Cludts I, Gunn G, Millner AH, Jordan G, Kar S, Kubiak R, Lotz GP, Palmer R, Peng K, Poetzl J, Richards S, Savoie N, Staack RF, Stubenrauch K, Wadhwa M, Waxenecker G, Yang TY, Zhang L.
Bioanalysis. 2022 May 17. doi: 10.4155/bio-2022-0081. Online ahead of print.
PMID: 35578991
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.
Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C.
Am J Cardiovasc Drugs. 2022 May 16. doi: 10.1007/s40256-022-00524-x. Online ahead of print.
PMID: 35570249
Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France.
Kedra J, Claudepierre P, Flipo RM, Garrido-Cumbrera M, Alliot-Launois F, Desfleurs E, Grange L, Gossec L.
J Rheumatol. 2022 May 15:jrheum.210864. doi: 10.3899/jrheum.210864. Online ahead of print.
PMID: 35569828
Establishment of baseline profiles of 50 bile acids in preclinical toxicity species: A comprehensive assessment of translational differences and study design considerations for biomarker development.
Sangaraju D, Katavolos P, Liang X, Chou C, Zabka TS, Dean B, Maher J.
Toxicol Appl Pharmacol. 2022 May 15;443:116008. doi: 10.1016/j.taap.2022.116008. Epub 2022 Apr 1.
PMID: 35378153
Label-free plasma proteomics for the identification of the putative biomarkers of oral squamous cell carcinoma.
Gautam SS, Singh RP, Karsauliya K, Sonker AK, Reddy PJ, Mehrotra D, Gupta S, Singh S, Kumar R, Singh SP.
J Proteomics. 2022 May 15;259:104541. doi: 10.1016/j.jprot.2022.104541. Epub 2022 Feb 26.
PMID: 35231661
Synthesis of a dual carbon-14-labeled calcitonin gene-related peptide receptor antagonist for use in a human absorption-distribution-metabolism-elimination study.
Turley WA, Easter JA, Burrell RC, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm. 2022 May 15;65(5):126-139. doi: 10.1002/jlcr.3966. Epub 2022 Mar 10.
PMID: 35199393
A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins.
Casalino E, Stine LB, Corin AJ, Thai CT, Quiroz J, Wilson SC, Labow M, Mittal S.
SLAS Discov. 2022 May 14:S2472-5552(22)13673-7. doi: 10.1016/j.slasd.2022.05.001. Online ahead of print.
PMID: 35580766
Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance.
Zamek-Gliszczynski MJ, Sangha V, Shen H, Feng B, Wittwer MB, Varma MVS, Liang X, Sugiyama Y, Zhang L, Bendayan R; International Transporter Consortium.
Clin Pharmacol Ther. 2022 May 13. doi: 10.1002/cpt.2644. Online ahead of print.
PMID: 35561119
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
Lotz GP, Benstein K, Bloem K, Buddiger H, Calonder C, Elm S, Fernandez E, Goodman J, Gorovits B, Grudzinska-Goebel J, Janssen M, Jawa V, Kramer D, Luo L, Malisauskas M, Michaut L, Schäfer M, Spindeldreher S, Ullmann M, Nana Weldingh K, Kromminga A, Snoeck V.
AAPS J. 2022 May 12;24(3):68. doi: 10.1208/s12248-022-00712-2.
PMID: 35554731
National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey.
McBride A, Hudson-DiSalle S, Pilz J, Hamm M, Boring B, Buie LW, DeRemer DL.
JCO Oncol Pract. 2022 May 11:OP2100883. doi: 10.1200/OP.21.00883. Online ahead of print.
PMID: 35544740
X-linked genes exhibit miR6891-5p-regulated skewing in Sjögren's syndrome.
Shaw TM, Zhang W, McCoy SS, Pagenkopf A, Carp DM, Garg S, Parker MH, Qiu X, Scofield RH, Galipeau J, Liang Y.
J Mol Med (Berl). 2022 May 10. doi: 10.1007/s00109-022-02205-3. Online ahead of print.
PMID: 35538149
Antibody charge variant modulation by in vitro enzymatic treatment in different Chinese hamster ovary cell cultures.
Xu J, Santos J, Anderson NS, Borys MC, Pendse G, Li ZJ.
Biotechnol Prog. 2022 May 10:e3268. doi: 10.1002/btpr.3268. Online ahead of print.
PMID: 35536540
Circumventing glass vial and diluent effects on solution stability of small molecule analytes during analytical method development and validation.
Huang Y, Hu Y, Yuill EM, Marriott AS, Chadwick J, Li J, Zang J, Miller SA.
J Pharm Biomed Anal. 2022 May 10;213:114676. doi: 10.1016/j.jpba.2022.114676. Epub 2022 Feb 24.
PMID: 35240407
Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.
Parcella K, Wang T, Eastman K, Zhang Z, Yin Z, Patel M, Tu Y, Zheng BZ, Walker MA, Saulnier MG, Frennesson D, Bowsher M, Gillis E, Peese K, Belema M, Cianci C, Dicker IB, McAuliffe B, Ding B, Falk P, Simmermacher J, Parker DD, Sivaprakasam P, Kish K, Lewis H, Hanumegowda U, Jenkins S, Kadow JF, Krystal M, Meanwell NA, Naidu BN.
ACS Med Chem Lett. 2022 May 9;13(6):972-980. doi: 10.1021/acsmedchemlett.2c00115. eCollection 2022 Jun 9.
PMID: 35707159
Biomarker Assay Validation by Mass Spectrometry.
Fernández-Metzler C, Ackermann B, Garofolo F, Arnold ME, DeSilva B, Gu H, Laterza O, Mao Y, Rose M, Vazvaei-Smith F, Steenwyk R.
AAPS J. 2022 May 9;24(3):66. doi: 10.1208/s12248-022-00707-z.
PMID: 35534647
Development of a LAG-3 immunohistochemistry assay for melanoma.
Johnson L, McCune B, Locke D, Hedvat C, Wojcik JB, Schroyer C, Yan J, Johnson K, Sanders-Cliette A, Samala S, Dillon LM, Anderson S, Shuster J.
J Clin Pathol. 2022 May 9:jclinpath-2022-208254. doi: 10.1136/jclinpath-2022-208254. Online ahead of print.
PMID: 35534200
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Homicsko K, Dummer R, Hoeller C, Wolchok JD, Hodi FS, Larkin J, Ascierto PA, Atkinson V, Robert C, Postow MA, Re S, Paulucci D, Dobler D, Michielin O.
Cancers (Basel). 2022 May 5;14(9):2300. doi: 10.3390/cancers14092300.
PMID: 35565428
Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays?
Hays A, Amaravadi L, Fernandez-Metzler C, King L, Mathews J, Ni Y, Quadrini K, Tinder C, Vazvaei F, Zeng J.
AAPS J. 2022 May 5;24(3):65. doi: 10.1208/s12248-022-00708-y.
PMID: 35511303
Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.
Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A.
Neuro Oncol. 2022 May 2:noac116. doi: 10.1093/neuonc/noac116. Online ahead of print.
PMID: 35511454
CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.
Wang J, Saung MT, Li K, Fu J, Fujiwara K, Niu N, Muth S, Wang J, Xu Y, Rozich N, Zlomke H, Chen S, Espinoza B, Henderson M, Funes V, Herbst B, Ding D, Twyman-Saint Victor C, Zhao Q, Narang A, He J, Zheng L.
J Exp Med. 2022 May 2;219(5):e20211631. doi: 10.1084/jem.20211631. Epub 2022 Apr 11.
PMID: 35404390
Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
Pagliano O, Morrison RM, Chauvin JM, Banerjee H, Davar D, Ding Q, Tanegashima T, Gao W, Chakka SR, DeBlasio R, Lowin A, Kara K, Ka M, Zidi B, Amin R, Raphael I, Zhang S, Watkins SC, Sander C, Kirkwood JM, Bosenberg M, Anderson AC, Kuchroo VK, Kane LP, Korman AJ, Rajpal A, West SM, Han M, Bee C, Deng X, Schebye XM, Strop P, Zarour HM.
J Clin Invest. 2022 May 2;132(9):e152864. doi: 10.1172/JCI152864.
PMID: 35316223
Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.
Gao W, Hu H, Dai L, He M, Yuan H, Zhang H, Liao J, Wen B, Li Y, Palmisano M, Traore MDM, Zhou S, Sun D.
Acta Pharm Sin B. 2022 May;12(5):2462-2478. doi: 10.1016/j.apsb.2022.02.015. Epub 2022 Feb 23.
PMID: 35646532
2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A - Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine).
Kaur S, Alley SC, Szapacs M, Wilson A, Ciccimaro E, Su D, Henderson N, Chen L, Garofolo F, Hengel S, Jian W, Kellie JF, Lee A, Mehl J, Palandra J, Qiu H, Savoie N, Shakleya D, Staelens L, Sugimoto H, Sumner G, Welink J, Wheller R, Xue YJ, Zeng J, Zhang J, Zhou H, Wang J, Summerfield S, Kavetska O, Dillen L, Ramanathan R, Baratta M, Dasgupta A, Edmison A, Ferrari L, Fischer S, Fraier D, Haidar S, Heermeier K, James C, Ji A, Luo L, Lima Santos GM, Post N, Rosenbaum AI, Sporring S, Surapaneni S, Vinter S, Wan K, Woolf E, Kavetska O, Cho SJ, Kossary E, Prior S, Abhari MR, Soo C, Wang YM, Bandukwala A, Cherry E, Cludts I, Ghosh S, Hopper S, Ishii-Watabe A, Kirshner S, Maher K, Maxfield K, Pedras-Vasconcelos J, Saito Y, Smith D, Solstad T, Verthelyi D, Wadhwa M, Wagner L, Waxenecker G, Yan H, Zhang L.
Bioanalysis. 2022 May;14(9):505-580. doi: 10.4155/bio-2022-0078. Epub 2022 May 17.
PMID: 35578993
2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (Part 2 - Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation).
Hersey S, Keller S, Mathews J, King L, Bandukwala A, Berisha F, Birchler M, Bower J, Clausen V, Duarte J, Garofolo F, Hopper S, Kar S, Mabrouk O, Marshall JC, McGuire K, Naughton M, Saito Y, Schuhmann I, Sperinde G, Teixeira P, Vitaliti A, Wang YM, Wnek R, Zhang Y, Spitz S, Decman V, Eck S, Estevam J, Goihberg P, Alcaide EG, Gonneau C, Hedrick MN, Hopkins G, Junker F, Nuti S, Sommer U, Standifer N, Stevens C, Stevens E, Hendricks C, Wadhwa M, Torri A, Ma M, Harris S, Kumar S, Partridge MA, Caiazzo T, Chilewski S, Cludts I, Coble K, Gorovits B, Grimaldi C, Jordan G, Kamerud J, Leary B, Liang M, Lim H, Mayer A, O'Connor E, Palackal N, Poetzl J, Prior S, Abhari MR, Savoie N, Soo C, Ware M, Wu B, Xu Y, Yang TY, Zoghbi J.
Bioanalysis. 2022 May;14(10):627-692. doi: 10.4155/bio-2022-0080. Epub 2022 May 17.
PMID: 35578974
The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review.
Mansfield AS, Brown RJ, Sammon C, Daumont MJ, McKenna M, Sanzari JK, Forde PM.\
TO Clin Res Rep. 2022 Mar 22;3(5):100315. doi: 10.1016/j.jtocrr.2022.100315. eCollection 2022 May.
PMID: 35516726
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.
Oliveira G, Stromhaug K, Cieri N, Iorgulescu JB, Klaeger S, Wolff JO, Rachimi S, Chea V, Krause K, Freeman SS, Zhang W, Li S, Braun DA, Neuberg D, Carr SA, Livak KJ, Frederick DT, Fritsch EF, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon CH, Keskin DB, Ott PA, Rodig SJ, Boland GM, Wu CJ.
Nature. 2022 May;605(7910):532-538. doi: 10.1038/s41586-022-04682-5. Epub 2022 May 4.
PMID: 35508657
Private Spaceflight: A New Landscape for Dealing with Medical Risk.
Griko YV, Loftus DJ, Stolc V, Peletskaya E.
Life Sci Space Res (Amst). 2022 May;33:41-47. doi: 10.1016/j.lssr.2022.03.001. Epub 2022 Mar 23.
PMID: 35491028
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P.
Lung Cancer. 2022 May;167:8-16. doi: 10.1016/j.lungcan.2022.03.012. Epub 2022 Mar 21.
PMID: 35367910
A global perspective in second-line treatment patterns for patients with advanced esophageal squamous cell carcinoma.
Jaffe DH, Gricar J, DeCongelio M, Mackie DS.
Thorac Cancer. 2022 May;13(9):1240-1257. doi: 10.1111/1759-7714.14334. Epub 2022 Mar 30.
PMID: 35355433
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A.
Leukemia. 2022 May;36(5):1432-1435. doi: 10.1038/s41375-022-01521-4. Epub 2022 Feb 26.
PMID: 35220402
Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma.
Howell TA, Matza LS, Jun MP, Garcia J, Powers A, Maloney DG.
Pharmacoecon Open. 2022 May;6(3):367-376. doi: 10.1007/s41669-021-00316-0. Epub 2022 Feb 7.
PMID: 35129829
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G.
Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3.
PMID: 35124183
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).
Sreekantha RK, Mussari CP, Dodd DS, Pasunoori L, Hegde S, Posy SL, Critton D, Ruepp S, Subramanian M, Salter-Cid LM, Tagore DM, Sarodaya S, Dudhgaonkar S, Poss MA, Schieven GL, Carter PH, Macor JE, Dyckman AJ.
ACS Med Chem Lett. 2022 Apr 25;13(5):812-818. doi: 10.1021/acsmedchemlett.2c00049. eCollection 2022 May 12.
PMID: 35586440
A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies.
Serelli-Lee V, Ito K, Koibuchi A, Tanigawa T, Ueno T, Matsushima N, Imai Y.
J Pers Med. 2022 Apr 21;12(5):669. doi: 10.3390/jpm12050669.
PMID: 35629092
Development of an enhanced formulation to minimize pharmacokinetic variabilities of a weakly basic drug compound.
Pu YE, Menger R, Tong Z, Gaebele T.
Pharm Dev Technol. 2022 Apr;27(4):406-413. doi: 10.1080/10837450.2022.2070206. Epub 2022 May 11.
PMID: 35502986
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL.
Oncologist. 2022 Mar 4;27(2):e194-e198. doi: 10.1093/oncolo/oyab036.
PMID: 35641218
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, Shen F, Hagner P, Li Y, Dobmeyer J, Gong N, Uttamsingh S, Pourdehnad M, Ribrag V.
EJHaem. 2022 Feb 14;3(2):394-405. doi: 10.1002/jha2.394. eCollection 2022 May.
PMID: 35846031
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J.
EJHaem. 2022 Jan 14;3(1):139-153. doi: 10.1002/jha2.375. eCollection 2022 Feb.
PMID: 35846221
Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England.
Hill NR, Groves L, Dickerson C, Boyce R, Lawton S, Hurst M, Pollock KG, Sugrue DM, Lister S, Arden C, Davies DW, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT.
J Med Econ. 2022 Jan-Dec;25(1):974-983. doi: 10.1080/13696998.2022.2102355.
PMID: 35834373
The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States.
Tabah A, Brady BL, Huggar D, Jariwala-Parikh K, Huey K, Copher R, LeBlanc TW.
J Med Econ. 2022 Jan-Dec;25(1):903-911. doi: 10.1080/13696998.2022.2091879.
PMID: 35723576
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M, Chaudhary MA, Yuan Y, Varol N, Dale P, Testa E, Klint J, Lee A, Lubinga SJ, Penrod JR.
J Med Econ. 2022 Jan-Dec;25(1):703-711. doi: 10.1080/13696998.2022.2077549.
PMID: 35659172
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M, Sandhu H, Maervoet J, Yuan Y, Chaudhary MA, Varol N, Lee A, Dale P, Jones C, Lubinga SJ, Penrod JR.
J Med Econ. 2022 Jan-Dec;25(1):660-668. doi: 10.1080/13696998.2022.2048573.
PMID: 35658806
Response to "Critical Analysis of Apixaban Dose Adjustment Criteria".
Mandt SR, Gaitonde P, Ajavon-Hartmann A, Klem C, Chan A, Bastien A.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221078841. doi: 10.1177/10760296221078841.
PMID: 35603638
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France.
Grumberg V, Chouaïd C, Cotté FE, Jouaneton B, Jolivel R, Gaudin AF, Reynaud D, Assié JB, Borget I.
J Med Econ. 2022 Jan-Dec;25(1):691-699. doi: 10.1080/13696998.2022.2079291.
PMID: 35587018
Optimization of Recombinant GPCR Proteins for Biophysical and Structural Studies Using Virus-like Particles.
Aertgeerts K, Ho TT, Yan YG.
Methods Mol Biol. 2022;2507:327-336. doi: 10.1007/978-1-0716-2368-8_17.
PMID: 35773590
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study.
Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G.
J Thromb Thrombolysis. 2022 Apr 30:1-11. doi: 10.1007/s11239-022-02644-2. Online ahead of print.
PMID: 35489004
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
Shah N, Mojebi A, Ayers D, Cope S, Dhanasiri S, Davies FE, Hari P, Patel P, Hege K, Dhanda D.
J Comp Eff Res. 2022 Apr 29. doi: 10.2217/cer-2022-0045. Online ahead of print.
PMID: 35485211
A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G, Luck B, Blom G, Harrison M, François M, Allain L, Wu Y, Bousraf Y.
J Pharm Sci. 2022 Apr 29:S0022-3549(22)00168-X. doi: 10.1016/j.xphs.2022.04.016. Online ahead of print.
PMID: 35500671
Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels.
Yu L, Lopez G, Rassa J, Wang Y, Basavanhally T, Browne A, Huang CP, Dorsey L, Jen J, Hersey S.
PLoS One. 2022 Apr 28;17(4):e0266889. doi: 10.1371/journal.pone.0266889. eCollection 2022.
PMID: 35482763
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE, Vollenhoven RV, Dörner T, Werth VP, Merrill JT, Furie R, Petronijevic M, Velasco Zamora B, Majdan M, Irazoque-Palazuelos F, Terbrueggen R, Delev N, Weiswasser M, Korish S, Stern M, Hersey S, Ye Y, Gaudy A, Liu Z, Gagnon R, Tang S, Schafer PH.
Ann Rheum Dis. 2022 Apr 27:annrheumdis-2022-222212. doi: 10.1136/annrheumdis-2022-222212. Online ahead of print.
PMID: 35477518
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Zhang J, Sy O, Mesa RA.
Br J Haematol. 2022 Apr 27. doi: 10.1111/bjh.18207. Online ahead of print.
PMID: 35476316
Assessment of Resonant Acoustic Mixing for Low-Dose Pharmaceutical Powder Blends.
Gupta S, Pu YE, Li M, Li Z, Osorio JG.
AAPS PharmSciTech. 2022 Apr 26;23(5):126. doi: 10.1208/s12249-022-02262-4.
PMID: 35474151
ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor.
Singer DE, Atlas SJ, Go AS, Lopes RD, Lubitz SA, McManus DD, Revkin JH, Mills D, Crosson LA, Lenane JC, Aronson RS.
Am Heart J. 2022 Apr 23:S0002-8703(22)00080-1. doi: 10.1016/j.ahj.2022.04.005. Online ahead of print.
PMID: 35472303
5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction.
Nakao K, Singh M, Sapkota K, Fitzgerald A, Hablitz JJ, Nakazawa K.
Transl Psychiatry. 2022 Apr 22;12(1):168. doi: 10.1038/s41398-022-01930-0.
PMID: 35459266
Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation.
Radisch S, Poltorak MP, Wagner M, Cletiu V, Radisch C, Treise I, Pann S, Weigt A, Artner S, Dreher S, Fechner F, Borjan B, Fraessle SP, Effenberger M, Benke E, Navratil G, Hentschel N, Busch DH, Schmidt T, Stemberger C, Germeroth L.
Sci Rep. 2022 Apr 21;12(1):6572. doi: 10.1038/s41598-022-10320-x.
PMID: 35449227
Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
Yamazoe S, Kotapati S, Hogan JM, West SM, Deng XA, Diong SJ, Arbanas J, Nguyen TA, Jashnani A, Gupta D, Rajpal A, Dollinger G, Strop P.
Bioconjug Chem. 2022 Apr 20;33(4):576-585. doi: 10.1021/acs.bioconjchem.1c00572. Epub 2022 Mar 28.
PMID: 35344340
Building consensus on author selection practices for industry-sponsored research: recommendations from an expert task force of medical publication professionals.
Carfagno ML, Schweers SA, Whann EA, Hodgson MB, Mittleman KD, Nastasee SA, Sorgenfrei T, Kodukulla MI; International Society for Medical Publication Professionals Authorship Task Force.
Curr Med Res Opin. 2022 Apr 19:1-8. doi: 10.1080/03007995.2022.2050111. Online ahead of print.
PMID: 35437066
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.
Edelberg JM, Sehnert AJ, Mealiffe ME, Del Rio CL, McDowell R.
Am J Cardiovasc Drugs. 2022 Apr 18. doi: 10.1007/s40256-022-00532-x. Online ahead of print.
PMID: 35435607
Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.
Torres AZ, Nussbaum NC, Parrinello CM, Bourla AB, Bowser BE, Wagner S, Tabano DC, George D, Miksad RA.
Adv Ther. 2022 Apr 17. doi: 10.1007/s12325-022-02091-8. Online ahead of print.
PMID: 35430670
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Matsue K, Sunami K, Matsumoto M, Kuroda J, Sugiura I, Iwasaki H, Chung W, Kuwayama S, Nishio M, Lee K, Iida S.
Int J Hematol. 2022 Apr 16. doi: 10.1007/s12185-022-03338-4. Online ahead of print.
PMID: 35429329
Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning.
He Q, Rehmann MS, Tian J, Xu J, Sabino L, Vandermark E, Basson Z, Po I, Bierilo K, Tremml G, Rizzi G, Langsdorf EF, Qian NX, Borys MC, Khetan A, Li ZJ.
Bioengineering (Basel). 2022 Apr 15;9(4):173. doi: 10.3390/bioengineering9040173.
PMID: 35447733
Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.
Nguyen T, Churchill M, Levin R, Valenzuela G, Merola JF, Ogdie A, Orbai AM, Scher JU, Kavanaugh A, Kianifard F, Rollins C, Calheiros R, Chambenoit O.
J Rheumatol. 2022 Apr 15:jrheum.210912. doi: 10.3899/jrheum.210912. Online ahead of print.
PMID: 35428722
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase 3 Results in DMARD-Naive Patients With Psoriatic Arthritis.
Mease PJ, Kavanaugh A, Ogdie A, Wells AF, Bergman M, Gladman DD, Richter S, Teng L, Jardon S, Smolen JS.
J Rheumatol. 2022 Apr 15:jrheum.210906. doi: 10.3899/jrheum.210906. Online ahead of print.
PMID: 35428720
Potential Impact of Sex and Body Mass Index on Response to Therapy in Psoriatic Arthritis: Post-hoc Analysis of Results From the SEAM-PsA Trial.
Mease PJ, Gladman DD, Merola JF, Deodhar A, Ogdie A, Collier DH, Liu L, Kavanaugh A.
J Rheumatol. 2022 Apr 15:jrheum.211037. doi: 10.3899/jrheum.211037. Online ahead of print.
PMID: 35428718
Effectiveness of 6-Month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ, Blachley T, Dube B, McLean RR, Kim N, Hur P, Ogdie A.
J Rheumatol. 2022 Apr 15:jrheum.211033. doi: 10.3899/jrheum.211033. Online ahead of print.
PMID: 35428716
Challenges in the Diagnosis and Assessment of Psoriatic Arthritis.
Ogdie A, Lindsay CA, Mease PJ, Callis Duffin K, Rosen CF, Siebert S.
J Rheumatol. 2022 Apr 15:jrheum.211337. doi: 10.3899/jrheum.211337. Online ahead of print.
PMID: 35428713
2021 GRAPPA Meet the Experts Session: A Summary of Presentations.
Armstrong AW, Reddy RM, FitzGerald O, Callis Duffin K, Helliwell PS, Mease PJ, Kavanaugh A, Merola JF, Tillet W, de Wit M.
J Rheumatol. 2022 Apr 15:jrheum.211326. doi: 10.3899/jrheum.211326. Online ahead of print.
PMID: 35428707
Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.
Zhang H, Chiang AY, Wang J.
Stat Med. 2022 Apr 15. doi: 10.1002/sim.9402. Online ahead of print.
PMID: 35428037
Thrombotic and Cardiovascular Events and Treatment Patterns Among Patients Hospitalized with COVID-19 in Japan: An Analysis of a Nationwide Medical Claims Database.
Terasaka N, Matsuo Y, Kataoka H, Miyata Y, Anazawa Y.
Cardiol Ther. 2022 Apr 15:1-12. doi: 10.1007/s40119-022-00263-9. Online ahead of print.
PMID: 35426621
Evaluation of chiral normal-phase liquid chromatography as a secondary tier in pharmaceutical chiral screening strategy.
Tai HC, Lin Z, Fabiano A, Zhou Y, Saurer EM, Ye YK, He BL.
J Chromatogr A. 2022 Apr 14;1672:463053. doi: 10.1016/j.chroma.2022.463053.
PMID: 35460990
Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M.
Neuro Oncol. 2022 Apr 14:noac099. doi: 10.1093/neuonc/noac099. Online ahead of print.
PMID: 35419607
Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study.
Durez P, Westhovens R, Baeke F, Elbez Y, Robert S, Ahmad HA.
BMC Rheumatol. 2022 Apr 14;6(1):24. doi: 10.1186/s41927-022-00252-4.
PMID: 35418172
Report of the First International Symposium on NUT Carcinoma.
French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI.
Clin Cancer Res. 2022 Apr 13:clincanres.0591.2022. doi: 10.1158/1078-0432.CCR-22-0591. Online ahead of print.
PMID: 35417004
2-Pyridine Carboxaldehyde for Semi-Automated Soft Spot Identification in Cyclic Peptides.
Zhang H, Chacko S, Cannon JR.
Int J Mol Sci. 2022 Apr 12;23(8):4269. doi: 10.3390/ijms23084269.
PMID: 35457087
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators.
N Engl J Med. 2022 Apr 11. doi: 10.1056/NEJMoa2202170. Online ahead of print.
PMID: 35403841
A vision for integrated publicly available information on regulated medical products.
Roberts K, Thakkar R, Aljuburi L, Boyce D, Curtis S, Dudinak J, Fitton H, Garner C, Garvin M, Longman S, Reilly E, Maitland J, Reisin Miller A, Pasté M, Rohrer M, Taisey M, Van Baelen K, Wegner M.
Clin Transl Sci. 2022 Apr 9. doi: 10.1111/cts.13275. Online ahead of print.
PMID: 35397194
Influence of Concomitant Methotrexate use on the Clinical Effectiveness, Retention, and Safety of Abatacept in Biologic-Naïve Patients with Rheumatoid Arthritis: Post-hoc Subgroup Analysis of ORIGAMI Study.
Azuma T, Misaki K, Kusaoi M, Suzuki Y, Higa S, Kumon Y, Yoshitama T, Naniwa T, Yamada S, Okano T, Takeuchi K, Ikeda K, Higami K, Inoo M, Sawada T, Kang C, Hayashi M, Nagaya Y, Hagiwara T, Shono E, Himeno S, Tanaka E, Inoue E, Yoshizawa Y, Kadode M, Yamanaka H, Harigai M.
Mod Rheumatol. 2022 Apr 7:roac032. doi: 10.1093/mr/roac032. Online ahead of print.
PMID: 35389481
Advances in mass spectrometry-based epitope mapping of protein therapeutics.
Liu XR, Huang RY, Zhao F, Chen G, Tao L.
J Pharm Biomed Anal. 2022 Apr 6;215:114754. doi: 10.1016/j.jpba.2022.114754. Online ahead of print.
PMID: 35427962
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM.
Cancer. 2022 Apr 5. doi: 10.1002/cncr.34180. Online ahead of print.
PMID: 35383908
Ni-Electrocatalytic C(sp 3 )-C(sp 3 ) Doubly Decarboxylative Coupling.
Zhang B, Gao Y, Hioki Y, Oderinde MS, Qiao JX, Rodriguez KX, Zhang HJ, Kawamata Y, Baran PS. Nature. 2022 Apr 5. doi: 10.1038/s41586-022-04691-4. Online ahead of print.
PMID: 35381598
The benefits, limitations and opportunities of preclinical models for neonatal drug development.
Campion S, Inselman A, Hayes B, Casiraghi C, Joseph D, Facchinetti F, Salomone F, Schmitt G, Hui J, Davis-Bruno K, Van Malderen K, Morford L, De Schaepdrijver L, Wiesner L, Kourula S, Seo S, Laffan S, Urmaliya V, Chen C.
Dis Model Mech. 2022 Apr 1;15(4):dmm049065. doi: 10.1242/dmm.049065. Epub 2022 Apr 25.
PMID: 35466995
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.
Kang YK, Reck M, Nghiem P, Feng Y, Plautz G, Kim HR, Owonikoko TK, Boku N, Chen LT, Lei M, Chang H, Lin WH, Roy A, Bello A, Sheng J.
J Immunother Cancer. 2022 Apr;10(4):e004273. doi: 10.1136/jitc-2021-004273.
PMID: 35383114
Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects.
Waddington JC, Coleman O, Mease PJ, Chandran V, O'Sullivan D, FitzGerald O, Pennington SR.
J Rheumatol. 2022 Apr 1:jrheum.211320. doi: 10.3899/jrheum.211320. Online ahead of print.
PMID: 35365582
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.
Stober C, McInnes IB, Raychaudhuri S, Mease PJ, Pennington SR, Scher JU, Chandran V, Armstrong AW, de Wit M, Cauli A, Jadon DR, Löve TJ, Ogdie A, O'Sullivan D, van Mens LJJ, Ritchlin CT, FitzGerald O.
J Rheumatol. 2022 Apr 1:jrheum.211336. doi: 10.3899/jrheum.211336. Online ahead of print.
PMID: 35365578
Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A, Hammer C, Haymaker CL, Horak CE, McGee HM, Monette A, Rudqvist NP, Spencer CN, Sweis RF, Vincent BG, Wennerberg E, Yuan J, Zappasodi R, Lucey VMH, Wells DK, LaVallee T.
Cancer Immunol Res. 2022 Apr 1;10(4):372-383. doi: 10.1158/2326-6066.CIR-20-0586.
PMID: 35362046
Meningococcal Vaccination Rates Among People With a New Diagnosis of HIV Infection in the US.
Ghaswalla PK, Marshall GS, Bengtson LGS, Buikema AR, Bancroft T, Koep E, Novy P, Hogea CS.
JAMA Netw Open. 2022 Apr 1;5(4):e228573. doi: 10.1001/jamanetworkopen.2022.8573.
PMID: 35486405
Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
Juarez-Garcia A, Sharma R, Hunger M, Kayaniyil S, Penrod JR, Chouaïd C.
Lung Cancer. 2022 Apr;166:205-220. doi: 10.1016/j.lungcan.2022.03.008. Epub 2022 Mar 9.
PMID: 35316754
RP-HPLC separation of interconvertible rotamers of a 5-tetrahydroisoquinolin-6-yl-pyridin-3-yl acetic acid derivative and confirmation by VT NMR and DFT study.
Chauthe SK, Sidduri P, Reddy M, Sistla R, Byri V, Uttaravalli MD, Botlagunta M, Kumar H, Gupta A, Gupta AK, Bajpai L, Bagadi M, Mathur A.
J Pharm Biomed Anal. 2022 Apr 1;212:114675. doi: 10.1016/j.jpba.2022.114675. Epub 2022 Feb 17.
PMID: 35192992
Synthesis of carbon-14 and stable isotope labeled Censavudine.
Burrell RC, Bonacorsi SJ Jr, Ortiz A, Benkovics T, Shi Z.
J Labelled Comp Radiopharm. 2022 Apr;65(4):112-122. doi: 10.1002/jlcr.3964. Epub 2022 Feb 10.
PMID: 35106813
Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Moore K, Thakkar N, Magee M, Sevinsky H, Vakkalagadda B, Lubin S, Llamoso C, Ackerman P. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0225121. doi: 10.1128/aac.02251-21. Epub 2022 Mar 22.
PMID: 35315687
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
Passamonti F, Heidel FH, Parikh RC, Ajmera M, Tang D, Nadal JA, Davis KL, Abraham P.
Future Oncol. 2022 Apr 7. doi: 10.2217/fon-2021-1358. Online ahead of print.
PMID: 35388710
Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.
Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Yung WKA, van den Bent M, Wen PY, Cloughesy TF.
Neuro Oncol. 2022 Apr 5:noac086. doi: 10.1093/neuonc/noac086. Online ahead of print.
PMID: 35380705
The Association of Illness-Related Uncertainty with Mental Health in Systemic Autoimmune Rheumatic Diseases.
Wallace ZS, Cook C, Finkelstein-Fox L, Fu X, Castelino FV, Choi HK, Perugino C, Stone JH, Park ER, Hall DL.
J Rheumatol. 2022 Apr 1:jrheum.211084. doi: 10.3899/jrheum.211084. Online ahead of print.
PMID: 35365580
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.
Deitelzweig S, Bergrath E, di Fusco M, Kang A, Savone M, Cappelleri JC, Russ C, Betts M, Cichewicz A, Schaible K, Tarpey J, Fahrbach K.
Future Cardiol. 2022 Apr 1. doi: 10.2217/fca-2021-0120. Online ahead of print.
PMID: 35360925
Kick-off meeting of the TOWWERS showcase project: 1 st
collaborative value-based healthcare anchored on real-world data involving the 5P.
Frappier J, Krelenbaum M, Villalba E, Martin P, Nour N, L'Espérance J, Perrault A, Decelle B, Larose AM, Viau V, Fahey R, Denault JF, Fauchon I, Huard M, Frappier M.
Expert Rev Pharmacoecon Outcomes Res. 2022 Apr 1:1-5. doi: 10.1080/14737167.2022.2055549. Online ahead of print.
PMID: 35312399
Orchestrating a β-Hydride Elimination Pathway in Palladium(II)-Catalyzed Arylation/Alkenylation of Cyclopropanols Using Organoboron Reagents.
Ramar T, Subbaiah MAM, Ilangovan A.
J Org Chem. 2022 Apr 1;87(7):4508-4523. doi: 10.1021/acs.joc.1c02735. Epub 2022 Mar 15.
PMID: 35289619
Analyzing longitudinal binary data in clinical studies.
Li Y, Feng D, Sui Y, Li H, Song Y, Zhan T, Cicconetti G, Jin M, Wang H, Chan I, Wang X.
Contemp Clin Trials. 2022 Apr;115:106717. doi: 10.1016/j.cct.2022.106717. Epub 2022 Feb 28.
PMID: 35240309
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81.
Golani LK, Divović B, Sharmin D, Pandey KP, Mian MY, Cerne R, Zahn NM, Meyer MJ, Tiruveedhula VVNPB, Smith JL, Ping X, Jin X, Lippa A, Schkeryantz JM, Arnold LA, Cook JM, Savić MM, Witkin JM. Biopharm Drug Dispos. 2022 Apr;43(2):66-75. doi: 10.1002/bdd.2313. Epub 2022 Mar 10.
PMID: 35194800
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S.
Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19.
PMID: 35182247
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.
Chimalakonda A, Singhal S, Darbenzio R, Dockens R, Marchisin D, Banerjee S, Girgis IG, Throup J, He B, Aras U, Murthy B.
Clin Pharmacol Drug Dev. 2022 Apr;11(4):442-453. doi: 10.1002/cpdd.1056. Epub 2022 Feb 19.
PMID: 35182043
The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity.
Zhuo J, Xia Q, Sharma N, Gao S, Lama S, Cui J, Feathers V, Shadick N, Weinblatt ME.
Rheumatol Ther. 2022 Apr;9(2):637-647. doi: 10.1007/s40744-022-00427-y. Epub 2022 Feb 16.
PMID: 35174462
Use of In Vitro Human Skin Models to Assess Potential Immune Activation In Response to Biotherapeutic Attributes and Process-related Impurities.
Tokuda JM, Xie J, Jawa V, Hawkins JM, Ferbas J, Joh NH, Joubert MK.
J Pharm Sci. 2022 Apr;111(4):1012-1023. doi: 10.1016/j.xphs.2022.02.001. Epub 2022 Feb 6.
PMID: 35139332
Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA.
Inguva S, Priyadarshini M, Shah R, Bhattacharya K.
Future Oncol. 2022 Apr;18(13):1569-1581. doi: 10.2217/fon-2021-1282. Epub 2022 Feb 7.
PMID: 35129377
Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma.
Nordstrom BL, Hamilton M, Collins JM, Earle D, Zhang Y, Srivastava S, Hernandez-Aya L.
Future Oncol. 2022 Apr;18(11):1343-1355. doi: 10.2217/fon-2021-0340. Epub 2022 Feb 7.
PMID: 35129375
Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.
Jawa V, Maamary J, Swanson M, Zhang S, Montgomery D.
J Pharm Sci. 2022 Apr;111(4):960-969. doi: 10.1016/j.xphs.2022.01.032. Epub 2022 Feb 3.
PMID: 35122828
Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study.
Kwon S, Ma W, Drew DA, Klempner SJ, Leonardo BM, Flynn JJ, Cao Y, Giovannucci EL, Bao Y, Fuchs CS, Song M, Chan AT.
Cancer Prev Res (Phila). 2022 Apr 1;15(4):265-272. doi: 10.1158/1940-6207.CAPR-21-0413.
PMID: 34980677
Enzymatic removal of sialic acid enables iCIEF stability monitoring of charge variants of a highly sialylated bispecific antibody.
Peters BH, Bautista J, Slaney TR, Guo H, Huang RY, Krause ME, Zeng M, Cheng J, Chen Z. Electrophoresis. 2022 Mar 31. doi: 10.1002/elps.202100259. Online ahead of print.
PMID: 35362108
A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: Importance in human fibrotic disease.
Layton TB, Williams L, Yang N, Zhang M, Lee C, Feldmann M, Trujillo G, Furniss D, Nanchahal J.
Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2120336119. doi: 10.1073/pnas.2120336119. Epub 2022 Mar 23.
PMID: 35320046
Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.
Liu J, Yin R, Wu L, Zhu J, Lou G, Wu X, Zhou Q, Gao Y, Kong B, Lu X, Wang J, Chen Y, Cheng Y, Wang Y, Lu W, Li W, Ma X, Hsu K.
Asia Pac J Clin Oncol. 2022 Mar 31. doi: 10.1111/ajco.13753. Online ahead of print.
PMID: 35357078
Current Approaches for Dissolution Similarity Assessment, Requirements, and Global Expectations.
Abend AM, Zhang L, Fredro-Kumbaradzi E, Hoffelder T, Cohen MJ, Anand O, Delvadia P, Mandula H, Zhang Z, Kotzagiorgis E, Lum S, Pereira VG, Barker A, Lavrich D, Kraemer J, Sharp-Suarez S.
AAPS J. 2022 Mar 29;24(3):50. doi: 10.1208/s12248-022-00691-4.
PMID: 35352186
An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow.
Aburub A, Chen Y, Chung J, Gao P, Good D, Hansmann S, Hawley M, Heimbach T, Hingle M, Kesisoglou F, Li R, Rose J, Tisaert C.
AAPS J. 2022 Mar 29;24(3):49. doi: 10.1208/s12248-022-00699-w.
PMID: 35348922
An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay.
Yang J, Mapelli C, Wang Z, Sum CS, Hua J, Lawrence RM, Ni Y, Seiffert DA.
Platelets. 2022 Mar 28:1-8. doi: 10.1080/09537104.2022.2053091. Online ahead of print.
PMID: 35343875
Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ, Gu T, Jun MP, McBride A.
Transplant Cell Ther. 2022 Mar 27:S2666-6367(22)01186-1. doi: 10.1016/j.jtct.2022.03.021. Online ahead of print.
PMID: 35354101
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V, Kurt M, Zhang L, Butler MO, Michielin O, Amadi A, Hernlund E, Johnson HM, Kotapati S, Moshyk A, Borrill J.
MDM Policy Pract. 2022 Mar 26;7(1):23814683221089659. doi: 10.1177/23814683221089659. eCollection 2022 Jan-Jun.
PMID: 35356551
Health state utilities for beta-thalassemia: a time trade-off study.
Martin AP, Ferri Grazzi E, Mighiu C, Chevli M, Shah F, Maher L, Shaikh A, Sagar A, Hubberstey H, Franks B, Ramos-Goñi JM, Oppe M, Tang D.
Eur J Health Econ. 2022 Mar 26. doi: 10.1007/s10198-022-01449-7. Online ahead of print.
PMID: 35347553
Liposome-Tethered Gold Nanoparticles Triggered by Pulsed NIR Light for Rapid Liposome Contents Release and Endosome Escape.
Veeren A, Ogunyankin MO, Shin JE, Zasadzinski JA.
Pharmaceutics. 2022 Mar 25;14(4):701. doi: 10.3390/pharmaceutics14040701.
PMID: 35456535
Methodological Considerations in Development of UV Imaging for Characterization of Intra-Tumoral Injectables Using cAMP as a Model Substance.
Bock F, Bøtker JP, Larsen SW, Lu X, Østergaard J.
Int J Mol Sci. 2022 Mar 25;23(7):3599. doi: 10.3390/ijms23073599.
PMID: 35408971
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
Perera V, Wang Z, Lubin S, Ueno T, Shiozaki T, Chen W, Xu X, Seiffert D, DeSouza M, Murthy B.
Sci Rep. 2022 Mar 25;12(1):5165. doi: 10.1038/s41598-022-08768-y.
PMID: 35338177
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.
Cartron G, Fox CP, Liu FF, Kostic A, Hasskarl J, Li D, Bonner A, Zhang Y, Maloney DG, Kuruvilla J.
Exp Hematol Oncol. 2022 Mar 25;11(1):17. doi: 10.1186/s40164-022-00268-z.
PMID: 35337365
A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.
Grumberg V, Roze S, Chevalier J, Borrill J, Gaudin AF, Branchoux S.
Int J Technol Assess Health Care. 2022 Mar 25;38(1):e28. doi: 10.1017/S0266462322000125.
PMID: 35331347
Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.
Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, Pattipati SN, Dandapani K, Dokania M, Vattikundala P, Sharma V, Elavazhagan S, Verma MK, Lal Das M, Wagh S, Balakrishnan A, Johnson BM, Santone KS, Thalody G, Denton R, Saminathan H, Holenarsipur VK, Kumar A, Rao A, Putlur SP, Sarvasiddhi SK, Shankar G, Louis JV, Ramarao M, Conway CM, Li YW, Pieschl R, Tian Y, Hong Y, Bristow L, Albright CF, Bronson JJ, Macor JE, Dzierba CD.
J Med Chem. 2022 Mar 24;65(6):4534-4564. doi: 10.1021/acs.jmedchem.1c02132. Epub 2022 Mar 9.
PMID: 35261239
Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain.
Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, Maishal TK, Thiyagarajan K, Jalagam P, Pattipati SN, Dandapani K, Dokania M, Vattikundala P, Sharma V, Elavazhagan S, Verma MK, Das ML, Wagh S, Balakrishnan A, Johnson BM, Santone KS, Thalody G, Denton R, Saminathan H, Holenarsipur VK, Kumar A, Rao A, Putlur SP, Sarvasiddhi SK, Shankar G, Louis JV, Ramarao M, Conway CM, Li YW, Pieschl R, Tian Y, Hong Y, Ditta J, Mathur A, Li J, Smith D, Pawluczyk J, Sun D, Yip S, Wu DR, Vetrichelvan M, Gupta A, Wilson A, Gopinathan S, Wason S, Bristow L, Albright CF, Bronson JJ, Macor JE, Dzierba CD.
J Med Chem. 2022 Mar 24;65(6):4457-4480. doi: 10.1021/acs.jmedchem.1c02131. Epub 2022 Mar 8.
PMID: 35257579
The Current States, Challenges, Ongoing Efforts, and Future Perspectives of Pharmaceutical Excipients in Pediatric Patients in Each Country and Region.
Saito J, Agrawal A, Patravale V, Pandya A, Orubu S, Zhao M, Andrews GP, Petit-Turcotte C, Landry H, Croker A, Nakamura H, Yamatani A, Salunke S.
Children (Basel). 2022 Mar 23;9(4):453. doi: 10.3390/children9040453.
PMID: 35455497
N-1 Perfusion Platform Development Using a Capacitance Probe for Biomanufacturing.
Rittershaus ESC, Rehmann MS, Xu J, He Q, Hill C, Swanberg J, Borys MC, Li ZJ, Khetan A. Bioengineering (Basel). 2022 Mar 22;9(4):128. doi: 10.3390/bioengineering9040128.
PMID: 35447688
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.
Willumsen N, Jensen C, Green G, Nissen NI, Neely J, Nelson DM, Pedersen RS, Frederiksen P, Chen IM, Boisen MK, Johansen AZ, Madsen DH, Svane IM, Lipton A, Leitzel K, Ali SM, Erler JT, Hurkmans DP, Mathijssen RHJ, Aerts J, Eslam M, George J, Christiansen C, Bissel MJ, Karsdal MA.
Cell Mol Life Sci. 2022 Mar 25;79(4):204. doi: 10.1007/s00018-022-04226-0.
PMID: 35332383
A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma.
Pape M, Vissers PAJ, Bertwistle D, McDonald L, Slingerland M, Haj Mohammad N, Beerepoot LV, Ruurda JP, Nieuwenhuijzen GAP, Jeene PM, van Laarhoven HWM, Verhoeven RHA.
Ther Adv Med Oncol. 2022 Mar 24;14:17588359221085557. doi: 10.1177/17588359221085557. eCollection 2022.
PMID: 35356260
A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.
Johnston SE, Lipkovich I, Dmitrienko A, Zhao YD.
Pharm Stat. 2022 Mar 24. doi: 10.1002/pst.2208. Online ahead of print.
PMID: 35322520
Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs.
Naidu BN, Patel M, McAuliffe B, Ding B, Cianci C, Simmermacher J, Jenkins S, Parker DD, Sivaprakasam P, Khan JA, Kish K, Lewis H, Hanumegowda U, Krystal M, Meanwell NA, Kadow JF.
J Med Chem. 2022 Mar 24;65(6):4949-4971. doi: 10.1021/acs.jmedchem.1c02169. Epub 2022 Mar 2.
PMID: 35235334
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, Thomas GV, Caruso B, Thompson RF, Wood MA, Hipfinger C, Hammond SA, Graff JN, Xia Z, Moran AE.
Nature. 2022 Mar 23. doi: 10.1038/s41586-022-04522-6. Online ahead of print.
PMID: 35322234
Cold Denaturation of Proteins in the Absence of Solvent: Implications for Protein Storage.
Norgate EL, Upton R, Hansen K, Bellina B, Brookes C, Politis A, Barran PE.
Angew Chem Int Ed Engl. 2022 Mar 21:e202115047. doi: 10.1002/anie.202115047. Online ahead of print.
PMID: 35313047
An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase.
Cheng Y, Liu L, Xue Y, Zhou S, Li Y.
J Clin Pharm Ther. 2022 Mar 20. doi: 10.1111/jcpt.13653. Online ahead of print.
PMID: 35307850
LPA 1
antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis.
Decato BE, Leeming DJ, Sand JMB, Fischer A, Du S, Palmer SM, Karsdal M, Luo Y, Minnich A.
Respir Res. 2022 Mar 18;23(1):61. doi: 10.1186/s12931-022-01980-4.
PMID: 35303880
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, Velasco J, Majdan M, Irazoque-Palazuelos F, Weiswasser M, Korish S, Ye Y, Gaudy A, Schafer PH, Liu Z, Agafonova N, Delev N.
N Engl J Med. 2022 Mar 17;386(11):1034-1045. doi: 10.1056/NEJMoa2106535.
PMID: 35294813
A Systematic Approach for the Evaluation, Validation and Implementation of Automated Colony Counting Systems.
Deutschmann S, Carpenter B, Duignan C, Knutsen C, Salvas J, Wysocki L, Plourde L, Johnson L, Eder W, Franz-Riethdorf M.
PDA J Pharm Sci Technol. 2022 Mar 16:pdajpst.2021.012646. doi: 10.5731/pdajpst.2021.012646. Online ahead of print.
PMID: 35296561
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).
Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y.
Clin Cancer Res. 2022 Mar 16:clincanres.0985.2021. doi: 10.1158/1078-0432.CCR-21-0985. Online ahead of print.
PMID: 35294546
Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission.
Russell MD, Nagra D, Clarke BD, Balachandran S, Buazon A, Boalch A, Bechman K, Adas MA, Alveyn EG, Rutherford AI, Galloway JB.
J Rheumatol. 2022 Mar 15:jrheum.211203. doi: 10.3899/jrheum.211203. Online ahead of print.
PMID: 35293331
Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.
Nash P.
J Rheumatol. 2022 Mar 15:jrheum.211329. doi: 10.3899/jrheum.211329. Online ahead of print.
PMID: 35293326
Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies.
McDermott G, Gill R, Gagne S, Byrne S, Huang W, Wang X, Prisco LC, Zaccardelli A, Martin LW, Masto L, Kronzer VL, Shadick N, Dellaripa PF, Doyle TJ, Sparks JA.
J Rheumatol. 2022 Mar 15:jrheum.211242. doi: 10.3899/jrheum.211242. Online ahead of print.
PMID: 35293341
GRAPPA 2020 Research Award Recipients.
Castillo RL, Yan D, Ashhurst AS, Elliott A, Angioni MM, Scher JU, Naik S, Neimann A, Byrne SN, Payne RJ, FitzGerald O, Pennington SR, Cauli A, Chandran V.
J Rheumatol. 2022 Mar 15:jrheum.211335. doi: 10.3899/jrheum.211335. Online ahead of print.
PMID: 35293338
Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases.
Takeshita J, Chau J, Callis Duffin K, Goel N.
J Rheumatol. 2022 Mar 15:jrheum.211330. doi: 10.3899/jrheum.211330. Online ahead of print.
PMID: 35293335
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
Carroll R, Bortolini M, Calleja A, Munro R, Kong S, Daumont MJ, Penrod JR, Lakhdari K, Lacoin L, Cheung WY.
BMC Cancer. 2022 Mar 10;22(1):255. doi: 10.1186/s12885-022-09342-5.
PMID: 35264135
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132).
Shi Y, Wang Y, Meng W, Brigance RP, Ryono DE, Bolton S, Zhang H, Chen S, Smirk R, Tao S, Tino JA, Williams KN, Sulsky R, Nielsen L, Ellsworth B, Wong MKY, Sun JH, Leith LW, Sun D, Wu DR, Gupta A, Rampulla R, Mathur A, Chen BC, Wang A, Fuentes-Catanio HG, Kunselman L, Cap M, Zalaznick J, Ma X, Liu H, Taylor JR, Zebo R, Jones B, Kalinowski S, Swartz J, Staal A, O'Malley K, Kopcho L, Muckelbauer JK, Krystek SR Jr, Spronk SA, Marcinkeviciene J, Everlof G, Chen XQ, Xu C, Li YX, Langish RA, Yang Y, Wang Q, Behnia K, Fura A, Janovitz EB, Pannacciulli N, Griffen S, Zinker BA, Krupinski J, Kirby M, Whaley J, Zahler R, Barrish JC, Robl JA, Cheng PTW.
J Med Chem. 2022 Mar 10;65(5):4291-4317. doi: 10.1021/acs.jmedchem.1c02110. Epub 2022 Feb 18.
PMID: 35179904
Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 Inhibitors.
Hartz RA, Ahuja VT, Nara SJ, Kumar CMV, Manepalli RKVLP, Sarvasiddhi SK, Honkhambe S, Patankar V, Dasgupta B, Rajamani R, Muckelbauer JK, Camac DM, Ghosh K, Pokross M, Kiefer SE, Brown JM, Hunihan L, Gulianello M, Lewis M, Lippy JS, Surti N, Hamman BD, Allen J, Kostich WA, Bronson JJ, Macor JE, Dzierba CD.
J Med Chem. 2022 Mar 10;65(5):4121-4155. doi: 10.1021/acs.jmedchem.1c01966. Epub 2022 Feb 16.
PMID: 35171586
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, Maira-Arce M, Ye X, Shi L, Guo S, Hamilton M, Bajorin DF.
Eur Urol Oncol. 2022 Mar 11:S2588-9311(22)00028-1. doi: 10.1016/j.euo.2022.02.003. Online ahead of print.
PMID: 35288066
Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.
Copher R, Kee A, Gerds A.
Oncologist. 2022 Mar 11;27(3):228-235. doi: 10.1093/oncolo/oyab058.
PMID: 35274711
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, Collins G, French T, Ghahramani N, Hinson P, Jelinic P, Marton MJ, McGregor K, Parsons J, Ramamurthy L, Sausen M, Sokol ES, Stenzinger A, Stires H, Timms KM, Turco D, Wang I, Williams JA, Wong-Ho E, Allen J. Oncologist. 2022 Mar 11;27(3):167-174. doi: 10.1093/oncolo/oyab053.
PMID: 35274707
Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.
Jecs E, Tahirovic YA, Wilson RJ, Miller EJ, Kim M, Truax V, Nguyen HH, Akins NS, Saindane M, Wang T, Sum CS, Cvijic ME, Schroeder GM, Burton SL, Derdeyn CA, Xu L, Jiang Y, Wilson LJ, Liotta DC.
J Med Chem. 2022 Mar 10;65(5):4058-4084. doi: 10.1021/acs.jmedchem.1c01564. Epub 2022 Feb 18.
PMID: 35179893
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Chen W, Bello A, Murthy B.
Clin Pharmacokinet. 2022 Mar 9. doi: 10.1007/s40262-022-01110-9. Online ahead of print.
PMID: 35262846
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer.
Ali AA, Tawk R, Xiao H, Semykina A, Montero AJ, Moussa RK, Popoola O, Diaby V.
Expert Rev Pharmacoecon Outcomes Res. 2022 Mar 9:1-7. doi: 10.1080/14737167.2022.2044309. Online ahead of print.
PMID: 35189767
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS.
Leuk Lymphoma. 2022 Mar 8:1-14. doi: 10.1080/10428194.2022.2043299. Online ahead of print.
PMID: 35259043
Formyl peptide receptor 2 and heart disease.
Lupisella JA, Shirude PS, Wurtz NR, Garcia RA.
Semin Immunol. 2022 Mar 8:101602. doi: 10.1016/j.smim.2022.101602. Online ahead of print.
PMID: 35277300
Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer.
Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S.
Clin Cancer Res. 2022 Mar 7:clincanres.2742.2021. doi: 10.1158/1078-0432.CCR-21-2742. Online ahead of print.
PMID: 35254415
Understanding Poor Milling Behavior of Voriconazole from Crystal Structure and Intermolecular Interactions.
Kaur A, Yadav JP, Sathe RY, Puri V, Bharatam PV, Bansal AK.
Mol Pharm. 2022 Mar 7;19(3):985-997. doi: 10.1021/acs.molpharmaceut.1c00978. Epub 2022 Feb 21.
PMID: 35188397
Global intercompany assessment of ICIEF platform comparability for the characterization of therapeutic proteins.
Madren S, McElroy W, Schultz-Kuszak K, Boumajny B, Shu Y, Sautter S, Zhao HC, Schadock-Hewitt A, Chumsae C, Ball N, Zhang X, Rish K, Zhang S, Wurm C, Cai S, Bauer SP, Stella C, Zheng L, Roper B, Michels DA, Wu G, Kocjan B, Birk M, Erdmann SE, He X, Whittaker B, Song Y, Barrett H, Strozyk K, Jing Y, Huang L, Mhatre V, McLean P, Yu T, Yang H, Mattila M.
Electrophoresis. 2022 Mar 4. doi: 10.1002/elps.202100348. Online ahead of print.
PMID: 35245390
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S.
Ann Rheum Dis. 2022 Mar 3:annrheumdis-2021-221664. doi: 10.1136/annrheumdis-2021-221664. Online ahead of print.
PMID: 35241426
Pathogen-associated T follicular helper cell plasticity is critical in anti-viral immunity.
Feng H, Zhao X, Xie J, Bai X, Fu W, Chen H, Tang H, Wang X, Dong C.
Sci China Life Sci. 2022 Mar 2. doi: 10.1007/s11427-021-2055-x. Online ahead of print.
PMID: 35258743
Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress.
Rivera DR, Kluetz PG, Abdallah K, Agrawal S, Angus DC, Califf RM, Garrett-Mayer E, Hyer R, Lowy DR, Khleif SN.
Cancer J. 2022 Mar-Apr 01;28(2):151-156. doi: 10.1097/PPO.0000000000000589.
PMID: 35333502
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model.
Zorn JA, Wheeler ML, Barnes RM, Kaberna J, Morishige W, Harris M, Huang RY, Lohre J, Chang YC, Chau B, Powers K, Schindler I, Neradugomma N, Thomas W, Liao X, Zhou Y, West SM, Wang F, Kotapati S, Chen G, Yamazoe S, Kosenko A, Dollinger G, Sproul T, Rajpal A, Strop P.
Sci Rep. 2022 Mar 3;12(1):3530. doi: 10.1038/s41598-022-06953-7.
PMID: 35241687
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
Bessette L, Mysler E, Kinch CD, Kwok K, Lukic T, On PV, van Vollenhoven RF.
J Rheumatol. 2022 Mar 1:jrheum.210707. doi: 10.3899/jrheum.210707. Online ahead of print.
PMID: 35232809
Young-GRAPPA at the Annual GRAPPA Meeting: Presentation of a New Group Within GRAPPA and Its Vision.
van Mens L, Ayan G, Coates LC, Coras R, Silva DLF, Herrera S, Ishchenko A, Jethwa H, Johnsson H, Simon D, Vivekanantham A, Proft F.
J Rheumatol. 2022 Mar 1:jrheum.211327. doi: 10.3899/jrheum.211327. Online ahead of print.
PMID: 35232806
Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study.
Owens AT, Sutton MB, Gao W, Fine JT, Xie J, Naidu SS, Desai NR.
Cardiol Ther. 2022 Mar 1. doi: 10.1007/s40119-022-00257-7. Online ahead of print.
PMID: 35230625
WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee.
Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L.
J Rheumatol. 2022 Mar 1:jrheum.210543. doi: 10.3899/jrheum.210543. Online ahead of print.
PMID: 35232805
Morphometrics and blood analytes of leatherback sea turtle hatchlings (Dermochelys coriacea) from Florida: reference intervals, temporal trends with clutch deposition date, and body size correlations.
Perrault JR, Page-Karjian A, Morgan AN, Burns LK, Stacy NI.
J Comp Physiol B. 2022 Mar;192(2):313-324. doi: 10.1007/s00360-021-01422-5. Epub 2022 Jan 8.
PMID: 34997274
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY.
Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23.
PMID: 35322232
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M.
J Immunother Cancer. 2022 Mar;10(3):e004316. doi: 10.1136/jitc-2021-004316.
PMID: 35304405
Quantifying uncertainty in method of moments estimates of the heterogeneity variance in random effects meta-analysis.
Sidik K, Jonkman JN.
Biom J. 2022 Mar;64(3):598-616. doi: 10.1002/bimj.202000222. Epub 2021 Dec 11.
PMID: 35285063
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.
Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M, Ishizuka JJ, Yates KB, Pope HW, Manguso RT, Shrestha Y, Wadsworth M, Hughes T, Shalek AK, Boehm JS, Hahn WC, Doench JG, Haining WN.
J Immunother Cancer. 2022 Mar;10(3):e003402. doi: 10.1136/jitc-2021-003402.
PMID: 35264433
An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.
Chan S, Belmar N, Ho S, Rogers B, Stickler M, Graham M, Lee E, Tran N, Zhang D, Gupta P, Sho M, MacDonough T, Woolley A, Kim H, Zhang H, Liu W, Zheng P, Dezso Z, Halliwill K, Ceccarelli M, Rhodes S, Thakur A, Forsyth CM, Xiong M, Tan SS, Iyer R, Lake M, Digiammarino E, Zhou L, Bigelow L, Longenecker K, Judge RA, Liu C, Trumble M, Remis JP, Fox M, Cairns B, Akamatsu Y, Hollenbaugh D, Harding F, Alvarez HM.
Nat Cancer. 2022 Mar;3(3):337-354. doi: 10.1038/s43018-022-00334-9. Epub 2022 Mar 7.
PMID: 35256819
Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Chang M, Bathena S, Christopher LJ, Shen H, Roy A.
Cancer Chemother Pharmacol. 2022 Mar;89(3):383-392. doi: 10.1007/s00280-021-04394-z. Epub 2022 Feb 11.
PMID: 35147740
Future of Biotransformation Science in the Pharmaceutical Industry.
Kramlinger VM, Dalvie D, Heck CJS, Kalgutkar AS, O'Neill J, Su D, Teitelbaum AM, Totah RA.
Drug Metab Dispos. 2022 Mar;50(3):258-267. doi: 10.1124/dmd.121.000658. Epub 2021 Dec 17.
PMID: 34921097
Simultaneous measurement of mouse and human albumin in chimeric mice with humanized livers.
Landry F, Shen H, Zhang Y, Uchiyama A, Miyata Y, Morikawa Y, Joshi B, Shipkova P.
Bioanalysis. 2022 Mar;14(5):267-278. doi: 10.4155/bio-2021-0250. Epub 2022 Feb 23.
PMID: 35195037
Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.
Burns L, Roux NL, Kalesnik-Orszulak R, Christian J, Hukkelhoven M, Rockhold F, O'Donnell J.
Clin Ther. 2022 Mar;44(3):420-437. doi: 10.1016/j.clinthera.2022.01.012. Epub 2022 Feb 15.
PMID: 35181179
Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study.
Page JH, Londhe AA, Brooks C, Zhang J, Sprafka JM, Bennett C, Braunlin M, Brown CA, Charuworn P, Cheng A, Gill K, He F, Ma J, Petersen J, Ayodele O, Bao Y, Carlson KB, Chang SC, Devercelli G, Jonsson-Funk M, Jiang J, Keenan HA, Ren K, Roehl KA, Sanders L, Wang L, Wei Z, Xia Q, Yu P, Zhou L, Zhu J, Gondek K, Critchlow CW, Bradbury BD.
BMJ Open. 2022 Feb 28;12(2):e055137. doi: 10.1136/bmjopen-2021-055137.
PMID: 35228287
Budget impact analysis of a machine learning algorithm to predict high risk of atrial fibrillation among primary care patients.
Szymanski T, Ashton R, Sekelj S, Petrungaro B, Pollock KG, Sandler B, Lister S, Hill NR, Farooqui U. Europace. 2022 Feb 28:euac016. doi: 10.1093/europace/euac016. Online ahead of print.
PMID: 35226101
Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Broughton EI, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G.
BMC Urol. 2022 Feb 26;22(1):27. doi: 10.1186/s12894-022-00959-z.
PMID: 35219307
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.
Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M.
Neurooncol Adv. 2022 Feb 26;4(1):vdac025. doi: 10.1093/noajnl/vdac025. eCollection 2022 Jan-Dec.
PMID: 35402913
Using a Model-based Material Sparing Approach for Formulation and Process Development of a Roller Compacted Drug Product.
Vasudevan KV, Pu YE, Amini H, Guarino C, Agrawal A, Akseli I.
Pharm Res. 2022 Feb 26. doi: 10.1007/s11095-022-03192-3. Online ahead of print.
PMID: 35218443
Discovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization.
Cherney EC, Zhang L, Lo J, Huynh T, Wei D, Ahuja V, Quesnelle C, Schieven GL, Futran A, Locke GA, Lin Z, Monereau L, Chaudhry C, Blum J, Li S, Fereshteh M, Li-Wang B, Gangwar S, Pan C, Chong C, Zhu X, Posy SL, Sack JS, Zhang P, Ruzanov M, Harner M, Akhtar F, Schroeder GM, Vite G, Fink B.
J Med Chem. 2022 Feb 24;65(4):3518-3538. doi: 10.1021/acs.jmedchem.1c01986. Epub 2022 Feb 2.
PMID: 35108011
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, De Claro RA, George B, Gormley N, Horowitz MM, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J.
Cytotherapy. 2022 Feb 23:S1465-3249(22)00023-8. doi: 10.1016/j.jcyt.2022.01.004. Online ahead of print.
PMID: 35219582
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM.
Gut. 2022 Feb 23:gutjnl-2021-325918. doi: 10.1136/gutjnl-2021-325918. Online ahead of print.
PMID: 35197323
Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.
Munir MB, Hlavacek P, Keshishian A, Guo JD, Mallampati R, Ferri M, Russ C, Emir B, Cato M, Yuce H, Hsu JC.
PLoS One. 2022 Feb 17;17(2):e0263903. doi: 10.1371/journal.pone.0263903. eCollection 2022.
PMID: 35176074
Superiority of Mesoporous Silica-Based Amorphous Formulations over Spray-Dried Solid Dispersions.
Zhang H, Li M, Li J, Agrawal A, Hui HW, Liu D.
Pharmaceutics. 2022 Feb 16;14(2):428. doi: 10.3390/pharmaceutics14020428.
PMID: 35214159
Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
Ahmad HA, Baker JF, Conaghan PG, Emery P, Huizinga TWJ, Elbez Y, Banerjee S, Østergaard M. Arthritis Res Ther. 2022 Feb 16;24(1):47. doi: 10.1186/s13075-022-02735-8.
PMID: 35172859
Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis.
Jadon DR, Kavanaugh A, Leung YY.
J Rheumatol. 2022 Feb 15:jrheum .211325. doi: 10.3899/jrheum.211325. Online ahead of print.
PMID: 35169062
Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis.
Lubberts E, Scher JU, FitzGerald O.
J Rheumatol. 2022 Feb 15:jrheum.211321. doi: 10.3899/jrheum.211321. Online ahead of print.
PMID: 35169059
Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features.
Hagedorn PH, Brown JM, Easton A, Pierdomenico M, Jones K, Olson RE, Mercer SE, Li D, Loy J, Høg AM, Jensen ML, Gill M, Cacace AM.
Nucleic Acid Ther. 2022 Feb 14. doi: 10.1089/nat.2021.0071. Online ahead of print.
PMID: 35166597
Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Callis Duffin K, Gladman DD, Goel N, Gottlieb AB, FitzGerald O, McFarland LV.
J Rheumatol. 2022 Feb 15:jrheum.211317. doi: 10.3899/jrheum.211317. Online ahead of print.
PMID: 35169061
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K, Lymp J, Mack T, Dell'Aringa J, Huang CP, Smith J, Peiser L, Kostic A.
Clin Pharmacol Ther. 2022 Feb 13. doi: 10.1002/cpt.2561. Online ahead of print.
PMID: 35156195
Repeatability and Reproducibility Assessment of the Apparent Diffusion Coefficient in the Prostate: A Trial of the ECOG-ACRIN Research Group (ACRIN 6701).
Boss MA, Snyder BS, Kim E, Flamini D, Englander S, Sundaram KM, Gumpeni N, Palmer SL, Choi H, Froemming AT, Persigehl T, Davenport MS, Malyarenko D, Chenevert TL, Rosen MA.
J Magn Reson Imaging. 2022 Feb 10. doi: 10.1002/jmri.28093. Online ahead of print.
PMID: 35143059
Redefining nonmeasurable multiple myeloma using mass spectrometry.
Giles HV, Cook MA, Drayson MT, Cook G, Wright NJ, North SJ, Harding S, Cairns DA, Hockaday A, Kaiser MF, Moss P, Davies FE, Morgan GJ, Jackson G, Pratt G.
Blood. 2022 Feb 10;139(6):946-950. doi: 10.1182/blood.2021013794.
PMID: 34871382
A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes.
Oliva EN, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Tang D, Yucel A, Hughes C, Shah F. J Clin Med. 2022 Feb 8;11(3):895. doi: 10.3390/jcm11030895.
PMID: 35160344
Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.
Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, Aronson R, Windecker S, Mehran R, Granger CB, Alexander JH.
J Am Coll Cardiol. 2022 Feb 8;79(5):417-427. doi: 10.1016/j.jacc.2021.11.035.
PMID: 35115097
Estimands in observational studies: Some considerations beyond ICH E9 (R1).
Li H, Wang C, Chen WC, Lu N, Song C, Tiwari R, Xu Y, Yue LQ.
Pharm Stat. 2022 Feb 6. doi: 10.1002/pst.2196. Online ahead of print.
PMID: 35128808
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators.
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
PMID: 35108470
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A.
J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844.
PMID: 35210307
Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Welsh RC, Dehghani P, Lopes R, Wojdyla DM, Aronson R, Granger CB, Windecker S, Vora AN, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander JH, Goodman S.
Open Heart. 2022 Feb;9(1):e001892. doi: 10.1136/openhrt-2021-001892.
PMID: 35172988
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
O'Byrne KJ, Lee KH, Kim SW, Park K, Nishio M, Sakai H, Ohe Y, Fukuhara T, Kang JH, Daga H, Yu CJ, Hotta K, Tanaka H, Takeda M, Yokoyama T, Nathan FE, Lee JS.
ESMO Open. 2022 Feb;7(1):100394. doi: 10.1016/j.esmoop.2022.100394. Epub 2022 Feb 12.
PMID: 35158207
Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, McDermott DF, Stephen Hodi F, Choueiri TK, Freeman GJ.
J Immunother Cancer. 2022 Feb;10(2):e003527. doi: 10.1136/jitc-2021-003527.
PMID: 35131863
Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab.
Chouaïd C, Grumberg V, Batisse A, Corre R, Giaj Levra M, Gaudin AF, Prodel M, Lortet-Tieulent J, Assié JB, Cotté FE.
JCO Clin Cancer Inform. 2022 Feb;6:e2100108. doi: 10.1200/CCI.21.00108.
PMID: 35113656
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
Khadka P, Reitman ZJ, Lu S, Buchan G, Gionet G, Dubois F, Carvalho DM, Shih J, Zhang S, Greenwald NF, Zack T, Shapira O, Pelton K, Hartley R, Bear H, Georgis Y, Jarmale S, Melanson R, Bonanno K, Schoolcraft K, Miller PG, Condurat AL, Gonzalez EM, Qian K, Morin E, Langhnoja J, Lupien LE, Rendo V, Digiacomo J, Wang D, Zhou K, Kumbhani R, Guerra Garcia ME, Sinai CE, Becker S, Schneider R, Vogelzang J, Krug K, Goodale A, Abid T, Kalani Z, Piccioni F, Beroukhim R, Persky NS, Root DE, Carcaboso AM, Ebert BL, Fuller C, Babur O, Kieran MW, Jones C, Keshishian H, Ligon KL, Carr SA, Phoenix TN, Bandopadhayay P.
Nat Commun. 2022 Feb 1;13(1):604. doi: 10.1038/s41467-022-28198-8.
PMID: 35105861
Two heads are better than one: current landscape of integrating QSP and machine learning : An ISoP QSP SIG white paper by the working group on the integration of quantitative systems pharmacology and machine learning.
Zhang T, Androulakis IP, Bonate P, Cheng L, Helikar T, Parikh J, Rackauckas C, Subramanian K, Cho CR; Working Group.
J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):5-18. doi: 10.1007/s10928-022-09805-z. Epub 2022 Feb 1.
PMID: 35103884
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.
Karagoz K, Stokes M, Ortiz-Estévez M, Towfic F, Flynt E, Gooding S, Pierceall W, Thakurta A.
Front Genet. 2022 Feb 9;13:831779. doi: 10.3389/fgene.2022.831779. eCollection 2022.
PMID: 35222546
Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis.
Østergaard M, Bird P, Pachai C, Du S, Wu C, Landis J, Fuerst T, Ahmad HA, Connolly SE, Conaghan PG. Rheumatology (Oxford). 2022 Feb 8:keac073. doi: 10.1093/rheumatology/keac073. Online ahead of print.
PMID: 35137002
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Bahlis NJ, Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Chung W, Lee K, Mouro J, Agarwal A, Reece D. Leuk Lymphoma. 2022 Feb 8:1-11. doi: 10.1080/10428194.2022.2030477. Online ahead of print.
PMID: 35133221
Systematic Screening for Atrial Fibrillation in Patients at Moderate-to-High Risk of Stroke　- Potential to Increase the Atrial Fibrillation Detection Rate (SCAN-AF).
Watanabe E, Takahashi N, Aronson R, Ohsawa A, Ishibashi Y, Murakawa Y; SCAN-AF Investigators. Circ J. 2022 Feb 5. doi: 10.1253/circj.CJ-21-0813. Online ahead of print.
PMID: 35125371
Doppler signal and bone erosions at the enthesis are independently associated with ultrasound joint erosive damage in psoriatic arthritis.
Smerilli G, Cipolletta E, Destro Castaniti GM, Di Matteo A, Di Carlo M, Moscioni E, Francioso F, Mashadi Mirza R, Grassi W, Filippucci E.
J Rheumatol. 2022 Feb 1:jrheum.210974. doi: 10.3899/jrheum.210974. Online ahead of print.
PMID: 35105703
Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN.
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
PMID: 35103762
Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target.
Feng Y, Liu L, Li J, Huang J, Xie JH, Menard L, Shi Y, Zhao X, Xie S, Zang W, Tan H, Yang Z, Ni L.
Oncol Rep. 2022 Feb;47(2):38. doi: 10.3892/or.2021.8249. Epub 2021 Dec 27.
PMID: 34958112
Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.
Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D.
Support Care Cancer. 2022 Feb;30(2):1377-1378. doi: 10.1007/s00520-021-06691-y.
PMID: 34792647
Systematic assessment of process analytical technologies for biologics.
Gillespie C, Wasalathanthri DP, Ritz DB, Zhou G, Davis KA, Wucherpfennig T, Hazelwood N.
Biotechnol Bioeng. 2022 Feb;119(2):423-434. doi: 10.1002/bit.27990. Epub 2021 Dec 13.
PMID: 34778948
Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
Wong PC, Crain EJ, Bozarth JM, Wu Y, Dilger AK, Wexler RR, Ewing WR, Gordon D, Luettgen JM.
J Thromb Haemost. 2022 Feb;20(2):399-408. doi: 10.1111/jth.15588. Epub 2021 Nov 24.
PMID: 34752670
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
Mantia CM, Werner L, Stwalley B, Ritchings C, Tarhini AA, Atkins MB, McDermott DF, Regan MM. Melanoma Res. 2022 Feb 1;32(1):35-44. doi: 10.1097/CMR.0000000000000793.
PMID: 34855329
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, Weiswasser M, Zhan X, Schafer PH, Werth VP. Lupus Sci Med. 2022 Feb;9(1):e000581. doi: 10.1136/lupus-2021-000581.
PMID: 35169036
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Willis C, Bauer H, Au TH, Menon J, Unni S, Tran D, Rivers Z, Akerley W, Schabath MB, Badin F, Sekhon A, Patel M, Xia B, Gustafson B, Villano JL, Thomas JM, Lubinga SJ, Cantrell MA, Brixner D, Stenehjem D.
Oncotarget. 2022 Jan 31;13:257-270. doi: 10.18632/oncotarget.28178. eCollection 2022.
PMID: 35111281
An imidazoacridine-based TADF material as an effective organic photosensitizer for visible-light-promoted [2 + 2] cycloaddition.
Sauvé ER, Mayder DM, Kamal S, Oderinde MS, Hudson ZM.
Chem Sci. 2022 Jan 27;13(8):2296-2302. doi: 10.1039/d1sc05098b. eCollection 2022 Feb 23.
PMID: 35310486
Improved therapeutic index of an acidic pH-selective antibody.
Lee PS, MacDonald KG, Massi E, Chew PV, Bee C, Perkins P, Chau B, Thudium K, Lohre J, Nandi P, Deyanova EG, Barman I, Gudmundsson O, Dollinger G, Sproul T, Engelhardt JJ, Strop P, Rajpal A. MAbs. 2022 Jan-Dec;14(1):2024642. doi: 10.1080/19420862.2021.2024642.
PMID: 35192429
Synthesis and evaluation of potent yaku'amide A analogs.
Lo CCL, Joaquin D, Moyá DA, Ramos A, Kastner DW, White SM, Christensen BL, Naglich JG, Degnen WJ, Castle SL.
Chem Sci. 2022 Jan 3;13(7):1899-1905. doi: 10.1039/d1sc05992k. eCollection 2022 Feb 16.
PMID: 35308852
Defining a Standard Set of Health Outcomes for Patients With Squamous Cell Carcinoma of the Head and Neck in Spain.
Arrazubi V, Cajaraville G, Cantero D, Giralt J, Mesia R, Monje F, Rueda A, Sistiaga A, Suarez J, Mut A, Comellas M, Lizán L.
Front Oncol. 2022 Jan 24;11:747520. doi: 10.3389/fonc.2021.747520. eCollection 2021.
PMID: 35141139
The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis.
Tremblay D, Cavalli L, Sy O, Rose S, Mascarenhas J.
Clin Lymphoma Myeloma Leuk. 2022 Jan 8:S2152-2650(22)00004-0. doi: 10.1016/j.clml.2022.01.003. Online ahead of print.
PMID: 35120852
Procedural complications associated with invasive diagnostic procedures after lung cancer screening with low-dose computed tomography.
Yang S, Shih YT, Huo J, Mehta HJ, Wu Y, Salloum RG, Alvarado M, Zhang D, Braithwaite D, Guo Y, Bian J.
Lung Cancer. 2022 Jan 4;165:141-144. doi: 10.1016/j.lungcan.2021.12.020. Online ahead of print.
PMID: 35124410
Upstream cell culture process characterization and in-process control strategy development at pandemic speed.
Xu J, Ou J, McHugh KP, Borys MC, Khetan A.
MAbs. 2022 Jan-Dec;14(1):2060724. doi: 10.1080/19420862.2022.2060724.
PMID: 35380922
Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis.
van de Wetering G, Ignacio T, Dhanda D, Patel V, Zhang Y, Zhuo J.
J Med Econ. 2022 Jan-Dec;25(1):421-427. doi: 10.1080/13696998.2022.2051912.
PMID: 35297738
Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes.
Kim JS, Koo J, Shin DI, Kim BS, Kim J, Kim EG, Hong KS, Yi H.
J Stroke. 2022 Jan;24(1):118-127. doi: 10.5853/jos.2021.02355. Epub 2022 Jan 31.
PMID: 35135065
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators.
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
PMID: 34986285
Relationship Between Endoscopic and Clinical Disease Activity With Fatigue in Inflammatory Bowel Disease.
Kamp KJ, Clark-Snustad K, Barahimi M, Lee S.
Gastroenterol Nurs. 2022 Jan-Feb 01;45(1):21-28. doi: 10.1097/SGA.0000000000000600.
PMID: 35020629
The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.
Wang T, Kadow JF, Meanwell NA, Krystal M.
Adv Exp Med Biol. 2022;1366:45-64. doi: 10.1007/978-981-16-8702-0_4.
PMID: 35412134
Virtual Populations for Quantitative Systems Pharmacology Models.
Cheng Y, Straube R, Alnaif AE, Huang L, Leil TA, Schmidt BJ.
Methods Mol Biol. 2022;2486:129-179. doi: 10.1007/978-1-0716-2265-0_8.
PMID: 35437722
Removal of lycopene substrate inhibition enables high carotenoid productivity in Yarrowia lipolytica.
Ma Y, Liu N, Greisen P, Li J, Qiao K, Huang S, Stephanopoulos G.
Nat Commun. 2022 Jan 31;13(1):572. doi: 10.1038/s41467-022-28277-w.
PMID: 35102143
TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y.
Stat Med. 2022 Jan 31. doi: 10.1002/sim.9337. Online ahead of print.
PMID: 35098585
Design for Solubility May Reveal Induction of Amide Hydrogen/Deuterium Exchange by Protein Self-Association.
Trainor K, Doyle CM, Metcalfe-Roach A, Steckner J, Lipovšek D, Malakian H, Langley D, Krystek SR Jr, Meiering EM.
J Mol Biol. 2022 Jan 30;434(2):167398. doi: 10.1016/j.jmb.2021.167398. Epub 2021 Dec 10.
PMID: 34902431
Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis.
Tang H, Li J, Zinker B, Boehm S, Mauer A, Rex-Rabe S, Glaser KJ, Fronheiser M, Bradstreet T, Nakao Y, Petrone T, Pena A, Villano M, Chow P, Malhi H, Charles ED, Hayes W, Ehman RL, Du S, Yin M.
J Magn Reson Imaging. 2022 Jan 29. doi: 10.1002/jmri.28077. Online ahead of print.
PMID: 35092323
Nucleation in protein aggregation in biotherapeutic development: a look into the heart of the event.
Das TK, Chou DK, Jiskoot W, Arosio P.
J Pharm Sci. 2022 Jan 27:S0022-3549(22)00029-6. doi: 10.1016/j.xphs.2022.01.017. Online ahead of print.
PMID: 35093334
Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
Danese M, Gricar J, Abraham P.
Future Oncol. 2022 Jan 27. doi: 10.2217/fon-2021-0460. Online ahead of print.
PMID: 35081734
Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278.
Gill MW, Murphy BJ, Cheng PPT, Sivaraman L, Davis M, Lehman-McKeeman L.
Toxicol Appl Pharmacol. 2022 Jan 25:115885. doi: 10.1016/j.taap.2022.115885. Online ahead of print.
PMID: 35090952
Real-world treatment patterns in resectable (stages I-III) non-small-cell lung cancer: a systematic literature review.
Waser N, Vo L, McKenna M, Penrod JR, Goring S.
Future Oncol. 2022 Jan 25. doi: 10.2217/fon-2021-1417. Online ahead of print.
PMID: 35073732
Treatment Patterns Among Patients with Rheumatoid Arthritis in Puerto Rico.
Miranda EM, Han X, Park SH, Suri S, Suryavanshi M.
Rheumatol Ther. 2022 Jan 24. doi: 10.1007/s40744-021-00408-7. Online ahead of print.
PMID: 35076904
Mechanistic insights into inter-chain disulfide bond reduction of IgG1 and IgG4 antibodies.
Song Y, Cai H, Tan Z, Mussa N, Li ZJ.
Appl Microbiol Biotechnol. 2022 Jan 24. doi: 10.1007/s00253-022-11778-5. Online ahead of print.
PMID: 35072737
Stress Factors in Primary Packaging, Transportation and Handling of Protein Drug Products and Their Impact on Product Quality.
Narhi LO, Chou DK, Christian TR, Gibson S, Jagannathan B, Jiskoot W, Jordan S, Sreedhara A, Waxman L, Das TK.
J Pharm Sci. 2022 Jan 23:S0022-3549(22)00021-1. doi: 10.1016/j.xphs.2022.01.011. Online ahead of print.
PMID: 35081407
[RWD] conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.
Li H, Tiwari R, Li QH.
J Biopharm Stat. 2022 Jan 23:1-15. doi: 10.1080/10543406.2021.2021227. Online ahead of print.
PMID: 35067183
Cation Exchange as a Single Polishing Step for Conjugated Peptides.
Rockwell L, Bao H, Insaidoo F, Ikechukwu I, Tugcu N, Kandula S.
Biotechnol Prog. 2022 Jan 23:e3238. doi: 10.1002/btpr.3238. Online ahead of print.
PMID: 35066999
Zero-Inflated Binomial Model for Meta-Analysis and Safety-Signal Detection.
Chakraborty A, Xu J, Tiwari R.
Ther Innov Regul Sci. 2022 Jan 22. doi: 10.1007/s43441-021-00353-1. Online ahead of print.
PMID: 35064554
Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate).
Baran SW, Brown PC, Baudy AR, Fitzpatrick SC, Frantz C, Fullerton A, Gan J, Hardwick RN, Hillgren KM, Kopec AK, Liras JL, Mendrick DL, Nagao R, Proctor WR, Ramsden D, Ribeiro AJS, Stresser D, Sung KE, Sura R, Tetsuka K, Tomlinson L, Van Vleet T, Wagoner MP, Wang Q, Arslan SY, Yoder G, Ekert JE.
ALTEX. 2022 Jan 21. doi: 10.14573/altex.2112203. Online ahead of print.
PMID: 35064273
Comparison of approaches for measuring adherence and persistence to oral oncologic therapies in patients diagnosed with metastatic renal cell carcinoma.
Chun DS, Hicks B, Peacock Hinton S, Jonsson-Funk M, Gooden K, Keil AP, Tan HJ, Stürmer T, Lund JL.
Cancer Epidemiol Biomarkers Prev. 2022 Jan 21:cebp.0341.2021. doi: 10.1158/1055-9965.EPI-21-0341. Online ahead of print.
PMID: 35064061
Surface Enrichment of Surfactants in Amorphous Drugs: An X-ray Photoelectron Spectroscopy Study.
Yu J, Li Y, Yao X, Que C, Huang L, Hui HW, Gong Y, Qian F, Yu L.
Mol Pharm. 2022 Jan 21. doi: 10.1021/acs.molpharmaceut.1c00786. Online ahead of print.
PMID: 35060740
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R.
J Clin Oncol. 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815. Epub 2021 Nov 29.
PMID: 34843406
Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
Shah H, Wang Y, Cheng SC, Gunasti L, Chen YH, Lako A, Guenette J, Rodig S, Jo VY, Uppaluri R, Haddad R, Schoenfeld JD, Jacene HA.
JAMA Otolaryngol Head Neck Surg. 2022 Jan 20. doi: 10.1001/jamaoto.2021.4052. Online ahead of print.
PMID: 35050348
Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma.
Signorovitch J, Moshyk A, Zhao J, Le TK, Burns L, Gooden K, Hamilton M.
Future Oncol. 2022 Jan 20. doi: 10.2217/fon-2021-1054. Online ahead of print.
PMID: 35048743
Emotional processing intervention (EMOPRINT): A blinded randomized control trial to treat facial affect recognition deficits in multiple sclerosis.
Genova HM, Lancaster K, Myszko Z, Morecraft J, Leddy J, Smith A, Chiaravalloti N, Lengenfelder J.
Mult Scler Relat Disord. 2022 Jan 19;59:103536. doi: 10.1016/j.msard.2022.103536. Online ahead of print.
PMID: 35093842
GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile.
Dicker I, Jeffrey JL, Protack T, Lin Z, Cockett M, Chen Y, Sit SY, Gartland M, Meanwell NA, Regueiro-Ren A, Drexler D, Cantone J, McAuliffe B, Krystal M.
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0187621. doi: 10.1128/AAC.01876-21. Epub 2021 Nov 15.
PMID: 34780263
Patterned microfluidic devices for rapid screening of metal-organic frameworks yield insights into polymorphism and non-monotonic growth.
Coliaie P, Bhawnani RR, Prajapati A, Ali R, Verma P, Giri G, Kelkar MS, Korde A, Langston M, Liu C, Nazemifard N, Patience D, Rosenbaum T, Skliar D, Nere NK, Singh MR.
Lab Chip. 2022 Jan 18;22(2):211-224. doi: 10.1039/d1lc01086g.
PMID: 34989369
Nonclinical toxicology development of a novel antibody antibiotic conjugate for treating invasive Staphylococcus Aureus infections.
Stagg NJ, Katavolos P, Achilles Poon K, Zhong S, Ljumanovic N, Kamath A, Cai H, Carrasco-Triguero M, Halpern W.
Toxicol Appl Pharmacol. 2022 Jan 15;435:115811. doi: 10.1016/j.taap.2021.115811. Epub 2021 Dec 9.
PMID: 34896194
Industry White Paper: Contemporary Opportunities and Challenges in Characterizing Crystallinity in Amorphous Solid Dispersions.
Chasse T, Conway SL, Danzer GD, Feng L, Leone AM, McNevin M, Smoliga J, Stroud PA, van Lishaut H.
J Pharm Sci. 2022 Jan 15:S0022-3549(22)00009-0. doi: 10.1016/j.xphs.2022.01.007. Online ahead of print.
PMID: 35041831
Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs.
Deitelzweig S, Sah J, Kang A, Russ C, Preib M, Dhamane AD, Ratiu A, Cato M, Alfred T, Levi E, Di Fusco M.
Am J Cardiol. 2022 Jan 15;163:43-49. doi: 10.1016/j.amjcard.2021.09.047.
PMID: 34930532
Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV.
AAPS J. 2022 Jan 14;24(1):29. doi: 10.1208/s12248-021-00673-y.
PMID: 35038051
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB.
Dermatol Ther (Heidelb). 2022 Jan 13. doi: 10.1007/s13555-021-00649-y. Online ahead of print.
PMID: 35025062
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Apolo AB, Choueiri TK.
Lancet Oncol. 2022 Jan 12:S1470-2045(21)00693-8. doi: 10.1016/S1470-2045(21)00693-8. Online ahead of print.
PMID: 35032437
Assessing detergent-mediated virus inactivation, protein stability and impurity clearance in biologics downstream processes.
Feroz H, Chennamsetty N, Byers S, Holstein M, Li ZJ, Ghose S.
Biotechnol Bioeng. 2022 Jan 12. doi: 10.1002/bit.28034. Online ahead of print.
PMID: 35023152
5-Bromo-2-chloro-4-fluoro-3-iodopyridine as a Halogen-rich Intermediate for the Synthesis of Pentasubstituted Pyridines.
Wu YJ, Porter GJ, Frennesson DB, Saulnier MG.
J Org Chem. 2022 Jan 12. doi: 10.1021/acs.joc.1c02507. Online ahead of print.
PMID: 35020387
Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations.
Wilczynski O, Boisbouvier A, Radoszycki L, Cotté FE, Gaudin AF, Lemasson H.
J Med Internet Res. 2022 Jan 11;24(1):e25792. doi: 10.2196/25792.
PMID: 35014969
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS.
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
PMID: 34818112
Predicting Food Effects: Are We There Yet?
Emami Riedmaier A.
AAPS J. 2022 Jan 10;24(1):25. doi: 10.1208/s12248-021-00674-x.
PMID: 35006448
Targeted protein degradation: from small molecules to complex organelles-a Keystone Symposia report.
Cable J, Weber-Ban E, Clausen T, Walters KJ, Sharon M, Finley DJ, Gu Y, Hanna J, Feng Y, Martens S, Simonsen A, Hansen M, Zhang H, Goodwin JM, Reggio A, Chang C, Ge L, Schulman BA, Deshaies RJ, Dikic I, Harper JW, Wertz IE, Thomä NH, Słabicki M, Frydman J, Jakob U, David DC, Bennett EJ, Bertozzi CR, Sardana R, Eapen VV, Carra S.
Ann N Y Acad Sci. 2022 Jan 8. doi: 10.1111/nyas.14745. Online ahead of print.
PMID: 35000205
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Gordon MS, Shapiro GI, Sarantopoulos J, Juric D, Lu B, Zarotiadou A, Connarn JN, Le Bruchec Y, Dumitru CD, Harvey RD.
Front Oncol. 2022 Jan 7;11:786120. doi: 10.3389/fonc.2021.786120. eCollection 2021.
PMID: 35070991
Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
Fernández O, Lázaro-Quintela M, Crespo G, Soto de Prado D, Pinto Á, Basterretxea L, Gómez de Liaño A, Etxaniz O, Blasco S, Gabás-Rivera C, Aceituno S, Palomar V, Polanco-Sánchez C.
Front Oncol. 2022 Jan 7;11:773366. doi: 10.3389/fonc.2021.773366. eCollection 2021.
PMID: 35070976
Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.
Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H.
Blood. 2022 Jan 7:blood.2021013404. doi: 10.1182/blood.2021013404. Online ahead of print.
PMID: 34995344
Role of membrane structure on the filtrate flux during monoclonal antibody filtration through virus retentive membranes.
Billups M, Minervini M, Holstein M, Feroz H, Ranjan S, Hung J, Bao H, Li ZJ, Ghose S, Zydney AL.
Biotechnol Prog. 2022 Jan 7:e3231. doi: 10.1002/btpr.3231. Online ahead of print.
PMID: 34994527
Pyrazole Containing Anti-HIV Agents: An Update.
Kumar S, Gupta S, Rani V, Sharma P.
Med Chem. 2022 Jan 6. doi: 10.2174/1573406418666220106163846. Online ahead of print.
PMID: 34994333
Patient and caregiver socioeconomic burden of first-line systemic therapy for advanced gastroesophageal adenocarcinoma.
Xiao H, Bertwistle D, Khela K, Middleton-Dalby C, Hall J.
Future Oncol. 2022 Jan 5. doi: 10.2217/fon-2021-1449. Online ahead of print.
PMID: 34984914
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W.
Ann Hematol. 2022 Jan 4. doi: 10.1007/s00277-021-04734-2. Online ahead of print.
PMID: 34981142
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes.
Vasalou C, Ferguson D, Li W, Muse V, Gibbons FD, Sonzini S, Zhang G, Pop-Damkov P, Gangl E, Balachander SB, Wen S, Schuller AG, Puri S, Mazza M, Ashford M, Fretland AJ, McGinnity DF, Jones RDO.
Mol Pharm. 2022 Jan 3;19(1):172-187. doi: 10.1021/acs.molpharmaceut.1c00715. Epub 2021 Dec 10.
PMID: 34890209
Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
Hamuro L, Hu Z, Passarell J, Barcomb H, Zhang J, Goldstein S, Bello A, Roy A, Zhu L.
Clin Cancer Res. 2022 Jan 3:clincanres.3149.2021. doi: 10.1158/1078-0432.CCR-21-3149. Online ahead of print.
PMID: 34980597
Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis.
Meehan M, Shah A, Lobo J, Oates J, Clinton C, Annapureddy N, Xie F, Zhuo J, Danila MI, England BR, Curtis JR.
Arthritis Res Ther. 2022 Jan 3;24(1):2. doi: 10.1186/s13075-021-02655-z.
PMID: 34980225
X-ray structure of a human cardiac muscle troponin C/troponin I chimera in two crystal forms.
Yan C, Sack JS.
Acta Crystallogr F Struct Biol Commun. 2022 Jan 1;78(Pt 1):17-24. doi: 10.1107/S2053230X21012395. Epub 2022 Jan 1.
PMID: 34981771
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.
Popmihajlov Z, Sutherland DJ, Horan GS, Ghosh A, Lynch DA, Noble PW, Richeldi L, Reiss TF, Greenberg S.
BMJ Open Respir Res. 2022 Jan;9(1):e001060. doi: 10.1136/bmjresp-2021-001060.
PMID: 35058236
The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension.
Yap C, Bedding A, de Bono J, Dimairo M, Espinasse A, Evans J, Hopewell S, Jaki T, Kightley A, Lee S, Liu R, Mander A, Solovyeva O, Weir CJ.
Nat Med. 2022 Jan;28(1):6-7. doi: 10.1038/s41591-021-01594-1.
PMID: 34992264
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B.
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
PMID: 34914889
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
Reich K, Korge B, Magnolo N, Manasterski M, Schwichtenberg U, Staubach-Renz P, Kaiser S, Roemmler-Zehrer J, Gómez NN, Lorenz-Baath K.
Dermatol Ther (Heidelb). 2022 Jan;12(1):203-221. doi: 10.1007/s13555-021-00658-x. Epub 2021 Dec 15.
PMID: 34913153
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M.
Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 9.
PMID: 34895481
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, Ricafort R, Heenen D, Bassan A, Berntgen M, Bird N, Bleickardt E, Bouchkouj N, Bross P, Brownstein C, Cohen SB, de Rojas T, Ehrlich L, Fox E, Gottschalk S, Hanssens L, Hawkins DS, Horak ID, Taylor DH, Johnson C, Karres D, Ligas F, Ludwinski D, Mamonkin M, Marshall L, Masouleh BK, Matloub Y, Maude S, McDonough J, Minard-Colin V, Norga K, Nysom K, Pappo A, Pearce L, Pieters R, Pule M, Quintás-Cardama A, Richardson N, Schüßler-Lenz M, Scobie N, Sersch MA, Smith MA, Sterba J, Tasian SK, Weigel B, Weiner SL, Zwaan CM, Lesa G, Vassal G.
Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25.
PMID: 34840026
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Ide T, Osawa M, Sanghavi K, Vezina HE.
Cancer Chemother Pharmacol. 2022 Jan;89(1):129-140. doi: 10.1007/s00280-021-04365-4. Epub 2021 Nov 26.
PMID: 34825942
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, Saad F, Petrylak DP, Pachynski RK.
Eur J Cancer. 2022 Jan;160:61-71. doi: 10.1016/j.ejca.2021.09.043. Epub 2021 Nov 18.
PMID: 34802864
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study.
Sorensen JB, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, Lacoin L, Daumont MJ, Penrod JR, O'Donnell JC, Brustugun OT, Ekman S.
Future Oncol. 2022 Jan;18(2):205-214. doi: 10.2217/fon-2021-0746. Epub 2021 Nov 17.
PMID: 34784783
Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.
Yasumatsu R, Shimizu Y, Hanai N, Kariya S, Yokota T, Fujii T, Tsukahara K, Ando M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Nekado T, Yamada T, Homma A.
Int J Clin Oncol. 2022 Jan;27(1):95-104. doi: 10.1007/s10147-021-02047-y. Epub 2021 Nov 13.
PMID: 34773525
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.
Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, Kroenke MA, Lamberth K, Manin A, Penny HL, Smith N, Terszowski G, Tourdot S, Spindeldreher S.
MAbs. 2022 Jan-Dec;14(1):1993522. doi: 10.1080/19420862.2021.1993522.
PMID: 34923896
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP.
J Med Econ. 2022 Jan-Dec;25(1):51-58. doi: 10.1080/13696998.2021.2011301.
PMID: 34907813
Machine Learning for In Silico ADMET Prediction.
Jia L, Gao H.
Methods Mol Biol. 2022;2390:447-460. doi: 10.1007/978-1-0716-1787-8_20.
PMID: 34731482
2021 Publications
A Randomized Phase 2 Trial of Azacitidine ± Durvalumab as First-line Therapy for Higher-Risk Myelodysplastic Syndromes.
Zeidan AM, Boss IW, Beach CL, Copeland WB, Thompson EG, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G.
Blood Adv. 2021 Dec 31:bloodadvances.2021005487. doi: 10.1182/bloodadvances.2021005487. Online ahead of print.
PMID: 34972214
Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA 1 ) antagonists.
Sivaraman L, Gill M, Nelson DM, Chadwick KD.
Toxicol Appl Pharmacol. 2021 Dec 30:115846. doi: 10.1016/j.taap.2021.115846. Online ahead of print.
PMID: 34974053
Ligand Enabled Pd(II)-Catalyzed γ-C(sp 3 )-H Lactamization of Native Amides.
Liu S, Zhuang Z, Qiao JX, Yeung KS, Su S, Cherney EC, Ruan Z, Ewing WR, Poss MA, Yu JQ.
J Am Chem Soc. 2021 Dec 29;143(51):21657-21666. doi: 10.1021/jacs.1c10183. Epub 2021 Dec 16.
PMID: 34914877
Characterization of the Morphological Nature of Hollow Spray Dried Dispersion Particles Using X-ray Submicron-Computed Tomography.
Gamble JF, Tobyn M, Zhang S, Zhu A, Šalplachta J, Matula J, Zikmund T, Kaiser J, Oberta P. AAPS PharmSciTech. 2021 Dec 28;23(1):40. doi: 10.1208/s12249-021-02184-7.
PMID: 34964066
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Cohen AT, Sah J, Dhamane AD, Lee T, Rosenblatt L, Hlavacek P, Emir B, Delinger R, Yuce H, Luo X.
Thromb Haemost. 2021 Dec 28. doi: 10.1055/s-0041-1740254. Online ahead of print.
PMID: 34963185
Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.
Ayodele O, Ren K, Zhao J, Signorovitch J, Jonsson Funk M, Zhu J, Bao Y, Gondek K, Keenan H; R&D COVID Alliance.
PLoS One. 2021 Dec 28;16(12):e0261707. doi: 10.1371/journal.pone.0261707. eCollection 2021.
PMID: 34962924
Behavior of weakly adsorbing protein impurities in flow-through ion-exchange chromatography.
Herman CE, Xu X, Traylor SJ, Ghose S, Li ZJ, Lenhoff AM.
J Chromatogr A. 2021 Dec 27;1664:462788. doi: 10.1016/j.chroma.2021.462788. Online ahead of print.
PMID: 34998025
Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets.
Rezaei L, Meruva S, Donovan MD.
AAPS PharmSciTech. 2021 Dec 27;23(1):38. doi: 10.1208/s12249-021-02169-6.
PMID: 34961912
A novel approach to augment single-arm clinical studies with real-world data.
Sachdeva A, Tiwari RC, Guha S.
J Biopharm Stat. 2021 Dec 27:1-17. doi: 10.1080/10543406.2021.2011902. Online ahead of print.
PMID: 34958629
Synergy and Complementarity between Focused Machine Learning and Physics-Based Simulation in Affinity Prediction.
Cleves AE, Johnson SR, Jain AN.
J Chem Inf Model. 2021 Dec 27;61(12):5948-5966. doi: 10.1021/acs.jcim.1c01382. Epub 2021 Dec 10.
PMID: 34890185
Knowledge and Perceptions Regarding Coronavirus (COVID-19) among Pediatric Dentists during Lockdown Period.
Mallineni SK, Nuvvula S, Bhumireddy JC, Ismail AF, Verma P, Sajja R, Alassaf A, Almulhim B, Alghamdi S, Saha A, Goyal V, Namineni S.
Int J Environ Res Public Health. 2021 Dec 25;19(1):209. doi: 10.3390/ijerph19010209.
PMID: 35010473
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study.
Grimm MO, Grünwald V, Müller-Huesmann H, Ivanyi P, Schostak M, von der Heyde E, Schultze-Seemann W, Belz H, Bögemann M, Wang M, Herber M, Bedke J; NORA Study Group.
Eur Urol Focus. 2021 Dec 23:S2405-4569(21)00306-0. doi: 10.1016/j.euf.2021.11.006. Online ahead of print.
PMID: 34953677
Inter-individual variability and differential tissue abundance of mitochondrial amidoxime reducing component (mARC) in humans.
Ahire D, Basit A, Christopher LJ, Iyer R, Leeder JS, Prasad B.
Drug Metab Dispos. 2021 Dec 23:DMD-AR-2021-000805. doi: 10.1124/dmd.121.000805. Online ahead of print.
PMID: 34949674
Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.
Harrold LR, Connolly SE, Wittstock K, Zhuo J, Kelly S, Lehman T, Shan Y, Rebello S, Guo L, Khaychuk V.
Rheumatol Ther. 2021 Dec 23. doi: 10.1007/s40744-021-00401-0. Online ahead of print.
PMID: 34940957
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Geynisman DM, Du EX, Yang X, Sendhil SR, Tejo VD, Betts KA, Huo S.
Future Oncol. 2021 Dec 23. doi: 10.2217/fon-2021-1109. Online ahead of print.
PMID: 34939424
Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001.
Nagy MA, Hilgraf R, Mortensen DS, Elsner J, Norris S, Tikhe J, Yoon W, Paisner D, Delgado M, Erdman P, Haelewyn J, Khambatta G, Xu L, Romanow WJ, Condroski K, Bahmanyar S, McCarrick M, Benish B, Blease K, LeBrun L, Moghaddam MF, Apuy J, Canan SS, Bennett BL, Satoh Y.
J Med Chem. 2021 Dec 23;64(24):18193-18208. doi: 10.1021/acs.jmedchem.1c01716. Epub 2021 Dec 13.
PMID: 34894681
Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure.
Meng W, Pi Z, Brigance R, Rossi KA, Schumacher WA, Bostwick JS, Gargalovic PS, Onorato JM, Luk CE, Generaux CN, Wang T, Wexler RR, Finlay HJ.
J Med Chem. 2021 Dec 23;64(24):18102-18113. doi: 10.1021/acs.jmedchem.1c01504. Epub 2021 Dec 2.
PMID: 34855405
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Oliva EN, Platzbecker U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P.
J Clin Med. 2021 Dec 22;11(1):27. doi: 10.3390/jcm11010027.
PMID: 35011768
Overcoming IMiD Resistance in T-cell Lymphomas Through Potent Degradation of ZFP91 and IKZF1.
Wu W, Nelson G, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, Nirmal AJ, Liu H, Yang L, Duffy J, Powers F, Stevenson KE, Jones M, Ng SY, Wu G, Jain S, Xu R, Amaka S, Trevisani C, Donaldson N, Hagner PR, de Leval L, Gaulard P, Iqbal J, Thakurta A, Fischer ES, Adelman K, Weinstock DM.
Blood. 2021 Dec 22:blood.2021014701. doi: 10.1182/blood.2021014701. Online ahead of print.
PMID: 34936696
Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia.
Zeidan AM, Boss IW, Beach CL, Copeland WB, Thompson EG, Fox BA, Hasle VE, Hellmann A, Taussig D, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. Blood Adv. 2021 Dec 21:bloodadvances.2021006138. doi: 10.1182/bloodadvances.2021006138. Online ahead of print.
PMID: 34933333
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Delforge M, Shah N, San-Miguel JF, Braverman J, Dhanda DS, Shi L, Guo S, Yu P, Liao W, Campbell TB, Munshi NC.
Blood Adv. 2021 Dec 21:bloodadvances.2021005913. doi: 10.1182/bloodadvances.2021005913. Online ahead of print.
PMID: 34933328
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, Choudhury L, Zemanek D, Zwas DR, Jacoby D, Wang A, Ho CY, Li W, Sehnert AJ, Olivotto I, Abraham TP.
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
PMID: 34915982
Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial.
Fudim M, Wojdyla DM, Alexander JH, Goodman SG, Mehran R, Windecker S, Aronson R, Vinereanu D, Halvorsen S, Bahit MC, Granger CB, Lopes RD.
J Am Heart Assoc. 2021 Dec 21;10(24):e023143. doi: 10.1161/JAHA.121.023143. Epub 2021 Dec 7.
PMID: 34873913
Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation.
Mamas MA, Batson S, Pollock KG, Grundy S, Matthew A, Chapman C, Manuel JA, Farooqui U, Mitchell SA.
Am J Cardiol. 2021 Dec 20:S0002-9149(21)01148-6. doi: 10.1016/j.amjcard.2021.11.021. Online ahead of print.
PMID: 34949473
Rapid at-line early cell death quantification using capacitance spectroscopy.
Wu S, Ketcham SA, Corredor CC, Both D, Drennen JK, Anderson CA.
Biotechnol Bioeng. 2021 Dec 19. doi: 10.1002/bit.28011. Online ahead of print.
PMID: 34927241
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways.
Ortiz-Estévez M, Towfic F, Flynt E, Stong N, Jang IS, Wang K, Trotter MWB, Thakurta A.
BMC Med Genomics. 2021 Dec 18;14(1):295. doi: 10.1186/s12920-021-01140-5.
PMID: 34922559
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.
Branchoux S, Sofeu CL, Gaudin AF, Kurt M, Moshyk A, Italiano A, Bellera C, Rondeau V.
ESMO Open. 2021 Dec 17;7(1):100340. doi: 10.1016/j.esmoop.2021.100340.
PMID: 34929616
Prevalence of pre-existing neutralizing antibodies against AAV serotypes 1, 2, 5, 6, 8, and 9 in sera of different pig strains.
Dai Y, Kavita U, Lampen MH, Gielen S, Banks G, Levesque PC, Kozhich A, Pillutla RC, Zhang YJ, Jawa V, Adam LP.
Hum Gene Ther. 2021 Dec 16. doi: 10.1089/hum.2021.213. Online ahead of print.
PMID: 34913759
A Cluster of Articles in Memory of Wim Jiskoot, Ph.D.
Crommelin DJA, Narhi LO, Das TK.
J Pharm Sci. 2021 Dec 15:S0022-3549(21)00688-2. doi: 10.1016/j.xphs.2021.12.010. Online ahead of print.
PMID: 34919968
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).
Sebastian M, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Liersch R, von der Heyde E, Wiegand J, Ukena D, Bargon J, Schütte W, Riera-Knorrenschild J, Fischer JR, Griesinger F, Allan V, Waldenberger D, Schumann C.
J Immunother. 2021 Dec 15. doi: 10.1097/CJI.0000000000000397. Online ahead of print.
PMID: 34908007
Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease.
Bhattacharya A, Travis D, Osterman MT, Lewis JD, Bhagya Rao B, Lee H, Lichtenstein GR.
J Clin Gastroenterol. 2021 Dec 15. doi: 10.1097/MCG.0000000000001637. Online ahead of print.
PMID: 34907922
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF.
Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10.
PMID: 34759043
High-Throughput Surface Plasmon Resonance Biosensors for Identifying Diverse Therapeutic Monoclonal Antibodies.
Matharu Z, Bee C, Schwarz F, Chen H, Tomlinson M, Wu G, Rakestraw G, Hornsby M, Drake A, Strop P, Rajpal A, Dollinger G.
Anal Chem. 2021 Dec 14;93(49):16474-16480. doi: 10.1021/acs.analchem.1c03548. Epub 2021 Dec 2.
PMID: 34854675
Mass spectrometric based investigation of differentially protected Azatryptophan derivatives by using Orbitrap MS: Differentiation of positional isomers under protonation and alkali-cationization conditions.
Gajjela R, Kandula RR, Kuppusamy P, Nimje RY, Gupta A, Bagadi M, Mathur A.
Rapid Commun Mass Spectrom. 2021 Dec 13:e9239. doi: 10.1002/rcm.9239. Online ahead of print.
PMID: 34904316
Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, Garrison LP.
Jr. Clin Ther. 2021 Dec 12:S0149-2918(21)00460-4. doi: 10.1016/j.clinthera.2021.11.006. Online ahead of print.
PMID: 34911641
Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S.
Urol Oncol. 2021 Dec 11:S1078-1439(21)00510-X. doi: 10.1016/j.urolonc.2021.11.014. Online ahead of print.
PMID: 34906410
Development, psychometric evaluation and cognitive debriefing of the rheumatoid arthritis symptom and impact questionnaire (RASIQ).
Becker B, Bracher M, Chauhan D, Rendas-Baum R, Lin X, Raymond K, O'Connor M, Kosinski M.
J Patient Rep Outcomes. 2021 Dec 11;5(1):129. doi: 10.1186/s41687-021-00400-3.
PMID: 34894330
Comparative Safety and Effectiveness of Apixaban vs. Warfarin in Oral Anticoagulant-Naïve Japanese Patients With Non-Valvular Atrial Fibrillation　- A Retrospective Chart Review Study.
Koretsune Y, Hoshino H, Matsuo Y, Ibuki T, Morimoto T.
Circ J. 2021 Dec 10. doi: 10.1253/circj.CJ-21-0682. Online ahead of print.
PMID: 34897136
Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-To-In Vivo Translation.
Shen H, Yang Z, Rodrigues AD.
Drug Metab Dispos. 2021 Dec 10:DMD-MR-2021-000695. doi: 10.1124/dmd.121.000695. Online ahead of print.
PMID: 34893475
Impact of Swelling of Spray Dried Dispersions in Dissolution Media on their Dissolution: An Investigation Based on UV Imaging.
Li J, Zordan C, Ponce S, Lu X.
J Pharm Sci. 2021 Dec 9:S0022-3549(21)00680-8. doi: 10.1016/j.xphs.2021.12.007. Online ahead of print.
PMID: 34896344
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
Jabado O, Maldonado MA, Schiff M, Weinblatt ME, Fleischmann R, Robinson WH, He A, Patel V, Greenfield A, Saini J, Galbraith D, Connolly SE.
Rheumatol Ther. 2021 Dec 8. doi: 10.1007/s40744-021-00404-x. Online ahead of print.
PMID: 34878629
Virus inactivation at moderately low pH varies with virus and buffer properties.
Joshi PU, Meingast CL, Xu X, Holstein M, Feroz H, Ranjan S, Ghose S, Li ZJ, Heldt CL. Biotechnol J. 2021 Dec 7:e2100320. doi: 10.1002/biot.202100320. Online ahead of print.
PMID: 34874097
Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations.
Katz JS, Chou DK, Christian TR, Das TK, Patel M, Singh SN, Wen Y.
J Pharm Sci. 2021 Dec 6:S0022-3549(21)00655-9. doi: 10.1016/j.xphs.2021.12.002. Online ahead of print.
PMID: 34883096
Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective.
Hariparsad N, Ramsden D, Taskar K, Badée J, Venkatakrishnan K, Reddy MB, Cabalu T, Mukherjee D, Rehmel J, Bolleddula J, Emami Riedmaier A, Prakash C, Chanteux H, Mao J, Umehara K, Shah K, De Zwart L, Dowty M, Kotsuma M, Li M, Pilla Reddy V, McGinnity DF, Parrott N.
Clin Pharmacol Ther. 2021 Dec 4. doi: 10.1002/cpt.2503. Online ahead of print.
PMID: 34862964
What makes a good prediction? Feature importance and beginning to open the black box of machine learning in genetics.
Musolf AM, Holzinger ER, Malley JD, Bailey-Wilson JE.
Hum Genet. 2021 Dec 4. doi: 10.1007/s00439-021-02402-z. Online ahead of print.
PMID: 34862561
Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults.
Spencer S, Chung JR, Belongia EA, Sundaram M, Meece J, Coleman LA, Zimmerman RK, Nowalk MP, Moehling Geffel K, Ross T, Carter CE, Shay D, Levine M, Liepkalns J, Kim JH, Sambhara S, Thompson MG, Flannery B.
Influenza Other Respir Viruses. 2021 Dec 3. doi: 10.1111/irv.12933. Online ahead of print.
PMID: 34859584
Ligand-controlled divergent dehydrogenative reactions of carboxylic acids via C-H activation.
Wang Z, Hu L, Chekshin N, Zhuang Z, Qian S, Qiao JX, Yu JQ.
Science. 2021 Dec 3;374(6572):1281-1285. doi: 10.1126/science.abl3939. Epub 2021 Nov 11.
PMID: 34762490
Thermodynamic Understanding of an Aza-Michael Reaction Enables Five-Step Synthesis of the Potent Integrin Inhibitor MK-0429.
Gupta A, Condakes ML.
J Org Chem. 2021 Dec 3;86(23):17523-17527. doi: 10.1021/acs.joc.1c02375. Epub 2021 Nov 1.
PMID: 34723526
Fluorescent quantum dots enable SARS-CoV-2 antiviral drug discovery and development.
Gorshkov K, Susumu K, Wolak M, Oh E.
Expert Opin Drug Discov. 2021 Dec 2:1-6. doi: 10.1080/17460441.2022.2005025. Online ahead of print.
PMID: 34817309
Anti-drug Antibody Validation Testing and Reporting Harmonization.
Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, Gleason C, Goodman J, Manning MS, Purushothama S, Richards S, Shen H, Zoghbi J, Amaravadi L, Barger T, Bowen S, Bowsher RR, Clements-Egan A, Geng D, Goletz TJ, Gunn GR, Hallett W, Hodsdon ME, Janelsins BM, Jawa V, Kamondi S, Kirshner S, Kramer D, Liang M, Lindley K, Liu S, Liu Z, McNally J, Mikulskis A, Nelson R, Ahbari MR, Qu Q, Ruppel J, Snoeck V, Song A, Yan H, Ware M.
AAPS J. 2021 Dec 1;24(1):4. doi: 10.1208/s12248-021-00649-y.
PMID: 34853961
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD).
Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A.
BMJ Open Respir Res. 2021 Dec;8(1):e001026. doi: 10.1136/bmjresp-2021-001026.
PMID: 34969771
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T.
ESMO Open. 2021 Dec;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 2.
PMID: 34864501
A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma.
Kato R, Kojima T, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Sugino Y, Hamamoto S, Nakaigawa N, Kabu K, Murakami H, Obara W.
Anticancer Res. 2021 Dec;41(12):6199-6209. doi: 10.21873/anticanres.15439.
PMID: 34848474
Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P, Daumont MJ, Lacoin L, Penrod JR, Carroll R, Venkatesan S, Ubhi H, Calleja A, Snee M.
Lung Cancer. 2021 Dec;162:185-193. doi: 10.1016/j.lungcan.2021.11.001. Epub 2021 Nov 10.
PMID: 34823894
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA.
Lancet Oncol. 2021 Dec;22(12):1692-1704. doi: 10.1016/S1470-2045(21)00545-3. Epub 2021 Nov 10.
PMID: 34774225
High throughput screening data for a case study of CHO cell culture process development.
He Q, Xu J, Vandermark E, Tian J, Qian Y, Chelius C, Lee J, Borys MC, Li ZJ, Pendse G.
Data Brief. 2021 Oct 17;39:107491. doi: 10.1016/j.dib.2021.107491. eCollection 2021 Dec.
PMID: 34712760
Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas.
Gibson EG, Campagne O, Selvo NS, Gajjar A, Stewart CF.
Cancer Chemother Pharmacol. 2021 Dec;88(6):1009-1020. doi: 10.1007/s00280-021-04357-4. Epub 2021 Sep 29.
PMID: 34586478
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ogasawara K, Wood-Horrall RN, Thomas M, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2021 Dec;88(6):941-952. doi: 10.1007/s00280-021-04346-7. Epub 2021 Sep 3.
PMID: 34477937
A Metabolomics Approach to Increasing Chinese Hamster Ovary (CHO) Cell Productivity.
Yao G, Aron K, Borys M, Li Z, Pendse G, Lee K.
Metabolites. 2021 Nov 30;11(12):823. doi: 10.3390/metabo11120823.
PMID: 34940581
Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
Meier-Schiesser B, Mellett M, Ramirez-Fort MK, Maul JT, Klug A, Winkelbeiner N, Fenini G, Schafer P, Contassot E, French LE. Int J Mol Sci. 2021 Nov 28;22(23):12878. doi: 10.3390/ijms222312878.
PMID: 34884681
Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health-an EFPIA View.
Herrero-Martinez E, Hussain N, Roux NL, MacDonald J, Mayer M, Palacios R, Kühler TC.
Clin Ther. 2021 Nov 27:S0149-2918(21)00456-2. doi: 10.1016/j.clinthera.2021.11.001. Online ahead of print.
PMID: 34848082
Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis.
Heijke R, Björk M, Thyberg I, Kastbom A, McDonald L, Sjöwall C.
Clin Rheumatol. 2021 Nov 27. doi: 10.1007/s10067-021-05982-3. Online ahead of print.
PMID: 34839415
An Interlaboratory Comparison on the Characterization of a Sub-micrometer Polydisperse Particle Dispersion.
Benkstein KD, Balakrishnan G, Bhirde A, Chalus P, Das TK, Do N, Duewer DL, Filonov N, Cheong FC, Garidel P, Gill NS, Grabarek AD, Grier DG, Hadley J, Hollingsworth AD, Howard WW, Jarzębski M, Jiskoot W, Kar SR, Kestens V, Khasa H, Kim YJ, Koulov A, Matter A, Philips LA, Probst C, Ramaye Y, Randolph TW, Ripple DC, Romeijn S, Saggu M, Schleinzer F, Snell JR, Tatarkiewicz JK, Wright HA, Yang DT.
J Pharm Sci. 2021 Nov 20:S0022-3549(21)00612-2. doi: 10.1016/j.xphs.2021.11.006. Online ahead of print.
PMID: 34808214
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
Nowakowski GS, Willenbacher W, Greil R, Larsen TS, Patel K, Jäger U, Manges RF, Trümper L, Everaus H, Kalakonda N, Brown P, Jørgensen JM, Cunningham D, Dell'Aringa J, Fox B, Rubio ND, Kilavuz N, Casadebaig ML, Manzke O, Munoz J.
Int J Hematol. 2021 Nov 19. doi: 10.1007/s12185-021-03241-4. Online ahead of print.
PMID: 34797531
Analysis of the Immunogenicity from Abatacept-Treated Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials.
Mora JR, Wong R, Shaikh M, Askelson M.
ACR Open Rheumatol. 2021 Nov 18. doi: 10.1002/acr2.11375. Online ahead of print.
PMID: 34792858
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H, Olsen MR, Carthon BC, Drakaki A, Percent IJ, Molina AM, Cho DC, Bendell JC, Gordan LN, Rezazadeh Kalebasty A, George DJ, Hutson TE, Arrowsmith ER, Zhang J, Zoco J, Johansen JL, Leung DK, Tykodi SS.
Cancer. 2021 Nov 16. doi: 10.1002/cncr.34016. Online ahead of print.
PMID: 34784056
Correction to: Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies.
McMahon ME, Abbott A, Babayan Y, Carhart J, Chen CW, Debie E, Fu M, Hoaglund-Hyzer C, Lennard A, Li H, Mazzeo T, McCaig L, Pischel S, Qiu F, Stephens D, Timpano R, Webb D, Wolfe C, Woodlief K, Wu Y.
AAPS J. 2021 Nov 15;23(6):118. doi: 10.1208/s12248-021-00646-1.
PMID: 34782955
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
Luo Y, Decato BE, Charles ED, Shevell DE, McNaney C, Shipkova P, Apfel A, Tirucherai GS, Sanyal AJ.
JHEP Rep. 2021 Nov 12;4(1):100392. doi: 10.1016/j.jhepr.2021.100392. eCollection 2022 Jan.
PMID: 34977519
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, Skandamis A, Kongnakorn T, Soto J.
PLoS One. 2021 Nov 12;16(11):e0259251. doi: 10.1371/journal.pone.0259251. eCollection 2021.
PMID: 34767564
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Garcia-Manero G, Mufti Obe GJ, Fenaux P, Buckstein RJ, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS.
Blood. 2021 Nov 10:blood.2021012589. doi: 10.1182/blood.2021012589. Online ahead of print.
PMID: 34758066
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG.
J Allergy Clin Immunol. 2021 Nov 10:S0091-6749(21)01690-0. doi: 10.1016/j.jaci.2021.11.001. Online ahead of print.
PMID: 34767869
Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivo.
Saenz SA, Local A, Carr T, Shakya A, Koul S, Hu H, Chourb L, Stedman J, Malley J, D'Agostino LA, Shanmugasundaram V, Malona J, Schwartz CE, Beebe L, Clements M, Rajaraman G, Cho J, Jiang L, Dubrovskiy A, Kreilein M, Shimanovich R, Hamann LG, Escoubet L, Ellis JM.
PLoS One. 2021 Nov 9;16(11):e0248034. doi: 10.1371/journal.pone.0248034. eCollection 2021.
PMID: 34752458
Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT, Creemers A, Meijer SL, de Boer OJ, Vos W, Hooijer GK, van Berge Henegouwen MI, Hulshof MC, Bergman JJ, Lei M, Bijlsma MF, Ylstra B, van Grieken NC, van Laarhoven HW.
J Pathol. 2021 Nov 7. doi: 10.1002/path.5832. Online ahead of print.
PMID: 34743329
Development and equivalence of new faces for inclusion in the Childhood Asthma Control Test (C-ACT) response scale.
Sully K, Bonner N, Bradley H, von Maltzahn R, Arbuckle R, Walker-Nthenda L, Mahon A, Becker B, O'Hara L, Bevans KB, Kosinski M, Zeiger RS, Mackenzie R, Nelsen L.
J Patient Rep Outcomes. 2021 Nov 6;5(1):118. doi: 10.1186/s41687-021-00390-2.
PMID: 34743264
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips DC, Leverson JD, MacBeth KJ, Nicolay B, Narayanaswamy R, Ronseaux S, Liu G, Chan SM.
Leukemia. 2021 Nov 6. doi: 10.1038/s41375-021-01468-y. Online ahead of print.
PMID: 34743189
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ.
Eur Urol. 2021 Nov 5:S0302-2838(21)02069-8. doi: 10.1016/j.eururo.2021.10.001. Online ahead of print.
PMID: 34750035
Acoustic ejection mass spectrometry: Development, applications, and future perspective.
Shou WZ.
Biomed Chromatogr. 2021 Nov 5:e5278. doi: 10.1002/bmc.5278. Online ahead of print.
PMID: 34741338
A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data.
Dudášová J, Laube R, Valiathan C, Wiener MC, Gheyas F, Fišer P, Ivanauskaite J, Liu F, Sachs JR.
NPJ Vaccines. 2021 Nov 4;6(1):133. doi: 10.1038/s41541-021-00377-6.
PMID: 34737322
Evaluating the Combined Impact of Temperature and Application of Interfacial Dilatational Stresses on Surface-mediated Protein Particle Formation in Monoclonal Antibody Formulations.
Griffin VP, Merritt K, Vaclaw C, Whitaker N, Volkin DB, Ogunyankin MO, Pace S, Dhar P.
J Pharm Sci. 2021 Nov 3:S0022-3549(21)00605-5. doi: 10.1016/j.xphs.2021.10.038. Online ahead of print.
PMID: 34742729
Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection.
Chiarot E, Naimo E, Corrado A, Giannetti P, Ros IMY, Bensi G.
Sci Rep. 2021 Nov 1;11(1):21384. doi: 10.1038/s41598-021-00941-z.
PMID: 34725414
Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype.
Hill MD, Quesnelle C, Tokarski J, Fang H, Fanslau C, Haarhoff Z, Kramer M, Madari S, Wiebesiek A, Morrison J, Simmermacher-Mayer J, Sinz M, Westhouse R, Xie C, Zhao J, Huang L, Sheriff S, Yan C, Marsilio F, Everlof G, Zvyaga T, Lee F, Gavai AV, Degnan AP.
Bioorg Med Chem Lett. 2021 Nov 1;51:128376. doi: 10.1016/j.bmcl.2021.128376. Epub 2021 Sep 21.
PMID: 34560263
Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge.
Vincent BG, Szustakowski JD, Doshi P, Mason M, Guinney J, Carbone DP.
JCO Precis Oncol. 2021 Nov;5:51-54. doi: 10.1200/PO.20.00371.
PMID: 34994587
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Regan MM, Mantia CM, Werner L, Tarhini AA, Larkin J, Stephen Hodi F, Wolchok J, Postow MA, Stwalley B, Moshyk A, Ritchings C, Re S, van Dijck W, McDermott DF, Atkins MB.
J Immunother Cancer. 2021 Nov;9(11):e003743. doi: 10.1136/jitc-2021-003743.
PMID: 34799400
Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer.
Stump CT, Roehle K, Manjarrez Orduno N, Dougan SK.
Open Biol. 2021 Nov;11(11):210245. doi: 10.1098/rsob.210245. Epub 2021 Nov 17.
PMID: 34784792
Utility of a next-generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide.
Nicolette J, Luijten M, Sasaki JC, Custer L, Embry M, Froetschl R, Johnson G, Ouedraogo G, Settivari R, Thybaud V, Dearfield KL.
Environ Mol Mutagen. 2021 Nov;62(9):512-525. doi: 10.1002/em.22467. Epub 2021 Nov 22.
PMID: 34775645
Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.
Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P.
Clin Ther. 2021 Nov;43(11):1983-1996.e3. doi: 10.1016/j.clinthera.2021.09.013. Epub 2021 Nov 2.
PMID: 34736769
Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration.
Perino AC, Fan J, Schmitt S, Guo JD, Hlavacek P, Din N, Kothari M, Pundi K, Russ C, Emir B, Turakhia MP.
Circ Cardiovasc Qual Outcomes. 2021 Nov;14(11):e008005. doi: 10.1161/CIRCOUTCOMES.121.008005. Epub 2021 Nov 2.
PMID: 34724801
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW, Bennett B, Trigg A, DeRosa M, Taylor F, Kiff C, Ntais D, Noon K, King MT, Cocks K.
Value Health. 2021 Nov;24(11):1651-1659. doi: 10.1016/j.jval.2021.05.022. Epub 2021 Aug 26.
PMID: 34711366
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
Cohen AT, Sah J, Dhamane AD, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X.
Adv Ther. 2021 Nov;38(11):5519-5533. doi: 10.1007/s12325-021-01918-0. Epub 2021 Sep 27.
PMID: 34570310
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T, Popat R, Suvannasankha A, Sarri G, Hughes R, Wang F, Hogea C, Ferrante SA, Gorsh B, Willson J, Kapetanakis V.
Adv Ther. 2021 Nov;38(11):5501-5518. doi: 10.1007/s12325-021-01884-7. Epub 2021 Sep 24.
PMID: 34561812
Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany.
Singh P, McDonald L, Waldenberger D, Welslau M, von der Heyde E, Gauler T, Dietz A.
Head Neck. 2021 Nov;43(11):3540-3551. doi: 10.1002/hed.26853. Epub 2021 Sep 6.
PMID: 34487397
Calculating qualified non-mutagenic impurity levels: Harmonization of approaches.
Graham JC, Powley MW, Udovic E, Glowienke S, Nicolette J, Parris P, Kenyon M, White A, Maisey A, Harvey J, Martin EA, Dowdy E, Masuda-Herrera M, Trejo-Martin A, Bercu J.
Regul Toxicol Pharmacol. 2021 Nov;126:105023. doi: 10.1016/j.yrtph.2021.105023. Epub 2021 Aug 4.
PMID: 34363920
Structural and Thermal Characterization of Halogenated Azidopyridines: Under-Reported Synthons for Medicinal Chemistry.
Mandler MD, Degnan AP, Zhang S, Aulakh D, Georges K, Sandhu B, Sarjeant A, Zhu Y, Traeger SC, Cheng PT, Ellsworth BA, Regueiro-Ren A.
Org Lett. 2021 Oct 29. doi: 10.1021/acs.orglett.1c03201. Online ahead of print.
PMID: 34714083
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.
Cheng PTW, Kaltenbach RF 3rd, Zhang H, Shi J, Tao S, Li J, Kennedy LJ, Walker SJ, Shi Y, Wang Y, Dhanusu S, Reddigunta R, Kumaravel S, Jusuf S, Smith D, Krishnananthan S, Li J, Wang T, Heiry R, Sum CS, Kalinowski SS, Hung CP, Chu CH, Azzara AV, Ziegler M, Burns L, Zinker BA, Boehm S, Taylor J, Sapuppo J, Mosure K, Everlof G, Guarino V, Zhang L, Yang Y, Ruan Q, Xu C, Apedo A, Traeger SC, Cvijic ME, Lentz KA, Tirucherai G, Sivaraman L, Robl J, Ellsworth BA, Rosen G, Gordon DA, Soars MG, Gill M, Murphy BJ.
J Med Chem. 2021 Oct 28. doi: 10.1021/acs.jmedchem.1c01256. Online ahead of print.
PMID: 34709814
Degradation of Protein Kinases: Ternary Complex, Cooperativity, and Selectivity.
Grigglestone CE, Yeung KS.
ACS Med Chem Lett. 2021 Oct 27;12(11):1629-1632. doi: 10.1021/acsmedchemlett.1c00543. eCollection 2021 Nov 11.
PMID: 34795847
Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial.
Budde K, Prashar R, Haller H, Rial M, Kamar N, Agarwal A, de Fijter J, Rostaing L, Berger S, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F.
J Am Soc Nephrol. 2021 Oct 27:ASN.2021050628. doi: 10.1681/ASN.2021050628. Online ahead of print.
PMID: 34706967
Signal transfer in human protein tyrosine phosphatase PTP1B from allosteric inhibitor P00058.
Chirgadze YN, Battaile KP, Likhachev IV, Balabaev NK, Gordon RD, Romanov V, Lin A, Karisch R, Lam R, Ruzanov M, Brazhnikov EV, Pai EF, Neel BG, Chirgadze NY.
J Biomol Struct Dyn. 2021 Oct 27:1-10. doi: 10.1080/07391102.2021.1994879. Online ahead of print.
PMID: 34705594
Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor.
Zhang Y, Parrish KE, Tortolani DR, Poss MA, Huang A, Wan H, Purandare AV, Donnell AF, Kempson J, Hou X, Pawluczyk J, Yip S, Luk E, Raghavan N, Swanson J, Smalley J, Murtaza A, Yang Z, Augustine-Rauch K, Lombardo LJ, Borzilleri R.
J Med Chem. 2021 Oct 27. doi: 10.1021/acs.jmedchem.0c02043. Online ahead of print.
PMID: 34704759
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG.
Blood. 2021 Oct 26:blood.2021011895. doi: 10.1182/blood.2021011895. Online ahead of print.
PMID: 34699592
Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Danese MD, Daumont M, Nwokeji E, Gleeson M, Penrod JR, Lubeck D.
Cancer Rep (Hoboken). 2021 Oct 26:e1568. doi: 10.1002/cnr2.1568. Online ahead of print.
PMID: 34698447
A chemometric model for the quantitative determination of isotopic impurities in d3-methylamine hydrochloride by Fourier-transform infrared spectroscopy.
Marriott AS, Boyd AM, Quirk E, Chadwick J.
J Pharm Biomed Anal. 2021 Oct 25;205:114337. doi: 10.1016/j.jpba.2021.114337. Epub 2021 Aug 21.
PMID: 34474232
Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis.
Sivakumar P, Ammar R, Thompson JR, Luo Y, Streltsov D, Porteous M, McCoubrey C, Cantu E 3rd, Beers MF, Jarai G, Christie JD.
Respir Res. 2021 Oct 24;22(1):273. doi: 10.1186/s12931-021-01860-3.
PMID: 34689792
A Tribute to Professor Saranjit Singh - A Critical Thinker, Innovator, Mentor, and Educator.
Ladumor MK, Paudel A, Modhave D, Sharma S, Balhara A, Singh DK, Ramalingam M, Shah R, Pavankumarraju S, Kurmi M, Mariappan TT, Bhutani H, Prasad B.
J Pharm Sci. 2021 Oct 23:S0022-3549(21)00566-9. doi: 10.1016/j.xphs.2021.10.024. Online ahead of print.
PMID: 34699842
Identification of 6-Hydroxypyrimidin-4(1 H )-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.
Pi Z, Johnson JA, Meng W, Phillips M, Schumacher WA, Bostwick JS, Gargalovic PS, Onorato JM, Generaux CN, Wang T, He Y, Gordon DA, Wexler RR, Finlay HJ.
ACS Med Chem Lett. 2021 Oct 22;12(11):1766-1772. doi: 10.1021/acsmedchemlett.1c00385. eCollection 2021 Nov 11.
PMID: 34795866
Microscale purification in support of high-throughput medicinal chemistry.
Barhate CL, Donnell AF, Davies M, Li L, Zhang Y, Yang F, Black R, Zipp G, Zhang Y, Cavallaro CL, Priestley ES, Weller HN.
Chem Commun (Camb). 2021 Oct 21;57(84):11037-11040. doi: 10.1039/d1cc03791a.
PMID: 34608906
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
Tan AR, Chan N, Kiesel BF, Stein MN, Moss RA, Malhotra J, Aisner J, Shah M, Gounder M, Lin H, Kane MP, Lin Y, Ji J, Chen A, Beumer JH, Mehnert JM.
Cancer Chemother Pharmacol. 2021 Oct 20. doi: 10.1007/s00280-021-04350-x. Online ahead of print.
PMID: 34669023
Analysis of N 15 -rat growth hormone after incubation with rat subcutaneous tissue and immune cells using ultra-pressure chromatography-mass spectrometry.
Varkhede N, Björn-Hendrik P, Moulder KR, Gao P, Schöneich C, Forrest ML.
Anal Biochem. 2021 Oct 19:114425. doi: 10.1016/j.ab.2021.114425. Online ahead of print.
PMID: 34678250
An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission.
Biavati L, Huff CA, Ferguson A, Sidorski A, Stevens MA, Rudraraju L, Zucchinetti C, Ali SA, Imus P, Gocke CB, Gittelman RM, Johnson S, Sanders C, Vignali M, Gandhi A, Ye X, Noonan KA, Borrello I.
Clin Cancer Res. 2021 Oct 19:clincanres.CCR-21-1916-A.2021. doi: 10.1158/1078-0432.CCR-21-1916. Online ahead of print.
PMID: 34667029
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H.
Lancet Oncol. 2021 Oct 18:S1470-2045(21)00494-0. doi: 10.1016/S1470-2045(21)00494-0. Online ahead of print.
PMID: 34672961
Sustainable Pd(OAc) 2  /Hydroquinone Cocatalyst System for Cis-Selective Dibenzoyloxylation of 1,3-Cyclohexadiene.
Stamoulis AG, Geng P, Schmidt MA, Eastgate MD, Borovika A, Fraunhoffer KJ, Stahl SS.
Angew Chem Int Ed Engl. 2021 Oct 18;60(43):23182-23186. doi: 10.1002/anie.202108499. Epub 2021 Sep 17.
PMID: 34399005
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An IQ Consortium Perspective.
Li C, Menon R, Walles M, Singh R, Upreti VV, Brackman D, Lee AJ, Endres CJ, Kumar S, Zhang D, Barletta F, Suri A, Haninzl D, Liao KH, Lalovic B, Beaumont M, Zuo P, Mayer AP, Wei D.
Clin Pharmacol Ther. 2021 Oct 17. doi: 10.1002/cpt.2448. Online ahead of print.
PMID: 34657311
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D.
Eur J Cancer. 2021 Oct 15:S0959-8049(21)00555-4. doi: 10.1016/j.ejca.2021.08.028. Online ahead of print.
PMID: 34663559
Corrigendum to "Investigation on hot melt extrusion and prediction on 3D printability of pharmaceutical grade polymers" [Int. J. Pharm. 604 (2021) 120755].
Tabriz AG, Scoutaris N, Gong Y, Hui HW, Kumar S, Douroumis D.
Int J Pharm. 2021 Oct 15:121187. doi: 10.1016/j.ijpharm.2021.121187. Online ahead of print.
PMID: 34663522
Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis.
Tsutsué S, Suzuki T, Kim H, Crawford B.
Future Oncol. 2021 Oct 15. doi: 10.2217/fon-2021-0988. Online ahead of print.
PMID: 34652217
Identification of 6-hydroxy-5-phenyl sulfonylpyrimidin-4(1H)-one APJ receptor agonists.
Tora G, Jiang J, Bostwick JS, Gargalovic PS, Onorato JM, Luk CE, Generaux C, Xu C, Galella MA, Wang T, He Y, Wexler RR, Finlay HJ.
Bioorg Med Chem Lett. 2021 Oct 15;50:128325. doi: 10.1016/j.bmcl.2021.128325. Epub 2021 Aug 14.
PMID: 34403724
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.
Cherney RJ, Anjanappa P, Selvakumar K, Batt DG, Brown GD, Rose AV, Vuppugalla R, Chen J, Pang J, Xu S, Yarde M, Tebben AJ, Paidi VR, Cvijic ME, Mathur A, Barrish JC, Mandlekar S, Zhao Q, Carter PH.
ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758.
doi: 10.1021/acsmedchemlett.1c00373. eCollection 2021 Nov 11.
PMID: 34795864
B Cell Mobilization, Dissemination, Fine Tuning of Local Antigen Specificity and Isotype Selection in Asthma.
Ohm-Laursen L, Meng H, Hoehn KB, Nouri N, Jiang Y, Clouser C, Johnstone TG, Hause R, Sandhar BS, Upton NEG, Chevretton EB, Lakhani R, Corrigan CJ, Kleinstein SH, Gould HJ.
Front Immunol. 2021 Oct 14;12:702074. doi: 10.3389/fimmu.2021.702074. eCollection 2021.
PMID: 34721376
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.
Subbaiah MAM, Meanwell NA.
J Med Chem. 2021 Oct 14;64(19):14046-14128. doi: 10.1021/acs.jmedchem.1c01215. Epub 2021 Sep 30.
PMID: 34591488
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.
Gavai AV, Norris D, Delucca G, Tortolani D, Tokarski JS, Dodd D, O'Malley D, Zhao Y, Quesnelle C, Gill P, Vaccaro W, Huynh T, Ahuja V, Han WC, Mussari C, Harikrishnan L, Kamau M, Poss M, Sheriff S, Yan C, Marsilio F, Menard K, Wen ML, Rampulla R, Wu DR, Li J, Zhang H, Li P, Sun D, Yip H, Traeger SC, Zhang Y, Mathur A, Zhang H, Huang C, Yang Z, Ranasinghe A, Everlof G, Raghavan N, Tye CK, Wee S, Hunt JT, Vite G, Westhouse R, Lee FY.
J Med Chem. 2021 Oct 14;64(19):14247-14265. doi: 10.1021/acs.jmedchem.1c00625. Epub 2021 Sep 20.
PMID: 34543572
BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage.
Kang Z, Fu P, Alcivar AL, Fu H, Redon C, Foo TK, Zuo Y, Ye C, Baxley R, Madireddy A, Buisson R, Bielinsky AK, Zou L, Shen Z, Aladjem MI, Xia B.
Nat Commun. 2021 Oct 13;12(1):5966. doi: 10.1038/s41467-021-26227-6.
PMID: 34645815
Chemoselective Electrosynthesis Using Rapid Alternating Polarity.
Kawamata Y, Hayashi K, Carlson E, Shaji S, Waldmann D, Simmons BJ, Edwards JT, Zapf CW, Saito M, Baran PS.
J Am Chem Soc. 2021 Oct 13;143(40):16580-16588. doi: 10.1021/jacs.1c06572. Epub 2021 Oct 1.
PMID: 34596395
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S.
J Clin Oncol. 2021 Oct 12:JCO2101015. doi: 10.1200/JCO.21.01015. Online ahead of print.
PMID: 34637336
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.
Cheng L, Qiu Y, Schmidt BJ, Wei GW.
J Pharmacokinet Pharmacodyn. 2021 Oct 12. doi: 10.1007/s10928-021-09785-6. Online ahead of print.
PMID: 34637069
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M.
J Thorac Oncol. 2021 Oct 11:S1556-0864(21)03207-X. doi: 10.1016/j.jtho.2021.09.010. Online ahead of print.
PMID: 34648948
A Selection of Macrocyclic Peptides That Bind STING From an mRNA-Display Library With Split Degenerate Codons.
Lin CW, Harner MJ, Douglas AE, Lafont V, Yu F, Lee VG, Poss MA, Swain JF, Wright M, Lipovšek D.
Angew Chem Int Ed Engl. 2021 Oct 11;60(42):22640-22645. doi: 10.1002/anie.202103043. Epub 2021 Sep 6.
PMID: 34383389
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis.
Vidula MK, Orlenko A, Zhao L, Salvador L, Small AM, Horton E, Cohen JB, Adusumalli S, Denduluri S, Kobayashi T, Hyman M, Fiorilli P, Magro C, Singh B, Pourmussa B, Greczylo C, Basso M, Ebert C, Yarde M, Li Z, Cvijic ME, Wang Z, Walsh A, Maranville J, Kick E, Luettgen J, Adam L, Schafer P, Ramirez-Valle F, Seiffert D, Moore JH, Gordon D, Chirinos JA.
Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2361. Online ahead of print.
PMID: 34632675
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Konecny GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, Fasching PA, Feisel-Schwickardi G, Poelcher M, Roman LD, Rody A, Karlan BY, Mullany SA, Chen H, Ray-Coquard IL, Provencher DM, Yachnin A, Cottu PH, Glaspy JA, Haluska P, Slamon DJ.
Gynecol Oncol. 2021 Oct 9:S0090-8258(21)01413-X. doi: 10.1016/j.ygyno.2021.09.025. Online ahead of print.
PMID: 34642026
The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review.
Sussman M, Barnes GD, Guo JD, Tao CY, Gillespie JA, Ferri M, Adair N, Cato MS, Shirkhorshidian I, Di Fusco M.
Curr Med Res Opin. 2021 Oct 9:1-12. doi: 10.1080/03007995.2021.1982684. Online ahead of print.
PMID: 34632887
iNucs: Inter-Nucleosome Interactions.
Oveisi M, Shukla M, Seymen N, Ohno M, Taniguchi Y, Nahata S, Loos R, Mufti GJ, Allshire RC, Dimitrov S, Karimi MM.
Bioinformatics. 2021 Oct 8:btab698. doi: 10.1093/bioinformatics/btab698. Online ahead of print.
PMID: 34623394
Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study).
Tamura N, Azuma T, Misaki K, Yamaguchi R, Hirano F, Sugiyama E, Kanai D, Murakawa Y, Oribe M, Kimata T, Aoki K, Sugiura T, Takasugi K, Takakubo Y, Tomita Y, Isozaki T, Nanki T, Katsuyama N, Kuroiwa T, Oshikawa H, Kaneko M, Fujinaga H, Saito K, Tanaka E, Inoue E, Yoshizawa Y, Matsumoto S, Yamanaka H, Harigai M.
Mod Rheumatol. 2021 Oct 8:roab090. doi: 10.1093/mr/roab090. Online ahead of print.
PMID: 34915575
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Garcia-Manero G, Döhner H, Wei AH, La Torre I, Skikne B, Beach CL, Santini V.
Clin Lymphoma Myeloma Leuk. 2021 Oct 8:S2152-2650(21)02070-X. doi: 10.1016/j.clml.2021.09.021. Online ahead of print.
PMID: 34758945
Two classes of myosin inhibitors, blebbistatin, and mavacamten, stabilize β-cardiac myosin in different structural and functional states.
Gollapudi SK, Ma W, Chakravarthy S, Combs AC, Sa N, Langer S, Irving TC, Nag S.
J Mol Biol. 2021 Oct 7:167295. doi: 10.1016/j.jmb.2021.167295. Online ahead of print.
PMID: 34627791
Assessment of Transporter-Mediated Drug Interactions for Enasidenib based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
Cheng Y, Wang X, Tong Z, Reyes J, Carayannopoulos L, Zhou S, Li Y.
J Clin Pharmacol. 2021 Oct 6. doi: 10.1002/jcph.1979. Online ahead of print.
PMID: 34617279
Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors.
Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS.
Clin Cancer Res. 2021 Oct 6:clincanres.1181.2021. doi: 10.1158/1078-0432.CCR-21-1181. Online ahead of print.
PMID: 34615718
Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials.
Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster H, Hiddemann W, Marcus RE, Kimby EK, Herold M, Sebban CJ, Gyan E, Foon KA, Nielsen TG, Vitolo U, Salles GA, Shi Q, Flowers CR.
Blood. 2021 Oct 6:blood.2020010263. doi: 10.1182/blood.2020010263. Online ahead of print.
PMID: 34614146
Digital pathology and artificial intelligence in translational medicine and clinical practice.
Baxi V, Edwards R, Montalto M, Saha S.
Mod Pathol. 2021 Oct 5:1-10. doi: 10.1038/s41379-021-00919-2. Online ahead of print.
PMID: 34611303
SMaSh: A Streptavidin Mass Shift Assay for Rapidly Quantifying Target Occupancy by Irreversible Inhibitors.
Labenski MT, Bateman LA, Voortman LT, Giammo G, Cantin S, Qiao L, Corin AF.
Biochemistry. 2021 Oct 5;60(39):2915-2924. doi: 10.1021/acs.biochem.1c00422. Epub 2021 Sep 23.
PMID: 34554726
Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings.
Nguyen HH, Tahirovic YA, Truax VM, Wilson RJ, Jecs E, Miller EJ, Kim MB, Akins NS, Xu L, Jiang Y, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.
ACS Med Chem Lett. 2021 Oct 4;12(10):1605-1612. doi: 10.1021/acsmedchemlett.1c00449. eCollection 2021 Oct 14.
PMID: 34676043
Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma.
Qi YA, Maity TK, Gao S, Gong T, Bahta M, Venugopalan A, Zhang X, Guha U.
Cancers (Basel). 2021 Oct 4;13(19):4977. doi: 10.3390/cancers13194977.
PMID: 34638461
Multi-arm multi-stage clinical trials for time-to-event outcomes.
Dixit V, Mitra P, Simonsen K.
J Biopharm Stat. 2021 Oct 4:1-14. doi: 10.1080/10543406.2021.1979575. Online ahead of print.
PMID: 34606418
BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, Goodman Z, Charles ED.
Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181. Online ahead of print.
PMID: 34605045
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.
Bota DA, Mason W, Kesari S, Magge R, Winograd B, Elias I, Reich SD, Levin N, Trikha M, Desjardins A.
Neurooncol Adv. 2021 Oct 2;3(1):vdab142. doi: 10.1093/noajnl/vdab142. eCollection 2021 Jan-Dec.
PMID: 34729484
Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans.
Sharda N, Khandelwal P, Zhang L, Caceres-Cortes J, Marathe P, Chimalakonda A.
Eur J Pharm Sci. 2021 Oct 1;165:105928. doi: 10.1016/j.ejps.2021.105928. Epub 2021 Jul 12.
PMID: 34265405
Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Heilbroner SP, Few R, Mueller J, Chalwa J, Charest F, Suryadevara S, Kratt C, Gomez-Caminero A, Dreyfus B, Neilan TG.
J Immunother Cancer. 2021 Oct;9(10):e002545. doi: 10.1136/jitc-2021-002545.
PMID: 34607896
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T.
ESMO Open. 2021 Oct;6(5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1.
PMID: 34607285
Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.
Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, Fabrizio D, Funari V, Newberg J, Bruce LK, Chen SJ, Baden J, Barrett JC, Beer P, Butler M, Cheng JH, Conroy J, Cyanam D, Eyring K, Garcia E, Green G, Gregersen VR, Hellmann MD, Keefer LA, Lasiter L, Lazar AJ, Li MC, Macconaill LE, Meier K, Mellert H, Pabla S, Pallavajjalla A, Pestano G, Salgado R, Samara R, Sokol ES, Stafford P, Budczies J, Stenzinger A, Tom W, Valkenburg KC, Wang X, Weigman V, Xie M, Xie Q, Zehir A, Zhao C, Zhao Y, Stewart MD, Allen J; TMB Consortium.
Ann Oncol. 2021 Oct 1:S0923-7534(21)04495-1. doi: 10.1016/j.annonc.2021.09.016. Online ahead of print.
PMID: 34606929
Spatiotemporal proteomic profiling of the pro-inflammatory response to lipopolysaccharide in the THP-1 human leukaemia cell line.
Mulvey CM, Breckels LM, Crook OM, Sanders DJ, Ribeiro ALR, Geladaki A, Christoforou A, Britovšek NK, Hurrell T, Deery MJ, Gatto L, Smith AM, Lilley KS.
Nat Commun. 2021 Oct 1;12(1):5773. doi: 10.1038/s41467-021-26000-9.
PMID: 34599159
The Interplay between Covid-19 and Spondyloarthritis or Its Treatment.
Rosenbaum JT, Weisman MH, Hamilton H, Shafer C, Aslanyan E, Howard RA, Ogle K, Reveille JD, Winthrop KL, Choi D.
J Rheumatol. 2021 Oct 1:jrheum.210742. doi: 10.3899/jrheum.210742. Online ahead of print.
PMID: 34599048
Endogenous plasma kynurenic acid in human: a newly discovered biomarker for drug-drug interactions involving in OAT1 and OAT3 inhibition.
Tang J, Shen H, Zhao X, Holenarsipur VK, Mariappan TT, Zhang Y, Panfen E, Zheng J, Humphreys WG, Lai Y.
Drug Metab Dispos. 2021 Oct 1:DMD-AR-2021-000486. doi: 10.1124/dmd.121.000486.
PMID: 34599018
Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis.
Tang CH, Furnback W, Wang BCM, Tang J, Tang D, Lu MY, Huang VW, Musallam KM.
Transfusion. 2021 Oct;61(10):2906-2917. doi: 10.1111/trf.16636. Epub 2021 Sep 10.
PMID: 34505291
Health-Related and Economic Burden Among Family Caregivers of Patients with Acute Myeloid Leukemia or Hematological Malignancies.
Yucel E, Zhang S, Panjabi S.
Adv Ther. 2021 Oct;38(10):5002-5024. doi: 10.1007/s12325-021-01872-x. Epub 2021 Sep 9.
PMID: 34499319
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, Patel A, Shen J, Girgis IG, Banerjee S, Throup J.
Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30.
PMID: 34471993
Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman JD.
JAMA Oncol. 2021 Oct 1;7(10):1521-1528. doi: 10.1001/jamaoncol.2021.2723.
PMID: 34410295
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA.
Cancer Immunol Res. 2021 Oct;9(10):1202-1213. doi: 10.1158/2326-6066.CIR-20-0983. Epub 2021 Aug 13.
PMID: 34389558
Synthesis of tritium labeled 30-KDa PEG and conjugation to form [3 H]Pegbelfermin.
Easter JA, Tian Y, Burrell RC, Hong Y, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm. 2021 Oct;64(12):477-481. doi: 10.1002/jlcr.3940. Epub 2021 Aug 23.
PMID: 34386991
Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys.
Thompson KE, Guillot M, Graziano MJ, Mangipudy RS, Chadwick KD.
Toxicol Appl Pharmacol. 2021 Oct 1;428:115673. doi: 10.1016/j.taap.2021.115673. Epub 2021 Aug 6.
PMID: 34364948
Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes.
Oorts M, an Brantegem P, Deferm N, Chatterjee S, Dreesen E, Cooreman A, Vinken M, Richert L, Annaert P.
J Pharmacol Exp Ther. 2021 Oct;379(1):20-32. doi: 10.1124/jpet.121.000695. Epub 2021 Aug 4.
PMID: 34349015
An Intercompany Perspective on Compatibility and In-use Stability Studies to Enable Administration Of Biopharmaceutical Drug Products.
Kamen DE, Crotts G, Narasimhan C, Hu Q, Bhargava AC, Muthurania K, Burton L, Gbormittah FO, Mathews L, Mills B, Hodge T, Saluja S, Singh SN, Tabish T, Wu Y, Stokes ESE.
J Pharm Sci. 2021 Sep 30:S0022-3549(21)00504-9. doi: 10.1016/j.xphs.2021.09.043. Online ahead of print.
PMID: 34600941
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group.
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
PMID: 34587385
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.
Van Bockstal MR, Cooks M, Nederlof I, Brinkhuis M, Dutman A, Koopmans M, Kooreman L, van der Vegt B, Verhoog L, Vreuls C, Westenend P, Kok M, van Diest PJ, Nauwelaers I, Laudus N, Denkert C, Rimm D, Siziopikou KP, Ely S, Zardavas D, Roberts M, Floris G, Hartman J, Acs B, Peeters D, Bartlett JMS, Dequeker E, Salgado R, Giudici F, Michiels S, Horlings H, van Deurzen CHM.
Cancers (Basel). 2021 Sep 29;13(19):4910. doi: 10.3390/cancers13194910.
PMID: 34638394
Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M.
Jpn J Clin Oncol. 2021 Sep 29:hyab161. doi: 10.1093/jjco/hyab161. Online ahead of print.
PMID: 34585728
Ensuring exchangeability in data-based priors for a Bayesian analysis of clinical trials.
Lin J, Gamalo-Siebers M, Tiwari R.
Pharm Stat. 2021 Sep 29. doi: 10.1002/pst.2172. Online ahead of print.
PMID: 34585501
Derivatization and determination of residual N,N-Carbonyldiimidazole by LC for an in-process control test.
Borges-Muñoz A, Patel H, Tattersall P.
J Pharm Biomed Anal. 2021 Sep 28;207:114395. doi: 10.1016/j.jpba.2021.114395. Online ahead of print.
PMID: 34628292
Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.
Wang T, Kadow JF, Meanwell NA.
Med Chem Res. 2021 Sep 28:1-26. doi: 10.1007/s00044-021-02787-6. Online ahead of print.
PMID: 34602806
G protein-coupled receptor kinase 5 regulates thrombin signaling in platelets via PAR-1.
Downes K, Zhao X, Gleadall NS, McKinney H, Kempster C, Batista J, Thomas P, Cooper M, Michael JV, Kreuzhuber R, Wedderburn K, Waller K, Varney B, Verdier H, Kriek N, Ashford SE, Stirrups KE, Dunster JL, McKenzie SE, Ouwehand WH, Gibbins JM, Yang J, Astle WJ, Ma P.
Blood Adv. 2021 Sep 28:bloodadvances.2021005453. doi: 10.1182/bloodadvances.2021005453. Online ahead of print.
PMID: 34581777
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics.
Chen G, Tao L, Li Z.
Drug Discov Today. 2021 Sep 24:S1359-6446(21)00404-9. doi: 10.1016/j.drudis.2021.09.010. Online ahead of print.
PMID: 34571276
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D.
Clin Transl Sci. 2021 Sep 24. doi: 10.1111/cts.13148. Online ahead of print.
PMID: 34558200
Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality.
Das TK, Sreedhara A, Colandene JD, Chou DK, Filipe V, Grapentin C, Searles J, Christian TR, Narhi LO, Jiskoot W. J Pharm Sci. 2021 Sep 23:S0022-3549(21)00500-1. doi: 10.1016/j.xphs.2021.09.030. Online ahead of print.
PMID: 34563537
Matrix and Sampling Effects on Quantification of Protein Biomarkers of Drug-Induced Liver Injury.
Anselm V, Sommersdorf C, Carrasco-Triguero M, Katavolos P, Planatscher H, Steinhilber A, Joos T, Poetz O.
J Proteome Res. 2021 Sep 23. doi: 10.1021/acs.jproteome.1c00478. Online ahead of print.
PMID: 34554759
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK.
JAMA Oncol. 2021 Sep 23:e213836. doi: 10.1001/jamaoncol.2021.3836. Online ahead of print.
PMID: 34554208
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH.
Haematologica. 2021 Sep 23. doi: 10.3324/haematol.2021.279174. Online ahead of print.
PMID: 34551506
XRCC3 loss leads to midgestational embryonic lethality in mice.
Prakash R, Freyer L, Saiz N, Gavrilov S, Wang RQ, Romanienko PJ, Lacy E, Hadjantonakis AK, Jasin M.
DNA Repair (Amst). 2021 Sep 22;108:103227. doi: 10.1016/j.dnarep.2021.103227. Online ahead of print.
PMID: 34601382
Nature Chose Phosphates and Chemists Should Too: How Emerging P(V) Methods Can Augment Existing Strategies.
Knouse KW, Flood DT, Vantourout JC, Schmidt MA, Mcdonald IM, Eastgate MD, Baran PS.
ACS Cent Sci. 2021 Sep 22;7(9):1473-1485. doi: 10.1021/acscentsci.1c00487. Epub 2021 Sep 10.
PMID: 34584948
TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, Clementelli C, Denis JF, Rahman AH, Tremblay G, Mascarenhas J, Mesa RA, O'Connor-McCourt M, Migliaccio AR, Hoffman R.
JCI Insight. 2021 Sep 22;6(18):e145651. doi: 10.1172/jci.insight.145651.
PMID: 34383713
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer.
Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, Klem C, Ferri M, Jiang J, Yuce H, Lip GYH.
JACC CardioOncol. 2021 Sep 21;3(3):411-424. doi: 10.1016/j.jaccao.2021.06.004. eCollection 2021 Sep.
PMID: 34604802
HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
Rigby W, Buckner JH, Louis Bridges S Jr, Nys M, Gao S, Polinsky M, Ray N, Bykerk V.
Arthritis Res Ther. 2021 Sep 18;23(1):245. doi: 10.1186/s13075-021-02607-7.
PMID: 34537057
Application of natural language processing techniques to identify off-label drug usage from various online health communities.
Dreyfus B, Chaudhary A, Bhardwaj P, Shree VK.
J Am Med Inform Assoc. 2021 Sep 18;28(10):2147-2154. doi: 10.1093/jamia/ocab124.
PMID: 34333625
Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine-1 Phosphate Receptor Subtypes 1 and 5.
Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R.
J Pharmacol Exp Ther. 2021 Sep 17:JPET-AR-2021-000741. doi: 10.1124/jpet.121.000741. Online ahead of print.
PMID: 34535564
Identifying transcriptional programs underlying cancer drug response with TraCe-seq.
Chang MT, Shanahan F, Nguyen TTT, Staben ST, Gazzard L, Yamazoe S, Wertz IE, Piskol R, Yang YA, Modrusan Z, Haley B, Evangelista M, Malek S, Foster SA, Ye X.
Nat Biotechnol. 2021 Sep 16. doi: 10.1038/s41587-021-01005-3. Online ahead of print.
PMID: 34531539
Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.
Gorovits B, Azadeh M, Buchlis G, Harrison T, Havert M, Jawa V, Long B, McNally J, Milton M, Nelson R, O'Dell M, Richards K, Vettermann C, Wu B.
AAPS J. 2021 Sep 16;23(6):108. doi: 10.1208/s12248-021-00628-3.
PMID: 34529177
Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies.
McMahon ME, Abbott A, Babayan Y, Carhart J, Chen CW, Debie E, Fu M, Hoaglund-Hyzer C, Lennard A, Li H, Mazzeo T, McCaig L, Pischel S, Qiu F, Stephens D, Timpano R, Webb D, Wolfe C, Woodlief K, Wu Y. AAPS
J. 2021 Sep 16;23(6):107. doi: 10.1208/s12248-021-00641-6.
PMID: 34529169
GPR120 inhibits colitis through regulation of CD4+T cell IL-10 production.
Yang W, Liu H, Xu L, Yu T, Zhao X, Yao S, Zhao Q, Barnes S, Cohn SM, Dann SM, Zhang H, Zuo X, Li Y, Cong Y.
Gastroenterology. 2021 Sep 15:S0016-5085(21)03497-1. doi: 10.1053/j.gastro.2021.09.018. Online ahead of print.
PMID: 34536451
Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative.
Snee M, Cheeseman S, Thompson M, Riaz M, Sopwith W, Lacoin L, Chaib C, Daumont MJ,Penrod JR, Hall G.
BMJ Open. 2021 Sep 15;11(9):e046396. doi: 10.1136/bmjopen-2020-046396.
PMID: 34526333
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA.
Invest New Drugs. 2021 Sep 13. doi: 10.1007/s10637-021-01175-6. Online ahead of print.
PMID: 34515877
Age-Related Change in Hepatic Clearance Inferred from Multiple Population Pharmacokinetic Studies: Comparison with Renal Clearance and Their Associations with Organ Weight and Blood Flow.
Soejima K, Sato H, Hisaka A.
Clin Pharmacokinet. 2021 Sep 13. doi: 10.1007/s40262-021-01069-z. Online ahead of print.
PMID: 34514537
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.
Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D.
Support Care Cancer. 2021 Sep 11. doi: 10.1007/s00520-021-06514-0. Online ahead of print.
PMID: 34510238
Decreased cortical Nrf2 gene expression in autism and its relationship to thiol and cobalamin status.
Schrier MS, Zhang Y, Trivedi MS, Deth RC.
Biochimie. 2021 Sep 10:S0300-9084(21)00209-1. doi: 10.1016/j.biochi.2021.09.006. Online ahead of print.
PMID: 34517051
A P(V) platform for oligonucleotide synthesis.
Huang Y, Knouse KW, Qiu S, Hao W, Padial NM, Vantourout JC, Zheng B, Mercer SE, Lopez-Ogalla J, Narayan R, Olson RE, Blackmond DG, Eastgate MD, Schmidt MA, McDonald IM, Baran PS.
Science. 2021 Sep 10;373(6560):1265-1270. doi: 10.1126/science.abi9727. Epub 2021 Sep 9.
PMID: 34516793
Surrogate model to screen for inactivation-based clearance of enveloped viruses during biotherapeutics process development.
Feroz H, Cetnar D, Hewlett R, Sharma S, Holstein M, Ghose S, Li ZJ.
Biotechnol J. 2021 Sep 10:e2100176. doi: 10.1002/biot.202100176. Online ahead of print.
PMID: 34506679
Engineering an Antibody V Gene-Selective Vaccine.
Ronsard L, Yousif AS, Peabody J, Okonkwo V, Devant P, Mogus AT, Barnes RM, Rohrer D, Lonberg N, Peabody D, Chackerian B, Lingwood D.
Front Immunol. 2021 Sep 9;12:730471. doi: 10.3389/fimmu.2021.730471. eCollection 2021.
PMID: 34566992
18 F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
Nienhuis PH, Antunes IF, Glaudemans AWJM, Jalving M, Leung D, Noordzij W, Slart RHJA, de Vries EF, Hospers GAP.
J Nucl Med. 2021 Sep 9:jnumed.121.262368. doi: 10.2967/jnumed.121.262368. Online ahead of print.
PMID: 34503964
Mild and Chemoselective Phosphorylation of Alcohols Using a Ψ-Reagent.
Ociepa M, Knouse KW, He D, Vantourout JC, Flood DT, Padial NM, Chen JS, Sanchez BB, Sturgell EJ, Zheng B, Qiu S, Schmidt MA, Eastgate MD, Baran PS.
Org Lett. 2021 Sep 9. doi: 10.1021/acs.orglett.1c02736. Online ahead of print.
PMID: 34499517
Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.
Elsner J, Cashion D, Robinson D, Bahmanyar S, Tehrani L, Fultz KE, Narla RK, Peng X, Tran T, Apuy J, LeBrun L, Leftheris K, Boylan JF, Zhu D, Riggs JR.
J Med Chem. 2021 Sep 9;64(17):12670-12679. doi: 10.1021/acs.jmedchem.1c00635. Epub 2021 Aug 30.
PMID: 34459599
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD Jr, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R, Grote L, Peluso T, Dimopoulos M.
Eur J Haematol. 2021 Sep 8. doi: 10.1111/ejh.13706. Online ahead of print.
PMID: 34496096
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
Dilger AK, Pabbisetty KB, Corte JR, De Lucca I, Fang T, Yang W, Pinto DJP, Wang Y, Zhu Y, Mathur A, Li J, Hou X, Smith D, Sun D, Zhang H, Krishnananthan S, Wu DR, Myers JE Jr, Sheriff S, Rossi KA, Chacko S, Zheng JJ, Galella MA, Ziemba T, Dierks EA, Bozarth JM, Wu Y, Crain E, Wong PC, Luettgen JM, Wexler RR, Ewing WR.
J Med Chem. 2021 Sep 8. doi: 10.1021/acs.jmedchem.1c00613. Online ahead of print.
PMID: 34494428
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG, Kuruvilla J, Liu FF, Kostic A, Kim Y, Bonner A, Zhang Y, Fox CP, Cartron G.
J Hematol Oncol. 2021 Sep 8;14(1):140. doi: 10.1186/s13045-021-01144-9.
PMID: 34493319
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A.
Front Oncol. 2021 Sep 6;11:696512. doi: 10.3389/fonc.2021.696512. eCollection 2021.
PMID: 34552864
Drug-Polymer Interactions in Acetaminophen/Hydroxypropylmethylcellulose Acetyl Succinate Amorphous Solid Dispersions Revealed by Multidimensional Multinuclear Solid-State NMR Spectroscopy.
Pugliese A, Toresco M, McNamara D, Iuga D, Abraham A, Tobyn M, Hawarden LE, Blanc F.
Mol Pharm. 2021 Sep 6;18(9):3519-3531. doi: 10.1021/acs.molpharmaceut.1c00427. Epub 2021 Aug 10.
PMID: 34375100
Quantitative GC determination of sodium triacetoxyborohydride (STAB).
Hale I, Chadwick J, Wethman R.
J Pharm Biomed Anal. 2021 Sep 5;203:114213. doi: 10.1016/j.jpba.2021.114213. Epub 2021 Jun 16.
PMID: 34252843
Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance.
Harigai M, Tsuritani K, Yoshizawa Y, Atsumi T, Tanaka Y.
Mod Rheumatol. 2021 Sep 4:roab050. doi: 10.1093/mr/roab050. Online ahead of print.
PMID: 34910191
The Super-Relaxed State and Length Dependent Activation in Porcine Myocardium.
Ma W, Henze M, Anderson RL, Gong H, Wong FL, Del Rio CL, Irving T.
Circ Res. 2021 Sep 3;129(6):617-630. doi: 10.1161/CIRCRESAHA.120.318647. Epub 2021 Aug 9.
PMID: 34365814
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. Reply.
Bajorin DF, Collette S, Galsky MD.
N Engl J Med. 2021 Sep 2;385(10):957. doi: 10.1056/NEJMc2110897.
PMID: 34469656
Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view.
Thielen FW, Kersten MJ, Kuizenga P, Hoogendoorn M, Posthuma EF, Stevens WB, A Uyl-de Groot C, Blommestein HM.
Expert Rev Anticancer Ther. 2021 Sep 2:1-12. doi: 10.1080/14737140.2021.1971520. Online ahead of print.
PMID: 34428992
Structure of the human marker of self 5-transmembrane receptor CD47.
Fenalti G, Villanueva N, Griffith M, Pagarigan B, Lakkaraju SK, Huang RY, Ladygina N, Sharma A, Mikolon D, Abbasian M, Johnson J, Hadjivassiliou H, Zhu D, Chamberlain PP, Cho H, Hariharan K.
Nat Commun. 2021 Sep 1;12(1):5218. doi: 10.1038/s41467-021-25475-w.
PMID: 34471125
Nickel-Catalyzed 1,2-Carboamination of Alkenyl Alcohols.
Kang T, Kim N, Cheng PT, Zhang H, Foo K, Engle KM.
J Am Chem Soc. 2021 Sep 1;143(34):13962-13970. doi: 10.1021/jacs.1c07112. Epub 2021 Aug 20.
PMID: 34415748
Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.
Annavarapu S, Gogate A, Pham T, Davies K, Singh P, Robert N.
CNS Oncol. 2021 Sep 1;10(3):CNS76. doi: 10.2217/cns-2021-0007. Epub 2021 Aug 11.
PMID: 34378977
Performance of 3 Composite Measures for Disease Activity in Peripheral Spondyloarthritis.
Beckers E, Been M, Webers C, Boonen A, Ten Klooster PM, Vonkeman HE, van Tubergen A.
J Rheumatol. 2021 Sep 1:jrheum.210075. doi: 10.3899/jrheum.210075. Online ahead of print.
PMID: 34470791
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Desai MY, Wolski K, Owens A, Naidu SS, Geske JB, Smedira NG, Schaff H, Lampl K, McErlean E, Sewell C, Zhang D, Edelberg JM, Sehnert AJ, Nissen SE.
Am Heart J. 2021 Sep;239:80-89. doi: 10.1016/j.ahj.2021.05.007. Epub 2021 May 24.
PMID: 34038706
Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
Frost C, Garonzik S, Shenker A, Barrett YC, LaCreta F.
Clin Pharmacol Drug Dev. 2021 Sep;10(9):974-984. doi: 10.1002/cpdd.990. Epub 2021 Aug 2.
PMID: 34342172
Cloud solutions for GxP laboratories: considerations for data storage.
Davis S, Usansky J, Mitra-Kaushik S, Kellie J, Honrine K, Woolf E, Adams J, Kelly R, Evens J, Pine S, Hochreiner H, Dawes M, Kentner J,
Crawford S. Bioanalysis. 2021 Sep;13(17):1313-1321. doi: 10.4155/bio-2021-0137. Epub 2021 Sep 13.
PMID: 34515519
Mapping EQ-5D-3L to EQ-5D-5L.
van Hout BA, Shaw JW.
Value Health. 2021 Sep;24(9):1285-1293. doi: 10.1016/j.jval.2021.03.009. Epub 2021 May 18.
PMID: 34452708
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
de Botton S, Brandwein JM, Wei AH, Pigneux A, Quesnel B, Thomas X, Legrand O, Recher C, Chantepie S, Hunault-Berger M, Boissel N, Nehme SA, Frattini MG, Tosolini A, Marion-Gallois R, Wang JJ, Cameron C, Siddiqui M, Hutton B, Milkovich G, Stein EM.
Cancer Med. 2021 Sep;10(18):6336-6343. doi: 10.1002/cam4.4182. Epub 2021 Aug 24.
PMID: 34427990
Reduced Compensatory β-Cell Proliferation in Nfatc3-Deficient Mice Fed on High-Fat Diet.
Hu L, He F, Luo Y, Luo H, Hai L, Li Y, Zhou Z, Liu F, Dai YS.
Exp Clin Endocrinol Diabetes. 2021 Sep;129(9):651-660. doi: 10.1055/a-1008-9110. Epub 2019 Sep 23.
PMID: 31546271
Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues.
Li QH, Deng Q, Ting N.
Ther Innov Regul Sci. 2021 Sep;55(5):1001-1005. doi: 10.1007/s43441-021-00299-4. Epub 2021 May 24.
PMID: 34028669
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Ogasawara K, Kam J, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2021 Sep;88(3):369-377. doi: 10.1007/s00280-021-04292-4. Epub 2021 May 21.
PMID: 34019108
A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma.
Ozawa T, Rodriguez M, Zhao G, Yao TW, Fischer WN, Jandeleit B, Koller K, Nicolaides T.
Cureus. 2021 Aug 31;13(8):e17595. doi: 10.7759/cureus.17595. eCollection 2021 Aug.
PMID: 34646647
Prospective Prediction of Plasma Pharmacokinetics of a Novel Immune-modulating Agent in Cancer Patients after Intra-tumoral Administration: Translation from Non-clinical Species to Humans.
Vuppugalla R, Sane R, Wichroski M, Gavai AK, Boyanapalli S, Yang Z.
Xenobiotica. 2021 Aug 31:1-30. doi: 10.1080/00498254.2021.1934606. Online ahead of print.
PMID: 34461800
Fast and high-resolution purification of a PEGylated protein using a z2 laterally-fed membrane chromatography device.
Chen G, Pagano J, Yu D, Ghose S, Li Z, Ghosh R.
J Chromatogr A. 2021 Aug 30;1652:462375. doi: 10.1016/j.chroma.2021.462375. Epub 2021 Jun 29.
PMID: 34256267
Factors associated with opioid prescriptions among women proximal to pregnancy in the United States.
Chen G, Delcher C, Xiao H, Roussos-Ross D, Huo J, Chen X.
Res Social Adm Pharm. 2021 Aug;17(8):1483-1488. doi: 10.1016/j.sapharm.2020.11.008. Epub 2020 Nov 17.
PMID: 33234451
Sub/supercritical Fluid Chromatography Purification and Desalting of a Cyclic Dinucleotide STING Agonist.
Li P, Yip H, Sun D, Kempson J, Caceres-Cortes J, Mathur A, Wu DR.
J Chromatogr A. 2021 Aug 30;1652:462356. doi: 10.1016/j.chroma.2021.462356. Epub 2021 Jun 22.
PMID: 34218126
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
Gasparetto C, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Ailawadhi S, Omel JL, Srinivasan S, Dhalla M, Catamero D, Kitali A, Agarwal A, Abonour R; Connect MM Registry Investigators.
Clin Lymphoma Myeloma Leuk. 2021 Aug 29:S2152-2650(21)00365-7. doi: 10.1016/j.clml.2021.08.007.
PMID: 34588149
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F, Roboz GJ, Wei AH, Döhner H, Pocock C, Selleslag D, Montesinos P, Sayar H, Musso M, Figuera-Alvarez A, Safah H, Tse W, Sohn SK, Hiwase D, Chevassut T, Pierdomenico F, La Torre I, Skikne B, Bailey R, Zhong J, Beach CL, Dombret H.
J Hematol Oncol. 2021 Aug 28;14(1):133. doi: 10.1186/s13045-021-01142-x.
PMID: 34454540
Patient-Specific Cell Communication Networks Associate With Disease Progression in Cancer.
Gibbs DL, Aguilar B, Thorsson V, Ratushny AV, Shmulevich I.
Front Genet. 2021 Aug 27;12:667382. doi: 10.3389/fgene.2021.667382. eCollection 2021.
PMID: 34512714
Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV.
AAPS J. 2021 Aug 27;23(5):103. doi: 10.1208/s12248-021-00623-8.
PMID: 34453265
No ordinary proteins: Adsorption and molecular orientation of monoclonal antibodies.
Kanthe A, Ilott A, Krause M, Zheng S, Li J, Bu W, Bera MK, Lin B, Maldarelli C, Tu RS.
Sci Adv. 2021 Aug 27;7(35):eabg2873. doi: 10.1126/sciadv.abg2873. Print 2021 Aug.
PMID: 34452912
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.
Papa P, Whitefield B, Mortensen DS, Cashion D, Huang D, Torres E, Parnes J, Sapienza J, Hansen J, Correa M, Delgado M, Harris R, Hegde S, Norris S, Bahmanyar S, Plantevin-Krenitsky V, Liu Z, Leftheris K, Kulkarni A, Bennett B, Hur EM, Ringheim G, Khambatta G, Chan H, Muir J, Blease K, Burnett K, LeBrun L, Morrison L, Celeridad M, Khattri R, Cathers BE.
J Med Chem. 2021 Aug 26;64(16):11886-11903. doi: 10.1021/acs.jmedchem.1c00388. Epub 2021 Aug 6.
PMID: 34355886
High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study.
Behrens F, Rech J, Thaçi D, Zinke S, Rothnie KJ, Oefner Daamen C, Leipe J.
Mod Rheumatol. 2021 Aug 26:1816597. doi: 10.1080/14397595.2020.1816597. Online ahead of print.
PMID: 34922390
Brief Synopsis: "Instruction Manual for Juvenile Clinical Pathology".
Provencher A, Katavolos P.
Toxicol Pathol. 2021 Aug 25:1926233211041338. doi: 10.1177/01926233211041338. Online ahead of print.
PMID: 34431401
The proliferation of belatacept-resistant T cells requires early IFNα pathway activation.
Herr F, Desterke C, Bargiel K, Vernochet A, Vanhove B, Vadanici R, Ye F, Dekeyser M, Durrbach A.
Am J Transplant. 2021 Aug 24. doi: 10.1111/ajt.16811. Online ahead of print.
PMID: 34431219
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones JA, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L, Leonard JP.
Blood. 2021 Aug 24:blood.2021011679. doi: 10.1182/blood.2021011679. Online ahead of print.
PMID: 34428285
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic.
Leung D, Bonacorsi S, Smith RA, Weber W, Hayes W.
Front Oncol. 2021 Aug 23;11:698425. doi: 10.3389/fonc.2021.698425. eCollection 2021.
PMID: 34497758
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction.
García RA, Lupisella JA, Ito BR, Hsu MY, Fernando G, Carson NL, Allocco JJ, Ryan CS, Zhang R, Wang Z, Heroux M, Carrier M, St-Onge S, Bouvier M, Dudhgaonkar S, Nagar J, Bustamante-Pozo MM, Garate-Carrillo A, Chen J, Ma X, Search DJ, Dierks EA, Kick EK, Wexler RR, Gordon DA, Ostrowski J, Wurtz NR, Villarreal F.
JACC Basic Transl Sci. 2021 Aug 23;6(8):676-689. doi: 10.1016/j.jacbts.2021.07.007. eCollection 2021 Aug.
PMID: 34466754
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Forsberg PA, Rossi AC, Boyer A, Pearse RN, Pekle KA, Jayabalan D, Lakritz S, Flicker K, Ribadeneyra D, Liotta B, Ely S, Boussi L, Allan JN, Coleman M, Niesvizky R, Mark TM.
Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26329. Online ahead of print.
PMID: 34424561
Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.
Tsutsué S, Makita S, Yi J, Crawford B.
Future Oncol. 2021 Aug 20:10.2217/fon-2021-0400. doi: 10.2217/fon-2021-0400. Online ahead of print.
PMID: 34414783
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.
Anisul M, Shilts J, Schwartzentruber J, Hayhurst J, Buniello A, Shaikho Elhaj Mohammed E, Zheng J, Holmes M, Ochoa D, Carmona M, Maranville J, Gaunt TR, Emilsson V, Gudnason V, McDonagh EM, Wright GJ, Ghoussaini M, Dunham I.
Elife. 2021 Aug 17;10:e69719. doi: 10.7554/eLife.69719.
PMID: 34402426
A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses.
Cimen Bozkus C, Blazquez AB, Enokida T, Bhardwaj N.
STAR Protoc. 2021 Aug 17;2(3):100758. doi: 10.1016/j.xpro.2021.100758. eCollection 2021 Sep 17.
PMID: 34458873
The effect of water on the large-scale supercritical fluid chromatography purification of two factor XIa active pharmaceutical ingredients.
Li P, Wu DR, Yip H, Sun D, Zhang H, Hou X, Kempson J, Mathur A.
J Chromatogr A. 2021 Aug 16;1651:462318. doi: 10.1016/j.chroma.2021.462318. Epub 2021 Jun 4.
PMID: 34161834
Large-scale supercritical fluid chromatography purification of unstable STING agonist intermediates.
Sun D, Wu DR, Li P, Yip H, Wang B, Hou X, Zhao R, Zhang H, Kempson J, Mathur A.
J Chromatogr A. 2021 Aug 16;1651:462309. doi: 10.1016/j.chroma.2021.462309. Epub 2021 Jun 6.
PMID: 34147835
A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.
Oliva EN, Ronnebaum SM, Zaidi O, Patel DA, Nehme SA, Chen C, Almeida AM.
Am J Blood Res. 2021 Aug 15;11(4):325-360. eCollection 2021.
PMID: 34540343
Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.
Okubo Y, Ohtsuki M, Komine M, Imafuku S, Kassir N, Petric R, Nemoto O.
J Dermatol. 2021 Aug 15. doi: 10.1111/1346-8138.16068. Online ahead of print.
PMID: 34396569
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA, Maity TK, Cultraro CM, Misra V, Zhang X, Ade C, Gao S, Milewski D, Nguyen KD, Ebrahimabadi MH, Hanada KI, Khan J, Sahinalp C, Yang JC, Guha U.
Mol Cell Proteomics. 2021 Aug 13;20:100136. doi: 10.1016/j.mcpro.2021.100136. Online ahead of print.
PMID: 34391887
Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study.
Tanaka Y, Matsubara T, Hashizume K, Amano N, Takeuchi T.
Mod Rheumatol. 2021 Aug 13:roab029. doi: 10.1093/mr/roab029. Online ahead of print.
PMID: 34897499
Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Takeno M, Dobashi H, Tanaka Y, Kono H, Sugii S, Kishimoto M, Cheng S, McCue S, Paris M, Chen M, Ishigatsubo Y.
Mod Rheumatol. 2021 Aug 12:roab008. doi: 10.1093/mr/roab008. Online ahead of print.
PMID: 34894266
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Young MH, Pietz G, Whalen E, Copeland W, Thompson E, Fox BA, Newhall KJ.
Sci Rep. 2021 Aug 12;11(1):16460. doi: 10.1038/s41598-021-95902-x.
PMID: 34385543
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
Hartz RA, Ahuja VT, Nara SJ, Kumar CMV, Brown JM, Bristow LJ, Rajamani R, Muckelbauer JK, Camac D, Kiefer SE, Hunihan L, Gulianello M, Lewis M, Easton A, Lippy JS, Surti N, Pattipati SN, Dokania M, Elavazhagan S, Dandapani K, Hamman BD, Allen J, Kostich W, Bronson JJ, Macor JE, Dzierba CD.
J Med Chem. 2021 Aug 12;64(15):11090-11128. doi: 10.1021/acs.jmedchem.1c00472. Epub 2021 Jul 16.
PMID: 34270254
Effective anti-BCMA retreatment in multiple myeloma.
Gazeau N, Beauvais D, Yakoub-Agha I, Mitra S, Campbell TB, Facon T, Manier S.
Blood Adv. 2021 Aug 10;5(15):3016-3020. doi: 10.1182/bloodadvances.2021004176.
PMID: 34351389
A chemoproteomics approach to determine the mechanism of testicular toxicity for the Bruton's tyrosine kinase inhibitor CC-292.
Labenski M, Voortman L, Medikonda AP, Sherratt PJ, Corin AF.
J Pharmacol Exp Ther. 2021 Aug 9:JPET-AR-2021-000614. doi: 10.1124/jpet.121.000614. Online ahead of print.
PMID: 34373353
Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment.
Frost CE, Ly V, Garonzik SM.
Drugs R D. 2021 Aug 7. doi: 10.1007/s40268-021-00359-y. Online ahead of print.
PMID: 34363188
Characteristics and outcomes of hospitalised adults with COVID-19 in a Global Health Research Network: a cohort study.
Zhu J, Wei Z, Suryavanshi M, Chen X, Xia Q, Jiang J, Ayodele O, Bradbury BD, Brooks C, Brown CA, Cheng A, Critchlow CW, Devercelli G, Gandhi V, Gondek K, Londhe AA, Ma J, Jonsson-Funk M, Keenan HA, Manne S, Ren K, Sanders L, Yu P, Zhang J, Zhou L, Bao Y.
BMJ Open. 2021 Aug 6;11(8):e051588. doi: 10.1136/bmjopen-2021-051588.
PMID: 34362806
Scalable Asymmetric Synthesis of the All  Cis  Triamino Cyclohexane Core of BMS-813160.
La Cruz TE, González-Bobes F, Eastgate MD, Sfouggatakis C, Zheng B, Kopp N, Xiao Y, Fan Y, Galindo KA, Pathirana C, Galella MA, Deerberg J.
J Org Chem. 2021 Aug 6. doi: 10.1021/acs.joc.1c01162. Online ahead of print.
PMID: 34355895
Radical Perfluoroalkylation of Arenes via Carbanion Intermediates.
Hernandez LW, Gallagher WP, Guerrero CA, Gonzalez-Bobes F, Coombs JR.
J Org Chem. 2021 Aug 6;86(15):10903-10913. doi: 10.1021/acs.joc.1c01296. Epub 2021 Jul 21.
PMID: 34286987
A Process Chemistry Benchmark for sp 2 -sp 3  Cross Couplings.
Beutner GL, Simmons EM, Ayers S, Bemis CY, Goldfogel MJ, Joe CL, Marshall J, Wisniewski SR.
J Org Chem. 2021 Aug 6;86(15):10380-10396. doi: 10.1021/acs.joc.1c01073. Epub 2021 Jul 13.
PMID: 34255510
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Carpenter J, Wu G, Wang Y, Cook EM, Wang T, Sitkoff D, Rossi KA, Mosure K, Zhuo X, Cao GG, Ziegler M, Azzara AV, Krupinski J, Soars MG, Ellsworth BA, Wacker DA.
ACS Med Chem Lett. 2021 Aug 5;12(9):1413-1420. doi: 10.1021/acsmedchemlett.1c00198. eCollection 2021 Sep 9.
PMID: 34531950
Quantification of azacitidine incorporation into human DNA/RNA by accelerator mass spectrometry as direct measure of target engagement.
Wang X, Vaes WHJ, van Duijn E, Nooijen I, Tong Z, de Menezes DL, Maxwell SE.
J Pharm Biomed Anal. 2021 Aug 5;202:114152. doi: 10.1016/j.jpba.2021.114152. Epub 2021 May 19.
PMID: 34051483
Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M.
Jpn J Clin Oncol. 2021 Aug 4:hyab114. doi: 10.1093/jjco/hyab114. Online ahead of print.
PMID: 34350454
Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
Lip GYH, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, Klem C, Ferri M, Jiang J, Yuce H, Deitelzweig S.
JAMA Netw Open. 2021 Aug 2;4(8):e2120064. doi: 10.1001/jamanetworkopen.2021.20064.
PMID: 34398204
Cost-effectiveness of nivolumab in patients with NSCLC in the United States.
Chaudhary MA, Lubinga SJ, Smare C, Hertel N, Penrod JR.
Am J Manag Care. 2021 Aug 1;27(8):e254-e260. doi: 10.37765/ajmc.2021.88726.
PMID: 34460179
Psoriatic Arthritis Diagnosis and Management in the Era of Telehealth.
Han G.
Cutis. 2021 Aug;108(2S):5-6. doi: 10.12788/cutis.0313.
PMID: 34662272
Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond.
Milstone LM, Jackson C, Becker RC, Camire R, Knabb R, Mann K, Ruf W, Wexler RR, Wood J.
J Thromb Thrombolysis. 2021 Aug;52(2):408-413. doi: 10.1007/s11239-021-02545-w. Epub 2021 Oct 12.
PMID: 34637116
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.
Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, Taylor LS, Kumar S, Tony Zhou Q.
Acta Pharm Sin B. 2021 Aug;11(8):2505-2536. doi: 10.1016/j.apsb.2021.05.014. Epub 2021 Jun 5.
PMID: 34522596
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, Jones RL, Cranmer LD, Pollack SM.
J Immunother Cancer. 2021 Aug;9(8):e002812. doi: 10.1136/jitc-2021-002812.
PMID: 34465597
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino L, Atkinson V, Arenberger P, Hill A, Fecher L, Millward M, Khushalani NI, de Pril V, Lobo M, Weber J.
J Immunother Cancer. 2021 Aug;9(8):e003188. doi: 10.1136/jitc-2021-003188.
PMID: 34452930
Management of lung cancer patients' quality of life in clinical practice: a Delphi study.
Westeel V, Bourdon M, Cortot AB, Debieuvre D, Toffart AC, Acquadro M, Arnould B, Lambert J, Cotte FE, Gaudin AF, Lemasson H.
ESMO Open. 2021 Aug;6(4):100239. doi: 10.1016/j.esmoop.2021.100239. Epub 2021 Aug 10.
PMID: 34388690
Cycling cancer persister cells arise from lineages with distinct programs.
Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, Hu B, Thakore PI, Tabaka M, Fulco CP, Colgan W, Cuevas BM, Hurvitz SA, Slamon DJ, Deik A, Pierce KA, Clish C, Hata AN, Zaganjor E, Lahav G, Politi K, Brugge JS, Regev A.
Nature. 2021 Aug;596(7873):576-582. doi: 10.1038/s41586-021-03796-6. Epub 2021 Aug 11.
PMID: 34381210
From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis.
Knabb RM, Wexler RR.
J Thromb Thrombolysis. 2021 Aug;52(2):403-407. doi: 10.1007/s11239-021-02529-w. Epub 2021 Aug 5.
PMID: 34351559
Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Snyder S, Albertson T, Garcia J, Gitlin M, Jun MP.
Adv Ther. 2021 Aug;38(8):4541-4555. doi: 10.1007/s12325-021-01839-y. Epub 2021 Jul 18.
PMID: 34279805
Dynamin-dependent vesicle twist at the final stage of clathrin-mediated endocytosis.
Cheng X, Chen K, Dong B, Yang M, Filbrun SL, Myoung Y, Huang TX, Gu Y, Wang G, Fang N.
Nat Cell Biol. 2021 Aug;23(8):859-869. doi: 10.1038/s41556-021-00713-x. Epub 2021 Jul 12.
PMID: 34253896
Concordance of 3 alternative teratogenicity assays with results from corresponding in vivo embryo-fetal development studies: Final report from the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) DruSafe working group 2.
McNerney M, Potter D, Augustine-Rauch K, Barrow P, Beyer B, Brannen K, Engel S, Enright BP, Nowland WS, Powles-Glover N, Powlin S, Schneidkraut MJ, Stanislaus D, Turner K, Graziano M.
Regul Toxicol Pharmacol. 2021 Aug;124:104984. doi: 10.1016/j.yrtph.2021.104984. Epub 2021 Jul 1.
PMID: 34216694
Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
Kaplan DL, Ung BL, Pelletier C, Udeze C, Khilfeh I, Tian M.
J Comp Eff Res. 2021 Aug;10(12):989-998. doi: 10.2217/cer-2020-0285. Epub 2021 Jun 30.
PMID: 34187202
Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor.
Chacko SA, Yang W, Wang Y, Tian Y, Hong Y, Wallace M, Wang B, Ewing WR, Luettgen JM, Shu YZ, Christopher LJ.
Xenobiotica. 2021 Aug;51(8):933-948. doi: 10.1080/00498254.2021.1943565. Epub 2021 Jul 5.
PMID: 34151691
Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X, Yuan H, Song Y, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S, Gao W, Sun D.
Biomaterials. 2021 Aug;275:120910. doi: 10.1016/j.biomaterials.2021.120910. Epub 2021 Jun 3.
PMID: 34144373
Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Soni M, Kiff C, Carroll R, Stein D, Saragoussi D, Nassar A, Maisey N, Tyas D.
Future Oncol. 2021 Aug;17(24):3163-3174. doi: 10.2217/fon-2021-0199. Epub 2021 Jun 8.
PMID: 34098737
TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study.
Bowles B, Ferrer A, Nishimura CJ, Pinto E Vairo F, Rey T, Leheup B, Sullivan J, Schoch K, Stong N, Agolini E, Cocciadiferro D, Williams A, Cummings A, Loddo S, Genovese S, Roadhouse C, McWalter K; Undiagnosed Diseases Network, Wentzensen IM, Li C, Babovic-Vuksanovic D, Lanpher BC, Dentici ML, Ankala A, Hamm JA, Dallapiccola B, Radio FC, Shashi V, Gérard B, Bloch-Zupan A, Smith RJ, Klee EW.
Am J Med Genet A. 2021 Aug;185(8):2417-2433. doi: 10.1002/ajmg.a.62347. Epub 2021 May 27.
PMID: 34042254
Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B.
Bai A, Shanmugasundaram V, Selkirk JV, Surapaneni S, Dalvie D.
Drug Metab Dispos. 2021 Aug;49(8):601-609. doi: 10.1124/dmd.121.000447. Epub 2021 May 19.
PMID: 34011531
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S.
Clin Lung Cancer. 2021 Jul 19:S1525-7304(21)00186-8. doi: 10.1016/j.cllc.2021.07.005. Online ahead of print.
PMID: 34489161
Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.
Hill MD, Fang H, Tokarski J, Fanslau C, Haarhoff Z, Huang C, Kramer M, Menard K, Monereau L, Morrison J, Ranasinghe A, Shields EE, Tye CK, Westhouse R, Everlof G, Sheriff S, Yan C, Marsilio F, Zhang L, Zvyaga T, Lee F, Gavai AV, Degnan AP.
Bioorg Med Chem Lett. 2021 Jul 15;44:128108. doi: 10.1016/j.bmcl.2021.128108. Epub 2021 May 13.
PMID: 33991625
Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis.
Erhardtsen E, Rasmussen DGK, Frederiksen P, Leeming DJ, Shevell D, Gluud LL, Karsdal MA, Aithal GP, Schattenberg JM.
JHEP Rep. 2021 Jul 10;3(4):100317. doi: 10.1016/j.jhepr.2021.100317. eCollection 2021 Aug.
PMID: 34466796
PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD.
Cohen CC, Castillo-Leon E, Farris AB, Caltharp SA, Cleeton RL, Sinclair EM, Shevell DE, Karsdal MA, Nielsen MJF, Leeming DJ, Vos MB.
Hepatol Commun. 2021 Jul 8. doi: 10.1002/hep4.1766. Online ahead of print.
PMID: 34558828
Apoptosis Marker Assays for HTS.
Riss TL, O’Brien MA, Moravec RA, Kupcho K, Niles AL.. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ Jr, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors.
Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–2021 Jul 1.
PMID: 34339159
A Novel Algorithm Using Within-leg Calibration for Enhanced Accuracy of Detection of Arthritis by Infrared Thermal Imaging in Children.
Zhao Y, Iyer RS, Thapa M, Biswas D, Bhide N, Scheck J, Cain K, Partridge SC, Wallace CA.
J Rheumatol. 2021 Jul 1:jrheum.210077. doi: 10.3899/jrheum.210077. Online ahead of print.
PMID: 34210832
Synthesis, structure-activity relationship studies and evaluation of a TLR 3/8/9 agonist and its analogues.
Sarkar A, Galasiti Kankanamalage AC, Zhang Q, Cheng H, Sivaprakasam P, Naglich J, Xie C, Gangwar S, Boger DL.
Med Chem Res. 2021 Jul;30(7):1377-1385. doi: 10.1007/s00044-021-02736-3. Epub 2021 May 18.
PMID: 34421287
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative.
Ekman S, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, Lacoin L, Daumont MJ, Penrod JR, Brustugun OT, Sørensen JB.
JTO Clin Res Rep. 2021 Mar 24;2(5):100165. doi: 10.1016/j.jtocrr.2021.100165. eCollection 2021 May.
PMID: 34590017
Atorvastatin and blood flow regulate expression of distinctive sets of genes in mouse carotid artery endothelium.
Kumar S, Sur S, Perez J, Demos C, Kang DW, Kim CW, Hu S, Xu K, Yang J, Jo H.
Curr Top Membr. 2021;87:97-130. doi: 10.1016/bs.ctm.2021.08.004. Epub 2021 Oct 6.
PMID: 34696890
Antibody blockade of CD96 by distinct molecular mechanisms.
Lee PS, Chau B, Barman I, Bee C, Jashnani A, Hogan JM, Aguilar B, Dollinger G, Rajpal A, Strop P.
MAbs. 2021 Jan-Dec;13(1):1979800. doi: 10.1080/19420862.2021.1979800.
PMID: 34595996
In Silico Meets In  Vitro  Techniques in ADMET Profiling of Drug Discovery (Part II).
Kar S, Chatterjee S.
Curr Drug Metab. 2021;22(7):502. doi: 10.2174/138920022207210812124757.
PMID: 34525918
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS, Li SS, Xie J, Sutton MB, Fine JT, Edelberg JM, Gao W, Spertus JA, Cohen DJ.
J Med Econ. 2021 Jan-Dec;24(1):1115-1123. doi: 10.1080/13696998.2021.1978242.
PMID: 34493144
Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate.
Qiu D, Huang Y, Chennamsetty N, Miller SA, Hay M.
MAbs. 2021 Jan-Dec;13(1):1974150. doi: 10.1080/19420862.2021.1974150.
PMID: 34486490
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
Smare C, Dave K, Juarez-Garcia A, Abraham P, Penrod JR, Camidge DR, Yuan Y.
J Med Econ. 2021 Jan-Dec;24(1):1124-1133. doi: 10.1080/13696998.2021.1974763.
PMID: 34465261
Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates.
Thompson JW, Clayton T, Khambatta G, Bateman LA, Carroll CW, Chamberlain PP, Matyskiela ME. Methods Mol Biol. 2021;2365:283-300. doi: 10.1007/978-1-0716-1665-9_15.
PMID: 34432250
Untargeted proteomics reveals upregulation of stress response pathways during CHO-based monoclonal antibody manufacturing process leading to disulfide bond reduction.
Park SY, Egan S, Cura AJ, Aron KL, Xu X, Zheng M, Borys M, Ghose S, Li Z, Lee K.
MAbs. 2021 Jan-Dec;13(1):1963094. doi: 10.1080/19420862.2021.1963094.
PMID: 34424810
The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model.
Sussman M, Di Fusco M, Tao CY, Guo JD, Gillespie JA, Ferri M, Adair N, Cato MS, Shirkhorshidian I, Barnes GD.
J Med Econ. 2021 Jan-Dec;24(1):1070-1082. doi: 10.1080/13696998.2021.1970954.
PMID: 34415229
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, Vannucchi A, Jurgutis M, Ribrag V, Rambaldi A, Koh LP, Rose S, Zhang J, Harrison C.Br J Haematol. 2021 Jul 30. doi: 10.1111/bjh.17727. Online ahead of print.
PMID: 34331348
Antibody toolkit reveals N-terminally ubiquitinated substrates of UBE2W.
Davies CW, Vidal SE, Phu L, Sudhamsu J, Hinkle TB, Chan Rosenberg S, Schumacher FR, Zeng YJ, Schwerdtfeger C, Peterson AS, Lill JR, Rose CM, Shaw AS, Wertz IE, Kirkpatrick DS, Koerber JT, et al.
Nat Commun. 2021 Jul 29;12(1):4608. doi: 10.1038/s41467-021-24669-6.
PMID: 34326324
Self-reporting data assets and their representation in the pharmaceutical industry.
Della Corte D, Colsman W, Fessenmayr H, Sawczuk da Silva A, Vanderwall DE, et al.
Drug Discov Today. 2021 Jul 28:S1359-6446(21)00328-7. doi: 10.1016/j.drudis.2021.07.019. Online ahead of print.
PMID: 34332096
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer BE, Landgren O, Lightbody ED, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner GA, Valente N, Weiss BM, Zamagni E, Kumar SK, et al.
Clin Cancer Res. 2021 Jul 28:clincanres.1059.2021. doi: 10.1158/1078-0432.CCR-21-1059. Online ahead of print.
PMID: 34321279
Real-World Treatment Patterns and Outcomes in Patients with Head and Neck Cancer: Point-in-Time Survey of Oncologists in Italy and Spain.
Singh P, Contente M, Bennett B, Hall J, Bailey H, Bailey A, Zarrelli L, Polanco Sanchez C, et al.
Adv Ther. 2021 Jul 28. doi: 10.1007/s12325-021-01851-2. Online ahead of print.
PMID: 34319551
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F, et al.
Blood Adv. 2021 Jul 27;5(14):2901-2908. doi: 10.1182/bloodadvances.2020004144.
PMID: 34297046
Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer's disease and related dementias (ADRD).
Zhang Y, Bian J, Huo J, Yang S, Guo Y, Shao H, et al.
Curr Med Res Opin. 2021 Jul 26:1-7. doi: 10.1080/03007995.2021.1953972. Online ahead of print.
PMID:  34252317
Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.
Baas P, Scherpereel A, Nowak AK, Oukessou A, Zalcman G, et al.
Lancet. 2021 Jul 24;398(10297):302. doi: 10.1016/S0140-6736(21)00876-X.
PMID: 34303436
Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe.
Singh P, Bennett B, Bailey T, Taylor-Stokes G, Rajkovic I, Contente M, Curtis S, Curtis C, et al.
BMC Cancer. 2021 Jul 24;21(1):854. doi: 10.1186/s12885-021-08557-2.
PMID: 34303346
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Snyder S, Chung KC, Jun MP, Gitlin M, et al.
Adv Ther. 2021 Jul 23. doi: 10.1007/s12325-021-01838-z. Online ahead of print.
PMID: 34302277
Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on αv Integrins.
Gallo E, Kelil A, Haughey M, Cazares-Olivera M, Yates BP, Zhang M, Wang NY, Blazer L, Carderelli L, Adams JJ, Kossiakoff AA, Wells JA, Xie W, Sidhu SS, et al.
J Mol Biol. 2021 Jul 23;433(15):167090. doi: 10.1016/j.jmb.2021.167090. Epub 2021 Jun 4.
PMID: 34090922
Specific White Matter Tracts and Diffusion Properties Predict Conversion From Mild Cognitive Impairment to Alzheimer's Disease.
Stone DB, Ryman SG, Hartman AP, Wertz CJ, Vakhtin AA; Alzheimer’s Disease Neuroimaging Initiative.
Front Aging Neurosci. 2021 Jul 23;13:711579. doi: 10.3389/fnagi.2021.711579. eCollection 2021.
PMID: 34366830
DGKζ exerts greater control than DGKα over CD8 +  T cell activity and tumor inhibition.
Gu J, Wang C, Cao C, Huang J, Holzhauer S, Desilva H, Wesley EM, Evans DB, Benci J, Wichroski M, Wee S, Riese MJ, et al.
Oncoimmunology. 2021 Jul 21;10(1):1941566. doi: 10.1080/2162402X.2021.1941566. eCollection 2021.
PMID: 34350062
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect ®  MM Registry.
Lee HC, Ailawadhi S, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Omel JL, Dhalla M, Liu L, Joshi P, Abonour R; Connect® MM Registry.
Blood Cancer J. 2021 Jul 23;11(7):134. doi: 10.1038/s41408-021-00524-1.
PMID: 34301916
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of phase 3 ozanimod trials.
Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA; ozanimod study investigators.
Eur J Neurol. 2021 Jul 22. doi: 10.1111/ene.15009. Online ahead of print.
PMID: 34292643
Transcriptome analysis reveals key genes modulated by ALK5 inhibition in a bleomycin model of systemic sclerosis.
Decato BE, Ammar R, Reinke-Breen L, Thompson JR, Azzara AV, et al.
Rheumatology (Oxford). 2021 Jul 21:keab580. doi: 10.1093/rheumatology/keab580. Online ahead of print.
PMID:  34289031
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma.
Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A, et al.
Oncotarget. 2021 Jul 20;12(15):1555-1563. doi: 10.18632/oncotarget.27973. eCollection 2021 Jul 20.
PMID: 34316334
Chemoselective, Scalable Nickel-Electrocatalytic O-Arylation of Alcohols.
Baran PS, Zhang HJ, Chen L, Oderinde MS, Edwards JT, Kawamata Y, et al.
Angew Chem Int Ed Engl. 2021 Jul 20. doi: 10.1002/anie.202107820. Online ahead of print.
PMID: 34288303
Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative.
Soares M, Antunes L, Redondo P, Borges M, Grimson F, Hermans R, Chaib C, Lacoin L, Juarez-Garcia A, Daumont MJ, Penrod JR, Bento MJ, Gonçalves FR, et al.
Eur J Cancer Care (Engl). 2021 Jul 20:e13496. doi: 10.1111/ecc.13496. Online ahead of print.
PMID: 34288191
Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30.
Piccinin C, Pe M, Kuliś D, Shaw JW, Wheelwright SJ, Bottomley A, et al.
Qual Life Res. 2021 Jul 20. doi: 10.1007/s11136-021-02955-6. Online ahead of print.
PMID: 34286416
The PROTACtable genome.
Schneider M, Radoux CJ, Hercules A, Ochoa D, Dunham I, Zalmas LP, Hessler G, Ruf S, Shanmugasundaram V, Hann MM, Thomas PJ, Queisser MA, Benowitz AB, Brown K, Leach AR, et al.
Nat Rev Drug Discov. 2021 Jul 20. doi: 10.1038/s41573-021-00245-x. Online ahead of print.
PMID: 34285415
Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review.
Anota A, Pozet A, Lemasson H, Cotté FE, Falcoz A, Eberst G, Mouillet G, Guerzider S, Charton É, Westeel V, et al.
Qual Life Res. 2021 Jul 20. doi: 10.1007/s11136-021-02945-8. Online ahead of print.
PMID: 34283382
Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014.
Chen Z, Babcock A, Sanogo V, Nelson DR, Xiao H, Diaby V, et al.
Expert Rev Pharmacoecon Outcomes Res. 2021 Jul 16:1-7. doi: 10.1080/14737167.2021.1927717. Online ahead of print.
PMID: 33985399
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).
Kalff A, Khong T, Ramachandran M, Walker P, Schwarer A, Roberts AW, Campbell P, Filshie R, Norton S, Reynolds J, Young M, Pierceall W, Thakurta A, Guo M, Oppermann U, Wang M, Ren Y, Kennedy N, Parekh S, Spencer A, et al.
Leuk Lymphoma. 2021 Jul 15:1-11. doi: 10.1080/10428194.2021.1948030. Online ahead of print.
PMID: 34263697
Investigation on hot melt extrusion and prediction on 3D printability of pharmaceutical grade polymers.
Tabriz AG, Scoutaris N, Gong Y, Hui HW, Kumar S, Douroumis D, et al.
Int J Pharm. 2021 Jul 15;604:120755. doi: 10.1016/j.ijpharm.2021.120755. Epub 2021 May 28.
PMID: 34052338
Stereoselective and Divergent Aza-Adenosine and Aza-Guanosine Syntheses from Xylofuranose, the Key Fragments of a STING Cyclic Dinucleotide Agonist.
Yuan C, Ortiz A, Xu Z, Zhu J, Schmidt MA, Rogers A, Eastgate M, et al.
J Org Chem. 2021 Jul 14. doi: 10.1021/acs.joc.1c00984. Online ahead of print.
PMID: 34259509
Effect of Baseline Disease Severity on Achievement of Treatment Target With Apremilast: Results From a Pooled Analysis.
Reich K, Mrowietz U, Menter A, Griffiths CEM, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M, et al.
J Eur Acad Dermatol Venereol. 2021 Jul 13. doi: 10.1111/jdv.17520. Online ahead of print.
PMID: 34255891
The use of proxies and proxy-reported measures: a report of the international society for quality of life research (ISOQOL) proxy task force.
Roydhouse JK, Cohen ML, Eshoj HR, Corsini N, Yucel E, Rutherford C, Wac K, Berrocal A, Lanzi A, Nowinski C, Roberts N, Kassianos AP, Sebille V, King MT, Mercieca-Bebber R; ISOQOL Proxy Task Force and the ISOQOL Board of Directors.
Qual Life Res. 2021 Jul 12. doi: 10.1007/s11136-021-02937-8. Online ahead of print.
PMID: 34254262
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J, Zhu D, Wong L, Escoubet L, Raymon HK, Hariharan K, et al.
Cancer Immunol Immunother. 2021 Jul 10. doi: 10.1007/s00262-021-03010-6. Online ahead of print.
PMID: 34247273
Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies.
Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D, et al.
J Pharm Biomed Anal. 2021 Jul 8;204:114255. doi: 10.1016/j.jpba.2021.114255. Online ahead of print.
PMID: 34304009
The importance of specific citrullinated clusterin and vimentin found in a multi-coloured bead-based citrulline-peptide array system in rheumatoid arthritis.
Yoshizawa Y, Nakao T, Tsuritani K, Yamada T, Watanabe N, Chiba A, Robinson WH, Miyake S, et al.
Clin Exp Rheumatol. 2021 Jul 8. Online ahead of print.
PMID: 34251306
The obesity paradox may not lead to functional gains in stroke patients undergoing acute inpatient rehabilitation.
Freeman C, Blough A, Rotich D, Curl A, Eickmeyer SM, et al.
PM R. 2021 Jul 8. doi: 10.1002/pmrj.12671. Online ahead of print.
PMID: 34240565
Synthesis and characterization of a series of N, N'-substituted urea derivatives by using electrospray ionization tandem mass spectrometry (ESI-MS/MS): Differentiation of positional isomers.
Singh DK, Chauthe SK, Anjanappa P, Kumar S, Arulraj RA, Gajjela R, Mohammed N, Kanthappa VT, Karmakar A, Gupta AK, Bajpai L, Bagadi M, Mathur A, et al.
Rapid Commun Mass Spectrom. 2021 Jul 8:e9161. doi: 10.1002/rcm.9161. Online ahead of print.
PMID: 34240514
Thymic lymphomas in a 6-Month rasH2-Tg mouse carcinogenicity study with the RORγt Inverse Agonist, BMS-986251.
Haggerty HG, Sathish JG, Gleason CR, Al-Haddawi M, Brodie TA, Bonnette KL, Lewis BS, Graziano MJ, et al.
Toxicol Sci. 2021 Jul 8:kfab086. doi: 10.1093/toxsci/kfab086. Online ahead of print.
PMID: 34240189
Author Correction: A one-step tRNA-CRISPR system for genome-wide genetic interaction mapping in mammalian cells.
Zhao Y, Tyrishkin K, Sjaarda C, Khanal P, Stafford J, Rauh M, Liu X, Babak T, Yang X, et al.
Sci Rep. 2021 Jul 8;11(1):14483. doi: 10.1038/s41598-021-92514-3.
PMID: 34238941
Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
Tencer T, Will O, Kumar J, Cambron-Mellott MJ, Mackie DS, Beusterien K, et al.
Curr Med Res Opin. 2021 Jul 8:1-10. doi: 10.1080/03007995.2021.1940911. Online ahead of print.
PMID: 34129418
Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.
Kumar J, Cambron-Mellott MJ, Tencer T, Will O, Mackie DS, Beusterien K, et al.
Patient Prefer Adherence. 2021 Jul 8;15:1515-1527. doi: 10.2147/PPA.S306498. eCollection 2021.
PMID: 34267507
Covid-19 Knowledge and Perceptions Among Dental Specialists: A Cross-Sectional Online Questionnaire Survey.
Aldhuwayhi S, Mallineni SK, Sakhamuri S, Thakare AA, Mallineni S, Sajja R, Sethi M, Nettam V, Mohammad AM, et al.
Risk Manag Healthc Policy. 2021 Jul 7;14:2851-2861. doi: 10.2147/RMHP.S306880. eCollection 2021.
PMID: 34262372
P(III) vs P(V): A P(V) Reagent for Thiophosphoramidate Linkages and Application to an Asymmetric Synthesis of a Cyclic Dinucleotide STING Agonist.
Zheng B, Hang C, Zhu J, Purdum GE, Sezen-Edmonds M, Treitler DS, Yu M, Yuan C, Zhu Y, Freitag A, Guo S, Zhu G, Hritzko B, Paulson J, Shackman JG, He BL, Fu W, Tai HC, Ayers S, Park H, Eastgate MD, Cohen B, Rogers A, Wang Q, Schmidt MA, et al.
J Org Chem. 2021 Jul 7. doi: 10.1021/acs.joc.1c01055. Online ahead of print.
PMID: 34232659
Predictive immune checkpoint blockade classifiers identify tumors responding to inhibition of PD-1 and/or CTLA-4.
Krijgsman O, Kemper K, Boshuizen J, Vredevoogd DW, Rozeman EA, Ibanez Molero S, de Bruijn B, Cornelissen-Steijger P, Shahrabi A, Del Castillo Velasco-Herrera M, Song JY, Ligtenberg MA, Kluin RJC, Kuilman T, Ross-Macdonald P, Haanen J, Adams DJ, Blank C, Peeper DS, et al.
Clin Cancer Res. 2021 Jul 6:clincanres.CCR-20-4218-A.2020. doi: 10.1158/1078-0432.CCR-20-4218. Online ahead of print.
PMID: 34230026
Molecular mechanism of interspecies differences in the binding affinity of TD139 to Galectin-3.
Kumar A, Paul M, Panda M, Jayaram S, Kalidindi N, Sale H, Vetrichelvan M, Gupta A, Mathur A, Beno B, Regueiro-Ren A, Cheng D, Ramarao M, Ghosh K, et al.
Glycobiology. 2021 Jul 6:cwab072. doi: 10.1093/glycob/cwab072. Online ahead of print.
PMID: 34228782
Qualitative and psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis.
Becker B, Raymond K, Hawkes C, Foster AM, Lovley A, Saucier C, Rizio AA, Bjorner JB, Kosinski M, et al.
J Patient Rep Outcomes. 2021 Jul 6;5(1):52. doi: 10.1186/s41687-021-00318-w.
PMID: 34228217
The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients With Primary Sjögren's Syndrome.
Verstappen GM, Gao L, Pringle S, Haacke EA, van der Vegt B, Liefers SC, Patel V, Hu Y, Mukherjee S, Carman J, Menard LC, Spijkervet FKL, Vissink A, Bootsma H, Kroese FGM, et al.
Front Immunol. 2021 Jul 6;12:681941. doi: 10.3389/fimmu.2021.681941. eCollection 2021.
PMID: 34295332
Acute Effects of Pimobendan on Cardiac Function in Dogs With Tachycardia Induced Dilated Cardiomyopathy: A Randomized, Placebo-Controlled, Crossover Study.
Abbott-Johnson K, Pierce KV, Roof S, Del Rio CL, Hamlin R, et al.
Front Vet Sci. 2021 Jul 1;8:646437. doi: 10.3389/fvets.2021.646437. eCollection 2021.
PMID: 34277749
High-Throughput Screening to Identify Small Molecules That Selectively Inhibit APOL1 Protein Level in Podocytes.
Choy J, Kan Y, Cifelli S, Johnson J, Chen M, Shiao LL, Zhou H, Previs S, Lei Y, Johnstone R, Liaw A, Saigal A, Hu L, Ramos R, Visconti R, McElroy WT, Kreamer A, Wildey MJ, Peier A, Shin MK, Imbriglio J, Ren Z, Hoek M, Weinglass A, Ai X, et al.
SLAS Discov. 2021 Jul 3:24725552211026245. doi: 10.1177/24725552211026245. Online ahead of print.
PMID: 34218698
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA, et al.
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
PMID: 34102137
Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K, Dodds M, Mack T, Lymp J, Dell'Aringa J, Smith J, et al.
Clin Pharmacokinet. 2021 Jul 3. doi: 10.1007/s40262-021-01055-5. Online ahead of print.
PMID: 34216384
Phylogenetic and Phylodynamic Analyses of HCV Strains Circulating among Patients Using Injectable Drugs in Central Italy.
Minosse C, Salichos L, Taibi C, Luzzitelli I, Nardozi D, Capobianchi MR, D'Offizi G, McPhee F, Garbuglia AR, et al.
Microorganisms. 2021 Jul 2;9(7):1432. doi: 10.3390/microorganisms9071432.
PMID: 34361868
Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making.
Gordon J, Stainthorpe A, Jones B, Jacob I, Hertel N, Diaz J, Yuan Y, Borrill J, et al.
Pharmacoecon Open. 2021 Jul 2. doi: 10.1007/s41669-021-00279-2. Online ahead of print.
PMID: 34216002
Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform.
Xia Y, Ji X, Jang IS, Surka C, Hsu C, Wang K, Rolfe M, Bence N, Lu G, et al.
Commun Biol. 2021 Jul 2;4(1):834. doi: 10.1038/s42003-021-02352-2.
PMID: 34215850
Ni-Catalyzed 1,2-Diarylation of Alkenyl Ketones: A Comparative Study of Carbonyl-Directed Reaction Systems.
Kleinmans R, Apolinar O, Derosa J, Karunananda MK, Li ZQ, Tran VT, Wisniewski SR, Engle KM, et al.
Org Lett. 2021 Jul 16;23(14):5311-5316. doi: 10.1021/acs.orglett.1c01447. Epub 2021 Jul 2.
PMID: 34213351
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.
Wu YJ, Meanwell NA, et al.
J Med Chem. 2021 Jul 22;64(14):9786-9874. doi: 10.1021/acs.jmedchem.1c00790. Epub 2021 Jul 2.
PMID: 34213340
Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.
Taube JM, Roman K, Engle EL, Wang C, Ballesteros-Merino C, Jensen SM, McGuire J, Jiang M, Coltharp C, Remeniuk B, Wistuba I, Locke D, Parra ER, Fox BA, Rimm DL, Hoyt C, et al.
J Immunother Cancer. 2021 Jul;9(7):e002197. doi: 10.1136/jitc-2020-002197.
PMID: 34266881
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.
Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Leif Bergsagel P, Chesi M, et al.
Blood Cancer Discov. 2021 Jul;2(4):354-369. doi: 10.1158/2643-3230.bcd-21-0038.
PMID: 34258584
Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E, Godin R, Nedjar H, Dasgupta K, Tagalakis V, et al.
Thromb Res. 2021 Jul;203:121-130. doi: 10.1016/j.thromres.2021.05.005. Epub 2021 May 11.
PMID: 34000493
A Stereocontrolled Synthesis of a Phosphorothioate Cyclic Dinucleotide-Based STING Agonist.
Kempson J, Zhang H, Hou X, Cornelius L, Zhao R, Wang B, Hong Z, Oderinde MS, Pawluczyk J, Wu DR, Sun D, Li P, Yip S, Smith A, Caceres-Cortes J, Aulakh D, Sarjeant AA, Park PK, Harikrishnan LS, Qin LY, Dodd DS, Fink B, Vite G, Mathur A, et al.
J Org Chem. 2021 Jul 2;86(13):8851-8861. doi: 10.1021/acs.joc.1c00784. Epub 2021 Jun 14.
PMID: 34126006
Nanopore sequencing of single-cell transcriptomes with scCOLOR-seq.
Philpott M, Watson J, Thakurta A, Brown T Jr, Brown T Sr, Oppermann U, Cribbs AP, et al.
Nat Biotechnol. 2021 Jul 1. doi: 10.1038/s41587-021-00965-w. Online ahead of print.
PMID: 34211161
Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals.
Kosmicki JA, Horowitz JE, Banerjee N, Lanche R, Marcketta A, Maxwell E, Bai X, Sun D, Backman JD, Sharma D, Kury FSP, Kang HM, O'Dushlaine C, Yadav A, Mansfield AJ, Li AH, Watanabe K, Gurski L, McCarthy SE, Locke AE, Khalid S, O'Keeffe S, Mbatchou J, Chazara O, Huang Y, Kvikstad E, O'Neill A, Nioi P, Parker MM, Petrovski S, Runz H, Szustakowski JD, Wang Q, Wong E, Cordova-Palomera A, Smith EN, Szalma S, Zheng X, Esmaeeli S, Davis JW, Lai YP, Chen X, Justice AE, Leader JB, Mirshahi T, Carey DJ, Verma A, Sirugo G, Ritchie MD, Rader DJ, Povysil G, Goldstein DB, Kiryluk K, Pairo-Castineira E, Rawlik K, Pasko D, Walker S, Meynert A, Kousathanas A, Moutsianas L, Tenesa A, Caulfield M, Scott R, Wilson JF, Baillie JK, Butler-Laporte G, Nakanishi T, Lathrop M, Richards JB; Regeneron Genetics Center; UKB Exome Sequencing Consortium, Jones M, Balasubramanian S, Salerno W, Shuldiner AR, Marchini J, Overton JD, Habegger L, Cantor MN, Reid JG, Baras A, Abecasis GR, Ferreira MAR, et al.
Am J Hum Genet. 2021 Jul 1;108(7):1350-1355. doi: 10.1016/j.ajhg.2021.05.017. Epub 2021 Jun 3.
PMID: 34115965
Spectrum and Outcome of Noninfectious Aortitis.
Ferfar Y, Morinet S, Espitia O, Agard C, Vautier M, Comarmond C, Desbois AC, Domont F, Resche-Rigon M, Cacoub P, Biard L, Saadoun D; French Study Group for Large Vessel Vasculitis (GEFA), et al.
J Rheumatol. 2021 Jul 1:jrheum.201274. doi: 10.3899/jrheum.201274. Online ahead of print.
PMID: 34210830
The future of immune checkpoint combinations with tumor-targeted small molecule drugs.
Sceneay J, Sinclair C, et al.
Emerg Top Life Sci. 2021 Jul 1:ETLS20210064. doi: 10.1042/ETLS20210064. Online ahead of print.
PMID: 34196724
Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology.
Sanghavi K, Vuppala P, Ivaturi V, Hamuro L, Roy A, Suryawanshi S, et al.
CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):748-759. doi: 10.1002/psp4.12642. Epub 2021 Jun 11.
PMID: 33955714
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
Huh KY, Choi Y, Nissel J, Palmisano M, Wang X, Liu L, Ramirez-Valle F, Lee H, et al.
Clin Transl Sci. 2021 Jul;14(4):1505-1511. doi: 10.1111/cts.13013. Epub 2021 May 1.
PMID: 33932093
Process analytics 4.0: A paradigm shift in rapid analytics for biologics development.
Wasalathanthri DP, Shah R, Ding J, Leone A, Li ZJ, et al.
Biotechnol Prog. 2021 Jul;37(4):e3177. doi: 10.1002/btpr.3177. Epub 2021 May 31.
PMID: 34036755
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis.
Ruperto N, Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Cimaz R, Dare J, Espada G, Faugier E, Ferrandiz M, Gerloni V, Quartier P, Silva CA, Wagner-Weiner L, Gandhi Y, Passarell J, Nys M, Wong R, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO).
J Rheumatol. 2021 Jul;48(7):1073-1081. doi: 10.3899/jrheum.200154. Epub 2021 Jan 15.
PMID: 33452173
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank.
Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, Wong E, Liu D, Wade Davis J, Haefliger C, Katrina Loomis A, Mikkilineni R, Noh HJ, Wadhawan S, Bai X, Hawes A, Krasheninina O, Ulloa R, Lopez AE, Smith EN, Waring JF, Whelan CD, Tsai EA, Overton JD, Salerno WJ, Jacob H, Szalma S, Runz H, Hinkle G, Nioi P, Petrovski S, Miller MR, Baras A, Mitnaul LJ, Reid JG; UKB-ESC Research Team.
Nat Genet. 2021 Jul;53(7):942-948. doi: 10.1038/s41588-021-00885-0. Epub 2021 Jun 28.
PMID: 34183854
Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types.
Szabo PM, Pant S, Ely S, Desai K, Anguiano E, Wang L, Edwards R, Green G, Zhang N, et al.
J Mol Diagn. 2021 Jun 29:S1525-1578(21)00172-0. doi: 10.1016/j.jmoldx.2021.06.002. Online ahead of print.
PMID: 34197924
Micafungin-Induced Cell Wall Damage Stimulates Morphological Changes Consistent with Microcycle Conidiation in Aspergillus nidulans.
Reese S, Chelius C, Riekhof W, Marten MR, Harris SD, et al.
J Fungi (Basel). 2021 Jun 29;7(7):525. doi: 10.3390/jof7070525.
PMID: 34210108
Affinity precipitation of monoclonal antibodies using ELP-Z in the elution without resolubilization mode.
Bhat M, Mullerpatan A, Chen J, Holstein M, Ghose S, Li ZJ, Cramer S, et al.
J Biotechnol. 2021 Jun 29;338:1-4. doi: 10.1016/j.jbiotec.2021.06.020. Online ahead of print.
PMID: 34197822
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients.
Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, Lipschitz M, Lako A, Duda DG, Rodig SJ, Hodi FS, Jain RK, et al.
NPJ Precis Oncol. 2021 Jun 29;5(1):62. doi: 10.1038/s41698-021-00197-w.
PMID: 34188163
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
Stegherr R, Schmoor C, Beyersmann J, Rufibach K, Jehl V, Brückner A, Eisele L, Künzel T, Kupas K, Langer F, Leverkus F, Loos A, Norenberg C, Voss F, Friede T, et al.
Trials. 2021 Jun 29;22(1):420. doi: 10.1186/s13063-021-05354-x.
PMID: 34187527
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, Kavanaugh WM, Vasiljeva O, Belvin M, Howng B, Irving B, Tipton K, West J, Mei L, Korman AJ, Sega E, Olivera I, Cirella A, Ochoa MC, Rodriguez ME, Melero A, Sanmamed MF, Engelhardt JJ, Melero I, et al.
Proc Natl Acad Sci U S A. 2021 Jun 29;118(26):e2025930118. doi: 10.1073/pnas.2025930118.
PMID: 34172583
Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies.
Fazeli MS, Khaychuk V, Wittstock K, Breznen B, Crocket G, Pourrahmat MM, Ferri L, et al.
Clin Med Insights Arthritis Musculoskelet Disord. 2021 Jun 28;14:11795441211028751. doi: 10.1177/11795441211028751. eCollection 2021.
PMID: 34262386
Site-selective tyrosine bioconjugation via photoredox catalysis for native-to-bioorthogonal protein transformation.
Li BX, Kim DK, Bloom S, Huang RY, Qiao JX, Ewing WR, Oblinsky DG, Scholes GD, MacMillan DWC, et al.
Nat Chem. 2021 Jun 28. doi: 10.1038/s41557-021-00733-y. Online ahead of print.
PMID: 34183819
Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma.
Wall MA, Turkarslan S, Wu WJ, Danziger SA, Reiss DJ, Mason MJ, Dervan AP, Trotter MWB, Bassett D, Hershberg RM, Lomana ALG, Ratushny AV, Baliga NS, et al.
NPJ Precis Oncol. 2021 Jun 28;5(1):60. doi: 10.1038/s41698-021-00185-0.
PMID: 34183722
Flexible use of copula-type model for dose-finding in drug combination clinical trials.
Hashizume K, Tshuchida J, Sozu T, et al.
Biometrics. 2021 Jun 28. doi: 10.1111/biom.13510. Online ahead of print.
PMID: 34181760
A functional three-dimensional microphysiological human model of myeloma bone disease.
Visconti RJ, Kolaja K, Cottrell JA, et al.
J Bone Miner Res. 2021 Jun 25. doi: 10.1002/jbmr.4404. Online ahead of print.
PMID: 34173283
Optimized damping parameters for empirical dispersion corrections to symmetry-adapted perturbation theory.
Schriber JB, Sirianni DA, Smith DGA, Burns LA, Sitkoff D, Cheney DL, Sherrill CD, et al.
J Chem Phys. 2021 Jun 21;154(23):234107. doi: 10.1063/5.0049745.
PMID: 34241276
Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Hiramatsu K, Barrett A, Miyata Y; PhRMA Japan Medical Affairs Committee Working Group 1.
Drugs Real World Outcomes. 2021 Jun 19. doi: 10.1007/s40801-021-00266-3. Online ahead of print.
PMID: 34148219
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD Jr, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS, et al.
Blood Cancer J. 2021 Jun 18;11(6):116. doi: 10.1038/s41408-021-00507-2.
PMID: 34145225
Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms.
Shah KK, Bennett B, Lenny A, Longworth L, Brazier JE, Oppe M, Pickard AS, Shaw JW, et al.
Eur J Health Econ. 2021 Jun 17. doi: 10.1007/s10198-021-01337-6. Online ahead of print.
PMID: 34142266
Idecabtagene Vicleucel in Relapsed Myeloma. Reply.
Munshi NC, Hege K, San-Miguel J, et al.
N Engl J Med. 2021 Jun 17;384(24):2357-2358. doi: 10.1056/NEJMc2105069.
PMID: 34133871
Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors.
Cherney EC, Zhang L, Guo W, Huang A, Williams D, Seitz S, Shan W, Zhu X, Gullo-Brown J, Maley D, Lin TA, Hunt JT, Huang C, Yang Z, D'Arienzo CJ, Discenza LN, Ranasinghe A, Grubb MF, Traeger SC, Li X, Johnston KA, Kopcho L, Fereshteh M, Foster KA, Stefanski K, Delpy D, Dhar G, Anandam A, Mahankali S, Padmanabhan S, Rajanna P, Murali V, Mariappan TT, Pattasseri S, Nimje RY, Hong Z, Kempson J, Rampulla R, Mathur A, Gupta A, Borzilleri R, Vite G, Balog A, et al.
ACS Med Chem Lett. 2021 Jun 16;12(7):1143-1150. doi: 10.1021/acsmedchemlett.1c00236. eCollection 2021 Jul 8.
PMID: 34267885
Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.
Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR, et al.
Viruses. 2021 Jun 16;13(6):1151. doi: 10.3390/v13061151.
PMID: 34208646
Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L, Kee A, Tian M, Mehta R, et al.
Drugs Real World Outcomes. 2021 Jun 16. doi: 10.1007/s40801-021-00251-w. Online ahead of print.
PMID: 34136997
Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk.
Johnsen SP, Rasmussen TB, Falstie-Jensen AM, Harboe L, Stynes G, Dybro L, Hansen ML, Brandes A, Grove EL, Münster AM, et al.
Basic Clin Pharmacol Toxicol. 2021 Jun 15. doi: 10.1111/bcpt.13625. Online ahead of print.
PMID: 34128322
Advanced continuous-flow microfluidic device for parallel screening of crystal polymorphs, morphology, and kinetics at controlled supersaturation.
Coliaie P, Kelkar MS, Langston M, Liu C, Nazemifard N, Patience D, Skliar D, Nere NK, Singh MR, et al.
Lab Chip. 2021 Jun 15;21(12):2333-2342. doi: 10.1039/d1lc00218j.
PMID: 34096561
Cartesian message passing neural networks for directional properties: Fast and transferable atomic multipoles.
Glick ZL, Koutsoukas A, Cheney DL, Sherrill CD, et al.
J Chem Phys. 2021 Jun 14;154(22):224103. doi: 10.1063/5.0050444.
PMID: 34241239
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K, Dodds M, Mack T, Lymp J, Dell'Aringa J, Smith J, et al.
Clin Pharmacokinet. 2021 Jun 14. doi: 10.1007/s40262-021-01039-5. Online ahead of print.
PMID: 34125421
Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.
Zamagni E, Dhanasiri S, Ghale A, Moore A, Roussel M, et al.
Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1924369. Online ahead of print.
PMID: 34121589
Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer.
Cohen AT, Keshishian A, Lee T, Rosenblatt L, Hlavacek P, Sah J, Luo X, et al.
Curr Med Res Opin. 2021 Jun 14:1-16. doi: 10.1080/03007995.2021.1932448. Online ahead of print.
PMID: 34030541
General population normative data for the EQ-5D-3L in the five largest European economies.
Janssen MF, Pickard AS, Shaw JW, et al.
Eur J Health Econ. 2021 Jun 12. doi: 10.1007/s10198-021-01326-9. Online ahead of print.
PMID: 34117986
Pediatric soft tissue neoplasms with BRAF activating mutations.
Mochel MC, Wojcik JB, Gowda M, Tye GW, Patel RM, Smith SC, et al.
Mod Pathol. 2021 Jun 11. doi: 10.1038/s41379-021-00852-4. Online ahead of print.
PMID: 34117348
A practical response adaptive block randomization (RABR) design with analytic type I error protection.
Zhan T, Cui L, Geng Z, Zhang L, Gu Y, Chan ISF, et al.
Stat Med. 2021 Jun 10. doi: 10.1002/sim.9104. Online ahead of print.
PMID: 34111902
Telomerase Reverse Transcriptase Increases Proliferation and Lifespan of Human NK Cells without Immortalization.
Streltsova MA, Ustiuzhanina MO, Barsov EV, Kust SA, Velichinskii RA, Kovalenko EI, et al.
Biomedicines. 2021 Jun 9;9(6):662. doi: 10.3390/biomedicines9060662.
PMID: 34207853
Mouse IL-2/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus.
Xie JH, Zhang Y, Loubeau M, Mangan P, Heimrich E, Tovar C, Zhou X, Madia P, Doyle M, Dudhgaonkar S, Rudra A, Subramani S, Young J, Salter-Cid L, Malek TR, Struthers M, et al.
J Immunol. 2021 Jun 9:ji2100078. doi: 10.4049/jimmunol.2100078. Online ahead of print.
PMID: 34108258
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients.
Wells AF, Edwards CJ, Kivitz AJ, Bird P, Guerette B, Delev N, Paris M, Teng L, Aelion JA, et al.
Rheumatology (Oxford). 2021 Jun 8:keab449. doi: 10.1093/rheumatology/keab449. Online ahead of print.
PMID: 34100922
Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers.
Paczesny S, Pasquini MC, Pavletic SZ, Agarwal A, Spellman S, Kean L, Bernatchez C, Gust J, Staedtke V, Perales MA, et al.
Blood Adv. 2021 Jun 8;5(11):2519-2522. doi: 10.1182/bloodadvances.2021004604.
PMID: 34100901
Opalescence Measurements: Improvements in Fundamental Knowledge, Identifying Sources of Analytical Biases, and Advanced Applications for the Development of Therapeutic Proteins.
Barros M, Zhang X, Kenrick S, Valente JJ, et al.
J Pharm Sci. 2021 Jun 7:S0022-3549(21)00303-8. doi: 10.1016/j.xphs.2021.06.013. Online ahead of print.
PMID: 34111445
Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset.
Waterhouse D, Lam J, Betts KA, Yin L, Gao S, Yuan Y, Hartman J, Rao S, Lubinga S, Stenehjem D.
Data Brief. 2021 Jun 6;37:107195. doi: 10.1016/j.dib.2021.107195. eCollection 2021 Aug.
PMID: 34169127
Mimicking Low pH Virus Inactivation Used in Antibody Manufacturing Processes: Effect of Processing Conditions and Biophysical Properties on Antibody Aggregation and Particle Formation.
Kim NA, Kar S, Li Z, Das TK, Carpenter JF, et al.
J Pharm Sci. 2021 Jun 6:S0022-3549(21)00292-6. doi: 10.1016/j.xphs.2021.06.002. Online ahead of print.
PMID: 34090901
A Novel Use of Nanocrystalline Suspensions to Develop Sub-Microgram Dose Micro-Tablets.
Meruva S, Thool P, Gong Y, Agrawal A, Karki S, Bowen W, Mitra B, Kumar S, et al.
J Pharm Sci. 2021 Jun 5:S0022-3549(21)00290-2. doi: 10.1016/j.xphs.2021.05.025. Online ahead of print.
PMID: 34097976
Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
Bienfait K, Chhibber A, Marshall JC, Armstrong M, Cox C, Shaw PM, Paulding C, et al.
Hum Genet. 2021 Jun 3. doi: 10.1007/s00439-021-02282-3. Online ahead of print.
PMID: 34081195
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD, et al.
N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
PMID: 34077643
Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.
Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R, et al.
JCO Precis Oncol. 2021 Jun 8;5:953-973. doi: 10.1200/PO.20.00412. eCollection 2021 Jun.
PMID: 34136742
Editorial overview: Hot targets and new modalities.
Ciulli A, Wertz IE, et al.
Curr Opin Chem Biol. 2021 Jun;62:A1-A3. doi: 10.1016/j.cbpa.2021.04.010. Epub 2021 Jun 8.
PMID: 34116929
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL, et al.
J Immunother Cancer. 2021 Jun;9(6):e002568. doi: 10.1136/jitc-2021-002568.
PMID: 34083421
Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
Harrold LR, Bryson J, Lehman T, Zhuo J, Gao S, Han X, Schrader A, Rebello S, Pappas DA, Sommers T, Kremer JM, et al.
Rheumatol Ther. 2021 Jun;8(2):937-953. doi: 10.1007/s40744-021-00310-2. Epub 2021 May 28.
PMID: 34047953
The role of ligand-binding assay and LC-MS in the bioanalysis of complex protein and oligonucleotide therapeutics.
Kotapati S, Deshpande M, Jashnani A, Thakkar D, Xu H, Dollinger G, et al.
Bioanalysis. 2021 Jun;13(11):931-954. doi: 10.4155/bio-2021-0009. Epub 2021 May 17.
PMID: 33998268
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, Li W, Dolan C, Reaney M, Sehnert AJ, Jacoby D, et al.
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
PMID: 34004177
Critical review of oncology clinical trial design under non-proportional hazards.
Ananthakrishnan R, Green S, Previtali A, Liu R, Li D, LaValley M, et al.
Crit Rev Oncol Hematol. 2021 Jun;162:103350. doi: 10.1016/j.critrevonc.2021.103350. Epub 2021 May 12.
PMID: 33989767
Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.
Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl, et al.
J.Adv Ther. 2021 Jun;38(6):3266-3280. doi: 10.1007/s12325-021-01756-0. Epub 2021 May 10.
PMID: 33970454
Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity.
Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Klem C, Rosenblatt L, Mardekian J, Jiang J, Yuce H, Lip GYH, et al.
Adv Ther. 2021 Jun;38(6):3166-3184. doi: 10.1007/s12325-021-01724-8. Epub 2021 May 7.
PMID: 33963511
Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases: A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer.
Shafrin J, May SG, Zhao LM, Bognar K, Yuan Y, Penrod JR, Romley JA.
Value Health. 2021 Jun;24(6):855-861. doi: 10.1016/j.jval.2020.06.021. Epub 2021 Mar 31.
PMID: 34119084
Qualitative analysis of actual Standard for Exchange of Nonclinical Data (SEND) datasets for Data Domains: Proposition from Japan Pharmaceutical Manufacturers Association SEND Taskforce Team on standardization of nonclinical data.
Sato G, Matsumoto I, Watanabe M, Kinomoto T, Nakajima M, Yamamoto M, Inoue Y, Kobayashi K, Tanaharu T, Kiya A, Yamaguchi T, Hayashi H, Motoyama K, Suzuki M, Watanabe K.
Regul Toxicol Pharmacol. 2021 Jun;122:104919. doi: 10.1016/j.yrtph.2021.104919. Epub 2021 Mar 20.
PMID: 33753112
Role of surface molecular environment and amorphous content in moisture sorption behavior of milled Terbutaline Sulphate.
Bagwan NUS, Sheokand S, Kaur A, Dubey G, Puri V, Bharatam PV, Bansal AK.
Eur J Pharm Sci. 2021 Jun 1;161:105782. doi: 10.1016/j.ejps.2021.105782. Epub 2021 Mar 3.
PMID: 33675911
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Lopes RD, Thomas L, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Friend K, Mardekian J, Pan X, Yuce H, Jones WS.
Am J Cardiol. 2021 Jun 1;148:69-77. doi: 10.1016/j.amjcard.2021.02.021. Epub 2021 Mar 3.
PMID: 33667438
Multimorbidity Accrual After Incident Rheumatoid Arthritis: A Wolf at the Door.
Sparks JA,
J Rheumatol. 2021 Jun 1:jrheum.210224. doi: 10.3899/jrheum.210224. Online ahead of print.
PMID: 34074680
Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers.
Ali S, & Esper P.
Clin J Oncol Nurs. 2021 Jun 1;25(3):321-328. doi: 10.1188/21.CJON.321-328.
PMID: 34019017
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.
Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Duval Modeste AB, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B; RIC-Mel network.
Int J Cancer. 2021 Jun 1;148(11):2789-2798. doi: 10.1002/ijc.33467. Epub 2021 Feb 19.
PMID: 33428772
Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors.
Fangusaro J, Cefalo MG, Garré ML, Marshall LV, Massimino M, Benettaib B, Biserna N, Poon J, Quan J, Conlin E, Lewandowski J, Simcock M, Jeste N, Hargrave DR, Doz F, Warren KE, et al.
Front Oncol. 2021 Jun 8;11:660892. doi: 10.3389/fonc.2021.660892. eCollection 2021.
PMID: 34168987
Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan.
Chen L, Ionescu-Ittu R, Romdhani H, Guerin A, Kessler P, Borentain M, Friend K, DeSouza M, Sato N, et al.
Cardiol Ther. 2021 Jun;10(1):211-228. doi: 10.1007/s40119-021-00212-y. Epub 2021 Feb 20.
PMID: 33609268
An Industry Perspective on the Challenges of Using Closed System Transfer Devices with Biologics and Communication Guidance to Healthcare Professionals.
Gopalrathnam G, Christian TR, Jagannathan B, Petoskey F, Kühnle B, Weiser S, Kagdi R, Saluja S, Bhattacharyya A, Burton L, Zamiri C, Hanley K, et al.
J Pharm Sci. 2021 Jun;110(6):2329-2335. doi: 10.1016/j.xphs.2021.02.008. Epub 2021 Feb 19.
PMID: 33617871
Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey.
Mitra MS, Datta K, Hutchinson R, Nicolette JJ, Pettersen JC, Wegesser TC, Bercu JP, et al.
Regul Toxicol Pharmacol. 2021 Jun;122:104895. doi: 10.1016/j.yrtph.2021.104895. Epub 2021 Feb 19.
PMID: 33610610
A custom ÄKTA avant configuration enabling automated parallel protein purification over a range of process scales.
Hollander C, Walrond SC, Connelly C, Megson L, Bove E, McDonagh T, et al.
Protein Expr Purif. 2021 Jun;182:105842. doi: 10.1016/j.pep.2021.105842. Epub 2021 Feb 11.
PMID: 33582289
Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns.
Ghanima W, Schultze A, Donaldson R, Brodin E, Halvorsen S, Graham S, Carroll R, Ulvestad M, Lambrelli D, et al.
Clin Ther. 2021 May 31:S0149-2918(21)00212-5. doi: 10.1016/j.clinthera.2021.04.017. Online ahead of print.
PMID: 34083030
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, Meiss F, Terheyden P, Gutzmer R, Buysse B, Oh K, Brokaw J, Le TK, Mathias SD, Scotto J, Lord-Bessen J, Moshyk A, Kotapati S, Middleton MR, et al.
BMC Cancer. 2021 May 29;21(1):642. doi: 10.1186/s12885-021-08032-y.
PMID: 34051732
Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
Wang R, Ascanelli C, Abdelbaki A, Fung A, Rasmusson T, Michaelides I, Roberts K, Lindon C, et al.
Commun Biol. 2021 May 28;4(1):640. doi: 10.1038/s42003-021-02158-2.
PMID: 34050235
Identification of Novel, Immunogenic HLA-DR-Presented Prevotella copri Peptides in Patients with Rheumatoid Arthritis: Patients with Rheumatoid Arthritis.
Pianta A, Chiumento G, Ramsden K, Wang Q, Strle K, Arvikar S, Costello CE, Steere AC, et al.
Arthritis Rheumatol. 2021 May 27. doi: 10.1002/art.41807. Online ahead of print.
PMID: 34042327
Native mass spectrometry and gas-phase fragmentation provide rapid and in-depth topological characterization of a PROTAC ternary complex.
Song JH, Wagner ND, Yan J, Li J, Huang RY, Balog AJ, Newitt JA, Chen G, Gross ML, et al.
Cell Chem Biol. 2021 May 26:S2451-9456(21)00222-1. doi: 10.1016/j.chembiol.2021.05.005. Online ahead of print.
PMID: 34081921
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B, et al.
J Hepatol. 2021 May 26:S0168-8278(21)00313-5. doi: 10.1016/j.jhep.2021.04.047. Online ahead of print.
PMID: 34051329
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.
Yang MG, Xiao Z, Zhao R, Tebben AJ, Wang B, Cherney RJ, Batt DG, Brown GD, Cvijic ME, Duncia JV, Gallela MA, Gardner DS, Khandelwal P, Malley MF, Pang J, Rose AV, Santella JB 3rd, Sarjeant AA, Xu S, Mathur A, Mandlekar S, Vuppugalla R, Zhao Q, Carter PH, et al.
ACS Med Chem Lett. 2021 May 25;12(6):969-975. doi: 10.1021/acsmedchemlett.1c00082. eCollection 2021 Jun 10.
PMID: 34141082
Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study.
Sekelj S, Sandler B, Johnston E, Pollock KG, Hill NR, Gordon J, Tsang C, Khan S, Ng FS, Farooqui U, et al.
Eur J Prev Cardiol. 2021 May 22;28(6):598-605. doi: 10.1177/2047487320942338.
PMID: 34021576
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
Palomba ML, Jun MP, Lymp J, Nguyen A, McGarvey N, Gitlin M, Pelletier C, Keating SJ, Godwin J, et al.
Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686. Online ahead of print.
PMID: 34018458
Myeloma NK cells are exhausted and have impaired regulation of activation.
D'Souza C, Keam SP, Yeang HXA, Neeson M, Richardson K, Hsu AK, Canfield R, Bezman N, Robbins M, Quach H, Ritchie DS, Harrison SJ, Trapani JA, Prince HM, Beavis PA, Darcy PK, Neeson PJ, et al.
Haematologica. 2021 May 20. doi: 10.3324/haematol.2020.277525. Online ahead of print.
PMID: 34011135
Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors.
Han X, Lobo F, Broder MS, Chang E, Gibbs SN, Ridley DJ, Yermilov I.
J Health Econ Outcomes Res. 2021 May 19;8(1):71-78. doi: 10.36469/jheor.2021.23684.
PMID: 34046511
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients.
Frerichs KA, Verkleij CPM, Dimopoulos MA, Marin Soto JA, Zweegman S, Young MH, Newhall KJ, Mutis T, van de Donk NWCJ, et al.
Cancers (Basel). 2021 May 18;13(10):2452. doi: 10.3390/cancers13102452.
PMID: 34070044
Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings.
Saboo S, Bapat P, Moseson DE, Kestur US, Taylor LS, et al.
Pharmaceutics. 2021 May 17;13(5):735. doi: 10.3390/pharmaceutics13050735.
PMID: 34067666
Toluidine blue staining of murine mast cells and quantitation by a novel, automated image analysis method using whole slide skin images.
Raja N, Naikodi S, Govindarajan A, Palanisamy K, et al.
J Histotechnol. 2021 May 17:1-6. doi: 10.1080/01478885.2021.1915934. Online ahead of print.
PMID: 33998401
Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice　- A Post-Marketing Surveillance.
Yamada N, Mo M, Ohsawa A, Sato M, Umeyama M, Shima D, Nakamura M, et al.
Circ J. 2021 May 15. doi: 10.1253/circj.CJ-20-0829. Online ahead of print.
PMID: 33994408
Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.
van Lint JA, Jessurun NT, Tas SW, van den Bemt BJF, Nurmohamed MT, van Doorn MBA, Spuls PI, van Tubergen AM, Ten Klooster PM, van Puijenbroek EP, Hoentjen F, Vonkeman HE, et al.
J Rheumatol. 2021 May 15:jrheum.201373. doi: 10.3899/jrheum.201373. Online ahead of print.
PMID: 33993115
Canadian Rheumatologists' Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis.
Gladman DD, Starr M, Cividino A, Gaudreau AJ, Jelley J, Nicholson D, Karsh J, et al.
J Rheumatol. 2021 May 15:jrheum.201195. doi: 10.3899/jrheum.201195. Online ahead of print.
PMID: 33993114
S CLIFF: A component-based, machine-learned, intermolecular force field.
Schriber JB, Nascimento DR, Koutsoukas A, Spronk SA, Cheney DL, Sherrill CD, et al.
J Chem Phys. 2021 May 14;154(18):184110. doi: 10.1063/5.0042989.
PMID: 34241025
Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors.
Xu L, Hartz RA, Beno BR, Ghosh K, Shukla JK, Kumar A, Patel D, Kalidindi N, Lemos N, Gautam SS, Kumar A, Ellsworth BA, Shah D, Sale H, Cheng D, Regueiro-Ren A, et al.
J Med Chem. 2021 May 27;64(10):6634-6655. doi: 10.1021/acs.jmedchem.0c02001. Epub 2021 May 14.
PMID: 33988358
Integrin αVβ1 regulates procollagen I production through a non-canonical transforming growth factor β signaling pathway in human hepatic stellate cells.
Han Z, Ma Y, Cao G, Ma Z, Chen R, Cvijic ME, Cheng D, et al.
Biochem J. 2021 May 14;478(9):1689-1703. doi: 10.1042/BCJ20200749.
PMID: 33876829
Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral Therapy.
Lapa D, Del Porto P, Minosse C, D'Offizi G, Antinori A, Capobianchi MR, Visco-Comandini U, McPhee F, Garbuglia AR, Zaccarelli M, et al.
J Clin Med. 2021 May 13;10(10):2092. doi: 10.3390/jcm10102092.
PMID: 34068071
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA, Mózes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, Levick CK, Young LAJ, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators.
J Hepatol. 2021 May 13:S0168-8278(21)00309-3. doi: 10.1016/j.jhep.2021.04.044. Online ahead of print.
PMID: 33991635
N -Ammonium Ylide Mediators for Electrochemical C-H Oxidation.
Saito M, Kawamata Y, Meanwell M, Navratil R, Chiodi D, Carlson E, Hu P, Chen L, Udyavara S, Kingston C, Tanwar M, Tyagi S, McKillican BP, Gichinga MG, Schmidt MA, Eastgate MD, Lamberto M, He C, Tang T, Malapit CA, Sigman MS, Minteer SD, Neurock M, Baran PS, et al.
J Am Chem Soc. 2021 May 26;143(20):7859-7867. doi: 10.1021/jacs.1c03780. Epub 2021 May 13.
PMID: 33983721
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration.
Wang H, Brown PC, Chow ECY, Ewart L, Ferguson SS, Fitzpatrick S, Freedman BS, Guo GL, Hedrich W, Heyward S, Hickman J, Isoherranen N, Li AP, Liu Q, Mumenthaler SM, Polli J, Proctor WR, Ribeiro A, Wang JY, Wange RL, Huang SM, et al.
Clin Transl Sci. 2021 May 13. doi: 10.1111/cts.13066. Online ahead of print.
PMID: 33982436
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K, et al.
Nat Commun. 2021 May 10;12(1):2607. doi: 10.1038/s41467-021-22874-x.
PMID: 33972549
Evaluation of fully-functionalized diazirine tags for chemical proteomic applications.
Conway LP, Jadhav AM, Homan RA, Li W, Rubiano JS, Hawkins R, Lawrence RM, Parker CG, et al.
Chem Sci. 2021 May 7;12(22):7839-7847. doi: 10.1039/d1sc01360b.
PMID: 34168837
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
Iwaki H, Leonard HL, Makarious MB, Bookman M, Landin B, Vismer D, Casey B, Gibbs JR, Hernandez DG, Blauwendraat C, Vitale D, Song Y, Kumar D, Dalgard CL, Sadeghi M, Dong X, Misquitta L, Scholz SW, Scherzer CR, Nalls MA, Biswas S, Singleton AB; Uniformed Services University of the Health Sciences Associates; AMP PD Whole Genome Sequencing Working Group; AMP PD consortium.
Mov Disord. 2021 May 7. doi: 10.1002/mds.28549. Online ahead of print.
PMID: 33960523
Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative.
Snee M, Cheeseman S, Thompson M, Riaz M, Sopwith W, Lacoin L, Chaib C, Manley Daumont M, Penrod JR, O'Donnell JC, Hall G, et al.
BMJ Open. 2021 May 3;11(5):e043442. doi: 10.1136/bmjopen-2020-043442.
PMID: 33941627
Dental nurse role in operatory during and post pandemic outbreak of COVID-19.
Sajja R.
J Family Med Prim Care. 2021 May;10(5):2047. doi: 10.4103/jfmpc.jfmpc_2229_20. Epub 2021 May 31.
PMID: 34195149
Evaluation of vanillin as a probe drug for aldehyde oxidase and phenotyping for its activity in a Western Indian Cohort.
Subash S, Gogtay NJ, Iyer KR, Gandhe P, Budania R, Thatte UM, et al.
Indian J Pharmacol. 2021 May-Jun;53(3):213-220. doi: 10.4103/ijp.IJP_463_18.
PMID: 34169906
Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys.
Wong PC and Quan ML.
Res Pract Thromb Haemost. 2021 May 28;5(4):e12524. doi: 10.1002/rth2.12524. eCollection 2021 May.
PMID: 34095733
The impact of ligand binding based assays critical reagent characterization and storage.
Haulenbeek J and Beaver CJ.
Bioanalysis. 2021 May;13(10):797-805. doi: 10.4155/bio-2020-0288. Epub 2021 May 18.
PMID: 34002637
Context matters in CAR T cell tonic signaling.
Hege K.
Nat Med. 2021 May;27(5):763-764. doi: 10.1038/s41591-021-01340-7.
PMID: 33972792
Calibrator material selection: a key criteria during biomarker assay method development.
Thankamony SP, Liu R, Peterson JE, Santockyte R, Olah T, Zhang Y, et al.
Bioanalysis. 2021 May;13(10):787-796. doi: 10.4155/bio-2020-0208. Epub 2021 May 7.
PMID: 33960820
Pain in Axial Spondyloarthritis: More to It Than Just Inflammation.
Magrey MN, Mease PJ, et al.
J Rheumatol. 2021 May 1:jrheum.210137. doi: 10.3899/jrheum.210137. Online ahead of print.
PMID: 33934079
Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.
Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB, et al.
J Rheumatol. 2021 May 1:jrheum.201532. doi: 10.3899/jrheum.201532. Online ahead of print.
PMID: 33934076
Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning.
Johansson FD, Collins JE, Yau V, Guan H, Kim SC, Losina E, Sontag D, Stratton J, Trinh H, Greenberg J, Solomon DH, et al.
J Rheumatol. 2021 May 1:jrheum.201626. doi: 10.3899/jrheum.201626. Online ahead of print.
PMID: 33934070
SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma.
Venugopalan A, Lynberg M, Cultraro CM, Nguyen KDP, Zhang X, Waris M, Dayal N, Abebe A, Maity TK, Guha U, et al.
Oncogene. 2021 May;40(18):3331-3346. doi: 10.1038/s41388-021-01764-y. Epub 2021 Apr 13.
PMID: 33850265
Genome-wide enhancer maps link risk variants to disease genes.
Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, Jones TR, Nguyen TH, Ulirsch JC, Lekschas F, Mualim K, Natri HM, Weeks EM, Munson G, Kane M, Kang HY, Cui A, Ray JP, Eisenhaure TM, Collins RL, Dey K, Pfister H, Price AL, Epstein CB, Kundaje A, Xavier RJ, Daly MJ, Huang H, Finucane HK, Hacohen N, Lander ES, Engreitz JM, et al.
Nature. 2021 May;593(7858):238-243. doi: 10.1038/s41586-021-03446-x. Epub 2021 Apr 7.
PMID: 33828297
United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument.
Revicki DA, King MT, Viney R, Pickard AS, Mercieca-Bebber R, Shaw JW, Müller F, Norman R, et al.
Med Decis Making. 2021 May;41(4):485-501. doi: 10.1177/0272989X211003569. Epub 2021 Apr 5.
PMID: 33813946
Novel techniques and the new age of biomarkers: panel discussion report.
Pasas-Farmer S, James C, Fandozzi C, Warrino D, Durham R, Hayes R, Cape S, Olah T.
Bioanalysis. 2021 May;13(9):675-678. doi: 10.4155/bio-2021-0049. Epub 2021 Mar 26.
PMID: 33769091
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A.
J Clin Oncol. 2021 May 1;39(13):1426-1436. doi: 10.1200/JCO.20.02619. Epub 2021 Mar 25.
PMID: 33764805
Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab.
Desai NR, Wade RL, Xiang P, Pinto L, Nunna S, Wang X, Exter J, Mues KE, Habib M, Chen CC.
Clin Cardiol. 2021 May;44(5):715-722. doi: 10.1002/clc.23600. Epub 2021 Mar 24.
PMID: 33760276
Evaluation of a polysaccharide-based chiral reversed-phase liquid chromatography screen strategy in pharmaceutical analysis.
Lin Z, Tai HC, Zhu G, Fabiano A, Borges-Muñoz A, Ye YK, He BL.
J Chromatogr A. 2021 May 24;1645:462085. doi: 10.1016/j.chroma.2021.462085. Epub 2021 Mar 22.
PMID: 33848654
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, De Botton S, Kiladjian JJ, Cayuela JM, Rolfe M, Chamberlain PP, Carr SA, Ebert BL.
Blood Cancer Discov. 2021 May;2(3):250-265. doi: 10.1158/2643-3230.bcd-20-0105. Epub 2021 Mar 10.
PMID: 34027417
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, Kumar G, Palmisano M, Tran JQ.
Drug Metab Dispos. 2021 May;49(5):405-419. doi: 10.1124/dmd.120.000220. Epub 2021 Mar 4.
PMID: 33674268
A Metal-Free Reductive N-Alkylation of Indoles with Aldehydes.
Clanton NA, Spiller TE, Ortiz E, Gao Z, Rodriguez-Poirier JM, DelMonte AJ, Frantz DE, et al.
Org Lett. 2021 May 7;23(9):3233-3236. doi: 10.1021/acs.orglett.1c00179. Epub 2021 Feb 25.
PMID: 33630601
Response-adaptive trial designs with accelerated Thompson sampling.
Wang J.
Pharm Stat. 2021 May;20(3):645-656. doi: 10.1002/pst.2098. Epub 2021 Feb 14.
PMID: 33586310
Development of HPLC-CAD stability indicating assay method for polyethylene glycol-conjugated phospholipid (DMPE-PEG 2000) and identification of its degradation products.
Kurmi M, Suryavanshi V, Panduranga NS, Jayaraman K, Bajpai L, Fish W, Hu Y, Bhutani H, et al.
J Pharm Biomed Anal. 2021 May 10;198:113967. doi: 10.1016/j.jpba.2021.113967. Epub 2021 Feb 12.
PMID: 33662758
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement.
Kim ES, Uldrick TS, Schenkel C, Bruinooge SS, Harvey RD, Magnuson A, Spira A, Wade JL, Stewart MD, Vega DM, Beaver JA, Denicoff AM, Ison G, Ivy SP, George S, Perez RP, Spears PA, Tap WD, Schilsky RL, et al.
Clin Cancer Res. 2021 May 1;27(9):2394-2399. doi: 10.1158/1078-0432.CCR-20-3852. Epub 2021 Feb 9.
PMID: 33563632
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 ☆ .
Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M, et al.
Ann Oncol. 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071. Epub 2021 Feb 1.
PMID: 33539946
A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping.
Singer BA, Keith S, Howerter A, Doll H, Pham T, Mehta R, et al.
Patient Prefer Adherence. 2021 May 12;15:975-987. doi: 10.2147/PPA.S297052. eCollection 2021.
PMID: 34012257
Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint.
Rosenberg AS, Facon T, Parikh K, Chung W, Srinivasan S, Kotey S, Tuscano J, et al.
Clin Lymphoma Myeloma Leuk. 2021 May;21(5):345-354.e4. doi: 10.1016/j.clml.2020.12.021. Epub 2020 Dec 27.
PMID: 33563582
Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study.
Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A, et al.
Int J Clin Oncol. 2021 May;26(5):1005-1006. doi: 10.1007/s10147-021-01879-y.
PMID: 33837490
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19.
Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS Jr, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG; Overcoming COVID-19 Investigators.
JAMA. 2021 Mar 16;325(11):1074-1087. doi: 10.1001/jama.2021.2091.
PMID: 33625505
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting.
Mease PJ, Calabrese LH, Callis Duffin K, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF.
J Rheumatol. 2021 Mar 15:jrheum.201671. doi: 10.3899/jrheum.201671. Online ahead of print.
PMID: 33722951
Pustular Psoriasis and Associated Musculoskeletal Disorders.
Callis Duffin K, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola J, Chau J, Kishimoto M, Furer V, Helliwell PS.
J Rheumatol. 2021 Mar 15:jrheum.201673. doi: 10.3899/jrheum.201673. Online ahead of print.
PMID: 33722939
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.
Gormley N, Fashoyin-Aje L, Locke T, Unger J, Little RF, Nooka A, Mezzi K, Popa-McKiver M, Kobos R, Biru Y, Williams TH, Anderson KC.
Blood Cancer Discov. 2021 Mar;2(2):119-124. doi: 10.1158/2643-3230.bcd-20-0123.
PMID: 34179821
Methodological considerations for measuring biofluid-based microRNA biomarkers.
Chorley BN, Atabakhsh E, Doran G, Gautier JC, Ellinger-Ziegelbauer H, Jackson D, Sharapova T, Yuen PST, Church RJ, Couttet P, Froetschl R, McDuffie J, Martinez V, Pande P, Peel L, Rafferty C, Simutis FJ, Harrill AH.
Crit Rev Toxicol. 2021 Mar;51(3):264-282. doi: 10.1080/10408444.2021.1907530. Epub 2021 May 26.
PMID: 34038674
Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study.
Tillett W, FitzGerald O, Coates LC, Packham J, Jadon DR, Massarotti M, Brook M, Lane S, Creamer P, Antony A, Korendowych E, Rambojun A, McHugh NJ, Helliwell PS; on behalf of the PROMPT Study Group.
J Rheumatol. 2021 Mar 1:jrheum.201675. doi: 10.3899/jrheum.201675. Online ahead of print.
PMID: 33649075
Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study.
Tillett W, FitzGerald O, Coates LC, Packham J, Jadon DR, Massarotti M, Brook M, Lane S, Creamer P, Antony A, Korendowych E, Rambojun A, McHugh NJ, Helliwell PS; PROMPT Study Group.
J Rheumatol. 2021 Mar 1:jrheum.201674. doi: 10.3899/jrheum.201674. Online ahead of print.
PMID: 33649073
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis.
Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Peltomaa R, Aaltonen K, Trokovic N, Kristianslund EK, Kvien TK, Provan SA, Gudbjornsson B, Grondal G, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson LTH, Askling J, et al.
J Rheumatol. 2021 Mar 1:jrheum.201467. doi: 10.3899/jrheum.201467. Online ahead of print.
PMID: 33649069
Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting.
Gladman DD, Helliwell PS, Poddubnyy D, Mease PJ, et al.
J Rheumatol. 2021 Mar 1:jrheum.201672. doi: 10.3899/jrheum.201672. Online ahead of print.
PMID: 33649067
Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database.
Soares M, Antunes L, Redondo P, Borges M, Hermans R, Patel D, Grimson F, Munro R, Chaib C, Lacoin L, Daumont M, Penrod JR, O'Donnell JC, Bento MJ, Gonçalves FR, et al.
Lung Cancer Manag. 2021 Feb 19;10(2):LMT46. doi: 10.2217/lmt-2020-0028.
PMID: 34084212
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.
Stober C, Jadon DR, Armstrong AW, Chandran V, de Wit M, Helliwell PS, Mease P, Ogdie A, O'Sullivan D, Pennington SR, Löve T, Cauli A, van Mens L, Waxman R, Scher JU, Barton A, Ritchlin CT, FitzGerald O, et al.
J Rheumatol. 2021 Feb 15:jrheum.201667. doi: 10.3899/jrheum.201667. Online ahead of print.
PMID: 33589562
GRAPPA 2020 Update From the Education Committee.
Mease PJ, Garg A, Helliwell PS; GRAPPA Education Committee.
J Rheumatol. 2021 Feb 15:jrheum.201678. doi: 10.3899/jrheum.201678. Online ahead of print.
PMID: 33589560
Diagnostic Delay in Psoriatic Arthritis: A Population-based Study.
Karmacharya P, Wright K, Achenbach SJ, Bekele D, Crowson CS, Ogdie A, Duarte-García A, Ernste FC, Tollefson MM, Davis JM 3rd.
J Rheumatol. 2021 Feb 15:jrheum.201199. doi: 10.3899/jrheum.201199. Online ahead of print.
PMID: 33589556
Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Callis Duffin K, Gottlieb AB, O'Sullivan D, Gladman DD, McFarland LV, et al.
J Rheumatol. 2021 Feb 15:jrheum.201666. doi: 10.3899/jrheum.201666. Online ahead of print.
PMID: 33589551
GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.
Coates LC, Corp N, van der Windt DA, Soriano ER, Kavanaugh A, et al.
J Rheumatol. 2021 Feb 15:jrheum.201681. doi: 10.3899/jrheum.201681. Online ahead of print.
PMID: 33589547
Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.
Ogdie A and Ritchlin CT.
J Rheumatol. 2021 Feb 15:jrheum.201669. doi: 10.3899/jrheum.201669. Online ahead of print.
PMID: 33589545
Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient.
McCord M, Lukas RV, Amidei C, Demars N, Gelb A, Buck J, Sachdev S, Feldman A, Tate M, Dixit K, Brat DJ, Jennings L, Horbinski C, et al.
Neurooncol Adv. 2021 Mar 15;3(1):vdab045. doi: 10.1093/noajnl/vdab045. eCollection 2021 Jan-Dec.
PMID: 34250480
Follicular lymphoma dynamics.
Milpied P, Gandhi AK, Cartron G, Pasqualucci L, Tarte K, Nadel B, Roulland S, et al.
Adv Immunol. 2021;150:43-103. doi: 10.1016/bs.ai.2021.05.002. Epub 2021 Jun 18.
PMID: 34176559
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Madduri D, Hagiwara M, Parikh K, Pelletier C, Delea TE, Kee A, Chari A, et al.
Future Oncol. 2021 Feb;17(5):503-515. doi: 10.2217/fon-2020-1003. Epub 2020 Dec 2.
PMID: 33522834
Application of First Principles Primary Drying Model to Lyophilization Process Design and Transfer: Case Studies From the Industry.
Tchessalov S, Latshaw D 2nd, Nulu S, Bentley M, Tharp T, Ewan S, Chen X, et al.
J Pharm Sci. 2021 Feb;110(2):968-981. doi: 10.1016/j.xphs.2020.11.013. Epub 2020 Nov 26.
PMID: 33248058
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study.
Felker GM, McMurray JJV, Cleland JG, O'Connor CM, Teerlink JR, Voors AA, Belohlavek J, Böhm M, Borentain M, Bueno H, Cole RT, DeSouza MM, Ezekowitz JA, Filippatos G, Lang NN, Kessler PD, Martinez FA, Mebazaa A, Metra M, Mosterd A, Pang PS, Ponikowski P, Sato N, Seiffert D, Ye J, et al.
JACC Heart Fail. 2021 Feb;9(2):146-157. doi: 10.1016/j.jchf.2020.10.012. Epub 2020 Nov 25.
PMID: 33248986
Enabling direct and definitive free fraction determination for highly-bound compounds in protein binding assay.
Zhang J, Pikul G, Horch J, Konovalov D, Li S, Cvijic ME, Shou W, Weller H, et al.
J Pharm Biomed Anal. 2021 Feb 5;194:113765. doi: 10.1016/j.jpba.2020.113765. Epub 2020 Nov 20.
PMID: 33272788
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
MacLachlan TK, Kronenberg S, Marshall N, Andrews L, Berens SJ, Brouta F, Fogal B, Freebern W, Herzyk D, Kamperschroer C, Kiessling A, Schneidkraut M, Maier C, et al.
Regul Toxicol Pharmacol. 2021 Feb;119:104825. doi: 10.1016/j.yrtph.2020.104825. Epub 2020 Nov 19.
PMID: 33220389
Scientific Best Practices for Primary Sequence Confirmation and Sequence Variant Analysis in the Development of Therapeutic Proteins.
Lund A, Ren D, Rogers RS, Rouse JC, Yu XC, Valliere-Douglass JF, et al.
J Pharm Sci. 2021 Feb;110(2):619-626. doi: 10.1016/j.xphs.2020.11.007. Epub 2020 Nov 17.
PMID: 33212163
Preclinical  in vitro  and  in vivo  pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy.
Grillo MP, Markova S, Evanchik M, Trellu M, Moliner P, Brun P, Perreard-Dumaine A, Vicat P, Driscoll JP, Carlson TJ, et al.
Xenobiotica. 2021 Feb;51(2):222-238. doi: 10.1080/00498254.2020.1839982. Epub 2020 Nov 16.
PMID: 33078965
The performance, reliability and potential application of in silico models for predicting the acute oral toxicity of pharmaceutical compounds.
Graham JC, Rodas M, Hillegass J, Schulze G, et al.
Regul Toxicol Pharmacol. 2021 Feb;119:104816. doi: 10.1016/j.yrtph.2020.104816. Epub 2020 Nov 6.
PMID: 33166621
Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach.
Kumar V, Yin M, Ishida K, Salphati L, Hop CECA, Rowbottom C, Xiao G, Lai Y, Mathias A, Chu X, Humphreys WG, Liao M, Nerada Z, Szilvásy N, Heyward S, Unadkat JD, et al.
Drug Metab Dispos. 2021 Feb;49(2):159-168. doi: 10.1124/dmd.120.000204. Epub 2020 Oct 13.
PMID: 33051248
Acoustic Ejection/Full-Scan Mass Spectrometry Analysis for High-Throughput Compound Quality Control.
Zhang J, Zhang Y, Liu C, Covey T, Nielsen J, Li S, Weller H, Shou W, et al.
SLAS Technol. 2021 Apr;26(2):178-188. doi: 10.1177/2472630320967625. Epub 2020 Nov 16.
PMID: 33196338
Selectivity in the Elaboration of Bicyclic Borazarenes.
Bhattacharjee A, Davies GHM, Saeednia B, Wisniewski SR, Molander GA, et al.
Adv Synth Catal. 2021 Apr 27;363(9):2256-2273. doi: 10.1002/adsc.202001384. Epub 2020 Dec 23.
PMID: 34335130
Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
Preston RA, Marbury T, Balaratnam G, Green M, Dixon S, Lehrer-Graiwer J, Washington C, et al.
J Clin Pharmacol. 2021 Apr;61(4):493-505. doi: 10.1002/jcph.1757. Epub 2020 Oct 20.
PMID: 33084052
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.
Liu Q, Xiao HY, Batt DG, Xiao Z, Zhu Y, Yang MG, Li N, Yip S, Li P, Sun D, Wu DR, Ruzanov M, Sack JS, Weigelt CA, Wang J, Li S, Shuster DJ, Xie JH, Song Y, Sherry T, Obermeier MT, Fura A, Stefanski K, Cornelius G, Chacko S, Khandelwal P, Dudhgaonkar S, Rudra A, Nagar J, Murali V, Govindarajan A, Denton R, Zhao Q, Meanwell NA, Borzilleri R, Dhar TGM, et al.
ACS Med Chem Lett. 2021 Apr 30;12(5):827-835. doi: 10.1021/acsmedchemlett.1c00112. eCollection 2021 May 13.
PMID: 34055233
Development and Validation of 3 Preliminary MRI Sacroiliac Joint Composite Structural Damage Scores In a 5-year Longitudinal Axial Spondyloarthritis Study.
Wetterslev M, Østergaard M, Sørensen IJ, Weber U, Loft AG, Kollerup G, Juul L, Thamsborg G, Madsen OR, Møller JM, Pedersen SJ, et al.
J Rheumatol. 2021 Apr 15:jrheum.201075. doi: 10.3899/jrheum.201075. Online ahead of print.
PMID: 33858979
Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.
Tanaka Y, Takeuchi T, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D, et al.
J Rheumatol. 2021 Apr 15:jrheum.201376. doi: 10.3899/jrheum.201376. Online ahead of print.
PMID: 33858976
Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ, McLean RR, Dube B, Liu M, Rebello S, Glynn M, Yi E, Park Y, Ogdie A, et al.
J Rheumatol. 2021 Apr 15:jrheum.201549. doi: 10.3899/jrheum.201549. Online ahead of print.
PMID: 33858974
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre-Sancho JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ, Blanco R; Tofacitinib PsA Clinical Practice Collaborative Group.
J Rheumatol. 2021 Apr 1:jrheum.201204. doi: 10.3899/jrheum.201204. Online ahead of print.
PMID: 33795330
GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.
Richlin CT, Armstrong A, Johnsson H, Mulder MLM.
J Rheumatol. 2021 Apr 1:jrheum.201670. doi: 10.3899/jrheum.201670. Online ahead of print.
PMID: 33795328
Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years.
Pope JE, Quansah K, Hassan S, Seung SJ, Flavin J, Kolb M.
J Rheumatol. 2021 Apr 1:jrheum.201049. doi: 10.3899/jrheum.201049. Online ahead of print.
PMID: 33795325
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M.
Lung Cancer. 2021 Apr 30:S0169-5002(21)00165-3. doi: 10.1016/j.lungcan.2021.04.022. Online ahead of print.
PMID: 33980420
FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective.
Bai JPF, Schmidt BJ, Gadkar KG, Damian V, Earp JC, Friedrich C, van der Graaf PH, Madabushi R, Musante CJ, Naik K, Rogge M, Zhu H.
AAPS J. 2021 Apr 30;23(3):60. doi: 10.1208/s12248-021-00585-x.
PMID: 33931790
"HIGH-RISK" HOST CELL PROTEINS (HCPs): A MULTI-COMPANY COLLABORATIVE VIEW.
Jones M, Palackal N, Wang F, Gaza-Bulseco G, Hurkmans K, Zhao Y, Chitikila C, Clavier S, Liu S, Menesale E, Schonenbach NS, Sharma S, Valax P, Waerner T, Zhang L, Connolly T.
Biotechnol Bioeng. 2021 Apr 30. doi: 10.1002/bit.27808. Online ahead of print.
PMID: 33930190
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Tang D, Abraham P, Lord-Bessen J, Rose S, Guo S, Liao W, Mesa RA.
Hemasphere. 2021 Apr 29;5(5):e562. doi: 10.1097/HS9.0000000000000562. eCollection 2021 May.
PMID: 33969275
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN.
Hemasphere. 2021 Apr 29;5(5):e553. doi: 10.1097/HS9.0000000000000553. eCollection 2021 May.
PMID: 33969273
Calcitonin gene-related peptide (CGRP) receptor antagonists: Heterocyclic modification of a novel azepinone lead.
Luo G, Jiang XJ, Chen L, Conway CM, Gulianello M, Kostich W, Keavy D, Signor LJ, Chen P, Davis C, Whiterock VJ, Schartman R, Widmann KA, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett. 2021 Apr 29;43:128077. doi: 10.1016/j.bmcl.2021.128077. Online ahead of print.
PMID: 33932522
Sensitive multiple myeloma disease monitoring by mass spectrometry.
Santockyte R, Jin C, Pratt J, Ammar R, Desai K, Bolisetty M, Das P, Popa-McKiver M, Puig O.
Blood Cancer J. 2021 Apr 29;11(4):78. doi: 10.1038/s41408-021-00473-9.
PMID: 33927186
Population Pharmacokinetics of CC-122.
Cheng Y, Chen J, Pourdehnad M, Zhou S, Li Y.
Clin Pharmacol. 2021 Apr 28;13:61-71. doi: 10.2147/CPAA.S310604. eCollection 2021.
PMID: 33958900
Detection of atrial fibrillation in asymptomatic at-risk individuals.
Langer A, Healey JS, Quinn FR, Honos G, Nault I, Tan M, Camara D, Newman DM, Godin R; AWARE AF Program. Int J Cardiol. 2021 Apr 28:S0167-5273(21)00737-3. doi: 10.1016/j.ijcard.2021.04.048. Online ahead of print.
PMID: 33932428
Novel Advances in Biotransformation and Bioactivation Research - 2020 year in review.
Khojasteh SC, Argikar UA, Driscoll JP, Heck CJS, King L, Jackson KD, Jian W, Kalgutkar AS, Miller GP, Kramlinger V, Rietjens IMCM, Teitelbaum AM, Wang K, Wei C.
Drug Metab Rev. 2021 Apr 28:1-91. doi: 10.1080/03602532.2021.1916028. Online ahead of print.
PMID: 33910427
Development and Validation of a Sensitive, Specific and Reproducible UPLC-MS/MS Method for the Quantification of OJT007, A Novel Anti-Leishmanial Agent: Application to a Pharmacokinetic Study.
Rincon Nigro M, Ma J, Awosemo OT, Xie H, Olaleye OA, Liang D.
Int J Environ Res Public Health. 2021 Apr 27;18(9):4624. doi: 10.3390/ijerph18094624.
PMID: 33925369
Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Patrick DL, Powers A, Jun MP, Kim Y, Garcia J, Dehner C, Maloney DG.
Blood Adv. 2021 Apr 27;5(8):2245-2255. doi: 10.1182/bloodadvances.2020003503.
PMID: 33904895
A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.
Mason EF, Pozdnyakova O, Roshal M, Fathi AT, Stein EM, Ferrell PB, Shaver AC, Frattini M, Wang H, Hua L, Mu J, Choe S, Xu R, Almon C, Cooper M, Stone RM, Hasserjian RP, Savona MR.
Blood Adv. 2021 Apr 27;5(8):2279-2283. doi: 10.1182/bloodadvances.2020003685.
PMID: 33904894
Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis.
Tasneen R, Mortensen DS, Converse PJ, Urbanowski ME, Upton A, Fotouhi N, Nuermberger E, Hawryluk N.
Antimicrob Agents Chemother. 2021 Apr 26:AAC.00253-21. doi: 10.1128/AAC.00253-21. Online ahead of print.
PMID: 33903099
Using continuous chromatography methodology to achieve high-productivity and high-purity enrichment of charge variants for analytical characterization.
Bigelow E, Song Y, Chen J, Holstein M, Huang Y, Duhamel L, Stone K, Furman R, Li ZJ, Ghose S.
J Chromatogr A. 2021 Apr 26;1643:462008. doi: 10.1016/j.chroma.2021.462008. Epub 2021 Mar 18.
PMID: 33780880
Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.
Cohan S, Tencer T, Arndorfer S, Zhu X, Zivkovic M, Kumar J.
Mult Scler Relat Disord. 2021 Apr 25;52:102972. doi: 10.1016/j.msard.2021.102972. Online ahead of print.
PMID: 33979770
Retrospective Assessment of Clonal Origin of Cell Lines.
Langsdorf E, Yu L, Kanevskaia L, Felkner R, Sturner S, McVey D, Khetan A.
Biotechnol Prog. 2021 Apr 25. doi: 10.1002/btpr.3157. Online ahead of print.
PMID: 33896120
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S.
Leuk Lymphoma. 2021 Apr 24:1-10. doi: 10.1080/10428194.2021.1913143. Online ahead of print.
PMID: 33896344
Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
Kim H, Cook G, Goodall S, Liew D.
Pharmacoecon Open. 2021 Apr 23. doi: 10.1007/s41669-021-00265-8. Online ahead of print.
PMID: 33891268
CHA 2 DS 2 -VASc and HAS-BLED risk scores and real-world oral anticoagulant prescribing decisions in atrial fibrillation.
Besford M, Leahy TP, Sammon C, Ulvestad M, Carroll R, Mehmud F, Alikhan R, Ramagopalan S.
Future Cardiol. 2021 Apr 23. doi: 10.2217/fca-2020-0175. Online ahead of print.
PMID: 33890499
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Cejalvo MJ, Bustamante G, González E, Vázquez-Álvarez J, García R, Ramírez-Payer Á, Pérez-Persona E, Abella E, Garzón S, García A, Jarque I, González MS, Sampol A, Motlló C, Martí JM, Alcalá M, Duro R, González Y, Sastre JL, Sarrà J, Lostaunau G, López R, de la Rubia J.
Ann Hematol. 2021 Apr 22. doi: 10.1007/s00277-021-04529-5. Online ahead of print.
PMID: 33885924
Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA.
Neuro Oncol. 2021 Apr 21:noab094. doi: 10.1093/neuonc/noab094. Online ahead of print.
PMID: 33880555
Solvent-Casted Films to Assist Polymer Selection for Amorphous Solid Dispersions During Preclinical Studies: In-vitro and In-vivo Exploration.
Mosquera-Giraldo LI, Donoso M, Stefanski K, Foster K, Gesenberg C, Abraham P, Ren Y, Rose A, Freeden C, Ranasinghe A.
Pharm Res. 2021 Apr 20. doi: 10.1007/s11095-021-03040-w. Online ahead of print.
PMID: 33880721
PCA062, a P-cadherin targeting antibody-drug-conjugate, displays potent anti-tumor activity against P-cadherin-expressing malignancies.
Sheng Q, D'Alessio JA, Menezes DL, Karim C, Tang Y, Tam A, Clark S, Ying C, Connor A, Mansfield KG, Rondeau JM, Ghoddusi M, Geyer FC, Gu J, McLaughlin ME, Newcombe R, Elliott G, Tschantz WR, Lehmann S, Miller K, Huber T, Rendahl KG, Jeffry U, Pryer NK, Lees E, Kwon P, Abraham JA, Damiano JS, Abrams TJ.
Mol Cancer Ther. 2021 Apr 20:molcanther.0708.2020. doi: 10.1158/1535-7163.MCT-20-0708. Online ahead of print.
PMID: 33879555
Physiochemical properties of enveloped viruses and arginine dictate inactivation.
Meingast CL, Joshi PU, Turpeinen DG, Xu X, Holstein M, Feroz H, Ranjan S, Ghose S, Li ZJ, Heldt CL.
Biotechnol J. 2021 Apr 20:e2000342. doi: 10.1002/biot.202000342. Online ahead of print.
PMID: 33877739
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR.
J Clin Oncol. 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. Epub 2021 Mar 8.
PMID: 33683919
Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects.
Kandasamy R, Hillhouse TM, Livingston KE, Kochan KE, Meurice C, Eans SO, Li MH, White AD, Roques BP, McLaughlin JP, Ingram SL, Burford NT, Alt A, Traynor JR.
Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2000017118. doi: 10.1073/pnas.2000017118.
PMID: 33846240
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U.
J Clin Oncol. 2021 Apr 20;39(12):1317-1328. doi: 10.1200/JCO.20.01366. Epub 2021 Feb 23.
PMID: 33621109
Pediatric Formulation Development - Challenges of Today and Strategies for Tomorrow: Summary Report from M-CERSI Workshop 2019.
Cheng Thiam Tan D, Mei Khong Y, Mount S, Galella E, Mitra B, Charlton S, Kuhli M, Ternik R, Walsh J, Rajapakshe A, Thompson K, Mehrotra S, Santangelo M, Liu J, Dixit T, Schaufelberger D, Jamzad S, Klein S, Hoag SW, Wang J, Pfuma Fletcher E, Khurana M, Alexander J, Radden E, Sood R, Selen A.
Eur J Pharm Biopharm. 2021 Apr 17:S0939-6411(21)00102-8. doi: 10.1016/j.ejpb.2021.04.011. Online ahead of print.
PMID: 33878432
A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence.
Kieran MW, Caron H, Winther JF, Henderson TO, Haupt R, Hjorth L, Hudson MM, Kremer LCM, van der Pal HJ, Pearson ADJ, Pereira L, Reaman G, Skinner R, Vassal G, Weiner SL, Horton Taylor D; ACCELERATE Long-Term Follow-Up Working Group.
Pediatr Blood Cancer. 2021 Apr 16:e29047. doi: 10.1002/pbc.29047. Online ahead of print.
PMID: 33860611
Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Deitelzweig S, Di Fusco M, Kang A, Savone M, Mokgokong R, Keshishian A, Gutierrez C, Cappelleri JC.
Curr Med Res Opin. 2021 Apr 16:1-12. doi: 10.1080/03007995.2021.1897555. Online ahead of print.
PMID: 33686900
Quantitative mapping of the cellular small RNA landscape with AQRNA-seq.
Hu JF, Yim D, Ma D, Huber SM, Davis N, Bacusmo JM, Vermeulen S, Zhou J, Begley TJ, DeMott MS, Levine SS, de Crécy-Lagard V, Dedon PC, Cao B.
Nat Biotechnol. 2021 Apr 15. doi: 10.1038/s41587-021-00874-y. Online ahead of print.
PMID: 33859402
An integrated Qual/Quan strategy for ganglioside lipidomics using high-resolution mass spectrometry and Skyline software.
Ranasinghe A, Ciccimaro E Jr, D'Arienzo C, Olah TV, Ponath P, Hnatyshyn S.
Rapid Commun Mass Spectrom. 2021 Apr 15;35(7):e9041. doi: 10.1002/rcm.9041.
PMID: 33415785
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Waterhouse D, Lam J, Betts KA, Yin L, Gao S, Yuan Y, Hartman J, Rao S, Lubinga S, Stenehjem D.
Lung Cancer. 2021 Apr 14;156:41-49. doi: 10.1016/j.lungcan.2021.04.007. Online ahead of print.
PMID: 33894493
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy.
Stenehjem D, Lubinga S, Betts KA, Tang W, Jenkins M, Yuan Y, Hartman J, Rao S, Lam J, Waterhouse D.
Future Oncol. 2021 Apr 14. doi: 10.2217/fon-2021-0230. Online ahead of print.
PMID: 33849296
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.
Oberg AL, Heinzen EP, Hou X, Al Hilli MM, Hurley RM, Wahner Hendrickson AE, Goergen KM, Larson MC, Becker MA, Eckel-Passow JE, Maurer MJ, Kaufmann SH, Haluska P, Weroha SJ.
Sci Rep. 2021 Apr 13;11(1):8076. doi: 10.1038/s41598-021-87470-x.
PMID: 33850213
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
CNS Drugs. 2021 Apr 13. doi: 10.1007/s40263-021-00805-0. Online ahead of print.
PMID: 33847901
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.
Mo Z, Wood S, Namiranian S, Mizukoshi R, Weng S, Jang IS, Fontanillo C, Baughman JM, Silva-Torres A, Slade M, Khater M, Wang K, Rolfe M, Lu G.
Blood Adv. 2021 Apr 13;5(7):2027-2039. doi: 10.1182/bloodadvances.2020003431.
PMID: 33847741
Antibody Disulfide Bond Reduction and Recovery during Biopharmaceutical Process Development - A Review.
Ren T, Tan Z, Ehamparanathan V, Lewandowski A, Ghose S, Li ZJ.
Biotechnol Bioeng. 2021 Apr 12. doi: 10.1002/bit.27790. Online ahead of print.
PMID: 33844277
Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.
Healy BC, Glanz BI, Swallow E, Signorovitch J, Hagan K, Silva D, Pelletier C, Chitnis T, Weiner H.
Mult Scler J Exp Transl Clin. 2021 Apr 11;7(2):2055217321999070. doi: 10.1177/2055217321999070. eCollection 2021 Apr-Jun.
PMID: 33953937
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
Hopson MB, Lee S, Accordino M, Trivedi M, Maurer M, Crew KD, Hershman DL, Kalinsky K.
Breast Cancer Res Treat. 2021 Apr 10. doi: 10.1007/s10549-021-06210-x. Online ahead of print.
PMID: 33837871
Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD.
Clin Cancer Res. 2021 Apr 9. doi: 10.1158/1078-0432.CCR-20-4574. Online ahead of print.
PMID: 33837006
Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting.
Kariya S, Shimizu Y, Hanai N, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Fujiwara A, Yamada T, Homma A.
Int J Clin Oncol. 2021 Apr 8. doi: 10.1007/s10147-021-01900-4. Online ahead of print.
PMID: 33830342
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani R, Moskowitz AJ, Bartlett NL, Vose J, Ramchandren R, Feldman T, LaCasce AS, Christian B, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF.
Blood. 2021 Apr 7:blood.2020009178. doi: 10.1182/blood.2020009178. Online ahead of print.
PMID: 33827139
New Peak Detection Performance Metrics from the MAM Consortium Interlaboratory Study.
Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Barysz HM, Jahn M, Niu B, Wang J, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H.
J Am Soc Mass Spectrom. 2021 Apr 7;32(4):913-928. doi: 10.1021/jasms.0c00415. Epub 2021 Mar 12.
PMID: 33710905
Miscalculating equilibrium constants for multivalent protein complexes: Site-binding concentration or protein molecular concentration?
Klakamp SL, Drake AW.
J Pharm Sci. 2021 Apr 6:S0022-3549(21)00195-7. doi: 10.1016/j.xphs.2021.03.026. Online ahead of print.
PMID: 33831440
The Development of Reaction Cascades to Synthesize Dimeric Coccinellid Alkaloids.
Lisnyak VG, Sherwood TC, Snyder SA.
Acc Chem Res. 2021 Apr 6;54(7):1610-1622. doi: 10.1021/acs.accounts.0c00806. Epub 2021 Mar 1.
PMID: 33646762
Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.
Kang HS, Kwon MJ, Haynes P, Liang Y, Ren Y, Lim H, Soh JS, Kim NY, Lee HK.
Pathol Res Pract. 2021 Apr 5;222:153434. doi: 10.1016/j.prp.2021.153434. Online ahead of print.
PMID: 33857852
Coming of age of Allotrope: Proceedings from the Fall 2020 Allotrope Connect.
Millecam T, Jarrett AJ, Young N, Vanderwall DE, Della Corte D.
Drug Discov Today. 2021 Apr 5:S1359-6446(21)00165-3. doi: 10.1016/j.drudis.2021.03.028. Online ahead of print.
PMID: 33831582
Insights into Glucose-6-phosphate Allosteric Activation of β-Glucosidase A.
A Gomes A, da Silva GF, Lakkaraju SK, Guimarães BG, MacKerell AD Jr, Magalhães MLB.
J Chem Inf Model. 2021 Apr 26;61(4):1931-1941. doi: 10.1021/acs.jcim.0c01450. Epub 2021 Apr 5.
PMID: 33819021
Automated and Faster Affinity Capture Method for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates.
Jashnani A, Kotapati S, Deshpande M, Yamazoe S, Strop P, Rajpal A, Dollinger G.
Anal Chem. 2021 Apr 6;93(13):5371-5376. doi: 10.1021/acs.analchem.0c04685. Epub 2021 Mar 22.
PMID: 33750099
Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC.
Ann Surg Oncol. 2021 Apr 3. doi: 10.1245/s10434-021-09816-z. Online ahead of print.
PMID: 33813673
Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO).
Hu CH, Neissel Valente MW, Halpern OS, Jusuf S, Khan JA, Locke GA, Duke GJ, Liu X, Duclos FJ, Wexler RR, Kick EK, Smallheer JM.
Bioorg Med Chem Lett. 2021 Apr 1;42:128010. doi: 10.1016/j.bmcl.2021.128010. Online ahead of print.
PMID: 33811992
A catalog of GWAS fine-mapping efforts in autoimmune disease.
Caliskan M, Brown CD, Maranville JC.
Am J Hum Genet. 2021 Apr 1;108(4):549-563. doi: 10.1016/j.ajhg.2021.03.009.
PMID: 33798443
Development of an international template to support patient submissions in Health Technology Assessments.
Cook N, Livingstone H, Dickson J, Taylor L, Morgan K, Coombes M, Wortley S, Oehrlein E, Vicente-Edo MJ, Waibel F, Liden B.
Int J Technol Assess Health Care. 2021 Apr 1;37(1):e50. doi: 10.1017/S0266462321000167.
PMID: 33789779
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators.
N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
PMID: 33789008
Achieving a low human dose for targeted covalent drugs: Pharmacokinetic and pharmacodynamic considerations on target characteristics and drug attributes.
Yang Z.
Biopharm Drug Dispos. 2021 Apr;42(4):150-159. doi: 10.1002/bdd.2263. Epub 2021 Apr 2.
PMID: 33547681
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kortüm KM, Saliba AE, Rasche L.
Nat Med. 2021 Apr;27(4):616-619. doi: 10.1038/s41591-021-01245-5. Epub 2021 Feb 22.
PMID: 33619368
Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).
Fisher MJ, Jones DTW, Li Y, Guo X, Sonawane PS, Waanders AJ, Phillips JJ, Weiss WA, Resnick AC, Gosline S, Banerjee J, Guinney J, Gnekow A, Kandels D, Foreman NK, Korshunov A, Ryzhova M, Massimi L, Gururangan S, Kieran MW, Wang Z, Fouladi M, Sato M, Øra I, Holm S, Markham SJ, Beck P, Jäger N, Wittmann A, Sommerkamp AC, Sahm F, Pfister SM, Gutmann DH.
Acta Neuropathol. 2021 Apr;141(4):605-617. doi: 10.1007/s00401-021-02276-5. Epub 2021 Feb 14.
PMID: 33585982
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma ☆ .
Tarhini AA, Toor K, Chan K, McDermott DF, Mohr P, Larkin J, Hodi FS, Lee CH, Rizzo JI, Johnson H, Moshyk A, Rao S, Kotapati S, Atkins MB.
ESMO Open. 2021 Apr;6(2):100050. doi: 10.1016/j.esmoop.2021.100050. Epub 2021 Feb 6.
PMID: 33556898
Identification and stratification of systemic lupus erythematosus patients into two transcriptionally distinct clusters based on IFN-I signature.
Shobha V, Mohan A, Malini AV, Chopra P, Karunanithi P, Subramani Thulasingam S, Selvam S, Deyati A, Srivastava R, Basavanthappa S, Lemos N, Sunitha SM, Mazumder Tagore D, Anand A, Pant S, Jayaswal V, Ramarao M, Dudhgaonkar S.
Lupus. 2021 Apr;30(5):762-774. doi: 10.1177/0961203321990107. Epub 2021 Jan 26.
PMID: 33497307
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
Reck M, Ciuleanu TE, Lee JS, Schenker M, Audigier-Valette C, Zurawski B, Linardou H, Otterson GA, Salman P, Nishio M, de la Mora Jimenez E, Lesniewski-Kmak K, Albert I, Ahmed S, Syrigos K, Penrod JR, Yuan Y, Blum SI, Nathan FE, Sun X, Moreno-Koehler A, Taylor F, O'Byrne KJ.
J Thorac Oncol. 2021 Apr;16(4):665-676. doi: 10.1016/j.jtho.2020.12.019. Epub 2021 Jan 21.
PMID: 33485960
Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma.
Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R.
J Comp Eff Res. 2021 Apr;10(5):343-352. doi: 10.2217/cer-2020-0236. Epub 2021 Jan 14.
PMID: 33442996
Spatial presence depends on 'coupling' between body sway and visual motion presented on head-mounted displays (HMDs).
Chowdhury NS, Luu W, Palmisano S, Ujike H, Kim J.
Appl Ergon. 2021 Apr;92:103355. doi: 10.1016/j.apergo.2021.103355. Epub 2021 Jan 11.
PMID: 33444884
Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation.
Rivers-Auty J, Tapia VS, White CS, Daniels MJD, Drinkall S, Kennedy PT, Spence HG, Yu S, Green JP, Hoyle C, Cook J, Bradley A, Mather AE, Peters R, Tzeng TC, Gordon MJ, Beattie JH, Brough D, Lawrence CB.
J Neurosci. 2021 Mar 31;41(13):3025-3038. doi: 10.1523/JNEUROSCI.1980-20.2020. Epub 2021 Feb 17.
PMID: 33597269
Hydrophilic and Functionalized Nanographene Oxide Incorporated Faster Dissolving Megestrol Acetate.
Islam MS, Renner F, Foster K, Oderinde MS, Stefanski K, Mitra S.
Molecules. 2021 Mar 31;26(7):1972. doi: 10.3390/molecules26071972.
PMID: 33807401
DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis.
Dwyer M, Lyman C, Ferrari H, Bergsland N, Fuchs TA, Jakimovski D, Schweser F, Weinstock-Guttmann B, Benedict RHB, Riolo J, Silva D, Zivadinov R.
Neuroimage Clin. 2021 Mar 29;30:102652. doi: 10.1016/j.nicl.2021.102652. Online ahead of print.
PMID: 33872992
Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis.
Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E.
Ther Adv Musculoskelet Dis. 2021 Mar 29;13:1759720X211002682. doi: 10.1177/1759720X211002682. eCollection 2021.
PMID: 33854570
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
MacBeth KJ, Chopra VS, Tang L, Zheng B, Avanzino B, See WL, Schwickart M, Figueroa ME, Quek L, DiMartino JF.
Exp Hematol. 2021 Mar 29:S0301-472X(21)00128-4. doi: 10.1016/j.exphem.2021.03.003. Online ahead of print.
PMID: 33794295
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Lei M, Siemers NO, Pandya D, Chang H, Sanchez T, Harbison C, Szabo PM, Janjigian Y, Ott PA, Sharma P, Bendell J, Evans TRJ, de Braud F, Chau I, Boyd Z.
Clin Cancer Res. 2021 Mar 29. doi: 10.1158/1078-0432.CCR-20-2790. Online ahead of print.
PMID: 33782030
Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM, Nwokeji ED, Boyd M, Penrod JR, Espirito JL, Robert NJ, Daumont MJ.
Future Oncol. 2021 Mar 26. doi: 10.2217/fon-2021-0047. Online ahead of print.
PMID: 33769073
Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate.
Johnson JA, Kim SH, Jiang J, Phillips M, Schumacher WA, Bostwick JS, Gargalovic PS, Onorato JM, Luk CE, Generaux C, He Y, Chen XQ, Xu C, Galella MA, Wang T, Gordon DA, Wexler RR, Finlay HJ.
J Med Chem. 2021 Mar 25;64(6):3086-3099. doi: 10.1021/acs.jmedchem.0c01878. Epub 2021 Mar 9.
PMID: 33689340
Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome.
Chen YH, Zastrow DB, Metcalfe RD, Gartner L, Krause F, Morton CJ, Marwaha S, Fresard L, Huang Y, Zhao C, McCormack C, Bick D, Worthey EA, Eng CM, Gold J, Undiagnosed Diseases Network, Montgomery SB, Fisher PG, Ashley EA, Wheeler MT, Parker MW, Shanmugasundaram V, Putoczki TL, Schmidt-Arras D, Laurence A, Bernstein JA, Griffin MDW, Uhlig HH.
J Allergy Clin Immunol. 2021 Mar 23:S0091-6749(21)00471-1. doi: 10.1016/j.jaci.2021.02.044. Online ahead of print.
PMID: 33771552
Fc-optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Campbell JR, McDonald BR, Mesko PB, Siemers NO, Singh PB, Selby M, Sproul TW, Korman AJ, Vlach LM, Houser J, Sambanthamoorthy S, Lu K, Hatcher SV, Lohre J, Jain R, Lan RY.
Cancer Res. 2021 Mar 23:canres.3585.2020. doi: 10.1158/0008-5472.CAN-20-3585. Online ahead of print.
PMID: 33757978
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.
Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, Snyder S, McGarvey N, Gitlin M, Pelletier C, Jun MP.
Blood Adv. 2021 Mar 23;5(6):1695-1705. doi: 10.1182/bloodadvances.2020003531.
PMID: 33720336
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB, Parkhomenko A, Bahit MC, Windecker S, Aronson R, Berwanger O, Halvorsen S, de Waha-Thiele S, Sinnaeve P, Darius H, Storey RF, Lopes RD.
Circulation. 2021 Mar 23;143(12):1215-1223. doi: 10.1161/CIRCULATIONAHA.120.051020. Epub 2021 Jan 19.
PMID: 33461308
Investigation into the Role of ERK in Tyrosine Kinase Inhibitor-Induced Neuropathy.
Belair DG, Sudak K, Connelly K, Collins ND, Kopytek SJ, Kolaja KL.
Toxicol Sci. 2021 Mar 22:kfab033. doi: 10.1093/toxsci/kfab033. Online ahead of print.
PMID: 33749749
Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients.
Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Jiang J, Yuce H, Lip GYH.
Therap Adv Gastroenterol. 2021 Mar 21;14:1756284821997352. doi: 10.1177/1756284821997352. eCollection 2021.
PMID: 33815568
Analysis of biopharmaceutical formulations by Time Domain Nuclear Magnetic Resonance (TD-NMR) spectroscopy: A potential method for detection of counterfeit biologic pharmaceuticals.
Akhunzada Z, Wu Y, Haby T, Jayawickrama D, McGeorge G, La Colla M, Bernstein J, Semones M, Abraham A.
J Pharm Sci. 2021 Mar 18:S0022-3549(21)00180-5. doi: 10.1016/j.xphs.2021.03.011. Online ahead of print.
PMID: 33745914
Response: Letter To The Editor.
Harris DE, Wang T, Lister S, Halcox J.
Eur Heart J Cardiovasc Pharmacother. 2021 Mar 18:pvab021. doi: 10.1093/ehjcvp/pvab021. Online ahead of print.
PMID: 33734310
Intermolecular Crossed [2 + 2] Cycloaddition Promoted by Visible-Light Triplet Photosensitization: Expedient Access to Polysubstituted 2-Oxaspiro[3.3]heptanes.
Murray PRD, Bussink WMM, Davies GHM, van der Mei FW, Antropow AH, Edwards JT, D'Agostino LA, Ellis JM, Hamann LG, Romanov-Michailidis F, Knowles RR.
J Am Chem Soc. 2021 Mar 17;143(10):4055-4063. doi: 10.1021/jacs.1c01173. Epub 2021 Mar 5.
PMID: 33666086
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.
Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, Patwardhan M, Tyler H, Raheja R, Stanley AM, Pineda-Salgado L, Bourdet DL, Andrade RJ, Hayashi PH, Dimick-Santos L, Rockey DC, Estilo A.
Drug Saf. 2021 Mar 16. doi: 10.1007/s40264-021-01051-5. Online ahead of print.
PMID: 33725335
Effect of Terminal Alkylation of Aryl and Heteroaryl Hydrazines in the Fischer Indole Synthesis.
Schmidt MA.
J Org Chem. 2021 Mar 16. doi: 10.1021/acs.joc.1c00203. Online ahead of print.
PMID: 33724835
Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition.
Swidorski JJ, Jenkins S, Hanumegowda U, Parker DD, Beno BR, Protack T, Ng A, Gupta A, Shanmugam Y, Dicker IB, Krystal M, Meanwell NA, Regueiro-Ren A.
Bioorg Med Chem Lett. 2021 Mar 15;36:127823. doi: 10.1016/j.bmcl.2021.127823. Epub 2021 Jan 26.
PMID: 33508465
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.
Braga Lemos M, Rodrigues SR, Schroeder T, Kulasekararaj AG, E Matos J, Tang D.
Eur J Haematol. 2021 Mar 14. doi: 10.1111/ejh.13619. Online ahead of print.
PMID: 33715214
U.S. FDA Approved Drugs from 2015-June 2020: A Perspective.
Bhutani P, Joshi G, Raja N, Bachhav N, Rajanna PK, Bhutani H, Paul AT, Kumar R.
J Med Chem. 2021 Mar 11;64(5):2339-2381. doi: 10.1021/acs.jmedchem.0c01786. Epub 2021 Feb 22.
PMID: 33617716
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313.
Yang MG, Beaudoin-Bertrand M, Xiao Z, Marcoux D, Weigelt CA, Yip S, Wu DR, Ruzanov M, Sack JS, Wang J, Yarde M, Li S, Shuster DJ, Xie JH, Sherry T, Obermeier MT, Fura A, Stefanski K, Cornelius G, Khandelwal P, Karmakar A, Basha M, Babu V, Gupta AK, Mathur A, Salter-Cid L, Denton R, Zhao Q, Dhar TGM.
J Med Chem. 2021 Mar 11;64(5):2714-2724. doi: 10.1021/acs.jmedchem.0c01992. Epub 2021 Feb 16.
PMID: 33591748
Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity.
Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigi M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Canadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Janne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA.
Cancer Discov. 2021 Mar 11:candisc.0913.2020. doi: 10.1158/2159-8290.CD-20-0913. Online ahead of print.
PMID: 33707236
Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.
O'Brien MM, Alonzo TA, Cooper TM, Levine JE, Brown PA, Slone T, August KJ, Benettaib B, Biserna N, Poon J, Patturajan M, Chen N, Simcock M, Zimmerman L, Kolb EA.
Pediatr Blood Cancer. 2021 Mar 10:e28946. doi: 10.1002/pbc.28946. Online ahead of print.
PMID: 33694257
A Multi-variate Mathematical Model for Simulating the Granule Size Distribution in Roller Compaction-Milling Process.
Amini H, Akseli I.
AAPS PharmSciTech. 2021 Mar 10;22(3):97. doi: 10.1208/s12249-021-01955-6.
PMID: 33694033
Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey.
Narváez J, Otón T, Calvo-Alén J, Escudero-Contreras A, Muñoz-Fernández S, Rodríguez-Heredia JM, Romero-Yuste S, Vela-Casasempere P, Luján S, Baquero JL, Carmona L.
Joint Bone Spine. 2021 Mar 6;88(4):105172. doi: 10.1016/j.jbspin.2021.105172. Online ahead of print.
PMID: 33689842
Process analytical technology for on-line monitoring of quality attributes during single-use ultrafiltration/diafiltration.
West JM, Feroz H, Xu X, Puri N, Holstein M, Ghose S, Ding J, Li ZJ.
Biotechnol Bioeng. 2021 Mar 5. doi: 10.1002/bit.27741. Online ahead of print.
PMID: 33666234
Origin Sample Prediction and Spatial Modeling of Antimicrobial Resistance in Metagenomic Sequencing Data.
Zhelyazkova M, Yordanova R, Mihaylov I, Kirov S, Tsonev S, Danko D, Mason C, Vassilev D.
Front Genet. 2021 Mar 4;12:642991. doi: 10.3389/fgene.2021.642991. eCollection 2021.
PMID: 33763122
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators.
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
PMID: 33657295
Solvent-specific, DAST-mediated intramolecular Friedel-Crafts reaction: access to dibenzoxepine-fused spirooxindoles.
Samikannu R, Sethuraman S, Akula N, Radhakrishnan V, Kamisetti S, Banu S, Vetrichelvan M, Gupta A, Li J, Rampulla R, Mathur A.
Org Biomol Chem. 2021 Mar 4;19(8):1760-1768. doi: 10.1039/d0ob02461a.
PMID: 33538747
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.
Zhang L, Cherney EC, Zhu X, Lin TA, Gullo-Brown J, Maley D, Johnston-Allegretto K, Kopcho L, Fereshteh M, Huang C, Li X, Traeger SC, Dhar G, Anandam A, Mahankali S, Padmanabhan S, Rajanna P, Murali V, Mariappan T, Borzilleri R, Vite G, Hunt JT, Balog A.
ACS Med Chem Lett. 2021 Mar 2;12(3):494-501. doi: 10.1021/acsmedchemlett.1c00014. eCollection 2021 Mar 11.
PMID: 33738077
Structures of mouse and human GITR-GITRL complexes reveal unique TNF superfamily interactions.
Wang F, Chau B, West SM, Kimberlin CR, Cao F, Schwarz F, Aguilar B, Han M, Morishige W, Bee C, Dollinger G, Rajpal A, Strop P.
Nat Commun. 2021 Mar 2;12(1):1378. doi: 10.1038/s41467-021-21563-z.
PMID: 33654081
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.
Martínez-López J, Mustjoki S, Porkka K, Klisovic RB, Wolf D, Busque L, Hernández-Boluda JC, Swanink R, Martin Regueira P, Lipton JH.
Leuk Lymphoma. 2021 Mar 2:1-7. doi: 10.1080/10428194.2021.1889536. Online ahead of print.
PMID: 33653205
Suppression of Electrostatic Mediated Antibody Liquid-Liquid Phase Separation by Charged and Noncharged Preferentially Excluded Excipients.
Banks DD, Cordia JF.
Mol Pharm. 2021 Mar 1;18(3):1285-1292. doi: 10.1021/acs.molpharmaceut.0c01138. Epub 2021 Feb 8.
PMID: 33555888
Loss-in-weight feeding, powder flow and electrostatic evaluation for direct compression hydroxypropyl methylcellulose (HPMC) to support continuous manufacturing.
Allenspach C, Timmins P, Lumay G, Holman J, Minko T.
Int J Pharm. 2021 Mar 1;596:120259. doi: 10.1016/j.ijpharm.2021.120259. Epub 2021 Jan 21.
PMID: 33486020
AAPS Perspective on the EURL Recommendation on the use of Non-Animal-Derived Antibodies.
Gorovits B, Hays A, Jani D, Jones C, King C, Lundequist A, Mora J, Partridge M, Pathania D, Ramaswamy SS, Rutwij D, Shen H, Starling G.
AAPS J. 2021 Mar 1;23(2):34. doi: 10.1208/s12248-021-00567-z.
PMID: 33649990
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J.
J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15.
PMID: 33449799
Substituted diaryl ether compounds as retinoic acid-related orphan Receptor-γt (RORγt) agonists.
Ruan Z, Park PK, Wei D, Purandare A, Wan H, O'Malley D, Stachura S, Perez H, Cavallaro CL, Weigelt CA, Sack JS, Ruzanov M, Khan J, Gururajan M, Wong JJ, Huang Y, Yarde M, Li Z, Chen C, Sun H, Borowski V, Xie JH, Anthony M, Agler M, Fink BE, Harikrishnan LS.
Bioorg Med Chem Lett. 2021 Mar 1;35:127778. doi: 10.1016/j.bmcl.2021.127778. Epub 2021 Jan 8.
PMID: 33422603
Best practices for selection of excipients for paediatrics - Workshop reflection.
Salunke S, Clapham D, Agrawal A, Hughes K, Nunn T.
Eur J Pharm Biopharm. 2021 Mar;160:77-81. doi: 10.1016/j.ejpb.2020.12.021. Epub 2021 Jan 2.
PMID: 33400989
Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma.
Gupta A, Arora P, Brenner D, Vanderpuye-Orgle J, Boyne DJ, Edmondson-Jones M, Parkhomenko E, Stevens W, Dudani S, Heng DYC, Wagner S, Borrill J, Wu E.
JCO Clin Cancer Inform. 2021 Mar;5:326-337. doi: 10.1200/CCI.20.00107.
PMID: 33764818
Understanding the pathway and kinetics of aspartic acid isomerization in peptide mapping methods for monoclonal antibodies.
Kuang J, Tao Y, Song Y, Chemmalil L, Mussa N, Ding J, Li ZJ.
Anal Bioanal Chem. 2021 Mar;413(8):2113-2123. doi: 10.1007/s00216-021-03176-z. Epub 2021 Feb 5.
PMID: 33543314
Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices.
Huysentruyt K, Kjoersvik O, Dobracki P, Savage E, Mishalov E, Cherry M, Leonard E, Taylor R, Patel B, Abatemarco D.
Drug Saf. 2021 Mar;44(3):261-272. doi: 10.1007/s40264-020-01030-2. Epub 2021 Feb 1.
PMID: 33523400
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (Part 2A - Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine).
Spitz S, Zhang Y, Fischer S, McGuire K, Sommer U, Amaravadi L, Bandukwala A, Eck S, Garofolo F, Islam R, Jordan G, King L, Saito Y, Sumner G, Terry L, Vitaliti A, Wang YM, Grimaldi C, Joyce A, Palmer R, Andisik M, Araya M, Azadeh M, Baltrukonis D, Elliott R, Haidar S, Kumar S, Mayer A, Neff F, Palackal N, Peng K, Abhari MR, Satterwhite C, Savoie N, Soo C, Vinter S, Welink J, Yan W, Maher K, Lanham D, Bertholet S, Dakappagari N, Gonneau C, Green C, Junker F, Kar S, Patti-Diaz L, Sarikonda S, McCausland M, Teixeira PC, Decman V, Estevam J, Hedrick M, Robert AH, Hopkins G, Nuti S, Tangri S, Wnek R, Dandamudi S, Dasgupta A, Edmison A, Faustino P, McGuinness M, Lima Santos GM, Mirza T, Shakleya D, Stojdl S, Tampal N, Zhang J, Cherry E, Cludts I, Exley A, Ishii-Watabe A, Kirshner S, Pedras-Vasconcelos J, Shen M, Siggers R, Solstad T, Verthelyi D, Yan H, Zhang L.
Bioanalysis. 2021 Mar;13(5):295-361. doi: 10.4155/bio-2021-0005. Epub 2021 Jan 29.
PMID: 33511867
The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What "Cost" to Patients?
Ciarametaro M, Houghton K, Wamble D, Dubois R.
Value Health. 2021 Mar;24(3):388-396. doi: 10.1016/j.jval.2020.10.024. Epub 2021 Jan 28.
PMID: 33641773
Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.
Lovell DJ, Huang B, Chen C, Angeles-Han ST, Simon TA, Brunner HI.
RMD Open. 2021 Mar;7(1):e001435. doi: 10.1136/rmdopen-2020-001435.
PMID: 33731444
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
Klijn SL, Fenwick E, Kroep S, Johannesen K, Malcolm B, Kurt M, Kiff C, Borrill J.
Pharmacoeconomics. 2021 Mar;39(3):345-356. doi: 10.1007/s40273-020-00989-1. Epub 2021 Jan 11.
PMID: 33428174
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.
Rivellese F, Manou-Stathopoulou S, Mauro D, Goldmann K, Pyne D, Rajakariar R, Gordon P, Schafer P, Bombardieri M, Pitzalis C, Lewis MJ.
Lupus Sci Med. 2021 Mar;8(1):e000445. doi: 10.1136/lupus-2020-000445.
PMID: 33727237
In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.
Gargalovic P, Wong P, Onorato J, Finlay H, Wang T, Yan M, Crain E, St-Onge S, Héroux M, Bouvier M, Xu C, Chen XQ, Generaux C, Lawrence M, Wexler R, Gordon D.
Circ Heart Fail. 2021 Mar;14(3):e007351. doi: 10.1161/CIRCHEARTFAILURE.120.007351. Epub 2021 Mar 5.
PMID: 33663236
High-molecular weight impurity screening by size-exclusion chromatography on a reversed-phase column.
Lin Z, Ye YK, Ling M, Shackman JG, Ileka KM, Raglione TV.
J Pharm Biomed Anal. 2021 Mar 20;196:113908. doi: 10.1016/j.jpba.2021.113908. Epub 2021 Jan 18.
PMID: 33497976
Development of an Actionable Framework to Address Cancer Care Disparities in Medically Underserved Populations in the United States: Expert Roundtable Recommendations.
Winkfield KM, Regnante JM, Miller-Sonet E, González ET, Freund KM, Doykos PM.
JCO Oncol Pract. 2021 Mar;17(3):e278-e293. doi: 10.1200/OP.20.00630. Epub 2021 Jan 18.
PMID: 33464925
A bridging immunogenicity assay for anti-cabiralizumab antibodies: overcoming the low assay cut point and drug tolerance challenges.
Yuan L, Gleason CR, Stocker D, Li L, Shen JX, Ji QC.
Bioanalysis. 2021 Mar;13(5):395-407. doi: 10.4155/bio-2020-0300. Epub 2021 Mar 4.
PMID: 33661021
Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe.
Mayall S, Kahlon R, Al-Dakkak I, Shen SW.
Pharmaceut Med. 2021 Mar;35(2):123-135. doi: 10.1007/s40290-021-00380-1. Epub 2021 Mar 4.
PMID: 33660230
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, Choueiri TK, Sznol M, Wind-Rotolo M.
J Immunother Cancer. 2021 Mar;9(3):e001506. doi: 10.1136/jitc-2020-001506.
PMID: 33658305
Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2.
Gyimesi M, Rauscher AÁ, Suthar SK, Hamow KÁ, Oravecz K, Lőrincz I, Borhegyi Z, Déri MT, Kiss ÁF, Monostory K, Szabó PT, Nag S, Tomasic I, Krans J, Tierney PJ, Kovács M, Kornya L, Málnási-Csizmadia A.
J Pharmacol Exp Ther. 2021 Mar;376(3):358-373. doi: 10.1124/jpet.120.000167. Epub 2021 Jan 19.
PMID: 33468641
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, Bennett K, Bourdeaut F, Brown PA, Chesler L, Clymer J, Fox E, French CA, Germovsek E, Giles FJ, Bender JG, Hattersley MM, Ludwinski D, Luptakova K, Maris J, McDonough J, Nikolova Z, Smith M, Tsiatis AC, Vibhakar R, Weiner S, Yi JS, Zheng F, Vassal G.
Eur J Cancer. 2021 Mar;146:115-124. doi: 10.1016/j.ejca.2021.01.018. Epub 2021 Feb 16.
PMID: 33601323
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, Ehman RA, Karsdal M, Nakajima A, Du S, Tirucherai GS, Klinger GH, Mora J, Yamaguchi M, Shevell DE, Loomba R.
Contemp Clin Trials. 2021 Feb 28;104:106335. doi: 10.1016/j.cct.2021.106335. Online ahead of print.
PMID: 33657443
Special Convening and Listening Session on Health Equity and Community Outreach and Engagement at National Cancer Institute-Designated Comprehensive Cancer Centers.
Doykos PM, Chen MS Jr, Watson K, Henderson V, Baskin ML, Downer S, Smith LA, Bhavaraju N, Dina S, Lathan CS.
Health Equity. 2021 Feb 26;5(1):84-90. doi: 10.1089/heq.2020.0155. eCollection 2021.
PMID: 33681694
Recommendations from a Dialogue on Evolving National Cancer Institute-Designated Comprehensive Cancer Center Community Outreach and Engagement Requirements: A Path Forward.
Doykos PM, Chen MS Jr, Watson K, Henderson V, Baskin ML, Downer S, Smith LA, Bhavaraju N, Dina S, Lathan CS.
Health Equity. 2021 Feb 26;5(1):76-83. doi: 10.1089/heq.2020.0156. eCollection 2021.
PMID: 33681693
Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape.
Fazeli MS, Khaychuk V, Wittstock K, Han X, Crocket G, Lin M, Hill SL, Ferri L.
Clin Exp Rheumatol. 2021 Feb 26. Online ahead of print.
PMID: 33635222
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J.
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
PMID: 33626253
Productivity improvement and charge variant modulation for intensified cell culture processes by adding a carboxypeptidase B (CpB) treatment step.
Xu J, Zheng S, Dawood Z, Hill C, Jin W, Xu X, Ding J, Borys MC, Ghose S, Li ZJ, Pendse G.
Biotechnol Bioeng. 2021 Feb 24. doi: 10.1002/bit.27723. Online ahead of print.
PMID: 33624836
Thoracic Lymph Duct Catheterization with a Venous Shunt in the Nonhuman Primate.
Ehrmann J, Generaux C, Ostergaard S, Johnson W, Rose A, Mendenhall V.
J Invest Surg. 2021 Feb 23:1-9. doi: 10.1080/08941939.2021.1874081. Online ahead of print.
PMID: 33622163
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial.
Lang NN, Ahmad FA, Cleland JG, O'Connor CM, Teerlink JR, Voors AA, Taubel J, Hodes AR, Anwar M, Karra R, Sakata Y, Ishihara S, Senior R, Khemka A, Prasad NG, DeSouza MM, Seiffert D, Ye JY, Kessler PD, Borentain M, Solomon SD, Felker GM, McMurray JJV.
Eur J Heart Fail. 2021 Feb 23. doi: 10.1002/ejhf.2138. Online ahead of print.
PMID: 33620131
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.
Degnan AP, Kumi GK, Allard CW, Araujo EV, Johnson WL, Zimmermann K, Pearce BC, Sheriff S, Futran A, Li X, Locke GA, You D, Morrison J, Parrish KE, Stromko C, Murtaza A, Liu J, Johnson BM, Vite GD, Wittman MD.
ACS Med Chem Lett. 2021 Feb 19;12(3):443-450. doi: 10.1021/acsmedchemlett.0c00660. eCollection 2021 Mar 11.
PMID: 33732413
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, Jagannath S.
J Med Case Rep. 2021 Feb 19;15(1):90. doi: 10.1186/s13256-020-02598-0.
PMID: 33608053
Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kabu K, Tajima Y, Oya M.
Jpn J Clin Oncol. 2021 Feb 17:hyaa266. doi: 10.1093/jjco/hyaa266. Online ahead of print.
PMID: 33594427
CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
Hansen JD, Correa M, Alexander M, Nagy M, Huang D, Sapienza J, Lu G, LeBrun LA, Cathers BE, Zhang W, Tang Y, Ammirante M, Narla RK, Piccotti JR, Pourdehnad M, Lopez-Girona A.
J Med Chem. 2021 Feb 25;64(4):1835-1843. doi: 10.1021/acs.jmedchem.0c01489. Epub 2021 Feb 16.
PMID: 33591756
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
Mult Scler Relat Disord. 2021 Feb 15;51:102844. doi: 10.1016/j.msard.2021.102844. Online ahead of print.
PMID: 33892317
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Morgensztern D, Dols MC, Ponce Aix S, Postmus PE, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Talbot D, Govindan R, Ong TJ.
Front Oncol. 2021 Feb 11;10:569715. doi: 10.3389/fonc.2020.569715. eCollection 2020.
PMID: 33643895
Bicyclic Ligand-Biased Agonists of S1P 1 : Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.
Gilmore JL, Xiao HY, Dhar TGM, Yang M, Xiao Z, Yang X, Taylor TL, McIntyre KW, Warrack BM, Shi H, Levesque PC, Marino AM, Cornelius G, Mathur A, Shen DR, Pang J, Cvijic ME, Lehman-McKeeman LD, Sun H, Xie J, Salter-Cid L, Carter PH, Dyckman AJ.
J Med Chem. 2021 Feb 11;64(3):1454-1480. doi: 10.1021/acs.jmedchem.0c01109. Epub 2021 Jan 25.
PMID: 33492963
DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate Modality.
Sivaprakasam P, McDonald I, Iwuagwu C, Chowdari NS, Peese KM, Langley DR, Cheng H, Luzung MR, Schmidt MA, Zheng B, Tan Y, Cho P, Rakshit S, Lakshminarasimhan T, Guturi S, Kanagavel K, Kanusu U, Niyogi AG, Sidhar S, Vaidyanathan R, Eastgate MD, Kotapati S, Deshpande M, Pan C, Cardarelli PM, Xie C, Rao C, Holder P, Sarma G, Vite G, Gangwar S.
ACS Med Chem Lett. 2021 Feb 10;12(3):404-412. doi: 10.1021/acsmedchemlett.0c00578. eCollection 2021 Mar 11.
PMID: 33738068
Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction.
Hanff TC, Cohen JB, Zhao L, Javaheri A, Zamani P, Prenner SB, Rietzschel E, Jia Y, Walsh A, Maranville J, Wang Z, Adam L, Ramirez-Valle F, Schafer P, Seiffert D, Gordon DA, Cvijic ME, Cappola TP, Chirinos JA.
JACC Basic Transl Sci. 2021 Feb 10;6(2):89-99. doi: 10.1016/j.jacbts.2020.11.011. eCollection 2021 Feb.
PMID: 33665511
Correction To: Case Study in the Design of a Surrogate Solution for Use in Biopharmaceutical Drug Product Process Development.
Boksa K, Walsh P, Shah A.
AAPS PharmSciTech. 2021 Feb 10;22(2):70. doi: 10.1208/s12249-021-01935-w.
PMID: 33566206
To lie or not to lie: Super-relaxing with myosins.
Nag S, Trivedi DV.
Elife. 2021 Feb 10;10:e63703. doi: 10.7554/eLife.63703.
PMID: 33565963
Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspective.
Pointon A, Maher J, Davis M, Baker T, Cichocki J, Ramsden D, Hale C, Kolaja KL, Levesque P, Sura R, Stresser DM, Gintant G.
Lab Chip. 2021 Feb 9;21(3):458-472. doi: 10.1039/d0lc01040e.
PMID: 33471007
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC.
Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5.
PMID: 33558511
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK.
Nat Commun. 2021 Feb 5;12(1):808. doi: 10.1038/s41467-021-21068-9.
PMID: 33547292
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study.
Choy E, Groves L, Sugrue D, Hurst M, Houghton J, Venkatachalam S, Patel YI, Maxwell JR, Pollock KG, Henning S.
BMC Rheumatol. 2021 Feb 4;5(1):3. doi: 10.1186/s41927-020-00173-0.
PMID: 33536080
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, Mendy D, Clayton T, Tindall E, Hsu C, Fontanillo C, Tran E, Contreras A, Ng SWK, Matyskiela M, Wang K, Chamberlain P, Cathers B, Carmichael J, Hansen J, Wang JCY, Minden MD, Fan J, Pierce DW, Pourdehnad M, Rolfe M, Lopez-Girona A, Dick JE, Lu G.
Blood. 2021 Feb 4;137(5):661-677. doi: 10.1182/blood.2020008676.
PMID: 33197925
TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells.
Wang F, Zhang C, Kwagh J, Strassle B, Li J, Huang M, Song Y, Lehman B, Westhouse R, Palanisamy K, Holenarsipur VK, Borzilleri R, Augustine-Rauch K.
iScience. 2021 Feb 3;24(3):102133. doi: 10.1016/j.isci.2021.102133. eCollection 2021 Mar 19.
PMID: 33665554
Anti-HEV IgG Avidity Testing: Utility for Diagnosing Acute and Resolved Genotype 3 Infections.
Minosse C, Lapa D, Coppola A, Rapagna F, D'Offizi G, Taibi C, Lionetti R, Capobianchi MR, McPhee F, Garbuglia AR.
Viruses. 2021 Feb 3;13(2):236. doi: 10.3390/v13020236.
PMID: 33546482
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R, Sharfman W, Atkins M, Spigel DR, Pavlick A, Monzon J, Kim KB, Ernst S, Khushalani NI, van Dijck W, Lobo M, Hogg D.
Melanoma Res. 2021 Feb 1;31(1):67-75. doi: 10.1097/CMR.0000000000000708.
PMID: 33234846
Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection.
Hedrich WD, Wang H.
Pharm Res. 2021 Feb;38(2):213-241. doi: 10.1007/s11095-021-02997-y. Epub 2021 Feb 22.
PMID: 33619640
Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.
Kelleher T, Cai J, Botwood NA, Labriola DF.
J Immunother Cancer. 2021 Feb;9(2):e001177. doi: 10.1136/jitc-2020-001177.
PMID: 33558277
Quantification of surrogate monoclonal antibodies in mouse serum using LC-MS/MS.
Mehl JT, Landry F, Discenza L, Sleczka B, Zhao Q, Shuster DJ, Madia P, DasGupta R, Rajendran S, Sun H, Ciccimaro E, Olah TV.
Bioanalysis. 2021 Feb;13(3):147-159. doi: 10.4155/bio-2020-0297. Epub 2021 Feb 5.
PMID: 33543654
The effectiveness of quality control samples in pharmaceutical bioanalysis.
Keller S, Quiroz J, Christopher D, Wickremsinhe E, Geng W, Hawthorne G, James C, Katterle Y, Li W, Liu G, Mayer A, Paton M, Pav J, Potter J, Vergis J, Wang J, Westcott-Baker L, Woolf E, Xue Y.
Bioanalysis. 2021 Feb;13(3):135-145. doi: 10.4155/bio-2020-0265. Epub 2021 Feb 4.
PMID: 33538614
Bayesian reaction optimization as a tool for chemical synthesis.
Shields BJ, Stevens J, Li J, Parasram M, Damani F, Alvarado JIM, Janey JM, Adams RP, Doyle AG.
Nature. 2021 Feb;590(7844):89-96. doi: 10.1038/s41586-021-03213-y. Epub 2021 Feb 3.
PMID: 33536653
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry.
Gottlieb AB, Merola JF, Cirulli J, Williams CC, Linowski GJ, Paris M, Litman HJ, Guo N, Emeanuru K, McLean RR, Cronin A, Strober B.
Dermatol Ther (Heidelb). 2021 Feb;11(1):253-263. doi: 10.1007/s13555-020-00479-4. Epub 2021 Jan 21.
PMID: 33475970
2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome (Part 1 - Recommendations on Industry/Regulators Consensus on BMV of Biotherapeutics by LCMS, Advanced Application in Hybrid Assays, Regulatory Challenges in Mass Spec, Innovation in Small Molecules, Peptides and Oligos).
Neubert H, Alley SC, Lee A, Jian W, Buonarati M, Edmison A, Garofolo F, Gorovits B, Haidar S, Mylott B, Nouri P, Qian M, Vinter S, Voelker T, Welink J, Wu J, Yang E, Yu H, Evans C, Summerfield S, Wang J, Bateman K, Boer J, Dean B, Dillen L, Faustino P, Ferrari L, Hughes N, Luo L, Olah T, Post N, Spellman DS, Sydor J, Zhang H, Zhang J, Zhang J, Fandozzi C, Wilson A, Fraier D, Beaver CJ, Dandamudi S, Dasgupta A, Elliott R, Ji A, Li W, McGuinness M, Lima Santos GM, Mirza T, Savoie N, Shakleya D, Sporring S, Stojdl S, Sundman P, Tampal N, Woolf E.
Bioanalysis. 2021 Feb;13(4):203-238. doi: 10.4155/bio-2020-0324. Epub 2021 Jan 20.
PMID: 33470871
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M.
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
PMID: 33476593
Synthesis and Preclinical Evaluation of
68 Ga-labeled Adnectin,
68 Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression.
Robu S, Richter A, Gosmann D, Seidl C, Leung D, Hayes W, Cohen D, Morin P, Donnelly DJ, Lipovšek D, Bonacorsi SJ, Smith A, Steiger K, Aulehner C, Krackhardt AM, Weber WA.
J Nucl Med. 2021 Jan 30:jnumed.120.258384. doi: 10.2967/jnumed.120.258384. Online ahead of print.
PMID: 33517324
Identification and characterization of 2 nd
generation EZH2 inhibitors with extended residence times and improved biological activity.
Stuckey JI, Cantone NR, Côté A, Arora S, Vivat V, Ramakrishnan A, Mertz JA, Khanna A, Brenneman J, Gehling VS, Moine L, Sims RJ 3rd, Audia JE, Trojer P, Levell JR, Cummings RT.
J Biol Chem. 2021 Jan 29;296:100349. doi: 10.1016/j.jbc.2021.100349. Online ahead of print.
PMID: 33524394
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.
Cherney EC, Zhang L, Nara S, Zhu X, Gullo-Brown J, Maley D, Lin TA, Hunt JT, Huang C, Yang Z, Darienzo C, Discenza L, Ranasinghe A, Grubb M, Ziemba T, Traeger SC, Li X, Johnston K, Kopcho L, Fereshteh M, Foster K, Stefanski K, Fargnoli J, Swanson J, Brown J, Delpy D, Seitz SP, Borzilleri R, Vite G, Balog A.
ACS Med Chem Lett. 2021 Jan 28;12(2):288-294. doi: 10.1021/acsmedchemlett.0c00668. eCollection 2021 Feb 11.
PMID: 33603977
Inhibition of MDM2 promotes anti-tumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment.
Wang HQ, Mulford IJ, Sharp F, Liang J, Kurtulus S, Trabucco G, Quinn DS, Longmire TA, Patel N, Patil R, Shirley MD, Chen Y, Wang H, Ruddy DA, Fabre C, Williams JA, Hammerman PS, Mataraza J, Platzer B, Halilovic E.
Cancer Res. 2021 Jan 27:canres.0189.2020. doi: 10.1158/0008-5472.CAN-20-0189. Online ahead of print.
PMID: 33504557
Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.
Sheng J, Zhang J, Baudelet C, Roy A.
J Clin Pharmacol. 2021 Jan 27. doi: 10.1002/jcph.1821. Online ahead of print.
PMID: 33501654
nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis.
Langer CJ, Gajra A, Gridelli C, Konduri K, Morgensztern D, Spigel D, Talbot D, Thomas M, Weiss J, Pilot R, Bhore R, Wolfsteiner M, Ong TJ, Socinski M.
Front Oncol. 2021 Jan 26;10:485587. doi: 10.3389/fonc.2020.485587. eCollection 2020.
PMID: 33575203
An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads.
Chaudhry C, Tebben A, Tokarski JS, Borzilleri R, Pitts WJ, Lippy J, Zhang L.
Drug Discov Today. 2021 Jan 23:S1359-6446(21)00048-9. doi: 10.1016/j.drudis.2021.01.018. Online ahead of print.
PMID: 33497831
Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.
Freeman L, Kee A, Tian M, Mehta R.
Clinicoecon Outcomes Res. 2021 Jan 22;13:65-75. doi: 10.2147/CEOR.S288296. eCollection 2021.
PMID: 33519217
Best practices for artificial intelligence in life sciences research.
Makarov VA, Stouch T, Allgood B, Willis CD, Lynch N.
Drug Discov Today. 2021 Jan 22:S1359-6446(21)00047-7. doi: 10.1016/j.drudis.2021.01.017. Online ahead of print.
PMID: 33493454
End-to-end collaboration to transform biopharmaceutical development and manufacturing.
Erickson J, Baker J, Barrett S, Brady C, Brower M, Carbonell R, Charlebois T, Coffman J, Connell-Crowley L, Coolbaugh M, Fallon E, Garr E, Gillespie C, Hart R, Haug A, Nyberg G, Phillips M, Pollard D, Qadan M, Ramos I, Rogers K, Schaefer G, Walther J, Lee K.
Biotechnol Bioeng. 2021 Jan 22. doi: 10.1002/bit.27688. Online ahead of print.
PMID: 33480041
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
PMID: 33485464
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Ogasawara K, Kassir N, Wang X, Benettaib B, Zhou S, Palmisano M, Li Y.
Pediatr Res. 2021 Jan 19. doi: 10.1038/s41390-020-01304-6. Online ahead of print.
PMID: 33469186
Breast cancer is marked by specific, Public T-cell receptor CDR3 regions shared by mice and humans.
Gordin M, Philip H, Zilberberg A, Gidoni M, Margalit R, Clouser C, Adams K, Vigneault F, Cohen IR, Yaari G, Efroni S.
PLoS Comput Biol. 2021 Jan 19;17(1):e1008486. doi: 10.1371/journal.pcbi.1008486. eCollection 2021 Jan.
PMID: 33465095
The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury.
Lebeau PF, Wassef H, Byun JH, Platko K, Ason B, Jackson S, Dobroff J, Shetterly S, Richards WG, Al-Hashimi AA, Won KD, Mbikay M, Prat A, Tang A, Paré G, Pasqualini R, Seidah NG, Arap W, Chrétien M, Austin RC.
J Clin Invest. 2021 Jan 19;131(2):e128650. doi: 10.1172/JCI128650.
PMID: 33211673
An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS).
Harris DE, Thayer D, Wang T, Brooks C, Murley G, Gravenor M, Hill NR, Lister S, Halcox J.
Eur Heart J Cardiovasc Pharmacother. 2021 Jan 16;7(1):40-49. doi: 10.1093/ehjcvp/pvz071.
PMID: 31774502
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Gooding S, Ansari-Pour N, Towfic F, Ortiz Estévez M, Chamberlain PP, Tsai KT, Flynt E, Hirst M, Rozelle D, Dhiman P, Neri P, Ramasamy K, Bahlis N, Vyas P, Thakurta A.
Blood. 2021 Jan 14;137(2):232-237. doi: 10.1182/blood.2020007081.
PMID: 33443552
Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements.
Badkar AV, Gandhi RB, Davis SP, LaBarre MJ.
Drug Des Devel Ther. 2021 Jan 13;15:159-170. doi: 10.2147/DDDT.S287323. eCollection 2021.
PMID: 33469268
Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study.
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G.
J Crohns Colitis. 2021 Jan 13:jjab012. doi: 10.1093/ecco-jcc/jjab012. Online ahead of print.
PMID: 33438008
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data.
Simon TA, Dong L, Winthrop KL.
Arthritis Res Ther. 2021 Jan 11;23(1):17. doi: 10.1186/s13075-020-02399-2.
PMID: 33430948
Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.
Benitez JA, Finlay D, Castanza A, Parisian AD, Ma J, Longobardi C, Campos A, Vadla R, Izurieta A, Scerra G, Koga T, Long T, Chavez L, Mesirov JP, Vuori K, Furnari F.
Neuro Oncol. 2021 Jan 11:noab001. doi: 10.1093/neuonc/noab001. Online ahead of print.
PMID: 33428749
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
Pazina T, MacFarlane AW 4th, Bernabei L, Dulaimi E, Kotcher R, Yam C, Bezman NA, Robbins MD, Ross EA, Campbell KS, Cohen AD.
Cancers (Basel). 2021 Jan 10;13(2):226. doi: 10.3390/cancers13020226.
PMID: 33435153
Continued insights into virus clearance validation across continuous capture chromatography.
Angelo JM, Potter K, Müller-Späth T, Xu X, Li ZJ, Ghose S.
Biotechnol Bioeng. 2021 Jan 9. doi: 10.1002/bit.27674. Online ahead of print.
PMID: 33421115
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.
Cohen A, Sah J, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X.
J Clin Med. 2021 Jan 8;10(2):200. doi: 10.3390/jcm10020200.
PMID: 33429844
Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies.
Huang RY, Wang Y, Jhatakia AD, Deng AX, Bee C, Deshpande S, Rangan VS, Bezman N, Gudmundsson O, Chen G.
J Am Soc Mass Spectrom. 2021 Jan 8. doi: 10.1021/jasms.0c00399. Online ahead of print.
PMID: 33415981
Rapid single cell evaluation of human disease and disorder targets using REVEAL: SingleCell™.
Kumar N, Golhar R, Sharma KS, Holloway JL, Sarangi S, Neuhaus I, Walsh AM, Pitluk ZW.
BMC Genomics. 2021 Jan 6;22(1):5. doi: 10.1186/s12864-020-07300-8.
PMID: 33407110
Case Study in the Design of a Surrogate Solution for Use in Biopharmaceutical Drug Product Process Development.
Boksa K, Walsh P, Shah A.
AAPS PharmSciTech. 2021 Jan 6;22(1):32. doi: 10.1208/s12249-020-01881-z.
PMID: 33404995
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.
Toor K, Middleton MR, Chan K, Amadi A, Moshyk A, Kotapati S.
BMC Cancer. 2021 Jan 5;21(1):3. doi: 10.1186/s12885-020-07538-1.
PMID: 33402121
Multisector Collaborations and Global Oncology: The Only Way Forward.
Blanchard C, Lubuzo B, Asirwa FC, Dlamini X, Msadabwe-Chikuni SC, Mwachiro M, Shyirambere C, Ruhangaza D, Milner DA Jr, Van Loon K, DeBoer R, Mtshali P, Dugan U, Baker E, Shulman LN.
JCO Glob Oncol. 2021 Jan;7:153-161. doi: 10.1200/GO.20.00492.
PMID: 33493021
A flow cytometric assay for HLA-DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials.
Quadrini KJ, Patti-Diaz L, Maghsoudlou J, Cuomo J, Hedrick MN, McCloskey TW.
Cytometry B Clin Cytom. 2021 Jan;100(1):103-114. doi: 10.1002/cyto.b.21987. Epub 2021 Jan 12.
PMID: 33432735
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
You D, Hillerman S, Locke G, Chaudhry C, Stromko C, Murtaza A, Fan Y, Koenitzer J, Chen Y, Briceno S, Bhadra R, Duperret E, Gullo-Brown J, Gao C, Zhao D, Feder J, Curtin J, Degnan AP, Kumi G, Wittman M, Johnson BM, Parrish KE, Gokulrangan G, Morrison J, Quigley M, Hunt JT, Salter-Cid L, Lees E, Sanjuan MA, Liu J.
J Immunother Cancer. 2021 Jan;9(1):e001402. doi: 10.1136/jitc-2020-001402.
PMID: 33408094
International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Nonproliferative and Proliferative Lesions of the Dog.
Woicke J, Al-Haddawi MM, Bienvenu JG, Caverly Rae JM, Chanut FJ, Colman K, Cullen JM, Davis W, Fukuda R, Huisinga M, Walker UJ, Kai K, Kovi RC, Macri NP, Marxfeld HA, Nikula KJ, Pardo ID, Rosol TJ, Sharma AK, Singh BP, Tamura K, Thibodeau MS, Vezzali E, Vidal JD, Meseck EK.
Toxicol Pathol. 2021 Jan;49(1):5-109. doi: 10.1177/0192623320968181.
PMID: 33393871
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH.
Lancet Oncol. 2021 Jan;22(1):118-131. doi: 10.1016/S1470-2045(20)30532-5.
PMID: 33387490
Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data.
Chaudhary MA, Holmberg C, Lakhdari K, Smare C, Theriou C, Dale P, Penrod JR.
J Med Econ. 2021 Jan-Dec;24(1):607-619. doi: 10.1080/13696998.2021.1917139.
PMID: 33870833
The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis.
Kim GHJ, Goldin JG, Hayes W, Oh A, Soule B, Du S.
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211004238. doi: 10.1177/17534666211004238.
PMID: 33781141
Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs.
Patel V, Pulungan Z, Shah A, Kambhampati M, Lobo F, Petrilla A.
J Med Econ. 2021 Jan-Dec;24(1):299-307. doi: 10.1080/13696998.2021.1881525.
PMID: 33502940
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
Roth JA, Yuan Y, Othus M, Danese M, Wagner S, Penrod JR, Ramsey SD.
J Med Econ. 2021 Jan-Dec;24(1):79-86. doi: 10.1080/13696998.2020.1857960.
PMID: 33334176
Fate Mapping of Cancer Cells in Metastatic Lymph Nodes Using Photoconvertible Proteins.
Pereira ER, Kedrin D, Padera TP.
Methods Mol Biol. 2021;2265:363-376. doi: 10.1007/978-1-0716-1205-7_26.
PMID: 33704727
Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes.
Block PD, Shinn B, Kim JH, Hann HW.
Hepat Oncol. 2020 Dec 29;8(1):HEP35. doi: 10.2217/hep-2020-0028.
PMID: 33680431
Measuring atropisomers of BMS-986142 using 2DLC as an enabling technology.
Wang Q, He BL, Shackman JG.
J Pharm Biomed Anal. 2021 Jan 30;193:113730. doi: 10.1016/j.jpba.2020.113730. Epub 2020 Oct 31.
PMID: 33181427
Electron-Passing Neural Networks for Atomic Charge Prediction in Systems with Arbitrary Molecular Charge.
Metcalf DP, Jiang A, Spronk SA, Cheney DL, Sherrill CD.
J Chem Inf Model. 2021 Jan 25;61(1):115-122. doi: 10.1021/acs.jcim.0c01071. Epub 2020 Dec 16.
PMID: 33326247
3D printed bilayer tablet with dual controlled drug release for tuberculosis treatment.
Ghanizadeh Tabriz A, Nandi U, Hurt AP, Hui HW, Karki S, Gong Y, Kumar S, Douroumis D.
Int J Pharm. 2021 Jan 25;593:120147. doi: 10.1016/j.ijpharm.2020.120147. Epub 2020 Dec 3.
PMID: 33278493
High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma.
Santockyte R, Puig O, Zheng N, Ouyang Z, Titsch C, Zhang YJ, Pillutla R, Zeng J.
Anal Chem. 2021 Jan 19;93(2):834-842. doi: 10.1021/acs.analchem.0c03357. Epub 2020 Dec 10.
PMID: 33300779
T4-mediated rescue of aortic malformations in hypothyroid rats indicates maternal thyroid status can affect great vessel development.
Augustine-Rauch K, Liaw JJ, Graziano M.
Toxicol Appl Pharmacol. 2021 Jan 15;411:115367. doi: 10.1016/j.taap.2020.115367. Epub 2020 Dec 17.
PMID: 33340518
Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity.
Oderinde MS, Ramirez A, Dhar TGM, Cornelius LAM, Jorge C, Aulakh D, Sandhu B, Pawluczyk J, Sarjeant AA, Meanwell NA, Mathur A, Kempson J.
J Org Chem. 2021 Jan 15;86(2):1730-1747. doi: 10.1021/acs.joc.0c02547. Epub 2020 Dec 24.
PMID: 33356273
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.
Mueller KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, Berry DA, Blank CU, DeMichele AM, Forde PM, Ibrahim N, Keegan P, Mitchell TC, Moss RA, Robert C, Sridhara R, Taube JM, Tetzlaff MT, Wargo JA, Flaherty KT, Kaplan MJ, Topalian SL, Ward AF, Hurlbert MS.
Clin Cancer Res. 2021 Jan 15;27(2):394-401. doi: 10.1158/1078-0432.CCR-20-3285. Epub 2020 Nov 13.
PMID: 33188142
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski JS, Khan J, Ruzanov M, Strnad J, Zupa-Fernandez A, Cheng L, Gillooly KM, Shuster D, Zhang Y, Thankappan A, McIntyre KW, Chaudhry C, Elzinga PA, Chiney M, Chimalakonda A, Lombardo LJ, Macor JE, Carter PH, Burke JR, Weinstein DS.
J Med Chem. 2021 Jan 14;64(1):677-694. doi: 10.1021/acs.jmedchem.0c01698. Epub 2020 Dec 28.
PMID: 33370104
Quaternary Charge-Transfer Complex Enables Photoenzymatic Intermolecular Hydroalkylation of Olefins.
Page CG, Cooper SJ, DeHovitz JS, Oblinsky DG, Biegasiewicz KF, Antropow AH, Armbrust KW, Ellis JM, Hamann LG, Horn EJ, Oberg KM, Scholes GD, Hyster TK.
J Am Chem Soc. 2021 Jan 13;143(1):97-102. doi: 10.1021/jacs.0c11462. Epub 2020 Dec 28.
PMID: 33369395
Data-smart machine learning methods for predicting composition-dependent Young's modulus of pharmaceutical compacts.
Thomas S, Palahnuk H, Amini H, Akseli I.
Int J Pharm. 2021 Jan 5;592:120049. doi: 10.1016/j.ijpharm.2020.120049. Epub 2020 Nov 7.
PMID: 33171260
A methodology employing retention modeling for achieving control space in liquid chromatography method development using quality by design approach.
Jayaraman K, Rajendran AK, Kumar GS, Bhutani H.
J Chromatogr A. 2021 Jan 4;1635:461658. doi: 10.1016/j.chroma.2020.461658. Epub 2020 Nov 4.
PMID: 33333351
Discovery of Annulating Reagents Enabling the One-Step and Highly Stereoselective Synthesis of Cyclopentyl and Cyclohexyl Cores.
McDaniel J, Farley CA, Ramirez A, Sandhu B, Sarjeant A, Shi Q, Han A, Gallagher WP, Hynes J Jr, Dhar TGM, Gonzalez-Bobes F, Coombs JR, Marcoux D.
Org Lett. 2021 Jan 1;23(1):60-65. doi: 10.1021/acs.orglett.0c03695. Epub 2020 Dec 22.
PMID: 33351641
Sustainability Challenges and Opportunities in Oligonucleotide Manufacturing.
Andrews BI, Antia FD, Brueggemeier SB, Diorazio LJ, Koenig SG, Kopach ME, Lee H, Olbrich M, Watson AL.
J Org Chem. 2021 Jan 1;86(1):49-61. doi: 10.1021/acs.joc.0c02291. Epub 2020 Nov 30.
PMID: 33253568
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Zeidner JF, Lee DJ, Frattini M, Fine GD, Costas J, Kolibaba K, Anthony SP, Bearss D, Smith BD.
Clin Cancer Res. 2021 Jan 1;27(1):60-69. doi: 10.1158/1078-0432.CCR-20-2649. Epub 2020 Sep 30.
PMID: 32998965
Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1).
Lau WL, Pearce B, Malakian H, Rodrigo I, Xie D, Gao M, Marsilio F, Chang C, Ruzanov M, Muckelbauer JK, Newitt JA, Lipovšek D, Sheriff S.
Acta Crystallogr F Struct Biol Commun. 2021 Jan 1;77(Pt 1):22-28. doi: 10.1107/S2053230X20016015. Epub 2020 Dec 22.
PMID: 33439152
Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases.
Karsdal MA, Kraus VB, Shevell D, Bay-Jensen AC, Schattenberg J, Rambabu Surabattula R, Schuppan D.
Autoimmun Rev. 2021 Jan;20(1):102706. doi: 10.1016/j.autrev.2020.102706. Epub 2020 Nov 12.
PMID: 33188918
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.
Hodkinson BP, Schaffer M, Brody JD, Jurczak W, Carpio C, Ben-Yehuda D, Avivi I, Forslund A, Özcan M, Alvarez J, Ceulemans R, Fourneau N, Younes A, Balasubramanian S.
Transl Oncol. 2021 Jan;14(1):100977. doi: 10.1016/j.tranon.2020.100977. Epub 2020 Dec 6.
PMID: 33395752
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Prager GW, Oehler L, Gerger A, Mlineritsch B, Andel J, Petzer A, Wilthoner K, Sliwa T, Pichler P, Winder T, Heibl S, Gruenberger B, Laengle F, Hubmann E, Korger M, Pecherstorfer M, Djanani A, Neumann HJ, Philipp-Abbrederis K, Wöll E, Trondl R, Arnold-Schrauf C, Eisterer W.
Eur J Cancer. 2021 Jan;143:101-112. doi: 10.1016/j.ejca.2020.11.003. Epub 2020 Dec 6.
PMID: 33296830
Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations.
Peters T, Soanes N, Abbas M, Ahmad J, Delumeau JC, Herrero-Martinez E, Paramananda M, Piper J, Smail-Aoudia F, van der Spuij W, Veizovic T, Winstanley G;
EFPIA International Pharmacovigilance Group.Drug Saf. 2021 Jan;44(1):17-28. doi: 10.1007/s40264-020-01008-0. Epub 2020 Dec 8.
PMID: 33289904
Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
Stenehjem DD, Lubinga SJ, Gupte-Singh K, Zhang Y, Le TK, Penrod JR, Smith CB.
Clin Lung Cancer. 2021 Jan;22(1):e35-e47. doi: 10.1016/j.cllc.2020.07.009. Epub 2020 Jul 29.
PMID: 33187914
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group.
Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16.
PMID: 33212063
2020 Publications
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses.
Sarikonda G, Mathieu M, Natalia M, Pahuja A, Xue Q, Pierog PL, Trampont PC, Decman V, Reynolds S, Hanafi LA, Sun YS, Eck S, Hedrick MN, Stewart JJ, Tangri S, Litwin V, Dakappagari N.
Cytometry B Clin Cytom. 2020 Dec 29. doi: 10.1002/cyto.b.21985. Online ahead of print.
PMID: 33373096
Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.
Lim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L.
J Clin Transl Hepatol. 2020 Dec 28;8(4):377-384. doi: 10.14218/JCTH.2020.00039. Epub 2020 Oct 10.
PMID: 33447520
Therapeutic potential of TLR8 agonist GS-9688 (selgantolimod) in chronic hepatitis B: re-modelling of antiviral and regulatory mediators.
Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, Chu R, Micolochick Steuer H, Lehar S, Peiser L, Palazzo A, Frey C, Davies J, Javanbakht H, Rosenberg WMC, Fletcher SP, Maini MK, Pallett LJ.
Hepatology. 2020 Dec 25. doi: 10.1002/hep.31695. Online ahead of print.
PMID: 33368377
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators.
N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444.
PMID: 33369355
Urinary miRNA biomarkers of drug-induced kidney injury and their site specificity within the nephron.
Chorley B, Ellinger-Ziegelbauer H, Tackett M, Simutis FJ, Harrill AH, McDuffie J, Atabakhsh E, Nassirpour R, Whiteley LO, Léonard JF, Carswell GK, Harpur E, Chen CL, Gautier JC.
Toxicol Sci. 2020 Dec 24:kfaa181. doi: 10.1093/toxsci/kfaa181. Online ahead of print.
PMID: 33367795
Site-Selective Functionalization of Methionine Residues via Photoredox Catalysis.
Kim J, Li BX, Huang RY, Qiao JX, Ewing WR, MacMillan DWC.
J Am Chem Soc. 2020 Dec 23;142(51):21260-21266. doi: 10.1021/jacs.0c09926. Epub 2020 Dec 8.
PMID: 33290649
Engaging Patients in Real-World Evidence: An Atrial Fibrillation Patient Advisory Board Case Example.
Oehrlein EM, Luo X, Savone M, Lobban T, Kang A, Lee B, Gale R, Schoch S, Perfetto E.
Patient. 2020 Dec 23. doi: 10.1007/s40271-020-00479-8. Online ahead of print.
PMID: 33355917
LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors.
Monaco KA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, McKay D, Guo R, Higgins S, Wang HQ, Liang J, Bui K, Green J, Aspesi P, Ambrose J, Mapa F, Griner L, Jaskelioff M, Fuller J, Crawford K, Pardee G, Widger S, Hammerman PS, Engelman JA, Stuart DD, Cooke VG, Caponigro G.
Clin Cancer Res. 2020 Dec 22:clincanres.2563.2020. doi: 10.1158/1078-0432.CCR-20-2563. Online ahead of print.
PMID: 33355204
Pharmacodynamics-based approach for efficacious human dose projection of BMS-986260, a small molecule transforming growth factor beta receptor 1 inhibitor.
Parrish KE, Swanson J, Cheng L, Luk E, Stetsko P, Smalley J, Shu YZ, Huang J, Pabalan JG, Sun Y, Zvyaga T, Cvijic ME, Burke J, Borzilleri R, Murtaza A, Augustine K, Yang Z.
Biopharm Drug Dispos. 2020 Dec 22. doi: 10.1002/bdd.2256. Online ahead of print.
PMID: 33354831
Comparability of European League Against Rheumatology-Recommended Pharmacological Treatments of Oral Ulcers Associated with Behçet's Disease: A Systematic Literature Review of Randomized Controlled Trials.
Nazareth T, Hart EM, Ronnebaum SM, Mehta S, Patel DA, Kötter I.
Open Access Rheumatol. 2020 Dec 21;12:323-335. doi: 10.2147/OARRR.S277036. eCollection 2020.
PMID: 33376418
Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer.
Von Hoff DD, Cridebring D, Tian OY, Han H, Bhore R, Franco T, Ondovik MS, Louis CU.
Oncologist. 2020 Dec 20. doi: 10.1002/onco.13645. Online ahead of print.
PMID: 33345430
Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation via Distinct Structural Degrons.
Matyskiela ME, Zhu J, Baughman JM, Clayton T, Slade M, Wong HK, Danga K, Zheng X, Labow M, LeBrun L, Lu G, Chamberlain PP, Thompson JW.
ACS Chem Biol. 2020 Dec 18;15(12):3149-3158. doi: 10.1021/acschembio.0c00674. Epub 2020 Nov 18.
PMID: 33206504
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England.
Rothwell B, Kiff C, Ling C, Brodtkorb TH.
Pharmacoecon Open. 2020 Dec 17. doi: 10.1007/s41669-020-00245-4. Online ahead of print.
PMID: 33332018
A cross-industry collaboration to assess if acute oral toxicity (Q)SAR models are fit-for-purpose for GHS classification and labelling.
Bercu J, Masuda-Herrera MJ, Trejo-Martin A, Hasselgren C, Lord J, Graham J, Schmitz M, Milchak L, Owens C, Lal SH, Robinson RM, Whalley S, Bellion P, Vuorinen A, Gromek K, Hawkins WA, van de Gevel I, Vriens K, Kemper R, Naven R, Ferrer P, Myatt GJ.
Regul Toxicol Pharmacol. 2020 Dec 17;120:104843. doi: 10.1016/j.yrtph.2020.104843. Online ahead of print.
PMID: 33340644
Leveraging the Value of CDISC SEND Data Sets for Cross-Study Analysis: Incidence of Microscopic Findings in Control Animals.
Carfagna MA, Anderson J, Eley C, Fukushima T, Horvath J, Houser W, Larsen B, Page T, Russo D, Sloan C, Snyder K, Thompson R, Ullmann G, Whittaker M.
Chem Res Toxicol. 2020 Dec 16. doi: 10.1021/acs.chemrestox.0c00317. Online ahead of print.
PMID: 33325690
Development and characterization of rat duodenal organoids for ADME and toxicology applications.
Hedrich WD, Panzica-Kelly JM, Chen SJ, Strassle B, Hasson C, Lecureux L, Wang L, Chen W, Sherry T, Gan J, Davis M.
Toxicology. 2020 Dec 15;446:152614. doi: 10.1016/j.tox.2020.152614. Epub 2020 Oct 24.
PMID: 33199268
Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development.
Yang W, Bhattachar SN, Patel PJ, Landis M, Patel D, Reid DL, Duvnjak Romic M.
Drug Discov Today. 2020 Dec 14:S1359-6446(20)30526-2. doi: 10.1016/j.drudis.2020.12.008. Online ahead of print.
PMID: 33333320
Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
Briggs E, Chapel S, Zhang P, Palmisano M, Tran JQ.
CPT Pharmacometrics Syst Pharmacol. 2020 Dec 12. doi: 10.1002/psp4.12580. Online ahead of print.
PMID: 33314790
The Impact of Product and Process Related Critical Quality Attributes on Immunogenicity and Adverse Immunological Effects of Biotherapeutics.
Wen Y, Jawa V.
J Pharm Sci. 2020 Dec 11:S0022-3549(20)30781-4. doi: 10.1016/j.xphs.2020.12.003. Online ahead of print.
PMID: 33316242
Aberrant interaction of FUS with the U1 snRNA provides a molecular mechanism of FUS induced amyotrophic lateral sclerosis.
Jutzi D, Campagne S, Schmidt R, Reber S, Mechtersheimer J, Gypas F, Schweingruber C, Colombo M, von Schroetter C, Loughlin FE, Devoy A, Hedlund E, Zavolan M, Allain FH, Ruepp MD.
Nat Commun. 2020 Dec 11;11(1):6341. doi: 10.1038/s41467-020-20191-3.
PMID: 33311468
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA.
Mult Scler Relat Disord. 2020 Dec 10;48:102673. doi: 10.1016/j.msard.2020.102673. Online ahead of print.
PMID: 33454584
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.
Verkleij CPM, Jhatakia A, Broekmans MEC, Frerichs KA, Zweegman S, Mutis T, Bezman NA, van de Donk NWCJ.
Cancers (Basel). 2020 Dec 10;12(12):3713. doi: 10.3390/cancers12123713.
PMID: 33321969
Synthesis and Structure-Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases.
Han W, Ding Y, Chen Z, Langowski JL, Bellamacina C, Rico A, Nishiguchi GA, Lan J, Atallah G, Lindvall M, Lin S, Zang R, Feucht P, Zavorotinskaya T, Dai Y, Garcia P, Burger MT.
J Med Chem. 2020 Dec 10;63(23):14885-14904. doi: 10.1021/acs.jmedchem.0c01279. Epub 2020 Dec 1.
PMID: 33258605
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches.
Xiao HY, Li N, Duan JJ, Jiang B, Lu Z, Ngu K, Tino J, Kopcho LM, Lu H, Chen J, Tebben AJ, Sheriff S, Chang CY, Yanchunas J Jr, Calambur D, Gao M, Shuster DJ, Susulic V, Xie JH, Guarino VR, Wu DR, Gregor KR, Goldstine CB, Hynes J Jr, Macor JE, Salter-Cid L, Burke JR, Shaw PJ, Dhar TGM.
J Med Chem. 2020 Dec 10;63(23):15050-15071. doi: 10.1021/acs.jmedchem.0c01732. Epub 2020 Dec 1.
PMID: 33261314
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Sun LQ, Mull E, D'Andrea S, Zheng B, Hiebert S, Gillis E, Bowsher M, Kandhasamy S, Baratam VR, Puttaswamy S, Pulicharla N, Vishwakrishnan S, Reddy S, Trivedi R, Sinha S, Sivaprasad S, Rao A, Desai S, Ghosh K, Anumula R, Kumar A, Rajamani R, Wang YK, Fang H, Mathur A, Rampulla R, Zvyaga TA, Mosure K, Jenkins S, Falk P, Tagore DM, Chen C, Rendunchintala K, Loy J, Meanwell NA, McPhee F, Scola PM.
J Med Chem. 2020 Dec 10;63(23):14740-14760. doi: 10.1021/acs.jmedchem.0c01296. Epub 2020 Nov 23.
PMID: 33226226
Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT.
Mol Cancer Ther. 2020 Dec 9:molcanther.0251.2020. doi: 10.1158/1535-7163.MCT-20-0251. Online ahead of print.
PMID: 33298590
Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Guo JD, Hlavacek P, Rosenblatt L, Keshishian A, Russ C, Mardekian J, Ferri M, Poretta T, Yuce H, McBane R.
Thromb Res. 2020 Dec 8;198:163-170. doi: 10.1016/j.thromres.2020.11.039. Online ahead of print.
PMID: 33348190
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability.
Takita H, Barnett S, Zhang Y, Ménochet K, Shen H, Ogungbenro K, Galetin A.
CPT Pharmacometrics Syst Pharmacol. 2020 Dec 8. doi: 10.1002/psp4.12582. Online ahead of print.
PMID: 33289952
Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
Gandhi Y, Passarell JA, Roy A, Murthy B.
J Clin Pharmacol. 2020 Dec 7. doi: 10.1002/jcph.1797. Online ahead of print.
PMID: 33284480
Multiple SARS-CoV-2 Introductions Shaped the Early Outbreak in Central Eastern Europe: Comparing Hungarian Data to a Worldwide Sequence Data-Matrix.
Kemenesi G, Zeghbib S, Somogyi BA, Tóth GE, Bányai K, Solymosi N, Szabo PM, Szabó I, Bálint Á, Urbán P, Herczeg R, Gyenesei A, Nagy Á, Pereszlényi CI, Babinszky GC, Dudás G, Terhes G, Zöldi V, Lovas R, Tenczer S, Kornya L, Jakab F.
Viruses. 2020 Dec 6;12(12):1401. doi: 10.3390/v12121401.
PMID: 33291299
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.
Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA, Poggesi I, Sharma P, Snoeys J, Shebley M, Tai G, Tse S, Upreti VV, Wang YH, Tsai A, Xia B, Zheng M, Zhu AZX, Hall S.
Clin Pharmacol Ther. 2020 Dec 3. doi: 10.1002/cpt.2125. Online ahead of print.
PMID: 33270249
Synthetic thick filaments: A new avenue for better understanding the myosin super-relaxed state in healthy, disease, and mavacamten-treated cardiac systems.
Gollapudi SK, Yu M, Gan QF, Nag S.
J Biol Chem. 2020 Dec 3:100114. doi: 10.1074/jbc.RA120.016506. Online ahead of print.
PMID: 33434580
Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life.
Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M.
J Patient Rep Outcomes. 2020 Dec 1;4(1):102. doi: 10.1186/s41687-020-00269-8.
PMID: 33259041
Computational insights into O-glycosylation in a CTLA4 Fc-fusion protein linker and its impact on protein quality attributes.
Song Y, Qian Y, Huang Z, Khattak SF, Li ZJ.
Comput Struct Biotechnol J. 2020 Dec 1;18:3925-3935. doi: 10.1016/j.csbj.2020.11.037. eCollection 2020.
PMID: 33335689
Updated Analysis of Complication Rates Associated With Invasive Diagnostic Procedures After Lung Cancer Screening.
Zhao H, Xu Y, Huo J, Burks AC, Ost DE, Shih YT.
JAMA Netw Open. 2020 Dec 1;3(12):e2029874. doi: 10.1001/jamanetworkopen.2020.29874.
PMID: 33326023
Evaluate the Impact of Diabetes on RA-related outcomes in an Electronic Health Record-Based Rheumatology Registry.
Yun H, Xie F, Chen L, Yang S, Ferri L, Alemao E, Curtis J.
J Rheumatol. 2020 Dec 1:jrheum.200486. doi: 10.3899/jrheum.200486. Online ahead of print.
PMID: 33262304
Best practices for optimization and validation of flow cytometry-based receptor occupancy assays.
Hilt E, Sun YS, McCloskey TW, Eck S, McIntosh T, Grugan KD, Lanham DF, Standifer N, Green C, Litwin V, Stewart JJ.
Cytometry B Clin Cytom. 2020 Dec 1. doi: 10.1002/cyto.b.21970. Online ahead of print.
PMID: 33259706
Patterns of drug release as a function of drug loading from amorphous solid dispersions: A comparison of five different polymers.
Saboo S, Moseson DE, Kestur US, Taylor LS.
Eur J Pharm Sci. 2020 Dec 1;155:105514. doi: 10.1016/j.ejps.2020.105514. Epub 2020 Aug 15.
PMID: 32810579
In Silico Meets In Vitro Techniques in ADMET Profiling of Drug Discovery (Part I).
Kar S, Chatterjee S.
Curr Drug Metab. 2020 Dec;21(10):745. doi: 10.2174/138920022110201126153901.
PMID: 33327905
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT.
J Immunother Cancer. 2020 Dec;8(2):e000705. doi: 10.1136/jitc-2020-000705.
PMID: 33268350
Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study.
Qiu B, Li G, Luo F, Cai X, Wu L, Chen J, Hu Y, Tang Z, Yang S, He J.
Transl Lung Cancer Res. 2020 Dec;9(6):2460-2468. doi: 10.21037/tlcr-20-1269.
PMID: 33489806
Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
Vessillier S, Fort M, O'Donnell L, Hinton H, Nadwodny K, Piccotti J, Rigsby P, Staflin K, Stebbings R, Mekala D, Willingham A, Wolf B; participants of the study.
Cytokine X. 2020 Dec;2(4):100042. doi: 10.1016/j.cytox.2020.100042.
PMID: 33458650
Reply.
Danese S, Chitkara D, Usiskin K.
Clin Gastroenterol Hepatol. 2020 Dec;18(13):3057-3058. doi: 10.1016/j.cgh.2020.03.023.
PMID: 33190745
Cross-company evaluation of the human lymphocyte activation assay.
Collinge M, Schneider P, Li D, Parish S, Dumont C, Freebern W, Ghanime J, Guimont-Derochers F, Langenkamp A, Lebron J, Li N, Marban C, Plitnick L, Wheeler J.
J Immunotoxicol. 2020 Dec;17(1):51-58. doi: 10.1080/1547691X.2020.1725694.
PMID: 32124652
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ.
Nat Metab. 2020 Dec;2(12):1401-1412. doi: 10.1038/s42255-020-00316-0. Epub 2020 Nov 30.
PMID: 33257855
Toxicologic Pathology Forum: Opinion on Obligatory Microscopic Examination of Intermediate-Dose Groups in Toxicity Studies With Biotherapeutics in Cynomolgus Monkeys.
Parrula C, Dincer Z, Geoly FJ, De Vera Mudry MC, Mysore J, Wuersch K.
Toxicol Pathol. 2020 Dec;48(8):939-943. doi: 10.1177/0192623320969098. Epub 2020 Nov 28.
PMID: 33252033
Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell.
Haeseleer F, Eichholz K, Tareen SU, Iwamoto N, Roederer M, Kirchhoff F, Park H, Okoye AA, Corey L.
AIDS Res Hum Retroviruses. 2020 Dec;36(12):998-1009. doi: 10.1089/AID.2020.0163. Epub 2020 Nov 5.
PMID: 32988211
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Tran JQ, Zhang P, Walker S, Ghosh A, Syto M, Wang X, Harris S, Palmisano M.
Adv Ther. 2020 Dec;37(12):4944-4958. doi: 10.1007/s12325-020-01500-0. Epub 2020 Oct 6.
PMID: 33025342
Impact of quercetin on pharmacokinetics of quetiapine: insights from  in-vivo  studies in wistar rats.
Bhutani P, Rajanna PK, Paul AT.
Xenobiotica. 2020 Dec;50(12):1483-1489. doi: 10.1080/00498254.2020.1792002. Epub 2020 Jul 14.
PMID: 32623931
Identification of extractables by liquid chromatography-high resolution mass spectrometry: A case study to understand the extraction profile of different disposable syringes.
Kurmi M, Prasad S, Panduranga NS, Jayaraman K, Bhutani H.
J Pharm Biomed Anal. 2020 Nov 30;191:113602. doi: 10.1016/j.jpba.2020.113602. Epub 2020 Sep 9.
PMID: 33010603
Rapid development of a bromochloropyridine regioisomer purity method enabled by strategic LC screening.
Borges-Muñoz A, Li L, Tattersall P.
J Pharm Biomed Anal. 2020 Nov 30;191:113594. doi: 10.1016/j.jpba.2020.113594. Epub 2020 Aug 28.
PMID: 32949956
Diverse crystal size effects in covalent organic frameworks.
Ma T, Wei L, Liang L, Yin S, Xu L, Niu J, Xue H, Wang X, Sun J, Zhang YB, Wang W.
Nat Commun. 2020 Nov 30;11(1):6128. doi: 10.1038/s41467-020-19858-8.
PMID: 33257671
Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R, Shaw J, Mühlbacher A, Lee TA, Walton S, Kohlmann T, Norman R, Pickard AS.
Qual Life Res. 2020 Nov 28. doi: 10.1007/s11136-020-02712-1. Online ahead of print.
PMID: 33247810
A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
Shankaran V, Xiao H, Bertwistle D, Zhang Y, You M, Abraham P, Chau I.
Adv Ther. 2020 Nov 26. doi: 10.1007/s12325-020-01567-9. Online ahead of print.
PMID: 33244736
Author Correction: Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY.
Nat Commun. 2020 Nov 26;11(1):6170. doi: 10.1038/s41467-020-20129-9.
PMID: 33243989
Metabolomic and quality data for early and late passages of an antibody-producing industrial CHO cell line.
Sowa SW, Qian Y, Aron KL, Xu P, Langsdorf E, Warrack B, Aranibar N, Tremml G, Xu J, McVey D, Reily M, Khetan A, Borys MC, Li ZJ.
Data Brief. 2020 Nov 26;33:106591. doi: 10.1016/j.dib.2020.106591. eCollection 2020 Dec.
PMID: 33318978
Axl and Mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host anti-tumor immunity.
Davra V, Kumar S, Geng K, Calianese D, Mehta D, Gadiyar V, Kasikara C, Lahey KC, Chang YJ, Wichroski M, Gao C, De Lorenzo MS, Kotenko SV, Bergsbaken T, Mishra PK, Gause WC, Quigley M, Spires TE, Birge RB.
Cancer Res. 2020 Nov 25:canres.2066.2020. doi: 10.1158/0008-5472.CAN-20-2066. Online ahead of print.
PMID: 33239426
Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates.
Chowdari NS, Zhang Y, McDonald I, Johnson W, Langley DR, Sivaprakasam P, Mate R, Huynh T, Kotapati S, Deshpande M, Pan C, Menezes D, Wang Y, Rao C, Sarma G, Warrack BM, Rangan VS, Mei-Chen S, Cardarelli P, Deshpande S, Passmore D, Rampulla R, Mathur A, Borzilleri R, Rajpal A, Vite G, Gangwar S.
J Med Chem. 2020 Nov 25;63(22):13913-13950. doi: 10.1021/acs.jmedchem.0c01385. Epub 2020 Nov 6.
PMID: 33155811
Development of a Platform for Near-Infrared Photoredox Catalysis.
Ravetz BD, Tay NES, Joe CL, Sezen-Edmonds M, Schmidt MA, Tan Y, Janey JM, Eastgate MD, Rovis T.
ACS Cent Sci. 2020 Nov 25;6(11):2053-2059. doi: 10.1021/acscentsci.0c00948. Epub 2020 Oct 20.
PMID: 33274281
Aryl Amination Using Soluble Weak Base Enabled by a Water-Assisted Mechanism.
Lau SH, Yu P, Chen L, Madsen-Duggan CB, Williams MJ, Carrow BP.
J Am Chem Soc. 2020 Nov 25;142(47):20030-20039. doi: 10.1021/jacs.0c09275. Epub 2020 Nov 12.
PMID: 33179489
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, Feng J, Tu HY, Wu L, Zhang Y, Luft A, Zhou JY, Ma Z, Lu Y, Hu C, Shi Y, Ying K, Zhong H, Poddubskaya E, Soo RA, Chia YH, Li A, Li A, Wu YL.
Lung Cancer. 2020 Nov 24;152:7-14. doi: 10.1016/j.lungcan.2020.11.013. Online ahead of print.
PMID: 33321441
Epigenetic Signatures and Plasticity of Intestinal and Other Stem Cells.
Saxena M, Shivdasani RA.
Annu Rev Physiol. 2020 Nov 24. doi: 10.1146/annurev-physiol-021119-034520. Online ahead of print.
PMID: 33234018
Optimization of a transient antibody expression platform towards high titer and efficiency.
Greene E, Cazacu D, Tamot N, Castellano S, Datar A, Kronkaitis A, Gebhard D, Reed J, Mawson P, Florin L, Rossi N, Lauer A, Juckem L, Nixon A, Wenger T, Sen S.
Biotechnol J. 2020 Nov 23:e2000251. doi: 10.1002/biot.202000251. Online ahead of print.
PMID: 33226178
Synthetic thick filaments: A new avenue for better understanding the myosin super-relaxed state in healthy, disease, and mavacamten-treated cardiac systems.
Gollapudi SK, Yu M, Gan QF, Nag S.
J Biol Chem. 2020 Nov 23:jbc.RA120.016506. doi: 10.1074/jbc.RA120.016506. Online ahead of print.
PMID: 33234590
Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data.
Kaur G, Mejia Saldarriaga M, Shah N, Catamero DD, Yue L, Ashai N, Goradia N, Heisler J, Xiao Z, Ghalib N, Aaron T, Cole D, Foreman R, Mantzaris I, Derman O, Bachier L, Sica RA, Kornblum N, Braunschweig I, Shastri A, Goel S, Verma A, Janakiram M.
Clin Lymphoma Myeloma Leuk. 2020 Nov 21:S2152-2650(20)30636-4. doi: 10.1016/j.clml.2020.11.013. Online ahead of print.
PMID: 33339770
CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice.
Kurian R, Hedrich W, Mackowiak B, Li L, Wang H.
Cells. 2020 Nov 21;9(11):2520. doi: 10.3390/cells9112520.
PMID: 33233444
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI.
Int J Lab Hematol. 2020 Nov 21. doi: 10.1111/ijlh.13400. Online ahead of print.
PMID: 33220019
Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.
Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A.
Int J Clin Oncol. 2020 Nov 21. doi: 10.1007/s10147-020-01829-0. Online ahead of print.
PMID: 33219460
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.
Ficial M, Jegede OA, Sant'Angelo M, Hou Y, Flaifel A, Pignon JC, Braun DA, Wind-Rotolo M, Sticco-Ivins MA, Catalano PJ, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Wu CJ, Atkins MB, McDermott DF, Shukla SA, Choueiri TK, Signoretti S.
Clin Cancer Res. 2020 Nov 20. doi: 10.1158/1078-0432.CCR-20-3084. Online ahead of print.
PMID: 33219016
A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation.
Lopes RD, Berger SE, Di Fusco M, Kang A, Russ C, Afriyie A, Earley A, Deshpande S, Mantovani LG.
Int J Cardiol. 2020 Nov 15;319:85-93. doi: 10.1016/j.ijcard.2020.06.061. Epub 2020 Jul 4.
PMID: 32634487
Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.
Poloyac SM, Bertz RJ, McDermott LA, Marathe P.
J Neurotrauma. 2020 Nov 15;37(22):2435-2444. doi: 10.1089/neu.2018.6295. Epub 2019 Apr 10.
PMID: 30816062
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR Substudy Analysis.
Saberi S, Cardim N, Yamani MH, Schulz-Menger J, Li W, Florea V, Sehnert AJ, Kwong RY, Jerosch-Herold M, Masri A, Owens A, Lakdawala NK, Kramer CM, Sherrid M, Seidler T, Wang A, Sedaghat-Hamedani F, Meder B, Havakuk O, Jacoby D.
Circulation. 2020 Nov 15. doi: 10.1161/CIRCULATIONAHA.120.052359. Online ahead of print.
PMID: 33190524
Derivation of DO-BITS, a score for predicting success on  Love Island : a retrospective, observational cohort study.
Simpson A, Graham S, Sammon C, Leahy TP, Ramagopalan SV.
Future Sci OA. 2020 Nov 13;7(1):FSO658. doi: 10.2144/fsoa-2020-0168.
PMID: 33437509
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Luo X.
Thromb Haemost. 2020 Nov 10. doi: 10.1055/s-0040-1718728. Online ahead of print.
PMID: 33171521
Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study.
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada AM, Jacob AT, Kinahan C, Francescone M, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes DL, Scotto L, Sokol L, Shustov AR, O'Connor OA.
Blood. 2020 Nov 10:blood.2020009004. doi: 10.1182/blood.2020009004. Online ahead of print.
PMID: 33171487
Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H.
Ann Rheum Dis. 2020 Nov 9:annrheumdis-2020-218599. doi: 10.1136/annrheumdis-2020-218599. Online ahead of print.
PMID: 33168545
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Maas RJ, Hoogstad-van Evert JS, Van der Meer JM, Mekers V, Rezaeifard S, Korman AJ, de Jonge PK, Cany J, Woestenenk R, Schaap NP, Massuger LF, Jansen JH, Hobo W, Dolstra H.
Oncoimmunology. 2020 Nov 8;9(1):1843247. doi: 10.1080/2162402X.2020.1843247.
PMID: 33224630
Outpatient management of patients presenting with venous thromboembolism: Retrospective cohort study at 11 community hospitals.
Khatib R, Nitti K, McDowell M, Szymialis R, Blair C, Glowacki N, Rhoades W.
J Thromb Thrombolysis. 2020 Nov 7. doi: 10.1007/s11239-020-02328-9. Online ahead of print.
PMID: 33161514
Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.
Liu Q, Batt DG, Weigelt CA, Yip S, Wu DR, Ruzanov M, Sack JS, Wang J, Yarde M, Li S, Shuster DJ, Xie JH, Sherry T, Obermeier MT, Fura A, Stefanski K, Cornelius G, Khandelwal P, Tino JA, Macor JE, Salter-Cid L, Denton R, Zhao Q, Dhar TGM.
ACS Med Chem Lett. 2020 Nov 6;11(12):2510-2518. doi: 10.1021/acsmedchemlett.0c00496. eCollection 2020 Dec 10.
PMID: 33335675
The 2020 Nobel Prize in Physiology or Medicine.
Meanwell NA, Georg GI, Wang S.
J Med Chem. 2020 Nov 5. doi: 10.1021/acs.jmedchem.0c01877. Online ahead of print.
PMID: 33147952
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu QS, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos F, de Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I.
Clin Cancer Res. 2020 Nov 4:clincanres.1830.2020. doi: 10.1158/1078-0432.CCR-20-1830. Online ahead of print.
PMID: 33148673
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJ.
PLoS Med. 2020 Nov 4;17(11):e1003323. doi: 10.1371/journal.pmed.1003323. eCollection 2020 Nov.
PMID: 33147277
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N.
Drug Saf. 2020 Nov 3. doi: 10.1007/s40264-020-01014-2. Online ahead of print.
PMID: 33141341
Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer.
Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y.
J Comp Eff Res. 2020 Nov 3. doi: 10.2217/cer-2020-0134. Online ahead of print.
PMID: 33140652
Antipeptide Immunocapture with In-Sample Calibration Curve Strategy for Sensitive and Robust LC-MS/MS Bioanalysis of Clinical Protein Biomarkers in Formalin-Fixed Paraffin-Embedded Tumor Tissues.
Zheng N, Taylor K, Gu H, Santockyte R, Wang XT, McCarty J, Adelakun O, Zhang YJ, Pillutla R, Zeng J.
Anal Chem. 2020 Nov 3;92(21):14713-14722. doi: 10.1021/acs.analchem.0c03271. Epub 2020 Oct 13.
PMID: 33047598
NMR-Based Assay for the  Ex Vivo  Determination of Soluble CD73 Activity in Serum.
He Y, Zhao Y, Nelson DM, Klippel A, Reily MD.
Anal Chem. 2020 Nov 3;92(21):14501-14508. doi: 10.1021/acs.analchem.0c02630. Epub 2020 Oct 19.
PMID: 32985862
Radiographic Read Paradigms and the Roles of the Central Imaging Laboratory in Neuro-Oncology Clinical Trials.
Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Yung WKA, Cloughesy TF, Goldin JG.
Neuro Oncol. 2020 Nov 1:noaa253. doi: 10.1093/neuonc/noaa253. Online ahead of print.
PMID: 33130879
Design, synthesis and SAR study of novel C2-pyrazolopyrimidine amides and amide isosteres as allosteric integrase inhibitors.
Patel M, Cianci C, Allard CW, Parker DD, Simmermacher J, Jenkins S, Mcauliffe B, Minassian B, Discotto L, Krystal M, Meanwell NA, Naidu BN.
Bioorg Med Chem Lett. 2020 Nov 1;30(21):127516. doi: 10.1016/j.bmcl.2020.127516. Epub 2020 Aug 27.
PMID: 32860982
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
Autio KA, Klebanoff CA, Schaer D, Kauh JSW, Slovin SF, Adamow M, Blinder VS, Brahmachary M, Carlsen M, Comen E, Danila DC, Doman TN, Durack JC, Fox JJ, Gluskin JS, Hoffman DM, Kang S, Kang P, Landa J, McAndrew PF, Modi S, Morris MJ, Novosiadly R, Rathkopf DE, Sanford R, Chapman SC, Tate CM, Yu D, Wong P, McArthur HL.
Clin Cancer Res. 2020 Nov 1;26(21):5609-5620. doi: 10.1158/1078-0432.CCR-20-0855. Epub 2020 Aug 26.
PMID: 32847933
Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
Hu Z, Wang C, Sitkoff D, Cheadle NL, Xu S, Muckelbauer JK, Adam LP, Wexler RR, Quan ML.
Bioorg Med Chem Lett. 2020 Nov 1;30(21):127474. doi: 10.1016/j.bmcl.2020.127474. Epub 2020 Aug 15.
PMID: 32805407
Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies.
Hu Z, Wang C, Glunz PW, Li J, Cheadle NL, Chen AY, Chen XQ, Myers JE, Guarino VR, Rose A, Sack JS, Sitkoff D, Taylor DS, Xu S, Yan C, Zhang H, Zhang L, Hennan J, Adam LP, Wexler RR, Quan ML.
Bioorg Med Chem Lett. 2020 Nov 1;30(21):127495. doi: 10.1016/j.bmcl.2020.127495. Epub 2020 Aug 13.
PMID: 32798651
Applications of small molecules in modulating productivity and product quality of recombinant proteins produced using cell cultures.
Xu P, Xu S, He C, Khetan A.
Biotechnol Adv. 2020 Nov 1;43:107577. doi: 10.1016/j.biotechadv.2020.107577. Epub 2020 Jun 12.
PMID: 32540474
Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction.
Kanagala P, Arnold JR, Khan JN, Singh A, Gulsin GS, Chan DCS, Cheng ASH, Yang J, Li Z, Gupta P, Squire IB, McCann GP, Ng LL.
Biomarkers. 2020 Nov;25(7):556-565. doi: 10.1080/1354750X.2020.1810319. Epub 2020 Aug 28.
PMID: 32803990
In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States.
Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, Guérin A, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L.
JACC Heart Fail. 2020 Nov;8(11):943-953. doi: 10.1016/j.jchf.2020.05.013. Epub 2020 Aug 12.
PMID: 32800512
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A, Pepin X, Aarons L, Wang Y, Darwich AS, Wood JM, Tannergren C, Karlsson E, Patterson C, Thörn H, Ruston L, Mattinson A, Carlert S, Berg S, Murphy D, Engman H, Laru J, Barker R, Flanagan T, Abrahamsson B, Budhdeo S, Franek F, Moir A, Hanisch G, Pathak SM, Turner D, Jamei M, Brown J, Good D, Vaidhyanathan S, Jackson C, Nicolas O, Beilles S, Nguefack JF, Louit G, Henrion L, Ollier C, Boulu L, Xu C, Heimbach T, Ren X, Lin W, Nguyen-Trung AT, Zhang J, He H, Wu F, Bolger MB, Mullin JM, van Osdol B, Szeto K, Korjamo T, Pappinen S, Tuunainen J, Zhu W, Xia B, Daublain P, Wong S, Varma MVS, Modi S, Schäfer KJ, Schmid K, Lloyd R, Patel A, Tistaert C, Bevernage J, Nguyen MA, Lindley D, Carr R, Rostami-Hodjegan A.
Eur J Pharm Biopharm. 2020 Nov;156:50-63. doi: 10.1016/j.ejpb.2020.08.006. Epub 2020 Aug 14.
PMID: 32805361
Advances of solid-state NMR spectroscopy in material sciences.
Abraham A, Salager E, Krishnan D, Su Y.
Magn Reson Chem. 2020 Nov;58(11):987. doi: 10.1002/mrc.5086.
PMID: 33006157
Metabolic understanding of disulfide reduction during monoclonal antibody production.
Cura AJ, Xu X, Egan S, Aron K, Jenkins L, Hageman T, Huang Y, Chollangi S, Borys M, Ghose S, Li ZJ.
Appl Microbiol Biotechnol. 2020 Nov;104(22):9655-9669. doi: 10.1007/s00253-020-10916-1. Epub 2020 Sep 30.
PMID: 32997205
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Stegmaier K, Bourdeaut F, Reaman G, Heenen D, Meyers ML, Armstrong SA, Brown P, De Carvalho D, Jabado N, Marshall L, Rivera M, Smith M, Adamson PC, Barone A, Baumann C, Blackman S, Buenger V, Donoghue M, Duncan AD, Fox E, Gadbaw B, Hattersley M, Ho P, Jacobs I, Kelly MJ, Kieran M, Lesa G, Ligas F, Ludwinski D, McDonough J, Nikolova Z, Norga K, Senderowicz A, Taube T, Weiner S, Karres D, Vassal G.
Eur J Cancer. 2020 Nov;139:135-148. doi: 10.1016/j.ejca.2020.08.014. Epub 2020 Sep 26.
PMID: 32992153
Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure.
Chirinos JA, Cohen JB, Zhao L, Hanff T, Sweitzer N, Fang J, Corrales-Medina V, Anmar R, Morley M, Zamani P, Bhattacharya P, Brandimarto J, Jia Y, Basso MD, Wang Z, Ebert C, Ramirez-Valle F, Schafer PH, Seiffert D, Gordon DA, Cappola T.
Hypertension. 2020 Nov;76(5):1526-1536. doi: 10.1161/HYPERTENSIONAHA.120.15829. Epub 2020 Sep 28.
PMID: 32981365
Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
Reynolds VL, Butler P, Abernathy MM, Aschenbrenner L, Best DD, Blank J, Crosby M, Custer L, Escobar PA, Kolaja K, Moggs J, Shuey D, Snyder C, Van Vleet T, Zhou J, Hart TK.
Regul Toxicol Pharmacol. 2020 Nov;117:104746. doi: 10.1016/j.yrtph.2020.104746. Epub 2020 Sep 8.
PMID: 32911461
Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Meah MN, Raftis J, Wilson SJ, Perera V, Garonzik SM, Murthy B, Everlof JG, Aronson R, Luettgen J, Newby DE.
Arterioscler Thromb Vasc Biol. 2020 Nov;40(11):2678-2685. doi: 10.1161/ATVBAHA.120.314960. Epub 2020 Sep 10.
PMID: 32907366
Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV.
Reppas C, Vrettos NN, Dressman J, Andreas CJ, Miyaji Y, Brown J, Etherson K, Hanley S, Karkossa F, Karlsson E, Klein S, Maier GM, McAllister M, Mistry N, Rosenblatt K, Schäfer KJ, Smith KL, Tomaszewska I, Williams J, Winge F, Vertzoni M.
Eur J Pharm Biopharm. 2020 Nov;156:40-49. doi: 10.1016/j.ejpb.2020.08.025. Epub 2020 Aug 31.
PMID: 32882421
Synthesis of stable-isotope-labeled N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide and N-(3-dimethylaminopropyl)-N'-ethylurea.
Cao K, Brailsford JA, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm. 2020 Nov;63(13):526-530. doi: 10.1002/jlcr.3877. Epub 2020 Sep 7.
PMID: 32845523
Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms.
Ward NC, Lui JB, Hernandez R, Yu L, Struthers M, Xie J, Santos Savio A, Dwyer CJ, Hsiung S, Yu A, Malek TR.
Diabetes. 2020 Nov;69(11):2400-2413. doi: 10.2337/db20-0186. Epub 2020 Aug 25.
PMID: 32843568
Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations.
Gintant G, Kaushik EP, Feaster T, Stoelzle-Feix S, Kanda Y, Osada T, Smith G, Czysz K, Kettenhofen R, Lu HR, Cai B, Shi H, Herron TJ, Dang Q, Burton F, Pang L, Traebert M, Abassi Y, Pierson JB, Blinova K.
Regul Toxicol Pharmacol. 2020 Nov;117:104756. doi: 10.1016/j.yrtph.2020.104756. Epub 2020 Aug 19.
PMID: 32822771
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW, Uetrecht JP, Miller ED, Pehlivanov ND, Haque SA, Harrison MJ, Kullak-Ublick GA, Li H, Patel NN, Patwardhan M, Price KD, Watkins PB, Chalasani NP.
J Autoimmun. 2020 Nov;114:102514. doi: 10.1016/j.jaut.2020.102514. Epub 2020 Aug 5.
PMID: 32768244
Incidence and prevalence of venous thromboembolism in Norway 2010-2017.
Ghanima W, Brodin E, Schultze A, Shepherd L, Lambrelli D, Ulvestad M, Ramagopalan S, Halvorsen S.
Thromb Res. 2020 Nov;195:165-168. doi: 10.1016/j.thromres.2020.07.011. Epub 2020 Jul 7.
PMID: 32707359
Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy.
Suzuki A, Kakugawa S, Miyoshi M, Hori M, Suzuki K, Furukawa Y, Ohta K.
Leukemia. 2020 Nov;34(11):3088-3090. doi: 10.1038/s41375-020-0860-7. Epub 2020 May 12.
PMID: 32398792
Solid state nuclear magnetic resonance studies of hydroxypropylmethylcellulose acetyl succinate polymer, a useful carrier in pharmaceutical solid dispersions.
Pugliese A, Hawarden LE, Abraham A, Tobyn M, Blanc F.
Magn Reson Chem. 2020 Nov;58(11):1036-1048. doi: 10.1002/mrc.4984. Epub 2020 Feb 3.
PMID: 31880823
Proposed Best Practice Guidelines for Scientific Response Documents: A Consensus Statement from phactMI.
Hermes-DeSantis ER, Johnson RM, Redlich A, Patel B, Flanigan-Minnick A, Wnorowski S, Cortes MM, Han CW, Vine E, Sarwar H, Haydar R, Jamil A, Huang T, Sandhu SK, Reilly P.
Ther Innov Regul Sci. 2020 Nov;54(6):1303-1311. doi: 10.1007/s43441-020-00151-1. Epub 2020 Apr 20.
PMID: 33258092
Mechanistic insights into viral clearance during the chromatography steps in antibody processes by using virus surrogates.
Dyer R, Song Y, Chen J, Bigelow E, McGinnis J, Jenkins L, Ghose S, Li ZJ.
Biotechnol Prog. 2020 Nov;36(6):e3057. doi: 10.1002/btpr.3057. Epub 2020 Aug 21.
PMID: 33405373
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ.
ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079.
PMID: 33246931
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH, Bonafede M.
Clin Ther. 2020 Nov;42(11):2136-2147.e3. doi: 10.1016/j.clinthera.2020.09.014. Epub 2020 Nov 5.
PMID: 33160682
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés.
Albiges L, Tannir N, Burotto M, Mcdermott D, Plimack E, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger C, Gurney H, Grimm M, Tomita Y, Castellano D, Rini B, Choueiri T, Shally Saggi S, Mchenry M, Motzer R.
Prog Urol. 2020 Nov;30(13):785-786. doi: 10.1016/j.purol.2020.07.155.
PMID: 33157721
Considerations for setting occupational exposure limits for novel pharmaceutical modalities.
Graham J, Hillegass J, Schulze G.
Regul Toxicol Pharmacol. 2020 Oct 31:104813. doi: 10.1016/j.yrtph.2020.104813. Online ahead of print.
PMID: 33144077
A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor Vβ Families.
Wang J, Urbanska K, Sharma P, Nejati R, Shaw L, Lim MS, Schuster SJ, Jr DJP.
Vaccines (Basel). 2020 Oct 31;8(4):E631. doi: 10.3390/vaccines8040631.
PMID: 33142718
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL, Czuczman MS, Martin P, Rosenbaum CA, Jung SH, Leonard JP, Cheson BD, Hsi ED.
Am J Surg Pathol. 2020 Oct 30. doi: 10.1097/PAS.0000000000001609. Online ahead of print.
PMID: 33136585
Transporter activity changes in non-alcoholic steatohepatitis: assessment with plasma coproporphyrin I and III.
Chatterjee S, Mukherjee S, Sivaprasad Lvj S, Naik T, Gautam SS, Murali BV, Hadambar AA, Gunti GR, Kuchibhotla V, Deyati A, Basavanthappa S, Ramarao M, Mariappan TT, Zinker BA, Zhang Y, Sinz M, Shen H.
J Pharmacol Exp Ther. 2020 Oct 30:JPET-AR-2020-000291. doi: 10.1124/jpet.120.000291. Online ahead of print.
PMID: 33127749
Immunoaffinity microflow liquid chromatography/tandem mass spectrometry for the quantitation of PD1 and PD-L1 in human tumor tissues.
Zhu Y, Zalaznick J, Sleczka B, Parrish K, Yang Z, Olah T, Shipkova P.
Rapid Commun Mass Spectrom. 2020 Oct 30;34(20):e8896. doi: 10.1002/rcm.8896.
PMID: 32666620
The Value of Hope: Patients' and Physicians' Preferences for Survival in Advanced Non-Small Cell Lung Cancer.
Hauber B, Penrod JR, Gebben D, Musallam L.
Patient Prefer Adherence. 2020 Oct 30;14:2093-2104. doi: 10.2147/PPA.S248295. eCollection 2020.
PMID: 33154633
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Döhner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P.
J Clin Oncol. 2020 Oct 29:JCO2001632. doi: 10.1200/JCO.20.01632. Online ahead of print.
PMID: 33119479
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect ®  MM Registry.
Abonour R, Rifkin RM, Gasparetto C, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Jagannath S, Narang M, Ailawadhi S, Omel JL, Lee HC, Srinivasan S, Kitali A, Agarwal A, Wagner L; CONNECT MM Registry Investigators.
Br J Haematol. 2020 Oct 29. doi: 10.1111/bjh.17131. Online ahead of print.
PMID: 33118614
Misannotated multi-nucleotide variants in public cancer genomics datasets lead to inaccurate mutation calls with significant implications.
Srinivasan S, Kalinava N, Aldana R, Li Z, van Hagen S, Rodenburg SYA, Wind-Rotolo M, Qian X, Sasson AS, Tang H, Kirov S.
Cancer Res. 2020 Oct 28:canres.2151.2020. doi: 10.1158/0008-5472.CAN-20-2151. Online ahead of print.
PMID: 33115802
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF, Hikichi Y, Baker T, Itakura E, Chandran N, Harrison J.
J Med Econ. 2020 Oct 28:1-11. doi: 10.1080/13696998.2020.1830781. Online ahead of print.
PMID: 33000994
An Industry Perspective on Compatibility Assessment of Closed System Drug-Transfer Devices for Biologics.
Besheer A, Burton L, Galas RJ Jr, Gokhale K, Goldbach P, Hu Q, Mathews L, Muthurania K, Narasimhan C, Singh SN, Stokes ES, Weiser S, Zamiri C, Zhou S.
J Pharm Sci. 2020 Oct 27:S0022-3549(20)30663-8. doi: 10.1016/j.xphs.2020.10.047. Online ahead of print.
PMID: 33127425
What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D, Zhou S, Gao W.
ACS Nano. 2020 Oct 27;14(10):12281-12290. doi: 10.1021/acsnano.9b09713. Epub 2020 Oct 6.
PMID: 33021091
Use of the ZDF rat to model dietary fat induced hypercoagulability is limited by progressive and fatal nephropathy.
Pugsley MK, Brooks MB, Fishman CE, Katavolos P, Chiang AY, Parish ST, Schultze AE, Pierson JB.
J Pharmacol Toxicol Methods. 2020 Oct 26:106933. doi: 10.1016/j.vascn.2020.106933. Online ahead of print.
PMID: 33122074
Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes.
Yoshikado T, Lee W, Toshimoto K, Morita K, Kiriake A, Chu X, Lee N, Kimoto E, Varma MVS, Kikuchi R, Scialis RJ, Shen H, Ishiguro N, Lotz R, Li AP, Kazuya M, Kusuhara H, Sugiyama Y.
J Pharm Sci. 2020 Oct 26:S0022-3549(20)30633-X. doi: 10.1016/j.xphs.2020.10.041. Online ahead of print.
PMID: 33122051
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
McHenry MB, Drake CG, Fizazi K.
Eur Urol. 2020 Oct 26:S0302-2838(20)30789-2. doi: 10.1016/j.eururo.2020.10.012. Online ahead of print.
PMID: 33121826
A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors.
Sheng J, Zhang L, Ma Y, Fang W, Zhao H, Bathena SP, Tendolkar A.
Oncologist. 2020 Oct 26. doi: 10.1002/onco.13577. Online ahead of print.
PMID: 33105036
Modeling performance of sample collection sites using whole exome sequencing metrics.
Kalinava N, Apfel A, Cartmell R, Srinivasan S, Chien MS, Kim KI, Golhar R, Bednarz KE, Pant S, Szustakowski J, Chasalow SD, Sasson A, Kirov S.
Biotechniques. 2020 Oct 26. doi: 10.2144/btn-2020-0086. Online ahead of print.
PMID: 33103912
Writing Your Next Medicinal Chemistry Article: Journal Bibliometrics and Guiding Principles for Industrial Authors.
Hatley RJD, Procopiou PA, McLachlan SP, Westendorf LE, Meanwell NA, Ewing WR, Macdonald SJF.
J Med Chem. 2020 Oct 26. doi: 10.1021/acs.jmedchem.0c01159. Online ahead of print.
PMID: 33103431
Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study).
Assié JB, Corre R, Levra MG, Calvet CY, Gaudin AF, Grumberg V, Jouaneton B, Cotté FE, Chouaïd C.
Ther Adv Med Oncol. 2020 Oct 26;12:1758835920967237. doi: 10.1177/1758835920967237. eCollection 2020.
PMID: 33403011
Azacitidine is removed effectively by hemodialysis.
Beer AGE, Laille E, Neuwirt H, Mayer G, Stauder R.
Leuk Lymphoma. 2020 Oct 25:1-3. doi: 10.1080/10428194.2020.1838505. Online ahead of print.
PMID: 33100080
Land O'Lakes Workshop on Microsampling: Enabling Broader Adoption.
Wickremsinhe ER, Ji QC, Gleason CR, Anderson M, Booth BP.
AAPS J. 2020 Oct 23;22(6):135. doi: 10.1208/s12248-020-00524-2.
PMID: 33098040
Realizing the Potential of the Patient Perspective.
Simon TA, Khouri MS, Kou TD, Gomez-Caminero A.
Patient Prefer Adherence. 2020 Oct 22;14:2001-2007. doi: 10.2147/PPA.S257355. eCollection 2020.
PMID: 33132698
Impact of virus-antibody interactions on viral clearance in anion exchange chromatography.
Hung J, Lam SF, Tan Z, Choy D, Chennamsetty N, Lewandowski A, Qi W, Lynch M, Ghose S, Li ZJ.
J Chromatogr A. 2020 Oct 22;1633:461635. doi: 10.1016/j.chroma.2020.461635. Online ahead of print.
PMID: 33128974
Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.
Jia J, Shang J, Tang H, Jiang J, Ning Q, Dou X, Zhang S, Zhang M, Han T, Tan D, Zhou X, Chen G, Sheng J, Su Z, Chen H, Dai E, Ye Y, Guo Y, Shen Y, Yuan J, Wei Z, Zhu S; EVOLVE Study Group.
Antivir Ther. 2020 Oct 22. doi: 10.3851/IMP3372. Online ahead of print.
PMID: 33090970
Authors' response.
LaGoy A, Evangelou EA, Somogyi T, DiGangi EA.
J Forensic Sci. 2020 Oct 21. doi: 10.1111/1556-4029.14593. Online ahead of print.
PMID: 33085776
Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.
Zecca C, Disanto G, Sacco R, MacLachlan S, Kuhle J, Ramagopalan SV, Gobbi C.
J Neurol. 2020 Oct 21. doi: 10.1007/s00415-020-10170-5. Online ahead of print.
PMID: 33084939
First-line immunotherapy versus targeted therapy in patients with  BRAF -mutant advanced melanoma: a real-world analysis.
Pavlick AC, Zhao R, Lee CH, Ritchings C, Rao S.
Future Oncol. 2020 Oct 21. doi: 10.2217/fon-2020-0643. Online ahead of print.
PMID: 33084375
Synthesis and Biological Evaluation of a Carbamate-Containing Tubulysin Antibody-Drug Conjugate.
Cheng H, Cong Q, Dervin D, Stevens A, Vemuri K, Huber M, Juliano J, Cuison S, Sung J, Passmore D, Chong C, Greenbaum M, Kwok E, Jiang J, Pan C, Rao-Naik C, Rangan V, Kempe T, Tatum A, Deshpande S, Cardarelli P, Vite G, Gangwar S.
Bioconjug Chem. 2020 Oct 21;31(10):2350-2361. doi: 10.1021/acs.bioconjchem.0c00429. Epub 2020 Sep 11.
PMID: 32881482
Expamers: a new technology to control T cell activation.
Poltorak MP, Graef P, Tschulik C, Wagner M, Cletiu V, Dreher S, Borjan B, Fraessle SP, Effenberger M, Turk M, Busch DH, Plitzko J, Kugler DG, Ragan S, Schmidt T, Stemberger C, Germeroth L.
Sci Rep. 2020 Oct 20;10(1):17832. doi: 10.1038/s41598-020-74595-8.
PMID: 33082362
Experimental model of congestive heart failure induced by transverse aortic constriction in BALB/c mice.
Tannu S, Allocco J, Yarde M, Wong P, Ma X.
J Pharmacol Toxicol Methods. 2020 Oct 20;106:106935. doi: 10.1016/j.vascn.2020.106935. Online ahead of print.
PMID: 33096237
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists.
Mercer SE, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Pin SS, Macci R, Schartman R, Signor LJ, Widmann KA, Whiterock VJ, Chen P, Xu C, Herbst JJ, Kostich WA, Thalody G, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett. 2020 Oct 20:127624. doi: 10.1016/j.bmcl.2020.127624. Online ahead of print.
PMID: 33096162
Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial.
Hill NR, Arden C, Beresford-Hulme L, Camm AJ, Clifton D, Davies DW, Farooqui U, Gordon J, Groves L, Hurst M, Lawton S, Lister S, Mallen C, Martin AC, McEwan P, Pollock KG, Rogers J, Sandler B, Sugrue DM, Cohen AT.
Contemp Clin Trials. 2020 Oct 19;99:106191. doi: 10.1016/j.cct.2020.106191. Online ahead of print.
PMID: 33091585
A phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
Hatake K, Chou T, Doi T, Terui Y, Kato H, Hirose T, Seo S, Pourdehnad M, Ogaki Y, Fujimoto H, Hagner PR, Yamamoto K.
Cancer Sci. 2020 Oct 19. doi: 10.1111/cas.14704. Online ahead of print.
PMID: 33075165
Total Synthesis of Meayamycin and  O -Acyl Analogues.
Gartshore C, Tadano S, Chanda PB, Sarkar A, Chowdari NS, Gangwar S, Zhang Q, Vite GD, Momirov J, Boger DL.
Org Lett. 2020 Oct 19. doi: 10.1021/acs.orglett.0c03308. Online ahead of print.
PMID: 33074680
Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.
O'Donnell JC, T Kim Le, Dobrin R, Higashi M, Pereira A, Wagner S, Yang A, Hukkelhoven M.
Future Oncol. 2020 Oct 19. doi: 10.2217/fon-2020-0591. Online ahead of print.
PMID: 33074018
Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA.
Deitelzweig S, Dhamane AD, Di Fusco M, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J.
J Med Econ. 2020 Oct 19:1-12. doi: 10.1080/13696998.2020.1832099. Online ahead of print.
PMID: 33021129
SPARC promotes insulin secretion through down-regulation of RGS4 protein in pancreatic β cells.
Hu L, He F, Huang M, Zhao Q, Cheng L, Said N, Zhou Z, Liu F, Dai YS.
Sci Rep. 2020 Oct 16;10(1):17581. doi: 10.1038/s41598-020-74593-w.
PMID: 33067534
A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity.
Park SH, Han X, Lobo F, Nanji S, Patel D.
Clinicoecon Outcomes Res. 2020 Oct 15;12:589-594. doi: 10.2147/CEOR.S263903. eCollection 2020.
PMID: 33116698
Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody.
Gamse JT, Freebern W, Haynes Ii R, Simutis F, Pazian M, Crona J, Haggerty HG, Graziano M, Bunch RT.
Toxicol Appl Pharmacol. 2020 Oct 15;409:115285. doi: 10.1016/j.taap.2020.115285. Online ahead of print.
PMID: 33069749
Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs.
Lee W, Koyama S, Morita K, Kiriake A, Kikuchi R, Chu X, Lee N, Scialis RJ, Shen H, Kimoto E, Tremaine L, Ishiguro N, Lotz R, Maeda K, Kusuhara H, Sugiyama Y.
AAPS J. 2020 Oct 15;22(6):133. doi: 10.1208/s12248-020-00512-6.
PMID: 33063163
Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
Tessier Y, Achanzar W, Mihalcik L, Amuzie C, Andersson P, Parry JD, Moggs J, Whiteley LO.
Nucleic Acid Ther. 2020 Oct 15. doi: 10.1089/nat.2020.0892. Online ahead of print.
PMID: 33054599
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
Connolly RM, Laille E, Vaishampayan U, Chung V, Kelly K, Dowlati A, Alese OB, Harvey RD, Haluska P, Siu LL, Kummar S, Piekarz R, Ivy SP, Anders NM, Downs M, O'Connor A, Scardina A, Saunders J, Rosner GL, Carducci MA, Rudek MA; ETCTN-9008 Study Team.
Clin Cancer Res. 2020 Oct 15;26(20):5329-5337. doi: 10.1158/1078-0432.CCR-20-1412. Epub 2020 Aug 14.
PMID: 32816943
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R, Sanders C, Hou J, Li XY, Ferrone S, Davar D, Kirkwood JM, Johnston RJ, Korman AJ, Smyth MJ, Zarour HM.
Clin Cancer Res. 2020 Oct 15;26(20):5520-5533. doi: 10.1158/1078-0432.CCR-20-0575. Epub 2020 Jun 26.
PMID: 32591463
Effect of coating excipients on chemical stability of active coated tablets.
Kestur U, Desai D, Zong Z, Abraham A, Fiske J.
Pharm Dev Technol. 2020 Oct 14:1-7. doi: 10.1080/10837450.2020.1832520. Online ahead of print.
PMID: 33021427
Serine-Selective Bioconjugation.
Vantourout JC, Adusumalli SR, Knouse KW, Flood DT, Ramirez A, Padial NM, Istrate A, Maziarz K, deGruyter JN, Merchant RR, Qiao JX, Schmidt MA, Deery MJ, Eastgate MD, Dawson PE, Bernardes GJL, Baran PS.
J Am Chem Soc. 2020 Oct 14;142(41):17236-17242. doi: 10.1021/jacs.0c05595. Epub 2020 Oct 5.
PMID: 32965106
Selective Capture and Recovery of Monoclonal Antibodies by Self-Assembling Supramolecular Polymers of High Affinity for Protein Binding.
Li Y, Lock LL, Mills J, Ou BS, Morrow M, Stern D, Wang H, Anderson CF, Xu X, Ghose S, Li ZJ, Cui H.
Nano Lett. 2020 Oct 14;20(10):6957-6965. doi: 10.1021/acs.nanolett.0c01297. Epub 2020 Sep 3.
PMID: 32852220
Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.
Parrott N, Suarez-Sharp S, Kesisoglou F, Pathak SM, Good D, Wagner C, Dallmann A, Mullin J, Patel N, Riedmaier AE, Mitra A, Raines K, Butler J, Kakhi M, Li M, Zhao Y, Tsakalozou E, Flanagan T, Dressman J, Pepin X.
J Pharm Sci. 2020 Oct 13:S0022-3549(20)30608-0. doi: 10.1016/j.xphs.2020.09.058. Online ahead of print.
PMID: 33058891
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 +  T Cells.
Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, Bald T.
Immunity. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010.
PMID: 33053330
Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis.
Bonafede M, Mehta R, Kim G, Sruti I, Tian M, Pelletier C, Goldfarb N.
Pharmacoecon Open. 2020 Oct 13. doi: 10.1007/s41669-020-00233-8. Online ahead of print.
PMID: 33051856
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Belch A, Bahlis N, White D, Cheung M, Chen C, Shustik C, Song K, Tosikyan A, Dispenzieri A, Anderson K, Brown D, Robinson S, Srinivasan S, Facon T.
Cancer Med. 2020 Oct 13. doi: 10.1002/cam4.3511. Online ahead of print.
PMID: 33049118
Endogenous Coproporphyrin I and III Are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR - ) Rats.
Bezençon J, Saran C, Hussner J, Beaudoin JJ, Zhang Y, Shen H, Fallon JK, Smith PC, Meyer Zu Schwabedissen HE, Brouwer KLR.
J Pharm Sci. 2020 Oct 12:S0022-3549(20)30607-9. doi: 10.1016/j.xphs.2020.10.017. Online ahead of print.
PMID: 33058892
Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling.
Hao HX, Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, Kowal C, Delach S, Wang Y, Goldoni S, Hastings WD, Wong K, Gao H, Meyer MJ, Moody S, LaMarche MJ, Engelman JA, Williams JA, Hammerman PS, Abrams TJ, Mohseni M, Caponigro G.
Clin Cancer Res. 2020 Oct 12:clincanres.2718.2020. doi: 10.1158/1078-0432.CCR-20-2718. Online ahead of print.
PMID: 33046519
Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS.
Clin Cancer Res. 2020 Oct 12:clincanres.2380.2020. doi: 10.1158/1078-0432.CCR-20-2380. Online ahead of print.
PMID: 33046517
Effects of azacitidine in 93 patients with  IDH1/2  mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.
Willekens C, Rahme R, Duchmann M, Vidal V, Saada V, Broutin S, Delahousse J, Renneville A, Marceau A, Clappier E, Uzunov M, Rossignol J, Pascal L, Simon L, Micol JB, Pasquier F, Raffoux E, Preudhomme C, Quivoron C, Itzykson R, Penard-Lacronique V, Paci A, Fenaux P, Attar EC, Frattini M, Braun T, Ades L, De Botton S.
Leuk Lymphoma. 2020 Oct 12:1-8. doi: 10.1080/10428194.2020.1832661. Online ahead of print.
PMID: 33043739
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K.
Cancer Cell. 2020 Oct 12;38(4):489-499.e3. doi: 10.1016/j.ccell.2020.08.007. Epub 2020 Sep 10.
PMID: 32916128
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL Jr, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A.
Cancer Cell. 2020 Oct 12;38(4):500-515.e3. doi: 10.1016/j.ccell.2020.08.005. Epub 2020 Sep 10.
PMID: 32916126
Clinical Characteristics of Acute Hepatitis E and Their Correlation with HEV Genotype 3 Subtypes in Italy.
Minosse C, Biliotti E, Lapa D, Rianda A, Marchili M, Luzzitelli I, Capobianchi MR, McPhee F, Garbuglia AR, D'Offizi G.
Pathogens. 2020 Oct 11;9(10):E832. doi: 10.3390/pathogens9100832.
PMID: 33050666
An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impact.
Hills A, Awigena-Cook J, Genenz K, Ostertag M, Butler S, Eggimann AV, Hubert A.
Cytotherapy. 2020 Oct 9:S1465-3249(20)30847-1. doi: 10.1016/j.jcyt.2020.08.011. Online ahead of print.
PMID: 33046395
Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
Kanouni T, Severin C, Cho RW, Yuen NY, Xu J, Shi L, Lai C, Del Rosario JR, Stansfield RK, Lawton LN, Hosfield D, O'Connell S, Kreilein MM, Tavares-Greco P, Nie Z, Kaldor SW, Veal JM, Stafford JA, Chen YK.
J Med Chem. 2020 Oct 9. doi: 10.1021/acs.jmedchem.0c00978. Online ahead of print.
PMID: 33034194
Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
Bihorel S, Singhal S, Shevell D, Sun H, Xie J, Basdeo S, Liu A, Dutta S, Ludwig E, Huang H, Lin KJ, Fura A, Throup J, Girgis IG.
Clin Pharmacol Drug Dev. 2020 Oct 8. doi: 10.1002/cpdd.878. Online ahead of print.
PMID: 33090733
A Detailed Protocol for Generation of Therapeutic Antibodies with Galactosylated Glycovariants at Laboratory Scale Using In-Vitro Glycoengineering Technology.
Voruganti S, Xu J, Li X, Balakrishnan G, Singh SM, Kar SR, Das TK.
J Pharm Sci. 2020 Oct 8:S0022-3549(20)30590-6. doi: 10.1016/j.xphs.2020.09.056. Online ahead of print.
PMID: 33039440
Appropriate Analysis of Duration of Response Data in Cancer Trials-Reply.
Weller M, Tatsuoka K, Reardon DA.
JAMA Oncol. 2020 Oct 8. doi: 10.1001/jamaoncol.2020.4664. Online ahead of print.
PMID: 33030510
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
Brunner HI, Wong R, Nys M, Kou TD, Dominique A, Martini A, Lovell DJ, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
Paediatr Drugs. 2020 Oct 8. doi: 10.1007/s40272-020-00422-2. Online ahead of print.
PMID: 33029724
Strategies for Setting Patient-Centric Commercial Specifications for Biotherapeutic Products.
Ruesch MN, Benetti L, Berkay E, Cirelli DJ, Frantz N, Gastens MH, Kelley WP, Kretsinger J, Lewis M, Novick S, Rellahan B, Pack L, Stroop CJM, Subashi A, Yin P, Zeng M, Stults J.
J Pharm Sci. 2020 Oct 7:S0022-3549(20)30579-7. doi: 10.1016/j.xphs.2020.09.048. Online ahead of print.
PMID: 33035537
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S.
Lancet Oncol. 2020 Oct 6:S1470-2045(20)30451-4. doi: 10.1016/S1470-2045(20)30451-4. Online ahead of print.
PMID: 33035459
Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets.
Meruva S, Rezaei L, Thool P, Donovan MD.
AAPS PharmSciTech. 2020 Oct 6;21(7):270. doi: 10.1208/s12249-020-01804-y.
PMID: 33025237
Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study.
Tsutsué S, Tobinai K, Yi J, Crawford B.
Future Oncol. 2020 Oct 6. doi: 10.2217/fon-2020-0832. Online ahead of print.
PMID: 33021099
Ultrahigh-Throughput and Chromatography-Free Bioanalysis of Polar Analytes with Acoustic Ejection Mass Spectrometry.
Wagner A, Zhang J, Liu C, Covey TR, Olah TV, Weller HBN, Shou WZ.
Anal Chem. 2020 Oct 6;92(19):13525-13531. doi: 10.1021/acs.analchem.0c03006. Epub 2020 Sep 25.
PMID: 32926623
Control of leached beta-glucan levels from depth filters by an improved depth filtration flush strategy.
Holstein M, Jang D, Urrea C, Botta LS, Grimm W, Ghose S, Li ZJ.
Biotechnol Prog. 2020 Oct 5:e3086. doi: 10.1002/btpr.3086. Online ahead of print.
PMID: 33016571
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES.
Benz AP, Eikelboom JW, Yusuf S, Hohnloser SH, Kahl A, Beresh H, Balasubramanian K, Healey JS, Connolly SJ.
Thromb Haemost. 2020 Oct 4. doi: 10.1055/s-0040-1717115. Online ahead of print.
PMID: 33011964
Effectiveness and Safety of Oral Anticoagulants Among Non-Valvular Atrial FibrillationPatients with Polypharmacy.
Lip GYH, Keshishian A, Kang A, Dhamane AD, Luo X, Klem C, Rosenblatt L, Mardekian J, Jiang J, Yuce H, Deitelzweig S.
Eur Heart J Cardiovasc Pharmacother. 2020 Oct 3:pvaa117. doi: 10.1093/ehjcvp/pvaa117. Online ahead of print.
PMID: 33010157
Defining and Manipulating B Cell Immunodominance Hierarchies to Elicit Broadly Neutralizing Antibody Responses against Influenza Virus.
Amitai A, Sangesland M, Barnes RM, Rohrer D, Lonberg N, Lingwood D, Chakraborty AK.
Cell Syst. 2020 Oct 2:S2405-4712(20)30335-5. doi: 10.1016/j.cels.2020.09.005. Online ahead of print.
PMID: 33031741
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C.
JAMA Oncol. 2020 Oct 1:e204564. doi: 10.1001/jamaoncol.2020.4564. Online ahead of print.
PMID: 33001135
Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia.
Ebrahimi-Fakhari D, Teinert J, Behne R, Wimmer M, D'Amore A, Eberhardt K, Brechmann B, Ziegler M, Jensen DM, Nagabhyrava P, Geisel G, Carmody E, Shamshad U, Dies KA, Yuskaitis CJ, Salussolia CL, Ebrahimi-Fakhari D, Pearson TS, Saffari A, Ziegler A, Kölker S, Volkmann J, Wiesener A, Bearden DR, Lakhani S, Segal D, Udwadia-Hegde A, Martinuzzi A, Hirst J, Perlman S, Takiyama Y, Xiromerisiou G, Vill K, Walker WO, Shukla A, Dubey Gupta R, Dahl N, Aksoy A, Verhelst H, Delgado MR, Kremlikova Pourova R, Sadek AA, Elkhateeb NM, Blumkin L, Brea-Fernández AJ, Dacruz-Álvarez D, Smol T, Ghoumid J, Miguel D, Heine C, Schlump JU, Langen H, Baets J, Bulk S, Darvish H, Bakhtiari S, Kruer MC, Lim-Melia E, Aydinli N, Alanay Y, El-Rashidy O, Nampoothiri S, Patel C, Beetz C, Bauer P, Yoon G, Guillot M, Miller SP, Bourinaris T, Houlden H, Robelin L, Anheim M, Alamri AS, Mahmoud AAH, Inaloo S, Habibzadeh P, Faghihi MA, Jansen AC, Brock S, Roubertie A, Darras BT, Agrawal PB, Santorelli FM, Gleeson J, Zaki MS, Sheikh SI, Bennett JT, Sahin M.
Brain. 2020 Oct 1;143(10):2929-2944. doi: 10.1093/brain/awz307.
PMID: 32979048
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI.
JAMA Oncol. 2020 Oct 1;6(10):1563-1570. doi: 10.1001/jamaoncol.2020.2955.
PMID: 32852531
Annulation reaction enables the identification of an exocyclic amide tricyclic chemotype as retinoic acid Receptor-Related orphan receptor gamma (RORγ/RORc) inverse agonists.
Marcoux D, Bertrand MB, Weigelt CA, Yip S, Galella M, Park H, Wu DR, Wang J, Yarde M, Cvijic ME, Li S, Hynes J Jr, Tino JA, Zhao Q, Dhar TGM.
Bioorg Med Chem Lett. 2020 Oct 1;30(19):127466. doi: 10.1016/j.bmcl.2020.127466. Epub 2020 Aug 5.
PMID: 32763309
Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists.
Duan JJ, Jiang B, Lu Z, Stachura S, Weigelt CA, Sack JS, Khan J, Ruzanov M, Wu DR, Yarde M, Shen DR, Zhao Q, Salter-Cid LM, Carter PH, Murali Dhar TG.
Bioorg Med Chem Lett. 2020 Oct 1;30(19):127441. doi: 10.1016/j.bmcl.2020.127441. Epub 2020 Jul 29.
PMID: 32736080
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, Siefker-Radtke A, Necchi A, Sharma P.
Clin Cancer Res. 2020 Oct 1;26(19):5120-5128. doi: 10.1158/1078-0432.CCR-19-4162. Epub 2020 Jun 12.
PMID: 32532789
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.
Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J.
J Immunother Cancer. 2020 Oct;8(2):e000537. doi: 10.1136/jitc-2020-000537.
PMID: 33106386
Evolving impact of long-term survival results on metastatic melanoma treatment.
Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA.
J Immunother Cancer. 2020 Oct;8(2):e000948. doi: 10.1136/jitc-2020-000948.
PMID: 33037115
Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
Wysham CH, Rosenstock J, Vetter ML, Wang H, Hardy E, Iqbal N.
BMJ Open Diabetes Res Care. 2020 Oct;8(1):e000773. doi: 10.1136/bmjdrc-2019-000773.
PMID: 33037036
Accelerating protein biomarker discovery and translation from proteomics research for clinical utility.
Chen J, Zheng N.
Bioanalysis. 2020 Oct;12(20):1469-1481. doi: 10.4155/bio-2020-0198. Epub 2020 Oct 2.
PMID: 33006485
Immunoaffinity enrichment LC-MS/MS quantitation of CDH17 in tissues.
Caporuscio C, Holmes D, Olah TV, Shipkova P.
Bioanalysis. 2020 Oct;12(20):1439-1447. doi: 10.4155/bio-2020-0162. Epub 2020 Oct 2.
PMID: 33006478
Technology outlook for real-time quality attribute and process parameter monitoring in biopharmaceutical development-A review.
Wasalathanthri DP, Rehmann MS, Song Y, Gu Y, Mi L, Shao C, Chemmalil L, Lee J, Ghose S, Borys MC, Ding J, Li ZJ.
Biotechnol Bioeng. 2020 Oct;117(10):3182-3198. doi: 10.1002/bit.27461. Epub 2020 Jul 1.
PMID: 32946122
Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F, Krishna G, Surapaneni S.
Cancer Chemother Pharmacol. 2020 Oct;86(4):461-473. doi: 10.1007/s00280-020-04131-y. Epub 2020 Sep 4.
PMID: 32886148
Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Tran JQ, Zhang P, Ghosh A, Liu L, Syto M, Wang X, Palmisano M.
Adv Ther. 2020 Oct;37(10):4381-4395. doi: 10.1007/s12325-020-01473-0. Epub 2020 Aug 28.
PMID: 32857315
Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.
Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, McCarthy L, Waterworth D, Nelson MR, Smith GD, Butterworth AS, Hemani G, Scott RA, Gaunt TR.
Nat Genet. 2020 Oct;52(10):1122-1131. doi: 10.1038/s41588-020-0682-6. Epub 2020 Sep 7.
PMID: 32895551
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Jamei M, Abrahamsson B, Brown J, Bevernage J, Bolger MB, Heimbach T, Karlsson E, Kotzagiorgis E, Lindahl A, McAllister M, Mullin JM, Pepin X, Tistaert C, Turner DB, Kesisoglou F.
Eur J Pharm Biopharm. 2020 Oct;155:55-68. doi: 10.1016/j.ejpb.2020.08.005. Epub 2020 Aug 8.
PMID: 32781025
IL-1 induces mitochondrial translocation of IRAK2 to suppress oxidative metabolism in adipocytes.
Zhou H, Wang H, Yu M, Schugar RC, Qian W, Tang F, Liu W, Yang H, McDowell RE, Zhao J, Gao J, Dongre A, Carman JA, Yin M, Drazba JA, Dent R, Hine C, Chen YR, Smith JD, Fox PL, Brown JM, Li X.
Nat Immunol. 2020 Oct;21(10):1219-1231. doi: 10.1038/s41590-020-0750-1. Epub 2020 Aug 10.
PMID: 32778760
Corrigendum to "Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease" American Journal of Medicine 131:09 (2018): 1074-1085.e4.
Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS.
Am J Med. 2020 Oct;133(10):1229-1238. doi: 10.1016/j.amjmed.2020.06.003. Epub 2020 Aug 5.
PMID: 32771226
Infections in patients with multiple sclerosis: A national cohort study in Sweden.
Castelo-Branco A, Chiesa F, Conte S, Bengtsson C, Lee S, Minton N, Niemcryk S, Lindholm A, Rosenlund M, Piehl F, Montgomery S.
Mult Scler Relat Disord. 2020 Oct;45:102420. doi: 10.1016/j.msard.2020.102420. Epub 2020 Jul 23.
PMID: 32736217
Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Zhang Y, Holenarsipur VK, Kandoussi H, Zeng J, Mariappan TT, Sinz M, Shen H.
Drug Metab Dispos. 2020 Oct;48(10):841-848. doi: 10.1124/dmd.120.000076. Epub 2020 Jul 28.
PMID: 32723847
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Khushalani NI, Diab A, Ascierto PA, Larkin J, Sandhu S, Sznol M, Koon HB, Jarkowski A, Zhou M, Statkevich P, Geese WJ, Long GV.
Future Oncol. 2020 Oct;16(28):2165-2175. doi: 10.2217/fon-2020-0351. Epub 2020 Jul 29.
PMID: 32723187
Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
Zhang Y, Chen C, Chen SJ, Chen XQ, Shuster DJ, Puszczalo PD, Fancher RM, Yang Z, Sinz M, Shen H.
J Pharmacol Exp Ther. 2020 Oct;375(1):139-151. doi: 10.1124/jpet.120.000139. Epub 2020 Jul 27.
PMID: 32719071
Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma.
Jang S, Poretta T, Bhagnani T, Harshaw Q, Burke M, Rao S.
Dermatol Ther (Heidelb). 2020 Oct;10(5):1001. doi: 10.1007/s13555-020-00422-7.
PMID: 32683664
Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance.
Lee I, Lee TA, Crawford SY, Kilpatrick RD, Calip GS, Jokinen JD.
Expert Opin Drug Saf. 2020 Oct;19(10):1357-1366. doi: 10.1080/14740338.2020.1792883. Epub 2020 Jul 27.
PMID: 32662668
Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs.
Belair DG, Visconti RJ, Hong M, Marella M, Peters MF, Scott CW, Kolaja KL.
Toxicol In Vitro. 2020 Oct;68:104928. doi: 10.1016/j.tiv.2020.104928. Epub 2020 Jul 3.
PMID: 32622998
Skin sensitization in silico protocol.
Johnson C, Ahlberg E, Anger LT, Beilke L, Benigni R, Bercu J, Bobst S, Bower D, Brigo A, Campbell S, Cronin MTD, Crooks I, Cross KP, Doktorova T, Exner T, Faulkner D, Fearon IM, Fehr M, Gad SC, Gervais V, Giddings A, Glowienke S, Hardy B, Hasselgren C, Hillegass J, Jolly R, Krupp E, Lomnitski L, Magby J, Mestres J, Milchak L, Miller S, Muster W, Neilson L, Parakhia R, Parenty A, Parris P, Paulino A, Paulino AT, Roberts DW, Schlecker H, Stidl R, Suarez-Rodrigez D, Szabo DT, Tice RR, Urbisch D, Vuorinen A, Wall B, Weiler T, White AT, Whritenour J, Wichard J, Woolley D, Zwickl C, Myatt GJ.
Regul Toxicol Pharmacol. 2020 Oct;116:104688. doi: 10.1016/j.yrtph.2020.104688. Epub 2020 Jul 1.
PMID: 32621976
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.
Gamberi B, Berthou C, Hernandez M, Semenzato G, Tholouli E, Hájek R, Caers J, Dimopoulos M, Minnema MC, Andreasson B, Parreira J, Crotty G, Remes K, Kueenburg E, Rosettani B, Di Micco A, Peters S, Bacon P, Blau IW.
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e629-e644. doi: 10.1016/j.clml.2020.05.006. Epub 2020 May 13.
PMID: 32605897
Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types.
Krigsfeld GS, Prince EA, Pratt J, Chizhevsky V, William Ragheb J, Novotny J Jr, Huron D.
J Clin Pathol. 2020 Oct;73(10):656-664. doi: 10.1136/jclinpath-2020-206466. Epub 2020 Jun 26.
PMID: 32591352
Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma.
Jang S, Poretta T, Bhagnani T, Harshaw Q, Burke M, Rao S.
Dermatol Ther (Heidelb). 2020 Oct;10(5):985-999. doi: 10.1007/s13555-020-00404-9. Epub 2020 Jun 16.
PMID: 32548707
Quality by design (QbD) approach to match tablet glossiness.
Mansuri N, Patel K, Mehta M, Vyas G, Reddy JP, Shah T, Steinbach D, Desai D.
Pharm Dev Technol. 2020 Oct;25(8):1010-1017. doi: 10.1080/10837450.2020.1772291. Epub 2020 Jun 12.
PMID: 32432492
Creating E-Labeling Platforms: An Industry Vision.
Roberts K, Thakkar R, Autor D, Bisordi F, Fitton H, Garner C, Garvin M, Honig P, Hukkelhoven M, Kowalski R, Milligan S, O'Dowd L, Olmstead S, Reilly E, Robertson AS, Rohrer M, Stewart J, Taisey M, Van Baelen K, Wegner M.
Clin Pharmacol Ther. 2020 Oct;108(4):716-718. doi: 10.1002/cpt.1865. Epub 2020 May 19.
PMID: 32337707
Integration of Acoustic Liquid Handling into Quantitative Analysis of Biological Matrix Samples.
Wang L, Dalglish G, Ouyang Z, David-Brown DG, Chiriac C, Duo J, Kozhich A, Ji QC, Peterson JE.
SLAS Technol. 2020 Oct;25(5):463-473. doi: 10.1177/2472630320915844. Epub 2020 Apr 30.
PMID: 32351162
Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.
Opfer R, Krüger J, Spies L, Hamann M, Wicki CA, Kitzler HH, Gocke C, Silva D, Schippling S.
Neuroimage Clin. 2020 Oct;28:102478. doi: 10.1016/j.nicl.2020.102478. Epub 2020 Oct 27.
PMID: 33269702
Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment.
Li Y, MacGorman K, Liu L, Chen J, Hoffmann M, Palmisano M, Zhou S.
Clin Pharmacol Drug Dev. 2020 Oct;9(7):785-796. doi: 10.1002/cpdd.760. Epub 2019 Dec 31.
PMID: 31891240
Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study.
Julien K, Leung HT, Fuertes C, Mori M, Wang MJ, Teo J, Weiss L, Hamilton S, DiFebo H, Noh YJ, Galway A, Koh J, Brutcher E, Zhao H, Shen Y, Tschaika M, To YY.
Oncologist. 2020 Oct;25(10):e1532-e1540. doi: 10.1634/theoncologist.2019-0591. Epub 2020 Aug 24.
PMID: 33400305
Currently Available Recombinant Alternatives to Horseshoe Crab Blood Lysates: Are They Comparable for the Detection of Environmental Bacterial Endotoxins? A Review.
Bolden J, Knutsen C, Levin J, Milne C, Morris T, Mozier N, Spreitzer I, von Wintzingerode F.
PDA J Pharm Sci Technol. 2020 Sep-Oct;74(5):602-611. doi: 10.5731/pdajpst.2020.012187. Epub 2020 Aug 14.
PMID: 32817324
Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer.
Abraham P, Wang L, Jiang Z, Gricar J, Tan H, Kelly RJ.
Future Oncol. 2020 Sep 30. doi: 10.2217/fon-2020-0516. Online ahead of print.
PMID: 32996811
Cobalt-Catalyzed C(sp 2 )-C(sp 3 ) Suzuki-Miyaura Cross Coupling.
Ludwig JR, Simmons EM, Wisniewski SR, Chirik PJ.
Org Lett. 2020 Sep 30. doi: 10.1021/acs.orglett.0c02934. Online ahead of print.
PMID: 32996312
Five-Year Outcomes With Nivolumab in Patients With Wild-Type  BRAF  Advanced Melanoma.
Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Rutkowski P, Hassel JC, McNeil CM, Kalinka EA, Lebbé C, Charles J, Hernberg MM, Savage KJ, Chiarion-Sileni V, Mihalcioiu C, Mauch C, Arance A, Cognetti F, Ny L, Schmidt H, Schadendorf D, Gogas H, Zoco J, Re S, Ascierto PA, Atkinson V.
J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995. Online ahead of print.
PMID: 32997575
COVID-19: A Catalyst to Accelerate Global Regulatory Transformation.
Stewart J, Honig P, AlJuburi L, Autor D, Berger S, Brady P, Fitton H, Garner C, Garvin M, Hukkelhoven M, Kowalski R, Milligan S, O'Dowd L, Reilly E, Roberts K, Robertson AS, Taisey M, Thakkar R, Van Baelen K, Wegner M.
Clin Pharmacol Ther. 2020 Sep 29:10.1002/cpt.2046. doi: 10.1002/cpt.2046. Online ahead of print.
PMID: 32990986
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data.
Gambacorti-Passerini C, Chen C, Davis C, Sen GP, Guyan C, Hehlmann R, Michallet M, Paquette R, Goldberg SL.
Eur J Haematol. 2020 Sep 28. doi: 10.1111/ejh.13524. Online ahead of print.
PMID: 32989776
Impact of polysorbate 80 grade on the interfacial properties and interfacial stress induced subvisible particle formation in monoclonal antibodies.
Vaclaw C, Merritt K, Pringle V, Whitaker N, Gokhale M, Carvalho T, Pan D, Liu Z, Bindra D, Khossravi M, Bolgar M, Volkin DB, Ogunyankin MO, Dhar P.
J Pharm Sci. 2020 Sep 25:S0022-3549(20)30565-7. doi: 10.1016/j.xphs.2020.09.035. Online ahead of print.
PMID: 32987092
Drug-induced cholestasis assay in primary hepatocytes.
Van Brantegem P, Chatterjee S, De Bruyn T, Annaert P, Deferm N.
MethodsX. 2020 Sep 25;7:101080. doi: 10.1016/j.mex.2020.101080. eCollection 2020.
PMID: 33088729
Reverse-phase HPLC purification for an extremely unstable glucuronide metabolite.
Sun D, Wu DR, Li P, Yip H, Mathur A.
J Pharm Biomed Anal. 2020 Sep 25;192:113651. doi: 10.1016/j.jpba.2020.113651. Online ahead of print.
PMID: 33010500
Development of low dose micro-tablets by high shear wet granulation process.
Gupta S, Thool P, Meruva S, Li J, Patel J, Agrawal A, Karki S, Bowen W, Mitra B.
Int J Pharm. 2020 Sep 25;587:119571. doi: 10.1016/j.ijpharm.2020.119571. Epub 2020 Jul 9.
PMID: 32652180
To Maintain Formulation Composition Similarity of Coated Tablets of Different Strengths: Should Coating be Based on Core Tablet Weight or Surface Area?
Reddy JP, Vyas G, Patel R, Rana S, Mansuri N, Dimuthu J, Shah T, Desai D.
Pharm Res. 2020 Sep 24;37(10):201. doi: 10.1007/s11095-020-02926-5.
PMID: 32968862
Collaborations between Clinical Pharmacologists in Japan and in the United States - Report from the IQ CPLG and JPMA CPTF Meeting in Tokyo, Japan.
Zhu T, Kayama M, Girish S, Sinha V, Bello A, Kawaguchi A, Czerniak R, Nagao L.
Clin Transl Sci. 2020 Sep 24. doi: 10.1111/cts.12853. Online ahead of print.
PMID: 32969589
First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y, Gaudy A, Schafer P, Thomas M, Weiss D, Chen N, Liu L, Xue Y, Carayannopoulos L, Palmisano M.
Clin Pharmacol Drug Dev. 2020 Sep 23. doi: 10.1002/cpdd.869. Online ahead of print.
PMID: 32969202
Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain.
Barrios V, Cinza-Sanjurjo S, Gavín O, Egocheaga I, Burgos-Pol R, Soto J, Polanco C, Suárez J, Casado MÁ.
Rev Esp Cardiol (Engl Ed). 2020 Sep 23:S1885-5857(20)30372-8. doi: 10.1016/j.rec.2020.06.033. Online ahead of print.
PMID: 32980294
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Gaudy A, Atsriku C, Ye Y, MacGorman K, Liu L, Xue Y, Surapaneni S, Palmisano M.
Eur J Clin Pharmacol. 2020 Sep 23. doi: 10.1007/s00228-020-03004-w. Online ahead of print.
PMID: 32965548
Chemical Modification of Linkers Provides Stable Linker-Payloads for the Generation of Antibody-Drug Conjugates.
Poudel YB, Chowdari NS, Cheng H, Iwuagwu CI, King HD, Kotapati S, Passmore D, Rampulla R, Mathur A, Vite G, Gangwar S.
ACS Med Chem Lett. 2020 Sep 22;11(11):2190-2194. doi: 10.1021/acsmedchemlett.0c00325. eCollection 2020 Nov 12.
PMID: 33214828
Hydrophobic property of cation-exchange resins affects monoclonal antibody aggregation.
Huang C, Wang Y, Xu X, Mills J, Jin W, Ghose S, Li ZJ.
J Chromatogr A. 2020 Sep 20;1631:461573. doi: 10.1016/j.chroma.2020.461573. Online ahead of print.
PMID: 33010710
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.
Samur MK, Aktas Samur A, Fulciniti M, Szalat R, Han T, Shammas M, Richardson P, Magrangeas F, Minvielle S, Corre J, Moreau P, Thakurta A, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.
J Clin Oncol. 2020 Sep 20;38(27):3107-3118. doi: 10.1200/JCO.20.00461. Epub 2020 Jul 20.
PMID: 32687451
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T.
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
PMID: 32888407
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR, Jotte RM, Aix SP, Gressot L, Morgensztern D, McCleod M, Socinski MA, Daniel D, Juan-Vidal O, Mileham KF, West H, Page R, Reinmuth N, Knoble J, Chen T, Bhore R, Wolfsteiner M, Ong TJ, Gridelli C, Thomas M; ABOUND.sqm Investigators.
Clin Lung Cancer. 2020 Sep 18:S1525-7304(20)30270-9. doi: 10.1016/j.cllc.2020.09.007. Online ahead of print.
PMID: 33097414
Imaging of the Effect of Alcohol-Containing Media on the Performance of Hypromellose Hydrophilic Matrix Tablets: Comparison of Direct Compression and Regular Grades of Polymer.
Mawla N, Hanley S, Walton K, Kaialy W, Hussain T, Ward A, Brown J, Conway BR, Timmins P, Asare-Addo K.
Pharmaceutics. 2020 Sep 18;12(9):889. doi: 10.3390/pharmaceutics12090889.
PMID: 32961942
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J.
Lancet Oncol. 2020 Sep 18:S1470-2045(20)30494-0. doi: 10.1016/S1470-2045(20)30494-0. Online ahead of print.
PMID: 32961119
Consensus recommendations on the use of  18 F-FDG PET/CT in lung disease.
Chen DL, Ballout S, Chen L, Cheriyan J, Choudhury G, Denis-Bacelar AM, Emond E, Erlandsson K, Fisk M, Fraioli F, Groves AM, Gunn RN, Hatazawa J, Holeman BF, Hutton BF, Iida H, Lee S, MacNee W, Matsunaga K, Mohan D, Parr D, Rashidnasab A, Rizzo G, Subramanian D, Tal-Singer R, Thielemans K, Tregay N, Van Beek EJR, Vass L, Vidal Melo MF, Wellen JW, Wilkinson I, Wilson FJ, Winkler T.
J Nucl Med. 2020 Sep 18:jnumed.120.244780. doi: 10.2967/jnumed.120.244780. Online ahead of print.
PMID: 32948678
Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.
Carnicelli AP, Al-Khatib SM, Xavier D, Dalgaard F, Merrill PD, Wojdyla DM, Lewis BS, Hanna M, Alexander JH, Lopes RD, Wallentin L, Granger CB.
Heart. 2020 Sep 16:heartjnl-2020-317229. doi: 10.1136/heartjnl-2020-317229. Online ahead of print.
PMID: 32938772
Leveraging Automation toward Development of a High-Throughput Gene Expression Profiling Platform.
Chen J, Futran A, Crithary A, Li S, Wolicki A, Fogarty K, Baldick J, Chase P, Arey BJ, Lippy J.
SLAS Discov. 2020 Sep 16:2472555220956593. doi: 10.1177/2472555220956593. Online ahead of print.
PMID: 32935608
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.
Srivastava AS, Ko S, Watterson SH, Pattoli MA, Skala S, Cheng L, Obermeier MT, Vickery R, Discenza LN, D'Arienzo CJ, Gillooly KM, Taylor TL, Pulicicchio C, McIntyre KW, Yip S, Li P, Sun D, Wu DR, Dai J, Wang C, Zhang Y, Wang B, Pawluczyk J, Kempson J, Zhao R, Hou X, Rampulla R, Mathur A, Galella MA, Salter-Cid L, Barrish JC, Carter PH, Fura A, Burke JR, Tino JA.
ACS Med Chem Lett. 2020 Sep 16;11(11):2195-2203. doi: 10.1021/acsmedchemlett.0c00335. eCollection 2020 Nov 12.
PMID: 33214829
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
Bursać S, Prodan Y, Pullen N, Bartek J, Volarević S.
Trends Cancer. 2020 Sep 15:S2405-8033(20)30235-1. doi: 10.1016/j.trecan.2020.08.003. Online ahead of print.
PMID: 32948502
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
de Bruyn G, Gordon DL, Steiner T, Tambyah P, Cosgrove C, Martens M, Bassily E, Chan ES, Patel D, Chen J, Torre-Cisneros J, Fernando De Magalhães Francesconi C, Gesser R, Jeanfreau R, Launay O, Laot T, Morfin-Otero R, Oviedo-Orta E, Park YS, Piazza FM, Rehm C, Rivas E, Self S, Gurunathan S.
Lancet Infect Dis. 2020 Sep 15:S1473-3099(20)30331-5. doi: 10.1016/S1473-3099(20)30331-5. Online ahead of print.
PMID: 32946836
Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry Perspective.
Kellie JF, Tran JC, Jian W, Jones B, Mehl JT, Ge Y, Henion J, Bateman KP.
J Am Soc Mass Spectrom. 2020 Sep 15. doi: 10.1021/jasms.0c00270. Online ahead of print.
PMID: 32869982
Open-label, Phase I Study of Nivolumab Combined with  nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer.
Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ.
Clin Cancer Res. 2020 Sep 15;26(18):4814-4822. doi: 10.1158/1078-0432.CCR-20-0099. Epub 2020 Jun 18.
PMID: 32554514
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Pierceall WE, Amatangelo MD, Bahlis NJ, Siegel DS, Rahman A, Van Oekelen O, Neri P, Young M, Chung W, Serbina N, Parekh S, Agarwal A, Thakurta A.
Clin Cancer Res. 2020 Sep 14. doi: 10.1158/1078-0432.CCR-20-1781. Online ahead of print.
PMID: 32928795
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
Boekhout AH, Rogiers A, Jozwiak K, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Ten Tije AJ, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Rozeman EA, Neyns B, Janssen KJ, van de Poll-Franse LV, Blank CU.
Acta Oncol. 2020 Sep 14:1-9. doi: 10.1080/0284186X.2020.1818823. Online ahead of print.
PMID: 32924708
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.
Bregman B, Teitsson S, Orsini I, Cotté FE, Amadi A, Moshyk A, Roze S, Gaudin AF.
Dermatol Ther (Heidelb). 2020 Sep 13. doi: 10.1007/s13555-020-00446-z. Online ahead of print.
PMID: 32920709
Preclinical optimization of an enterotoxigenic  Escherichia coli  adjuvanted subunit vaccine using response surface design of experiments.
Poncet D, Hessler C, Liang H, Gautheron S, Sergent M, Rintala ND, Seydoux E, Huang PD, Argilla D, Ruiz S, Heinrichs J, Maciel M Jr, Orr MT.
NPJ Vaccines. 2020 Sep 11;5:83. doi: 10.1038/s41541-020-00228-w. eCollection 2020.
PMID: 32983577
Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection Fraction.
Selvaraj S, Kim J, Ansari BA, Zhao L, Cvijic ME, Fronheiser M, Mohan-Rao Vanjarapu J, Kumar AA, Suri A, Yenigalla S, Satija V, Ans AH, Narvaez-Guerra O, Herrera-Enriquez K, Obeid MJ, Lee JJ, Jehangir Q, Seiffert DA, Car BD, Gordon DA, Chirinos JA.
JACC Cardiovasc Imaging. 2020 Sep 11:S1936-878X(20)30647-1. doi: 10.1016/j.jcmg.2020.07.022. Online ahead of print.
PMID: 32950445
Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study.
Cotté FE, Voillot P, Bennett B, Falissard B, Tzourio C, Foulquié P, Gaudin AF, Lemasson H, Grumberg V, McDonald L, Faviez C, Schück S.
J Med Internet Res. 2020 Sep 11;22(9):e19694. doi: 10.2196/19694.
PMID: 32915159
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M, Antunes L, Redondo P, Borges M, Hermans R, Patel D, Grimson F, Munro R, Chaib C, Lacoin L, Daumont M, Penrod JR, O'Donnell JC, Bento MJ, Rocha Gonçalves F.
BMC Pulm Med. 2020 Sep 10;20(1):240. doi: 10.1186/s12890-020-01270-z.
PMID: 32912174
Divalent N I  Compounds: Identifying new Carbocyclic Carbenes to Design Nitreones using Quantum Chemical Methods.
Patel N, Arfeen M, Singh T, Bhagat S, Sakhare A, Bharatam PV.
J Comput Chem. 2020 Sep 10. doi: 10.1002/jcc.26417. Online ahead of print.
PMID: 32964506
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G Jr, Gunuganti V, Li A, Aanur N, Spigel DR.
J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131. Online ahead of print.
PMID: 32910710
Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial.
Imafuku S, Nemoto O, Okubo Y, Komine M, Schafer P, Petric R, Ohtsuki M.
J Dermatol. 2020 Sep 10. doi: 10.1111/1346-8138.15596. Online ahead of print.
PMID: 32909643
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
Asahina Y, Wurtz NR, Arakawa K, Carson N, Fujii K, Fukuchi K, Garcia R, Hsu MY, Ishiyama J, Ito B, Kick E, Lupisella J, Matsushima S, Ohata K, Ostrowski J, Saito Y, Tsuda K, Villarreal F, Yamada H, Yamaoka T, Wexler R, Gordon D, Kohno Y.
J Med Chem. 2020 Sep 10;63(17):9003-9019. doi: 10.1021/acs.jmedchem.9b02101. Epub 2020 May 24.
PMID: 32407089
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Dimopoulos M, Weisel K, Moreau P, Anderson LD Jr, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen TV, Biyukov T, Peluso T, Richardson P.
Leukemia. 2020 Sep 7. doi: 10.1038/s41375-020-01021-3. Online ahead of print.
PMID: 32895455
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones JA, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PE, Vardi A, Ramsay AG.
Blood. 2020 Sep 6:blood.2020006073. doi: 10.1182/blood.2020006073. Online ahead of print.
PMID: 33024998
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey J, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS.
Blood. 2020 Sep 5:blood.2020007233. doi: 10.1182/blood.2020007233. Online ahead of print.
PMID: 33024987
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG.
Blood Cancer J. 2020 Sep 4;10(9):91. doi: 10.1038/s41408-020-00357-4.
PMID: 32887873
Synthesis of Differentially Protected Azatryptophan Analogs via Pd 2 (dba) 3 /XPhos Catalyzed Negishi Coupling of  N -Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected  tert -Butyl ( R )-2-Amino-3-iodopropanoate.
Nimje RY, Vytla D, Kuppusamy P, Velayuthaperumal R, Jarugu LB, Reddy CA, Chikkananjaiah NK, Rampulla RA, Cavallaro CL, Li J, Mathur A, Gupta A, Roy A.
J Org Chem. 2020 Sep 4;85(17):11519-11530. doi: 10.1021/acs.joc.0c00973. Epub 2020 Aug 25.
PMID: 32786620
Rapid fingerprinting of a highly glycosylated fusion protein by microfluidic chip-based capillary electrophoresis-mass spectrometry.
Deyanova EG, Huang RY, Madia PA, Nandi P, Gudmundsson O, Chen G.
Electrophoresis. 2020 Sep 3. doi: 10.1002/elps.202000132. Online ahead of print.
PMID: 32885501
Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development.
Bhagat R, Bojarski L, Chevalier S, Görtz DR, Le Meignen S, Makowski M, Nadolny P, Pillwein M, Suprin M, Turri S.
Ther Innov Regul Sci. 2020 Sep 3. doi: 10.1007/s43441-020-00209-0. Online ahead of print.
PMID: 32885397
Synthesis of functionalized derivatives of the gamma-secretase modulator BMS-932481 and identification of its major metabolite.
Zhang Y, Boy KM, Wu YJ, Ramirez A, Toyn JH, Ahlijanian MK, Albright CF, Zhuo X, Johnson BM, Denton RR, Olson RE, Thompson LA 3rd, Macor JE.
Bioorg Med Chem Lett. 2020 Sep 2;30(22):127530. doi: 10.1016/j.bmcl.2020.127530. Online ahead of print.
PMID: 32890687
Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase.
Sivaprakasam P, Wang Z, Meanwell NA, Khan JA, Langley DR, Johnson SR, Li G, Pendri A, Connolly TP, Gao M, Camac DM, Klakouski C, Zvyaga T, Cianci C, McAuliffe B, Ding B, Discotto L, Krystal MR, Jenkins S, Peese KM, Narasimhulu Naidu B.
Bioorg Med Chem Lett. 2020 Sep 2;30(22):127531. doi: 10.1016/j.bmcl.2020.127531. Online ahead of print.
PMID: 32890685
Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting.
Escudero-Vilaplana V, Calles A, Collado-Borrell R, Belén Marzal-Alfaro M, Polanco C, Garrido C, Suarez J, Ortiz A, Appierto M, Comellas M, Lizán L.
Front Oncol. 2020 Sep 2;10:1645. doi: 10.3389/fonc.2020.01645. eCollection 2020.
PMID: 32984036
High-resolution purification of a therapeutic PEGylated protein using a cuboid packed-bed device.
Chen G, Umatheva U, Pagano J, Yu D, Ghose S, Li Z, Ghosh R.
J Chromatogr A. 2020 Sep 2;1630:461524. doi: 10.1016/j.chroma.2020.461524. Online ahead of print.
PMID: 32920248
Modified Goldilocks Design with strict type I error control in confirmatory clinical trials.
Zhan T, Zhang H, Hartford A, Mukhopadhyay S.
J Biopharm Stat. 2020 Sep 2;30(5):821-833. doi: 10.1080/10543406.2020.1744620. Epub 2020 Apr 16.
PMID: 32297825
Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
Shaw SA, Vokits BP, Dilger AK, Viet A, Clark CG, Abell LM, Locke GA, Duke G, Kopcho LM, Dongre A, Gao J, Krishnakumar A, Jusuf S, Khan J, Spronk SA, Basso MD, Zhao L, Cantor GH, Onorato JM, Wexler RR, Duclos F, Kick EK.
Bioorg Med Chem. 2020 Sep 1;28(22):115723. doi: 10.1016/j.bmc.2020.115723. Online ahead of print.
PMID: 33007547
Quantifying drug tissue biodistribution by integrating high content screening with deep-learning analysis.
Li Z, Xiao Y, Peng J, Locke D, Holmes D, Li L, Hamilton S, Cook E, Myer L, Vanderwall D, Cloutier N, Siddiqui AM, Whitehead P, Bishop R, Zhao L, Cvijic ME.
Sci Rep. 2020 Sep 1;10(1):14408. doi: 10.1038/s41598-020-71347-6.
PMID: 32873881
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI.
Clin Cancer Res. 2020 Sep 1. doi: 10.1158/1078-0432.CCR-20-2063. Online ahead of print.
PMID: 32873572
Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.
Griffin GK, Weirather JL, Roemer M, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Gjini E, Chapuy B, Rosenthal M, Xu J, Chen BJ, Sohani A, Lovitch SB, Abramson J, Ishizuka JJ, Kim AI, Jacobson CA, LaCasce AS, Fletcher CDM, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ.
Blood. 2020 Sep 1:blood.2020006464. doi: 10.1182/blood.2020006464. Online ahead of print.
PMID: 32871584
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.
Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA.
J Clin Invest. 2020 Sep 1;130(9):4704-4709. doi: 10.1172/JCI136760.
PMID: 32749238
Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists.
Jiang B, Duan JJ, Stachura S, Karmakar A, Hemagiri H, Raut DK, Gupta AK, Weigelt CA, Khan J, Sack JS, Wu DR, Yarde M, Shen DR, Galella MA, Mathur A, Zhao Q, Salter-Cid LM, Carter PH, Dhar TGM.
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127392. doi: 10.1016/j.bmcl.2020.127392. Epub 2020 Jul 10.
PMID: 32738966
Enhancement of covalent aggregate quantification of protein therapeutics by non-reducing capillary gel electrophoresis using sodium hexadecyl sulfate (CE-SHS).
Guan Q, Knihtila R, Atsma J, Tulsan R, Singh S, Kar S, Beckman J, Ding J, Li ZJ.
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122230. doi: 10.1016/j.jchromb.2020.122230. Epub 2020 Jun 10.
PMID: 32585496
Cross-linking of poly (vinyl alcohol) films under acidic and thermal stress.
Desai SD, Kundu I, Swamy NP, Crull GB, Pan D, Zhao J, Shah RP, Venkatesh C, Vig B, Varia SA, Badawy SIF, Desikan S, Bhutani H.
Eur J Pharm Sci. 2020 Sep 1;152:105429. doi: 10.1016/j.ejps.2020.105429. Epub 2020 Jun 17.
PMID: 32561460
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Van Oekelen O, Parekh S, Cho HJ, Vishnuvardhan N, Madduri D, Richter J, Ip C, Lau K, Florendo E, Mancia IS, Thomas J, Verina D, Chan E, Zarychta K, La L, Strumolo G, Melnekoff DT, Leshchenko VV, Kim-Schulze S, Couto S, Wang M, Pierceall WE, Thakurta A, Laganà A, Jagannath S, Chari A.
Leuk Lymphoma. 2020 Sep;61(9):2208-2215. doi: 10.1080/10428194.2020.1805111. Epub 2020 Aug 19.
PMID: 32812822
A peptide immunoaffinity LC-MS/MS strategy for quantifying the GPCR protein, S1PR1 in human colon biopsies.
Zhang H, Ciccimaro E, Zalaznick J, Sleczka BG, Menard L, Olah TV, Shipkova P.
Bioanalysis. 2020 Sep;12(18):1311-1324. doi: 10.4155/bio-2020-0115. Epub 2020 Sep 18.
PMID: 32945691
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
Bonomi P, Stuccio N, Delgra CJ, Chuk MK, Spira A, Deitz AC, Blumenthal GM, Ferris A, Gong Y, He J, Basu Roy U, Selig W.
Ther Innov Regul Sci. 2020 Sep;54(5):1208-1214. doi: 10.1007/s43441-020-00145-z. Epub 2020 Mar 26.
PMID: 32865803
Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
Yasaka M, Umeyama M, Kataoka H, Inoue H.
J Stroke Cerebrovasc Dis. 2020 Sep;29(9):105034. doi: 10.1016/j.jstrokecerebrovasdis.2020.105034. Epub 2020 Jun 24.
PMID: 32807446
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.
Coart E, Suciu S, Squifflet P, Saad ED, Moshyk A, de Schaetzen G, Buyse M, Weber JS, Eggermont A, Kotapati S.
Eur J Cancer. 2020 Sep;137:171-174. doi: 10.1016/j.ejca.2020.07.011. Epub 2020 Aug 7.
PMID: 32777716
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner PR, Nikolova Z, Ribrag V.
Lancet Haematol. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3.
PMID: 32758434
Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, Sickmann T, Rieken S, Pukrop T, Höller C, Eigentler TK, Meier F.
Cancer Treat Rev. 2020 Sep;89:102083. doi: 10.1016/j.ctrv.2020.102083. Epub 2020 Jul 18.
PMID: 32736188
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ, Zwaan CM, Kolb EA, Karres D, Guillot J, Kim SY, Marshall L, Tasian SK, Smith M, Cooper T, Adamson PC, Barry E, Benettaib B, Binlich F, Borgman A, Brivio E, Capdeville R, Delgado D, Faller D, Fogelstrand L, Fraenkel PG, Hasle H, Heenen D, Kaspers G, Kieran M, Klusmann JH, Lesa G, Ligas F, Mappa S, Mohamed H, Moore A, Morris J, Nottage K, Reinhardt D, Scobie N, Simko S, Winkler T, Norga K, G, Vassal G.
Eur J Cancer. 2020 Sep;136:116-129. doi: 10.1016/j.ejca.2020.04.038. Epub 2020 Jul 17.
PMID: 32688206
Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.
Nho K, Nudelman K, Allen M, Hodges A, Kim S, Risacher SL, Apostolova LG, Lin K, Lunnon K, Wang X, Burgess JD, Ertekin-Taner N, Petersen RC, Wang L, Qi Z, He A, Neuhaus I, Patel V, Foroud T, Faber KM, Lovestone S, Simmons A, Weiner MW, Saykin AJ;
Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2020 Sep;16(9):1213-1223. doi: 10.1002/alz.12092. Epub 2020 Aug 5.
PMID: 32755048
Application of the Gyrolab microfluidic platform to measure picomolar affinity of a PD-L1-binding Adnectin™ radioligand for positron emission tomography.
Dai Z, Juneja J, Schneeweis L, Cohen D, Marsilio F, Morin P, DasGupta R.
Biotechniques. 2020 Sep;69(3):200-205. doi: 10.2144/btn-2020-0080. Epub 2020 Jul 16.
PMID: 32672060
Toward further simplification of elotuzumab therapy by subcutaneous administration.
Shimura Y, Tsukamoto T, Yamaguchi J, Kuwahara-Ota S, Isa R, Nishiyama D, Kobayashi T, Horiike S, Suzuki A, Kuroda J.
Int J Hematol. 2020 Sep;112(3):427-428. doi: 10.1007/s12185-020-02942-6. Epub 2020 Jul 13.
PMID: 32656639
Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.
Westhovens R, Connolly SE, Margaux J, Vanden Berghe M, Maertens M, Van den Berghe M, Elbez Y, Chartier M, Baeke F, Robert S, Malaise M.
Rheumatol Int. 2020 Sep;40(9):1409-1421. doi: 10.1007/s00296-020-04619-z. Epub 2020 Jun 17.
PMID: 32556473
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G.
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):819-828. doi: 10.1016/S2468-1253(20)30188-6. Epub 2020 Jun 15.
PMID: 32553149
Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture.
Hoyle C, Redondo-Castro E, Cook J, Tzeng TC, Allan SM, Brough D, Lemarchand E.
Immunology. 2020 Sep;161(1):39-52. doi: 10.1111/imm.13221. Epub 2020 Jun 22.
PMID: 32445196
Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D, Patil D, McDonald L, Patel V, Lobo F.
J Med Econ. 2020 Sep;23(9):1025-1031. doi: 10.1080/13696998.2020.1772271. Epub 2020 Jun 13.
PMID: 32427547
Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency.
Huang M, Kong B, Zhang M, Rizzolo D, Armstrong LE, Schumacher JD, Chow MD, Lee YH, Joseph LB, Stofan M, Zhang L, Guo GL.
Lab Invest. 2020 Sep;100(9):1158-1168. doi: 10.1038/s41374-020-0439-y. Epub 2020 May 13.
PMID: 32404932
Accelerating the Adoption of eSource in Clinical Research: A Transcelerate Point of View.
Parab AA, Mehta P, Vattikola A, Denney CK, Cherry M, Maniar RM, Kjaer J.
Ther Innov Regul Sci. 2020 Sep;54(5):1141-1151. doi: 10.1007/s43441-020-00138-y. Epub 2020 Mar 3.
PMID: 32128701
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention.
Oyagüez I, Suárez C, López-Sendón JL, González-Juanatey JR, de Andrés-Nogales F, Suárez J, Polanco C, Soto J.
Pharmacoecon Open. 2020 Sep;4(3):485-497. doi: 10.1007/s41669-019-00186-7.
PMID: 31673882
Development of Resilience Among Rheumatoid Arthritis Patients: A Qualitative Study.
Shaw Y, Bradley M, Zhang C, Dominique A, Michaud K, McDonald D, Simon TA.
Arthritis Care Res (Hoboken). 2020 Sep;72(9):1257-1265. doi: 10.1002/acr.24024.
PMID: 31282121
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Armand P, Janssens AM, Gritti G, Radford J, Timmerman JM, Pinto A, Mercadal Vilchez S, Johnson PWM, Cunningham D, Leonard JP, Rodig SJ, Martín-Regueira P, Sumbul A, Samakoglu S, Tang H, Ansell SM.
Blood. 2020 Aug 31:blood.2019004753. doi: 10.1182/blood.2019004753. Online ahead of print.
PMID: 32870269
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM, Rolf MG, Wisialowski TA, Achanzar W, Bahinski A, Bass A, Benson CT, Chaudhary KW, Couvreur N, Dota C, Engwall MJ, Michael Foley C, Gallacher D, Greiter-Wilke A, Guillon JM, Guth B, Himmel HM, Hegele-Hartung C, Ito M, Jenkinson S, Chiba K, Lagrutta A, Levesque P, Martel E, Okai Y, Peri R, Pointon A, Qu Y, Teisman A, Traebert M, Yoshinaga T, Gintant GA, Leishman DJ, Valentin JP.
Clin Pharmacol Ther. 2020 Aug 31. doi: 10.1002/cpt.2029. Online ahead of print.
PMID: 32866317
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalization.
Shi Q, Xiao Z, Yang MG, Marcoux D, Cherney RJ, Yip S, Li P, Wu DR, Weigelt CA, Sack J, Khan J, Ruzanov M, Wang J, Yarde M, Ellen Cvijic M, Li S, Shuster DJ, Xie J, Sherry T, Obermeier M, Fura A, Stefanski K, Cornelius G, Chacko S, Shu YZ, Khandelwal P, Hynes J Jr, Tino JA, Salter-Cid L, Denton R, Zhao Q, Dhar TGM.
Bioorg Med Chem Lett. 2020 Aug 31;30(23):127521. doi: 10.1016/j.bmcl.2020.127521. Online ahead of print.
PMID: 32882417
Cyclic tailor-made amino acids in the design of modern pharmaceuticals.
Liu J, Han J, Izawa K, Sato T, White S, Meanwell NA, Soloshonok VA.
Eur J Med Chem. 2020 Aug 31;208:112736. doi: 10.1016/j.ejmech.2020.112736. Online ahead of print.
PMID: 32966895
Impact of the column on effluent pH in cation exchange pH gradient chromatography, a practical study.
Farsang E, Horváth K, Beck A, Wang Q, Lauber M, Guillarme D, Fekete S.
J Chromatogr A. 2020 Aug 30;1626:461350. doi: 10.1016/j.chroma.2020.461350. Epub 2020 Jun 17.
PMID: 32797830
Advancing stereoisomeric separation of an atropisomeric Bruton's tyrosine kinase inhibitor by using sub-2 µm immobilized polysaccharide-based chiral columns in supercritical fluid chromatography.
He BL, Kleinsorge NG, Zhang L, Kleintop B.
J Chromatogr A. 2020 Aug 30;1626:461320. doi: 10.1016/j.chroma.2020.461320. Epub 2020 Jun 7.
PMID: 32797816
Model-Based Meta-Analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development.
Leil TA, Lu Y, Bouillon-Pichault M, Wong R, Nowak M.
Clin Pharmacol Ther. 2020 Aug 29. doi: 10.1002/cpt.2023. Online ahead of print.
PMID: 32860421
Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality.
Jiang R, Kohlmann T, Lee TA, Mühlbacher A, Shaw J, Walton S, Pickard AS.
Eur J Health Econ. 2020 Aug 28. doi: 10.1007/s10198-020-01224-6. Online ahead of print.
PMID: 32860093
High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: a cross-sectional study.
Behrens F, Rech J, Thaçi D, Zinke S, Rothnie KJ, Oefner Daamen C, Leipe J.
Mod Rheumatol. 2020 Aug 28:1-23. doi: 10.1080/14397595.2020.1816597. Online ahead of print.
PMID: 32856975
Effects of Manipulating Fibroblast Growth Factor Expression on Sindbis Virus Replication In Vitro and in  Aedes aegypti  Mosquitoes.
Wu W, Simmons CA, Moffitt J, Clem RJ, Passarelli AL.
Viruses. 2020 Aug 26;12(9):943. doi: 10.3390/v12090943.
PMID: 32858937
Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study.
Brandwein JM, Saini L, Geddes MN, Yusuf D, Liu F, Schwann K, Billawala A, Westcott C, Kurniawan JA, Cheung WY.
Am J Blood Res. 2020 Aug 25;10(4):124-133. eCollection 2020.
PMID: 32923092
A Single Human V H -gene Allows for a Broad-Spectrum Antibody Response Targeting Bacterial Lipopolysaccharides in the Blood.
Sangesland M, Yousif AS, Ronsard L, Kazer SW, Zhu AL, Gatter GJ, Hayward MR, Barnes RM, Quirindongo-Crespo M, Rohrer D, Lonberg N, Kwon D, Shalek AK, Lingwood D.
Cell Rep. 2020 Aug 25;32(8):108065. doi: 10.1016/j.celrep.2020.108065.
PMID: 32846123
Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.
Williams LM, McCann FE, Cabrita MA, Layton T, Cribbs A, Knezevic B, Fang H, Knight J, Zhang M, Fischer R, Bonham S, Steenbeek LM, Yang N, Sood M, Bainbridge C, Warwick D, Harry L, Davidson D, Xie W, Sundstrӧm M, Feldmann M, Nanchahal J.
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20753-20763. doi: 10.1073/pnas.2004281117. Epub 2020 Aug 5.
PMID: 32759223
Fit-for-purpose protein biomarker assay validation strategies using hybrid immunocapture-liquid chromatography-tandem-mass spectrometry platform: Quantitative analysis of total soluble cluster of differentiation 73.
Zhao Y, Gu H, Postelnek J, DeMichele M, Yuan L, Zhang YJ, Zeng J.
Anal Chim Acta. 2020 Aug 22;1126:144-153. doi: 10.1016/j.aca.2020.06.023. Epub 2020 Jun 18.
PMID: 32736718
(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration.
Subbaiah MAM, Ramar T, Subramani L, Desai SD, Sinha S, Mandlekar S, Jenkins SM, Krystal MR, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Kadow JF, Meanwell NA.
Eur J Med Chem. 2020 Aug 21;207:112749. doi: 10.1016/j.ejmech.2020.112749. Online ahead of print.
PMID: 33065417
Synthesis of 1-( tert -Butyl) 4-Methyl (1 R ,2 S ,4 R )-2-Methylcyclohexane-1,4-dicarboxylate from Hagemann's  tert -Butyl Ester for an Improved Synthesis of BMS-986251.
Cornelius LAM, Li J, Smith D, Krishnananthan S, Yip S, Wu DR, Pawluczyk J, Aulakh D, Sarjeant AA, Kempson J, Tino JA, Mathur A, Murali Dhar TG, Cherney RJ.
J Org Chem. 2020 Aug 21;85(16):10988-10993. doi: 10.1021/acs.joc.0c01169. Epub 2020 Aug 7.
PMID: 32687358
Pd- and Ni-Based Systems for the Catalytic Borylation of Aryl (Pseudo)halides with B 2 (OH) 4 .
Munteanu C, Spiller TE, Qiu J, DelMonte AJ, Wisniewski SR, Simmons EM, Frantz DE.
J Org Chem. 2020 Aug 21;85(16):10334-10349. doi: 10.1021/acs.joc.0c00929. Epub 2020 Jul 22.
PMID: 32662636
Single-step purification of a small non-mAb biologic by peptide-ELP-based affinity precipitation.
Mullerpatan A, Kane E, Ghosh R, Nascimento A, Andersen H, Cramer S, Karande P.
Biotechnol Bioeng. 2020 Aug 19. doi: 10.1002/bit.27539. Online ahead of print.
PMID: 32813285
Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
Tsutsué S, Tobinai K, Yi J, Crawford B.
PLoS One. 2020 Aug 18;15(8):e0237509. doi: 10.1371/journal.pone.0237509. eCollection 2020.
PMID: 32810157
Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.
Bayraktar S, Batoo S, Al-Hattab E, Basu S, Okuno S, Glück S.
Future Oncol. 2020 Aug 17. doi: 10.2217/fon-2020-0234. Online ahead of print.
PMID: 32805138
OX40 agonistic antibody reverses immune suppression and improves survival in sepsis.
Unsinger J, Walton AH, Blood T, Tenney DJ, Quigley M, Drewry AM, Hotchkiss RS.
J Leukoc Biol. 2020 Aug 17. doi: 10.1002/JLB.5HI0720-043R. Online ahead of print.
PMID: 33264454
Model based strategies towards protein A resin lifetime optimization and supervision.
Feidl F, Luna MF, Podobnik M, Vogg S, Angelo J, Potter K, Wiggin E, Xu X, Ghose S, Li ZJ, Morbidelli M, Butté A.
J Chromatogr A. 2020 Aug 16;1625:461261. doi: 10.1016/j.chroma.2020.461261. Epub 2020 May 25.
PMID: 32709318
Rapid and efficient chiral method development for lamivudine and tenofovir disoproxil fumarate fixed dose combination using ultra-high performance supercritical fluid chromatography: A design of experiment approach.
Kurmi M, Jayaraman K, Natarajan S, Kumar GS, Bhutani H, Bajpai L.
J Chromatogr A. 2020 Aug 16;1625:461257. doi: 10.1016/j.chroma.2020.461257. Epub 2020 Jun 2.
PMID: 32709317
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C; CA184-043, Investigators.
Eur Urol. 2020 Aug 15:S0302-2838(20)30604-7. doi: 10.1016/j.eururo.2020.07.032. Online ahead of print.
PMID: 32811715
Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden.
Castelo-Branco A, Chiesa F, Bengtsson CE, Lee S, Minton NN, Niemcryk S, Lindholm A, Rosenlund M, Piehl F, Montgomery S.
Mult Scler J Exp Transl Clin. 2020 Aug 14;6(3):2055217320947761. doi: 10.1177/2055217320947761. eCollection 2020 Jul-Sep.
PMID: 32864156
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ.
Breast Cancer Res. 2020 Aug 14;22(1):89. doi: 10.1186/s13058-020-01320-8.
PMID: 32795346
Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity.
Gonzalez Guerrico AM, Lieske J, Klee G, Kumar S, Lopez-Baez V, Wright AM, Bobart S, Shevell D, Maldonado M, Troost JP, Hogan MC; Nephrotic Syndrome Study Network Consortium (NEPTUNE).
Kidney Int Rep. 2020 Aug 14;5(11):2021-2031. doi: 10.1016/j.ekir.2020.08.001. eCollection 2020 Nov.
PMID: 33163723
Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study.
Sekelj S, Sandler B, Johnston E, Pollock KG, Hill NR, Gordon J, Tsang C, Khan S, Ng FS, Farooqui U.
Eur J Prev Cardiol. 2020 Aug 13:2047487320942338. doi: 10.1177/2047487320942338. Online ahead of print.
PMID: 32787456
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P 1 ) Modulators: Optimization of the PK, PD, and Safety Profiles.
Xiao Z, Yang MG, Dhar TGM, Xiao HY, Gilmore JL, Marcoux D, McIntyre KW, Taylor TL, Shi H, Levesque PC, Marino AM, Cornelius G, Mathur A, Shen DR, Cvijic ME, Lehman-McKeeman LD, Sun H, Xie JH, Carter PH, Dyckman AJ.
ACS Med Chem Lett. 2020 Aug 11;11(9):1766-1772. doi: 10.1021/acsmedchemlett.0c00333. eCollection 2020 Sep 10.
PMID: 32944145
RECENT ADVANCES IN INSTRUMENTAL APPROACHES TO TIME-OF-FLIGHT MASS SPECTROMETRY.
Brais CJ, Ibañez JO, Schwartz AJ, Ray SJ.
Mass Spectrom Rev. 2020 Aug 10. doi: 10.1002/mas.21650. Online ahead of print.
PMID: 32779281
To use or not to use propensity score matching?
Wang J.
Pharm Stat. 2020 Aug 10. doi: 10.1002/pst.2051. Online ahead of print.
PMID: 32776719
Real-time monitoring of quality attributes by in-line Fourier transform infrared spectroscopic sensors at ultrafiltration and diafiltration of bioprocess.
Wasalathanthri DP, Feroz H, Puri N, Hung J, Lane G, Holstein M, Chemmalil L, Both D, Ghose S, Ding J, Li ZJ.
Biotechnol Bioeng. 2020 Aug 10. doi: 10.1002/bit.27532. Online ahead of print.
PMID: 32776504
meta-Selective C-H Arylation of Fluoroarenes and Simple Arenes.
Liu LY, Qiao JX, Yeung KS, Ewing WR, Yu JQ.
Angew Chem Int Ed Engl. 2020 Aug 10;59(33):13831-13835. doi: 10.1002/anie.202002865. Epub 2020 Jul 9.
PMID: 32333462
The catalytic domain of the histone methyltransferase NSD2/MMSET is required for the generation of B1 cells in mice.
Dobenecker MW, Marcello J, Becker A, Rudensky E, Bhanu NV, Carrol T, Garcia BA, Prinjha R, Yurchenko V, Tarakhovsky A.
FEBS Lett. 2020 Aug 9. doi: 10.1002/1873-3468.13903. Online ahead of print.
PMID: 32862441
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J, Gale RP, Mead AJ; RESUME trialists.
Leukemia. 2020 Aug 7. doi: 10.1038/s41375-020-0979-6. Online ahead of print.
PMID: 32770086
Geographic Variation in Knowledge of Palliative Care Among US Adults: Findings From 2018 Health Information National Trends Survey.
Chen G, Hong YR, Wilkie DJ, Kittleson S, Huo J, Bian J.
Am J Hosp Palliat Care. 2020 Aug 6:1049909120946266. doi: 10.1177/1049909120946266. Online ahead of print.
PMID: 32757758
Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
Leach MW, Clarke DO, Dudal S, Han C, Li C, Yang Z, Brennan FR, Bailey WJ, Chen Y, Deslandes A, Loberg LI, Mayawala K, Rogge MC, Todd M, Chemuturi NV.
Clin Pharmacol Ther. 2020 Aug 5. doi: 10.1002/cpt.2009. Online ahead of print.
PMID: 32757299
Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma.
Gooding S, Ansari-Pour N, Towfic F, Ortiz Estevez M, Chamberlain PP, Tsai KT, Flynt E, Hirst M, Rozelle D, Dhiman P, Neri P, Ramasamy K, Bahlis NJ, Vyas P, Thakurta A.
Blood. 2020 Aug 4:blood.2020007081. doi: 10.1182/blood.2020007081. Online ahead of print.
PMID: 32750105
Integrated Approach for Characterizing Bispecific Antibody/Antigens Complexes and Mapping Binding Epitopes with SEC/MALS, Native Mass Spectrometry, and Protein Footprinting.
Huang RY, Wang F, Wheeler M, Wang Y, Langish R, Chau B, Dong J, Morishige W, Bezman N, Strop P, Rajpal A, Gudmundsson O, Chen G.
Anal Chem. 2020 Aug 4;92(15):10709-10716. doi: 10.1021/acs.analchem.0c01876. Epub 2020 Jul 22.
PMID: 32639723
Enhancing Host-Cell Protein Detection in Protein Therapeutics Using HILIC Enrichment and Proteomic Analysis.
Wang Q, Slaney TR, Wu W, Ludwig R, Tao L, Leone A.
Anal Chem. 2020 Aug 4;92(15):10327-10335. doi: 10.1021/acs.analchem.0c00360. Epub 2020 Jul 17.
PMID: 32614163
Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers.
Samuel G, Crow J, Klein JB, Merchant ML, Nissen E, Koestler DC, Laurence K, Liang X, Neville K, Staggs V, Ahmed A, Atay S, Godwin AK.
Oncotarget. 2020 Aug 4;11(31):2995-3012. doi: 10.18632/oncotarget.27678. eCollection 2020 Aug 4.
PMID: 32821345
MethylResolver-a method for deconvoluting bulk DNA methylation profiles into known and unknown cell contents.
Arneson D, Yang X, Wang K.
Commun Biol. 2020 Aug 3;3(1):422. doi: 10.1038/s42003-020-01146-2.
PMID: 32747663
Determining the Impact of Roller Compaction Processing Conditions on Granule and API Properties.
Clarke J, Gamble JF, Jones JW, Tobyn M, Dawson N, Davies C, Ingram A, Greenwood R.
AAPS PharmSciTech. 2020 Aug 2;21(6):218. doi: 10.1208/s12249-020-01773-2.
PMID: 32743765
LC/MS/MS-based quantitation of pig and human S100A1 protein in cardiac tissues: Application to gene therapy.
Sleczka BG, Levesque PC, Adam LP, Olah TV, Shipkova P.
Anal Biochem. 2020 Aug 1;602:113766. doi: 10.1016/j.ab.2020.113766. Epub 2020 May 8.
PMID: 32389692
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM, Kulikauskas R, Chung CH, Martens UM, Ferris RL, Stein JE, Engle EL, Devriese LA, Lao CD, Gu J, Li B, Chen T, Barrows A, Horvath A, Taube JM, Nghiem P.
J Clin Oncol. 2020 Aug 1;38(22):2476-2487. doi: 10.1200/JCO.20.00201. Epub 2020 Apr 23.
PMID: 32324435
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC, Ahmad HA, Yazici Y, Bergman MJ.
Rheumatology (Oxford). 2020 Aug 1;59(8):2090-2098. doi: 10.1093/rheumatology/kez455.
PMID: 31819995
Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma.
Hogg D, Monzon JG, Ernst S, Song X, McWhirter E, Savage KJ, Skinn B, Romeyer F, Smylie M.
Curr Oncol. 2020 Aug;27(4):204-214. doi: 10.3747/co.27.5985. Epub 2020 Aug 1.
PMID: 32905202
Excretion balance and pharmacokinetics following a single oral dose of [ 14 C]-fedratinib in healthy subjects.
Ogasawara K, Xu C, Kanamaluru V, Siebers N, Surapaneni S, Ridoux L, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2020 Aug;86(2):307-314. doi: 10.1007/s00280-020-04121-0. Epub 2020 Aug 3.
PMID: 32748109
Qualified method for the estimation of di-18:1 bis(monoacylglycero)phosphate in urine, a noninvasive biomarker to monitor drug-induced phospholipidosis.
Murali BV, Kurawattimath V, Bhutani P, Onorato J, Naikodi SB, Kole P, Rajanna PK.
Bioanalysis. 2020 Aug;12(15):1049-1059. doi: 10.4155/bio-2020-0114. Epub 2020 Jul 31.
PMID: 32735140
Recent advances in inhibitors of C-terminal SRC kinase.
P O'Malley D.
Future Med Chem. 2020 Aug;12(16):1447-1449. doi: 10.4155/fmc-2020-0125. Epub 2020 Jul 8.
PMID: 32638626
Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR.
J Comp Eff Res. 2020 Aug;9(11):767-779. doi: 10.2217/cer-2020-0045. Epub 2020 Jul 8.
PMID: 32638609
Viral myocarditis involves the generation of autoreactive T cells with multiple antigen specificities that localize in lymphoid and non-lymphoid organs in the mouse model of CVB3 infection.
Basavalingappa RH, Arumugam R, Lasrado N, Yalaka B, Massilamany C, Gangaplara A, Riethoven JJ, Xiang SH, Steffen D, Reddy J.
Mol Immunol. 2020 Aug;124:218-228. doi: 10.1016/j.molimm.2020.06.017. Epub 2020 Jun 29.
PMID: 32615275
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.
Al-Huniti N, Feng Y, Yu JJ, Lu Z, Nagase M, Zhou D, Sheng J.
CPT Pharmacometrics Syst Pharmacol. 2020 Aug;9(8):419-427. doi: 10.1002/psp4.12542. Epub 2020 Jul 22.
PMID: 32589767
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, Doz F, Moreno L, Ruggiero A, Gerber NU, Fagioli F, Hingorani P, Melcón SG, Slepetis R, Chen N, le Bruchec Y, Simcock M, Vassal G.
Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15.
PMID: 32554315
A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
Hinata N, Yonese J, Masui S, Nakai Y, Shirotake S, Tatsugami K, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Ochi K, Kaneko H, Uemura H.
Int J Clin Oncol. 2020 Aug;25(8):1533-1542. doi: 10.1007/s10147-020-01692-z. Epub 2020 Jun 9.
PMID: 32519026
Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance.
Yamazaki N, Kiyohara Y, Uhara H, Tsuchida T, Maruyama K, Shakunaga N, Itakura E, Komoto A.
J Dermatol. 2020 Aug;47(8):834-848. doi: 10.1111/1346-8138.15388. Epub 2020 Jun 8.
PMID: 32515086
Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Gu X, Wang L, Gan J, Fancher RM, Tian Y, Hong Y, Lai Y, Sinz M, Shen H.
Drug Metab Dispos. 2020 Aug;48(8):724-734. doi: 10.1124/dmd.120.090670. Epub 2020 Jun 1.
PMID: 32482623
Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD, Rajpura J, Hlavacek P, Keshishian A, Sah J, Delinger R, Mu Q, Mardekian J, Russ C, Okano GJ, Rosenblatt L.
J Manag Care Spec Pharm. 2020 Aug;26(8):1017-1026. doi: 10.18553/jmcp.2020.19311. Epub 2020 May 26.
PMID: 32452277
Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry.
Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED.
Rheumatol Int. 2020 Aug;40(8):1239-1248. doi: 10.1007/s00296-020-04602-8. Epub 2020 May 24.
PMID: 32449040
An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results.
Gann PH, Deaton RJ, McMahon N, Collins MH, Dellon ES, Hirano I, Hua SY, Rodriguez C, Harris S.
J Allergy Clin Immunol. 2020 Aug;146(2):367-376.e3. doi: 10.1016/j.jaci.2020.03.045. Epub 2020 May 11.
PMID: 32407835
Incident depression in patients diagnosed with multiple sclerosis: a multi-database study.
Persson R, Lee S, Yood MU, Wagner MR, Minton N, Niemcryk S, Lindholm A, Evans AM, Jick S.
Eur J Neurol. 2020 Aug;27(8):1556-1560. doi: 10.1111/ene.14314. Epub 2020 Jun 8.
PMID: 32397001
Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.
Wilson H, Pagano G, de Natale ER, Mansur A, Caminiti SP, Polychronis S, Middleton LT, Price G, Schmidt KF, Gunn RN, Rabiner EA, Politis M.
Mov Disord. 2020 Aug;35(8):1416-1427. doi: 10.1002/mds.28064. Epub 2020 Apr 29.
PMID: 32347983
The importance and future of biochemical engineering.
Whitehead TA, Banta S, Bentley WE, Betenbaugh MJ, Chan C, Clark DS, Hoesli CA, Jewett MC, Junker B, Koffas M, Kshirsagar R, Lewis A, Li CT, Maranas C, Terry Papoutsakis E, Prather KLJ, Schaffer S, Segatori L, Wheeldon I.
Biotechnol Bioeng. 2020 Aug;117(8):2305-2318. doi: 10.1002/bit.27364. Epub 2020 May 29.
PMID: 32343367
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate AS, Vural F, Cascavilla N, Basu S, Johnson P, Byeff P, Hus M, Rodríguez-Otero P, Muelduer E, Anttila P, Hayden PJ, Krauth MT, Lucio P, Ben-Yehuda D, Mendeleeva L, Guo S, Yu X, Grote L, Biyukov T, Dhanasiri S, Richardson P.
Leuk Lymphoma. 2020 Aug;61(8):1850-1859. doi: 10.1080/10428194.2020.1747066. Epub 2020 Apr 9.
PMID: 32268815
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.
Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G.
Leukemia. 2020 Aug;34(8):2064-2073. doi: 10.1038/s41375-020-0805-1. Epub 2020 Apr 7.
PMID: 32265500
Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types.
Ptacek J, Locke D, Finck R, Cvijic ME, Li Z, Tarolli JG, Aksoy M, Sigal Y, Zhang Y, Newgren M, Finn J.
Lab Invest. 2020 Aug;100(8):1111-1123. doi: 10.1038/s41374-020-0417-4. Epub 2020 Mar 23.
PMID: 32203152
Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Li Y, Kassir N, Wang X, Palmisano M, Zhou S.
J Clin Pharmacol. 2020 Aug;60(8):1061-1075. doi: 10.1002/jcph.1602. Epub 2020 Mar 13.
PMID: 32168381
Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing.
Cai W, Leil TA, Gibiansky L, Krishna M, Zhang H, Gu H, Sun H, Throup J, Banerjee S, Girgis I.
Clin Pharmacol Drug Dev. 2020 Aug;9(6):689-698. doi: 10.1002/cpdd.784. Epub 2020 Feb 18.
PMID: 32068354
Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States.
Guo JD, Hlavacek P, Poretta T, Wygant G, Lane D, Gorritz M, Wang X, Chen CC, Wade RL, Pan X, Rajpura J, Stwalley B, Rosenblatt L.
J Thromb Thrombolysis. 2020 Aug;50(2):386-394. doi: 10.1007/s11239-019-02032-3.
PMID: 31955338
Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA.
Oguz M, Lanitis T, Li X, Wygant G, Singer DE, Friend K, Hlavacek P, Nikolaou A, Mattke S.
Appl Health Econ Health Policy. 2020 Aug;18(4):533-545. doi: 10.1007/s40258-019-00542-y.
PMID: 31849021
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
Harris
S,  Tran JQ ,  Southworth
H,  Spencer
CM,  Cree
BAC,
Zamvil
SS.
Neurol Neuroimmunol Neuroinflamm 2020 Jul 31;7(5):e839. doi: 10.1212/NXI.0000000000000839. Print 2020 Sep.
PMID: 32737072
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF.
Blood. 2020 Jul 30:blood.2020006158. doi: 10.1182/blood.2020006158. Online ahead of print.
PMID: 32730593
Symptoms and impacts in anemia of chronic kidney disease.
Mathias SD, Blum SI, Sikirica V, Johansen KL, Colwell HH, Okoro T.
J Patient Rep Outcomes. 2020 Jul 29;4(1):64. doi: 10.1186/s41687-020-00215-8.
PMID: 32728779
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
Mussari CP, Dodd DS, Sreekantha RK, Pasunoori L, Wan H, Posy SL, Critton D, Ruepp S, Subramanian M, Watson A, Davies P, Schieven GL, Salter-Cid LM, Srivastava R, Tagore DM, Dudhgaonkar S, Poss MA, Carter PH, Dyckman AJ.
ACS Med Chem Lett. 2020 Jul 29;11(9):1751-1758. doi: 10.1021/acsmedchemlett.0c00264. eCollection 2020 Sep 10.
PMID: 32944143
AP-Net: An atomic-pairwise neural network for smooth and transferable interaction potentials.
Glick ZL, Metcalf DP, Koutsoukas A, Spronk SA, Cheney DL, Sherrill CD.
J Chem Phys. 2020 Jul 28;153(4):044112. doi: 10.1063/5.0011521.
PMID: 32752707
Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings.
Burton T, Hlavacek P, Guo JD, Rosenblatt L, Mardekian J, Ferri M, Russ C, Kline JA.
Hosp Pract (1995). 2020 Jul 28:1-10. doi: 10.1080/21548331.2020.1769988. Online ahead of print.
PMID: 32720816
Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance.
Lee I, Jokinen JD, Crawford SY, Calip GS, Kilpatrick RD, Lee TA.
Ther Innov Regul Sci. 2020 Jul 27. doi: 10.1007/s43441-020-00199-z. Online ahead of print.
PMID: 32720297
Lymphatic Distribution of Etanercept Following Intravenous and Subcutaneous Delivery to Rats.
Gao X, Voronin G, Generaux C, Rose A, Kozhich A, Dalglish G, Rosa R, Oh S, Kagan L.
Pharm Res. 2020 Jul 27;37(8):155. doi: 10.1007/s11095-020-02860-6.
PMID: 32720159
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Delev N, Teng L, Wollenhaupt J.
ACR Open Rheumatol. 2020 Jul 25;2(8):459-70. doi: 10.1002/acr2.11156. Online ahead of print.
PMID: 32710493
Characterization of individuals with selected muscular dystrophies from the expanded pilot of the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) in the United States.
Wallace B, Smith KT, Thomas S, Conway KM, Westfield C, Andrews JG, Weinert RO, Do TQN, Street N;
Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).Birth Defects Res. 2020 Jul 24. doi: 10.1002/bdr2.1764. Online ahead of print.
PMID: 32710484
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
Ailawadhi S, Jagannath S, Lee HC, Narang M, Rifkin RM, Terebelo HR, Durie BGM, Toomey K, Hardin JW, Gasparetto CJ, Wagner L, Omel JL, He M, Yue L, Flick ED, Agarwal A, Abonour R; Connect MM Registry Investigators.
Cancer. 2020 Jul 24;126(19):4332-40. doi: 10.1002/cncr.33089. Online ahead of print.
PMID: 32706404
Molecular Underpinnings of Severe Coronavirus Disease 2019.
Plenge RM.
JAMA. 2020 Jul 24. doi: 10.1001/jama.2020.14015. Online ahead of print.
PMID: 32706364
Framework and case study for establishing impactful global health programs through academia - biopharmaceutical industry partnerships.
Pastakia SD, Tran DN, Manji I, Schellhase E, Karwa R, Miller ML, Aruasa W, Khan ZM.
Res Social Adm Pharm. 2020 Jul 24:S1551-7411(20)30162-5. doi: 10.1016/j.sapharm.2020.07.018. Online ahead of print.
PMID: 32792324
Transition-Metal-Catalyzed Cycloaddition Reactions to Access Seven-Membered Rings.
Trost BM, Zuo Z, Schultz JE.
Chemistry. 2020 Jul 23. doi: 10.1002/chem.202002713. Online ahead of print.
PMID: 32705722
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.
Uyl-de Groot CA, Ramsden R, Lee D, Boersma J, Zweegman S, Dhanasiri S.
Eur J Haematol. 2020 Jul 23;105(5):635-45. doi: 10.1111/ejh.13497. Online ahead of print.
PMID: 32705720
Risperidone- and paliperidone-induced hepatotoxicity: Case report and review of literature.
Khorassani F, Sousonis F, Lopez LV.
Am J Health Syst Pharm. 2020 Jul 23:zxaa224. doi: 10.1093/ajhp/zxaa224. Online ahead of print.
PMID: 32699878
A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity.
Roex MCJ, Hageman L, Veld SAJ, van Egmond E, Hoogstraten C, Stemberger C, Germeroth L, Einsele H, Falkenburg JHF, Jedema I.
Blood. 2020 Jul 23;136(4):455-467. doi: 10.1182/blood.2019004443.
PMID: 32483595
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments.
Gottlieb K, Daperno M, Usiskin K, Sands BE, Ahmad H, Howden CW, Karnes W, Oh YS, Modesto I, Marano C, Stidham RW, Reinisch W.
Gut. 2020 Jul 22:gutjnl-2020-320690. doi: 10.1136/gutjnl-2020-320690. Online ahead of print.
PMID: 32699100
The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE).
Leahy TP, Ramagopalan S, Sammon C.
BMC Health Serv Res. 2020 Jul 22;20(1):675. doi: 10.1186/s12913-020-05529-3.
PMID: 32698805
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A.
J Hepatol. 2020 Jul 22:S0168-8278(20)30479-7. doi: 10.1016/j.jhep.2020.07.026. Online ahead of print.
PMID: 32710922
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N, Kassir N, Laadem A, Giuseppi AC, Shetty J, Maxwell SE, Sriraman P, Ritland S, Linde PG, Budda B, Reynolds JG, Zhou S, Palmisano M.
J Clin Pharmacol. 2020 Jul 21. doi: 10.1002/jcph.1696. Online ahead of print.
PMID: 32696522
Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review.
Holstein M, Hung J, Feroz H, Ranjan S, Du C, Ghose S, Li ZJ.
Biotechnol Bioeng. 2020 Jul 20. doi: 10.1002/bit.27510. Online ahead of print.
PMID: 32687221
Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
Kaplan DL, Ung BL, Pelletier C, Udeze C, Khilfeh I, Tian M.
Clinicoecon Outcomes Res. 2020 Jul 17;12:369-377. doi: 10.2147/CEOR.S251775. eCollection 2020.
PMID: 32765022
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Hawkins R, Fife K, Hurst M, Wang M, Naicker N, Nolasco S, Eisen T, Matakidou A, Gordon J.
BMC Cancer. 2020 Jul 17;20(1):670. doi: 10.1186/s12885-020-07154-z.
PMID: 32680483
A novel semi-mechanistic tumor growth fraction model for translation of preclinical efficacy of anti-glypican 3 antibody drug conjugate to human.
Singh R, Kozhich A, Pan C, Lee F, Cardarelli P, Vangipuram R, Iyer R, Marathe P.
Biopharm Drug Dispos. 2020 Jul 17. doi: 10.1002/bdd.2249. Online ahead of print.
PMID: 32678919
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Ogasawara K, Xu C, Yin J, Darpo B, Carayannopoulos L, Xue H, Palmisano M, Krishna G.
Clin Pharmacol Drug Dev. 2020 Jul 16. doi: 10.1002/cpdd.850. Online ahead of print.
PMID: 32673446
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, Castellano D, Choueiri TK, Donskov F, Gurney H, Oudard S, Richardet M, Peltola K, Alva AS, Carducci M, Wagstaff J, Chevreau C, Fukasawa S, Tomita Y, Gauler TC, Kollmannsberger CK, Schutz FA, Larkin J, Cella D, McHenry MB, Saggi SS, Tannir NM.
Cancer. 2020 Jul 16. doi: 10.1002/cncr.33033. Online ahead of print.
PMID: 32673417
A CFD model for predicting protein aggregation in low-pH virial inactivation for mAb production.
Xing Z, Jin W, Xu X, Song Y, Huang C, Borys MC, Ghose S, Li ZJ.
Biotechnol Bioeng. 2020 Jul 16. doi: 10.1002/bit.27505. Online ahead of print.
PMID: 32672835
Publisher Correction: Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells.
Kramer J, Himmel HM, Lindqvist A, Stoelzle-Feix S, Chaudhary KW, Li D, Bohme GA, Bridgland-Taylor M, Hebeisen S, Fan J, Renganathan M, Imredy J, Humphries ESA, Brinkwirth N, Strassmaier T, Ohtsuki A, Danker T, Vanoye C, Polonchuk L, Fermini B, Pierson JB, Gintant G.
Sci Rep. 2020 Jul 14;10(1):11884. doi: 10.1038/s41598-020-68819-0.
PMID: 32665705
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
Santini V, Fenaux P, Giagounidis A, Platzbecker U, List AF, Haferlach T, Zhong J, Wu C, Mavrommatis K, Beach CL, MacBeth KJ, Almeida A.
Leukemia. 2020 Jul 13. doi: 10.1038/s41375-020-0961-3. Online ahead of print.
PMID: 32661294
Model-Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time-Varying M Protein.
Ide T, Roy A, Imai Y, Vezina HE.
J Clin Pharmacol. 2020 Jul 12. doi: 10.1002/jcph.1698. Online ahead of print.
PMID: 32656777
Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A.
BMC Palliat Care. 2020 Jul 10;19(1):103. doi: 10.1186/s12904-020-00610-4.
PMID: 32650765
IL-31 transgenic mice show reduced allergen-induced lung inflammation.
Neuper T, Neureiter D, Sarajlic M, Strandt H, Bauer R, Schwarz H, Suchanek P, Korotchenko E, Dillon SR, Hammerl P, Stoecklinger A, Weiss R, Horejs-Hoeck J.
Eur J Immunol. 2020 Jul 10. doi: 10.1002/eji.202048547. Online ahead of print.
PMID: 32648940
Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.
Yang W, Wang Y, Lai A, Clark CG, Corte JR, Fang T, Gilligan PJ, Jeon Y, Pabbisetty KB, Rampulla RA, Mathur A, Kaspady M, Neithnadka PR, Arumugam A, Raju S, Rossi KA, Myers JE Jr, Sheriff S, Lou Z, Zheng JJ, Chacko SA, Bozarth JM, Wu Y, Crain EJ, Wong PC, Seiffert DA, Luettgen JM, Lam PYS, Wexler RR, Ewing WR.
J Med Chem. 2020 Jul 9;63(13):7226-7242. doi: 10.1021/acs.jmedchem.0c00464. Epub 2020 Jun 17.
PMID: 32456431
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Hansen JD, Correa M, Nagy MA, Alexander M, Plantevin V, Grant V, Whitefield B, Huang D, Kercher T, Harris R, Narla RK, Leisten J, Tang Y, Moghaddam M, Ebinger K, Piccotti J, Havens CG, Cathers B, Carmichael J, Daniel T, Vessey R, Hamann LG, Leftheris K, Mendy D, Baculi F, LeBrun LA, Khambatta G, Lopez-Girona A.
J Med Chem. 2020 Jul 9;63(13):6648-6676. doi: 10.1021/acs.jmedchem.9b01928. Epub 2020 Mar 19.
PMID: 32130004
Interferon-independent STING signaling promotes resistance to HSV-1 in vivo.
Yamashiro LH, Wilson SC, Morrison HM, Karalis V, Chung JJ, Chen KJ, Bateup HS, Szpara ML, Lee AY, Cox JS, Vance RE.
Nat Commun. 2020 Jul 7;11(1):3382. doi: 10.1038/s41467-020-17156-x.
PMID: 32636381
Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity.
Fleming TR, Labriola D, Wittes J.
JAMA. 2020 Jul 7;324(1):33-34. doi: 10.1001/jama.2020.9286.
PMID: 32463422
Epitope and Paratope Mapping of PD-1/Nivolumab by Mass Spectrometry-Based Hydrogen-Deuterium Exchange, Cross-linking, and Molecular Docking.
Zhang MM, Huang RY, Beno BR, Deyanova EG, Li J, Chen G, Gross ML.
Anal Chem. 2020 Jul 7;92(13):9086-9094. doi: 10.1021/acs.analchem.0c01291. Epub 2020 Jun 10.
PMID: 32441507
Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies.
Schenck L, Erdemir D, Saunders Gorka L, Merritt JM, Marziano I, Ho R, Lee M, Bullard J, Boukerche M, Ferguson S, Florence AJ, Khan SA, Sun CC.
Mol Pharm. 2020 Jul 6;17(7):2232-2244. doi: 10.1021/acs.molpharmaceut.0c00198. Epub 2020 Jun 10.
PMID: 32392068
Assessment of impact of daily huddles and visual displays on medication delivery timeliness in a large academic medical center.
Smith AJF, Ahern SP, Shermock KM, Feller TT, Hill JD.
Am J Health Syst Pharm. 2020 Jul 4:zxaa210. doi: 10.1093/ajhp/zxaa210. Online ahead of print.
PMID: 32620969
Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals.
Radeva D, Hopkin G, Mossialos E, Borrill J, Osipenko L, Naci H.
Int J Technol Assess Health Care. 2020 Jul 3:1-6. doi: 10.1017/S0266462320000422. Online ahead of print.
PMID: 32618536
Amplifying the Voice of the Patient in Clinical Research: Development of Toolkits for Use in Designing and Conducting Patient-Centered Clinical Studies.
TransCelerate Biopharma Toolkits Core Team, Elmer M, Florek C, Gabryelski L, Greene A, Inglis AM, Johnson KL, Keiper T, Ludlam S, Sharpe TJ, Shay K, Somers F, Sutherland C, Teufel M, Yates S.
Ther Innov Regul Sci. 2020 Jul 2. doi: 10.1007/s43441-020-00176-6. Online ahead of print.
PMID: 32617912
A generalizable data-driven multicellular model of pancreatic ductal adenocarcinoma.
Aguilar B, Gibbs DL, Reiss DJ, McConnell M, Danziger SA, Dervan A, Trotter M, Bassett D, Hershberg R, Ratushny AV, Shmulevich I.
Gigascience. 2020 Jul 1;9(7):giaa075. doi: 10.1093/gigascience/giaa075.
PMID: 32696951
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies.
Li Y, Palmisano M, Sun D, Zhou S.
Clin Pharmacol. 2020 Jul 1;12:83-96. doi: 10.2147/CPAA.S255789. eCollection 2020.
PMID: 32669879
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M.
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
PMID: 32437507
Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
Patel M, Naidu BN, Dicker I, Higley H, Lin Z, Terry B, Protack T, Krystal M, Jenkins S, Parker D, Panja C, Rampulla R, Mathur A, Meanwell NA, Walker MA.
Bioorg Med Chem. 2020 Jul 1;28(13):115541. doi: 10.1016/j.bmc.2020.115541. Epub 2020 May 4.
PMID: 32389483
Factors associated with non-prescription of oral anticoagulant treatment in non-valvular atrial fibrillation patients with dementia: a CPRD-HES study.
Besford M, Graham S, Sammon C, Mehmud F, Allan V, Alikhan R, Ramagopalan S.
Age Ageing. 2020 Jul 1;49(4):679-682. doi: 10.1093/ageing/afaa045.
PMID: 32242616
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH, Bonafede M.
Adv Ther. 2020 Jul;37(7):3163-3177. doi: 10.1007/s12325-020-01367-1. Epub 2020 May 20.
PMID: 32436028
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR).
Okishio K, Morita R, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, Kozuki T, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Yada N, Ohe Y.
ESMO Open. 2020 Jul;5(4):e000656. doi: 10.1136/esmoopen-2019-000656.
PMID: 32690620
Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer.
Fujiwara K, Saung MT, Jing H, Herbst B, Zarecki M, Muth S, Wu A, Bigelow E, Chen L, Li K, Jurcak N, Blair AB, Ding D, Wichroski M, Blum J, Cheadle N, Koenitzer J, Zheng L.
J Immunother Cancer. 2020 Jul;8(2):e000351. doi: 10.1136/jitc-2019-000351.
PMID: 32675194
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM.
J Immunother Cancer. 2020 Jul;8(2):e000891. doi: 10.1136/jitc-2020-000891.
PMID: 32661118
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, Ascierto PA, McEwan P, Wagner S, Borrill J, Wu E.
J Immunother Cancer. 2020 Jul;8(2):e000648. doi: 10.1136/jitc-2020-000648.
PMID: 32661115
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
Chen N, Kassir N, Laadem A, Maxwell SE, Sriraman P, Giuseppi AC, Ritland S, Linde PG, Budda B, Reynolds JG, Zhou S, Palmisano M.
CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):395-404. doi: 10.1002/psp4.12521. Epub 2020 Jun 30.
PMID: 32602651
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
Goldstein D, Von Hoff DD, Chiorean EG, Reni M, Tabernero J, Ramanathan RK, Botteman M, Aly A, Margunato-Debay S, Lu B, Louis CU, McGovern D, Lee CK.
Pancreas. 2020 Jul;49(6):744-750. doi: 10.1097/MPA.0000000000001563.
PMID: 32541630
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E, Danchin N, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cotté FE, Gollety S, Falissard B, Belhassen M, Steg PG.
Stroke. 2020 Jul;51(7):2066-2075. doi: 10.1161/STROKEAHA.120.028825. Epub 2020 Jun 16.
PMID: 32539675
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Ogasawara K, LoRusso PM, Olszanski AJ, Rixe O, Xu C, Yin J, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2020 Jul;86(1):87-95. doi: 10.1007/s00280-020-04102-3. Epub 2020 Jun 14.
PMID: 32537715
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P, Gricar J, Zhang Y, Shankaran V.
Adv Ther. 2020 Jul;37(7):3392-3403. doi: 10.1007/s12325-020-01394-y. Epub 2020 Jun 12.
PMID: 32533533
Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis.
Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J.
J Comp Eff Res. 2020 Jul;9(10):737-750. doi: 10.2217/cer-2020-0042. Epub 2020 Jun 3.
PMID: 32490682
Large-scale implementation of a pragmatic atrial fibrillation screening program in Canadian community practice.
Andrade JG, Godin R, Nault I.
Pacing Clin Electrophysiol. 2020 Jul;43(7):768-769. doi: 10.1111/pace.13966. Epub 2020 Jun 11.
PMID: 32460368
A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
Li M, Lin C, Deng H, Strnad J, Bernabei L, Vogl DT, Burke JJ, Nefedova Y.
Mol Cancer Ther. 2020 Jul;19(7):1530-1538. doi: 10.1158/1535-7163.MCT-19-1020. Epub 2020 May 5.
PMID: 32371579
Minimization of artifact protein aggregation using tetradecyl sulfate and hexadecyl sulfate in capillary gel electrophoresis under reducing conditions.
Guan Q, Atsma J, Tulsan R, Voronov S, Ding J, Beckman J, Li ZJ.
Electrophoresis. 2020 Jul;41(13-14):1245-1252. doi: 10.1002/elps.201900435. Epub 2020 May 17.
PMID: 32297333
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis.
Mease PJ, McInnes IB, Strand V, FitzGerald O, Ahmad HA, Elbez Y, Banerjee S.
Rheumatol Int. 2020 Jul;40(7):1021-1028. doi: 10.1007/s00296-020-04564-x. Epub 2020 Apr 30.
PMID: 32356115
The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy.
Tkacz J, Garcia J, Gitlin M, McMorrow D, Snyder S, Bonafede M, Chung KC, Maziarz RT.
Leuk Lymphoma. 2020 Jul;61(7):1601-1609. doi: 10.1080/10428194.2020.1734592. Epub 2020 Apr 9.
PMID: 32270727
Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats.
Rak GD, White MR, Augustine-Rauch K, Newsome C, Graziano MJ, Schulze GE.
J Appl Toxicol. 2020 Jul;40(7):931-946. doi: 10.1002/jat.3954. Epub 2020 Feb 15.
PMID: 32061184
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Dan Rozelle, Danziger SA, Ratushny A; Multiple Myeloma DREAM Consortium, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J.
Leukemia. 2020 Jul;34(7):1866-1874. doi: 10.1038/s41375-020-0742-z. Epub 2020 Feb 14.
PMID: 32060406
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y.
J Am Acad Dermatol. 2020 Jul;83(1):96-103. doi: 10.1016/j.jaad.2020.01.072. Epub 2020 Feb 4.
PMID: 32032692
Recommended Practices for Macerating Human Thyroid Cartilage.
LaGoy A, Evangelou EA, Somogyi T, DiGangi EA.
J Forensic Sci. 2020 Jul;65(4):1266-1273. doi: 10.1111/1556-4029.14289. Epub 2020 Feb 7.
PMID: 32031684
Feeding tricarboxylic acid cycle intermediates improves lactate consumption and antibody production in Chinese hamster ovary cell cultures.
Zhang X, Jiang R, Lin H, Xu S.
Biotechnol Prog. 2020 Jul;36(4):e2975. doi: 10.1002/btpr.2975. Epub 2020 Feb 21.
PMID: 32012447
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis.
Ahmad HA, Baker JF, Østergaard M, Emery P, Durez P, Ye J, Banerjee S, Conaghan PG.
Arthritis Care Res (Hoboken). 2020 Jul;72(7):959-964. doi: 10.1002/acr.24072. Epub 2020 May 26.
PMID: 31549793
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Arroyo R, Bury DP, Guo JD, Margolin DH, Melanson M, Daizadeh N, Cella D.
Mult Scler. 2020 Jul;26(8):955-963. doi: 10.1177/1352458519849796. Epub 2019 May 30.
PMID: 31144568
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS.
Front Immunol. 2020 Jun 30;11:1301. doi: 10.3389/fimmu.2020.01301. eCollection 2020.
PMID: 32695107
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Lip GYH, Keshishian AV, Kang AL, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Garcia Reeves AB, Yuce H, Deitelzweig S.
J Intern Med. 2020 Jun 30. doi: 10.1111/joim.13140. Online ahead of print.
PMID: 32602228
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
Armand P, Lesokhin A, Borrello I, Timmerman J, Gutierrez M, Zhu L, Popa McKiver M, Ansell SM.
Leukemia. 2020 Jun 29. doi: 10.1038/s41375-020-0939-1. Online ahead of print.
PMID: 32601377
Real-World Experience with Apremilast in the Treatment of Adults with Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
Poulin Y, Beauchemin C, Royer C, Gaudreau AJ, Yim C, Liu FF, Lachaine J.
J Cutan Med Surg. 2020 Jun 29:1203475420936652. doi: 10.1177/1203475420936652. Online ahead of print.
PMID: 32597685
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis.
Degboé Y, Schiff M, Weinblatt M, Fleischmann R, Ahmad HA, Constantin A.
J Clin Med. 2020 Jun 26;9(6):2017. doi: 10.3390/jcm9062017.
PMID: 32604962
The Universal Patient Language: A Set of Resources and Tools to Design Patient Communications That Support Better Health Literacy.
Bartlett S, Dezii C, Sandt K.
Stud Health Technol Inform. 2020 Jun 25;269:264-274. doi: 10.3233/SHTI200041.
PMID: 32594001
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
Johnson BM, Shu YZ, Zhuo X, Meanwell NA.
J Med Chem. 2020 Jun 25;63(12):6315-6386. doi: 10.1021/acs.jmedchem.9b01877. Epub 2020 Mar 17.
PMID: 32182061
Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M.
Head Neck. 2020 Jun 24;42(10):2852-62. doi: 10.1002/hed.26331. Online ahead of print.
PMID: 32583557
Author Correction: Cellular census of human fibrosis defines functionally distinct stromal cell types and states.
Layton TB, Williams L, McCann F, Zhang M, Fritzsche M, Colin-York H, Cabrita M, Ng MTH, Feldmann M, Sansom SN, Furniss D, Xie W, Nanchahal J.
Nat Commun. 2020 Jun 24;11(1):3275. doi: 10.1038/s41467-020-17073-z.
PMID: 32581254
Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB.
Bryk R, Mundhra S, Jiang X, Wood M, Pfau D, Weber E, Park S, Zhang L, Wilson C, Van der Westhuyzen R, Street L, Chibale K, Zimmerman M, Dartois V, Pastore N, Ballabio A, Hawryluk N, Canan S, Khetani V, Camardo J, Nathan C.
PLoS Pathog. 2020 Jun 23;16(6):e1008567. doi: 10.1371/journal.ppat.1008567. eCollection 2020 Jun.
PMID: 32574211
Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative.
Mikita JS, Mitchel J, Gatto NM, Laschinger J, Tcheng JE, Zeitler EP, Swern AS, Flick ED, Dowd C, Lystig T, Calvert SB.
Ther Innov Regul Sci. 2020 Jun 22. doi: 10.1007/s43441-020-00185-5. Online ahead of print.
PMID: 32572772
Correction to: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population.
Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL.
J Thromb Thrombolysis. 2020 Jun 20. doi: 10.1007/s11239-020-02161-0. Online ahead of print.
PMID: 32564179
Quantifying Target Occupancy of Small Molecules Within Living Cells.
Robers MB, Friedman-Ohana R, Huber KVM, Kilpatrick L, Vasta JD, Berger BT, Chaudhry C, Hill S, Müller S, Knapp S, Wood KV.
Annu Rev Biochem. 2020 Jun 20;89:557-581. doi: 10.1146/annurev-biochem-011420-092302. Epub 2020 Mar 24.
PMID: 32208767
Pediatric cancer research: Surviving COVID-19.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP.
Pediatr Blood Cancer. 2020 Jun 18:e28435. doi: 10.1002/pbc.28435. Online ahead of print.
PMID: 32558190
ARID1A  mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.
Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P.
Sci Transl Med. 2020 Jun 17;12(548):eabc4220. doi: 10.1126/scitranslmed.abc4220.
PMID: 32554706
Benchmarking Patient Recruitment and Retention Practices.
Lamberti MJ, Smith Z, Henry R, Howe D, Goodwin M, Williams A, Getz K.
Ther Innov Regul Sci. 2020 Jun 16. doi: 10.1007/s43441-020-00186-4. Online ahead of print.
PMID: 32548703
Osmolality as a lever to modulate the N-glycolylneuraminicacid (Neu5Gc) level of a recombinant glycoprotein produced in Chinese hamster ovary cells.
Xu S, Borys M, Khetan A, Pla I.
Biotechnol Prog. 2020 Jun 15:e3038. doi: 10.1002/btpr.3038. Online ahead of print.
PMID: 32542945
Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy.
Blair TC, Bambina S, Alice AF, Kramer GF, Medler TR, Baird JR, Broz ML, Tormoen GW, Troesch V, Crittenden MR, Gough MJ.
J Immunol. 2020 Jun 15;204(12):3416-3424. doi: 10.4049/jimmunol.2000194. Epub 2020 Apr 27.
PMID: 32341058
Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (RORγt) agonists.
Harikrishnan LS, Gill P, Kamau MG, Qin LY, Ruan Z, O'Malley D, Huynh T, Stachura S, Cavallaro CL, Lu Z, J-W Duan J, Weigelt CA, Sack JS, Ruzanov M, Khan J, Gururajan M, Wong JJ, Huang Y, Yarde M, Li Z, Chen C, Sun H, Borowski V, Murtaza A, Fink BE.
Bioorg Med Chem Lett. 2020 Jun 15;30(12):127204. doi: 10.1016/j.bmcl.2020.127204. Epub 2020 Apr 20.
PMID: 32334911
Characterization of a novel hydroxypropyl methylcellulose (HPMC) direct compression grade excipient for pharmaceutical tablets.
Allenspach C, Timmins P, Sharif S, Minko T.
Int J Pharm. 2020 Jun 15;583:119343. doi: 10.1016/j.ijpharm.2020.119343. Epub 2020 Apr 17.
PMID: 32305364
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
McFarlane JJ, Kochenderfer MD, Olsen MR, Bauer TM, Molina A, Hauke RJ, Reeves JA, Babu S, Van Veldhuizen P, Somer B, Gunuganti V, Schnadig I, George S, Page RD, Arrowsmith E, Jain RK, Zhang J, McHenry MB, Johansen JL, Vogelzang NJ.
Clin Genitourin Cancer. 2020 Jun 14:S1558-7673(20)30141-5. doi: 10.1016/j.clgc.2020.06.002. Online ahead of print.
PMID: 32641261
The Role of Cocrystallization-Mediated Altered Crystallographic Properties on the Tabletability of Rivaroxaban and Malonic Acid.
Kale DP, Puri V, Kumar A, Kumar N, Bansal AK.
Pharmaceutics. 2020 Jun 12;12(6):546. doi: 10.3390/pharmaceutics12060546.
PMID: 32545503
Sericin: A Versatile Protein Biopolymer with Therapeutic Significance.
Suryawanshi R, Kanoujia J, Parashar P, Saraf SA.
Curr Pharm Des. 2020 Jun 12. doi: 10.2174/1381612826666200612165253. Online ahead of print.
PMID: 32532189
Catalytic α-Hydroarylation of Acrylates and Acrylamides via an Interrupted Hydrodehalogenation Reaction.
Vasquez AM, Gurak JA Jr, Joe CL, Cherney EC, Engle KM.
J Am Chem Soc. 2020 Jun 10;142(23):10477-10484. doi: 10.1021/jacs.0c03040. Epub 2020 May 28.
PMID: 32379433
The Roles of Signaling in Cytoskeletal Changes, Random Movement, Direction-Sensing and Polarization of Eukaryotic Cells.
Cheng Y, Felix B, Othmer HG.
Cells. 2020 Jun 10;9(6):1437. doi: 10.3390/cells9061437.
PMID: 32531876
Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.
Nair S, Kumar SR, Paidi VR, Sistla R, Kantheti D, Polimera SR, Thangavel S, Mukherjee AJ, Das M, Bhide RS, Pitts WJ, Murugesan N, Dudhgoankar S, Nagar J, Subramani S, Mazumder D, Carman JA, Holloway DA, Li X, Fereshteh MP, Ruepp S, Palanisamy K, Mariappan TT, Maddi S, Saxena A, Elzinga P, Chimalakonda A, Ruan Q, Ghosh K, Bose S, Sack J, Yan C, Kiefer SE, Xie D, Newitt JA, Saravanakumar SP, Rampulla RA, Barrish JC, Carter PH, Hynes J Jr.
ACS Med Chem Lett. 2020 Jun 10;11(7):1402-1409. doi: 10.1021/acsmedchemlett.0c00082. eCollection 2020 Jul 9.
PMID: 32676146
Pd II  -Catalyzed Enantioselective C(sp 3  )-H Arylation of Cyclobutyl Ketones Using a Chiral Transient Directing Group.
Xiao LJ, Hong K, Luo F, Hu L, Ewing WR, Yeung KS, Yu JQ.
Angew Chem Int Ed Engl. 2020 Jun 8;59(24):9594-9600. doi: 10.1002/anie.202000532. Epub 2020 Apr 1.
PMID: 32155313
Medical biotechnology as a paradigm for forest restoration and introduction of the transgenic American chestnut.
Aucott M, Parker RA.
Conserv Biol. 2020 Jun 7. doi: 10.1111/cobi.13566. Online ahead of print.
PMID: 32506503
Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study.
Simon TA, Harikrishnan GP, Kawabata H, Singhal S, Brunner HI, Lovell DJ.
Pediatr Rheumatol Online J. 2020 Jun 5;18(1):43. doi: 10.1186/s12969-020-00426-9.
PMID: 32503658
Distributed Regression Analysis Application in Large Distributed Data Networks: Analysis of Precision and Operational Performance.
Her Q, Malenfant J, Zhang Z, Vilk Y, Young J, Tabano D, Hamilton J, Johnson R, Raebel M, Boudreau D, Toh S.
JMIR Med Inform. 2020 Jun 4;8(6):e15073. doi: 10.2196/15073.
PMID: 32496200
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N.
Blood. 2020 Jun 4;135(23):2041-2048. doi: 10.1182/blood.2019002729.
PMID: 32232482
Pd-Catalyzed γ-C(sp 3 )-H Fluorination of Free Amines.
Chen YQ, Singh S, Wu Y, Wang Z, Hao W, Verma P, Qiao JX, Sunoj RB, Yu JQ.
J Am Chem Soc. 2020 Jun 3;142(22):9966-9974. doi: 10.1021/jacs.9b13537. Epub 2020 May 18.
PMID: 32363869
Cellular census of human fibrosis defines functionally distinct stromal cell types and states.
Layton TB, Williams L, McCann F, Zhang M, Fritzsche M, Colin-York H, Cabrita M, Ng MTH, Feldmann M, Sansom SN, Furniss D, Xie W, Nanchahal J.
Nat Commun. 2020 Jun 2;11(1):2768. doi: 10.1038/s41467-020-16264-y.
PMID: 32488016
KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease.
Billi AC, Ludwig JE, Fritz Y, Rozic R, Swindell WR, Tsoi LC, Gruzska D, Abdollahi-Roodsaz S, Xing X, Diaconu D, Uppala R, Camhi MI, Klenotic PA, Sarkar MK, Husni ME, Scher JU, McDonald C, Kahlenberg JM, Midura RJ, Gudjonsson JE, Ward NL.
J Clin Invest. 2020 Jun 1;130(6):3151-3157. doi: 10.1172/JCI133159.
PMID: 32155135
Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank.
Seltzer JH, Farrell A, Goldenberg N, Hornik C, Keene D, Krucoff MW, Lipardi C, Massicotte P, Mentzer D, Monagle P, Thornburg C, Revkin JH, Walker S, Gajjar D.
Am Heart J. 2020 Jun;224:138-147. doi: 10.1016/j.ahj.2020.02.012. Epub 2020 Feb 28.
PMID: 32388153
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma.
Hemstock M, Amadi A, Kupas K, Roskell N, Kotapati S, Gooden K, Middleton MR, Schadendorf D.
Eur J Cancer. 2020 Jun;132:176-186. doi: 10.1016/j.ejca.2020.03.011. Epub 2020 May 4.
PMID: 32380428
New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.
Pavlos R, Deshpande P, Chopra A, Leary S, Strautins K, Nolan D, Thorborn D, Shaefer M, Rauch A, Dunn D, Montaner J, Rachlis A, Almeida CA, Choo L, James I, Redwood AJ, Li Y, Gaudieri S, Mallal SA, Phillips EJ.
Hum Immunol. 2020 Jun;81(6):300-304. doi: 10.1016/j.humimm.2020.02.011. Epub 2020 Mar 12.
PMID: 32173028
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Sunami K, Matsue K, Suzuki K, Takezako N, Shinagawa A, Sakurai S, Tamakoshi H, Biyukov T, Peluso T, Richardson P.
Cancer Sci. 2020 Jun;111(6):2116-2122. doi: 10.1111/cas.14415. Epub 2020 May 13.
PMID: 32297407
A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach.
Wang X, Chen J, Reyes J, Zhou S, Palmisano M, Li Y.
Oncol Ther. 2020 Jun;8(1):91-102. doi: 10.1007/s40487-019-0097-7. Epub 2019 Jul 19.
PMID: 32700065
Software-aided detection and structural characterization of cyclic peptide metabolites in biological matrix by high-resolution mass spectrometry.
Yao M, Cai T, Duchoslav E, Ma L, Guo X, Zhu M.
J Pharm Anal. 2020 Jun;10(3):240-246. doi: 10.1016/j.jpha.2020.05.012. Epub 2020 May 26.
PMID: 32612870
Current status and future directions of high-throughput ADME screening in drug discovery.
Shou WZ.
J Pharm Anal. 2020 Jun;10(3):201-208. doi: 10.1016/j.jpha.2020.05.004. Epub 2020 May 23.
PMID: 32612866
Developing Biotherapeutics in the New Decade.
Meng WS, Sahin E, Wen Y.
J Pharm Innov. 2020 Jun;15(2):201. doi: 10.1007/s12247-020-09454-0. Epub 2020 May 29.
PMID: 32582399
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J.
J Immunother Cancer. 2020 Jun;8(1):e000842. doi: 10.1136/jitc-2020-000842. Epub 2020 Jun 23.
PMID: 32581042
Recommendations for singlet-based approach in ligand binding assays: an IQ Consortium perspective.
Pillutla R, Gorovits B, Gleason C, Quiroz J, Christopher D, Braun M, Brockus C, Donaldson D, Haslberger T, He L, Qian M, Sydor J, Wickremsinhe E, Williams L.
Bioanalysis. 2020 Jun;12(12):823-834. doi: 10.4155/bio-2020-0094. Epub 2020 Jun 19.
PMID: 32558588
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, Lebbé C, Svane IM, McNeil C, Rutkowski P, Loquai C, Mortier L, Hamid O, Bastholt L, Dreno B, Schadendorf D, Garbe C, Nyakas M, Grob JJ, Thomas L, Liszkay G, Smylie M, Hoeller C, Ferraresi V, Grange F, Gutzmer R, Pikiel J, Hosein F, Simsek B, Maio M.
J Immunother Cancer. 2020 Jun;8(1):e000391. doi: 10.1136/jitc-2019-000391.
PMID: 32503946
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK.
Nat Med. 2020 Jun;26(6):909-918. doi: 10.1038/s41591-020-0839-y. Epub 2020 May 29.
PMID: 32472114
Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
Ogasawara K, Smith WB, Xu C, Yin J, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2020 Jun;85(6):1109-1117. doi: 10.1007/s00280-020-04084-2. Epub 2020 May 24.
PMID: 32449142
Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept (ORENCIA) patient alert cards in patients with rheumatoid arthritis.
Artime E, Kahlon R, Méndez I, Kou T, Garrido-Estepa M, Qizilbash N.
Pharmacoepidemiol Drug Saf. 2020 Jun;29(6):664-674. doi: 10.1002/pds.5012. Epub 2020 May 12.
PMID: 32394485
Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants.
Allan V, Ramagopalan SV, Mardekian J, Jenkins A, Li X, Pan X, Luo X.
J Comp Eff Res. 2020 Jun;9(9):603-614. doi: 10.2217/cer-2020-0013. Epub 2020 Mar 18.
PMID: 32186922
Inoculum size and traits of the infecting clinical strain define the protection level against Mycobacterium tuberculosis infection in a rabbit model.
Tsenova L, Fallows D, Kolloli A, Singh P, O'Brien P, Kushner N, Kaplan G, Subbian S.
Eur J Immunol. 2020 Jun;50(6):858-872. doi: 10.1002/eji.201948448. Epub 2020 Mar 20.
PMID: 32130727
Prevalence of Sjögren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry.
Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED.
Clin Rheumatol. 2020 Jun;39(6):1899-1905. doi: 10.1007/s10067-020-05004-8. Epub 2020 Mar 4.
PMID: 32130579
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA.
Am J Hematol. 2020 Jun;95(6):594-603. doi: 10.1002/ajh.25777. Epub 2020 Apr 17.
PMID: 32129512
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.
Prior H, Baldrick P, Beken S, Booler H, Bower N, Brooker P, Brown P, Burlinson B, Burns-Naas LA, Casey W, Chapman M, Clarke D, de Haan L, Doehr O, Downes N, Flaherty M, Gellatly N, Moesgaard SG, Harris J, Holbrook M, Hui J, Jones D, Jones K, Kedar H, Mahl A, Manninen A, McGuire A, Mortimer-Cassen E, Peraza M, Pugsley MK, Richard J, Roberts R, Roosen W, Rothfuss A, Schoenmakers A, Sewell F, Weaver R, Weir L, Wolfreys A, Kimber I.
Regul Toxicol Pharmacol. 2020 Jun;113:104624. doi: 10.1016/j.yrtph.2020.104624. Epub 2020 Feb 29.
PMID: 32126256
Scientific Regulatory Policy Committee Points to Consider*: Nuisance Factors, Block Effects, and Batch Effects in Nonclinical Safety Assessment Studies.
Schultze AE, Bennet B, Rae JC, Chiang AY, Frazier K, Katavolos P, McKinney L, Patrick DJ, Tripathi N.
Toxicol Pathol. 2020 Jun;48(4):537-548. doi: 10.1177/0192623320906385. Epub 2020 Mar 3.
PMID: 32122253
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Roussel M, Hebraud B, Hulin C, Perrot A, Caillot D, Stoppa AM, Macro M, Escoffre M, Arnulf B, Belhadj K, Karlin L, Garderet L, Facon T, Guo S, Weng J, Dhanasiri S, Leleu X, Moreau P, Attal M.
Leuk Lymphoma. 2020 Jun;61(6):1323-1333. doi: 10.1080/10428194.2020.1719091. Epub 2020 Feb 22.
PMID: 32090636
A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
Park SH, Han X, Lobo F, Kratochvil D, Patel D.
J Med Econ. 2020 Jun;23(6):624-630. doi: 10.1080/13696998.2020.1732991. Epub 2020 May 19.
PMID: 32075453
Infections in patients diagnosed with multiple sclerosis: A multi-database study.
Persson R, Lee S, Ulcickas Yood M, Wagner Usn Mc CM, Minton N, Niemcryk S, Lindholm A, Evans AM, Jick SS.
Mult Scler Relat Disord. 2020 Jun;41:101982. doi: 10.1016/j.msard.2020.101982. Epub 2020 Feb 4.
PMID: 32070858
Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Santini V, Almeida A, Giagounidis A, Skikne B, Beach CL, Weaver J, Tu N, Fenaux P.
Leuk Lymphoma. 2020 Jun;61(6):1475-1483. doi: 10.1080/10428194.2020.1719088. Epub 2020 Feb 17.
PMID: 32064987
Cell-Based In Vitro Assay Automation: Balancing Technology and Data Reproducibility/Predictability.
Thomas-Fowlkes B, Cifelli S, Souza S, Visconti R, Struck A, Weinglass A, Wildey MJ.
SLAS Technol. 2020 Jun;25(3):276-285. doi: 10.1177/2472630320902095. Epub 2020 Jan 31.
PMID: 32003291
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Vilsbøll T, Ekholm E, Johnsson E, Garcia-Sanchez R, Dronamraju N, Jabbour SA, Lind M.
Diabetes Obes Metab. 2020 Jun;22(6):957-968. doi: 10.1111/dom.13981. Epub 2020 Feb 23.
PMID: 32003150
The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life.
Park R, Shaw JW, Korn A, McAuliffe J.
J Cancer Surviv. 2020 Jun;14(3):363-376. doi: 10.1007/s11764-020-00853-3. Epub 2020 Jan 16.
PMID: 31950409
Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.
Hopson MB, Onishi M, Awad D, Buono D, Maurer M, Crew KD, Shane E, Hershman DL, Kalinsky K.
Clin Breast Cancer. 2020 Jun;20(3):e327-e333. doi: 10.1016/j.clbc.2019.12.001. Epub 2019 Dec 5.
PMID: 31926840
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A, McInnes I, Queiro R, Guerette B, Brunori M, Teng L, Smolen JS.
Arthritis Care Res (Hoboken). 2020 Jun;72(6):814-821. doi: 10.1002/acr.24134. Epub 2020 May 8.
PMID: 31909868
Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials.
Purnajo I, Beaumont JL, Polinsky M, Alemao E, Everly MJ.
Am J Transplant. 2020 Jun;20(6):1650-1658. doi: 10.1111/ajt.15757. Epub 2020 Jan 11.
PMID: 31874117
Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells.
Cerchio R Jr, Marinaro C, Foo TK, Xia B, Chen S.
Melanoma Res. 2020 Jun;30(3):303-308. doi: 10.1097/CMR.0000000000000652.
PMID: 31855905
Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection.
Batteson R, Hart R, Hemstock M, Gooden K, Kotapati S, Roze S, Lee D, Amadi A.
Pharmacoecon Open. 2020 Jun;4(2):343-351. doi: 10.1007/s41669-019-00181-y.
PMID: 31587138
Hepatocyte spheroids as a viable  in vitro  model for recapitulation of complex  in vivo  metabolism pathways of loratadine in humans.
Chacko SA, Ly VT, Christopher LJ, Gan J.
Xenobiotica. 2020 Jun;50(6):621-629. doi: 10.1080/00498254.2019.1675100. Epub 2019 Oct 10.
PMID: 31566996
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.
Alemao E, Postema R, Elbez Y, Mamane C, Finckh A.
Clin Exp Rheumatol. 2020 May-Jun;38(3):455-466. Epub 2019 Nov 16.
PMID: 31770089
Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
Bogdanffy MS, Lesniak J, Mangipudy R, Sistare FD, Colman K, Garcia-Tapia D, Monticello T, Blanset D.
Int J Toxicol. 2020 May/Jun;39(3):198-206. doi: 10.1177/1091581820919896. Epub 2020 May 6.
PMID: 32372678
Practical Applications of Biofluorescent Particle Counting in Environmental Monitoring Investigations.
Prasad A, Milling A, Hauschild J, Ruh AC, Horsch J, Weber J, Yan L, Plourde L, Claassen M, Villari P, IJzerman-Boon P, Forng RY, Henry RB, Portmann R, Shereefa S, Urwyler S, Dassu D.
PDA J Pharm Sci Technol. 2020 May-Jun;74(3):318-323. doi: 10.5731/pdajpst.2019.009969. Epub 2019 Dec 16.
PMID: 31843986
Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study.
Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Fusco MD, Garcia Reeves AB, Yuce H, Lip GYH.
J Clin Med. 2020 May 28;9(6):1633. doi: 10.3390/jcm9061633.
PMID: 32481607
Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting.
Lang KM, Harrison KL, Williamson PR, Huntly BJP, Ossenkoppele G, Geissler J, Bereczky T, Hernández-Rivas JM, Chevrou-Séverac H, Goodbody R, Schulze-Rath R, Bullinger L.
Trials. 2020 May 27;21(1):437. doi: 10.1186/s13063-020-04384-1.
PMID: 32460828
Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
Li Y, Kassir N, Chen N, Wang X, Palmisano M, Zhou S.
Clin Pharmacol Drug Dev. 2020 May 27. doi: 10.1002/cpdd.803. Online ahead of print.
PMID: 32459889
Sesquiterpenoids from Cultures of the Basidiomycetes  Irpex lacteus .
Wang M, Du JX, Hui-Xiang Y, Dai Q, Liu YP, He J, Wang Y, Li ZH, Feng T, Liu JK.
J Nat Prod. 2020 May 22;83(5):1524-1531. doi: 10.1021/acs.jnatprod.9b01177. Epub 2020 Apr 21.
PMID: 32315183
Nucleophilic (Radio)Fluorination of Redox-Active Esters via Radical-Polar Crossover Enabled by Photoredox Catalysis.
Webb EW, Park JB, Cole EL, Donnelly DJ, Bonacorsi SJ, Ewing WR, Doyle AG.
J Am Chem Soc. 2020 May 20;142(20):9493-9500. doi: 10.1021/jacs.0c03125. Epub 2020 May 7.
PMID: 32378889
Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment.
MacEwan JP, Gupte-Singh K, Zhao LM, Reckamp KL.
MDM Policy Pract. 2020 May 21;5(1):2381468320922208. doi: 10.1177/2381468320922208. eCollection 2020 Jan-Jun.
PMID: 32548305
Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan.
Tahara M, Doi I, Murata T, Mishina S, Takai S, Kaneko H.
J Health Econ Outcomes Res. 2020 May 20;7(1):43-51. doi: 10.36469/jheor.2020.12853. eCollection 2020.
PMID: 32685597
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, McCanna S, Butler B, Ruffini PA, Liu Y, Rosato RR, Chang JC.
Breast Cancer Res. 2020 May 20;22(1):52. doi: 10.1186/s13058-020-01294-7.
PMID: 32434589
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.
Teijeira Á, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria I, Andueza MP, Nieto CP, Resano L, Azpilikueta A, Allegretti M, de Pizzol M, Ponz-Sarvisé M, Rouzaut A, Sanmamed MF, Schalper K, Carleton M, Mellado M, Rodriguez-Ruiz ME, Berraondo P, Perez-Gracia JL, Melero I.
Immunity. 2020 May 19;52(5):856-871.e8. doi: 10.1016/j.immuni.2020.03.001. Epub 2020 Apr 13.
PMID: 32289253
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, Aronson R, Windecker S, Mehran R, Lopes RD.
Circulation. 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29.
PMID: 32223444
Rapid and cost-effective LC-MS/MS method for determination of hydroxycitric acid in plasma: Application in the determination of pharmacokinetics in commercial Garcinia preparations.
Bhutani P, U R, H N S, Ranjanna PK, Paul AT.
Biomed Chromatogr. 2020 May 19:e4902. doi: 10.1002/bmc.4902. Online ahead of print.
PMID: 32428251
Costs and Cost Drivers of Providing Option B+ Services to Mother-Baby Pairs for PMTCT of HIV in Health Centre IV Facilities in Jinja District, Uganda.
Mukose AD, Kebede S, Muhumuza C, Makumbi F, Komakech H, Bayiga E, Busobozi D, Musinguzi J, Kuznik A, Stegman P, Forsythe S, Kagaayi J.
Biomed Res Int. 2020 May 18;2020:2875864. doi: 10.1155/2020/2875864. eCollection 2020.
PMID: 32550228
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Vogelzang NJ, Olsen MR, McFarlane JJ, Arrowsmith E, Bauer TM, Jain RK, Somer B, Lam ET, Kochenderfer MD, Molina A, Doshi G, Lingerfelt B, Hauke RJ, Gunuganti V, Schnadig I, Van Veldhuizen P, Fleming M, Galamaga R, Gupta M, Hool H, Hutson T, Zhang J, McHenry MB, Johansen JL, Tykodi SS.
Clin Genitourin Cancer. 2020 May 16:S1558-7673(20)30104-X. doi: 10.1016/j.clgc.2020.05.006. Online ahead of print.
PMID: 32718906
Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden.
Qing T, Mohsen H, Marczyk M, Ye Y, O'Meara T, Zhao H, Townsend JP, Gerstein M, Hatzis C, Kluger Y, Pusztai L.
Nat Commun. 2020 May 15;11(1):2438. doi: 10.1038/s41467-020-16293-7.
PMID: 32415133
Ligand-Enabled Pd(II)-Catalyzed C(sp 3 )-H Lactonization Using Molecular Oxygen as Oxidant.
Qian S, Li ZQ, Li M, Wisniewski SR, Qiao JX, Richter JM, Ewing WR, Eastgate MD, Chen JS, Yu JQ.
Org Lett. 2020 May 15;22(10):3960-3963. doi: 10.1021/acs.orglett.0c01243. Epub 2020 Apr 24.
PMID: 32330054
Corrigendum to "A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm" [Toxicology and Applied Pharmacology volume 394C (2020) 114961].
Ridder BJ, Leishman DJ, Bridgland-Taylor M, Samieegohar M, Han X, Wu WW, Randolph A, Tran P, Sheng J, Danker T, Lindqvist A, Konrad D, Hebeisen S, Polonchuk L, Gissinger E, Renganathan M, Koci B, Wei H, Fan J, Levesque P, Kwagh J, Imredy J, Zhai J, Rogers M, Humphries E, Kirby R, Stoelzle-Feix S, Brinkwirth N, Rotordam MG, Becker N, Friis S, Rapedius M, Goetze TA, Strassmaier T, Okeyo G, Kramer J, Kuryshev Y, Wu C, Himmel H, Mirams GR, Strauss DG, Bardenet R, Li Z.
Toxicol Appl Pharmacol. 2020 May 15;395:114983. doi: 10.1016/j.taap.2020.114983. Epub 2020 Apr 2.
PMID: 32247767
BRAF  and  DIS3  Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, Rosenthal A, Sawyer J, Tian E, Flynt E, Hoering A, Johnson SK, Rutherford MW, Wardell CP, Bauer MA, Dumontet C, Facon T, Thanendrarajan S, Schinke CD, Zangari M, van Rhee F, Barlogie B, Cairns D, Jackson G, Thakurta A, Davies FE, Morgan GJ, Walker BA.
Clin Cancer Res. 2020 May 15;26(10):2422-2432. doi: 10.1158/1078-0432.CCR-19-1507. Epub 2020 Jan 27.
PMID: 31988198
Rapid Compound Integrity Assessment for High-Throughput Screening Hit Triaging.
Shou WZ, Gerritz SW, Harden D, Lawrence RM, Chase P, Chin J, Surti N, Lippy JS, Weller HN, Nielsen J, Weerakoon D.
SLAS Discov. 2020 May 13:2472555220919097. doi: 10.1177/2472555220919097. Online ahead of print.
PMID: 32400264
Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?
Justo N, Nilsson J, Korytowsky B, Dalen J, Madison T, McGuire A.
PLoS One. 2020 May 12;15(5):e0232669. doi: 10.1371/journal.pone.0232669. eCollection 2020.
PMID: 32396541
Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma.
Kamal M, Wang XS, Shi Q, Zyczynski TM, Davis C, Williams LA, Lin HK, Garcia-Gonzalez A, Cleeland CS, Orlowski R.
Support Care Cancer. 2020 May 11. doi: 10.1007/s00520-020-05493-y. Online ahead of print.
PMID: 32390093
Pharmacological inhibition of RORC2 enhances human Th17-Treg stability and function.
Boardman DA, Garcia RV, Ivison SM, Bressler B, Dhar TM, Zhao Q, Levings MK.
Eur J Immunol. 2020 May 10. doi: 10.1002/eji.201948435. Online ahead of print.
PMID: 32388860
Bridging size and charge variants of a therapeutic monoclonal antibody by two-dimensional liquid chromatography.
Chen Z, Zeng M, Park SJ, Balakrishnan G, Zhou K, Pan D, Das TK.
J Pharm Biomed Anal. 2020 May 10;183:113178. doi: 10.1016/j.jpba.2020.113178. Epub 2020 Feb 14.
PMID: 32086124
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, Yeung CCS, Sheih A, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Shadman M, Riddell SR, Maloney DG, Turtle CJ.
Blood. 2020 May 7;135(19):1650-1660. doi: 10.1182/blood.2019002936.
PMID: 32076701
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Talamo G, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Reece D, Pierceall WE, Chung W, Zafar F, Agarwal A, Bahlis NJ.
Leukemia. 2020 May 6. doi: 10.1038/s41375-020-0813-1. Online ahead of print.
PMID: 32376855
Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma.
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C.
Clinicoecon Outcomes Res. 2020 May 6;12:241-252. doi: 10.2147/CEOR.S238725. eCollection 2020.
PMID: 32440174
Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.
Chirinos JA, Zhao L, Jia Y, Frej C, Adamo L, Mann D, Shewale SV, Millar JS, Rader DJ, French B, Brandimarto J, Margulies KB, Parks JS, Wang Z, Seiffert DA, Fang J, Sweitzer N, Chistoffersen C, Dahlbäck B, Car BD, Gordon DA, Cappola TP, Javaheri A.
Circulation. 2020 May 5;141(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.045323. Epub 2020 Apr 2.
PMID: 32237898
Ni(COD)(DQ): An Air-Stable 18-Electron Nickel(0)-Olefin Precatalyst.
Tran VT, Li ZQ, Apolinar O, Derosa J, Joannou MV, Wisniewski SR, Eastgate MD, Engle KM.
Angew Chem Int Ed Engl. 2020 May 4;59(19):7409-7413. doi: 10.1002/anie.202000124. Epub 2020 Mar 18.
PMID: 32065839
Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals.
Mei H, Han J, White S, Graham DJ, Izawa K, Sato T, Fustero S, Meanwell NA, Soloshonok VA.
Chemistry. 2020 May 2. doi: 10.1002/chem.202000617. Online ahead of print.
PMID: 32359086
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm.
Ridder BJ, Leishman DJ, Bridgland-Taylor M, Samieegohar M, Han X, Wu WW, Randolph A, Tran P, Sheng J, Danker T, Lindqvist A, Konrad D, Hebeisen S, Polonchuk L, Gissinger E, Renganathan M, Koci B, Wei H, Fan J, Levesque P, Kwagh J, Imredy J, Zhai J, Rogers M, Humphries E, Kirby R, Stoelzle-Feix S, Brinkwirth N, Rotordam MG, Becker N, Friis S, Rapedius M, Goetze TA, Strassmaier T, Okeyo G, Kramer J, Kuryshev Y, Wu C, Himmel H, Mirams GR, Strauss DG, Bardenet R, Li Z.
Toxicol Appl Pharmacol. 2020 May 1;394:114961. doi: 10.1016/j.taap.2020.114961. Epub 2020 Mar 21.
PMID: 32209365
Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
Dercle L, Fronheiser M, Lu L, Du S, Hayes W, Leung DK, Roy A, Wilkerson J, Guo P, Fojo AT, Schwartz LH, Zhao B.
Clin Cancer Res. 2020 May 1;26(9):2151-2162. doi: 10.1158/1078-0432.CCR-19-2942. Epub 2020 Mar 20.
PMID: 32198149
Response to "Letter to the Editor concerning: 'A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants'".
Cohen AT, Hill NR, Luo X, Masseria C, Abariga SA, Ashaye AO.
Int J Cardiol. 2020 May 1;306:101. doi: 10.1016/j.ijcard.2019.11.141. Epub 2019 Nov 28.
PMID: 31898985
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.
Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Sanmamed MF, Melero I.
Nat Med. 2020 May;26(5):688-692. doi: 10.1038/s41591-020-0856-x. Epub 2020 May 11.
PMID: 32405062
Challenges and recommendations in developing LC-MS/MS bioanalytical assays of labile glucuronides and parent compounds in the presence of glucuronide metabolites.
Yuan L, Sophia Xu X, Ji QC.
Bioanalysis. 2020 May;12(9):615-624. doi: 10.4155/bio-2020-0055. Epub 2020 May 22.
PMID: 32441529
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB; Society for Immunotherapy of Cancer (SITC) Pathology Task Force.
J Immunother Cancer. 2020 May;8(1):e000155. doi: 10.1136/jitc-2019-000155.
PMID: 32414858
MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma.
Jaimes C, Vajapeyam S, Brown D, Kao PC, Ma C, Greenspan L, Gupta N, Goumnerova L, Bandopahayay P, Dubois F, Greenwald NF, Zack T, Shapira O, Beroukhim R, Ligon KL, Chi S, Kieran MW, Wright KD, Poussaint TY.
AJNR Am J Neuroradiol. 2020 May;41(5):874-881. doi: 10.3174/ajnr.A6546. Epub 2020 May 7.
PMID: 32381545
Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus.
Lip GYH, Keshishian AV, Kang AL, Li X, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Nadkarni A, Pan X, Di Fusco M, Garcia Reeves AB, Yuce H, Deitelzweig SB.
Mayo Clin Proc. 2020 May;95(5):929-943. doi: 10.1016/j.mayocp.2019.05.032.
PMID: 32370854
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L.
J Manag Care Spec Pharm. 2020 May;26(5):639-651. doi: 10.18553/jmcp.2020.26.5.639.
PMID: 32347184
Viral contamination in biologic manufacture and implications for emerging therapies.
Barone PW, Wiebe ME, Leung JC, Hussein ITM, Keumurian FJ, Bouressa J, Brussel A, Chen D, Chong M, Dehghani H, Gerentes L, Gilbert J, Gold D, Kiss R, Kreil TR, Labatut R, Li Y, Müllberg J, Mallet L, Menzel C, Moody M, Monpoeho S, Murphy M, Plavsic M, Roth NJ, Roush D, Ruffing M, Schicho R, Snyder R, Stark D, Zhang C, Wolfrum J, Sinskey AJ, Springs SL.
Nat Biotechnol. 2020 May;38(5):563-572. doi: 10.1038/s41587-020-0507-2. Epub 2020 Apr 27.
PMID: 32341561
A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2020 May;85(5):995-1001. doi: 10.1007/s00280-020-04074-4. Epub 2020 Apr 22.
PMID: 32318809
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G.
Cancer Chemother Pharmacol. 2020 May;85(5):899-906. doi: 10.1007/s00280-020-04067-3. Epub 2020 Apr 4.
PMID: 32248324
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.
Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T.
Cancer Chemother Pharmacol. 2020 May;85(5):1009-1010. doi: 10.1007/s00280-020-04056-6.
PMID: 32215699
Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.
George MD, Baker JF, Winthrop KL, Goldstein SD, Alemao E, Chen L, Wu Q, Xie F, Curtis JR.
Ann Rheum Dis. 2020 May;79(5):573-580. doi: 10.1136/annrheumdis-2019-216802. Epub 2020 Mar 24.
PMID: 32209540
Accelerating the development of innovative cellular therapy products for the treatment of cancer.
Stewart MD, Keane A, Butterfield LH, Levine BL, Thompson B, Xu Y, Ramsborg C, Lee A, Kalos M, Koerner C, Moore T, Markovic I, Lasiter L, Ibrahim R, Bluestone J, Sigal E, Allen J.
Cytotherapy. 2020 May;22(5):239-246. doi: 10.1016/j.jcyt.2020.01.014. Epub 2020 Mar 18.
PMID: 32199724
Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus.
Heijke R, Björk M, Frodlund M, McDonald L, Alemao E, Sjöwall C.
Lupus. 2020 May;29(6):625-630. doi: 10.1177/0961203320912338. Epub 2020 Mar 18.
PMID: 32188304
Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis.
Mole S, Faizo AAA, Hernandez-Lopez H, Griffiths M, Stevenson A, Roberts S, Graham SV.
J Gen Virol. 2020 May;101(5):523-532. doi: 10.1099/jgv.0.001402. Epub 2020 Mar 13.
PMID: 32182205
Approaches for the identification of chronic kidney disease in CPRD-HES-linked studies.
Ramagopalan S, Leahy TP, Stamp E, Sammon C.
J Comp Eff Res. 2020 May;9(7):441-446. doi: 10.2217/cer-2019-0190. Epub 2020 Mar 9.
PMID: 32148084
Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.
Jagannath S, Rifkin RM, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Wagner L, Narang M, Ailawadhi S, Omel JL, Srinivasan S, He M, Ung B, Kitali A, Flick ED, Agarwal A, Abonour R; CONNECT MM Registry Investigators.
Clin Lymphoma Myeloma Leuk. 2020 May;20(5):272-276. doi: 10.1016/j.clml.2019.10.002. Epub 2019 Oct 14.
PMID: 32144027
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR.
Adv Ther. 2020 May;37(5):2098-2115. doi: 10.1007/s12325-020-01262-9. Epub 2020 Mar 5.
PMID: 32141018
Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress.
Huizinga TW, Holers VM, Anolik J, Brenner MB, Buckley CD, Bykerk V, Connolly SE, Deane KD, Guo J, Hodge M, Hoffmann S, Nestle F, Pitzalis C, Raychaudhuri S, Yamamoto K, Li Z, Klareskog L.
Ann Rheum Dis. 2020 May;79(5):553-555. doi: 10.1136/annrheumdis-2019-216846. Epub 2020 Mar 5.
PMID: 32139419
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R.
Am J Hematol. 2020 May;95(5):510-520. doi: 10.1002/ajh.25757. Epub 2020 Feb 29.
PMID: 32052473
Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.
Stauder R, Lambert J, Desruol-Allardin S, Savre I, Gaugler L, Stojkov I, Siebert U, Chevrou-Séverac H.
Eur J Haematol. 2020 May;104(5):476-487. doi: 10.1111/ejh.13389. Epub 2020 Mar 3.
PMID: 31985078
A novel approach enables imaged capillary isoelectric focusing analysis of PEGylated proteins.
Zhang X, Chemmalil L, Ding J, Li Z.
Electrophoresis. 2020 May;41(9):735-742. doi: 10.1002/elps.201900406. Epub 2020 Feb 3.
PMID: 31967659
Effective temperature shift strategy development and scale confirmation for simultaneous optimization of protein productivity and quality in Chinese hamster ovary cells.
McHugh KP, Xu J, Aron KL, Borys MC, Li ZJ.
Biotechnol Prog. 2020 May;36(3):e2959. doi: 10.1002/btpr.2959. Epub 2020 Jan 17.
PMID: 31930722
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R, Cohen EEW, Venkatachalam M, Young K, Singh P, Shaw JW, Korytowsky B, Abraham P, Harrington KJ.
J Med Econ. 2020 May;23(5):442-447. doi: 10.1080/13696998.2020.1715414. Epub 2020 Jan 29.
PMID: 31928375
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS, Johnstone TG, Baturevych A, Hause RJ, Ragan SP, Clouser CR, Jones JC, Ponce R, Krejsa CM, Salmon RA, Ports MO.
J Immunother. 2020 May;43(4):107-120. doi: 10.1097/CJI.0000000000000307.
PMID: 31899702
Covariate adjustment for randomized controlled trials revisited.
Wang J.
Pharm Stat. 2020 May;19(3):255-261. doi: 10.1002/pst.1988. Epub 2019 Dec 21.
PMID: 31863636
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, DʼHaens G.
Am J Gastroenterol. 2020 May;115(5):738-745. doi: 10.14309/ajg.0000000000000493.
PMID: 31850931
Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells.
Dhanasiri S.
Bone Marrow Transplant. 2020 May;55(5):987-988. doi: 10.1038/s41409-019-0749-0. Epub 2019 Nov 21.
PMID: 31754250
Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy.
Mashiko S, Edelmayer RM, Bi Y, Olson LM, Wetter JB, Wang J, Maari C, Saint-Cyr Proulx E, Kaimal V, Li X, Salte K, Garcet S, Kannan AK, Huang SM, Cao X, Liu Z, Krueger JG, Sarfati M, Bissonnette R, Smith KM.
J Invest Dermatol. 2020 May;140(5):1015-1025.e4. doi: 10.1016/j.jid.2019.09.027. Epub 2019 Nov 9.
PMID: 31715177
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
Taskar KS, Pilla Reddy V, Burt H, Posada MM, Varma M, Zheng M, Ullah M, Emami Riedmaier A, Umehara KI, Snoeys J, Nakakariya M, Chu X, Beneton M, Chen Y, Huth F, Narayanan R, Mukherjee D, Dixit V, Sugiyama Y, Neuhoff S.
Clin Pharmacol Ther. 2020 May;107(5):1082-1115. doi: 10.1002/cpt.1693. Epub 2019 Dec 31.
PMID: 31628859
Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.
Kanagala P, Arnold JR, Singh A, Chan DCS, Cheng ASH, Khan JN, Gulsin GS, Yang J, Zhao L, Gupta P, Squire IB, Ng LL, McCann GP.
PLoS One. 2020 Apr 29;15(4):e0232280. doi: 10.1371/journal.pone.0232280. eCollection 2020.
PMID: 32349122
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB.
Circulation. 2020 Apr 28;141(17):1384-1392. doi: 10.1161/CIRCULATIONAHA.119.044059. Epub 2020 Mar 12.
PMID: 32160801
Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States.
Deitelzweig S, Baker CL, Dhamane AD, Mardekian J, Dina O, Rosenblatt L, Russ C, Poretta T, Lingohr-Smith M, Lin J.
J Drug Assess. 2020 Apr 24;9(1):87-96. doi: 10.1080/21556660.2020.1750418. eCollection 2020.
PMID: 32489717
Nickel/Photoredox-Catalyzed Methylation of (Hetero)aryl Chlorides Using Trimethyl Orthoformate as a Methyl Radical Source.
Kariofillis SK, Shields BJ, Tekle-Smith MA, Zacuto MJ, Doyle AG.
J Am Chem Soc. 2020 Apr 22;142(16):7683-7689. doi: 10.1021/jacs.0c02805. Epub 2020 Apr 10.
PMID: 32275411
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Roper N, Brown AL, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, El Meskini R, Ohler ZW, Maity TK, Venugopalan A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Panchenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U.
Cell Rep Med. 2020 Apr 21;1(1):100007. doi: 10.1016/j.xcrm.2020.100007.
PMID: 32483558
Characterization of BAY 1905254, an immune checkpoint inhibitor targeting the immunoglobulin-like domain containing receptor 2 (ILDR2).
Huetter J, Gritzan U, Gutcher I, Doecke WD, Luetke-Eversloh MV, Golfier S, Roider HG, Frisk AL, Hunter J, Pow A, Drake A, Levine Z, Levy O, Azulay M, Barbiro I, Cojocaru G, Vaknin I, Kreft B, Roese L.
Cancer Immunol Res. 2020 Apr 20. pii: canimm.0321.2019. doi: 10.1158/2326-6066.CIR-19-0321. [Epub ahead of print]
PMID: 32312711
Comparative efficacy and safety of current therapies for early rheumatoid arthritis: a systematic literature review and network meta-analysis.
Paul D, Fazeli MS, Mintzer L, Duarte L, Gupta K, Ferri L.
Clin Exp Rheumatol. 2020 Apr 17. [Epub ahead of print] Review.
PMID: 32301430
Is aspirin a substrate of MDR1/P-glycoprotein?
Singh R, Naik T, Nigam A, Chatterjee S, Rajanna P, Shen H, Iyer R.
Xenobiotica. 2020 Apr 17:1-26. doi: 10.1080/00498254.2020.1757785. [Epub ahead of print]
PMID: 32302241
High-Throughput Platform to Identify Antibody Conjugation Sites from Antibody-Drug Conjugate Libraries.
Yamazoe S, Hogan JM, West SM, Deng XA, Kotapati S, Shao X, Holder P, Lamba V, Huber M, Qiang C, Gangwar S, Rao C, Dollinger G, Rajpal A, Strop P.
Bioconjug Chem. 2020 Apr 15;31(4):1199-1208. doi: 10.1021/acs.bioconjchem.0c00146. Epub 2020 Mar 27.
PMID: 32178516
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, de Mingo Pulido A, Mandula J, Zhang S, Thevenot P, Biswas S, Abdalla SK, Costich TL, Hänggi K, Anadon CM, Flores ER, Haura EB, Mehrotra S, Pilon-Thomas S, Ruffell B, Munn DH, Cubillos-Ruiz JR, Conejo-Garcia JR, Rodriguez PC.
Immunity. 2020 Apr 14;52(4):668-682.e7. doi: 10.1016/j.immuni.2020.03.004.
PMID: 32294407
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.
Mato A, Nabhan C, Lamanna N, Kay NE, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Swern AS, Sullivan K, Flick ED, Gressett Ussery SM, Gharibo M, Kiselev P, Sharman JP.
Blood Adv. 2020 Apr 14;4(7):1407-1418. doi: 10.1182/bloodadvances.2019001145.
PMID: 32271900
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study.
Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Egenod T, Rabeau A, Fayette J, Sanchez ML, Labourey JL, Westeel V, Lamoureux P, Cotte FE, Allan V, Daumont M, Dumanoir J, Reynaud D, Calvet CY, Ozan N, Pérol M.
Oncoimmunology. 2020 Apr 12;9(1):1744898. doi: 10.1080/2162402X.2020.1744898.
PMID: 33457089
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Augustin M, Kleyn CE, Conrad C, Sator PG, Ståhle M, Eyerich K, Radtke MA, Bundy C, Mellars L, Greggio C, Cordey M, Koscielny V, Griffiths CEM.
J Eur Acad Dermatol Venereol. 2020 Apr 11. doi: 10.1111/jdv.16431. Online ahead of print.
PMID: 32279378
Macrofilaricides: An Unmet Medical Need for Filarial Diseases.
Hawryluk NA.
ACS Infect Dis. 2020 Apr 10;6(4):662-671. doi: 10.1021/acsinfecdis.9b00469. Epub 2020 Mar 5.
PMID: 32091199
An Improved P III /P V ═O-Catalyzed Reductive C-N Coupling of Nitroaromatics and Boronic Acids by Mechanistic Differentiation of Rate- and Product-Determining Steps.
Li G, Nykaza TV, Cooper JC, Ramirez A, Luzung MR, Radosevich AT.
J Am Chem Soc. 2020 Apr 8;142(14):6786-6799. doi: 10.1021/jacs.0c01666. Epub 2020 Mar 25.
PMID: 32178514
Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.
Saboo S, Kestur US, Flaherty DP, Taylor LS.
Mol Pharm. 2020 Apr 6;17(4):1261-1275. doi: 10.1021/acs.molpharmaceut.9b01272. Epub 2020 Mar 17.
PMID: 32134677
Investigation of Within-Tablet Dynamics for Extended Release of a Poorly Soluble Basic Drug from Hydrophilic Matrix Tablets Using ATR-FTIR Imaging.
Zahoor FD, Mader KT, Timmins P, Brown J, Sammon C.
Mol Pharm. 2020 Apr 6;17(4):1090-1099. doi: 10.1021/acs.molpharmaceut.9b01063. Epub 2020 Mar 2.
PMID: 32069060
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD.
Cancers (Basel). 2020 Apr 3;12(4):869. doi: 10.3390/cancers12040869.
PMID: 32260077
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S, Katada J, Saito K, Jenkins A, Li B, Mardekian J, Terayama Y.
Open Heart. 2020 Apr 1;7(1):e001232. doi: 10.1136/openhrt-2019-001232. eCollection 2020.
PMID: 32341789
Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC.
JAMA Netw Open. 2020 Apr 1;3(4):e202072. doi: 10.1001/jamanetworkopen.2020.2072.
PMID: 32250433
Circulating and tissue matricellular RNA and protein expression in calcific aortic valve disease.
Kossar AP, Anselmo W, Grau JB, Liu Y, Small A, Carter SL, Salvador L, Zhao L, Cvijic ME, Li Z, Yarde M, Rioux N, Rader DJ, Levy RJ, Ferrari G.
Physiol Genomics. 2020 Apr 1;52(4):191-199. doi: 10.1152/physiolgenomics.00104.2019. Epub 2020 Feb 24.
PMID: 32089075
Discovery and SAR of aryl hydroxy pyrimidinones as potent small molecule agonists of the GPCR APJ.
Myers MC, Bilder DM, Cavallaro CL, Chao HJ, Su S, Burford NT, Nayeem A, Wang T, Yan M, Langish RA, Dabros M, Li YX, Rose AV, Behnia K, Onorato JM, Gargalovic PS, Wexler RR, Lawrence RM.
Bioorg Med Chem Lett. 2020 Apr 1;30(7):126955. doi: 10.1016/j.bmcl.2020.126955. Epub 2020 Jan 22.
PMID: 32035698
Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.
Hudson M, Dell'Aniello S, Shen S, Simon TA, Ernst P,
Suissa S.Rheumatology (Oxford). 2020 Apr 1;59(4):820-827. doi: 10.1093/rheumatology/kez359.
PMID: 31504972
Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithm.
Hill NR, Sandler B, Mokgokong R, Lister S, Ward T, Boyce R, Farooqui U, Gordon J.
J Med Econ. 2020 Apr;23(4):386-393. doi: 10.1080/13696998.2019.1706543. Epub 2020 Jan 10.
PMID: 31855091
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Escudier B, Motzer RJ, Tannir NM, Porta C, Tomita Y, Maurer MA, McHenry MB, Rini BI.
Eur Urol. 2020 Apr;77(4):449-453. doi: 10.1016/j.eururo.2019.10.025. Epub 2019 Nov 13.
PMID: 31732098
A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.
Wang R, Shao X, Zheng J, Saci A, Qian X, Pak I, Roy A, Bello A, Rizzo JI, Hosein F, Moss RA, Wind-Rotolo M, Feng Y.
Clin Pharmacol Ther. 2020 Apr;107(4):978-987. doi: 10.1002/cpt.1724. Epub 2019 Dec 19.
PMID: 31721173
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, Couto S, Wang M, Ren Y, Ortiz M, Towfic F, Flynt JE, Pierceall W, Thakurta A.
Leukemia. 2020 Apr;34(4):1197-1201. doi: 10.1038/s41375-019-0620-8. Epub 2019 Nov 12.
PMID: 31719682
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B.
Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8.
PMID: 31702836
Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
Peichl P, Alten R, Galeazzi M, Lorenz HM, Nüßlein H, Navarro F, Elbez Y, Chartier M, Hackl R, Rauch C, Connolly SE.
Wien Med Wochenschr. 2020 Apr;170(5-6):132-140. doi: 10.1007/s10354-019-00710-8. Epub 2019 Oct 25.
PMID: 31654156
Microhomology-mediated end joining drives complex rearrangements and overexpression of  MYC  and  PVT1  in multiple myeloma.
Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, Ryan KR, Bauer MA, Wardell CP, Hoering A, Mavrommatis K, Trotter M, Deshpande S, Yaccoby S, Tian E, Keats J, Auclair D, Jackson GH, Davies FE, Thakurta A, Morgan GJ, Walker BA.
Haematologica. 2020 Apr;105(4):1055-1066. doi: 10.3324/haematol.2019.217927. Epub 2019 Jun 20.
PMID: 31221783
Fast understanding of phases and phase separation in liquid crystal drug delivery systems using deuterium solid-state NMR.
Abraham A, Chan E, Park H.
Solid State Nucl Magn Reson. 2020 Apr;106:101642. doi: 10.1016/j.ssnmr.2020.101642. Epub 2020 Jan 11.
PMID: 32035327
Strategies for method comparison when changes in the immunogenicity method are needed within a clinical program.
Mora JR, White JT, Chilewski SD, Qu Q, Stocker D, Luo L, Lavelle A.
Bioanalysis. 2020 Apr;12(7):431-443. doi: 10.4155/bio-2019-0300. Epub 2020 Apr 28.
PMID: 32343147
Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling.
Lee JB, Zhou S, Chiang M, Zang X, Kim TH, Kagan L.
Biopharm Drug Dispos. 2020 Apr;41(4-5):192-205. doi: 10.1002/bdd.2229. Epub 2020 May 16.
PMID: 32342986
STK11  and  KEAP1  mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.
Papillon-Cavanagh S, Doshi P, Dobrin R, Szustakowski J, Walsh AM.
ESMO Open. 2020 Apr;5(2):e000706. doi: 10.1136/esmoopen-2020-000706.
PMID: 32312757
The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants.
Singhal S, Girgis IG, Xie J, Dutta S, Shevell DE, Throup J.
Expert Opin Investig Drugs. 2020 Apr;29(4):411-422. doi: 10.1080/13543784.2020.1742322.
PMID: 32306792
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex.
Matyskiela ME, Clayton T, Zheng X, Mayne C, Tran E, Carpenter A, Pagarigan B, McDonald J, Rolfe M, Hamann LG, Lu G, Chamberlain PP.
Nat Struct Mol Biol. 2020 Apr;27(4):319-322. doi: 10.1038/s41594-020-0405-9. Epub 2020 Apr 6.
PMID: 32251415
Quality of life with second or third line  nab -paclitaxel-based regimens in advanced non-small-cell lung cancer.
Ponce Aix S, Talbot D, Govindan R, Dols MC, Postmus PE, Lewanski C, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Ong TJ, Morgensztern D.
Future Oncol. 2020 Apr;16(12):749-762. doi: 10.2217/fon-2019-0796. Epub 2020 Mar 31.
PMID: 32228198
Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection.
Schober K, Voit F, Grassmann S, Müller TR, Eggert J, Jarosch S, Weißbrich B, Hoffmann P, Borkner L, Nio E, Fanchi L, Clouser CR, Radhakrishnan A, Mihatsch L, Lückemeier P, Leube J, Dössinger G, Klein L, Neuenhahn M, Oduro JD, Cicin-Sain L, Buchholz VR, Busch DH.
Nat Immunol. 2020 Apr;21(4):434-441. doi: 10.1038/s41590-020-0628-2. Epub 2020 Mar 16.
PMID: 32205883
Late-stage oxidative C(sp 3 )-H methylation.
Feng K, Quevedo RE, Kohrt JT, Oderinde MS, Reilly U, White MC.
Nature. 2020 Apr;580(7805):621-627. doi: 10.1038/s41586-020-2137-8. Epub 2020 Mar 16.
PMID: 32179876
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM.
Lancet Haematol. 2020 Apr;7(4):e309-e319. doi: 10.1016/S2352-3026(19)30284-4. Epub 2020 Mar 5.
PMID: 32145771
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group.
J Pathol. 2020 Apr;250(5):667-684. doi: 10.1002/path.5406. Epub 2020 Apr 9.
PMID: 32129476
Nonindependence of patient data in the clinical practice research datalink: a case study in atrial fibrillation patients.
Sammon CJ, Leahy TP, Ramagopalan S.
J Comp Eff Res. 2020 Apr;9(6):395-403. doi: 10.2217/cer-2019-0191. Epub 2020 Feb 14.
PMID: 32056446
Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients.
Temrikar ZH, Suryawanshi S, Meibohm B.
Paediatr Drugs. 2020 Apr;22(2):199-216. doi: 10.1007/s40272-020-00382-7.
PMID: 32052309
Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase ® .
Vogel U, van Stekelenborg J, Dreyfus B, Garg A, Habib M, Hosain R, Wisniewski A.
Drug Saf. 2020 Apr;43(4):351-362. doi: 10.1007/s40264-019-00899-y.
PMID: 32020559
Collagen biology and non-invasive biomarkers of liver fibrosis.
Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.
Liver Int. 2020 Apr;40(4):736-750. doi: 10.1111/liv.14390. Epub 2020 Feb 19.
PMID: 31997561
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber RD, Piccart M, Mobus V, de Azambuja E; APHINITY Steering Committee and Investigators.
Clin Breast Cancer. 2020 Apr;20(2):174-181.e3. doi: 10.1016/j.clbc.2019.06.016. Epub 2019 Sep 5.
PMID: 31924513
A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
Grant TS, Burns D, Kiff C, Lee D.
Pharmacoeconomics. 2020 Apr;38(4):385-395. doi: 10.1007/s40273-019-00867-5.
PMID: 31848900
Risk Assessment Approach to Microbiological Controls of Cell Therapies.
Cundell T, Drummond S, Ford I, Reber D, Singer D; members of the Pharmaceutical Microbiology Expert Discussion Group.
PDA J Pharm Sci Technol. 2020 Mar-Apr;74(2):229-248. doi: 10.5731/pdajpst.2019.010546. Epub 2020 Jan 15.
PMID: 31941793
A 15-gene immune, stromal and proliferation gene signature that significantly associates with poor survival in patients with pancreatic ductal adenocarcinoma.
Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A.
Clin Cancer Res. 2020 Mar 31. pii: clincanres.4044.2019. doi: 10.1158/1078-0432.CCR-19-4044. [Epub ahead of print]
PMID: 32234757
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.
Cherney RJ, Cornelius LAM, Srivastava A, Weigelt CA, Marcoux D, Duan JJ, Shi Q, Batt DG, Liu Q, Yip S, Wu DR, Ruzanov M, Sack J, Khan J, Wang J, Yarde M, Cvijic ME, Mathur A, Li S, Shuster D, Khandelwal P, Borowski V, Xie J, Obermeier M, Fura A, Stefanski K, Cornelius G, Tino JA, Macor JE, Salter-Cid L, Denton R, Zhao Q, Carter PH, Dhar TGM.
ACS Med Chem Lett. 2020 Mar 31;11(6):1221-1227. doi: 10.1021/acsmedchemlett.0c00063. eCollection 2020 Jun 11.
PMID: 32551004
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
Moreno V, Sepulveda JM, Vieito M, Hernández-Guerrero T, Doger B, Saavedra O, Ferrero O, Sarmiento R, Arias M, De Alvaro J, Di Martino J, Zuraek M, Sanchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Hanna B, Nikolova Z, Braña I.
Ann Oncol. 2020 Mar 30:S0923-7534(20)36381-X. doi: 10.1016/j.annonc.2020.03.294. Online ahead of print.
PMID: 32240793
Impact of Expansion of PGY1 Pharmacy Residency Program From 2 to 4 Residents.
Brophy A, Bente J, Sobolewski K, DeStefano D, Costello J.
J Pharm Pract. 2020 Mar 27:897190020912934. doi: 10.1177/0897190020912934. [Epub ahead of print]
PMID: 32216571
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells.
Kramer J, Himmel HM, Lindqvist A, Stoelzle-Feix S, Chaudhary KW, Li D, Bohme GA, Bridgland-Taylor M, Hebeisen S, Fan J, Renganathan M, Imredy J, Humphries ESA, Brinkwirth N, Strassmaier T, Ohtsuki A, Danker T, Vanoye C, Polonchuk L, Fermini B, Pierson JB, Gintant G.
Sci Rep. 2020 Mar 27;10(1):5627. doi: 10.1038/s41598-020-62344-w.
PMID: 32221320
Impact of Expansion of PGY1 Pharmacy Residency Program From 2 to 4 Residents.
Brophy A, Bente J, Sobolewski K, DeStefano D, Costello J.
J Pharm Pract. 2020 Mar 27:897190020912934. doi: 10.1177/0897190020912934. Online ahead of print.
PMID: 32216571
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators.
N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182.
PMID: 32212518
Prevalence of chronic kidney disease in the community using data from OxRen: a UK population-based cohort study.
Hirst JA, Hill N, O'Callaghan CA, Lasserson D, McManus RJ, Ogburn E, Mena JMO, Shine B, Taylor CJ, Vazquez-Montes MD, Yang Y, Hobbs FR.
Br J Gen Pract. 2020 Mar 26;70(693):e285-e293. doi: 10.3399/bjgp20X708245. Print 2020 Apr.
PMID: 32041766
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
Risueño A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew CP, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, Pourdehnad M, Gandhi AK, Trotter MWB.
Blood. 2020 Mar 26;135(13):1008-1018. doi: 10.1182/blood.2019002414.
PMID: 31977005
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V.
Blood. 2020 Mar 26;135(13):996-1007. doi: 10.1182/blood.2019002395.
PMID: 31977002
Enantiodivergent Formation of C-P Bonds: Synthesis of P-Chiral Phosphines and Methylphosphonate Oligonucleotides.
Xu D, Rivas-Bascón N, Padial NM, Knouse KW, Zheng B, Vantourout JC, Schmidt MA, Eastgate MD, Baran PS.
J Am Chem Soc. 2020 Mar 25;142(12):5785-5792. doi: 10.1021/jacs.9b13898. Epub 2020 Mar 16.
PMID: 32109356
Triggers of Inflammatory Heart Disease.
Lasrado N, Yalaka B, Reddy J.
Front Cell Dev Biol. 2020 Mar 24;8:192. doi: 10.3389/fcell.2020.00192. eCollection 2020.
PMID: 32266270
Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction.
Chirinos JA, Orlenko A, Zhao L, Basso MD, Cvijic ME, Li Z, Spires TE, Yarde M, Wang Z, Seiffert DA, Prenner S, Zamani P, Bhattacharya P, Kumar A, Margulies KB, Car BD, Gordon DA, Moore JH, Cappola TP.
J Am Coll Cardiol. 2020 Mar 24;75(11):1281-1295. doi: 10.1016/j.jacc.2019.12.069.
PMID: 32192654
Single cell force profiling of human myofibroblasts reveals a biophysical spectrum of cell states.
Layton TB, Williams L, Colin-York H, McCann FE, Cabrita M, Feldmann M, Brown C, Xie W, Fritzsche M, Furniss D, Nanchahal J.
Biol Open. 2020 Mar 24;9(3):bio049809. doi: 10.1242/bio.049809.
PMID: 32139395
Long-Term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis.
Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A, Straumann A, Safroneeva E, Rodriguez C, Minton N, Hua SY, Hirano I.
Clin Gastroenterol Hepatol. 2020 Mar 21:S1542-3565(20)30348-7. doi: 10.1016/j.cgh.2020.03.036. Online ahead of print.
PMID: 32205221
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Catlett IM, Nowak M, Kundu S, Zheng N, Liu A, He B, Girgis IG, Grasela DM.
Br J Clin Pharmacol. 2020 Mar 21;86(9):1849-59. doi: 10.1111/bcp.14290. Online ahead of print.
PMID: 32198939
Iridium(I)-Catalyzed α-C(sp 3 )-H Alkylation of Saturated Azacycles.
Verma P, Richter JM, Chekshin N, Qiao JX, Yu JQ.
J Am Chem Soc. 2020 Mar 18;142(11):5117-5125. doi: 10.1021/jacs.9b12320. Epub 2020 Mar 9.
PMID: 32098471
Rational Development of Remote C-H Functionalization of Biphenyl: Experimental and Computational Studies.
Fan Z, Bay KL, Chen X, Zhuang Z, Park HS, Yeung KS, Houk KN, Yu JQ.
Angew Chem Int Ed Engl. 2020 Mar 16;59(12):4770-4777. doi: 10.1002/anie.201915624. Epub 2020 Feb 12.
PMID: 31943648
Role of wetting agents and disintegrants in development of danazol nanocrystalline tablets.
Meruva S, Thool P, Gong Y, Karki S, Bowen W, Kumar S.
Int J Pharm. 2020 Mar 15;577:119026. doi: 10.1016/j.ijpharm.2020.119026. Epub 2020 Jan 12.
PMID: 31940456
Assessment of Glucose Control Metrics by Discriminant Ratio.
Moscardó V, Herrero P, Reddy M, Hill N, Georgiou P, Oliver N.
Diabetes Technol Ther. 2020 Mar 12. doi: 10.1089/dia.2019.0415. [Epub ahead of print]
PMID: 32163723
New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.
Pavlos R, Deshpande P, Chopra A, Leary S, Strautins K, Nolan D, Thorborn D, Shaefer M, Rauch A, Dunn D, Montaner J, Rachlis A, Almeida CA, Choo L, James I, Redwood AJ, Li Y, Gaudieri S, Mallal SA, Phillips EJ.
Hum Immunol. 2020 Mar 12. pii: S0198-8859(19)31410-7. doi: 10.1016/j.humimm.2020.02.011. [Epub ahead of print]
PMID: 32173028
A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG).
Ghadessi M, Tang R, Zhou J, Liu R, Wang C, Toyoizumi K, Mei C, Zhang L, Deng CQ, Beckman RA.
Orphanet J Rare Dis. 2020 Mar 12;15(1):69. doi: 10.1186/s13023-020-1332-x.
PMID: 32164754
Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors.
Li G, Meanwell NA, Krystal MR, Langley DR, Naidu BN, Sivaprakasam P, Lewis H, Kish K, Khan JA, Ng A, Trainor GL, Cianci C, Dicker IB, Walker MA, Lin Z, Protack T, Discotto L, Jenkins S, Gerritz SW, Pendri A.
J Med Chem. 2020 Mar 12;63(5):2620-2637. doi: 10.1021/acs.jmedchem.9b01681. Epub 2020 Feb 21.
PMID: 32081010
Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs.
Zhang M, Haughey M, Wang NY, Blease K, Kapoun AM, Couto S, Belka I, Hoey T, Groza M, Hartke J, Bennett B, Cain J, Gurney A, Benish B, Castiglioni P, Drew C, Lachowicz J, Carayannopoulos L, Nathan SD, Distler J, Brenner DA, Hariharan K, Cho H, Xie W.
PLoS One. 2020 Mar 11;15(3):e0229445. doi: 10.1371/journal.pone.0229445. eCollection 2020.
PMID: 32160239
Proteomic Modulation in the Dorsal Spinal Cord Following Spinal Cord Stimulation Therapy in an In Vivo Neuropathic Pain Model.
Tilley DM, Lietz CB, Cedeno DL, Kelley CA, Li L, Vallejo R.
Neuromodulation. 2020 Mar 10:10.1111/ner.13103. doi: 10.1111/ner.13103. Online ahead of print.
PMID: 32157770
Investigation on the Effect of Capillary Microsampling on Hematologic and Toxicokinetic Evaluation in Regulatory Safety Studies in Mice.
Wang B, Wang L, Batog A, Brodie T, Ramaiah L, Chadwick KD, Su T, Mangipudy R, Pilutla RC, Ji QC.
AAPS J. 2020 Mar 9;22(2):55. doi: 10.1208/s12248-020-00438-z.
PMID: 32152888
Allele-Selective Knockdown of MYH7 Using Antisense Oligonucleotides.
Anderson BR, Jensen ML, Hagedorn PH, Little SC, Olson RE, Ammar R, Kienzle B, Thompson J, McDonald I, Mercer S, Vikesaa J, Nordbo B, Iben L, Cao Y, Natale J, Dalton-Kay G, Cacace A, Hansen BR, Hedtjärn M, Koch T, Bristow LJ.
Mol Ther Nucleic Acids. 2020 Mar 6;19:1290-1298. doi: 10.1016/j.omtn.2020.01.012. Epub 2020 Jan 21.
PMID: 32092825
Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma.
Liu H, Niu D, Tham Sjin RT, Dubrovskiy A, Zhu Z, McDonald JJ, Fahnoe K, Wang Z, Munson M, Scholte A, Barrague M, Fitzgerald M, Liu J, Kothe M, Sun F, Murtie J, Ge J, Rocnik J, Harvey D, Ospina B, Perron K, Zheng G, Shehu E, D'Agostino LA.
ACS Med Chem Lett. 2020 Mar 6;11(10):1899-1904. doi: 10.1021/acsmedchemlett.9b00601. eCollection 2020 Oct 8.
PMID: 33062171
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, Larson MC, Maurer MJ, Slager S, Macon WR, King RL, Feldman AL, Gandhi AK, Link BK, Habermann TM, Yang ZZ, Ansell SM, Cerhan JR, Witzig TE, Nowakowski GS, Novak AJ.
Leukemia. 2020 Mar 5:10.1038/s41375-020-0766-4. doi: 10.1038/s41375-020-0766-4. Online ahead of print.
PMID: 32139889
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network.
Reichermeier KM, Straube R, Reitsma JM, Sweredoski MJ, Rose CM, Moradian A, den Besten W, Hinkle T, Verschueren E, Petzold G, Thomä NH, Wertz IE, Deshaies RJ, Kirkpatrick DS.
Mol Cell. 2020 Mar 5;77(5):1092-1106.e9. doi: 10.1016/j.molcel.2019.12.013. Epub 2020 Jan 20.
PMID: 31973889
Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.
Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, Vinereanu D, Granger CB, Goodman SG, Aronson R, Windecker S, Thiele H, Valgimigli M, Mehran R, Alexander JH.
Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11.
PMID: 31707833
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ, Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang H, Pearson AT, Snyder LA, Korman AJ, Tomlins SA, Yegnasubramanian S, Drake CG.
J Clin Invest. 2020 Mar 2;130(3):1405-1416. doi: 10.1172/JCI128672.
PMID: 32015231
Absence of GP130 cytokine receptor signaling causes extended Stüve-Wiedemann syndrome.
Chen YH, Grigelioniene G, Newton PT, Gullander J, Elfving M, Hammarsjö A, Batkovskyte D, Alsaif HS, Kurdi WIY, Abdulwahab F, Shanmugasundaram V, Devey L, Bacrot S, Brodszki J, Huber C, Hamel B, Gisselsson D, Papadogiannakis N, Jedrycha K, Gürtl-Lackner B, Chagin AS, Nishimura G, Aschenbrenner D, Alkuraya FS, Laurence A, Cormier-Daire V, Uhlig HH.
J Exp Med. 2020 Mar 2;217(3):e20191306. doi: 10.1084/jem.20191306.
PMID: 31914175
Hybrid mode of hydrophobic interaction chromatography of monoclonal antibodies and related biomolecules: Influence of elution conditions on chromatographic performance using poly (alkyl aspartamide) silica columns.
Srikoti M, Bolgar MS, Kazakevich Y.
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Mar 1;1140:121984. doi: 10.1016/j.jchromb.2020.121984. Epub 2020 Jan 28.
PMID: 32014662
Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial.
Bahit MC, Granger CB, Alexander JH, Mulder H, Wojdyla DM, Hanna M, Goto S, Xavier D, Verheugt FWA, Lanas F, Hijazi Z, Wallentin L, Lopes RD.
Int J Cardiol. 2020 Mar 1;302:53-58. doi: 10.1016/j.ijcard.2019.12.060. Epub 2019 Dec 30.
PMID: 31932116
Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.
Aly A, Singh P, Korytowsky B, Ling YL, Kale HP, Dastani HB, Botteman MF, Norden AD.
Neurooncol Pract. 2020 Mar;7(2):164-175. doi: 10.1093/nop/npz042. Epub 2019 Sep 30.
PMID: 32626585
Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?
Rodrigues AD, Lai Y, Shen H, Varma MVS, Rowland A, Oswald S.
Drug Metab Dispos. 2020 Mar;48(3):205-216. doi: 10.1124/dmd.119.089615. Epub 2019 Dec 26.
PMID: 31879282
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.
Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, Ishikawa T, Kobayashi T, Kiguchi T, Nagai H, Ohtsu T, Kalambakas S, Fustier P, Midorikawa S, Tobinai K.
Int J Hematol. 2020 Mar;111(3):409-416. doi: 10.1007/s12185-019-02802-y. Epub 2019 Dec 19.
PMID: 31858429
Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Maglinte GA, Abraham P, Patel D, Shangguan T, Chau I.
Clin Colorectal Cancer. 2020 Mar;19(1):32-38.e3. doi: 10.1016/j.clcc.2019.09.001. Epub 2019 Sep 24.
PMID: 31813769
Letter to the Editor concerning "Bacteria: back pain, leg pain and Modic sign: a surgical multicenter comparative study" by Fritzell, P., Welinder-Olsson, C., Jönsson, B. et al. Eur Spine J (2019).
Capoor MN, McDowell A, Birkenmaier C, Ahmed FS, Coscia E, Raz A, Mavrommatis K, Fischetti VA, Slaby O.
Eur Spine J. 2020 Mar;29(3):628-630. doi: 10.1007/s00586-019-06237-1. Epub 2019 Dec 3.
PMID: 31797137
Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization.
Wälchli R, Ressurreição M, Vogg S, Feidl F, Angelo J, Xu X, Ghose S, Jian Li Z, Le Saoût X, Souquet J, Broly H, Morbidelli M.
Biotechnol Bioeng. 2020 Mar;117(3):687-700. doi: 10.1002/bit.27237. Epub 2019 Dec 11.
PMID: 31784982
Evaluating REMS Burden: A Comparative Time Analysis of 3 Channels for REMS Stakeholders to Perform Mandatory REMS Tasks.
Chapman J, Freeman J, Hechavarria J, Dodeja P, Sheehan P.
Ther Innov Regul Sci. 2020 Mar;54(2):318-323. doi: 10.1007/s43441-019-00060-y. Epub 2020 Jan 6.
PMID: 32072583
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.
Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T.
Cancer Chemother Pharmacol. 2020 Mar;85(3):621-626. doi: 10.1007/s00280-020-04037-9. Epub 2020 Feb 8.
PMID: 32036412
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R, Garcia MA, Isla D, Jassem J, Appel W, Milanowski J, Van Meerbeeck JP, Wolf J, Li A, Acevedo A, Popat S.
Eur J Cancer. 2020 Mar;127:160-172. doi: 10.1016/j.ejca.2019.11.019. Epub 2020 Feb 3.
PMID: 32028209
Mapping binding epitopes of monoclonal antibodies targeting major histocompatibility complex class I chain-related A (MICA) with hydrogen/deuterium exchange and electron-transfer dissociation mass spectrometry.
Huang RY, Kuhne M, Deshpande S, Rangan V, Srinivasan M, Wang Y, Chen G.
Anal Bioanal Chem. 2020 Mar;412(7):1693-1700. doi: 10.1007/s00216-020-02409-x. Epub 2020 Jan 29.
PMID: 31993727
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jiménez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R Jr, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G.
Eur J Cancer. 2020 Mar;127:52-66. doi: 10.1016/j.ejca.2019.12.029. Epub 2020 Jan 24.
PMID: 31986450
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, López-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P.
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294. doi: 10.1016/S2468-1253(19)30327-9. Epub 2020 Jan 14.
PMID: 31953079
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ.
J Immunother Cancer. 2020 Mar;8(1):e000398. doi: 10.1136/jitc-2019-000398.
PMID: 32238470
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, Wenz P, Baden J, Barrett JC, Chaudhary R, Chen L, Chen WS, Cheng JH, Cyanam D, Dickey JS, Gupta V, Hellmann M, Helman E, Li Y, Maas J, Papin A, Patidar R, Quinn KJ, Rizvi N, Tae H, Ward C, Xie M, Zehir A, Zhao C, Dietel M, Stenzinger A, Stewart M, Allen J; TMB Harmonization Consortium.
J Immunother Cancer. 2020 Mar;8(1):e000147. doi: 10.1136/jitc-2019-000147.
PMID: 32217756
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.
Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D, Askan G, Bhanot U, Elyada E, Park Y, Tuveson DA, Gönen M, Leach SD, Wolchok JD, DeMatteo RP, Merghoub T, Balachandran VP.
Nature. 2020 Mar;579(7797):130-135. doi: 10.1038/s41586-020-2015-4. Epub 2020 Feb 19.
PMID: 32076273
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J.
J Comp Eff Res. 2020 Mar;9(4):275-285. doi: 10.2217/cer-2019-0169. Epub 2020 Jan 17.
PMID: 31948278
Kinetic modeling of Chinese hamster ovary cell culture: factors and principles.
Tang P, Xu J, Louey A, Tan Z, Yongky A, Liang S, Li ZJ, Weng Y, Liu S.
Crit Rev Biotechnol. 2020 Mar;40(2):265-281. doi: 10.1080/07388551.2019.1711015. Epub 2020 Jan 12.
PMID: 31928250
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, Prenner S, Zamani P, Seiffert DA, Car BD, Gordon DA, Margulies K, Cappola T, Chirinos JA.
JACC Heart Fail. 2020 Mar;8(3):172-184. doi: 10.1016/j.jchf.2019.09.009. Epub 2020 Jan 8.
PMID: 31926856
Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.
Lee CW, Ren YJ, Marella M, Wang M, Hartke J, Couto SS.
J Immunol Methods. 2020 Mar;478:112714. doi: 10.1016/j.jim.2019.112714. Epub 2019 Nov 26.
PMID: 31783023
Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.
Sharpley FA, Djebbari F, Fourali S, Kothari J, Lynes JA, McLain-Smith S, Ramasamy K.
Leuk Lymphoma. 2020 Mar;61(3):732-736. doi: 10.1080/10428194.2019.1683737. Epub 2019 Nov 27.
PMID: 31771382
Evaluation of correlation between bioanalytical methods.
Gleason CR, Ji QC, Wickremsinhe ER.
Bioanalysis. 2020 Mar;12(6):419-426. doi: 10.4155/bio-2020-0019. Epub 2020 Apr 14.
PMID: 32285680
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study.
Schafer PH, Kivitz AJ, Ma J, Korish S, Sutherland D, Li L, Azaryan A, Kosek J, Adams M, Capone L, Hur EM, Hough DR, Ringheim GE.
Rheumatol Ther. 2020 Mar;7(1):101-119. doi: 10.1007/s40744-019-00182-7. Epub 2019 Nov 13.
PMID: 31721017
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
Shakhnovich V, Meibohm B, Rosenberg A, Kierzek AM, Hasenkamp R, Funk RS, Thalhauser CJ, van der Graaf PH, Wang YC, Hamuro L.
Clin Transl Sci. 2020 Mar;13(2):219-223. doi: 10.1111/cts.12717. Epub 2019 Nov 25.
PMID: 31762152
SEND harmonization & cross-study analysis: A proposal to better harvest the value from SEND data.
Carfagna MA, Bjerregaard TG, Fukushima T, Houser W, Sloan C, Snyder K, Anderson J, Page T.
Regul Toxicol Pharmacol. 2020 Mar;111:104542. doi: 10.1016/j.yrtph.2019.104542. Epub 2019 Nov 20.
PMID: 31756353
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza VK, Weisel K.
Leuk Lymphoma. 2020 Mar;61(3):668-679. doi: 10.1080/10428194.2019.1683736. Epub 2019 Nov 11.
PMID: 31709875
Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall.
Condon DM, Chapman R, Shaunfield S, Kallen MA, Beaumont JL, Eek D, Mitra D, Benjamin KL, McQuarrie K, Liu J, Shaw JW, Martin Nguyen A, Keating K, Cella D.
Qual Life Res. 2020 Mar;29(3):745-753. doi: 10.1007/s11136-019-02344-0. Epub 2019 Nov 7.
PMID: 31701432
A Bayesian zero-inflated binomial regression and its application in dose-finding study.
Wanitjirattikal P, Shi C.
J Biopharm Stat. 2020 Mar;30(2):322-333. doi: 10.1080/10543406.2019.1684313. Epub 2019 Nov 6.
PMID: 31693441
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH.
Leuk Lymphoma. 2020 Mar;61(3):650-659. doi: 10.1080/10428194.2019.1675879. Epub 2019 Oct 24.
PMID: 31647335
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan DS.
J Thorac Oncol. 2020 Mar;15(3):392-403. doi: 10.1016/j.jtho.2019.10.006. Epub 2019 Oct 18.
PMID: 31634667
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR.
J Thorac Oncol. 2020 Mar;15(3):426-435. doi: 10.1016/j.jtho.2019.10.004. Epub 2019 Oct 17.
PMID: 31629915
Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.
Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF.
Leukemia. 2020 Mar;34(3):831-844. doi: 10.1038/s41375-019-0600-z. Epub 2019 Oct 17.
PMID: 31624377
Evaluation of Therapeutics for Severely Debilitating or Life-Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development.
Liu M, Fields FO, Prescott JS, Bello A, Bower N, Darakjy S, Hartke J, Kadambi V, Lapadula D, Stoch A, Derzi M.
Clin Pharmacol Ther. 2020 Mar;107(3):514-520. doi: 10.1002/cpt.1673. Epub 2019 Nov 22.
PMID: 31608984
Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM, Korytowsky B, Singh P, Cai Q, Cappell K, Jariwala-Parikh K, Sill B, Parikh ND.
J Gastrointest Cancer. 2020 Mar;51(1):217-226. doi: 10.1007/s12029-019-00230-z.
PMID: 31011982
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.
Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, Ishikawa T, Kobayashi T, Kiguchi T, Nagai H, Ohtsu T, Kalambakas S, Fustier P, Midorikawa S, Tobinai K.
Int J Hematol. 2020 Mar;111(3):409-416. doi: 10.1007/s12185-019-02802-y. Epub 2019 Dec 19.
PMID: 31858429
New Technologies to Image Tumors.
McNamara G, Lucas J, Beeler JF, Basavanhally A, Lee G, Hedvat CV, Baxi VA, Locke D, Borowsky A, Levenson R.
Cancer Treat Res. 2020 Mar;180:51-94. doi: 10.1007/978-3-030-38862-1_2.
PMID: 32215866
Discovery of New Immune Checkpoints: Family Grows Up.
Kong X.
Adv Exp Med Biol. 2020 Mar;1248:61-82. doi: 01007/978-981-15-3266-5_4. Review.
PMID: 32185707
i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
Hyatt A, Gough K, Murnane A, Au-Yeung G, Dawson T, Pearson E, Dhillon H, Sandhu S, Williams N, Paton E, Billett A, Traill A, Andersen H, Beedle V, Milne D.
BMJ Open. 2020 Feb 28;10(2):e036059. doi: 10.1136/bmjopen-2019-036059.
PMID: 32114479
Armoring the Interface with Surfactants to Prevent the Adsorption of Monoclonal Antibodies.
Kanthe AD, Krause M, Zheng S, Ilott A, Li J, Bu W, Bera MK, Lin B, Maldarelli C, Tu RS.
ACS Appl Mater Interfaces. 2020 Feb 26;12(8):9977-9988. doi: 10.1021/acsami.9b21979. Epub 2020 Feb 17.
PMID: 32013386
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.
Brunner HI, Tzaribachev N, Cornejo GV, Joos R, Gervais E, Cimaz R, Calvo Penadés I, Cuttica R, Lutz T, Quartier P, Gandhi Y, Nys M, Wong R, Martini A, Lovell DJ, Ruperto N; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation.
Pediatr Rheumatol Online J. 2020 Feb 22;18(1):19. doi: 10.1186/s12969-020-0410-x.
PMID: 32087715
Approaches for machine learning intermolecular interaction energies and application to energy components from symmetry adapted perturbation theory.
Metcalf DP, Koutsoukas A, Spronk SA, Claus BL, Loughney DA, Johnson SR, Cheney DL, Sherrill CD.
J Chem Phys. 2020 Feb 21;152(7):074103. doi: 10.1063/1.5142636.
PMID: 32087645
Differential RNA splicing as a potentially important driver mechanism in multiple myeloma.
Bauer MA, Ashby C, Wardell C, Boyle EM, Ortiz M, Flynt E, Thakurta A, Morgan G, Walker BA.
Haematologica. 2020 Feb 20. pii: haematol.2019.235424. doi: 10.3324/haematol.2019.235424. [Epub ahead of print]
PMID: 32079689
Effect of restricted dissolved oxygen on expression of Clostridium difficile toxin A subunit from E. coli.
Sharma AK, Phue J, Khatipov E, Dalal N, Anderson ED, Shiloach J.
Sci Rep. 2020 Feb 20;10(1):3059. doi: 10.1038/s41598-020-59978-1.
PMID: 32080292
Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
Belair DG, Lu G, Waller LE, Gustin JA, Collins ND, Kolaja KL.
Sci Rep. 2020 Feb 18;10(1):2864. doi: 10.1038/s41598-020-59542-x.
PMID: 32071327
Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
Bettinger JA, Liberator P, Halperin SA, Vaudry W, Sadarangani M, Hao L, Lambert N, Jansen KU, Anderson AS, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT).
Vaccine. 2020 Feb 18;38(8):2026-2033. doi: 10.1016/j.vaccine.2019.12.051. Epub 2020 Jan 23.
PMID: 31983586
Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Santini V, Almeida A, Giagounidis A, Skikne B, Beach CL, Weaver J, Tu N, Fenaux P.
Leuk Lymphoma. 2020 Feb 17:1-9. doi: 10.1080/10428194.2020.1719088. [Epub ahead of print]
PMID:
Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Prenner SB, Kumar A, Zhao L, Cvijic ME, Basso M, Spires T, Li Z, Yarde M, Bhattacharya P, Zamani P, Mazurek J, Wang Z, Seiffert D, Gordon DA, Chirinos JA.
Am J Cardiol. 2020 Feb 15;125(4):575-582. doi: 10.1016/j.amjcard.2019.11.006. Epub 2019 Nov 19.
PMID: 31843232
Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Fang T, Corte JR, Gilligan PJ, Jeon Y, Osuna H, Rossi KA, Myers JE Jr, Sheriff S, Lou Z, Zheng JJ, Harper TW, Bozarth JM, Wu Y, Luettgen JM, Seiffert DA, Wexler RR, Lam PYS.
Bioorg Med Chem Lett. 2020 Feb 15;30(4):126949. doi: 10.1016/j.bmcl.2020.126949. Epub 2020 Jan 7.
PMID: 31932224
Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
Huisman M, Niemeijer AL, Windhorst B, Schuit R, Leung D, Hayes W, Poot A, Bahce I, Radonic T, Oprea-Lager D, Hoekstra O, Thunnissen E, Hendrikse H, Smit E, De Langen J, Boellaard R.
J Nucl Med. 2020 Feb 14. pii: jnumed.119.240895. doi: 10.2967/jnumed.119.240895. [Epub ahead of print]
PMID: 32060213
Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis.
Hagberg KW, Persson R, Vasilakis-Scaramozza C, Niemcryk S, Peng M, Paris M, Lindholm A, Jick S.
Clin Epidemiol. 2020 Feb 12;12:153-161. doi: 10.2147/CLEP.S239511. eCollection 2020.
PMID: 32104099
Synthesis of Cyclobutane-Fused Tetracyclic Scaffolds via Visible-Light Photocatalysis for Building Molecular Complexity.
Oderinde MS, Mao E, Ramirez A, Pawluczyk J, Jorge C, Cornelius LAM, Kempson J, Vetrichelvan M, Pitchai M, Gupta A, Gupta AK, Meanwell NA, Mathur A, Dhar TGM.
J Am Chem Soc. 2020 Feb 12;142(6):3094-3103. doi: 10.1021/jacs.9b12129. Epub 2020 Jan 22.
PMID: 31927959
Glutathione and Reactive Oxygen Species Dual-Responsive Block Copolymer Prodrugs for Boosting Tumor Site-Specific Drug Release and Enhanced Antitumor Efficacy.
Yin W, Ke W, Lu N, Wang Y, Japir AAMM, Mohammed F, Wang Y, Pan Y, Ge Z.
Biomacromolecules. 2020 Feb 10;21(2):921-929. doi: 10.1021/acs.biomac.9b01578. Epub 2020 Jan 30.
PMID: 31961134
Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation.
Rasmussen PV, Dalgaard F, Gislason GH, Brandes A, Johnsen SP, Grove EL, Torp-Pedersen C, Dybro L, Harboe L, Münster AB, Pedersen L, Blanche P, Pallisgaard JL, Hansen ML.
Eur Heart J. 2020 Feb 7. pii: ehz964. doi: 10.1093/eurheartj/ehz964. [Epub ahead of print]
PMID: 32030399
A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies.
Phillips JA, Grandhi TSP, Davis M, Gautier JC, Hariparsad N, Keller D, Sura R, Van Vleet TR.
Lab Chip. 2020 Feb 7;20(3):468-476. doi: 10.1039/c9lc00925f. Epub 2020 Jan 28.
PMID: 31989145
Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization.
Fowler S, Chen WLK, Duignan DB, Gupta A, Hariparsad N, Kenny JR, Lai WG, Liras J, Phillips JA, Gan J.
Lab Chip. 2020 Feb 7;20(3):446-467. doi: 10.1039/c9lc00857h. Epub 2020 Jan 14.
PMID: 31932816
Integrative network modeling reveals mechanisms underlying T cell exhaustion.
Bolouri H, Young M, Beilke J, Johnson R, Fox B, Huang L, Santini CC, Hill CM, Vries AVV, Shannon PT, Dervan A, Sivakumar P, Trotter M, Bassett D, Ratushny A.
Sci Rep. 2020 Feb 5;10(1):1915. doi: 10.1038/s41598-020-58600-8.
PMID: 32024856
Near Infrared-Triggered Liposome Cages for Rapid, Localized Small Molecule Delivery.
Shin JE, Ogunyankin MO, Zasadzinski JA.
Sci Rep. 2020 Feb 3;10(1):1706. doi: 10.1038/s41598-020-58764-3.
PMID: 32015363
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
Guarino VR, Olson RE, Everlof JG, Wang N, McDonald I, Haskell R, Clarke W, Lentz KA.
Bioorg Med Chem Lett. 2020 Feb 1;30(3):126856. doi: 10.1016/j.bmcl.2019.126856. Epub 2019 Dec 16.
PMID: 31870650
Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors.
Peese KM, Naidu BN, Patel M, Li C, Langley DR, Terry B, Protack T, Gali V, Lin Z, Samanta HK, Zheng M, Jenkins S, Dicker IB, Krystal MR, Meanwell NA, Walker MA.
Bioorg Med Chem Lett. 2020 Feb 1;30(3):126784. doi: 10.1016/j.bmcl.2019.126784. Epub 2019 Nov 9.
PMID: 31761656
Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography-Tandem Mass Spectrometry: Current State and Future Vision.
Neubert H, Shuford CM, Olah TV, Garofolo F, Schultz GA, Jones BR, Amaravadi L, Laterza OF, Xu K, Ackermann BL.
Clin Chem. 2020 Feb 1;66(2):282-301. doi: 10.1093/clinchem/hvz022.
PMID: 32040572
Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial.
Montalescot G, Brotons C, Cosyns B, Crijns HJ, D'Angelo A, Drouet L, Eberli F, Lane DA, Besse B, Chan A, Vicaut E, Darius H; AEGEAN Study Investigators.
Am J Cardiovasc Drugs. 2020 Feb;20(1):61-71. doi: 10.1007/s40256-019-00356-2.
PMID: 31243691
Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
Zhao X, Shen J, Ivaturi V, Gopalakrishnan M, Feng Y, Schmidt BJ, Statkevich P, Goodman V, Gobburu J, Bello A, Roy A, Agrawal S.
Ann Oncol. 2020 Feb;31(2):302-309. doi: 10.1016/j.annonc.2019.10.015. Epub 2019 Dec 9.
PMID: 31959348
Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study.
Alemao E, Bao Y, Weinblatt ME, Shadick N.
Arthritis Care Res (Hoboken). 2020 Feb;72(2):176-183. doi: 10.1002/acr.24071. Epub 2020 Jan 13.
PMID: 31529682
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Siegel DS, Schiller GJ, Song KW, Agajanian R, Stockerl-Goldstein K, Kaya H, Sebag M, Samaras C, Malek E, Talamo G, Seet CS, Mouro J, Pierceall WE, Zafar F, Chung W, Srinivasan S, Agarwal A, Bahlis NJ.
Br J Haematol. 2020 Feb;188(4):501-510. doi: 10.1111/bjh.16213. Epub 2019 Oct 6.
PMID: 31588567
Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
Bei D, Osawa M, Uemura S, Ohno T, Gobburu J, Roy A, Hasegawa M.
Cancer Sci. 2020 Feb;111(2):528-535. doi: 10.1111/cas.14252. Epub 2020 Jan 21.
PMID: 31773815
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Fenn K, Maurer M, Lee SM, Crew KD, Trivedi MS, Accordino MK, Hershman DL, Kalinsky K.
Clin Breast Cancer. 2020 Feb;20(1):80-86. doi: 10.1016/j.clbc.2019.08.004. Epub 2019 Aug 29.
PMID: 31570268
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.
Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG.
Clin Gastroenterol Hepatol. 2020 Feb;18(2):457-467.e21. doi: 10.1016/j.cgh.2019.07.010. Epub 2019 Jul 12.
PMID: 31306800
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
Ogasawara K, Newhall K, Maxwell SE, Dell'Aringa J, Komashko V, Kilavuz N, Delarue R, Czuczman M, Sternas L, Rose S, Beach CL, Novick S, Zhou S, Palmisano M, Li Y.
Clin Pharmacokinet. 2020 Feb;59(2):217-227. doi: 10.1007/s40262-019-00804-x.
PMID: 31332669
Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development.
Roth SE, Avigan MI, Bourdet D, Brott D, Church R, Dash A, Keller D, Sherratt P, Watkins PB, Westcott-Baker L, Lentini S, Merz M, Ramaiah L, Ramaiah SK, Stanley AM, Marcinak J.
Clin Pharmacol Ther. 2020 Feb;107(2):333-346. doi: 10.1002/cpt.1571. Epub 2019 Sep 14. Review.
PMID: 31314926
Adverse events associated with weight-based, high-dose montelukast exposures in children.
Arnold DH, Bowman N, Reiss TF, Hartert TV, Akers WS, Seger DL.
Clin Toxicol (Phila). 2020 Feb;58(2):145-146. doi: 10.1080/15563650.2019.1609686. Epub 2019 May 6. No abstract available. Erratum in:  Clin Toxicol (Phila). 2020 Feb;58(2):e1 .
PMID: 31056949
Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis.
Harrold LR, Shan Y, Connolly SE, Alemao E, Rebello S, Guo L, Kremer JM.
Curr Med Res Opin. 2020 Feb;36(2):337-342. doi: 10.1080/03007995.2019.1680354. Epub 2019 Oct 24.
PMID: 31612736
Validation of obesity coding among newly treated nonvalvular atrial fibrillation patients using an integrated electronic medical record and claims database.
Jain R, Watzker A, Luo X, Kang AL, Baker CL, Rosenblatt L, Mardekian J, Menzin J.
Curr Med Res Opin. 2020 Feb;36(2):189-197. doi: 10.1080/03007995.2019.1666448. Epub 2019 Sep 28.
PMID: 31564172
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM, Tampi RP, Racila A, Qiu Y, Burns L, Younossi I, Nader F.
Diabetes Care. 2020 Feb;43(2):283-289. doi: 10.2337/dc19-1113. Epub 2019 Oct 28.
PMID: 31658974
Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs.
Casarin J, Song C, Multinu F, Cappuccio S, Liu E, Butler KA, Glaser GE, Cliby WA, Langstraat CL, Ghezzi F, Fu AZ, Mariani A.
Gynecol Oncol. 2020 Feb;156(2):451-458. doi: 10.1016/j.ygyno.2019.11.016. Epub 2019 Nov 25.
PMID: 31780236
Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department.
Deitelzweig S, Hlavacek P, Mardekian J, Rosenblatt L, Russ C, Tuell K, Lingohr-Smith M, Lin J, Guo JD.
Hosp Pract (1995). 2020 Feb;48(1):41-48. doi: 10.1080/21548331.2020.1718925. Epub 2020 Feb 6.
PMID: 31976776
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W, Zhang Z, Barcellona C, Maes P, Fiorillo L.
J Am Acad Dermatol. 2020 Feb;82(2):389-397. doi: 10.1016/j.jaad.2019.08.019. Epub 2019 Aug 10.
PMID: 31408686
Key factors associated with uncontrolled asthma - the Asthma Control in Latin America Study.
Neffen H, Chahuàn M, Hernández DD, Vallejo-Perez E, Bolivar F, Sánchez MH, Galleguillos F, Castaños C, S Silva R, Giugno E, Pavie J, Contreras R, Lamarao F, Moraes Dos Santos F, Rodriguez C, Tobler J, Viana K, Vieira C, Soares C.
J Asthma. 2020 Feb;57(2):113-122. doi: 10.1080/02770903.2018.1553050. Epub 2019 Mar 27.
PMID: 30915868
Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study.
Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M.
J Cardiol. 2020 Feb;75(2):208-215. doi: 10.1016/j.jjcc.2019.07.007. Epub 2019 Aug 15.
PMID: 31421933
Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database.
Uno S, Goto R, Suzuki K, Iwasaki K, Takeshima T, Ohtsu T.
J Med Econ. 2020 Feb;23(2):166-173. doi: 10.1080/13696998.2019.1686870. Epub 2019 Nov 18.
PMID: 31682533
Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
Abraham P, Kish JK, Korytowsky B, Radtchenko J, Singh P, Shaw J, Feinberg B.
J Med Econ. 2020 Feb;23(2):125-131. doi: 10.1080/13696998.2019.1676760. Epub 2019 Oct 18.
PMID: 31581922
Tunable Two-Compartment On-Demand Sustained Drug Release Based on Lipid Gels.
Wang X, Huang L, Zhang Y, Meng F, Donoso M, Haskell R, Luo L.
J Pharm Sci. 2020 Feb;109(2):1059-1067. doi: 10.1016/j.xphs.2019.10.021. Epub 2019 Oct 17.
PMID:31629734
Effect of Moisture Sorption on Free Volume and Relaxation of Spray Dried Dispersions: Relation to Drug Recrystallization.
Li J, Hubert M, Pinnamaneni S, Tao L, Zhao J, Sharif S, Ramakrishnan RK, Nazarenko S.
J Pharm Sci. 2020 Feb;109(2):1050-1058. doi: 10.1016/j.xphs.2019.10.018. Epub 2019 Oct 14.
PMID: 31622601
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.
Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.
PMID: 31578169
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
Giaj Levra M, Cotté FE, Corre R, Calvet C, Gaudin AF, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assié JB, Chouaïd C.
Lung Cancer. 2020 Feb;140:99-106. doi: 10.1016/j.lungcan.2019.12.017. Epub 2019 Dec 31.
PMID: 31911324
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R, Okishio K, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, Kozuki T, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Ueda J, Ohe Y.
Lung Cancer. 2020 Feb;140:8-18. doi: 10.1016/j.lungcan.2019.11.014. Epub 2019 Nov 20.
PMID: 31838169
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD.
Melanoma Res. 2020 Feb;30(1):71-75. doi: 10.1097/CMR.0000000000000633.
PMID: 31425479
A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton's Tyrosine Kinase.
Ong LL, Vasta JD, Monereau L, Locke G, Ribeiro H, Pattoli MA, Skala S, Burke JR, Watterson SH, Tino JA, Meisenheimer PL, Arey B, Lippy J, Zhang L, Robers MB, Tebben A, Chaudhry C.
SLAS Discov. 2020 Feb;25(2):176-185. doi: 10.1177/2472555219884881. Epub 2019 Nov 9.
PMID: 31709883
Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
Chu CE, Porten SP, Grossfeld GD, Meng MV.
Urol Clin North Am. 2020 Feb;47(1):111-118. doi: 10.1016/j.ucl.2019.09.013. Review.
PMID: 31757294
Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.
Siegel CA, Yang F, Eslava S, Cai Z.
Clin Transl Gastroenterol. 2020 Feb;11(2):e00128. doi: 10.14309/ctg.0000000000000128.
PMID: 32463619
An Evaluation of T-Cell Functionality After Flow Cytometry Sorting Revealed p38 MAPK Activation.
Andrä I, Ulrich H, Dürr S, Soll D, Henkel L, Angerpointner C, Ritter J, Przibilla S, Stadler H, Effenberger M, Busch DH, Schiemann M.
Cytometry A. 2020 Feb;97(2):171-183. doi: 10.1002/cyto.a.23964. Epub 2020 Jan 16.
PMID: 31944553
From single-arm studies to externally controlled studies. Methodological considerations and guidelines.
Cucherat M, Laporte S, Delaitre O, Behier JM; participants of Giens XXXV Round Table Clinical Research, d'Andon A, Binlich F, Bureau S, Cornu C, Fouret C, Hoog Labouret N, Laviolle B, Miadi-Fargier H, Paoletti X, Roustit M, Simon T, Varoqueaux N, Vicaut E, Westerloppe J.
Therapie. 2020 Jan - Feb;75(1):21-27. doi: 10.1016/j.therap.2019.11.007. Epub 2019 Dec 16.
PMID: 32063399
Des études mono-bras aux études de comparaison externe. Considérations méthodologiques et recommandations.
Cucherat M, Laporte S, Delaitre O, Behier JM; participants à la table ronde 'Recherche clinique' des Ateliers de Giens XXXV, d'Andon A, Binlich F, Bureau S, Cornu C, Fouret C, Hoog Labouret N, Laviolle B, Miadi-Fargier H, Paoletti X, Roustit M, Simon T, Varoqueaux N, Vicaut E, Westerloppe J.
Therapie. 2020 Jan-Feb;75(1):13-19. doi: 10.1016/j.therap.2019.12.002. Epub 2019 Dec 13.
PMID: 32063401
Acceptability and content validity of patient-reported measures considered from the rheumatoid arthritis patient's perspective.
Shaw Y, Zhang C, Bradley M, Simon TA, Schumacher R, McDonald D, Michaud K.
Arthritis Care Res (Hoboken). 2020 Jan 31. doi: 10.1002/acr.24156. [Epub ahead of print]
PMID: 32004411
Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma.
Nowakowski GS, Chiappella A, Witzig TE, Scott DW, Spina M, Gascoyne RD, Zhang L, Russo J, Kang J, Zhang J, Xu Y, Vitolo U.
Haematologica. 2020 Jan 31;105(2):e72-e75. doi: 10.3324/haematol.2019.220475. Print 2020. No abstract available.
PMID: 31221781
Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties.
Kurmi M, Sahu A, Balhara A, Singh IP, Kulkarni S, Singh NK, Garg P, Singh S.
J Pharm Biomed Anal. 2020 Jan 30;178:112911. doi: 10.1016/j.jpba.2019.112911. Epub 2019 Oct 6.
PMID: 31627078
Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study.
Aurisicchio L, Fridman A, Mauro D, Sheloditna R, Chiappori A, Bagchi A, Ciliberto G.
J Transl Med. 2020 Jan 30;18(1):39. doi: 10.1186/s12967-020-02228-9.
PMID: 32000810
Author Correction: Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY.
Nat Commun. 2020 Jan 30;11(1):701. doi: 10.1038/s41467-020-14427-5.
PMID: 32001685
Considerations for Soluble Protein Biomarker Blood Sample Matrix Selection.
Mathews JA, Ni YG, Wang C, Peterson JE, Ray C, Zhao X, Duan D, Hamon S, Allinson J, Hokom M, Wegner G.
AAPS J. 2020 Jan 29;22(2):38. doi: 10.1208/s12248-020-0412-0.
PMID: 31997095
Immunogenicity Risk Assessment for PEGylated Therapeutics.
Mora JR, White JT, DeWall SL.
AAPS J. 2020 Jan 28;22(2):35. doi: 10.1208/s12248-020-0420-0.
PMID: 31993858
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.
Velaparthi U, Darne CP, Warrier J, Liu P, Rahaman H, Augustine-Rauch K, Parrish K, Yang Z, Swanson J, Brown J, Dhar G, Anandam A, Holenarsipur VK, Palanisamy K, Wautlet BS, Fereshteh MP, Lippy J, Tebben AJ, Sheriff S, Ruzanov M, Yan C, Gupta A, Gupta AK, Vetrichelvan M, Mathur A, Gelman M, Singh R, Kinsella T, Murtaza A, Fargnoli J, Vite G, Borzilleri RM.
ACS Med Chem Lett. 2020 Jan 28;11(2):172-178. doi: 10.1021/acsmedchemlett.9b00552. eCollection 2020 Feb 13.
PMID: 32071685
Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.
Weycker D, Wygant GD, Guo JD, Lee T, Luo X, Rosenblatt L, Mardekian J, Atwood M, Hanau A, Cohen AT.
Blood Adv. 2020 Jan 28;4(2):432-439. doi: 10.1182/bloodadvances.2019001081.
PMID: 31990332
Decoding the small size challenges of mini-tablets for enhanced dose flexibility and micro-dosing.
Mitra B, Thool P, Meruva S, Aycinena JA, Li J, Patel J, Patel K, Agarwal A, Karki S, Bowen W.
Int J Pharm. 2020 Jan 25;574:118905. doi: 10.1016/j.ijpharm.2019.118905. Epub 2019 Dec 3.
PMID: 31809860
Prognosis, Biology, and Targeting of  TP53  Dysregulation in Multiple Myeloma.
Flynt E, Bisht K, Sridharan V, Ortiz M, Towfic F, Thakurta A.
Cells. 2020 Jan 24;9(2). pii: E287. doi: 10.3390/cells9020287. Review.
PMID: 31991614
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
Corte JR, Pinto DJP, Fang T, Osuna H, Yang W, Wang Y, Lai A, Clark CG, Sun JH, Rampulla R, Mathur A, Kaspady M, Neithnadka PR, Li YC, Rossi KA, Myers JE Jr, Sheriff S, Lou Z, Harper TW, Huang C, Zheng JJ, Bozarth JM, Wu Y, Wong PC, Crain EJ, Seiffert DA, Luettgen JM, Lam PYS, Wexler RR, Ewing WR.
J Med Chem. 2020 Jan 23;63(2):784-803. doi: 10.1021/acs.jmedchem.9b01768. Epub 2020 Jan 2.
PMID: 31833761
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report.
Muralikrishnan S, Ronan LK, Coker S, Rauschkolb PK, Shirai K.
Case Rep Oncol. 2020 Jan 21;13(1):43-48. doi: 10.1159/000504930. eCollection 2020 Jan-Apr.
PMID: 32110218
Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches.
Lamore SD, Kohnken RA, Peters MF, Kolaja KL.
Chem Res Toxicol. 2020 Jan 21;33(1):125-136. doi: 10.1021/acs.chemrestox.9b00387. Epub 2020 Jan 10.
PMID: 31840498
Use of Zebrafish in Drug Discovery Toxicology.
Cassar S, Adatto I, Freeman JL, Gamse JT, Iturria I, Lawrence C, Muriana A, Peterson RT, Van Cruchten S, Zon LI.
Chem Res Toxicol. 2020 Jan 21;33(1):95-118. doi: 10.1021/acs.chemrestox.9b00335. Epub 2019 Nov 16.
PMID: 31625720
Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry.
Baudy AR, Otieno MA, Hewitt P, Gan J, Roth A, Keller D, Sura R, Van Vleet TR, Proctor WR.
Lab Chip. 2020 Jan 21;20(2):215-225. doi: 10.1039/c9lc00768g. Epub 2019 Dec 4.
PMID: 31799979
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Medvedeva IV, Stokes ME, Eisinger D, LaBrie ST, Ai J, Trotter MWB, Schafer P, Yang R.
Sci Rep. 2020 Jan 17;10(1):605. doi: 10.1038/s41598-020-57542-5.
PMID: 31953524
Can real-world data really replace randomised clinical trials?
Ramagopalan SV, Simpson A, Sammon C.
BMC Med. 2020 Jan 15;18(1):13. doi: 10.1186/s12916-019-1481-8. No abstract available.
PMID: 31937304
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS.
Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31.
PMID: 31672767
Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe.
Verleger K, Penrod JR, Manley Daumont M, Solem C, Luo L, Macahilig C, Hertel N.
Clinicoecon Outcomes Res. 2020 Jan 15;12:23-33. doi: 10.2147/CEOR.S223760. eCollection 2020.
PMID: 32021337
Applications of fluorine-containing amino acids for drug design.
Mei H, Han J, Klika KD, Izawa K, Sato T, Meanwell NA, Soloshonok VA.
Eur J Med Chem. 2020 Jan 15;186:111826. doi: 10.1016/j.ejmech.2019.111826. Epub 2019 Nov 4. Review.
PMID: 31740056
Irp2 regulates insulin production through iron-mediated Cdkal1-catalyzed tRNA modification.
Santos MCFD, Anderson CP, Neschen S, Zumbrennen-Bullough KB, Romney SJ, Kahle-Stephan M, Rathkolb B, Gailus-Durner V, Fuchs H, Wolf E, Rozman J, de Angelis MH, Cai WM, Rajan M, Hu J, Dedon PC, Leibold EA.
Nat Commun. 2020 Jan 15;11(1):296. doi: 10.1038/s41467-019-14004-5.
PMID: 31941883
Nickel-Catalyzed 1,2-Diarylation of Alkenyl Carboxylates: A Gateway to 1,2,3-Trifunctionalized Building Blocks.
Derosa J, Kang T, Tran VT, Wisniewski SR, Karunananda MK, Jankins TC, Xu KL, Engle KM.
Angew Chem Int Ed Engl. 2020 Jan 13;59(3):1201-1205. doi: 10.1002/anie.201913062. Epub 2019 Dec 12.
PMID: 31693286
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, McCanna S, Butler B, Ruffini PA, Liu Y, Rosato RR, Chang JC.
Breast Cancer Res. 2020 Jan 10;22(1):4. doi: 10.1186/s13058-019-1243-8.
PMID: 31924241
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.
Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A.
Front Oncol. 2020 Jan 10;9:1483. doi: 10.3389/fonc.2019.01483. eCollection 2019.
PMID: 31998643
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF.
N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.
PMID: 31914241
Increased MSX level improves biological productivity and production stability in multiple recombinant GS CHO cell lines.
Tian J, He Q, Oliveira C, Qian Y, Egan S, Xu J, Qian NX, Langsdorf E, Warrack B, Aranibar N, Reily M, Borys M, Li ZJ.
Eng Life Sci. 2020 Jan 9;20(3-4):112-125. doi: 10.1002/elsc.201900124. eCollection 2020 Mar.
PMID: 32874175
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
Danese S, Neurath MF, Kopoń A, Zakko SF, Simmons TC, Fogel R, Siegel CA, Panaccione R, Zhan X, Usiskin K, Chitkara D.
Clin Gastroenterol Hepatol. 2020 Jan 8. pii: S1542-3565(20)30005-7. doi: 10.1016/j.cgh.2019.12.032. [Epub ahead of print]
PMID: 31926340
Application of in-sample calibration curve methodology for regulated bioanalysis: Critical considerations in method development, validation and sample analysis.
Yuan L, Gu H, Zeng J, Pillutla RC, Ji QC.
J Pharm Biomed Anal. 2020 Jan 5;177:112844. doi: 10.1016/j.jpba.2019.112844. Epub 2019 Aug 29.
PMID: 31491659
The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules.
Yang W, Gadgil P, Krishnamurthy VR, Landis M, Mallick P, Patel D, Patel PJ, Reid DL, Sanchez-Felix M.
AAPS J. 2020 Jan 3;22(2):21. doi: 10.1208/s12248-019-0402-2.
PMID: 31900602
Application and Impact of Human Dose Projection from Discovery to Early Drug Development.
Patel D, Yang W, Lipert M, Wu T.
AAPS PharmSciTech. 2020 Jan 2;21(2):44. doi: 10.1208/s12249-019-1598-2. Review.
PMID: 31897807
Design, synthesis and biological evaluation of phenol-linked uncialamycin antibody-drug conjugates.
Poudel YB, Rao C, Kotapati S, Deshpande M, Thevanayagam L, Pan C, Cardarelli J, Chowdari N, Kaspady M, Samikannu R, Kuppusamy P, Saravanakumar P, Arunachalam PN, Deshpande S, Rangan V, Rampulla R, Mathur A, Vite GD, Gangwar S.
Bioorg Med Chem Lett. 2020 Jan 1;30(1):126782. doi: 10.1016/j.bmcl.2019.126782. Epub 2019 Nov 9.
PMID: 31767265
Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.
Xu J, Xu X, Huang C, Angelo J, Oliveira CL, Xu M, Xu X, Temel D, Ding J, Ghose S, Borys MC, Li ZJ.
MAbs. 2020 Jan 1;12(1):1770669. doi: 10.1080/19420862.2020.1770669.
PMID: 32425110
Control of Antibody Impurities Induced by Riboflavin in Culture Media During Production.
Wallace A, Trimble S, Valliere-Douglass JF, Allen M, Eakin C, Balland A, Reddy P, Treuheit MJ.
J Pharm Sci. 2020 Jan;109(1):566-575. doi: 10.1016/j.xphs.2019.10.039. Epub 2019 Oct 26.
PMID: 31669653
Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus.
Katz P, Pedro S, Alemao E, Yazdany J, Dall'Era M, Trupin L, Rush S, Michaud K.
ACR Open Rheumatol. 2020 Jan;2(1):53-60. doi: 10.1002/acr2.11100. Epub 2019 Dec 4.
PMID: 31943975
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N.
Aliment Pharmacol Ther. 2020 Jan;51(1):90-109. doi: 10.1111/apt.15579. Epub 2019 Nov 25. Review.
PMID: 31762074
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers.
Galliverti G, Wullschleger S, Tichet M, Murugan D, Zangger N, Horton W, Korman AJ, Coussens LM, Swartz MA, Hanahan D.
Cancer Immunol Res. 2020 Jan;8(1):131-145. doi: 10.1158/2326-6066.CIR-19-0315. Epub 2019 Nov 26.
PMID: 31771984
Connect MM Registry as a national reference for United States multiple myeloma patients.
Ailawadhi S, Jagannath S, Narang M, Rifkin RM, Terebelo HR, Toomey K, Durie BGM, Hardin JW, Gasparetto CJ, Wagner L, Omel JL, Kumar V, Yue L, Kitali A, Agarwal A, Abonour R; Connect MM Registry Investigators.
Cancer Med. 2020 Jan;9(1):35-42. doi: 10.1002/cam4.2656. Epub 2019 Nov 7.
PMID: 31701679
Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors.
Sanghavi K, Zhang J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Vezina HE.
CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):29-39. doi: 10.1002/psp4.12477. Epub 2019 Dec 1.
PMID: 31709718
Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
Wu JJ, Pelletier C, Ung B, Tian M.
Curr Med Res Opin. 2020 Jan;36(1):169-176. doi: 10.1080/03007995.2019.1668204. Epub 2019 Sep 28.
PMID: 31517542
Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination.
Routray R, Tetarenko N, Abu-Assal C, Mockute R, Assuncao B, Chen H, Bao S, Danysz K, Desai S, Cicirello S, Willis V, Alford SH, Krishnamurthy V, Mingle E.
Drug Saf. 2020 Jan;43(1):57-66. doi: 10.1007/s40264-019-00869-4.
PMID: 31605285
Application of the adverse outcome pathway framework to genotoxic modes of action.
Sasaki JC, Allemang A, Bryce SM, Custer L, Dearfield KL, Dietz Y, Elhajouji A, Escobar PA, Fornace AJ Jr, Froetschl R, Galloway S, Hemmann U, Hendriks G, Li HH, Luijten M, Ouedraogo G, Peel L, Pfuhler S, Roberts DJ, Thybaud V, van Benthem J, Yauk CL, Schuler M.
Environ Mol Mutagen. 2020 Jan;61(1):114-134. doi: 10.1002/em.22339. Epub 2019 Oct 31.
PMID: 31603995
Potential of machine learning methods to identify patients with nonvalvular atrial fibrillation.
Suzuki R, Katada J, Ramagopalan S, McDonald L.
Future Cardiol. 2020 Jan;16(1):43-52. doi: 10.2217/fca-2019-0056. Epub 2019 Dec 3.
PMID: 31793345
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.
Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, Garzon N, Ibrahim M, Raybold B, Liaw D, Rutstein M, Galsky MD.
Future Oncol. 2020 Jan;16(2):4359-4368. doi: 10.2217/fon-2019-0611. Epub 2019 Dec 11.
PMID: 31823654
Consistency of recording of chemotherapy cycles in the National Cancer Registration and Analysis Service Systemic Anti-Cancer Therapy database and the Hospital Episode Statistics Admitted Patient Care database.
McDonald L, Sammon C, Carroll R, Harish A, C AS, Tyas D, Ramagopalan SV.
Future Oncol. 2020 Jan;16(3):4455-4460. doi: 10.2217/fon-2019-0669. Epub 2019 Dec 10.
PMID: 31820657
Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T.
Gastric Cancer. 2020 Jan;23(1):142. doi: 10.1007/s10120-019-01021-y.
PMID: 31679092
Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T.
Gastric Cancer. 2020 Jan;23(1):133-141. doi: 10.1007/s10120-019-01008-9. Epub 2019 Sep 23. Erratum in:  Gastric Cancer. 2019 Nov 3;: .
PMID: 31549264
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.
Ambavane A, Yang S, Atkins MB, Rao S, Shah A, Regan MM, McDermott DF, Michaelson MD.
Immunotherapy. 2020 Jan;12(1):37-51. doi: 10.2217/imt-2019-0199. Epub 2020 Jan 29.
PMID: 31992108
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction.
Kanagala P, Arnold JR, Cheng ASH, Singh A, Khan JN, Gulsin GS, Yang J, Zhao L, Gupta P, Squire IB, Ng LL, McCann GP.
Int J Cardiovasc Imaging. 2020 Jan;36(1):101-110. doi: 10.1007/s10554-019-01684-9. Epub 2019 Aug 10.
PMID: 31401742
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.
Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N.
Int J Hematol. 2020 Jan;111(1):65-74. doi: 10.1007/s12185-019-02757-0. Epub 2019 Nov 7.
PMID: 31701481
Incidence of seroconversion and sero-reversion in patients with multiple sclerosis (MS) who had been treated with natalizumab: A systematic review and meta-analysis.
Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M.
J Clin Neurosci. 2020 Jan;71:129-134. doi: 10.1016/j.jocn.2019.08.103. Epub 2019 Sep 23.
PMID: 31558363
Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics.
Gaudy A, Hwang R, Palmisano M, Chen N.
J Clin Pharmacol. 2020 Jan;60(1):67-74. doi: 10.1002/jcph.1506. Epub 2019 Aug 7.
PMID: 31392755
Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer.
Chau I, Ayers D, Goring S, Cope S, Korytowsky B, Abraham P.
J Comp Eff Res. 2020 Jan;9(2):103-114. doi: 10.2217/cer-2019-0145. Epub 2019 Dec 24.
PMID: 31872771
Therapeutic inertia in the management of moderate-to-severe plaque psoriasis.
Halioua B, Corgibet F, Maghia R, Hello S, Caillet G, Nicolas C, Riboulet JL, Mahé E.
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):e30-e32. doi: 10.1111/jdv.15882. Epub 2019 Sep 2. No abstract available.
PMID: 31419345
Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation.
Alam ME, Slaney TR, Wu L, Das TK, Kar S, Barnett GV, Leone A, Tessier PM.
J Pharm Sci. 2020 Jan;109(1):656-669. doi: 10.1016/j.xphs.2019.10.051. Epub 2019 Oct 31.
PMID: 31678251
A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
Hubert M, Yang DT, Kwok SC, Rios A, Das TK, Patel A, Wuchner K, Antochshuk V, Junge F, Bou-Assaf GM, Cao S, Saggu M, Montrond L, Afonina N, Kolhe P, Loladze V, Narhi L.
J Pharm Sci. 2020 Jan;109(1):830-844. doi: 10.1016/j.xphs.2019.10.025. Epub 2019 Oct 21.
PMID: 31647951
Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy.
Das TK, Narhi LO, Sreedhara A, Menzen T, Grapentin C, Chou DK, Antochshuk V, Filipe V.
J Pharm Sci. 2020 Jan;109(1):116-133. doi: 10.1016/j.xphs.2019.09.023. Epub 2019 Oct 5. Review.
PMID: 31593689
An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
Halley J, Chou YR, Cicchino C, Huang M, Sharma V, Tan NC, Thakkar S, Zhou LL, Al-Azzam W, Cornen S, Gauden M, Gu Z, Kar S, Lazar AC, Mehndiratta P, Smith J, Sosic Z, Weisbach P, Stokes ESE.
J Pharm Sci. 2020 Jan;109(1):6-21. doi: 10.1016/j.xphs.2019.09.018. Epub 2019 Sep 26.
PMID: 31563512
Structure-Function Assessment and High-Throughput Quantification of Site-Specific Aspartate Isomerization in Monoclonal Antibody Using a Novel Analytical Tool Kit.
Zhou K, Cao X, Bautista J, Chen Z, Hershey N, Ludwig R, Tao L, Zeng M, Das TK.
J Pharm Sci. 2020 Jan;109(1):422-428. doi: 10.1016/j.xphs.2019.08.018. Epub 2019 Aug 27.
PMID: 31469998
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J.
Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19.
PMID: 31427722
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, Koyama D, Izumi T, Yasui H, Suzuki A, Furukawa Y.
Leukemia. 2020 Jan;34(1):180-195. doi: 10.1038/s41375-019-0525-6. Epub 2019 Jul 29.
PMID: 31358854
Incident cardiovascular disease in patients diagnosed with multiple sclerosis: A multi-database study.
Persson R, Lee S, Yood MU, Wagner M, Minton N, Niemcryk S, Lindholm A, Evans A, Jick S.
Mult Scler Relat Disord. 2020 Jan;37:101423. doi: 10.1016/j.msard.2019.101423. Epub 2019 Oct 1.
PMID: 32172996
Analysis of historical negative control group data from the rat in vivo micronucleus assay.
Lovell DP, Fellows M, Saul J, Whitwell J, Custer L, Dertinger S, Escobar P, Fiedler R, Hemmann U, Kenny J, Smith R, van der Leede BM, Zeller A.
Mutat Res. 2020 Jan;849:503086. doi: 10.1016/j.mrgentox.2019.503086. Epub 2019 Oct 12.
PMID: 32087845
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes.
Smare C, Lakhdari K, Doan J, Posnett J, Johal S.
Pharmacoeconomics. 2020 Jan;38(1):97-108. doi: 10.1007/s40273-019-00845-x.
PMID: 31741315
A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation.
Hill NR, Sandler B, Bergrath E, Milenković D, Ashaye AO, Farooqui U, Cohen AT.
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029619898764. doi: 10.1177/1076029619898764.
PMID: 31918558
Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models.
Wang F, Tsai JC, Davis JH, Chau B, Dong J, West SM, Hogan JM, Wheeler ML, Bee C, Morishige W, Cayton T, David-Brown D, Zhang C, Kozhich A, Sproul T, Dollinger G, Rajpal A, Strop P.
MAbs. 2020 Jan-Dec;12(1):1685350. doi: 10.1080/19420862.2019.1685350.
PMID: 31856660
Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics.
Chen Z, Qian Y, Song Y, Xu X, Tao L, Mussa N, Ghose S, Li ZJ.
MAbs. 2020 Jan-Dec;12(1):1829338. doi: 10.1080/19420862.2020.1829338.
PMID: 33044887
Optimization and kinetic modeling of interchain disulfide bond reoxidation of monoclonal antibodies in bioprocesses.
Tang P, Tan Z, Ehamparanathan V, Ren T, Hoffman L, Du C, Song Y, Tao L, Lewandowski A, Ghose S, Li ZJ, Liu S.
MAbs. 2020 Jan-Dec;12(1):1829336. doi: 10.1080/19420862.2020.1829336.
PMID: 33031716
On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies.
Tan Z, Ehamparanathan V, Ren T, Tang P, Hoffman L, Kuang J, Liu P, Huang C, Du C, Tao L, Chemmalil L, Lewandowski A, Ghose S, Li ZJ, Liu S.
MAbs. 2020 Jan-Dec;12(1):1829333. doi: 10.1080/19420862.2020.1829333.
PMID: 33016217
Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies.
Bolisetty P, Tremml G, Xu S, Khetan A.
MAbs. 2020 Jan-Dec;12(1):1763727. doi: 10.1080/19420862.2020.1763727.
PMID: 32449878
Investigation of anomalous charge variant profile reveals discrete pH-dependent conformations and conformation-dependent charge states within the CDR3 loop of a therapeutic mAb.
Lan W, Valente JJ, Ilott A, Chennamsetty N, Liu Z, Rizzo JM, Yamniuk AP, Qiu D, Shackman HM, Bolgar MS.
MAbs. 2020 Jan-Dec;12(1):1763138. doi: 10.1080/19420862.2020.1763138.
PMID: 32432964
2019 Publications
Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment.
Li Y, MacGorman K, Liu L, Chen J, Hoffmann M, Palmisano M, Zhou S.
Clin Pharmacol Drug Dev. 2019 Dec 31. doi: 10.1002/cpdd.760. [Epub ahead of print]
PMID: 31891240
Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.
Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S.
J Carcinog. 2019 Dec 31;18:5. doi: 10.4103/jcar.JCar_14_19. eCollection 2019. Review.
PMID: 31949426
Solid state nuclear magnetic resonance studies of hydroxypropylmethylcellulose acetyl succinate polymer, a useful carrier in pharmaceutical solid dispersions.
Pugliese A, Hawarden LE, Abraham A, Tobyn M, Blanc F.
Magn Reson Chem. 2019 Dec 27. doi: 10.1002/mrc.4984. [Epub ahead of print]
PMID: 31880823
Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials.
Purnajo I, Beaumont JL, Polinsky M, Alemao E, Everly MJ.
Am J Transplant. 2019 Dec 24. doi: 10.1111/ajt.15757. [Epub ahead of print]
PMID: 31874117
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, Lawitz EJ, Halegoua-DeMarzio D, Kundu S, Noviello S, Luo Y, Christian R.
Lancet. 2019 Dec 22;392(10165):2705-2717. doi: 10.1016/S0140-6736(18)31785-9. Epub 2018 Dec 13.
PMID: 30554783
Covariate adjustment for randomized controlled trials revisited.
Wang J.
Pharm Stat. 2019 Dec 21. doi: 10.1002/pst.1988. [Epub ahead of print]
PMID: 31863636
Inflammatory bowel disease - one entity with many molecular faces.
Szymańska S, Matuszczyk M, Osuch M, Meglicka M, Szymanska E, Bierła J, Kierkuś J.
Prz Gastroenterol. 2019 Dec 20;14(4):228-232. doi: 10.5114/pg.2019.90249. Epub 2019 Dec 20. Review.
PMID: 31988668
Cancer diagnosis and care among rural-to-urban migrants in China.
Myerson R, Lu T, Yuan Y, Liu GG.
BMJ Glob Health. 2019 Dec 18;4(6):e001923. doi: 10.1136/bmjgh-2019-001923. eCollection 2019.
PMID: 31908866
An Integrated Approach for Determining a Protein-Protein Binding Interface in Solution and an Evaluation of Hydrogen-Deuterium Exchange Kinetics for Adjudicating Candidate Docking Models.
Zhang MM, Beno BR, Huang RY, Adhikari J, Deyanova EG, Li J, Chen G, Gross ML.
Anal Chem. 2019 Dec 17;91(24):15709-15717. doi: 10.1021/acs.analchem.9b03879. Epub 2019 Nov 22.
PMID: 31710208
Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA.
Oguz M, Lanitis T, Li X, Wygant G, Singer DE, Friend K, Hlavacek P, Nikolaou A, Mattke S.
Appl Health Econ Health Policy. 2019 Dec 17. doi: 10.1007/s40258-019-00542-y. [Epub ahead of print]
PMID: 31849021
Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells.
Cerchio R Jr, Marinaro C, Foo TK, Xia B, Chen S.
Melanoma Res. 2019 Dec 17. doi: 10.1097/CMR.0000000000000652. [Epub ahead of print]
PMID:31855905
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Colombel JF, Rossiter G, Usiskin K, Ather S, Zhan X, DʼHaens G.
Am J Gastroenterol. 2019 Dec 16. doi: 10.14309/ajg.0000000000000493. [Epub ahead of print]
PMID: 31850931
Practical applications of bio-fluorescent particle counting in Environmental Monitoring investigations.
Prasad A, Villari P, Henry R', Weber J, Hauschild J, Yan L, Horsch J, Shereefa S, Rau JE, Milling A, Bolden JS, Plourde L, Claassen M, IJzerman-Boon P, Forng RY, Portmann R, Urwyler S, Dassu D.
PDA J Pharm Sci Technol. 2019 Dec 16. pii: pdajpst.2019.009969. doi: 10.5731/pdajpst.2019.009969. [Epub ahead of print]
PMID: 31843986
Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS, Younes AI, Barsoumian HB, Quigley M, Menon H, Gao C, Spires T, Reilly TP, Cadena AP, Cushman TR, Schoenhals JE, Li A, Nguyen QN, Cortez MA, Welsh JW.
Clin Cancer Res. 2019 Dec 15;25(24):7576-7584. doi: 10.1158/1078-0432.CCR-19-0795. Epub 2019 Sep 20.
PMID: 31540976
Colocalization of GWAS and eQTL signals at loci with multiple signals identifies additional candidate genes for body fat distribution.
Wu Y, Broadaway KA, Raulerson CK, Scott LJ, Pan C, Ko A, He A, Tilford C, Fuchsberger C, Locke AE, Stringham HM, Jackson AU, Narisu N, Kuusisto J, Pajukanta P, Collins FS, Boehnke M, Laakso M, Lusis AJ, Civelek M, Mohlke KL.
Hum Mol Genet. 2019 Dec 15;28(24):4161-4172. doi: 10.1093/hmg/ddz263.
PMID: 31691812
Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Fletcher AM, Tellier P, Douville J, Mansell P, Graziano MJ, Mangipudy RS, Brodie TA, Achanzar WE.
Toxicol Lett. 2019 Dec 15;317:120-129. doi: 10.1016/j.toxlet.2019.09.023. Epub 2019 Sep 30.
PMID: 31580884
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G Jr, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC.
Cancer Manag Res. 2019 Dec 13;11:10463-10476. doi: 10.2147/CMAR.S208720. eCollection 2019.
PMID: 31853198
First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial.
Liu MC, Janni W, Georgoulias V, Yardley DA, Harbeck N, Wei X, McGovern D, Beck R.
Cancer Manag Res. 2019 Dec 12;11:10427-10433. doi: 10.2147/CMAR.S208712. eCollection 2019.
PMID: 31849532
Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
Wang R, Zheng J, Shao X, Ishii Y, Roy A, Bello A, Lee R, Zhang J, Wind-Rotolo M, Feng Y.
J Immunother Cancer. 2019 Dec 11;7(1):348. doi: 10.1186/s40425-019-0819-2.
PMID: 31829287
An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J, Palaska C, Kelly T, Hutchings A, Parnaby A.
Orphanet J Rare Dis. 2019 Dec 11;14(1):287. doi: 10.1186/s13023-019-1246-7.
PMID: 31829218
Visualizing the Selectivity and Dynamics of Interferon Signaling In Vivo.
Stifter SA, Bhattacharyya N, Sawyer AJ, Cootes TA, Stambas J, Doyle SE, Feigenbaum L, Paul WE, Britton WJ, Sher A, Feng CG.
Cell Rep. 2019 Dec 10;29(11):3539-3550.e4. doi: 10.1016/j.celrep.2019.11.021.
PMID: 31825834
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF.
J Clin Oncol. 2019 Dec 10;37(35):3350-3358. doi: 10.1200/JCO.19.00345. Epub 2019 Sep 9.
PMID: 31498030
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC, Ahmad HA, Yazici Y, Bergman MJ.
Rheumatology (Oxford). 2019 Dec 9. pii: kez455. doi: 10.1093/rheumatology/kez455. [Epub ahead of print]
PMID: 31819995
Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.
Hopson MB, Onishi M, Awad D, Buono D, Maurer M, Crew KD, Shane E, Hershman DL, Kalinsky K.
Clin Breast Cancer. 2019 Dec 5. pii: S1526-8209(19)30759-1. doi: 10.1016/j.clbc.2019.12.001. [Epub ahead of print]
PMID: 31926840
Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.
Hopson MB, Onishi M, Awad D, Buono D, Maurer M, Crew KD, Shane E, Hershman DL, Kalinsky K.
Clin Breast Cancer. 2019 Dec 5. pii: S1526-8209(19)30759-1. doi: 10.1016/j.clbc.2019.12.001. [Epub ahead of print]
PMID: 31926840
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrøm T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J, Potpara TS, Raev D, Sabaté M, de Waha-Thiele S, Welsh RC, Xavier D, Mehran R, Alexander JH; AUGUSTUS Investigators.
Circulation. 2019 Dec 3;140(23):1921-1932. doi: 10.1161/CIRCULATIONAHA.119.043308. Epub 2019 Sep 26.
PMID: 31557056
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Vora AN, Alexander JH, Wojdyla DM, Aronson R, Granger CB, Darius H, Windecker S, Mehran R, Averkov O, Budaj A, Kong DF, Kobalava Z, Mehta RH, Mirza Z, Guimaraes PO, Parkhomenko A, Quadros A, Thiele H, Goodman SG, Lopes RD.
Circulation. 2019 Dec 3;140(23):1960-1963. doi: 10.1161/CIRCULATIONAHA.119.043754. Epub 2019 Sep 25. No abstract available.
PMID: 31553201
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrøm T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J, Potpara TS, Raev D, Sabaté M, de Waha-Thiele S, Welsh RC, Xavier D, Mehran R, Alexander JH; AUGUSTUS Investigators.
Circulation. 2019 Dec 3;140(23):1921-1932. doi: 10.1161/CIRCULATIONAHA.119.043308. Epub 2019 Sep 26.
PMID: 31557056
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Vora AN, Alexander JH, Wojdyla DM, Aronson R, Granger CB, Darius H, Windecker S, Mehran R, Averkov O, Budaj A, Kong DF, Kobalava Z, Mehta RH, Mirza Z, Guimaraes PO, Parkhomenko A, Quadros A, Thiele H, Goodman SG, Lopes RD.
Circulation. 2019 Dec 3;140(23):1960-1963. doi: 10.1161/CIRCULATIONAHA.119.043754. Epub 2019 Sep 25. No abstract available.
PMID: 31553201
Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.
Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, Wang Z, Rangan VS, Jiang D, von Eyben R, Liang R, Agarwal S, Colevas AD, Korman A, Allen CT, Uppaluri R, Koong AC, Giaccia A, Le QT.
J Clin Invest. 2019 Dec 2;129(12):5553-5567. doi: 10.1172/JCI129025.
PMID: 31710313
Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.
Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, Wang Z, Rangan VS, Jiang D, von Eyben R, Liang R, Agarwal S, Colevas AD, Korman A, Allen CT, Uppaluri R, Koong AC, Giaccia A, Le QT.
J Clin Invest. 2019 Dec 2;129(12):5553-5567. doi: 10.1172/JCI129025.
PMID: 31710313
The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.
Saab S, Chang OS, Nagaoka K, Hung MC, Yamaguchi H.
Am J Cancer Res. 2019 Dec 1;9(12):2719-2729. eCollection 2019.
PMID: 31911857
The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.
Saab S, Chang OS, Nagaoka K, Hung MC, Yamaguchi H.
Am J Cancer Res. 2019 Dec 1;9(12):2719-2729. eCollection 2019.
PMID: 31911857
A generic method for intact and subunit level characterization of mAb charge variants by native mass spectrometry.
Leblanc Y, Faid V, Lauber MA, Wang Q, Bihoreau N, Chevreux G.
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Dec 1;1133:121814. doi: 10.1016/j.jchromb.2019.121814. Epub 2019 Oct 16.
PMID: 31731217
The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study.
Garonzik S, Byon W, Myers E, Li X, Marchisin D, Murthy B.
Am J Cardiovasc Drugs. 2019 Dec;19(6):561-567. doi: 10.1007/s40256-019-00348-2.
PMID: 31030414
Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.
Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V, Ringold S, Vesely R, Schrandt S, Jaki T, Bili A, Chung JB, De Bono S, Douglass W, Enejosa JV, Kanik KS, Knobe K, Kunder R, Leite-Schnell JC, Suehiro RM, Wong RL, Mieszkalski KL, Marrow LC, Siebenaler K, Fraulo E, Kimura Y.
Arthritis Rheumatol. 2019 Dec;71(12):1976-1984. doi: 10.1002/art.41043. Epub 2019 Nov 1.
PMID: 31313532
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (Part 2 - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity).
Booth B, Stevenson L, Pillutla R, Buonarati M, Beaver C, Fraier D, Garofolo F, Haidar S, Islam R, James C, Kadavil J, Kavetska O, Li F, Satterwhite C, Savoie N, Subramaniam S, Tampal N, Thway T, Woolf E, Blaye OL, Andisik M, Briscoe C, Cape S, Dasgupta A, Fischer S, Haidar S, Hayes R, Kamerud J, Lima Santos GM, Nehls C, Soo C, Vinter S, Whale E, Xu K, Cho SJ, Edmison A, Kassim S, Rocha TC, Welink J, Amur S, Bandukwala A, Cherry E, Hopper S, Ishii-Watabe A, Kirshner S, Maher K, Pedras-Vasconcelos J, Saito Y, Saunders TS, Skibeli V, Verthelyi D, Wang YM, Yan H.
Bioanalysis. 2019 Dec;11(23):2099-2132. doi: 10.4155/bio-2019-0270. Epub 2019 Dec 9.
PMID: 31833782
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).
Piccoli S, Mehta D, Vitaliti A, Allinson J, Amur S, Eck S, Green C, Hedrick M, Hopper S, Ji A, Joyce A, Litwin V, Maher K, Mathews J, Peng K, Safavi A, Wang YM, Zhang Y, Amaravadi L, Palackal N, Thankamony S, Beaver C, Bame E, Emrich T, Grimaldi C, Haulenbeek J, Joyce A, Kakkanaiah V, Lanham D, Maher K, Mayer A, Trampont PC, Vermet L, Dakappagari N, Fleener C, Garofolo F, Rogers C, Tangri S, Xu Y, Liang M, Rajadhyaksha M, Richards S, Schweighardt B, Purushothama S, Baltrukonis D, Brumm J, Cherry E, Delcarpini J, Gleason C, Kirshner S, Kubiak R, Pan L, Partridge M, Pedras-Vasconcelos J, Qu Q, Skibeli V, Saunders TS, Staack RF, Stubenrauch K, Torri A, Verthelyi D, Yan H, Gorovits B, Palmer R, Milton M, Long B, Corsaro B, Farrokhi V, Fiscella M, Henderson N, Jawa V, McNally J, Murphy R, Waldner H, Yang TY.
Bioanalysis. 2019 Dec;11(24):2207-2244. doi: 10.4155/bio-2019-0271. Epub 2019 Dec 10.
PMID: 31820675
Exploratory biomarker assays: key assay parameters to evaluate in the face of evolving biomarker context-of-use.
Thankamony SP, Zhang Y.
Bioanalysis. 2019 Dec;11(23):2095-2097. doi: 10.4155/bio-2019-0223. Epub 2019 Nov 28. No abstract available.
PMID: 31777269
Development of a prognostic model for overall survival in multiple myeloma using the Connect ®  MM Patient Registry.
Terebelo HR, Abonour R, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, Jagannath S, Wagner L, Narang M, Flick ED, Srinivasan S, Yue L, Kitali A, Agarwal A, Rifkin RM; CONNECT MM Registry Investigators.
Br J Haematol. 2019 Dec;187(5):602-614. doi: 10.1111/bjh.16139. Epub 2019 Aug 5.
PMID: 31382320
Myocardial Microvascular Dysfunction in Rheumatoid Arthritis Quantitation by 13N-Ammonia Positron Emission Tomography/Computed Tomography .
Amigues I, Russo C, Giles JT, Tugcu A, Weinberg R, Bokhari S, Bathon JM.
Circ Cardiovasc Imaging. 2019 Dec;12(1):e007495. doi: 10.1161/CIRCIMAGING.117.007495.
PMID: 30636512
Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies.
Zhang J, Sanghavi K, Shen J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Zhu L.
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):962-970. doi: 10.1002/psp4.12476. Epub 2019 Dec 1.
PMID: 31710163
Antibodies to Modulate Surface Receptor Systems Are Often Bivalent and Must Compete in a Two-Dimensional Cell Contact Region.
Schmidt BJ, Bee C, Han M, Jing Y, Cheng Y, Tenney DJ, Leil TA.
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):873-877. doi: 10.1002/psp4.12468. Epub 2019 Oct 23. No abstract available.
PMID: 31529681
The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study.
Garonzik S, Byon W, Myers E, Li X, Marchisin D, Murthy B.
Am J Cardiovasc Drugs. 2019 Dec;19(6):561-567. doi: 10.1007/s40256-019-00348-2.
PMID: 31030414
Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.
Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V, Ringold S, Vesely R, Schrandt S, Jaki T, Bili A, Chung JB, De Bono S, Douglass W, Enejosa JV, Kanik KS, Knobe K, Kunder R, Leite-Schnell JC, Suehiro RM, Wong RL, Mieszkalski KL, Marrow LC, Siebenaler K, Fraulo E, Kimura Y.
Arthritis Rheumatol. 2019 Dec;71(12):1976-1984. doi: 10.1002/art.41043. Epub 2019 Nov 1.
PMID: 31313532
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (Part 2 - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity).
Booth B, Stevenson L, Pillutla R, Buonarati M, Beaver C, Fraier D, Garofolo F, Haidar S, Islam R, James C, Kadavil J, Kavetska O, Li F, Satterwhite C, Savoie N, Subramaniam S, Tampal N, Thway T, Woolf E, Blaye OL, Andisik M, Briscoe C, Cape S, Dasgupta A, Fischer S, Haidar S, Hayes R, Kamerud J, Lima Santos GM, Nehls C, Soo C, Vinter S, Whale E, Xu K, Cho SJ, Edmison A, Kassim S, Rocha TC, Welink J, Amur S, Bandukwala A, Cherry E, Hopper S, Ishii-Watabe A, Kirshner S, Maher K, Pedras-Vasconcelos J, Saito Y, Saunders TS, Skibeli V, Verthelyi D, Wang YM, Yan H.
Bioanalysis. 2019 Dec;11(23):2099-2132. doi: 10.4155/bio-2019-0270. Epub 2019 Dec 9.
PMID: 31833782
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).
Piccoli S, Mehta D, Vitaliti A, Allinson J, Amur S, Eck S, Green C, Hedrick M, Hopper S, Ji A, Joyce A, Litwin V, Maher K, Mathews J, Peng K, Safavi A, Wang YM, Zhang Y, Amaravadi L, Palackal N, Thankamony S, Beaver C, Bame E, Emrich T, Grimaldi C, Haulenbeek J, Joyce A, Kakkanaiah V, Lanham D, Maher K, Mayer A, Trampont PC, Vermet L, Dakappagari N, Fleener C, Garofolo F, Rogers C, Tangri S, Xu Y, Liang M, Rajadhyaksha M, Richards S, Schweighardt B, Purushothama S, Baltrukonis D, Brumm J, Cherry E, Delcarpini J, Gleason C, Kirshner S, Kubiak R, Pan L, Partridge M, Pedras-Vasconcelos J, Qu Q, Skibeli V, Saunders TS, Staack RF, Stubenrauch K, Torri A, Verthelyi D, Yan H, Gorovits B, Palmer R, Milton M, Long B, Corsaro B, Farrokhi V, Fiscella M, Henderson N, Jawa V, McNally J, Murphy R, Waldner H, Yang TY.
Bioanalysis. 2019 Dec;11(24):2207-2244. doi: 10.4155/bio-2019-0271. Epub 2019 Dec 10.
PMID: 31820675
Exploratory biomarker assays: key assay parameters to evaluate in the face of evolving biomarker context-of-use.
Thankamony SP, Zhang Y.
Bioanalysis. 2019 Dec;11(23):2095-2097. doi: 10.4155/bio-2019-0223. Epub 2019 Nov 28. No abstract available.
PMID: 31777269
Development of a prognostic model for overall survival in multiple myeloma using the Connect ®  MM Patient Registry.
Terebelo HR, Abonour R, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, Jagannath S, Wagner L, Narang M, Flick ED, Srinivasan S, Yue L, Kitali A, Agarwal A, Rifkin RM; CONNECT MM Registry Investigators.
Br J Haematol. 2019 Dec;187(5):602-614. doi: 10.1111/bjh.16139. Epub 2019 Aug 5.
PMID: 31382320
Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P, Guo JD, Rosenblatt L, Keshishian A, Russ C, Mardekian J, Ferri M, Poretta T, Yuce H, McBane R.
Curr Med Res Opin. 2019 Dec;35(12):2043-2051. doi: 10.1080/03007995.2019.1653067. Epub 2019 Sep 3.
PMID: 31387467
Chemical and physical instabilities in manufacturing and storage of therapeutic proteins.
Krause ME, Sahin E.
Curr Opin Biotechnol. 2019 Dec;60:159-167. doi: 10.1016/j.copbio.2019.01.014. Epub 2019 Mar 9. Review.
PMID: 30861476
Early Access to Medicines Scheme: real-world data collection.
Pang H, Wang M, Kiff C, Soni M, Stein D, Tyas D.
Drug Discov Today. 2019 Dec;24(12):2231-2233. doi: 10.1016/j.drudis.2019.06.009. Epub 2019 Jun 19.
PMID: 31228615
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Schafer PH, Adams M, Horan G, Truzzi F, Marconi A, Pincelli C.
Drugs R D. 2019 Dec;19(4):329-338. doi: 10.1007/s40268-019-00284-1.
PMID: 31598889
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary.
Bueno H, de Graeff P, Richard-Lordereau I, Emmerich J, Fox KA, Friedman CP, Gaudin C, El-Gazayerly A, Goldman S, Hemmrich M, Henderson RA, Himmelmann A, Irs A, Jackson N, James SK, Katus HA, Laslop A, Laws I, Mehran R, Ong S, Prasad K, Roffi M, Rosano GM, Rose M, Sinnaeve PR, Stough WG, Thygesen K, Van de Werf F, Varin C, Verheugt FW, de Los Angeles Alonso García M.
Eur Heart J Acute Cardiovasc Care. 2019 Dec;8(8):745-754. doi: 10.1177/2048872616649859. Epub 2016 Jun 29.
PMID: 27357206
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.
Mesia R, Bossi P, Hansen AR, Hsieh CY, Licitra LF, Tan EH, Chen P, Miller J, Siu LL, Haddad RI.
Eur J Cancer. 2019 Dec;123:138-145. doi: 10.1016/j.ejca.2019.10.002. Epub 2019 Nov 4.
PMID: 31698327
Considering B7-CD28 as a family through sequence and structure.
West SM, Deng XA.
Exp Biol Med (Maywood). 2019 Dec;244(17):1577-1583. doi: 10.1177/1535370219855970. Epub 2019 Jun 17. No abstract available.
PMID: 31208204
Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
Hari P, Ung B, Abouzaid S, Agarwal A, Parikh K.
Future Oncol. 2019 Dec;15(35):4045-4056. doi: 10.2217/fon-2019-0422. Epub 2019 Oct 18.
PMID: 31625415
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE; Liver Forum Pediatric Working Group.
Gastroenterology. 2019 Dec;157(6):1448-1456.e1. doi: 10.1053/j.gastro.2019.08.048. Epub 2019 Sep 12. No abstract available.
PMID: 31520612
Improving health determinants outside of the clinic does not mean outside of clinical science.
Smith T, Mattingly TJ, Slabaugh L.
Healthc (Amst). 2019 Dec;7(4). pii: S2213-0764(19)30148-4. doi: 10.1016/j.hjdsi.2019.06.001. Epub 2019 Jun 27.
PMID: 31257162
Hydrogen-Deuterium Exchange and Hydroxyl Radical Footprinting for Mapping Hydrophobic Interactions of Human Bromodomain with a Small Molecule Inhibitor.
Li KS, Schaper Bergman ET, Beno BR, Huang RY, Deyanova E, Chen G, Gross ML.
J Am Soc Mass Spectrom. 2019 Dec;30(12):2795-2804. doi: 10.1007/s13361-019-02316-1. Epub 2019 Nov 12.
PMID: 31720974
Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K, MacGorman K, Liu L, Chen J, Carayannopoulos LN, Zhou S, Palmisano M, Li Y.
J Clin Pharmacol. 2019 Dec;59(12):1620-1631. doi: 10.1002/jcph.1453. Epub 2019 Jun 6.
PMID: 31172535
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
Yokota K, Uchi H, Uhara H, Yoshikawa S, Takenouchi T, Inozume T, Ozawa K, Ihn H, Fujisawa Y, Qureshi A, de Pril V, Otsuka Y, Weber J, Yamazaki N.
J Dermatol. 2019 Dec;46(12):1197-1201. doi: 10.1111/1346-8138.15103. Epub 2019 Oct 22.
PMID: 31638282
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P.
J Dermatol Sci. 2019 Dec;96(3):126-133. doi: 10.1016/j.jdermsci.2019.09.003. Epub 2019 Sep 10.
PMID: 31787506
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
Wang Y, Coyne K, Sofen H, Santanello N, Currie B, Zhang Z, Nograles K.
J Dermatolog Treat. 2019 Dec;30(8):775-783. doi: 10.1080/09546634.2019.1577546. Epub 2019 Mar 5.
PMID: 30747550
Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].
Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M.
J Hepatol. 2019 Dec;71(6):1278. doi: 10.1016/j.jhep.2019.09.013. Epub 2019 Oct 25. No abstract available.
PMID: 31668671
Meeting Report of the 34th Annual Meeting of the Academy of Surgical Research: Summary of Presentations, Labs, and Workshops, Focusing on Experimental Surgery, Charleston, SC, September 26-28, 2018.
Graham ML, Stoll LJ, Ehrmann J.
J Invest Surg. 2019 Dec;32(8):773-784. doi: 10.1080/08941939.2019.1649767. Epub 2019 Aug 28.
PMID: 31455106
Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A, Poulsen PB, Dybro L, Kloster B, Lorentzen A, Olsen J, Kümler T.
J Med Econ. 2019 Dec;22(12):1321-1327. doi: 10.1080/13696998.2019.1668193. Epub 2019 Sep 27.
PMID: 31516054
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors.
Mileham KF, Schenkel C, Chuk MK, Buchmeier A, Perez RP, Hurley P, Levit LA, Garrett-Mayer E, Davis C, Bruinooge SS, Vose J.
J Oncol Pract. 2019 Dec;15(12):e1050-e1065. doi: 10.1200/JOP.19.00366. Epub 2019 Oct 24.
PMID: 31647695
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC.
J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1. Review.
PMID: 31042108
Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
Chartrand S, Lee JS, Swigris JJ, Stanchev L, Fischer A.
Lung. 2019 Dec;197(6):709-713. doi: 10.1007/s00408-019-00276-7. Epub 2019 Oct 3.
PMID: 31583453
Prevalence of Sexual Dysfunction in Women with Multiple Sclerosis: a Systematic Review and Meta-Analysis.
Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M.
Maedica (Buchar). 2019 Dec;14(4):408-412. doi: 10.26574/maedica.2019.14.4.408.
PMID: 32153674
Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.
Stenehjem DD, Au TH, Ngorsuraches S, Ma J, Bauer H, Wanishayakorn T, Nelson RS, Pfeiffer CM, Schwartz J, Korytowsky B, Oderda G, Brixner DI.
Melanoma Res. 2019 Dec;29(6):626-634. doi: 10.1097/CMR.0000000000000572.
PMID: 30688762
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
Works M, Soni N, Hauskins C, Sierra C, Baturevych A, Jones JC, Curtis W, Carlson P, Johnstone TG, Kugler D, Hause RJ, Jiang Y, Wimberly L, Clouser CR, Jessup HK, Sather B, Salmon RA, Ports MO.
Mol Cancer Ther. 2019 Dec;18(12):2246-2257. doi: 10.1158/1535-7163.MCT-18-1146. Epub 2019 Aug 8.
PMID: 31395689
Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs.
Wang Y, Dix MM, Bianco G, Remsberg JR, Lee HY, Kalocsay M, Gygi SP, Forli S, Vite G, Lawrence RM, Parker CG, Cravatt BF.
Nat Chem. 2019 Dec;11(12):1113-1123. doi: 10.1038/s41557-019-0351-5. Epub 2019 Oct 28.
PMID: 31659311
Parameter estimation for roller compaction process using an instrumented vector TF mini roller compactor.
Reddy JP, Phanse R, Nesarikar V.
Pharm Dev Technol. 2019 Dec;24(10):1250-1257. doi: 10.1080/10837450.2019.1658775. Epub 2019 Sep 9.
PMID: 31437082
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE).
Fleischmann R, Weinblatt M, Ahmad H, Maldonado MA, Alemao E, Ye J, Schiff M.
Rheumatol Ther. 2019 Dec;6(4):559-571. doi: 10.1007/s40744-019-00174-7. Epub 2019 Oct 22.
PMID: 31642045
Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.
Suissa S, Hudson M, Dell'Aniello S, Shen S, Simon TA, Ernst P.
Semin Arthritis Rheum. 2019 Dec;49(3):366-372. doi: 10.1016/j.semarthrit.2019.03.007. Epub 2019 Mar 16.
PMID: 30979397
Identification of novel glutathione conjugates of terbinafine in liver microsomes and hepatocytes across species.
Patil A, Ladumor MK, Kamble SH, Johnson BM, Subramanian M, Sinz MW, Singh DK, Putlur S, Bhutani P, Ahire DS, Singh S.
Xenobiotica. 2019 Dec;49(12):1403-1413. doi: 10.1080/00498254.2019.1581959. Epub 2019 Mar 7.
PMID: 30747549
Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification.
Jin W, Xing Z, Song Y, Huang C, Xu X, Ghose S, Li ZJ.
MAbs. 2019 Nov-Dec;11(8):1479-1491. doi: 10.1080/19420862.2019.1658493. Epub 2019 Sep 2.
PMID: 31441367
Process intensification in fed-batch production bioreactors using non-perfusion seed cultures.
Yongky A, Xu J, Tian J, Oliveira C, Zhao J, McFarland K, Borys MC, Li ZJ.
MAbs. 2019 Nov-Dec;11(8):1502-1514. doi: 10.1080/19420862.2019.1652075. Epub 2019 Aug 19.
PMID: 31379298
Balancing Container Closure Integrity and Aesthetics for a Robust Aseptic or Sterile Vial Packaging System.
Oni Y, Song X, Schrader M, Kulshrestha A, Franck J, Asselta R, Flores-Crespo C, Mantri RV.
PDA J Pharm Sci Technol. 2019 Nov-Dec;73(6):572-587. doi: 10.5731/pdajpst.2018.009670. Epub 2019 May 17.
PMID: 31101708
Determinants of treatment in patients with stage IV renal cell carcinoma.
Hollenbeak CS, Schaefer EW, Doan J, Raman JD.
BMC Urol. 2019 Nov 29;19(1):123. doi: 10.1186/s12894-019-0559-0.
PMID: 31783828
An observational study of INR control according to NICE criteria in patients with non-valvular atrial fibrillation-The SAIL Warfarin Out of Range Descriptors Study (SWORDS).
Harris DE, Thayer D, Wang T, Brooks C, Murley G, Gravenor M, Hill NR, Lister S, Halcox J.
Eur Heart J Cardiovasc Pharmacother. 2019 Nov 27. pii: pvz071. doi: 10.1093/ehjcvp/pvz071. [Epub ahead of print]
PMID: 31774502
Biphenyl Acid Derivatives as APJ Receptor Agonists.
Su S, Clarke A, Han Y, Chao HJ, Bostwick J, Schumacher W, Wang T, Yan M, Hsu MY, Simmons E, Luk C, Xu C, Dabros M, Galella M, Onorato J, Gordon D, Wexler R, Gargalovic PS, Lawrence RM.
J Med Chem. 2019 Nov 27;62(22):10456-10465. doi: 10.1021/acs.jmedchem.9b01513. Epub 2019 Nov 14.
PMID: 31724863
Lipid order and charge protect killer T cells from accidental death.
Rudd-Schmidt JA, Hodel AW, Noori T, Lopez JA, Cho HJ, Verschoor S, Ciccone A, Trapani JA, Hoogenboom BW, Voskoboinik I.
Nat Commun. 2019 Nov 27;10(1):5396. doi: 10.1038/s41467-019-13385-x.
PMID: 31776337
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With  nab -Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.
Goldman JW, Waterhouse DM, George B, O'Dwyer PJ, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, Kelly K.
Front Oncol. 2019 Nov 26;9:1256. doi: 10.3389/fonc.2019.01256. eCollection 2019.
PMID: 31850192
Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells.
Dhanasiri S.
Bone Marrow Transplant. 2019 Nov 21. doi: 10.1038/s41409-019-0749-0. [Epub ahead of print] No abstract available.
PMID: 31754250
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
PMID: 31562796
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.
J Clin Oncol. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9.
PMID: 31398081
Palladium(0)-Catalyzed Directed syn-1,2-Carboboration and -Silylation: Alkene Scope, Applications in Dearomatization, and Stereocontrol by a Chiral Auxiliary.
Liu Z, Chen J, Lu HX, Li X, Gao Y, Coombs JR, Goldfogel MJ, Engle KM.
Angew Chem Int Ed Engl. 2019 Nov 18;58(47):17068-17073. doi: 10.1002/anie.201910304. Epub 2019 Oct 8. Review.
PMID: 31538388
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.
Alemao E, Postema R, Elbez Y, Mamane C, Finckh A.
Clin Exp Rheumatol. 2019 Nov 16. [Epub ahead of print]
PMID: 31770089
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M.
Clin Cancer Res. 2019 Nov 15;25(22):6709-6720. doi: 10.1158/1078-0432.CCR-19-0526. Epub 2019 Oct 1.
PMID: 31573956
One-Step Diastereoselective Pyrrolidine Synthesis Using a Sulfinamide Annulating Reagent.
Shi Q, Greenwood NS, Meehan MC, Park H, Galella M, Sandhu B, Khandelwal P, Coombs JR, Gallagher WP, Guerrero CA, Hynes J Jr, Dhar TGM, Gonzalez Bobes F, Marcoux D.
Org Lett. 2019 Nov 15;21(22):9198-9202. doi: 10.1021/acs.orglett.9b03560. Epub 2019 Oct 24.
PMID: 31647672
Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis.
Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M.
BMC Neurol. 2019 Nov 14;19(1):286. doi: 10.1186/s12883-019-1473-5.
PMID: 31727014
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.
Marcoux D, Duan JJ, Shi Q, Cherney RJ, Srivastava AS, Cornelius L, Batt DG, Liu Q, Beaudoin-Bertrand M, Weigelt CA, Khandelwal P, Vishwakrishnan S, Selvakumar K, Karmakar A, Gupta AK, Basha M, Ramlingam S, Manjunath N, Vanteru S, Karmakar S, Maddala N, Vetrichelvan M, Gupta A, Rampulla RA, Mathur A, Yip S, Li P, Wu DR, Khan J, Ruzanov M, Sack JS, Wang J, Yarde M, Cvijic ME, Li S, Shuster DJ, Borowski V, Xie JH, McIntyre KW, Obermeier MT, Fura A, Stefanski K, Cornelius G, Hynes J Jr, Tino JA, Macor JE, Salter-Cid L, Denton R, Zhao Q, Carter PH, Dhar TGM.
J Med Chem. 2019 Nov 14;62(21):9931-9946. doi: 10.1021/acs.jmedchem.9b01369. Epub 2019 Oct 31.
PMID: 31638797
Clinical outcomes and treatment patterns among Medicare patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease.
Wilson LE, Luo X, Li X, Mardekian J, Garcia Reeves AB, Skinner A.
PLoS One. 2019 Nov 14;14(11):e0225052. doi: 10.1371/journal.pone.0225052. eCollection 2019.
PMID: 31725743
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment.
García RA, Ito BR, Lupisella JA, Carson NA, Hsu MY, Fernando G, Heroux M, Bouvier M, Dierks E, Kick EK, Gordon DA, Chen J, Mintier G, Carrier M, St-Onge S, Shah H, Towne J, Bucardo MS, Ma X, Ryan CS, Wurtz NR, Ostrowski J, Villarreal FJ.
JACC Basic Transl Sci. 2019 Nov 13;4(8):905-920. doi: 10.1016/j.jacbts.2019.07.005. eCollection 2019 Dec.
PMID: 31909300
Tumor mutational burden in lung cancer: a systematic literature review.
Willis C, Fiander M, Tran D, Korytowsky B, Thomas JM, Calderon F, Zyczynski TM, Brixner D, Stenehjem DD.
Oncotarget. 2019 Nov 12;10(61):6604-6622. doi: 10.18632/oncotarget.27287. eCollection 2019 Nov 12. Review.
PMID: 31762941
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, Singhal S, Suissa S, Gomez-Caminero A.
Arthritis Res Ther. 2019 Nov 8;21(1):228. doi: 10.1186/s13075-019-1992-x.
PMID: 31703717
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, Mistry T, Lindquist KC, Van Blarcom T, Strop P, Chaparro-Riggers J, Liu SH.
Sci Rep. 2019 Nov 8;9(1):16735. doi: 10.1038/s41598-019-53130-4.
PMID: 31700121
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL.
JAMA Oncol. 2019 Nov 7:1-8. doi: 10.1001/jamaoncol.2019.3848. [Epub ahead of print]
PMID: 31697308
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN.
J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5.
PMID: 31487218
Pharmacological Characterization of GPCR Agonists, Antagonists, Allosteric Modulators and Biased Ligands from HTS Hits to Lead Optimization.
Sum CS, Murphy BJ, Li Z, Wang T, Zhang L, Cvijic ME.
In: Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Coussens NP, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kahl SD, Kales SC, Kirshner S, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-2019 Nov 1.
PMID: 31693331
Predicting atrial fibrillation in primary care using machine learning.
Hill NR, Ayoubkhani D, McEwan P, Sugrue DM, Farooqui U, Lister S, Lumley M, Bakhai A, Cohen AT, O'Neill M, Clifton D, Gordon J.
PLoS One. 2019 Nov 1;14(11):e0224582. doi: 10.1371/journal.pone.0224582. eCollection 2019.
PMID: 31675367
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
Campbell D, Blazer M, Bloudek L, Brokars J, Makenbaeva D.
Am Health Drug Benefits. 2019 Nov;12(7):333-342.
PMID: 32055281
A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study.
Payne RM, Burns KM, Glatz AC, Li D, Li X, Monagle P, Newburger JW, Swan EA, Wheaton O, Male C; Pediatric Heart Network Investigators.
Am Heart J. 2019 Nov;217:52-63. doi: 10.1016/j.ahj.2019.08.002. Epub 2019 Aug 9.
PMID: 31493728
2019 White Paper on Recent Issues in Bioanalysis: Chromatographic Assays (Part 1 - Innovation in Small Molecules and Oligonucleotides & Mass Spectrometric Method Development Strategies for Large Molecule Bioanalysis).
Fandozzi C, Evans C, Wilson A, Su D, Anderson M, Clausen V, Dillen L, Garofolo F, Holliman C, Nickbarg E, Olah T, Ramanathan R, Zhang H, Kaur S, Pillutla R, Yu H, Bateman K, Donato LD, Hengel S, Jian W, Jones B, Kellie J, Lee A, Palandra J, Savoie N, Shipkova P, Spitz S, Su D, Szapacs M, Wang J, Wright K, Zeng J.
Bioanalysis. 2019 Nov;11(22):2029-2048. doi: 10.4155/bio-2019-0260. Epub 2019 Dec 6.
PMID: 31808716
Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.
Hamuro L, Statkevich P, Bello A, Roy A, Bajaj G.
Clin Pharmacol Ther. 2019 Nov;106(5):1018-1027. doi: 10.1002/cpt.1502. Epub 2019 Jul 10.
PMID: 31090921
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
Alten R, Feist E, Lorenz HM, Nüßlein H, Voll RE, Chartier M, Elbez Y, Rauch C.
Clin Rheumatol. 2019 Nov;38(11):3049-3059. doi: 10.1007/s10067-019-04648-5. Epub 2019 Jul 12.
PMID: 31300979
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.
Kierzek AM, Hickling TP, Figueroa I, Kalvass JC, Nijsen M, Mohan K, Veldman GM, Yamada A, Sayama H, Yokoo S, Gulati A, Dhanikula RS, Gokemeijer J, Leil TA, Thalhauser CJ, Giorgi M, Swat MJ, Chelliah V, Small BG, Benson N, Walker M, Gadkar K, Quarmby V, Deng R, Ferrante A, Dickinson GL, Van Der Walt JS, Zhou L, Chen X, Jones HM, Narula J, Tourdot S, Lavé T, Ribba B, van der Graaf PH.
CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):773-776. doi: 10.1002/psp4.12465. Epub 2019 Oct 8. No abstract available.
PMID: 31529677
Linking Tumor Growth Dynamics to Survival in Ipilimumab-Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling.
Feng Y, Wang X, Suryawanshi S, Bello A, Roy A.
CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):825-834. doi: 10.1002/psp4.12454. Epub 2019 Aug 13.
PMID: 31334596
Influence of Diabetes Complications on HbA 1c  Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis.
Shao H, Lin J, Zhuo X, Rolka DB, Gregg EW, Zhang P.
Diabetes Care. 2019 Nov;42(11):2136-2142. doi: 10.2337/dc19-0381. Epub 2019 Sep 17.
PMID: 31530661
Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A.
Panfen E, Chen W, Zhang Y, Sinz M, Marathe P, Gan J, Shen H.
Drug Metab Dispos. 2019 Nov;47(11):1352-1360. doi: 10.1124/dmd.119.087197. Epub 2019 Aug 19.
PMID: 31427432
Characterization of therapeutic antibody fragmentation using automated capillary western blotting as an orthogonal analytical technique.
Zhu Y, Ahluwalia D, Chen Y, Belakavadi M, Katiyar A, Das TK.
Electrophoresis. 2019 Nov;40(21):2888-2898. doi: 10.1002/elps.201900119. Epub 2019 Jul 16.
PMID: 31271455
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).
Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Nathan P.
Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30.
PMID: 31581055
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD.
Eur Urol. 2019 Nov;76(5):599-603. doi: 10.1016/j.eururo.2019.06.025. Epub 2019 Jul 1.
PMID: 31272788
Suspected cancer symptoms and blood test results in primary care before a diagnosis of lung cancer: a case-control study.
McDonald L, Carroll R, Harish A, Tanna N, Mehmud F, Alikhan R, Ramagopalan SV.
Future Oncol. 2019 Nov;15(33):3755-3762. doi: 10.2217/fon-2019-0442. Epub 2019 Oct 31.
PMID: 31668096
Comparison of accelerometer-derived physical activity levels between individuals with and without cancer: a UK Biobank study.
McDonald L, Oguz M, Carroll R, Thakkar P, Yang F, Dhalwani N, Cox A, Merinopoulou E, Malcolm B, Mehmud F, Ramagopalan S.
Future Oncol. 2019 Nov;15(33):3763-3774. doi: 10.2217/fon-2019-0443. Epub 2019 Oct 22.
PMID: 31637942
Automated extraction of treatment patterns from social media posts: an exploratory analysis in renal cell carcinoma.
Ramagopalan SV, Malcolm B, Merinopoulou E, McDonald L, Cox A.
Future Oncol. 2019 Nov;15(31):3587-3596. doi: 10.2217/fon-2019-0406. Epub 2019 Sep 4.
PMID: 31483164
Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma.
Tsutsumida A, Fukushima S, Yokota K, Yoshikawa S, Yamasaki O, Tanemura A, Okuyama R, Uhara H, Muto Y, Miyashita A, Akiyama M, Kaji T, Koga H, Kato J, Katayama T, Itakura E, Yamazaki N, Kiyohara Y.
J Dermatol. 2019 Nov;46(11):947-955. doi: 10.1111/1346-8138.15073. Epub 2019 Sep 17.
PMID: 31531895
Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.
Jabbour EJ, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D.
J Med Econ. 2019 Nov;22(11):1113-1118. doi: 10.1080/13696998.2019.1618316. Epub 2019 May 31.
PMID: 31074658
Increasing value of autopsies in patients with brain tumors in the molecular era.
Ahrendsen JT, Filbin MG, Chi SN, Manley PE, Wright KD, Bandopadhayay P, Clymer JR, Yeo KK, Kieran MW, Jones R, Lidov HG, Ligon KL, Alexandrescu S.
J Neurooncol. 2019 Nov;145(2):349-355. doi: 10.1007/s11060-019-03302-z. Epub 2019 Sep 30.
PMID: 31571114
A Proposal for an Alternative Approach to Particle Size Method Development During Early-Stage Small Molecule Pharmaceutical Development.
Gamble JF, Dawson N, Murphy D, Theophilus A, Kippax P.
J Pharm Sci. 2019 Nov;108(11):3515-3520. doi: 10.1016/j.xphs.2019.08.007. Epub 2019 Aug 21.
PMID: 31445006
Two-year abatacept retention rate in clinical practice in the French ACTION cohort.
Mariette X, Schaeverbeke T, Gaudin P, Chartier M, Heitzmann J, Vannier-Moreau V, Hilliquin P, Cantagrel A.
Joint Bone Spine. 2019 Nov;86(6):753-759. doi: 10.1016/j.jbspin.2019.07.006. Epub 2019 Jul 25.
PMID: 31352138
Human or mouse? Practice makes perfect.
Stanislawczyk L.
Lab Anim (NY). 2019 Nov;48(11):319. doi: 10.1038/s41684-019-0419-2. No abstract available.
PMID: 31645691
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y.
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Erratum in:  Lancet Oncol. 2019 Nov;20(11):e613 .
PMID: 31582355
A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, Tyas D, Sowdani A.
Med Decis Making. 2019 Nov;39(8):899-909. doi: 10.1177/0272989X19881967. Epub 2019 Nov 9.
PMID: 31707911
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG, Kuang B, Han B, Mirsky M, Pardo I, Buetow B, Martin TG, Wolf JL, Shelton D, Rajpal A, Strop P, Chaparro-Riggers J, Sasu BJ.
Mol Cancer Ther. 2019 Nov;18(11):2008-2020. doi: 10.1158/1535-7163.MCT-19-0007. Epub 2019 Aug 21.
PMID: 31434693
Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B.
Oncologist. 2019 Nov;24(11):1453-1461. doi: 10.1634/theoncologist.2019-0129. Epub 2019 May 30.
PMID: 31147488
Elucidating spray-dried dispersion dissolution mechanisms with focused beam reflectance measurement: contribution of polymer chemistry and particle properties to performance.
Rawlinson-Malone CF, Ferreira AP, Nicholls D, Nicholson S.
Pharm Dev Technol. 2019 Nov;24(9):1055-1062. doi: 10.1080/10837450.2018.1559189. Epub 2019 Jun 26.
PMID: 30640552
A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017.
Cha AS, Law EH, Shaw JW, Pickard AS.
Qual Life Res. 2019 Nov;28(11):3065-3069. doi: 10.1007/s11136-019-02249-y. Epub 2019 Jul 18.
PMID: 31321671
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F, Ramji A, Shafran SD, McPhee F, Yang R, Noviello S, Linaberry M; ALLY-3C study team.
Antivir Ther. 2019 Nov;24(1):35-44. doi: 10.3851/IMP3278.
PMID: 30382942
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention.
Oyagüez I, Suárez C, López-Sendón JL, González-Juanatey JR, de Andrés-Nogales F, Suárez J, Polanco C, Soto J.
Pharmacoecon Open. 2019 Oct 31. doi: 10.1007/s41669-019-00186-7. [Epub ahead of print]
PMID: 31673882
Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life Cycle.
Mathaes R, Narhi L, Hawe A, Matter A, Bechtold-Peters K, Kenrick S, Kar S, Laskina O, Carpenter J, Cavicchi R, Koepf E, Lewis EN, De Silva R, Ripple D.
AAPS J. 2019 Oct 30;22(1):1. doi: 10.1208/s12248-019-0384-0.
PMID: 31677011
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Paul D, Vukelja SJ, Ann Holmes F, Blum JL, McIntyre KJ, Lindquist DL, Osborne CR, Sanchez IJ, Goldschmidt JH, Wang Y, Asmar L, Strauss L, O'Shaughnessy J.
NPJ Breast Cancer. 2019 Oct 28;5:36. doi: 10.1038/s41523-019-0132-8. eCollection 2019.
PMID: 31667338
Anti-Markovnikov Hydroamination of Unactivated Alkenes with Primary Alkyl Amines.
Miller DC, Ganley JM, Musacchio AJ, Sherwood TC, Ewing WR, Knowles RR.
J Am Chem Soc. 2019 Oct 23;141(42):16590-16594. doi: 10.1021/jacs.9b08746. Epub 2019 Oct 14.
PMID: 31603324
Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.
Gesenberg C, Mathias NR, Xu Y, Crison J, Savant I, Saari A, Good DJ, Hemenway JN, Narang AS, Schartman RR, Zheng N, Buzescu A, Patel J.
Pharm Res. 2019 Oct 21;36(12):164. doi: 10.1007/s11095-019-2698-0.
PMID: 31637544
The hepatoprotective activities of  Kalimeris indica  ethanol extract against liver injury in vivo.
Wang GK, Zhang N, Wang Y, Liu JS, Wang G, Zhou ZY, Lu CC, Yang JS.
Food Sci Nutr. 2019 Oct 18;7(11):3797-3807. doi: 10.1002/fsn3.1241. eCollection 2019 Nov.
PMID: 31763029
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD.
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
PMID: 31562797
Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.
Dicker I, Zhang S, Ray N, Beno BR, Regueiro-Ren A, Joshi S, Cockett M, Krystal M, Lataillade M.
PLoS One. 2019 Oct 17;14(10):e0224076. doi: 10.1371/journal.pone.0224076. eCollection 2019. Erratum in:  PLoS One. 2019 Nov 5;14(11):e0224976 .
PMID: 31622432
Benzothiazole-based compounds as potent endothelial lipase inhibitors.
Meng W, Adam LP, Behnia K, Zhao L, Yang R, Kopcho LM, Locke GA, Taylor DS, Yin X, Wexler RR, Finlay H.
Bioorg Med Chem Lett. 2019 Oct 15;29(20):126673. doi: 10.1016/j.bmcl.2019.126673. Epub 2019 Sep 6.
PMID: 31519373
Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.
Sangesland M, Ronsard L, Kazer SW, Bals J, Boyoglu-Barnum S, Yousif AS, Barnes R, Feldman J, Quirindongo-Crespo M, McTamney PM, Rohrer D, Lonberg N, Chackerian B, Graham BS, Kanekiyo M, Shalek AK, Lingwood D.
Immunity. 2019 Oct 15;51(4):735-749.e8. doi: 10.1016/j.immuni.2019.09.001. Epub 2019 Sep 25.
PMID: 31563464
Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.
Pang L, Sager P, Yang X, Shi H, Sannajust F, Brock M, Wu JC, Abi-Gerges N, Lyn-Cook B, Berridge BR, Stockbridge N.
Circ Res. 2019 Oct 11;125(9):855-867. doi: 10.1161/CIRCRESAHA.119.315378. Epub 2019 Oct 10.
PMID: 31600125
Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection.
Batteson R, Hart R, Hemstock M, Gooden K, Kotapati S, Roze S, Lee D, Amadi A.
Pharmacoecon Open. 2019 Oct 5. doi: 10.1007/s41669-019-00181-y. [Epub ahead of print]
PMID: 31587138
Risk of Recurrent Bleeding Events in Nonvalvular Atrial Fibrillation Treated with Vitamin K Antagonists: A Clinical Practice Research Datalink Study.
Alikhan R, Lefevre C, Menown I, Lister S, Bird A, You M, Evans D, Sammon C.
TH Open. 2019 Oct 4;3(4):e316-e324. doi: 10.1055/s-0039-1698413. eCollection 2019 Oct.
PMID: 31592518
Hemilabile Benzyl Ether Enables γ-C(sp 3 )-H Carbonylation and Olefination of Alcohols.
Tanaka K, Ewing WR, Yu JQ.
J Am Chem Soc. 2019 Oct 2;141(39):15494-15497. doi: 10.1021/jacs.9b08238. Epub 2019 Sep 18.
PMID: 31519108
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.
Clark CG, Rossi KA, Corte JR, Fang T, Smallheer JM, De Lucca I, Nirschl DS, Orwat MJ, Pinto DJP, Hu Z, Wang Y, Yang W, Jeon Y, Ewing WR, Myers JE Jr, Sheriff S, Lou Z, Bozarth JM, Wu Y, Rendina A, Harper T, Zheng J, Xin B, Xiang Q, Luettgen JM, Seiffert DA, Wexler RR, Lam PYS.
Bioorg Med Chem Lett. 2019 Oct 1;29(19):126604. doi: 10.1016/j.bmcl.2019.08.008. Epub 2019 Aug 16.
PMID: 31445854
Allogeneic murine pregnancy models for assessing the developmental effects of immune-stimulating antibodies: Challenges in reproducibility.
Thompson KE, Danberry TL, Bunch RT, Graziano MJ, McNerney ME.
Birth Defects Res. 2019 Oct 1;111(16):1178-1191. doi: 10.1002/bdr2.1542. Epub 2019 Jun 22.
PMID: 31228335
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.
Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse AN, Kauer N, Blazquez R, Hacker L, Decking SM, Bohn T, Faerber S, Evert K, Aigle L, Amslinger S, Landa M, Krijgsman O, Rozeman EA, Brummer C, Siska PJ, Singer K, Pektor S, Miederer M, Peter K, Gottfried E, Herr W, Marchiq I, Pouyssegur J, Roush WR, Ong S, Warren S, Pukrop T, Beckhove P, Lang SA, Bopp T, Blank CU, Cleveland JL, Oefner PJ, Dettmer K, Selby M, Kreutz M.
Cell Rep. 2019 Oct 1;29(1):135-150.e9. doi: 10.1016/j.celrep.2019.08.068.
PMID: 31577944
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.
Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C.
J Antimicrob Chemother. 2019 Oct 1;74(10):2994-3002. doi: 10.1093/jac/dkz265.
PMID: 31273386
Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN.
Adv Ther. 2019 Oct;36(10):2783-2796. doi: 10.1007/s12325-019-01060-y. Epub 2019 Aug 22.
PMID: 31440980
Stereospecific interactions between histidine and monoclonal antibodies.
Baek Y, Emami P, Singh N, Ilott A, Sahin E, Zydney A.
Biotechnol Bioeng. 2019 Oct;116(10):2632-2639. doi: 10.1002/bit.27109. Epub 2019 Jul 24.
PMID: 31286487
Control of antibody high and low molecular weight species by depth filtration-based cell culture harvesting.
Yu D, Mayani M, Song Y, Xing Z, Ghose S, Li ZJ.
Biotechnol Bioeng. 2019 Oct;116(10):2610-2620. doi: 10.1002/bit.27081. Epub 2019 Jun 29.
PMID: 31184373
The effects of buffer condition on the fouling behavior of MVM virus filtration of an Fc-fusion protein.
Namila F, Zhang D, Traylor S, Nguyen T, Singh N, Wickramasinghe R, Qian X.
Biotechnol Bioeng. 2019 Oct;116(10):2621-2631. doi: 10.1002/bit.27085. Epub 2019 Jul 6.
PMID: 31184371
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.
Cancer Immunol Res. 2019 Oct;7(10):1633-1646. doi: 10.1158/2326-6066.CIR-18-0579. Epub 2019 Aug 20.
PMID: 31431433
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study.
Picard F, Van Ganse E, Ducrocq G, Danchin N, Falissard B, Hanon O, Belhassen M, Ginoux M, Lefevre C, Cotte FE, Mahé I, Steg PG.
Clin Cardiol. 2019 Oct;42(10):851-859. doi: 10.1002/clc.23231. Epub 2019 Jul 17.
PMID: 31313832
A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC).
Shah R, Botteman M, Solem CT, Luo L, Doan J, Cella D, Motzer RJ.
Clin Genitourin Cancer. 2019 Oct;17(5):356-365.e1. doi: 10.1016/j.clgc.2019.05.010. Epub 2019 May 31.
PMID: 31272883
Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A, Parikh K, Ni Q, Abouzaid S.
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):645-655. doi: 10.1016/j.clml.2019.06.007. Epub 2019 Jun 18.
PMID: 31377207
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Byon W, Garonzik S, Boyd RA, Frost CE.
Clin Pharmacokinet. 2019 Oct;58(10):1265-1279. doi: 10.1007/s40262-019-00775-z. Review.
PMID: 31089975
Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
Ueno T, Osawa M, Shiozaki T, Green M, Garimella T.
Clin Pharmacol Drug Dev. 2019 Oct;8(7):903-913. doi: 10.1002/cpdd.646. Epub 2019 Jan 22.
PMID: 30667592
Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.
Dhamane AD, Baker CL, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J.
Curr Med Res Opin. 2019 Oct;35(10):1769-1776. doi: 10.1080/03007995.2019.1623187. Epub 2019 Jun 5.
PMID: 31120309
Developments in the treatment of HCV genotype 3 infection.
McPhee F.
Expert Rev Anti Infect Ther. 2019 Oct;17(10):775-785. doi: 10.1080/14787210.2019.1676730. Epub 2019 Oct 21. Review.
PMID: 31584833
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab.
Hotchkiss RS, Colston E, Yende S, Crouser ED, Martin GS, Albertson T, Bartz RR, Brakenridge SC, Delano MJ, Park PK, Donnino MW, Tidswell M, Mayr FB, Angus DC, Coopersmith CM, Moldawer LL, Catlett IM, Girgis IG, Ye J, Grasela DM.
Intensive Care Med. 2019 Oct;45(10):1360-1371. doi: 10.1007/s00134-019-05704-z. Epub 2019 Oct 1.
PMID: 31576433
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
Zhang J, Cai J, Bello A, Roy A, Sheng J.
J Clin Pharmacol. 2019 Oct;59(10):1415-1424. doi: 10.1002/jcph.1432. Epub 2019 May 22.
PMID: 31115908
Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation.
Martin AL, Reeves AG, Berger SE, Fusco MD, Wygant GD, Savone M, Snook K, Nejati M, Lanitis T.
J Comp Eff Res. 2019 Oct;8(14):1147-1166. doi: 10.2217/cer-2019-0089. Epub 2019 Aug 22.
PMID: 31436488
Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study.
Ramagopalan SV, Sicras-Mainar A, Polanco-Sanchez C, Carroll R, de Bobadilla JF.
J Comp Eff Res. 2019 Oct;8(14):1201-1212. doi: 10.2217/cer-2019-0079. Epub 2019 Jul 23.
PMID: 31333045
Electrostatic-field and surface-shape similarity for virtual screening and pose prediction.
Cleves AE, Johnson SR, Jain AN.
J Comput Aided Mol Des. 2019 Oct;33(10):865-886. doi: 10.1007/s10822-019-00236-6. Epub 2019 Oct 24.
PMID: 31650386
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F.
J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4.
PMID: 31279902
Forced Oxidative Degradation Pathways of the Imidazole Moiety of Daclatasvir.
Huang Y, Su BN, Marshall J, Miller SA.
J Pharm Sci. 2019 Oct;108(10):3312-3318. doi: 10.1016/j.xphs.2019.05.022. Epub 2019 May 27.
PMID: 31145924
Cyclization of N-Terminal Glutamic Acid to pyro-Glutamic Acid Impacts Monoclonal Antibody Charge Heterogeneity Despite Its Appearance as a Neutral Transformation.
Liu Z, Valente J, Lin S, Chennamsetty N, Qiu D, Bolgar M.
J Pharm Sci. 2019 Oct;108(10):3194-3200. doi: 10.1016/j.xphs.2019.05.023. Epub 2019 May 27.
PMID: 31145921
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.
Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in:  Lancet Oncol. 2019 Aug 21;: .
PMID: 31427204
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, Crinò L, Planchard D, Butts C, Drilon A, Wojcik-Tomaszewska J, Otterson GA, Agrawal S, Li A, Penrod JR, Brahmer J.
Lancet Oncol. 2019 Oct;20(10):1395-1408. doi: 10.1016/S1470-2045(19)30407-3. Epub 2019 Aug 14.
PMID: 31422028
VISTA is an acidic pH-selective ligand for PSGL-1.
Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, Corbett M, Rankin AL, Dibella R, Campbell L, Martin GH, Lemar H, Cayton T, Huang RY, Deng X, Nayeem A, Chen H, Ergel B, Rizzo JM, Yamniuk AP, Dutta S, Ngo J, Shorts AO, Ramakrishnan R, Kozhich A, Holloway J, Fang H, Wang YK, Yang Z, Thiam K, Rakestraw G, Rajpal A, Sheppard P, Quigley M, Bahjat KS, Korman AJ.
Nature. 2019 Oct;574(7779):565-570. doi: 10.1038/s41586-019-1674-5. Epub 2019 Oct 23.
PMID: 31645726
Evaluation of the Implementation of Additional Risk Minimization Activities in Europe, the USA, and Japan.
Yasuoka Y, Kaneko M, Narukawa M.
Pharmaceut Med. 2019 Oct;33(5):417-424. doi: 10.1007/s40290-019-00303-1.
PMID: 31933232
Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies.
Saine ME, Carbonari DM, Newcomb CW, Gallagher AM, Blak BT, Roy JA, Wood J, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd.
Pharmacoepidemiol Drug Saf. 2019 Oct;28(10):1328-1335. doi: 10.1002/pds.4853. Epub 2019 Jul 22.
PMID: 31328342
Exposure assessments in reproductive and developmental toxicity testing: An IQ-DruSafe industry survey on current practices and experiences in support of exposure-based high dose selection.
Andrews PA, McNerney ME, DeGeorge JJ.
Regul Toxicol Pharmacol. 2019 Oct;107:104413. doi: 10.1016/j.yrtph.2019.104413. Epub 2019 Jun 20.
PMID: 31229519
Genetic toxicology in silico protocol.
Hasselgren C, Ahlberg E, Akahori Y, Amberg A, Anger LT, Atienzar F, Auerbach S, Beilke L, Bellion P, Benigni R, Bercu J, Booth ED, Bower D, Brigo A, Cammerer Z, Cronin MTD, Crooks I, Cross KP, Custer L, Dobo K, Doktorova T, Faulkner D, Ford KA, Fortin MC, Frericks M, Gad-McDonald SE, Gellatly N, Gerets H, Gervais V, Glowienke S, Van Gompel J, Harvey JS, Hillegass J, Honma M, Hsieh JH, Hsu CW, Barton-Maclaren TS, Johnson C, Jolly R, Jones D, Kemper R, Kenyon MO, Kruhlak NL, Kulkarni SA, Kümmerer K, Leavitt P, Masten S, Miller S, Moudgal C, Muster W, Paulino A, Lo Piparo E, Powley M, Quigley DP, Reddy MV, Richarz AN, Schilter B, Snyder RD, Stavitskaya L, Stidl R, Szabo DT, Teasdale A, Tice RR, Trejo-Martin A, Vuorinen A, Wall BA, Watts P, White AT, Wichard J, Witt KL, Woolley A, Woolley D, Zwickl C, Myatt GJ.
Regul Toxicol Pharmacol. 2019 Oct;107:104403. doi: 10.1016/j.yrtph.2019.104403. Epub 2019 Jun 11.
PMID: 31195068
Comparison of immune system development in nonclinical species and humans: Closing information gaps for immunotoxicity testing and human translatability.
Skaggs H, Chellman GJ, Collinge M, Enright B, Fuller CL, Krayer J, Sivaraman L, Weinbauer GF.
Reprod Toxicol. 2019 Oct;89:178-188. doi: 10.1016/j.reprotox.2019.06.005. Epub 2019 Jun 21. Review. No abstract available.
PMID: 31233776
Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
Mattila J, Curtis S, Webb-Vargas Y, Wilson E, Galperina O, Roush D, Tobler S, Stanley B, Clark M, Weaver J, Pike J, Yu D, Li X, Flicker A, Kindermann J, Schuelke N, Whitcombe R, Bennett L.
PDA J Pharm Sci Technol. 2019 Sep-Oct;73(5):470-486. doi: 10.5731/pdajpst.2018.009605. Epub 2019 May 17.
PMID: 31101706
Comparative electrophysiology and pharmacology of hiPSC cardiomyocyte 2D mono-cultures and 2D co-cultures with human ventricular fibroblasts.
Shi H, Huang M, Kwagh J, Levesque P.
J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.037. Epub 2019 Oct 17. No abstract available.
PMID: 31963065
Evaluating the use of microelectrode array technology and cell-based neuronal culture models for proconvulsant risk assessment: progress from the HESI NeuTox consortium.
Millard DC, Nicolini AM, Arrowood CA, Hayes HB, Bradley JA, Strock CJ, Freudenrich TM, Wallace K, Shafer TJ, Cato MJ, Chaudhary KW, Saavedra L, Haag D, Feaster TK, Anson BD, Luerman G, Hess D, Shi Y, Li J, Shi H, Levesque P, Kreir M, Lu HR, Suzuki I, Odawara A, Miyamoto N, Ojima A, Kanda Y, Blinova K, Herr D, Roberts R, Pierson J.
J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.076. Epub 2019 Oct 17. No abstract available.
PMID: 31963054
Characterization of a renal hypertensive model in telemetrized cynomolgus monkeys.
Arthur SR, Love A, Bounous DI, Ehrmann J, Lehman B, Johnson W, Smith R, Adamo R, Gill M, Hennan J.
J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.044. Epub 2019 Oct 17. No abstract available.
PMID: 31963043
Characterization of contractile properties of hIPSC-CMs cultured with or without fibroblast and chronic electrical stimulation.
Huang M, Shi H, Levesque P.
J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.164. Epub 2019 Oct 17. No abstract available.
PMID: 31962937
GSK3732394: a Multi-specific Inhibitor of HIV Entry.
Wensel D, Sun Y, Davis J, Li Z, Zhang S, McDonagh T, Langley D, Mitchell T, Tabruyn S, Nef P, Cockett M, Krystal M.
J Virol. 2019 Sep 30;93(20). pii: e00907-19. doi: 10.1128/JVI.00907-19. Print 2019 Oct 15.
PMID: 31375580
Mechanistic modeling based process development for monoclonal antibody monomer-aggregate separations in multimodal cation exchange chromatography.
Zhang L, Parasnavis S, Li Z, Chen J, Cramer S.
J Chromatogr A. 2019 Sep 27;1602:317-325. doi: 10.1016/j.chroma.2019.05.056. Epub 2019 Jun 6.
PMID: 31248584
Discovery of Pyridazinone and Pyrazolo[1,5- a ]pyridine Inhibitors of C-Terminal Src Kinase.
O'Malley DP, Ahuja V, Fink B, Cao C, Wang C, Swanson J, Wee S, Gavai AV, Tokarski J, Critton D, Paiva AA, Johnson BM, Szapiel N, Xie D.
ACS Med Chem Lett. 2019 Sep 25;10(10):1486-1491. doi: 10.1021/acsmedchemlett.9b00354. eCollection 2019 Oct 10.
PMID: 31620238
Metabolomic adaptations and correlates of survival to immune checkpoint blockade.
Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, Schreiber SL, Stephen Hodi F, Sellers WR, Garraway LA, Clish CB, Choueiri TK, Giannakis M.
Nat Commun. 2019 Sep 25;10(1):4346. doi: 10.1038/s41467-019-12361-9.
PMID: 31554815
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early, Poor Prognosis Rheumatoid Arthritis.
Ahmad HA, Baker JF, Østergaard M, Emery P, Durez P, Ye J, Banerjee S, Conaghan PG.
Arthritis Care Res (Hoboken). 2019 Sep 24. doi: 10.1002/acr.24072. [Epub ahead of print]
PMID: 31549793
Comparing record linkage software programs and algorithms using real-world data.
Karr AF, Taylor MT, West SL, Setoguchi S, Kou TD, Gerhard T, Horton DB.
PLoS One. 2019 Sep 24;14(9):e0221459. doi: 10.1371/journal.pone.0221459. eCollection 2019.
PMID: 31550255
Reduced Compensatory β-Cell Proliferation in Nfatc3-Deficient Mice Fed on High-Fat Diet.
Hu L, He F, Luo Y, Luo H, Hai L, Li Y, Zhou Z, Liu F, Dai YS.
Exp Clin Endocrinol Diabetes. 2019 Sep 23. doi: 10.1055/a-1008-9110. [Epub ahead of print]
PMID: 31546271
Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance.
Fousteri G, Dave Jhatakia A.
Viruses. 2019 Sep 21;11(10). pii: E885. doi: 10.3390/v11100885. Review.
PMID: 31546586
meta  C-H Arylation of Electron-Rich Arenes: Reversing the Conventional Site Selectivity.
Liu LY, Qiao JX, Yeung KS, Ewing WR, Yu JQ.
J Am Chem Soc. 2019 Sep 18;141(37):14870-14877. doi: 10.1021/jacs.9b07887. Epub 2019 Sep 6.
PMID: 31449745
Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry.
Shackman JG.
MethodsX. 2019 Sep 18;6:2176-2180. doi: 10.1016/j.mex.2019.09.017. eCollection 2019.
PMID: 31667117
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.
de Jong LA, Groeneveld J, Stevanovic J, Rila H, Tieleman RG, Huisman MV, Postma MJ, van Hulst M.
PLoS One. 2019 Sep 17;14(9):e0222658. doi: 10.1371/journal.pone.0222658. eCollection 2019.
PMID: 31527894
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.
Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.
PMID: 31246283
To Go or Stay: The Development, Benefit, and Detriment of Tissue-Resident Memory CD8 T Cells during Central Nervous System Viral Infections.
Mockus TE, Ren HM; Shwetank, Lukacher AE.
Viruses. 2019 Sep 11;11(9). pii: E842. doi: 10.3390/v11090842. Review.
PMID: 31514273
A note on the empirical Bayes heterogeneity variance estimator in meta-analysis.
Sidik K, Jonkman JN.
Stat Med. 2019 Sep 10;38(20):3804-3816. doi: 10.1002/sim.8197. Epub 2019 Jun 18.
PMID: 31209917
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber RD, Piccart M, Mobus V, de Azambuja E; APHINITY Steering Committee and Investigators.
Clin Breast Cancer. 2019 Sep 5. pii: S1526-8209(19)30656-1. doi: 10.1016/j.clbc.2019.06.016. [Epub ahead of print]
PMID: 31924513
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.
Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, Choueiri TK.
JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.3158. [Epub ahead of print] No abstract available.
PMID: 31486842
Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach.
Feldman CH, Yoshida K, Xu C, Frits ML, Shadick NA, Weinblatt ME, Connolly SE, Alemao E, Solomon DH.
ACR Open Rheumatol. 2019 Sep 4;1(9):552-559. doi: 10.1002/acr2.11068. eCollection 2019 Nov.
PMID: 31777839
Validity of social media for assessing treatment patterns in oncology patients: a case study in melanoma.
McDonald L, Behl V, Sundar V, Mehmud F, Malcolm B, Ramagopalan S.
JAMIA Open. 2019 Sep 3;2(4):416-422. doi: 10.1093/jamiaopen/ooz013. eCollection 2019 Dec.
PMID: 32025637
Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
Shen H, Yao M, Sinz M, Marathe P, Rodrigues AD, Zhu M.
Mol Pharm. 2019 Sep 3;16(9):4065-4076. doi: 10.1021/acs.molpharmaceut.9b00472. Epub 2019 Aug 7.
PMID: 31335150
Emerging biomaterials for downstream manufacturing of therapeutic proteins.
Li Y, Stern D, Lock LL, Mills J, Ou SH, Morrow M, Xu X, Ghose S, Li ZJ, Cui H.
Acta Biomater. 2019 Sep 1;95:73-90. doi: 10.1016/j.actbio.2019.03.015. Epub 2019 Mar 9. Review.
PMID: 30862553
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.
Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.
PMID: 31239321
Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.
Ahmad HA, Baker JF, Østergaard M, Ye J, Emery P, Conaghan PG.
Adv Ther. 2019 Sep;36(9):2384-2393. doi: 10.1007/s12325-019-01020-6. Epub 2019 Jul 5.
PMID: 31278695
Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes.
George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, Hsu JY, Simon TA, Wu Q, Xie F, Yang S, Curtis JR.
Arthritis Care Res (Hoboken). 2019 Sep;71(9):1224-1233. doi: 10.1002/acr.23843. Epub 2019 Jul 11.
PMID: 30740938
Perspectives on exploring hybrid LBA/LC-MS approach for clinical immunogenicity testing.
Jiang H, Myler H, Zeng J, Mora J, Kolaitis G, Pillutla R.
Bioanalysis. 2019 Sep;11(17):1605-1617. doi: 10.4155/bio-2018-0107. Epub 2019 Jun 18. Review.
PMID: 31208198
Best practices in bioassay development to support registration of biopharmaceuticals.
White JR, Abodeely M, Ahmed S, Debauve G, Johnson E, Meyer DM, Mozier NM, Naumer M, Pepe A, Qahwash I, Rocnik E, Smith JG, Stokes ES, Talbot JJ, Wong PY.
Biotechniques. 2019 Sep;67(3):126-137. doi: 10.2144/btn-2019-0031. Epub 2019 Aug 5.
PMID: 31379198
Virus clearance validation across continuous capture chromatography.
Angelo J, Chollangi S, Müller-Späth T, Jusyte S, Xu X, Ghose S, Li Z.
Biotechnol Bioeng. 2019 Sep;116(9):2275-2284. doi: 10.1002/bit.27012. Epub 2019 May 27.
PMID: 31062872
Suitability of a generic virus safety evaluation for monoclonal antibody investigational new drug applications.
Sipple P, Nguyen T, Patel K, Jaffe N, Chen Y, Khetan A.
Biotechnol Prog. 2019 Sep;35(5):e2850. doi: 10.1002/btpr.2850. Epub 2019 Jun 9.
PMID: 31125511
Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.
Bajaj G, Suryawanshi S, Roy A, Gupta M.
Br J Clin Pharmacol. 2019 Sep;85(9):2045-2058. doi: 10.1111/bcp.13996. Epub 2019 Jul 17.
PMID: 31140642
Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model.
Chen Y, Cabalu TD, Callegari E, Einolf H, Liu L, Parrott N, Peters SA, Schuck E, Sharma P, Tracey H, Upreti VV, Zheng M, Zhu AZX, Hall SD.
CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):685-695. doi: 10.1002/psp4.12449. Epub 2019 Aug 7.
PMID: 31215774
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Schadendorf D.
Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21.
PMID: 31445199
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A.
Eur J Cancer. 2019 Sep;119:1-10. doi: 10.1016/j.ejca.2019.07.001. Epub 2019 Aug 7.
PMID: 31400634
In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development.
Zane P, Gieschen H, Kersten E, Mathias N, Ollier C, Johansson P, Van den Bergh A, Van Hemelryck S, Reichel A, Rotgeri A, Schäfer K, Müllertz A, Langguth P.
Eur J Pharm Biopharm. 2019 Sep;142:222-231. doi: 10.1016/j.ejpb.2019.06.010. Epub 2019 Jun 21. Review.
PMID: 31233862
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.
Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G.
Int J Clin Oncol. 2019 Sep;24(9):1089-1098. doi: 10.1007/s10147-019-01450-w. Epub 2019 Jun 19.
PMID: 31218529
Commonly used definitions in real-world studies may underestimate the prevalence of renal disease among nonvalvular atrial fibrillation patients.
Schultze A, Graham S, Nordstrom BL, Mehmud F, Ramagopalan SV.
J Comp Eff Res. 2019 Sep;8(12):961-968. doi: 10.2217/cer-2019-0070. Epub 2019 Jul 18.
PMID: 31317772
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M.
J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7. Erratum in:  J Hepatol. 2019 Dec;71(6):1278 .
PMID: 31176752
Deuterated active pharmaceutical ingredients: A science-based proposal for synthesis, analysis, and control. Part 1: Framing the problem.
Czeskis B, Elmore CS, Haight A, Hesk D, Maxwell BD, Miller SA, Raglione T, Schildknegt K, Traverse JF, Wang P.
J Labelled Comp Radiopharm. 2019 Sep;62(11):690-694. doi: 10.1002/jlcr.3743. Epub 2019 Jun 18.
PMID: 31034626
Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform.
Qi Z, Wang L, Desai K, Cogswell J, Stern M, Lawson B, Kerkar SP, Vitazka P.
J Mol Diagn. 2019 Sep;21(5):796-807. doi: 10.1016/j.jmoldx.2019.04.011. Epub 2019 Jun 27.
PMID: 31255795
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, Leighl NB, Chandler JC, Couture F, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA.
J Thorac Oncol. 2019 Sep;14(9):1628-1639. doi: 10.1016/j.jtho.2019.05.010. Epub 2019 May 20.
PMID: 31121324
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E.
Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1. Epub 2019 Aug 8.
PMID: 31402321
Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM.
Lung Cancer. 2019 Sep;135:196-204. doi: 10.1016/j.lungcan.2019.07.010. Epub 2019 Jul 13.
PMID: 31446995
Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.
Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Yoshizawa Y, Chinen I, Nakao T, Koike T.
Mod Rheumatol. 2019 Sep;29(5):747-755. doi: 10.1080/14397595.2018.1524998. Epub 2018 Oct 25.
PMID: 30217117
Hindered dialkyl ether synthesis with electrogenerated carbocations.
Xiang J, Shang M, Kawamata Y, Lundberg H, Reisberg SH, Chen M, Mykhailiuk P, Beutner G, Collins MR, Davies A, Del Bel M, Gallego GM, Spangler JE, Starr J, Yang S, Blackmond DG, Baran PS.
Nature. 2019 Sep;573(7774):398-402. doi: 10.1038/s41586-019-1539-y. Epub 2019 Sep 9.
PMID: 31501569
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P.
Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.
PMID: 31422216
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada.
Quon PL, Xiao Y, Sorensen S, Monfared AAT.
Pharmacoecon Open. 2019 Sep;3(3):321-331. doi: 10.1007/s41669-018-0112-1.
PMID: 30617952
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada.
Foo J, Morel C, Bergman M, Baerwald C, Rodriguez-Heredia JM, Marshall A, Polanco-Sánchez C, Postema R.
Rheumatol Int. 2019 Sep;39(9):1621-1630. doi: 10.1007/s00296-019-04352-2. Epub 2019 Jun 25.
PMID: 31240388
Overview and considerations for the reporting of clinical pathology interpretations in nonclinical toxicology studies.
Aulbach A, Vitsky A, Arndt T, Ramaiah L, Logan M, Siska W, Cregar L, Tripathi N, Adedeji A, Provencher A, Gupta A, Jordan H, Bounous D, Boone L.
Vet Clin Pathol. 2019 Sep;48(3):389-399. doi: 10.1111/vcp.12772. Review.
PMID: 31556157
Interpretative considerations for clinical pathology findings in nonclinical toxicology studies.
Aulbach A, Vitsky A, Arndt T, Ramaiah L, Logan M, Siska W, Cregar L, Tripathi N, Adedeji A, Provencher A, Gupta A, Jordan H, Bounous D, Boone L.
Vet Clin Pathol. 2019 Sep;48(3):383-388. doi: 10.1111/vcp.12773. Epub 2019 Sep 24. Review.
PMID: 31549731
Real-world clinical outcomes among individuals with chronic HCV infection in China: CCgenos study.
Rao H, Xie Q, Shang J, Gao Z, Chen H, Sun Y, Jiang J, Niu J, Zhang L, Wang L, Zhao L, Li J, Yang R, Zhu S, Li R, Wei L.
Antivir Ther. 2019 Sept;24(7):473-483. doi: 10.3851/IMP3334.
PMID: 31566575
Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
Deniz B, Ambavane A, Yang S, Altincatal A, Doan J, Rao S, Michaelson MD.
PLoS One. 2019 Aug 29;14(8):e0215761. doi: 10.1371/journal.pone.0215761. eCollection 2019.
PMID: 31465470
Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY.
Nat Commun. 2019 Aug 28;10(1):3850. doi: 10.1038/s41467-019-11719-3. Erratum in:  Nat Commun. 2020 Jan 30;11(1):701 .
PMID: 31462642
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.
Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ, Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM, Priestley ES, Marinier A.
J Med Chem. 2019 Aug 22;62(16):7400-7416. doi: 10.1021/acs.jmedchem.9b00186. Epub 2019 Aug 5.
PMID: 31246024
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.
Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmet L, Herbert ZT, Sun Y, Weatherbee JL, Alberta JA, Daley JF, Rozenblatt-Rosen O, Condurat AL, Qian K, Khadka P, Segal RA, Haas-Kogan D, Filbin MG, Suva ML, Regev A, Stiles CD, Kieran MW, Goumnerova L, Ligon KL, Shalek AK, Bandopadhayay P, Beroukhim R.
Nat Commun. 2019 Aug 19;10(1):3731. doi: 10.1038/s41467-019-11493-2.
PMID: 31427603
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
Lu Z, Duan JJ, Xiao H, Neels J, Wu DR, Weigelt CA, Sack JS, Khan J, Ruzanov M, An Y, Yarde M, Karmakar A, Vishwakrishnan S, Baratam V, Shankarappa H, Vanteru S, Babu V, Basha M, Kumar Gupta A, Kumaravel S, Mathur A, Zhao Q, Salter-Cid LM, Carter PH, Murali Dhar TG.
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2265-2269. doi: 10.1016/j.bmcl.2019.06.036. Epub 2019 Jun 20.
PMID: 31257087
Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
Crane HM, Nance RM, Heckbert SR, Ritchings C, Rosenblatt L, Budoff M, Wood BR, Tirschwell DL, Kim HN, Mathews WC, Geng E, Moore RD, Hunt PW, Eron JJ, Burkholder GA, Drozd DR, Chow FC, Becker KJ, Zunt JR, Ho EL, Kalani R, Huffer A, Whitney BM, Saag MS, Kitahata MM, Delaney JAC.
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):e141-e147. doi: 10.1097/QAI.0000000000002071.
PMID: 31135582
RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation.
Sivakumar P, Thompson JR, Ammar R, Porteous M, McCoubrey C, Cantu E 3rd, Ravi K, Zhang Y, Luo Y, Streltsov D, Beers MF, Jarai G, Christie JD.
ERJ Open Res. 2019 Aug 12;5(3). pii: 00117-2019. doi: 10.1183/23120541.00117-2019. eCollection 2019 Jul.
PMID: 31423451
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM.
J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21.
PMID: 31112476
Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis.
Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D.
BMJ Open. 2019 Aug 5;9(8):e029066. doi: 10.1136/bmjopen-2019-029066.
PMID: 31383704
Oxidative degradation pathways of beclabuvir hydrochloride mediated by hydrogen peroxide and UV/Vis light.
Ye Q, Huang Y, Grier S, Miller SA.
J Pharm Biomed Anal. 2019 Aug 5;172:388-394. doi: 10.1016/j.jpba.2019.05.017. Epub 2019 May 8.
PMID: 31100536
Development of simple isocratic HPLC methods for siRNA quantitation in lipid-based nanoparticles.
Huang Z, Fish WP.
J Pharm Biomed Anal. 2019 Aug 5;172:253-258. doi: 10.1016/j.jpba.2019.04.026. Epub 2019 Apr 27.
PMID: 31071650
Streamlining the polishing step development process via physicochemical characterization of monoclonal antibody aggregates.
Doss HR, Raman M, Knihtila R, Chennamsetty N, Wang D, Shupe A, Mussa N.
J Chromatogr A. 2019 Aug 2;1598:101-112. doi: 10.1016/j.chroma.2019.03.044. Epub 2019 Mar 22.
PMID: 30954243
Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase.
Kim SH, Johnson JA, Jiang J, Parkhurst B, Phillips M, Pi Z, Qiao JX, Tora G, Ye Chen A, Liu E, Yin X, Yang R, Zhao L, Taylor DS, Basso M, Behnia K, Onorato J, Chen XQ, Abell LM, Lu H, Locke G, Caporuscio C, Adam LP, Gordon D, Wexler RR, Finlay HJ.
Bioorg Med Chem Lett. 2019 Aug 1;29(15):1918-1921. doi: 10.1016/j.bmcl.2019.05.048. Epub 2019 May 25. Erratum in:  Bioorg Med Chem Lett. 2019 Sep 1;29(17):2525 .
PMID: 31176700
Therapeutic protein purity and fragmented species characterization by capillary electrophoresis sodium dodecyl sulfate using systematic hybrid cleavage and forced degradation.
Duhamel L, Gu Y, Barnett G, Tao Y, Voronov S, Ding J, Mussa N, Li ZJ.
Anal Bioanal Chem. 2019 Aug;411(21):5617-5629. doi: 10.1007/s00216-019-01942-8. Epub 2019 Jun 18.
PMID: 31214752
Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Moore K, Magee M, Sevinsky H, Chang M, Lubin S, Myers E, Ackerman P, Llamoso C.
Br J Clin Pharmacol. 2019 Aug;85(8):1771-1780. doi: 10.1111/bcp.13964. Epub 2019 Jun 5.
PMID: 30980734
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.
Coker SA, Hurwitz HI, Sharma S, Wang D, Jordaan P, Zarate JP, Lewis LD.
Cancer Chemother Pharmacol. 2019 Aug;84(2):383-392. doi: 10.1007/s00280-019-03880-9. Epub 2019 Jun 11.
PMID: 31187169
Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.
Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA.
Cancer Discov. 2019 Aug;9(8):1102-1123. doi: 10.1158/2159-8290.CD-19-0094. Epub 2019 Jun 13.
PMID: 31197017
Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Osawa M, Ueno T, Shiozaki T, Ishikawa H, Li H, Garimella T.
Clin Pharmacol Drug Dev. 2019 Aug;8(6):802-817. doi: 10.1002/cpdd.649. Epub 2019 Jan 10.
PMID: 30629858
Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials.
Vetter ML, Johnsson K, Hardy E, Wang H, Iqbal N.
Diabetes Ther. 2019 Aug;10(4):1249-1270. doi: 10.1007/s13300-019-0627-1. Epub 2019 May 10.
PMID: 31077072
Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV.
Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6.
PMID: 31168885
Health and functional status, health events, use of healthcare services and costs associated with overactive bladder among the medically complex vulnerable elderly in the US.
Chuang CC, Yang E, Zou KH, Araiza A, Wang A, Luo X.
Int J Clin Pract. 2019 Aug;73(8):e13207. doi: 10.1111/ijcp.13207. Epub 2018 Jul 16.
PMID: 30011108
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH.
J Am Geriatr Soc. 2019 Aug;67(8):1662-1671. doi: 10.1111/jgs.15956. Epub 2019 May 21.
PMID: 31112292
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL.
J Thromb Thrombolysis. 2019 Aug;48(2):240-249. doi: 10.1007/s11239-019-01838-5.
PMID: 30924051
Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma.
Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S.
Leuk Lymphoma. 2019 Aug;60(8):2085-2087. doi: 10.1080/10428194.2018.1551537. Epub 2019 Jan 11. No abstract available.
PMID: 30632821
A nondestructive and noninvasive method to determine water content in lyophilized proteins using low-field time-domain NMR.
Abraham A, Elkassabany O, Krause ME, Ott A.
Magn Reson Chem. 2019 Aug;57(10):873-877. doi: 10.1002/mrc.4864. Epub 2019 Apr 29.
PMID: 30861192
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer.
Chang H, Sasson A, Srinivasan S, Golhar R, Greenawalt DM, Geese WJ, Green G, Zerba K, Kirov S, Szustakowski J.
Mol Diagn Ther. 2019 Aug;23(4):507-520. doi: 10.1007/s40291-019-00408-y.
PMID: 31250328
The trials and tribulations of CAR-T cell development for cancer and AIDS.
Hege K.
Nat Med. 2019 Aug;25(8):1183. doi: 10.1038/s41591-019-0538-8. No abstract available.
PMID: 31388173
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K, Contente M, Simpson S, DeRosa M, Taylor FC, Shaw JW.
Pharmacoeconomics. 2019 Aug;37(8):1041-1047. doi: 10.1007/s40273-019-00798-1.
PMID: 30972702
Addition of Optimized Bovine Serum Albumin Level in a High-Throughput Caco-2 Assay Enabled Accurate Permeability Assessment for Lipophilic Compounds.
Cai X, Madari S, Walker A, Paiva A, Li Y, Herbst J, Shou W, Weller H.
SLAS Discov. 2019 Aug;24(7):738-744. doi: 10.1177/2472555219848483. Epub 2019 May 10.
PMID: 31076010
United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV.
Value Health. 2019 Aug;22(8):931-941. doi: 10.1016/j.jval.2019.02.009. Epub 2019 May 25.
PMID: 31426935
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M.
JAMA Oncol. 2019 Jul 25. doi: 10.1001/jamaoncol.2019.2187. [Epub ahead of print]
PMID: 31343665
Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1.
Hamuro L, Tirucherai GS, Crawford SM, Nayeem A, Pillutla RC, DeSilva BS, Leil TA, Thalhauser CJ.
AAPS J. 2019 Jul 24;21(5):94. doi: 10.1208/s12248-019-0361-7.
PMID: 31342199
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.
Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD, Carman JA, Zhou X, Banas D, Chaudhry C, Li S, D'Arienzo C, Chimalakonda A, Yang X, Xie JH, Pang J, Zhao Q, Rose SM, Huang J, Moslin RM, Wrobleski ST, Weinstein DS, Salter-Cid LM.
Sci Transl Med. 2019 Jul 24;11(502). pii: eaaw1736. doi: 10.1126/scitranslmed.aaw1736.
PMID: 31341059
A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance.
Kavita U, Miller W, Ji QC, Pillutla RC.
AAPS J. 2019 Jul 22;21(5):92. doi: 10.1208/s12248-019-0360-8.
PMID: 31332587
Implementation of a mathematical model for the photochemical kinetics of a solid form active pharmaceutical ingredient.
La Cruz TE, Carvalho TC, Ramírez A, Tábora JE.
Int J Pharm. 2019 Jul 20;566:500-512. doi: 10.1016/j.ijpharm.2019.05.054. Epub 2019 May 23.
PMID: 31129341
In Praise of Remarkably Powerful Centamolecular Therapeutic Agents.
Meanwell NA, Ewing WR.
ACS Med Chem Lett. 2019 Jul 18;10(8):1094-1097. doi: 10.1021/acsmedchemlett.9b00286. eCollection 2019 Aug 8.
PMID: 31413789
Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR).
Povsic M, Enstone A, Wyn R, Kornalska K, Penrod JR, Yuan Y.
PLoS One. 2019 Jul 18;14(7):e0219622. doi: 10.1371/journal.pone.0219622. eCollection 2019.
PMID: 31318909
Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y.
Front Pharmacol. 2019 Jul 17;10:749. doi: 10.3389/fphar.2019.00749. eCollection 2019.
PMID: 31379564
Pharmacokinetics of 40 kDa PEG in rodents using high-field NMR spectroscopy.
Khandelwal P, Zhang L, Chimalakonda A, Caceres-Cortes J, Huang C, Marathe P, Reily MD.
J Pharm Biomed Anal. 2019 Jul 15;171:30-34. doi: 10.1016/j.jpba.2019.03.066. Epub 2019 Apr 1.
PMID: 30959317
Predicting High-Concentration Interactions of Monoclonal Antibody Solutions: Comparison of Theoretical Approaches for Strongly Attractive Versus Repulsive Conditions.
Calero-Rubio C, Saluja A, Sahin E, Roberts CJ.
J Phys Chem B. 2019 Jul 11;123(27):5709-5720. doi: 10.1021/acs.jpcb.9b03779. Epub 2019 Jun 26.
PMID: 31241333
The development of resilience among rheumatoid arthritis patients: a qualitative study.
Shaw Y, Bradley M, Zhang C, Dominique A, Michaud K, McDonald D, Simon TA.
Arthritis Care Res (Hoboken). 2019 Jul 8. doi: 10.1002/acr.24024. [Epub ahead of print]
PMID: 31282121
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F.
Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8.
PMID: 31277699
Identification and biochemical analyses of selective CB 2  agonists.
Scott CE, Tang Y, Alt A, Burford NT, Gerritz SW, Ogawa LM, Zhang L, Kendall DA.
Eur J Pharmacol. 2019 Jul 5;854:1-8. doi: 10.1016/j.ejphar.2019.03.054. Epub 2019 Apr 3.
PMID: 30951717
Decarboxylative Intramolecular Arene Alkylation Using N-(Acyloxy)phthalimides, an Organic Photocatalyst, and Visible Light.
Sherwood TC, Xiao HY, Bhaskar RG, Simmons EM, Zaretsky S, Rauch MP, Knowles RR, Dhar TGM.
J Org Chem. 2019 Jul 5;84(13):8360-8379. doi: 10.1021/acs.joc.9b00432. Epub 2019 Mar 27.
PMID: 30905152
Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes.
Gulsin GS, Kanagala P, Chan DCS, Cheng ASH, Athithan L, Graham-Brown MPM, Singh A, Yang J, Li Z, Khunti K, Davies MJ, Arnold JR, Squire IB, Ng LL, McCann GP.
Ther Adv Endocrinol Metab. 2019 Jul 5;10:2042018819861593. doi: 10.1177/2042018819861593. eCollection 2019.
PMID: 31308926
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.
J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.
PMID: 31272507
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.
Potluri R, Ranjan S, Bhandari H, Johnson H, Moshyk A, Kotapati S.
Exp Hematol Oncol. 2019 Jul 3;8:14. doi: 10.1186/s40164-019-0138-9. eCollection 2019.
PMID: 31312536
Near-Complete Genome Sequence of a Hepatitis A Subgenotype IB Virus Isolated from Frozen Raspberries.
Chen H, Wang W, Wang S, Hu Y.
Microbiol Resour Announc. 2019 Jul 3;8(27). pii: e00522-19. doi: 10.1128/MRA.00522-19.
PMID: 31270195
Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis.
Gu H, Zhao Y, DeMichele M, Zheng N, Zhang YJ, Pillutla R, Zeng J.
Anal Chem. 2019 Jul 2;91(13):8652-8659. doi: 10.1021/acs.analchem.9b02136. Epub 2019 Jun 21.
PMID: 31180205
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saci, Callahan MK, Rosenberg J.
J Clin Oncol. 2019 Jul 1;37(19):1608-1616. doi: 10.1200/JCO.19.00538. Epub 2019 May 17. Erratum in:  J Clin Oncol. 2019 Aug 10;37(23):2094 .
PMID: 31100038
Microbiota Metabolite Short-Chain Fatty Acids Facilitate Mucosal Adjuvant Activity of Cholera Toxin through GPR43.
Yang W, Xiao Y, Huang X, Chen F, Sun M, Bilotta AJ, Xu L, Lu Y, Yao S, Zhao Q, Liu Z, Cong Y.
J Immunol. 2019 Jul 1;203(1):282-292. doi: 10.4049/jimmunol.1801068. Epub 2019 May 10.
PMID: 31076530
Impact of depth filtration on disulfide bond reduction during downstream processing of monoclonal antibodies from CHO cell cultures.
O'Mara B, Gao ZH, Kuruganti M, Mallett R, Nayar G, Smith L, Meyer JD, Therriault J, Miller C, Cisney J, Fann J.
Biotechnol Bioeng. 2019 Jul;116(7):1669-1683. doi: 10.1002/bit.26964. Epub 2019 Apr 4.
PMID: 30883673
Mass Balance Model with Donnan Equilibrium Accurately Describes Unusual pH and Excipient Profiles during Diafiltration of Monoclonal Antibodies.
Baek Y, Singh N, Arunkumar A, Borwankar A, Zydney AL.
Biotechnol J. 2019 Jul;14(7):e1800517. doi: 10.1002/biot.201800517. Epub 2019 May 20.
PMID: 30791230
Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Schwartzberg L, Korytowsky B, Penrod JR, Zhang Y, Le TK, Batenchuk C, Krug L.
Clin Lung Cancer. 2019 Jul;20(4):287-296.e4. doi: 10.1016/j.cllc.2019.04.004. Epub 2019 Apr 19.
PMID: 31130450
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
Khouri J, Reu F, Majhail NS, Gerds A, Jagadeesh D, Dean R, Sobecks R, Hamilton BK, Pohlman B, Hill BT, Corrigan D, Kalaycio M, Bolwell BJ, Liu HD.
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e374-e376. doi: 10.1016/j.clml.2019.03.019. Epub 2019 Apr 8. No abstract available.
PMID: 31053548
Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics.
Billington S, Salphati L, Hop CECA, Chu X, Evers R, Burdette D, Rowbottom C, Lai Y, Xiao G, Humphreys WG, Nguyen TB, Prasad B, Unadkat JD.
Clin Pharmacol Ther. 2019 Jul;106(1):228-237. doi: 10.1002/cpt.1373. Epub 2019 Mar 18.
PMID: 30673124
Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
Yee SW, Giacomini MM, Shen H, Humphreys WG, Horng H, Brian W, Lai Y, Kroetz DL, Giacomini KM.
Clin Transl Sci. 2019 Jul;12(4):388-399. doi: 10.1111/cts.12625. Epub 2019 Apr 13.
PMID: 30982223
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J.
Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11.
PMID: 31195357
Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Antunes L, Rocha-Gonçalves F, Chacim S, Lefèvre C, Pereira M, Pereira S, Zagorska A, Bento MJ.
Eur J Cancer Care (Engl). 2019 Jul;28(4):e13026. doi: 10.1111/ecc.13026. Epub 2019 Mar 3.
PMID: 30828907
Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation.
Berben P, Ashworth L, Beato S, Bevernage J, Bruel JL, Butler J, Dressman J, Schäfer K, Hutchins P, Klumpp L, Mann J, Nicolai J, Ojala K, Patel S, Powell S, Rosenblatt K, Tomaszewska I, Williams J, Augustijns P.
Eur J Pharm Biopharm. 2019 Jul;140:141-148. doi: 10.1016/j.ejpb.2019.04.017. Epub 2019 Apr 30.
PMID: 31051249
Impact of atrial fibrillation awareness campaigns: interrupted time series using the Clinical Practice Research Datalink.
Allan V, Sammon CJ, McDonald L, Mehmud F, Alikhan R, Ramagopalan SV.
Future Cardiol. 2019 Jul;15(4):311-318. doi: 10.2217/fca-2019-0025. Epub 2019 Jun 26.
PMID: 31241353
Renal function and oral anticoagulant treatment of incident non-valvular atrial fibrillation: a retrospective study.
Ramagopalan SV, Stamp E, Sammon CJ, Besford M, Carroll R, Mehmud F, Alikhan R.
Future Cardiol. 2019 Jul;15(4):301-309. doi: 10.2217/fca-2019-0012. Epub 2019 May 29.
PMID: 31140872
Extracting data from a chemotherapy prescription platform for real-world oncology research in the UK: a pilot study.
McDonald L, Stein D, Carroll R, Soni M, Schultze A, Ramagopalan S, Wagstaff J.
Future Oncol. 2019 Jul;15(21):2471-2477. doi: 10.2217/fon-2019-0150. Epub 2019 Jun 4.
PMID: 31161801
Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
Cope S, Keeping ST, Goldgrub R, Ayers D, Jansen JP, Penrod JR, Korytowsky B, Juarez-Garcia A, Yuan Y.
J Comp Eff Res. 2019 Jul;8(10):733-751. doi: 10.2217/cer-2018-0130. Epub 2019 Jun 25.
PMID: 31237143
Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries.
Lafuma A, Cotté FE, Le Tourneau C, Emery C, Gaudin AF, Torreton E, Gourmelen J, Bonastre J.
J Med Econ. 2019 Jul;22(7):698-705. doi: 10.1080/13696998.2019.1594837. Epub 2019 Apr 2.
PMID: 30895832
Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A, Johnson C, Yang S, Botteman MF, Rao S, Hussain A.
J Med Econ. 2019 Jul;22(7):662-670. doi: 10.1080/13696998.2019.1591424. Epub 2019 Mar 25.
PMID: 30836812
International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin.
Guimarães PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Hijazi Z, Hylek EM, Gersh BJ, Garcia DA, Verheugt FWA, Hanna M, Flaker G, Vinereanu D, Granger CB.
J Thromb Thrombolysis. 2019 Jul;48(1):27-34. doi: 10.1007/s11239-019-01858-1.
PMID: 30972712
A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y, Fang W, Zhang Y, Yang Y, Hong S, Zhao Y, Tendolkar A, Chen L, Xu D, Sheng J, Zhao H, Zhang L.
Oncologist. 2019 Jul;24(7):891-e431. doi: 10.1634/theoncologist.2019-0284. Epub 2019 May 2.
PMID: 31048330
The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden.
Wood R, Taylor-Stokes G, Smith F, Chaib C.
Qual Life Res. 2019 Jul;28(7):1849-1861. doi: 10.1007/s11136-019-02152-6. Epub 2019 Mar 2.
PMID: 30825160
Analysis of exposure margins in developmental toxicity studies for detection of human teratogens.
Andrews PA, Blanset D, Costa PL, Green M, Green ML, Jacobs A, Kadaba R, Lebron JA, Mattson B, McNerney ME, Minck D, Oliveira LC, Theunissen PT, DeGeorge JJ.
Regul Toxicol Pharmacol. 2019 Jul;105:62-68. doi: 10.1016/j.yrtph.2019.04.005. Epub 2019 Apr 11.
PMID: 30981719
An IQ Consortium Perspective on The Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on the Need for Nonhuman Primates in Biomedical Research, Production and Testing of Products and Devices (Update 2017).
Adams K, Clemons D, Impelluso LC, Lee D, Maguire S, Myers A, Petursson C, Schulingkamp R, Trouba K, Wright M.
Toxicol Pathol. 2019 Jul;47(5):649-655. doi: 10.1177/0192623319857976. Epub 2019 Jul 7.
PMID: 31280699
Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG.
Arch Cardiovasc Dis. 2019 Jun - Jul;112(6-7):400-409. doi: 10.1016/j.acvd.2019.02.003. Epub 2019 Apr 20.
PMID: 31014991
Utilizing Native Directing Groups: Mechanistic Understanding of a Direct Arylation Leads to Formation of Tetracyclic Heterocycles via Tandem Intermolecular, Intramolecular C-H Activation.
Wisniewski SR, Savage SA, Romero EO, Eastgate MD, Tan Y, Simmons EM, Plata RE, Sowa JR Jr, Blackmond DG.
J Org Chem. 2019 Jun 21;84(12):7961-7970. doi: 10.1021/acs.joc.9b00823. Epub 2019 Jun 4.
PMID: 31117568
Four Yellow Monoterpenoid Quinoline Alkaloids from the Stem of Tabernaemontana bovina.
Wu J, Yu Y, Wang Y, Bao MF, Shi BB, Schinnerl J, Cai XH.
Org Lett. 2019 Jun 21;21(12):4554-4558. doi: 10.1021/acs.orglett.9b01453. Epub 2019 Jun 10.
PMID: 31179705
Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, Hsu JY, Simon TA, Wu Q, Xie F, Yang S, Curtis JR.
Ann Intern Med. 2019 Jun 18;170(12):825-836. doi: 10.7326/M18-2217. Epub 2019 May 21.
PMID: 31108503
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Nadkarni A, Shank TC.
BMC Cardiovasc Disord. 2019 Jun 13;19(1):142. doi: 10.1186/s12872-019-1116-1.
PMID: 31195999
Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD.
Feakins B, Oke J, McFadden E, Aronson J, Lasserson D, O'Callaghan C, Taylor C, Hill N, Stevens R, Perera R.
BMJ Open. 2019 Jun 12;9(6):e028062. doi: 10.1136/bmjopen-2018-028062. Erratum in:  BMJ Open. 2019 Jul 1;9(7):e028062corr1 .
PMID: 31196901
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ Jr, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G.
Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.
PMID: 31185212
Polymersome nanoreactors with tumor pH-triggered selective membrane permeability for prodrug delivery, activation, and combined oxidation-chemotherapy.
Mukerabigwi JF, Yin W, Zha Z, Ke W, Wang Y, Chen W, Japir AAMM, Wang Y, Ge Z.
J Control Release. 2019 Jun 10;303:209-222. doi: 10.1016/j.jconrel.2019.04.032. Epub 2019 Apr 23.
PMID: 31026547
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, Mistry T, Lindquist KC, Van Blarcom T, Strop P, Chaparro-Riggers J, Liu SH.
Sci Rep. 2019 Jun 10;9(1):8420. doi: 10.1038/s41598-019-44874-0. Erratum in:  Sci Rep. 2019 Nov 8;9(1):16735 .
PMID: 31182754
Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G, Pedro S, Schumacher R, Simon TA, Michaud K.
Arthritis Res Ther. 2019 Jun 7;21(1):141. doi: 10.1186/s13075-019-1921-z.
PMID: 31174592
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D, Bessette L, Alemao E, Haraoui B, Postema R, Raynauld JP, Coupal L.
Arthritis Res Ther. 2019 Jun 6;21(1):138. doi: 10.1186/s13075-019-1917-8.
PMID: 31171024
Catalytic Ring Expansions of Cyclic Alcohols Enabled by Proton-Coupled Electron Transfer.
Zhao K, Yamashita K, Carpenter JE, Sherwood TC, Ewing WR, Cheng PTW, Knowles RR.
J Am Chem Soc. 2019 Jun 5;141(22):8752-8757. doi: 10.1021/jacs.9b03973. Epub 2019 May 23.
PMID: 31117664
Interlaboratory Comparison of Hydrogen-Deuterium Exchange Mass Spectrometry Measurements of the Fab Fragment of NISTmAb.
Hudgens JW, Gallagher ES, Karageorgos I, Anderson KW, Filliben JJ, Huang RY, Chen G, Bou-Assaf GM, Espada A, Chalmers MJ, Harguindey E, Zhang HM, Walters BT, Zhang J, Venable J, Steckler C, Park I, Brock A, Lu X, Pandey R, Chandramohan A, Anand GS, Nirudodhi SN, Sperry JB, Rouse JC, Carroll JA, Rand KD, Leurs U, Weis DD, Al-Naqshabandi MA, Hageman TS, Deredge D, Wintrode PL, Papanastasiou M, Lambris JD, Li S, Urata S.
Anal Chem. 2019 Jun 4;91(11):7336-7345. doi: 10.1021/acs.analchem.9b01100. Epub 2019 May 14.
PMID: 31045344
Induction of a Th17 Phenotype in Human Skin-A Mimic of Dermal Inflammatory Diseases.
Garrett SM, Zhao Q, Feghali-Bostwick C.
Methods Protoc. 2019 Jun 4;2(2). pii: E45. doi: 10.3390/mps2020045.
PMID: 31164624
Investigations on the Relationship between Ovarian, Endocrine, and Renal Findings in Nonclinical Safety Studies of the γ-secretase Inhibitor Avagacestat.
Simutis FJ, Sanderson TP, Pilcher GD, Graziano MJ.
Toxicol Sci. 2019 Jun 4. pii: kfz129. doi: 10.1093/toxsci/kfz129. [Epub ahead of print]
PMID: 31165171
Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate.
Zhang Y, Panfen E, Fancher M, Sinz M, Marathe P, Shen H.
Mol Pharm. 2019 Jun 3;16(6):2342-2353. doi: 10.1021/acs.molpharmaceut.8b01226. Epub 2019 May 13.
PMID: 31039308
A survey of core replacements in indole-based HIV-1 attachment inhibitors.
Wang T, Wallace OB, Zhang Z, Fang H, Yang Z, Robinson BA, Spicer TP, Gong YF, Blair WS, Shi PY, Lin PF, Deshpande M, Meanwell NA, Kadow JF.
Bioorg Med Chem Lett. 2019 Jun 1;29(11):1423-1429. doi: 10.1016/j.bmcl.2019.03.018. Epub 2019 Mar 28.
PMID: 30940396
Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.
De Wit S, Florence E, Vandekerkhove L, Goffard JC, Vandercam B, Van Wijngaerden E, Moutschen M, Demeester R, Lacor P, Delforge M, van Frankenhuijsen M, Lacante P.
Acta Clin Belg. 2019 Jun;74(3):143-150. doi: 10.1080/17843286.2018.1462753. Epub 2018 May 2.
PMID: 29718781
Optimization of microflow LC-MS/MS and its utility in quantitative discovery bioanalysis.
Zhang J, Shou W, Ogura T, Li S, Weller H.
Bioanalysis. 2019 Jun;11(11):1117-1127. doi: 10.4155/bio-2019-0076.
PMID: 31251100
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
Zhou L, Higashimori M, Shen K, Zhang Z, Sheng J, Xu H, Horiuchi M, Ichikawa K, Al-Huniti N, Zhou D.
Clin Pharmacol Ther. 2019 Jun;105(6):1303-1320. doi: 10.1002/cpt.1352. Epub 2019 Feb 25. Review. No abstract available.
PMID: 30802932
Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a US Observational Cohort.
Alemao E, Iannaccone CK, Weinblatt ME, Shadick NA.
Clin Ther. 2019 Jun;41(6):1057-1065.e3. doi: 10.1016/j.clinthera.2019.04.029. Epub 2019 May 23.
PMID: 31130229
A Flexible Approach for Context-Dependent Assessment of Quantitative Systems Pharmacology Models.
Ramanujan S, Chan JR, Friedrich CM, Thalhauser CJ.
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):340-343. doi: 10.1002/psp4.12409. Epub 2019 May 14. No abstract available. Erratum in:  CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):124 .
PMID: 30983158
Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops.
Czechowska K, Lannigan J, Wang L, Arcidiacono J, Ashhurst TM, Barnard RM, Bauer S, Bispo C, Bonilla DL, Brinkman RR, Cabanski M, Chang HD, Chakrabarti L, Chojnowski G, Cotleur B, Degheidy H, Dela Cruz GV, Eck S, Elliott J, Errington R, Filby A, Gagnon D, Gardner R, Green C, Gregory M, Groves CJ, Hall C, Hammes F, Hedrick M, Hoffman R, Icha J, Ivaska J, Jenner DC, Jones D, Kerckhof FM, Kukat C, Lanham D, Leavesley S, Lee M, Lin-Gibson S, Litwin V, Liu Y, Molloy J, Moore JS, Müller S, Nedbal J, Niesner R, Nitta N, Ohlsson-Wilhelm B, Paul NE, Perfetto S, Portat Z, Props R, Radtke S, Rayanki R, Rieger A, Rogers S, Rubbens P, Salomon R, Schiemann M, Sharpe J, Sonder SU, Stewart JJ, Sun Y, Ulrich H, Van Isterdael G, Vitaliti A, van Vreden C, Weber M, Zimmermann J, Vacca G, Wallace P, Tárnok A.
Cytometry A. 2019 Jun;95(6):598-644. doi: 10.1002/cyto.a.23777. No abstract available.
PMID: 31207046
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
Ruggeri M, Rolli FR, Kondili LA, Drago C, De Solda F, Nappi C, Cicchetti A.
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):363-374. doi: 10.1080/14737167.2019.1537784. Epub 2018 Oct 31.
PMID: 30351994
Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C.
J Med Econ. 2019 Jun;22(6):531-544. doi: 10.1080/13696998.2019.1569446. Epub 2019 Jan 30.
PMID: 30638416
Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A, Maxwell R, Xia Y, Cardarelli P, Oyasu M, Belcaid Z, Kim E, Hung A, Luksik AS, Garzon-Muvdi T, Jackson CM, Mathios D, Theodros D, Cogswell J, Brem H, Pardoll DM, Lim M.
J Neurooncol. 2019 Jun;143(2):241-249. doi: 10.1007/s11060-019-03172-5. Epub 2019 Apr 25.
PMID: 31025274
Probing the Tryptophan Environment in Therapeutic Proteins: Implications for Higher Order Structure on Tryptophan Oxidation.
Barnett GV, Balakrishnan G, Chennamsetty N, Hoffman L, Bongers J, Tao L, Huang Y, Slaney T, Das TK, Leone A, Kar SR.
J Pharm Sci. 2019 Jun;108(6):1944-1952. doi: 10.1016/j.xphs.2018.12.027. Epub 2019 Jan 11.
PMID: 30639740
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T.
Lancet Neurol. 2019 Jun;18(6):549-558. doi: 10.1016/S1474-4422(19)30139-5.
PMID: 31122495
Applications of machine learning in drug discovery and development.
Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S.
Nat Rev Drug Discov. 2019 Jun;18(6):463-477. doi: 10.1038/s41573-019-0024-5. Review.
PMID: 30976107
High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
Lee JS, Ahmad H, Shim SC, Bae SC, Song YW, Lee EY.
Patient. 2019 Jun;12(3):319-326. doi: 10.1007/s40271-018-0347-z.
PMID: 30484084
Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
Harrold LR, Litman HJ, Connolly SE, Alemao E, Kelly S, Rebello S, Hua W, Kremer JM.
Rheumatol Ther. 2019 Jun;6(2):217-230. doi: 10.1007/s40744-019-0149-3. Epub 2019 Mar 13.
PMID: 30868550
Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.
Montastruc F, Renoux C, Hudson M, Dell'Aniello S, Simon TA, Suissa S.
Semin Arthritis Rheum. 2019 Jun;48(6):1053-1058. doi: 10.1016/j.semarthrit.2019.01.009. Epub 2019 Jan 25.
PMID: 30772001
Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
Keirstead ND, Janovitz EB, Meehan JT, LeRoy BE, Megill JR, Peterson RA, Masson RG, Marxfeld HA.
Toxicol Pathol. 2019 Jun;47(4):461-468. doi: 10.1177/0192623319835170. Epub 2019 Apr 24.
PMID: 31018785
Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat.
Padmanabhan S, Kaur H, Rao A, Saxena A, Gupta YK, Mariappan TT, Holenarsipur VK.
Xenobiotica. 2019 Jun;49(6):646-654. doi: 10.1080/00498254.2018.1489166. Epub 2018 Sep 7.
PMID: 29898636
Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis.
Marshall A, Gupta K, Pazirandeh M, Bonafede M, McMorrow D.
Clinicoecon Outcomes Res. 2019 May 31;11:361-371. doi: 10.2147/CEOR.S197117. eCollection 2019.
PMID: 31213863
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Arroyo R, Bury DP, Guo JD, Margolin DH, Melanson M, Daizadeh N, Cella D.
Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796. [Epub ahead of print]
PMID: 31144568
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a  post hoc  analysis of a phase III trial.
McInnes IB, Ferraccioli G, D'Agostino MA, Le Bars M, Banerjee S, Ahmad HA, Elbez Y, Mease PJ.
RMD Open. 2019 May 30;5(1):e000934. doi: 10.1136/rmdopen-2019-000934. eCollection 2019.
PMID: 31245054
Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials.
Simon TA, Soule BP, Hochberg M, Fleming D, Torbeyns A, Banerjee S, Boers M.
ACR Open Rheumatol. 2019 May 29;1(4):251-257. doi: 10.1002/acr2.1034. eCollection 2019 Jun.
PMID: 31777801
Application of ultrasound-guided cholecystocentesis to the evaluation of the metabolite profiling in bile of dogs and cynomolgus monkeys.
Dierks EA, Luk CE, Cai H, MacGuire J, Fox M, Smalley J, Fancher RM, Janovitz E, Foster K, Sun Q.
Pharmacol Res Perspect. 2019 May 27;7(3):e00488. doi: 10.1002/prp2.488. eCollection 2019 Jun.
PMID: 31149343
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.
J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in:  J Immunother Cancer. 2019 Jul 4;7(1):167 .
PMID: 31113486
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Kasikara C, Davra V, Calianese D, Geng K, Spires TE, Quigley M, Wichroski M, Sriram G, Suarez-Lopez L, Yaffe MB, Kotenko SV, De Lorenzo MS, Birge RB.
Cancer Res. 2019 May 15;79(10):2669-2683. doi: 10.1158/0008-5472.CAN-18-2614. Epub 2019 Mar 15.
PMID: 30877108
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD.
Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
PMID: 30773022
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study.
Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M.
J Arrhythm. 2019 May 9;35(3):506-514. doi: 10.1002/joa3.12184. eCollection 2019 Jun.
PMID: 31293700
Small-Scale Tools to Assess the Impact of Interfacial and Shear Stress on Biologic Drug Products.
Ogunyankin MO, Deshmukh S, Krause ME, Carvalho T, Huang M, Ilott A, Remy B, Khossravi M.
AAPS PharmSciTech. 2019 May 6;20(5):184. doi: 10.1208/s12249-019-1378-z.
PMID: 31062111
Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage.
Hart AC, Abell L, Guo J, Mertzman ME, Padmanabha R, Macor JE, Chaudhry C, Lu H, O'Malley K, Shaw PJ, Weigelt C, Pokross M, Kish K, Kim KS, Cornelius L, Douglas AE, Calambur D, Zhang P, Carpenter B, Pitts WJ.
ACS Med Chem Lett. 2019 May 6;11(3):266-271. doi: 10.1021/acsmedchemlett.9b00065. eCollection 2020 Mar 12.
PMID: 32184955
Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor.
Finlay HJ, Jiang J, Rampulla R, Salvati ME, Qiao JX, Wang TC, Lawrence RM, Harikrishnan LS, Kamau MG, Taylor DS, Chen AYA, Yin X, Huang CS, Chang M, Chen XQ, Sleph PG, Xu C, Li J, Levesque P, Adam LP, Wexler RR.
ACS Med Chem Lett. 2019 May 6;10(6):911-916. doi: 10.1021/acsmedchemlett.9b00086. eCollection 2019 Jun 13.
PMID: 31223447
And They Said It Couldn't Be Done: Predicting Known Driver Mutations From H&E Slides.
Montalto MC, Edwards R.
J Pathol Inform. 2019 May 6;10:17. doi: 10.4103/jpi.jpi_91_18. eCollection 2019. No abstract available.
PMID: 31149368
Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner.
Alam ME, Barnett GV, Slaney TR, Starr CG, Das TK, Tessier PM.
Mol Pharm. 2019 May 6;16(5):1939-1949. doi: 10.1021/acs.molpharmaceut.8b01311. Epub 2019 Apr 16.
PMID: 30916563
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology.
Retzler J, Davies H, Jenks M, Kiff C, Taylor M.
Clinicoecon Outcomes Res. 2019 May 3;11:309-324. doi: 10.2147/CEOR.S191382. eCollection 2019.
PMID: 31118714
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population.
Abruzzese E, Bosi A, Breccia M, D'Adda M, Di Renzo N, Liberati AM, Porrini R, Orlandi EM, Pane F, Pungolino E, Sorà F, Stagno F, Sen GP, Gentilini F, De Solda F, Gambacorti-Passerini C.
Mediterr J Hematol Infect Dis. 2019 May 1;11(1):e2019025. doi: 10.4084/MJHID.2019.025. eCollection 2019.
PMID: 31205629
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM.
Am J Hematol. 2019 May;94(5):539-545. doi: 10.1002/ajh.25435. Epub 2019 Feb 25.
PMID: 30740766
Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
Guimarães PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A, Carnicelli A, Lewis BS, Hanna M, Wallentin L, Vinereanu D, Alexander JH, Granger CB.
Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9.
PMID: 30907005
Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Alten R, Mariette X, Lorenz HM, Nüßlein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M.
Clin Rheumatol. 2019 May;38(5):1535. doi: 10.1007/s10067-019-04545-x.
PMID: 30972577
Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Alten R, Mariette X, Lorenz HM, Nüßlein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M.
Clin Rheumatol. 2019 May;38(5):1413-1424. doi: 10.1007/s10067-019-04449-w. Epub 2019 Feb 21. Erratum in:  Clin Rheumatol. 2019 Apr 11;: .
PMID: 30790095
Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).
Hotchkiss RS, Colston E, Yende S, Angus DC, Moldawer LL, Crouser ED, Martin GS, Coopersmith CM, Brakenridge S, Mayr FB, Park PK, Ye J, Catlett IM, Girgis IG, Grasela DM.
Crit Care Med. 2019 May;47(5):632-642. doi: 10.1097/CCM.0000000000003685.
PMID: 30747773
Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review.
Branchoux S, Bellera C, Italiano A, Rustand D, Gaudin AF, Rondeau V.
Crit Rev Oncol Hematol. 2019 May;137:35-42. doi: 10.1016/j.critrevonc.2019.02.013. Epub 2019 Mar 1.
PMID: 31014514
Some observations on the liquid crystalline and gel behaviors of aqueous dispersions of a prodrug.
Tao L, Li J, Pinamanenni S, Raghavan K.
Drug Dev Ind Pharm. 2019 May;45(5):819-825. doi: 10.1080/03639045.2019.1576721. Epub 2019 Feb 13.
PMID: 30715959
The changing face of venous thromboembolism management in England.
Ramagopalan SV, Carroll R, Ulvestad M, Mehmud F, Alikhan R.
Future Cardiol. 2019 May;15(3):183-185. doi: 10.2217/fca-2019-0003. Epub 2019 Mar 25. Review.
PMID: 30907131
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.
Ekman S, Griesinger F, Baas P, Chao D, Chouaid C, O'Donnell JC, Penrod JR, Daumont M, Lacoin L, McKenney A, Khovratovich M, Munro RE, Durand-Zaleski I, Johnsen SP.
Future Oncol. 2019 May;15(14):1551-1563. doi: 10.2217/fon-2019-0025. Epub 2019 Mar 11.
PMID: 30852916
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, Rao S, McDermott DF.
Immunotherapy. 2019 May;11(7):617-629. doi: 10.2217/imt-2018-0208. Epub 2019 Mar 11.
PMID: 30852924
Whose Benchmark Is Right? Validating Venous Thromboembolism Events Between Trauma Registries and Hospital Administrative Databases.
Miano TA, Abelian G, Seamon MJ, Chreiman K, Reilly PM, Martin ND.
J Am Coll Surg. 2019 May;228(5):752-759.e3. doi: 10.1016/j.jamcollsurg.2019.02.037. Epub 2019 Feb 15.
PMID: 30772443
Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA.
Tarhini A, Atzinger C, Gupte-Singh K, Johnson C, Macahilig C, Rao S.
J Comp Eff Res. 2019 May;8(7):461-473. doi: 10.2217/cer-2019-0003. Epub 2019 Mar 5.
PMID: 30832505
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Baudelet C, Cai J, Chang J.
J Thorac Oncol. 2019 May;14(5):867-875. doi: 10.1016/j.jtho.2019.01.006. Epub 2019 Jan 17.
PMID: 30659987
Anticoagulant selection for patients with VTE-Evidence from a systematic literature review of network meta-analyses.
Cohen AT, Berger SE, Milenković D, Hill NR, Lister S.
Pharmacol Res. 2019 May;143:166-177. doi: 10.1016/j.phrs.2019.03.017. Epub 2019 Mar 21.
PMID: 30905806
Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism.
Yeh R, Tay YD, Tabacco G, Dercle L, Kuo JH, Bandeira L, McManus C, Leung DK, Lee JA, Bilezikian JP.
Radiology. 2019 May;291(2):469-476. doi: 10.1148/radiol.2019182122. Epub 2019 Mar 5.
PMID: 30835187
Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.
Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.
PMID: 30721326
The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers.
Wood R, Taylor-Stokes G, Lees M.
Support Care Cancer. 2019 May;27(5):1709-1719. doi: 10.1007/s00520-018-4419-3. Epub 2018 Aug 18.
PMID: 30121787
Pharma Collaboration for Transparent Medical Information (phactMI) Benchmark Study: Trends, Drivers, Success Factors, and Value of Globalization in Medical Information.
Giffin SA, Shah R, Soloff A, Vaysman AM, Oreper J, Gažo A, Gandhi P, Shah I, Malieckal T, Boulos D, Flowers T, Stevens CA, Rocco MS, Patel AS, Albano D.
Ther Innov Regul Sci. 2019 May;53(3):332-339. doi: 10.1177/2168479018779920. Epub 2018 Jun 19.
PMID: 29916261
PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design.
O'Brien SH, Li D, Mitchell LG, Hess T, Zee P, Yee DL, Newburger JW, Sung L, Rodriguez V.
Thromb Haemost. 2019 May;119(5):844-853. doi: 10.1055/s-0039-1679938. Epub 2019 Mar 12.
PMID: 30861550
Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R, Umebayashi H, Takei S, Okamoto N, Iwata N, Yamasaki Y, Nakagishi Y, Kizawa T, Kobayashi I, Imagawa T, Kinjo N, Amano N, Takahashi Y, Mori M, Itoh Y, Yokota S.
Pediatr Rheumatol Online J. 2019 Apr 30;17(1):17. doi: 10.1186/s12969-019-0319-4.
PMID: 31039807
A Radical Approach to Anionic Chemistry: Synthesis of Ketones, Alcohols, and Amines.
Ni S, Padial NM, Kingston C, Vantourout JC, Schmitt DC, Edwards JT, Kruszyk MM, Merchant RR, Mykhailiuk PK, Sanchez BB, Yang S, Perry MA, Gallego GM, Mousseau JJ, Collins MR, Cherney RJ, Lebed PS, Chen JS, Qin T, Baran PS.
J Am Chem Soc. 2019 Apr 24;141(16):6726-6739. doi: 10.1021/jacs.9b02238. Epub 2019 Apr 16.
PMID: 30943023
Role of Cdc23/Mcm10 in generating the ribonucleotide imprint at the mat1 locus in fission yeast.
Singh B, Bisht KK, Upadhyay U, Kushwaha AC, Nanda JS, Srivastava S, Saini JK, Klar AJS, Singh J.
Nucleic Acids Res. 2019 Apr 23;47(7):3422-3433. doi: 10.1093/nar/gkz092.
PMID: 30759238
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.
J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
PMID: 30785829
Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production.
Isidro-Llobet A, Kenworthy MN, Mukherjee S, Kopach ME, Wegner K, Gallou F, Smith AG, Roschangar F.
J Org Chem. 2019 Apr 19;84(8):4615-4628. doi: 10.1021/acs.joc.8b03001. Epub 2019 Mar 22.
PMID: 30900880
Utilizing Native Directing Groups: Synthesis of a Selective I Kur  Inhibitor, BMS-919373, via a Regioselective C-H Arylation.
Wisniewski SR, Stevens JM, Yu M, Fraunhoffer KJ, Romero EO, Savage SA.
J Org Chem. 2019 Apr 19;84(8):4704-4714. doi: 10.1021/acs.joc.8b02254. Epub 2018 Nov 15.
PMID: 30395712
C-H Arylation in the Formation of a Complex Pyrrolopyridine, the Commercial Synthesis of the Potent JAK2 Inhibitor, BMS-911543.
Fox RJ, Cuniere NL, Bakrania L, Wei C, Strotman NA, Hay M, Fanfair D, Regens C, Beutner GL, Lawler M, Lobben P, Soumeillant MC, Cohen B, Zhu K, Skliar D, Rosner T, Markwalter CE, Hsiao Y, Tran K, Eastgate MD.
J Org Chem. 2019 Apr 19;84(8):4661-4669. doi: 10.1021/acs.joc.8b02383. Epub 2018 Nov 12.
PMID: 30388009
Effects of Multiple Catalyst Deactivation Pathways and Continuous Ligand Recycling on the Kinetics of Pd-Catalyzed C-N Coupling Reactions.
Strotman NA, Soumeillant MC, Zhu K, Markwalter CE, Wei CS, Hsiao Y, Eastgate MD.
J Org Chem. 2019 Apr 19;84(8):4653-4660. doi: 10.1021/acs.joc.8b02214. Epub 2018 Oct 24.
PMID: 30336032
Synthesis of 2'-Methyl-6-methoxyguanosine from the Parent Ribonucleoside Guanosine.
Yuan C, Chen K, Eastgate M.
J Org Chem. 2019 Apr 19;84(8):4646-4652. doi: 10.1021/acs.joc.8b02194. Epub 2018 Oct 11.
PMID: 30253104
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators.
N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.
PMID: 30883055
A robust data-driven genomic signature for idiopathic pulmonary fibrosis with applications for translational model selection.
Ammar R, Sivakumar P, Jarai G, Thompson JR.
PLoS One. 2019 Apr 18;14(4):e0215565. doi: 10.1371/journal.pone.0215565. eCollection 2019.
PMID: 30998768
Report on the AAPS Immunogenicity Guidance Forum.
Myler H, Gorovits B, Phillips K, Devanarayan V, Clements-Egan A, Gunn GR, Kirshner S, DeSilva B, Shah VP.
AAPS J. 2019 Apr 16;21(4):55. doi: 10.1208/s12248-019-0328-8.
PMID: 30993501
Quadrupole Dalton-Based Controlled Proteolysis Method for Characterization of Higher Order Protein Structure.
Cao X, Flagg SC, Li X, Chennamsetty N, Balakrishnan G, Das TK.
Anal Chem. 2019 Apr 16;91(8):5339-5345. doi: 10.1021/acs.analchem.9b00306. Epub 2019 Apr 4.
PMID: 30915848
CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis.
Zhang H, Watanabe R, Berry GJ, Nadler SG, Goronzy JJ, Weyand CM.
J Am Coll Cardiol. 2019 Apr 16;73(14):1811-1823. doi: 10.1016/j.jacc.2019.01.049.
PMID: 30975299
Safety of Apixaban Administered via Nasogastric Tube.
Odell K, Costello J.
Cardiology. 2019 April 12;142(1):39. doi: 10.1159/000495577. Epub 2019 Apr 12. No abstract available.
PMID: 30982047
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
Watterson SH, Liu Q, Beaudoin Bertrand M, Batt DG, Li L, Pattoli MA, Skala S, Cheng L, Obermeier MT, Moore R, Yang Z, Vickery R, Elzinga PA, Discenza L, D'Arienzo C, Gillooly KM, Taylor TL, Pulicicchio C, Zhang Y, Heimrich E, McIntyre KW, Ruan Q, Westhouse RA, Catlett IM, Zheng N, Chaudhry C, Dai J, Galella MA, Tebben AJ, Pokross M, Li J, Zhao R, Smith D, Rampulla R, Allentoff A, Wallace MA, Mathur A, Salter-Cid L, Macor JE, Carter PH, Fura A, Burke JR, Tino JA.
J Med Chem. 2019 Apr 11;62(7):3228-3250. doi: 10.1021/acs.jmedchem.9b00167. Epub 2019 Mar 29.
Aryl hydrocarbon receptor acts as a tumor suppressor in a syngeneic MC38 colon carcinoma tumor model.
Yakkundi P, Gonsalves E, Galou-Lameyer M, Selby MJ, Chan WK.
Hypoxia (Auckl). 2019 Apr 10;7:1-16. doi: 10.2147/HP.S196301. eCollection 2019.
PMID: 31119183
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J.
J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.
PMID: 30811280
Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.
Poloyac SM, Bertz RJ, McDermott LA, Marathe P.
J Neurotrauma. 2019 Apr 10. doi: 10.1089/neu.2018.6295. [Epub ahead of print]
PMID: 30816062
Recent advances in 3Rs and laboratory animal science: Report on the International Conference of LASA (India).
Singh VP, Yadav S, Joshi H, Devan SRK, Yadav DK, Singh RP.
ALTEX. 2019 April 10;36(2):322-328. doi: 10.14573/altex.1901041. No abstract available.
PMID: 31032864
High-Throughput Analysis of Clinical Flow Cytometry Data by Automated Gating.
Lee H, Sun Y, Patti-Diaz L, Hedrick M, Ehrhardt AG.
Bioinform Biol Insights. 2019 Apr 3;13:1177932219838851. doi: 10.1177/1177932219838851. eCollection 2019.
PMID: 30983860
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM.
Ann Oncol. 2019 Apr 1;30(4):589-596. doi: 10.1093/annonc/mdz019.
PMID: 30689736
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.
PMID: 30670497
Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
Montastruc F, Renoux C, Dell'Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S.
Rheumatology (Oxford). 2019 Apr 1;58(4):683-691. doi: 10.1093/rheumatology/key352.
PMID: 30535094
Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients.
Moudgil A, Dharnidharka VR, Feig DI, Warshaw BL, Perera V, Murthy B, Roberts ME, Polinsky MS, Ettenger RB.
Am J Transplant. 2019 Apr;19(4):1218-1223. doi: 10.1111/ajt.15236. Epub 2019 Jan 22.
PMID: 30582294
Assessment of CE-based baseline disturbances using simulation and targeted experimental evaluation-impact on the purity determination of therapeutic proteins.
Gu Y, Voronov S, Ding J, Mussa N, Li ZJ.
Anal Bioanal Chem. 2019 Apr;411(11):2425-2437. doi: 10.1007/s00216-019-01704-6. Epub 2019 Mar 18.
PMID: 30880351
Perspectives on gender parity in bioanalysis: an interview with Binodh DeSilva.
De Silva B.
Bioanalysis. 2019 Apr;11(7):663-664. doi: 10.4155/bio-2019-0068. Epub 2019 Apr 18.
PMID: 30997822
Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC-MS.
Santockyte R, Zeng J, Zheng N.
Bioanalysis. 2019 Apr;11(8):785-795. doi: 10.4155/bio-2018-0277. Epub 2019 Apr 17.
PMID: 30994008
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
Osawa M, Hasegawa M, Bello A, Roy A, Hruska MW.
Cancer Chemother Pharmacol. 2019 Apr;83(4):705-715. doi: 10.1007/s00280-019-03771-z. Epub 2019 Jan 21.
PMID: 30666395
CD96 Is an Immune Checkpoint That Regulates CD8 +  T-cell Antitumor Function.
Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ.
Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20.
PMID: 30894377
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, Hwang P, Caro L, Robertson M, Charles ED, Platt H.
Clin Transl Gastroenterol. 2019 Apr;10(4):e00007. doi: 10.14309/ctg.0000000000000007.
PMID: 30939489
Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada.
Byrne K, Hallworth P, Monfared AAT, Moshyk A, Shaw JW.
Curr Oncol. 2019 Apr;26(2):e167-e174. doi: 10.3747/co.26.3946. Epub 2019 Apr 1.
PMID: 31043823
A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation.
Kumar V, Salphati L, Hop CECA, Xiao G, Lai Y, Mathias A, Chu X, Humphreys WG, Liao M, Heyward S, Unadkat JD.
Drug Metab Dispos. 2019 Apr;47(4):350-357. doi: 10.1124/dmd.118.084988. Epub 2019 Jan 8.
PMID: 30622164
Idealhalers Versus Realhalers: Is It Possible to Bypass Deposition in the Upper Respiratory Tract?
Weers JG, Son YJ, Glusker M, Haynes A, Huang D, Kadrichu N, Le J, Li X, Malcolmson R, Miller DP, Tarara TE, Ung K, Clark A.
J Aerosol Med Pulm Drug Deliv. 2019 Apr;32(2):55-69. doi: 10.1089/jamp.2018.1497. Epub 2018 Dec 6.
PMID: 30481087
Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects.
Osawa M, Ueno T, Shiozaki T, Li H, Garimella T.
J Clin Pharmacol. 2019 Apr;59(4):557-565. doi: 10.1002/jcph.1347. Epub 2018 Dec 19.
PMID: 30566237
Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin.
Ramagopalan SV, Graham S, Carroll R, Raluy-Callado M, Nordstrom BL, Donaldson R, Colby C, Mehmud F, Alikhan R.
J Comp Eff Res. 2019 Apr;8(6):371-379. doi: 10.2217/cer-2019-0005. Epub 2019 Feb 8.
PMID: 30734571
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Norden AD, Korytowsky B, You M, Kim Le T, Dastani H, Bobiak S, Singh P.
J Manag Care Spec Pharm. 2019 Apr;25(4):428-436. doi: 10.18553/jmcp.2019.25.4.428.
PMID: 30917077
Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
An J, Bider-Canfield Z, Kang J, Alemao E, Connolly SE, Lin AT, Cheetham TC.
J Manag Care Spec Pharm. 2019 Apr;25(4):469-477. doi: 10.18553/jmcp.2019.25.4.469.
PMID: 30917075
The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A, Paul D.
J Med Econ. 2019 Apr;22(4):350-358. doi: 10.1080/13696998.2019.1571498. Epub 2019 Feb 12.
PMID: 30653389
Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics.
Kretsinger J, Frantz N, Hart SA, Kelley WP, Kitchen B, Novick S, Rellahan B, Stranges D, Stroop CJM, Yin P, Gastens MH.
J Pharm Sci. 2019 Apr;108(4):1442-1452. doi: 10.1016/j.xphs.2018.11.042. Epub 2018 Dec 6.
PMID: 30528942
Representative Scale-Down Lyophilization Cycle Development Using a Seven-Vial Freeze-Dryer (MicroFD ® ).
Goldman JM, Chen X, Register JT, Nesarikar V, Iyer L, Wu Y, Mugheirbi N, Rowe J.
J Pharm Sci. 2019 Apr;108(4):1486-1495. doi: 10.1016/j.xphs.2018.11.018. Epub 2018 Nov 20.
PMID: 30468831
Unmasking of oestrogen-dependent changes in left ventricular structure and function in aged female rats: a potential model for pre-heart failure with preserved ejection fraction.
Bustamante M, Garate-Carrillo A, R Ito B, Garcia R, Carson N, Ceballos G, Ramirez-Sanchez I, Omens J, Villarreal F.
J Physiol. 2019 Apr;597(7):1805-1817. doi: 10.1113/JP277479. Epub 2019 Feb 12.
PMID: 30681142
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.
Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators.
J Thromb Thrombolysis. 2019 Apr;47(3):345-352. doi: 10.1007/s11239-019-01823-y.
PMID: 30790160
Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma.
Khadirnaikar S, Kumar P, Pandi SN, Malik R, Dhanasekaran SM, Shukla SK.
Mol Carcinog. 2019 Apr;58(4):544-553. doi: 10.1002/mc.22949. Epub 2018 Dec 21.
PMID: 30520148
Single-cell transcriptomic analysis of the lateral hypothalamic area reveals molecularly distinct populations of inhibitory and excitatory neurons.
Mickelsen LE, Bolisetty M, Chimileski BR, Fujita A, Beltrami EJ, Costanzo JT, Naparstek JR, Robson P, Jackson AC.
Nat Neurosci. 2019 Apr;22(4):642-656. doi: 10.1038/s41593-019-0349-8. Epub 2019 Mar 11.
PMID: 30858605
A changing landscape: Temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006-2015.
Münster AM, Rasmussen TB, Falstie-Jensen AM, Harboe L, Stynes G, Dybro L, Hansen ML, Brandes A, Grove EL, Johnsen SP.
Thromb Res. 2019 Apr;176:46-53. doi: 10.1016/j.thromres.2019.02.009. Epub 2019 Feb 13.
PMID: 30776687
A mouse model of heart failure exhibiting pulmonary edema and pleural effusion: Useful for testing new drugs.
Ma X, Tannu S, Allocco J, Pan J, Dipiero J, Wong P.
J Pharmacol Toxicol Methods. 2019 Mar - Apr;96:78-86. doi: 10.1016/j.vascn.2019.02.001. Epub 2019 Feb 6.
PMID: 30738210
Toxicity of Pexacerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist, in Rats and Dogs.
White MR, Graziano MJ, Sanderson TP.
Int J Toxicol. 2019 Mar/Apr;38(2):110-120. doi: 10.1177/1091581819827501. Epub 2019 Feb 13.
PMID: 30760067
Assessing the risk of drug crystallization in vivo.
Ruepp S, Janovitz E, Brodie T, White R, Santella J, Hynes J, Carman J, Pan D, Wu Y, Hanumegowda U, Gemzik B, Megill J, DiPiero J, Drexler D, Su CC, Hageman M.
J Pharmacol Toxicol Methods. 2019 Mar - Apr;96:1-8. doi: 10.1016/j.vascn.2018.12.003. Epub 2018 Dec 13.
PMID: 30553974
Continuous Microbiological Environmental Monitoring for Process Understanding and Reduced Interventions in Aseptic Manufacturing.
Weber J, Hauschild J, Ijzerman-Boon P, Forng RY, Horsch J, Yan L, Prasad A, Henry RB, Claassen M, Villari P, Shereefa S, Wyatt J, Bolden JS, Pycke JT, Dassu D.
PDA J Pharm Sci Technol. 2019 Mar-Apr;73(2):121-134. doi: 10.5731/pdajpst.2018.008722. Epub 2018 Oct 25.
PMID: 30361285
Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW, Avgerinos S, Ballard R, Brussel A, Clark P, Dowd C, Gerentes L, Hart I, Keumurian FJ, Kindermann J, Leung JC, Ly N, Mink S, Minning S, Mullberg J, Murphy M, Nöske K, Parriott S, Shum B, Wiebe ME, Springs SL.
PDA J Pharm Sci Technol. 2019 Mar-Apr;73(2):191-203. doi: 10.5731/pdajpst.2018.008862. Epub 2018 Oct 25.
PMID: 30361281
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab.
Pradier MF, Reis B, Jukofsky L, Milletti F, Ohtomo T, Perez-Cruz F, Puig O.
BMC Cancer. 2019 Mar 28;19(1):278. doi: 10.1186/s12885-019-5472-0.
PMID: 30922327
Congruent release of drug and polymer: A "sweet spot" in the dissolution of amorphous solid dispersions.
Saboo S, Mugheirbi NA, Zemlyanov DY, Kestur US, Taylor LS.
J Control Release. 2019 Mar 28;298:68-82. doi: 10.1016/j.jconrel.2019.01.039. Epub 2019 Feb 4.
PMID: 30731151
Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the  In Vitro  Potency of Direct-Acting Antiviral Agents.
McPhee F, Ueland J, Vellucci V, Bowden S, Sievert W, Zhou N.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02205-18. doi: 10.1128/AAC.02205-18. Print 2019 Apr.
PMID: 30718256
Interfacial Stress in the Development of Biologics: Fundamental Understanding, Current Practice, and Future Perspective.
Li J, Krause ME, Chen X, Cheng Y, Dai W, Hill JJ, Huang M, Jordan S, LaCasse D, Narhi L, Shalaev E, Shieh IC, Thomas JC, Tu R, Zheng S, Zhu L.
AAPS J. 2019 Mar 26;21(3):44. doi: 10.1208/s12248-019-0312-3.
PMID: 30915582
Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance.
Liu J, Curtin J, You D, Hillerman S, Li-Wang B, Eraslan R, Xie J, Swanson J, Ho CP, Oppenheimer S, Warrack BM, McNaney CA, Nelson DM, Blum J, Kim T, Fereshteh M, Reily M, Shipkova P, Murtaza A, Sanjuan M, Hunt JT, Salter-Cid L.
PLoS One. 2019 Mar 26;14(3):e0212670. doi: 10.1371/journal.pone.0212670. eCollection 2019.
PMID: 30913212
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A.
PLoS One. 2019 Mar 25;14(3):e0213614. doi: 10.1371/journal.pone.0213614. eCollection 2019.
PMID: 30908512
Stability behaviour of antiretroviral drugs and their combinations. 9: Identification of incompatible excipients.
Kurmi M, Sahu A, Ladumor MK, Kumar Bansal A, Singh S.
J Pharm Biomed Anal. 2019 Mar 20;166:174-182. doi: 10.1016/j.jpba.2019.01.009. Epub 2019 Jan 8.
PMID: 30654205
Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective.
Macaulay R, Ahuja A, Ademisoye E, Juarez-Garcia A, Shaw JW.
Clinicoecon Outcomes Res. 2019 Mar 19;11:199-219. doi: 10.2147/CEOR.S177343. eCollection 2019.
PMID: 30936729
Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype.
Mukherjee S, Zhelnin L, Sanfiz A, Pan J, Li Z, Yarde M, McCarty J, Jarai G.
Am J Transl Res. 2019 Mar 15;11(3):1531-1540. eCollection 2019.
PMID: 30972180
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.
J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.
PMID: 30871617
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P 1 ) Modulator Advanced into Clinical Trials.
Gilmore JL, Xiao HY, Dhar TGM, Yang MG, Xiao Z, Xie J, Lehman-McKeeman LD, Gong L, Sun H, Lecureux L, Chen C, Wu DR, Dabros M, Yang X, Taylor TL, Zhou XD, Heimrich EM, Thomas R, McIntyre KW, Borowski V, Warrack BM, Li Y, Shi H, Levesque PC, Yang Z, Marino AM, Cornelius G, D'Arienzo CJ, Mathur A, Rampulla R, Gupta A, Pragalathan B, Shen DR, Cvijic ME, Salter-Cid LM, Carter PH, Dyckman AJ.
J Med Chem. 2019 Mar 14;62(5):2265-2285. doi: 10.1021/acs.jmedchem.8b01695. Epub 2019 Mar 6.
PMID: 30785748
New epitopes in ovalbumin provide insights for cancer neoepitopes.
Karandikar SH, Sidney J, Sette A, Selby MJ, Korman AJ, Srivastava PK.
JCI Insight. 2019 Mar 14;5. pii: 127882. doi: 10.1172/jci.insight.127882.
PMID: 30869653
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?
Amberg A, Anger LT, Bercu J, Bower D, Cross KP, Custer L, Harvey JS, Hasselgren C, Honma M, Johnson C, Jolly R, Kenyon MO, Kruhlak NL, Leavitt P, Quigley DP, Miller S, Snodin D, Stavitskaya L, Teasdale A, Trejo-Martin A, White AT, Wichard J, Myatt GJ.
Mutagenesis. 2019 Mar 6;34(1):67-82. doi: 10.1093/mutage/gey020.
PMID: 30189015
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
Rapisuwon S, Izar B, Batenchuk C, Avila A, Mei S, Sorger P, Parks JM, Cooper SJ, Wagner D, Zeck JC, Charabaty AJ, Atkins MB.
J Immunother Cancer. 2019 Mar 4;7(1):61. doi: 10.1186/s40425-019-0533-0.
PMID: 30832716
Linking (Pyr) 1 apelin-13 pharmacokinetics to efficacy: Stabilization and measurement of a high clearance peptide in rodents.
Onorato JM, Xu C, Chen XQ, Rose AV, Generaux C, Lentz K, Shipkova P, Arthur S, Hennan JK, Haskell R, Myers MC, Lawrence RM, Finlay HJ, Basso M, Bostwick J, Fernando G, Garcia R, Hellings S, Hsu MY, Zhang R, Zhao L, Gargalovic P.
Anal Biochem. 2019 Mar 1;568:41-50. doi: 10.1016/j.ab.2018.12.022. Epub 2018 Dec 31.
PMID: 30605634
IL-17A Recruits Rab35 to IL-17R to Mediate PKCα-Dependent Stress Fiber Formation and Airway Smooth Muscle Contractility.
Bulek K, Chen X, Parron V, Sundaram A, Herjan T, Ouyang S, Liu C, Majors A, Zepp J, Gao J, Dongre A, Bodaszewska-Lubas M, Echard A, Aronica M, Carman J, Garantziotis S, Sheppard D, Li X.
J Immunol. 2019 Mar 1;202(5):1540-1548. doi: 10.4049/jimmunol.1801025. Epub 2019 Jan 25.
PMID: 30683702
Author Correction: A shape-shifting redox foldase contributes to Proteus mirabilis copper resistance.
Furlong EJ, Lo AW, Kurth F, Premkumar L, Totsika M, Achard MES, Halili MA, Heras B, Whitten AE, Choudhury HG, Schembri MA, Martin JL.
Nat Commun. 2019 Mar 1;10(1):976. doi: 10.1038/s41467-019-08920-9.
PMID: 30824772
Bioanalytical challenges and unique considerations to support pharmacokinetic characterization of bispecific biotherapeutics.
Ma M, Colletti K, Yang TY, Leung S, Pederson S, Hottenstein CS, Xu X, Warrino D, Wakshull E.
Bioanalysis. 2019 Mar;11(5):427-435. doi: 10.4155/bio-2018-0146. Epub 2019 Mar 19.
PMID: 30887822
Systematic Interpolation Method Predicts Antibody Monomer-Dimer Separation by Gradient Elution Chromatography at High Protein Loads.
Creasy A, Reck J, Pabst T, Hunter A, Barker G, Carta G.
Biotechnol J. 2019 Mar;14(3):e1800132. doi: 10.1002/biot.201800132. Epub 2018 Jun 11.
PMID: 29809318
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
Yusko E, Vignali M, Wilson RK, Mardis ER, Hodi FS, Horak C, Chang H, Woods DM, Robins H, Weber J.
Cancer Immunol Res. 2019 Mar;7(3):458-465. doi: 10.1158/2326-6066.CIR-18-0226. Epub 2019 Jan 11.
PMID: 30635271
The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.
Li J, Chen G.
Drug Discov Today. 2019 Mar;24(3):829-834. doi: 10.1016/j.drudis.2018.12.008. Epub 2018 Dec 21. Review.
PMID: 30583089
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.
Tarhini A, McDermott D, Ambavane A, Gupte-Singh K, Aponte-Ribero V, Ritchings C, Benedict A, Rao S, Regan MM, Atkins M.
Immunotherapy. 2019 Mar;11(4):283-295. doi: 10.2217/imt-2018-0168. Epub 2018 Dec 19.
PMID: 30563395
Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X, Ludwig EA, Passarell J, Bello A, Roy A, Hruska MW.
J Clin Pharmacol. 2019 Mar;59(3):364-373. doi: 10.1002/jcph.1324. Epub 2018 Oct 19.
PMID: 30339279
Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D.
Leuk Lymphoma. 2019 Mar;60(3):668-674. doi: 10.1080/10428194.2018.1492124. Epub 2018 Aug 20.
PMID: 30124372
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA.
Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. No abstract available.
PMID: 30315237
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC.
Nat Med. 2019 Mar;25(3):454-461. doi: 10.1038/s41591-019-0357-y. Epub 2019 Feb 25.
PMID: 30804515
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T.
Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20.
PMID: 30458579
Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y.
Pharmacoecon Open. 2019 Mar;3(1):127. doi: 10.1007/s41669-018-0096-x.
PMID: 30206825
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y.
Pharmacoecon Open. 2019 Mar;3(1):43-54. doi: 10.1007/s41669-018-0080-5. Erratum in:  Pharmacoecon Open. 2018 Sep 11;: .
PMID: 29790020
Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group.
Birkebak J, Buckley LA, Dambach D, Musvasva E, Price K, Ralston S, Sacaan A.
Regul Toxicol Pharmacol. 2019 Mar;102:40-46. doi: 10.1016/j.yrtph.2018.12.012. Epub 2018 Dec 19.
PMID: 30576687
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses.
Amberg A, Andaya RV, Anger LT, Barber C, Beilke L, Bercu J, Bower D, Brigo A, Cammerer Z, Cross KP, Custer L, Dobo K, Gerets H, Gervais V, Glowienke S, Gomez S, Van Gompel J, Harvey J, Hasselgren C, Honma M, Johnson C, Jolly R, Kemper R, Kenyon M, Kruhlak N, Leavitt P, Miller S, Muster W, Naven R, Nicolette J, Parenty A, Powley M, Quigley DP, Reddy MV, Sasaki JC, Stavitskaya L, Teasdale A, Trejo-Martin A, Weiner S, Welch DS, White A, Wichard J, Woolley D, Myatt GJ.
Regul Toxicol Pharmacol. 2019 Mar;102:53-64. doi: 10.1016/j.yrtph.2018.12.007. Epub 2018 Dec 15.
PMID: 30562600
Xenobiotic Transporters in the Kidney: Function and Role in Toxicity.
Shen H, Scialis RJ, Lehman-McKeeman L.
Semin Nephrol. 2019 Mar;39(2):159-175. doi: 10.1016/j.semnephrol.2018.12.010. Review.
PMID: 30827339
Kidney Safety Assessment: Current Practices in Drug Development.
Troth SP, Simutis F, Friedman GS, Todd S, Sistare FD.
Semin Nephrol. 2019 Mar;39(2):120-131. doi: 10.1016/j.semnephrol.2018.12.002. Review.
PMID: 30827335
Assessing seizure liability using multi-electrode arrays (MEA).
Fan J, Thalody G, Kwagh J, Burnett E, Shi H, Lewen G, Chen SJ, Levesque P.
Toxicol In Vitro. 2019 Mar;55:93-100. doi: 10.1016/j.tiv.2018.12.001. Epub 2018 Dec 4.
PMID: 30528373
Structure, heterogeneity and developability assessment of therapeutic antibodies.
Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, Nowak C, Xiang T, Dong DD, Sun J, Beck A, Liu H.
MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17. Review.
PMID: 30543482
Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan.
DiBonaventura MD, Shah-Manek B, Higginbottom K, Penrod JR, Yuan Y.
Ther Clin Risk Manag. 2019 Feb 28;15:355-366. doi: 10.2147/TCRM.S183216. eCollection 2019.
PMID: 30881001
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists.
Duan JJ, Lu Z, Jiang B, Stachura S, Weigelt CA, Sack JS, Khan J, Ruzanov M, Galella MA, Wu DR, Yarde M, Shen DR, Shuster DJ, Borowski V, Xie JH, Zhang L, Vanteru S, Gupta AK, Mathur A, Zhao Q, Foster W, Salter-Cid LM, Carter PH, Dhar TGM.
ACS Med Chem Lett. 2019 Feb 26;10(3):367-373. doi: 10.1021/acsmedchemlett.9b00010. eCollection 2019 Mar 14.
PMID: 30891142
Role of FcγRs in Antibody-Based Cancer Therapy.
Graziano RF, Engelhardt JJ.
Curr Top Microbiol Immunol. 2019 Feb 22;423:13-34. doi: 10.1007/82_2019_150. Review.
PMID: 30790079
First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing.
Zaborenko N, Shi Z, Corredor CC, Smith-Goettler BM, Zhang L, Hermans A, Neu CM, Alam MA, Cohen MJ, Lu X, Xiong L, Zacour BM.
AAPS J. 2019 Feb 21;21(3):32. doi: 10.1208/s12248-019-0297-y. Review.
PMID: 30790200
Identification of Imidazo[1,2- b ]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.
Liu C, Lin J, Moslin R, Tokarski JS, Muckelbauer J, Chang C, Tredup J, Xie D, Park H, Li P, Wu DR, Strnad J, Zupa-Fernandez A, Cheng L, Chaudhry C, Chen J, Chen C, Sun H, Elzinga P, D'arienzo C, Gillooly K, Taylor TL, McIntyre KW, Salter-Cid L, Lombardo LJ, Carter PH, Aranibar N, Burke JR, Weinstein DS.
ACS Med Chem Lett. 2019 Feb 21;10(3):383-388. doi: 10.1021/acsmedchemlett.9b00035. eCollection 2019 Mar 14.
PMID: 30891145
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.
Costa MJ, Kudaravalli J, Ma JT, Ho WH, Delaria K, Holz C, Stauffer A, Chunyk AG, Zong Q, Blasi E, Buetow B, Tran TT, Lindquist K, Dorywalska M, Rajpal A, Shelton DL, Strop P, Liu SH.
Sci Rep. 2019 Feb 21;9(1):2443. doi: 10.1038/s41598-019-38745-x.
PMID: 30792442
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A.
J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.
PMID: 30620669
A convenient strategy to overcome interference in LC-MS/MS analysis: Application in a microdose absolute bioavailability study.
Yuan L, Huang C, Liu-Kreyche P, Voronin K, Fancher RM, Allentoff A, Zheng N, Iyer R, Zhu L, Pillutla R, Ji QC.
J Pharm Biomed Anal. 2019 Feb 20;165:198-206. doi: 10.1016/j.jpba.2018.12.014. Epub 2018 Dec 10.
PMID: 30553110
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.
Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D.
Sci Adv. 2019 Feb 20;5(2):eaav2437. doi: 10.1126/sciadv.aav2437. eCollection 2019 Feb.
PMID: 30801016
Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481.
Boy KM, Guernon JM, Zuev DS, Xu L, Zhang Y, Shi J, Marcin LR, Higgins MA, Wu YJ, Krishnananthan S, Li J, Trehan A, Smith D, Toyn JH, Meredith JE, Burton CR, Kimura SR, Zvyaga T, Zhuo X, Lentz KA, Grace JE, Denton R, Morrison JS, Mathur A, Albright CF, Ahlijanian MK, Olson RE, Thompson LA, Macor JE.
ACS Med Chem Lett. 2019 Feb 17;10(3):312-317. doi: 10.1021/acsmedchemlett.8b00541. eCollection 2019 Mar 14.
PMID: 30891132
A practical workflow for capillary microsampling in nonclinical studies.
Wang L, Wang B, Chadwick KD, Su T, Mangipudy R, Pillutla RC, Ji QC.
Bioanalysis. 2019 Feb 15. doi: 10.4155/bio-2018-0224. [Epub ahead of print]
PMID: 30767556
Discovery of new indole-based acylsulfonamide Na v 1.7 inhibitors.
Wu YJ, Venables B, Guernon J, Chen J, Sit SY, Rajamani R, Knox RJ, Matchett M, Pieschl RL, Herrington J, Bristow LJ, Meanwell NA, Thompson LA, Dzierba C.
Bioorg Med Chem Lett. 2019 Feb 15;29(4):659-663. doi: 10.1016/j.bmcl.2018.12.013. Epub 2018 Dec 6.
PMID: 30638874
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.
Spergel SH, Mertzman ME, Kempson J, Guo J, Stachura S, Haque L, Lippy JS, Zhang RF, Galella M, Pitt S, Shen G, Fura A, Gillooly K, McIntyre KW, Tang V, Tokarski J, Sack JS, Khan J, Carter PH, Barrish JC, Nadler SG, Salter-Cid LM, Schieven GL, Wrobleski ST, Pitts WJ.
ACS Med Chem Lett. 2019 Feb 13;10(3):306-311. doi: 10.1021/acsmedchemlett.8b00508. eCollection 2019 Mar 14.
PMID: 30891131
Pd II  -Catalyzed Enantioselective C(sp 3  )-H Activation/Cross-Coupling Reactions of Free Carboxylic Acids.
Hu L, Shen PX, Shao Q, Hong K, Qiao JX, Yu JQ.
Angew Chem Int Ed Engl. 2019 Feb 11;58(7):2134-2138. doi: 10.1002/anie.201813055. Epub 2019 Jan 16.
PMID: 30536546
Ligand-Promoted Non-Directed C-H Cyanation of Arenes.
Liu LY, Yeung KS, Yu JQ.
Chemistry. 2019 Feb 11;25(9):2199-2202. doi: 10.1002/chem.201805772. Epub 2019 Jan 16.
PMID: 30478935
Degradation of the extracellular matrix is part of the pathology of ulcerative colitis.
Kirov S, Sasson A, Zhang C, Chasalow S, Dongre A, Steen H, Stensballe A, Andersen V, Birkelund S, Bennike TB.
Mol Omics. 2019 Feb 11;15(1):67-76. doi: 10.1039/c8mo00239h.
PMID: 30702115
Second Generation Inhibitors of HIV-1 Maturation.
Regueiro-Ren A, Dicker IB, Hanumegowda U, Meanwell NA.
ACS Med Chem Lett. 2019 Feb 8;10(3):287-294. doi: 10.1021/acsmedchemlett.8b00656. eCollection 2019 Mar 14.
PMID: 30891128
Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography.
Yip SH, Wu DR, Li P, Sun D, Watterson SH, Zhao R, Tino J, Mathur A.
J Chromatogr A. 2019 Feb 8;1586:106-115. doi: 10.1016/j.chroma.2018.12.006. Epub 2018 Dec 14.
PMID: 30578026
Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.
Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.
RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.
PMID: 30997151
In-Sample Calibration Curve Using Multiple Isotopologue Reaction Monitoring of a Stable Isotopically Labeled Analyte for Instant LC-MS/MS Bioanalysis and Quantitative Proteomics.
Gu H, Zhao Y, DeMichele M, Zheng N, Zhang YJ, Pillutla R, Zeng J.
Anal Chem. 2019 Feb 5;91(3):2536-2543. doi: 10.1021/acs.analchem.8b05656. Epub 2019 Jan 22.
PMID: 30615432
Molecular characterization of a precision-cut rat lung slice model for the evaluation of antifibrotic drugs.
Huang X, Li L, Ammar R, Zhang Y, Wang Y, Ravi K, Thompson J, Jarai G.
Am J Physiol Lung Cell Mol Physiol. 2019 Feb 1;316(2):L348-L357. doi: 10.1152/ajplung.00339.2018. Epub 2018 Nov 29.
PMID: 30489156
Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy.
Chowdari NS, Pan C, Rao C, Langley DR, Sivaprakasam P, Sufi B, Derwin D, Wang Y, Kwok E, Passmore D, Rangan VS, Deshpande S, Cardarelli P, Vite G, Gangwar S.
Bioorg Med Chem Lett. 2019 Feb 1;29(3):466-470. doi: 10.1016/j.bmcl.2018.12.021. Epub 2018 Dec 11.
PMID: 30579797
Relative quantitation of endogenous proteins by quadrupole-time of flight and tandem mass spectrometry.
Gautam SS, Wagh S, Babu S, Gudihal R, Rajagopalan S, Kole P, Mandlekar S, Subramanian M.
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Feb 1;1106-1107:11-18. doi: 10.1016/j.jchromb.2018.12.023. Epub 2018 Dec 28. No abstract available.
PMID: 30615973
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.
J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196. Review.
PMID: 30561713
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J.
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in:  JAMA Oncol. 2019 Feb 1;5(2):271 .
PMID: 30543350
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.
JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514. Erratum in:  JAMA Oncol. 2019 Feb 1;5(2):271 .
PMID: 30422243
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.
JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.
PMID: 30383184
Environmental risk assessment of metformin and its transformation product guanylurea. I. Environmental fate.
Straub JO, Caldwell DJ, Davidson T, D'Aco V, Kappler K, Robinson PF, Simon-Hettich B, Tell J.
Chemosphere. 2019 Feb;216:844-854. doi: 10.1016/j.chemosphere.2018.10.036. Epub 2018 Oct 9.
PMID: 30449313
Environmental risk assessment of metformin and its transformation product guanylurea: II. Occurrence in surface waters of Europe and the United States and derivation of predicted no-effect concentrations.
Caldwell DJ, D'Aco V, Davidson T, Kappler K, Murray-Smith RJ, Owen SF, Robinson PF, Simon-Hettich B, Straub JO, Tell J.
Chemosphere. 2019 Feb;216:855-865. doi: 10.1016/j.chemosphere.2018.10.038. Epub 2018 Oct 15.
PMID: 30385066
Challenges and Opportunities With Oncology Drug Development in China.
Bajaj G, Gupta M, Wang HH, Barrett JS, Tan M, Rupalla K, Bertz R, Sheng J.
Clin Pharmacol Ther. 2019 Feb;105(2):363-375. doi: 10.1002/cpt.1017. Epub 2018 Mar 8. Review.
PMID: 29328503
A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need.
Ermakov S, Schmidt BJ, Musante CJ, Thalhauser CJ.
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):62-76. doi: 10.1002/psp4.12373. Epub 2019 Jan 30.
PMID: 30417600
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A.
Heart. 2019 Feb;105(3):235-242. doi: 10.1136/heartjnl-2018-313351. Epub 2018 Sep 12.
PMID: 30209126
Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H.
Int J Urol. 2019 Feb;26(2):202-210. doi: 10.1111/iju.13830. Epub 2018 Oct 21.
PMID: 30345560
Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis.
Li X, Roy A, Murthy B.
J Clin Pharmacol. 2019 Feb;59(2):245-257. doi: 10.1002/jcph.1308. Epub 2018 Sep 19.
PMID: 30229926
Current Trends in the Surgical Treatment of Open-Book Pelvic Ring Injuries: An International Survey Among Experienced Trauma Surgeons.
Moed BR, Barla J, Israel HA, Tovar S, Joeris A.
J Orthop Trauma. 2019 Feb;33 Suppl 2:S61-S65. doi: 10.1097/BOT.0000000000001411.
PMID: 30688862
Pulse Proteolysis: An Orthogonal Tool for Protein Formulation Screening.
Iyer LK, Phanse R, Xu M, Lan W, Krause ME, Bolgar M, Hart S.
J Pharm Sci. 2019 Feb;108(2):842-850. doi: 10.1016/j.xphs.2018.09.018. Epub 2018 Sep 23.
PMID: 30257193
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, Eder JP, Steele NL, Pieters A, Fairchild J, Antonia SJ.
J Thorac Oncol. 2019 Feb;14(2):237-244. doi: 10.1016/j.jtho.2018.10.003. Epub 2018 Oct 10.
PMID: 30316010
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.
Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.
PMID: 30642819
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ.
Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15. Erratum in:  Lancet Oncol. 2019 Jun;20(6):e293 .
PMID: 30658932
Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials.
Buch MH, Johnsen A, Schiff M.
Clin Exp Rheumatol. 2019 Jan-Feb;37(1):127-132. Epub 2018 Aug 21.
PMID: 30148437
Dissolution Testing in Drug Product Development: Workshop Summary Report.
Abend A, Curran D, Kuiper J, Lu X, Li H, Hermans A, Kotwal P, Diaz DA, Cohen MJ, Zhang L, Stippler E, Drazer G, Lin Y, Raines K, Yu L, Coutant CA, Grady H, Krämer J, Pope-Miksinski S, Suarez-Sharp S.
AAPS J. 2019 Jan 28;21(2):21. doi: 10.1208/s12248-018-0288-4.
PMID: 30690680
Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART.
Bui JK, Cyktor JC, Fyne E, Campellone S, Mason SW, Mellors JW.
PLoS One. 2019 Jan 25;14(1):e0211112. doi: 10.1371/journal.pone.0211112. eCollection 2019.
PMID: 30682108
Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na V 1.7 Inhibitors for the Treatment of Pain.
Luo G, Chen L, Easton A, Newton A, Bourin C, Shields E, Mosure K, Soars MG, Knox RJ, Matchett M, Pieschl RL, Post-Munson DJ, Wang S, Herrington J, Graef J, Newberry K, Sivarao DV, Senapati A, Bristow LJ, Meanwell NA, Thompson LA, Dzierba C.
J Med Chem. 2019 Jan 24;62(2):831-856. doi: 10.1021/acs.jmedchem.8b01550. Epub 2019 Jan 8. Erratum in:  J Med Chem. 2019 Feb 28;62(4):2213 .
PMID: 30576602
PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
Stillhart C, Pepin X, Tistaert C, Good D, Van Den Bergh A, Parrott N, Kesisoglou F.
AAPS J. 2019 Jan 23;21(2):19. doi: 10.1208/s12248-019-0292-3.
PMID: 30673891
Review of Biomarkers in Ocular Matrices: Challenges and Opportunities.
Tamhane M, Cabrera-Ghayouri S, Abelian G, Viswanath V.
Pharm Res. 2019 Jan 23;36(3):40. doi: 10.1007/s11095-019-2569-8. Review.
PMID: 30673862
Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting.
Degli Esposti L, Perrone V, Sangiorgi D, Alessandrini D, Buda S, Cantini F, Mazzini E, Toma C, De Solda F.
Patient Prefer Adherence. 2019 Jan 22;13:187-194. doi: 10.2147/PPA.S178603. eCollection 2019.
PMID: 30774314
Bringing Macrolactamization Full Circle: Self-Cleaving Head-to-Tail Macrocyclization of Unprotected Peptides via Mild N-Acyl Urea Activation.
Arbour CA, Belavek KJ, Tariq R, Mukherjee S, Tom JK, Isidro-Llobet A, Kopach ME, Stockdill JL.
J Org Chem. 2019 Jan 18;84(2):1035-1041. doi: 10.1021/acs.joc.8b02418. Epub 2019 Jan 2.
PMID: 30566351
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.
Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB 3rd, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.
ACS Med Chem Lett. 2019 Jan 16;10(3):300-305. doi: 10.1021/acsmedchemlett.8b00439. eCollection 2019 Mar 14.
PMID: 30891130
Real-world data and the patient perspective: the PROmise of social media?
McDonald L, Malcolm B, Ramagopalan S, Syrad H.
BMC Med. 2019 Jan 16;17(1):11. doi: 10.1186/s12916-018-1247-8.
PMID: 30646913
Direct Carbon Isotope Exchange through Decarboxylative Carboxylation.
Kingston C, Wallace MA, Allentoff AJ, deGruyter JN, Chen JS, Gong SX, Bonacorsi S Jr, Baran PS.
J Am Chem Soc. 2019 Jan 16;141(2):774-779. doi: 10.1021/jacs.8b12035. Epub 2019 Jan 3.
PMID: 30605319
The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu 4  PAM development candidate.
Panarese JD, Engers DW, Wu YJ, Guernon JM, Chun A, Gregro AR, Bender AM, Capstick RA, Wieting JM, Bronson JJ, Macor JE, Westphal R, Soars M, Engers JE, Felts AS, Rodriguez AL, Emmitte KA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW.
Bioorg Med Chem Lett. 2019 Jan 15;29(2):342-346. doi: 10.1016/j.bmcl.2018.10.050. Epub 2018 Nov 1.
PMID: 30503632
PTEN Expression, Not Mutation Status in  TSC1, TSC2 , or  mTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.
Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan VE, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ.
Clin Cancer Res. 2019 Jan 15;25(2):506-514. doi: 10.1158/1078-0432.CCR-18-1833. Epub 2018 Oct 16.
PMID: 30327302
Comparison of imaged capillary isoelectric focusing and cation exchange chromatography for monitoring dextrose-mediated glycation of monoclonal antibodies in infusion solutions.
Demirdirek B, Lan W, Qiu D, Ding W, Iyer LK, Bolgar MS, Valente JJ.
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 15;1105:156-163. doi: 10.1016/j.jchromb.2018.12.021. Epub 2018 Dec 17.
PMID: 30594826
DNA RETENTION ON DEPTH FILTERS.
Khanal O, Xu X, Singh N, Traylor SJ, Huang C, Ghose S, Li ZJ, Lenhoff AM.
J Memb Sci. 2019 Jan 15;570-571:464-471. doi: 10.1016/j.memsci.2018.10.058. Epub 2018 Oct 24.
PMID: 31223185
Subunit mass analysis for monitoring multiple attributes of monoclonal antibodies.
Liu P, Zhu X, Wu W, Ludwig R, Song H, Li R, Zhou J, Tao L, Leone AM.
Rapid Commun Mass Spectrom. 2019 Jan 15;33(1):31-40. doi: 10.1002/rcm.8301.
PMID: 30286260
Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.
Lai YT, Wang T, O'Dell S, Louder MK, Schön A, Cheung CSF, Chuang GY, Druz A, Lin B, McKee K, Peng D, Yang Y, Zhang B, Herschhorn A, Sodroski J, Bailer RT, Doria-Rose NA, Mascola JR, Langley DR, Kwong PD.
Nat Commun. 2019 Jan 3;10(1):47. doi: 10.1038/s41467-018-07851-1.
PMID: 30604750
Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds.
Huang X, Cai H, Ammar R, Zhang Y, Wang Y, Ravi K, Thompson J, Jarai G.
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G15-G24. doi: 10.1152/ajpgi.00281.2018. Epub 2018 Nov 8.
PMID: 30406699
Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.
Karsdal MA, Hjuler ST, Luo Y, Rasmussen DGK, Nielsen MJ, Holm Nielsen S, Leeming DJ, Goodman Z, Arch RH, Patel K, Schuppan D.
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G25-G31. doi: 10.1152/ajpgi.00158.2018. Epub 2018 Aug 30.
PMID: 30160980
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.
Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA.
J Clin Oncol. 2019 Jan 1;37(1):72-80. doi: 10.1200/JCO.18.00145. Epub 2018 Oct 19.
PMID: 30339040
Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read Sequencing.
Haj AK, Arbanas JM, Yamniuk AP, Karl JA, Bussan HE, Drinkwater KY, Graham ME, Ericsen AJ, Prall TM, Moore K, Cheng L, Gao M, Graziano RF, Loffredo JT, Wiseman RW, O'Connor DH.
J Immunol. 2019 Jan 1;202(1):151-159. doi: 10.4049/jimmunol.1800843. Epub 2018 Dec 10.
PMID: 30530595
RORγt Represses IL-10 Production in Th17 Cells To Maintain Their Pathogenicity in Inducing Intestinal Inflammation.
Sun M, He C, Chen L, Yang W, Wu W, Chen F, Cao AT, Yao S, Dann SM, Dhar TGM, Salter-Cid L, Zhao Q, Liu Z, Cong Y.
J Immunol. 2019 Jan 1;202(1):79-92. doi: 10.4049/jimmunol.1701697. Epub 2018 Nov 26.
PMID: 30478092
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Menges B, Lin J, Nadkarni A.
Adv Ther. 2019 Jan;36(1):162-174. doi: 10.1007/s12325-018-0840-8. Epub 2018 Nov 29.
PMID: 30499067
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Michallet M, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL.
Am J Hematol. 2019 Jan;94(1):46-54. doi: 10.1002/ajh.25306. Epub 2018 Oct 31.
PMID: 30290003
Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome.
Pringle S, Wang X, Verstappen GMPJ, Terpstra JH, Zhang CK, He A, Patel V, Jones RE, Baird DM, Spijkervet FKL, Vissink A, Bootsma H, Coppes RP, Kroese FGM.
Arthritis Rheumatol. 2019 Jan;71(1):133-142. doi: 10.1002/art.40659.
PMID: 29984480
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.
Chu GC, Chung LWK, Gururajan M, Hsieh CL, Josson S, Nandana S, Sung SY, Wang R, Wu JB, Zhau HE.
Asian J Urol. 2019 Jan;6(1):65-81. doi: 10.1016/j.ajur.2018.11.003. Epub 2018 Nov 28. Review.
PMID: 30775250
Model-assisted process characterization and validation for a continuous two-column protein A capture process.
Baur D, Angelo J, Chollangi S, Müller-Späth T, Xu X, Ghose S, Li ZJ, Morbidelli M.
Biotechnol Bioeng. 2019 Jan;116(1):87-98. doi: 10.1002/bit.26849. Epub 2018 Nov 6.
PMID: 30298905
Modeling and measuring extracellular matrix alterations in fibrosis: challenges and perspectives for antifibrotic drug discovery.
Sivakumar P, Kitson C, Jarai G.
Connect Tissue Res. 2019 Jan;60(1):62-70. doi: 10.1080/03008207.2018.1500557. Epub 2018 Aug 3. Review.
PMID: 30071759
Preface.
Sinz M.
Curr Drug Metab. 2019;20(1):2. doi: 10.2174/138920022001190125110659. No abstract available.
PMID: 30887914
Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations.
Akhunzada ZS, Hubert M, Sahin E, Pratt J.
Curr Pharm Biotechnol. 2019;20(3):232-244. doi: 10.2174/1389201020666190214100840.
PMID: 30767738
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE.
Haematologica. 2019 Jan;104(1):93-101. doi: 10.3324/haematol.2018.188987. Epub 2018 Aug 9.
PMID: 30093398
Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
Vaidhyanathan S, Wang X, Crison J, Varia S, Gao JZH, Saxena A, Good D.
J Pharm Sci. 2019 Jan;108(1):741-749. doi: 10.1016/j.xphs.2018.11.005. Epub 2018 Nov 13.
PMID: 30439460
Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects.
Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, Singh Gautam S, Zhang Y, Gan J, Shipkova PA, Marathe P, Humphreys WG.
J Pharmacol Exp Ther. 2019 Jan;368(1):136-145. doi: 10.1124/jpet.118.252643. Epub 2018 Oct 25.
PMID: 30361237
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.
Barnett S, Ogungbenro K, Ménochet K, Shen H, Humphreys WG, Galetin A.
J Pharmacol Exp Ther. 2019 Jan;368(1):125-135. doi: 10.1124/jpet.118.253062. Epub 2018 Oct 12.
PMID: 30314992
Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus.
Srikumar BN, Naidu PS, Kalidindi N, Paschapur M, Adepu B, Subramani S, Nagar J, Srivastava R, Sreedhara MV, Prasad DS, Das ML, Louis JV, Kuchibhotla VK, Dudhgaonkar S, Pieschl RL, Li YW, Bristow LJ, Ramarao M, Vikramadithyan RK.
J Psychopharmacol. 2019 Jan;33(1):25-36. doi: 10.1177/0269881118812102. Epub 2018 Nov 28.
PMID: 30484737
Symptom Onset in Aortic Stenosis: Relation to Sex Differences in Left Ventricular Remodeling.
Singh A, Chan DCS, Greenwood JP, Dawson DK, Sonecki P, Hogrefe K, Kelly DJ, Dhakshinamurthy V, Lang CC, Khoo JP, Sprigings D, Steeds RP, Zhang R, Ford I, Jerosch-Herold M, Yang J, Li Z, Ng LL, McCann GP.
JACC Cardiovasc Imaging. 2019 Jan;12(1):96-105. doi: 10.1016/j.jcmg.2017.09.019. Epub 2017 Dec 13.
PMID: 29248646
Modulating cell culture oxidative stress reduces protein glycation and acidic charge variant formation.
Chung S, Tian J, Tan Z, Chen J, Zhang N, Huang Y, Vandermark E, Lee J, Borys M, Li ZJ.
MAbs. 2019 Jan;11(1):205-216. doi: 10.1080/19420862.2018.1537533. Epub 2019 Jan 3.
PMID: 30602334
Systematic development of temperature shift strategies for Chinese hamster ovary cells based on short duration cultures and kinetic modeling.
Xu J, Tang P, Yongky A, Drew B, Borys MC, Liu S, Li ZJ.
MAbs. 2019 Jan;11(1):191-204. doi: 10.1080/19420862.2018.1525262. Epub 2018 Oct 2.
PMID: 30230966
Characterization of CD28 null  T cells in idiopathic pulmonary fibrosis.
Habiel DM, Espindola MS, Kitson C, Azzara AV, Coelho AL, Stripp B, Hogaboam CM.
Mucosal Immunol. 2019 Jan;12(1):212-222. doi: 10.1038/s41385-018-0082-8. Epub 2018 Oct 12.
PMID: 30315241
Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study.
Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS, Christian R.
Obesity (Silver Spring). 2019 Jan;27(1):41-49. doi: 10.1002/oby.22344. Epub 2018 Dec 6.
PMID: 30520566
Adsorption of polypropylene oxide-polyethylene oxide type surfactants at surfaces of pharmaceutical relevant materials: effect of surface energetics and surfactant structures.
Li J, Rudraraju S, Zheng S, Jaiswal A.
Pharm Dev Technol. 2019 Jan;24(1):70-79. doi: 10.1080/10837450.2018.1425431. Epub 2018 Jan 18.
PMID: 29304723
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M.
Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.
PMID: 30191365
Accelerating Adoption of Patient-Facing Technologies in Clinical Trials: A Pharmaceutical Industry Perspective on Opportunities and Challenges.
Polhemus AM, Kadhim H, Barnes S, Zebrowski SE, Simmonds A, Masand SN, Banner J, Dupont M.
Ther Innov Regul Sci. 2019 Jan;53(1):8-24. doi: 10.1177/2168479018801566. Epub 2018 Oct 29.
PMID: 30373404
Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
Baker CL, Dhamane AD, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619870249. doi: 10.1177/1076029619870249.
PMID: 31418293
Exercise Behaviors and Fatigue in Patients Receiving Immunotherapy for Advanced Melanoma: A Cross-Sectional Survey via Social Media.
Hyatt A, Drosdowsky A, Williams N, Paton E, Bennett F, Andersen H, Mathai J, Milne D.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419864431. doi: 10.1177/1534735419864431.
PMID: 31382768
2018 Publications
Nickel-Catalyzed 1,2-Diarylation of Simple Alkenyl Amides.
Derosa J, Kleinmans R, Tran VT, Karunananda MK, Wisniewski SR, Eastgate MD, Engle KM.
J Am Chem Soc. 2018 Dec 26;140(51):17878-17883. doi: 10.1021/jacs.8b11942. Epub 2018 Dec 17.
PMID: 30525575
Overcoming the Limitations of γ- and δ-C-H Arylation of Amines through Ligand Development.
Chen YQ, Wang Z, Wu Y, Wisniewski SR, Qiao JX, Ewing WR, Eastgate MD, Yu JQ.
J Am Chem Soc. 2018 Dec 26;140(51):17884-17894. doi: 10.1021/jacs.8b07109. Epub 2018 Dec 14.
PMID: 30500192
Impact of electroviscous effect on viscosity in developing highly concentrated protein formulations: Lessons from non-protein charged colloids.
Li J, Cheng Y, Chen X, Zheng S.
Int J Pharm X. 2018 Dec 24;1:100002. doi: 10.1016/j.ijpx.2018.100002. eCollection 2019 Dec. Review.
PMID: 31545855
Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings.
Trocio J, Rosen VM, Gupta A, Dina O, Vo L, Hlavacek P, Rosenblatt L.
Clinicoecon Outcomes Res. 2018 Dec 19;11:23-49. doi: 10.2147/CEOR.S179080. eCollection 2019.
PMID: 30588051
A Middle-Up Approach with Online Capillary Isoelectric Focusing/Mass Spectrometry for In-Depth Characterization of Cetuximab Charge Heterogeneity.
Dai J, Zhang Y.
Anal Chem. 2018 Dec 18;90(24):14527-14534. doi: 10.1021/acs.analchem.8b04396. Epub 2018 Dec 4.
PMID: 30451489
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants.
Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M.
Alzheimers Dement (N Y). 2018 Dec 17;4:746-755. doi: 10.1016/j.trci.2018.10.007. eCollection 2018.
PMID: 30581980
A novel solution phase PAI-1/uPA-biotin complex assay for the measurement of active PAI-1 in plasma.
Ma Z, Cheng D.
Anal Biochem. 2018 Dec 15;563:35-39. doi: 10.1016/j.ab.2018.09.020. Epub 2018 Sep 29.
PMID: 30278155
Discovery and synthesis of tetrahydropyrimidinedione-4-carboxamides as endothelial lipase inhibitors.
Hu CH, Wang TC, Qiao JX, Haque L, Chen AYA, Taylor DS, Ying X, Onorato JM, Galella M, Shen H, Huang CS, Toussaint N, Li YX, Abell L, Adam LP, Gordon D, Wexler RR, Finlay HJ.
Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3721-3725. doi: 10.1016/j.bmcl.2018.10.022. Epub 2018 Oct 15.
PMID: 30348490
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, Kim J, Taube JM, Burger PC, Selby M, Taitt C, Korman A, Ye X, Drake CG, Brem H, Pardoll DM, Lim M.
Int J Cancer. 2018 Dec 15;143(12):3201-3208. doi: 10.1002/ijc.31661. Epub 2018 Sep 24.
PMID: 30248181
Impact of Tryptophan Oxidation in Complementarity-Determining Regions of Two Monoclonal Antibodies on Structure-Function Characterized by Hydrogen-Deuterium Exchange Mass Spectrometry and Surface Plasmon Resonance.
Hageman T, Wei H, Kuehne P, Fu J, Ludwig R, Tao L, Leone A, Zocher M, Das TK.
Pharm Res. 2018 Dec 10;36(1):24. doi: 10.1007/s11095-018-2545-8.
PMID: 30536043
Direct Lewis Acid Catalyzed Conversion of Enantioenriched N-Acyloxazolidinones to Chiral Esters, Amides, and Acids.
Stevens JM, Parra-Rivera AC, Dixon DD, Beutner GL, DelMonte AJ, Frantz DE, Janey JM, Paulson J, Talley MR.
J Org Chem. 2018 Dec 7;83(23):14245-14261. doi: 10.1021/acs.joc.8b02451. Epub 2018 Nov 19.
PMID: 30412670
Methods for determining key components in a mathematical model for tumor-immune dynamics in multiple myeloma.
Gallaher J, Larripa K, Renardy M, Shtylla B, Tania N, White D, Wood K, Zhu L, Passey C, Robbins M, Bezman N, Shelat S, Jay Cho H, Moore H.
J Theor Biol. 2018 Dec 7;458:31-46. doi: 10.1016/j.jtbi.2018.08.037. Epub 2018 Aug 30.
PMID: 30172689
Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial.
Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA, Mease PJ.
Arthritis Res Ther. 2018 Dec 6;20(1):269. doi: 10.1186/s13075-018-1769-7.
PMID: 30522501
Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study.
Matsubara T, Inoue H, Nakajima T, Tanimura K, Sagawa A, Sato Y, Osano K, Nagano S, Ueki Y, Hanyu T, Hashizume K, Amano N, Tanaka Y, Takeuchi T.
RMD Open. 2018 Dec 4;4(2):e000813. doi: 10.1136/rmdopen-2018-000813. eCollection 2018. Erratum in:  RMD Open. 2019 Dec 5;5(2):e000813corr1 .
PMID: 30622737
TLR-stimulated IRAKM activates caspase-8 inflammasome in microglia and promotes neuroinflammation.
Zhang CJ, Jiang M, Zhou H, Liu W, Wang C, Kang Z, Han B, Zhang Q, Chen X, Xiao J, Fisher A, Kaiser WJ, Murayama MA, Iwakura Y, Gao J, Carman J, Dongre A, Dubyak G, Abbott DW, Shi FD, Ransohoff RM, Li X.
J Clin Invest. 2018 Dec 3;128(12):5399-5412. doi: 10.1172/JCI121901. Epub 2018 Oct 29.
PMID: 30372424
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Cella D, McKendrick J, Kudlac A, Palumbo A, Oukessou A, Vij R, Zyczynski T, Davis C.
Ann Hematol. 2018 Dec;97(12):2455-2463. doi: 10.1007/s00277-018-3469-4. Epub 2018 Sep 4.
PMID: 30178193
Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis.
Sreih AG, Ezzedine R, Leng L, Fan J, Yao J, Reid D, Piecychna M, Carette S, Cuthbertson D, Dellaripa P, Hoffman GS, Khalidi NA, Koening CL, Langford CA, Mahr A, McAlear CA, Maksimowicz-Mckinnon K, Monach PA, Seo P, Specks U, St Clair EW, Stone JH, Ytterberg SR, Edberg J, Merkel PA, Bucala R.
Arthritis Rheumatol. 2018 Dec;70(12):2077-2086. doi: 10.1002/art.40655. Epub 2018 Oct 22.
PMID: 29953750
Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.
Juergens RA, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume MN, Faghih A, Labbé C, Owen S, Shepherd FA, Villeneuve J, Romeyer F, Pettersson F, Butts C.
Curr Oncol. 2018 Dec;25(6):384-392. doi: 10.3747/co.25.4287. Epub 2018 Dec 1.
PMID: 30607113
Evaluation of a tiered in vitro testing strategy for assessing the ocular and dermal irritation/corrosion potential of pharmaceutical compounds for worker safety.
Graham JC, Wilt N, Costin GE, Villano C, Bader J, Krawiec L, Sly E, Gould J.
Cutan Ocul Toxicol. 2018 Dec;37(4):380-390. doi: 10.1080/15569527.2018.1483944. Epub 2018 Jul 23.
PMID: 30035615
Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors.
Hamamoto Y, Shin N, Hoshino T, Kanai T.
Future Oncol. 2018 Dec;14(30):3187-3198. doi: 10.2217/fon-2018-0509. Epub 2018 Sep 6. Review.
PMID: 30188189
A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.
Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, Chen T, Zhu L, Poojary S, Basak S, Qi Z, Spreafico A, Fischer BS, Desai J.
Invest New Drugs. 2018 Dec;36(6):1026-1036. doi: 10.1007/s10637-018-0597-6. Epub 2018 Apr 10.
PMID: 29637471
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C, Albitar M, Zerba K, Sudarsanam S, Chizhevsky V, Jin C, Burns V.
J Clin Pathol. 2018 Dec;71(12):1078-1083. doi: 10.1136/jclinpath-2018-205362. Epub 2018 Oct 1.
PMID: 30275099
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.
J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.
PMID: 30268698
Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing.
Leane M, Pitt K, Reynolds GK, Dawson N, Ziegler I, Szepes A, Crean AM, Dall Agnol R, The Manufacturing Classification System McS Working Group.
Pharm Dev Technol. 2018 Dec;23(10):964-977. doi: 10.1080/10837450.2018.1534863. Epub 2018 Nov 13. Review.
PMID: 30320539
Multivariate analysis as a method to understand variability in a complex excipient, and its contribution to formulation performance.
Tobyn M, Ferreira AP, Lightfoot J, Martin EB, Ghimire M, Vesey C, Kasuboski-Freeman A, Rajabi-Siahboomi A.
Pharm Dev Technol. 2018 Dec;23(10):1146-1155. doi: 10.1080/10837450.2018.1534862. Epub 2018 Nov 14.
PMID: 30303433
Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations.
Gould JC, Carvajal I, Davidson T, Graham J, Hillegass J, Julien S, Kozhich A, Wang B, Wei H, Yamniuk AP, Mathias N, Haggerty HG, Graziano M.
Regul Toxicol Pharmacol. 2018 Dec;100:35-44. doi: 10.1016/j.yrtph.2018.10.003. Epub 2018 Oct 3.
PMID: 30291877
On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.
Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in:  Rheumatol Int. 2019 Feb 5;: .
PMID: 30341453
Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence.
Muñoz-Fernández S, Otón-Sánchez T, Carmona L, Calvo-Alén J, Escudero A, Narváez J, Rodríguez Heredia JM, Romero Yuste S, Vela P, Luján Valdés S, Royo García A, Baquero JL.
Rheumatol Int. 2018 Dec;38(12):2289-2296. doi: 10.1007/s00296-018-4152-8. Epub 2018 Sep 24.
PMID: 30251128
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S.
Stroke. 2018 Dec;49(12):2933-2944. doi: 10.1161/STROKEAHA.118.020232. Erratum in:  Stroke. 2020 Feb;51(2):e44 .  Stroke. 2020 Apr;51(4):e71 .
PMID: 30571400
Practical Strategies for Navigating Toxicologic Pathology in One's Early Career…and Beyond!
Carreira V, Palanisamy G, Quist E, Nelson K, Fossey S, Zimmerman B, Ramaiah L, Schafer KA.
Toxicol Pathol. 2018 Dec;46(8):1037-1048. doi: 10.1177/0192623318805716. Epub 2018 Oct 23.
PMID: 30352538
Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors.
Zhuo X, Wang YZ, Yeung KS, Zhu J, Huang XS, Parcella KE, Eastman KJ, Kadow JF, Meanwell NA, Shu YZ, Johnson BM.
Xenobiotica. 2018 Dec;48(12):1215-1226. doi: 10.1080/00498254.2017.1409915. Epub 2017 Dec 12.
PMID: 29182424
Evaluation of an ATP-Bioluminescence Rapid Microbial Screening Method for In-Process Biologics.
Spaeth S, Tran Q, Liu Z.
PDA J Pharm Sci Technol. 2018 Nov-Dec;72(6):574-583. doi: 10.5731/pdajpst.2018.008557. Epub 2018 Jun 27.
PMID: 29954921
Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor.
Katzman BM, Cox BD, Prosser AR, Alcaraz AA, Murat B, Héroux M, Tebben A, Zhang Y, Schroeder GM, Snyder JP, Wilson LJ, Liotta DC.
ACS Med Chem Lett. 2018 Nov 30;10(1):67-73. doi: 10.1021/acsmedchemlett.8b00441. eCollection 2019 Jan 10.
PMID: 30655949
Gradient elution behavior of proteins in hydrophobic interaction chromatography with a U-shaped retention factor curve under overloaded conditions.
Creasy A, Lomino J, Carta G.
J Chromatogr A. 2018 Nov 30;1578:28-34. doi: 10.1016/j.chroma.2018.10.003. Epub 2018 Oct 7.
PMID: 30316612
2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity).
Neubert H, Olah T, Lee A, Fraser S, Dodge R, Laterza O, Szapacs M, Alley SC, Saad OM, Amur S, Chen L, Cherry E, Cho SJ, Cludts I, Donato LD, Edmison A, Ferrari L, Garofolo F, Haidar S, Hopper S, Hottenstein S, Ishii-Watabe A, Kassim S, Kurki P, Lima Santos GM, Miscoria G, Palandra J, Pedras-Vasconcelos J, Piccoli S, Rogstad S, Saito Y, Savoie N, Sikorski T, Spitz S, Staelens L, Verthelyi D, Vinter S, Wadhwa M, Wang YM, Welink J, Weng N, Whale E, Woolf E, Wu J, Yan H, Yu H, Zhou S.
Bioanalysis. 2018 Nov 29. doi: 10.4155/bio-2018-0285. [Epub ahead of print]
2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA/cell-based assays: immunogenicity, biomarkers and PK assays).
Stevenson L, Richards S, Pillutla R, Torri A, Kamerud J, Mehta D, Keller S, Purushothama S, Gorovits B, Litwin V, Stebbins C, Marini J, Beaver C, Sperinde G, Siguenza P, Staack RF, Qiu Y, Amaravadi L, Amur S, Fleener CA, Baltrukonis D, Catlett I, Cherry E, Chung S, Cludts I, Donato LD, Fischer S, Fraser S, Garofolo F, Green C, Gunn G, Haidar S, Haulenbeek J, Henderson N, Hopper S, Ishii-Watabe A, Islam R, Janelsins B, Jawa V, Kakkanaiah V, Kamondi S, Kolaitis G, Kubiak RJ, Kumar S, Kurki P, Liang M, Liu P, Maxfield K, Myler H, Palackal N, Palmer R, Pedras-Vasconcelos J, Piccoli S, Rhyne P, Saito Y, Savoie N, Schick E, Schweighardt B, Shih J, Song A, Sriraman P, Staelens L, Sumner G, Sun Y, Ullmann M, Verthelyi D, Wadhwa M, Wang YM, Xu Y, Yan H, Yang TY, Zeng R.
Bioanalysis. 2018 Nov 29. doi: 10.4155/bio-2018-0287. [Epub ahead of print]
PMID: 30488726
Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.
Menard LC, Fischer P, Kakrecha B, Linsley PS, Wambre E, Liu MC, Rust BJ, Lee D, Penhallow B, Manjarrez Orduno N, Nadler SG.
Front Immunol. 2018 Nov 26;9:2728. doi: 10.3389/fimmu.2018.02728. eCollection 2018.
PMID: 30534127
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Campbell D, O'Day K, Hertel N, Penrod JR, Manley Daumont M, Lees M.
Popul Health Metr. 2018 Nov 26;16(1):17. doi: 10.1186/s12963-018-0174-4.
PMID: 30477516
Development of a Chemiluminescent ELISA Method for the Detection of Total Anti-Adeno Associated Virus Serotype 9 (AAV9) Antibodies.
Kavita U, Dai Y, Salvador L, Miller W, Adam LP, Levesque PC, Zhang YJ, Ji QC, Pillutla RC.
Hum Gene Ther Methods. 2018 Nov 22. doi: 10.1089/hgtb.2018.131. [Epub ahead of print]
PMID: 30351228
Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase.
Johnson JA, Tora G, Pi Z, Phillips M, Yin X, Yang R, Zhao L, Chen AY, Taylor DS, Basso M, Rose A, Behnia K, Onorato J, Chen XQ, Abell LM, Lu H, Locke G, Caporuscio C, Galella M, Adam LP, Gordon D, Wexler RR, Finlay HJ.
ACS Med Chem Lett. 2018 Nov 21;9(12):1263-1268. doi: 10.1021/acsmedchemlett.8b00424. eCollection 2018 Dec 13.
PMID: 30613337
Detection of correlated hidden factors from single cell transcriptomes using Iteratively Adjusted-SVA (IA-SVA).
Lee D, Cheng A, Lawlor N, Bolisetty M, Ucar D.
Sci Rep. 2018 Nov 19;8(1):17040. doi: 10.1038/s41598-018-35365-9.
PMID: 30451954
Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States.
Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, Gupta A, Pan X, Mardekian J, Lingohr-Smith M, Menges B, Marshall A, Nadkarni A.
Clin Appl Thromb Hemost. 2018 Nov 15:1076029618800806. doi: 10.1177/1076029618800806. [Epub ahead of print]
PMID: 30433823
Intermolecular Reductive C-N Cross Coupling of Nitroarenes and Boronic Acids by P III /P V ═O Catalysis.
Nykaza TV, Cooper JC, Li G, Mahieu N, Ramirez A, Luzung MR, Radosevich AT.
J Am Chem Soc. 2018 Nov 14;140(45):15200-15205. doi: 10.1021/jacs.8b10769. Epub 2018 Nov 2.
PMID: 30372615
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).
Li J, Kennedy LJ, Walker SJ, Wang H, Li JJ, Hong Z, O'Connor SP, Ye XY, Chen S, Wu S, Yoon DS, Nayeem A, Camac DM, Ramamurthy V, Morin PE, Sheriff S, Wang M, Harper TW, Golla R, Seethala R, Harrity T, Ponticiello RP, Morgan NN, Taylor JR, Zebo R, Maxwell B, Moulin F, Gordon DA, Robl JA.
ACS Med Chem Lett. 2018 Nov 13;9(12):1170-1174. doi: 10.1021/acsmedchemlett.8b00307. eCollection 2018 Dec 13.
PMID: 30613321
Model assisted comparison of Protein A resins and multi-column chromatography for capture processes.
Baur D, Angelo JM, Chollangi S, Xu X, Müller-Späth T, Zhang N, Ghose S, Li ZJ, Morbidelli M.
J Biotechnol. 2018 Nov 10;285:64-73. doi: 10.1016/j.jbiotec.2018.08.014. Epub 2018 Aug 27.
PMID: 30165118
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.
N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.
PMID: 30403938
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang P, Xu A, Liao-Chan S, Sen D, Nager AR, Oakdale NS, Brown C, Wang F, Yang Y, Lindquist K, Yeung YA, Salek-Ardakani S, Chaparro-Riggers J.
Nat Commun. 2018 Nov 8;9(1):4679. doi: 10.1038/s41467-018-07136-7.
PMID: 30410017
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ.
Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.
PMID: 30405135
Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors.
Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.
ACS Med Chem Lett. 2018 Nov 5;9(12):1217-1222. doi: 10.1021/acsmedchemlett.8b00379. eCollection 2018 Dec 13.
PMID: 30613329
Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate-CO 2  Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance.
Al-Gousous J, Sun KX, McNamara DP, Hens B, Salehi N, Langguth P, Bermejo M, Amidon GE, Amidon GL.
Mol Pharm. 2018 Nov 5;15(11):5291-5301. doi: 10.1021/acs.molpharmaceut.8b00783. Epub 2018 Oct 26.
PMID: 30362350
Phase Diagrams of Polymer-Dispersed Liquid Crystal Systems of Itraconazole/Component Immiscibility Induced by Molecular Anisotropy.
Kozyra A, Mugheirbi NA, Paluch KJ, Garbacz G, Tajber L.
Mol Pharm. 2018 Nov 5;15(11):5192-5206. doi: 10.1021/acs.molpharmaceut.8b00724. Epub 2018 Oct 10.
PMID: 30252481
Nanocrystallization of Rare Tolbutamide Form V in Mesoporous MCM-41 Silica.
Nartowski KP, Malhotra D, Hawarden LE, Fábián L, Khimyak YZ.
Mol Pharm. 2018 Nov 5;15(11):4926-4932. doi: 10.1021/acs.molpharmaceut.8b00575. Epub 2018 Oct 8.
PMID: 30247039
The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.
Polli JW, McCurdy CR, Wurster DE, DeSilva BS, Bak A, Bendayan R, Meibohm B, Templeton AC, Weiser W; AAPS Leadership.
AAPS J. 2018 Nov 3;21(1):2. doi: 10.1208/s12248-018-0273-y. No abstract available.
PMID: 30392015
Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents.
Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A.
Infect Drug Resist. 2018 Nov 2;11:2117-2127. doi: 10.2147/IDR.S179158. eCollection 2018.
PMID: 30464554
Potent Triazolopyridine Myeloperoxidase Inhibitors.
Wurtz NR, Viet A, Shaw SA, Dilger A, Valente MN, Khan JA, Jusuf S, Narayanan R, Fernando G, Lo F, Liu X, Locke GA, Kopcho L, Abell LM, Sleph P, Basso M, Zhao L, Wexler RR, Duclos F, Kick EK.
ACS Med Chem Lett. 2018 Nov 1;9(12):1175-1180. doi: 10.1021/acsmedchemlett.8b00308. eCollection 2018 Dec 13.
PMID: 30613322
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X.
Ann Oncol. 2018 Nov 1;29(11):2208-2213. doi: 10.1093/annonc/mdy408.
PMID: 30215677
2018 White Paper on Recent Issues in Bioanalysis: 'A global bioanalytical community perspective on last decade of incurred samples reanalysis (ISR)' (Part 1 - small molecule regulated bioanalysis, small molecule biomarkers, peptides & oligonucleotide bioanalysis).
Welink J, Xu Y, Yang E, Wilson A, Henderson N, Luo L, Fraser S, Kavita U, Musuku A, James C, Fraier D, Zhang Y, Goykhman D, Summerfield S, Woolf E, Verhaeghe T, Hughes N, Behling A, Brown K, Bulychev A, Buonarati M, Cherry E, Cho SJ, Cludts I, Dillen L, Dodge R, Edmison A, Garofolo F, Green R, Haidar S, Hottenstein C, Ishii-Watabe A, Jang HG, Ji A, Jones B, Kassim S, Ma M, Lima Santos GM, Norris DA, Owen T, Piccoli S, Ramanathan R, Röhl I, Rosenbaum AI, Saito Y, Sangster T, Savoie N, Stebbins C, Sydor J, de Merbel NV, Verthelyi D, Vinter S, Whale E.
Bioanalysis. 2018 Nov 1;10(22):1781-1801. doi: 10.4155/bio-2018-0268. Epub 2018 Nov 29.
PMID: 30488725
IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells.
Ward NC, Yu A, Moro A, Ban Y, Chen X, Hsiung S, Keegan J, Arbanas JM, Loubeau M, Thankappan A, Yamniuk AP, Davis JH, Struthers M, Malek TR.
J Immunol. 2018 Nov 1;201(9):2579-2592. doi: 10.4049/jimmunol.1800907. Epub 2018 Oct 3.
PMID: 30282751
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.
Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L.
Open Heart. 2018 Nov 1;5(2):e000908. doi: 10.1136/openhrt-2018-000908. eCollection 2018.
PMID: 30487982
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Tepper PG, Mardekian J, Masseria C, Phatak H, Kamble S, Abdulsattar Y, Petkun W, Lip GYH.
PLoS One. 2018 Nov 1;13(11):e0205989. doi: 10.1371/journal.pone.0205989. eCollection 2018.
PMID: 30383768
Enhanced Understanding of Pharmaceutical Materials Through Advanced Characterisation and Analysis.
Ferreira AP, Gamble JF, Leane MM, Park H, Olusanmi D, Tobyn M.
AAPS PharmSciTech. 2018 Nov;19(8):3462-3480. doi: 10.1208/s12249-018-1198-6. Epub 2018 Nov 8. Review.
PMID: 30411240
The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.
Polli JW, McCurdy CR, Wurster DE, DeSilva BS, Bak A, Bendayan R, Meibohm B, Templeton AC, Weiser W; AAPS Leadership.
AAPS PharmSciTech. 2018 Nov;19(8):3325-3327. doi: 10.1208/s12249-018-1200-3. Epub 2018 Nov 3. No abstract available.
PMID: 30390237
Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.
Nance RM, Crane HM, Ritchings C, Rosenblatt L, Budoff M, Heckbert SR, Drozd DR, Mathews WC, Geng E, Hunt PW, Feinstein MJ, Moore RD, Hsue P, Eron JJ, Burkholder GA, Rodriguez B, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC.
AIDS Res Hum Retroviruses. 2018 Nov;34(11):916-921. doi: 10.1089/AID.2018.0053. Epub 2018 Aug 21.
PMID: 29984593
Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies.
Ritacco FV, Wu Y, Khetan A.
Biotechnol Prog. 2018 Nov;34(6):1407-1426. doi: 10.1002/btpr.2706. Epub 2018 Oct 5. Review.
PMID: 30290072
Patient-reported outcomes with nivolumab in advanced solid cancers.
Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, Shaw JW.
Cancer Treat Rev. 2018 Nov;70:75-87. doi: 10.1016/j.ctrv.2018.08.001. Epub 2018 Aug 2. Review.
PMID: 30125799
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
Palmer SM, Snyder L, Todd JL, Soule B, Christian R, Anstrom K, Luo Y, Gagnon R, Rosen G.
Chest. 2018 Nov;154(5):1061-1069. doi: 10.1016/j.chest.2018.08.1058. Epub 2018 Sep 7.
PMID: 30201408
Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.
Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, Galetin A, Giacomini KM, Hanna I, Kusuhara H, Lai Y, Rodrigues D, Sugiyama Y, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium.
Clin Pharmacol Ther. 2018 Nov;104(5):836-864. doi: 10.1002/cpt.1216. Review.
PMID: 30347454
Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation.
Cirincione B, Kowalski K, Nielsen J, Roy A, Thanneer N, Byon W, Boyd R, Wang X, Leil T, LaCreta F, Ueno T, Oishi M, Frost C.
CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):728-738. doi: 10.1002/psp4.12347. Epub 2018 Sep 30.
PMID: 30259707
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.
Simonsen KL, Fracasso PM, Bernstein SH, Wind-Rotolo M, Gupta M, Comprelli A, Reilly TP, Cassidy J.
Eur J Cancer. 2018 Nov;103:259-266. doi: 10.1016/j.ejca.2018.07.127. Epub 2018 Oct 3.
PMID: 30292142
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Meng Y, Hertel N, Ellis J, Morais E, Johnson H, Philips Z, Roskell N, Walker A, Lee D.
Eur J Health Econ. 2018 Nov;19(8):1163-1172. doi: 10.1007/s10198-018-0964-4. Epub 2018 Mar 9.
PMID: 29524005
Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Osawa M, Ueno T, Ishikawa H, Imai Y, Garimella T.
J Clin Pharmacol. 2018 Nov;58(11):1468-1478. doi: 10.1002/jcph.1274. Epub 2018 Jul 31.
PMID: 30063254
Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
Ueno T, Osawa M, Imai Y, Ishikawa H, Garimella T.
J Clin Pharmacol. 2018 Nov;58(11):1479-1488. doi: 10.1002/jcph.1262. Epub 2018 Jul 31.
PMID: 30063245
Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases.
Ramagopalan S, Allan V, Saragoni S, Esposti LD, Alessandrini D, Perrone V, Buda S, Stynes G, Toma C, DeSolda F; a LHUs group.
J Comp Eff Res. 2018 Nov;7(11):1063-1071. doi: 10.2217/cer-2018-0054. Epub 2018 Aug 13.
PMID: 30101611
Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing.
Xu W, Sank M, Cummings J, Carl S, Juhel M, Gleason C, Dodge R, DeSilva BS, Kolaitis G, Pillutla R.
J Immunol Methods. 2018 Nov;462:34-41. doi: 10.1016/j.jim.2018.08.003. Epub 2018 Aug 9.
PMID: 30099014
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T.
J Manag Care Spec Pharm. 2018 Nov;24(11):1116-1127. doi: 10.18553/jmcp.2018.17488. Epub 2018 Sep 13.
PMID: 30212268
Optimization of combination therapy for chronic myeloid leukemia with dosing constraints.
Moore H, Strauss L, Ledzewicz U.
J Math Biol. 2018 Nov;77(5):1533-1561. doi: 10.1007/s00285-018-1262-6. Epub 2018 Jul 10.
PMID: 29992481
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.
Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Erratum in:  Lancet Oncol. 2018 Dec;19(12):e668 .  Lancet Oncol. 2018 Nov;19(11):e581 .
PMID: 30361170
Unique pattern of neutrophil migration and function during tumor progression.
Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, Lin C, Alicea-Torres K, Sehgal M, Nefedova Y, Zhou J, Languino LR, Clendenin C, Vonderheide RH, Mulligan C, Nam B, Hockstein N, Masters G, Guarino M, Schug ZT, Altieri DC, Gabrilovich DI.
Nat Immunol. 2018 Nov;19(11):1236-1247. doi: 10.1038/s41590-018-0229-5. Epub 2018 Oct 15.
PMID: 30323345
Extended release of flurbiprofen from tromethamine-buffered HPMC hydrophilic matrix tablets.
Pygall S, Kujawinski S, Timmins P, Melia C.
Pharm Dev Technol. 2018 Nov;23(9):874-881. doi: 10.1080/10837450.2017.1301470. Epub 2017 Mar 16.
PMID: 28298171
AggScore: Prediction of aggregation-prone regions in proteins based on the distribution of surface patches.
Sankar K, Krystek SR Jr, Carl SM, Day T, Maier JKX.
Proteins. 2018 Nov;86(11):1147-1156. doi: 10.1002/prot.25594. Epub 2018 Sep 27.
PMID: 30168197
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, Vo L, Mardekian J, Pan X, Burns L, Atwood M, Hanau A, Cohen AT.
Thromb Haemost. 2018 Nov;118(11):e1-e2. doi: 10.1055/s-0039-3400530. Epub 2020 Jan 27. No abstract available.
PMID: 31986533
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, Vo L, Mardekian J, Pan X, Burns L, Atwood M, Hanau A, Cohen AT.
Thromb Haemost. 2018 Nov;118(11):1951-1961. doi: 10.1055/s-0038-1673689. Epub 2018 Oct 24. Erratum in:  Thromb Haemost. 2018 Nov;118(11):e1-e2 .
PMID: 30357780
A General Amino Acid Synthesis Enabled by Innate Radical Cross-Coupling.
Ni S, Garrido-Castro AF, Merchant RR, de Gruyter JN, Schmitt DC, Mousseau JJ, Gallego GM, Yang S, Collins MR, Qiao JX, Yeung KS, Langley DR, Poss MA, Scola PM, Qin T, Baran PS.
Angew Chem Int Ed Engl. 2018 Oct 26;57(44):14560-14565. doi: 10.1002/anie.201809310. Epub 2018 Oct 15.
PMID: 30212610
Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects.
Frost C, Shenker A, Jhee S, Yu Z, Wang J, Bragat A, Pursley J, LaCreta F.
Clin Pharmacol. 2018 Oct 24;10:153-163. doi: 10.2147/CPAA.S169505. eCollection 2018.
PMID: 30498375
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
Morales-Ramirez J, Bogner JR, Molina JM, Lombaard J, Dicker IB, Stock DA, DeGrosky M, Gartland M, Pene Dumitrescu T, Min S, Llamoso C, Joshi SR, Lataillade M.
PLoS One. 2018 Oct 23;13(10):e0205368. doi: 10.1371/journal.pone.0205368. eCollection 2018.
PMID: 30352054
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C.
BMC Cancer. 2018 Oct 22;18(1):1013. doi: 10.1186/s12885-018-4958-5.
PMID: 30348130
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.
J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in:  J Immunother Cancer. 2019 Mar 14;7(1):73 .
PMID: 30348216
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.
Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA.
J Immunother Cancer. 2018 Oct 19;6(1):108. doi: 10.1186/s40425-018-0426-7.
PMID: 30340549
Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.
Zhang Y, Zhao Y, Tebben AJ, Sheriff S, Ruzanov M, Fereshteh MP, Fan Y, Lippy J, Swanson J, Ho CP, Wautlet BS, Rose A, Parrish K, Yang Z, Donnell AF, Zhang L, Fink BE, Vite GD, Augustine-Rauch K, Fargnoli J, Borzilleri RM.
ACS Med Chem Lett. 2018 Oct 17;9(11):1117-1122. doi: 10.1021/acsmedchemlett.8b00357. eCollection 2018 Nov 8.
PMID: 30429955
Discovery of VU2957 (Valiglurax): An mGlu 4  Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.
Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, Rodriguez AL, Felts AS, Engers JL, Loch MT, Emmitte KA, Castelhano AL, Kates MJ, Nader MA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW.
ACS Med Chem Lett. 2018 Oct 16;10(3):255-260. doi: 10.1021/acsmedchemlett.8b00426. eCollection 2019 Mar 14.
PMID: 30891122
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.
Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L.
Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125.
PMID: 29871978
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.
Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.
PMID: 30204239
A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent  In Vitro  and  In Vivo  Antitumor Activity in Preclinical Models of Small Cell Lung Cancer.
Ponath P, Menezes D, Pan C, Chen B, Oyasu M, Strachan D, LeBlanc H, Sun H, Wang XT, Rangan VS, Deshpande S, Cristea S, Park KS, Sage J, Cardarelli PM.
Clin Cancer Res. 2018 Oct 15;24(20):5178-5189. doi: 10.1158/1078-0432.CCR-18-0018. Epub 2018 Jul 18.
PMID: 30021910
A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants.
Cohen AT, Hill NR, Luo X, Masseria C, Abariga SA, Ashaye AO.
Int J Cardiol. 2018 Oct 15;269:174-181. doi: 10.1016/j.ijcard.2018.06.114. Epub 2018 Jun 30.
PMID: 30037626
Erratum: Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells.
Curtin JC, Lorenzi MV.
Oncotarget. 2018 Oct 5;9(78):34856. doi: 10.18632/oncotarget.26220. eCollection 2018 Oct 5.
PMID: 30410683
Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.
Alemao E, Al MJ, Boonen AA, Stevenson MD, Verstappen SMM, Michaud K, Weinblatt ME, Rutten-van Mölken MPMH.
PLoS One. 2018 Oct 5;13(10):e0205013. doi: 10.1371/journal.pone.0205013. eCollection 2018.
PMID: 30289926
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S.
N Engl J Med. 2018 Oct 4;379(14):1313-1321. doi: 10.1056/NEJMoa1806382. Epub 2018 Sep 11.
PMID: 30205746
canvasDesigner: a versatile interactive high-resolution scientific multi-panel visualization toolkit.
Zhang B, Zhao S, Neuhaus I.
Bioinformatics. 2018 Oct 1;34(19):3419-3420. doi: 10.1093/bioinformatics/bty377.
PMID: 29726919
Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
Liu Q, Batt DG, Chaudhry C, Lippy JS, Pattoli MA, Surti N, Xu S, Carter PH, Burke JR, Tino JA.
Bioorg Med Chem Lett. 2018 Oct 1;28(18):3080-3084. doi: 10.1016/j.bmcl.2018.07.041. Epub 2018 Jul 30.
PMID: 30097367
Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice.
Hashimoto A, Gao C, Mastio J, Kossenkov A, Abrams SI, Purandare AV, Desilva H, Wee S, Hunt J, Jure-Kunkel M, Gabrilovich DI.
Cancer Res. 2018 Oct 1;78(19):5644-5655. doi: 10.1158/0008-5472.CAN-18-1229. Epub 2018 Aug 23.
PMID: 30139814
Development and Characterization of a Model for Inducing Fetal Hemoglobin Production in Cynomolgus Macaques ( Macaca fasicularis ).
Kundu MC, Gore LR, Maguire S, Gilmartin AG.
Comp Med. 2018 Oct 1;68(5):396-402. doi: 10.30802/AALAS-CM-17-000124. Epub 2018 Aug 9.
PMID: 30092854
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT.
J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. Erratum in:  J Clin Oncol. 2019 Feb 10;37(5):443 .
PMID: 30110194
Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies.
Korytowsky B, Radtchenko J, Nwokeji ED, Tuell KW, Kish JK, Feinberg BA.
Am J Manag Care. 2018 Oct;24(20 Suppl):S439-S447.
PMID: 30362811
Mechanisms of precipitate formation during the purification of an Fc-fusion protein.
Greene DG, Traylor SJ, Guo J, Choe LH, Modla S, Xu X, Singh N, Lock LL, Ghose S, Li ZJ, Lee KH, Wagner NJ, Lenhoff AM.
Biotechnol Bioeng. 2018 Oct;115(10):2489-2503. doi: 10.1002/bit.26746. Epub 2018 Jul 25.
PMID: 29896879
Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.
Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.
Diabetes Care. 2018 Oct;41(10):2096-2104. doi: 10.2337/dc17-0662. Epub 2018 Aug 21.
PMID: 30131396
A novel co-processing method to manufacture an API for extended release formulation via formation of agglomerates of active ingredient and hydroxypropyl methylcellulose during crystallization.
Rosenbaum T, Erdemir D, Chang SY, Kientzler D, Wang S, Chan SH, Brown J, Hanley S, Kiang S.
Drug Dev Ind Pharm. 2018 Oct;44(10):1606-1612. doi: 10.1080/03639045.2018.1483386. Epub 2018 Aug 14.
PMID: 29916275
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, Dastani H, Spigel DR, Gralla RJ.
Eur J Cancer. 2018 Oct;102:23-30. doi: 10.1016/j.ejca.2018.05.005. Epub 2018 Aug 10.
PMID: 30103096
Buffer exchange path influences the stability and viscosity upon storage of a high concentration protein.
Krause ME, Narang AS, Barker G, Herzer S, Deshmukh S, Lan W, Fichana D, Wasylyk JM, Demirdirek B, Zhang L, Fiske J, McGann M, Adams ML, Gandhi RB.
Eur J Pharm Biopharm. 2018 Oct;131:60-69. doi: 10.1016/j.ejpb.2018.07.014. Epub 2018 Jul 18.
PMID: 30031090
Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, Sabater J, Ritchings C, Aponte-Ribero V, Regan MM, Atkins M.
Immunotherapy. 2018 Oct;10(14):1241-1252. doi: 10.2217/imt-2018-0085. Epub 2018 Sep 3.
PMID: 30175642
Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine.
Nelson RE, Ma J, Crook J, Knippenberg K, Nyman H, Paul D, Esker S, LaFleur J.
J Manag Care Spec Pharm. 2018 Oct;24(10):1052-1066. doi: 10.18553/jmcp.2018.24.10.1052.
PMID: 30247099
Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.
Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D.
J Med Econ. 2018 Oct;21(10):1036-1040. doi: 10.1080/13696998.2018.1508023. Epub 2018 Aug 15.
PMID: 30071761
Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain.
Hopp SC, Bihlmeyer NA, Corradi JP, Vanderburg C, Cacace AM, Das S, Clark TW, Betensky RA, Hyman BT, Hudry E.
J Neurochem. 2018 Oct;147(1):24-39. doi: 10.1111/jnc.14469. Epub 2018 Sep 7.
PMID: 29806693
Enhanced Precision of Circular Dichroism Spectral Measurements Permits Detection of Subtle Higher Order Structural Changes in Therapeutic Proteins.
Barnett GV, Balakrishnan G, Chennamsetty N, Meengs B, Meyer J, Bongers J, Ludwig R, Tao L, Das TK, Leone A, Kar SR.
J Pharm Sci. 2018 Oct;107(10):2559-2569. doi: 10.1016/j.xphs.2018.06.007. Epub 2018 Jun 18.
PMID: 29913140
Optimization of Primary Drying in Lyophilization During Early-Phase Drug Development Using a Definitive Screening Design With Formulation and Process Factors.
Goldman JM, More HT, Yee O, Borgeson E, Remy B, Rowe J, Sadineni V.
J Pharm Sci. 2018 Oct;107(10):2592-2600. doi: 10.1016/j.xphs.2018.06.001. Epub 2018 Jun 8.
PMID: 29890172
Data standards for model-informed drug development: an ISoP initiative.
Radivojevic A, Corrigan B, Downie N, Fox R, Fiedler-Kelly J, Liu H, Melhem M, Radke D, Schaefer P, Su J, Swat MJ, Teuscher NS, Thanneer N, Zong A, Wilkins JJ.
J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):659-661. doi: 10.1007/s10928-018-9595-8. Epub 2018 Jul 25. No abstract available.
PMID: 30046963
Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry.
Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR.
J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1.
PMID: 29961696
Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: part 2-The Patient Assessment for Low Back Pain-Impacts (PAL-I).
Bushnell DM, Blum SI, Liedgens H, Martin ML, Freynhagen R, Wallace M, Argoff C, Eerdekens M, Kok M, Patrick DL.
Pain. 2018 Oct;159(10):2066-2075. doi: 10.1097/j.pain.0000000000001309.
PMID: 29889120
End-to-End Sample Tracking in the Laboratory Using a Custom Internet of Things Device.
Neil W, Zipp G, Nemeth G, Russo MF, Nirschl DS.
SLAS Technol. 2018 Oct;23(5):412-422. doi: 10.1177/2472630318783979. Epub 2018 Jul 17.
PMID: 30016131
Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
Galeazzi M, Alten R, Chartier M, Elbez Y, Fusaro E, Le Bars M, Lorenz HM, Pagano Mariano G, Muratore M, Nüßlein HG, Patanè G.
Clin Exp Rheumatol. 2018 Sep-Oct;36(5):935-936. Epub 2018 Mar 21. No abstract available.
PMID: 29600933
International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G.
Cell Rep. 2018 Sep 25;24(13):3582-3592. doi: 10.1016/j.celrep.2018.08.079.
PMID: 30257217
Differential sensitivity of chronic high-fat-diet-induced obesity in Sprague-Dawley rats.
Devan SRK, Arumugam S, Shankar G, Poosala S.
J Basic Clin Physiol Pharmacol. 2018 Sep 25;29(5):553-563. doi: 10.1515/jbcpp-2017-0030. No abstract available.
PMID: 30076779
Evaluation of chromatofocusing as a capture method for monoclonal antibody products.
Liu Y, Deldari S, Guo H, Narahari CR, Bates RC, Swanson R, Ghose S, Li ZJ, Frey DD.
J Chromatogr A. 2018 Sep 21;1568:108-122. doi: 10.1016/j.chroma.2018.07.028. Epub 2018 Jul 6.
PMID: 30072232
Enantioselective Synthesis of a γ-Secretase Modulator via Vinylogous Dynamic Kinetic Resolution.
Strotman NA, Ramirez A, Simmons EM, Soltani O, Parsons AT, Fan Y, Sawyer JR, Rosner T, Janey JM, Tran K, Li J, La Cruz TE, Pathirana C, Ng AT, Deerberg J.
J Org Chem. 2018 Sep 21;83(18):11133-11144. doi: 10.1021/acs.joc.8b01734. Epub 2018 Aug 13.
PMID: 30102035
Unlocking P(V): Reagents for chiral phosphorothioate synthesis.
Knouse KW, deGruyter JN, Schmidt MA, Zheng B, Vantourout JC, Kingston C, Mercer SE, Mcdonald IM, Olson RE, Zhu Y, Hang C, Zhu J, Yuan C, Wang Q, Park P, Eastgate MD, Baran PS.
Science. 2018 Sep 21;361(6408):1234-1238. doi: 10.1126/science.aau3369. Epub 2018 Aug 2.
PMID: 30072577
A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements.
Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, Sugiyama M, Lu SN, Wang LY, Yuan Y, L'Italien G, Yang HI, Mizokami M, Chen CJ, Lee MH.
Clin Transl Gastroenterol. 2018 Sep 20;9(9):183. doi: 10.1038/s41424-018-0050-3.
PMID: 30237482
Fucosyl monosialoganglioside: Quantitative analysis of specific potential biomarkers of lung cancer in biological matrices using immunocapture extraction/tandem mass spectrometry.
Ranasinghe A, Mehl J, D'Arienzo C, Nabbie F, Chiu C, Thevanayagam L, Srinivasan M, Hogan J, Ponath P, Olah T.
Rapid Commun Mass Spectrom. 2018 Sep 15;32(17):1481-1490. doi: 10.1002/rcm.8194.
PMID: 29876976
Factor XIa Inhibitors as New Anticoagulants.
Quan ML, Pinto DJP, Smallheer JM, Ewing WR, Rossi KA, Luettgen JM, Seiffert DA, Wexler RR.
J Med Chem. 2018 Sep 13;61(17):7425-7447. doi: 10.1021/acs.jmedchem.8b00173. Epub 2018 May 18. Review.
PMID: 29775297
Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.
Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang KW, Lagging M.
J Virol. 2018 Sep 12;92(19). pii: e01087-18. doi: 10.1128/JVI.01087-18. Print 2018 Oct 1.
PMID: 30045981
Evidence-based pregnancy testing in clinical trials: Recommendations from a multi-stakeholder development process.
Morse JE, Calvert SB, Jurkowski C, Tassinari M, Sewell CA, Myers ER.
PLoS One. 2018 Sep 12;13(9):e0202474. doi: 10.1371/journal.pone.0202474. eCollection 2018.
PMID: 30208049
RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models.
Wong OK, Tran TT, Ho WH, Casas MG, Au M, Bateman M, Lindquist KC, Rajpal A, Shelton DL, Strop P, Liu SH.
Oncotarget. 2018 Sep 11;9(71):33446-33458. doi: 10.18632/oncotarget.26002. eCollection 2018 Sep 11.
PMID: 30323890
In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.
Tsume Y, Patel S, Fotaki N, Bergstrӧm C, Amidon GL, Brasseur JG, Mudie DM, Sun D, Bermejo M, Gao P, Zhu W, Sperry DC, Vertzoni M, Parrott N, Lionberger R, Kambayashi A, Hermans A, Lu X, Amidon GE.
AAPS J. 2018 Sep 6;20(6):100. doi: 10.1208/s12248-018-0260-3. No abstract available.
PMID: 30191341
Google searches do not correlate with melanoma incidence in majority English speaking countries.
McDonald L, Simpson A, Graham S, Schultze A, Nordstrom B, Durani P, Mehmud F, Ramagopalan SV.
NPJ Digit Med. 2018 Sep 5;1:44. doi: 10.1038/s41746-018-0050-4. eCollection 2018.
PMID: 31304324
Under-recording of hospital bleeding events in UK primary care: a linked Clinical Practice Research Datalink and Hospital Episode Statistics study.
McDonald L, Sammon CJ, Samnaliev M, Ramagopalan S.
Clin Epidemiol. 2018 Sep 4;10:1155-1168. doi: 10.2147/CLEP.S170304. eCollection 2018.
PMID: 30233250
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE.
Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3. No abstract available.
PMID: 30190469
Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis.
Sun M, Wu W, Chen L, Yang W, Huang X, Ma C, Chen F, Xiao Y, Zhao Y, Ma C, Yao S, Carpio VH, Dann SM, Zhao Q, Liu Z, Cong Y.
Nat Commun. 2018 Sep 3;9(1):3555. doi: 10.1038/s41467-018-05901-2.
PMID: 30177845
LC-MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drug-drug interactions.
Santockyte R, Kandoussi H, Chen W, Zheng N, Venkatarangan L, Gan J, Shen H, Bonacorsi SJ, Easter J, Burrell R, Zhang YJ, Zeng J.
Bioanalysis. 2018 Sep 1;10(18):1473-1485. doi: 10.4155/bio-2018-0170. Epub 2018 Sep 14.
PMID: 30215261
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS.
Am J Med. 2018 Sep;131(9):1075-1085.e4. doi: 10.1016/j.amjmed.2018.05.007. Epub 2018 May 26.
PMID: 29807001
Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.
Everly MJ, Roberts M, Townsend R, Bray RA, Gebel HM.
Am J Transplant. 2018 Sep;18(9):2305-2313. doi: 10.1111/ajt.14939. Epub 2018 Jun 16.
PMID: 29767445
Bioinspired supramolecular engineering of self-assembling immunofibers for high affinity binding of immunoglobulin G.
Li Y, Lock LL, Wang Y, Ou SH, Stern D, Schön A, Freire E, Xu X, Ghose S, Li ZJ, Cui H.
Biomaterials. 2018 Sep;178:448-457. doi: 10.1016/j.biomaterials.2018.04.032. Epub 2018 Apr 16.
PMID: 29706234
Early identification of unusually clustered mutations and root causes in therapeutic antibody development.
Qian Y, Chen Z, Huang X, Wang X, Xu X, Kirov S, Ludwig R, Qian NX, Ravi K, Tao L, Borys MC, Li ZJ.
Biotechnol Bioeng. 2018 Sep;115(9):2377-2382. doi: 10.1002/bit.26728. Epub 2018 Jun 6.
PMID: 29777592
Ultrafiltration behavior of partially retained proteins and completely retained proteins using equally-staged single pass tangential flow filtration membranes.
Arunkumar A, Zhang J, Singh N, Ghose S, Li ZJ.
Biotechnol Prog. 2018 Sep;34(5):1137-1148. doi: 10.1002/btpr.2671. Epub 2018 Jul 27.
PMID: 30019541
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A.
Clin Pharmacol Ther. 2018 Sep;104(3):564-574. doi: 10.1002/cpt.983. Epub 2018 Jan 17.
PMID: 29243231
Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery.
Coussens NP, Sittampalam GS, Guha R, Brimacombe K, Grossman A, Chung TDY, Weidner JR, Riss T, Trask OJ, Auld D, Dahlin JL, Devanaryan V, Foley TL, McGee J, Kahl SD, Kales SC, Arkin M, Baell J, Bejcek B, Gal-Edd N, Glicksman M, Haas JV, Iversen PW, Hoeppner M, Lathrop S, Sayers E, Liu H, Trawick B, McVey J, Lemmon VP, Li Z, McManus O, Minor L, Napper A, Wildey MJ, Pacifici R, Chin WW, Xia M, Xu X, Lal-Nag M, Hall MD, Michael S, Inglese J, Simeonov A, Austin CP.
Clin Transl Sci. 2018 Sep;11(5):461-470. doi: 10.1111/cts.12570. Epub 2018 Jul 24. Review.
PMID: 29877628
Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
Kohsaka S, Katada J, Saito K, Terayama Y.
Curr Med Res Opin. 2018 Sep;34(9):1627-1634. doi: 10.1080/03007995.2018.1478282. Epub 2018 May 30.
PMID: 29772946
Costs associated with adverse events for systemic therapies in metastatic melanoma.
Fu AZ, Li Z, Tang J, Mahmood S, Whisman T, Qiu Y.
J Comp Eff Res. 2018 Sep;7(9):867-879. doi: 10.2217/cer-2018-0022. Epub 2018 Sep 7.
PMID: 30192155
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H.
J Gastroenterol. 2018 Sep;53(9):1089-1097. doi: 10.1007/s00535-018-1445-3. Epub 2018 Mar 2.
PMID: 29500489
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L.
J Manag Care Spec Pharm. 2018 Sep;24(9):911-920. doi: 10.18553/jmcp.2018.24.9.911.
PMID: 30156450
Sticking and Picking in Pharmaceutical Tablet Compression: An IQ Consortium Review.
Chattoraj S, Daugherity P, McDermott T, Olsofsky A, Roth WJ, Tobyn M.
J Pharm Sci. 2018 Sep;107(9):2267-2282. doi: 10.1016/j.xphs.2018.04.029. Epub 2018 May 8. Review.
PMID: 29751009
An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
Boetzel R, Ceszlak A, Day C, Drumm P, Gil Bejar J, Glennon J, Harris L, Heghes CI, Horga R, Jacobs PL, Keurentjes WJTM, King F, Lee CW, Lewen N, Marchant CA, Maris FA, Nye W, Powell S, Rockstroh H, Rutter L, Schweitzer M, Shannon E, Smallshaw L, Teasdale A, Thompson S, Wilkinson D.
J Pharm Sci. 2018 Sep;107(9):2335-2340. doi: 10.1016/j.xphs.2018.04.009. Epub 2018 Apr 18.
PMID: 29679706
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N.
J Thorac Oncol. 2018 Sep;13(9):1363-1372. doi: 10.1016/j.jtho.2018.05.015. Epub 2018 May 23.
PMID: 29802888
Comment on structural basis of DUX4/IGH-driven transactivation.
Aihara H, Shi K, Lee JK, Bosnakovski D, Kyba M.
Leukemia. 2018 Sep;32(9):2090-2092. doi: 10.1038/s41375-018-0217-7. Epub 2018 Jul 27. No abstract available.
PMID: 30054554
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.
Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.
PMID: 29866947
Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.
Yoon H, Karapetyan L, Choudhary A, Kosozi R, Bali GS, Zaidi AH, Atasoy A, Forastiere AA, Gibson MK.
Oncologist. 2018 Sep;23(9):1004-e102. doi: 10.1634/theoncologist.2017-0657. Epub 2018 May 16.
PMID: 29769385
Solubility enhancement and solid-state characterisation.
Tobyn M.
Pharm Dev Technol. 2018 Sep;23(7):663. doi: 10.1080/10837450.2018.1505305. No abstract available.
PMID: 30106327
The Near-Term Viability and Benefits of eLabels for Patients, Clinical Sites, and Sponsors.
Smith-Gick J, Barnes N, Barone R, Bedford J, James JR, Reisner SF, Stephenson M.
Ther Innov Regul Sci. 2018 Sep;52(5):537-545. doi: 10.1177/2168479018765463. Epub 2018 Apr 2.
PMID: 29714582
Application of dynamic modeling for survival estimation in advanced renal cell carcinoma.
Deniz B, Altincatal A, Ambavane A, Rao S, Doan J, Malcolm B, Michaelson MD, Yang S.
PLoS One. 2018 Aug 30;13(8):e0203406. doi: 10.1371/journal.pone.0203406. eCollection 2018.
PMID: 30161244
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.
Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD.
Nat Commun. 2018 Aug 29;9(1):3503. doi: 10.1038/s41467-018-05992-x.
PMID: 30158554
Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma.
Moyes KW, Davis A, Hoglund V, Haberthur K, Lieberman NA, Kreuser SA, Deutsch GH, Franco S, Locke D, Carleton MO, Gilbertson DG, Simmons R, Winter C, Silber J, Gonzalez-Cuyar LF, Ellenbogen RG, Crane CA.
Oncoimmunology. 2018 Aug 27;7(11):e1507668. doi: 10.1080/2162402X.2018.1507668. eCollection 2018.
PMID: 30377570
NF-κB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model.
Peterson JM, Wang DJ, Shettigar V, Roof SR, Canan BD, Bakkar N, Shintaku J, Gu JM, Little SC, Ratnam NM, Londhe P, Lu L, Gaw CE, Petrosino JM, Liyanarachchi S, Wang H, Janssen PML, Davis JP, Ziolo MT, Sharma SM, Guttridge DC.
Nat Commun. 2018 Aug 24;9(1):3431. doi: 10.1038/s41467-018-05910-1.
PMID: 30143619
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.
Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.
J Med Chem. 2018 Aug 23;61(16):7168-7188. doi: 10.1021/acs.jmedchem.8b00450. Epub 2018 Aug 15.
PMID: 30052039
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
PMID: 30134131
Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
Speck RM, Lenderking WR, Shaw JW.
J Patient Rep Outcomes. 2018 Aug 22;2:35. doi: 10.1186/s41687-018-0063-4. eCollection 2017.
PMID: 30175317
Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
Rose RE, Hernandez D, Falk PJ, Ericson K, Zhou N, Thiry A, McPhee F.
Hepatol Commun. 2018 Aug 21;2(9):1123-1135. doi: 10.1002/hep4.1231. eCollection 2018 Sep.
PMID: 30202825
Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison.
Glauche I, Kuhn M, Baldow C, Schulze P, Rothe T, Liebscher H, Roy A, Wang X, Roeder I.
Sci Rep. 2018 Aug 17;8(1):12330. doi: 10.1038/s41598-018-29923-4.
PMID: 30120281
An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis.
Luo Y, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, Collen R, Idowu M, Contos MJ, Mirshahi F, Daita K, Asgharpour A, Siddiqui MS, Jarai G, Rosen G, Christian R, Sanyal AJ.
Sci Rep. 2018 Aug 17;8(1):12414. doi: 10.1038/s41598-018-30457-y.
PMID: 30120271
Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu 4  positive allosteric modulators that mitigate CYP1A2 induction liability.
Engers DW, Bollinger SR, Engers JL, Panarese JD, Breiner MM, Gregro A, Blobaum AL, Bronson JJ, Wu YJ, Macor JE, Rodriguez AL, Zamorano R, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR.
Bioorg Med Chem Lett. 2018 Aug 15;28(15):2641-2646. doi: 10.1016/j.bmcl.2018.06.034. Epub 2018 Jun 19.
PMID: 29958762
Multimonth Prescription of Antiretroviral Therapy Among Children and Adolescents: Experiences From the Baylor International Pediatric AIDS Initiative in 6 African Countries.
Kim MH, Wanless RS, Caviness AC, Golin R, Amzel A, Ahmed S, Mhango J, Damba D, Kayabu A, Chodota M, Dlamini S, Chidah N, Mokhali M, Calles NR, Abrams EJ.
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S71-S80. doi: 10.1097/QAI.0000000000001730. Erratum in:  J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):e107 .
PMID: 29994828
Ligand-Enabled β-C(sp 3 )-H Olefination of Free Carboxylic Acids.
Zhuang Z, Yu CB, Chen G, Wu QF, Hsiao Y, Joe CL, Qiao JX, Poss MA, Yu JQ.
J Am Chem Soc. 2018 Aug 15;140(32):10363-10367. doi: 10.1021/jacs.8b06527. Epub 2018 Aug 2.
PMID: 30029574
Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy.
Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L; ARISTOTLE Investigators.
J Am Coll Cardiol. 2018 Aug 14;72(7):721-733. doi: 10.1016/j.jacc.2018.05.058.
PMID: 30092948
Tunable normal phase enantioselectivity of amino acid esters via mobile phase composition.
Yang A, Shackman JG, Ye YK.
J Chromatogr A. 2018 Aug 10;1562:128-133. doi: 10.1016/j.chroma.2018.05.054. Epub 2018 May 28.
PMID: 29859686
In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats.
Gilibili RR, Kurawattimath V, Murali BV, Lai Y, Mariappan TT, Shen H, Chatterjee S.
Pharmaceutics. 2018 Aug 8;10(3). pii: E125. doi: 10.3390/pharmaceutics10030125.
PMID: 30096834
Overcoming the stability, solubility and extraction challenges in reversed-phase UHPLC-MS/MS bioanalysis of a phosphate drug and its prodrug in blood lysate.
Yuan L, Basdeo S, Ji QC.
J Pharm Biomed Anal. 2018 Aug 5;157:36-43. doi: 10.1016/j.jpba.2018.05.006. Epub 2018 May 5.
PMID: 29758468
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
Manjarrez-Orduño N, Menard LC, Kansal S, Fischer P, Kakrecha B, Jiang C, Cunningham M, Greenawalt D, Patel V, Yang M, Golhar R, Carman JA, Lezhnin S, Dai H, Kayne PS, Suchard SJ, Bernstein SH, Nadler SG.
Front Immunol. 2018 Aug 3;9:1613. doi: 10.3389/fimmu.2018.01613. eCollection 2018.
PMID: 30123214
Development and validation of a functional cell-based neutralizing antibody assay for ipilimumab.
Xu W, Cummings J, Sank M, Juhel M, Li X, Gleason C, DeSilva BS, Dodge RW, Pillutla R.
Bioanalysis. 2018 Aug 1;10(16):1273-1287. doi: 10.4155/bio-2018-0109. Epub 2018 Jun 27.
PMID: 29947549
Concerted application of LC-MS and ligand binding assays to better understand exposure of a large molecule drug.
Xu W, Jiang H, Titsch C, Gadkari S, Batog A, Wang B, Hippeli L, Yamamoto B, Chadwick K, Wheeler J, Thompson C, Stahl J, Willett S, DeSilva BS, Myler H, Dodge RW, Pillutla RC.
Bioanalysis. 2018 Aug 1;10(16):1261-1272. doi: 10.4155/bio-2018-0108. Epub 2018 Jun 20.
PMID: 29923414
Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.
Millard D, Dang Q, Shi H, Zhang X, Strock C, Kraushaar U, Zeng H, Levesque P, Lu HR, Guillon JM, Wu JC, Li Y, Luerman G, Anson B, Guo L, Clements M, Abassi YA, Ross J, Pierson J, Gintant G.
Toxicol Sci. 2018 Aug 1;164(2):550-562. doi: 10.1093/toxsci/kfy110.
PMID: 29718449
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, Pinilla-Ibarz J, Abruzzese E.
Ann Hematol. 2018 Aug;97(8):1357-1367. doi: 10.1007/s00277-018-3295-8. Epub 2018 Mar 20.
PMID: 29556695
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG.
Arthritis Rheumatol. 2018 Aug;70(8):1331-1342. doi: 10.1002/art.40476. Epub 2018 Jul 12.
PMID: 29534336
Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.
Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X, Furst DE, Ranganath VK, Maldonado M, Lee T, Reddy ST.
Atherosclerosis. 2018 Aug;275:107-114. doi: 10.1016/j.atherosclerosis.2018.04.003. Epub 2018 Apr 17.
PMID: 29886354
High-efficiency affinity precipitation of multiple industrial mAbs and Fc-fusion proteins from cell culture harvests using Z-ELP-E2 nanocages.
Swartz AR, Xu X, Traylor SJ, Li ZJ, Chen W.
Biotechnol Bioeng. 2018 Aug;115(8):2039-2047. doi: 10.1002/bit.26717. Epub 2018 May 9.
PMID: 29679468
Contributions of depth filter components to protein adsorption in bioprocessing.
Khanal O, Singh N, Traylor SJ, Xu X, Ghose S, Li ZJ, Lenhoff AM.
Biotechnol Bioeng. 2018 Aug;115(8):1938-1948. doi: 10.1002/bit.26707. Epub 2018 May 1.
PMID: 29663326
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG.
Br J Haematol. 2018 Aug;182(4):495-503. doi: 10.1111/bjh.15384. Epub 2018 May 29.
PMID: 29808907
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T.
Clin Pharmacokinet. 2018 Aug;57(8):911-928. doi: 10.1007/s40262-017-0624-3. Review.
PMID: 29353349
Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.
Diao L, Meibohm B.
Curr Pharmacol Rep. 2018 Aug;4(4):285-291. doi: 10.1007/s40495-018-0142-5. Epub 2018 May 3.
PMID: 30319936
Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
Mathieu C, Catrinoiu D, Ranetti AE, Johnsson E, Hansen L, Chen H, Garcia-Sanchez R, Iqbal N, Celiñski A.
Diabetes Ther. 2018 Aug;9(4):1703-1711. doi: 10.1007/s13300-018-0445-x. Epub 2018 May 25.
PMID: 29802530
Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H, Christopher L, Lai Y, Gong J, Kandoussi H, Garonzik S, Perera V, Garimella T, Humphreys WG.
Drug Metab Dispos. 2018 Aug;46(8):1075-1082. doi: 10.1124/dmd.118.081125. Epub 2018 May 18.
PMID: 29777022
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease.
Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, Gersh BJ, Avezum A, Hanna M, Held C, Wallentin L, Granger CB, Alexander JH.
Heart. 2018 Aug;104(15):1292-1299. doi: 10.1136/heartjnl-2017-312272. Epub 2018 Jan 19.
PMID: 29352007
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.
Chen W, Ward T, Tan MP, Yan J, Wang PF, Wygant GD, Gordon J.
J Comp Eff Res. 2018 Aug;7(8):785-795. doi: 10.2217/cer-2018-0005. Epub 2018 Jun 4.
PMID: 29860879
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R.
J Rheumatol. 2018 Aug;45(8):1085-1092. doi: 10.3899/jrheum.170344. Epub 2018 Apr 15.
PMID: 29657147
The expanding role of prodrugs in contemporary drug design and development.
Rautio J, Meanwell NA, Di L, Hageman MJ.
Nat Rev Drug Discov. 2018 Aug;17(8):559-587. doi: 10.1038/nrd.2018.46. Epub 2018 Apr 27. Review.
PMID: 29700501
Weight Loss and Timing of J Tube Removal in Biliopancreatic Diversion with Duodenal Switch Patients Who Report Physical or Sexual Abuse.
Hulme PA, Kupzyk KA, Anthone GJ, Capron KA, Nguyen T.
Obes Surg. 2018 Aug;28(8):2361-2367. doi: 10.1007/s11695-018-3166-3.
PMID: 29512037
Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM, Doan J, Gebben DJ, Boeri M, Fishman M.
Pharmacoeconomics. 2018 Aug;36(8):973-986. doi: 10.1007/s40273-018-0640-7.
PMID: 29869777
Miniaturized High-Throughput Multiparameter Flow Cytometry Assays Measuring In Vitro Human Dendritic Cell Maturation and T-Cell Activation in Mixed Lymphocyte Reactions.
Fan Y, Naglich JG, Koenitzer JD, Ribeiro H, Lippy J, Blum J, Li X, Milburn C, Barnhart B, Zhang L, Fereshteh MP.
SLAS Discov. 2018 Aug;23(7):742-750. doi: 10.1177/2472555218775409. Epub 2018 Jun 6.
PMID: 29873570
Response to the Letter to the Editor Submitted by Dr. JoAnn C. L. Schuh.
Woicke J, Haile S, Mysore J, Peden M, Lejeune T, Sanderson TP, Brodie T.
Toxicol Pathol. 2018 Aug;46(6):721. doi: 10.1177/0192623318794180. No abstract available.
PMID: 30160207
Implementation of Plate Imaging for Demonstration of Monoclonality in Biologics Manufacturing Development.
Zingaro K, Shaw D, Carson J, Mayer-Bartschmid A, Bender C, Alves C, Mcvey D, Qian NX, Wei Q, Laird MW, Zhu Y, Emmins R, Follit JA, Porter A, Racher AJ, Milne S, Carubelli I, Du Z, Khatri A, Failly M, Broly H, Lee F, Reeser M, Spidel J, Anderson K, Demaria C, Di-Carlo J, Gill J, Lundquist A, Kumar SR, Gill T.
PDA J Pharm Sci Technol. 2018 Jul-Aug;72(4):438-450. doi: 10.5731/pdajpst.2018.008789. Epub 2018 Apr 18.
PMID: 29669815
Erratum for John Mattila, Mike Clark, Shengjiang Liu, et al.: "Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration".
Mattila J, Clark M, Liu S, Pieracci J, Gervais TR, Wilson E, Galperina O, Li X, Roush D, Zoeller K, Brough H, Simpson-Platre C.
PDA J Pharm Sci Technol. 2018 Jul-Aug;72(4):451. doi: 10.5731/pdajpst.2017.007963. Epub 2018 Mar 15. No abstract available.
PMID: 29545323
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
Meanwell NA.
J Med Chem. 2018 Jul 26;61(14):5822-5880. doi: 10.1021/acs.jmedchem.7b01788. Epub 2018 Feb 5. Review.
PMID: 29400967
CD226 opposes TIGIT to disrupt Tregs in melanoma.
Fourcade J, Sun Z, Chauvin JM, Ka M, Davar D, Pagliano O, Wang H, Saada S, Menna C, Amin R, Sander C, Kirkwood JM, Korman AJ, Zarour HM.
JCI Insight. 2018 Jul 26;3(14). pii: 121157. doi: 10.1172/jci.insight.121157. eCollection 2018 Jul 26.
PMID: 30046006
TCFH-NMI: Direct Access to N-Acyl Imidazoliums for Challenging Amide Bond Formations.
Beutner GL, Young IS, Davies ML, Hickey MR, Park H, Stevens JM, Ye Q.
Org Lett. 2018 Jul 20;20(14):4218-4222. doi: 10.1021/acs.orglett.8b01591. Epub 2018 Jun 29.
PMID: 29956545
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, Hodi FS.
Sci Transl Med. 2018 Jul 18;10(450). pii: eaar3342. doi: 10.1126/scitranslmed.aar3342.
PMID: 30021886
Act1 is a negative regulator in T and B cells via direct inhibition of STAT3.
Zhang CJ, Wang C, Jiang M, Gu C, Xiao J, Chen X, Martin BN, Tang F, Yamamoto E, Xian Y, Wang H, Li F, Sartor RB, Smith H, Husni ME, Shi FD, Gao J, Carman J, Dongre A, McKarns SC, Coppieters K, Jørgensen TN, Leonard WJ, Li X.
Nat Commun. 2018 Jul 16;9(1):2745. doi: 10.1038/s41467-018-04974-3.
PMID: 30013031
Time to really share real-world data?
Graham S, McDonald L, Wasiak R, Lees M, Ramagopalan S.
F1000Res. 2018 Jul 11;7:1054. doi: 10.12688/f1000research.15517.1. eCollection 2018.
PMID: 30364186
Adventures in Atropisomerism: Total Synthesis of a Complex Active Pharmaceutical Ingredient with Two Chirality Axes.
Beutner G, Carrasquillo R, Geng P, Hsiao Y, Huang EC, Janey J, Katipally K, Kolotuchin S, La Porte T, Lee A, Lobben P, Lora-Gonzalez F, Mack B, Mudryk B, Qiu Y, Qian X, Ramirez A, Razler TM, Rosner T, Shi Z, Simmons E, Stevens J, Wang J, Wei C, Wisniewski SR, Zhu Y.
Org Lett. 2018 Jul 6;20(13):3736-3740. doi: 10.1021/acs.orglett.8b01218. Epub 2018 Jun 17.
PMID: 29909639
Directed, Palladium(II)-Catalyzed Intermolecular Aminohydroxylation of Alkenes Using a Mild Oxidation System.
Zeng T, Liu Z, Schmidt MA, Eastgate MD, Engle KM.
Org Lett. 2018 Jul 6;20(13):3853-3857. doi: 10.1021/acs.orglett.8b01440. Epub 2018 Jun 11.
PMID: 29888604
Single-crystal x-ray diffraction structures of covalent organic frameworks.
Ma T, Kapustin EA, Yin SX, Liang L, Zhou Z, Niu J, Li LH, Wang Y, Su J, Li J, Wang X, Wang WD, Wang W, Sun J, Yaghi OM.
Science. 2018 Jul 6;361(6397):48-52. doi: 10.1126/science.aat7679.
PMID: 29976818
Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma.
Motzer RJ, McHenry MB, Chen AC.
N Engl J Med. 2018 Jul 5;379(1):92-93. doi: 10.1056/NEJMc1805988. No abstract available.
PMID: 29972749
IL22 Inhibits Epithelial Stem Cell Expansion in an Ileal Organoid Model.
Zwarycz B, Gracz AD, Rivera KR, Williamson IA, Samsa LA, Starmer J, Daniele MA, Salter-Cid L, Zhao Q, Magness ST.
Cell Mol Gastroenterol Hepatol. 2018 Jul 4;7(1):1-17. doi: 10.1016/j.jcmgh.2018.06.008. eCollection 2019.
PMID: 30364840
Critical considerations for immunocapture enrichment LC-MS bioanalysis of protein therapeutics and biomarkers.
Zhao Y, Gu H, Zheng N, Zeng J.
Bioanalysis. 2018 Jul 1;10(13):987-995. doi: 10.4155/bio-2018-0062. Epub 2018 Jul 4.
PMID: 29972311
The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor.
Naidu BN, Walker MA, Sorenson ME, Ueda Y, Matiskella JD, Connolly TP, Dicker IB, Lin Z, Bollini S, Terry BJ, Higley H, Zheng M, Parker DD, Wu D, Adams S, Krystal MR, Meanwell NA.
Bioorg Med Chem Lett. 2018 Jul 1;28(12):2124-2130. doi: 10.1016/j.bmcl.2018.05.027. Epub 2018 May 14.
PMID: 29779976
Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.
Am J Transplant. 2018 Jul;18(7):1774-1782. doi: 10.1111/ajt.14738. Epub 2018 Apr 17.
PMID: 29573335
De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.
Am J Transplant. 2018 Jul;18(7):1783-1789. doi: 10.1111/ajt.14721. Epub 2018 Apr 2.
PMID: 29509295
Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles.
Chung S, Tian J, Tan Z, Chen J, Lee J, Borys M, Li ZJ.
Biotechnol Bioeng. 2018 Jul;115(7):1646-1665. doi: 10.1002/bit.26587. Epub 2018 Mar 31. Review.
PMID: 29532901
STK11/LKB1  Mutations and PD-1 Inhibitor Resistance in  KRAS -Mutant Lung Adenocarcinoma.
Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.
Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.
PMID: 29773717
Tumor-Specific Inhibition of  In Situ  Vaccination by Distant Untreated Tumor Sites.
Morris ZS, Guy EI, Werner LR, Carlson PM, Heinze CM, Kler JS, Busche SM, Jaquish AA, Sriramaneni RN, Carmichael LL, Loibner H, Gillies SD, Korman AJ, Erbe AK, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.
Cancer Immunol Res. 2018 Jul;6(7):825-834. doi: 10.1158/2326-6066.CIR-17-0353. Epub 2018 May 10.
PMID: 29748391
Assessment and modelling of antibacterial combination regimens.
Rao GG, Li J, Garonzik SM, Nation RL, Forrest A.
Clin Microbiol Infect. 2018 Jul;24(7):689-696. doi: 10.1016/j.cmi.2017.12.004. Epub 2017 Dec 18. Review.
PMID: 29269090
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy VP, Zheng M, de Zwart L, Beneton M, Bouzom F, Chen J, Chen Y, Cleary Y, Collins C, Dickinson GL, Djebli N, Einolf HJ, Gardner I, Huth F, Kazmi F, Khalil F, Lin J, Odinecs A, Patel C, Rong H, Schuck E, Sharma P, Wu SP, Xu Y, Yamazaki S, Yoshida K, Rowland M.
Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2. Review.
PMID: 29315504
Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study.
Prasad B, Bhatt DK, Johnson K, Chapa R, Chu X, Salphati L, Xiao G, Lee C, Hop CECA, Mathias A, Lai Y, Liao M, Humphreys WG, Kumer SC, Unadkat JD.
Drug Metab Dispos. 2018 Jul;46(7):943-952. doi: 10.1124/dmd.118.080523. Epub 2018 Apr 25.
PMID: 29695616
Conformational Assessment of Adnectin and Adnectin-Drug Conjugate by Hydrogen/Deuterium Exchange Mass Spectrometry.
Huang RY, O'Neil SR, Lipovšek D, Chen G.
J Am Soc Mass Spectrom. 2018 Jul;29(7):1524-1531. doi: 10.1007/s13361-018-1966-2. Epub 2018 May 7.
PMID: 29736601
Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects.
Byon W, Nepal S, Schuster AE, Shenker A, Frost CE.
J Clin Pharmacol. 2018 Jul;58(7):965-971. doi: 10.1002/jcph.1097. Epub 2018 Mar 26.
PMID: 29578609
Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH, Zhao J, Ptaszynska A.
J Diabetes. 2018 Jul;10(7):589-599. doi: 10.1111/1753-0407.12634. Epub 2018 Jan 25.
PMID: 29215189
Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood.
Sorokin AV, Domenichiello AF, Dey AK, Yuan ZX, Goyal A, Rose SM, Playford MP, Ramsden CE, Mehta NN.
J Invest Dermatol. 2018 Jul;138(7):1518-1528. doi: 10.1016/j.jid.2018.02.003. Epub 2018 Feb 15.
PMID: 29454560
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM.
Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.
PMID: 29654064
Transcriptome alterations of prefrontal cortical parvalbumin neurons in schizophrenia.
Enwright Iii JF, Huo Z, Arion D, Corradi JP, Tseng G, Lewis DA.
Mol Psychiatry. 2018 Jul;23(7):1606-1613. doi: 10.1038/mp.2017.216. Epub 2017 Nov 7.
PMID: 29112193
Thymic tuft cells promote an IL-4-enriched medulla and shape thymocyte development.
Miller CN, Proekt I, von Moltke J, Wells KL, Rajpurkar AR, Wang H, Rattay K, Khan IS, Metzger TC, Pollack JL, Fries AC, Lwin WW, Wigton EJ, Parent AV, Kyewski B, Erle DJ, Hogquist KA, Steinmetz LM, Locksley RM, Anderson MS.
Nature. 2018 Jul;559(7715):627-631. doi: 10.1038/s41586-018-0345-2. Epub 2018 Jul 18.
PMID: 30022164
Enhancing tablet disintegration characteristics of a highly water-soluble high-drug-loading formulation by granulation process.
Pandey P, Levins C, Pafiakis S, Zacour B, Bindra DS, Trinh J, Buckley D, Gour S, Sharif S, Stamato H.
Pharm Dev Technol. 2018 Jul;23(6):587-595. doi: 10.1080/10837450.2016.1264416. Epub 2016 Dec 15.
PMID: 27879156
In silico toxicology protocols.
Myatt GJ, Ahlberg E, Akahori Y, Allen D, Amberg A, Anger LT, Aptula A, Auerbach S, Beilke L, Bellion P, Benigni R, Bercu J, Booth ED, Bower D, Brigo A, Burden N, Cammerer Z, Cronin MTD, Cross KP, Custer L, Dettwiler M, Dobo K, Ford KA, Fortin MC, Gad-McDonald SE, Gellatly N, Gervais V, Glover KP, Glowienke S, Van Gompel J, Gutsell S, Hardy B, Harvey JS, Hillegass J, Honma M, Hsieh JH, Hsu CW, Hughes K, Johnson C, Jolly R, Jones D, Kemper R, Kenyon MO, Kim MT, Kruhlak NL, Kulkarni SA, Kümmerer K, Leavitt P, Majer B, Masten S, Miller S, Moser J, Mumtaz M, Muster W, Neilson L, Oprea TI, Patlewicz G, Paulino A, Lo Piparo E, Powley M, Quigley DP, Reddy MV, Richarz AN, Ruiz P, Schilter B, Serafimova R, Simpson W, Stavitskaya L, Stidl R, Suarez-Rodriguez D, Szabo DT, Teasdale A, Trejo-Martin A, Valentin JP, Vuorinen A, Wall BA, Watts P, White AT, Wichard J, Witt KL, Woolley A, Woolley D, Zwickl C, Hasselgren C.
Regul Toxicol Pharmacol. 2018 Jul;96:1-17. doi: 10.1016/j.yrtph.2018.04.014. Epub 2018 Apr 17.
PMID: 29678766
Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes.
Zhou M, Tang Q, Lang L, Xing J, Tatsuoka K.
Stat Med. 2018 Jun 30;37(14):2187-2207. doi: 10.1002/sim.7685. Epub 2018 Apr 17.
PMID: 29664214
A Combined In Vitro/In Silico Approach to Identifying Off-Target Receptor Toxicity.
Leedale J, Sharkey KJ, Colley HE, Norton ÁM, Peeney D, Mason CL, Sathish JG, Murdoch C, Sharma P, Webb SD.
iScience. 2018 Jun 29;4:84-96. doi: 10.1016/j.isci.2018.05.012. Epub 2018 May 18.
PMID: 30240756
A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.
Wensel D, Sun Y, Davis J, Li Z, Zhang S, McDonagh T, Fabrizio D, Cockett M, Krystal M.
J Virol. 2018 Jun 29;92(14). pii: e00421-18. doi: 10.1128/JVI.00421-18. Print 2018 Jul 15.
PMID: 29743355
The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan.
Cornwell AB, Llop JR, Salzman P, Thakar J, Samuelson AV.
J Vis Exp. 2018 Jun 29;(136). doi: 10.3791/57819.
PMID: 30010651
PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor.
Hangeland JJ, Abell LM, Adam LP, Jiang J, Friends TJ, Haque LE, Neels J, Onorato JM, Chen AYA, Taylor DS, Yin X, Harrity TW, Basso MD, Yang R, Sleph PG, Gordon DA, Huang CS, Wexler RR, Finlay HJ, Lawrence RM.
ACS Med Chem Lett. 2018 Jun 15;9(7):673-678. doi: 10.1021/acsmedchemlett.8b00138. eCollection 2018 Jul 12.
PMID: 30034599
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG.
Front Cardiovasc Med. 2018 Jun 12;5:55. doi: 10.3389/fcvm.2018.00055. eCollection 2018.
PMID: 29946549
Assessment of Density Functional Methods for Geometry Optimization of Bimolecular van der Waals Complexes.
Sirianni DA, Alenaizan A, Cheney DL, Sherrill CD.
J Chem Theory Comput. 2018 Jun 12;14(6):3004-3013. doi: 10.1021/acs.jctc.8b00114. Epub 2018 May 29.
PMID: 29763302
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
Colston E, Grasela D, Gardiner D, Bucy RP, Vakkalagadda B, Korman AJ, Lowy I.
PLoS One. 2018 Jun 7;13(6):e0198158. doi: 10.1371/journal.pone.0198158. eCollection 2018.
PMID: 29879143
Detection and Identification of the Vibrational Markers for the Quantification of Methionine Oxidation in Therapeutic Proteins.
Balakrishnan G, Barnett GV, Kar SR, Das TK.
Anal Chem. 2018 Jun 5;90(11):6959-6966. doi: 10.1021/acs.analchem.8b01238. Epub 2018 May 17.
PMID: 29741878
Discovery, identification and mitigation of isobaric sulfate metabolite interference to a phosphate prodrug in LC-MS/MS bioanalysis: Critical role of method development in ensuring assay quality.
Yuan L, Ji QC.
J Pharm Biomed Anal. 2018 Jun 5;155:141-147. doi: 10.1016/j.jpba.2018.03.064. Epub 2018 Apr 4.
PMID: 29631074
Evolution of fit-for-purpose biomarker validations: an LBA perspective.
Neely RJ.
Bioanalysis. 2018 Jun 1;10(12):905-907. doi: 10.4155/bio-2017-0267. Epub 2018 Jun 20.
PMID: 29923756
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
Venables BL, Sin N, Wang AX, Sun LQ, Tu Y, Hernandez D, Sheaffer A, Lee M, Dunaj C, Zhai G, Barry D, Friborg J, Yu F, Knipe J, Sandquist J, Falk P, Parker D, Good AC, Rajamani R, McPhee F, Meanwell NA, Scola PM.
Bioorg Med Chem Lett. 2018 Jun 1;28(10):1853-1859. doi: 10.1016/j.bmcl.2018.04.009. Epub 2018 Apr 5.
PMID: 29650290
Rethinking developmental toxicity testing: Evolution or revolution?
Scialli AR, Daston G, Chen C, Coder PS, Euling SY, Foreman J, Hoberman AM, Hui J, Knudsen T, Makris SL, Morford L, Piersma AH, Stanislaus D, Thompson KE.
Birth Defects Res. 2018 Jun 1;110(10):840-850. doi: 10.1002/bdr2.1212. Epub 2018 Feb 12.
PMID: 29436169
Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat.
Simutis FJ, Sanderson TP, Pilcher GD, Graziano MJ.
Toxicol Sci. 2018 Jun 1;163(2):525-542. doi: 10.1093/toxsci/kfy048.
PMID: 29529279
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, Mehran R, Windecker S, Alexander JH.
Am Heart J. 2018 Jun;200:17-23. doi: 10.1016/j.ahj.2018.03.001. Epub 2018 Mar 9.
PMID: 29898844
Prodromal symptoms of multiple sclerosis in primary care.
Disanto G, Zecca C, MacLachlan S, Sacco R, Handunnetthi L, Meier UC, Simpson A, McDonald L, Rossi A, Benkert P, Kuhle J, Ramagopalan SV, Gobbi C.
Ann Neurol. 2018 Jun;83(6):1162-1173. doi: 10.1002/ana.25247. Epub 2018 May 30.
PMID: 29740872
Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
Gong J, Iacono L, Iyer RA, Humphreys WG, Zheng M.
Br J Clin Pharmacol. 2018 Jun;84(6):1335-1345. doi: 10.1111/bcp.13565. Epub 2018 Apr 10.
PMID: 29469197
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C.
Diabetes Obes Metab. 2018 Jun;20(6):1542-1546. doi: 10.1111/dom.13258. Epub 2018 Mar 25.
PMID: 29446523
Performing studies using the UK Clinical Practice Research Datalink: to link or not to link?
McDonald L, Schultze A, Carroll R, Ramagopalan SV.
Eur J Epidemiol. 2018 Jun;33(6):601-605. doi: 10.1007/s10654-018-0389-5. Epub 2018 Apr 4.
PMID: 29619668
Protection of therapeutic antibodies from visible light induced degradation: Use safe light in manufacturing and storage.
Du C, Barnett G, Borwankar A, Lewandowski A, Singh N, Ghose S, Borys M, Li ZJ.
Eur J Pharm Biopharm. 2018 Jun;127:37-43. doi: 10.1016/j.ejpb.2018.02.007. Epub 2018 Feb 7.
PMID: 29427628
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Shafrin J, Skornicki M, Brauer M, Villeneuve J, Lees M, Hertel N, Penrod JR, Jansen J.
Health Policy. 2018 Jun;122(6):607-613. doi: 10.1016/j.healthpol.2018.04.008. Epub 2018 Apr 26.
PMID: 29731176
Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.
Zhu L, Li H, Chan P, Eley T, Gandhi Y, Bifano M, Osawa M, Ueno T, Hughes E, AbuTarif M, Bertz R, Garimella T.
Infect Dis Ther. 2018 Jun;7(2):261-275. doi: 10.1007/s40121-018-0197-y. Epub 2018 Mar 27.
PMID: 29589331
Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
LaFleur J, Bress AP, Myers J, Rosenblatt L, Crook J, Knippenberg K, Bedimo R, Tebas P, Nyman H, Esker S.
Infect Dis Ther. 2018 Jun;7(2):293-308. doi: 10.1007/s40121-018-0194-1. Epub 2018 Feb 28.
PMID: 29492905
Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N, Koh HA, Lin KJ, Stwalley B, Felber E.
J Oncol Pharm Pract. 2018 Jun;24(4):253-263. doi: 10.1177/1078155217697484. Epub 2017 Mar 10.
PMID: 29284347
An Unexpected Degradation Pathway of a 1,2,4-Triazolo[4,3-a]pyridine Derivative: The Formation of 2 Cationic Pseudodimers of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Drug Candidate in a Stressed Capsule Formulation.
Huang Y, Wang Q, Wu Y.
J Pharm Sci. 2018 Jun;107(6):1633-1641. doi: 10.1016/j.xphs.2018.02.009. Epub 2018 Feb 17.
PMID: 29458062
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
Bonomi P, Blumenthal G, Ferris AS, Stewart DJ, Selig WKD, Krug LM, Allen J, Ison G, Langer CJ, Melemed A, Odogwu L, Basu Roy U, Sandler A.
J Thorac Oncol. 2018 Jun;13(6):748-751. doi: 10.1016/j.jtho.2018.02.013. No abstract available.
PMID: 29793646
Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.
Zhang Y, Pitchiaya S, Cieślik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier SM, Watt AT, Guo S, Wei JT, Feng FY, Malik R, Chinnaiyan AM.
Nat Genet. 2018 Jun;50(6):814-824. doi: 10.1038/s41588-018-0120-1. Epub 2018 May 28.
PMID: 29808028
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.
Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.
PMID: 29884413
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Sevinsky H, Zaru L, Wang R, Xu X, Pikora C, Correll TA, Eley T.
Pediatr Infect Dis J. 2018 Jun;37(6):e157-e165. doi: 10.1097/INF.0000000000001855.
PMID: 29206748
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
Cotton MF, Liberty A, Torres-Escobar I, Gonzalez-Tome MI, Lissens J, Zaru L, Klauck I, Cambilargiu D, Pikora C, Correll TA.
Pediatr Infect Dis J. 2018 Jun;37(6):e149-e156. doi: 10.1097/INF.0000000000001856.
PMID: 29206747
The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature.
Enstone A, Greaney M, Povsic M, Wyn R, Penrod JR, Yuan Y.
Pharmacoecon Open. 2018 Jun;2(2):125-139. doi: 10.1007/s41669-017-0045-0. Review.
PMID: 29623624
Statistics and Biology: Not Your Average Relationship.
Nadon R, Kayne P.
SLAS Discov. 2018 Jun;23(5):437-439. doi: 10.1177/2472555218769904. No abstract available.
PMID: 29781352
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L.
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
PMID: 29658845
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park SM, Youn JI, Chowdhury T, Park CK, Brem H, Pardoll DM, Lim M.
Oncoimmunology. 2018 May 24;7(8):e1466769. doi: 10.1080/2162402X.2018.1466769. eCollection 2018.
PMID: 30221069
Considerations for the Use of Polysorbates in Biopharmaceuticals.
Jones MT, Mahler HC, Yadav S, Bindra D, Corvari V, Fesinmeyer RM, Gupta K, Harmon AM, Hinds KD, Koulov A, Liu W, Maloney K, Wang J, Yeh PY, Singh SK.
Pharm Res. 2018 May 24;35(8):148. doi: 10.1007/s11095-018-2430-5. Review.
PMID: 29797101
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.
Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3. Erratum in:  Cancer Cell. 2019 Feb 11;35(2):329 .
PMID: 29731394
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD.
Cancer Cell. 2018 May 14;33(5):843-852.e4. doi: 10.1016/j.ccell.2018.03.018. Epub 2018 Apr 12.
PMID: 29657128
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.
J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in:  J Clin Oncol. 2018 Sep 10;36(26):2748 .
PMID: 29584546
A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers.
Shen H.
Bioanalysis. 2018 May 1;10(9):625-631. doi: 10.4155/bio-2017-0265. Epub 2018 May 16. No abstract available.
PMID: 29768022
UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions.
Kandoussi H, Zeng J, Shah K, Paterson P, Santockyte R, Kadiyala P, Shen H, Shipkova P, Langish R, Burrrell R, Easter J, Mariannino T, Marathe P, Lai Y, Zhang Y, Pillutla R.
Bioanalysis. 2018 May 1;10(9):633-644. doi: 10.4155/bio-2017-0246. Epub 2018 May 11.
PMID: 29749254
Cancer subtype identification using somatic mutation data.
Kuijjer ML, Paulson JN, Salzman P, Ding W, Quackenbush J.
Br J Cancer. 2018 May;118(11):1492-1501. doi: 10.1038/s41416-018-0109-7. Epub 2018 May 16.
PMID: 29765148
Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons.
Mauricio D, Hramiak I.
Eur Endocrinol. 2018 May;14(Suppl1):2-9. doi: 10.17925/EE.2018.14supp1.2. Epub 2018 May 11. Review.
PMID: 30034546
Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
Suzuki F, Hatanaka N, Bando E, Nakamura K, Komoto A.
Hepatol Int. 2018 May;12(3):244-253. doi: 10.1007/s12072-018-9872-z. Epub 2018 Jun 9.
PMID: 29900486
2017 Publications
Impact of CO 2 -solvent separators on the degradation of benzyl-2,3-dihydroxypiperidine-1-carboxylate during preparative supercritical fluid chromatographic (SFC) purification.
Asokan K, Naidu H, Madam R, Shaikh KM, Reddy M, Kumar H, Shirude PS, Rajendran M, Sarabu R, Wu DR, Bajpai L, Zhang Y.
J Chromatogr A. 2017 Dec 29;1530:176-184. doi: 10.1016/j.chroma.2017.11.025. Epub 2017 Nov 14.
PMID: 29162234
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nüßlein HG, Chartier M, Elbez Y, Rauch C, Le Bars M.
RMD Open. 2017 Dec 29;3(2):e000538. doi: 10.1136/rmdopen-2017-000538. eCollection 2017.
PMID: 29435360
Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD, Rollin L, Larkin J.
N Engl J Med. 2017 Dec 21;377(25):2503-2504. doi: 10.1056/NEJMc1714339. No abstract available.
PMID: 29262279
Identification of 5-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophene-2-Carboxamides as Novel and Selective Monoamine Oxidase B Inhibitors Used to Improve Memory and Cognition.
Kaplan AP, Keenan T, Scott R, Zhou X, Bourchouladze R, McRiner AJ, Wilson ME, Romashko D, Miller R, Bletsch M, Anderson G, Stanley J, Zhang A, Lee D, Nikpur J.
ACS Chem Neurosci. 2017 Dec 20;8(12):2746-2758. doi: 10.1021/acschemneuro.7b00282. Epub 2017 Sep 20.
PMID: 28857544
Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.
Jecs E, Miller EJ, Wilson RJ, Nguyen HH, Tahirovic YA, Katzman BM, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.
ACS Med Chem Lett. 2017 Dec 20;9(2):89-93. doi: 10.1021/acsmedchemlett.7b00406. eCollection 2018 Feb 8.
PMID: 29456793
Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.
Weed MR, Polino J, Signor L, Bookbinder M, Keavy D, Benitex Y, Morgan DG, King D, Macor JE, Zaczek R, Olson R, Bristow LJ.
PLoS One. 2017 Dec 19;12(12):e0187609. doi: 10.1371/journal.pone.0187609. eCollection 2017.
PMID: 29261656
Assessment and modelling of antibacterial combination regimens.
Rao GG, Li J, Garonzik SM, Nation RL, Forrest A.
Clin Microbiol Infect. 2017 Dec 18. pii: S1198-743X(17)30677-8. doi: 10.1016/j.cmi.2017.12.004. [Epub ahead of print] Review.
PMID: 29269090
Drug-target interactions that involve the replacement or displacement of magnesium ions.
Meanwell NA.
Bioorg Med Chem Lett. 2017 Dec 15;27(24):5355-5372. doi: 10.1016/j.bmcl.2017.11.002. Epub 2017 Nov 10. Review.
PMID: 29132752
Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
Neubauer AS, Minartz C, Herrmann KH, Baerwald CGO.
Clin Exp Rheumatol. 2017 Dec 15. [Epub ahead of print]
PMID: 29303709
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A.
Clin Pharmacol Ther. 2017 Dec 15. doi: 10.1002/cpt.983. [Epub ahead of print]
PMID: 29243231
Na V  channel variants in patients with painful and nonpainful peripheral neuropathy.
Wadhawan S, Pant S, Golhar R, Kirov S, Thompson J, Jacobsen L, Qureshi I, Ajroud-Driss S, Freeman R, Simpson DM, Smith AG, Hoke A, Bristow LJ.
Neurol Genet. 2017 Dec 15;3(6):e207. doi: 10.1212/NXG.0000000000000207. eCollection 2017 Dec.
PMID: 29264398
Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study.
Koretsune Y, Ikeda T, Kozuma K, Hirano T, Yasaka M, Kida M, Chachin M, Imura M.
Patient Prefer Adherence. 2017 Dec 15;11:1987-1996. doi: 10.2147/PPA.S152579. eCollection 2017.
PMID: 29290682
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
Pinto DJP, Orwat MJ, Smith LM 2nd, Quan ML, Lam PYS, Rossi KA, Apedo A, Bozarth JM, Wu Y, Zheng JJ, Xin B, Toussaint N, Stetsko P, Gudmundsson O, Maxwell B, Crain EJ, Wong PC, Lou Z, Harper TW, Chacko SA, Myers JE Jr, Sheriff S, Zhang H, Hou X, Mathur A, Seiffert DA, Wexler RR, Luettgen JM, Ewing WR.
J Med Chem. 2017 Dec 14;60(23):9703-9723. doi: 10.1021/acs.jmedchem.7b01171. Epub 2017 Nov 17.
PMID: 29077405
Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors.
Zhuo X, Wang YZ, Yeung KS, Zhu J, Huang XS, Parcella KE, Eastman KJ, Kadow JF, Meanwell NA, Shu YZ, Johnson BM.
Xenobiotica. 2017 Dec 12:1-12. doi: 10.1080/00498254.2017.1409915. [Epub ahead of print]
PMID: 29182424
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE.
J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.
PMID: 29023213
Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.
Wilson RJ, Jecs E, Miller EJ, Nguyen HH, Tahirovic YA, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Paiva AA, Schroeder GM, Wilson LJ, Liotta DC.
ACS Med Chem Lett. 2017 Dec 8;9(1):17-22. doi: 10.1021/acsmedchemlett.7b00381. eCollection 2018 Jan 11.
PMID: 29348805
Symptom Onset in Aortic Stenosis: Relation to Sex Differences in Left Ventricular Remodeling.
Singh A, Chan DCS, Greenwood JP, Dawson DK, Sonecki P, Hogrefe K, Kelly DJ, Dhakshinamurthy V, Lang CC, Khoo JP, Sprigings D, Steeds RP, Zhang R, Ford I, Jerosch-Herold M, Yang J, Li Z, Ng LL, McCann GP.
JACC Cardiovasc Imaging. 2017 Dec 8. pii: S1936-878X(17)30987-7. doi: 10.1016/j.jcmg.2017.09.019. [Epub ahead of print]
PMID: 29248646
Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH, Zhao J, Ptaszynska A.
J Diabetes. 2017 Dec 7. doi: 10.1111/1753-0407.12634. [Epub ahead of print]
PMID: 29215189
Codon-Directed Determination of the Biological Causes of Sequence Variants in Therapeutic Proteins.
Jiang T, Song H, Slaney TR, Wu W, Langsdorf E, Gupta G, Ludwig R, Tao L, McVey D, Das TK.
Anal Chem. 2017 Dec 5;89(23):12749-12755. doi: 10.1021/acs.analchem.7b02914. Epub 2017 Nov 14.
PMID: 29086552
Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
Mann J, Dressman J, Rosenblatt K, Ashworth L, Muenster U, Frank K, Hutchins P, Williams J, Klumpp L, Wielockx K, Berben P, Augustijns P, Holm R, Hofmann M, Patel S, Beato S, Ojala K, Tomaszewska I, Bruel JL, Butler J.
Mol Pharm. 2017 Dec 4;14(12):4192-4201. doi: 10.1021/acs.molpharmaceut.7b00198. Epub 2017 Aug 23.
PMID: 28737403
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Sevinsky H, Zaru L, Wang R, Xu X, Pikora C, Correll TA, Eley T.
Pediatr Infect Dis J. 2017 Dec 4. doi: 10.1097/INF.0000000000001855. [Epub ahead of print]
PMID: 29206748
Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study .
Gelderblom H, Judson IR, Benson C, Merimsky O, Grignani G, Katz D, Freivogel KW, Stein D, Jobanputra M, Mungul A, Manson SC, Sanfilippo R.
Acta Oncol. 2017 Dec;56(12):1769-1775. doi: 10.1080/0284186X.2017.1332779. Epub 2017 Jul 19.
PMID: 28723233
Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.
Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, Alexander JH, Lopes RD.
Am J Med. 2017 Dec;130(12):1440-1448.e1. doi: 10.1016/j.amjmed.2017.06.026. Epub 2017 Jul 21.
PMID: 28739198
Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP.
Am J Transplant. 2017 Dec;17(12):3219-3227. doi: 10.1111/ajt.14452. Epub 2017 Sep 5.
PMID: 28758341
2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays).
Gupta S, Richards S, Amaravadi L, Piccoli S, Desilva B, Pillutla R, Stevenson L, Mehta D, Carrasco-Triguero M, Neely R, Partridge M, Staack RF, Zhao X, Gorovits B, Kolaitis G, Sumner G, Stubenrauch KG, Zou L, Amur S, Beaver C, Berger I, Berisha F, Birnboeck H, Bower J, Cho SJ, Cludts I, Cocea L, Donato LD, Fischer S, Fraser S, Garofolo F, Haidar S, Haulenbeek J, Hottenstein C, Hu J, Ishii-Watabe A, Islam R, Jani D, Kadavil J, Kamerud J, Kramer D, Kurki P, MacMannis S, McNally J, Mullan A, Papadimitriou A, Pedras-Vasconcelos J, Ray S, Safavi A, Saito Y, Savoie N, Fjording MS, Scheibner K, Smeraglia J, Song A, Stouffer B, Tampal N, der Strate BV, Verch T, Welink J, Xu Y, Yang TY, Yengi L, Zeng J, Zhang Y, Zhang Y, Zoog S.
Bioanalysis. 2017 Dec;9(24):1967-1996. doi: 10.4155/bio-2017-4974. Epub 2017 Dec 5.
PMID: 29205064
2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies' inputs).
Neubert H, Song A, Lee A, Wei C, Duggan J, Xu K, Woolf E, Evans C, Palandra J, Laterza O, Amur S, Berger I, Bustard M, Cancilla M, Chen SC, Cho SJ, Ciccimaro E, Cludts I, Cocea L, D'Arienzo C, Danan-Leon L, Donato LD, Garofolo F, Haidar S, Ishii-Watabe A, Jiang H, Kadavil J, Kassim S, Kurki P, Blaye OL, Liu K, Mathews R, Lima Santos GM, Niwa M, Pedras-Vasconcelos J, Qian M, Rago B, Saad O, Saito Y, Savoie N, Su D, Szapacs M, Tampal N, Vinter S, Wang J, Welink J, Whale E, Wilson A, Xue YJ.
Bioanalysis. 2017 Dec;9(23):1895-1912. doi: 10.4155/bio-2017-4973. Epub 2017 Dec 5.
PMID: 29205053
Analytical considerations for quantitative LC-MS strategies for measuring antibody drug-target engagement in tissues.
Shipkova P, Ciccimaro E, Olah TV.
Bioanalysis. 2017 Dec;9(23):1845-1847. doi: 10.4155/bio-2017-0215. Epub 2017 Nov 24. No abstract available.
PMID: 29171760
CRISPR-DAV: CRISPR NGS data analysis and visualization pipeline.
Wang X, Tilford C, Neuhaus I, Mintier G, Guo Q, Feder JN, Kirov S.
Bioinformatics. 2017 Dec 1;33(23):3811-3812. doi: 10.1093/bioinformatics/btx518.
PMID: 28961906
Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads.
Donnell AF, Zhang Y, Stang EM, Wei DD, Tebben AJ, Perez HL, Schroeder GM, Pan C, Rao C, Borzilleri RM, Vite GD, Gangwar S.
Bioorg Med Chem Lett. 2017 Dec 1;27(23):5267-5271. doi: 10.1016/j.bmcl.2017.10.028. Epub 2017 Oct 16.
PMID: 29102228
Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR, Girgis NM, Yamada DH, Smith AA, Chan SR, Grewal IS, Quigley M, Verona RI.
Cancer Immunol Res. 2017 Dec;5(12):1109-1121. doi: 10.1158/2326-6066.CIR-17-0258. Epub 2017 Nov 2.
PMID: 29097420
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ.
Clin Mol Hepatol. 2017 Dec;23(4):331-339. doi: 10.3350/cmh.2016.0040. Epub 2017 Sep 26.
PMID: 28946736
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
D'Agostino MA, Alten R, Mysler E, Le Bars M, Ye J, Murthy B, Heitzmann J, Vadanici R, Ferraccioli G.
Clin Rheumatol. 2017 Dec;36(12):2655-2665. doi: 10.1007/s10067-017-3788-1. Epub 2017 Aug 18.
PMID: 28822046
Use of Hybrid Capillary Tube Apparatus on 400 MHz NMR for Quantitation of Crucial Low-Quantity Metabolites Using aSICCO Signal.
Tiwari R, Ahire D, Kumar H, Sinha S, Chauthe SK, Subramanian M, Iyer R, Sarabu R, Bajpai L.
Drug Metab Dispos. 2017 Dec;45(12):1215-1224. doi: 10.1124/dmd.117.077073. Epub 2017 Sep 21.
PMID: 28935657
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.
Eur Urol. 2017 Dec;72(6):962-971. doi: 10.1016/j.eururo.2017.02.010. Epub 2017 Mar 3. Erratum in:  Eur Urol. 2018 Jan 3;: .
PMID: 28262413
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.
J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.
PMID: 28915085
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA.
J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25.
PMID: 28841387
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016
Study.
Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A.
J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.
PMID: 28678668
Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.
Bajaj G, Gupta M, Feng Y, Statkevich P, Roy A.
J Clin Pharmacol. 2017 Dec;57(12):1527-1533. doi: 10.1002/jcph.962. Epub 2017 Aug 11. No abstract available.
PMID: 28800166
A mechanistic kinetic description of lactate dehydrogenase elucidating cancer diagnosis and inhibitor evaluation.
Tang P, Xu J, Oliveira CL, Li ZJ, Liu S.
J Enzyme Inhib Med Chem. 2017 Dec;32(1):564-571. doi: 10.1080/14756366.2016.1275606.
PMID: 28114833
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.
Kao JH, Yu ML, Peng CY, Heo J, Chu CJ, Chang TT, Lee YJ, Hu TH, Yoon KT, Paik SW, Lim YS, Ahn SH, Isakov V, McPhee F, Hu W, Scott Swenson E, Yin PD, Treitel M.
J Gastroenterol Hepatol. 2017 Dec;32(12):1998-2005. doi: 10.1111/jgh.13796.
PMID: 28370350
IL-17A-Induced PLET1 Expression Contributes to Tissue Repair and Colon Tumorigenesis.
Zepp JA, Zhao J, Liu C, Bulek K, Wu L, Chen X, Hao Y, Wang Z, Wang X, Ouyang W, Kalady MF, Carman J, Yang WP, Zhu J, Blackburn C, Huang YH, Hamilton TA, Su B, Li X.
J Immunol. 2017 Dec 1;199(11):3849-3857. doi: 10.4049/jimmunol.1601540. Epub 2017 Oct 25.
PMID: 29070673
Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs.
Di L, Breen C, Chambers R, Eckley ST, Fricke R, Ghosh A, Harradine P, Kalvass JC, Ho S, Lee CA, Marathe P, Perkins EJ, Qian M, Tse S, Yan Z, Zamek-Gliszczynski MJ.
J Pharm Sci. 2017 Dec;106(12):3442-3452. doi: 10.1016/j.xphs.2017.09.005. Epub 2017 Sep 18. Review.
PMID: 28927987
Preclinical Characterization of ( R )-3-((3 S ,4 S )-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate  N -Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.
Bristow LJ, Gulia J, Weed MR, Srikumar BN, Li YW, Graef JD, Naidu PS, Sanmathi C, Aher J, Bastia T, Paschapur M, Kalidindi N, Kumar KV, Molski T, Pieschl R, Fernandes A, Brown JM, Sivarao DV, Newberry K, Bookbinder M, Polino J, Keavy D, Newton A, Shields E, Simmermacher J, Kempson J, Li J, Zhang H, Mathur A, Kallem RR, Sinha M, Ramarao M, Vikramadithyan RK, Thangathirupathy S, Warrier J, Islam I, Bronson JJ, Olson RE, Macor JE, Albright CF, King D, Thompson LA, Marcin LR, Sinz M.
J Pharmacol Exp Ther. 2017 Dec;363(3):377-393. doi: 10.1124/jpet.117.242784. Epub 2017 Sep 27.
PMID: 28954811
Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.
Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, Singh A, Khiabanian H, Pine SR.
Mol Cancer Ther. 2017 Dec;16(12):2759-2769. doi: 10.1158/1535-7163.MCT-17-0439. Epub 2017 Oct 4.
PMID: 28978720
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
Gibson E, Koblbauer I, Begum N, Dranitsaris G, Liew D, McEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M.
Pharmacoeconomics. 2017 Dec;35(12):1257-1270. doi: 10.1007/s40273-017-0558-5.
PMID: 28866758
Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin.
Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D, Wallentin L, Granger CB, Alexander JH; ARISTOTLE Investigators.
Stroke. 2017 Dec;48(12):3266-3273. doi: 10.1161/STROKEAHA.117.017574. Epub 2017 Oct 31.
PMID: 29089455
The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma.
Shafrin J, Sullivan J, Chou JW, Neely MN, Doan JF, Maclean JR.
Cancer Manag Res. 2017 Nov 29;9:731-739. doi: 10.2147/CMAR.S148199. eCollection 2017.
PMID: 29238223
On evaluation of consistency in multi-regional clinical trials.
Ying L, Song F, Chow SC, Zeng N, Zheng J, Li X, Henry D, Sethuraman V.
J Biopharm Stat. 2017 Nov 28:1-17. doi: 10.1080/10543406.2017.1397008. [Epub ahead of print]
PMID: 29182430
Ligand-accelerated non-directed C-H functionalization of arenes.
Wang P, Verma P, Xia G, Shi J, Qiao JX, Tao S, Cheng PTW, Poss MA, Farmer ME, Yeung KS, Yu JQ.
Nature. 2017 Nov 22;551(7681):489-493. doi: 10.1038/nature24632.
PMID: 29168802
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.
J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.
PMID: 29162153
Measurement of cAMP for G αs - and G αi  Protein-Coupled Receptors (GPCRs).
Wang T, Li Z, Cvijic ME, Zhang L, Sum CS.
In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Hass JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2017 Nov 20.
PMID: 29165978
Measurement of β-Arrestin Recruitment for GPCR Targets.
Wang T, Li Z, Cvijic ME, Krause C, Zhang L, Sum CS.
In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Hass JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2017 Nov 20.
PMID: 29165975
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.
Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L.
J Clin Oncol. 2017 Nov 20;35(33):3753-3759. doi: 10.1200/JCO.2017.74.4102. Epub 2017 Oct 2.
PMID: 28968172
CITU: A Peptide and Decarboxylative Coupling Reagent.
deGruyter JN, Malins LR, Wimmer L, Clay KJ, Lopez-Ogalla J, Qin T, Cornella J, Liu Z, Che G, Bao D, Stevens JM, Qiao JX, Allen MP, Poss MA, Baran PS.
Org Lett. 2017 Nov 17;19(22):6196-6199. doi: 10.1021/acs.orglett.7b03121. Epub 2017 Nov 8.
PMID: 29115835
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
Fathi H, Clark A, Hill NR, Dusheiko G.
BMC Infect Dis. 2017 Nov 16;17(1):722. doi: 10.1186/s12879-017-2820-z. Review.
PMID: 29145802
Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation.
Durham TA, Hassmiller Lich K, Viera AJ, Fine JP, Mukherjee J, Weinberger M, Dusetzina SB.
Am J Cardiol. 2017 Nov 15;120(10):1820-1829. doi: 10.1016/j.amjcard.2017.07.091. Epub 2017 Aug 12.
PMID: 28867127
Imaged capillary isoelectric focusing in native condition: A novel and successful example.
Zhang X, Chemmalil L, Ding J, Mussa N, Li Z.
Anal Biochem. 2017 Nov 15;537:13-19. doi: 10.1016/j.ab.2017.08.014. Epub 2017 Aug 24.
PMID: 28844814
Design and synthesis of a novel series of (1'S,2R,4'S)-3H-4'-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2'-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor.
Cook J, Zusi FC, Hill MD, Fang H, Pearce B, Park H, Gallagher L, McDonald IM, Bristow L, Macor JE, Olson RE.
Bioorg Med Chem Lett. 2017 Nov 15;27(22):5002-5005. doi: 10.1016/j.bmcl.2017.10.009. Epub 2017 Oct 10.
PMID: 29050783
Identification and quantification of signal peptide variants in an IgG1 monoclonal antibody produced in mammalian cell lines.
Huang Y, Fu J, Ludwig R, Tao L, Bongers J, Ma L, Yao M, Zhu M, Das T, Russell R.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:193-200. doi: 10.1016/j.jchromb.2017.08.046. Epub 2017 Oct 12.
PMID: 29078145
Enablement of the direct analysis of excipients in monoclonal antibody formulations through the incorporation of a wide pore C18 protein trap with hydrophilic interaction liquid chromatography.
Huang JZ, Lin S, Huang Z, Bolgar MS.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:131-135. doi: 10.1016/j.jchromb.2017.10.034. Epub 2017 Oct 16.
PMID: 29059588
Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication.
Chapman S, Dale P, Svedsater H, Stynes G, Vyas N, Price D, Horne R.
NPJ Prim Care Respir Med. 2017 Nov 14;27(1):61. doi: 10.1038/s41533-017-0061-7.
PMID: 29138431
Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation.
Yin MT, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Overton ET; A5280 Study Team.
AIDS. 2017 Nov 13;31(17):2337-2344. doi: 10.1097/QAD.0000000000001621.
PMID: 28832406
Conformation Preservation of α-Helical Peptides within Supramolecular Filamentous Assemblies.
Li Y, Wang Y, Ou SH, Lock LL, Xu X, Ghose S, Li ZJ, Cui H.
Biomacromolecules. 2017 Nov 13;18(11):3611-3620. doi: 10.1021/acs.biomac.7b00992. Epub 2017 Sep 27.
PMID: 28891286
Catabolic Effects of Human PTH (1-34) on Bone: Requirement of Monocyte Chemoattractant Protein-1 in Murine Model of Hyperparathyroidism.
Siddiqui JA, Johnson J, Le Henaff C, Bitel CL, Tamasi JA, Partridge NC.
Sci Rep. 2017 Nov 10;7(1):15300. doi: 10.1038/s41598-017-15563-7.
PMID:29127344
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
PMID: 28891423
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.
Martyanov V, Kim GJ, Hayes W, Du S, Ganguly BJ, Sy O, Lee SK, Bogatkevich GS, Schieven GL, Schiopu E, Marangoni RG, Goldin J, Whitfield ML, Varga J.
PLoS One. 2017 Nov 9;12(11):e0187580. doi: 10.1371/journal.pone.0187580. eCollection 2017.
PMID: 29121645
Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.
Jia J, Tang H, Ning Q, Jiang J, Dou X, Zhang M, Zhang S, Shang J, Lu W, Ye Y, Wang X, Li M, Liu J, Bo Q, Tan W; EVOLVE Study Group.
Antivir Ther. 2017 Nov 8. doi: 10.3851/IMP. [Epub ahead of print]
PMID: 29116050
Transcriptome alterations of prefrontal cortical parvalbumin neurons in schizophrenia.
Enwright Iii JF, Huo Z, Arion D, Corradi JP, Tseng G, Lewis DA.
Mol Psychiatry. 2017 Nov 7. doi: 10.1038/mp.2017.216. [Epub ahead of print]
PMID: 29112193
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.
Cell. 2017 Nov 2;171(4):934-949.e15. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.
PMID: 29033130
Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.
Xue L, Clements-Egan A, Amaravadi L, Birchler M, Gorovits B, Liang M, Myler H, Purushothama S, Manning MS, Sung C.
AAPS J. 2017 Nov;19(6):1576-1586. doi: 10.1208/s12248-017-0153-x. Epub 2017 Nov 6.
PMID: 29110222
Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys.
Morse BL, MacGuire JG, Marino AM, Zhao Y, Fox M, Zhang Y, Shen H, Griffith Humphreys W, Marathe P, Lai Y.
AAPS J. 2017 Nov;19(6):1878-1889. doi: 10.1208/s12248-017-0151-z. Epub 2017 Oct 10.
PMID: 29019117
Recommendations for Selection and Characterization of Protein Biomarker Assay Calibrator Material.
Cowan KJ, Amaravadi L, Cameron MJ, Fink D, Jani D, Kamat M, King L, Neely RJ, Ni Y, Rhyne P, Riffon R, Zhu Y.
AAPS J. 2017 Nov;19(6):1550-1563. doi: 10.1208/s12248-017-0146-9. Epub 2017 Oct 2.
PMID: 28971363
How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective.
Gokemeijer J, Jawa V, Mitra-Kaushik S.
AAPS J. 2017 Nov;19(6):1587-1592. doi: 10.1208/s12248-017-0143-z. Epub 2017 Oct 2.
PMID: 28971356
Approaches for Establishing Clinically Relevant Dissolution Specifications for Immediate Release Solid Oral Dosage Forms.
Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, Mao Y, Zhang L, Webster GK, Lin Y, Hahn DA, Coutant CA, Grady H.
AAPS J. 2017 Nov;19(6):1537-1549. doi: 10.1208/s12248-017-0117-1. Epub 2017 Aug 22.
PMID: 28831727
Prevalence of Co-existing Autoimmune Disease in Rheumatoid Arthritis: A Cross-Sectional Study.
Simon TA, Kawabata H, Ray N, Baheti A, Suissa S, Esdaile JM.
Adv Ther. 2017 Nov;34(11):2481-2490. doi: 10.1007/s12325-017-0627-3. Epub 2017 Oct 24.
PMID: 29067557
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.
Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.
PMID:  28815757
2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines 'Scientific'? (Part 1 - LCMS: small molecules, peptides and small molecule biomarkers).
Welink J, Yang E, Hughes N, Rago B, Woolf E, Sydor J, Coppola L, Ackermann B, Li W, Alley SC, Arnold M, Berger I, Briscoe C, Buonarati M, Bustard M, Cancilla M, Cho SJ, Duggan J, Fraier D, Garofolo F, Green R, Haidar S, Hittle L, Ishii-Watabe A, Islam R, Jenkins R, Jones B, Kadavil J, Kassim S, Kavetska O, Blaye OL, Lee A, Liu H, Mehl J, Lima Santos GM, Musuku A, Ramanathan R, Saito Y, Savoie N, Summerfield S, Surapaneni S, Szapacs M, Tampal N, Verhaeghe T, Vinter S, Whale E.
Bioanalysis. 2017 Nov;9(22):1807-1825. doi: 10.4155/bio-2017-4975. Epub 2017 Nov 17.
PMID: 29148835
Enantioselective supercritical fluid chromatography-tandem mass spectrometry method for simultaneous estimation of risperidone and its 9-hydroxyl metabolites in rat plasma.
Prasad TR, Joseph S, Kole P, Kumar A, Subramanian M, Rajagopalan S, Kr P.
Bioanalysis. 2017 Nov;9(22):1739-1750. doi: 10.4155/bio-2017-0168. Epub 2017 Nov 9.
PMID: 29120220
The future of immunocapture-capillary electrophoresis-high resolution mass spectrometry.
Wang L, Dodge RW, Ji QC.
Bioanalysis. 2017 Nov;9(21):1627-1631. doi: 10.4155/bio-2017-4977. Epub 2017 Nov 2. No abstract available.
PMID: 29095042
Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.
Bioorg Med Chem Lett. 2017 Nov 1;27(21):4908-4913. doi: 10.1016/j.bmcl.2017.09.029. Epub 2017 Sep 18.
PMID: 28947151
pH variations during diafiltration due to buffer nonidealities.
Baek Y, Yang D, Singh N, Arunkumar A, Ghose S, Li ZJ, Zydney AL.
Biotechnol Prog. 2017 Nov;33(6):1555-1560. doi: 10.1002/btpr.2544. Epub 2017 Sep 4.
PMID: 28840650
Comparative study of therapeutic antibody candidates derived from mini-pool and clonal cell lines.
Fan L, Rizzi G, Bierilo K, Tian J, Yee JC, Russell R, Das TK.
Biotechnol Prog. 2017 Nov;33(6):1456-1462. doi: 10.1002/btpr.2477. Epub 2017 May 2.
PMID: 28393481
A Blueprint to Advance Colorectal Cancer Immunotherapies.
Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.
Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.
PMID: 29038296
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.
Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.
Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.
PMID: 29092942
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y.
Curr Med Res Opin. 2017 Nov;33(11):1955-1963. doi: 10.1080/03007995.2017.1374935. Epub 2017 Sep 12.
PMID: 28857611
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A.
Eur J Cancer. 2017 Nov;86:358-363. doi: 10.1016/j.ejca.2017.09.032. Epub 2017 Nov 5.
PMID: 29100190
Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.
Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P.
Eur J Health Econ. 2017 Nov;18(8):1001-1011. doi: 10.1007/s10198-016-0844-8. Epub 2016 Nov 1.
PMID:  27803989
A photochemical kinetic model for solid dosage forms.
Carvalho TC, La Cruz TE, Tábora JE.
Eur J Pharm Biopharm. 2017 Nov;120:63-72. doi: 10.1016/j.ejpb.2017.08.010. Epub 2017 Aug 20.
PMID: 28834735
Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.
Zhang MZ, Wang X, Yang H, Fogo AB, Murphy BJ, Kaltenbach R, Cheng P, Zinker B, Harris RC.
J Am Soc Nephrol. 2017 Nov;28(11):3300-3311. doi: 10.1681/ASN.2017010107. Epub 2017 Jul 24.
PMID: 28739650
Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.
Nadkarni A, McMorrow D, Patel C, Fowler R, Smith D.
J Comp Eff Res. 2017 Nov;6(8):671-682. doi: 10.2217/cer-2016-0090. Epub 2017 Aug 9.
PMID: 28791875
Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
Nadkarni A, McMorrow D, Fowler R, Smith D.
J Comp Eff Res. 2017 Nov;6(8):659-669. doi: 10.2217/cer-2017-0010. Epub 2017 Aug 9.
PMID: 28791873
A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines.
Zhao Q, Kim T, Pang J, Sun W, Yang X, Wang J, Song Y, Zhang H, Sun H, Rangan V, Deshpande S, Tang H, Cvijic ME, Westhouse R, Olah T, Xie J, Struthers M, Salter-Cid L.
J Leukoc Biol. 2017 Nov;102(5):1271-1280. doi: 10.1189/jlb.5A0717-302. Epub 2017 Sep 12.
PMID: 28899907
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J.
J Manag Care Spec Pharm. 2017 Nov;23(11):1191-1201. doi: 10.18553/jmcp.2017.17060. Epub 2017 Aug 11.
PMID: 29083968
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Saint-Laurent Thibault C, Moorjaney D, Ganz ML, Sill B, Hede S, Yuan Y, Gorsh B.
J Med Econ. 2017 Nov;20(11):1123-1125. doi: 10.1080/13696998.2017.1360313. Epub 2017 Aug 11. No abstract available.
PMID: 28745536
Understanding the Delamination Risk of a Trilayer Tablet Using Minipiloting Tools.
Tao J, Robertson-Lavalle S, Pandey P, Badawy S.
J Pharm Sci. 2017 Nov;106(11):3346-3352. doi: 10.1016/j.xphs.2017.07.005. Epub 2017 Jul 16.
PMID: 28720384
Mapping the Binding Interface in a Noncovalent Size Variant of a Monoclonal Antibody Using Native Mass Spectrometry, Hydrogen-Deuterium Exchange Mass Spectrometry, and Computational Analysis.
Yan Y, Wei H, Jusuf S, Krystek SR Jr, Chen J, Chen G, Ludwig RT, Tao L, Das TK.
J Pharm Sci. 2017 Nov;106(11):3222-3229. doi: 10.1016/j.xphs.2017.06.009. Epub 2017 Jun 17.
PMID: 28634122
Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y, Wang Z, Perlstein I, Wang J, LaCreta F, Frost RJA, Frost C.
J Thromb Haemost. 2017 Nov;15(11):2125-2137. doi: 10.1111/jth.13815. Epub 2017 Oct 9.
PMID: 28846831
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators.
Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876. doi: 10.1016/S2213-8587(17)30308-X. Epub 2017 Sep 14. Erratum in:  Lancet Diabetes Endocrinol. 2017 Dec;5(12 ):e8 .
PMID: 28919061
Forced degradation of recombinant monoclonal antibodies: A practical guide.
Nowak C, K Cheung J, M Dellatore S, Katiyar A, Bhat R, Sun J, Ponniah G, Neill A, Mason B, Beck A, Liu H.
MAbs. 2017 Nov/Dec;9(8):1217-1230. doi: 10.1080/19420862.2017.1368602. Epub 2017 Aug 30.
PMID: 28853987
Determination of process variables affecting drug particle attrition withinmulti-component blends during powder feed transmission.
Gamble JF, Dennis AB, Hutchins P, Jones JW, Musembi P, Tobyn M.
Pharm Dev Technol. 2017 Nov;22(7):904-909. doi: 10.1080/10837450.2016.1200616. Epub 2016 Jun 27.
PMID: 27344924
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.
Jin T, Lavoie H, Sahmi M, David M, Hilt C, Hammell A, Therrien M.
Nat Commun. 2017 Oct 31;8(1):1211. doi: 10.1038/s41467-017-01274-0.
PMID: 29084939
Lack of data sharing in observational studies.
McDonald L, Schultze A, Simpson A, Graham S, Wasiak R, Ramagopalan SV.
BMJ. 2017 Oct 24;359:j4866. doi: 10.1136/bmj.j4866. No abstract available.
PMID: 29066583
Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties.
Subbaiah MAM, Meanwell NA, Kadow JF.
Eur J Med Chem. 2017 Oct 20;139:865-883. doi: 10.1016/j.ejmech.2017.07.044. Epub 2017 Jul 22. Review.
PMID: 28865281
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.
J Clin Oncol. 2017 Oct 20;35(30):3449-3457. doi: 10.1200/JCO.2016.71.7629. Epub 2017 Aug 30.
PMID: 28854067
Societal preferences for adjuvant melanoma health states: UK and Australia.
Middleton MR, Atkins MB, Amos K, Wang PF, Kotapati S, Sabater J, Beusterien K.
BMC Cancer. 2017 Oct 17;17(1):689. doi: 10.1186/s12885-017-3673-y.
PMID: 29041898
Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
Burchill MA, Roby JA, Crochet N, Wind-Rotolo M, Stone AE, Edwards MG, Dran RJ, Kriss MS, Gale M Jr, Rosen HR.
PLoS One. 2017 Oct 17;12(10):e0186213. doi: 10.1371/journal.pone.0186213. eCollection 2017.
PMID: 29040318
Real-world data really matter.
McDonald L, Ramagopalan SV, Lees M.
CMAJ. 2017 Oct 16;189(41):E1293. doi: 10.1503/cmaj.733383. No abstract available.
PMID: 29038323
Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes.
Mariappan TT, Shen H, Marathe P.
Curr Drug Metab. 2017 Oct 16;18(8):757-768. doi: 10.2174/1389200218666170724110818.
PMID: 28738769
Discovery of non-zwitterionic aryl sulfonamides as Na v 1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.
Wu YJ, Guernon J, McClure A, Luo G, Rajamani R, Ng A, Easton A, Newton A, Bourin C, Parker D, Mosure K, Barnaby O, Soars MG, Knox RJ, Matchett M, Pieschl R, Herrington J, Chen P, Sivarao DV, Bristow LJ, Meanwell NA, Bronson J, Olson R, Thompson LA, Dzierba C.
Bioorg Med Chem. 2017 Oct 15;25(20):5490-5505. doi: 10.1016/j.bmc.2017.08.012. Epub 2017 Aug 9
PMID: 28818462
Radiosynthesis and preclinical PET evaluation of  89 Zr-nivolumab (BMS-936558) in healthy non-human primates.
Cole EL, Kim J, Donnelly DJ, Smith RA, Cohen D, Lafont V, Morin PE, Huang RY, Chow PL, Hayes W, Bonacorsi S Jr..
Bioorg Med Chem. 2017 Oct 15;25(20):5407-5414. doi: 10.1016/j.bmc.2017.07.066. Epub 2017 Aug 4.
PMID: 28803798
Discovery of highly potent, selective, covalent inhibitors of JAK3.
Kempson J, Ovalle D, Guo J, Wrobleski ST, Lin S, Spergel SH, Duan JJ, Jiang B, Lu Z, Das J, Yang BV, Hynes J Jr, Wu H, Tokarski J, Sack JS, Khan J, Schieven G, Blatt Y, Chaudhry C, Salter-Cid LM, Fura A, Barrish JC, Carter PH, Pitts WJ.
Bioorg Med Chem Lett. 2017 Oct 15;27(20):4622-4625. doi: 10.1016/j.bmcl.2017.09.023. Epub 2017 Sep 11.
PMID: 28927786
Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark.
Poulsen PB, Johnsen SP, Hansen ML, Brandes A, Husted S, Harboe L, Dybro L.
Clinicoecon Outcomes Res. 2017 Oct 13;9:617-627. doi: 10.2147/CEOR.S145813. eCollection 2017.
PMID: 29066923
Characteristic rotational behaviors of rod-shaped cargo revealed by automated five-dimensional single particle tracking.
Chen K, Gu Y, Sun W, Bin Dong, Wang G, Fan X, Xia T, Fang N.
Nat Commun. 2017 Oct 12;8(1):887. doi: 10.1038/s41467-017-01001-9.
PMID: 29026088
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy.
Sangiorgi D, Perrone V, Buda S, Boglione L, Cariti G, Lefevre C, Nappi C, Degli Esposti L.
Clinicoecon Outcomes Res. 2017 Oct 10;9:609-616. doi: 10.2147/CEOR.S136456. eCollection 2017.
PMID:  29066922
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G, Maguire A.
PLoS One. 2017 Oct 10;12(10):e0185642. doi: 10.1371/journal.pone.0185642. eCollection 2017.
PMID: 29016695
IRAK2 directs stimulus-dependent nuclear export of inflammatory mRNAs.
Zhou H, Bulek K, Li X, Herjan T, Yu M, Qian W, Wang H, Zhou G, Chen X, Yang H, Hong L, Zhao J, Qin L, Fukuda K, Flotho A, Gao J, Dongre A, Carman JA, Kang Z, Su B, Kern TS, Smith JD, Hamilton TA, Melchior F, Fox PL, Li X.
Elife. 2017 Oct 9;6. pii: e29630. doi: 10.7554/eLife.29630.
PMID: 28990926
Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
Szabo SM, Hirji I, Johnston KM, Juarez-Garcia A, Connors JM.
PLoS One. 2017 Oct 9;12(10):e0180261. doi: 10.1371/journal.pone.0180261. eCollection 2017.
PMID: 28991893
Development of the Large-Scale Synthesis of Tetrahydropyran Glycine, a Precursor to the HCV NS5A Inhibitor BMS-986097.
Mathur A, Wang B, Smith D, Li J, Pawluczyk J, Sun JH, Wong MK, Krishnananthan S, Wu DR, Sun D, Li P, Yip S, Chen BC, Baran PS, Chen Q, Lopez OD, Yong Z, Bender JA, Nguyen VN, Romine JL, Laurent DRS, Wang G, Kadow JF, Meanwell NA, Belema M, Zhao R.
J Org Chem. 2017 Oct 6;82(19):10376-10387. doi: 10.1021/acs.joc.7b01852. Epub 2017 Sep 14.
PMID: 28877441
A Mild, Functional Group Tolerant Addition of Organozinc Nucleophiles to N-Activated Quinolines and Isoquinolines.
Luzung MR, Dixon DD, Ortiz A, Guerrero CA, Ayers S, Ho J, Schmidt MA, Strotman NA, Eastgate MD.
J Org Chem. 2017 Oct 6;82(19):10715-10721. doi: 10.1021/acs.joc.7b01882. Epub 2017 Sep 7.
PMID: 28809492
Synergistic inhibition of Aβ production by combinations of γ-secretase modulators.
Robertson AS, Iben LG, Wei C, Meredith JE Jr, Drexler DM, Banks M, Vite GD, Olson RE, Thompson LA, Albright CF, Ahlijanian MK, Toyn JH.
Eur J Pharmacol. 2017 Oct 5;812:104-112. doi: 10.1016/j.ejphar.2017.07.019. Epub 2017 Jul 8.
PMID: 28690193
A polychromatic turbidity microplate assay to distinguish discovery stage drug molecules with beneficial precipitation properties.
Morrison J, Nophsker M, Elzinga P, Donoso M, Park H, Haskell R.
Int J Pharm. 2017 Oct 5;531(1):24-34. doi: 10.1016/j.ijpharm.2017.07.086. Epub 2017 Aug 7.
PMID: 28797968
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
PMID: 28889792
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models.
Lewis KE, Selby MJ, Masters G, Valle J, Dito G, Curtis WR, Garcia R, Mink KA, Waggie KS, Holdren MS, Grosso JF, Korman AJ, Jure-Kunkel M, Dillon SR.
Oncoimmunology. 2017 Oct 4;7(1):e1377873. doi: 10.1080/2162402X.2017.1377873. eCollection 2017.
PMID: 29296539
Standard Curves Are Necessary to Determine Pharmacological Properties for Ligands in Functional Assays Using Competition Binding Technologies.
Burford NT, Watson J, Alt A.
Assay Drug Dev Technol. 2017 Oct/Nov;15(7):320-329. doi: 10.1089/adt.2017.811.
PMID: 29120673
Immunoaffinity LC-MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker.
Zhang H, Gu H, Shipkova P, Ciccimaro E, Sun H, Zhao Q, Olah TV.
Bioanalysis. 2017 Oct;9(20):1573-1588. doi: 10.4155/bio-2017-0152. Epub 2017 Oct 26.
PMID: 29072496
Spotting of external calibration standards on blank dried blood spots as a resource-sparing protocol.
Nigam A, Kole P, Kurawattimath V, Mandlekar S, Subramanian M.
Bioanalysis. 2017 Oct;9(19):1441-1450. doi: 10.4155/bio-2017-0143. Epub 2017 Oct 21.
PMID: 29056076
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M.
Clin Cancer Res. 2017 Oct 1;23(19):5671-5678. doi: 10.1158/1078-0432.CCR-17-0025. Epub 2017 Jun 27.
PMID: 28655793
Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States.
Coutinho AD, Makenbaeva D, Farrelly E, Landsman-Blumberg PB, Lenihan D.
Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):676-683. doi: 10.1016/j.clml.2017.06.011. Epub 2017 Jun 17.
PMID: 28729178
Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, Ueno T, Hughes E, Bertz R, Garimella T, AbuTarif M.
Clin Pharmacokinet. 2017 Oct;56(10):1173-1183. doi: 10.1007/s40262-016-0504-2.
PMID: 28066880
Coccidioidomycosis in an Indoor-housed Rhesus Macaque ( Macaca mulatta ).
Kundu MC, Ringenberg MA, d'Epagnier DL, Haag HL, Maguire S.
Comp Med. 2017 Oct 1;67(5):452-455.
PMID: 28935008
Model-based Meta-Analysis on the Efficacy of Pharmacological Treatments for Idiopathic Pulmonary Fibrosis.
Chan P, Bax L, Chen C, Zhang N, Huang SP, Soares H, Rosen G, AbuTarif M.
CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):695-704. doi: 10.1002/psp4.12227. Epub 2017 Sep 7.
PMID: 28699195
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J.
Curr Med Res Opin. 2017 Oct;33(10):1745-1754. doi: 10.1080/03007995.2017.1334638. Epub 2017 Aug 29.
PMID: 28849676
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
Wong H, Bohnert T, Damian-Iordache V, Gibson C, Hsu CP, Krishnatry AS, Liederer BM, Lin J, Lu Q, Mettetal JT, Mudra DR, Nijsen MJMA, Schroeder P, Schuck E, Suryawanshi S, Trapa P, Tsai A, Wang H, Wu F.
Drug Discov Today. 2017 Oct;22(10):1447-1459. doi: 10.1016/j.drudis.2017.04.015. Epub 2017 May 2.
PMID: 28476536
Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.
Hariparsad N, Ramsden D, Palamanda J, Dekeyser JG, Fahmi OA, Kenny JR, Einolf H, Mohutsky M, Pardon M, Siu YA, Chen L, Sinz M, Jones B, Walsky R, Dallas S, Balani SK, Zhang G, Buckley D, Tweedie D.
Drug Metab Dispos. 2017 Oct;45(10):1049-1059. doi: 10.1124/dmd.116.074567. Epub 2017 Jun 23.
PMID: 28646080
Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.
Ewart L, Fabre K, Chakilam A, Dragan Y, Duignan DB, Eswaraka J, Gan J, Guzzie-Peck P, Otieno M, Jeong CG, Keller DA, de Morais SM, Phillips JA, Proctor W, Sura R, Van Vleet T, Watson D, Will Y, Tagle D, Berridge B.
Exp Biol Med (Maywood). 2017 Oct;242(16):1579-1585. doi: 10.1177/1535370217715441. Epub 2017 Jun 16.
PMID: 28622731
Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE, Cotreau M, Han TH, Gupta M.
J Clin Pharmacol. 2017 Oct;57 Suppl 10:S11-S25. doi: 10.1002/jcph.981.
PMID: 28921650
Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Sheng J, Srivastava S, Sanghavi K, Lu Z, Schmidt BJ, Bello A, Gupta M.
J Clin Pharmacol. 2017 Oct;57 Suppl 10:S26-S42. doi: 10.1002/jcph.990.
PMID: 28921644
The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation.
Wang DD, Yu Y, Kassir N, Zhu M, Hanley WD, Earp JC, Chow AT, Gupta M, Hu C.
J Clin Pharmacol. 2017 Oct;57(10):1268-1278. doi: 10.1002/jcph.921. Epub 2017 May 17.
PMID: 28513856
Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, Jawa V.
J Pharm Sci. 2017 Oct;106(10):2946-2954. doi: 10.1016/j.xphs.2017.05.030. Epub 2017 May 31. Review.
PMID: 28576695
Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T, Kaneko H, Mishina S, Wang F, Morita S.
J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2102-2110. doi: 10.1016/j.jstrokecerebrovasdis.2017.04.030. Epub 2017 May 19.
PMID: 28532651
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Mariette X, Alten R, Nüßlein HG, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.
Joint Bone Spine. 2017 Oct;84(5):571-576. doi: 10.1016/j.jbspin.2016.10.011. Epub 2016 Dec 30.
PMID: 28043761
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.
Pancera M, Lai YT, Bylund T, Druz A, Narpala S, O'Dell S, Schön A, Bailer RT, Chuang GY, Geng H, Louder MK, Rawi R, Soumana DI, Finzi A, Herschhorn A, Madani N, Sodroski J, Freire E, Langley DR, Mascola JR, McDermott AB, Kwong PD.
Nat Chem Biol. 2017 Oct;13(10):1115-1122. doi: 10.1038/nchembio.2460. Epub 2017 Aug 21.
PMID: 28825711
A functional genomics predictive network model identifies regulators of inflammatory bowel disease.
Peters LA, Perrigoue J, Mortha A, Iuga A, Song WM, Neiman EM, Llewellyn SR, Di Narzo A, Kidd BA, Telesco SE, Zhao Y, Stojmirovic A, Sendecki J, Shameer K, Miotto R, Losic B, Shah H, Lee E, Wang M, Faith JJ, Kasarskis A, Brodmerkel C, Curran M, Das A, Friedman JR, Fukui Y, Humphrey MB, Iritani BM, Sibinga N, Tarrant TK, Argmann C, Hao K, Roussos P, Zhu J, Zhang B, Dobrin R, Mayer LF, Schadt EE.
Nat Genet. 2017 Oct;49(10):1437-1449. doi: 10.1038/ng.3947. Epub 2017 Sep 11.
PMID: 28892060
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen CJ, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Sum Kenneth Li W, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M.
Oral Oncol. 2017 Oct;73:138-146. doi: 10.1016/j.oraloncology.2017.07.023. Epub 2017 Sep 1.
PMID: 28939066
Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatment.
Srikumar BN, Paschapur M, Kalidindi N, Adepu B, Das ML, Sreedhara MV, Kuchibhotla VK, Pieschl RL, Li YW, Ega DSP, Louis JV, Murugesan S, Naidu PS, Ramarao M, Bristow LJ, Vikramadithyan RK.
Pharmacol Biochem Behav. 2017 Oct;161:53-61. doi: 10.1016/j.pbb.2017.09.003. Epub 2017 Sep 11.
PMID: 28911960
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D.
Clinicoecon Outcomes Res. 2017 Sep 27;9:569-571. doi: 10.2147/CEOR.S143377. eCollection 2017. No abstract available.
PMID: 29026324
Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.
LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C.
AIDS. 2017 Sep 24;31(15):2095-2106. doi: 10.1097/QAD.0000000000001594.
PMID: 28692532
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).
Azpilikueta A, Bolaños E, Lang V, Labiano S, Aznar MA, Etxeberria I, Teijeira A, Rodriguez-Ruiz ME, Perez-Gracia JL, Jure-Kunkel M, Zapata JM, Rodriguez MS, Melero I.
Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017.
PMID: 29296520
Unintended consequences of machine learning in medicine?
McDonald L, Ramagopalan SV, Cox AP, Oguz M.
F1000Res. 2017 Sep 19;6:1707. doi: 10.12688/f1000research.12693.1. eCollection 2017.
PMID: 29250316
A review of data sharing statements in observational studies published in the BMJ: A cross-sectional study.
McDonald L, Schultze A, Simpson A, Graham S, Wasiak R, Ramagopalan SV.
Version 2. F1000Res. 2017 Sep 19 [revised 2017 Jan 1];6:1708. doi: 10.12688/f1000research.12673.2. eCollection 2017.
PMID: 29167735
Decarboxylative Alkynylation.
Smith JM, Qin T, Merchant RR, Edwards JT, Malins LR, Liu Z, Che G, Shen Z, Shaw SA, Eastgate MD, Baran PS.
Angew Chem Int Ed Engl. 2017 Sep 18;56(39):11906-11910. doi: 10.1002/anie.201705107. Epub 2017 Aug 1.
PMID: 28636185
Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.
Lee MH, Huang YH, Chen HY, Khor SS, Chang YH, Lin YJ, Jen CL, Lu SN, Yang HI, Nishida N, Sugiyama M, Mizokami M, Yuan Y, L'Italien G, Tokunaga K, Chen CJ; REVEAL-HCV Cohort Study Group.
Hepatology. 2017 Sep 16. doi: 10.1002/hep.29531. [Epub ahead of print]
PMID: 28921602
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, Finckenstein FG, Park JS, Roy A.
Clin Cancer Res. 2017 Sep 15;23(18):5394-5405. doi: 10.1158/1078-0432.CCR-16-2842.
PMID: 28916617
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Pollack PS, Chadwick KD, Smith DM, Billger M, Hirshberg B, Iqbal N, Boulton DW.
Cardiovasc Diabetol. 2017 Sep 13;16(1):113. doi: 10.1186/s12933-017-0595-6. Review.
PMID: 28903775
Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme.
Goods BA, Hernandez AL, Lowther DE, Lucca LE, Lerner BA, Gunel M, Raddassi K, Coric V, Hafler DA, Love JC.
PLoS One. 2017 Sep 7;12(9):e0181538. doi: 10.1371/journal.pone.0181538. eCollection 2017.
PMID: 28880903
Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.
Chang RK, Mathias N, Hussain MA.
AAPS J. 2017 Sep;19(5):1348-1358. doi: 10.1208/s12248-017-0112-6. Epub 2017 Jul 5.
PMID: 28681160
The Impact of Disintegrant Type, Surfactant, and API Properties on the Processability and Performance of Roller Compacted Formulations of Acetaminophen and Aspirin.
Zhao J, Koo O, Pan D, Wu Y, Morkhade D, Rana S, Saha P, Marin A.
AAPS J. 2017 Sep;19(5):1387-1395. doi: 10.1208/s12248-017-0104-6. Epub 2017 Jun 12.
PMID: 28608238
Singlicate Ligand Binding Assay Using an Automated Microfluidic System: a Clinical Case Study.
Jiang H, Kozhich A, Cummings J, Gambardella J, Zambito F, Titsch C, Haulenbeek J, Phillips K, Fergus R, Myler H.
AAPS J. 2017 Sep;19(5):1461-1468. doi: 10.1208/s12248-017-0105-5. Epub 2017 Jun 6.
PMID: 28589510
Belatacept-Resistant Rejection Is Associated With CD28 +  Memory CD8 T Cells.
Mathews DV, Wakwe WC, Kim SC, Lowe MC, Breeden C, Roberts ME, Farris AB, Strobert EA, Jenkins JB, Larsen CP, Ford ML, Townsend R, Adams AB.
Am J Transplant. 2017 Sep;17(9):2285-2299. doi: 10.1111/ajt.14349. Epub 2017 Jul 11.
PMID: 28502128
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.
Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.
PMID: 28473423
Technologies and strategies for bioanalysis of biopharmaceuticals.
Zhang YJ, An HJ.
Bioanalysis. 2017 Sep;9(18):1343-1347. doi: 10.4155/bio-2017-4981. No abstract available.
PMID: 28956635
Challenges and opportunities in bioanalytical support for gene therapy medicinal product development.
Ma M, Balasubramanian N, Dodge R, Zhang Y.
Bioanalysis. 2017 Sep;9(18):1423-1430. doi: 10.4155/bio-2017-0116. Epub 2017 Sep 18.
PMID: 28920452
Macrocyclic factor XIa inhibitors.
Wang C, Corte JR, Rossi KA, Bozarth JM, Wu Y, Sheriff S, Myers JE Jr, Luettgen JM, Seiffert DA, Wexler RR, Quan ML.
Bioorg Med Chem Lett. 2017 Sep 1;27(17):4056-4060. doi: 10.1016/j.bmcl.2017.07.048. Epub 2017 Jul 25.
PMID: 28780160
Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: Effects of physical properties.
Baek Y, Singh N, Arunkumar A, Borys M, Li ZJ, Zydney AL.
Biotechnol Bioeng. 2017 Sep;114(9):2057-2065. doi: 10.1002/bit.26326. Epub 2017 May 18.
PMID: 28464237
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P.
Br J Haematol. 2017 Sep;178(6):896-905. doi: 10.1111/bjh.14787. Epub 2017 Jul 5.
PMID: 28677826
Focused microwave irradiation-assisted immunohistochemistry to study effects of ketamine on phospho-ERK expression in the mouse brain.
Fernandes A, Li YW.
Brain Res. 2017 Sep 1;1670:86-95. doi: 10.1016/j.brainres.2017.05.008. Epub 2017 May 10.
PMID: 28501494
Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study.
Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG.
Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15.
PMID: 28419856
Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.
Hamuro L, Chan P, Tirucherai G, AbuTarif M.
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):596-603. doi: 10.1002/psp4.12220. Epub 2017 Aug 29.
PMID: 28643370
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Deitelzweig S, Farmer C, Luo X, Vo L, Li X, Hamilton M, Horblyuk R, Ashaye A.
Curr Med Res Opin. 2017 Sep;33(9):1583-1594. doi: 10.1080/03007995.2017.1347090. Epub 2017 Jul 6. Review.
PMID: 28644048
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L.
Curr Med Res Opin. 2017 Sep;33(9):1595-1604. doi: 10.1080/03007995.2017.1345729. Epub 2017 Jul 11.
PMID: 28635338
Health-related quality of life results from the phase III CheckMate 067 study.
Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV.
Eur J Cancer. 2017 Sep;82:80-91. doi: 10.1016/j.ejca.2017.05.031. Epub 2017 Jun 23.
PMID: 28651159
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S.
Eur Urol. 2017 Sep;72(3):368-376. doi: 10.1016/j.eururo.2017.03.037. Epub 2017 Apr 12.
PMID:28410865
Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study.
Lai TS, Lee MH, Yang HI, You SL, Lu SN, Wang LY, Yuan Y, L'Italien G, Chien KL, Chen CJ; REVEAL-HCV Study Group.
Hepatology. 2017 Sep;66(3):784-793. doi: 10.1002/hep.29192. Epub 2017 Jul 18.
PMID: 28370058
A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials.
Young TC, Srinivasan S, Vetter ML, Sethuraman V, Bhagwagar Z, Zwirtes R, Narasimhan P, Chuang T, Smyth BJ.
J Clin Pharmacol. 2017 Sep;57(9):1079-1087. doi: 10.1002/jcph.913. Epub 2017 May 16.
PMID: 28510323
Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetReal.
Makady A, Stegenga H, Ciaglia A, Debray TP, Lees M, Happich M, Ryll B, Abrams K, Thwaites R, Garner S, Jonsson P, Goettsch W.
J Comp Eff Res. 2017 Sep;6(6):485-490. doi: 10.2217/cer-2017-0044. Epub 2017 Aug 31.
PMID: 28857631
A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
Kavita U, Duo J, Crawford SM, Liu R, Valcin J, Gleason C, Dong H, Gadkari S, Dodge RW, Pillutla RC, DeSilva BS.
J Immunol Methods. 2017 Sep;448:91-104. doi: 10.1016/j.jim.2017.06.002. Epub 2017 Jun 16.
PMID: 28625864
Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva D.
J Med Econ. 2017 Sep;20(9):1007-1012. doi: 10.1080/13696998.2017.1345750. Epub 2017 Jul 6.
PMID: 28681664
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J, Trocio J, Gupta K, Mardekian J, Lingohr-Smith M, Menges B, You M, Nadkarni A.
J Med Econ. 2017 Sep;20(9):952-961. doi: 10.1080/13696998.2017.1341902. Epub 2017 Jun 22.
PMID: 28604139
Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.
Kunos CA, Galanis E, Buchsbaum J, Shi Q, Strauss LC, Coleman CN, Ahmed MM.
J Neurooncol. 2017 Sep;134(3):551-557. doi: 10.1007/s11060-017-2458-0. Epub 2017 May 30. Review.
PMID: 28560665
Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone.
Cheng Y, Chen S, Freeden C, Chen W, Zhang Y, Abraham P, Nelson DM, Humphreys WG, Gan J, Lai Y.
J Pharmacol Exp Ther. 2017 Sep;362(3):385-394. doi: 10.1124/jpet.117.242370. Epub 2017 Jun 23.
PMID: 28645914
High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease.
Lai TS, Lee MH, Yang HI, You SL, Lu SN, Wang LY, Yuan Y, L'Italien G, Chien KL, Chen CJ; REVEAL-HCV Study Group.
Kidney Int. 2017 Sep;92(3):703-709. doi: 10.1016/j.kint.2017.03.021. Epub 2017 May 20.
PMID: 28532708
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.
Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.
PMID: 28734759
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H, D'Alteroche L, Leroy V, Bourliere M, Hubert-Fouchard I, Guyader D, Rosa I, Nguyen-Khac E, Fedchuk L, Akremi R, Bennai Y, Filipovics A, Zhao Y, Bronowicki JP.
Liver Int. 2017 Sep;37(9):1314-1324. doi: 10.1111/liv.13383. Epub 2017 Mar 8.
PMID: 28177199
A Functional Na V 1.7-Na V Ab Chimera with a Reconstituted High-Affinity ProTx-II Binding Site.
Rajamani R, Wu S, Rodrigo I, Gao M, Low S, Megson L, Wensel D, Pieschl RL, Post-Munson DJ, Watson J, Langley DR, Ahlijanian MK, Bristow LJ, Herrington J.
Mol Pharmacol. 2017 Sep;92(3):310-317. doi: 10.1124/mol.117.108712. Epub 2017 Jun 23.
PMID: 28645932
Mold Control and Detection in Biological Drug Substance Manufacturing Facilities: An Industry Perspective.
Bawa A, Asefi S, Ramsey S, Arbesser-Rastburg C, Paul M, Leira F, Landeryou T, Reddy B, Murphy M, Daddis B, Bain D.
PDA J Pharm Sci Technol. 2017 Sep-Oct;71(5):413-420. doi: 10.5731/pdajpst.2016.007351. Epub 2017 Jun 16.
PMID: 28624776
Small Molecule PET Tracers in Drug Discovery.
Donnelly DJ.
Semin Nucl Med. 2017 Sep;47(5):454-460. doi: 10.1053/j.semnuclmed.2017.05.006. Review.
PMID: 28826520
Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome.
Trachtman H, Gipson DS, Somers M, Spino C, Adler S, Holzman L, Kopp JB, Sedor J, Overfield S, Elegbe A, Maldonado M, Greka A.
Kidney Int Rep. 2017 Aug 31;3(1):115-121. doi: 10.1016/j.ekir.2017.08.013. eCollection 2018 Jan.
PMID: 29340321
Discrete particle modeling and micromechanical characterization of bilayer tablet compaction.
Yohannes B, Gonzalez M, Abebe A, Sprockel O, Nikfar F, Kiang S, Cuitiño AM.
Int J Pharm. 2017 Aug 30;529(1-2):597-607. doi: 10.1016/j.ijpharm.2017.07.032. Epub 2017 Jul 13.
PMID: 28713000
Palladium(II)-Catalyzed Site-Selective C(sp 3  )-H Alkynylation of Oligopeptides: A Linchpin Approach for Oligopeptide-Drug
Conjugation.
Liu T, Qiao JX, Poss MA, Yu JQ.
Angew Chem Int Ed Engl. 2017 Aug 28;56(36):10924-10927. doi: 10.1002/anie.201706367. Epub 2017 Aug 7.
PMID: 28714148
Improving Accuracy, Diversity, and Speed with Prime Macrocycle Conformational Sampling.
Sindhikara D, Spronk SA, Day T, Borrelli K, Cheney DL, Posy SL.
J Chem Inf Model. 2017 Aug 28;57(8):1881-1894. doi: 10.1021/acs.jcim.7b00052. Epub 2017 Aug 8.
PMID: 28727915
Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).
Chouaïd C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin AF, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté FE, Souquet PJ.
PLoS One. 2017 Aug 25;12(8):e0182798. doi: 10.1371/journal.pone.0182798. eCollection 2017.
PMID: 28841679
The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature.
Enstone A, Greaney M, Povsic M, Wyn R, Penrod JR, Yuan Y.
Pharmacoecon Open. 2017 Aug 18. doi: 10.1007/s41669-017-0045-0. [Epub ahead of print] Review.
PMID: 29623624
An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register.
Carroll R, Ramagopalan SV, Cid-Ruzafa J, Lambrelli D, McDonald L.
Version 2. F1000Res. 2017 Aug 14 [revised 2017 Jan 1];6:1447. doi: 10.12688/f1000research.12198.2. eCollection 2017.
PMID: 29188016
Downstream Processing Technologies/Capturing and Final Purification : Opportunities for Innovation, Change, and Improvement. A Review of Downstream Processing Developments in Protein Purification.
Singh N, Herzer S.
Adv Biochem Eng Biotechnol. 2017 Aug 10. doi: 10.1007/10_2017_12. [Epub ahead of print]
PMID: 28795201
Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
Fernandes J, Bregman B, Combemale P, Amaz C, de Léotoing L, Vainchtock A, Gaudin AF.
BMC Health Serv Res. 2017 Aug 8;17(1):542. doi: 10.1186/s12913-017-2472-0.
PMID: 28789648
Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.
Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR.
Viruses. 2017 Aug 7;9(8). pii: E212. doi: 10.3390/v9080212.
PMID: 28783119
Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.
Briggs AH, Bhatt DL, Scirica BM, Raz I, Johnston KM, Szabo SM, Bergenheim K, Mukherjee J, Hirshberg B, Mosenzon O.
Diabetes Res Clin Pract. 2017 Aug;130:24-33. doi: 10.1016/j.diabres.2016.12.019. Epub 2017 Jan 23.
PMID: 28554140
An improved protocol for amino acid type-selective isotope labeling in insect cells.
Zhang Y, Wei H, Xie D, Calambur D, Douglas A, Gao M, Marsilio F, Metzler WJ, Szapiel N, Zhang P, Witmer MR, Mueller L, Hedin D.
J Biomol NMR. 2017 Aug;68(4):237-247. doi: 10.1007/s10858-017-0117-6. Epub 2017 Jul 15.
PMID: 28711957
Chromatoprobe as a sample-sparing technique for residual solvent analysis of drug discovery candidates by gas chromatography.
Poronsky CJ, Cutrone JQ.
J Pharm Anal. 2017 Aug;7(4):265-269. doi: 10.1016/j.jpha.2017.03.009. Epub 2017 Apr 3.
PMID: 29404048
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.
Bandyopadhyay S, Connolly SE, Jabado O, Ye J, Kelly S, Maldonado MA, Westhovens R, Nash P, Merrill JT, Townsend RM.
Lupus Sci Med. 2017 Jul 28;4(1):e000206. doi: 10.1136/lupus-2017-000206. eCollection 2017.
PMID: 29214034
Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, Szustakowski JD.
PLoS One. 2017 Jul 27;12(7):e0179726. doi: 10.1371/journal.pone.0179726. eCollection 2017.
PMID: 28749946
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
Gillooly KM, Pulicicchio C, Pattoli MA, Cheng L, Skala S, Heimrich EM, McIntyre KW, Taylor TL, Kukral DW, Dudhgaonkar S, Nagar J, Banas D, Watterson SH, Tino JA, Fura A, Burke JR.
PLoS One. 2017 Jul 24;12(7):e0181782. doi: 10.1371/journal.pone.0181782. eCollection 2017.
PMID: 28742141
Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.
Burack WR, Spence JM, Spence JP, Spence SA, Rock PJ, Shenoy GN, Shultz LD, Bankert RB, Bernstein SH.
Blood Adv. 2017 Jul 7;1(16):1263-1273. doi: 10.1182/bloodadvances.2017005892. eCollection 2017 Jul 11.
PMID: 29296768
Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor.
Parcella K, Eastman K, Yeung KS, Grant-Young KA, Zhu J, Wang T, Zhang Z, Yin Z, Parker D, Mosure K, Fang H, Wang YK, Lemm J, Zhuo X, Hanumegowda U, Liu M, Rigat K, Donoso M, Tuttle M, Zvyaga T, Haarhoff Z, Meanwell NA, Soars MG, Roberts SB, Kadow JF.
ACS Med Chem Lett. 2017 Jun 29;8(7):771-774. doi: 10.1021/acsmedchemlett.7b00211. eCollection 2017 Jul 13.
PMID: 28740615
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Pazina T, James AM, MacFarlane AW 4th, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS.
Oncoimmunology. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853. eCollection 2017.
PMID: 28932638
2016 Publications
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Mariette X, Alten R, Nüßlein HG, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.
Joint Bone Spine.
2016 Dec 30. pii: S1297-319X(16)30210-X. doi: 10.1016/j.jbspin.2016.10.011. [Epub ahead of print]
PMID: 28043761
Designer vaccine nanodiscs for personalized cancer immunotherapy.
Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ.
Nat Mater.
2016 Dec 26. doi: 10.1038/nmat4822. [Epub ahead of print]
PMID: 28024156
Real-World Experience With Daclatasvir Plus Sofosbuvir ± Ribavirin for Post-Liver Transplant HCV Recurrence and Severe Liver Disease.
Herzer K, Welzel TM, Spengler U, Hinrichsen H, Klinker H, Berg T, Ferenci P, Peck-Radosavljevic M, Inderson A, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.
Transpl Int.
2016 Dec 24. doi: 10.1111/tri.12910. [Epub ahead of print]
PMID: 28012215
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
McPhee F, Hernandez D, Zhou N.
Antivir Ther . 2016 Dec 23. doi: 10.3851/IMP3120. [Epub ahead of print]
PMID: 28008868
Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study.
Goozee R, O'Daly O, Handley R, Reis Marques T, Taylor H, McQueen G, Hubbard K, Pariante C, Mondelli V, Reinders AA, Dazzan P.
Hum Brain Mapp.
2016 Dec 23. doi: 10.1002/hbm.23485. [Epub ahead of print]
PMID: 28009070
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D.
Eur J Health Econ.
2016 Dec 22. doi: 10.1007/s10198-016-0865-3. [Epub ahead of print]
PMID: 28008546
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P 1
Receptor Modulator.
Yang MG, Xiao Z, Dhar TG, Xiao HY, Gilmore JL, Marcoux D, Xie JH, McIntyre KW, Taylor TL, Borowski V, Heimrich E, Li YW, Feng J, Fernandes A, Yang Z, Balimane P, Marino AM, Cornelius G, Warrack BM, Mathur A, Wu DR, Li P, Gupta A, Pragalathan B, Shen DR, Cvijic ME, Lehman-McKeeman LD, Salter-Cid L, Barrish JC, Carter PH, Dyckman AJ.
J Med Chem . 2016 Dec 22;59(24):11138-11147. doi: 10.1021/acs.jmedchem.6b01433.
PMID: 28002964
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.
Cook J, Zusi FC, McDonald IM, King D, Hill MD, Iwuagwu C, Mate RA, Fang H, Zhao R, Wang B, Cutrone J, Ma B, Gao Q, Knox RJ, Matchett M, Gallagher L, Ferrante M, Post-Munson D, Molski T, Easton A, Miller R, Jones K, Digavalli S, Healy F, Lentz K, Benitex Y, Clarke W, Natale J, Siuciak JA, Lodge N, Zaczek R, Denton R, Morgan D, Bristow LJ, Macor JE, Olson RE.
J Med Chem.
2016 Dec 22;59(24):11171-11181. doi: 10.1021/acs.jmedchem.6b01506.
PMID: 27958732
Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression.
Degnan AP, Tora GO, Huang H, Conlon DA, Davis CD, Hanumegowda UM, Hou X, Hsiao Y, Hu J, Krause R, Li YW, Newton AE, Pieschl RL, Raybon J, Rosner T, Sun JH, Taber MT, Taylor SJ, Wong MK, Zhang H, Lodge NJ, Bronson JJ, Macor JE, Gillman KW.
ACS Chem Neurosci.
2016 Dec 21;7(12):1635-1640. doi: 10.1021/acschemneuro.6b00337.
PMID: 27744678
Evaluation of automated Wes system as an analytical and characterization tool to support monoclonal antibody drug product development.
Wang J, Valdez A, Chen Y.
J Pharm Biomed Anal.
2016 Dec 21. pii: S0731-7085(16)30669-0. doi: 10.1016/j.jpba.2016.12.024. [Epub ahead of print]
PMID: 28069351
Phase 2 Placebo-Controlled, Double-Blind Trial of Dasatinib Added to Gemcitabine for Patients with Locally-Advanced Pancreatic Cancer.
Evans TR, Van Cutsem E, Moore MJ, Bazin IS, Rosemurgy A, Bodoky G, Deplanque G, Harrison M, Melichar B, Pezet D, Elekes A, Rock E, Lin C, Strauss L, O'Dwyer PJ.
Ann Oncol.
2016 Dec 19. pii: mdw607. doi: 10.1093/annonc/mdw607. [Epub ahead of print]
PMID: 27998964
Revised Reply to Letter to the Editor with regards to manuscript AR-15-1750.R1.
Fleischmann R, Connolly SE, Maldonado MA, Schiff M.
Arthritis Rheumatol.
2016 Dec 19. doi: 10.1002/art.40021. [Epub ahead of print] No abstract available.
PMID: 27992708
Systematic interpolation method predicts protein chromatographic elution with salt gradients, pH gradients and combined salt/pH gradients.
Creasy A, Barker G, Carta G.
Biotechnol J . 2016 Dec 19. doi: 10.1002/biot.201600636. [Epub ahead of print]
PMID: 27992113
Drug-Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization.
Gan J, Zhang H, Humphreys WG.
Chem Res Toxicol.
2016 Dec 19;29(12):2040-2057.
PMID: 27989144
Functionalized triazines as potent HCV entry inhibitors.
Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.
Bioorg Med Chem Lett . 2016 Dec 18. pii: S0960-894X(16)31304-X. doi: 10.1016/j.bmcl.2016.12.038. [Epub ahead of print]
PMID: 28089701
Difluorocyclobutylacetylenes as positive allosteric modulators of mGluR5 with reduced bioactivation potential.
Degnan AP, Maxwell D, Balakrishnan A, Brown JM, Easton A, Gulianello M, Hanumegowda U, Hill-Drzewi M, Miller R, Santone KS, Senapati A, Shields EE, Sivarao DV, Westphal R, Whiterock VJ, Zhuo X, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2016 Dec 15;26(24):5871-5876. doi: 10.1016/j.bmcl.2016.11.014.
PMID: 27856084
Characterization of TAP Ambr 250 disposable bioreactors, as a reliable scale-down model for biologics process development.
Xu P, Clark C, Ryder T, Sparks C, Zhou J, Wang M, Russell R, Scott C.
Biotechnol Prog . 2016 Dec 15. doi: 10.1002/btpr.2417. [Epub ahead of print]
PMID: 27977912
Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists.
Zheng Y, Qin L, Zacarías NV, de Vries H, Han GW, Gustavsson M, Dabros M, Zhao C, Cherney RJ, Carter P, Stamos D, Abagyan R, Cherezov V, Stevens RC, IJzerman AP, Heitman LH, Tebben A, Kufareva I, Handel TM.
Nature.
2016 Dec 15;540(7633):458-461. doi: 10.1038/nature20605.
PMID: 27926736
Enhancing tablet disintegration characteristics of a highly water-soluble high-drug-loading formulation by granulation process.
Pandey P, Levins C, Pafiakis S, Zacour B, Bindra DS, Trinh J, Buckley D, Gour S, Sharif S, Stamato H.
Pharm Dev Technol.
2016 Dec 15:1-9. [Epub ahead of print]
PMID: 27879156
Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43.
Wu W, Sun M, Chen F, Cao AT, Liu H, Zhao Y, Huang X, Xiao Y, Yao S, Zhao Q, Liu Z, Cong Y.
Mucosal Immunol . 2016 Dec 14. doi: 10.1038/mi.2016.114. [Epub ahead of print]
PMID: 27966553
Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
Nkhoma ET, Rosenblatt L, Myers J, Villasis-Keever A, Coumbis J.
PLoS One . 2016 Dec 12;11(12):e0166982. doi: 10.1371/journal.pone.0166982.
PMID: 27941989
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Sulkowski MS, Flamm S, Kayali Z, Lawitz EJ, Kwo P, McPhee F, Torbeyns A, Hughes EA, Swenson ES, Yin PD, Linaberry M.
Liver Int.
2016 Dec 10. doi: 10.1111/liv.13335. [Epub ahead of print]
PMID: 27943563
The cellular kinetics of lung alveolar epithelial cells and its relationship with lung tissue repair after acute lung injury.
Zeng L, Yang XT, Li HS, Li Y, Yang C, Gu W, Zhou YH, Du J, Wang HY, Sun JH, Wen DL, Jiang JX.
Respir Res . 2016 Dec 7;17(1):164.
PMID: 27923370
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OA, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI.; study team..
Antivir Ther.
2016 Dec 6. doi: 10.3851/IMP3112. [Epub ahead of print]
PMID: 27922453
A carbon dioxide stripping model for mammalian cell culture in manufacturing scale bioreactors.
Xing Z, Lewis AM, Borys MC, Li ZJ.
Biotechnol Bioeng . 2016 Dec 6. doi: 10.1002/bit.26232. [Epub ahead of print]
PMID: 27922179
John Staniforth-An appreciation: The non-conformist nonconformist.
Tobyn M, Price R.
Int J Pharm.
2016 Dec 5;514(2):333-334. doi: 10.1016/j.ijpharm.2016.10.028. No abstract available.
PMID: 27780744
Development of aqueous dispersions of Coenzyme Q 10
for pulmonary delivery and the dynamics of active vibrating-mesh aerosolization.
Carvalho TC, McCook JP, Narain NR, McConville JT.
Int J Pharm.
2016 Dec 5;514(2):407-419. doi: 10.1016/j.ijpharm.2016.10.011.
PMID: 27732894
Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail.
Tye CK, Wang Z, Dockens RC, Vakkalagadda B, Wang C, Zhang Y, Su CC, Hageman MJ.
Int J Pharm.
2016 Dec 5;514(2):364-373. doi: 10.1016/j.ijpharm.2016.06.028.
PMID: 27291974
Use of similarity scoring in the development of oral solid dosage forms.
Ferreira AP, Olusanmi D, Sprockel O, Abebe A, Nikfar F, Tobyn M.
Int J Pharm.
2016 Dec 5;514(2):335-340. doi: 10.1016/j.ijpharm.2015.09.046.
PMID: 26423176
Discrepancies in column parameters presented in hydrophobic subtraction model manuscripts.
Shackman JG.
J Chromatogr A . 2016 Dec 2;1475:116-118. doi: 10.1016/j.chroma.2016.11.006. No abstract available.
PMID: 27842900
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists.
Hill MD, Fang H, King HD, Iwuagwu CI, McDonald IM, Cook J, Zusi FC, Mate RA, Knox RJ, Post-Munson D, Easton A, Miller R, Lentz K, Clarke W, Benitex Y, Lodge N, Zaczek R, Denton R, Morgan D, Bristow L, Macor JE, Olson R.
ACS Med Chem Lett.
2016 Dec 1;8(1):133-137. doi: 10.1021/acsmedchemlett.6b00471.
PMID: 28105289
Reasons for non-intensification of treatment in people with type 2 diabetes receiving oral monotherapy: Outcomes from the prospective DIAttitude study.
Balkau B, Halimi S, Blickle JF, Vergès B, Avignon A, Attali C, Chartier I, Amelineau E.
Ann Endocrinol
(Paris). 2016 Dec;77(6):649-657. doi: 10.1016/j.ando.2016.03.001.
PMID: 27646493
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity).
Richards S, Amaravadi L, Pillutla R, Birnboeck H, Torri A, Cowan KJ, Papadimitriou A, Garofolo F, Satterwhite C, Piccoli S, Wu B, Krinos-Fiorotti C, Allinson J, Berisha F, Cocea L, Croft S, Fraser S, Galliccia F, Gorovits B, Gupta S, Gupta V, Haidar S, Hottenstein C, Ishii-Watabe A, Jani D, Kadavil J, Kamerud J, Kramer D, Litwin V, Lima Santos GM, Nelson R, Ni Y, Pedras-Vasconcelos J, Qiu Y, Rhyne P, Safavi A, Saito Y, Savoie N, Scheibner K, Schick E, Siguenza PY, Smeraglia J, Staack RF, Subramanyam M, Sumner G, Thway T, Uhlinger D, Ullmann M, Vitaliti A, Welink J, Whiting CC, Xue L, Zeng R.
Bioanalysis.
2016 Dec;8(23):2475-2496.
PMID: 27855512
UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions.
Zheng N, Christopher LJ, Ma X, Ji QC, Buzescu A, Kandoussi H, Garonzik SM, LaCreta F, Aubry AF, Arnold ME, Zeng J.
Bioanalysis.
2016 Dec;8(23):2429-2443.
PMID: 27855510
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies).
Song A, Lee A, Garofolo F, Kaur S, Duggan J, Evans C, Palandra J, Donato LD, Xu K, Bauer R, Bustard M, Chen L, Cocea L, Croft S, Galliccia F, Haidar S, Hughes N, Ishii-Watabe A, Islam R, Jones B, Kadavil J, Krantz C, Lima Santos GM, Olah T, Pedras-Vasconcelos J, Staelens L, Saito Y, Savoie N, Scheibner K, Spitz S, Tampal N, Thomas E, Vinter S, Wakelin-Smith J, Welink J, Zeng J, Zhou S.
Bioanalysis.
2016 Dec;8(23):2457-2474.
PMID: 27855509
A simple, fast, sensitive and robust LC-MS/MS bioanalytical assay for evaluating 7α-hydroxy-4-cholesten-3-one biomarker in a clinical program.
Yuan L, Luo Y, Kandoussi H, Ji QC.
Bioanalysis.
2016 Dec;8(23):2445-2455.
PMID: 27855505
Robust Ki67 detection in human blood by flow cytometry for clinical studies.
Sun Y, Yang K, Bridal T, Ehrhardt AG.
Bioanalysis.
2016 Dec;8(23):2399-2413.
PMID: 27807982
Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X, Zhang T, Yue S, Wang J, Luo H, Zhang Y, Li Z, Che J, Yang H, Li H, Zhu M, Lu C.
Biochem Pharmacol . 2016 Dec 1;121:67-77. doi: 10.1016/j.bcp.2016.09.012.
PMID: 27666601
[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.
Shan W, Balog A, Nation A, Zhu X, Chen J, Cvijic ME, Geng J, Rizzo CA, Spires T Jr, Attar RM, Obermeier M, Traeger S, Dai J, Zhang Y, Galella M, Trainor G, Vite GD, Gavai AV.
Bioorg Med Chem Lett.
2016 Dec 1;26(23):5707-5711. doi: 10.1016/j.bmcl.2016.10.059.
PMID: 27836399
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.
Wu YJ, Guernon J, Rajamani R, Toyn JH, Ahlijanian MK, Albright CF, Muckelbauer J, Chang C, Camac D, Macor JE, Thompson LA.
Bioorg Med Chem Lett.
2016 Dec 1;26(23):5729-5731. doi: 10.1016/j.bmcl.2016.10.055.
PMID: 27816517
Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
Passey C, Darbenzio R, Jou YM, Lynch M, Gupta M.
Cancer Chemother Pharmacol . 2016 Dec;78(6):1237-1244.
PMID: 27796540
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation.
Pinyol C, Cepeda JM, Roldan I, Roldan V, Jimenez S, Gonzalez P, Soto J.
Cardiol Ther.
2016 Dec;5(2):171-186.
PMID: 27457613
Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations.
Chan P, Mould DR, Tarif MA, Reynolds L, LaCreta F, Bertz R, Bifano M.
Clin Pharmacokinet.
2016 Dec;55(12):1559-1572.
PMID: 27319000
Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review.
Chow D, Shikuma C, Ritchings C, Guo M, Rosenblatt L.
Infect Dis Ther.
2016 Dec;5(4):473-489. Review.
PMID: 27677263
Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F.
J Antimicrob Chemother.
2016 Dec;71(12):3495-3505.
PMID: 27605597
Collaborating to improve the use of free-energy and other quantitative methods in drug discovery.
Sherborne B, Shanmugasundaram V, Cheng AC, Christ CD, DesJarlais RL, Duca JS, Lewis RA, Loughney DA, Manas ES, McGaughey GB, Peishoff CE, van Vlijmen H.
J Comput Aided Mol Des . 2016 Dec;30(12):1139-1141. doi: 10.1007/s10822-016-9996-y.
PMID: 28013427
Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
Wei L, Li J, Yang X, Wang G, Feng B, Hou J, Duan Z, Jia J, Ren H, Niu J, Chen X, Wang FS, Shang J, Bo Q, Li R, Liu Y, Zhuang H.
J Gastroenterol Hepatol.
2016 Dec;31(12):1995-2003. doi: 10.1111/jgh.13399.
PMID: 27043040
The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity.
Tran SB, Maxwell BD, Burrell R, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm.
2016 Dec;59(14):665-672. doi: 10.1002/jlcr.3433.
PMID: 27624665
The synthesis and analysis of [phenyl- 14
C(U)]BMS-770767 and [ 13
C 6
]BMS-770767 for use in discovery biotransformation, human ADME and bioanalytical studies.
Maxwell BD, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm . 2016 Dec;59(14):657-664. doi: 10.1002/jlcr.3428.
PMID: 27460954
Literature review of the distribution of hepatitis C virus genotypes across Europe.
Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I.
J Med Virol.
2016 Dec;88(12):2157-2169. doi: 10.1002/jmv.24573.
PMID: 27171396
Resolution and Sensitivity of Inline Focused Beam Reflectance Measurement During Wet Granulation in Pharmaceutically Relevant Particle Size Ranges.
Narang AS, Stevens T, Hubert M, Paruchuri S, Macias K, Bindra D, Gao Z, Badawy S.
J Pharm Sci.
2016 Dec;105(12):3594-3602. doi: 10.1016/j.xphs.2016.09.001.
PMID: 27745886
Technical Decision Making With Higher Order Structure Data: Perspectives on Higher Order Structure Characterization From the Biopharmaceutical Industry.
Weiss WF 4th, Gabrielson JP, Al-Azzam W, Chen G, Davis DL, Das TK, Hayes DB, Houde D, Singh SK.
J Pharm Sci.
2016 Dec;105(12):3465-3470. doi: 10.1016/j.xphs.2016.09.003.
PMID: 27743675
Autoxidation of betulonaldehyde.
Ayers S, Benkovics T, Marshall J, Tan Y.
Planta Med.
2016 Dec;81(S 01):S1-S381. No abstract available.
PMID: 27975757
Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences.
Ward T, Gordon J, Bennett H, Webster S, Sugrue D, Jones B, Brenner M, McEwan P.
Public Health.
2016 Dec;141:42-51. doi: 10.1016/j.puhe.2016.08.002.
PMID: 27932014
Progression-free survival, overall survival and quality of life: What is their medicoeconomic importance in oncology?
Pavlovic M, Garnier J, Durand-Zaleski I; participants of Round Table n(o) 3 of Giens XXXI., Bilbault P, Gaudin AF, Le Jeunne C, Lalaude O, Roze S, de Sahb R, Sapède C.
Therapie.
2016 Dec;71(6):625-632. doi: 10.1016/j.therap.2016.03.004.
PMID: 27639631
Evaluation of microRNAs-208 and 133a/b as differential biomarkers of acute cardiac and skeletal muscle toxicity in rats.
Calvano J, Achanzar W, Murphy B, DiPiero J, Hixson C, Parrula C, Burr H, Mangipudy R, Tirmenstein M.
Toxicol Appl Pharmacol.
2016 Dec 1;312:53-60. doi: 10.1016/j.taap.2015.11.015.
PMID: 26627004
MicroRNA as biomarkers of mitochondrial toxicity.
Baumgart BR, Gray KL, Woicke J, Bunch RT, Sanderson TP, Van Vleet TR.
Toxicol Appl Pharmacol.
2016 Dec 1;312:26-33. doi: 10.1016/j.taap.2015.10.007.
PMID: 26476301
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight.
Hatswell AJ, Porter J, Lee D, Hertel N, Latimer NR.
Value Health.
2016 Dec;19(8):1055-1058. doi: 10.1016/j.jval.2016.04.013.
PMID: 27987632
A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
Bohensky MA, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew D.
Value Health.
2016 Dec;19(8):1009-1015. doi: 10.1016/j.jval.2016.05.013.
PMID: 27987627
Reducing blood volume requirements for clinical pathology testing in toxicologic studies-points to consider.
Poitout-Belissent F, Aulbach A, Tripathi N, Ramaiah L.
Vet Clin Pathol.
2016 Dec;45(4):534-551. doi: 10.1111/vcp.12429.
PMID: 27935623
Additive free preparative chiral SFC separations of 2,2-dimethyl-3-aryl-propanoic acids.
Wu DR, Yip SH, Li P, Sun D, Kempson J, Mathur A.
J Pharm Biomed Anal.
2016 Nov 30;131:54-63. doi: 10.1016/j.jpba.2016.08.009.
PMID: 27522108
Use of Spray-Dried Dispersions in Early Pharmaceutical Development: Theoretical and Practical Challenges.
Li J, Patel D, Wang G.
AAPS J.
2016 Nov 28. [Epub ahead of print]
PMID: 27896684
Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
Cirincione B, Edwards J, Mager DE.
AAPS J . 2016 Nov 28. [Epub ahead of print]
PMID: 27896683
Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
Lin Z, Cantone J, Lu H, Nowicka-Sans B, Protack T, Yuan T, Yang H, Liu Z, Drexler D, Regueiro-Ren A, Meanwell NA, Cockett M, Krystal M, Lataillade M, Dicker IB.
PLoS Pathog.
2016 Nov 28;12(11):e1005990. doi: 10.1371/journal.ppat.1005990.
PMID: 27893830
Surface induced three-peak elution behavior of a monoclonal antibody during cation exchange chromatography.
Guo J, Creasy AD, Barker G, Carta G.
J Chromatogr A.
2016 Nov 25;1474:85-94. doi: 10.1016/j.chroma.2016.10.061.
PMID: 27802880
Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I, safety, clinical trial.
Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, Difede D, Shafazand S, Khan A, Pujol MV, LaRussa VF, Lancaster LH, Rosen GD, Fishman J, Mageto YN, Mendizabal A, Hare JM.
Chest.
2016 Nov 24. pii: S0012-3692(16)62462-5. doi: 10.1016/j.chest.2016.10.061. [Epub ahead of print]
PMID: 27890713
A novel liquid chromatography tandem mass spectrometry method for the estimation of bilirubin glucuronides and its application to in vitro enzyme assays.
Putluru SP, Matta MK, Ahire D, Subramanian M, Sinz M, Mandlekar S.
Drug Metab Lett.
2016 Nov 24. [Epub ahead of print]
PMID: 27908259
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N.
Am J Kidney Dis.
2016 Nov 23. pii: S0272-6386(16)30572-8. doi: 10.1053/j.ajkd.2016.09.021. [Epub ahead of print]
PMID: 27889299
Synthesis of unlabelled and stable-isotope-labelled glucuronide metabolites of dapagliflozin and synthesis of stable-isotope-labelled dapagliflozin.
Cao K, Brailsford JA, Yao M, Caceres-Cortes J, Espina R, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm.
2016 Nov 21. doi: 10.1002/jlcr.3484. [Epub ahead of print]
PMID: 27868223
A comparison of the variance estimation methods for heteroscedastic nonlinear models.
Sidik K, Jonkman JN.
Stat
Med . 2016 Nov 20;35(26):4856-4874. doi: 10.1002/sim.7024.
PMID: 27383279
Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β 2 -Agonists.
Bollu V, Guérin A, Gauthier G, Hiscock R, Wu EQ.
Drugs Real World Outcomes.
2016 Nov 18. [Epub ahead of print]
PMID: 27864792
Investigation of the "true" extraction recovery of analytes from multiple types of tissues and its impact on tissue bioanalysis using two model compounds.
Yuan L, Ma L, Dillon L, Fancher RM, Sun H, Zhu M, Lehman-McKeeman L, Aubry AF, Ji QC.
Anal Chim Acta.
2016 Nov 16;945:57-66. doi: 10.1016/j.aca.2016.09.039.
PMID: 27968716
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Ekholm E, Hansen L, Johnsson E, Iqbal N, Carlsson B, Chen H, Hirshberg B.
Endocr Pract . 2016 Nov 16. [Epub ahead of print]
PMID: 27849380
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, Exposito MJ, Zeuzem S.
Antivir Ther . 2016 Nov 15. doi: 10.3851/IMP3108. [Epub ahead of print]
PMID: 27845298
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M.
Clin Cancer Res.
2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839.
PMID: 27169994
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S, Nagai H, Kinoshita G, Miyoshi M, Robbins M, Pandya D, Bleickardt E, Chou T.
Int J Hematol.
2016 Nov 15. [Epub ahead of print]
PMID: 27848182
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.
Agrawal S, Feng Y, Roy A, Kollia G, Lestini B.
J Immunother Cancer . 2016 Nov 15;4:72.
PMID: 27879974
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C.
J Clin Oncol.
2016 Nov 14:JCO2015661389. [Epub ahead of print]
PMID: 28068177
Identification of Tricyclic Agonists of Sphingosine-1-phosphate Receptor 1 (S1P 1 ) Employing Ligand-Based Drug Design.
Xiao HY, Watterson SH, Langevine CM, Srivastava AS, Ko SS, Zhang Y, Cherney RJ, Guo WW, Gilmore JL, Sheppeck JE 2nd, Wu DR, Li P, Ramasamy D, Arunachalam P, Mathur A, Taylor TL, Shuster DJ, McIntyre KW, Shen DR, Yarde M, Cvijic ME, Marino AM, Balimane PV, Yang Z, Banas DM, Cornelius G, D'Arienzo CJ, Warrack BM, Lehman-McKeeman L, Salter-Cid LM, Xie J, Barrish JC, Carter PH, Dyckman AJ, Dhar TG.
J Med Chem.
2016 Nov 10;59(21):9837-9854.
PMID: 27726358
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.
N Engl J Med.
2016 Nov 10;375(19):1856-1867.
PMID: 27718784
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A.
N Engl J Med.
2016 Nov 10;375(19):1845-1855.
PMID: 27717298
Untargeted screening of unknown xenobiotics and potential toxins in plasma of poisoned patients using high-resolution mass spectrometry: Generation of xenobiotic fingerprint using background subtraction.
Chen C, Wohlfarth A, Xu H, Su D, Wang X, Jiang H, Feng Y, Zhu M.
Anal Chim Acta.
2016 Nov 9;944:37-43. doi: 10.1016/j.aca.2016.09.034.
PMID: 27776637
Pd-Catalyzed γ-C(sp 3 )-H Arylation of Free Amines Using a Transient Directing Group.
Wu Y, Chen YQ, Liu T, Eastgate MD, Yu JQ.
J Am Chem Soc . 2016 Nov 9;138(44):14554-14557.
PMID: 27786439
Development of an HTS-Compatible Assay for Discovery of Melanoma-Related Microphthalmia Transcription Factor Disruptors Using AlphaScreen Technology.
Wang J, Fang P, Chase P, Tshori S, Razin E, Spicer TP, Scampavia L, Hodder P, Guo M.
J Biomol Screen . 2016 Nov 8. pii: 1087057116675274. [Epub ahead of print]
PMID: 27827304
Advances in analytical methodologies to guide bioprocess engineering for bio-therapeutics.
Saldova R, Kilcoyne M, Stöckmann H, Millán Martín S, Lewis AM, Tuite CM, Gerlach JQ, Le Berre M, Borys MC, Li ZJ, Abu-Absi NR, Leister K, Joshi L, Rudd PM.
Methods.
2016 Nov 8. pii: S1046-2023(16)30434-0. doi: 10.1016/j.ymeth.2016.11.002. [Epub ahead of print]
PMID: 27832969
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Yau TC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RT, Bottaro DP.
Clin Cancer Res.
2016 Nov 7. pii: clincanres.1789.2016. [Epub ahead of print]
PMID: 27821605
Understanding the Impact of Chemical Variability and Calibration Algorithms on Prediction of Solid Fraction of Roller Compacted Ribbons Using Near-Infrared (NIR) Spectroscopy.
Talwar S, Nunes C, Stevens T, Nesarikar V, Timmins P, Anderson CA, Drennen JK 3rd.
Appl Spectrosc.
2016 Nov 4. pii: 0003702816671960. [Epub ahead of print]
PMID: 27815436
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M.
J Immunother Cancer . 2016 Nov 4;4:74.
PMID: 27822377
Reply to Letter to the Editor.
Fleischmann R, Connolly SE, Maldonado MA, Schiff M.
Arthritis Rheumatol.
2016 Nov 3. doi: 10.1002/art.39978. [Epub ahead of print] Review. No abstract available.
PMID: 27813366
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ.
N Engl J Med.
2016 Nov 3;375(18):1749-1755.
PMID: 27806233
Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.
Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R, White JT, Xu Y, Gupta S.
AAPS J.
2016 Nov;18(6):1335-1350.
PMID: 27495119
Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.
Argikar UA, Potter PM, Hutzler JM, Marathe PH.
AAPS J.
2016 Nov;18(6):1391-1405. Review.
PMID: 27495117
Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors.
Richter JM, Cheney DL, Bates JA, Wei A, Luettgen JM, Rendina AR, Harper TM, Narayanan R, Wong PC, Seiffert D, Wexler RR, Priestley ES.
ACS Med Chem Lett . 2016 Nov 1;8(1):67-72. doi: 10.1021/acsmedchemlett.6b00375.
PMID: 28105277
A Review of Daclatasvir Drug-Drug Interactions.
Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M, Bertz R, Eley T.
Adv Ther.
2016 Nov;33(11):1867-1884. Review.
PMID: 27664109
Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
Durrbach A, Pestana JM, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D, Matas A, Wekerle T, Polinsky M, Meier-Kriesche HU, Munier S, Grinyó JM.
Am J Transplant.
2016 Nov;16(11):3192-3201. doi: 10.1111/ajt.13830.
PMID: 27130868
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M.
Ann Hepatol.
2016 Nov-Dec 2016;15(6):834-845.
PMID: 27740516
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV, Granell M, Oriol A, Martinez-Lopez J, Blade J, Hernandez MT, Martín J, Gironella M, Lynch M, Bleickardt E, Paliwal P, Singhal A, San-Miguel J.
Br J Haematol.
2016 Nov;175(3):448-456. doi: 10.1111/bjh.14263.
PMID: 27434748
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.
Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.
Cancer Res.
2016 Nov 1;76(21):6266-6277.
PMID: 27634762
Highlights From the American Association of Pharmaceutical Scientists/ International Transporter Consortium Joint Workshop on Drug Transporters in Absorption, Distribution, Metabolism, and Excretion: From the Bench to the Bedside - Clinical Pharmacology Considerations.
Ronaldson PT, Bauer B, El-Kattan AF, Shen H, Salphati L, Louie SW.
Clin Pharmacol Ther.
2016 Nov;100(5):419-422. doi: 10.1002/cpt.439.
PMID: 27500791
Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects.
Theunissen PT, Beken S, Beyer BK, Breslin WJ, Cappon GD, Chen CL, Chmielewski G, De Schaepdrijver L, Enright B, Foreman JE, Harrouk W, Hew KW, Hoberman AM, Hui JY, Knudsen TB, Laffan SB, Makris SL, Martin M, McNerney ME, Siezen CL, Stanislaus DJ, Stewart J, Thompson KE, Tornesi B, Van der Laan JW, Weinbauer GF, Wood S, Piersma AH.
Crit Rev Toxicol . 2016 Nov;46(10):900-910.
PMID: 27848393
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Matthaei S, Aggarwal N, Garcia-Hernandez P, Iqbal N, Chen H, Johnsson E, Chin A, Hansen L.
Diabetes Obes Metab . 2016 Nov;18(11):1128-1133. doi: 10.1111/dom.12741.
PMID: 27403645
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Mathieu C, Herrera Marmolejo M, González González JG, Hansen L, Chen H, Johnsson E, Garcia-Sanchez R, Iqbal N.
Diabetes Obes Metab.
2016 Nov;18(11):1134-1137. doi: 10.1111/dom.12737.
PMID: 27385192
Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.
Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, Lee C, Lai Y, Liao M, Mathias A, Evers R, Humphreys W, Hop CE, Kumer SC, Unadkat JD.
Drug Metab Dispos . 2016 Nov;44(11):1752-1758.
PMID: 27543206
Non-cytochrome P450-mediated bioactivation and its toxicological relevance.
Gan J, Ma S, Zhang D.
Drug Metab Rev.
2016 Nov;48(4):473-501.
PMID: 27533622
Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.
Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P.
Eur J Health Econ.
2016 Nov 1. [Epub ahead of print]
PMID: 27803989
Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
Bedimo R, Rosenblatt L, Myers J.
HIV Clin Trials. 2016
Nov;17(6):246-266.
PMID: 27809711
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Yang W, Han P, Min KW, Wang B, Mansfield T, T'Joen C, Iqbal N, Johnsson E, Ptaszynska A.
J Diabetes. 2016 Nov;8(6):796-808. doi: 10.1111/1753-0407.12357.
PMID: 26589253
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L.
J Gastroenterol Hepatol . 2016 Nov;31(11):1860-1867. doi: 10.1111/jgh.13379.
PMID: 27003037
Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation.
Zwirtes R, Narasimhan P, Wind-Rotolo MM, Xu D, Hruska MW, Kishnani N, Colston EM, Srinivasan S.
J Interferon Cytokine Res.
2016 Nov;36(11):644-651.
PMID: 27710263
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao JH, Lee KS, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S.
J Interferon Cytokine Res.
2016 Nov;36(11):635-643.
PMID: 27327078
Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis.
An J, Alemao E, Reynolds K, Kawabata H, Solomon DH, Liao KP, Niu F, Cheetham TC.
J Rheumatol . 2016 Nov;43(11):1989-1996.
PMID: 27585690
PS01.74: Systemic Treatment Sequencing in US Medicare Patients with Extensive Disease (ED)-Small Cell Lung Cancer (SCLC): Topic: Medical Oncology.
Danese M, Gleeson M, Lubeck D, Korytowsky B, Bobiak S.
J Thorac Oncol.
2016 Nov;11(11S):S317-S318. doi: 10.1016/j.jtho.2016.09.109. No abstract available.
PMID: 27969541
PS01.73: Have We Shifted the Therapeutic Innovation Frontier? A US Assessment of Advanced Non-Small Cell Lung Cancer (advNSCLC): Topic: Medical Oncology.
Korytowsky B, Justo N, Nilsson J, Madison T, Dalen J, McGuire A.
J Thorac Oncol.
2016 Nov;11(11S):S316-S317. doi: 10.1016/j.jtho.2016.09.108. No abstract available.
PMID: 27969540
PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology.
Blumenschein G Jr, Chandler J, Garon EB, Waterhouse D, Goldman JW, Gunuganti VK, Boccia R, Spigel D, Glaspy J, Berry DA, Korytowsky B, Zhu J, Lin WH, Bennett K, Reynolds C.
J Thorac Oncol.
2016 Nov;11(11S):S307. doi: 10.1016/j.jtho.2016.09.094. No abstract available.
PMID: 27969526
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy: Topic: Medical Oncology.
Owonikoko T, Ready N, Postmus P, Reck M, Peters S, Pieters A, Selvaggi G, Fairchild J, Govindan R.
J Thorac Oncol.
2016 Nov;11(11S):S306-S307. doi: 10.1016/j.jtho.2016.09.093. No abstract available.
PMID: 27969525
ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology.
Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Hellmann MD.
J Thorac Oncol.
2016 Nov;11(11S):S250-S251. doi: 10.1016/j.jtho.2016.09.008. No abstract available.
PMID: 27969442
ORAL01.02: Biopsies in Initial Diagnosis of Non-Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy: Topic: Medical Oncology.
Hussein M, Richards DA, Ulrich B, Korytowsky B, Pandya D, Cogswell J, Batenchuk C, Burns V.
J Thorac Oncol.
2016 Nov;11(11S):S249-S250. doi: 10.1016/j.jtho.2016.09.007. No abstract available.
PMID: 27969441
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE.
Lancet Oncol.
2016 Nov;17(11):1590-1598. doi: 10.1016/S1470-2045(16)30496-X.
PMID: 27733243
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.
Lancet Oncol.
2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7.
PMID: 27622997
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kowdley KV, Nelson DR, Lalezari JP, Box T, Gitlin N, Poleynard G, Rabinovitz M, Ravendhran N, Sheikh AM, Siddique A, Bhore R, Noviello S, Rana K.
Liver Int.
2016 Nov;36(11):1611-1618. doi: 10.1111/liv.13165.
PMID: 27188960
Some practical considerations in three-arm non-inferiority trial design.
Zhou M, Kundu S.
Pharm Stat.
2016 Nov;15(6):550-559. doi: 10.1002/pst.1779.
PMID: 27681603
Autoxidation Products of Betulonaldehyde.
Ayers S, Benkovics T, Marshall J, Tan Y, Strotman NA, Kiau S.
J Nat Prod.
2016 Oct 28;79(10):2758-2761.
PMID: 27684353
Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
Gerber DE, Urbanic JJ, Langer C, Hu C, Chang IF, Lu B, Movsas B, Jeraj R, Curran WJ, Bradley JD.
Clin Lung Cancer . 2016 Oct 26. pii: S1525-7304(16)30352-7. doi: 10.1016/j.cllc.2016.10.009. [Epub ahead of print]
PMID: 27923550
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB.
Heart.
2016 Oct 24. pii: heartjnl-2016-309901. doi: 10.1136/heartjnl-2016-309901. [Epub ahead of print]
PMID: 27798052
Discovery of Highly Potent Liver X Receptor β Agonists.
Kick EK, Busch BB, Martin R, Stevens WC, Bollu V, Xie Y, Boren BC, Nyman MC, Nanao MH, Nguyen L, Plonowski A, Schulman IG, Yan G, Zhang H, Hou X, Valente MN, Narayanan R, Behnia K, Rodrigues AD, Brock B, Smalley J, Cantor GH, Lupisella J, Sleph P, Grimm D, Ostrowski J, Wexler RR, Kirchgessner T, Mohan R.
ACS Med Chem Lett . 2016 Oct 23;7(12):1207-1212.
PMID: 27994765
Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects.
Theunissen PT, Beken S, Beyer B, Breslin WJ, Cappon GD, Chen CL, Chmielewski G, de Schaepdrijver L, Enright B, Foreman JE, Harrouk W, Hew KW, Hoberman AM, Y Hui J, Knudsen TB, Laffan SB, Makris SL, Martin M, McNerney ME, Siezen CL, Stanislaus DJ, Stewart J, Thompson KE, Tornesi B, Van der Laan JW, Weinbauer GF, Wood S, Piersma AH.
Crit Rev Toxicol.
2016 Oct 21:1-13. [Epub ahead of print]
PMID: 27766926
Dual roles for regulatory T cell depletion and co-stimulatory signaling in agonistic GITR targeting for tumor immunotherapy.
Mahne A, Mauze S, Joyce-Shaikh B, Xia J, Bowman E, Beebe A, Cua D, Jain R.
Cancer Res.
2016 Oct 20. pii: canres.0797.2016. doi: 10.1158/0008-5472.CAN-16-0797. [Epub ahead of print]
PMID: 28122327
Results From an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Segal NH, Logan TF, Hodi FS, McDermott DF, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt HE, Sznol M, Levy R.
Clin Cancer Res.
2016 Oct 18. pii: clincanres.1272.2016. [Epub ahead of print]
PMID: 27756788
A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
Flisiak R, Shiffman M, Arenas J, Cheinquer H, Nikitin I, Dong Y, Rana K, Srinivasan S.
PLoS One.
2016 Oct 17;11(10):e0164563. doi: 10.1371/journal.pone.0164563.
PMID: 27749900
Regulatory Forum*: Progress toward ICH S1 Revision.
Peden WM.
Toxicol Pathol.
2016 Oct 17. pii: 0192623316673201. [Epub ahead of print]
PMID: 27753636
Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.
Ladziata VU, Glunz PW, Zou Y, Zhang X, Jiang W, Jacutin-Porte S, Cheney DL, Wei A, Luettgen JM, Harper TM, Wong PC, Seiffert D, Wexler RR, Priestley ES.
Bioorg Med Chem Lett . 2016 Oct 15;26(20):5051-5057. doi: 10.1016/j.bmcl.2016.08.088.
PMID: 27612545
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I.
Cancer Res.
2016 Oct 15;76(20):5994-6005.
PMID: 27550452
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
Watterson SH, De Lucca GV, Shi Q, Langevine CM, Liu Q, Batt DG, Beaudoin Bertrand M, Gong H, Dai J, Yip S, Li P, Sun D, Wu DR, Wang C, Zhang Y, Traeger SC, Pattoli MA, Skala S, Cheng L, Obermeier MT, Vickery R, Discenza LN, D'Arienzo CJ, Zhang Y, Heimrich E, Gillooly KM, Taylor TL, Pulicicchio C, McIntyre KW, Galella MA, Tebben AJ, Muckelbauer JK, Chang C, Rampulla R, Mathur A, Salter-Cid L, Barrish JC, Carter PH, Fura A, Burke JR, Tino JA.
J Med Chem.
2016 Oct 13;59(19):9173-9200.
PMID: 27583770
Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor.
Ahmad S, Washburn WN, Hernandez AS, Bisaha S, Ngu K, Wang W, Pelleymounter MA, Longhi D, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Zhang H, Gemzik B, Janovitz EB, Huang C, Zhang L, Robl JA, Murphy BJ.
J Med Chem.
2016 Oct 13;59(19):8848-8858.
PMID: 27564419
Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samples.
Qi Z, Wang L, He A, Ma-Edmonds M, Cogswell J.
Bioanalysis.
2016 Oct 7. [Epub ahead of print]
PMID: 27712086
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 - small molecules, peptides and small molecule biomarkers by LCMS).
Yang E, Welink J, Cape S, Woolf E, Sydor J, James C, Goykhman D, Arnold M, Addock N, Bauer R, Buonarati M, Ciccimaro E, Dodda R, Evans C, Garofolo F, Hughes N, Islam R, Nehls C, Wilson A, Briscoe C, Bustard M, Coppola L, Croft S, Drexler D, Ferrari L, Fraier D, Jenkins R, Kadavil J, King L, Li W, Lima Santos GM, Musuku A, Ramanathan R, Saito Y, Savoie N, Summerfield S, Sun R, Tampal N, Vinter S, Wakelin-Smith J, Yue Q.
Bioanalysis.
2016 Oct 7. [Epub ahead of print]
PMID: 27712081
Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study.
Rosenblatt L, Farr AM, Nkhoma ET, Nelson JK, Ritchings C, Johnston SS.
BMC Infect Dis.
2016 Oct 7;16(1):547. No abstract available.
PMID: 27717332
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L.
Eur Heart J.
2016 Oct 7;37(38):2869-2878.
PMID: 27071819
Synthesis of Fmoc-Protected Arylphenylalanines (Bip Derivatives) via Nonaqueous Suzuki-Miyaura Cross-Coupling Reactions.
Qiao JX, Fraunhoffer KJ, Hsiao Y, Li YX, Wang C, Wang TC, Poss MA.
J Org Chem.
2016 Oct 7;81(19):9499-9506.
PMID: 27615449
Novel platens to measure the hardness of a pentagonal shaped tablet.
Malladi J, Sidik K, Wu S, McCann R, Dougherty J, Parab P, Carragher T.
Pharm Dev Technol.
2016 Oct 4:1-10. [Epub ahead of print]
PMID: 27607150
Development of 1 H -Pyrazolo[3,4- b ]pyridines as Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators.
Hill MD, Fang H, Brown JM, Molski T, Easton A, Han X, Miller R, Hill-Drzewi M, Gallagher L, Matchett M, Gulianello M, Balakrishnan A, Bertekap RL, Santone KS, Whiterock VJ, Zhuo X, Bronson JJ, Macor JE, Degnan AP.
ACS Med Chem Lett.
2016 Oct 3;7(12):1082-1086.
PMID: 27994742
Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective.
Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, Bhattacharya A, Citrome L, Enck R, Fletcher J, Haller D, Chen TT, Laine C.
BMJ.
2016 Oct 3;355:i5078. doi: 10.1136/bmj.i5078. No abstract available.
PMID: 27697753
In-line ATR-UV and Raman Spectroscopy for Monitoring API Dissolution Process During Liquid-Filled Soft-Gelatin Capsule Manufacturing.
Wan B, Zordan CA, Lu X, McGeorge G.
AAPS PharmSciTech.
2016 Oct;17(5):1173-81. doi: 10.1208/s12249-015-0456-0.
PMID: 26604007
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
Novotny JF Jr, Cogswell J, Inzunza H, Harbison C, Horak C, Averbuch S.
Ann Oncol.
2016 Oct;27(10):1966-9. doi: 10.1093/annonc/mdw288. No abstract available.
PMID: 27502705
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP.
Ann Oncol.
2016 Oct;27(10):1940-6. doi: 10.1093/annonc/mdw265.
PMID: 27405322
Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
D'Agostino MA, Wakefield RJ, Berner-Hammer H, Vittecoq O, Filippou G, Balint P, Möller I, Iagnocco A, Naredo E, Østergaard M, Boers M, Gaillez C, Van Holder K, Le Bars M; OMERACT-EULAR-Ultrasound Task Force..
Ann Rheum Dis . 2016 Oct;75(10):1763-9. doi: 10.1136/annrheumdis-2015-207709.
PMID: 26590174
A validated LC-MS/MS method for the quantitative measurement of creatinine as an endogenous biomarker in human plasma.
Zhao Y, Liu G, Angeles A, Christopher LJ, Wang Z, Arnold ME, Shen JX.
Bioanalysis.
2016 Oct;8(19):1997-2005. doi: 10.4155/bio-2016-0086.
PMID: 27611058
HCV NS5A replication complex inhibitors.
Gao M, O'Boyle DR 2nd, Roberts S.
Curr Opin Pharmacol.
2016 Oct;30:151-157. doi: 10.1016/j.coph.2016.07.014. Review.
PMID: 27643675
Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
Wysham CH, MacConell L, Hardy E.
Diabetes Care.
2016 Oct;39(10):1768-76. doi: 10.2337/dc16-0238.
PMID: 27436275
Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective.
Fahmi OA, Shebley M, Palamanda J, Sinz MW, Ramsden D, Einolf HJ, Chen L, Wang H.
Drug Metab Dispos.
2016 Oct;44(10):1720-30. doi: 10.1124/dmd.116.071076.
PMID: 27422672
Oxygen-dependent regulation of c-di-GMP synthesis by SadC controls alginate production in Pseudomonas aeruginosa.
Schmidt A, Hammerbacher AS, Bastian M, Nieken KJ, Klockgether J, Merighi M, Lapouge K, Poschgan C, Kölle J, Acharya KR, Ulrich M, Tümmler B, Unden G, Kaever V, Lory S, Haas D, Schwarz S, Döring G.
Environ Microbiol . 2016 Oct;18(10):3390-3402. doi: 10.1111/1462-2920.13208.
PMID: 26743546
Novel statistical approach for evaluating flow cytometric in vitro micronucleus data.
Wojciechowski JP, Gleason CR, Roberts DJ, Custer LL.
Environ Mol Mutagen.
2016 Oct;57(8):623-629. doi: 10.1002/em.22038.
PMID: 27545269
P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057: Track: Immunotherapy.
Gralla RJ, Spigel D, Bennett B, Taylor F, Penrod JR, Derosa M, Dastani H, Orsini L, Mathias C, Reck M.
J Thorac Oncol.
2016 Oct;11(10S):S247. doi: 10.1016/j.jtho.2016.08.117. No abstract available.
PMID: 27676580
P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.
Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, Spigel D, Kohlhaeufl M, Garassino M, Chow LQ, Gettinger S, Gerber DE, Havel L, Ramalingam SS, Dy GK, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Lopes G.
J Thorac Oncol.
2016 Oct;11(10S):S238-S239. doi: 10.1016/j.jtho.2016.08.107. No abstract available.
PMID: 27676570
P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.
Borghaei H, Brahmer J, Horn L, Ready N, Steins M, Felip E, Paz-Ares L, Xx X, Barlesi F, Antonia S, Fayette J, Rizvi N, Crino L, Reck M, Erich Eberhardt WE, Hellmann M, Desai K, Li A, Healey D, Spigel D, Mathias C.
J Thorac Oncol.
2016 Oct;11(10S):S237-S238. doi: 10.1016/j.jtho.2016.08.106. No abstract available.
PMID: 27676569
P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153: Track: Immunotherapy.
Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, Mccleod MJ, Li A, Waxman IM, Aanur N, Agrawal S, Richardet E.
J Thorac Oncol.
2016 Oct;11(10S):S236. doi: 10.1016/j.jtho.2016.08.104. No abstract available.
PMID: 27676567
PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057.
Gralla RJ, Spigel D, Bennett B, Taylor F, Penrod JR, Derosa M, Dastani H, Orsini L, Mathias C, Reck M.
J Thorac Oncol.
2016 Oct;11(10S):S171. doi: 10.1016/j.jtho.2016.08.009. No abstract available.
PMID: 27676476
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhore R, Noviello S.
Liver Int.
2016 Oct;36(10):1433-41. doi: 10.1111/liv.13128.
PMID: 27009831
Investigating investment in biopharmaceutical R&D.
Carter PH, Berndt ER, DiMasi JA, Trusheim M.
Nat Rev Drug Discov.
2016 Oct;15(10):673-4. doi: 10.1038/nrd.2016.104. No abstract available.
PMID: 27616295
Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction.
Chen Y, Wang S, Wang S, Liu C, Su C, Hageman M, Hussain M, Haskell R, Stefanski K, Qian F.
Pharm Res.
2016 Oct;33(10):2445-58. doi: 10.1007/s11095-016-1969-2.
PMID: 27283830
Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function.
Baumgart BR, Wang F, Kwagh J, Storck C, Euler C, Fuller M, Simic D, Sharma S, Arnold JJ, Cameron CE, Van Vleet TR, Flint O, Bunch RT, Davies MH, Graziano MJ, Sanderson TP.
Toxicol Sci.
2016 Oct;153(2):396-408. doi: 10.1093/toxsci/kfw135.
PMID: 27466212
Mixtures, Metabolites, and Mechanisms: Understanding Toxicology Using Zebrafish.
Gamse JT, Gorelick DA.
Zebrafish.
2016 Oct;13(5):377-8. doi: 10.1089/zeb.2016.1370.
PMID: 27618129
Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care.
Johnson ME, Lefèvre C, Collings SL, Evans D, Kloss S, Ridha E, Maguire A.
BMJ Open.
2016 Sep 26;6(9):e011471. doi: 10.1136/bmjopen-2016-011471.
PMID: 27678530
Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
Wu YJ, Guernon J, Shi J, Marcin L, Higgins M, Rajamani R, Muckelbauer J, Lewis H, Chang C, Camac D, Toyn JH, Ahlijanian MK, Albright CF, Macor JE, Thompson LA.
J Med Chem.
2016 Sep 22;59(18):8593-600. doi: 10.1021/acs.jmedchem.6b01012.
PMID: 27559936
Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).
Engers DW, Blobaum AL, Gogliotti RD, Cheung YY, Salovich JM, Garcia-Barrantes PM, Daniels JS, Morrison R, Jones CK, Soars MG, Zhuo X, Hurley J, Macor JE, Bronson JJ, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR.
ACS Chem Neurosci.
2016 Sep 21;7(9):1192-200. doi: 10.1021/acschemneuro.6b00035.
PMID: 27075300
Population pharmacokinetics of exenatide.
Cirincione B, Mager DE.
Br J Clin Pharmacol.
2016 Sep 21. doi: 10.1111/bcp.13135. [Epub ahead of print]
PMID: 27650681
Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.
Rosenblatt L, Farr AM, Nkhoma ET, Nelson JK, Ritchings C, Johnston SS.
BMC Infect Dis . 2016 Sep 19;16:492. doi: 10.1186/s12879-016-1827-1. Erratum in:
BMC Infect Dis. 2016 Oct 7;16(1):547 .
PMID: 27643691
Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.
Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.
ACS Med Chem Lett.
2016 Sep 17;7(12):1077-1081.
PMID: 27994741
Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands.
Alt A.
Curr Protoc Pharmacol.
2016 Sep 16;74:9.20.1-9.20.23. doi: 10.1002/cpph.12.
PMID: 27636112
Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets.
LaCreta F, Griffen SC, Liu X, Smith C, Hines C, Volk K, Tejwani R, Boulton DW.
Int J Pharm.
2016 Sep 10;511(1):288-95. doi: 10.1016/j.ijpharm.2016.07.017.
PMID: 27418571
An integrated approach for profiling oxidative metabolites and glutathione adducts using liquid chromatography coupled with ultraviolet detection and triple quadrupole-linear ion trap mass spectrometry.
Chen G, Cheng Z, Zhang K, Jiang H, Zhu M.
J Pharm Biomed Anal.
2016 Sep 10;129:482-91. doi: 10.1016/j.jpba.2016.07.048.
PMID: 27497649
Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
Chi A, Wen S, Monga M, Almubarak M, He X, Rojanasakul Y, Tse W, Remick SC.
PLoS One.
2016 Sep 9;11(9):e0162453. doi: 10.1371/journal.pone.0162453.
PMID: 27611833
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, Chen B, Cardarelli PM, Blanset D, Korman AJ.
PLoS One.
2016 Sep 9;11(9):e0161779. doi: 10.1371/journal.pone.0161779. Erratum in:
PLoS One. 2016 Nov 18;11(11):e0167251 .
PMID: 27610613
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
Sun LQ, Mull E, Zheng B, D'Andrea S, Zhao Q, Wang AX, Sin N, Venables BL, Sit SY, Chen Y, Chen J, Cocuzza A, Bilder DM, Mathur A, Rampulla R, Chen BC, Palani T, Ganesan S, Arunachalam PN, Falk P, Levine S, Chen C, Friborg J, Yu F, Hernandez D, Sheaffer AK, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Ng A, Mueller L, Grasela DM, Adams S, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Wang YK, Fang H, Cockett MI, Meanwell NA, McPhee F, Scola PM.
J Med Chem.
2016 Sep 8;59(17):8042-60. doi: 10.1021/acs.jmedchem.6b00821.
PMID: 27564532
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).
De Lucca GV, Shi Q, Liu Q, Batt DG, Beaudoin Bertrand M, Rampulla R, Mathur A, Discenza L, D'Arienzo C, Dai J, Obermeier M, Vickery R, Zhang Y, Yang Z, Marathe P, Tebben AJ, Muckelbauer JK, Chang CJ, Zhang H, Gillooly K, Taylor T, Pattoli MA, Skala S, Kukral DW, McIntyre KW, Salter-Cid L, Fura A, Burke JR, Barrish JC, Carter PH, Tino JA.
J Med Chem.
2016 Sep 8;59(17):7915-35. doi: 10.1021/acs.jmedchem.6b00722.
PMID: 27531604
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.
Gut.
2016 Sep 7. pii: gutjnl-2016-312444. doi: 10.1136/gutjnl-2016-312444. [Epub ahead of print] Erratum in:
Gut. 2016 Dec;65(12 ):2060 .
PMID: 27605539
Redox-Active Esters in Fe-Catalyzed C-C Coupling.
Toriyama F, Cornella J, Wimmer L, Chen TG, Dixon DD, Creech G, Baran PS.
J Am Chem Soc.
2016 Sep 7;138(35):11132-5. doi: 10.1021/jacs.6b07172.
PMID: 27548696
Implementation of USP antibody standard for system suitability in capillary electrophoresis sodium dodecyl sulfate (CE-SDS) for release and stability methods.
Esterman AL, Katiyar A, Krishnamurthy G.
J Pharm Biomed Anal . 2016 Sep 5;128:447-54. doi: 10.1016/j.jpba.2016.06.006.
PMID: 27344634
Characterization of human metabolism and disposition of levo-tetrahydropalmatine: Qualitative and quantitative determination of oxidative and conjugated metabolites.
Xiao W, Shen G, Zhuang X, Ran X, Zhu M, Li H.
J Pharm Biomed Anal.
2016 Sep 5;128:371-81. doi: 10.1016/j.jpba.2016.06.015.
PMID: 27343900
Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.
Aubry AF, Dean B, Diczfalusy U, Goodenough A, Iffland A, McLeod J, Weng N, Yang Z.
AAPS J . 2016 Sep;18(5):1056-66. doi: 10.1208/s12248-016-9949-3. Review.
PMID: 27350147
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, Chakrapani S, Shor B, Boni J, Johnson TR.
AAPS J.
2016 Sep;18(5):1101-16. doi: 10.1208/s12248-016-9929-7.
PMID: 27198897
Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration.
Shen H, Wang L, Chen W, Menard K, Hong Y, Tian Y, Bonacorsi SJ, Humphreys WG, Lee FY, Gan J.
Acta Pharm Sin B.
2016 Sep;6(5):460-467.
PMID: 27709015
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J.
Am Heart J.
2016 Sep;179:59-68. doi: 10.1016/j.ahj.2016.06.008.
PMID: 27595680
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G.
Am J Hematol . 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423.
PMID: 27192969
Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.
Fleischmann R, Connolly SE, Maldonado MA, Schiff M.
Arthritis Rheumatol.
2016 Sep;68(9):2083-9. doi: 10.1002/art.39714.
PMID: 27111089
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S.
Arthritis Rheumatol.
2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.
PMID: 27059799
A simple, effective approach for rapid development of high-throughput and reliable LC-MS/MS bioanalytical assays.
Yuan L, Aubry AF, Ji QC.
Bioanalysis.
2016 Sep;8(17):1809-22. doi: 10.4155/bio-2016-0100.
PMID: 27491843
Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool box.
Huang H, Degnan AP, Balakrishnan A, Easton A, Gulianello M, Huang Y, Matchett M, Mattson G, Miller R, Santone KS, Senapati A, Shields EE, Sivarao DV, Snyder LB, Westphal R, Whiterock VJ, Yang F, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2016 Sep 1;26(17):4165-9. doi: 10.1016/j.bmcl.2016.07.065.
PMID: 27496211
Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors.
Bhide RS, Neels J, Qin LY, Ruan Z, Stachura S, Weigelt C, Sack JS, Stefanski K, Gu X, Xie JH, Goldstine CB, Skala S, Pedicord DL, Ruepp S, Dhar TG, Carter PH, Salter-Cid LM, Poss MA, Davies P.
Bioorg Med Chem Lett.
2016 Sep 1;26(17):4256-60. doi: 10.1016/j.bmcl.2016.07.047.
PMID: 27476421
CHO cells knocked out for TSC2 display an improved productivity of antibodies under fed batch conditions.
McVey D, Aronov M, Rizzi G, Cowan A, Scott C, Megill J, Russell R, Tirosh B.
Biotechnol Bioeng.
2016 Sep;113(9):1942-52. doi: 10.1002/bit.25951.
PMID: 26888596
Combined metabolomics and proteomics reveals hypoxia as a cause of lower productivity on scale-up to a 5000-liter CHO bioprocess.
Gao Y, Ray S, Dai S, Ivanov AR, Abu-Absi NR, Lewis AM, Huang Z, Xing Z, Borys MC, Li ZJ, Karger BL.
Biotechnol J.
2016 Sep;11(9):1190-200. doi: 10.1002/biot.201600030.
PMID: 27213298
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC.
Clin Lung Cancer.
2016 Sep;17(5):e121-e129. doi: 10.1016/j.cllc.2016.01.003.
PMID: 26898325
A practical approach for the scale-up of roller compaction process.
Shi W, Sprockel OL.
Eur J Pharm Biopharm.
2016 Sep;106:15-9. doi: 10.1016/j.ejpb.2016.02.005.
PMID: 26883853
Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.
Santagostino E, Pol S, Olveira A, Reesink HW, van Erpecum K, Bogomolov P, Xu D, Critelli L, Srinivasan S, Cooney E.
Haemophilia . 2016 Sep;22(5):692-9. doi: 10.1111/hae.12947.
PMID: 27339614
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Zoulim F, Białkowska-Warzecha J, Diculescu MM, Goldis AE, Heyne R, Mach T, Marcellin P, Petersen J, Simon K, Bendahmane S, Klauck I, Wasiak W, Janssen HL.
Hepatol Int.
2016 Sep;10(5):779-88. doi: 10.1007/s12072-016-9737-2.
PMID: 27206517
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Lip GY, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, Bruno A, Phatak H.
Int J Clin Pract.
2016 Sep;70(9):752-63. doi: 10.1111/ijcp.12863.
PMID: 27550177
Effect of rate of pyrolysis on the textural properties of naturally-templated porous carbons from alginic acid.
Marriott AS, Hunt AJ, Bergström E, Thomas-Oates J, Clark JH.
J Anal Appl Pyrolysis.
2016 Sep;121:62-66.
PMID: 27695151
Development of a Human Whole Blood Screening Platform to Monitor JAK/STAT Signaling Using High-Throughput Flow Cytometry.
Fereshteh MP, Li X, Li S, Fan Y, Zhang R, Farr GA, Kolodin G, Lippy J, Naglich JG, Schieven G, Schweizer L, Zhang L.
J Biomol Screen.
2016 Sep;21(8):866-74. doi: 10.1177/1087057116645095.
PMID: 27142718
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD.
J Clin Oncol . 2016 Sep 1;34(25):2980-7. doi: 10.1200/JCO.2016.66.9929.
PMID: 27354485
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S.
J Clin Oncol.
2016 Sep 1;34(25):2969-79. doi: 10.1200/JCO.2016.66.9861.
PMID: 27354481
Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective.
Tucker G, DeSilva B, Dressman J, Ito M, Kumamoto T, Mager D, Mahler HC, Maitland-van der Zee AH, Pauletti GM, Sasaki H, Shah V, Tang D, Ward M.
J Pharm Sci.
2016 Sep;105(9):2489-97. doi: 10.1016/j.xphs.2015.12.001.
PMID: 26886325
Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain.
Kostich W, Hamman BD, Li YW, Naidu S, Dandapani K, Feng J, Easton A, Bourin C, Baker K, Allen J, Savelieva K, Louis JV, Dokania M, Elavazhagan S, Vattikundala P, Sharma V, Das ML, Shankar G, Kumar A, Holenarsipur VK, Gulianello M, Molski T, Brown JM, Lewis M, Huang Y, Lu Y, Pieschl R, O'Malley K, Lippy J, Nouraldeen A, Lanthorn TH, Ye G, Wilson A, Balakrishnan A, Denton R, Grace JE, Lentz KA, Santone KS, Bi Y, Main A, Swaffield J, Carson K, Mandlekar S, Vikramadithyan RK, Nara SJ, Dzierba C, Bronson J, Macor JE, Zaczek R, Westphal R, Kiss L, Bristow L, Conway CM, Zambrowicz B, Albright CF.
J Pharmacol Exp Ther.
2016 Sep;358(3):371-86. doi: 10.1124/jpet.116.235333.
PMID: 27411717
Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
Lai Y, Mandlekar S, Shen H, Holenarsipur VK, Langish R, Rajanna P, Murugesan S, Gaud N, Selvam S, Date O, Cheng Y, Shipkova P, Dai J, Humphreys WG, Marathe P.
J Pharmacol Exp Ther.
2016 Sep;358(3):397-404. doi: 10.1124/jpet.116.234914.
PMID: 27317801
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators..
JAMA Cardiol.
2016 Sep 1;1(6):673-81. doi: 10.1001/jamacardio.2016.1829.
PMID: 27463942
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI.
JAMA Oncol . 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.
PMID: 27243803
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A.
Lancet Oncol . 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X.
PMID: 27451390
Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS/MS detection.
Zheng N, Zeng J, Ji QC, Angeles A, Aubry AF, Basdeo S, Buzescu A, Landry IS, Jariwala N, Turley W, Burrell R, Arnold ME.
Anal Chim Acta.
2016 Aug 31;934:170-9. doi: 10.1016/j.aca.2016.05.057.
PMID: 27506357
Harmonizing Global Biospecimen Consent Practices to Advance Translational Research: A Call to Action.
Warner AW, Moore H, Reinhard D, Ball LA, Knoppers BM.
Clin Pharmacol Ther.
2016 Aug 25. doi: 10.1002/cpt.461. [Epub ahead of print]
PMID: 27558027
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.
Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, Park JS, Waxman IM, Roy A, Gupta M.
J Clin Pharmacol.
2016 Aug 25. doi: 10.1002/jcph.818. [Epub ahead of print]
PMID: 27557786
2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph.
Meanwell NA.
J Med Chem.
2016 Aug 25;59(16):7311-51. doi: 10.1021/acs.jmedchem.6b00915.
PMID: 27501244
IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function.
Singh B, Jegga AG, Shanmukhappa KS, Edukulla R, Khurana GH, Medvedovic M, Dillon SR, Madala SK.
PLoS One . 2016 Aug 24;11(8):e0161877. doi: 10.1371/journal.pone.0161877. Erratum in:
PLoS One. 2017 Jan 23;12 (1):e0170446 .
PMID: 27556734
Application of X-ray microtomography for the characterisation of hollow polymer-stabilised spray dried amorphous dispersion particles.
Gamble JF, Terada M, Holzner C, Lavery L, Nicholson SJ, Timmins P, Tobyn M.
Int J Pharm.
2016 Aug 20;510(1):1-8. doi: 10.1016/j.ijpharm.2016.05.051.
PMID: 27262271
2015 Publications
Measuring the sticking of mefenamic acid powders on stainless steel surface.
Wang Z, Shah UV, Olusanmi D, Narang AS, Hussain MA, Gamble JF, Tobyn MJ, Heng JY.
Int J Pharm.
2015 Dec 30;496(2):407-13. doi: 10.1016/j.ijpharm.2015.09.067.
PMID: 26456293
Synergistic Activity of Combined NS5A Inhibitors.
O'Boyle DR 2nd, Nower PT, Gao M, Fridell R, Wang C, Hewawasam P, Lopez O, Tu Y, Meanwell NA, Belema M, Roberts SB, Cockett M, Sun JH.
Antimicrob Agents Chemother.
2015 Dec 28;60(3):1573-83. doi: 10.1128/AAC.02639-15.
PMID: 26711745
Characterization and quantification of histidine degradation in therapeutic protein formulations by size exclusion-hydrophilic interaction two dimensional-liquid chromatography with stable-isotope labeling mass spectrometry.
Wang C, Chen S, Brailsford JA, Yamniuk AP, Tymiak AA, Zhang Y.
J Chromatogr A.
2015 Dec 24;1426:133-9. doi: 10.1016/j.chroma.2015.11.065.
PMID: 26674608
The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.
Larkin J, Hatswell AJ, Nathan P, Lebmeier M, Lee D.
PLoS One.
2015 Dec 23;10(12):e0145524. doi: 10.1371/journal.pone.0145524.
PMID: 26700304
Genetic Architecture of Atherosclerosis in Mice: A Systems Genetics Analysis of Common Inbred Strains.
Bennett BJ, Davis RC, Civelek M, Orozco L, Wu J, Qi H, Pan C, Packard RR, Eskin E, Yan M, Kirchgessner T, Wang Z, Li X, Gregory JC, Hazen SL, Gargalovic PS, Lusis AJ.
PLoS Genet.
2015 Dec 22;11(12):e1005711. doi: 10.1371/journal.pgen.1005711. Erratum in:
PLoS Genet. 2016 Mar;12(3):e1005913 .
PMID: 26694027
Asymmetric Synthesis of Heterocyclic Analogues of a CGRP Receptor Antagonist for Treating Migraine.
Luo G, Chen L, Conway CM, Kostich W, Macor JE, Dubowchik GM.
Org Lett.
2015 Dec 18;17(24):5982-5. doi: 10.1021/acs.orglett.5b02921.
PMID: 26650258
General Method for the Preparation of Electron-Deficient Imidazo[1,2-a]pyridines and Related Heterocycles.
McDonald IM, Peese KM.
Org Lett.
2015 Dec 18;17(24):6002-5. doi: 10.1021/acs.orglett.5b02966.
PMID: 26598965
Post-pellet-digestion precipitation and solid phase extraction: A practical and efficient workflow to extract surrogate peptides for ultra-high performance liquid chromatography--tandem mass spectrometry bioanalysis of a therapeutic antibody in the low ng/mL range.
Gong C, Zheng N, Zeng J, Aubry AF, Arnold ME.
J Chromatogr A.
2015 Dec 11;1424:27-36. doi: 10.1016/j.chroma.2015.10.049.
PMID: 26525666
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Mărgulescu AD, Wallentin L, Atar D.
Eur Heart J.
2015 Dec 7;36(46):3268-75. doi: 10.1093/eurheartj/ehv447.
PMID: 26371113
Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
Good DJ, Hartley R, Mathias N, Crison J, Tirucherai G, Timmins P, Hussain M, Haddadin R, Koo O, Nikfar F, Fung NK.
Mol Pharm.
2015 Dec 7;12(12):4434-44. doi: 10.1021/acs.molpharmaceut.5b00624.
PMID: 26536519
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.
Huang A, Jayaraman L, Fura A, Vite GD, Trainor GL, Gottardis MM, Spires TE, Spires VM, Rizzo CA, Obermeier MT, Elzinga PA, Todderud G, Fan Y, Newitt JA, Beyer SM, Zhu Y, Warrack BM, Goodenough AK, Tebben AJ, Doweyko AM, Gold DL, Balog A.
ACS Med Chem Lett.
2015 Dec 2;7(1):40-5. doi: 10.1021/acsmedchemlett.5b00310.
PMID: 26819663
Finite Element Method (FEM) Modeling of Freeze-drying: Monitoring Pharmaceutical Product Robustness During Lyophilization.
Chen X, Sadineni V, Maity M, Quan Y, Enterline M, Mantri RV.
AAPS PharmSciTech.
2015 Dec;16(6):1317-26. doi: 10.1208/s12249-015-0318-9.
PMID: 25791415
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors.
Bloudek LM, Makenbaeva D, Eaddy M.
Am Health Drug Benefits . 2015 Dec;8(9):472-80.
PMID: 26834933
The impact of dasatinib on pregnancy outcomes.
Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF.
Am J Hematol.
2015 Dec;90(12):1111-5. doi: 10.1002/ajh.24186.
PMID: 26348106
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity).
Amaravadi L, Song A, Myler H, Thway T, Kirshner S, Devanarayan V, Ni YG, Garofolo F, Birnboeck H, Richards S, Gupta S, Luo L, Kingsley C, Salazar-Fontana L, Fraser S, Gorovits B, Allinson J, Barger T, Chilewski S, Fjording MS, Haidar S, Islam R, Jaitner B, Kamerud J, Katori N, Krinos-Fiorotti C, Lanham D, Ma M, McNally J, Morimoto A, Mytych D, Nogueira da Costa A, Papadimitriou A, Pillutla R, Ray S, Safavi A, Savoie N, Schaefer M, Shih J, Smeraglia J, Skelly MF, Spond J, Staack RF, Stouffer B, Tampal N, Torri A, Welink J, Yang TY, Zoghbi J.
Bioanalysis . 2015 Dec;7(24):3107-24. doi: 10.4155/bio.15.226.
PMID: 26635247
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies).
Ackermann B, Neubert H, Hughes N, Garofolo F, Abberley L, Alley SC, Brown-Augsburger P, Bustard M, Chen LZ, Heinrich J, Katori N, Kaur S, Kirkovsky L, Laterza OF, Le Blaye O, Lévesque A, Santos GM, Olah T, Savoie N, Skelly M, Spitz S, Szapacs M, Tampal N, Wang J, Welink J, Wieling J, Haidar S, Vinter S, Whale E, Witte B.
Bioanalysis . 2015 Dec;7(23):3019-34. doi: 10.4155/bio.15.214.
PMID: 26627049
So you think your assay is robust?
Aubry AF, Weng N.
Bioanalysis.
2015 Dec;7(23):2969-71. doi: 10.4155/bio.15.198. No abstract available.
PMID: 26616477
Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.
Datta D, Arion D, Corradi JP, Lewis DA.
Biol Psychiatry.
2015 Dec 1;78(11):775-85. doi: 10.1016/j.biopsych.2015.03.030.
PMID: 25981171
Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
Mick R, Chen TT.
Cancer Immunol Res.
2015 Dec;3(12):1292-8. doi: 10.1158/2326-6066.CIR-15-0260. Review.
PMID: 26644449
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
Koguchi Y, Hoen HM, Bambina SA, Rynning MD, Fuerstenberg RK, Curti BD, Urba WJ, Milburn C, Bahjat FR, Korman AJ, Bahjat KS.
Cancer Res.
2015 Dec 1;75(23):5084-92. doi: 10.1158/0008-5472.CAN-15-2303.
PMID: 26627641
Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines.
Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J.
Clin Lymphoma Myeloma Leuk . 2015 Dec;15(12):797-802. doi: 10.1016/j.clml.2015.09.008.
PMID: 26603185
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Eley T, Garimella T, Li W, Bertz RJ.
Clin Pharmacokinet.
2015 Dec;54(12):1205-22. doi: 10.1007/s40262-015-0299-6. Review.
PMID: 26177803
Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan.
Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, Liu LZ, Tang AC, Feng Wang P, Okumura K.
Clin Ther.
2015 Dec 1;37(12):2837-51. doi: 10.1016/j.clinthera.2015.10.007.
PMID: 26608819
Hypoglycaemic episodes in patients with type 2 diabetes--risk factors and associations with patient-reported outcomes: The PANORAMA Study.
Simon D, de Pablos-Velasco P, Parhofer KG, Gönder-Frederick L, Duprat Lomon I, Vandenberghe H, Eschwège E, Bradley C.
Diabetes Metab . 2015 Dec;41(6):470-9. doi: 10.1016/j.diabet.2015.08.007.
PMID: 26455870
Health state utilities associated with attributes of treatments for hepatitis C.
Matza LS, Sapra SJ, Dillon JF, Kalsekar A, Davies EW, Devine MK, Jordan JB, Landrian AS, Feeny DH.
Eur J Health Econ.
2015 Dec;16(9):1005-18. doi: 10.1007/s10198-014-0649-6.
PMID: 25481796
Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Liu X, Johnson M, Mardekian J, Phatak H, Thompson J, Cohen AT.
J Am Heart Assoc.
2015 Dec 1;4(12). pii: e002340. doi: 10.1161/JAHA.115.002340.
PMID: 26627879
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators..
J Am Heart Assoc.
2015 Dec 1;4(12). pii: e002015. doi: 10.1161/JAHA.115.002015.
PMID: 26627878
The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis.
Nadkarni A, You M, Resuehr H, Curtis JR.
J Arthritis.
2015 Dec;4(4). pii: 178.
PMID: 26835182
Development of a Model Protein Interaction Pair as a Benchmarking Tool for the Quantitative Analysis of 2-Site Protein-Protein Interactions.
Yamniuk AP, Newitt JA, Doyle ML, Arisaka F, Giannetti AM, Hensley P, Myszka DG, Schwarz FP, Thomson JA, Eisenstein E.
J Biomol Tech.
2015 Dec;26(4):125-41. doi: 10.7171/jbt.15-2604-001.
PMID: 26543437
Comparison of Ensemble and Single Molecule Methods for Particle Characterization and Binding Analysis of a PEGylated Single-Domain Antibody.
Schneeweis LA, Obenauer-Kutner L, Kaur P, Yamniuk AP, Tamura J, Jaffe N, O'Mara BW, Lindsay S, Doyle M, Bryson J.
J Pharm Sci . 2015 Dec;104(12):4015-24. doi: 10.1002/jps.24624.
PMID: 26343417
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699.
Yang Z, Wang H, Salcedo TW, Suchard SJ, Xie JH, Schneeweis LA, Fleener CA, Calore JD, Shi R, Zhang SX, Rodrigues AD, Car BD, Marathe PH, Nadler SG.
J Pharmacol Exp Ther.
2015 Dec;355(3):506-15. doi: 10.1124/jpet.115.227249.
PMID: 26442523
Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
Burchill MA, Golden-Mason L, Wind-Rotolo M, Rosen HR.
J Viral Hepat.
2015 Dec;22(12):983-91. doi: 10.1111/jvh.12465.
PMID: 26482547
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators..
Lancet Haematol.
2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0.
PMID: 26686406
Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study.
Fauchier L, Samson A, Chaize G, Gaudin AF, Vainchtock A, Bailly C, Cotté FE.
Open Heart.
2015 Dec 1;2(1):e000290. doi: 10.1136/openhrt-2015-000290.
PMID: 26688739
Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.
Pavia-Ruz N, Rossouw M, Sáez-Llorens X, Bunupuradah T, Taylor M, Yang R, Sevinsky H, Krystal M, Lataillade M, Seekins D, Biguenet S.
Pediatr Infect Dis J.
2015 Dec;34(12):1355-60. doi: 10.1097/INF.0000000000000913.
PMID: 26379163
Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.
Radawski C, Morrato E, Hornbuckle K, Bahri P, Smith M, Juhaeri J, Mol P, Levitan B, Huang HY, Coplan P, Li H; BRACE Special Interest Group..
Pharmacoepidemiol Drug Saf.
2015 Dec;24(12):1233-40. doi: 10.1002/pds.3859. Review.
PMID: 26456379
The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
Tremaine L, Brian W, DelMonte T, Francke S, Groenen P, Johnson K, Li L, Pearson K, Marshall JC.
Pharmacogenomics . 2015 Dec;16(18):2055-67. doi: 10.2217/pgs.15.141. Review.
PMID: 26616152
Caring for relatives with lung cancer in Europe: an evaluation of caregivers' experience.
Jassem J, Penrod JR, Goren A, Gilloteau I.
Qual Life Res.
2015 Dec;24(12):2843-52. doi: 10.1007/s11136-015-1028-1.
PMID: 26068731
Potential seminal transport of pharmaceuticals to the conceptus.
Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL, DeLise AM, Hui JY, Moffat GJ, Stewart J, Thompson KE.
Reprod Toxicol.
2015 Dec;58:213-21. doi: 10.1016/j.reprotox.2015.10.015. Review.
PMID: 26545974
Pregnancy outcomes following exposure to abatacept during pregnancy.
Kumar M, Ray L, Vemuri S, Simon TA.
Semin Arthritis Rheum.
2015 Dec;45(3):351-6. doi: 10.1016/j.semarthrit.2015.06.016.
PMID: 26210783
Erratum to: Iron metabolism and iron supplementation in cancer patients.
Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H.
Wien Klin Wochenschr.
2015 Dec;127(23-24):920-1. doi: 10.1007/s00508-015-0893-5. No abstract available.
PMID: 26613899
Iron metabolism and iron supplementation in cancer patients.
Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H.
Wien Klin Wochenschr.
2015 Dec;127(23-24):907-19. doi: 10.1007/s00508-015-0842-3. Review. Erratum in:
Wien Klin Wochenschr. 2015 Dec;127(23-24):920-1 .
PMID: 26373748
Impact of moisture and magnesium stearate functionality on manufacturability of wet granulated metformin tablets.
Kestur U, Desai D, Sharif S, Wong B, Guo H, Tang D, Chan S.
Pharm Dev Technol.
2015 Nov 29:1-9. [Epub ahead of print]
PMID: 26616157
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
Qiao JX, Wang TC, Adam LP, Chen AY, Taylor DS, Yang RZ, Zhuang S, Sleph PG, Li JP, Li D, Yin X, Chang M, Chen XQ, Shen H, Li J, Smith D, Wu DR, Leith L, Harikrishnan LS, Kamau MG, Miller MM, Bilder D, Rampulla R, Li YX, Xu C, Lawrence RM, Poss MA, Levesque P, Gordon DA, Huang CS, Finlay HJ, Wexler RR, Salvati ME.
J Med Chem.
2015 Nov 25;58(22):9010-26. doi: 10.1021/acs.jmedchem.5b01363.
PMID: 26524347
Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk.
Lee MH, Yang HI, Lu SN, Lin YJ, Jen CL, Wong KH, Chan SY, Chen LC, Wang LY, L'Italien G, Yuan Y, Chen CJ.
Sci Rep.
2015 Nov 25;5:17030. doi: 10.1038/srep17030.
PMID: 26602024
Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.
Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J.
Am J Clin Oncol.
2015 Nov 17. [Epub ahead of print]
PMID: 26580245
Macrocyclic prolinyl acyl guanidines as inhibitors of β-secretase (BACE).
Boy KM, Guernon JM, Wu YJ, Zhang Y, Shi J, Zhai W, Zhu S, Gerritz SW, Toyn JH, Meredith JE, Barten DM, Burton CR, Albright CF, Good AC, Grace JE, Lentz KA, Olson RE, Macor JE, Thompson LA 3rd.
Bioorg Med Chem Lett.
2015 Nov 15;25(22):5040-7. doi: 10.1016/j.bmcl.2015.10.031.
PMID: 26497283
Applications of Fluorine in Medicinal Chemistry.
Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA.
J Med Chem.
2015 Nov 12;58(21):8315-59. doi: 10.1021/acs.jmedchem.5b00258. Review.
PMID: 26200936
Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Sun JH, O'Boyle DR 2nd, Fridell RA, Langley DR, Wang C, Roberts SB, Nower P, Johnson BM, Moulin F, Nophsker MJ, Wang YK, Liu M, Rigat K, Tu Y, Hewawasam P, Kadow J, Meanwell NA, Cockett M, Lemm JA, Kramer M, Belema M, Gao M.
Nature.
2015 Nov 12;527(7577):245-8. doi: 10.1038/nature15711.
PMID: 26536115
Comparison of pharmaceutical formulations: ATR-FTIR spectroscopic imaging to study drug-carrier interactions.
Ewing AV, Biggart GD, Hale CR, Clarke GS, Kazarian SG.
Int J Pharm.
2015 Nov 10;495(1):112-21. doi: 10.1016/j.ijpharm.2015.08.068.
PMID: 26319636
Effect of milling temperatures on surface area, surface energy and cohesion of pharmaceutical powders.
Shah UV, Wang Z, Olusanmi D, Narang AS, Hussain MA, Tobyn MJ, Heng JY.
Int J Pharm.
2015 Nov 10;495(1):234-40. doi: 10.1016/j.ijpharm.2015.08.061.
PMID: 26315119
Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis.
Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L.
Biologics.
2015 Nov 6;9:119-27. doi: 10.2147/BTT.S89286.
PMID: 26604680
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
BMC Health Serv Res.
2015 Nov 5;15:496. doi: 10.1186/s12913-015-1139-y.
PMID: 26541516
Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
Fernandes A, Wojcik T, Baireddy P, Pieschl R, Newton A, Tian Y, Hong Y, Bristow L, Li YW.
Eur J Pharmacol.
2015 Nov 5;766:1-8. doi: 10.1016/j.ejphar.2015.08.044.
PMID: 26325093
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators..
N Engl J Med . 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665.
PMID: 26406148
Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide.
Kimoto E, Li R, Scialis RJ, Lai Y, Varma MV.
Mol Pharm.
2015 Nov 2;12(11):3943-52. doi: 10.1021/acs.molpharmaceut.5b00411.
PMID: 26378985
Development of a Generic Anti-PEG Antibody Assay Using BioScale's Acoustic Membrane MicroParticle Technology.
Dong H, Mora JR, Brockus C, Chilewski SD, Dodge R, Merrifield C, Dickerson WM, DeSilva B.
AAPS J.
2015 Nov;17(6):1511-6. doi: 10.1208/s12248-015-9799-4.
PMID: 26139446
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A.
Am J Hematol.
2015 Nov;90(11):1060-4. doi: 10.1002/ajh.24174. Review.
PMID: 26284693
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
Krajsová I, Arenberger P, Lakomý R, Kubala E, Březinová I, Poprach A, Šťastný M, Mužík J, Melichar B.
Anticancer Res.
2015 Nov;35(11):6303-10.
PMID: 26504067
Application of Low- and Mid-Frequency Raman Spectroscopy to Characterize the Amorphous-Crystalline Transformation of Indomethacin.
Larkin PJ, Wasylyk J, Raglione M.
Appl Spectrosc.
2015 Nov;69(11):1217-28. doi: 10.1366/15-07926.
PMID: 26647045
Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey.
Sabouret P, Bricard M, Hermann MA, Cotté FE, Deret-Bixio L, Rushton-Smith S.
Arch Cardiovasc Dis.
2015 Nov;108(11):544-53. doi: 10.1016/j.acvd.2015.05.005.
PMID: 26113478
2014 Publications
Development of an ELP-Z based mAb affinity precipitation process using scaled-down filtration techniques.
Sheth RD, Bhut BV, Jin M, Li Z, Chen W, Cramer SM.
J Biotechnol.
2014 Dec 20;192 Pt A:11-9. doi: 10.1016/j.jbiotec.2014.09.020.
PMID: 25285370
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir.
Friborg J, Zhou N, Han Z, Yang X, Falk P, Mendez P, McPhee F.
Infect Dis Ther.
2014 Dec 17. [Epub ahead of print]
PMID: 25516102
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ, Lu Z, Jiang B, Yang BV, Doweyko LM, Nirschl DS, Haque LE, Lin S, Brown G, Hynes J Jr, Tokarski JS, Sack JS, Khan J, Lippy JS, Zhang RF, Pitt S, Shen G, Pitts WJ, Carter PH, Barrish JC, Nadler SG, Salter-Cid LM, McKinnon M, Fura A, Schieven GL, Wrobleski ST.
Bioorg Med Chem Lett.
2014 Dec 15;24(24):5721-6. doi: 10.1016/j.bmcl.2014.10.061.
PMID: 25453808
Electrophilicity of pyridazine-3-carbonitrile, pyrimidine-2-carbonitrile, and pyridine-carbonitrile derivatives: a chemical model to describe the formation of thiazoline derivatives in human liver microsomes.
Sinha S, Ahire D, Wagh S, Mullick D, Sistla R, Selvakumar K, Cortes JC, Putlur SP, Mandlekar S, Johnson BM.
Chem Res Toxicol.
2014 Dec 15;27(12):2052-61. doi: 10.1021/tx500256j.
PMID: 25372409
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.
Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD.
Blood . 2014 Dec 11;124(25):3692-8. doi: 10.1182/blood-2014-08-595496.
PMID: 25320240
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.
Hangeland JJ, Friends TJ, Rossi KA, Smallheer JM, Wang C, Sun Z, Corte JR, Fang T, Wong PC, Rendina AR, Barbera FA, Bozarth JM, Luettgen JM, Watson CA, Zhang G, Wei A, Ramamurthy V, Morin PE, Bisacchi GS, Subramaniam S, Arunachalam P, Mathur A, Seiffert DA, Wexler RR, Quan ML.
J Med Chem.
2014 Dec 11;57(23):9915-32. doi: 10.1021/jm5010607.
PMID: 25405503
Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans.
Lu Y, Griffen SC, Boulton DW, Leil TA.
Front Pharmacol.
2014 Dec 10;5:274. doi: 10.3389/fphar.2014.00274.
PMID: 25540623
Controlling the chemical stability of a moisture-sensitive drug product through monitoring and identification of coating process microenvironment.
Kestur U, Pandey P, Badawy S, Lin J, Desai D.
Int J Pharm.
2014 Dec 10;476(1-2):93-8. doi: 10.1016/j.ijpharm.2014.09.030.
PMID: 25261712
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA.
N Engl J Med.
2014 Dec 4;371(23):2189-99. doi: 10.1056/NEJMoa1406498.
PMID: 25409260
Strategy to improve the quantitative LC-MS analysis of molecular ions resistant to gas-phase collision induced dissociation: application to disulfide-rich cyclic peptides.
Ciccimaro E, Ranasinghe A, D'Arienzo C, Xu C, Onorato J, Drexler DM, Josephs JL, Poss M, Olah T.
Anal Chem.
2014 Dec 2;86(23):11523-7. doi: 10.1021/ac502678y.
PMID: 25371986
Stable isotope labeling by amino acids in cell culture-based liquid chromatography-mass spectrometry assay to measure microtubule dynamics in neuronal cell cultures.
Polson C, Cantone JL, Wei C, Drexler DM, Meredith JE Jr.
Anal Biochem.
2014 Dec 1;466:65-71. doi: 10.1016/j.ab.2014.08.011.
PMID: 25175011
Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.
Liu M, Tuttle M, Gao M, Lemm JA.
Antimicrob Agents Chemother.
2014 Dec;58(12):7416-23. doi: 10.1128/AAC.03851-14.
PMID: 25267677
Artifactual prolongation of activated partial thromboplastin time with PEGylated compounds in silica-based assays.
Murphy B, Parrula MC, Perigard CJ, Li J.
Blood Coagul Fibrinolysis.
2014 Dec;25(8):876-82. doi: 10.1097/MBC.0000000000000176.
PMID: 25192241
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ.
CNS Spectr.
2014 Dec;19(6):528-34. doi: 10.1017/S109285291300103X.
PMID: 24642260
Novel tactics for designing water-soluble molecules in drug discovery.
Walker MA.
Expert Opin Drug Discov.
2014 Dec;9(12):1421-33. doi: 10.1517/17460441.2014.960839. Review.
PMID: 25226793
Labware additives identified to be selective monoamine oxidase-B inhibitors.
Stewart J, Drexler DM, Leet JE, McNaney CA, Herbst JJ.
J Biomol Screen.
2014 Dec;19(10):1409-14. doi: 10.1177/1087057114551523.
PMID: 25296658
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group..
J Hepatol.
2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022.
PMID: 25064437
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, Pol S, Terg R, Younes Z, He B, Eley T, Cohen D, Yu F, Hernandez D, McPhee F, Mendez P, Hughes E.
J Hepatol.
2014 Dec;61(6):1220-7. doi: 10.1016/j.jhep.2014.07.011.
PMID: 25038486
Dynamically optimizing experiment schedules of a laboratory robot system with simulated annealing.
Cabrera C, Fine-Morris M, Pokross M, Kish K, Michalczyk S, Cahn M, Klei H, Russo MF.
J Lab Autom.
2014 Dec;19(6):517-27. doi: 10.1177/2211068214546493.
PMID: 25117530
Myocardial matrix metalloproteinase-2: inside out and upside down.
DeCoux A, Lindsey ML, Villarreal F, Garcia RA, Schulz R.
J Mol Cell Cardiol . 2014 Dec;77:64-72. doi: 10.1016/j.yjmcc.2014.09.016. Review.
PMID: 25261607
Oral delivery of highly lipophilic poorly water-soluble drugs: spray-dried dispersions to improve oral absorption and enable high-dose toxicology studies of a P2Y1 antagonist.
Chen XQ, Stefanski K, Shen H, Huang C, Caporuscio C, Yang W, Lam P, Su C, Gudmundsson O, Hageman M.
J Pharm Sci.
2014 Dec;103(12):3924-31. doi: 10.1002/jps.24199.
PMID: 25308627
The authors reply.
Kohan DE, Fioretto P, Tang W, List JF.
Kidney Int.
2014 Dec;86(6):1272. doi: 10.1038/ki.2014.291. No abstract available.
PMID: 25427094
Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis.
Glauser TA, Ruderman EM, Kummerle D, Kelly S.
Rheumatol Ther.
2014 Dec;1(1):31-44.
PMID: 27747761
Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats.
Subramanian M, Kurawattimath V, Pocha K, Freeden C, Rao I, Mariappan TT, Marathe PH, Vikramadithyan RK, Abraham P, Kulkarni CP, Katnapally P, Nutakki R, Paruchury S, Bhutani P, Mandlekar S.
Xenobiotica.
2014 Dec;44(12):1108-16. doi: 10.3109/00498254.2014.932470.
PMID: 24947446
Is hypoglycemia fear independently associated with health-related quality of life?
Shi L, Shao H, Zhao Y, Thomas NA.
Health Qual Life Outcomes.
2014 Nov 30;12:167. doi: 10.1186/s12955-014-0167-3.
PMID: 25433668
Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
Rigat KL, Lu H, Wang YK, Argyrou A, Fanslau C, Beno B, Wang Y, Marcinkeviciene J, Ding M, Gentles RG, Gao M, Abell LM, Roberts SB.
J Biol Chem.
2014 Nov 28;289(48):33456-68. doi: 10.1074/jbc.M114.613653.
PMID: 25301950
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD.
Nature . 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.
PMID: 25428507
Independent and joint effect of type 2 diabetes and gastric and hepatobiliary diseases on risk of pancreatic cancer risk: 10-year follow-up of population-based cohort.
Lin CC, Chiang JH, Li CI, Hsieh TF, Liu CS, Lin WY, Lee YD, Li TC.
Br J Cancer.
2014 Nov 25;111(11):2180-6. doi: 10.1038/bjc.2014.525.
PMID: 25275365
Decoupling the contribution of dispersive and acid-base components of surface energy on the cohesion of pharmaceutical powders.
Shah UV, Olusanmi D, Narang AS, Hussain MA, Tobyn MJ, Heng JY.
Int J Pharm.
2014 Nov 20;475(1-2):592-6. doi: 10.1016/j.ijpharm.2014.09.018.
PMID: 25223493
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A; ARISTOTLE Investigators..
Circulation . 2014 Nov 18;130(21):1847-58. doi: 10.1161/CIRCULATIONAHA.114.011204.
PMID: 25294786
Reductions in brain 5-HT1B receptor availability in primarily cocaine-dependent humans.
Matuskey D, Bhagwagar Z, Planeta B, Pittman B, Gallezot JD, Chen J, Wanyiri J, Najafzadeh S, Ropchan J, Geha P, Huang Y, Potenza MN, Neumeister A, Carson RE, Malison RT.
Biol Psychiatry.
2014 Nov 15;76(10):816-22. doi: 10.1016/j.biopsych.2013.11.022.
PMID: 24433854
Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials.
Dobbels F, Wong S, Min Y, Sam J, Kalsekar A.
Transplantation . 2014 Nov 15;98(9):960-8. doi: 10.1097/TP.0000000000000159.
PMID: 24831918
Adaptation of the pore diffusion model to describe multi-addition batch uptake high-throughput screening experiments.
Traylor SJ, Xu X, Li Y, Jin M, Li ZJ.
J Chromatogr A.
2014 Nov 14;1368:100-6. doi: 10.1016/j.chroma.2014.09.058.
PMID: 25311484
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F.
Clin Pharmacol.
2014 Nov 13;6:179-87. doi: 10.2147/CPAA.S61131.
PMID: 25419161
Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development.
Leil TA, Bertz R.
Front Pharmacol.
2014 Nov 10;5:247. doi: 10.3389/fphar.2014.00247.
PMID: 25426074
Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone.
Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, Demicco M, Bruce D, Hwang C, Bertz R, Bifano M.
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):19628. doi: 10.7448/IAS.17.4.19628.
PMID: 25394132
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):19605. doi: 10.7448/IAS.17.4.19605.
PMID: 25394109
Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens.
Nkhoma E, Kumar M, Hines P, Moorthy V, Klauck I, Keever AV.
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):19560. doi: 10.7448/IAS.17.4.19560.
PMID: 25394067
No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting.
Farr AM, Johnston SS, Ritchings C, Brouillette M, Rosenblatt L.
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):19538. doi: 10.7448/IAS.17.4.19538.
PMID: 25394047
Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis.
Lalezari J, Latiff GH, Brinson C, Echevarria J, Treviño-Pérez S, Bogner JR, Stock D, Joshi SR, Hanna GJ, Lataillade M.
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):19530. doi: 10.7448/IAS.17.4.19530.
PMID: 25394039
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis.
Brinson C, Lalezari J, Gulam LH, Thompson M, Echevarria J, Treviño-Pérez S, Stock D, Samit JR, George HJ, Lataillade M.
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):19529. doi: 10.7448/IAS.17.4.19529.
PMID: 25394038
Evaluation of acoustic membrane microparticle (AMMP) technology for a sensitive ligand binding assay to support pharmacokinetic determinations of a biotherapeutic.
Chilewski SD, Dickerson WM, Mora JR, Saab A, Alderman EM.
AAPS J.
2014 Nov;16(6):1366-71. doi: 10.1208/s12248-014-9659-7.
PMID: 25245223
Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing.
Mora J, Given Chunyk A, Dysinger M, Purushothama S, Ricks C, Osterlund K, Theobald V.
AAPS J.
2014 Nov;16(6):1175-84. doi: 10.1208/s12248-014-9660-1. Review.
PMID: 25193269
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.
Hanna MS, Mohan P, Knabb R, Gupta E, Frost C, Lawrence JH.
Ann N Y Acad Sci.
2014 Nov;1329:93-106. doi: 10.1111/nyas.12567. Review.
PMID: 25377080
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD.
Ann Oncol.
2014 Nov;25(11):2277-84. doi: 10.1093/annonc/mdu441.
PMID: 25210016
Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists.
Kim KS, Zhang L, Williams D, Perez HL, Stang E, Borzilleri RM, Posy S, Lei M, Chaudhry C, Emanuel S, Talbott R.
Bioorg Med Chem Lett.
2014 Nov 1;24(21):5022-9. doi: 10.1016/j.bmcl.2014.09.022.
PMID: 25278234
Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders.
Yoon DS, Wu SC, Seethala R, Golla R, Nayeem A, Everlof JG, Gordon DA, Hamann LG, Robl JA.
Bioorg Med Chem Lett . 2014 Nov 1;24(21):5045-9. doi: 10.1016/j.bmcl.2014.09.012.
PMID: 25266782
Hypoxia influences protein transport and epigenetic repression of CHO cell cultures in shake flasks.
Qian Y, Xing Z, Lee S, Mackin NA, He A, Kayne PS, He Q, Qian NX, Li ZJ.
Biotechnol J . 2014 Nov;9(11):1413-24. doi: 10.1002/biot.201400315.
PMID: 25271019
Effects of glutamine and asparagine on recombinant antibody production using CHO-GS cell lines.
Xu P, Dai XP, Graf E, Martel R, Russell R.
Biotechnol Prog.
2014 Nov-Dec;30(6):1457-68. doi: 10.1002/btpr.1957.
PMID: 25079388
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Kasichayanula S, Boulton DW, Luo WL, Rodrigues AD, Yang Z, Goodenough A, Lee M, Jemal M, LaCreta F.
Br J Clin Pharmacol.
2014 Nov;78(5):1122-34. doi: 10.1111/bcp.12425.
PMID: 24837659
Bacillus Calmette-Guérin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice.
Vijaya Kumar K, Rudra A, Sreedhara MV, Siva Subramani T, Prasad DS, Das ML, Murugesan S, Yadav R, Trivedi RK, Louis JV, Li YW, Bristow LJ, Naidu PS, Vikramadithyan RK.
Brain Behav Immun . 2014 Nov;42:204-11. doi: 10.1016/j.bbi.2014.06.205.
PMID: 25016199
Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
Deitelzweig SB, Jing Y, Swindle JP, Makenbaeva D.
Clin Ther.
2014 Nov 1;36(11):1566-1573.e3. doi: 10.1016/j.clinthera.2014.09.016.
PMID: 25438725
Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.
Hansen L, Iqbal N, Ekholm E, Cook W, Hirshberg B.
Endocr Pract.
2014 Nov;20(11):1187-97. doi: 10.4158/EP14489.OR.
PMID: 25370334
Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, Harak C, Hoppe S, Gao M, Penin F, Lohmann V, Bartenschlager R.
Gastroenterology.
2014 Nov;147(5):1094-105.e25. doi: 10.1053/j.gastro.2014.07.019.
PMID: 25046163
The paradox of public participation in the healthcare in Poland--what citizens want, and what they think.
Kolasa K, Dohnalik J, Borek E, Siemiątkowski M, Scibiorski C.
Health Policy.
2014 Nov;118(2):159-65. doi: 10.1016/j.healthpol.2014.09.015.
PMID: 25445113
A commentary on scale-up of pan coating process using microenvironmental control.
Pandey P, Bindra DS.
J Pharm Sci.
2014 Nov;103(11):3412-5. doi: 10.1002/jps.24191. Review.
PMID: 25257120
Insight to the thermodynamic stability of molecular crystals through crystallographic studies of a multipolymorph system.
Ng AT, Lai C, Dabros M, Gao Q.
J Pharm Sci.
2014 Nov;103(11):3423-31. doi: 10.1002/jps.24135.
PMID: 25252084
Excipient-process interactions and their impact on tablet compaction and film coating.
Pandey P, Bindra DS, Gour S, Trinh J, Buckley D, Badawy S.
J Pharm Sci.
2014 Nov;103(11):3666-74. doi: 10.1002/jps.24169.
PMID: 25223603
Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry.
Satoh T, Gemma A, Kudoh S, Sakai F, Yamaguchi K, Watanabe T, Ishiguro M, Inoshiri S, Izawa M, Sugihara K, Sakata Y.
Jpn J Clin Oncol . 2014 Nov;44(11):1032-9. doi: 10.1093/jjco/hyu128.
PMID: 25210144
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; HALLMARK-DUAL Study Team..
Lancet . 2014 Nov 1;384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X. Erratum in: Lancet. 2014 Nov 1;384(9954):1576.
PMID: 25078304
Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century".
Bertagnolli MM, Canetta R, Nass SJ.
Oncologist.
2014 Nov;19(11):1179-85. doi: 10.1634/theoncologist.2014-0240.
PMID: 25326161
A practical approach to a viral detection pipeline using existing viral and non-viral sequence resources.
Bekkari K, Shpungin J, Thompson JR.
PDA J Pharm Sci Technol.
2014 Nov-Dec;68(6):595-601. doi: 10.5731/pdajpst.2014.01022.
PMID: 25475634
Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study.
Frings V, van Velden FH, Velasquez LM, Hayes W, van de Ven PM, Hoekstra OS, Boellaard R.
Radiology.
2014 Nov;273(2):539-48. doi: 10.1148/radiol.14132807.
PMID: 24865311
Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development.
Mangipudy R, Burkhardt J, Kadambi VJ.
Regul Toxicol Pharmacol.
2014 Nov;70(2):439-41. doi: 10.1016/j.yrtph.2014.07.014.
PMID: 25058855
Survey of Treatment Costs to Hepatitis C in China.
Duan ZP, Zhou HY, Duan C, Wang Z, Chen Y, Zheng SJ, Liu S, Tang A, Li H.
Value Health.
2014 Nov;17(7):A805. doi: 10.1016/j.jval.2014.08.515. No abstract available.
PMID: 27203036
Cost-Effectiveness of Antiviral Therapy for Chronic Hepatitis B: A Systematic Review.
Chen W, Tang Z, Wang X, Li J, Luo Z.
Value Health.
2014 Nov;17(7):A805. doi: 10.1016/j.jval.2014.08.518. No abstract available.
PMID: 27203032
From Regulatory Approval to Subsidised Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand, Taiwan And Thailand.
Kim H, Jung H, Chou P, Kunihara T, Tosanguan J, Tang Z, Brydon S, Cook G.
Value Health.
2014 Nov;17(7):A794. doi: 10.1016/j.jval.2014.08.454. No abstract available.
PMID: 27202972
Discontinuation/Interruption of Warfarin Therapy in Patients with Non-Valvular Atrial Fibrillation.
Wang J, Qiao Y, Spivey CA, Liu X, Phatak H, Mardekian J, Claflin AB, Kachroo S, Abdulsatter Y, Parker RB.
Value Health . 2014 Nov;17(7):A763. doi: 10.1016/j.jval.2014.08.272. No abstract available.
PMID: 27202796
Health Care Utilization and Costs After Warfarin Discontinuation Among Patients with Non-Valvular Atrial Fibrillation.
Wang J, Qiao Y, Spivey CA, Liu X, Phatak H, Mardekian J, Claflin AB, Kachroo S, Abdulsatter Y, Parker RB.
Value Health.
2014 Nov;17(7):A756. doi: 10.1016/j.jval.2014.08.230. No abstract available.
PMID: 27202755
Cost Minimization Analysis Of Clinical Option Scenarios For Metformin And Acarbose In Treatment Of Type 2 Diabetes: Based On Direct And Indirect Treatment Comparison Results.
Gu S, Xu X, Shi L, Sawhney M, Hu H, Dong H.
Value Health.
2014 Nov;17(7):A745. doi: 10.1016/j.jval.2014.08.165. No abstract available.
PMID: 27202690
The Incidence, Prevalence, and Survival of Malignant Melanoma in Taiwan.
Chang HY, Feng HL, Wang L, Chou P, Wang PF.
Value Health.
2014 Nov;17(7):A740. doi: 10.1016/j.jval.2014.08.135. No abstract available.
PMID: 27202661
Anticipated Price Disclosure: Impact on Funding Decisions in Australia.
Harrison JP, Cook G, Kim H.
Value Health.
2014 Nov;17(7):A723-4. doi: 10.1016/j.jval.2014.08.037. No abstract available.
PMID: 27202568
Modelling the Relationship between Sustained Virologic Response and Treatment Uptake Rates on Future Prevalence and Incidence of Hepatitis C in the UK.
Bennett H, McEwan P, Ward T, Kalsekar A, Yuan Y.
Value Health.
2014 Nov;17(7):A682. doi: 10.1016/j.jval.2014.08.2547. No abstract available.
PMID: 27202526
The Epidemiologic Burden of Hepatitis C Virus Infection in Egypt.
Szabo SM, Juarez-Garcia A, Levy AR, Donato BM.
Value Health.
2014 Nov;17(7):A666. doi: 10.1016/j.jval.2014.08.2455. No abstract available.
PMID: 27202436
Cost-Effectiveness of Ipilimumab in Previously Untreated Patients for Advanced Melanoma in Sweden.
Barzey V, Asukai Y, Gueron B, Holmberg C, Kotapati S.
Value Health.
2014 Nov;17(7):A642-3. doi: 10.1016/j.jval.2014.08.2322. No abstract available.
PMID: 27202303
Patient Count Projections for Advanced Melanoma by Line of Therapy and Other Clinical Characteristics in EU Countries: Results from The UK, Germany, France, Italy and Spain (EU-5).
Gueron B, Kish JK, O'Day K, Martel MJ, Manley Daumont M.
Value Health.
2014 Nov;17(7):A619. doi: 10.1016/j.jval.2014.08.2191. No abstract available.
PMID: 27202177
The Relative Efficacy of Treatments in First-Line Management of Newly Diagnosed Chronic Myeloid Leukaemia: Systematic Literature Review and Indirect Comparison.
Kroes M, Zagorska A, Osei-Assibey G, Paine A.
Value Health.
2014 Nov;17(7):A615. doi: 10.1016/j.jval.2014.08.2165. No abstract available.
PMID: 27202156
Health Care Costs in Patients Treated with Ipilimumab for Advanced Melanoma Results of a Retrospective Chart Review.
Tarhini A, Rao AS, Corman S, Botteman M, Ji X, Mehta S, Margolin K.
Value Health.
2014 Nov;17(7):A615. doi: 10.1016/j.jval.2014.08.2167. No abstract available.
PMID: 27202153
Patient Reported Utilities In First-Line Advanced Or Metastatic Melanoma: Analysis Of Trial CA184-024.
Porter J, Lee D, Hertel N, Hatswell AJ.
Value Health.
2014 Nov;17(7):A569. doi: 10.1016/j.jval.2014.08.1900. No abstract available.
PMID: 27201894
Modelling Survival in the Presence of Different Mechanisms of Action: Ipilimumab and Vemurafenib in Advanced Melanoma.
Lee D, Porter J, Hertel N, Hatswell AJ.
Value Health.
2014 Nov;17(7):A557. doi: 10.1016/j.jval.2014.08.1832. No abstract available.
PMID: 27201833
Cost-Effectiveness Analysis of Ipilimumab in Previously Untreated Patients With Unresectable Malignant Melanoma in Scotland.
Lee D, Porter J, Hatswell AJ, Hertel N, Walker A.
Value Health.
2014 Nov;17(7):A549-50. doi: 10.1016/j.jval.2014.08.1789. No abstract available.
PMID: 27201787
Treatment Patterns and Health Resource Utilization Among Atrial Fibrillation Patients in United Arab Emirates and Saudi Arabia.
Johnston K, Osenenko KM, Donato BM, Qatami L, Alawi AA, Binbrek AS, Hersi AS, Mould JF, Levy AR.
Value Health.
2014 Nov;17(7):A504. doi: 10.1016/j.jval.2014.08.1527. No abstract available.
PMID: 27201532
Clinical and Demographics Characteristics of Non-Valvular Atrial Fibrillation Patients Switching From Warfarin To Novel Oral Anticoagulants.
Kachroo S, Pan X, Liu L, Kawabata H, Phatak H.
Value Health.
2014 Nov;17(7):A500-1. doi: 10.1016/j.jval.2014.08.1506. No abstract available.
PMID: 27201512
Literature Review Of Pro Measures Assessing Anticoagulant Therapy.
Barrett AM, Harris NI, DeMuro C, Kachroo S, Phatak H.
Value Health.
2014 Nov;17(7):A495-6. doi: 10.1016/j.jval.2014.08.1477. No abstract available.
PMID: 27201485
Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism.
Lanitis T, Hamilton M, Rublee DA, Leipold R, Quon P, Browne C, Cohen AT.
Value Health.
2014 Nov;17(7):A488. doi: 10.1016/j.jval.2014.08.1434. No abstract available.
PMID: 27201443
Cost Effectiveness Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients.
Pradelli L, Calandriello M, Di VR, Bellone M, Tubaro M.
Value Health.
2014 Nov;17(7):A487-8. doi: 10.1016/j.jval.2014.08.1432. No abstract available.
PMID: 27201441
Pharmacoeconomic Assessment Of Apixaban Versus Standard Of Care For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients.
Pradelli L, Calandriello M, Di VR, Bellone M, Tubaro M.
Value Health.
2014 Nov;17(7):A486-7. doi: 10.1016/j.jval.2014.08.1427. No abstract available.
PMID: 27201435
Burden Of Cardiovascular Complications In Patients With Atrial Fibrillation In France.
Fauchier L, Samson A, Chaize G, Gaudin AF, Vainchtock A, Bailly C, Cotté FE.
Value Health.
2014 Nov;17(7):A483. doi: 10.1016/j.jval.2014.08.1404. No abstract available.
PMID: 27201414
Budget Impact Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients.
Pradelli L, Calandriello M, Di VR, Bellone M, Tubaro M.
Value Health . 2014 Nov;17(7):A479. doi: 10.1016/j.jval.2014.08.1383. No abstract available.
PMID: 27201393
Risk Factors Associated With Venous Thromboembolism Recurrence In A European Population.
Hamilton M, Gupta S, Goren A, Auziere S, Claflin AB, Reboul R, Phatak H.
Value Health.
2014 Nov;17(7):A477. doi: 10.1016/j.jval.2014.08.1369. No abstract available.
PMID: 27201384
Real World Incidences And Hospital Cost Of Venous And Pulmonary Thromboembolic Events In France.
Bouee S, Emery C, Samson A, Bailly C, Cotté FE.
Value Health.
2014 Nov;17(7):A477. doi: 10.1016/j.jval.2014.08.1370. No abstract available.
PMID: 27201381
Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism.
Hamilton M, Phatak H, Lanitis T, Mardekian J, Rublee DA, Leipold R, Quon P, Browne C, Cohen AT.
Value Health.
2014 Nov;17(7):A475. doi: 10.1016/j.jval.2014.08.1358. No abstract available.
PMID: 27201370
Comparison of Post-Authorisation Measures From Regulatory Authorities With Additional Evidence Requirements From HTA Bodies in Germany.
Ruof J, Staab TR, Slawik L, Orben T, Bosch S.
Value Health.
2014 Nov;17(7):A427. doi: 10.1016/j.jval.2014.08.1073. No abstract available.
PMID: 27201102
Characterizing Work Productivity Loss In Incident Rheumatoid Arthritis In Sweden.
Banefelt J, Gustavsson A, Borgström F, Alemao E.
Value Health.
2014 Nov;17(7):A383. doi: 10.1016/j.jval.2014.08.2629. No abstract available.
PMID: 27200860
Treating to the Target of Das28 < 2.6 in Rheumatoid Arthritis: the Impact of Efficacy on Cost Effectiveness.
Alemao E, Johal S, Al MJ, Rutten-van MM.
Value Health.
2014 Nov;17(7):A378-9. doi: 10.1016/j.jval.2014.08.2605. No abstract available.
PMID: 27200834
Drug Usage Analysis and Health Care Resources Consumption in Patients With Rheumatoid Arthritis.
Degli EL, Sangiorgi D, Calandriello M, Buda S.
Value Health.
2014 Nov;17(7):A373. doi: 10.1016/j.jval.2014.08.2576. No abstract available.
PMID: 27200805
Real World Studies Using Japanese Administrative Databases: Chronic Hepatitis C Treatment Pattern And Resource Use.
Crawford B, Tang A, Li H, Burns L, Wada K, McDonald J.
Value Health.
2014 Nov;17(7):A370-1. doi: 10.1016/j.jval.2014.08.843. No abstract available.
PMID: 27200790
Mean Annual Cost Of Patients Hospitalized For Chronic Hepatitis C In France: The Hepc-Lone Study.
Abergel A, Rotily M, Gaudin AF, De LL, Vainchtock A, Akremi R, Branchoux S.
Value Health . 2014 Nov;17(7):A364. doi: 10.1016/j.jval.2014.08.809. No abstract available.
PMID: 27200756
Burden Of Hospitalizations Related To Chronic Hepatitis C In France: Evolution Between 2009 And 2012.
Rotily M, Abergel A, Branchoux S, De LL, Vainchtock A, Akremi R, Gaudin AF.
Value Health . 2014 Nov;17(7):A364. doi: 10.1016/j.jval.2014.08.808. No abstract available.
PMID: 27200755
Treatment Patterns Among Type 2 Diabetes Mellitus Patients in Saudi Arabia.
Levy AR, Szabo SM, Osenenko KM, Korol EE, Qatami L, Al JS, Al SA, Al SS, Maclean R, Donato BM.
Value Health.
2014 Nov;17(7):A362. doi: 10.1016/j.jval.2014.08.795. No abstract available.
PMID: 27200742
Glycemic, Lipid, and Blood Pressure Control Among Individuals with Type 2 Diabetes Mellitus in Saudi Arabia.
Osenenko KM, Szabo SM, Donato BM, Korol EE, Qatami L, Al Jaser S, Al Saggabi A, El Seid ME, Maclean R, Levy AR.
Value Health.
2014 Nov;17(7):A333-4. doi: 10.1016/j.jval.2014.08.635. No abstract available.
PMID: 27200581
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Models Due to Differing Patient Weights.
Hatswell AJ, Porter J, Hertel N, Lee D.
Value Health.
2014 Nov;17(7):A323-4. doi: 10.1016/j.jval.2014.08.568. No abstract available.
PMID: 27200530
P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion development.
Garcia RA, Yan M, Search D, Zhang R, Carson NL, Ryan CS, Smith-Monroy C, Zheng J, Chen J, Kong Y, Tang H, Hellings SE, Wardwell-Swanson J, Dinchuk JE, Psaltis GC, Gordon DA, Glunz PW, Gargalovic PS.
PLoS One.
2014 Oct 31;9(10):e111385. doi: 10.1371/journal.pone.0111385.
PMID: 25360548
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators*..
Circulation.
2014 Oct 28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389. Erratum in:
Circulation. 2015 Oct 13;132(15):e198 .
PMID: 25189213
Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications.
Marušić A, Hren D, Mansi B, Lineberry N, Bhattacharya A, Garrity M, Clark J, Gesell T, Glasser S, Gonzalez J, Hustad C, Lannon MM, Mooney LA, Peña T.
BMC Med.
2014 Oct 24;12:197. doi: 10.1186/s12916-014-0197-z.
PMID: 25604352
Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models.
Ermakov S, Forster P, Pagidala J, Miladinov M, Wang A, Baillie R, Bartlett D, Reed M, Leil TA.
Front Pharmacol.
2014 Oct 22;5:232. doi: 10.3389/fphar.2014.00232.
PMID: 25374542
Resource use and cost implications of implementing a heart failure program for patients with systolic heart failure in Swedish primary health care.
Agvall B, Paulsson T, Foldevi M, Dahlström U, Alehagen U.
Int J Cardiol.
2014 Oct 20;176(3):731-8. doi: 10.1016/j.ijcard.2014.07.105.
PMID: 25131925
Gene signature-guided dasatinib therapy in metastatic breast cancer.
Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF.
Clin Cancer Res.
2014 Oct 15;20(20):5265-71. doi: 10.1158/1078-0432.CCR-14-0800. Erratum in:
Clin Cancer Res. 2015 Jun 1;21(11):2653 .
PMID: 25172932
Use of a carboxylesterase inhibitor of phenylmethanesulfonyl fluoride to stabilize epothilone D in rat plasma for a validated UHPLC-MS/MS assay.
Yuan L, Fu Y, Zhang D, Xia YQ, Peng Q, Aubry AF, Arnold ME.
J Chromatogr B Analyt Technol Biomed Life Sci.
2014 Oct 15;969:60-8. doi: 10.1016/j.jchromb.2014.08.006.
PMID: 25151331
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators..
J Am Coll Cardiol.
2014 Oct 14;64(15):1541-50. doi: 10.1016/j.jacc.2014.07.967.
PMID: 25301455
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.
Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, Lawson D, Bartell H, Kudchadkar R, Gunter NT, Mehnert JM, Lipson EJ.
J Immunother Cancer . 2014 Oct 14;2(1):33. doi: 10.1186/s40425-014-0033-1.
PMID: 25317333
A validated LC-MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma.
Yuan L, Jiang H, Zheng N, Xia YQ, Ouyang Z, Zeng J, Akinsanya B, Valentine JL, Moehlenkamp JD, Deng Y, Aubry AF, Arnold ME.
J Chromatogr B Analyt Technol Biomed Life Sci.
2014 Oct 12;973C:1-8. doi: 10.1016/j.jchromb.2014.10.005. [Epub ahead of print]
PMID: 25464088
Insights into chiral recognition mechanism in supercritical fluid chromatography III. Non-halogenated polysaccharide stationary phases.
Khater S, Zhang Y, West C.
J Chromatogr A.
2014 Oct 10;1363:278-93. doi: 10.1016/j.chroma.2014.06.084.
PMID: 25035237
Insights into chiral recognition mechanism in supercritical fluid chromatography IV. Chlorinated polysaccharide stationary phases.
Khater S, Zhang Y, West C.
J Chromatogr A.
2014 Oct 10;1363:294-310. doi: 10.1016/j.chroma.2014.06.026.
PMID: 24973802
Understanding API-polymer proximities in amorphous stabilized composite drug products using fluorine-carbon 2D HETCOR solid-state NMR.
Abraham A, Crull G.
Mol Pharm . 2014 Oct 6;11(10):3754-9. doi: 10.1021/mp400629j.
PMID: 25152063
Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry.
Huang RY, Chen G.
Anal Bioanal Chem.
2014 Oct;406(26):6541-58. doi: 10.1007/s00216-014-7924-3. Review.
PMID: 24948090
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.
Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, Zhang D, Byon W, Boyd RA, LaCreta F.
Br J Clin Pharmacol.
2014 Oct;78(4):877-85. doi: 10.1111/bcp.12393.
PMID: 24697979
4-Benzothiazole-7-hydroxyindolinyl diaryl ureas are potent P2Y1 antagonists with favorable pharmacokinetics: low clearance and small volume of distribution.
Qiao JX, Wang TC, Hiebert S, Hu CH, Schumacher WA, Spronk SA, Clark CG, Han Y, Hua J, Price LA, Shen H, Chacko SA, Everlof G, Bostwick JS, Steinbacher TE, Li YX, Huang CS, Seiffert DA, Rehfuss R, Wexler RR, Lam PY.
ChemMedChem.
2014 Oct;9(10):2327-43. doi: 10.1002/cmdc.201402141.
PMID: 24989964
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH; 4B Study Group..
Diabetes Care.
2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876.
PMID: 25011946
The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
Roy D, Chadwick KD, Tatarkiewicz K, LaCerte C, Bergholm AM, Brodie T, Mangipudy RS, Parkes D, Graziano MJ, Reilly TP.
Diabetes Obes Metab . 2014 Oct;16(10):910-21. doi: 10.1111/dom.12294.
PMID: 24666399
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF.
Drug Saf.
2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4.
PMID: 25096959
Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles.
Herrmann K, Shan K, Brunell SC, Chen S.
Endocr Pract.
2014 Oct;20(10):1070-5. doi: 10.4158/EP13477.OR.
PMID: 25100363
Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen.
Burford NT, Wehrman T, Bassoni D, O'Connell J, Banks M, Zhang L, Alt A.
J Biomol Screen . 2014 Oct;19(9):1255-65. doi: 10.1177/1087057114542975.
PMID: 25047277
Clinical effectiveness of stress-reduction techniques in patients with hypertension: systematic review and meta-analysis.
Nagele E, Jeitler K, Horvath K, Semlitsch T, Posch N, Herrmann KH, Grouven U, Hermanns T, Hemkens LG, Siebenhofer A.
J Hypertens.
2014 Oct;32(10):1936-44; discussion 1944. doi: 10.1097/HJH.0000000000000298. Review.
PMID: 25084308
The synthesis of 14C-labeled N-succinimidyl-3-maleimidopropionate, a linker molecule for PEGylated biologics.
Cao K, Maxwell BD, Bonacorsi SJ.
J Labelled Comp Radiopharm . 2014 Oct;57(12):667-9. doi: 10.1002/jlcr.3225.
PMID: 25303408
Utilization of Zwitterion-based solutions to dissect the relative effects of solution pH and ionic strength on the aggregation behavior and conformational stability of a fusion protein.
Zhou R, Nashine V, Palm T, Gandhi R, Adams M.
J Pharm Sci. 2014 Oct;103(10):3065-74. doi: 10.1002/jps.24118.
PMID: 25139470
A combination turbidity and supernatant microplate assay to rank-order the supersaturation limits of early drug candidates.
Morrison JS, Nophsker MJ, Haskell RJ.
J Pharm Sci.
2014 Oct;103(10):3022-32. doi: 10.1002/jps.24090.
PMID: 25070886
Peak purity assessment in a triple-active fixed-dose combination drug product related substances method using a commercial two-dimensional liquid chromatography system.
Shackman JG, Kleintop BL.
J Sep Sci.
2014 Oct;37(19):2688-95. doi: 10.1002/jssc.201400515.
PMID: 25045066
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.
Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C, Lencioni R.
Liver Cancer.
2014 Oct;3(3-4):439-50. doi: 10.1159/000343872. Review.
PMID: 26280005
Nontraditional applications in clinical pathology.
Jordan HL, Register TC, Tripathi NK, Bolliger AP, Everds N, Zelmanovic D, Poitout F, Bounous DI, Wescott D, Ramaiah SK.
Toxicol Pathol.
2014 Oct;42(7):1058-68. doi: 10.1177/0192623314522109. Review.
PMID: 24705882
Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.
McCrindle BW, Li JS, Manlhiot C, Tweddell JS, Giglia TM, Massicotte MP, Monagle P, Krishnamurthy R, Mahaffey KW, Michelson AD, Verdun N, Almond CS, Newburger JW, Brandão LR, Esmon CT, Manco-Johnson MJ, Ichord R, Ortel TL, Chan AK, Portman R, Rose M, Strony J, Kaltman JR.
Circulation.
2014 Sep 30;130(14):1192-203. doi: 10.1161/CIRCULATIONAHA.113.008428. No abstract available.
PMID: 25266860
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
Oncotarget.
2014 Sep 30;5(18):8637-50.
PMID: 25226617
Reverse transcriptase and intron number evolution.
Zhou K, Kuo A, Grigoriev IV.
Stem Cell Investig.
2014 Sep 28;1:17. doi: 10.3978/j.issn.2306-9759.2014.08.01.
PMID: 27358863
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA, Wang Y, Broekema M, Rossi K, O'Connor S, Hong Z, Wu G, Malmstrom SE, Hung CP, LaMarre L, Chimalakonda A, Zhang L, Xin L, Cai H, Chu C, Boehm S, Zalaznick J, Ponticiello R, Sereda L, Han SP, Zebo R, Zinker B, Luk CE, Wong R, Everlof G, Li YX, Wu CK, Lee M, Griffen S, Miller KJ, Krupinski J, Robl JA.
J Med Chem.
2014 Sep 25;57(18):7499-508. doi: 10.1021/jm501175v.
PMID: 25208139
Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
Washburn WN, Manfredi M, Devasthale P, Zhao G, Ahmad S, Hernandez A, Robl JA, Wang W, Mignone J, Wang Z, Ngu K, Pelleymounter MA, Longhi D, Zhao R, Wang B, Huang N, Flynn N, Azzara AV, Barrish JC, Rohrbach K, Devenny JJ, Rooney S, Thomas M, Glick S, Godonis HE, Harvey SJ, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Maxwell BD, Yang H, Apedo A, Gemzik B, Janovitz EB, Huang C, Zhang L, Freeden C, Murphy BJ.
J Med Chem.
2014 Sep 25;57(18):7509-22. doi: 10.1021/jm500026w.
PMID: 25165888
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.
Santella JB 3rd, Gardner DS, Duncia JV, Wu H, Dhar M, Cavallaro C, Tebben AJ, Carter PH, Barrish JC, Yarde M, Briceno SW, Cvijic ME, Grafstrom RR, Liu R, Patel SR, Watson AJ, Yang G, Rose AV, Vickery RD, Caceres-Cortes J, Caporuscio C, Camac DM, Khan JA, An Y, Foster WR, Davies P, Hynes J Jr.
J Med Chem.
2014 Sep 25;57(18):7550-64. doi: 10.1021/jm5003167.
PMID: 25101488
Synthesis of the 6-azaindole containing HIV-1 attachment inhibitor pro-drug, BMS-663068.
Chen K, Risatti C, Bultman M, Soumeillant M, Simpson J, Zheng B, Fanfair D, Mahoney M, Mudryk B, Fox RJ, Hsaio Y, Murugesan S, Conlon DA, Buono FG, Eastgate MD.
J Org Chem.
2014 Sep 19;79(18):8757-67. doi: 10.1021/jo5016008.
PMID: 25144249
Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery.
Leil TA, Frost C, Wang X, Pfister M, LaCreta F.
CPT Pharmacometrics Syst Pharmacol.
2014 Sep 17;3:e136. doi: 10.1038/psp.2014.34.
PMID: 25229619
Selecting the correct weighting factors for linear and quadratic calibration curves with least-squares regression algorithm in bioanalytical LC-MS/MS assays and impacts of using incorrect weighting factors on curve stability, data quality, and assay performance.
Gu H, Liu G, Wang J, Aubry AF, Arnold ME.
Anal Chem.
2014 Sep 16;86(18):8959-66. doi: 10.1021/ac5018265.
PMID: 25157966
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.
Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD.
J Immunother Cancer.
2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3.
PMID: 26196012
Identification of human liver microsomal proteins adducted by a reactive metabolite using shotgun proteomics.
Yang Y, Xiao Q, Humphreys WG, Dongre A, Shu YZ.
Chem Res Toxicol.
2014 Sep 15;27(9):1537-46. doi: 10.1021/tx500181p.
PMID: 25105203
Development of an LC-MS/MS method for high throughput quantification of metformin uptake in transporter inhibition assays.
Vath M, Gallagher L, Shou W, Weller H, Elkin L, Zhang J.
J Chromatogr B Analyt Technol Biomed Life Sci.
2014 Sep 15;967:211-8. doi: 10.1016/j.jchromb.2014.07.024.
PMID: 25125398
Effect of crystal habits on the surface energy and cohesion of crystalline powders.
Shah UV, Olusanmi D, Narang AS, Hussain MA, Gamble JF, Tobyn MJ, Heng JY.
Int J Pharm.
2014 Sep 10;472(1-2):140-7. doi: 10.1016/j.ijpharm.2014.06.014.
PMID: 24928138
Tandem ring-closing metathesis/transfer hydrogenation: practical chemoselective hydrogenation of alkenes.
Connolly T, Wang Z, Walker MA, McDonald IM, Peese KM.
Org Lett.
2014 Sep 5;16(17):4444-7. doi: 10.1021/ol5019739.
PMID: 25140991
Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes.
Iqbal N, Allen E, Öhman P.
Clin Interv Aging.
2014 Sep 4;9:1479-87. doi: 10.2147/CIA.S68193.
PMID: 25214775
No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database.
Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH.
J Int AIDS Soc.
2014 Sep 4;17:19214. doi: 10.7448/IAS.17.1.19214.
PMID: 25192857
Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, Bahit MC, Gersh BJ, Hanna M, Horowitz J, Lopes RD, Wallentin L, Xavier D, Alexander JH; ARISTOTLE Investigators..
Am Heart J.
2014 Sep;168(3):303-9. doi: 10.1016/j.ahj.2014.06.005.
PMID: 25173541
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Wang C, Jia L, O'Boyle DR 2nd, Sun JH, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA.
Antimicrob Agents Chemother.
2014 Sep;58(9):5155-63. doi: 10.1128/AAC.02788-14.
PMID: 24936600
Current advances and strategies towards fully automated sample preparation for regulated LC-MS/MS bioanalysis.
Zheng N, Jiang H, Zeng J.
Bioanalysis.
2014 Sep;6(18):2441-59. doi: 10.4155/bio.14.161. Review.
PMID: 25384595
Development and validation of an LC-MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target.
Gong C, Zeng J, Akinsanya B, Jiang H, Mora J, Chilewski S, Gambardella J, Allentoff A, Gleason C, Aubry AF, DeSilva BS, Arnold ME.
Bioanalysis.
2014 Sep;6(18):2371-83. doi: 10.4155/bio.14.181.
PMID: 25384590
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ.
Cancer Immunol Res . 2014 Sep;2(9):846-56. doi: 10.1158/2326-6066.CIR-14-0040.
PMID: 24872026
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Eley T, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M.
Clin Drug Investig.
2014 Sep;34(9):661-71. doi: 10.1007/s40261-014-0219-9.
PMID: 25117173
Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.
Cotté FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A, Huguet M.
Clin Ther.
2014 Sep 1;36(9):1160-8. doi: 10.1016/j.clinthera.2014.07.016.
PMID: 25151574
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, Im K, Stahre C, Buskila A, Iqbal N, Greenberger N, Lerch MM.
Diabetes Care.
2014 Sep;37(9):2435-41. doi: 10.2337/dc13-2546.
PMID: 24914244
Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.
Bounthavong M, Tran JN, Golshan S, Piland NF, Morello CM, Blickensderfer A, Best JH.
Diabetes Metab.
2014 Sep;40(4):284-91. doi: 10.1016/j.diabet.2014.06.002.
PMID: 25059703
New advances in treating thrombotic diseases.
Schumacher WA, Wang X, Wong PC.
Drug Discov Today.
2014 Sep;19(9):1433-4. doi: 10.1016/j.drudis.2014.06.015. No abstract available.
PMID: 24959954
Tissue factor-fVIIa inhibition: update on an unfinished quest for a novel oral antithrombotic.
Priestley ES.
Drug Discov Today.
2014 Sep;19(9):1440-4. doi: 10.1016/j.drudis.2014.05.023. Review.
PMID: 24881783
Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.
Timmins P, Brown J, Meanwell NA, Hanna GJ, Zhu L, Kadow JF.
Drug Discov Today.
2014 Sep;19(9):1288-93. doi: 10.1016/j.drudis.2014.03.025.
PMID: 24727410
New models for elevating the practice and status of community-based nursing across the spectrum of cancer care in Central and Eastern Europe.
Grimes C, Wanless RS, Damonti J.
Eur J Oncol Nurs.
2014 Sep;18 Suppl 2:S97-122. doi: 10.1016/j.ejon.2014.07.008. Erratum in: Eur J Oncol Nurs. 2014 Dec;18(6):649.
PMID: 25174879
Suppression of peak tailing of phosphate prodrugs in reversed-phase liquid chromatography.
Zhang J, Wang Q, Kleintop B, Raglione T.
J Pharm Biomed Anal . 2014 Sep;98:247-52. doi: 10.1016/j.jpba.2014.05.027.
PMID: 24946148
Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel.
Petri M, Bechtel B, Dennis G, Shah M, McLaughlin T, Kan H, Molta C.
Lupus.
2014 Sep;23(10):1006-13. doi: 10.1177/0961203314532699.
PMID: 24786783
Introduction to the HESI DART Drugs in Semen Consortium.
Chen CL, Beyer BK, Breslin WJ, DeLise AM, Hui JY, Moffat GJ, Thompson KE.
Reprod Toxicol.
2014 Sep;48:113-4. doi: 10.1016/j.reprotox.2014.04.007. No abstract available.
PMID: 24803405
Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease.
Wes PD, Easton A, Corradi J, Barten DM, Devidze N, DeCarr LB, Truong A, He A, Barrezueta NX, Polson C, Bourin C, Flynn ME, Keenan S, Lidge R, Meredith J, Natale J, Sankaranarayanan S, Cadelina GW, Albright CF, Cacace AM.
PLoS One.
2014 Aug 25;9(8):e106050. doi: 10.1371/journal.pone.0106050. Erratum in:
PLoS One. 2015;10(3):e0121509 .
PMID: 25153994
A novel and cost effective method of removing excess albumin from plasma/serum samples and its impacts on LC-MS/MS bioanalysis of therapeutic proteins.
Liu G, Zhao Y, Angeles A, Hamuro LL, Arnold ME, Shen JX.
Anal Chem.
2014 Aug 19;86(16):8336-43. doi: 10.1021/ac501837t.
PMID: 25083595
Stability of indomethacin with relevance to the release from amorphous solid dispersions studied with ATR-FTIR spectroscopic imaging.
Ewing AV, Clarke GS, Kazarian SG.
Eur J Pharm Sci.
2014 Aug 18;60:64-71. doi: 10.1016/j.ejps.2014.05.001.
PMID: 24832964
Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.
Li YW, Langdon S, Pieschl R, Strong T, Wright RN, Rohrbach K, Lelas S, Lodge NJ.
Eur J Pharmacol . 2014 Aug 15;737:47-56. doi: 10.1016/j.ejphar.2014.03.024.
PMID: 24821570
Monitoring process induced attrition of drug substance particles within formulated blends.
Gamble JF, Hoffmann M, Hughes H, Hutchins P, Tobyn M.
Int J Pharm.
2014 Aug 15;470(1-2):77-87. doi: 10.1016/j.ijpharm.2014.04.028.
PMID: 24793838
Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure.
Casey MJ, Wen X, Kayler LK, Aiyer R, Scornik JC, Meier-Kriesche HU.
Transplantation.
2014 Aug 15;98(3):306-11. doi: 10.1097/TP.0000000000000057.
PMID: 24717218
Quantitative analysis of polyethylene glycol (PEG) and PEGylated proteins in animal tissues by LC-MS/MS coupled with in-source CID.
Gong J, Gu X, Achanzar WE, Chadwick KD, Gan J, Brock BJ, Kishnani NS, Humphreys WG, Iyer RA.
Anal Chem.
2014 Aug 5;86(15):7642-9. doi: 10.1021/ac501507g.
PMID: 25003239
NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats.
Sivarao DV, Chen P, Yang Y, Li YW, Pieschl R, Ahlijanian MK.
Front Psychiatry.
2014 Aug 5;5:96. doi: 10.3389/fpsyt.2014.00096.
PMID: 25140157
Determination of residual acetone and acetone related impurities in drug product intermediates prepared as Spray Dried Dispersions (SDD) using gas chromatography with headspace autosampling (GCHS).
Quirk E, Doggett A, Bretnall A.
J Pharm Biomed Anal.
2014 Aug 5;96:37-44. doi: 10.1016/j.jpba.2014.03.027.
PMID: 24721204
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.
Stevanović J, Pompen M, Le HH, Rozenbaum MH, Tieleman RG, Postma MJ.
PLoS One.
2014 Aug 5;9(8):e103974. doi: 10.1371/journal.pone.0103974.
PMID: 25093723
Independent data monitoring committees: preparing a path for the future.
Hess CN, Roe MT, Gibson CM, Temple RJ, Pencina MJ, Zarin DA, Anstrom KJ, Alexander JH, Sherman RE, Fiedorek FT, Mahaffey KW, Lee KL, Chow SC, Armstrong PW, Califf RM.
Am Heart J.
2014 Aug;168(2):135-41.e1. doi: 10.1016/j.ahj.2014.05.003.
PMID: 25066551
Bioavailability of therapeutic proteins by inhalation--worker safety aspects.
Pfister T, Dolan D, Bercu J, Gould J, Wang B, Bechter R, Barle EL, Pfannkuch F, Flueckiger A.
Ann Occup Hyg.
2014 Aug;58(7):899-911. doi: 10.1093/annhyg/meu038. Review.
PMID: 24958792
LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column.
Pursley J, Shen JX, Schuster A, Dang OT, Lehman J, Buonarati MH, Song Y, Aubry AF, Arnold ME.
Bioanalysis.
2014 Aug;6(15):2071-82. doi: 10.4155/bio.14.66.
PMID: 25322783
Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.
Gong H, Yang M, Xiao Z, Doweyko AM, Cunningham M, Wang J, Habte S, Holloway D, Burke C, Shuster D, Gao L, Carman J, Somerville JE, Nadler SG, Salter-Cid L, Barrish JC, Weinstein DS.
Bioorg Med Chem Lett.
2014 Aug 1;24(15):3268-73. doi: 10.1016/j.bmcl.2014.06.010.
PMID: 24980053
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
Orwat MJ, Qiao JX, He K, Rendina AR, Luettgen JM, Rossi KA, Xin B, Knabb RM, Wexler RR, Lam PY, Pinto DJ.
Bioorg Med Chem Lett.
2014 Aug 1;24(15):3341-5. doi: 10.1016/j.bmcl.2014.05.101.
PMID: 24951330
Affinity precipitation of a monoclonal antibody from an industrial harvest feedstock using an ELP-Z stimuli responsive biopolymer.
Sheth RD, Jin M, Bhut BV, Li Z, Chen W, Cramer SM.
Biotechnol Bioeng.
2014 Aug;111(8):1595-603. doi: 10.1002/bit.25230.
PMID: 24595842
Cancer immunotherapy highlights from the 2014 ASCO Meeting.
Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N.
Cancer Immunol Res . 2014 Aug;2(8):714-9. doi: 10.1158/2326-6066.CIR-14-0119.
PMID: 25092813
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M, Iqbal N, Lu J, Hirshberg B.
Diabetes Res Clin Pract.
2014 Aug;105(2):185-91. doi: 10.1016/j.diabres.2014.05.006.
PMID: 24947443
Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
Salphati L, Chu X, Chen L, Prasad B, Dallas S, Evers R, Mamaril-Fishman D, Geier EG, Kehler J, Kunta J, Mezler M, Laplanche L, Pang J, Rode A, Soars MG, Unadkat JD, van Waterschoot RA, Yabut J, Schinkel AH, Scheer N.
Drug Metab Dispos.
2014 Aug;42(8):1301-13. doi: 10.1124/dmd.114.057976.
PMID: 24855184
Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy.
Loftus EV Jr, Davis KL, Wang CC, Dastani H, Luo A.
Inflamm Bowel Dis.
2014 Aug;20(8):1361-7. doi: 10.1097/MIB.0000000000000089.
PMID: 24918320
Therapeutic potential of chloroquine in a murine model of inflammatory bowel disease.
Nagar J, Ranade S, Kamath V, Singh S, Karunanithi P, Subramani S, Venkatesh K, Srivastava R, Dudhgaonkar S, Vikramadithyan RK.
Int Immunopharmacol.
2014 Aug;21(2):328-35. doi: 10.1016/j.intimp.2014.05.005.
PMID: 24859061
Integrating High-Content Analysis into a Multiplexed Screening Approach to Identify and Characterize GPCR Agonists.
Zhu Y, Watson J, Chen M, Shen DR, Yarde M, Agler M, Burford N, Alt A, Jayachandra S, Cvijic ME, Zhang L, Dyckman A, Xie J, O'Connell J, Banks M, Weston A.
J Biomol Screen.
2014 Aug;19(7):1079-89. doi: 10.1177/1087057114533146.
PMID: 24789006
Chronic lumbar intrathecal catheterization for the collection of cerebrospinal fluid in the canine.
West W, Ehrmann J, Johnson W.
J Invest Surg.
2014 Aug;27(4):226-33. doi: 10.3109/08941939.2014.882450.
PMID: 24694254
Synthesis of carbon-14 and stable isotope labeled Avagacestat: a novel gamma secretase inhibitor for the treatment of Alzheimer's disease.
Burrell RC, Easter JA, Cassidy MP, Gillman KW, Olson RE, Bonacorsi SJ.
J Labelled Comp Radiopharm.
2014 Aug;57(10):600-5. doi: 10.1002/jlcr.3224.
PMID: 25196195
Challenges in accurate quantitation of lysophosphatidic acids in human biofluids.
Onorato JM, Shipkova P, Minnich A, Aubry AF, Easter J, Tymiak A.
J Lipid Res.
2014 Aug;55(8):1784-96. doi: 10.1194/jlr.D050070.
PMID: 24872406
Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering.
Mitchell T, Chao G, Sitkoff D, Lo F, Monshizadegan H, Meyers D, Low S, Russo K, DiBella R, Denhez F, Gao M, Myers J, Duke G, Witmer M, Miao B, Ho SP, Khan J, Parker RA.
J Pharmacol Exp Ther.
2014 Aug;350(2):412-24. doi: 10.1124/jpet.114.214221.
PMID: 24917546
Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
Yang W, Wang Y, Lai A, Qiao JX, Wang TC, Hua J, Price LA, Shen H, Chen XQ, Wong P, Crain E, Watson C, Huang CS, Seiffert DA, Rehfuss R, Wexler RR, Lam PY.
J Med Chem.
2014 Jul 24;57(14):6150-64. doi: 10.1021/jm5006226.
PMID: 24931384
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
Coppens M, Synhorst D, Eikelboom JW, Yusuf S, Shestakovska O, Connolly SJ.
Eur Heart J.
2014 Jul 21;35(28):1856-63. doi: 10.1093/eurheartj/ehu048.
PMID: 24569032
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L.
Eur Heart J . 2014 Jul 21;35(28):1864-72. doi: 10.1093/eurheartj/ehu046.
PMID: 24561548
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Lip GY.
Eur Heart J.
2014 Jul 21;35(28):1897-906. doi: 10.1093/eurheartj/ehu006.
PMID: 24513791
Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes.
Azoulay L, Dell'Aniello S, Simon TA, Renoux C, Suissa S.
Eur Heart J.
2014 Jul 21;35(28):1881-7. doi: 10.1093/eurheartj/eht499.
PMID: 24353282
Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy.
Badawy SI, Lin J, Gokhale M, Desai S, Nesarikar VV, LaMarche KR, Subramanian GA, Narang AS.
Int J Pharm.
2014 Jul 20;469(1):111-20. doi: 10.1016/j.ijpharm.2014.04.059.
PMID: 24780101
Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
Johnson JA, Xu N, Jeon Y, Finlay HJ, Kover A, Conder ML, Sun H, Li D, Levesque P, Hsueh MM, Harper TW, Wexler RR, Lloyd J.
Bioorg Med Chem Lett.
2014 Jul 15;24(14):3018-22. doi: 10.1016/j.bmcl.2014.05.035.
PMID: 24881565
Development of a highly sensitive liquid chromatography/tandem mass spectrometry method to quantify total and free levels of a target protein, interferon-gamma-inducible protein-10, at picomolar levels in human serum.
Zhang H, Xiao Q, Xin B, Trigona W, Tymiak AA, Dongre AR, Olah TV.
Rapid Commun Mass Spectrom.
2014 Jul 15;28(13):1535-43. doi: 10.1002/rcm.6928.
PMID: 24861605
The effect of additives on the zinc carbenoid-mediated cyclopropanation of a dihydropyrrole.
Ramirez A, Truc VC, Lawler M, Ye YK, Wang J, Wang C, Chen S, Laporte T, Liu N, Kolotuchin S, Jones S, Bordawekar S, Tummala S, Waltermire RE, Kronenthal D.
J Org Chem.
2014 Jul 3;79(13):6233-43. doi: 10.1021/jo500966m.
PMID: 24915024
Quantitative targeted proteomics for membrane transporter proteins: method and application.
Qiu X, Zhang H, Lai Y.
AAPS J.
2014 Jul;16(4):714-26. doi: 10.1208/s12248-014-9607-6. Review.
PMID: 24830943
Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence.
Foster NL, Hackett JS, White G, Chenevert S, Svarvar P, Bain L, Carrillo MC.
Alzheimers Dement . 2014 Jul;10(4):503-8. doi: 10.1016/j.jalz.2014.05.003.
PMID: 24985689
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease.
Hill DL, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephenson D.
Alzheimers Dement.
2014 Jul;10(4):421-9.e3. doi: 10.1016/j.jalz.2013.07.003.
PMID: 24985687
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma.
Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A.
Br J Clin Pharmacol.
2014 Jul;78(1):106-17. doi: 10.1111/bcp.12323.
PMID: 24433434
The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1.
Tran TD, Wakenhut F, Pickford C, Shaw S, Westby M, Smith-Burchnell C, Watson L, Paradowski M, Milbank J, Brimage RA, Halstead R, Glen R, Wilson CP, Adam F, Hay D, Chiva JY, Nichols C, Blakemore DC, Gardner I, Dayal S, Pike A, Webster R, Pryde DC.
ChemMedChem.
2014 Jul;9(7):1378-86. doi: 10.1002/cmdc.201400045.
PMID: 24729513
Antibody-drug conjugates: current status and future directions.
Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM.
Drug Discov Today.
2014 Jul;19(7):869-81. doi: 10.1016/j.drudis.2013.11.004. Review.
PMID: 24239727
[Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
Ariza R, Van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, Janssen K.
Farm Hosp.
2014 Jul 1;38(4):257-65. doi: 10.7399/fh.2014.38.4.1137. Spanish.
PMID: 25137158
Synthesis of a stable isotopically labeled universal surrogate peptide for use as an internal standard in LC-MS/MS bioanalysis of human IgG and Fc-fusion protein drug candidates.
Voronin K, Allentoff AJ, Bonacorsi SJ Jr, Mapelli C, Gong SX, Lee V, Riexinger D, Sanghvi N, Jiang H, Zeng J.
J Labelled Comp Radiopharm.
2014 Jul;57(9):579-83. doi: 10.1002/jlcr.3218.
PMID: 25089024
1H NMR-based lipidomics of rodent fur: species-specific lipid profiles and SCD1 inhibitor-related dermal toxicity.
Khandelwal P, Stryker S, Chao H, Aranibar N, Lawrence RM, Madireddi M, Zhao W, Chen L, Reily MD.
J Lipid Res.
2014 Jul;55(7):1366-74. doi: 10.1194/jlr.M049155.
PMID: 24755647
Patients' perspectives on residual symptoms in bipolar disorder: a focus group study.
Samalin L, Bellivier F, Giordana B, Yon L, Milhiet V, El-Hage W, Courtet P, Hacques E, Bedira N, Dillenschneider A, Llorca PM.
J Nerv Ment Dis.
2014 Jul;202(7):550-5. doi: 10.1097/NMD.0000000000000157.
PMID: 24921420
Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors.
Lodge NJ, Li YW, Chin FT, Dischino DD, Zoghbi SS, Deskus JA, Mattson RJ, Imaizumi M, Pieschl R, Molski TF, Fujita M, Dulac H, Zaczek R, Bronson JJ, Macor JE, Innis RB, Pike VW.
Nucl Med Biol.
2014 Jul;41(6):524-35. doi: 10.1016/j.nucmedbio.2014.03.005.
PMID: 24793011
Advancing the 3Rs in regulatory toxicology - Carcinogenicity testing: Scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union.
Annys E, Billington R, Clayton R, Bremm KD, Graziano M, McKelvie J, Ragan I, Schwarz M, van der Laan JW, Wood C, Öberg M, Wester P, Woodward KN.
Regul Toxicol Pharmacol.
2014 Jul;69(2):234-42. doi: 10.1016/j.yrtph.2014.04.009.
PMID: 24768934
2013 Publications
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors.
Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.
ACS Med Chem Lett . 2013 Dec 26;5(2):188-92. doi: 10.1021/ml400453z.
PMID: 24900796
Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds.
Ruel R, L'Heureux A, Thibeault C, Lapointe P, Martel A, Qiao JX, Hua J, Price LA, Wu Q, Chang M, Zheng J, Huang CS, Wexler RR, Rehfuss R, Lam PY.
Bioorg Med Chem Lett.
2013 Dec 15;23(24):6825-8. doi: 10.1016/j.bmcl.2013.10.009.
PMID: 24269480
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Ellsworth BA, Sher PM, Wu X, Wu G, Sulsky RB, Gu Z, Murugesan N, Zhu Y, Yu G, Sitkoff DF, Carlson KE, Kang L, Yang Y, Lee N, Baska RA, Keim WJ, Cullen MJ, Azzara AV, Zuvich E, Thomas MA, Rohrbach KW, Devenny JJ, Godonis HE, Harvey SJ, Murphy BJ, Everlof GG, Stetsko PI, Gudmundsson O, Johnghar S, Ranasinghe A, Behnia K, Pelleymounter MA, Ewing WR.
J Med Chem.
2013 Dec 12;56(23):9586-600. doi: 10.1021/jm4010835.
PMID: 24182233
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects.
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C.
Clin Pharmacol . 2013 Dec 6;5:177-84. doi: 10.2147/CPAA.S51981. Erratum in: Clin Pharmacol. 2014;6:61.
PMID: 24353445
Orthogonal high-throughput thermal scanning method for rank ordering protein formulations.
Nashine VC, Kroetsch AM, Sahin E, Zhou R, Adams ML.
AAPS PharmSciTech . 2013 Dec;14(4):1360-6. doi: 10.1208/s12249-013-0026-2.
PMID: 24002823
BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue.
Wang F, Flint OP.
Antimicrob Agents Chemother . 2013 Dec;57(12):6205-12. doi: 10.1128/AAC.01206-13.
PMID: 24080659
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE.
Br J Clin Pharmacol.
2013 Dec;76(6):908-16. doi: 10.1111/bcp.12114.
PMID: 23488672
Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.
Clin Ther.
2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006.
PMID: 24119767
Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.
Shen H, Yang Z, Zhao W, Zhang Y, Rodrigues AD.
Drug Metab Dispos.
2013 Dec;41(12):2095-103. doi: 10.1124/dmd.113.053215.
PMID: 24026623
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA.
J Clin Oncol.
2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802.
PMID: 24145345
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.
Andersen H, Meyer J, Freeman J, Doyle SE, Klucher K, Miller DM, Hausman D, Hillson JL.
J Clin Transl Hepatol.
2013 Dec;1(2):116-24. doi: 10.14218/JCTH.2013.00014. Review.
PMID: 26357610
Evaluation of integrated Raman-DSC technology in early pharmaceutical development: characterization of polymorphic systems.
Huang J, Dali M.
J Pharm Biomed Anal . 2013 Dec;86:92-9. doi: 10.1016/j.jpba.2013.08.004.
PMID: 23995752
The effect of the physical state of binders on high-shear wet granulation and granule properties: a mechanistic approach to understand the high-shear wet granulation process. part IV. the impact of rheological state and tip-speeds.
Li J, Tao L, Buckley D, Tao J, Gao J, Hubert M.
J Pharm Sci.
2013 Dec;102(12):4384-94. doi: 10.1002/jps.23750.
PMID: 24135976
Imaging dehydration kinetics of a channel hydrate form of the HIV-1 attachment inhibitor prodrug BMS-663068.
Leane MM, Gamble JF, Brown J, Hughes H, Crull G, Engstrom J, Gao Q, Bunker M, Rutherford S, Parker A, Roberts CJ, Tobyn M.
J Pharm Sci.
2013 Dec;102(12):4375-83. doi: 10.1002/jps.23747.
PMID: 24129913
Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.
Qiao JX, Wang TC, Ruel R, Thibeault C, L'Heureux A, Schumacher WA, Spronk SA, Hiebert S, Bouthillier G, Lloyd J, Pi Z, Schnur DM, Abell LM, Hua J, Price LA, Liu E, Wu Q, Steinbacher TE, Bostwick JS, Chang M, Zheng J, Gao Q, Ma B, McDonnell PA, Huang CS, Rehfuss R, Wexler RR, Lam PY.
J Med Chem . 2013 Nov 27;56(22):9275-95. doi: 10.1021/jm4013906.
PMID: 24164581
Practical and economical implementation of online H/D exchange in LC-MS.
Shah RP, Garg A, Putlur SP, Wagh S, Kumar V, Rao V, Singh S, Mandlekar S, Desikan S.
Anal Chem . 2013 Nov 19;85(22):10904-12. doi: 10.1021/ac402339s.
PMID: 24117319
Introduction of a new scaling approach for particle size reduction in toothed rotor-stator wet mills.
Engstrom J, Wang C, Lai C, Sweeney J.
Int J Pharm . 2013 Nov 18;456(2):261-8. doi: 10.1016/j.ijpharm.2013.08.084.
PMID: 24012859
Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain.
Wu YJ, Conway CM, Sun LQ, Machet F, Chen J, Chen P, He H, Bourin C, Calandra V, Polino JL, Davis CD, Heman K, Gribkoff VK, Boissard CG, Knox RJ, Thompson MW, Fitzpatrick W, Weaver D, Harden DG, Natale J, Dworetzky SI, Starrett JE Jr.
Bioorg Med Chem Lett.
2013 Nov 15;23(22):6188-91. doi: 10.1016/j.bmcl.2013.08.092.
PMID: 24070783
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.
Clin Cancer Res.
2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189.
PMID: 24030703
Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy.
Mathias NR, Xu Y, Patel D, Grass M, Caldwell B, Jager C, Mullin J, Hansen L, Crison J, Saari A, Gesenberg C, Morrison J, Vig B, Raghavan K.
Mol Pharm . 2013 Nov 4;10(11):4063-73. doi: 10.1021/mp400426f.
PMID: 24032349
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Li Z, Terry B, Olds W, Protack T, Deminie C, Minassian B, Nowicka-Sans B, Sun Y, Dicker I, Hwang C, Lataillade M, Hanna GJ, Krystal M.
Antimicrob Agents Chemother . 2013 Nov;57(11):5500-8. doi: 10.1128/AAC.01195-13.
PMID: 23979732
Gene expression analyses of mouse aortic endothelium in response to atherogenic stimuli.
Erbilgin A, Siemers N, Kayne P, Yang WP, Berliner J, Lusis AJ.
Arterioscler Thromb Vasc Biol . 2013 Nov;33(11):2509-17. doi: 10.1161/ATVBAHA.113.301989.
PMID: 23990205
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F.
Br J Clin Pharmacol.
2013 Nov;76(5):776-86. doi: 10.1111/bcp.12106.
PMID: 23451769
Metabolomics in drug discovery and development.
Robertson DG, Frevert U.
Clin Pharmacol Ther.
2013 Nov;94(5):559-61. doi: 10.1038/clpt.2013.120.
PMID: 24145714
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.
Suchard SJ, Davis PM, Kansal S, Stetsko DK, Brosius R, Tamura J, Schneeweis L, Bryson J, Salcedo T, Wang H, Yang Z, Fleener CA, Ignatovich O, Plummer C, Grant S, Nadler SG.
J Immunol.
2013 Nov 1;191(9):4599-610. doi: 10.4049/jimmunol.1300470.
PMID: 24081989
Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.
Narang AS, Chang RK, Hussain MA.
J Pharm Sci.
2013 Nov;102(11):3867-82. doi: 10.1002/jps.23691.
PMID: 24037829
Crystal structure of rat intestinal alkaline phosphatase--role of crown domain in mammalian alkaline phosphatases.
Ghosh K, Mazumder Tagore D, Anumula R, Lakshmaiah B, Kumar PP, Singaram S, Matan T, Kallipatti S, Selvam S, Krishnamurthy P, Ramarao M.
J Struct Biol.
2013 Nov;184(2):182-92. doi: 10.1016/j.jsb.2013.09.017.
PMID: 24076154
Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms.
Desai D, Wang J, Wen H, Li X, Timmins P.
Pharm Dev Technol.
2013 Nov-Dec;18(6):1265-76. doi: 10.3109/10837450.2012.660699. Review.
PMID: 22339230
Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease.
Easton A, Sankaranarayanan S, Tanghe A, Terwel D, Lin AX, Hoque N, Bourin C, Gu H, Ahlijanian M, Bristow L.
Psychopharmacology (Berl).
2013 Nov;230(2):279-89. doi: 10.1007/s00213-013-3152-3.
PMID: 23783773
Statistical issues and challenges in immuno-oncology.
Chen TT.
J Immunother Cancer . 2013 Oct 21;1:18. doi: 10.1186/2051-1426-1-18.
PMID: 24829754
Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.
Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X.
Am J Cardiol.
2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063.
PMID: 23831166
Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies.
Barbosa MD, Gokemeijer J, Martin AD, Bush A.
Anal Biochem.
2013 Oct 15;441(2):174-9. doi: 10.1016/j.ab.2013.07.019.
PMID: 23886888
Fully validated LC-MS/MS assay for the simultaneous quantitation of coadministered therapeutic antibodies in cynomolgus monkey serum.
Jiang H, Zeng J, Titsch C, Voronin K, Akinsanya B, Luo L, Shen H, Desai DD, Allentoff A, Aubry AF, Desilva BS, Arnold ME.
Anal Chem.
2013 Oct 15;85(20):9859-67. doi: 10.1021/ac402420v.
PMID: 24024648
Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3-phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core.
Xiao HY, Wu DR, Sheppeck JE 2nd, Habte SF, Cunningham MD, Somerville JE, Barrish JC, Nadler SG, Dhar TG.
Bioorg Med Chem Lett.
2013 Oct 15;23(20):5571-4. doi: 10.1016/j.bmcl.2013.08.049.
PMID: 24011644
Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists.
Tora G, Degnan AP, Conway CM, Kostich WA, Davis CD, Pin SS, Schartman R, Xu C, Widmann KA, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett.
2013 Oct 15;23(20):5684-8. doi: 10.1016/j.bmcl.2013.08.031.
PMID: 23993336
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.
Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF.
PLoS One.
2013 Oct 7;8(10):e76523. doi: 10.1371/journal.pone.0076523.
PMID: 24116116
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators..
N Engl J Med.
2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684.
PMID: 23992601
Amino acids as promoieties in prodrug design and development.
Vig BS, Huttunen KM, Laine K, Rautio J.
Adv Drug Deliv Rev . 2013 Oct;65(10):1370-85. doi: 10.1016/j.addr.2012.10.001. Review.
PMID: 23099277
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
Eley T, Huang SP, Conradie F, Zorrilla CD, Josipovic D, Botes M, Osiyemi O, Hardy H, Bertz R, McGrath D.
AIDS Res Hum Retroviruses . 2013 Oct;29(10):1287-92. doi: 10.1089/AID.2013.0002.
PMID: 23782005
Cost of venous thromboembolism in hospitalized medically ill patients.
Pendergraft T, Atwood M, Liu X, Phatak H, Liu LZ, Oster G.
Am J Health Syst Pharm . 2013 Oct 1;70(19):1681-7. doi: 10.2146/ajhp130099.
PMID: 24048605
Systematic investigation of orthogonal SPE sample preparation for the LC-MS/MS bioanalysis of a monoclonal antibody after pellet digestion.
Yuan L, Aubry AF, Arnold ME, Ji QC.
Bioanalysis.
2013 Oct;5(19):2379-91. doi: 10.4155/bio.13.224.
PMID: 24066623
Conference report: energized bioanalytical solutions at the 2012 Eastern Analytical Symposium & Exposition.
Liu A, Aubry AF.
Bioanalysis.
2013 Oct;5(19):2341-4. doi: 10.4155/bio.13.228.
PMID: 24066619
Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.
Gilmore JL, Sheppeck JE 2nd, Wang J, Dhar TG, Cavallaro C, Doweyko AM, Mckay L, Cunningham MD, Habte SF, Nadler SG, Dodd JH, Somerville JE, Barrish JC.
Bioorg Med Chem Lett.
2013 Oct 1;23(19):5448-51. doi: 10.1016/j.bmcl.2013.06.085.
PMID: 23916594
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C.
Eley T, He B, Huang SP, Li W, Pasquinelli C, Rodrigues AD, Grasela DM, Bertz RJ.
Clin Pharmacol Drug Dev . 2013 Oct;2(4):316-27. doi: 10.1002/cpdd.52.
PMID: 27121936
Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
Gao M.
Curr Opin Virol.
2013 Oct;3(5):514-20. doi: 10.1016/j.coviro.2013.06.014. Review.
PMID: 23896281
Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery research.
Tang H, Shen DR, Han YH, Kong Y, Balimane P, Marino A, Gao M, Wu S, Xie D, Soars MG, O'Connell JC, Rodrigues AD, Zhang L, Cvijic ME.
J Biomol Screen . 2013 Oct;18(9):1072-83. doi: 10.1177/1087057113494807.
PMID: 24062352
Establishing a high-throughput and automated cancer cell proliferation panel for oncology lead optimization.
Lei M, Ribeiro H, Kolodin G, Gill J, Wang YS, Maloney D, Fan Y, Li S, Myer L, Beluch M, Zhang L, Schweizer L.
J Biomol Screen . 2013 Oct;18(9):1043-53. doi: 10.1177/1087057113491825.
PMID: 23733846
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.
Mankoski R, Stockton G, Manos G, Marler S, McQuade R, Forbes RA, Marcus R.
J Child Adolesc Psychopharmacol . 2013 Oct;23(8):572-6. doi: 10.1089/cap.2012.0075.
PMID: 24138011
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.
J Clin Oncol.
2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009.
PMID: 23980090
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.
J Clin Oncol . 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410.
PMID: 23980084
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P, Valero V.
J Geriatr Oncol.
2013 Oct;4(4):346-52. doi: 10.1016/j.jgo.2013.07.006.
PMID: 24472478
Neither direct nor developmental exposure to bisphenol A alters the severity of experimental inflammatory colitis in mice.
Roy A, Gaylo A, Cao W, Saubermann LJ, Lawrence BP.
J Immunotoxicol . 2013 Oct-Dec;10(4):334-40. doi: 10.3109/1547691X.2012.747231.
PMID: 23282445
A computational method for planning complex compound distributions under container, liquid handler, and assay constraints.
Russo MF, Wild D, Hoffman S, Paulson J, Neil W, Nirschl DS.
J Lab Autom . 2013 Oct;18(5):391-403. doi: 10.1177/2211068213486651.
PMID: 23603752
An alternative and robust synthesis of [(13) C4 ]Baraclude® (entecavir).
Easter JA, Burrell RC, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm . 2013 Oct;56(12):632-6. doi: 10.1002/jlcr.3064.
PMID: 24285240
Mechanistic insights into the scale-up of the roller compaction process: a practical and dimensionless approach.
Rowe JM, Crison JR, Carragher TJ, Vatsaraj N, McCann RJ, Nikfar F.
J Pharm Sci.
2013 Oct;102(10):3586-95. doi: 10.1002/jps.23659.
PMID: 23934748
A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
O'Boyle DR 2nd, Nower PT, Sun JH, Fridell R, Wang C, Valera L, Gao M.
J Virol Methods . 2013 Oct;193(1):68-76. doi: 10.1016/j.jviromet.2013.04.024.
PMID: 23684844
NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
Lelas S, Li YW, Wallace-Boone TL, Taber MT, Newton AE, Pieschl RL, Davis CD, Molski TF, Newberry KS, Parker MF, Gillman KW, Bronson JJ, Macor JE, Lodge NJ.
Neuropharmacology.
2013 Oct;73:232-40. doi: 10.1016/j.neuropharm.2013.05.038.
PMID: 23770339
MK-801 disrupts and nicotine augments 40 Hz auditory steady state responses in the auditory cortex of the urethane-anesthetized rat.
Sivarao DV, Frenkel M, Chen P, Healy FL, Lodge NJ, Zaczek R.
Neuropharmacology . 2013 Oct;73:1-9. doi: 10.1016/j.neuropharm.2013.05.006.
PMID: 23688921
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.
Gould JC, Kasichayanula S, Shepperly DC, Boulton DW.
Regul Toxicol Pharmacol . 2013 Oct;67(1):89-97. doi: 10.1016/j.yrtph.2013.07.002.
PMID: 23851069
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).
Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG.
J Med Chem . 2013 Sep 26;56(18):7343-57. doi: 10.1021/jm4008906.
PMID: 23964740
A safe, effective, and facility compatible cleaning in place procedure for affinity resin in large-scale monoclonal antibody purification.
Wang L, Dembecki J, Jaffe NE, O'Mara BW, Cai H, Sparks CN, Zhang J, Laino SG, Russell RJ, Wang M.
J Chromatogr A . 2013 Sep 20;1308:86-95. doi: 10.1016/j.chroma.2013.07.096.
PMID: 23953712
Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.
Bolton SA, Sutton JC, Anumula R, Bisacchi GS, Jacobson B, Slusarchyk WA, Treuner UD, Wu SC, Zhao G, Pi Z, Sheriff S, Smirk RA, Bisaha S, Cheney DL, Wei A, Schumacher WA, Hartl KS, Liu E, Zahler R, Seiler SM.
Bioorg Med Chem Lett . 2013 Sep 15;23(18):5239-43. doi: 10.1016/j.bmcl.2013.06.028.
PMID: 23927973
Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors.
Glunz PW, Zhang X, Zou Y, Delucca I, Nirschl AH, Cheng X, Weigelt CA, Cheney DL, Wei A, Anumula R, Luettgen JM, Rendina AR, Harpel M, Luo G, Knabb R, Wong PC, Wexler RR, Priestley ES.
Bioorg Med Chem Lett.
2013 Sep 15;23(18):5244-8. doi: 10.1016/j.bmcl.2013.06.027.
PMID: 23845220
MicroRNA changes associated with atypical CYP1A1 inducer BMS-764459.
Simic D, Euler C, Haines E, He A, Peden WM, Bunch RT, Sanderson T, Van Vleet T.
Toxicology . 2013 Sep 15;311(3):169-77. doi: 10.1016/j.tox.2013.06.006.
PMID: 23831372
DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues.
Harstad EB, Rosenblum JS, Gorrell MD, Achanzar WE, Minimo L, Wu J, Rosini-Marthaler L, Gullo R, Ordway ND, Kirby MS, Chadwick KD, Cosma GN, Moyer CF.
Regul Pept.
2013 Sep 10;186:26-35. doi: 10.1016/j.regpep.2013.07.003.
PMID: 23850796
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
Juday T, Correll T, Anene A, Broder MS, Ortendahl J, Bentley T.
Clinicoecon Outcomes Res . 2013 Sep 2;5:437-45. doi: 10.2147/CEOR.S47486.
PMID: 24039438
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z, Zhou N, Sun Y, Ray N, Lataillade M, Hanna GJ, Krystal M.
Antimicrob Agents Chemother . 2013 Sep;57(9):4172-80. doi: 10.1128/AAC.00513-13.
PMID: 23774428
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW.
Br J Clin Pharmacol.
2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.
PMID: 23210765
Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis.
Laurito MP, Parise ER.
Braz J Infect Dis . 2013 Sep-Oct;17(5):555-63. doi: 10.1016/j.bjid.2013.02.009. Review.
PMID: 24055394
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.
Jure-Kunkel M, Masters G, Girit E, Dito G, Lee F, Hunt JT, Humphrey R.
Cancer Immunol Immunother.
2013 Sep;62(9):1533-45. doi: 10.1007/s00262-013-1451-5.
PMID: 23873089
A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors.
Barrett YC, Wang Z, Knabb RM.
Clin Appl Thromb Hemost.
2013 Sep;19(5):522-8. doi: 10.1177/1076029612441859.
PMID: 22473028
Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent.
Gokhale M, Thakur A, Rinaldi F.
Drug Dev Ind Pharm.
2013 Sep;39(9):1315-27. doi: 10.3109/03639045.2012.728226.
PMID: 23039020
Novel drug discovery opportunities for colorectal cancer.
Curtin JC.
Expert Opin Drug Discov . 2013 Sep;8(9):1153-64. doi: 10.1517/17460441.2013.807249. Review.
PMID: 23768167
[Ipilimumab].
Tokudome T.
Gan To Kagaku Ryoho . 2013 Sep;40(9):1140-4. Japanese.
PMID: 24047771
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D.
Hepatology.
2013 Sep;58(3):902-11. doi: 10.1002/hep.26388.
PMID: 23504694
Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
Tirmenstein M, Dorr TE, Janovitz EB, Hagan D, Abell LM, Onorato JM, Whaley JM, Graziano MJ, Reilly TP.
Int J Toxicol . 2013 Sep-Oct;32(5):336-50. doi: 10.1177/1091581813505331.
PMID: 24097127
Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Ray N, Hwang C, Healy MD, Whitcomb J, Lataillade M, Wind-Rotolo M, Krystal M, Hanna GJ.
J Acquir Immune Defic Syndr . 2013 Sep 1;64(1):7-15. doi: 10.1097/QAI.0b013e31829726f3.
PMID: 23614999
Development of a validated liquid chromatography tandem mass spectrometry assay for a PEGylated adnectin in cynomolgus monkey plasma using protein precipitation and trypsin digestion.
Dawes ML, Gu H, Wang J, Schuster AE, Haulenbeek J.
J Chromatogr B Analyt Technol Biomed Life Sci.
2013 Sep 1;934:1-7. doi: 10.1016/j.jchromb.2013.06.027.
PMID: 23891912
The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B.
Tang H, Griffin J, Innaimo S, Lehman-Mckeeman L, Llamoso C.
J Clin Transl Hepatol . 2013 Sep;1(1):51-8. doi: 10.14218/JCTH.2013.00006. Review.
PMID: 26357607
Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression.
Parker RA, Garcia R, Ryan CS, Liu X, Shipkova P, Livanov V, Patel P, Ho SP.
J Lipid Res.
2013 Sep;54(9):2400-9. doi: 10.1194/jlr.M038331.
PMID: 23614904
A rapid, accurate and robust UHPLC-MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies.
Zheng N, Zeng J, Akinsanya B, Buzescu A, Xia YQ, Ly V, Trouba K, Peng Q, Aubry AF, Arnold ME.
J Pharm Biomed Anal . 2013 Sep;83:237-48. doi: 10.1016/j.jpba.2013.05.019.
PMID: 23770636
Investigation of monoclonal antibody fragmentation artifacts in non-reducing SDS-PAGE.
Zhu ZC, Chen Y, Ackerman MS, Wang B, Wu W, Li B, Obenauer-Kutner L, Zhao R, Tao L, Ihnat PM, Liu J, Gandhi RB, Qiu B.
J Pharm Biomed Anal . 2013 Sep;83:89-95. doi: 10.1016/j.jpba.2013.04.030.
PMID: 23708435
Semi-preparative LC-SPE-cryoflow NMR for impurity identifications: use of mother liquor as a better source of impurities.
Rinaldi F, Fan J, Pathirana C, Palaniswamy V.
Magn Reson Chem . 2013 Sep;51(9):517-22. doi: 10.1002/mrc.3979.
PMID: 23788325
Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use.
Burns LC, Orsini L, L'italien G.
Value Health . 2013 Sep-Oct;16(6 Suppl):S16-9. doi: 10.1016/j.jval.2013.06.007.
PMID: 24034307
Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
O'Donnell JC.
Value Health . 2013 Sep-Oct;16(6 Suppl):S1-3. doi: 10.1016/j.jval.2013.06.004.
PMID: 24034305
Characterizations of HCV NS5A replication complex inhibitors.
O'Boyle Ii DR, Sun JH, Nower PT, Lemm JA, Fridell RA, Wang C, Romine JL, Belema M, Nguyen VN, Laurent DR, Serrano-Wu M, Snyder LB, Meanwell NA, Langley DR, Gao M.
Virology.
2013 Sep;444(1-2):343-54. doi: 10.1016/j.virol.2013.06.032.
PMID: 23896639
Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines.
Friborg J, Lin B, Chen C, McPhee F.
Virology . 2013 Sep;444(1-2):384-93. doi: 10.1016/j.virol.2013.07.005.
PMID: 23891156
Addressing the need for biomarker liquid chromatography/mass spectrometry assays: a protocol for effective method development for the bioanalysis of endogenous compounds in cerebrospinal fluid.
Benitex Y, McNaney CA, Luchetti D, Schaeffer E, Olah TV, Morgan DG, Drexler DM.
Rapid Commun Mass Spectrom . 2013 Aug 30;27(16):1882-6. doi: 10.1002/rcm.6639.
PMID: 23857934
Lewis base catalysis of the Mukaiyama directed aldol reaction: 40 years of inspiration and advances.
Beutner GL, Denmark SE.
Angew Chem Int Ed Engl.
2013 Aug 26;52(35):9086-96. doi: 10.1002/anie.201302084. Review.
PMID: 23843275
Enhancing Cancer Drug Discovery through Novel Cell Signaling Pathway Panel Strategy.
Schweizer L, Zhang L.
Cancer Growth Metastasis.
2013 Aug 20;6:53-9. doi: 10.4137/CGM.S11134.
PMID: 24665207
HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.
Belema M, Nguyen VN, St Laurent DR, Lopez OD, Qiu Y, Good AC, Nower PT, Valera L, O'Boyle DR 2nd, Sun JH, Liu M, Fridell RA, Lemm JA, Gao M, Knipe JO, Meanwell NA, Snyder LB.
Bioorg Med Chem Lett . 2013 Aug 1;23(15):4428-35. doi: 10.1016/j.bmcl.2013.05.040.
PMID: 23803586
Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.
Karyekar CS, Frederich R, Ravichandran S.
Int J Clin Pract.
2013 Aug;67(8):759-67. doi: 10.1111/ijcp.12212.
PMID: 23795975
Utility of gastric-retained alginate gels to modulate pharmacokinetic profiles in rats.
Foster KA, Sun H, Fancher RM, Proszynski M, Dixon G, Ford K, Cornelius G, Gudmundsson OS, Hageman MJ.
J Pharm Sci.
2013 Aug;102(8):2440-9. doi: 10.1002/jps.23630.
PMID: 23744594
Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity.
Yamniuk AP, Ditto N, Patel M, Dai J, Sejwal P, Stetsko P, Doyle ML.
J Pharm Sci . 2013 Aug;102(8):2424-39. doi: 10.1002/jps.23618.
PMID: 23712759
3D matched pairs: integrating ligand- and structure-based knowledge for ligand design and receptor annotation.
Posy SL, Claus BL, Pokross ME, Johnson SR.
J Chem Inf Model . 2013 Jul 22;53(7):1576-88. doi: 10.1021/ci400201k.
PMID: 23809058
Multicomponent synthesis of 1-aryl 1,2,4-triazoles.
Tam A, Armstrong IS, La Cruz TE.
Org Lett.
2013 Jul 19;15(14):3586-9. doi: 10.1021/ol401428x.
PMID: 23815306
Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complex.
Kim SH, Constantine KL, Duke GJ, Goldfarb V, Hunt JT, Johnson S, Kish K, Klei HE, McDonnell PA, Metzler WJ, Mueller L, Poss MA, Fairchild CR, Bhide RS.
Bioorg Med Chem Lett . 2013 Jul 15;23(14):4107-11. doi: 10.1016/j.bmcl.2013.05.052.
PMID: 23747226
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
Wrobleski ST, Lin S, Dhar TG, Dyckman AJ, Li T, Pitt S, Zhang R, Fan Y, Doweyko AM, Tokarski JS, Kish KF, Kiefer SE, Sack JS, Newitt JA, Witmer MR, McKinnon M, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
Bioorg Med Chem Lett.
2013 Jul 15;23(14):4120-6. doi: 10.1016/j.bmcl.2013.05.047.
PMID: 23746475
2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents.
Pi Z, Sutton J, Lloyd J, Hua J, Price L, Wu Q, Chang M, Zheng J, Rehfuss R, Huang CS, Wexler RR, Lam PY.
Bioorg Med Chem Lett.
2013 Jul 15;23(14):4206-9. doi: 10.1016/j.bmcl.2013.05.025.
PMID: 23743287
Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.
Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS.
Clin Cancer Res . 2013 Jul 15;19(14):3977-86. doi: 10.1158/1078-0432.CCR-12-3243.
PMID: 23741070
Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.
Chimalakonda AP, Yadav R, Marathe P.
AAPS J.
2013 Jul;15(3):717-27. doi: 10.1208/s12248-013-9477-3.
PMID: 23588584
A comparison of the likelihood ratio test and the variance-stabilising transformation-based tests for detecting association of rare variants.
Xing G, Ku HC, Xing C.
Ann Hum Genet.
2013 Jul;77(4):333-5. doi: 10.1111/ahg.12022.
PMID: 23488943
Adverse events in patients with liver cancer.
Dreyfus B, Kawabata HM, Gomez-Caminero A.
Anticancer Drugs . 2013 Jul;24(6):630-5. doi: 10.1097/CAD.0b013e3283607f4f.
PMID: 23525070
Rapid development of multiple 'fit-for-purpose' assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs.
Liu R, Pillutla R, DeSilva B, Zhang YJ.
Bioanalysis . 2013 Jul;5(14):1751-63. doi: 10.4155/bio.13.152.
PMID: 23862707
A generic template for automated bioanalytical ligand-binding assays using modular robotic scripts in support of discovery biotherapeutic programs.
Duo J, Dong H, DeSilva B, Zhang YJ.
Bioanalysis . 2013 Jul;5(14):1735-50. doi: 10.4155/bio.13.154.
PMID: 23862706
Sample reduction strategies in discovery bioanalysis.
Cai X, Zhang J, Shou WZ.
Bioanalysis . 2013 Jul;5(13):1691-701. doi: 10.4155/bio.13.133. Review.
PMID: 23822131
Heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 receptor antagonist.
Luo G, Chen L, Hu S, Huang Y, Mattson G, Iben LG, Russell JW, Clarke WJ, Hogan JB, Antal-Zimanyi I, Poindexter GS.
Bioorg Med Chem Lett.
2013 Jul 1;23(13):3814-7. doi: 10.1016/j.bmcl.2013.04.095.
PMID: 23726344
The discovery of BMS-457, a potent and selective CCR1 antagonist.
Gardner DS, Santella JB 3rd, Duncia JV, Carter PH, Dhar TG, Wu H, Guo W, Cavallaro C, Van Kirk K, Yarde M, Briceno SW, Grafstrom RR, Liu R, Patel SR, Tebben AJ, Camac D, Khan J, Watson A, Yang G, Rose A, Foster WR, Cvijic ME, Davies P, Hynes J Jr.
Bioorg Med Chem Lett.
2013 Jul 1;23(13):3833-40. doi: 10.1016/j.bmcl.2013.04.079.
PMID: 23707259
Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.
Zhao G, Kwon C, Bisaha SN, Stein PD, Rossi KA, Cao X, Ung T, Wu G, Hung CP, Malmstrom SE, Zhang G, Qu Q, Gan J, Keim WJ, Cullen MJ, Rohrbach KW, Devenny J, Pelleymounter MA, Miller KJ, Robl JA.
Bioorg Med Chem Lett . 2013 Jul 1;23(13):3914-9. doi: 10.1016/j.bmcl.2013.04.061.
PMID: 23683593
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ.
Cancer Immunol Res.
2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013.
PMID: 24777248
A new perspective on the mechanical evaluation of granular material.
Chan SH, Wang SS, Lai C, Grosso J.
Drug Dev Ind Pharm . 2013 Jul;39(7):1126-32. doi: 10.3109/03639045.2012.715353.
PMID: 22934612
Characterization of recombinantly expressed rat and monkey intestinal alkaline phosphatases: in vitro studies and in vivo correlations.
Subramanian M, Paruchury S, Singh Gautam S, Pratap Singh S, Arla R, Pahwa S, Jana S, Katnapally P, Yoganand V, Lakshmaiah B, Mazumder Tagore D, Ghosh K, Marathe P, Mandlekar S.
Drug Metab Dispos . 2013 Jul;41(7):1425-32. doi: 10.1124/dmd.113.051987.
PMID: 23633529
Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
Pujadas-Mestres L, Escolar G, Arellano-Rodrigo E, Galán AM.
Drugs Today (Barc).
2013 Jul;49(7):425-36. doi: 10.1358/dot.2013.49.7.1980498. Review.
PMID: 23914351
The synthesis of a carbon-14 labeled pegylated Adnectin™ for placental transfer studies in guinea pigs.
Maxwell BD, Cao K, Bonacorsi S, Sivaraman L, Wang B, McNerney M, Wang L, Christopher LJ, Fung NK, Wang J, Arnold ME.
J Labelled Comp Radiopharm . 2013 Jul-Aug;56(9-10):492-4. doi: 10.1002/jlcr.3077.
PMID: 24285527
Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.
Krejsa CM, Holly RD, Heipel M, Bannink KM, Johnson R, Roque R, Heffernan J, Hill J, Chin L, Wagener F, Shiota F, Henderson K, Sivakumar PV, Ren HP, Barahmand-Pour F, Foster D, Clegg C, Kindsvogel W, Ponce R, Hughes SD, Waggie K.
PLoS One . 2013 Jun 25;8(6):e67256. doi: 10.1371/journal.pone.0067256.
PMID: 23825648
Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.
Burford NT, Clark MJ, Wehrman TS, Gerritz SW, Banks M, O'Connell J, Traynor JR, Alt A.
Proc Natl Acad Sci U S A.
2013 Jun 25;110(26):10830-5. doi: 10.1073/pnas.1300393110.
PMID: 23754417
New azole antagonists with high affinity for the P2Y(1) receptor.
Ruel R, L'Heureux A, Thibeault C, Daris JP, Martel A, Price LA, Wu Q, Hua J, Wexler RR, Rehfuss R, Lam PY.
Bioorg Med Chem Lett.
2013 Jun 15;23(12):3519-22. doi: 10.1016/j.bmcl.2013.04.041.
PMID: 23668989
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study.
Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP.
Clin Pharmacol.
2013 Jun 10;5:85-97. doi: 10.2147/CPAA.S42796.
PMID: 23788844
Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Iv GA.
Arch Pathol Lab Med . 2013 Jun;137(6):820-7. doi: 10.5858/arpa.2012-0367-OA.
PMID: 23030695
Dual universal peptide approach to bioanalysis of human monoclonal antibody protein drug candidates in animal studies.
Furlong MT, Zhao S, Mylott W, Jenkins R, Gao M, Hegde V, Tamura J, Tymiak A, Jemal M.
Bioanalysis . 2013 Jun;5(11):1363-76. doi: 10.4155/bio.13.55.
PMID: 23742306
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.
Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N, Moench P, Denton R, Macci R, Schartman R, Whiterock V, Davis C, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett . 2013 Jun 1;23(11):3157-61. doi: 10.1016/j.bmcl.2013.04.012.
PMID: 23632269
Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.
Wang TC, Qiao JX, Clark CG, Jua J, Price LA, Wu Q, Chang M, Zheng J, Huang CS, Everlof G, Schumacher WA, Wong PC, Seiffert DA, Stewart AB, Bostwick JS, Crain EJ, Watson CA, Rehfuss R, Wexler RR, Lam PY.
Bioorg Med Chem Lett.
2013 Jun 1;23(11):3239-43. doi: 10.1016/j.bmcl.2013.03.125.
PMID: 23602442
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.
Brown J, Chien C, Timmins P, Dennis A, Doll W, Sandefer E, Page R, Nettles RE, Zhu L, Grasela D.
J Pharm Sci . 2013 Jun;102(6):1742-51. doi: 10.1002/jps.23476.
PMID: 23681563
FAM129B is a novel regulator of Wnt/β-catenin signal transduction in melanoma cells.
Conrad W, Major MB, Cleary MA, Ferrer M, Roberts B, Marine S, Chung N, Arthur WT, Moon RT, Berndt JD, Chien AJ.
Version 2.
F1000Res . 2013 May 31 [revised 2013 Jan 1];2:134. doi: 10.12688/f1000research.2-134.v2.
PMID: 24358901
The impact of palladium(II) reduction pathways on the structure and activity of palladium(0) catalysts.
Wei CS, Davies GH, Soltani O, Albrecht J, Gao Q, Pathirana C, Hsiao Y, Tummala S, Eastgate MD.
Angew Chem Int Ed Engl . 2013 May 27;52(22):5822-6. doi: 10.1002/anie.201210252. No abstract available.
PMID: 23610043
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I.
PLoS One . 2013 May 22;8(5):e63818. doi: 10.1371/journal.pone.0063818.
PMID: 23717490
Conformationally restricted homotryptamines. Part 6: indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.
Ditta JL, Denhart DJ, Deskus JA, Epperson JR, Meng Z, Gao Q, Mattson GK, Lapaglia MA, Taber MT, Molski TF, Lodge NJ, Mattson RJ, Macor JE.
Bioorg Med Chem Lett.
2013 May 15;23(10):2948-50. doi: 10.1016/j.bmcl.2013.03.045.
PMID: 23578689
Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor.
Liu C, Lin J, Everlof G, Gesenberg C, Zhang H, Marathe PH, Malley M, Galella MA, McKinnon M, Dodd JH, Barrish JC, Schieven GL, Leftheris K.
Bioorg Med Chem Lett.
2013 May 15;23(10):3028-33. doi: 10.1016/j.bmcl.2013.03.022.
PMID: 23578688
Characterization of disulfide linkages in recombinant human granulocyte-colony stimulating factor.
Mo J, Tymiak AA, Chen G.
Rapid Commun Mass Spectrom.
2013 May 15;27(9):940-6. doi: 10.1002/rcm.6530.
PMID: 23592195
Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet.
Alexander AJ, Zhang L, Hooker TF, Tomasella FP.
J Pharm Biomed Anal . 2013 May 5;78-79:243-51. doi: 10.1016/j.jpba.2013.02.019.
PMID: 23507686
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Roberts S, Fridell RA, Gao M.
Antimicrob Agents Chemother . 2013 May;57(5):2054-65. doi: 10.1128/AAC.02494-12.
PMID: 23403428
High-resolution MS for structural characterization of protein therapeutics: advances and future directions.
Wei H, Tymiak AA, Chen G.
Bioanalysis.
2013 May;5(10):1299-313. doi: 10.4155/bio.13.80. Review.
PMID: 23721450
High-resolution MS in regulated bioanalysis: where are we now and where do we go from here?
Fung EN, Jemal M, Aubry AF.
Bioanalysis . 2013 May;5(10):1277-84. doi: 10.4155/bio.13.81.
PMID: 23721448
Expedient data mining for nontargeted high-resolution LC-MS profiles of biological samples.
Hnatyshyn S, Shipkova P, Sanders M.
Bioanalysis . 2013 May;5(10):1195-210. doi: 10.4155/bio.13.86.
PMID: 23721443
Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications.
Thevanayagam L, Bell A, Chakraborty I, Sufi B, Gangwar S, Zang A, Rangan V, Rao C, Wang Z, Pan C, Chong C, Cardarelli P, Deshpande S, Srinivasan M.
Bioanalysis . 2013 May;5(9):1073-81. doi: 10.4155/bio.13.57.
PMID: 23641697
Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.
Upreti VV, Keung CF, Boulton DW, Chang M, Li L, Tang A, Hsiang BC, Quamina-Edghill D, Frevert EU, Lacreta FP.
Clin Drug Investig . 2013 May;33(5):365-74. doi: 10.1007/s40261-013-0075-z.
PMID: 23549864
Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012.
Carter PH.
Expert Opin Ther Pat . 2013 May;23(5):549-68. doi: 10.1517/13543776.2013.771168. Review.
PMID: 23428142
A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study.
Furlong MT, Savant I, Yuan M, Scott L, Mylott W, Mariannino T, Kadiyala P, Roongta V, Arnold ME.
J Chromatogr B Analyt Technol Biomed Life Sci.
2013 May 1;926:36-41. doi: 10.1016/j.jchromb.2013.02.031.
PMID: 23542721
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F.
J Clin Virol.
2013 May;57(1):13-8. doi: 10.1016/j.jcv.2012.12.020. Erratum in: J Clin Virol. 2016 Apr;77:115.
PMID: 23384816
Effects of dapagliflozin on cardiovascular risk factors.
Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J.
Postgrad Med . 2013 May;125(3):181-9. doi: 10.3810/pgm.2013.05.2667. Review.
PMID: 23748519
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, Lacreta F, Frost CE.
Clin Pharmacol.
2013 Apr 16;5:59-66. doi: 10.2147/CPAA.S41999.
PMID: 23637566
Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
Wu YJ, He H, Bertekap R, Westphal R, Lelas S, Newton A, Wallace T, Taber M, Davis C, Macor JE, Bronson J.
Bioorg Med Chem.
2013 Apr 15;21(8):2217-28. doi: 10.1016/j.bmc.2013.02.010.
PMID: 23477943
Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor.
Priestley ES, De Lucca I, Zhou J, Zhou J, Saiah E, Stanton R, Robinson L, Luettgen JM, Wei A, Wen X, Knabb RM, Wong PC, Wexler RR.
Bioorg Med Chem Lett.
2013 Apr 15;23(8):2432-5. doi: 10.1016/j.bmcl.2013.02.013.
PMID: 23478148
A high-speed liquid chromatography/tandem mass spectrometry platform using multiplexed multiple-injection chromatography controlled by single software and its application in discovery ADME screening.
Zhang J, Vath M, Ferraro C, Li Y, Murphy K, Zvyaga T, Weller H, Shou W.
Rapid Commun Mass Spectrom . 2013 Apr 15;27(7):731-7. doi: 10.1002/rcm.6514.
PMID: 23495019
Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: practical considerations in assay development and validation.
Liu G, Ji QC, Dodge R, Sun H, Shuster D, Zhao Q, Arnold M.
J Chromatogr A . 2013 Apr 5;1284:155-62. doi: 10.1016/j.chroma.2013.02.016.
PMID: 23466204
Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.
Denhart DJ, Zuev D, Ditta JL, Hartz RA, Ahuja VT, Mattson RJ, Huang H, Mattson GK, Zueva L, Nielsen JM, Kozlowski ES, Lodge NJ, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2013 Apr 1;23(7):2052-5. doi: 10.1016/j.bmcl.2013.02.009.
PMID: 23465610
Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors.
Dreyfus B, Kawabata H, Gomez A.
Cancer Epidemiol.
2013 Apr;37(2):191-6. doi: 10.1016/j.canep.2012.11.001.
PMID: 23246035
Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
Zhang D, Frost CE, He K, Rodrigues AD, Wang X, Wang L, Goosen TC, Humphreys WG.
Drug Metab Dispos.
2013 Apr;41(4):906-15. doi: 10.1124/dmd.112.050575.
PMID: 23386703
Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG.
Drug Metab Dispos . 2013 Apr;41(4):827-35. doi: 10.1124/dmd.112.050260.
PMID: 23382458
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
Washburn WN, Poucher SM.
Expert Opin Investig Drugs . 2013 Apr;22(4):463-86. doi: 10.1517/13543784.2013.774372. Review.
PMID: 23452053
Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534.
Lodge NJ, Lelas S, Li YW, Molski T, Grace J, Sivarao DV, Post-Munson D, Healy F, Bronson JJ, Hartz R, Macor JE, Zaczek R.
Neuropharmacology . 2013 Apr;67:284-93. doi: 10.1016/j.neuropharm.2012.10.025.
PMID: 23174340
Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors.
Zhao G, Kwon C, Wang A, Robertson JG, Marcinkeviciene J, Parker RA, Kirby MS, Hamann LG.
Bioorg Med Chem Lett . 2013 Mar 15;23(6):1622-5. doi: 10.1016/j.bmcl.2013.01.104.
PMID: 23416006
Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors.
Zhang X, Glunz PW, Jiang W, Schmitt A, Newman M, Barbera FA, Bozarth JM, Rendina AR, Wei A, Wen X, Rossi KA, Luettgen JM, Wong PC, Knabb RM, Wexler RR, Scott Priestley E.
Bioorg Med Chem Lett.
2013 Mar 15;23(6):1604-7. doi: 10.1016/j.bmcl.2013.01.094.
PMID: 23416003
Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists.
McDonald IM, Mate RA, Zusi FC, Huang H, Post-Munson DJ, Ferrante MA, Gallagher L, Bertekap RL Jr, Knox RJ, Robertson BJ, Harden DG, Morgan DG, Lodge NJ, Dworetzky SI, Olson RE, Macor JE.
Bioorg Med Chem Lett . 2013 Mar 15;23(6):1684-8. doi: 10.1016/j.bmcl.2013.01.070.
PMID: 23414838
Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.
Finlay HJ, Jiang J, Caringal Y, Kover A, Conder ML, Xing D, Levesque P, Harper T, Hsueh MM, Atwal K, Blanar M, Wexler R, Lloyd J.
Bioorg Med Chem Lett . 2013 Mar 15;23(6):1743-7. doi: 10.1016/j.bmcl.2013.01.064.
PMID: 23414837
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.
Han X, Civiello RL, Conway CM, Cook DA, Davis CD, Degnan AP, Jiang XJ, Macci R, Mathias NR, Moench P, Pin SS, Schartman R, Signor LJ, Thalody G, Tora G, Whiterock V, Xu C, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett.
2013 Mar 15;23(6):1870-3. doi: 10.1016/j.bmcl.2013.01.011. Erratum in: Bioorg Med Chem Lett. 2013 Jun 15;23(12):3674.
PMID: 23402880
Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D.
Clin Cancer Res.
2013 Mar 15;19(6):1587-95. doi: 10.1158/1078-0432.CCR-12-1359.
PMID: 23340299
Effects of column back pressure on supercritical fluid chromatography separations of enantiomers using binary mobile phases on 10 chiral stationary phases.
Wang C, Zhang Y.
J Chromatogr A.
2013 Mar 15;1281:127-34. doi: 10.1016/j.chroma.2013.01.050.
PMID: 23394748
A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma.
Yuan L, Jiang H, Ouyang Z, Xia YQ, Zeng J, Peng Q, Lange RW, Deng Y, Arnold ME, Aubry AF.
J Chromatogr B Analyt Technol Biomed Life Sci.
2013 Mar 15;921-922:81-6. doi: 10.1016/j.jchromb.2013.01.029.
PMID: 23435345
A simplified and completely automated workflow for regulated LC-MS/MS bioanalysis using cap-piercing direct sampling and evaporation-free solid phase extraction.
Zheng N, Buzescu A, Pasas-Farmer S, Arnold ME, Ouyang Z, Jemal M, Peng Q, Van Vleet T, Zeng J.
J Chromatogr B Analyt Technol Biomed Life Sci.
2013 Mar 15;921-922:64-74. doi: 10.1016/j.jchromb.2013.01.028.
PMID: 23435343
Investigating the applicability of inverse gas chromatography to binary powdered systems: an application of surface heterogeneity profiles to understanding preferential probe-surface interactions.
Gamble JF, Davé RN, Kiang S, Leane MM, Tobyn M, Wang SS.
Int J Pharm.
2013 Mar 10;445(1-2):39-46. doi: 10.1016/j.ijpharm.2013.01.061.
PMID: 23380622
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.
Lane RM, He Y.
Alzheimers Dement.
2013 Mar;9(2):e1-73. doi: 10.1016/j.jalz.2010.12.005. Review.
PMID: 22402324
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F.
Antimicrob Agents Chemother.
2013 Mar;57(3):1312-22. doi: 10.1128/AAC.02239-12.
PMID: 23274666
Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.
Boulton DW, Kasichayanula S, Keung CF, Arnold ME, Christopher LJ, Xu XS, Lacreta F.
Br J Clin Pharmacol . 2013 Mar;75(3):763-8. doi: 10.1111/j.1365-2125.2012.04391.x.
PMID: 22823746
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Bain G, King CD, Schaab K, Rewolinski M, Norris V, Ambery C, Bentley J, Yamada M, Santini AM, van de Wetering de Rooij J, Stock N, Zunic J, Hutchinson JH, Evans JF.
Br J Clin Pharmacol . 2013 Mar;75(3):779-90. doi: 10.1111/j.1365-2125.2012.04386.x.
PMID: 22803688
Insight into tissue unbound concentration: utility in drug discovery and development.
Mariappan TT, Mandlekar S, Marathe P.
Curr Drug Metab . 2013 Mar;14(3):324-40. Review.
PMID: 23167621
Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW.
Diabetes Obes Metab.
2013 Mar;15(3):280-3. doi: 10.1111/dom.12024.
PMID: 23061428
Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010).
Jing Y, Guo Z, Kalsekar I, Forbes RA, Hebden T, Thase ME.
Int Clin Psychopharmacol . 2013 Mar;28(2):87-90. doi: 10.1097/YIC.0b013e32835ce232.
PMID: 23262644
Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation.
Shen H, Yang Z, Mintier G, Han YH, Chen C, Balimane P, Jemal M, Zhao W, Zhang R, Kallipatti S, Selvam S, Sukrutharaj S, Krishnamurthy P, Marathe P, Rodrigues AD.
J Pharmacol Exp Ther . 2013 Mar;344(3):673-85. doi: 10.1124/jpet.112.200691.
PMID: 23297161
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF, Dockens RC, Meredith JE Jr, Olson RE, Slemmon R, Lentz KA, Wang JS, Denton RR, Pilcher G, Rhyne PW, Raybon JJ, Barten DM, Burton C, Toyn JH, Sankaranarayanan S, Polson C, Guss V, White R, Simutis F, Sanderson T, Gillman KW, Starrett JE Jr, Bronson J, Sverdlov O, Huang SP, Castaneda L, Feldman H, Coric V, Zaczek R, Macor JE, Houston J, Berman RM, Tong G.
J Pharmacol Exp Ther . 2013 Mar;344(3):686-95. doi: 10.1124/jpet.112.199356.
PMID: 23275065
Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant.
Leane MM, Sinclair W, Qian F, Haddadin R, Brown A, Tobyn M, Dennis AB.
Pharm Dev Technol . 2013 Mar-Apr;18(2):359-66. doi: 10.3109/10837450.2011.619544.
PMID: 22268601
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, Grasela D.
Pharmacotherapy . 2013 Mar;33(3):284-94. doi: 10.1002/phar.1205.
PMID: 23456732
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 13. Synthesis and profiling of a novel amminium prodrug of the HIV-1 attachment inhibitor BMS-585248.
Regueiro-Ren A, Simmermacher-Mayer J, Sinz M, Johnson KA, Huang XS, Jenkins S, Parker D, Rahematpura S, Zheng M, Meanwell NA, Kadow JF.
J Med Chem . 2013 Feb 28;56(4):1670-6. doi: 10.1021/jm301638a.
PMID: 23374053
Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.
Chao H, Turdi H, Herpin TF, Roberge JY, Liu Y, Schnur DM, Poss MA, Rehfuss R, Hua J, Wu Q, Price LA, Abell LM, Schumacher WA, Bostwick JS, Steinbacher TE, Stewart AB, Ogletree ML, Huang CS, Chang M, Cacace AM, Arcuri MJ, Celani D, Wexler RR, Lawrence RM.
J Med Chem . 2013 Feb 28;56(4):1704-14. doi: 10.1021/jm301708u.
PMID: 23368907
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).
Regueiro-Ren A, Xue QM, Swidorski JJ, Gong YF, Mathew M, Parker DD, Yang Z, Eggers B, D'Arienzo C, Sun Y, Malinowski J, Gao Q, Wu D, Langley DR, Colonno RJ, Chien C, Grasela DM, Zheng M, Lin PF, Meanwell NA, Kadow JF.
J Med Chem.
2013 Feb 28;56(4):1656-69. doi: 10.1021/jm3016377.
PMID: 23360431
Improved ruggedness of an ion-pairing liquid chromatography/tandem mass spectrometry assay for the quantitative analysis of the triphosphate metabolite of a nucleoside reverse transcriptase inhibitor in peripheral blood mononuclear cells.
Zhao Y, Liu G, Liu Y, Yuan L, Hawthorne D, Shen JX, Guha M, Aubry A.
Rapid Commun Mass Spectrom.
2013 Feb 15;27(3):481-8. doi: 10.1002/rcm.6473.
PMID: 23280981
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.
Lopez OD, Nguyen VN, St Laurent DR, Belema M, Serrano-Wu MH, Goodrich JT, Yang F, Qiu Y, Ripka AS, Nower PT, Valera L, Liu M, O'Boyle DR 2nd, Sun JH, Fridell RA, Lemm JA, Gao M, Good AC, Meanwell NA, Snyder LB.
Bioorg Med Chem Lett . 2013 Feb 1;23(3):779-84. doi: 10.1016/j.bmcl.2012.11.086.
PMID: 23273521
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F.
Br J Clin Pharmacol . 2013 Feb;75(2):476-87. doi: 10.1111/j.1365-2125.2012.04369.x.
PMID: 22759198
Comparison of vascular leak syndrome in mice treated with IL21 or IL2.
Sivakumar PV, Garcia R, Waggie KS, Anderson-Haley M, Nelson A, Hughes SD.
Comp Med . 2013 Feb;63(1):13-21.
PMID: 23561933
Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development.
Sinz MW.
Drug Metab Rev.
2013 Feb;45(1):3-14. doi: 10.3109/03602532.2012.743560. Review.
PMID: 23330538
Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC, White A, Luettgen J.
Hosp Pract (1995).
2013 Feb;41(1):19-25. doi: 10.3810/hp.2013.02.1009.
PMID: 23466964
Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
Yang Z, Vakkalagadda B, Shen G, Ahlers CM, Has T, Christopher LJ, Kurland JF, Roongta V, Masson E, Zhang S.
J Clin Pharmacol.
2013 Feb;53(2):217-27. doi: 10.1177/0091270012439208.
PMID: 23436267
Real-time monitoring of thermodynamic microenvironment in a pan coater.
Pandey P, Bindra DS.
J Pharm Sci.
2013 Feb;102(2):336-40. doi: 10.1002/jps.23379.
PMID: 23161333
Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles.
Fridell RA, Valera L, Qiu D, Kirk MJ, Wang C, Gao M.
J Virol.
2013 Feb;87(4):2320-9. doi: 10.1128/JVI.02861-12.
PMID: 23236071
Processing challenges with solid dosage formulations containing vitamin E TPGS.
Pandey P, Sinko PD, Bindra DS, Hamey R, Gour S, Vema-Varapu C.
Pharm Dev Technol.
2013 Feb;18(1):296-304. doi: 10.3109/10837450.2012.737807.
PMID: 23136832
A combined experimental and modeling approach to study the effects of high-shear wet granulation process parameters on granule characteristics.
Pandey P, Tao J, Chaudhury A, Ramachandran R, Gao JZ, Bindra DS.
Pharm Dev Technol.
2013 Feb;18(1):210-24. doi: 10.3109/10837450.2012.700933.
PMID: 22780851
Establishment of a molecular embryonic stem cell developmental toxicity assay.
Panzica-Kelly JM, Brannen KC, Ma Y, Zhang CX, Flint OP, Lehman-McKeeman LD, Augustine-Rauch KA.
Toxicol Sci.
2013 Feb;131(2):447-57. doi: 10.1093/toxsci/kfs293.
PMID: 23042729
Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.
Gillman KW, Parker MF, Silva M, Degnan AP, Tora GO, Lodge NJ, Li YW, Lelas S, Taber M, Krause RG, Bertekap RL, Newton AE, Pieschl RL, Lengyel KD, Johnson KA, Taylor SJ, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2013 Jan 15;23(2):407-11. doi: 10.1016/j.bmcl.2012.11.094.
PMID: 23253443
BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA, Cohen LJ, Korman AJ, Cardarelli PM.
Clin Cancer Res.
2013 Jan 15;19(2):357-66. doi: 10.1158/1078-0432.CCR-12-2333.
PMID: 23213054
Comparison of chromatographic techniques for diastereomer separation of a diverse set of drug-like compounds.
Ebinger K, Weller HN.
J Chromatogr A.
2013 Jan 11;1272:150-4. doi: 10.1016/j.chroma.2012.11.065.
PMID: 23261288
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.
Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA.
Antimicrob Agents Chemother . 2013 Jan;57(1):611-3. doi: 10.1128/AAC.01874-12.
PMID: 23089758
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R.
Antivir Ther . 2013;18(7):931-40. doi: 10.3851/IMP2674.
PMID: 23963204
Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review.
Eley T, Bertz R, Hardy H, Burger D.
Antivir Ther.
2013;18(3):361-75. doi: 10.3851/IMP2473. Review.
PMID: 23676668
Fit-for-purpose bioanalytical cross-validation for LC-MS/MS assays in clinical studies.
Xu X, Ji QC, Jemal M, Gleason C, Shen JX, Stouffer B, Arnold ME.
Bioanalysis . 2013 Jan;5(1):83-90. doi: 10.4155/bio.12.291.
PMID: 23256474
Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
Hernandez D, Falk P, Yu F, Zhai G, Quan Y, Faria T, Cao K, Scola P, McPhee F.
Biochem Pharmacol . 2013 Jan 1;85(1):21-8. doi: 10.1016/j.bcp.2012.10.002.
PMID: 23063413
Inhibitors of HIV-1 attachment. Part 11: the discovery and structure-activity relationships associated with 4,6-diazaindole cores.
Bender JA, Yang Z, Eggers B, Gong YF, Lin PF, Parker DD, Rahematpura S, Zheng M, Meanwell NA, Kadow JF.
Bioorg Med Chem Lett.
2013 Jan 1;23(1):218-22. doi: 10.1016/j.bmcl.2012.10.118.
PMID: 23206859
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.
Wang T, Yang Z, Zhang Z, Gong YF, Riccardi KA, Lin PF, Parker DD, Rahematpura S, Mathew M, Zheng M, Meanwell NA, Kadow JF, Bender JA.
Bioorg Med Chem Lett.
2013 Jan 1;23(1):213-7. doi: 10.1016/j.bmcl.2012.10.120.
PMID: 23200254
Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agents.
Yeung KS, Qiu Z, Xue Q, Fang H, Yang Z, Zadjura L, D'Arienzo CJ, Eggers BJ, Riccardi K, Shi PY, Gong YF, Browning MR, Gao Q, Hansel S, Santone K, Lin PF, Meanwell NA, Kadow JF.
Bioorg Med Chem Lett.
2013 Jan 1;23(1):198-202. doi: 10.1016/j.bmcl.2012.10.115.
PMID: 23200252
Inhibitors of HIV-1 attachment. Part 8: the effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors.
Yeung KS, Qiu Z, Yin Z, Trehan A, Fang H, Pearce B, Yang Z, Zadjura L, D'Arienzo CJ, Riccardi K, Shi PY, Spicer TP, Gong YF, Browning MR, Hansel S, Santone K, Barker J, Coulter T, Lin PF, Meanwell NA, Kadow JF.
Bioorg Med Chem Lett . 2013 Jan 1;23(1):203-8. doi: 10.1016/j.bmcl.2012.10.117.
PMID: 23200249
Inhibitors of HIV-1 attachment. Part 9: an assessment of oral prodrug approaches to improve the plasma exposure of a tetrazole-containing derivative.
Yeung KS, Qiu Z, Yang Z, Zadjura L, D'Arienzo CJ, Browning MR, Hansel S, Huang XS, Eggers BJ, Riccardi K, Lin PF, Meanwell NA, Kadow JF.
Bioorg Med Chem Lett.
2013 Jan 1;23(1):209-12. doi: 10.1016/j.bmcl.2012.10.125.
PMID: 23200244
Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
Fevig JM, Feng J, Rossi KA, Miller KJ, Wu G, Hung CP, Ung T, Malmstrom SE, Zhang G, Keim WJ, Cullen MJ, Rohrbach KW, Qu Q, Gan J, Pelleymounter MA, Robl JA.
Bioorg Med Chem Lett.
2013 Jan 1;23(1):330-5. doi: 10.1016/j.bmcl.2012.10.091.
PMID: 23177783
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, Castaneda L, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens R.
Br J Clin Pharmacol . 2013 Jan;75(1):136-45. doi: 10.1111/j.1365-2125.2012.04339.x.
PMID: 22616739
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso JF, Jure-Kunkel MN.
Cancer Immun . 2013;13:5. Review.
PMID: 23390376
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Karyekar CS, Ravichandran S, Allen E, Fleming D, Frederich R.
Clin Interv Aging.
2013;8:419-30. doi: 10.2147/CIA.S41246.
PMID: 23626461
Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.
Nadkarni A, Kalsekar I, You M, Forbes R, Hebden T.
Clinicoecon Outcomes Res.
2013;5:49-57. doi: 10.2147/CEOR.S36526.
PMID: 23378778
Determination of relative Notch1 and gamma-secretase-related gene expression in puromycin-treated microdissected rat kidneys.
Simic D, Simutis F, Euler C, Thurby C, Peden WM, Bunch RT, Pilcher G, Sanderson T, Van Vleet T.
Gene Expr.
2013;16(1):39-47.
PMID: 24397211
γ -Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?
Toyn JH, Rowley A, Matsuoka Y, Tomita T, Imbimbo BP.
Int J Alzheimers Dis . 2013;2013:849128. doi: 10.1155/2013/849128. No abstract available.
PMID: 23710414
Methods: implementation of in vitro and ex vivo phagocytosis and respiratory burst function assessments in safety testing.
Freebern WJ, Bigwarfe TJ, Price KD, Haggerty HG.
J Immunotoxicol.
2013 Jan-Mar;10(1):106-17. doi: 10.3109/1547691X.2012.736427.
PMID: 23173903
The rat whole embryo culture assay using the Dysmorphology Score system.
Zhang C, Panzica-Kelly J, Augustine-Rauch K.
Methods Mol Biol.
2013;947:423-50. doi: 10.1007/978-1-62703-131-8_30.
PMID: 23138920
11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice.
García RA, Search DJ, Lupisella JA, Ostrowski J, Guan B, Chen J, Yang WP, Truong A, He A, Zhang R, Yan M, Hellings SE, Gargalovic PS, Ryan CS, Watson LM, Langish RA, Shipkova PA, Carson NL, Taylor JR, Yang R, Psaltis GC, Harrity TW, Robl JA, Gordon DA.
PLoS One.
2013;8(2):e53192. doi: 10.1371/journal.pone.0053192.
PMID: 23383297
Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors.
Wang XD, Inzunza H, Chang H, Qi Z, Hu B, Malone D, Cogswell J.
PLoS One . 2013;8(1):e54415. doi: 10.1371/journal.pone.0054415.
PMID: 23349881
Integrated histopathological and urinary metabonomic investigation of the pathogenesis of microcystin-LR toxicosis.
Cantor GH, Beckonert O, Bollard ME, Keun HC, Ebbels TM, Antti H, Wijsman JA, Bible RH, Breau AP, Cockerell GL, Holmes E, Lindon JC, Nicholson JK.
Vet Pathol . 2013 Jan;50(1):159-71. doi: 10.1177/0300985812443839.
PMID: 22552484
2012 Publications
Bioactivation of 2-(alkylthio)-1,3,4-thiadiazoles and 2-(alkylthio)-1,3-benzothiazoles.
Yang Y, Qiu F, Josephs JL, Humphreys WG, Shu YZ.
Chem Res Toxicol.
2012 Dec 17;25(12):2770-9. doi: 10.1021/tx3003998.
PMID: 23148672
Surfactant choice and the physical stability of nanosuspensions as a function of pH.
Donoso MD, Haskell RJ, Schartman RR.
Int J Pharm.
2012 Dec 15;439(1-2):1-7. doi: 10.1016/j.ijpharm.2012.09.012.
PMID: 22982488
Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation.
Badawy SI, Narang AS, LaMarche K, Subramanian G, Varia SA.
Int J Pharm.
2012 Dec 15;439(1-2):324-33. doi: 10.1016/j.ijpharm.2012.09.011.
PMID: 22981985
Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.
Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE.
J Med Chem.
2012 Dec 13;55(23):10644-51. doi: 10.1021/jm3013147.
PMID: 23153230
Evaluation of the performance characteristics of bilayer tablets: Part I. Impact of material properties and process parameters on the strength of bilayer tablets.
Kottala N, Abebe A, Sprockel O, Bergum J, Nikfar F, Cuitiño AM.
AAPS PharmSciTech.
2012 Dec;13(4):1236-42. doi: 10.1208/s12249-012-9845-9.
PMID: 22976242
Evaluation of the performance characteristics of bilayer tablets: Part II. Impact of environmental conditions on the strength of bilayer tablets.
Kottala N, Abebe A, Sprockel O, Bergum J, Nikfar F, Cuitiño AM.
AAPS PharmSciTech . 2012 Dec;13(4):1190-6. doi: 10.1208/s12249-012-9846-8.
PMID: 22965660
Simple and efficient digestion of a monoclonal antibody in serum using pellet digestion: comparison with traditional digestion methods in LC-MS/MS bioanalysis.
Yuan L, Arnold ME, Aubry AF, Ji QC.
Bioanalysis.
2012 Dec;4(24):2887-96. doi: 10.4155/bio.12.284.
PMID: 23244280
Automated dried blood spots standard and QC sample preparation using a robotic liquid handler.
Yuan L, Zhang D, Aubry AF, Arnold ME.
Bioanalysis . 2012 Dec;4(23):2795-804. doi: 10.4155/bio.12.264.
PMID: 23216120
Development of oral extended release formulations of 6-hydroxybuspirone.
Nicholson SJ, Timmins P, Dockens RC, Connor A, Croop R, Ferrie P, Zeng J, Dennis AB, Wilding I.
Biopharm Drug Dispos.
2012 Dec;33(9):522-35. doi: 10.1002/bdd.1819.
PMID: 23065950
Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
Upreti VV, Hsiang CB, Li L, Xu X, LaCreta FP, Boulton DW.
Diabetes Obes Metab . 2012 Dec;14(12):1155-7. doi: 10.1111/j.1463-1326.2012.01635.x.
PMID: 22776778
Structural mass spectrometry in biologics discovery: advances and future trends.
Mo J, Tymiak AA, Chen G.
Drug Discov Today . 2012 Dec;17(23-24):1323-30. doi: 10.1016/j.drudis.2012.07.006. Review.
PMID: 22819924
Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
Barbosa MD, Kumar S, Loughrey H, Singh SK.
Drug Discov Today . 2012 Dec;17(23-24):1282-8. doi: 10.1016/j.drudis.2012.07.003. Review.
PMID: 22796124
Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
Gong J, Gan J, Masson E, Syed S, Xia YQ, Williams D, Pursley J, Jemal M, Humphreys WG, Iyer RA.
Drug Metab Dispos.
2012 Dec;40(12):2374-80. doi: 10.1124/dmd.112.047340.
PMID: 22983304
Microbial transformation of 2-amino-4-methyl-3-nitropyridine.
Tully T, Liu M, Huang Y, Ye Q, Patel RN, Goswami A.
J Ind Microbiol Biotechnol . 2012 Dec;39(12):1789-99. doi: 10.1007/s10295-012-1189-7.
PMID: 22926342
Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.
Cavallaro CL, Briceno S, Chen J, Cvijic ME, Davies P, Hynes J Jr, Liu RQ, Mandlekar S, Rose AV, Tebben AJ, Van Kirk K, Watson A, Wu H, Yang G, Carter PH.
J Med Chem.
2012 Nov 26;55(22):9643-53. doi: 10.1021/jm300896d.
PMID: 23075267
Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.
Jiang H, Zeng J, Li W, Bifano M, Gu H, Titsch C, Easter J, Burrell R, Kandoussi H, Aubry AF, Arnold ME.
Anal Chem.
2012 Nov 20;84(22):10031-7. doi: 10.1021/ac3024558.
PMID: 23106420
2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitors.
Parker MF, Barten DM, Bergstrom CP, Bronson JJ, Corsa JA, Dee MF, Gai Y, Guss VL, Higgins MA, Keavy DJ, Loo A, Mate RA, Marcin LR, McElhone KE, Polson CT, Roberts SB, Macor JE.
Bioorg Med Chem Lett.
2012 Nov 15;22(22):6828-31. doi: 10.1016/j.bmcl.2012.09.057.
PMID: 23046960
Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis.
Gerritz SW, Zhai W, Shi S, Zhu S, Toyn JH, Meredith JE Jr, Iben LG, Burton CR, Albright CF, Good AC, Tebben AJ, Muckelbauer JK, Camac DM, Metzler W, Cook LS, Padmanabha R, Lentz KA, Sofia MJ, Poss MA, Macor JE, Thompson LA 3rd.
J Med Chem.
2012 Nov 8;55(21):9208-23. doi: 10.1021/jm300931y.
PMID: 23030502
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM.
Arch Neurol.
2012 Nov;69(11):1430-40.
PMID: 22892585
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents.
Deskus JA, Dischino DD, Mattson RJ, Ditta JL, Parker MF, Denhart DJ, Zuev D, Huang H, Hartz RA, Ahuja VT, Wong H, Mattson GK, Molski TF, Grace JE Jr, Zueva L, Nielsen JM, Dulac H, Li YW, Guaraldi M, Azure M, Onthank D, Hayes M, Wexler E, McDonald J, Lodge NJ, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2012 Nov 1;22(21):6651-5. doi: 10.1016/j.bmcl.2012.08.112.
PMID: 23010264
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Tong G, Castaneda L, Wang JS, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright C, Dockens RC.
Clin Drug Investig.
2012 Nov;32(11):761-9. doi: 10.1007/s40261-012-0006-4.
PMID: 23018285
Characterization and identification of alanine to serine sequence variants in an IgG4 monoclonal antibody produced in mammalian cell lines.
Fu J, Bongers J, Tao L, Huang D, Ludwig R, Huang Y, Qian Y, Basch J, Goldstein J, Krishnan R, You L, Li ZJ, Russell RJ.
J Chromatogr B Analyt Technol Biomed Life Sci . 2012 Nov 1;908:1-8. doi: 10.1016/j.jchromb.2012.09.023.
PMID: 23122394
Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD).
Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A.
J Diabetes Complications . 2012 Nov-Dec;26(6):513-6. doi: 10.1016/j.jdiacomp.2012.06.008.
PMID: 22889712
Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database.
Hirji I, Andersson SW, Guo Z, Hammar N, Gomez-Caminero A.
J Diabetes Complications . 2012 Nov-Dec;26(6):501-5. doi: 10.1016/j.jdiacomp.2012.06.012.
PMID: 22840886
Application of a design of experiment approach in the development of a sensitive bioanalytical assay in human plasma.
Dawes ML, Bergum JS, Schuster AE, Aubry AF.
J Pharm Biomed Anal.
2012 Nov;70:401-7. doi: 10.1016/j.jpba.2012.06.011.
PMID: 22776736
A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study.
Furlong MT, He B, Mylott W, Zhao S, Mariannino T, Shen J, Stouffer B.
J Pharm Biomed Anal.
2012 Nov;70:574-9. doi: 10.1016/j.jpba.2012.05.026.
PMID: 22709607
Evaluation of mobile phase gradient supercritical fluid chromatography for impurity profiling of pharmaceutical compounds.
Alexander AJ, Hooker TF, Tomasella FP.
J Pharm Biomed Anal.
2012 Nov;70:77-86. doi: 10.1016/j.jpba.2012.05.025.
PMID: 22687460
Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats.
Vuppugalla R, Zhang Y, Chang S, Rodrigues AD, Marathe PH.
Xenobiotica.
2012 Nov;42(11):1058-68. doi: 10.3109/00498254.2012.684104.
PMID: 22574883
Addressing drug effects on cut point determination for an anti-drug antibody assay.
Barbosa MD, Gleason CR, Phillips KR, Berisha F, Stouffer B, Warrack BM, Chen G.
J Immunol Methods.
2012 Oct 31;384(1-2):152-6. doi: 10.1016/j.jim.2012.06.014.
PMID: 22750627
Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors.
Miller MM, Liu Y, Jiang J, Johnson JA, Kamau M, Nirschl DS, Wang Y, Harikrishnan L, Taylor DS, Chen AY, Yin X, Seethala R, Peterson TL, Zvyaga T, Zhang J, Huang CS, Wexler RR, Poss MA, Lawrence RM, Adam LP, Salvati ME.
Bioorg Med Chem Lett.
2012 Oct 15;22(20):6503-8. doi: 10.1016/j.bmcl.2012.08.011.
PMID: 22995620
Influence of compaction properties and interfacial topography on the performance of bilayer tablets.
Kottala N, Abebe A, Sprockel O, Akseli I, Nikfar F, Cuitiño AM.
Int J Pharm . 2012 Oct 15;436(1-2):171-8. doi: 10.1016/j.ijpharm.2012.05.026.
PMID: 22728259
Roller compaction process development and scale up using Johanson model calibrated with instrumented roll data.
Nesarikar VV, Patel C, Early W, Vatsaraj N, Sprockel O, Jerzweski R.
Int J Pharm . 2012 Oct 15;436(1-2):486-507. doi: 10.1016/j.ijpharm.2012.06.027.
PMID: 22721851
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, Chen C, Lee MS, Mosure K, Sun LQ, Sinz M, Meanwell NA, Colonno RJ, Knipe J, Scola P.
Antimicrob Agents Chemother . 2012 Oct;56(10):5387-96. doi: 10.1128/AAC.01186-12.
PMID: 22869577
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.
Pelosi LA, Voss S, Liu M, Gao M, Lemm JA.
Antimicrob Agents Chemother.
2012 Oct;56(10):5230-9. doi: 10.1128/AAC.01209-12.
PMID: 22850513
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project..
Arch Neurol.
2012 Oct;69(10):1310-7.
PMID: 22801723
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.
St Laurent DR, Belema M, Gao M, Goodrich J, Kakarla R, Knipe JO, Lemm JA, Liu M, Lopez OD, Nguyen VN, Nower PT, O'Boyle D 2nd, Qiu Y, Romine JL, Serrano-Wu MH, Sun JH, Valera L, Yang F, Yang X, Meanwell NA, Snyder LB.
Bioorg Med Chem Lett.
2012 Oct 1;22(19):6063-6. doi: 10.1016/j.bmcl.2012.08.049.
PMID: 22959243
Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
Cherney RJ, Mo R, Meyer DT, Pechulis AD, Guaciaro MA, Lo YC, Yang G, Miller PB, Scherle PA, Zhao Q, Cvijic ME, Barrish JC, Decicco CP, Carter PH.
Bioorg Med Chem Lett.
2012 Oct 1;22(19):6181-4. doi: 10.1016/j.bmcl.2012.08.002.
PMID: 22939233
The cloning of the gene for hereditary hemochromatosis.
Feder JN, Thomas W.
Clin Chem.
2012 Oct;58(10):1485-6. No abstract available.
PMID: 22691273
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Dockens R, Wang JS, Castaneda L, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Tong G.
Clin Pharmacokinet.
2012 Oct 1;51(10):681-93.
PMID: 23018531
Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole.
Boulton DW, Kollia GD, Mallikaarjun S, Kornhauser DM.
J Clin Pharm Ther . 2012 Oct;37(5):565-70. doi: 10.1111/j.1365-2710.2012.01331.x.
PMID: 22943745
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
Nettles RE, Schürmann D, Zhu L, Stonier M, Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, Hanna GJ, Bertz R, Grasela D.
J Infect Dis.
2012 Oct 1;206(7):1002-11. doi: 10.1093/infdis/jis432.
PMID: 22896665
Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
Iloeje UH, Yang HI, Chen CJ.
Liver Int . 2012 Oct;32(9):1333-41. doi: 10.1111/j.1478-3231.2012.02805.x. Review.
PMID: 22510145
Impact of excipient interactions on solid dosage form stability.
Narang AS, Desai D, Badawy S.
Pharm Res.
2012 Oct;29(10):2660-83. doi: 10.1007/s11095-012-0782-9. Review.
PMID: 22707362
Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.
Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, Hussain M.
Pharm Res . 2012 Oct;29(10):2765-76.
PMID: 22315020
Cannabinoid receptor antagonist-induced striated muscle toxicity and ethylmalonic-adipic aciduria in beagle dogs.
Tomlinson L, Tirmenstein MA, Janovitz EB, Aranibar N, Ott KH, Kozlosky JC, Patrone LM, Achanzar WE, Augustine KA, Brannen KC, Carlson KE, Charlap JH, Dubrow KM, Kang L, Rosini LT, Panzica-Kelly JM, Flint OP, Moulin FJ, Megill JR, Zhang H, Bennett MJ, Horvath JJ.
Toxicol Sci.
2012 Oct;129(2):268-79. doi: 10.1093/toxsci/kfs217.
PMID: 22821849
Application of lipid-based formulations in drug discovery.
Chen XQ, Gudmundsson OS, Hageman MJ.
J Med Chem . 2012 Sep 27;55(18):7945-56. Review. No abstract available.
PMID: 22779739
Efficient and scalable enantioselective synthesis of a CGRP antagonist.
Leahy DK, Fan Y, Desai LV, Chan C, Zhu J, Luo G, Chen L, Hanson RL, Sugiyama M, Rosner T, Cuniere N, Guo Z, Hsiao Y, Gao Q.
Org Lett.
2012 Sep 21;14(18):4938-41.
PMID: 22954228
Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
He L, Seitz SP, Trainor GL, Tortolani D, Vaccaro W, Poss M, Tarby CM, Tokarski JS, Penhallow B, Hung CY, Attar R, Lin TA.
Bioorg Med Chem Lett . 2012 Sep 15;22(18):5995-8. doi: 10.1016/j.bmcl.2012.07.002.
PMID: 22902653
Utility of in situ sodium alginate/karaya gum gels to facilitate gastric retention in rodents.
Foster KA, Morgen M, Murri B, Yates I, Fancher RM, Ehrmann J, Gudmundsson OS, Hageman MJ.
Int J Pharm.
2012 Sep 15;434(1-2):406-12. doi: 10.1016/j.ijpharm.2012.06.009.
PMID: 22692076
Addressing the medicinal chemistry bottleneck: a lean approach to centralized purification.
Weller HN, Nirschl DS, Paulson JL, Hoffman SL, Bullock WH.
ACS Comb Sci.
2012 Sep 10;14(9):520-6. doi: 10.1021/co300075g.
PMID: 22909004
The use of modeling tools to drive efficient oral product design.
Mathias NR, Crison J.
AAPS J.
2012 Sep;14(3):591-600. doi: 10.1208/s12248-012-9372-3. Review.
PMID: 22644702
Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics.
Bergeson JG, Kalsekar I, Jing Y, You M, Forbes RA, Hebden T.
Am Health Drug Benefits . 2012 Sep;5(6):379-86.
PMID: 24991334
Evolution of end points for cancer immunotherapy trials.
Hoos A.
Ann Oncol.
2012 Sep;23 Suppl 8:viii47-52. doi: 10.1093/annonc/mds263.
PMID: 22918928
2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines.
DeSilva B, Garofolo F, Rocci M, Martinez S, Dumont I, Landry F, Dicaire C, Szekely-Klepser G, Weiner R, Arnold M, Bansal S, Bateman K, Bauer R, Booth B, Davis S, Dudal S, Gouty D, Grundy J, Haidar S, Hayes R, Jemal M, Kaur S, Kelley M, Knutsson M, Le Blaye O, Lee J, Lowes S, Ma M, Mitsuoka T, Neto JT, Nicholson R, Ormsby E, Sailstad J, Stevenson L, Tang D, Welink J, Viswanathan CT, Wang L, Woolf E, Yang E.
Bioanalysis.
2012 Sep;4(18):2213-26. doi: 10.4155/bio.12.205.
PMID: 23046264
Enoxaparin dosing after discharge from US hospitals in patients with total knee replacement.
Wright R, Kawabata H, Pan X, Simon TA, Ramacciotti E.
Clin Appl Thromb Hemost . 2012 Sep;18(5):514-8. doi: 10.1177/1076029611433643.
PMID: 22345487
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD.
Drug Metab Dispos.
2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575.
PMID: 22648560
Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic.
Wang H, Wang L, Cao K, Emanuel SL, Morin P, Lin Z, Shen G, Hosbach J, Zhang D, Bonacorsi S, Rodrigues AD, Yang Z.
Drug Metab Dispos . 2012 Sep;40(9):1677-85. doi: 10.1124/dmd.112.044792.
PMID: 22627466
A novel ring oxidation of 4- or 5-substituted 2H-oxazole to corresponding 2-oxazolone catalyzed by cytosolic aldehyde oxidase.
Arora VK, Philip T, Huang S, Shu YZ.
Drug Metab Dispos . 2012 Sep;40(9):1668-76. doi: 10.1124/dmd.112.044545.
PMID: 22621803
ABRF-MIRG benchmark study: molecular interactions in a three-component system.
Yamniuk AP, Edavettal SC, Bergqvist S, Yadav SP, Doyle ML, Calabrese K, Parsons JF, Eisenstein E.
J Biomol Tech.
2012 Sep;23(3):101-14. doi: 10.7171/jbt.12-2303-003.
PMID: 22942790
A Bayesian approach for inference from a bridging study with binary outcomes.
Gandhi M, Mukherjee B, Biswas D.
J Biopharm Stat . 2012 Sep;22(5):935-51. doi: 10.1080/10543406.2012.698436. Review.
PMID: 22946941
Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.
Vakkalagadda B, Park JS, Ahlers CM, Dorizio S, Has T, Roongta V, Heller KN, Derbin GM, Zhang S.
J Clin Pharmacol . 2012 Sep;52(9):1350-6. doi: 10.1177/0091270011417826.
PMID: 22031621
Formation of reactive impurities in aqueous and neat polyethylene glycol 400 and effects of antioxidants and oxidation inducers.
Hemenway JN, Carvalho TC, Rao VM, Wu Y, Levons JK, Narang AS, Paruchuri SR, Stamato HJ, Varia SA.
J Pharm Sci.
2012 Sep;101(9):3305-18. doi: 10.1002/jps.23198.
PMID: 22610374
Degradation kinetics and mechanism of an oxadiazole derivative, design of a stable drug product for BMS-708163, a γ-secretase inhibitor drug candidate.
Hartley RF, Huang Y, Cassidy M, Razler TM, Qian F, Hussain MA.
J Pharm Sci.
2012 Sep;101(9):3124-33. doi: 10.1002/jps.23050.
PMID: 22262489
Acid-catalyzed hydrolysis of BMS-582664: degradation product identification and mechanism elucidation.
Zhao F, Derbin G, Miller S, Badawy S, Hussain M.
J Pharm Sci.
2012 Sep;101(9):3526-30. doi: 10.1002/jps.23028.
PMID: 22189636
Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling.
Brown J, Crison J, Timmins P.
Ther Deliv . 2012 Sep;3(9):1047-59. Review.
PMID: 23035591
Comparison of 1-Ethyl-3-(3-Dimethylaminopropyl) Carbodiimide Based Strategies to Crosslink Antibodies on Amine-Functionalized Platforms for Immunodiagnostic Applications.
Vashist SK.
Diagnostics (Basel).
2012 Aug 27;2(3):23-33. doi: 10.3390/diagnostics2030023.
PMID: 26859395
Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound.
Burton L, Ying W, Gandhi R, West R, Huang C, Zhou S, Shah K, Chen J, Shen X.
Int J Pharm.
2012 Aug 20;433(1-2):94-101. doi: 10.1016/j.ijpharm.2012.04.075.
PMID: 22569200
Internal multiple-scattering hole-enhanced Raman spectroscopy: improved backscattering Fourier transform Raman sampling in pharmaceutical tablets utilizing cylindrical-conical holes.
Larkin PJ, Santangelo M, Šašiċ S.
Appl Spectrosc.
2012 Aug;66(8):892-902. doi: 10.1366/12-06677.
PMID: 22800376
What is next for dried blood spots?
Ji QC, Liu G, D'Arienzo CJ, Olah TV, Arnold ME.
Bioanalysis . 2012 Aug;4(16):2059-65. doi: 10.4155/bio.12.168.
PMID: 22946921
Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites.
Wei C, Grace JE Jr, Zvyaga TA, Drexler DM.
Bioanalysis . 2012 Aug;4(15):1895-905. doi: 10.4155/bio.12.151.
PMID: 22943620
Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
Xu XS, Dueker SR, Christopher LJ, Lohstroh PN, Keung CF, Cao KK, Bonacorsi SJ, Cojocaru L, Shen JX, Humphreys WG, Stouffer B, Arnold ME.
Bioanalysis.
2012 Aug;4(15):1855-70. doi: 10.4155/bio.12.171.
PMID: 22943617
A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies.
Furlong MT, Ouyang Z, Wu S, Tamura J, Olah T, Tymiak A, Jemal M.
Biomed Chromatogr.
2012 Aug;26(8):1024-32. doi: 10.1002/bmc.2759.
PMID: 22623136
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD, Sielecki TM, Arvanitis AG, Galka A, Johnson TL, Takvorian AG, Rafalski M, Kasireddy-Polam P, Vig S, Dasgupta B, Zhang G, Molski TF, Wong H, Zaczek RC, Lodge NJ, Combs AP, Gilligan PJ, Trainor GL, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2012 Aug 1;22(15):4986-9. doi: 10.1016/j.bmcl.2012.06.034.
PMID: 22749422
Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients.
Zhou Z, Shen J, Hong Y, Kaul S, Pfister M, Roy A.
Clin Pharmacol Ther.
2012 Aug;92(2):251-7. doi: 10.1038/clpt.2012.84.
PMID: 22760001
Assessing cell fusion and cytokinesis failure as mechanisms of clone 9 hepatocyte multinucleation in vitro.
Simic D, Euler C, Thurby C, Peden M, Tannehill-Gregg S, Bunch T, Sanderson T, Van Vleet T.
Curr Protoc Toxicol.
2012 Aug;Chapter 14:Unit 14.9.1-17. doi: 10.1002/0471140856.tx1409s53.
PMID: 22896007
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
Soars MG, Barton P, Ismair M, Jupp R, Riley RJ.
Drug Metab Dispos . 2012 Aug;40(8):1641-8. doi: 10.1124/dmd.111.042382.
PMID: 22587986
Reduction of N-terminal methionylation while increasing titer by lowering metabolic and protein production rates in E. coli auto-induced fed-batch fermentation.
Xu J, Qian Y, Skonezny PM, You L, Xing Z, Meyers DS, Stankavage RJ, Pan SH, Li ZJ.
J Ind Microbiol Biotechnol.
2012 Aug;39(8):1199-208. doi: 10.1007/s10295-012-1127-8.
PMID: 22526331
GPCR assay automation for leveraging lead optimization.
Cvijic ME, Chen J, Kubala S, Nolfo J, Kolodin G, Zhang L.
J Lab Autom.
2012 Aug;17(4):266-74. doi: 10.1177/2211068212442502.
PMID: 22505604
Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography-tandem mass spectrometry.
Cai X, Walker A, Cheng C, Paiva A, Li Y, Kolb J, Herbst J, Shou W, Weller H.
J Pharm Sci. 2012
Aug;101(8):2755-62. doi: 10.1002/jps.23194.
PMID: 22611052
A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis.
Bird JE, Wang X, Smith PL, Barbera F, Huang C, Schumacher WA.
J Thromb Thrombolysis . 2012 Aug;34(2):199-207. doi: 10.1007/s11239-012-0745-3.
PMID: 22588534
Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA.
Obesity (Silver Spring).
2012 Aug;20(8):1645-52. doi: 10.1038/oby.2012.59.
PMID: 22402735
Influenza nucleoprotein: promising target for antiviral chemotherapy.
Cianci C, Gerritz SW, Deminie C, Krystal M.
Antivir Chem Chemother.
2012 Jul 26;23(3):77-91. doi: 10.3851/IMP2235. Review.
PMID: 22837443
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.
Frederich R, McNeill R, Berglind N, Fleming D, Chen R.
Diabetol Metab Syndr . 2012 Jul 24;4(1):36. doi: 10.1186/1758-5996-4-36.
PMID: 22828124
Synthetic approaches to a chiral 4-amino-3-hydroxy piperidine with pharmaceutical relevance.
Ortiz A, Young IS, Sawyer JR, Hsiao Y, Singh A, Sugiyama M, Corbett RM, Chau M, Shi Z, Conlon DA.
Org Biomol Chem.
2012 Jul 21;10(27):5253-7. doi: 10.1039/c2ob25411e.
PMID: 22648308
Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey.
Kalsekar I, Wagner JS, DiBonaventura M, Bates J, Forbes R, Hebden T.
Health Qual Life Outcomes . 2012 Jul 17;10:81. doi: 10.1186/1477-7525-10-81.
PMID: 22805425
Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.
Chaturvedula PV, Pin S, Tholady G, Conway CM, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett.
2012 Jul 15;22(14):4719-22. doi: 10.1016/j.bmcl.2012.05.118.
PMID: 22732695
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
Han X, Civiello RL, Conway CM, Cook DA, Davis CD, Macci R, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Chaturvedula PV, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett.
2012 Jul 15;22(14):4723-7. doi: 10.1016/j.bmcl.2012.05.074.
PMID: 22727645
Separation and detection of bis-maleimide-polyethylene glycol and mono-maleimide-polyethylene glycol by reversed-phase high pressure liquid chromatography.
Tang L, Jariwala F, Bolgar M, Lloyd DK.
2012 Jul 13;1246:117-22. doi: 10.1016/j.chroma.2012.03.044.
PMID: 22503616
Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
Harikrishnan LS, Finlay HJ, Qiao JX, Kamau MG, Jiang J, Wang TC, Li J, Cooper CB, Poss MA, Adam LP, Taylor DS, Chen AY, Yin X, Sleph PG, Yang RZ, Sitkoff DF, Galella MA, Nirschl DS, Van Kirk K, Miller AV, Huang CS, Chang M, Chen XQ, Salvati ME, Wexler RR, Lawrence RM.
J Med Chem.
2012 Jul 12;55(13):6162-75. doi: 10.1021/jm300611v.
PMID: 22650305
A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.
Jiang H, Zeng J, Kandoussi H, Liu Y, Wang X, Bifano M, Cojocaru L, Ryan J, Arnold ME.
J Chromatogr A.
2012 Jul 6;1245:117-21. doi: 10.1016/j.chroma.2012.05.028.
PMID: 22640838
In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.
Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ, Matiskella JD, Ueda Y, Wang T, Kadow JF, Meanwell NA, Krystal M.
Antimicrob Agents Chemother . 2012 Jul;56(7):3498-507. doi: 10.1128/AAC.00426-12.
PMID: 22547625
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, Hernandez D, Lee MS, Chaniewski S, Sheaffer AK, Pasquinelli C.
Antimicrob Agents Chemother . 2012 Jul;56(7):3670-81. doi: 10.1128/AAC.00308-12.
PMID: 22508297
A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds.
Grubb MF, Humphreys WG, Josephs JL.
Bioanalysis.
2012 Jul;4(14):1747-61. doi: 10.4155/BIO.12.134.
PMID: 22877221
An immune-active tumor microenvironment favors clinical response to ipilimumab.
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V.
Cancer Immunol Immunother . 2012 Jul;61(7):1019-31. doi: 10.1007/s00262-011-1172-6.
PMID: 22146893
Case study: technology initiative led to advanced lead optimization screening processes at
Bristol-Myers
Squibb , 2004-2009.
Zhang L, Cvijic ME, Lippy J, Myslik J, Brenner SL, Binnie A, Houston JG.
Drug Discov Today . 2012 Jul;17(13-14):733-40. doi: 10.1016/j.drudis.2012.02.012. Review.
PMID: 22425710
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Su H, Boulton DW, Barros A Jr, Wang L, Cao K, Bonacorsi SJ Jr, Iyer RA, Humphreys WG, Christopher LJ.
Drug Metab Dispos . 2012 Jul;40(7):1345-56. doi: 10.1124/dmd.112.045450.
PMID: 22496391
Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents.
Sheehan JJ, Reilly KR, Fu DJ, Alphs L.
Innov Clin Neurosci . 2012 Jul;9(7-8):17-23.
PMID: 22984648
Preclinical safety, pharmacokinetics, and pharmacodynamics of recombinant human interleukin-21 in cynomolgus macaques (Macaca fascicularis).
Waggie KS, Holdren MS, Byrnes-Blake K, Pedersen S, Ponce R, Hughes S, Miller DM.
Int J Toxicol.
2012 Jul-Aug;31(4):303-16. doi: 10.1177/1091581812449661.
PMID: 22723515
Mitigation of signal suppression caused by the use of trifluoroacetic acid in liquid chromatography mobile phases during liquid chromatography/mass spectrometry analysis via post-column addition of ammonium hydroxide.
Chan CC, Bolgar MS, Dalpathado D, Lloyd DK.
Rapid Commun Mass Spectrom.
2012 Jun 30;26(12):1507-14. doi: 10.1002/rcm.6240.
PMID: 22592995
Systematic evaluation of the root cause of non-linearity in liquid chromatography/tandem mass spectrometry bioanalytical assays and strategy to predict and extend the linear standard curve range.
Yuan L, Zhang D, Jemal M, Aubry AF.
Rapid Commun Mass Spectrom . 2012 Jun 30;26(12):1465-74. doi: 10.1002/rcm.6252.
PMID: 22592990
Expression Profile of Drug and Nutrient Absorption Related Genes in Madin-Darby Canine Kidney (MDCK) Cells Grown under Differentiation Conditions.
Quan Y, Jin Y, Faria TN, Tilford CA, He A, Wall DA, Smith RL, Vig BS.
Pharmaceutics.
2012 Jun 18;4(2):314-33. doi: 10.3390/pharmaceutics4020314.
PMID: 24300234
Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.
Perez HL, Banfi P, Bertrand J, Cai ZW, Grebinski JW, Kim K, Lippy J, Modugno M, Naglich J, Schmidt RJ, Tebben A, Vianello P, Wei DD, Zhang L, Galvani A, Lombardo LJ, Borzilleri RM.
Bioorg Med Chem Lett.
2012 Jun 15;22(12):3946-50. doi: 10.1016/j.bmcl.2012.04.103.
PMID: 22608961
Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists.
Schroeder GM, Wei D, Banfi P, Cai ZW, Lippy J, Menichincheri M, Modugno M, Naglich J, Penhallow B, Perez HL, Sack J, Schmidt RJ, Tebben A, Yan C, Zhang L, Galvani A, Lombardo LJ, Borzilleri RM.
Bioorg Med Chem Lett.
2012 Jun 15;22(12):3951-6. doi: 10.1016/j.bmcl.2012.04.106.
PMID: 22608393
Esterase inhibitors as ester-containing drug stabilizers and their hydrolytic products: potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry.
Zheng N, Fung EN, Buzescu A, Arnold ME, Zeng J.
Rapid Commun Mass Spectrom . 2012 Jun 15;26(11):1291-304. doi: 10.1002/rcm.6230.
PMID: 22555922
Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
Gu H, Wang J, Aubry AF, Jiang H, Zeng J, Easter J, Wang JS, Dockens R, Bifano M, Burrell R, Arnold ME.
Anal Chem.
2012 Jun 5;84(11):4844-50. doi: 10.1021/ac300442v.
PMID: 22540405
Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix(®), a CTLA-4-Fc fusion protein, in renal and liver transplant patients.
Myler HA, Phillips KR, Dong H, Tabler E, Shaikh M, Coats V, Hay L, Tacey R, Stouffer B.
Bioanalysis . 2012 Jun;4(10):1215-26. doi: 10.4155/bio.12.79.
PMID: 22651565
Conference report: bioanalytical sessions at the 2011 Eastern Analytical Symposium.
Dawes M, Zhao Y, Aubry AF.
Bioanalysis . 2012 Jun;4(10):1151-3. doi: 10.4155/bio.12.103.
PMID: 22651557
Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight.
Rohrbach K, Thomas MA, Glick S, Fung EN, Wang V, Watson L, Gregory P, Antel J, Pelleymounter MA.
Diabetes Obes Metab.
2012 Jun;14(6):555-64. doi: 10.1111/j.1463-1326.2012.01563.x.
PMID: 22268426
In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Zhou L, Dockens RC, Liu-Kreyche P, Grossman SJ, Iyer RA.
Drug Metab Dispos . 2012 Jun;40(6):1093-103. doi: 10.1124/dmd.111.043596.
PMID: 22381334
A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S.
Drug Metab Lett.
2012 Jun 1;6(2):134-44.
PMID: 23061481
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
Pinto DJ, Qiao JX, Knabb RM.
Expert Opin Ther Pat.
2012 Jun;22(6):645-61. doi: 10.1517/13543776.2012.680438. Review.
PMID: 22655676
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.
Sun JH, O'Boyle Ii DR, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M.
Hepatology . 2012 Jun;55(6):1692-9. doi: 10.1002/hep.25581.
PMID: 22234905
Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Syed S, Clemens PL, Lathers D, Kollia G, Dhar A, Walters I, Masson E.
J Clin Pharmacol . 2012 Jun;52(6):914-21. doi: 10.1177/0091270011407495.
PMID: 21659627
A user-friendly robotic sample preparation program for fully automated biological sample pipetting and dilution to benefit the regulated bioanalysis.
Jiang H, Ouyang Z, Zeng J, Yuan L, Zheng N, Jemal M, Arnold ME.
J Lab Autom.
2012 Jun;17(3):211-21. doi: 10.1177/2211068211429775.
PMID: 22357562
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators..
Lancet Neurol.
2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.
PMID: 22572202
Mechanistic understanding of protein-silicone oil interactions.
Li J, Pinnamaneni S, Quan Y, Jaiswal A, Andersson FI, Zhang X.
Pharm Res.
2012 Jun;29(6):1689-97. doi: 10.1007/s11095-012-0696-6.
PMID: 22350802
Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait.
Bird JE, Smith PL, Wang X, Schumacher WA, Barbera F, Revelli JP, Seiffert D.
Thromb Haemost.
2012 Jun;107(6):1141-50. doi: 10.1160/TH-11-10-0682.
PMID: 22398951
Regulatory forum opinion piece: blind reading of histopathology slides in general toxicology studies.
Neef N, Nikula KJ, Francke-Carroll S, Boone L.
Toxicol Pathol.
2012 Jun;40(4):697-9. doi: 10.1177/0192623312438737.
PMID: 22407309
Development of a streamlined rat whole embryo culture assay for classifying teratogenic potential of pharmaceutical compounds.
Zhang C, Cao J, Kenyon JR, Panzica-Kelly JM, Gong L, Augustine-Rauch K.
Toxicol Sci.
2012 Jun;127(2):535-46. doi: 10.1093/toxsci/kfs112.
PMID: 22430072
Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.
Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, Cadelina GW, Decarr LB, Yang L, Liu V, Fessler C, Protassio J, Riff T, Turner H, Janus CG, Sankaranarayanan S, Polson C, Meredith JE, Gray G, Hanna A, Olson RE, Kim SH, Vite GD, Lee FY, Albright CF.
J Neurosci.
2012 May 23;32(21):7137-45. doi: 10.1523/JNEUROSCI.0188-12.2012.
PMID: 22623658
An evaluation of process parameters to improve coating efficiency of an active tablet film-coating process.
Wang J, Hemenway J, Chen W, Desai D, Early W, Paruchuri S, Chang SY, Stamato H, Varia S.
Int J Pharm.
2012 May 10;427(2):163-9. doi: 10.1016/j.ijpharm.2012.01.033.
PMID: 22301427
Recent development in software and automation tools for high-throughput discovery bioanalysis.
Shou WZ, Zhang J.
Bioanalysis . 2012 May;4(9):1097-109. doi: 10.4155/bio.12.51. Review.
PMID: 22612689
A bioanalytical strategy utilizing dried blood spot sampling and LC-MS/MS in discovery toxicology studies.
Discenza L, Obermeier MT, Westhouse R, Olah TV, D'Arienzo CJ.
Bioanalysis . 2012 May;4(9):1057-64. doi: 10.4155/bio.12.69.
PMID: 22612686
Discovery bioanalysis. Foreward.
Shou WZ.
Bioanalysis . 2012 May;4(9):983-4. doi: 10.4155/bio.12.102. No abstract available.
PMID: 22612675
Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.
Carter PH, Brown GD, King SR, Voss ME, Tebben AJ, Cherney RJ, Mandlekar S, Lo YC, Yang G, Miller PB, Scherle PA, Zhao Q, Decicco CP.
Bioorg Med Chem Lett.
2012 May 1;22(9):3311-6. doi: 10.1016/j.bmcl.2012.03.007.
PMID: 22475558
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.
Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR.
Cancer Immunol Immunother . 2012 May;61(5):733-7. doi: 10.1007/s00262-012-1227-3.
PMID: 22382362
Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN.
Expert Opin Ther Pat.
2012 May;22(5):483-94. doi: 10.1517/13543776.2012.680437. Review.
PMID: 22583331
Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling.
Crison JR, Timmins P, Keung A, Upreti VV, Boulton DW, Scheer BJ.
J Pharm Sci.
2012 May;101(5):1773-82. doi: 10.1002/jps.23063.
PMID: 22334460
Effect of physical states of binders on high-shear wet granulation and granule properties: a mechanistic approach toward understanding high-shear wet granulation process, part 3: effect of binder rheological properties.
Li J, Tao L, Buckley D, Tao J, Gao J, Hubert M.
J Pharm Sci.
2012 May;101(5):1877-87. doi: 10.1002/jps.23059.
PMID: 22271364
Investigation of freeze/thaw-related quality attributes of a liquid biopharmaceutical formulation: the role of saccharide excipients.
Zhou R, Schlam RF, Yin S, Gandhi RB, Adams ML.
PDA J Pharm Sci Technol.
2012 May-Jun;66(3):221-35. doi: 10.5731/pdajpst.2012.00861.
PMID: 22634588
Galactose can be an inducer for production of therapeutic proteins by auto-induction using E. coli BL21 strains.
Xu J, Banerjee A, Pan SH, Li ZJ.
Protein Expr Purif.
2012 May;83(1):30-6. doi: 10.1016/j.pep.2012.02.014.
PMID: 22425658
Glycine to glutamic acid misincorporation observed in a recombinant protein expressed by Escherichia coli cells.
Huang Y, O'Mara B, Conover M, Ludwig R, Fu J, Tao L, Li ZJ, Rieble S, Grace MJ, Russell RJ.
Protein Sci.
2012 May;21(5):625-32. doi: 10.1002/pro.2046.
PMID: 22362707
Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.
Nita ME, Eliaschewitz FG, Ribeiro E, Asano E, Barbosa E, Takemoto M, Donato B, Rached R, Rahal E.
Rev Assoc Med Bras (1992).
2012 May-Jun;58(3):294-301. English, Portuguese.
PMID: 22735220
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.
Thromb Haemost.
2012 May;107(5):916-24. doi: 10.1160/TH11-09-0634.
PMID: 22398784
Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeys.
Haggerty HG, Proctor SJ.
Toxicol Sci.
2012 May;127(1):159-68. doi: 10.1093/toxsci/kfs081.
PMID: 22331490
Calcitonin gene-related peptide (CGRP) receptor antagonists: novel aspartates and succinates.
Luo G, Chen L, Pin SS, Xu C, Conway CM, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett.
2012 Apr 15;22(8):2912-6. doi: 10.1016/j.bmcl.2012.02.066.
PMID: 22429471
Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group.
Luo G, Chen L, Civiello R, Pin SS, Xu C, Kostich W, Kelley M, Conway CM, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett . 2012 Apr 15;22(8):2917-21. doi: 10.1016/j.bmcl.2012.02.065.
PMID: 22429470
Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.
Ding M, He F, Hudyma TW, Zheng X, Poss MA, Kadow JF, Beno BR, Rigat KL, Wang YK, Fridell RA, Lemm JA, Qiu D, Liu M, Voss S, Pelosi LA, Roberts SB, Gao M, Knipe J, Gentles RG.
Bioorg Med Chem Lett.
2012 Apr 15;22(8):2866-71. doi: 10.1016/j.bmcl.2012.02.063.
PMID: 22424979
Instrumented roll technology for the design space development of roller compaction process.
Nesarikar VV, Vatsaraj N, Patel C, Early W, Pandey P, Sprockel O, Gao Z, Jerzewski R, Miller R, Levin M.
Int J Pharm.
2012 Apr 15;426(1-2):116-31. doi: 10.1016/j.ijpharm.2012.01.032.
PMID: 22286023
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor.
Finlay HJ, Lloyd J, Vaccaro W, Kover A, Yan L, Bhave G, Prol J, Huynh T, Bhandaru R, Caringal Y, DiMarco J, Gan J, Harper T, Huang C, Conder ML, Sun H, Levesque P, Blanar M, Atwal K, Wexler R.
J Med Chem.
2012 Apr 12;55(7):3036-48. doi: 10.1021/jm201386u. Erratum in: J Med Chem. 2013 Sep 12;56(17):7133.
PMID: 22409629
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM.
Antimicrob Agents Chemother . 2012 Apr;56(4):1838-44. doi: 10.1128/AAC.05854-11.
PMID: 22290978
Evaluation and optimization of compound solubilization and delivery methods in a two-tiered ion channel lead optimization triage.
Hendricson AW, Gallagher L, Matchett M, Ferrante M, Spence S, Paiva T, Shou W, Tertyshnikova S, Krambis M, Post-Munson D, Zhang L, Knox R.
Assay Drug Dev Technol.
2012 Apr;10(2):202-11. doi: 10.1089/adt.2011.0385.
PMID: 22085018
Interpersonal interactions, job demands and work-related outcomes in pharmacy.
Gaither CA, Nadkarni A.
Int J Pharm Pract.
2012 Apr;20(2):80-9. doi: 10.1111/j.2042-7174.2011.00165.x.
PMID: 22416932
Design of an automated enhanced-throughput platform for functional characterization of positive allosteric modulator-induced leftward shifts in apparent agonist potency in vitro.
Hendricson A, Matchett M, Ferrante M, Ferrante C, Hunnicutt E, Westphal R, Kostich W, Huang Y, Masias N, Hong D, Bertekap R, Burford N, Watson J, Alt A, Myslik J, Zhang L, Knox R.
J Lab Autom.
2012 Apr;17(2):104-15. doi: 10.1177/2211068211435301.
PMID: 22357567
Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.
Narang AS, Yamniuk AP, Zhang L, Comezoglu SN, Bindra DS, Varia S, Doyle ML, Badawy S.
J Pharm Pharmacol.
2012 Apr;64(4):553-65. doi: 10.1111/j.2042-7158.2011.01435.x.
PMID: 22420661
Effect of powder substrate on foaml drainage and collapse: implications to foam granulation.
Koo OM, Ji J, Li J.
J Pharm Sci.
2012 Apr;101(4):1385-90. doi: 10.1002/jps.23053.
PMID: 22234920
Cytochrome P450 11A1 bioactivation of a kinase inhibitor in rats: use of radioprofiling, modulation of metabolism, and adrenocortical cell lines to evaluate adrenal toxicity.
Zhang D, Flint O, Wang L, Gupta A, Westhouse RA, Zhao W, Raghavan N, Caceres-Cortes J, Marathe P, Shen G, Zhang Y, Allentoff A, Josephs J, Gan J, Borzilleri R, Humphreys WG.
Chem Res Toxicol.
2012 Mar 19;25(3):556-71. doi: 10.1021/tx200524d.
PMID: 22295996
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.
Ross-Macdonald P, de Silva H, Patel V, Truong A, He A, Neuhaus I, Tilford C, Ji R, Siemers N, Greer A, Carboni J, Gottardis M, Menard K, Lee F, Dodier M, Frennesson D, Sampognaro A, Saulnier M, Trainor G, Vyas D, Zimmermann K, Wittman M.
Bioorg Med Chem . 2012 Mar 15;20(6):1961-72. doi: 10.1016/j.bmc.2011.10.090.
PMID: 22137930
Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1).
Harikrishnan LS, Srivastava N, Kayser LE, Nirschl DS, Kumaragurubaran K, Roy A, Gupta A, Karmakar S, Karatt T, Mathur A, Burford NT, Chen J, Kong Y, Cvijic M, Cooper CB, Poss MA, Trainor GL, Wong TW.
Bioorg Med Chem Lett.
2012 Mar 15;22(6):2287-90. doi: 10.1016/j.bmcl.2012.01.082.
PMID: 22365758
Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.
Xu XS, Demers R, Gu H, Christopher LJ, Su H, Cojocaru L, Boulton DW, Kirby M, Stouffer B, Humphreys WG, Arnold ME.
J Chromatogr B Analyt Technol Biomed Life Sci.
2012 Mar 15;889-890:77-86. doi: 10.1016/j.jchromb.2012.01.033.
PMID: 22349123
Solid phase synthesis of 1,5-diarylpyrazole-4-carboxamides: discovery of antagonists of the CB-1 receptor.
Pendri A, Dodd DS, Chen J, Cvijic ME, Kang L, Baska RA, Carlson KE, Burford NT, Sun C, Ewing WR, Gerritz SW.
ACS Comb Sci.
2012 Mar 12;14(3):197-204. doi: 10.1021/co200147y.
PMID: 22340081
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).
Kadow JF, Ueda Y, Meanwell NA, Connolly TP, Wang T, Chen CP, Yeung KS, Zhu J, Bender JA, Yang Z, Parker D, Lin PF, Colonno RJ, Mathew M, Morgan D, Zheng M, Chien C, Grasela D.
J Med Chem.
2012 Mar 8;55(5):2048-56. doi: 10.1021/jm201218m.
PMID: 22356441
Blindly using Wald's test can miss rare disease-causal variants in case-control association studies.
Xing G, Lin CY, Wooding SP, Xing C.
Ann Hum Genet.
2012 Mar;76(2):168-77. doi: 10.1111/j.1469-1809.2011.00700.x.
PMID: 22256951
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Wang C, Huang H, Valera L, Sun JH, O'Boyle DR 2nd, Nower PT, Jia L, Qiu D, Huang X, Altaf A, Gao M, Fridell RA.
Antimicrob Agents Chemother . 2012 Mar;56(3):1350-8. doi: 10.1128/AAC.05977-11.
PMID: 22214777
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O'Boyle DR 2nd, Gao M, Fridell RA.
Antimicrob Agents Chemother . 2012 Mar;56(3):1588-90. doi: 10.1128/AAC.06169-11.
PMID: 22203595
Cassette incubation followed by bioanalysis using high-resolution MS for in vitro ADME screening assays.
Zhang J, Maloney J, Drexler DM, Cai X, Stewart J, Mayer C, Herbst J, Weller H, Shou WZ.
Bioanalysis . 2012 Mar;4(5):581-93. doi: 10.4155/bio.12.2.
PMID: 22409555
Automated and unbiased analysis of LC-MS metabolomic data.
Hnatyshyn S, Shipkova P.
Bioanalysis . 2012 Mar;4(5):541-54. doi: 10.4155/bio.12.9.
PMID: 22409552
Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS.
Ranasinghe A, Ramanathan R, Jemal M, D'Arienzo CJ, Humphreys WG, Olah TV.
Bioanalysis . 2012 Mar;4(5):511-28. doi: 10.4155/bio.12.13.
PMID: 22409550
HRMS: current usage, future directions and the promise of integration with unified data streams suited to post-acquisition mining.
Josephs JL.
Bioanalysis . 2012 Mar;4(5):471-6. doi: 10.4155/bio.12.17. No abstract available.
PMID: 22409545
The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena.
Ramanathan R, Korfmacher W.
Bioanalysis . 2012 Mar;4(5):467-9. doi: 10.4155/bio.12.16. No abstract available.
PMID: 22409544
A mechanistic study on the effect of dexamethasone in moderating cell death in Chinese Hamster Ovary cell cultures.
Jing Y, Qian Y, Ghandi M, He A, Borys MC, Pan SH, Li ZJ.
Biotechnol Prog . 2012 Mar-Apr;28(2):490-6. doi: 10.1002/btpr.747.
PMID: 22140034
Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P.
Clin Drug Investig.
2012 Mar 1;32(3):189-202. doi: 10.2165/11597060-000000000-00000.
PMID: 22292415
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, Castaneda L, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens RC.
Clin Ther.
2012 Mar;34(3):654-67. doi: 10.1016/j.clinthera.2012.01.022.
PMID: 22381714
A modified serial blood sampling technique and utility of dried-blood spot technique in estimation of blood concentration: application in mouse pharmacokinetics.
Kurawattimath V, Pocha K, Mariappan TT, Trivedi RK, Mandlekar S.
Eur J Drug Metab Pharmacokinet.
2012 Mar;37(1):23-30. doi: 10.1007/s13318-011-0066-5. Erratum in: Eur J Drug Metab Pharmacokinet. 2011 Dec;36(4):263.
PMID: 21948266
Using hydrogen/deuterium exchange mass spectrometry to study conformational changes in granulocyte colony stimulating factor upon PEGylation.
Wei H, Ahn J, Yu YQ, Tymiak A, Engen JR, Chen G.
J Am Soc Mass Spectrom . 2012 Mar;23(3):498-504. doi: 10.1007/s13361-011-0310-x.
PMID: 22227798
An active film-coating approach to enhance chemical stability of a potent drug molecule.
Desai D, Rao V, Guo H, Li D, Stein D, Hu FY, Kiesnowski C.
Pharm Dev Technol.
2012 Mar-Apr;17(2):227-35. doi: 10.3109/10837450.2010.531737.
PMID: 21073265
Role of patent analysis in corporate R&D.
Barcelon Yang C.
Pharm Pat Anal.
2012 Mar;1(1):5-7. doi: 10.4155/ppa.12.1. No abstract available.
PMID: 24236705
Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.
Luo G, Chen L, Conway CM, Denton R, Keavy D, Gulianello M, Huang Y, Kostich W, Lentz KA, Mercer SE, Schartman R, Signor L, Browning M, Macor JE, Dubowchik GM.
ACS Med Chem Lett.
2012 Feb 27;3(4):337-41. doi: 10.1021/ml300021s.
PMID: 24900474
Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
Huang F, Xu LA, Khambata-Ford S.
Clin Cancer Res.
2012 Feb 15;18(4):1156-66. doi: 10.1158/1078-0432.CCR-11-1135.
PMID: 22294722
Structures of adnectin/protein complexes reveal an expanded binding footprint.
Ramamurthy V, Krystek SR Jr, Bush A, Wei A, Emanuel SL, Das Gupta R, Janjua A, Cheng L, Murdock M, Abramczyk B, Cohen D, Lin Z, Morin P, Davis JH, Dabritz M, McLaughlin DC, Russo KA, Chao G, Wright MC, Jenny VA, Engle LJ, Furfine E, Sheriff S.
Structure.
2012 Feb 8;20(2):259-69. doi: 10.1016/j.str.2011.11.016.
PMID: 22325775
Regioselective synthesis of 1,4-disubstituted imidazoles.
Schmidt MA, Eastgate MD.
Org Biomol Chem . 2012 Feb 7;10(5):1079-87. doi: 10.1039/c1ob06690k.
PMID: 22169998
Quantitative analysis of tris(2-carboxyethyl)phosphine by anion-exchange chromatography and evaporative light-scattering detection.
Tan Z, Ihnat PM, Nayak VS, Russell RJ.
J Pharm Biomed Anal . 2012 Feb 5;59:167-72. doi: 10.1016/j.jpba.2011.09.034.
PMID: 22019701
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Kasichayanula S, Chang M, Liu X, Shyu WC, Griffen SC, LaCreta FP, Boulton DW.
Adv Ther.
2012 Feb;29(2):163-77. doi: 10.1007/s12325-011-0098-x.
PMID: 22271159
Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).
Yang MG, Xiao Z, Shi Q, Cherney RJ, Tebben AJ, De Lucca GV, Santella JB 3rd, Mo R, Cvijic ME, Zhao Q, Barrish JC, Carter PH.
Bioorg Med Chem Lett.
2012 Feb 1;22(3):1384-7. doi: 10.1016/j.bmcl.2011.12.057.
PMID: 22225639
Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).
Carlson BX, Ketter TA, Sun W, Timko K, McQuade RD, Sanchez R, Vester-Blokland E, Marcus R.
Bipolar Disord.
2012 Feb;14(1):41-53. doi: 10.1111/j.1399-5618.2011.00974.x.
PMID: 22329471
Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs.
Whiterock VJ, Morgan DG, Lentz KA, Orcutt TL, Sinz MW.
Drug Metab Dispos . 2012 Feb;40(2):228-31. doi: 10.1124/dmd.111.041848.
PMID: 22074769
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L, Liao S, Child M, Zhang J, Persson A, Sevinsky H, Eley T, Xu X, Krystal M, Farajallah A, McGrath D, Molina JM, Bertz R.
J Antimicrob Chemother.
2012 Feb;67(2):465-8. doi: 10.1093/jac/dkr490.
PMID: 22121190
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.
Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, Vuppugalla R, Zhang Y, Ruepp SU, Trainor GL, Lombardo L, Pedicord D, Gottardis MM, Ross-Macdonald P, de Silva H, Hosbach J, Emanuel SL, Blat Y, Fitzpatrick E, Taylor TL, McIntyre KW, Michaud E, Mulligan C, Lee FY, Woolfson A, Lasho TL, Pardanani A, Tefferi A, Lorenzi MV.
Leukemia . 2012 Feb;26(2):280-8. doi: 10.1038/leu.2011.292.
PMID: 22015772
A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L, Stouffer B.
J Pharm Biomed Anal.
2012 Jan 25;58:130-5. doi: 10.1016/j.jpba.2011.09.008.
PMID: 21982905
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C.
N Engl J Med.
2012 Jan 19;366(3):216-24. doi: 10.1056/NEJMoa1104430.
PMID: 22256805
Surface energy analysis as a tool to probe the surface energy characteristics of micronized materials--a comparison with inverse gas chromatography.
Gamble JF, Leane M, Olusanmi D, Tobyn M, Supuk E, Khoo J, Naderi M.
Int J Pharm.
2012 Jan 17;422(1-2):238-44. doi: 10.1016/j.ijpharm.2011.11.002.
PMID: 22100516
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, Hortobagyi G, Roche H, Conte P, Revicki DA.
Cancer . 2012 Jan 15;118(2):461-8. doi: 10.1002/cncr.26213.
PMID: 21598243
A mechanistic study on the amidation of esters mediated by sodium formamide.
Ramirez A, Mudryk B, Rossano L, Tummala S.
J Org Chem . 2012 Jan 6;77(1):775-9. doi: 10.1021/jo2021828.
PMID: 22087875
AlMe(3)-promoted formation of amides from acids and amines.
Li J, Subramaniam K, Smith D, Qiao JX, Li JJ, Qian-Cutrone J, Kadow JF, Vite GD, Chen BC.
Org Lett.
2012 Jan 6;14(1):214-7. doi: 10.1021/ol203007s.
PMID: 22148911
Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.
Hu S, Huang Y, Deshpande M, Luo G, Bruce MA, Chen L, Mattson G, Iben LG, Zhang J, Russell JW, Clarke WJ, Hogan JB, Ortiz A, Flint O, Henwood A, Gao Q, Antal-Zimanyi I, Poindexter GS.
ACS Med Chem Lett . 2012 Jan 4;3(3):222-6. doi: 10.1021/ml200265m.
PMID: 24900458
Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC-MS-based bioanalytical methods in drug discovery.
Sleczka BG, D'Arienzo CJ, Tymiak AA, Olah TV.
Bioanalysis . 2012 Jan;4(1):29-40. doi: 10.4155/bio.11.293.
PMID: 22191592
Pellet digestion: a simple and efficient sample preparation technique for LC-MS/MS quantification of large therapeutic proteins in plasma.
Ouyang Z, Furlong MT, Wu S, Sleczka B, Tamura J, Wang H, Suchard S, Suri A, Olah T, Tymiak A, Jemal M.
Bioanalysis . 2012 Jan;4(1):17-28. doi: 10.4155/bio.11.286.
PMID: 22191591
In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
Gan J, Liu-Kreyche P, Humphreys WG.
Cancer Chemother Pharmacol.
2012 Jan;69(1):51-6. doi: 10.1007/s00280-011-1672-2.
PMID: 21594721
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
Whaley JM, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, List JF.
Diabetes Metab Syndr Obes . 2012;5:135-48. doi: 10.2147/DMSO.S22503.
PMID: 22923998
Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib.
Gong J, Gan J, Iyer RA.
Drug Metab Dispos.
2012 Jan;40(1):219-26. doi: 10.1124/dmd.111.042457.
PMID: 21989950
Evaporative light scattering detection based HPLC method for the determination of polysorbate 80 in therapeutic protein formulations.
Nayak VS, Tan Z, Ihnat PM, Russell RJ, Grace MJ.
J Chromatogr Sci.
2012 Jan;50(1):21-5. doi: 10.1093/chromsci/bmr015.
PMID: 22291052
A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Zhang L, Boulton DW, Pfister M.
J Clin Pharmacol.
2012 Jan;52(1 Suppl):126S-33S. doi: 10.1177/0091270011415627.
PMID: 22232748
Inferences on Small Area Proportions.
Chen S, Lahiri P.
J Indian Soc Agric Stat . 2012;66(1):121-124.
PMID: 24453380
Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS, Bates JA, Jing Y, Hebden T, Forbes RA, Chang E.
J Med Econ.
2012;15(1):105-11. doi: 10.3111/13696998.2011.632042.
PMID: 21991926
Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects.
Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K.
J Neurochem.
2012 Jan;120(2):325-33. doi: 10.1111/j.1471-4159.2011.07553.x.
PMID: 22023354
Effect of antioxidants and silicates on peroxides in povidone.
Narang AS, Rao VM, Desai DS.
J Pharm Sci.
2012 Jan;101(1):127-39. doi: 10.1002/jps.22729.
PMID: 22109686
Size-exclusion chromatography with multi-angle light scattering for elucidating protein aggregation mechanisms.
Sahin E, Roberts CJ.
Methods Mol Biol.
2012;899:403-23. doi: 10.1007/978-1-61779-921-1_25. Review.
PMID: 22735967
Zebrafish embryo developmental toxicology assay.
Panzica-Kelly JM, Zhang CX, Augustine-Rauch K.
Methods Mol Biol.
2012;889:25-50. doi: 10.1007/978-1-61779-867-2_4.
PMID: 22669658
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.
Wichroski MJ, Fang J, Eggers BJ, Rose RE, Mazzucco CE, Pokornowski KA, Baldick CJ, Anthony MN, Dowling CJ, Barber LE, Leet JE, Beno BR, Gerritz SW, Agler ML, Cockett MI, Tenney DJ.
PLoS One.
2012;7(8):e42609. doi: 10.1371/journal.pone.0042609.
PMID: 22880053
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St John E, Moreno E, Kozal M.
PLoS One.
2012;7(2):e30118. doi: 10.1371/journal.pone.0030118.
PMID: 22355307
Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies.
Fabian TJ, Cain ZJ, Ammerman D, Eudicone JM, Tang Y, Rollin LM, Forbes RA, Berman RM, Baker RA.
Prim Care Companion CNS Disord.
2012;14(6). pii: PCC.12m01394. doi: 10.4088/PCC.12m01394.
PMID: 23585999
Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials.
Dunner DL, Laubmeier KK, Manos G, Forbes RA, Baker RA, Berman RM.
Prim Care Companion CNS Disord.
2012;14(6). pii: PCC.12m01380. doi: 10.4088/PCC.12m01380.
PMID: 23585997
Fifty years of "the pill": risk reduction and discovery of benefits beyond contraception, reflections, and forecast.
Chadwick KD, Burkman RT, Tornesi BM, Mahadevan B.
Toxicol Sci.
2012 Jan;125(1):2-9. doi: 10.1093/toxsci/kfr242.
PMID: 21940817
2011 Publications
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT.
ACS Med Chem Lett.
2011 Dec 21;3(2):106-11. doi: 10.1021/ml2002423.
PMID: 24900436
Communication: Quantum polarized fluctuating charge model: a practical method to include ligand polarizability in biomolecular simulations.
Kimura SR, Rajamani R, Langley DR.
J Chem Phys.
2011 Dec 21;135(23):231101. doi: 10.1063/1.3671638.
PMID: 22191857
Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin.
Jones GS, Savage SA, Ivy S, Benitez PL, Ramirez A.
J Org Chem.
2011 Dec 16;76(24):10332-7. doi: 10.1021/jo202052a. Erratum in: J Org Chem. 2013 May 3;78(9):4627.
PMID: 22054301
Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi Y, O'Connor SP, Sitkoff D, Zhang J, Shi M, Bisaha SN, Wang Y, Li C, Ruan Z, Lawrence RM, Klei HE, Kish K, Liu EC, Seiler SM, Schweizer L, Steinbacher TE, Schumacher WA, Robl JA, Macor JE, Atwal KS, Stein PD.
Bioorg Med Chem Lett.
2011 Dec 15;21(24):7516-21. doi: 10.1016/j.bmcl.2011.06.098.
PMID: 22041058
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators..
N Engl J Med . 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899.
PMID: 22077144
A high-throughput spectrophotometric approach for evaluation of precipitation resistance.
Chandran S, Gesenberg C, Levons J, Hubert M, Raghavan K.
J Pharm Biomed Anal . 2011 Dec 5;56(4):698-704. doi: 10.1016/j.jpba.2011.07.009.
PMID: 21816556
Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
Wu Y, Levons J, Narang AS, Raghavan K, Rao VM.
AAPS PharmSciTech.
2011 Dec;12(4):1248-63. doi: 10.1208/s12249-011-9677-z. Review.
PMID: 21948318
Approach to evaluating dried blood spot sample stability during drying process and discovery of a treated card to maintain analyte stability by rapid on-card pH modification.
Liu G, Ji QC, Jemal M, Tymiak AA, Arnold ME.
Anal Chem.
2011 Dec 1;83(23):9033-8. doi: 10.1021/ac2023876.
PMID: 21995953
Strategy and its implications of protein bioanalysis utilizing high-resolution mass spectrometric detection of intact protein.
Ruan Q, Ji QC, Arnold ME, Humphreys WG, Zhu M.
Anal Chem.
2011 Dec 1;83(23):8937-44. doi: 10.1021/ac201540t.
PMID: 21970614
Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A.
Antimicrob Agents Chemother . 2011 Dec;55(12):5746-52. doi: 10.1128/AAC.00554-11.
PMID: 21930880
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).
Watterson SH, Langevine CM, Van Kirk K, Kempson J, Guo J, Spergel SH, Das J, Moquin RV, Dyckman AJ, Nirschl D, Gregor K, Pattoli MA, Yang X, McIntyre KW, Yang G, Galella MA, Booth-Lute H, Chen L, Yang Z, Wang-Iverson D, McKinnon M, Dodd JH, Barrish JC, Burke JR, Pitts WJ.
Bioorg Med Chem Lett.
2011 Dec 1;21(23):7006-12. doi: 10.1016/j.bmcl.2011.09.111.
PMID: 22018461
Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil.
Jenkins SM, Zvyaga T, Johnson SR, Hurley J, Wagner A, Burrell R, Turley W, Leet JE, Philip T, Rodrigues AD.
Drug Metab Dispos.
2011 Dec;39(12):2421-30. doi: 10.1124/dmd.111.041947.
PMID: 21911547
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM.
Hepatology . 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.
PMID: 21837752
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.
Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M.
Hepatology . 2011 Dec;54(6):1924-35. doi: 10.1002/hep.24594.
PMID: 21809362
Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients.
Hasegawa M, Imai Y, Hiraoka M, Ito K, Roy A.
J Pharmacokinet Pharmacodyn . 2011 Dec;38(6):803-32. doi: 10.1007/s10928-011-9221-5.
PMID: 22002809
Are circulating gonadotropin isoforms naturally occurring biased agonists? Basic and therapeutic implications.
Arey BJ, López FJ.
Rev Endocr Metab Disord . 2011 Dec;12(4):275-88. doi: 10.1007/s11154-011-9188-y. Review.
PMID: 21706143
Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential.
LeCureux L, Cheng CS, Herbst J, Reilly TP, Lehman-McKeeman L, Otieno M.
Toxicol In Vitro.
2011 Dec;25(8):1934-43. doi: 10.1016/j.tiv.2011.06.017.
PMID: 21767630
Bioanalytical strategies for developing highly sensitive liquid chromatography/tandem mass spectrometry based methods for the peptide GLP-1 agonists in support of discovery PK/PD studies.
Zhang H, Xin B, Caporuscio C, Olah TV.
Rapid Commun Mass Spectrom.
2011 Nov 30;25(22):3427-35. doi: 10.1002/rcm.5241.
PMID: 22002697
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Wang W, Devasthale P, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Li YX, Zahler R, Kirby MS, Hamann LG.
Bioorg Med Chem Lett . 2011 Nov 15;21(22):6646-51. doi: 10.1016/j.bmcl.2011.09.074.
PMID: 21996520
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).
Wu SC, Yoon D, Chin J, van Kirk K, Seethala R, Golla R, He B, Harrity T, Kunselman LK, Morgan NN, Ponticiello RP, Taylor JR, Zebo R, Harper TW, Li W, Wang M, Zhang L, Sleczka BG, Nayeem A, Sheriff S, Camac DM, Morin PE, Everlof JG, Li YX, Ferraro CA, Kieltyka K, Shou W, Vath MB, Zvyaga TA, Gordon DA, Robl JA.
Bioorg Med Chem Lett . 2011 Nov 15;21(22):6693-8. doi: 10.1016/j.bmcl.2011.09.058.
PMID: 21983444
Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
Ye XY, Chen SY, Nayeem A, Golla R, Seethala R, Wang M, Harper T, Sleczka BG, Li YX, He B, Kirby M, Gordon DA, Robl JA.
Bioorg Med Chem Lett.
2011 Nov 15;21(22):6699-704. doi: 10.1016/j.bmcl.2011.09.055.
PMID: 21983439
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
Thompson LA, Shi J, Decicco CP, Tebben AJ, Olson RE, Boy KM, Guernon JM, Good AC, Liauw A, Zheng C, Copeland RA, Combs AP, Trainor GL, Camac DM, Muckelbauer JK, Lentz KA, Grace JE, Burton CR, Toyn JH, Barten DM, Marcinkeviciene J, Meredith JE, Albright CF, Macor JE.
Bioorg Med Chem Lett . 2011 Nov 15;21(22):6909-15. doi: 10.1016/j.bmcl.2011.06.116.
PMID: 21974952
Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.
Yang Y, Miller KJ, Zhu Y, Hong Y, Tian Y, Murugesan N, Gu Z, O'Tanyi E, Keim WJ, Rohrbach KW, Johnghar S, Behnia K, Pelleymounter MA, Carlson KE, Ewing WR.
Bioorg Med Chem Lett.
2011 Nov 15;21(22):6856-60. doi: 10.1016/j.bmcl.2011.09.016.
PMID: 21962575
Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE).
Boy KM, Guernon JM, Shi J, Toyn JH, Meredith JE, Barten DM, Burton CR, Albright CF, Marcinkeviciene J, Good AC, Tebben AJ, Muckelbauer JK, Camac DM, Lentz KA, Bronson JJ, Olson RE, Macor JE, Thompson LA 3rd.
Bioorg Med Chem Lett.
2011 Nov 15;21(22):6916-24. doi: 10.1016/j.bmcl.2011.06.109.
PMID: 21782431
Quantitative estimation of circulating metabolites without synthetic standards by ultra-high-performance liquid chromatography/high resolution accurate mass spectrometry in combination with UV correction.
Yang Y, Grubb MF, Luk CE, Humphreys WG, Josephs JL.
Rapid Commun Mass Spectrom.
2011 Nov 15;25(21):3245-51. doi: 10.1002/rcm.5220.
PMID: 22006386
Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping.
Bongers J, Devincentis J, Fu J, Huang P, Kirkley DH, Leister K, Liu P, Ludwig R, Rumney K, Tao L, Wu W, Russell RJ.
J Chromatogr A . 2011 Nov 11;1218(45):8140-9. doi: 10.1016/j.chroma.2011.08.089.
PMID: 21978954
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J, Yang R, Wirtz V, Sheppard L, Farajallah A, McGrath D.
AIDS Care . 2011 Nov;23(11):1500-4. doi: 10.1080/09540121.2011.565033.
PMID: 21732894
The importance of HT-ADME in drug discovery.
Morgan D.
Bioanalysis.
2011 Nov;3(21):2385-7. doi: 10.4155/bio.11.253.
PMID: 22074279
The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.
Vachharajani NN, Raymond RH, Shyu WC, Stouffer BC, Boulton DW.
Br J Clin Pharmacol . 2011 Nov;72(5):775-86. doi: 10.1111/j.1365-2125.2011.04003.x.
PMID: 21545481
X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase.
Muckelbauer J, Sack JS, Ahmed N, Burke J, Chang CY, Gao M, Tino J, Xie D, Tebben AJ.
Chem Biol Drug Des.
2011 Nov;78(5):739-48. doi: 10.1111/j.1747-0285.2011.01230.x.
PMID: 21883956
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW.
Clin Ther . 2011 Nov;33(11):1798-808. doi: 10.1016/j.clinthera.2011.09.011.
PMID: 22030444
Incidence of serious upper and lower gastrointestinal events in older adults with and without Alzheimer's disease.
Wu JH, Guo Z, Kumar S, Lapuerta P.
J Am Geriatr Soc . 2011 Nov;59(11):2053-61. doi: 10.1111/j.1532-5415.2011.03667.x.
PMID: 22091628
Regeneration of tetrabutylammonium ion-pairing reagent distribution in a gradient elution of reversed phase ion-pair chromatography.
Zhang J, Raglione T, Wang Q, Kleintop B, Tomasella F, Liang X.
J Chromatogr Sci . 2011 Nov-Dec;49(10):825-31.
PMID: 22080812
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.
Qiu D, Lemm JA, O'Boyle DR 2nd, Sun JH, Nower PT, Nguyen V, Hamann LG, Snyder LB, Deon DH, Ruediger E, Meanwell NA, Belema M, Gao M, Fridell RA.
J Gen Virol.
2011 Nov;92(Pt 11):2502-11. doi: 10.1099/vir.0.034801-0.
PMID: 21795470
Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by fourier transform raman spectroscopy.
Sinclair W, Leane M, Clarke G, Dennis A, Tobyn M, Timmins P.
J Pharm Sci.
2011 Nov;100(11):4687-99. doi: 10.1002/jps.22658.
PMID: 21681752
Phase behavior of TPGS-PEG400/1450 systems and their application to liquid formulation: a formulation platform approach.
Li J, Yang B, Levons J, Pinnamaneni S, Raghavan K.
J Pharm Sci . 2011 Nov;100(11):4907-21. doi: 10.1002/jps.22659.
PMID: 21656767
Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
Abell LM, Liu EC.
J Pharmacol Exp Ther . 2011 Nov;339(2):589-96. doi: 10.1124/jpet.111.184895.
PMID: 21828263
Selective MMP13 inhibitors.
Li JJ, Johnson AR.
Med Res Rev.
2011 Nov;31(6):863-94. doi: 10.1002/med.20204. Review.
PMID: 20196103
Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.
Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM, Wong TW, Rupnow BA.
Mol Cancer Res.
2011 Nov;9(11):1551-61. doi: 10.1158/1541-7786.MCR-11-0126.
PMID: 21954435
Examining determinants of self management behaviors in patients with diabetes: an application of the Theoretical Model of Effortful Decision Making and Enactment.
Nadkarni A, Kucukarslan SN, Bagozzi RP, Yates JF, Erickson SR.
Patient Educ Couns.
2011 Nov;85(2):148-53. doi: 10.1016/j.pec.2010.09.027.
PMID: 21041057
Optimal response-adaptive randomized designs for multi-armed survival trials.
Sverdlov O, Tymofyeyev Y, Wong WK.
Stat Med.
2011 Oct 30;30(24):2890-910. doi: 10.1002/sim.4331.
PMID: 21823146
Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791826).
Weinstein DS, Gong H, Doweyko AM, Cunningham M, Habte S, Wang JH, Holloway DA, Burke C, Gao L, Guarino V, Carman J, Somerville JE, Shuster D, Salter-Cid L, Dodd JH, Nadler SG, Barrish JC.
J Med Chem.
2011 Oct 27;54(20):7318-33. doi: 10.1021/jm200879j.
PMID: 21899328
SDRS--an algorithm for analyzing large-scale dose-response data.
Ji RR, Siemers NO, Lei M, Schweizer L, Bruccoleri RE.
Bioinformatics.
2011 Oct 15;27(20):2921-3. doi: 10.1093/bioinformatics/btr489.
PMID: 21865301
Targeted quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profile modes.
Xia YQ, Lau J, Olah T, Jemal M.
Rapid Commun Mass Spectrom . 2011 Oct 15;25(19):2863-78. doi: 10.1002/rcm.5178.
PMID: 21913265
Small molecule receptor protein tyrosine phosphatase γ (RPTPγ) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop.
Sheriff S, Beno BR, Zhai W, Kostich WA, McDonnell PA, Kish K, Goldfarb V, Gao M, Kiefer SE, Yanchunas J, Huang Y, Shi S, Zhu S, Dzierba C, Bronson J, Macor JE, Appiah KK, Westphal RS, O'Connell J, Gerritz SW.
J Med Chem.
2011 Oct 13;54(19):6548-62. doi: 10.1021/jm2003766.
PMID: 21882820
The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase.
Ding M, He F, Poss MA, Rigat KL, Wang YK, Roberts SB, Qiu D, Fridell RA, Gao M, Gentles RG.
Org Biomol Chem.
2011 Oct 7;9(19):6654-62. doi: 10.1039/c1ob05525a.
PMID: 21800000
Development of a cyclic adenosine monophosphate assay for Gi-coupled G protein-coupled receptors by utilizing the endogenous calcitonin activity in Chinese hamster ovary cells.
Wang Y, Kong Y, Shei GJ, Kang L, Cvijic ME.
Assay Drug Dev Technol.
2011 Oct;9(5):522-31. doi: 10.1089/adt.2010.0361.
PMID: 21561374
Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma.
Fung EN, Xia YQ, Aubry AF, Zeng J, Olah T, Jemal M.
J Chromatogr B Analyt Technol Biomed Life Sci.
2011 Oct 1;879(27):2919-27. doi: 10.1016/j.jchromb.2011.08.025.
PMID: 21907643
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R, Marathe P, He H, Jones RD, Yates JW, Jones HM, Gibson CR, Chien JY, Ring BJ, Adkison KK, Ku MS, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.
J Pharm Sci.
2011 Oct;100(10):4111-26. doi: 10.1002/jps.22551.
PMID: 21480234
The effect of PEGylation on the stability of small therapeutic proteins.
Palm T, Esfandiary R, Gandhi R.
Pharm Dev Technol . 2011 Oct;16(5):441-8. doi: 10.3109/10837450.2010.535830.
PMID: 21261458
Investigation into the impact of sub-populations of agglomerates on the particle size distribution and flow properties of conventional microcrystalline cellulose grades.
Gamble JF, Chiu WS, Tobyn M.
Pharm Dev Technol.
2011 Oct;16(5):542-8. doi: 10.3109/10837450.2010.495395.
PMID: 20565228
Pitfalls in meta-analyses on adverse events reported from clinical trials.
Huang HY, Andrews E, Jones J, Skovron ML, Tilson H.
Pharmacoepidemiol Drug Saf.
2011 Oct;20(10):1014-20. doi: 10.1002/pds.2208.
PMID: 21858897
Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA.
Chem Res Toxicol.
2011 Sep 19;24(9):1420-56. doi: 10.1021/tx200211v. Review.
PMID: 21790149
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis.
Goodenough AK, Onorato JM, Ouyang Z, Chang S, Rodrigues AD, Kasichayanula S, Huang SP, Turley W, Burrell R, Bifano M, Jemal M, LaCreta F, Tymiak A, Wang-Iverson D.
Chem Res Toxicol.
2011 Sep 19;24(9):1575-85. doi: 10.1021/tx2001898.
PMID: 21728364
Apixaban versus warfarin in patients with atrial fibrillation.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators..
N Engl J Med.
2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039.
PMID: 21870978
Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers.
Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, Discotto L, McAuliffe B, Minassian BF, Shi S, Zhu S, Zhai W, Pendri A, Li G, Poss MA, Edavettal S, McDonnell PA, Lewis HA, Maskos K, Mörtl M, Kiefersauer R, Steinbacher S, Baldwin ET, Metzler W, Bryson J, Healy MD, Philip T, Zoeckler M, Schartman R, Sinz M, Leyva-Grado VH, Hoffmann HH, Langley DR, Meanwell NA, Krystal M.
Proc Natl Acad Sci U S A.
2011 Sep 13;108(37):15366-71. doi: 10.1073/pnas.1107906108.
PMID: 21896751
Prevalence and outcome of HIV-associated malignancies among children.
Tukei VJ, Kekitiinwa A, Beasley RP.
AIDS . 2011 Sep 10;25(14):1789-93. doi: 10.1097/QAD.0b013e3283498115.
PMID: 21673560
Effects of CYP inhibitors on precocene I metabolism and toxicity in rat liver slices.
Ly VT, Brock B.
Chem Biol Interact.
2011 Sep 5;193(2):109-18. doi: 10.1016/j.cbi.2011.05.011.
PMID: 21741958
A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.
Juday T, Grimm K, Zoe-Powers A, Willig J, Kim E.
AIDS Care.
2011 Sep;23(9):1154-62. doi: 10.1080/09540121.2010.543884.
PMID: 21500025
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Wang X, Boffito M, Zhang J, Chung E, Zhu L, Wu Y, Patterson K, Kashuba A, Tebas P, Child M, Mahnke L, Bertz R.
AIDS Patient Care STDS.
2011 Sep;25(9):509-15. doi: 10.1089/apc.2011.0113.
PMID: 21770762
Preannealing of poly(A) template and oligo(dT) primer is not required for hepatitis C virus RNA-dependent RNA polymerase activity.
Wang YK.
Anal Biochem.
2011 Sep 1;416(1):132-4. doi: 10.1016/j.ab.2011.04.019.
PMID: 21565152
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
Jing Y, Kalsekar I, Curkendall SM, Carls GS, Bagalman E, Forbes RA, Hebden T, Thase ME.
Clin Ther.
2011 Sep;33(9):1246-57. doi: 10.1016/j.clinthera.2011.07.015.
PMID: 21840058
1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase.
Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, Marathe P.
Drug Metab Dispos.
2011 Sep;39(9):1674-9. doi: 10.1124/dmd.111.039834.
PMID: 21677062
In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H, Su H, Ma L, Yao M, Iyer RA, Humphreys WG, Christopher LJ.
Drug Metab Dispos . 2011 Sep;39(9):1658-67. doi: 10.1124/dmd.111.039776.
PMID: 21673131
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.
He K, Luettgen JM, Zhang D, He B, Grace JE Jr, Xin B, Pinto DJ, Wong PC, Knabb RM, Lam PY, Wexler RR, Grossman SJ.
Eur J Drug Metab Pharmacokinet.
2011 Sep;36(3):129-39. doi: 10.1007/s13318-011-0037-x.
PMID: 21461793
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, Arikan D, Farajallah A, Bertz R.
J Antimicrob Chemother.
2011 Sep;66(9):2075-82. doi: 10.1093/jac/dkr266.
PMID: 21712242
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL.
J Clin Psychiatry.
2011 Sep;72(9):1270-6. doi: 10.4088/JCP.09m05933.
PMID: 21813076
Vacuum decay container closure integrity leak test method development and validation for a lyophilized product-package system.
Patel J, Mulhall B, Wolf H, Klohr S, Guazzo DM.
PDA J Pharm Sci Technol.
2011 Sep-Oct;65(5):486-505. doi: 10.5731/pdajpst.2011.00780.
PMID: 22293838
Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.
Lu X, Xiao B, Lo L, Bolgar MS, Lloyd DK.
J Pharm Biomed Anal.
2011 Aug 25;56(1):23-9. doi: 10.1016/j.jpba.2011.04.026.
PMID: 21620602
Apixaban with antiplatelet therapy after acute coronary syndrome.
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators..
N Engl J Med.
2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819.
PMID: 21780946
Opportunities and challenges in the development of experimental drug combinations for cancer.
Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM.
J Natl Cancer Inst.
2011 Aug 17;103(16):1222-6. doi: 10.1093/jnci/djr246.
PMID: 21765011
A convenient strategy for quantitative determination of drug concentrations in tissue homogenates using a liquid chromatography/tandem mass spectrometry assay for plasma samples.
Jiang H, Zeng J, Zheng N, Kandoussi H, Peng Q, Valentine JL, Lange RW, Arnold ME.
Anal Chem.
2011 Aug 15;83(16):6237-44. doi: 10.1021/ac200820q.
PMID: 21692511
Molecular characterization and identification of surrogate substrates for diacylglycerol lipase α.
Pedicord DL, Flynn MJ, Fanslau C, Miranda M, Hunihan L, Robertson BJ, Pearce BC, Yu XC, Westphal RS, Blat Y.
Biochem Biophys Res Commun.
2011 Aug 12;411(4):809-14. doi: 10.1016/j.bbrc.2011.07.037.
PMID: 21787747
Modifying conventional high-performance liquid chromatography systems to achieve fast separations with Fused-Core columns: a case study.
Alexander AJ, Waeghe TJ, Himes KW, Tomasella FP, Hooker TF.
J Chromatogr A . 2011 Aug 12;1218(32):5456-69. doi: 10.1016/j.chroma.2011.06.026.
PMID: 21742337
Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.
Lemm JA, Leet JE, O'Boyle DR 2nd, Romine JL, Huang XS, Schroeder DR, Alberts J, Cantone JL, Sun JH, Nower PT, Martin SW, Serrano-Wu MH, Meanwell NA, Snyder LB, Gao M.
Antimicrob Agents Chemother.
2011 Aug;55(8):3795-802. doi: 10.1128/AAC.00146-11.
PMID: 21576451
LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays.
Aubry AF.
Bioanalysis . 2011 Aug;3(16):1819-25. doi: 10.4155/bio.11.166. Review.
PMID: 21877891
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
Dyckman AJ, Li T, Pitt S, Zhang R, Shen DR, McIntyre KW, Gillooly KM, Shuster DJ, Doweyko AM, Sack JS, Kish K, Kiefer SE, Newitt JA, Zhang H, Marathe PH, McKinnon M, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
Bioorg Med Chem Lett.
2011 Aug 1;21(15):4633-7. doi: 10.1016/j.bmcl.2011.05.091.
PMID: 21705217
Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.
Kasichayanula S, Liu X, Zhang W, Pfister M, Reele SB, Aubry AF, LaCreta FP, Boulton DW.
Diabetes Obes Metab.
2011 Aug;13(8):770-3. doi: 10.1111/j.1463-1326.2011.01397.x.
PMID: 21435141
New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
Pendri A, Meanwell NA, Peese KM, Walker MA.
Expert Opin Ther Pat . 2011 Aug;21(8):1173-89. doi: 10.1517/13543776.2011.586631. Review.
PMID: 21599420
Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.
Mankoski R, Zhao J, Carson WH, Mathew SJ, Forbes RA.
J Child Adolesc Psychopharmacol . 2011 Aug;21(4):359-64. doi: 10.1089/cap.2010.0100
PMID: 21823911
Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR.
J Enzyme Inhib Med Chem.
2011 Aug;26(4):514-26. doi: 10.3109/14756366.2010.535793.
PMID: 21171894
A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits.
Wong PC, Crain EJ, Watson CA, Schumacher WA.
J Thromb Thrombolysis.
2011 Aug;32(2):129-37. doi: 10.1007/s11239-011-0599-0.
PMID: 21614454
Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles.
Gong L, Aranibar N, Han YH, Zhang Y, Lecureux L, Bhaskaran V, Khandelwal P, Klaassen CD, Lehman-McKeeman LD.
Toxicol Sci.
2011 Aug;122(2):587-97. doi: 10.1093/toxsci/kfr114.
PMID: 21561886
Drug metabolite profiling and identification by high-resolution mass spectrometry.
Zhu M, Zhang H, Humphreys WG.
J Biol Chem.
2011 Jul 22;286(29):25419-25. doi: 10.1074/jbc.R110.200055. Review.
PMID: 21632546
Role of tumor vascular architecture in drug delivery.
Narang AS, Varia S.
Adv Drug Deliv Rev.
2011 Jul 18;63(8):640-58. doi: 10.1016/j.addr.2011.04.002. Review.
PMID: 21514334
Pyrazole-based sulfonamide and sulfamides as potent inhibitors of mammalian 15-lipoxygenase.
Ngu K, Weinstein DS, Liu W, Langevine C, Combs DW, Zhuang S, Chen X, Madsen CS, Harper TW, Ahmad S, Robl JA.
Bioorg Med Chem Lett.
2011 Jul 15;21(14):4141-5. doi: 10.1016/j.bmcl.2011.05.107.
PMID: 21696952
Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
Wang H, Robl JA, Hamann LG, Simpkins L, Golla R, Li YX, Seethala R, Zvyaga T, Gordon DA, Li JJ.
Bioorg Med Chem Lett.
2011 Jul 15;21(14):4146-9. doi: 10.1016/j.bmcl.2011.05.101.
PMID: 21689935
A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma.
Jiang H, Zeng J, Deng Y, Xia YQ, Ouyang Z, Jemal M, Salcedo TW, Arnold ME.
J Chromatogr B Analyt Technol Biomed Life Sci.
2011 Jul 15;879(22):2064-72. doi: 10.1016/j.jchromb.2011.05.036.
PMID: 21704571
Cloning, purification, crystallization and preliminary X-ray analysis of the catalytic domain of human receptor-like protein tyrosine phosphatase γ in three different crystal forms.
Kish K, McDonnell PA, Goldfarb V, Gao M, Metzler WJ, Langley DR, Bryson JW, Kiefer SE, Carpenter B, Kostich WA, Westphal RS, Sheriff S.
Acta Crystallogr Sect F Struct Biol Cryst Commun.
2011 Jul 1;67(Pt 7):768-74. doi: 10.1107/S1744309111017209.
PMID: 21795790
Impact of the implementation of a well-designed electronic laboratory notebook on bioanalytical laboratory function.
Zeng J, Hillman M, Arnold M.
Bioanalysis.
2011 Jul;3(13):1501-11. doi: 10.4155/bio.11.116. Review.
PMID: 21728774
Cell culture and gene transcription effects of copper sulfate on Chinese hamster ovary cells.
Qian Y, Khattak SF, Xing Z, He A, Kayne PS, Qian NX, Pan SH, Li ZJ.
Biotechnol Prog.
2011 Jul;27(4):1190-4. doi: 10.1002/btpr.630.
PMID: 21595052
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Upreti VV, Boulton DW, Li L, Ching A, Su H, Lacreta FP, Patel CG.
Br J Clin Pharmacol . 2011 Jul;72(1):92-102. doi: 10.1111/j.1365-2125.2011.03937.x.
PMID: 21651615
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Patel CG, Kornhauser D, Vachharajani N, Komoroski B, Brenner E, Handschuh del Corral M, Li L, Boulton DW.
Diabetes Obes Metab . 2011 Jul;13(7):604-14. doi: 10.1111/j.1463-1326.2011.01381.x.
PMID: 21332626
To measure is to know: an approach to CADD performance metrics.
Loughney D, Claus BL, Johnson SR.
Drug Discov Today.
2011 Jul;16(13-14):548-54. doi: 10.1016/j.drudis.2011.05.003.
PMID: 21605697
Theory-guided efficient strategy to maximize speed and resolution in rapid gradient LC-MS/MS bioanalysis.
Wang J, Jia J, Aubry A, Arnold M, Jemal M.
J Chromatogr B Analyt Technol Biomed Life Sci.
2011 Jul 1;879(21):1917-26. doi: 10.1016/j.jchromb.2011.05.019.
PMID: 21664884
Development of a canine model to enable the preclinical assessment of pH-dependent absorption of test compounds.
Fancher RM, Zhang H, Sleczka B, Derbin G, Rockar R, Marathe P.
J Pharm Sci.
2011 Jul;100(7):2979-88. doi: 10.1002/jps.22486.
PMID: 21254068
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M.
J Virol.
2011 Jul;85(14):7312-20. doi: 10.1128/JVI.00253-11.
PMID: 21593143
Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R.
Postgrad Med.
2011 Jul;123(4):63-70. doi: 10.3810/pgm.2011.07.2305.
PMID: 21680990
A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.
Guo Z, L'italien GJ, Jing Y, Baker RA, Forbes RA, Hebden T, Kim E.
Prog Neuropsychopharmacol Biol Psychiatry.
2011 Jul 1;35(5):1326-32. doi: 10.1016/j.pnpbp.2011.03.020.
PMID: 21515328
Case studies with new excipients: development, implementation and regulatory approval.
Koo OM, Varia SA.
Ther Deliv.
2011 Jul;2(7):949-56. Review.
PMID: 22833905
How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M, Moore N, Lechat P; participants of Round Table N° 3 of Giens XXVI..
Therapie . 2011 Jul-Aug;66(4):331-4, 327-30. English, French.
PMID: 21851796
Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, III.
Bamberger M, Moore N, Lechat P; participants à la Table Ronde N◦ 3 de Giens XXVI..
Therapie . 2011 Jul-Aug;66(4):327-30. doi: 10.2515/therapie/2011043. French. No abstract available.
PMID: 27392459
Transcriptional profiling of liver and effect of glucocorticoids in a rat adjuvant-induced arthritis model.
Song YL, Foster WR, Shuster DJ, Nadler SG, Salter-Cid L, Sasseville VG.
Vet Pathol.
2011 Jul;48(4):885-95. doi: 10.1177/0300985810390018.
PMID: 21149847
Overview of strategies for addressing BRIs in drug discovery: Impact on optimization and design.
Humphreys WG.
Chem Biol Interact.
2011 Jun 30;192(1-2):56-9. doi: 10.1016/j.cbi.2011.01.005. Review.
PMID: 21238435
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD.
N Engl J Med.
2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621.
PMID: 21639810
The use of atomic spectroscopy in the pharmaceutical industry for the determination of trace elements in pharmaceuticals.
Lewen N.
J Pharm Biomed Anal.
2011 Jun 25;55(4):653-61. doi: 10.1016/j.jpba.2010.11.030. Review.
PMID: 21159460
A stepwise strategy employing automated screening and DryLab modeling for the development of robust methods for challenging high performance liquid chromatography separations: a case study.
Jayaraman K, Alexander AJ, Hu Y, Tomasella FP.
Anal Chim Acta.
2011 Jun 24;696(1-2):116-24. doi: 10.1016/j.aca.2011.04.010.
PMID: 21621040
Comparison of near infrared and microwave resonance sensors for at-line moisture determination in powders and tablets.
Corredor CC, Bu D, Both D.
Anal Chim Acta.
2011 Jun 24;696(1-2):84-93. doi: 10.1016/j.aca.2011.03.048.
PMID: 21621036
Estimation of the extent of in vivo formation of a mutagenic aromatic amine from a potent thyromimetic compound: correlation of in vitro and in vivo findings.
Behnia K, Cornelius G, Wang J, Shipkova P, Johnghar S, Washburn W, Brigance R, Stetsko P, Henwood A, Wojciechowski JP, Marathe P, Rodrigues AD, Humphreys WG.
Chem Res Toxicol.
2011 Jun 20;24(6):905-12. doi: 10.1021/tx200087q.
PMID: 21574629
Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
Wong TW, Lee FY, Emanuel S, Fairchild C, Fargnoli J, Fink B, Gavai A, Hammell A, Henley B, Hilt C, Hunt JT, Krishnan B, Kukral D, Lewin A, Malone H, Norris D, Oppenheimer S, Vite G, Yu C.
Clin Cancer Res . 2011 Jun 15;17(12):4031-41. doi: 10.1158/1078-0432.CCR-10-3417.
PMID: 21531814
Investigation into stability of poly(vinyl alcohol)-based Opadry® II films.
Koo OM, Fiske JD, Yang H, Nikfar F, Thakur A, Scheer B, Adams ML.
AAPS PharmSciTech.
2011 Jun;12(2):746-54. doi: 10.1208/s12249-011-9630-1.
PMID: 21647800
Structural basis for CARM1 inhibition by indole and pyrazole inhibitors.
Sack JS, Thieffine S, Bandiera T, Fasolini M, Duke GJ, Jayaraman L, Kish KF, Klei HE, Purandare AV, Rosettani P, Troiani S, Xie D, Bertrand JA.
Biochem J.
2011 Jun 1;436(2):331-9. doi: 10.1042/BJ20102161.
PMID: 21410432
Common infections in the lung transplant recipient.
Sims KD, Blumberg EA.
Clin Chest Med.
2011 Jun;32(2):327-41. doi: 10.1016/j.ccm.2011.02.010. Review.
PMID: 21511093
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.
Pfützner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators..
Diabetes Obes Metab.
2011 Jun;13(6):567-76. doi: 10.1111/j.1463-1326.2011.01385.x.
PMID: 21342412
A high-throughput screen for receptor protein tyrosine phosphatase-gamma selective inhibitors.
Appiah KK, Kostich WA, Gerritz SW, Huang Y, Hamman BD, Allen J, Zhang W, Lanthorn TH, Albright CF, Westphal R, Banks MN, O'Connell JC.
J Biomol Screen . 2011 Jun;16(5):476-85. doi: 10.1177/1087057111399336.
PMID: 21406618
Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study.
Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Corey-Lisle PK, Aman MG.
J Child Adolesc Psychopharmacol . 2011 Jun;21(3):229-36. doi: 10.1089/cap.2009.0121.
PMID: 21663425
Evaluation of a new preparative supercritical fluid chromatography system for compound library purification: the TharSFC SFC-MS Prep-100 system.
Ebinger K, Weller HN, Kiplinger J, Lefebvre P.
J Lab Autom.
2011 Jun;16(3):241-9. doi: 10.1016/j.jala.2010.03.005.
PMID: 21609708
It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS.
Ramanathan R, Jemal M, Ramagiri S, Xia YQ, Humpreys WG, Olah T, Korfmacher WA.
J Mass Spectrom.
2011 Jun;46(6):595-601. doi: 10.1002/jms.1921.
PMID: 21630388
Health care costs associated with treatment modification in type 2 diabetes mellitus patients taking oral anti-diabetic drugs.
Nrishnarajah G, Bhosle M, Chapman R.
Manag Care.
2011 Jun;20(6):42-8.
PMID: 21739924
Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice.
Bird JE, Smith PL, Bostwick JS, Shipkova P, Schumacher WA.
Thromb Res.
2011 Jun;127(6):560-4. doi: 10.1016/j.thromres.2011.02.007.
PMID: 21396684
Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes.
Chen C, Han YH, Yang Z, Rodrigues AD.
Xenobiotica . 2011 Jun;41(6):476-85. doi: 10.3109/00498254.2011.560971.
PMID: 21381897
Bioactivation of substituted thiophenes including α-chlorothiophene-containing compounds in human liver microsomes.
Chen W, Caceres-Cortes J, Zhang H, Zhang D, Humphreys WG, Gan J.
Chem Res Toxicol.
2011 May 16;24(5):663-9. doi: 10.1021/tx100386z.
PMID: 21417487
The synthesis and evaluation of a novel class of (E)-3-(1-cyclohexyl-1H-pyrazol-3-yl)-2-methylacrylic acid hepatitis C virus polymerase NS5B inhibitors.
Martin SW, Glunz P, Beno BR, Bergstrom C, Romine JL, Priestley ES, Newman M, Gao M, Roberts S, Rigat K, Fridell R, Qiu D, Knobloh G, Wang YK.
Bioorg Med Chem Lett.
2011 May 15;21(10):2869-72. doi: 10.1016/j.bmcl.2011.03.086.
PMID: 21507645
Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus.
Zheng X, Hudyma TW, Martin SW, Bergstrom C, Ding M, He F, Romine J, Poss MA, Kadow JF, Chang CH, Wan J, Witmer MR, Morin P, Camac DM, Sheriff S, Beno BR, Rigat KL, Wang YK, Fridell R, Lemm J, Qiu D, Liu M, Voss S, Pelosi L, Roberts SB, Gao M, Knipe J, Gentles RG.
Bioorg Med Chem Lett.
2011 May 15;21(10):2925-9. doi: 10.1016/j.bmcl.2011.03.067.
PMID: 21486696
SAR studies on a series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides: potent inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus.
Gentles RG, Ding M, Zheng X, Chupak L, Poss MA, Beno BR, Pelosi L, Liu M, Lemm J, Wang YK, Roberts S, Gao M, Kadow J.
Bioorg Med Chem Lett.
2011 May 15;21(10):3142-7. doi: 10.1016/j.bmcl.2011.03.008.
PMID: 21450465
Internal standard tracked dilution to overcome challenges in dried blood spots and robotic sample preparation for liquid chromatography/tandem mass spectrometry assays.
Liu G, Snapp HM, Ji QC.
Rapid Commun Mass Spectrom . 2011 May 15;25(9):1250-6. doi: 10.1002/rcm.4990.
PMID: 21488123
Ultrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen.
Wagner AD, Kolb JM, Ozbal CC, Herbst JJ, Olah TV, Weller HN, Zvyaga TA, Shou WZ.
Rapid Commun Mass Spectrom.
2011 May 15;25(9):1231-40. doi: 10.1002/rcm.4984.
PMID: 21488121
Enzymatic preparation of 5-hydroxy-L-proline, N-Cbz-5-hydroxy-L-proline, and N-Boc-5-hydroxy-L-proline from (α-N-protected)-L-ornithine using a transaminase or an amine oxidase.
Hanson RL, Johnston RM, Goldberg SL, Parker WL, Patel RN.
Enzyme Microb Technol . 2011 May 6;48(6-7):445-53. doi: 10.1016/j.enzmictec.2011.03.007.
PMID: 22113015
Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe.
Abu-Absi NR, Kenty BM, Cuellar ME, Borys MC, Sakhamuri S, Strachan DJ, Hausladen MC, Li ZJ.
Biotechnol Bioeng.
2011 May;108(5):1215-21. doi: 10.1002/bit.23023.
PMID: 21449033
Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients.
Yoshitsugu H, Sakurai T, Ishikawa H, Roy A, Bifano M, Pfister M, Seriu T, Hiraoka M.
Diagn Microbiol Infect Dis.
2011 May;70(1):91-100. doi: 10.1016/j.diagmicrobio.2010.12.009.
PMID: 21513847
Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.
Drug Metab Dispos.
2011 May;39(5):891-903. doi: 10.1124/dmd.110.037341.
PMID: 21289073
Fatty acid and water-soluble polymer-based controlled release drug delivery system.
Desai D, Kothari S, Chen W, Wang J, Huang M, Sharma L.
J Pharm Sci.
2011 May;100(5):1900-12. doi: 10.1002/jps.22397.
PMID: 21374622
Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H, Lee FY, Gan J.
J Pharmacol Exp Ther . 2011 May;337(2):423-32. doi: 10.1124/jpet.110.175604.
PMID: 21262849
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.
Wong PC, Pinto DJ, Zhang D.
J Thromb Thrombolysis.
2011 May;31(4):478-92. doi: 10.1007/s11239-011-0551-3. Review.
PMID: 21318583
Large sample inference for an assay quality measure used in high-throughput screening.
Majumdar A, Stock D.
Pharm Stat.
2011 May-Jun;10(3):227-31. doi: 10.1002/pst.452. No abstract available.
PMID: 20931668
Synopsis of some recent tactical application of bioisosteres in drug design.
Meanwell NA.
J Med Chem.
2011 Apr 28;54(8):2529-91. doi: 10.1021/jm1013693. No abstract available.
PMID: 21413808
Metabolomic and transcriptomic changes induced by overnight (16 h) fasting in male and female Sprague-Dawley rats.
Robertson DG, Ruepp SU, Stryker SA, Hnatyshyn SY, Shipkova PA, Aranibar N, Mcnaney CA, Fiehn O, Reily MD.
Chem Res Toxicol.
2011 Apr 18;24(4):481-7. doi: 10.1021/tx200074f.
PMID: 21381695
Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase.
Gentles RG, Sheriff S, Beno BR, Wan C, Kish K, Ding M, Zheng X, Chupak L, Poss MA, Witmer MR, Morin P, Wang YK, Rigat K, Lemm J, Voss S, Liu M, Pelosi L, Roberts SB, Gao M, Kadow JF.
Bioorg Med Chem Lett.
2011 Apr 15;21(8):2212-5. doi: 10.1016/j.bmcl.2011.03.011. Erratum in: Bioorg Med Chem Lett. 2011 Sep 15;21(18):5650-1.
PMID: 21441029
Potential CRF1R PET imaging agents: N-fluoroalkyl-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-amines.
Zuev D, Mattson RJ, Huang H, Mattson GK, Zueva L, Nielsen JM, Kozlowski ES, Huang XS, Wu D, Gao Q, Lodge NJ, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2011 Apr 15;21(8):2484-8. doi: 10.1016/j.bmcl.2011.02.050.
PMID: 21411322
Development and evaluation of a multiple-plate fraction collector for sample processing: application to radioprofiling in drug metabolism studies.
Barros A Jr, Ly VT, Chando TJ, Ruan Q, Donenfeld SL, Holub DP, Christopher LJ.
J Pharm Biomed Anal . 2011 Apr 5;54(5):979-86. doi: 10.1016/j.jpba.2010.11.029.
PMID: 21168298
Optimization of Exactive Orbitrap™ acquisition parameters for quantitative bioanalysis.
Wong RL, Xin B, Olah T.
Bioanalysis.
2011 Apr;3(8):863-71. doi: 10.4155/bio.11.37.
PMID: 21510760
Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, Kornhauser DM, Patel CG.
Clin Pharmacokinet.
2011 Apr;50(4):253-65. doi: 10.2165/11584350-000000000-00000.
PMID: 21348538
Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.
Pfister M, Whaley JM, Zhang L, List JF.
Clin Pharmacol Ther.
2011 Apr;89(4):621-5. doi: 10.1038/clpt.2011.16. Review. No abstract available.
PMID: 21346749
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW.
Diabetes Obes Metab.
2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x.
PMID: 21226818
NMR-based metabolomics of mammalian cell and tissue cultures.
Aranibar N, Borys M, Mackin NA, Ly V, Abu-Absi N, Abu-Absi S, Niemitz M, Schilling B, Li ZJ, Brock B, Russell RJ 2nd, Tymiak A, Reily MD.
J Biomol NMR.
2011 Apr;49(3-4):195-206. doi: 10.1007/s10858-011-9490-8.
PMID: 21373840
Scale considerations for selection of saccharide excipients for liquid formulations.
Zhou R, Schlam RF, Yin S, Gandhi RB, Adams ML.
J Pharm Sci . 2011 Apr;100(4):1605-6. doi: 10.1002/jps.22378. No abstract available.
PMID: 24081479
Pharmacokinetic-pharmacodynamic modeling of rifampicin-mediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice.
Raybon JJ, Pray D, Morgan DG, Zoeckler M, Zheng M, Sinz M, Kim S.
J Pharmacol Exp Ther.
2011 Apr;337(1):75-82. doi: 10.1124/jpet.110.176677.
PMID: 21205914
Transformation of anionically activated trifluoromethyl groups to heterocycles under mild aqueous conditions.
Qiao JX, Wang TC, Hu C, Li J, Wexler RR, Lam PY.
Org Lett.
2011 Apr 1;13(7):1804-7. doi: 10.1021/ol200326u.
PMID: 21381681
Good documentation practice in clinical research.
Bargaje C.
Perspect Clin Res.
2011 Apr;2(2):59-63. doi: 10.4103/2229-3485.80368.
PMID: 21731856
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, Salvati ME, Attar RM, Gottardis MM.
Prostate.
2011 Apr;71(5):480-8. doi: 10.1002/pros.21263.
PMID: 20878947
JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats.
Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Welty N, Shoblock JR, Motley ST, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P.
Psychopharmacology
(Berl). 2011 Apr;214(4):829-41. doi: 10.1007/s00213-010-2092-4.
PMID: 21086115
Metabolism of [2-14C]p-hydroxyphenyl acetic acid in rat, monkey and human hepatocytes and in bile-duct cannulated rats.
Zhou L, Liu-Kreyche P, Iyer RA.
Xenobiotica.
2011 Apr;41(4):312-9. doi: 10.3109/00498254.2010.540681.
PMID: 21143006
Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
Burford NT, Watson J, Bertekap R, Alt A.
Biochem Pharmacol.
2011 Mar 15;81(6):691-702. doi: 10.1016/j.bcp.2010.12.012. Review.
PMID: 21184747
Apixaban in patients with atrial fibrillation.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators..
N Engl J Med.
2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432.
PMID: 21309657
Advances in mass spectrometry applied to pharmaceutical metabolomics.
Drexler DM, Reily MD, Shipkova PA.
Anal Bioanal Chem . 2011 Mar;399(8):2645-53. doi: 10.1007/s00216-010-4370-8. Review.
PMID: 21107980
Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling.
Aranibar N, Vassallo JD, Rathmacher J, Stryker S, Zhang Y, Dai J, Janovitz EB, Robertson D, Reily M, Lowe-Krentz L, Lehman-McKeeman L.
Anal Biochem . 2011 Mar 1;410(1):84-91. doi: 10.1016/j.ab.2010.11.023.
PMID: 21094120
Biotherapeutic bioanalysis: a multi-indication case study review.
Myler HA, Given A, Kolz K, Mora JR, Hristopoulos G.
Bioanalysis.
2011 Mar;3(6):623-43. doi: 10.4155/bio.11.33. Review.
PMID: 21417732
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
Harikrishnan LS, Kamau MG, Wan H, Inghrim JA, Zimmermann K, Sang X, Mastalerz HA, Johnson WL, Zhang G, Lombardo LJ, Poss MA, Trainor GL, Tokarski JS, Lorenzi MV, You D, Gottardis MM, Baldwin KF, Lippy J, Nirschl DS, Qiu R, Miller AV, Khan J, Sack JS, Purandare AV.
Bioorg Med Chem Lett.
2011 Mar 1;21(5):1425-8. doi: 10.1016/j.bmcl.2011.01.022.
PMID: 21282055
Demonstrating β-glucan and yeast peptide clearance in biopharmaceutical downstream processes.
Jiang C, Scherfner S, Dick LW Jr, Mahon D, Qiu D, Cheng KC, Shukla AA.
Biotechnol Prog.
2011 Mar-Apr;27(2):442-50. doi: 10.1002/btpr.568. Erratum in: Biotechnol Prog. 2011 Jul-Aug;27(4):1195. Dick, Lawrence W Jr [added]; Mahon, David [added]; Qiu, Difei [added]; Cheng, Kuang-Chuan [added].
PMID: 21365784
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.
Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R.
Bipolar Disord.
2011 Mar;13(2):133-44. doi: 10.1111/j.1399-5618.2011.00898.x.
PMID: 21443567
Factors associated with complete adherence to HIV combination antiretroviral therapy.
Juday T, Gupta S, Grimm K, Wagner S, Kim E.
HIV Clin Trials . 2011 Mar-Apr;12(2):71-8. doi: 10.1310/hct1202-71.
PMID: 21498150
Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L, Persson A, Mahnke L, Eley T, Li T, Xu X, Agarwala S, Dragone J, Bertz R.
J Clin Pharmacol.
2011 Mar;51(3):368-77. doi: 10.1177/0091270010367651.
PMID: 20457590
Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ.
J Gen Intern Med.
2011 Mar;26(3):239-44. doi: 10.1007/s11606-010-1549-9.
PMID: 20978862
Utility of quantitative whole-body autoradiography (QWBA) and imaging mass spectrometry (IMS) by matrix-assisted laser desorption/ionization (MALDI) in the assessment of ocular distribution of drugs.
Drexler DM, Tannehill-Gregg SH, Wang L, Brock BJ.
J Pharmacol Toxicol Methods.
2011 Mar-Apr;63(2):205-8. doi: 10.1016/j.vascn.2010.10.003.
PMID: 21040797
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
List JF, Whaley JM.
Kidney Int Suppl.
2011 Mar;(120):S20-7. doi: 10.1038/ki.2010.512. Review.
PMID: 21358698
Mapping progress in toxicology research by the content of the best papers published in Society of Toxicology Journals: a synopsis of the best paper awardees (1974-2011).
Lehman-McKeeman LD.
Toxicol Sci.
2011 Mar;120 Suppl 1:S1-7. doi: 10.1093/toxsci/kfq369. No abstract available.
PMID: 21342918
Metabolomics in toxicology: preclinical and clinical applications.
Robertson DG, Watkins PB, Reily MD.
Toxicol Sci.
2011 Mar;120 Suppl 1:S146-70. doi: 10.1093/toxsci/kfq358. Review. No abstract available.
PMID: 21127352
Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept.
Li T, Wells G, Westhovens R, Emery P, Becker JC, Tugwell P.
Value Health.
2011 Mar-Apr;14(2):361-70. doi: 10.1016/j.jval.2010.10.008.
PMID: 21296603
Chiral separation of potent corticotropin-releasing factor-1 receptor antagonists by supercritical fluid chromatography.
Qian-Cutrone J, Hartz R, Ahuja VT, Vrudhula VM, Wu DR, Dalterio RA, Wang-Iverson D, Bronson JJ.
J Pharm Biomed Anal.
2011 Feb 20;54(3):602-6. doi: 10.1016/j.jpba.2010.09.031.
PMID: 21036503
Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, Krystal M, Lin P, Colonno R, Grasela DM.
Antimicrob Agents Chemother.
2011 Feb;55(2):722-8. doi: 10.1128/AAC.00759-10.
PMID: 21078951
In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Zhou N, Nowicka-Sans B, Zhang S, Fan L, Fang J, Fang H, Gong YF, Eggers B, Langley DR, Wang T, Kadow J, Grasela D, Hanna GJ, Alexander L, Colonno R, Krystal M, Lin PF.
Antimicrob Agents Chemother.
2011 Feb;55(2):729-37. doi: 10.1128/AAC.01173-10.
PMID: 21078948
Implications of differences in bioanalytical regulations between Canada, USA and South America.
Arnold ME.
Bioanalysis.
2011 Feb;3(3):253-8. doi: 10.4155/bio.10.187.
PMID: 21320043
Tissue distribution and elimination of [14C]apixaban in rats.
Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, Zhang D.
Drug Metab Dispos.
2011 Feb;39(2):256-64. doi: 10.1124/dmd.110.036442.
PMID: 21071521
Metabolism and disposition of 14C-labeled peliglitazar in humans.
Wang L, Munsick C, Chen S, Bonacorsi S, Cheng PT, Humphreys WG, Zhang D.
Drug Metab Dispos . 2011 Feb;39(2):228-38. doi: 10.1124/dmd.110.035089.
PMID: 20978103
A review of electronic laboratory notebooks available in the market today.
Rubacha M, Rattan AK, Hosselet SC.
J Lab Autom.
2011 Feb;16(1):90-8. doi: 10.1016/j.jala.2009.01.002.
PMID: 21609689
Hazard identification of strong dermal sensitizers.
Gould JC, Taylor S.
Toxicol Mech Methods.
2011 Feb;21(2):86-92. doi: 10.3109/15376516.2010.484622.
PMID: 20500014
Urinary metabolites of 2-bromoethanamine identified by stable isotope labelling: evidence for carbamoylation and glutathione conjugation.
Shipkova P, Vassallo JD, Aranibar N, Hnatyshyn S, Zhang H, Clayton TA, Cantor GH, Sanders M, Coen M, Lindon JC, Holmes E, Nicholson JK, Lehman-McKeeman L.
Xenobiotica.
2011 Feb;41(2):144-54. doi: 10.3109/00498254.2010.529179.
PMID: 21043805
A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection.
Wu ST, Ouyang Z, Olah TV, Jemal M.
Rapid Commun Mass Spectrom.
2011 Jan 30;25(2):281-90. doi: 10.1002/rcm.4856.
PMID: 21192023
Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383.
Sitkoff DF, Lee N, Ellsworth BA, Huang Q, Kang L, Baska R, Huang Y, Sun C, Pendri A, Malley MF, Scaringe RP, Gougoutas JZ, Reggio PH, Ewing WR, Pelleymounter MA, Carlson KE.
Eur J Pharmacol.
2011 Jan 25;651(1-3):9-17. doi: 10.1016/j.ejphar.2010.10.056.
PMID: 21044623
Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE, Norris D, Mastalerz H, Chen P, Goyal B, Zhao Y, Kim SH, Vite GD, Lee FY, Zhang H, Oppenheimer S, Tokarski JS, Wong TW, Gavai AV.
Bioorg Med Chem Lett.
2011 Jan 15;21(2):781-5. doi: 10.1016/j.bmcl.2010.11.100.
PMID: 21177105
Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine.
Hong H, Caceres-Cortes J, Su H, Huang X, Roongta V, Bonacorsi S Jr, Hong Y, Tian Y, Iyer RA, Humphreys WG, Christopher LJ.
Chem Res Toxicol.
2011 Jan 14;24(1):125-34. doi: 10.1021/tx100337s.
PMID: 21080678
Trends in kinase selectivity: insights for target class-focused library screening.
Posy SL, Hermsmeier MA, Vaccaro W, Ott KH, Todderud G, Lippy JS, Trainor GL, Loughney DA, Johnson SR.
J Med Chem.
2011 Jan 13;54(1):54-66. doi: 10.1021/jm101195a.
PMID: 21128601
Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.
Romine JL, St Laurent DR, Leet JE, Martin SW, Serrano-Wu MH, Yang F, Gao M, O'Boyle DR 2nd, Lemm JA, Sun JH, Nower PT, Huang XS, Deshpande MS, Meanwell NA, Snyder LB.
ACS Med Chem Lett.
2011 Jan 11;2(3):224-9. doi: 10.1021/ml1002647.
PMID: 24900306
One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.
Kim E, You M, Pikalov A, Van-Tran Q, Jing Y.
BMC Psychiatry . 2011 Jan 7;11:6. doi: 10.1186/1471-244X-11-6.
PMID: 21214937
FDR-FET: an optimizing gene set enrichment analysis method.
Ji RR, Ott KH, Yordanova R, Bruccoleri RE.
Adv Appl Bioinform Chem.
2011;4:37-42. doi: 10.2147/AABC.S15840.
PMID: 21918636
Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
Sheaffer AK, Lee MS, Hernandez D, Chaniewski S, Yu F, Falk P, Friborg J, Zhai G, McPhee F.
Antivir Ther.
2011;16(5):705-18. doi: 10.3851/IMP1825.
PMID: 21817192
The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T, Xu X, Bertz R.
Antivir Ther.
2011;16(2):157-64. doi: 10.3851/IMP1724.
PMID: 21447864
The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
Sevinsky H, Eley T, Persson A, Garner D, Yones C, Nettles R, Krantz K, Bertz R, Zhang J.
Antivir Ther.
2011;16(2):149-56. doi: 10.3851/IMP1725.
PMID: 21447863
Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis.
Dyckman AJ, Langevine CM, Quesnelle C, Kempson J, Guo J, Gill P, Spergel SH, Watterson SH, Li T, Nirschl DS, Gillooly KM, Pattoli MA, McIntyre KW, Chen L, McKinnon M, Dodd JH, Barrish JC, Burke JR, Pitts WJ.
Bioorg Med Chem Lett.
2011 Jan 1;21(1):383-6. doi: 10.1016/j.bmcl.2010.10.133.
PMID: 21087862
Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1.
Marcin LR, Higgins MA, Zusi FC, Zhang Y, Dee MF, Parker MF, Muckelbauer JK, Camac DM, Morin PE, Ramamurthy V, Tebben AJ, Lentz KA, Grace JE, Marcinkeviciene JA, Kopcho LM, Burton CR, Barten DM, Toyn JH, Meredith JE, Albright CF, Bronson JJ, Macor JE, Thompson LA.
Bioorg Med Chem Lett . 2011 Jan 1;21(1):537-41. doi: 10.1016/j.bmcl.2010.10.079.
PMID: 21078556
Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
Boulton DW, Smith CH, Li L, Huang J, Tang A, LaCreta FP.
Clin Drug Investig.
2011;31(9):619-30. doi: 10.2165/11590290-000000000-00000.
PMID: 21819160
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.
Patel CG, Li L, Girgis S, Kornhauser DM, Frevert EU, Boulton DW.
Clin Pharmacol.
2011;3:13-25. doi: 10.2147/CPAA.S15227.
PMID: 22287853
Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation.
Budd D, Burns LC, Guo Z, L'italien G, Lapuerta P.
Clinicoecon Outcomes Res.
2011;3:189-95. doi: 10.2147/CEOR.S22265.
PMID: 22046104
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, Li T, LaCreta FP, Boulton DW.
Diabetes Obes Metab.
2011 Jan;13(1):47-54. doi: 10.1111/j.1463-1326.2010.01314.x.
PMID: 21114603
Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
Chen G, Warrack BM, Goodenough AK, Wei H, Wang-Iverson DB, Tymiak AA.
Drug Discov Today.
2011 Jan;16(1-2):58-64. doi: 10.1016/j.drudis.2010.11.003. Review.
PMID: 21093608
Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.
Zhang D, Raghavan N, Wang L, Xue Y, Obermeier M, Chen S, Tao S, Zhang H, Cheng PT, Li W, Ramanathan R, Yang Z, Humphreys WG.
Drug Metab Dispos.
2011 Jan;39(1):123-31. doi: 10.1124/dmd.110.035048.
PMID: 20876787
A comparison of approaches to control for confounding factors by regression models.
Xing G, Lin CY, Xing C.
Hum Hered.
2011;72(3):194-205. doi: 10.1159/000332743.
PMID: 22086357
Tau transgenic mice as models for cerebrospinal fluid tau biomarkers.
Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL, Yang L, Sankaranarayanan S, Wes PD, Flynn ME, Meredith JE, Ahlijanian MK, Albright CF.
J Alzheimers Dis . 2011;24 Suppl 2:127-41. doi: 10.3233/JAD-2011-110161.
PMID: 21422517
A combined desorption ionization by charge exchange (DICE) and desorption electrospray ionization (DESI) source for mass spectrometry.
Chan CC, Bolgar MS, Miller SA, Attygalle AB.
J Am Soc Mass Spectrom . 2011 Jan;22(1):173-8. doi: 10.1007/s13361-010-0001-z.
PMID: 21472555
Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y, Johnston SS, Fowler R, Bates JA, Forbes RA, Hebden T.
J Med Econ.
2011;14(6):777-86. doi: 10.3111/13696998.2011.625066.
PMID: 21954966
The effect of the physical states of binders on high-shear wet granulation and granule properties: a mechanistic approach towards understanding high-shear wet granulation process. Part I. Physical characterization of binders.
Li J, Tao L, Dali M, Buckley D, Gao J, Hubert M.
J Pharm Sci.
2011 Jan;100(1):164-73. doi: 10.1002/jps.22260.
PMID: 20575065
The effect of the physical states of binders on high-shear wet granulation and granule properties: a mechanistic approach toward understanding high-shear wet granulation process. Part II. Granulation and granule properties.
Li J, Tao L, Dali M, Buckley D, Gao J, Hubert M.
J Pharm Sci.
2011 Jan;100(1):294-310. doi: 10.1002/jps.22261.
PMID: 20575062
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, Gokemeijer J, Morin P, Morse BA, Carvajal IM, Fabrizio D, Wright MC, Das Gupta R, Gosselin M, Cataldo D, Ryseck RP, Doyle ML, Wong TW, Camphausen RT, Cload ST, Marsh HN, Gottardis MM, Furfine ES.
MAbs.
2011 Jan-Feb;3(1):38-48.
PMID: 21099371
Methods for combinatorial and parallel library design.
Schnur DM, Beno BR, Tebben AJ, Cavallaro C.
Methods Mol Biol . 2011;672:387-434. doi: 10.1007/978-1-60761-839-3_16.
PMID: 20838978
Beyond rhodopsin: G protein-coupled receptor structure and modeling incorporating the beta2-adrenergic and adenosine A(2A) crystal structures.
Tebben AJ, Schnur DM.
Methods Mol Biol.
2011;672:359-86. doi: 10.1007/978-1-60761-839-3_15. Review.
PMID: 20838977
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.
Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, Carson W, Baker RA, Marcus RN.
Neuropsychiatr Dis Treat.
2011;7:303-12. doi: 10.2147/NDT.S18333.
PMID: 21655344
Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy.
Feng Y, Gastonguay MR, Pollock BG, Frank E, Kepple GH, Bies RR.
Neuropsychiatr Dis Treat.
2011;7:117-25. doi: 10.2147/NDT.S15921.
PMID: 21552314
Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines.
Chang H, Jackson DG, Kayne PS, Ross-Macdonald PB, Ryseck RP, Siemers NO.
PLoS One.
2011;6(6):e21097. doi: 10.1371/journal.pone.0021097.
PMID: 21701589
A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder.
McIntyre RS, McElroy SL, Eudicone JM, Forbes RA, Carlson BX, Baker RA.
Prim Care Companion CNS Disord.
2011;13(6). pii: PCC.11m01182. doi: 10.4088/PCC.11m01182.
PMID: 22454801
Adnectins: engineered target-binding protein therapeutics.
Lipovsek D.
Protein Eng Des Sel . 2011 Jan;24(1-2):3-9. doi: 10.1093/protein/gzq097. Review.
PMID: 21068165
Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.
Lee F, Jure-Kunkel MN, Salvati ME.
Ther Adv Med Oncol.
2011 Jan;3(1):11-25. doi: 10.1177/1758834010386402.
PMID: 21789152
Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants.
Maclean JR, Pfister M, Zhou Z, Roy A, Tuomari VA, Heifets M.
Ther Clin Risk Manag.
2011;7:149-56. doi: 10.2147/TCRM.S16870.
PMID: 21691585
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Barrett YC, Wang J, Knabb R, Mohan P.
Thromb Haemost.
2011 Jan;105(1):181-9. doi: 10.1160/TH10-06-0393.
PMID: 20941459
2010 Publications
An integrated bioanalytical platform for supporting high-throughput serum protein binding screening.
Zhang J, Shou WZ, Vath M, Kieltyka K, Maloney J, Elvebak L, Stewart J, Herbst J, Weller HN.
Rapid Commun Mass Spectrom . 2010 Dec 30;24(24):3593-601. doi: 10.1002/rcm.4817.
PMID: 21080511
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators..
N Engl J Med.
2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885.
PMID: 21175312
Defining process design space for a hydrophobic interaction chromatography (HIC) purification step: application of quality by design (QbD) principles.
Jiang C, Flansburg L, Ghose S, Jorjorian P, Shukla AA.
Biotechnol Bioeng . 2010 Dec 15;107(6):985-97. doi: 10.1002/bit.22894.
PMID: 20683852
Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists.
Yang BV, Weinstein DS, Doweyko LM, Gong H, Vaccaro W, Huynh T, Xiao HY, Doweyko AM, McKay L, Holloway DA, Somerville JE, Habte S, Cunningham M, McMahon M, Townsend R, Shuster D, Dodd JH, Nadler SG, Barrish JC.
J Med Chem.
2010 Dec 9;53(23):8241-51. doi: 10.1021/jm100957a.
PMID: 21073190
Investigation into the degree of variability in the solid-state properties of common pharmaceutical excipients-anhydrous lactose.
Gamble JF, Chiu WS, Gray V, Toale H, Tobyn M, Wu Y.
AAPS PharmSciTech.
2010 Dec;11(4):1552-7. doi: 10.1208/s12249-010-9527-4.
PMID: 21049309
Identifying, evaluating, and controlling bioanalytical risks resulting from nonuniform matrix ion suppression/enhancement and nonlinear liquid chromatography-mass spectrometry assay response.
Liu G, Ji QC, Arnold ME.
Anal Chem.
2010 Dec 1;82(23):9671-7. doi: 10.1021/ac1013018.
PMID: 21038862
Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma.
Aubry AF, Gu H, Magnier R, Morgan L, Xu X, Tirmenstein M, Wang B, Deng Y, Cai J, Couerbe P, Arnold M.
Bioanalysis.
2010 Dec;2(12):2001-9. doi: 10.4155/bio.10.139.
PMID: 21110743
5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J, Moquin RV, Dyckman AJ, Li T, Pitt S, Zhang R, Shen DR, McIntyre KW, Gillooly K, Doweyko AM, Newitt JA, Sack JS, Zhang H, Kiefer SE, Kish K, McKinnon M, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
Bioorg Med Chem Lett.
2010 Dec 1;20(23):6886-9. doi: 10.1016/j.bmcl.2010.10.034.
PMID: 21035336
A dysmorphology score system for assessing embryo abnormalities in rat whole embryo culture.
Zhang CX, Danberry T, Jacobs MA, Augustine-Rauch K.
Birth Defects Res B Dev Reprod Toxicol.
2010 Dec;89(6):485-92. doi: 10.1002/bdrb.20262.
PMID: 21058394
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN.
Diabetes Ther.
2010 Dec;1(2):57-92. doi: 10.1007/s13300-010-0006-4.
PMID: 22127746
Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
Miller KJ, Wacker DA.
Future Med Chem . 2010 Dec;2(12):1761-75. doi: 10.4155/fmc.10.261.
PMID: 21428799
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC, Wang Z, Frost C, Shenker A.
Thromb Haemost.
2010 Dec;104(6):1263-71. doi: 10.1160/TH10-05-0328.
PMID: 20978714
Metabolomics and mechanisms: sometimes the fisher catches a big fish.
Cantor GH.
Toxicol Sci.
2010 Dec;118(2):321-3. doi: 10.1093/toxsci/kfq297. No abstract available.
PMID: 20864629
Interview with Dr. Mark Cockett: current trends in screening for antiviral therapeutics. Interviewed by Nina N. Brahme and Devin J. Noblin.
Cockett M.
Yale J Biol Med.
2010 Dec;83(4):235-40.
PMID: 21165343
Effect of force feeder on tablet strength during compression.
Narang AS, Rao VM, Guo H, Lu J, Desai DS.
Int J Pharm.
2010 Nov 30;401(1-2):7-15. doi: 10.1016/j.ijpharm.2010.08.027.
PMID: 20816733
Effect of mobile phase pH, aqueous-organic ratio, and buffer concentration on electrospray ionization tandem mass spectrometric fragmentation patterns: implications in liquid chromatography/tandem mass spectrometric bioanalysis.
Wang J, Aubry A, Bolgar MS, Gu H, Olah TV, Arnold M, Jemal M.
Rapid Commun Mass Spectrom.
2010 Nov 30;24(22):3221-9. doi: 10.1002/rcm.4748.
PMID: 20972995
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL.
Cancer Immun.
2010 Nov 24;10:11.
PMID: 21090563
Identifying and overcoming bioanalytical challenges associated with chlorine-containing dehydrogenation metabolites.
Furlong MT, Wujcik CE, Ji C, Su Y.
Rapid Commun Mass Spectrom.
2010 Nov 15;24(21):3092-102. doi: 10.1002/rcm.4741.
PMID: 20941755
Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors.
King HD, Meng Z, Deskus JA, Sloan CP, Gao Q, Beno BR, Kozlowski ES, Lapaglia MA, Mattson GK, Molski TF, Taber MT, Lodge NJ, Mattson RJ, Macor JE.
J Med Chem.
2010 Nov 11;53(21):7564-72. doi: 10.1021/jm100515z.
PMID: 20949929
Orthogonality of SFC versus HPLC for small molecule library separation.
Weller HN, Ebinger K, Bullock W, Edinger KJ, Hermsmeier MA, Hoffman SL, Nirschl DS, Swann T, Zhao J, Kiplinger J, Lefebvre P.
J Comb Chem.
2010 Nov 8;12(6):877-82. doi: 10.1021/cc100118y.
PMID: 20923153
Viable mouse gene ablations that robustly alter brain Aβ levels are rare.
Toyn JH, Lin XA, Thompson MW, Guss V, Meredith JE Jr, Sankaranarayanan S, Barrezueta N, Corradi J, Majumdar A, Small DL, Hansard M, Lanthorn T, Westphal RS, Albright CF.
BMC Neurosci.
2010 Nov 5;11:143. doi: 10.1186/1471-2202-11-143.
PMID: 21054826
Development and validation of a specific and sensitive GC-FID method for the determination of impurities in 5-chlorovaleroyl chloride.
Tang L, Kim A, Miller SA, Lloyd DK.
J Pharm Biomed Anal . 2010 Nov 2;53(3):309-14. doi: 10.1016/j.jpba.2010.03.042.
PMID: 20439146
Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
Rigat K, Wang Y, Hudyma TW, Ding M, Zheng X, Gentles RG, Beno BR, Gao M, Roberts SB.
Antiviral Res.
2010 Nov;88(2):197-206. doi: 10.1016/j.antiviral.2010.08.014.
PMID: 20813137
Targeting lymphocyte co-stimulation: from bench to bedside.
Felix NJ, Suri A, Salter-Cid L, Nadler SG, Gujrathi S, Corbo M, Aranda R.
Autoimmunity.
2010 Nov;43(7):514-25. doi: 10.3109/08916931003674741. Review.
PMID: 20429850
Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors.
O'Connor SP, Wang Y, Simpkins LM, Brigance RP, Meng W, Wang A, Kirby MS, Weigelt CA, Hamann LG.
Bioorg Med Chem Lett.
2010 Nov 1;20(21):6273-6. doi: 10.1016/j.bmcl.2010.08.090.
PMID: 20833042
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, Zhang S.
Drug Metab Dispos.
2010 Nov;38(11):2049-59. doi: 10.1124/dmd.110.034850.
PMID: 20668249
N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.
Carter PH, Hynes J.
Expert Opin Ther Pat . 2010 Nov;20(11):1609-18. doi: 10.1517/13543776.2010.518144.
PMID: 20858032
Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?
Yang Z, Rodrigues AD.
J Clin Pharmacol.
2010 Nov;50(11):1330-8. doi: 10.1177/0091270009360041.
PMID: 20197489
Comparative physical, mechanical and crystallographic properties of a series of gemfibrozil salts.
David SE, Ramirez M, Timmins P, Conway BR.
J Pharm Pharmacol.
2010 Nov;62(11):1519-25. doi: 10.1111/j.2042-7158.2010.01025.x.
PMID: 21039537
Drug discovery approaches to target Wnt signaling in cancer stem cells.
Curtin JC, Lorenzi MV.
Oncotarget.
2010 Nov;1(7):552-66. Review.
PMID: 21317452
Effect of the design of the stopper including dimension, type, and vent area on lyophilization process.
Mungikar A, Ludzinski M, Kamat M.
PDA J Pharm Sci Technol.
2010 Nov-Dec;64(6):507-16.
PMID: 21502061
Challenges and promises of developing thrombin receptor antagonists.
Yang J, Xu K, Seiffert D.
Recent Pat Cardiovasc Drug Discov.
2010 Nov;5(3):162-70. Review.
PMID: 20874673
Recent strategies for the synthesis of pyridine derivatives.
Hill MD.
Chemistry.
2010 Oct 25;16(40):12052-62. doi: 10.1002/chem.201001100.
PMID: 20827696
Sialylation enhancement of CTLA4-Ig fusion protein in Chinese hamster ovary cells by dexamethasone.
Jing Y, Qian Y, Li ZJ.
Biotechnol Bioeng.
2010 Oct 15;107(3):488-96. doi: 10.1002/bit.22827.
PMID: 20521303
Application of the Gyrolab™ platform to ligand-binding assays: a user's perspective.
Mora JR, Obenauer-Kutner L, Vimal Patel V.
Bioanalysis.
2010 Oct;2(10):1711-5. doi: 10.4155/bio.10.122.
PMID: 21083323
Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
Lin S, Wrobleski ST, Hynes J Jr, Pitt S, Zhang R, Fan Y, Doweyko AM, Kish KF, Sack JS, Malley MF, Kiefer SE, Newitt JA, McKinnon M, Trzaskos J, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
Bioorg Med Chem Lett.
2010 Oct 1;20(19):5864-8. doi: 10.1016/j.bmcl.2010.07.102.
PMID: 20732813
Morphological score assignment guidelines for the dechorionated zebrafish teratogenicity assay.
Panzica-Kelly JM, Zhang CX, Danberry TL, Flood A, DeLan JW, Brannen KC, Augustine-Rauch KA.
Birth Defects Res B Dev Reprod Toxicol.
2010 Oct;89(5):382-95. doi: 10.1002/bdrb.20260.
PMID: 20836125
Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.
Patel CG, Zhang J, Li L, Gooding L, Croop R, Li T, Boulton DW.
J Clin Pharmacol.
2010 Oct;50(10):1211-6. doi: 10.1177/0091270009360532. No abstract available.
PMID: 20150522
Good clinical practice regulatory inspections: Lessons for Indian investigator sites.
Marwah R, Van de Voorde K, Parchman J.
Perspect Clin Res.
2010 Oct;1(4):151-5. doi: 10.4103/2229-3485.71776.
PMID: 21350732
The impact of dichotomization in longitudinal data analysis: a simulation study.
Yoo B.
Pharm Stat.
2010 Oct-Dec;9(4):298-312. doi: 10.1002/pst.396.
PMID: 19904810
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R.
Semin Oncol.
2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.
PMID: 21074069
Roadmap to risk evaluation and mitigation strategies (REMS) success.
Balian JD, Wherry JC, Malhotra R, Perentesis V.
Ther Adv Drug Saf.
2010 Oct;1(1):21-38. doi: 10.1177/2042098610381419. Review.
PMID: 25083193
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Liu C, Lin J, Wrobleski ST, Lin S, Hynes J, Wu H, Dyckman AJ, Li T, Wityak J, Gillooly KM, Pitt S, Shen DR, Zhang RF, McIntyre KW, Salter-Cid L, Shuster DJ, Zhang H, Marathe PH, Doweyko AM, Sack JS, Kiefer SE, Kish KF, Newitt JA, McKinnon M, Dodd JH, Barrish JC, Schieven GL, Leftheris K.
J Med Chem.
2010 Sep 23;53(18):6629-39. doi: 10.1021/jm100540x.
PMID: 20804198
Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM, Carboni JM.
Cancer Res.
2010 Sep 15;70(18):7221-31. doi: 10.1158/0008-5472.CAN-10-0391.
PMID: 20807811
Factor Xa inhibitors: next-generation antithrombotic agents.
Pinto DJ, Smallheer JM, Cheney DL, Knabb RM, Wexler RR.
J Med Chem.
2010 Sep 9;53(17):6243-74. doi: 10.1021/jm100146h. Review. No abstract available.
PMID: 20503967
The use of inductively coupled plasma-atomic emission spectroscopy (ICP-AES) in the determination of lithium in cleaning validation swabs.
Lewen N, Nugent D.
J Pharm Biomed Anal.
2010 Sep 5;52(5):652-5. doi: 10.1016/j.jpba.2010.02.015.
PMID: 20227219
A novel small molecule inhibitor of hepatitis C virus entry.
Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, Pokornowski KA, Rose RE, Eggers BJ, Hsu M, Zhai W, Zhai G, Gerritz SW, Poss MA, Meanwell NA, Cockett MI, Tenney DJ.
PLoS Pathog.
2010 Sep 2;6(9):e1001086. doi: 10.1371/journal.ppat.1001086.
PMID: 20838466
Structural mass spectrometry in protein therapeutics discovery.
Kim YJ, Doyle ML.
Anal Chem.
2010 Sep 1;82(17):7083-9. doi: 10.1021/ac101575d.
PMID: 20698501
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
Fridell RA, Qiu D, Wang C, Valera L, Gao M.
Antimicrob Agents Chemother.
2010 Sep;54(9):3641-50. doi: 10.1128/AAC.00556-10.
PMID: 20585111
Development and validation of flow cytometry methods for pharmacodynamic clinical biomarkers.
Wu DY, Patti-Diaz L, Hill CG.
Bioanalysis.
2010 Sep;2(9):1617-26. doi: 10.4155/bio.10.33. Review.
PMID: 21083290
Characterization and development of a Luminex(®)-based assay for the detection of human IL-23.
Rizzi G, Zhang YJ, Latek R, Weiner R, Rhyne PW.
Bioanalysis . 2010 Sep;2(9):1561-72. doi: 10.4155/bio.10.68.
PMID: 21083285
Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.
Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.
Bioorg Med Chem Lett . 2010 Sep 1;20(17):5027-30. doi: 10.1016/j.bmcl.2010.07.045.
PMID: 20675137
Glucocorticoid receptor-mediated reduction of IgG-fusion protein aggregation in Chinese hamster ovary cells.
Qian Y, Jing Y, Li ZJ.
Biotechnol Prog . 2010 Sep-Oct;26(5):1417-23. doi: 10.1002/btpr.456.
PMID: 20549677
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.
Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M.
Clin Pharmacol Ther . 2010 Sep;88(3):375-82. doi: 10.1038/clpt.2010.106.
PMID: 20686477
Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.
Dinchuk JE, Cao C, Huang F, Reeves KA, Wang J, Myers F, Cantor GH, Zhou X, Attar RM, Gottardis M, Carboni JM.
Endocrinology.
2010 Sep;151(9):4123-32. doi: 10.1210/en.2010-0032.
PMID: 20610571
Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions.
Gu H, Deng Y, Wang J, Aubry AF, Arnold ME.
J Chromatogr B Analyt Technol Biomed Life Sci.
2010 Sep 1;878(25):2319-26. doi: 10.1016/j.jchromb.2010.06.041.
PMID: 20674522
Fostering culture and optimizing organizational structure for implementing model-based drug development.
Zhang L, Allerheiligen SR, Lalonde RL, Stanski DR, Pfister M.
J Clin Pharmacol . 2010 Sep;50(9 Suppl):146S-150S. doi: 10.1177/0091270010376976.
PMID: 20881228
Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium-glucose cotransporter-2 inhibition.
Zhang L, Ng CM, List JF, Pfister M.
J Clin Pharmacol.
2010 Sep;50(9 Suppl):113S-120S. doi: 10.1177/0091270010376974.
PMID: 20881224
Use of enthalpy and Gibbs free energy to evaluate the risk of amorphous formation.
Hsieh DS, Sarsfield BA, Davidovich M, DiMemmo LM, Chang SY, Kiang S.
J Pharm Sci.
2010 Sep;99(9):4096-105. doi: 10.1002/jps.22239.
PMID: 20564337
Solid-state interactions of a drug substance and excipients and their impact on tablet dissolution: a thermal-mechanical facilitated process-induced transformation or PIT.
Wang J, Davidovich M, Desai D, Bu D, Hussain M, Morris K.
J Pharm Sci.
2010 Sep;99(9):3849-62. doi: 10.1002/jps.22222.
PMID: 20533436
Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians.
Upadhyaya N, Chang R, Davis C, Conti MC, Salinas-Garcia D, Tang H.
Postgrad Med.
2010 Sep;122(5):165-75. doi: 10.3810/pgm.2010.09.2213.
PMID: 20861600
Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.
N Engl J Med.
2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.
PMID:
Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion?
Qian F, Huang J, Zhu Q, Haddadin R, Gawel J, Garmise R, Hussain M.
Int J Pharm.
2010 Aug 16;395(1-2):232-5. doi: 10.1016/j.ijpharm.2010.05.033.
PMID: 20562003
Defining process design space for monoclonal antibody cell culture.
Abu-Absi SF, Yang L, Thompson P, Jiang C, Kandula S, Schilling B, Shukla AA.
Biotechnol Bioeng . 2010 Aug 15;106(6):894-905. doi: 10.1002/bit.22764.
PMID: 20589669
Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
Meng W, Brigance RP, Chao HJ, Fura A, Harrity T, Marcinkeviciene J, O'Connor SP, Tamura JK, Xie D, Zhang Y, Klei HE, Kish K, Weigelt CA, Turdi H, Wang A, Zahler R, Kirby MS, Hamann LG.
J Med Chem.
2010 Aug 12;53(15):5620-8. doi: 10.1021/jm100634a.
PMID: 20684603
One-pot synthesis of azaindoles via palladium-catalyzed alpha-heteroarylation of ketone enolates.
Spergel SH, Okoro DR, Pitts W.
J Org Chem . 2010 Aug 6;75(15):5316-9. doi: 10.1021/jo100623d.
PMID: 20593785
Effect of inadequate response to treatment in patients with depression.
Knoth RL, Bolge SC, Kim E, Tran QV.
Am J Manag Care.
2010 Aug;16(8):e188-96.
PMID: 20690785
Liquid-liquid extraction coupled with LC/MS/MS for monitoring of malonyl-CoA in rat brain tissue.
Onorato JM, Chen L, Shipkova P, Ma Z, Azzara AV, Devenny JJ, Liang N, Haque TS, Cheng D.
Anal Bioanal Chem.
2010 Aug;397(7):3137-42. doi: 10.1007/s00216-010-3879-1.
PMID: 20549491
DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors.
D'Arienzo CJ, Ji QC, Discenza L, Cornelius G, Hynes J, Cornelius L, Santella JB, Olah T.
Bioanalysis.
2010 Aug;2(8):1415-22. doi: 10.4155/bio.10.94.
PMID: 21083342
Evaluating and defining sample preparation procedures for DBS LC-MS/MS assays.
Liu G, Patrone L, Snapp HM, Batog A, Valentine J, Cosma G, Tymiak A, Ji QC, Arnold ME.
Bioanalysis . 2010 Aug;2(8):1405-14. doi: 10.4155/bio.10.106.
PMID: 21083341
Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
Brigance RP, Meng W, Fura A, Harrity T, Wang A, Zahler R, Kirby MS, Hamann LG.
Bioorg Med Chem Lett.
2010 Aug 1;20(15):4395-8. doi: 10.1016/j.bmcl.2010.06.063.
PMID: 20598534
Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.
Xiao HY, Balog A, Attar RM, Fairfax D, Fleming LB, Holst CL, Martin GS, Rossiter LM, Chen J, Cvjic ME, Dell-John J, Geng J, Gottardis MM, Han WC, Nation A, Obermeier M, Rizzo CA, Schweizer L, Spires T Jr, Shan W, Gavai A, Salvati ME, Vite G.
Bioorg Med Chem Lett . 2010 Aug 1;20(15):4491-5. doi: 10.1016/j.bmcl.2010.06.034.
PMID: 20584610
The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs.
Su J, Brook RA, Kleinman NL, Corey-Lisle P.
Hepatology . 2010 Aug;52(2):436-42. doi: 10.1002/hep.23726.
PMID: 20683943
HCS road: an enterprise system for integrated HCS data management and analysis.
Jackson D, Lenard M, Zelensky A, Shaikh M, Scharpf JV, Shaginaw R, Nawade M, Agler M, Cloutier NJ, Fennell M, Guo Q, Wardwell-Swanson J, Zhao D, Zhu Y, Miller C, Gill J.
J Biomol Screen.
2010 Aug;15(7):882-91. doi: 10.1177/1087057110374233.
PMID: 20639503
Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Marathe P, Tang Y, Sleczka B, Rodrigues D, Gavai A, Wong T, Christopher L, Zhang H.
J Pharm Sci . 2010 Aug;99(8):3579-93. doi: 10.1002/jps.22099.
PMID: 20166197
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC, Jiang X.
Thromb Haemost.
2010 Aug;104(2):302-10. doi: 10.1160/TH10-02-0097.
PMID: 20589316
BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
Wong PC, Luettgen JM, Rendina AR, Kettner CA, Xin B, Knabb RM, Wexler R, Priestley ES.
Thromb Haemost.
2010 Aug;104(2):261-9. doi: 10.1160/TH10-01-0025.
PMID: 20589312
Paracelsus and formaldehyde 2010: the dose to the target organ makes the poison.
Lehman-McKeeman L.
Toxicol Sci.
2010 Aug;116(2):361-3. doi: 10.1093/toxsci/kfq164. No abstract available.
PMID: 20587505
Use of high-resolution mass spectrometry to investigate a metabolite interference during liquid chromatography/tandem mass spectrometric quantification of a small molecule in toxicokinetic study samples.
Furlong M, Bessire A, Song W, Huntington C, Groeber E.
Rapid Commun Mass Spectrom.
2010 Jul 15;24(13):1902-10. doi: 10.1002/rcm.4587.
PMID: 20533320
An electrophoretic mobility shift assay for the identification and kinetic analysis of acetyl transferase inhibitors.
Fanslau C, Pedicord D, Nagulapalli S, Gray H, Pang S, Jayaraman L, Lippy J, Blat Y.
Anal Biochem . 2010 Jul 1;402(1):65-8. doi: 10.1016/j.ab.2010.03.025.
PMID: 20338149
Novel MS solutions inspired by MIST.
Ramanathan R, Josephs JL, Jemal M, Arnold M, Humphreys WG.
Bioanalysis . 2010 Jul;2(7):1291-313. doi: 10.4155/bio.10.83. Review.
PMID: 21083241
NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.
Caceres-Cortes J, Reily MD.
Bioanalysis.
2010 Jul;2(7):1263-76. doi: 10.4155/bio.10.77. Review.
PMID: 21083239
Conference report: Inaugural Applied Pharmaceutical Analysis: India 2010 conference.
Ramanathan R, Chaudhary A.
Bioanalysis . 2010 Jul;2(7):1181-4. doi: 10.4155/bio.10.78.
PMID: 21083232
The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
Soares HD.
Curr Opin Investig Drugs.
2010 Jul;11(7):795-801. Review.
PMID: 20571975
A simple and promising tool to improve self-monitoring of blood glucose in patients with diabetes.
Nadkarni A, Kucukarslan SN, Bagozzi RP, Yates JF, Erickson SR.
Diabetes Res Clin Pract . 2010 Jul;89(1):30-7. doi: 10.1016/j.diabres.2010.03.011.
PMID: 20381890
Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H, Su H, Sun H, Allentoff A, Ekhato IV, Chando T, Caceres-Cortes J, Roongta V, Iyer RA, Humphreys WG, Christopher LJ.
Drug Metab Dispos.
2010 Jul;38(7):1189-201. doi: 10.1124/dmd.110.032755.
PMID: 20363952
Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters.
Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD.
Drug Metab Dispos . 2010 Jul;38(7):1064-71. doi: 10.1124/dmd.109.031526.
PMID: 20360303
Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD.
Drug Metab Dispos.
2010 Jul;38(7):1072-82. doi: 10.1124/dmd.109.031518.
PMID: 20360302
A simple reversed phase high-performance liquid chromatography method for polysorbate 80 quantitation in monoclonal antibody drug products.
Adamo M, Dick LW Jr, Qiu D, Lee AH, Devincentis J, Cheng KC.
J Chromatogr B Analyt Technol Biomed Life Sci.
2010 Jul 1;878(21):1865-70. doi: 10.1016/j.jchromb.2010.04.039.
PMID: 20537600
Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.
Zhao Q.
J Leukoc Biol.
2010 Jul;88(1):41-55. doi: 10.1189/jlb.1009671. Review.
PMID: 20360402
Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
Qian F, Huang J, Hussain MA.
J Pharm Sci . 2010 Jul;99(7):2941-7. doi: 10.1002/jps.22074.
PMID: 20127825
Modeling of pan coating processes: Prediction of tablet content uniformity and determination of critical process parameters.
Chen W, Chang SY, Kiang S, Marchut A, Lyngberg O, Wang J, Rao V, Desai D, Stamato H, Early W.
J Pharm Sci.
2010 Jul;99(7):3213-25. doi: 10.1002/jps.22044.
PMID: 20091834
Exploration of structure-activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis.
Haque TS, Martinez RL, Lee VG, Riexinger DG, Lei M, Feng M, Koplowitz B, Mapelli C, Cooper CB, Zhang G, Huang C, Ewing WR, Krupinski J.
Peptides.
2010 Jul;31(7):1353-60. doi: 10.1016/j.peptides.2010.04.013.
PMID: 20420872
Effect of spray-dried mannitol on the performance of microcrystalline cellulose-based wet granulated tablet formulation.
Badawy SI, Shah KR, Surapaneni MS, Szemraj MM, Hussain M.
Pharm Dev Technol.
2010 Jul-Aug;15(4):339-45. doi: 10.3109/10837450903229065.
PMID: 20088677
MORPH: a new tool for ligand design.
Beno BR, Langley DR.
J Chem Inf Model.
2010 Jun 28;50(6):1159-64. doi: 10.1021/ci9004964.
PMID: 20481489
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.
Lancet.
2010 Jun 26;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2.
PMID: 20609968
5-arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists.
Schmitz WD, Brenner AB, Bronson JJ, Ditta JL, Griffin CR, Li YW, Lodge NJ, Molski TF, Olson RE, Zhuo X, Macor JE.
Bioorg Med Chem Lett . 2010 Jun 15;20(12):3579-83. doi: 10.1016/j.bmcl.2010.04.121.
PMID: 20483614
Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.
Zuev D, Vrudhula VM, Michne JA, Dasgupta B, Pin SS, Huang XS, Wu D, Gao Q, Zhang J, Taber MT, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett.
2010 Jun 15;20(12):3669-74. doi: 10.1016/j.bmcl.2010.04.094.
PMID: 20471832
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, Seekins D, Krystal M, Mancini M, McGrath D, Simen B, Egholm M, Kozal M.
PLoS One.
2010 Jun 3;5(6):e10952. doi: 10.1371/journal.pone.0010952.
PMID: 20532178
In vitro developmental toxicology assays: A review of the state of the science of rodent and zebrafish whole embryo culture and embryonic stem cell assays.
Augustine-Rauch K, Zhang CX, Panzica-Kelly JM.
Birth Defects Res C Embryo Today . 2010 Jun;90(2):87-98. doi: 10.1002/bdrc.20175. Review.
PMID: 20544698
Non-competitive inhibition by active site binders.
Blat Y.
Chem Biol Drug Des.
2010 Jun;75(6):535-40. doi: 10.1111/j.1747-0285.2010.00972.x. Review.
PMID: 20374252
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Zhang L, Feng Y, List J, Kasichayanula S, Pfister M.
Diabetes Obes Metab.
2010 Jun;12(6):510-6. doi: 10.1111/j.1463-1326.2010.01216.x.
PMID: 20518806
Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis.
Schumacher WA, Bostwick JS, Stewart AB, Steinbacher TE, Xin B, Wong PC.
J Cardiovasc Pharmacol.
2010 Jun;55(6):609-16. doi: 10.1097/FJC.0b013e3181daded3.
PMID: 20224421
LC-MS/MS method using unbonded silica column and aqueous/methanol mobile phase for the simultaneous quantification of a drug candidate and co-administered metformin in rat plasma.
Discenza L, D'Arienzo C, Olah T, Jemal M.
J Chromatogr B Analyt Technol Biomed Life Sci.
2010 Jun 1;878(19):1583-9. doi: 10.1016/j.jchromb.2010.04.018.
PMID: 20451474
Colloidal phase behavior of pH-responsive, amphiphilic PEGylated poly(carboxylic acid)s and effect on kinetic solubility under acidic conditions.
Adams ML, Rao VM, Thakur A, Hussain MA.
Pharm Dev Technol . 2010 Jun;15(3):266-75. doi: 10.3109/10837450903170772.
PMID: 22716467
Roller compaction: application of an in-gap ribbon porosity calculation for the optimization of downstream granule flow and compactability characteristics.
Gamble JF, Tobyn M, Dennis AB, Shah T.
Pharm Dev Technol.
2010 Jun;15(3):223-9. doi: 10.3109/10837450903095342.
PMID: 22716462
Muscling mussels: metabolomic evaluation of toxicity.
Robertson DG.
Toxicol Sci.
2010 Jun;115(2):305-6. doi: 10.1093/toxsci/kfq088. No abstract available.
PMID: 20478983
Investigation of bioactivation of ticlopidine using linear ion trap/orbitrap mass spectrometry and an improved mass defect filtering technique.
Ruan Q, Zhu M.
Chem Res Toxicol.
2010 May 17;23(5):909-17. doi: 10.1021/tx1000046.
PMID: 20297803
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.
Velaparthi U, Saulnier MG, Wittman MD, Liu P, Frennesson DB, Zimmermann K, Carboni JM, Gottardis M, Li A, Greer A, Clarke W, Yang Z, Menard K, Lee FY, Trainor G, Vyas D.
Bioorg Med Chem Lett.
2010 May 15;20(10):3182-5. doi: 10.1016/j.bmcl.2010.03.057.
PMID: 20399649
Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).
Watterson SH, Xiao Z, Dodd DS, Tortolani DR, Vaccaro W, Potin D, Launay M, Stetsko DK, Skala S, Davis PM, Lee D, Yang X, McIntyre KW, Balimane P, Patel K, Yang Z, Marathe P, Kadiyala P, Tebben AJ, Sheriff S, Chang CY, Ziemba T, Zhang H, Chen BC, DelMonte AJ, Aranibar N, McKinnon M, Barrish JC, Suchard SJ, Murali Dhar TG.
J Med Chem.
2010 May 13;53(9):3814-30. doi: 10.1021/jm100348u.
PMID: 20405922
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG.
Nature.
2010 May 6;465(7294):96-100. doi: 10.1038/nature08960.
PMID: 20410884
Pooled sample strategy in conjunction with high-resolution liquid chromatography-mass spectrometry-based background subtraction to identify toxicological markers in dogs treated with ibipinabant.
Zhang H, Patrone L, Kozlosky J, Tomlinson L, Cosma G, Horvath J.
Anal Chem.
2010 May 1;82(9):3834-9. doi: 10.1021/ac100287a.
PMID: 20387806
Protection against HIV-envelope-induced neuronal cell destruction by HIV attachment inhibitors.
Zhang S, Alexander L, Wang T, Agler M, Zhou N, Fang H, Kadow J, Clapham P, Lin PF.
Arch Virol.
2010 May;155(5):777-81. doi: 10.1007/s00705-010-0644-x.
PMID: 20300783
Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK, Chen XT, Tarby C, Kaltenbach R, Cai ZW, Tokarski JS, An Y, Sack JS, Wautlet B, Gullo-Brown J, Henley BJ, Jeyaseelan R, Kellar K, Manne V, Trainor GL, Lombardo LJ, Fargnoli J, Borzilleri RM.
Bioorg Med Chem Lett.
2010 May 1;20(9):2998-3002. doi: 10.1016/j.bmcl.2010.01.042.
PMID: 20382527
Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation.
Ye XY, Chen S, Zhang H, Locke KT, O'Malley K, Zhang L, Srivastava R, Miao B, Meyers D, Monshizadegan H, Search D, Grimm D, Zhang R, Lippy J, Twamley C, Muckelbauer JK, Chang C, An Y, Hosagrahara V, Zhang L, Yang TJ, Mukherjee R, Cheng PT, Tino JA.
Bioorg Med Chem Lett . 2010 May 1;20(9):2933-7. doi: 10.1016/j.bmcl.2010.03.019.
PMID: 20356736
Disaggregation of high-molecular weight species during downstream processing to recover functional monomer.
Xu X, Didio DM, Leister KJ, Ghose S.
Biotechnol Prog . 2010 May-Jun;26(3):717-26. doi: 10.1002/btpr.373.
PMID: 20039266
Feed development for fed-batch CHO production process by semisteady state analysis.
Khattak SF, Xing Z, Kenty B, Koyrakh I, Li ZJ.
Biotechnol Prog . 2010 May-Jun;26(3):797-804. doi: 10.1002/btpr.362.
PMID: 20014108
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG.
Depress Anxiety.
2010 May;27(5):417-25. doi: 10.1002/da.20695.
PMID: 20455246
Lubrication in tablet formulations.
Wang J, Wen H, Desai D.
Eur J Pharm Biopharm.
2010 May;75(1):1-15. doi: 10.1016/j.ejpb.2010.01.007. Review.
PMID: 20096779
Effect of body position on limb lead electrocardiographic findings in sedated cynomolgus macaques (Macaca fascicularis).
Taylor K, Gleason C.
J Am Assoc Lab Anim Sci.
2010 May;49(3):352-6.
PMID: 20587168
A tris (2-carboxyethyl) phosphine (TCEP) related cleavage on cysteine-containing proteins.
Liu P, O'Mara BW, Warrack BM, Wu W, Huang Y, Zhang Y, Zhao R, Lin M, Ackerman MS, Hocknell PK, Chen G, Tao L, Rieble S, Wang J, Wang-Iverson DB, Tymiak AA, Grace MJ, Russell RJ.
J Am Soc Mass Spectrom.
2010 May;21(5):837-44. doi: 10.1016/j.jasms.2010.01.016.
PMID: 20189823
Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs.
Haque TS, Lee VG, Riexinger D, Lei M, Malmstrom S, Xin L, Han S, Mapelli C, Cooper CB, Zhang G, Ewing WR, Krupinski J.
Peptides.
2010 May;31(5):950-5. doi: 10.1016/j.peptides.2010.01.008.
PMID: 20138099
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW.
Postgrad Med.
2010 May;122(3):16-27. doi: 10.3810/pgm.2010.05.2138.
PMID: 20463410
Recent advances in large-scale production of monoclonal antibodies and related proteins.
Shukla AA, Thömmes J.
Trends Biotechnol.
2010 May;28(5):253-61. doi: 10.1016/j.tibtech.2010.02.001. Review.
PMID: 20304511
Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM, Wenke G, Regueiro-Ren A, Yordanova R, Corradi JP, Adams SP.
Chem Res Toxicol.
2010 Apr 19;23(4):749-55. doi: 10.1021/tx9003825.
PMID: 20356072
gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
Cherney RJ, Mo R, Meyer DT, Voss ME, Yang MG, Santella JB 3rd, Duncia JV, Lo YC, Yang G, Miller PB, Scherle PA, Zhao Q, Mandlekar S, Cvijic ME, Barrish JC, Decicco CP, Carter PH.
Bioorg Med Chem Lett.
2010 Apr 15;20(8):2425-30. doi: 10.1016/j.bmcl.2010.03.035.
PMID: 20346664
Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells.
Borys MC, Dalal NG, Abu-Absi NR, Khattak SF, Jing Y, Xing Z, Li ZJ.
Biotechnol Bioeng.
2010 Apr 15;105(6):1048-57. doi: 10.1002/bit.22644.
PMID: 20039310
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
Li J, Kennedy LJ, Shi Y, Tao S, Ye XY, Chen SY, Wang Y, Hernández AS, Wang W, Devasthale PV, Chen S, Lai Z, Zhang H, Wu S, Smirk RA, Bolton SA, Ryono DE, Zhang H, Lim NK, Chen BC, Locke KT, O'Malley KM, Zhang L, Srivastava RA, Miao B, Meyers DS, Monshizadegan H, Search D, Grimm D, Zhang R, Harrity T, Kunselman LK, Cap M, Kadiyala P, Hosagrahara V, Zhang L, Xu C, Li YX, Muckelbauer JK, Chang C, An Y, Krystek SR, Blanar MA, Zahler R, Mukherjee R, Cheng PT, Tino JA.
J Med Chem.
2010 Apr 8;53(7):2854-64. doi: 10.1021/jm9016812.
PMID: 20218621
Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method.
Browning MR, Drexler DM, Olah TV, Morgan DG.
Bioanalysis.
2010 Apr;2(4):745-53. doi: 10.4155/bio.10.25.
PMID: 21083272
Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC-MS/MS.
Fung EN, Zheng N, Arnold ME, Zeng J.
Bioanalysis.
2010 Apr;2(4):733-43. doi: 10.4155/bio.10.30.
PMID: 21083271
Semiparametric Bayesian inference for repeated fractional measurement data.
Yang Y, Müller P, Rosner GL.
Chil J Stat.
2010 Apr 1;1(1):59-74.
PMID: 21822354
Disposition of [1'-(14)C]stavudine after oral administration to humans.
Zhou L, Kaul S, Liu-Kreyche P, Tran SB, Espina RR, Warrack BM, Roongta VA, Iyer RA.
Drug Metab Dispos . 2010 Apr;38(4):655-66. doi: 10.1124/dmd.109.030239.
PMID: 20053818
An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis.
Suchard SJ, Stetsko DK, Davis PM, Skala S, Potin D, Launay M, Dhar TG, Barrish JC, Susulic V, Shuster DJ, McIntyre KW, McKinnon M, Salter-Cid L.
J Immunol.
2010 Apr 1;184(7):3917-26. doi: 10.4049/jimmunol.0901095.
PMID: 20190141
Bacterial infections in cynomolgus monkeys given small molecule immunomodulatory antagonists.
Price KD.
J Immunotoxicol.
2010 Apr-Jun;7(2):128-37. doi: 10.3109/15476910903493276. Review.
PMID: 20136396
Overview of known non-human primate pathogens with potential to affect colonies used for toxicity testing.
Sasseville VG, Mansfield KG.
J Immunotoxicol.
2010 Apr-Jun;7(2):79-92. doi: 10.3109/15476910903213521. Review.
PMID: 19909217
Clinical veterinarian's perspective of non-human primate (NHP) use in drug safety studies.
Taylor K.
J Immunotoxicol.
2010 Apr-Jun;7(2):114-9. doi: 10.1080/15476910903213539. Review.
PMID: 19775234
Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
Yang Z, Zadjura LM, Marino AM, D'Arienzo CJ, Malinowski J, Gesenberg C, Lin PF, Colonno RJ, Wang T, Kadow JF, Meanwell NA, Hansel SB.
J Pharm Sci.
2010 Apr;99(4):2135-52. doi: 10.1002/jps.21948.
PMID: 19780144
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Boulton DW, Balch AH, Royzman K, Patel CG, Berman RM, Mallikaarjun S, Reeves RA.
J Psychopharmacol . 2010 Apr;24(4):537-46. doi: 10.1177/0269881108096522.
PMID: 18832427
Impact of missing data on type 1 error rates in non-inferiority trials.
Yoo B.
Pharm Stat.
2010 Apr-Jun;9(2):87-99. doi: 10.1002/pst.378.
PMID: 19408241
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.
Gillman KW, Starrett JE Jr, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA, Williams R, Meredith JE Jr, Burton CR, Barten DM, Toyn JH, Roberts SB, Lentz KA, Houston JG, Zaczek R, Albright CF, Decicco CP, Macor JE, Olson RE.
ACS Med Chem Lett.
2010 Mar 22;1(3):120-4. doi: 10.1021/ml1000239.
PMID: 24900185
Copper-catalyzed chlorination of functionalized arylboronic acids.
Wu H, Hynes J Jr.
Org Lett.
2010 Mar 19;12(6):1192-5. doi: 10.1021/ol9029337.
PMID: 20184339
Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).
Vrudhula VM, Dasgupta B, Pin SS, Burris KD, Balanda LA, Fung LK, Fiedler T, Browman KE, Taber MT, Zhang J, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett.
2010 Mar 15;20(6):1905-9. doi: 10.1016/j.bmcl.2010.01.127.
PMID: 20185312
Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA, Ahuja VT, Schmitz WD, Molski TF, Mattson GK, Lodge NJ, Bronson JJ, Macor JE.
Bioorg Med Chem Lett.
2010 Mar 15;20(6):1890-4. doi: 10.1016/j.bmcl.2010.01.129.
PMID: 20176478
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators..
Lancet . 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5.
PMID: 20206776
Mild and general method for the alpha-arylation of heteroaromatic ketones.
Desai LV, Ren DT, Rosner T.
Org Lett.
2010 Mar 5;12(5):1032-5. doi: 10.1021/ol1000318.
PMID: 20146430
Inhibition of factor XIa as a new approach to anticoagulation.
Schumacher WA, Luettgen JM, Quan ML, Seiffert DA.
Arterioscler Thromb Vasc Biol.
2010 Mar;30(3):388-92. doi: 10.1161/ATVBAHA.109.197178. Review.
PMID: 20139363
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Sang X, Frennesson DB, Struzynski C, Seitz SP, He L, Carboni JM, Li A, Greer AF, Gottardis M, Attar RM, Yang Z, Balimane P, Discenza LN, Lee FY, Sinz M, Kim S, Vyas D.
Bioorg Med Chem Lett.
2010 Mar 1;20(5):1744-8. doi: 10.1016/j.bmcl.2010.01.087.
PMID: 20153189
Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
Donato BM, Burns L, Willey V, Cohenuram M, Oliveria S, Yood MU.
Clin Ther.
2010 Mar;32(3):546-54. doi: 10.1016/j.clinthera.2010.03.007.
PMID: 20399992
In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG.
Drug Metab Dispos.
2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165.
PMID: 19996149
In silico prediction of biliary excretion of drugs in rats based on physicochemical properties.
Luo G, Johnson S, Hsueh MM, Zheng J, Cai H, Xin B, Chong S, He K, Harper TW.
Drug Metab Dispos . 2010 Mar;38(3):422-30. doi: 10.1124/dmd.108.026260.
PMID: 19995888
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ.
Drug Metab Dispos . 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Erratum in: Drug Metab Dispos. 2010 May;38(5):887. Frost, Charles A [corrected to Frost, Charles E].
PMID: 19940026
Recent development in high-throughput bioanalytical support for in vitro ADMET profiling.
Shou WZ, Zhang J.
Expert Opin Drug Metab Toxicol.
2010 Mar;6(3):321-36. doi: 10.1517/17425250903547829. Review.
PMID: 20163321
Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
Yuan Y, Trivedi D, Maclean R, Rosenblatt L.
J Med Econ.
2010 Mar;13(1):33-41. doi: 10.3111/13696990903508021.
PMID: 20001596
Applications of HILIC for targeted and non-targeted LC/MS analyses in drug discovery.
Onorato JM, Langish R, Bellamine A, Shipkova P.
J Sep Sci.
2010 Mar;33(6-7):923-9. doi: 10.1002/jssc.200900659.
PMID: 20127913
Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study.
Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Lu SN, Chen CJ.
Liver Int.
2010 Mar;30(3):423-9. doi: 10.1111/j.1478-3231.2009.02147.x.
PMID: 19840258
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.
Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, Miller K, Sanders K, Short S, Sperinde J, Prasad G, Williams S, Kerbel R, Ebos J, Mutsaers A, Mendlein JD, Harris AS, Furfine ES.
MAbs.
2010 Mar-Apr;2(2):199-208.
PMID: 20190562
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.
J Clin Oncol.
2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890.
PMID: 20100958
Phenyltriazolinones as potent factor Xa inhibitors.
Quan ML, Pinto DJ, Rossi KA, Sheriff S, Alexander RS, Amparo E, Kish K, Knabb RM, Luettgen JM, Morin P, Smallwood A, Woerner FJ, Wexler RR.
Bioorg Med Chem Lett.
2010 Feb 15;20(4):1373-7. doi: 10.1016/j.bmcl.2010.01.011.
PMID: 20100660
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.
Lloyd J, Finlay HJ, Vacarro W, Hyunh T, Kover A, Bhandaru R, Yan L, Atwal K, Conder ML, Jenkins-West T, Shi H, Huang C, Li D, Sun H, Levesque P.
Bioorg Med Chem Lett.
2010 Feb 15;20(4):1436-9. doi: 10.1016/j.bmcl.2009.12.085.
PMID: 20097068
Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempra) in human plasma: method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants.
Xu XS, Zeng J, Mylott W, Arnold M, Waltrip J, Iacono L, Mariannino T, Stouffer B.
J Chromatogr B Analyt Technol Biomed Life Sci.
2010 Feb 15;878(5-6):525-37. doi: 10.1016/j.jchromb.2009.12.014.
PMID: 20083444
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW, Langley DR, Colonno RJ, Tenney DJ.
PLoS One.
2010 Feb 12;5(2):e9195. doi: 10.1371/journal.pone.0009195.
PMID: 20169198
Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators.
Xiao HY, Wu DR, Malley MF, Gougoutas JZ, Habte SF, Cunningham MD, Somerville JE, Dodd JH, Barrish JC, Nadler SG, Dhar TG.
J Med Chem.
2010 Feb 11;53(3):1270-80. doi: 10.1021/jm901551w.
PMID: 20047280
Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food.
Kaul S, Ji P, Lu M, Nguyen KL, Shangguan T, Grasela D.
Am J Health Syst Pharm.
2010 Feb 1;67(3):217-22. doi: 10.2146/ajhp090327.
PMID: 20101064
Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.
Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W.
Bioorg Med Chem Lett.
2010 Feb 1;20(3):853-6. doi: 10.1016/j.bmcl.2009.12.084.
PMID: 20060717
Oxime carbamate--discovery of a series of novel FAAH inhibitors.
Sit SY, Conway CM, Xie K, Bertekap R, Bourin C, Burris KD.
Bioorg Med Chem Lett.
2010 Feb 1;20(3):1272-7. doi: 10.1016/j.bmcl.2009.11.080.
PMID: 20036536
Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles.
Marcin LR, Mattson RJ, Gao Q, Wu D, Molski TF, Mattson GK, Lodge NJ.
Bioorg Med Chem Lett.
2010 Feb 1;20(3):1027-30. doi: 10.1016/j.bmcl.2009.12.043.
PMID: 20034793
Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
Ahmad S, Ngu K, Miller KJ, Wu G, Hung CP, Malmstrom S, Zhang G, O'Tanyi E, Keim WJ, Cullen MJ, Rohrbach KW, Thomas M, Ung T, Qu Q, Gan J, Narayanan R, Pelleymounter MA, Robl JA.
Bioorg Med Chem Lett.
2010 Feb 1;20(3):1128-33. doi: 10.1016/j.bmcl.2009.12.014.
PMID: 20022752
Profiling of host cell proteins by two-dimensional difference gel electrophoresis (2D-DIGE): Implications for downstream process development.
Jin M, Szapiel N, Zhang J, Hickey J, Ghose S.
Biotechnol Bioeng.
2010 Feb 1;105(2):306-16. doi: 10.1002/bit.22532.
PMID: 19739084
Development of a zebrafish embryo teratogenicity assay and quantitative prediction model.
Brannen KC, Panzica-Kelly JM, Danberry TL, Augustine-Rauch KA.
Birth Defects Res B Dev Reprod Toxicol.
2010 Feb;89(1):66-77. doi: 10.1002/bdrb.20223.
PMID: 20166227
Preformulation designed to enable discovery and assess developability.
Hageman MJ.
Comb Chem High Throughput Screen.
2010 Feb;13(2):90-100. Review.
PMID: 20053164
Clinically validated approaches to the treatment of autoimmune diseases.
Carter PH, Zhao Q.
Expert Opin Investig Drugs . 2010 Feb;19(2):195-213. doi: 10.1517/13543780903418452. Review.
PMID: 20050823
Spiroindenes and spiroindanes as antagonists of CC chemokine receptor 2: WO 2009023754.
Carter PH.
Expert Opin Ther Pat.
2010 Feb;20(2):283-9. doi: 10.1517/13543770903490437.
PMID: 20100008
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C.
Lancet Oncol.
2010 Feb;11(2):155-64. doi: 10.1016/S1470-2045(09)70334-1.
PMID: 20004617
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr, Mortillo S, Wautlet BS, Krishnan B, Kukral D, Malone H, Lewin AC, Henley BJ, Fargnoli J.
Mol Cancer Ther.
2010 Feb;9(2):369-78. doi: 10.1158/1535-7163.MCT-09-0472.
PMID: 20103604
Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition.
Fletcher AM, Bregman CL, Woicke J, Salcedo TW, Zidell RH, Janke HE, Fang H, Janusz WJ, Schulze GE, Mense MG.
Toxicol Pathol . 2010 Feb;38(2):267-79. doi: 10.1177/0192623309357950.
PMID: 20100840
Mechanism-based inhibition of human cytochrome P4503A4 by domperidone.
Chang SY, Fancher RM, Zhang H, Gan J.
Xenobiotica.
2010 Feb;40(2):138-45. doi: 10.3109/00498250903406762.
PMID: 20082577
Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
Zhu L, Butterton J, Persson A, Stonier M, Comisar W, Panebianco D, Breidinger S, Zhang J, Bertz R.
Antivir Ther.
2010;15(8):1107-14. doi: 10.3851/IMP1673.
PMID: 21149917
Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies.
Tenney DJ.
Antivir Ther.
2010;15(3 Pt B):529-35. doi: 10.3851/IMP1504.
PMID: 20516575
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
Simon TA, Askling J, Lacaille D, Franklin J, Wolfe F, Covucci A, Suissa S, Hochberg MC; Abatacept Epidemiology Study Group..
Arthritis Res Ther.
2010;12(2):R67. doi: 10.1186/ar2984.
PMID: 20398273
Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography.
Jemal M, Ouyang Z, Xia YQ.
Biomed Chromatogr.
2010 Jan;24(1):2-19. doi: 10.1002/bmc.1373. Review.
PMID: 20017121
Modeling kinetics of a large-scale fed-batch CHO cell culture by Markov chain Monte Carlo method.
Xing Z, Bishop N, Leister K, Li ZJ.
Biotechnol Prog . 2010 Jan-Feb;26(1):208-19. doi: 10.1002/btpr.284.
PMID: 19834967
Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Kim S, Dinchuk JE, Anthony MN, Orcutt T, Zoeckler ME, Sauer MB, Mosure KW, Vuppugalla R, Grace JE Jr, Simmermacher J, Dulac HA, Pizzano J, Sinz M.
Drug Metab Dispos.
2010 Jan;38(1):16-24. doi: 10.1124/dmd.109.029637.
PMID: 19833845
Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation.
Zhuo X, Hartz RA, Bronson JJ, Wong H, Ahuja VT, Vrudhula VM, Leet JE, Huang S, Macor JE, Shu YZ.
Drug Metab Dispos.
2010 Jan;38(1):5-15. doi: 10.1124/dmd.109.028910.
PMID: 19833844
A latent class model for testing for linkage and classifying families when the sample may contain segregating and non-segregating families.
Bastone LA, Spielman RS, Wang X, Ten Have TR, Putt ME.
Hum Hered . 2010;70(2):75-91. doi: 10.1159/000312819.
PMID: 20558995
Solid phase synthesis of novel pyrrolidinedione analogs as potent HIV-1 integrase inhibitors.
Pendri A, Troyer TL, Sofia MJ, Walker MA, Naidu BN, Banville J, Meanwell NA, Dicker I, Lin Z, Krystal M, Gerritz SW.
J Comb Chem.
2010 Jan-Feb;12(1):84-90. doi: 10.1021/cc9001026.
PMID: 19902958
Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey.
Kim E, Gupta S, Bolge S, Chen CC, Whitehead R, Bates JA.
J Med Econ.
2010;13(2):185-92. doi: 10.3111/13696991003723023.
PMID: 20235753
Non-invasive systemic drug delivery: developability considerations for alternate routes of administration.
Mathias NR, Hussain MA.
J Pharm Sci.
2010 Jan;99(1):1-20. doi: 10.1002/jps.21793. Review.
PMID: 19499570
Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits.
Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B, Xin B, Luettgen JM, Wong PC.
J Thromb Thrombolysis.
2010 Jan;29(1):70-80. doi: 10.1007/s11239-009-0401-8.
PMID: 19851712
Identification of hepatitis C virus NS5A inhibitors.
Lemm JA, O'Boyle D 2nd, Liu M, Nower PT, Colonno R, Deshpande MS, Snyder LB, Martin SW, St Laurent DR, Serrano-Wu MH, Romine JL, Meanwell NA, Gao M.
J Virol . 2010 Jan;84(1):482-91. doi: 10.1128/JVI.01360-09.
PMID: 19812153
Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models.
Marathe PH, Rodrigues AD.
Methods Mol Biol.
2010;596:385-403. doi: 10.1007/978-1-60761-416-6_17.
PMID: 19949933
Synthesis of natural products containing the pyrrolic ring.
Young IS, Thornton PD, Thompson A.
Nat Prod Rep.
2010 Jan;27(12):1801-39. doi: 10.1039/c0np00014k. Review. No abstract available.
PMID: 20936222
Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey.
Bates JA, Whitehead R, Bolge SC, Kim E.
Prim Care Companion J Clin Psychiatry.
2010;12(5). pii: PCC.09m00883. doi: 10.4088/PCC.09m00883yel.
PMID: 21274363
Safety assessment considerations and strategies for targeted small molecule cancer therapeutics in drug discovery.
Westhouse RA.
Toxicol Pathol.
2010 Jan;38(1):165-8. doi: 10.1177/0192623309354341. Review.
PMID: 19907054
Last update on: November 2023

February 26, 2024
© 2024
Bristol-Myers Squibb Company